data_2lmo_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lmo _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 N--CA 1.456 -0.162 0 CA-C-O 120.712 0.291 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.2 t -126.01 133.77 68.15 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.018 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -106.24 165.87 10.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.467 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.414 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 8.2 p80 -92.34 169.58 10.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.385 0.612 . . . . 0.0 110.249 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 96.2 mm-40 -151.71 -179.96 7.88 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.008 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -126.04 126.71 44.69 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.904 0.383 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.2 mt -128.39 127.73 43.16 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.978 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -135.66 138.57 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.272 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -130.96 135.73 47.9 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.52 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.0 p90 -123.48 128.97 50.55 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.97 130.96 52.27 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 122.13 0.967 . . . . 0.0 112.788 -178.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -125.5 167.5 14.92 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 64.6 t0 . . . . . 0 N--CA 1.474 0.749 0 CA-C-N 118.289 0.495 . . . . 0.0 112.119 -178.83 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 74.1 tttt . . . . . 0 N--CA 1.464 0.242 0 N-CA-C 114.683 1.364 . . . . 0.0 114.683 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -77.53 101.4 1.64 Allowed Glycine 0 CA--C 1.507 -0.461 0 CA-C-O 114.823 -3.209 . . . . 0.0 105.505 168.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 147.73 25.98 Favored 'General case' 0 C--N 1.355 0.838 1 CA-C-N 125.483 4.642 . . . . 0.0 108.621 -178.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.521 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -152.73 112.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.397 -171.704 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 32' ' ' ILE . 56.5 mt -121.93 103.48 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 176.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.65 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -116.55 107.49 1.63 Allowed Glycine 0 CA--C 1.505 -0.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 177.272 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.51 ' H ' HD22 ' B' ' 34' ' ' LEU . 70.2 mt -142.66 153.66 43.63 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 123.295 1.521 . . . . 0.0 113.085 -177.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.469 ' SD ' ' C ' ' G' ' 31' ' ' ILE . 28.5 ttm -119.96 119.58 33.86 Favored 'General case' 0 CA--C 1.5 -0.949 0 CA-C-N 112.643 -2.071 . . . . 0.0 108.433 178.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.53 66.91 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.09 -102.13 0.01 OUTLIER Glycine 0 C--N 1.356 1.65 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.75 171.99 38.71 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.6 t -131.56 139.16 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.838 0.351 . . . . 0.0 110.415 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.357 179.811 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.36 158.54 44.01 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.683 0.277 . . . . 0.0 110.37 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.51 ' OE2' ' NE2' ' B' ' 13' ' ' HIS . 81.2 tt0 -146.56 146.26 30.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.272 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.1 m -136.88 159.68 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.163 0.506 . . . . 0.0 111.283 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.51 ' NE2' ' OE2' ' B' ' 11' ' ' GLU . 96.0 m-70 -149.83 163.52 37.81 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.067 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -115.04 178.39 4.3 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -97.2 175.09 6.41 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.775 -179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -117.49 138.67 51.71 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.73 127.27 40.1 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-O 121.051 0.453 . . . . 0.0 111.589 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -126.85 130.49 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.097 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -124.23 134.01 53.37 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.395 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -136.2 123.48 21.85 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.727 -0.215 . . . . 0.0 111.031 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . 0.433 ' O ' ' CG ' ' B' ' 22' ' ' GLU . . . -126.86 117.55 22.82 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 120.946 0.403 . . . . 0.0 111.067 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.433 ' CG ' ' O ' ' B' ' 21' ' ' ALA . 83.3 mt-10 -165.47 133.8 3.16 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.617 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.9 t70 . . . . . 0 N--CA 1.471 0.605 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 177.238 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.275 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.91 152.29 29.49 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.535 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -143.28 118.35 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 113.914 -1.494 . . . . 0.0 109.059 -175.126 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.1 tt -122.65 114.74 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.686 0.755 . . . . 0.0 109.705 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -117.5 116.9 3.62 Favored Glycine 0 N--CA 1.463 0.498 0 N-CA-C 107.877 -2.089 . . . . 0.0 107.877 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.51 HD22 ' H ' ' A' ' 34' ' ' LEU . 79.6 mt -134.62 147.0 50.09 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 114.444 1.276 . . . . 0.0 114.444 -176.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.464 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 3.2 ttm -122.48 118.35 28.11 Favored 'General case' 0 CA--C 1.505 -0.779 0 CA-C-N 113.469 -1.696 . . . . 0.0 109.366 177.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.09 70.16 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.18 112.18 3.46 Favored Glycine 0 C--N 1.358 1.785 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.43 147.94 12.74 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.628 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -127.82 136.3 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.572 179.704 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.5 t . . . . . 0 N--CA 1.466 0.364 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.572 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 80.0 m-70 -152.12 119.26 5.88 Favored 'General case' 0 N--CA 1.463 0.219 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.35 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -136.61 164.78 27.42 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -155.88 178.63 10.04 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.873 0.368 . . . . 0.0 110.557 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -167.72 106.92 0.54 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.208 178.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mt -122.12 121.15 36.24 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -129.26 125.97 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 CA-C-O 121.027 0.442 . . . . 0.0 111.971 -179.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -120.52 113.94 21.03 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -116.92 132.96 56.57 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.185 0.194 . . . . 0.0 110.641 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.91 138.1 25.37 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 85.1 tt0 -161.88 144.1 11.49 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.474 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 20.3 t0 . . . . . 0 CA--C 1.543 0.685 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.187 178.233 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.192 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.424 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -106.37 157.87 17.3 Favored 'General case' 0 CA--C 1.482 -1.665 0 N-CA-C 101.764 -3.421 . . . . 0.0 101.764 175.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.424 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 2.0 mt -140.02 122.65 16.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 117.94 -1.504 . . . . 0.0 111.74 -173.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.4 HG23 HD11 ' C' ' 32' ' ' ILE . 1.1 mt -117.75 112.59 39.31 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.14 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.78 102.81 0.87 Allowed Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.427 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 7.0 tt -134.73 138.52 44.44 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.654 1.216 . . . . 0.0 113.29 -175.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 25.9 ttm -117.99 120.5 38.0 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 113.705 -1.588 . . . . 0.0 108.724 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.423 ' CG1' ' O ' ' C' ' 36' ' ' VAL . 4.0 p -125.36 71.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.39 -100.86 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.437 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.51 -157.83 29.8 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -133.9 160.24 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.004 0.43 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.831 179.986 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 m . . . . . 0 CA--C 1.536 0.439 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.572 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 80.9 m-70 -78.4 124.63 28.33 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.145 -0.622 . . . . 0.0 111.727 -179.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -148.45 167.97 23.91 Favored 'General case' 0 C--N 1.342 0.28 0 CA-C-O 121.244 0.545 . . . . 0.0 109.985 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.63 177.69 10.67 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.591 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.61 114.09 0.62 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.21 0.528 . . . . 0.0 111.779 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 35.5 tp -123.72 121.59 35.87 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.215 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -126.62 125.48 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.465 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 35.8 m-85 -117.21 120.87 39.58 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.187 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -128.34 122.41 31.48 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.828 0.347 . . . . 0.0 111.175 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.65 135.55 40.26 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.166 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.7 mt-10 -117.57 124.39 48.55 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.111 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 77.8 m-20 . . . . . 0 CA--C 1.548 0.889 0 N-CA-C 112.852 0.686 . . . . 0.0 112.852 -179.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.473 -2.0 0 CA-C-O 122.086 0.946 . . . . 0.0 108.923 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -143.36 108.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 CA-C-N 113.535 -1.666 . . . . 0.0 107.955 -176.561 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.53 121.89 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.087 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.626 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -125.94 103.22 0.68 Allowed Glycine 0 C--N 1.311 -0.813 0 N-CA-C 105.526 -3.03 . . . . 0.0 105.526 175.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.573 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.4 tt -127.78 131.33 49.62 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-O 122.171 0.986 . . . . 0.0 111.747 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.487 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 17.0 ttm -112.05 121.81 46.02 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 113.985 -1.462 . . . . 0.0 110.011 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -110.95 75.43 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.803 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -31.85 -96.24 0.01 OUTLIER Glycine 0 C--N 1.353 1.502 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.9 175.29 17.49 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 10.0 p -139.7 141.51 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.92 0.39 . . . . 0.0 110.608 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.563 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . 0.514 ' CE1' ' N ' ' F' ' 9' ' ' GLY . 88.1 m-85 -107.89 135.04 49.95 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.832 0.348 . . . . 0.0 110.211 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.52 138.63 58.51 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.186 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 72.6 t -122.38 131.28 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.619 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 96.1 m-70 -121.41 114.99 22.08 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.385 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' O ' ' E' ' 13' ' ' HIS . 2.7 m80 -142.46 168.31 20.03 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.641 0.734 . . . . 0.0 110.124 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -151.63 168.95 23.35 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.079 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -146.36 111.36 5.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 31.9 mt -122.99 121.81 37.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 14.3 p -140.16 135.87 37.22 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 CA-C-O 121.944 0.878 . . . . 0.0 112.883 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.573 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 36.7 m-85 -117.72 117.23 28.77 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 114.327 -1.306 . . . . 0.0 109.927 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -113.3 119.56 38.12 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.699 0.285 . . . . 0.0 111.105 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.6 137.86 53.38 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 120.972 0.415 . . . . 0.0 110.01 178.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -79.47 73.83 6.11 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 118.309 -1.356 . . . . 0.0 111.158 -177.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.608 ' O ' ' O ' ' E' ' 24' ' ' VAL . 1.3 p30 -171.49 109.92 0.29 Allowed 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.663 176.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.608 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.8 t -45.27 -132.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.698 1.237 . . . . 0.0 112.582 177.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.526 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -138.76 80.99 0.27 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.613 ' O ' ' N ' ' F' ' 30' ' ' ALA . 28.6 m . . . . . 0 C--O 1.214 -0.808 0 CA-C-O 121.294 0.568 . . . . 0.0 110.734 -179.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.246 0.893 0 CA-C-O 121.473 0.654 . . . . 0.0 110.251 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.421 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 1.1 mt -148.57 126.09 2.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.946 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' L' ' 35' ' ' MET . 89.3 mt -128.99 128.15 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 120.901 0.381 . . . . 0.0 111.946 -178.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 121.34 4.69 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 47.9 tp -127.93 124.67 37.91 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.499 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 8.9 ttt -129.84 126.27 37.64 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 120.31 -0.556 . . . . 0.0 111.547 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 51.3 t -109.94 86.84 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -75.0 96.9 0.99 Allowed Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.2 170.8 43.1 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -128.45 135.06 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-O 120.911 0.386 . . . . 0.0 109.999 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.795 -179.791 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . 0.514 ' N ' ' CE1' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 79.8 t80 -84.66 130.82 34.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . 0.529 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 98.3 mt-10 -59.08 154.13 16.44 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.514 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 t -96.25 132.82 39.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.773 0.32 . . . . 0.0 110.703 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -153.13 113.98 4.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.204 0.526 . . . . 0.0 111.867 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -155.1 173.72 16.19 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -151.92 175.65 12.27 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.855 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -132.17 114.48 14.54 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.745 179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 49.0 tp -122.68 118.77 28.89 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 77.2 t -133.35 130.0 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -113.64 111.82 22.47 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 175.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -141.81 152.86 44.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.005 0.907 . . . . 0.0 112.244 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.46 149.14 29.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.291 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -136.79 144.39 43.7 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -178.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.571 ' CG ' ' H ' ' F' ' 24' ' ' VAL . 62.2 t0 177.75 -118.48 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.863 177.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.571 ' H ' ' CG ' ' F' ' 23' ' ' ASP . 13.2 p -102.18 126.41 56.23 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.568 0 CA-C-O 121.124 0.488 . . . . 0.0 110.659 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -31.4 -83.15 0.01 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.007 177.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 13.2 t 73.08 179.96 0.22 Allowed 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 124.456 1.102 . . . . 0.0 110.183 -176.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -89.42 172.7 8.82 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 118.544 2.794 . . . . 0.0 118.544 -173.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -39.09 106.33 0.05 Allowed 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 109.268 -3.605 . . . . 0.0 119.894 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.61 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . 148.02 -97.22 0.18 Allowed Glycine 0 N--CA 1.483 1.8 0 C-N-CA 120.492 -0.861 . . . . 0.0 115.224 171.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.613 ' N ' ' O ' ' E' ' 26' ' ' SER . . . 56.2 166.02 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 103.186 -2.894 . . . . 0.0 103.186 -173.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.444 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 1.6 mt -140.08 119.37 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 124.098 3.135 . . . . 0.0 111.447 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . 0.4 HD12 HG23 ' F' ' 32' ' ' ILE . 57.7 mt -123.87 136.23 60.92 Favored 'Isoleucine or valine' 0 C--N 1.347 0.483 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.512 -176.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.44 125.16 5.16 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 46.9 tp -118.64 120.8 38.51 Favored 'General case' 0 N--CA 1.47 0.54 0 O-C-N 122.642 -0.328 . . . . 0.0 110.229 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -118.37 119.38 34.45 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 116.952 -0.113 . . . . 0.0 111.098 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 p -153.21 82.47 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.763 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.531 ' H ' ' CD1' ' L' ' 31' ' ' ILE . . . -71.4 101.11 0.94 Allowed Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.26 161.51 34.51 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -141.86 143.7 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 110.604 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 t . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.4 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' G' ' 13' ' ' HIS . 6.3 p-80 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 120.666 0.269 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 8.2 m80 -81.72 167.92 18.63 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-O 121.126 0.489 . . . . 0.0 109.961 -179.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.447 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 51.0 tp60 -163.17 172.32 15.0 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.563 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.447 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 99.7 mttt -138.72 139.81 38.5 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -138.83 120.68 15.41 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.213 0.53 . . . . 0.0 110.902 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.41 134.36 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.767 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -129.2 125.31 36.7 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 120.939 0.4 . . . . 0.0 110.592 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.402 ' CD1' ' C ' ' G' ' 20' ' ' PHE . 19.5 t80 -113.46 123.26 49.61 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.17 131.81 53.16 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 121.805 0.812 . . . . 0.0 112.472 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' G' ' 23' ' ' ASP . 18.6 pt-20 -102.48 -173.08 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.771 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.483 ' N ' ' CB ' ' H' ' 23' ' ' ASP . 19.3 t70 -23.83 132.96 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' G' ' 26' ' ' SER . 11.7 t -89.33 113.56 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 114.197 -1.365 . . . . 0.0 108.162 177.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . -44.92 91.55 0.01 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.402 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.552 ' O ' ' O ' ' G' ' 27' ' ' ASN . 16.1 m 138.92 172.34 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.577 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.552 ' O ' ' O ' ' G' ' 26' ' ' SER . 90.9 m-20 -43.07 -178.67 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 O-C-N 123.429 0.456 . . . . 0.0 111.066 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -72.07 -114.7 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.767 178.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 50.32 91.33 0.01 OUTLIER Glycine 0 C--N 1.344 0.974 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.0 163.26 12.32 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 117.326 -1.75 . . . . 0.0 108.629 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.469 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -152.56 109.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 CA-C-N 112.966 -1.924 . . . . 0.0 109.618 -172.806 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.418 ' N ' ' SD ' ' A' ' 35' ' ' MET . 5.1 mt -100.95 111.05 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.25 99.0 0.68 Allowed Glycine 0 CA--C 1.503 -0.661 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.407 ' H ' HD23 ' H' ' 34' ' ' LEU . 12.0 mt -138.65 141.58 39.06 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-O 122.965 1.364 . . . . 0.0 111.572 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.65 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 38.0 ttp -109.66 114.96 29.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 112.957 -1.928 . . . . 0.0 107.158 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.41 66.03 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.78 110.92 4.02 Favored Glycine 0 C--N 1.359 1.828 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.63 178.99 0.11 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.8 m . . . . . 0 N--CA 1.467 0.422 0 CA-C-O 120.782 0.325 . . . . 0.0 110.749 179.781 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 78.2 t . . . . . 0 CA--C 1.521 -0.156 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' I' ' 13' ' ' HIS . 3.5 t60 -140.06 100.23 3.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.894 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 13.9 t-80 -141.88 159.07 42.97 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.631 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 71.1 mt-30 -162.0 178.52 8.78 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.966 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -130.51 132.4 45.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 69.0 mt -120.9 111.74 17.91 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.54 127.22 74.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.143 0.497 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -117.1 112.94 21.59 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.381 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.24 121.2 44.66 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.37 132.39 48.55 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.256 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -164.58 125.73 2.13 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 119.857 -0.737 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.483 ' CB ' ' N ' ' G' ' 23' ' ' ASP . 0.9 OUTLIER -176.64 109.36 0.08 Allowed 'General case' 0 CA--C 1.544 0.723 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.6 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.285 173.818 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.092 0 N-CA-C 105.728 -1.952 . . . . 0.0 105.728 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.2 129.6 9.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 118.735 -1.186 . . . . 0.0 112.429 -172.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.464 ' C ' ' SD ' ' B' ' 35' ' ' MET . 67.3 mt -112.64 117.63 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.351 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 102.06 0.91 Allowed Glycine 0 N--CA 1.466 0.648 0 N-CA-C 108.017 -2.033 . . . . 0.0 108.017 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.407 HD23 ' H ' ' G' ' 34' ' ' LEU . 89.7 mt -131.96 131.37 42.55 Favored 'General case' 0 CA--C 1.498 -1.025 0 CA-C-O 122.005 0.907 . . . . 0.0 112.791 -177.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 42.1 ttp -108.61 116.86 32.78 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.193 -1.367 . . . . 0.0 107.546 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.17 67.5 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.218 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 38' ' ' GLY . . . -94.04 110.91 4.06 Favored Glycine 0 C--N 1.372 2.568 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 37' ' ' GLY . . . 31.59 -159.57 0.0 OUTLIER Glycine 0 CA--C 1.524 0.616 0 CA-C-O 121.777 0.654 . . . . 0.0 113.06 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -138.97 159.55 29.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.74 -0.73 . . . . 0.0 109.385 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.633 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.546 ' O ' ' CG ' ' I' ' 13' ' ' HIS . 41.0 t . . . . . 0 N--CA 1.466 0.342 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.546 ' CG ' ' O ' ' I' ' 12' ' ' VAL . 71.6 m80 -159.39 173.12 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.979 0.419 . . . . 0.0 111.092 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 -179.44 4.66 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.547 ' OE1' ' N ' ' H' ' 15' ' ' GLN . 8.9 mm-40 -95.83 173.88 7.24 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-O 121.328 0.585 . . . . 0.0 111.741 -178.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -114.33 139.29 49.58 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -119.49 122.78 42.44 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 121.188 0.518 . . . . 0.0 111.706 -179.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -130.96 122.2 51.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.957 178.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -111.24 107.18 16.4 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.301 -1.741 . . . . 0.0 106.301 176.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -115.63 127.42 55.19 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 120.75 0.309 . . . . 0.0 111.04 -177.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.37 128.54 25.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 122.112 0.958 . . . . 0.0 112.796 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -108.88 164.75 12.12 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 175.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 27.3 t70 60.71 -110.64 0.45 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 116.83 -1.948 . . . . 0.0 108.653 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -45.63 132.1 2.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 122.743 1.259 . . . . 0.0 112.581 -175.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.67 82.84 0.76 Allowed Glycine 0 CA--C 1.519 0.322 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.022 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 5.3 p -99.07 172.52 7.34 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-O 121.547 0.689 . . . . 0.0 110.269 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.851 HD21 ' H ' ' I' ' 27' ' ' ASN . 0.5 OUTLIER -62.12 171.02 1.93 Allowed 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.037 175.56 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' J' ' 26' ' ' SER . 89.6 mttt 55.37 110.69 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.475 ' H ' ' CA ' ' J' ' 30' ' ' ALA . . . 67.53 92.37 0.05 OUTLIER Glycine 0 N--CA 1.474 1.168 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -173.86 156.11 2.74 Favored 'General case' 0 C--N 1.271 -2.816 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 177.1 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.458 ' C ' ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -142.09 117.75 5.87 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 C-N-CA 117.14 -1.824 . . . . 0.0 109.982 -174.448 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.601 ' N ' ' SD ' ' C' ' 35' ' ' MET . 16.1 tt -115.08 121.0 66.2 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-O 122.114 0.959 . . . . 0.0 111.174 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.31 99.38 1.11 Allowed Glycine 0 CA--C 1.505 -0.576 0 N-CA-C 105.819 -2.913 . . . . 0.0 105.819 176.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 tt -123.37 127.63 48.75 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 122.545 1.164 . . . . 0.0 111.245 -177.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttm -108.87 118.9 37.98 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 114.227 -1.352 . . . . 0.0 111.195 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.14 67.43 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 177.383 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -42.67 -103.26 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.67 -162.44 14.56 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -115.93 135.52 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.01 0.433 . . . . 0.0 110.48 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.784 -179.984 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.572 ' H ' ' CD2' ' K' ' 13' ' ' HIS . 0.1 OUTLIER . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.511 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 27.7 m170 -61.98 118.32 7.12 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 119.964 -0.694 . . . . 0.0 110.565 -179.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 2.7 t-80 -135.75 164.04 28.81 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 83.2 mt-30 -155.81 177.01 11.89 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.269 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -172.27 128.24 0.56 Allowed 'General case' 0 C--O 1.239 0.522 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.521 178.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mp -117.76 123.27 45.6 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.75 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -127.45 126.55 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.623 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -120.97 106.8 11.94 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -114.8 128.04 56.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.575 -0.703 . . . . 0.0 112.184 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.43 123.64 36.58 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-O 121.97 0.891 . . . . 0.0 111.617 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.452 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 81.2 mm-40 -128.11 113.08 15.3 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 114.414 -1.266 . . . . 0.0 110.479 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' J' ' 24' ' ' VAL . 30.9 t0 -174.79 138.31 0.48 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.816 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' J' ' 23' ' ' ASP . 3.7 m -16.95 -110.22 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -166.83 92.3 0.1 Allowed Glycine 0 CA--C 1.534 1.246 0 C-N-CA 119.83 -1.176 . . . . 0.0 113.892 -173.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' J' ' 27' ' ' ASN . 0.4 OUTLIER -63.26 -173.22 0.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.101 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' J' ' 26' ' ' SER . 77.5 m-20 -77.88 172.8 12.91 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 116.602 2.075 . . . . 0.0 116.602 -172.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.413 ' CE ' ' O ' ' K' ' 28' ' ' LYS . 6.5 mmtm -44.12 111.85 0.34 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 110.959 -2.837 . . . . 0.0 118.154 -177.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.84 94.42 1.56 Allowed Glycine 0 CA--C 1.501 -0.783 0 CA-C-N 114.209 -1.36 . . . . 0.0 114.501 176.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.475 ' CA ' ' H ' ' I' ' 29' ' ' GLY . . . -84.49 170.17 13.75 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 102.057 -3.312 . . . . 0.0 102.057 173.1 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.443 ' CG2' ' SD ' ' D' ' 35' ' ' MET . 0.4 OUTLIER -150.45 123.22 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 CA-C-N 120.985 1.72 . . . . 0.0 111.752 -177.294 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.492 ' CG1' ' CZ ' ' L' ' 20' ' ' PHE . 97.4 mt -109.89 117.27 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.385 178.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.14 102.08 1.17 Allowed Glycine 0 C--O 1.238 0.38 0 N-CA-C 106.282 -2.727 . . . . 0.0 106.282 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.438 ' CD1' ' CZ ' ' L' ' 19' ' ' PHE . 7.9 tt -132.74 139.18 47.48 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-O 121.675 0.75 . . . . 0.0 112.562 -176.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.8 ttp -123.7 125.74 45.3 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 114.734 -1.121 . . . . 0.0 112.6 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.0 OUTLIER -123.63 70.05 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.287 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -44.6 -100.78 0.01 OUTLIER Glycine 0 C--N 1.357 1.716 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.98 150.8 8.16 Favored Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.327 -0.37 0 CA-C-O 120.856 0.36 . . . . 0.0 110.224 179.912 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 N--CA 1.465 0.323 0 CA-C-O 120.717 0.294 . . . . 0.0 110.278 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 48.3 t -141.06 166.25 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.983 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.572 ' CD2' ' H ' ' J' ' 12' ' ' VAL . 1.2 m-70 -115.89 161.93 18.08 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.9 174.75 4.14 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-O 121.23 0.538 . . . . 0.0 109.868 -178.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -142.03 176.67 8.77 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.017 -179.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -149.42 135.47 18.93 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.051 0.453 . . . . 0.0 110.822 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -127.72 111.34 13.58 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 78.9 t -134.66 127.27 49.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' L' ' 20' ' ' PHE . 3.4 m-30 -113.31 141.37 47.11 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.484 ' HA ' ' HA ' ' L' ' 20' ' ' PHE . 77.9 t80 -136.4 117.87 14.77 Favored 'General case' 0 N--CA 1.505 2.311 0 CA-C-N 120.858 1.663 . . . . 0.0 114.128 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . 0.797 ' H ' ' H ' ' L' ' 21' ' ' ALA . . . -121.91 126.17 48.06 Favored 'General case' 0 C--N 1.398 2.707 0 CA-C-O 123.13 1.443 . . . . 0.0 112.061 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.567 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 82.5 tt0 -89.63 124.7 34.81 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.249 -178.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -123.87 131.81 53.64 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.063 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.42 113.64 11.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.175 179.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' K' ' 26' ' ' SER . . . 59.41 91.35 0.01 OUTLIER Glycine 0 CA--C 1.529 0.954 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.861 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' CB ' ' K' ' 27' ' ' ASN . 3.7 p -43.67 170.27 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.654 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER 157.49 -179.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 122.891 1.329 . . . . 0.0 114.007 178.873 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.654 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 52.4 mttp -29.62 112.49 0.08 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 119.365 3.098 . . . . 0.0 119.365 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.01 91.62 0.65 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 119.814 2.686 . . . . 0.0 119.814 173.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.465 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -143.62 155.22 44.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 101.916 -3.364 . . . . 0.0 101.916 170.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.481 HG22 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -145.96 121.39 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 118.553 -1.259 . . . . 0.0 111.158 -176.563 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' E' ' 35' ' ' MET . 96.7 mt -120.74 127.64 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.488 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.55 110.64 1.88 Allowed Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 178.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -121.63 118.65 29.71 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.224 -0.488 . . . . 0.0 110.637 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.447 ' SD ' ' C ' ' K' ' 35' ' ' MET . 6.2 tmm? -118.99 117.51 29.01 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.867 178.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -113.29 79.69 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 120.981 0.42 . . . . 0.0 110.162 178.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.29 100.58 2.59 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.72 172.78 42.64 Favored Glycine 0 CA--C 1.524 0.608 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.463 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.465 0.317 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.589 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t . . . . . 0 N--CA 1.467 0.382 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -158.0 107.39 2.08 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 120.872 0.368 . . . . 0.0 111.388 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 54.6 t-80 -153.81 166.95 31.29 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.522 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 84.5 mt-30 -152.7 178.88 9.14 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.129 0.49 . . . . 0.0 110.991 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -154.84 125.36 6.91 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.352 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -120.78 115.59 23.59 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.507 -0.121 . . . . 0.0 110.773 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -125.66 126.71 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.438 ' CZ ' ' CD1' ' J' ' 34' ' ' LEU . 5.0 m-30 -99.09 125.35 44.59 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.71 ' HB2' ' N ' ' K' ' 21' ' ' ALA . 1.6 p90 -32.47 159.9 0.0 OUTLIER 'General case' 0 C--O 1.158 -3.758 0 N-CA-C 121.05 3.722 . . . . 0.0 121.05 -172.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.797 ' H ' ' H ' ' K' ' 21' ' ' ALA . . . -78.62 157.14 28.77 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.068 174.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.456 ' OE1' ' O ' ' L' ' 20' ' ' PHE . 0.0 OUTLIER 178.67 -169.41 0.09 Allowed 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -177.114 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.562 ' OD1' ' N ' ' K' ' 27' ' ' ASN . 20.8 t0 -62.97 106.09 0.77 Allowed 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 87.0 t -36.16 142.84 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -178.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -98.75 82.94 0.61 Allowed Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 178.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 67.6 m -69.15 -171.69 0.35 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' L' ' 28' ' ' LYS . 96.3 m-20 -81.13 177.41 9.05 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.313 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.546 ' O ' ' O ' ' L' ' 27' ' ' ASN . 86.2 tttt 39.81 104.16 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 178.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.19 -101.19 1.85 Allowed Glycine 0 N--CA 1.467 0.715 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -177.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.465 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -61.88 170.0 2.29 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 118.222 1.011 . . . . 0.0 108.652 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.531 ' CD1' ' H ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -166.11 153.41 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 118.642 -1.223 . . . . 0.0 112.413 -177.885 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.7 mt -125.31 128.01 72.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.063 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.35 121.38 5.03 Favored Glycine 0 N--CA 1.469 0.853 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -119.77 118.62 31.35 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' E' ' 32' ' ' ILE . 3.9 ttp -117.36 119.94 36.64 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.474 ' O ' ' C ' ' L' ' 37' ' ' GLY . 35.8 m -130.46 76.29 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.643 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.474 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 23.9 -112.63 0.01 OUTLIER Glycine 0 C--N 1.352 1.428 0 N-CA-C 112.234 -0.346 . . . . 0.0 112.234 178.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.76 -150.56 15.97 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.51 158.29 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.816 0.341 . . . . 0.0 110.35 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.676 -179.636 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 . . . . . 0 N--CA 1.466 0.348 0 CA-C-O 120.853 0.359 . . . . 0.0 110.429 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -121.9 132.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -151.83 166.79 30.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.411 ' CD2' ' CE1' ' B' ' 13' ' ' HIS . 93.0 m-70 -132.13 179.5 6.06 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -95.25 177.43 5.86 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.587 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -116.37 145.31 43.32 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.893 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.7 tp -128.22 123.0 33.12 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 121.268 0.556 . . . . 0.0 111.872 -179.152 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.54 131.43 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.335 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -137.52 132.7 33.61 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.133 0.492 . . . . 0.0 111.599 -179.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.3 p90 -133.14 129.94 38.56 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.24 158.12 39.77 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.446 ' CB ' ' O ' ' B' ' 22' ' ' GLU . 22.5 pt-20 -143.88 150.65 38.75 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.915 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 . . . . . 0 N--CA 1.466 0.35 0 C-N-CA 119.706 -0.797 . . . . 0.0 111.202 -178.63 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.383 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.05 101.06 0.27 Allowed Glycine 0 CA--C 1.484 -1.891 0 N-CA-C 106.962 -2.455 . . . . 0.0 106.962 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.635 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . -83.33 151.79 25.4 Favored 'General case' 0 N--CA 1.438 -1.039 0 C-N-CA 114.861 -2.736 . . . . 0.0 108.78 -175.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' G' ' 35' ' ' MET 0.3 0.3 OUTLIER -166.34 108.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.41 -2.475 0 CA-C-N 109.253 -3.612 . . . . 0.0 104.97 -168.806 . . . . . . . . 4 4 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.465 ' N ' ' HE3' ' H' ' 35' ' ' MET . 17.8 tt -119.58 123.46 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 121.56 0.695 . . . . 0.0 110.032 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.573 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -124.3 116.8 2.91 Favored Glycine 0 CA--C 1.507 -0.468 0 N-CA-C 108.144 -1.982 . . . . 0.0 108.144 178.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 35.0 mt -136.21 148.15 47.97 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 122.905 1.336 . . . . 0.0 111.572 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.449 ' SD ' ' C ' ' G' ' 32' ' ' ILE . 12.0 ttm -121.18 124.0 43.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 112.475 -2.148 . . . . 0.0 109.362 -179.076 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.6 71.9 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.99 -96.47 0.01 OUTLIER Glycine 0 C--N 1.357 1.721 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 178.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.59 -162.76 36.55 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -131.0 160.76 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.855 0.359 . . . . 0.0 110.273 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.466 -179.662 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.04 140.71 47.61 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -110.57 137.65 47.98 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.909 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.7 159.95 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.815 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.589 ' HE2' HE21 ' B' ' 15' ' ' GLN . 79.9 t60 -140.64 124.02 16.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.37 -0.377 . . . . 0.0 109.999 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 p-80 -149.32 166.74 28.08 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 121.239 0.543 . . . . 0.0 109.846 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.589 HE21 ' HE2' ' B' ' 13' ' ' HIS . 76.9 mt-30 -153.84 179.72 8.62 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.592 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -163.71 109.12 1.06 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.059 179.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -130.31 118.72 21.72 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.77 131.36 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.347 0.594 . . . . 0.0 110.866 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.91 131.14 55.13 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.1 t80 -128.37 119.95 26.02 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 132.68 53.21 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.863 -179.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 22' ' ' GLU . 81.8 tt0 -155.15 133.37 11.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.295 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 60.6 t0 . . . . . 0 N--CA 1.469 0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.518 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.67 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.388 -7.855 0 CA-C-O 117.675 -1.625 . . . . 0.0 114.279 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.67 ' CB ' ' O ' ' B' ' 29' ' ' GLY 0.451 . . 113.93 -131.84 0.0 OUTLIER 'General case' 1 N--CA 1.366 -4.645 0 C-N-CA 114.019 -3.072 . . . . 0.0 106.355 -175.777 . . . . . . . . 4 3 . 1 . 002 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.57 ' CD1' ' N ' ' B' ' 31' ' ' ILE 0.366 2.2 mp -70.07 120.92 18.65 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.877 0 CA-C-N 109.245 -3.616 . . . . 0.0 113.458 175.045 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.9 tt -125.83 118.28 51.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 175.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.676 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -124.65 119.37 3.64 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 96.4 mt -136.61 131.25 33.48 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 122.901 1.334 . . . . 0.0 113.277 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.45 ' HE2' ' SD ' ' C' ' 35' ' ' MET . 33.7 tpp -113.34 118.23 33.99 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.545 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -122.53 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.3 103.6 2.49 Favored Glycine 0 C--N 1.358 1.753 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.72 162.63 19.5 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.9 t -133.99 138.18 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 120.699 0.285 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.349 -179.976 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 50.2 t . . . . . 0 N--CA 1.466 0.352 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -149.93 129.35 12.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.003 0.43 . . . . 0.0 111.005 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.558 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 71.8 t60 -138.47 166.21 24.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.558 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 83.4 mt-30 -156.18 169.64 24.06 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.915 178.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -157.81 108.49 2.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.727 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.5 tp -125.77 118.89 26.52 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -129.01 126.19 64.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.278 0.561 . . . . 0.0 112.029 -179.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.05 104.74 12.43 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -116.86 126.17 52.62 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.24 141.13 23.71 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-O 123.446 1.594 . . . . 0.0 115.09 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.457 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 93.5 mt-10 -137.5 73.75 1.46 Allowed 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.65 -2.523 . . . . 0.0 104.269 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.495 ' O ' ' CA ' ' B' ' 29' ' ' GLY . 25.1 t70 . . . . . 0 N--CA 1.467 0.402 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -175.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.457 -3.556 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.498 ' CB ' ' O ' ' B' ' 30' ' ' ALA . . . -153.23 162.81 40.89 Favored 'General case' 0 N--CA 1.38 -3.959 0 N-CA-C 101.618 -3.475 . . . . 0.0 101.618 177.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . 0.273 3.0 mp -126.63 115.95 43.47 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.283 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.448 -174.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.502 ' O ' ' SD ' ' J' ' 35' ' ' MET . 4.9 mt -101.37 110.38 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.022 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.61 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -121.81 109.15 1.41 Allowed Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 105.869 -2.892 . . . . 0.0 105.869 176.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.43 ' HG ' ' N ' ' C' ' 35' ' ' MET . 0.6 OUTLIER -147.42 147.66 30.48 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 123.493 1.616 . . . . 0.0 113.178 -177.061 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.621 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 29.6 ttm -122.9 128.02 49.75 Favored 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 112.0 -2.364 . . . . 0.0 109.101 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.436 ' CG1' ' O ' ' C' ' 36' ' ' VAL . 4.9 p -132.45 71.55 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.31 112.93 4.23 Favored Glycine 0 C--N 1.361 1.948 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.601 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.77 -144.34 0.07 OUTLIER Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.0 141.69 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 m . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 117.907 -1.044 . . . . 0.0 110.738 -179.824 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 121.26 0.553 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.54 -179.16 4.37 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.091 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.51 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 77.0 t60 -77.07 169.48 18.26 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.732 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.441 ' H ' ' CG ' ' D' ' 14' ' ' HIS . 87.5 mt-30 -146.3 176.91 9.41 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.529 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -151.42 113.88 4.6 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 120.477 -0.489 . . . . 0.0 112.053 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.0 117.6 22.82 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -142.71 149.22 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 -178.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 2.5 m-30 -118.89 120.61 37.82 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.749 -1.569 . . . . 0.0 108.894 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -117.5 118.94 33.56 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 118.39 0.541 . . . . 0.0 109.988 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.64 121.6 35.96 Favored 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.887 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -164.83 106.34 0.83 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 59.5 t0 . . . . . 0 CA--C 1.545 0.76 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 174.506 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.428 0 N-CA-C 102.341 -3.207 . . . . 0.0 102.341 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.61 123.59 3.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 117.865 -1.534 . . . . 0.0 112.351 -170.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.5 mt -111.32 119.46 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-O 121.315 0.578 . . . . 0.0 110.129 178.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.699 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -127.01 100.48 0.55 Allowed Glycine 0 C--N 1.311 -0.817 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.433 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.5 tt -124.92 130.58 52.65 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.04 0.924 . . . . 0.0 111.964 -177.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.54 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.4 ttt -112.89 123.32 50.04 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 114.056 -1.429 . . . . 0.0 110.365 179.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.82 78.15 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-N 116.262 -0.426 . . . . 0.0 109.987 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.1 105.13 0.08 OUTLIER Glycine 0 C--N 1.348 1.211 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.24 -154.1 2.66 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.17 143.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.09 0.472 . . . . 0.0 110.329 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.473 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -140.97 150.49 43.15 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.409 ' OE1' ' C ' ' F' ' 11' ' ' GLU . 79.4 mm-40 -142.3 140.03 32.04 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.204 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 59.4 t -128.79 133.58 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.315 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -78.34 -168.67 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.437 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 37.8 p-80 -146.73 177.32 9.18 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 120.988 0.423 . . . . 0.0 110.087 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -100.26 169.68 8.96 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.24 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.79 120.75 13.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.613 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -122.2 121.83 37.76 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.667 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -130.49 126.83 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 120.562 -0.455 . . . . 0.0 112.192 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE2' ' CD2' ' D' ' 19' ' ' PHE . 10.8 m-85 -115.88 115.6 26.51 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 176.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.516 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 66.3 t80 -123.74 124.97 43.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.666 -177.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.9 139.74 41.83 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-O 121.114 0.483 . . . . 0.0 111.218 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.516 ' OE2' ' CZ ' ' E' ' 20' ' ' PHE . 8.6 mm-40 -108.49 119.88 40.79 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -166.81 101.18 0.56 Allowed 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.345 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -73.35 -158.84 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.711 0.767 . . . . 0.0 112.084 -178.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 62.17 79.61 0.13 Allowed Glycine 0 CA--C 1.526 0.776 0 CA-C-N 114.233 -1.349 . . . . 0.0 111.842 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.566 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 26.3 t . . . . . 0 N--CA 1.441 -0.89 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.245 0.832 0 CA-C-O 122.108 0.956 . . . . 0.0 110.39 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 1.0 OUTLIER -147.16 124.29 3.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.302 -1.317 . . . . 0.0 107.819 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 77.9 mt -123.19 130.24 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-O 120.958 0.409 . . . . 0.0 112.048 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.31 121.1 3.23 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 18.6 tp -125.7 123.36 38.72 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.629 -0.285 . . . . 0.0 110.812 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 12.8 ttt -117.86 117.81 30.3 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.219 178.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.6 t -122.54 83.81 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -16.34 -95.19 0.01 OUTLIER Glycine 0 N--CA 1.471 1.03 0 O-C-N 123.404 0.44 . . . . 0.0 112.833 -179.118 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.33 176.57 18.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 m -100.53 142.61 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 0.0 110.245 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.478 -179.865 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -82.88 137.47 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.704 0.288 . . . . 0.0 110.624 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . 0.409 ' C ' ' OE1' ' E' ' 11' ' ' GLU . 82.4 tt0 -159.03 159.85 35.2 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.467 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -80.93 131.07 34.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -85.36 146.69 26.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.837 0.351 . . . . 0.0 111.364 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 83.5 m-70 -94.88 179.49 5.22 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -79.82 166.25 21.91 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 120.12 -0.632 . . . . 0.0 110.767 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -135.96 118.8 16.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 22.7 mt -122.5 120.45 33.91 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.28 130.9 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.209 0.528 . . . . 0.0 112.266 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -119.64 123.83 44.81 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -139.69 130.93 26.64 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.589 0.709 . . . . 0.0 112.025 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.23 133.96 51.35 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.554 178.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.44 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 81.0 tt0 -76.65 90.48 3.38 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.937 -178.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' E' ' 26' ' ' SER . 15.7 t70 173.87 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.632 178.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 m -58.85 130.72 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.379 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.85 85.31 0.16 Allowed Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.419 -0.896 . . . . 0.0 111.709 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.9 p -64.67 -174.45 0.14 Allowed 'General case' 0 N--CA 1.442 -0.829 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.443 ' O ' ' O ' ' F' ' 28' ' ' LYS . 21.2 m120 -90.7 178.59 6.03 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 119.876 -0.73 . . . . 0.0 109.61 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.3 mttt 27.95 102.12 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 113.099 0.778 . . . . 0.0 113.099 177.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.72 -101.62 0.24 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 120.134 -1.032 . . . . 0.0 113.662 177.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.81 167.47 0.77 Allowed 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.08 126.86 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 118.105 -1.438 . . . . 0.0 111.416 -176.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 5.1 mp -127.39 133.01 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.193 -178.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.7 131.8 6.33 Favored Glycine 0 N--CA 1.469 0.893 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -127.23 125.48 41.07 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 24.4 ttt -128.37 126.68 41.17 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.818 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -118.17 81.15 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.438 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -45.29 100.9 0.02 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.873 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.82 162.01 35.78 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -136.14 145.96 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 120.788 0.327 . . . . 0.0 110.454 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.875 -1.059 . . . . 0.0 110.68 -179.647 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 . . . . . 0 CA--C 1.527 0.075 0 CA-C-O 120.691 0.282 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.424 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 22.8 m80 -97.55 178.65 5.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -118.26 -177.08 3.2 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.23 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.59 154.44 17.92 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.174 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.1 tp -131.15 118.23 20.19 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.088 0.47 . . . . 0.0 110.439 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -124.94 131.03 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.752 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 t80 -129.98 127.96 41.09 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.036 0.446 . . . . 0.0 110.304 179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.523 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -130.3 128.59 41.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.89 123.04 46.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.981 0.42 . . . . 0.0 110.505 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' G' ' 23' ' ' ASP . 43.6 tt0 -141.06 142.28 34.19 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.913 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.48 ' O ' ' O ' ' G' ' 22' ' ' GLU . 97.5 m-20 50.54 113.88 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.937 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.545 ' N ' ' OD2' ' H' ' 23' ' ' ASP . 70.0 t -149.34 112.84 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.283 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.21 -91.02 0.01 OUTLIER Glycine 0 CA--C 1.529 0.924 0 CA-C-O 121.466 0.481 . . . . 0.0 112.898 177.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.78 ' O ' ' O ' ' G' ' 27' ' ' ASN . 21.2 p -161.76 174.57 13.03 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.78 ' O ' ' O ' ' G' ' 26' ' ' SER . 81.7 m-20 -9.42 160.03 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 17.1 pttp 179.26 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.1 100.93 0.68 Allowed Glycine 0 N--CA 1.469 0.898 0 N-CA-C 107.061 -2.416 . . . . 0.0 107.061 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.42 157.43 22.48 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 123.473 1.606 . . . . 0.0 113.301 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.83 111.61 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 CA-C-N 111.766 -2.47 . . . . 0.0 108.671 -178.197 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.449 ' C ' ' SD ' ' A' ' 35' ' ' MET . 1.9 mt -99.1 109.25 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.59 105.75 1.04 Allowed Glycine 0 CA--C 1.504 -0.645 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 18.1 mt -139.46 145.32 38.67 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 123.061 1.41 . . . . 0.0 112.709 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 48.4 ttp -113.87 114.24 25.98 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.538 -1.664 . . . . 0.0 106.803 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.1 71.0 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -157.1 95.98 0.15 Allowed Glycine 0 C--N 1.355 1.604 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -138.16 -176.87 14.78 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m . . . . . 0 N--CA 1.464 0.271 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.907 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 N--CA 1.465 0.29 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -152.57 97.67 2.28 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.429 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.424 ' CE1' ' O ' ' G' ' 14' ' ' HIS . 54.2 p-80 -108.1 166.45 10.72 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -152.54 168.9 24.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.778 0.799 . . . . 0.0 111.377 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -169.58 117.35 0.6 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.71 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -122.33 118.5 28.63 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -121.03 124.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.474 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 83.5 m-85 -119.7 106.55 12.24 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -116.41 124.65 50.55 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.455 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.98 130.04 49.28 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.813 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -159.33 114.78 2.49 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.823 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.545 ' OD2' ' N ' ' G' ' 24' ' ' VAL . 28.5 t0 -174.65 123.3 0.27 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 178.343 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' H' ' 23' ' ' ASP . 13.0 t . . . . . 0 N--CA 1.465 0.307 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.911 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.323 0 N-CA-C 101.077 -3.675 . . . . 0.0 101.077 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -134.08 118.72 29.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 118.005 -1.478 . . . . 0.0 109.835 -178.295 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.428 HD11 HG23 ' H' ' 32' ' ' ILE . 1.3 mt -109.78 115.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.461 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.44 97.42 0.68 Allowed Glycine 0 CA--C 1.508 -0.345 0 N-CA-C 106.914 -2.475 . . . . 0.0 106.914 176.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 mp -127.02 133.51 50.51 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-O 122.552 1.168 . . . . 0.0 111.456 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.676 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 43.7 ttp -111.16 117.38 33.08 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-N 113.595 -1.639 . . . . 0.0 107.895 178.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -113.05 67.65 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.957 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.81 -101.62 0.01 OUTLIER Glycine 0 C--N 1.352 1.446 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.56 164.85 11.53 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.27 141.71 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.765 -179.936 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' I' ' 13' ' ' HIS . 43.1 t . . . . . 0 N--CA 1.468 0.455 0 CA-C-O 120.977 0.418 . . . . 0.0 111.331 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.693 ' CG ' ' H ' ' I' ' 14' ' ' HIS . 44.6 t-80 -125.82 -172.35 2.58 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.047 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.693 ' H ' ' CG ' ' I' ' 13' ' ' HIS . 0.1 OUTLIER -76.45 166.65 23.12 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.204 0.526 . . . . 0.0 109.795 -179.205 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -148.65 170.68 17.59 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.174 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -150.35 137.78 19.68 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 121.041 -0.264 . . . . 0.0 111.149 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 52.8 mt -130.99 124.5 31.09 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.33 137.83 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.474 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 60.8 m-85 -120.44 123.85 44.01 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.136 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.626 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 3.4 t80 -124.27 124.44 42.42 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.101 -177.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.83 126.05 42.7 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 122.49 1.138 . . . . 0.0 113.451 -178.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -154.28 82.83 1.12 Allowed 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.462 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.473 ' OD2' ' O ' ' H' ' 23' ' ' ASP . 13.1 t70 -105.79 -114.13 0.25 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.667 ' O ' ' N ' ' I' ' 26' ' ' SER . 58.2 t -85.45 130.69 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.933 0 N-CA-C 104.426 -2.435 . . . . 0.0 104.426 176.088 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.551 ' CA ' ' H ' ' J' ' 24' ' ' VAL . . . -42.98 82.66 0.0 OUTLIER Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.189 -1.005 . . . . 0.0 111.974 -176.117 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.667 ' N ' ' O ' ' I' ' 24' ' ' VAL . 11.4 p -65.63 -176.2 0.33 Allowed 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 177.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.492 ' O ' ' O ' ' I' ' 28' ' ' LYS . 0.2 OUTLIER -81.42 179.2 7.95 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.671 177.631 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' I' ' 27' ' ' ASN . 85.0 tttt -42.39 -106.42 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.984 0.897 . . . . 0.0 110.036 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.668 ' O ' ' N ' ' J' ' 31' ' ' ILE . . . -82.8 96.98 1.92 Allowed Glycine 0 CA--C 1.45 -3.973 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.562 ' O ' ' C ' ' I' ' 29' ' ' GLY . . . -68.73 -151.17 0.01 OUTLIER 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 101.899 -3.371 . . . . 0.0 101.899 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.708 ' CD1' ' N ' ' I' ' 31' ' ' ILE . 0.0 OUTLIER -102.62 104.01 15.89 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 CA-C-N 123.782 2.992 . . . . 0.0 109.964 -176.0 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.621 ' N ' ' SD ' ' C' ' 35' ' ' MET . 2.6 mt -107.11 114.2 45.48 Favored 'Isoleucine or valine' 0 C--N 1.362 1.131 0 CA-C-N 113.765 -1.561 . . . . 0.0 111.126 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.409 ' N ' ' CE ' ' B' ' 35' ' ' MET . . . -115.54 97.98 0.82 Allowed Glycine 0 C--O 1.242 0.641 0 N-CA-C 105.502 -3.039 . . . . 0.0 105.502 175.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.78 132.83 46.67 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-O 122.268 1.032 . . . . 0.0 111.077 -177.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.61 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.0 ttp -113.68 121.55 44.46 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.345 -178.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.51 70.03 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 177.126 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -41.12 -100.66 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.81 -160.59 33.68 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 54.7 t -122.46 134.94 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 120.859 0.361 . . . . 0.0 110.04 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 70.1 t . . . . . 0 C--O 1.218 -0.582 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.604 -179.984 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.463 0.199 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -146.45 135.62 22.68 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.054 0.454 . . . . 0.0 111.523 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -152.43 155.94 38.53 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -153.38 173.64 15.38 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.441 0.639 . . . . 0.0 111.706 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -155.93 129.33 8.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.596 -1.184 . . . . 0.0 107.887 178.275 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.84 116.94 24.52 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.5 123.62 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.253 0.549 . . . . 0.0 110.896 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -120.88 109.06 14.67 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 179.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.626 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 3.7 p90 -148.94 151.36 34.48 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 117.772 -1.571 . . . . 0.0 114.649 -178.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.01 155.88 34.96 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.156 -1.384 . . . . 0.0 111.169 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -127.22 144.03 51.13 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -178.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.468 ' CG ' ' O ' ' I' ' 26' ' ' SER . 10.9 t0 -103.68 134.26 47.31 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.867 178.179 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.551 ' H ' ' CA ' ' I' ' 25' ' ' GLY . 57.4 t -110.43 111.78 37.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.661 179.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.23 90.37 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 N-CA-C 115.708 1.043 . . . . 0.0 115.708 174.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.613 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.8 p 170.68 174.83 0.06 Allowed 'General case' 0 C--N 1.343 0.324 0 CA-C-N 118.369 1.084 . . . . 0.0 111.379 176.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.8 m120 -28.04 -179.55 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.563 ' HZ2' ' CB ' ' K' ' 26' ' ' SER . 55.3 tttt -130.51 -107.31 0.27 Allowed 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.748 1.388 . . . . 0.0 114.748 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 41.61 91.81 0.01 OUTLIER Glycine 0 N--CA 1.481 1.677 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 -176.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' I' ' 29' ' ' GLY . . . -140.61 157.73 45.02 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -177.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.668 ' N ' ' O ' ' I' ' 29' ' ' GLY . 0.1 OUTLIER -146.18 128.11 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.53 0 CA-C-O 121.461 0.648 . . . . 0.0 112.506 -178.286 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.54 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.3 tt -109.25 118.41 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.52 101.66 0.99 Allowed Glycine 0 N--CA 1.47 0.963 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.05 131.68 50.88 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-O 121.431 0.634 . . . . 0.0 112.583 -177.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.699 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.2 ttp -113.82 120.6 41.3 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.015 178.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.74 67.46 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.97 121.4 9.58 Favored Glycine 0 C--N 1.355 1.593 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.54 -136.8 0.03 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 N--CA 1.466 0.366 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.535 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 . . . . . 0 N--CA 1.464 0.271 0 CA-C-O 120.695 0.284 . . . . 0.0 110.797 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 m -139.83 134.21 37.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.156 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -124.3 119.17 28.52 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.315 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.89 162.55 24.15 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-O 121.485 0.66 . . . . 0.0 109.444 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' L' ' 15' ' ' GLN . 85.4 mt-30 -151.35 178.78 8.92 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.353 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -172.69 128.15 0.51 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -124.39 123.44 40.18 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.825 0.345 . . . . 0.0 110.117 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.48 125.38 65.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.74 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -115.77 114.92 25.44 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -122.05 123.64 42.09 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.01 128.08 39.62 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 121.49 0.662 . . . . 0.0 111.31 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -99.12 128.29 45.22 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 120.176 -0.609 . . . . 0.0 111.782 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.421 ' CG ' ' O ' ' L' ' 22' ' ' GLU . 9.2 p-10 -142.86 136.58 28.84 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.116 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.1 112.27 24.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.577 -176.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.69 91.5 0.01 OUTLIER Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.563 ' CB ' ' HZ2' ' J' ' 28' ' ' LYS . 5.4 t -42.32 154.63 0.05 Allowed 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.64 -0.78 . . . . 0.0 110.931 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.545 ' H ' ' CD ' ' J' ' 28' ' ' LYS . 84.7 m-20 -126.97 -179.86 5.05 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.746 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.401 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.7 mttt -30.12 107.29 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.473 1.286 . . . . 0.0 114.473 -177.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.36 -96.48 1.74 Allowed Glycine 0 N--CA 1.47 0.93 0 CA-C-N 113.996 -1.456 . . . . 0.0 116.208 172.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.535 ' CB ' ' HZ1' ' J' ' 28' ' ' LYS . . . 72.22 153.28 0.13 Allowed 'General case' 0 C--O 1.249 1.051 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 -174.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.425 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.2 OUTLIER -149.65 127.47 2.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 117.001 -1.88 . . . . 0.0 111.82 -176.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.504 ' O ' ' CE ' ' E' ' 35' ' ' MET . 82.7 mt -118.84 120.08 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.001 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -119.93 107.86 1.39 Allowed Glycine 0 N--CA 1.467 0.749 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 mt -121.43 120.6 35.45 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -117.97 124.78 49.03 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.188 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.05 80.77 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.799 178.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.8 102.87 0.61 Allowed Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.78 -146.79 18.03 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.661 -179.913 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t . . . . . 0 N--CA 1.465 0.294 0 CA-C-O 121.137 0.494 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -155.24 140.29 17.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.694 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -150.4 171.46 16.98 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 89.0 mt-30 -147.02 173.53 12.37 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.464 0.65 . . . . 0.0 111.228 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -155.55 130.26 9.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.494 179.157 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . 0.445 ' C ' ' CD2' ' L' ' 17' ' ' LEU . 7.6 tt -132.5 125.31 30.31 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -129.39 129.21 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 121.147 0.499 . . . . 0.0 111.835 -179.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -113.43 114.27 26.34 Favored 'General case' 0 C--N 1.341 0.215 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -140.64 136.83 33.1 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 122.104 0.954 . . . . 0.0 112.249 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.16 151.84 30.58 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.386 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.421 ' O ' ' CG ' ' K' ' 23' ' ' ASP . 81.8 tt0 -75.11 95.15 3.02 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.991 -178.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' L' ' 24' ' ' VAL . 67.9 t0 -175.36 136.1 0.35 Allowed 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.981 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.522 ' N ' ' OD1' ' L' ' 23' ' ' ASP . 33.5 m -71.02 111.28 4.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.95 -91.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.007 0 CA-C-N 114.894 -1.048 . . . . 0.0 115.528 -176.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 10.0 p -71.24 176.67 4.36 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 122.967 1.365 . . . . 0.0 114.362 -175.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.541 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 4.9 t-20 85.89 178.65 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 111.412 -2.631 . . . . 0.0 114.486 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.541 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.1 mttt -40.99 104.49 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 116.61 2.078 . . . . 0.0 116.61 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.0 -101.24 0.3 Allowed Glycine 0 N--CA 1.473 1.161 0 N-CA-C 115.823 1.089 . . . . 0.0 115.823 173.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -58.37 172.8 0.43 Allowed 'General case' 0 CA--C 1.508 -0.636 0 CA-C-O 119.106 -0.474 . . . . 0.0 111.335 -177.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.602 ' CD1' ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -134.78 118.6 25.82 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 C-N-CA 118.405 -1.318 . . . . 0.0 111.148 179.661 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.62 133.23 68.75 Favored 'Isoleucine or valine' 0 C--O 1.23 0.072 0 CA-C-N 113.77 -1.559 . . . . 0.0 109.786 -178.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.3 118.88 2.49 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.381 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.6 mp -114.5 124.34 51.65 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 177.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.9 tmm? -117.51 120.53 38.37 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.616 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.72 81.13 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.549 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 44.13 -101.39 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.53 -169.29 37.76 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.82 136.24 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.904 0.383 . . . . 0.0 110.672 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.813 179.726 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 N--CA 1.466 0.327 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.51 133.55 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 120.952 0.406 . . . . 0.0 110.737 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -135.8 -175.7 4.05 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.067 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -80.03 164.79 23.16 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-O 121.23 0.538 . . . . 0.0 109.836 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -153.5 177.45 10.9 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.462 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -147.57 131.34 16.99 Favored 'General case' 0 N--CA 1.466 0.374 0 C-N-CA 121.118 -0.233 . . . . 0.0 110.809 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -133.4 115.44 14.84 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.326 0.584 . . . . 0.0 110.135 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.63 133.44 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.072 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -145.72 148.93 33.54 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.681 0.753 . . . . 0.0 111.511 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 p90 -135.92 149.3 48.9 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.717 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.81 136.54 27.24 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 122.275 1.035 . . . . 0.0 113.312 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' A' ' 23' ' ' ASP . 98.8 mt-10 -111.51 178.72 4.24 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.532 -1.667 . . . . 0.0 107.705 177.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.519 ' H ' ' CB ' ' B' ' 23' ' ' ASP . 95.7 m-20 . . . . . 0 C--N 1.33 -0.256 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 122.016 0.912 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.3 99.2 2.59 Favored Glycine 0 CA--C 1.493 -1.289 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.205 -176.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.18 160.66 20.83 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.392 -176.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.519 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -146.74 111.79 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.775 -175.295 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 46.8 mt -121.29 104.88 15.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 177.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.641 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -113.96 114.2 3.26 Favored Glycine 0 CA--C 1.502 -0.78 0 N-CA-C 105.827 -2.909 . . . . 0.0 105.827 176.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 5.6 tp -146.04 144.93 30.37 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 122.754 1.264 . . . . 0.0 113.382 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.597 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 17.5 ttm -112.91 117.36 31.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.888 178.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.89 67.3 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 177.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.3 -101.71 0.01 OUTLIER Glycine 0 C--N 1.366 2.21 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.95 -166.13 39.21 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.97 158.08 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.836 0.35 . . . . 0.0 110.735 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.915 -1.04 . . . . 0.0 110.533 -179.866 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -105.2 132.95 50.76 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -137.85 160.53 39.03 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.114 0.483 . . . . 0.0 111.14 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 50.9 t -122.41 134.45 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.893 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -109.07 114.83 28.9 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.985 0.421 . . . . 0.0 111.445 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.47 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 83.5 t60 -142.23 160.45 40.22 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.47 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 78.9 mt-30 -159.27 179.11 9.28 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.13 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -161.35 119.02 2.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.519 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -130.61 122.64 27.83 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.12 137.12 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 121.066 0.46 . . . . 0.0 110.582 178.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -128.87 138.33 51.96 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.879 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -123.15 131.49 53.71 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.21 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.48 125.71 29.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 120.673 -0.411 . . . . 0.0 111.86 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 82.5 tt0 -170.82 139.76 1.53 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.448 179.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.519 ' CB ' ' H ' ' A' ' 23' ' ' ASP . 14.3 p-10 . . . . . 0 C--N 1.344 0.329 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.429 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.445 ' O ' HG13 ' C' ' 31' ' ' ILE . . . -104.99 154.35 20.23 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 103.294 -2.854 . . . . 0.0 103.294 176.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 2.0 mt -139.8 108.14 3.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.753 -173.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' B' ' 32' ' ' ILE . 5.1 tt -122.37 116.55 49.4 Favored 'Isoleucine or valine' 0 C--O 1.241 0.646 0 CA-C-O 122.069 0.938 . . . . 0.0 109.619 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.667 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -127.99 117.92 2.72 Favored Glycine 0 N--CA 1.453 -0.188 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 mp -141.91 149.93 40.83 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-O 123.147 1.451 . . . . 0.0 113.214 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 24.2 ttm -121.69 118.75 29.9 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 112.769 -2.014 . . . . 0.0 107.822 177.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -112.57 68.71 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -179.6 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.82 -101.5 0.12 Allowed Glycine 0 C--N 1.352 1.417 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.599 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.41 167.71 35.49 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.4 m -131.74 161.92 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.906 0.384 . . . . 0.0 110.242 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.648 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.466 0.337 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -117.26 136.98 52.7 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 120.723 0.297 . . . . 0.0 111.57 -178.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 24.0 t-80 -141.37 163.2 33.6 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.663 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 83.0 mt-30 -156.03 169.74 23.77 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 121.183 0.516 . . . . 0.0 111.064 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -155.91 115.98 3.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.443 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 44.4 tp -121.5 124.09 43.6 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -133.38 127.28 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 113.466 0.913 . . . . 0.0 113.466 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 50.6 m-85 -117.47 119.29 34.61 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -122.46 126.37 47.75 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 117.827 0.285 . . . . 0.0 111.421 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.12 149.2 37.79 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 115.435 1.642 . . . . 0.0 115.435 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 28.0 mt-10 -154.45 138.69 16.59 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 114.398 -1.274 . . . . 0.0 110.857 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 26.2 t0 . . . . . 0 N--CA 1.484 1.273 0 N-CA-C 114.504 1.298 . . . . 0.0 114.504 176.782 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.477 -2.308 0 CA-C-O 117.522 -1.71 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.426 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -149.75 134.51 17.73 Favored 'General case' 0 CA--C 1.47 -2.113 0 C-N-CA 115.933 -2.307 . . . . 0.0 108.115 173.044 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.445 HG13 ' O ' ' B' ' 30' ' ' ALA 0.274 3.5 mt -138.78 102.22 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 CA-C-N 110.469 -3.059 . . . . 0.0 105.045 -175.837 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.515 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.9 mt -109.19 118.14 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-N 115.059 -0.973 . . . . 0.0 111.427 -176.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.708 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -129.92 99.08 0.44 Allowed Glycine 0 CA--C 1.5 -0.901 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.169 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.403 HD23 ' CZ ' ' D' ' 19' ' ' PHE . 3.7 mp -132.05 147.35 52.44 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 122.64 1.209 . . . . 0.0 111.924 -177.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.494 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 26.7 ttm -129.01 127.94 42.64 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.87 -1.968 . . . . 0.0 110.375 -179.098 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.75 72.24 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.9 102.76 2.39 Favored Glycine 0 C--N 1.364 2.102 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 -178.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.4 154.61 25.86 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.0 m -134.72 161.57 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-O 120.735 0.302 . . . . 0.0 110.477 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.256 179.664 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -85.78 166.42 16.09 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.884 0.373 . . . . 0.0 110.097 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.563 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 43.7 p-80 -76.52 175.11 9.54 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.225 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -140.62 173.36 11.57 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.189 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -141.04 130.75 24.17 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.494 0.664 . . . . 0.0 112.258 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 49.5 tp -122.54 120.31 33.46 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.761 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 19.8 t -134.79 128.35 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.522 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 65.2 m-85 -125.46 115.32 20.06 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.771 177.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' D' ' 20' ' ' PHE . 0.0 OUTLIER -147.84 159.09 44.21 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 122.786 1.279 . . . . 0.0 113.949 179.129 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.74 156.33 38.91 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.867 -1.515 . . . . 0.0 112.013 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 33.1 mt-10 -148.24 141.71 25.35 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.685 -179.559 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.514 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.8 OUTLIER . . . . . 0 N--CA 1.476 0.867 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.447 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.457 -2.597 0 CA-C-O 122.819 1.295 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.98 99.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.062 0 CA-C-N 112.083 -2.326 . . . . 0.0 106.144 -176.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 mt -108.16 124.61 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.427 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.743 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.08 100.55 0.58 Allowed Glycine 0 C--N 1.309 -0.934 0 N-CA-C 105.331 -3.108 . . . . 0.0 105.331 174.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.79 120.7 35.37 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.524 0.678 . . . . 0.0 110.148 -177.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.471 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.5 ttt -112.99 115.43 28.37 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.682 -1.145 . . . . 0.0 108.068 178.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -112.43 77.31 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.495 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -4.12 -101.93 0.0 OUTLIER Glycine 0 C--N 1.368 2.324 0 O-C-N 123.608 0.568 . . . . 0.0 112.899 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.5 -170.62 39.72 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.59 159.73 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.436 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -139.82 123.67 17.52 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 120.744 0.306 . . . . 0.0 110.636 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -136.96 139.69 41.68 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.349 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -133.87 138.76 49.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 -139.74 126.86 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.37 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.576 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 45.4 t-80 -156.08 167.2 31.16 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.898 0.856 . . . . 0.0 110.952 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.576 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 47.5 tt0 -164.02 168.24 19.46 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.307 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.499 ' HZ3' ' CG2' ' E' ' 18' ' ' VAL . 53.8 tttm -135.44 120.19 18.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.465 178.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 36.1 mt -107.34 118.83 37.75 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . 0.499 ' CG2' ' HZ3' ' E' ' 16' ' ' LYS . 21.5 t -128.96 121.58 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -115.62 115.76 26.97 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 176.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' F' ' 20' ' ' PHE . 25.3 t80 -142.21 149.09 39.2 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.078 1.51 . . . . 0.0 115.078 -175.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . 0.426 ' N ' ' CD1' ' E' ' 20' ' ' PHE . . . -149.73 138.63 21.06 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -110.97 111.85 23.26 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.432 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' O ' ' C ' ' E' ' 24' ' ' VAL . 0.3 OUTLIER 176.37 122.52 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -178.049 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.456 ' C ' ' O ' ' E' ' 23' ' ' ASP . 41.5 t -37.32 117.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 121.595 0.712 . . . . 0.0 110.332 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.81 89.6 0.48 Allowed Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.919 -178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 46.7 t . . . . . 0 N--CA 1.447 -0.624 0 CA-C-O 122.616 1.198 . . . . 0.0 111.765 -177.386 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.41 ' O ' HG22 ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.239 0.516 0 N-CA-C 105.575 -2.009 . . . . 0.0 105.575 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.461 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.1 OUTLIER -148.16 128.54 4.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 121.543 0.687 . . . . 0.0 111.086 -178.548 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 91.9 mt -128.19 128.59 68.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.109 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.4 124.58 5.64 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tt -130.17 121.71 26.79 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.513 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 9.4 ttt -123.15 125.37 45.01 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 121.065 -0.254 . . . . 0.0 111.477 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.3 t -127.59 78.64 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.496 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 13.77 -109.25 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 N-CA-C 114.107 0.403 . . . . 0.0 114.107 177.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -150.1 165.27 29.8 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -130.28 136.3 58.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' F' ' 39' ' ' VAL . 46.3 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.358 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -108.15 136.12 48.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.814 0.34 . . . . 0.0 110.609 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.23 133.83 47.7 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.245 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.71 135.27 51.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 31.3 p-80 -155.91 128.09 7.59 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.041 0.448 . . . . 0.0 111.593 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 62.5 m80 -151.09 171.58 17.13 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -151.1 171.16 17.78 Favored 'General case' 0 C--N 1.313 -1.015 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.331 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -141.71 127.2 18.89 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.67 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.57 126.78 54.65 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.74 119.76 52.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.13 0.49 . . . . 0.0 111.934 -178.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -113.7 105.93 13.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' E' ' 20' ' ' PHE . 5.7 m-85 -139.29 131.28 27.85 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 122.608 1.195 . . . . 0.0 112.558 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . 0.434 ' O ' ' OD1' ' F' ' 23' ' ' ASP . . . -148.94 163.16 38.29 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.357 178.818 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -71.15 85.03 0.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.818 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 11.1 p30 -165.3 112.77 0.98 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.844 178.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.58 ' O ' ' N ' ' F' ' 26' ' ' SER . 98.1 t -70.74 132.55 33.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.583 178.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.6 83.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.206 -1.558 . . . . 0.0 109.206 177.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.58 ' N ' ' O ' ' F' ' 24' ' ' VAL . 13.1 p -66.07 -174.18 0.23 Allowed 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 122.492 1.139 . . . . 0.0 112.276 -177.14 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -81.63 179.08 7.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 112.722 -2.036 . . . . 0.0 111.719 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -37.25 104.22 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.553 -0.748 . . . . 0.0 109.66 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.404 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 167.88 -100.67 0.17 Allowed Glycine 0 C--O 1.217 -0.956 0 N-CA-C 108.843 -1.703 . . . . 0.0 108.843 -174.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.24 166.02 0.08 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 119.674 1.737 . . . . 0.0 107.659 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.404 HG12 ' O ' ' F' ' 29' ' ' GLY . 0.1 OUTLIER -143.43 130.31 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 118.093 -1.443 . . . . 0.0 112.604 -175.123 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -128.98 122.87 57.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.909 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 122.34 5.41 Favored Glycine 0 N--CA 1.468 0.833 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 36.7 mt -119.66 120.37 36.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' L' ' 32' ' ' ILE . 19.9 ttt -130.88 134.53 46.87 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.873 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 p -156.96 89.41 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.742 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.39 94.83 0.23 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.757 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.81 167.77 29.91 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.706 -0.957 . . . . 0.0 110.706 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' E' ' 40' ' ' VAL . 30.9 m -132.08 157.12 43.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.893 0.378 . . . . 0.0 110.531 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.697 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.601 0.239 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' H' ' 14' ' ' HIS . 57.0 p-80 -152.93 169.98 21.52 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? -154.31 170.54 21.06 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.379 179.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.6 mttm -156.63 164.27 38.37 Favored 'General case' 0 C--O 1.222 -0.37 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.747 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 2.9 mp -146.71 175.93 10.24 Favored 'General case' 0 C--O 1.172 -3.02 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . 0.968 ' C ' ' O ' ' H' ' 18' ' ' VAL . 94.0 t -156.62 170.51 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 118.724 -2.485 . . . . 0.0 110.099 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' H' ' 18' ' ' VAL . 26.3 p90 -162.58 105.2 1.09 Allowed 'General case' 0 C--O 1.169 -3.169 0 O-C-N 121.375 -0.828 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.729 ' N ' ' H ' ' H' ' 20' ' ' PHE . 35.3 t80 -109.78 108.19 18.45 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.549 -1.344 . . . . 0.0 110.839 177.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . 0.566 ' N ' ' O ' ' H' ' 20' ' ' PHE . . . -82.42 103.12 11.74 Favored 'General case' 0 C--O 1.178 -2.684 0 C-N-CA 124.682 1.193 . . . . 0.0 111.012 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.546 ' H ' ' HA ' ' H' ' 21' ' ' ALA . 73.7 mt-10 -75.39 147.92 39.61 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 120.27 1.395 . . . . 0.0 111.86 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.445 ' CG ' ' N ' ' G' ' 24' ' ' VAL . 7.8 p-10 -156.02 -144.75 0.14 Allowed 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.159 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' G' ' 23' ' ' ASP . 18.3 t -29.58 103.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 114.988 -1.006 . . . . 0.0 112.501 178.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.39 -94.41 0.09 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.643 178.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.2 m -71.18 174.17 6.72 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 119.138 1.469 . . . . 0.0 110.388 -178.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -78.71 173.33 12.57 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.511 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.548 ' HZ2' ' CB ' ' I' ' 26' ' ' SER . 13.0 mmtt -46.04 111.77 0.4 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 174.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 94.29 1.74 Allowed Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -177.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.43 -179.92 7.08 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-O 122.349 1.071 . . . . 0.0 111.157 -178.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.462 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.12 109.18 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 CA-C-N 113.28 -1.782 . . . . 0.0 108.91 -177.924 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.597 ' N ' ' SD ' ' A' ' 35' ' ' MET . 2.4 mt -107.02 112.41 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.96 98.39 0.82 Allowed Glycine 0 CA--C 1.499 -0.927 0 N-CA-C 106.851 -2.5 . . . . 0.0 106.851 176.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -125.22 133.9 52.55 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 122.305 1.05 . . . . 0.0 110.475 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.641 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 42.7 ttp -109.93 120.08 41.35 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 113.8 -1.546 . . . . 0.0 108.973 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -134.5 70.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.32 106.09 2.9 Favored Glycine 0 C--N 1.365 2.139 0 N-CA-C 111.614 -0.594 . . . . 0.0 111.614 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.78 179.03 2.36 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 112.017 -0.433 . . . . 0.0 112.017 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 28.0 m . . . . . 0 N--CA 1.464 0.228 0 CA-C-N 115.436 -0.382 . . . . 0.0 110.273 179.783 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.2 t . . . . . 0 N--CA 1.466 0.329 0 N-CA-C 110.383 -0.229 . . . . 0.0 110.383 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 p-80 -174.88 -172.35 0.61 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 111.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' G' ' 14' ' ' HIS . 82.4 m-70 -149.09 163.49 37.4 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -160.25 167.44 27.56 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.427 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' G' ' 16' ' ' LYS . 73.1 mttt -156.57 151.67 26.31 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -134.16 123.57 24.6 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . 0.968 ' O ' ' C ' ' G' ' 18' ' ' VAL . 65.3 t -125.59 141.69 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 118.113 -1.435 . . . . 0.0 113.838 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -118.62 115.01 23.66 Favored 'General case' 0 N--CA 1.472 0.644 0 O-C-N 120.723 -1.236 . . . . 0.0 109.722 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.729 ' H ' ' N ' ' G' ' 20' ' ' PHE . 8.2 t80 -109.89 106.89 16.63 Favored 'General case' 0 C--O 1.25 1.107 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 179.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . 0.546 ' HA ' ' H ' ' G' ' 22' ' ' GLU . . . -90.42 120.09 31.24 Favored 'General case' 0 C--N 1.36 1.052 0 O-C-N 124.864 1.352 . . . . 0.0 110.461 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.477 ' O ' ' CB ' ' H' ' 23' ' ' ASP . 82.4 tt0 -153.26 156.53 38.63 Favored 'General case' 0 C--N 1.359 1.022 0 C-N-CA 117.898 -1.521 . . . . 0.0 113.125 -177.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' H' ' 22' ' ' GLU . 0.9 OUTLIER 149.23 121.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.448 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 25.0 m . . . . . 0 C--N 1.328 -0.343 0 C-N-CA 119.802 -0.759 . . . . 0.0 109.718 -179.002 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.405 -2.678 1 N-CA-C 99.706 -4.183 . . . . 0.0 99.706 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.696 ' CD1' ' N ' ' H' ' 31' ' ' ILE . 1.9 mp -82.02 103.74 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.344 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.287 174.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' B' ' 35' ' ' MET . 18.6 tt -121.32 121.34 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 CA-C-O 121.614 0.721 . . . . 0.0 111.009 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.82 116.59 2.39 Favored Glycine 0 C--O 1.244 0.74 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -130.83 128.8 41.38 Favored 'General case' 0 C--O 1.244 0.813 0 CA-C-O 121.785 0.802 . . . . 0.0 110.785 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.667 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 40.1 ttp -106.09 115.88 30.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.423 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -120.2 70.54 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.209 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.637 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.77 -100.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.02 -159.71 24.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.3 142.56 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.852 0.358 . . . . 0.0 110.781 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.671 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 121.863 0.839 . . . . 0.0 111.852 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.546 ' O ' ' CG ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -149.27 109.04 4.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.658 179.034 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.1 m170 -114.17 162.49 16.45 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.641 0.734 . . . . 0.0 110.673 -179.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -153.0 172.8 16.27 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.495 178.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.11 132.95 0.68 Allowed 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.838 -179.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 tt -124.99 125.92 44.64 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.46 126.58 72.09 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.543 -178.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -108.2 103.5 12.7 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 175.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.492 ' CE1' ' CZ ' ' H' ' 20' ' ' PHE . 25.7 t80 -117.32 131.06 56.88 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.864 0.302 . . . . 0.0 110.643 -178.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.29 145.94 31.45 Favored 'General case' 0 C--O 1.243 0.714 0 CA-C-O 122.043 0.925 . . . . 0.0 113.338 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -137.61 135.29 36.46 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.81 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.464 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 48.0 t0 -139.5 137.84 35.86 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -92.12 113.19 26.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 C-N-CA 118.685 -1.206 . . . . 0.0 111.806 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.91 86.97 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 CA-C-N 113.744 -1.571 . . . . 0.0 115.255 176.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.615 ' HG ' ' H ' ' I' ' 27' ' ' ASN . 30.9 t -140.68 169.95 16.69 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-N 118.487 1.144 . . . . 0.0 109.147 175.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.615 ' H ' ' HG ' ' I' ' 26' ' ' SER . 89.7 m-20 -30.51 170.79 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 O-C-N 124.009 0.818 . . . . 0.0 112.896 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' K' ' 25' ' ' GLY . 86.3 mttt -108.37 -112.23 0.3 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 173.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.86 90.73 0.01 OUTLIER Glycine 0 N--CA 1.466 0.66 0 CA-C-N 116.09 -0.505 . . . . 0.0 112.155 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.01 161.9 36.5 Favored 'General case' 0 C--O 1.248 1.005 0 CA-C-O 122.221 1.01 . . . . 0.0 108.35 177.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.478 ' CD1' ' N ' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -139.69 133.07 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 CA-C-N 113.455 -1.702 . . . . 0.0 110.089 -175.957 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.494 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.1 mt -113.39 114.85 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 178.472 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.26 96.06 1.05 Allowed Glycine 0 CA--C 1.497 -1.058 0 N-CA-C 105.231 -3.148 . . . . 0.0 105.231 175.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 6.6 tp -114.05 125.91 54.52 Favored 'General case' 0 CA--C 1.502 -0.87 0 CA-C-O 121.738 0.78 . . . . 0.0 112.026 -177.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.708 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 4.6 ttp -119.14 109.92 16.45 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.914 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.2 75.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.141 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -26.72 -98.37 0.01 OUTLIER Glycine 0 C--N 1.363 2.08 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 178.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -151.03 19.39 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -124.59 138.92 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.82 0.343 . . . . 0.0 110.358 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.603 -179.47 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t . . . . . 0 N--CA 1.467 0.401 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 6.2 t-80 -148.93 143.15 26.0 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.252 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' J' ' 13' ' ' HIS . 46.9 m-70 -141.28 163.66 32.35 Favored 'General case' 0 CA--C 1.51 -0.576 0 CA-C-O 121.482 0.658 . . . . 0.0 110.052 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.418 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 50.9 tt0 -156.02 170.76 21.41 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.06 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . 0.418 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 54.2 mtmt -157.01 134.52 10.68 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -123.83 124.51 42.82 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -140.94 141.69 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 118.768 -1.173 . . . . 0.0 113.867 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.637 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 5.5 m-85 -111.45 110.01 20.24 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.03 120.89 42.14 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.455 0.571 . . . . 0.0 111.429 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . 0.461 ' CB ' HD21 ' J' ' 27' ' ' ASN . . . -125.51 117.58 23.93 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.499 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 97.2 mt-10 -120.12 142.37 48.98 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.834 -178.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 4.3 t70 146.31 159.21 0.0 OUTLIER 'General case' 0 C--N 1.345 0.407 0 O-C-N 124.373 1.046 . . . . 0.0 109.201 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 2.4 m -62.97 -110.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.8 93.04 0.14 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.957 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.841 ' O ' ' O ' ' J' ' 27' ' ' ASN . 15.4 p -153.91 -170.61 3.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.841 ' O ' ' O ' ' J' ' 26' ' ' SER . 50.2 m-20 -19.65 178.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 125.049 1.468 . . . . 0.0 114.258 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.588 ' O ' ' N ' ' J' ' 30' ' ' ALA . 58.0 tttp 138.88 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.246 -177.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' J' ' 28' ' ' LYS . . . -45.31 101.46 0.03 OUTLIER Glycine 0 N--CA 1.481 1.68 1 CA-C-O 128.54 4.411 . . . . 0.0 108.384 -174.271 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.588 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -99.51 -124.17 0.16 Allowed 'General case' 1 N--CA 1.368 -4.569 4 N-CA-C 89.89 -7.818 . . . . 0.0 89.89 177.972 . . . . . . . . 4 3 . 1 . 003 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.752 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 1.2 mp -76.99 102.89 3.82 Favored 'Isoleucine or valine' 0 C--N 1.257 -3.422 0 C-N-CA 115.006 -2.678 . . . . 0.0 109.583 176.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.471 ' C ' ' SD ' ' D' ' 35' ' ' MET . 14.2 tt -115.08 121.39 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-O 121.322 0.582 . . . . 0.0 109.476 178.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.58 113.83 2.09 Favored Glycine 0 N--CA 1.466 0.681 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.48 ' CD2' ' CZ ' ' L' ' 19' ' ' PHE . 0.0 OUTLIER -125.16 128.11 47.89 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 122.019 0.914 . . . . 0.0 111.702 -178.4 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.743 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 32.7 ttp -107.63 119.26 38.93 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.329 -1.305 . . . . 0.0 109.445 178.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.02 72.83 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 38' ' ' GLY . . . -56.71 113.21 4.06 Favored Glycine 0 C--N 1.36 1.898 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -56.99 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 N--CA 1.466 0.347 0 CA-C-O 120.955 0.407 . . . . 0.0 111.003 -179.444 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 N--CA 1.463 0.193 0 CA-C-O 120.837 0.351 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 56.9 t -123.94 133.13 70.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -146.96 147.87 31.17 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.389 -0.524 . . . . 0.0 111.39 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 54.5 m80 -146.9 164.35 33.18 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.716 0.769 . . . . 0.0 110.593 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 80.8 mt-30 -154.57 179.1 9.36 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.388 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -169.79 131.79 1.11 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.562 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.97 120.53 36.64 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.28 124.93 65.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 121.032 0.444 . . . . 0.0 111.793 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.637 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 41.0 m-85 -115.75 110.25 18.84 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.067 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -120.98 127.36 51.72 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -177.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.21 137.68 36.2 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.582 0.706 . . . . 0.0 112.49 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -105.98 123.7 48.41 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 116.189 -0.459 . . . . 0.0 112.22 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' J' ' 26' ' ' SER . 49.3 t0 -172.37 114.68 0.31 Allowed 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.459 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 8.5 p -79.58 131.34 34.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.244 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.563 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . 58.82 82.38 0.06 OUTLIER Glycine 0 N--CA 1.467 0.7 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.07 178.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p -67.32 -172.08 0.2 Allowed 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.541 0.686 . . . . 0.0 110.172 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.495 ' C ' ' ND2' ' L' ' 27' ' ' ASN . 30.6 p-10 -79.63 179.28 7.59 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.47 ' O ' ' O ' ' K' ' 27' ' ' ASN . 81.2 tttt -43.65 -110.11 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.569 -0.742 . . . . 0.0 112.596 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.4 94.15 1.69 Allowed Glycine 0 N--CA 1.471 1.006 0 CA-C-O 119.992 -0.338 . . . . 0.0 112.859 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.02 173.48 11.73 Favored 'General case' 0 C--O 1.24 0.554 0 N-CA-C 104.317 -2.475 . . . . 0.0 104.317 176.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -151.72 136.93 10.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 C-N-CA 117.35 -1.74 . . . . 0.0 112.116 -174.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.415 HG21 HD11 ' K' ' 32' ' ' ILE . 89.7 mt -122.71 117.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.632 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.513 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -118.08 107.93 1.56 Allowed Glycine 0 C--N 1.334 0.467 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 178.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 51.9 tp -119.99 121.84 39.83 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 110.464 -0.198 . . . . 0.0 110.464 -178.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.402 ' SD ' ' C ' ' K' ' 35' ' ' MET . 6.3 tmm? -120.34 120.25 35.47 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.704 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.509 ' O ' ' C ' ' K' ' 37' ' ' GLY . 96.1 t -133.68 82.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.509 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -7.87 -97.81 0.0 OUTLIER Glycine 0 C--N 1.349 1.276 0 O-C-N 123.504 0.502 . . . . 0.0 113.703 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.25 -168.85 38.85 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.386 -179.758 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.464 0.241 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 31.8 p-80 -159.67 154.11 23.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 0.0 111.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -151.54 169.29 22.44 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.024 179.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -157.58 178.21 10.53 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.995 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -143.4 138.38 29.33 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.498 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 mt -121.68 119.43 31.77 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 m -143.01 135.91 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.48 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 4.0 m-30 -116.33 127.91 55.09 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -141.55 139.44 33.19 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.777 0.798 . . . . 0.0 111.893 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 142.95 34.63 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.78 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.43 100.96 6.18 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.974 -179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -173.84 133.4 0.45 Allowed 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.9 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 113.75 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 54.39 -91.21 0.01 OUTLIER Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -178.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.5 p 152.5 176.71 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 122.006 0.908 . . . . 0.0 110.058 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.495 ' ND2' ' C ' ' K' ' 27' ' ' ASN . 18.4 m-20 -51.74 -179.45 0.01 OUTLIER 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 113.892 -1.504 . . . . 0.0 111.664 178.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -60.58 111.66 1.69 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.923 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . 81.07 -93.19 1.5 Allowed Glycine 0 N--CA 1.468 0.787 0 CA-C-N 114.993 -1.003 . . . . 0.0 112.22 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.45 ' CB ' ' O ' ' L' ' 29' ' ' GLY . . . 79.11 165.56 0.2 Allowed 'General case' 0 CA--C 1.507 -0.684 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 -175.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.576 ' CD1' ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -149.87 131.93 5.87 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 CA-C-N 122.07 2.214 . . . . 0.0 111.583 178.038 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' F' ' 35' ' ' MET . 15.4 pt -124.46 142.08 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.115 -178.277 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.75 120.43 2.52 Favored Glycine 0 N--CA 1.463 0.457 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 20.0 mt -115.62 118.66 33.74 Favored 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 4.6 ttt -111.01 117.46 33.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.175 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -145.1 81.41 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.97 102.08 0.22 Allowed Glycine 0 C--N 1.337 0.621 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.072 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.65 178.95 34.17 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.3 136.59 59.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 120.842 0.353 . . . . 0.0 110.325 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.616 -179.698 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 . . . . . 0 N--CA 1.466 0.343 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -144.14 141.94 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.879 0.371 . . . . 0.0 110.668 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -141.75 -168.97 2.8 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.828 -179.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 73.7 m-70 -75.92 168.77 19.41 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 121.295 0.569 . . . . 0.0 110.087 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HG2' ' H ' ' A' ' 16' ' ' LYS . 48.5 tt0 -158.33 173.98 15.85 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.361 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.404 ' H ' ' HG2' ' A' ' 15' ' ' GLN . 88.9 tttt -144.27 126.35 15.51 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.621 0.248 . . . . 0.0 110.886 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.21 120.82 22.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.978 0.418 . . . . 0.0 110.046 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.32 136.9 50.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.795 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -129.67 132.01 46.56 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 111.396 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -114.84 123.06 48.23 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.9 123.44 42.52 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.385 0.612 . . . . 0.0 111.249 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -141.78 124.68 16.13 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.73 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.3 t0 . . . . . 0 C--N 1.327 -0.389 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.287 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 29' ' ' GLY . 78.3 tttt . . . . . 0 N--CA 1.469 0.5 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 28' ' ' LYS . . . 45.39 92.98 0.01 OUTLIER Glycine 0 N--CA 1.468 0.829 0 CA-C-O 118.191 -1.338 . . . . 0.0 110.261 178.194 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.04 160.36 15.1 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 116.627 -2.029 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -152.22 117.87 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 111.836 -2.438 . . . . 0.0 108.958 -171.736 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.472 ' O ' ' CG2' ' A' ' 32' ' ' ILE . 12.6 tt -128.85 109.28 18.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.613 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -122.31 119.86 4.13 Favored Glycine 0 CA--C 1.51 -0.263 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 178.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 8.4 tt -164.86 162.69 21.01 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.321 -176.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 5.1 ttp -135.45 143.24 45.79 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.244 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 m -121.89 71.53 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.764 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -47.05 -97.46 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.2 -168.85 30.83 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.43 134.35 66.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.635 -179.707 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -109.89 135.06 51.36 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.939 0.4 . . . . 0.0 110.708 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.94 161.29 28.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.1 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 m -131.04 160.85 41.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.46 ' CD2' ' N ' ' B' ' 13' ' ' HIS . 2.8 m-70 -127.74 124.27 37.38 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.711 0.291 . . . . 0.0 110.628 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 55.2 t60 -153.92 162.58 41.11 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.495 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 73.5 mt-30 -159.22 175.91 12.85 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.792 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -153.94 126.9 8.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.149 178.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 mt -124.7 114.46 19.35 Favored 'General case' 0 C--O 1.233 0.214 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -124.48 128.99 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.812 0.339 . . . . 0.0 110.344 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -125.7 123.32 38.63 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.036 -179.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -118.16 125.56 50.46 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 131.93 41.29 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.415 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.47 ' CB ' ' O ' ' C' ' 22' ' ' GLU . 16.6 pt-20 -158.39 154.88 27.68 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 120.185 -0.606 . . . . 0.0 112.561 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.47 ' N ' ' OD1' ' B' ' 23' ' ' ASP . 1.0 OUTLIER . . . . . 0 CA--C 1.535 0.378 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.439 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.202 0 N-CA-C 105.864 -2.894 . . . . 0.0 105.864 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.08 161.61 15.03 Favored 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.469 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -141.62 121.11 10.92 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.294 -172.346 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.6 mt -110.53 115.11 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.953 178.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.428 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -120.04 93.65 0.54 Allowed Glycine 0 CA--C 1.507 -0.443 0 N-CA-C 104.198 -3.561 . . . . 0.0 104.198 174.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.3 mt -122.58 140.22 53.04 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 122.958 1.361 . . . . 0.0 113.054 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 12.1 ttt -127.7 123.3 35.12 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 113.789 -1.55 . . . . 0.0 111.027 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.71 72.98 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.962 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.085 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -98.2 103.34 2.79 Favored Glycine 0 C--N 1.354 1.549 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.28 172.13 34.53 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -154.23 147.42 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 110.949 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.372 179.668 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 N--CA 1.463 0.224 0 CA-C-O 121.104 0.478 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -124.69 131.26 53.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.375 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -143.49 168.55 19.58 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.402 0.62 . . . . 0.0 109.878 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -159.53 172.99 16.85 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.625 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -166.61 114.75 0.87 Allowed 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 tp -121.74 121.72 37.92 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -130.03 124.99 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -114.48 106.36 14.19 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -113.26 127.14 56.06 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.15 0.5 . . . . 0.0 111.564 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.66 125.25 44.46 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.952 178.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' B' ' 22' ' ' GLU . 97.2 mt-10 -143.57 158.76 43.41 Favored 'General case' 0 C--O 1.222 -0.345 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.988 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.531 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 22.4 t0 . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.284 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.579 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.424 -5.626 0 N-CA-C 104.601 -3.4 . . . . 0.0 104.601 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.507 ' O ' ' C ' ' C' ' 29' ' ' GLY . . . -79.55 -140.47 0.03 OUTLIER 'General case' 0 N--CA 1.388 -3.564 1 N-CA-C 97.605 -4.961 . . . . 0.0 97.605 177.877 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.662 ' CD1' ' N ' ' C' ' 31' ' ' ILE . 1.0 OUTLIER -81.17 106.56 12.47 Favored 'Isoleucine or valine' 0 C--N 1.246 -3.904 0 C-N-CA 114.451 -2.9 . . . . 0.0 110.153 -177.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.498 ' O ' ' CE ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -108.68 122.52 63.37 Favored 'Isoleucine or valine' 0 C--N 1.363 1.161 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.766 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -138.76 113.23 0.93 Allowed Glycine 0 C--N 1.314 -0.666 0 N-CA-C 106.871 -2.492 . . . . 0.0 106.871 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.479 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 0.0 OUTLIER -140.65 158.55 43.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 123.115 1.436 . . . . 0.0 111.842 -176.673 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.479 ' CE ' ' O ' ' I' ' 32' ' ' ILE . 24.4 tpp -129.35 124.22 33.73 Favored 'General case' 0 CA--C 1.491 -1.289 0 CA-C-N 112.613 -2.085 . . . . 0.0 107.167 178.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' C' ' 37' ' ' GLY . 48.7 t -116.9 70.98 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.049 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.32 -101.09 0.01 OUTLIER Glycine 0 C--N 1.377 2.829 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.086 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.83 -158.82 30.41 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -134.59 161.53 40.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.83 0.347 . . . . 0.0 110.341 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.662 -179.576 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 54.2 t . . . . . 0 N--CA 1.465 0.313 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 33.0 m-70 -118.38 106.08 12.36 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.59 -178.993 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.429 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 60.8 m170 -108.67 166.51 10.74 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -152.82 172.51 16.62 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.03 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -157.08 114.5 3.11 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 60.3 mt -119.81 115.4 23.77 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -129.82 127.07 63.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.479 ' CE2' ' CD2' ' C' ' 34' ' ' LEU . 7.9 m-85 -116.07 117.76 30.98 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -132.9 128.56 36.82 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.944 -177.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 130.36 45.12 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.537 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 79.7 tt0 -141.81 107.91 5.21 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 119.945 -0.702 . . . . 0.0 112.777 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 71.8 m-20 . . . . . 0 CA--C 1.534 0.327 0 O-C-N 123.872 0.732 . . . . 0.0 110.158 178.248 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.579 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.432 -1.364 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.459 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.2 OUTLIER -150.92 125.07 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 116.683 -2.007 . . . . 0.0 111.846 -172.27 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.457 ' O ' ' CG2' ' D' ' 32' ' ' ILE . 3.7 tt -116.31 116.99 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.502 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.83 119.39 3.31 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 178.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.438 HD12 ' N ' ' D' ' 35' ' ' MET . 14.8 tp -138.84 126.46 21.96 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.161 0.981 . . . . 0.0 112.026 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.588 ' SD ' ' CA ' ' J' ' 33' ' ' GLY . 20.8 ttt -106.35 119.84 40.3 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.191 177.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.461 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -107.99 76.75 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.144 -178.579 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -26.43 -97.42 0.01 OUTLIER Glycine 0 C--N 1.354 1.552 0 N-CA-C 112.004 -0.438 . . . . 0.0 112.004 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.31 165.63 33.71 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.32 161.43 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.825 0.345 . . . . 0.0 110.474 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.3 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.492 179.689 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -103.58 131.17 50.95 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.862 0.363 . . . . 0.0 110.367 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -143.67 148.92 36.48 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.218 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.436 ' CG2' ' H ' ' F' ' 12' ' ' VAL . 0.2 OUTLIER -148.12 -153.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.462 -179.382 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.424 ' ND1' ' C ' ' E' ' 13' ' ' HIS . 7.2 t-80 -70.77 142.25 51.4 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 121.464 0.65 . . . . 0.0 112.68 -177.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -146.03 169.7 18.14 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 50.4 tt0 -155.39 168.01 28.51 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.924 -0.71 . . . . 0.0 112.233 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -148.75 123.48 9.88 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.614 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 34.0 tp -120.8 114.21 21.29 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.43 129.02 68.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 121.381 0.61 . . . . 0.0 111.999 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -124.07 123.93 41.42 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.619 ' CE1' ' CD1' ' F' ' 20' ' ' PHE . 2.0 t80 -133.64 130.14 37.85 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.718 0.294 . . . . 0.0 110.768 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.72 130.35 34.04 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.23 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -122.96 141.09 52.32 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 19.5 p-10 -165.49 113.74 0.99 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.563 177.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.09 131.0 31.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.196 -178.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 72.78 84.51 0.24 Allowed Glycine 0 CA--C 1.532 1.12 0 CA-C-N 116.007 -0.542 . . . . 0.0 114.12 177.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' E' ' 25' ' ' GLY . 88.7 p . . . . . 0 N--CA 1.453 -0.284 0 C-N-CA 123.666 0.786 . . . . 0.0 111.765 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.439 -0.985 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.417 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.3 OUTLIER -147.38 124.66 3.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 118.402 -1.319 . . . . 0.0 109.553 -178.151 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 66.1 mt -123.73 124.47 69.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.705 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.416 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -127.27 110.31 1.18 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 177.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 43.5 mt -119.02 128.9 54.8 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.3 ttt -133.3 131.16 39.85 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 119.781 -0.768 . . . . 0.0 112.222 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.512 ' O ' ' C ' ' E' ' 37' ' ' GLY . 40.1 t -130.65 81.73 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.576 179.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 19.02 -102.7 0.01 OUTLIER Glycine 0 C--N 1.352 1.472 0 CA-C-N 117.848 0.294 . . . . 0.0 112.84 179.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.02 -174.51 46.79 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -135.69 161.71 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.798 0.332 . . . . 0.0 110.677 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.5 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -147.23 155.78 42.38 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.099 0.476 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -101.72 143.89 31.1 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.957 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . 0.436 ' H ' ' CG2' ' E' ' 12' ' ' VAL . 55.5 t -118.84 129.59 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.404 0.621 . . . . 0.0 110.54 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -154.49 130.12 9.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.045 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -145.74 170.38 16.63 Favored 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -148.28 175.22 11.25 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.221 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.13 131.86 31.1 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -121.87 120.82 35.64 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.1 t -131.7 125.82 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.985 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -117.48 115.68 25.64 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE1' ' E' ' 20' ' ' PHE . 34.7 t80 -128.3 123.19 33.4 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.967 0.413 . . . . 0.0 110.084 179.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.84 134.33 36.82 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.494 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 80.1 tt0 -92.2 75.66 5.36 Favored 'General case' 0 N--CA 1.463 0.21 0 C-N-CA 119.888 -0.725 . . . . 0.0 112.066 -178.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 19.3 m-20 -142.81 107.93 4.96 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 175.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 85.6 t -45.69 140.79 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.066 -177.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.85 83.61 1.63 Allowed Glycine 0 C--N 1.333 0.392 0 N-CA-C 107.865 -2.094 . . . . 0.0 107.865 177.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -68.63 -170.79 0.23 Allowed 'General case' 0 N--CA 1.434 -1.266 0 CA-C-O 122.393 1.092 . . . . 0.0 111.805 -177.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.438 ' O ' ' C ' ' F' ' 28' ' ' LYS . 49.9 p30 -80.23 179.19 7.78 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 113.014 -1.903 . . . . 0.0 108.781 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.438 ' C ' ' O ' ' F' ' 27' ' ' ASN . 98.8 mttt -36.82 104.16 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 122.072 0.939 . . . . 0.0 109.445 -178.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . 0.46 ' O ' HG13 ' F' ' 31' ' ' ILE . . . 168.07 -100.71 0.17 Allowed Glycine 0 C--O 1.209 -1.412 0 CA-C-O 117.308 -1.829 . . . . 0.0 109.28 -173.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.48 164.06 0.55 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.51 2.655 . . . . 0.0 106.808 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -146.25 131.18 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 118.119 -1.433 . . . . 0.0 112.175 -177.148 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.4 mm -115.5 125.54 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.51 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 125.24 4.49 Favored Glycine 0 N--CA 1.473 1.151 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.106 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 mt -124.68 128.02 48.19 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -130.81 127.63 39.04 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 121.699 0.761 . . . . 0.0 112.571 -179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 48.8 t -147.38 86.66 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.813 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.45 96.79 1.28 Allowed Glycine 0 C--N 1.339 0.698 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.071 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.21 163.57 31.54 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 62.2 t -123.88 135.61 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.307 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 75.8 m80 . . . . . 0 N--CA 1.475 0.78 0 CA-C-O 120.92 0.39 . . . . 0.0 111.704 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.434 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 94.3 m-70 -107.72 179.14 4.32 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.668 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.427 HE21 ' CD ' ' H' ' 16' ' ' LYS . 52.3 tt0 -100.07 172.66 7.06 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.714 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.4 mttm -149.19 165.58 31.41 Favored 'General case' 0 C--O 1.217 -0.639 0 CA-C-O 121.193 0.521 . . . . 0.0 111.419 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 7.0 tt -145.14 161.84 38.49 Favored 'General case' 0 C--O 1.171 -3.039 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . 0.958 ' C ' ' O ' ' H' ' 18' ' ' VAL . 86.3 t -156.07 170.77 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 118.701 -2.499 . . . . 0.0 110.529 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . 0.562 ' O ' ' CD2' ' G' ' 19' ' ' PHE . 31.2 p90 -158.86 108.32 1.96 Allowed 'General case' 0 C--O 1.165 -3.344 0 CA-C-O 118.373 -0.823 . . . . 0.0 109.803 -178.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.748 ' N ' ' H ' ' H' ' 20' ' ' PHE . 43.6 t80 -119.52 106.27 12.05 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 121.471 1.941 . . . . 0.0 112.026 178.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . 0.738 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -114.74 113.0 23.71 Favored 'General case' 0 C--O 1.174 -2.887 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.256 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' H' ' 22' ' ' GLU . 94.9 mt-10 -75.01 144.41 43.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 118.898 0.772 . . . . 0.0 112.032 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 33.4 m-20 -140.62 -142.24 0.14 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.975 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' G' ' 23' ' ' ASP . 13.7 t -27.44 103.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.318 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.455 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 172.0 92.77 0.08 OUTLIER Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 86.66 179.9 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.793 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -63.73 170.88 3.01 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.309 0.576 . . . . 0.0 111.459 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.85 112.07 0.51 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.106 176.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.52 94.31 2.35 Favored Glycine 0 CA--C 1.486 -1.75 0 CA-C-O 122.493 1.052 . . . . 0.0 110.841 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.31 -179.05 3.72 Favored 'General case' 0 N--CA 1.421 -1.922 0 CA-C-N 112.795 -1.702 . . . . 0.0 110.607 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.608 ' CD1' ' N ' ' G' ' 31' ' ' ILE . 0.0 OUTLIER -141.62 112.65 3.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 113.335 -1.757 . . . . 0.0 106.41 179.415 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 18.5 tt -117.31 117.65 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-O 121.708 0.766 . . . . 0.0 110.414 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.16 106.41 2.35 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 105.904 -2.878 . . . . 0.0 105.904 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.504 ' H ' HD21 ' H' ' 34' ' ' LEU . 13.2 tp -132.81 130.52 39.96 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 122.604 1.192 . . . . 0.0 111.535 -177.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.613 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 24.7 ttp -102.81 124.19 47.87 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.16 179.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.9 70.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.98 -100.53 1.47 Allowed Glycine 0 C--N 1.354 1.572 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.7 170.25 24.04 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.33 -0.243 0 CA-C-O 120.832 0.348 . . . . 0.0 110.708 -179.796 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t . . . . . 0 N--CA 1.461 0.116 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.613 ' CD2' ' ND1' ' I' ' 13' ' ' HIS . 7.3 p-80 -158.68 152.01 22.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.672 0.749 . . . . 0.0 111.785 -179.484 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.509 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 15.9 m80 -144.64 162.27 37.07 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.2 mm-40 -152.96 172.91 16.09 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.313 0.578 . . . . 0.0 110.087 178.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' G' ' 16' ' ' LYS . 76.7 tttt -176.04 136.86 0.31 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.026 -0.988 . . . . 0.0 108.467 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 77.0 mt -141.07 132.3 26.51 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . 0.958 ' O ' ' C ' ' G' ' 18' ' ' VAL . 76.8 t -124.6 146.07 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 C-N-CA 118.184 -1.407 . . . . 0.0 113.385 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -125.19 119.33 28.21 Favored 'General case' 0 N--CA 1.478 0.949 0 O-C-N 120.141 -1.6 . . . . 0.0 111.479 -179.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.748 ' H ' ' N ' ' G' ' 20' ' ' PHE . 50.3 t80 -105.69 111.82 24.65 Favored 'General case' 0 C--O 1.248 0.981 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . 0.738 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -93.97 113.44 25.44 Favored 'General case' 0 C--N 1.352 0.717 0 CA-C-O 118.631 -0.7 . . . . 0.0 112.734 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.64 ' H ' ' CB ' ' G' ' 21' ' ' ALA . 48.6 tt0 -149.02 124.85 10.55 Favored 'General case' 0 C--N 1.379 1.884 0 C-N-CA 117.899 -1.52 . . . . 0.0 112.094 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.501 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 66.5 t0 -125.07 114.69 19.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.484 0.659 . . . . 0.0 110.252 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 40.1 t . . . . . 0 C--N 1.316 -0.879 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 179.223 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.413 ' O ' ' O ' ' I' ' 31' ' ' ILE . . . . . . . . 0 CA--C 1.477 -1.834 1 N-CA-C 93.853 -6.351 . . . . 0.0 93.853 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' N ' ' H' ' 31' ' ' ILE . 0.9 OUTLIER -94.43 110.69 24.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 CA-C-N 124.149 3.159 . . . . 0.0 108.602 177.09 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.558 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -112.86 110.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.361 1.075 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.686 -179.582 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -120.24 102.34 0.87 Allowed Glycine 0 N--CA 1.462 0.401 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.504 HD21 ' H ' ' G' ' 34' ' ' LEU . 2.6 mt -136.84 149.46 47.73 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-O 122.508 1.147 . . . . 0.0 112.844 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.469 ' SD ' ' O ' ' B' ' 31' ' ' ILE . 28.7 ttp -111.9 126.02 54.66 Favored 'General case' 0 CA--C 1.505 -0.772 0 CA-C-N 113.236 -1.802 . . . . 0.0 110.467 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -125.27 65.57 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.2 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.285 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -51.65 -104.6 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.81 -141.8 5.09 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -122.82 135.98 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.768 0.318 . . . . 0.0 110.288 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.495 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.509 ' CG1' ' HE2' ' H' ' 14' ' ' HIS . 77.3 t . . . . . 0 N--CA 1.471 0.614 0 CA-C-O 120.804 0.335 . . . . 0.0 110.173 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.631 ' HE2' ' NE2' ' I' ' 15' ' ' GLN . 75.4 t60 -150.86 104.75 3.19 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.864 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.526 ' NE2' ' O ' ' J' ' 12' ' ' VAL . 64.7 m170 -112.6 160.12 18.18 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.37 0.605 . . . . 0.0 110.205 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.631 ' NE2' ' HE2' ' I' ' 13' ' ' HIS . 84.0 mt-30 -154.06 167.56 29.38 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.401 178.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . 0.432 ' CG ' ' O ' ' I' ' 15' ' ' GLN . 95.2 mttt -164.69 128.46 2.47 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 108.993 -0.744 . . . . 0.0 108.993 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.2 mt -126.97 126.14 42.69 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 19.8 t -125.0 129.92 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.414 ' CE1' ' CD1' ' H' ' 34' ' ' LEU . 0.5 OUTLIER -133.57 108.64 8.72 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.185 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.422 ' CG ' ' CZ ' ' J' ' 20' ' ' PHE . 4.0 p90 -143.57 153.82 42.95 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 118.624 -1.23 . . . . 0.0 112.797 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.46 141.48 51.87 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.964 -1.016 . . . . 0.0 112.962 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -150.99 99.86 2.74 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.072 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' H' ' 23' ' ' ASP . 3.1 t70 -103.05 120.24 40.31 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.11 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 27.5 m -59.21 121.36 6.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 81.97 90.31 0.61 Allowed Glycine 0 CA--C 1.535 1.305 0 N-CA-C 116.918 1.527 . . . . 0.0 116.918 174.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.523 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.4 p 137.43 167.3 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 124.902 1.281 . . . . 0.0 110.707 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.535 ' OD1' ' ND2' ' J' ' 27' ' ' ASN . 16.2 m-20 -49.84 178.15 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 115.841 1.793 . . . . 0.0 115.841 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 12.9 tttt -61.82 -111.24 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.052 0 CA-C-N 113.177 -1.829 . . . . 0.0 114.912 172.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -79.59 96.3 1.52 Allowed Glycine 0 CA--C 1.458 -3.492 0 CA-C-N 110.762 -2.927 . . . . 0.0 114.677 -175.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.554 ' O ' ' C ' ' I' ' 29' ' ' GLY . . . -76.61 -136.45 0.02 OUTLIER 'General case' 0 N--CA 1.412 -2.329 1 N-CA-C 93.992 -6.299 . . . . 0.0 93.992 169.066 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.699 ' CD1' ' N ' ' I' ' 31' ' ' ILE . 0.4 OUTLIER -98.46 121.91 49.55 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 1 CA-C-N 127.308 4.594 . . . . 0.0 111.412 -176.631 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.479 ' O ' ' CE ' ' C' ' 35' ' ' MET . 7.7 mt -112.09 112.26 39.74 Favored 'Isoleucine or valine' 0 C--N 1.359 1.022 0 CA-C-N 114.83 -1.077 . . . . 0.0 108.276 177.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.91 104.94 1.72 Allowed Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 107.295 -2.322 . . . . 0.0 107.295 177.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 65.0 mt -137.39 133.2 34.53 Favored 'General case' 0 C--O 1.24 0.561 0 CA-C-O 122.751 1.262 . . . . 0.0 113.549 -176.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 57.0 ttp -113.47 122.68 48.04 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-N 113.649 -1.614 . . . . 0.0 109.153 178.257 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.7 70.69 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -118.46 -103.57 2.15 Favored Glycine 0 C--N 1.36 1.881 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 178.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.49 -174.17 31.95 Favored Glycine 0 CA--C 1.522 0.501 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.113 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -132.82 161.9 40.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 CA-C-O 121.15 0.5 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 32.1 m . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.438 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.526 ' O ' ' NE2' ' I' ' 14' ' ' HIS . 19.3 m . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 120.231 0.062 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -84.4 114.43 21.89 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.993 -0.283 . . . . 0.0 110.66 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.489 ' NE2' ' CG2' ' J' ' 12' ' ' VAL . 49.6 m170 -134.78 165.2 25.83 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-O 121.827 0.822 . . . . 0.0 110.641 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.41 HE21 HD12 ' J' ' 17' ' ' LEU . 37.5 tt0 -161.84 166.81 25.82 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.823 178.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -156.98 135.33 11.31 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . 0.41 HD12 HE21 ' J' ' 15' ' ' GLN . 11.0 mp -122.16 120.41 34.14 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -125.92 130.12 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -140.3 126.81 20.19 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.657 ' CG ' ' CZ ' ' K' ' 20' ' ' PHE . 51.2 p90 -158.75 160.53 36.45 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.619 1.711 . . . . 0.0 115.619 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.1 119.02 32.11 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 114.071 -1.422 . . . . 0.0 108.279 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -157.08 157.16 34.04 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-O 122.116 0.96 . . . . 0.0 113.494 -177.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.498 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 51.8 p-10 -157.54 -131.41 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 178.092 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.498 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 3.7 p -108.38 112.33 39.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.512 ' N ' ' OE1' ' K' ' 22' ' ' GLU . . . 32.02 87.94 0.01 OUTLIER Glycine 0 C--N 1.342 0.896 0 CA-C-O 118.218 -1.323 . . . . 0.0 110.781 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.572 ' O ' ' N ' ' K' ' 24' ' ' VAL . 82.8 p -96.57 168.35 10.59 Favored 'General case' 0 CA--C 1.497 -1.079 0 CA-C-N 120.772 2.286 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.535 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 84.3 m-20 -61.91 179.07 0.29 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 116.501 2.037 . . . . 0.0 116.501 175.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . 0.472 53.1 tttt -59.02 106.98 0.47 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 110.424 -3.08 . . . . 0.0 116.321 170.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.69 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -63.08 109.6 2.81 Favored Glycine 1 CA--C 1.435 -4.967 0 CA-C-O 125.192 2.551 . . . . 0.0 108.826 -173.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.69 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . -52.79 -124.69 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.518 2 CA-C-N 104.888 -5.656 . . . . 0.0 97.823 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.785 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -93.43 115.25 31.8 Favored 'Isoleucine or valine' 0 C--N 1.263 -3.186 1 CA-C-N 126.896 4.407 . . . . 0.0 114.63 -173.485 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.507 ' C ' ' SD ' ' D' ' 35' ' ' MET . 16.1 tt -122.27 115.4 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . 0.588 ' CA ' ' SD ' ' D' ' 35' ' ' MET . . . -118.01 118.55 4.1 Favored Glycine 0 N--CA 1.464 0.51 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.409 HD22 ' CE2' ' K' ' 19' ' ' PHE . 2.2 mt -134.91 127.45 30.66 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.502 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 63.8 ttp -109.2 122.01 46.39 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.711 176.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.55 70.99 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.378 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.784 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.69 106.91 3.47 Favored Glycine 0 C--N 1.361 1.933 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 178.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -110.39 149.88 17.6 Favored Glycine 0 N--CA 1.464 0.552 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.631 -179.674 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.703 0.287 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.447 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 42.8 t -126.25 130.8 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-O 121.024 0.44 . . . . 0.0 110.542 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 69.2 m-70 -103.57 129.0 50.72 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.244 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.556 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 49.4 t60 -136.44 165.19 26.4 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 178.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.556 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 81.7 mt-30 -157.37 176.45 12.66 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.403 178.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -173.05 133.82 0.54 Allowed 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -125.89 122.4 35.93 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -127.97 129.29 69.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-O 120.908 0.385 . . . . 0.0 110.437 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.409 ' CE2' HD22 ' J' ' 34' ' ' LEU . 1.9 t80 -131.25 123.89 29.39 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.657 ' CZ ' ' CG ' ' J' ' 20' ' ' PHE . 52.4 p90 -144.77 151.39 38.78 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.67 138.17 30.43 Favored 'General case' 0 CA--C 1.543 0.7 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.244 -178.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' J' ' 25' ' ' GLY . 36.2 tt0 -89.5 134.09 34.26 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.654 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' J' ' 29' ' ' GLY . 13.8 m-20 -148.97 119.59 7.48 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' J' ' 26' ' ' SER . 6.0 p -120.37 121.61 66.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.37 84.87 0.01 OUTLIER Glycine 0 N--CA 1.484 1.854 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 12.8 p -46.22 165.28 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -179.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -109.22 170.57 7.97 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 112.733 -2.03 . . . . 0.0 107.151 171.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -38.37 111.08 0.15 Allowed 'General case' 0 CA--C 1.551 1.015 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 175.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 91.93 0.36 Allowed Glycine 0 N--CA 1.483 1.824 0 N-CA-C 117.832 1.893 . . . . 0.0 117.832 171.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.19 157.54 43.56 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 173.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.411 ' O ' ' O ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -146.92 137.26 17.44 Favored 'Isoleucine or valine' 0 C--O 1.242 0.698 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.848 -176.77 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.88 126.2 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.428 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.98 122.27 4.92 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.601 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 21.7 tp -120.6 121.07 37.57 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 114.91 -0.645 . . . . 0.0 110.257 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.416 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 15.9 ttt -117.14 116.6 27.62 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -139.91 79.76 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 38' ' ' GLY . . . -52.93 104.17 0.17 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.183 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 37' ' ' GLY . . . -55.35 -165.72 0.03 OUTLIER Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.467 0.395 0 CA-C-O 120.967 0.413 . . . . 0.0 110.382 -179.736 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.466 0.33 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -95.76 151.97 18.9 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.108 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 62.3 m80 -80.7 177.51 8.98 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -129.98 177.57 7.18 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.656 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -147.7 150.32 34.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -127.25 124.61 39.27 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -124.52 130.48 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 120.903 0.382 . . . . 0.0 110.496 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -133.31 120.49 21.1 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -144.68 140.13 28.43 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.56 135.83 38.76 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.1 mt-10 -85.17 76.1 10.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 119.099 -1.04 . . . . 0.0 112.528 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -118.2 122.07 42.08 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 120.929 0.395 . . . . 0.0 111.127 178.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' L' ' 26' ' ' SER . 18.0 t -88.96 123.2 41.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.581 ' N ' ' O ' ' L' ' 24' ' ' VAL . 88.2 p -63.14 -178.33 0.23 Allowed 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 121.403 0.621 . . . . 0.0 109.882 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -81.82 177.51 8.84 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.588 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -38.8 103.99 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.284 177.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 165.73 -100.78 0.18 Allowed Glycine 0 C--O 1.22 -0.763 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.671 -177.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.39 170.87 0.2 Allowed 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.416 HG22 HD13 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -153.97 145.87 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 118.099 -1.44 . . . . 0.0 112.427 -176.553 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 13.6 tt -138.2 137.46 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.78 123.91 4.65 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 mt -117.36 119.78 36.17 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.76 119.82 36.65 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.32 81.66 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.655 -0.248 . . . . 0.0 110.88 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.56 101.64 0.22 Allowed Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.01 168.99 33.06 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -131.18 159.12 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 120.699 0.285 . . . . 0.0 110.396 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.781 -179.63 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.679 0.276 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.6 t -121.21 134.62 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.418 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -96.72 -176.53 3.62 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.144 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -81.02 171.26 15.19 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.419 ' HG3' ' N ' ' A' ' 16' ' ' LYS . 61.8 tp60 -152.48 171.63 17.79 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.498 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . 0.419 ' N ' ' HG3' ' A' ' 15' ' ' GLN . 99.4 mttt -145.58 119.74 9.49 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.49 0.186 . . . . 0.0 111.104 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -132.03 120.32 22.25 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 120.91 0.386 . . . . 0.0 110.061 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -142.23 139.28 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.662 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -135.87 140.2 43.95 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.386 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -139.75 135.44 33.11 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.072 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.39 124.27 47.29 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.648 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -172.75 99.91 0.14 Allowed 'General case' 0 CA--C 1.527 0.093 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.2 t0 . . . . . 0 N--CA 1.469 0.476 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -179.594 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 28' ' ' LYS . 0.1 OUTLIER . . . . . 0 CA--C 1.544 0.739 0 CA-C-O 121.881 0.848 . . . . 0.0 112.19 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.8 101.52 0.8 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 176.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.33 153.57 24.53 Favored 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 116.528 -2.069 . . . . 0.0 111.035 -175.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.54 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -142.55 111.93 2.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 111.674 -2.512 . . . . 0.0 107.869 -173.449 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 7.8 mt -109.32 107.7 23.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -126.27 102.62 0.65 Allowed Glycine 0 CA--C 1.508 -0.4 0 N-CA-C 107.074 -2.411 . . . . 0.0 107.074 178.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 mt -138.36 149.12 45.27 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 122.666 1.222 . . . . 0.0 113.76 -177.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.428 ' SD ' ' HA3' ' H' ' 33' ' ' GLY . 97.7 mmm -109.65 107.25 17.24 Favored 'General case' 0 CA--C 1.498 -1.043 0 CA-C-N 112.684 -2.053 . . . . 0.0 106.507 175.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -98.04 71.91 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.76 102.73 2.4 Favored Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.08 146.62 14.01 Favored Glycine 0 CA--C 1.526 0.781 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.463 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.4 p -144.59 144.35 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.778 0.323 . . . . 0.0 110.649 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.102 -0.952 . . . . 0.0 110.537 179.967 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -118.62 140.88 49.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -61.57 134.11 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.572 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 4.6 p -143.13 143.89 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.904 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -124.77 146.67 49.09 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 120.487 0.184 . . . . 0.0 110.661 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.528 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 98.5 m-70 -153.89 162.07 41.51 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.589 0.709 . . . . 0.0 110.842 178.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.5 mm-40 -158.16 174.21 15.54 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.476 177.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -157.85 125.57 5.26 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 52.9 tp -130.99 122.58 27.09 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.993 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.44 133.06 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.899 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -131.06 130.07 42.76 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.391 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -132.23 125.73 31.81 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.288 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.38 125.97 45.96 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -168.37 117.76 0.74 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 178.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 50.3 t0 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -179.699 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.482 -1.988 0 N-CA-C 104.897 -3.281 . . . . 0.0 104.897 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 161.73 14.18 Favored 'General case' 0 CA--C 1.483 -1.623 0 C-N-CA 116.293 -2.163 . . . . 0.0 108.608 -175.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.423 ' O ' ' HE2' ' H' ' 35' ' ' MET . 0.0 OUTLIER -145.31 127.64 9.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 112.572 -2.104 . . . . 0.0 108.14 -173.74 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.444 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.6 OUTLIER -121.59 115.99 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 CA-C-O 121.044 0.45 . . . . 0.0 109.993 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.57 99.74 0.63 Allowed Glycine 0 N--CA 1.462 0.368 0 N-CA-C 105.622 -2.991 . . . . 0.0 105.622 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 75.1 mt -124.94 137.91 54.25 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.328 1.061 . . . . 0.0 112.903 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.549 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.3 ttm -119.38 115.08 23.36 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 114.012 -1.449 . . . . 0.0 107.604 178.192 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' B' ' 36' ' ' VAL . 3.3 p -126.84 66.88 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -54.65 -102.57 0.01 OUTLIER Glycine 0 C--N 1.357 1.726 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.55 152.55 15.91 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -130.88 135.62 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.833 0.349 . . . . 0.0 110.189 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.206 179.502 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.3 t . . . . . 0 CA--C 1.513 -0.452 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' D' ' 13' ' ' HIS . 51.3 p-80 -161.87 141.74 10.13 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.618 -0.833 . . . . 0.0 112.085 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.51 ' H ' ' CE1' ' B' ' 14' ' ' HIS . 17.1 m80 -121.39 163.21 19.08 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.413 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 57.1 tt0 -168.62 169.23 10.37 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . 0.413 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 62.8 pttt -158.61 132.91 7.94 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.877 0.846 . . . . 0.0 111.396 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 tt -120.31 125.23 47.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.279 -1.328 . . . . 0.0 108.01 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 20.5 t -127.47 123.3 61.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.187 0.518 . . . . 0.0 112.133 -178.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CB ' ' CE1' ' D' ' 19' ' ' PHE . 2.1 m-85 -112.95 110.6 20.77 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.494 ' CE2' ' CD2' ' D' ' 20' ' ' PHE . 7.4 t80 -116.25 118.11 31.87 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.228 -178.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.56 129.33 55.28 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 121.038 0.447 . . . . 0.0 111.469 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -158.56 101.85 1.69 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.972 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 . . . . . 0 N--CA 1.465 0.323 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.4 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.535 0 CA-C-O 124.054 1.919 . . . . 0.0 116.727 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.43 173.36 6.61 Favored 'General case' 0 N--CA 1.42 -1.961 1 N-CA-C 99.988 -4.079 . . . . 0.0 99.988 166.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.26 111.4 3.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 117.923 -1.511 . . . . 0.0 111.44 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.596 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.0 OUTLIER -108.97 121.87 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.493 178.492 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -128.43 119.47 3.08 Favored Glycine 0 C--O 1.237 0.335 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.414 ' CD1' ' CZ ' ' D' ' 19' ' ' PHE . 3.6 tt -142.61 142.88 32.19 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 122.481 1.134 . . . . 0.0 112.935 -177.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.408 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 0.1 OUTLIER -113.89 118.26 33.71 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.909 178.907 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.04 73.83 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.49 106.05 3.14 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 111.196 -0.761 . . . . 0.0 111.196 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.51 161.08 20.47 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -130.66 135.75 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.75 0.309 . . . . 0.0 110.641 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.598 179.377 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m . . . . . 0 N--CA 1.465 0.279 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.501 ' CD2' ' CD2' ' C' ' 14' ' ' HIS . 46.7 t60 -153.84 148.93 26.84 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.227 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -99.79 -178.68 3.94 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.337 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 44.0 tt0 -84.55 167.91 15.88 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.716 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.502 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 95.5 mttt -119.86 139.23 52.7 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.6 mt -122.52 121.99 37.84 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.544 0.211 . . . . 0.0 110.462 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -129.84 128.02 64.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.092 0.472 . . . . 0.0 111.586 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.488 ' CE1' ' CB ' ' C' ' 19' ' ' PHE . 7.9 m-85 -122.86 119.8 31.6 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 13.7 t80 -112.87 118.67 35.55 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.75 111.59 22.87 Favored 'General case' 0 C--O 1.251 1.184 0 CA-C-O 122.552 1.168 . . . . 0.0 111.92 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.436 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 66.4 tt0 -139.31 178.25 7.33 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.436 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 19.8 p30 . . . . . 0 C--N 1.318 -0.788 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . . . . . . 1 N--CA 1.348 -5.569 1 N-CA-C 100.162 -4.014 . . . . 0.0 100.162 . . . . . . . . . 3 2 . 1 . 005 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.777 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 1.2 mp -76.78 113.87 16.4 Favored 'Isoleucine or valine' 0 C--N 1.255 -3.509 0 CA-C-N 123.247 2.749 . . . . 0.0 113.913 -174.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.482 ' O ' ' CG2' ' D' ' 32' ' ' ILE . 2.6 tt -121.32 112.65 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 175.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 110.89 1.71 Allowed Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 178.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.412 HD23 ' H ' ' C' ' 34' ' ' LEU . 21.2 mt -133.5 132.94 41.59 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 119.408 -0.917 . . . . 0.0 112.493 -176.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.502 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.9 ttm -109.78 126.64 53.98 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.153 178.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.2 t -121.41 79.27 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 CA-C-N 116.671 -0.241 . . . . 0.0 110.989 -178.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -44.34 103.18 0.04 OUTLIER Glycine 0 C--N 1.357 1.72 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 177.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.12 -166.63 29.05 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -122.47 136.21 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 121.021 0.439 . . . . 0.0 110.35 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.2 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.953 -1.023 . . . . 0.0 110.419 179.94 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -114.1 134.71 54.7 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.913 0.387 . . . . 0.0 110.807 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -119.34 148.13 43.53 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.311 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . 0.468 ' CG1' ' CE1' ' E' ' 14' ' ' HIS . 72.8 t -123.79 134.09 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.176 0.512 . . . . 0.0 110.398 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -118.99 101.99 8.43 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.118 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.468 ' CE1' ' CG1' ' E' ' 12' ' ' VAL . 50.6 m170 -130.02 169.1 15.71 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-O 121.609 0.718 . . . . 0.0 110.264 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -149.22 174.73 12.06 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.632 -1.167 . . . . 0.0 108.314 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -154.34 112.02 3.47 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.493 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.8 tp -121.45 117.1 26.03 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -130.93 127.76 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -118.53 115.98 25.71 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 36.1 t80 -114.98 122.88 47.61 Favored 'General case' 0 N--CA 1.471 0.609 0 O-C-N 122.385 -0.197 . . . . 0.0 111.171 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.56 132.72 42.87 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.999 -0.28 . . . . 0.0 110.633 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.14 136.64 39.73 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.615 -0.834 . . . . 0.0 112.94 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.436 ' OD2' ' OD1' ' F' ' 23' ' ' ASP . 46.3 t0 -138.1 131.47 30.59 Favored 'General case' 0 C--N 1.368 1.382 0 CA-C-O 121.353 0.597 . . . . 0.0 112.559 178.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' E' ' 25' ' ' GLY . 37.8 t -111.44 113.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.606 177.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . 32.74 88.77 0.01 OUTLIER Glycine 0 CA--C 1.534 1.258 0 CA-C-O 121.794 0.663 . . . . 0.0 112.297 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.491 ' OG ' ' OG ' ' F' ' 26' ' ' SER . 3.4 p . . . . . 0 N--CA 1.445 -0.696 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.458 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.252 1.219 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.458 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.0 OUTLIER -154.33 122.82 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 117.147 -1.821 . . . . 0.0 110.442 -175.152 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 93.5 mt -121.58 127.13 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.255 -177.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.94 118.99 1.94 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 mt -123.87 123.64 40.89 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.807 -0.696 . . . . 0.0 109.951 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -120.01 122.88 42.12 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.147 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 t -114.17 86.51 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.722 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.91 97.35 0.22 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.09 168.86 38.74 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.5 t -123.5 135.97 61.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.219 -0.532 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.385 -179.807 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -114.77 135.78 53.8 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.811 0.339 . . . . 0.0 110.779 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -85.6 159.86 19.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 81.1 t -94.78 133.68 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.194 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.658 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 p-80 -139.97 125.95 19.68 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.335 0.588 . . . . 0.0 110.722 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.65 ' CG ' ' H ' ' F' ' 15' ' ' GLN . 82.7 t60 -156.97 177.25 11.72 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.65 ' H ' ' CG ' ' F' ' 14' ' ' HIS . 86.9 mt-30 -144.21 173.87 11.38 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -148.94 112.43 5.02 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.277 0.561 . . . . 0.0 111.605 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -124.68 120.47 31.93 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -127.53 128.67 70.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-O 121.817 0.818 . . . . 0.0 112.704 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -115.09 104.98 12.41 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.403 ' CE2' ' OE2' ' F' ' 22' ' ' GLU . 18.7 t80 -114.94 120.71 40.83 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 -177.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.27 129.54 33.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' CE2' ' F' ' 20' ' ' PHE . 73.5 mm-40 -92.6 92.4 8.0 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.507 -178.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 25.5 t0 -147.41 107.98 4.13 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 120.791 0.329 . . . . 0.0 111.5 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 m -77.49 -131.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.31 0.576 . . . . 0.0 110.147 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.15 85.44 0.01 OUTLIER Glycine 0 CA--C 1.528 0.879 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.927 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.491 ' OG ' ' OG ' ' E' ' 26' ' ' SER . 3.7 t -61.82 -178.39 0.15 Allowed 'General case' 0 N--CA 1.44 -0.95 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.417 ' N ' ' OG ' ' E' ' 26' ' ' SER . 59.5 t30 -80.16 172.78 13.32 Favored 'General case' 0 C--N 1.316 -0.866 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.228 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -45.45 110.73 0.27 Allowed 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.153 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.0 92.95 0.32 Allowed Glycine 0 N--CA 1.463 0.48 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.503 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 162.5 19.71 Favored 'General case' 0 CA--C 1.489 -1.396 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 173.283 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.48 116.47 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 115.625 -2.43 . . . . 0.0 112.728 -175.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 tt -125.95 135.55 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.029 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.31 128.02 4.37 Favored Glycine 0 CA--C 1.531 1.043 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.022 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -119.66 124.37 46.13 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 0.4 OUTLIER -130.64 129.63 42.92 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.36 0.6 . . . . 0.0 112.363 -178.885 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.556 ' N ' ' SD ' ' F' ' 35' ' ' MET . 7.7 p -152.95 81.89 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.702 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.56 101.51 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.249 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -151.19 160.46 28.69 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 12.7 p -137.46 141.62 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 120.837 0.351 . . . . 0.0 110.907 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.629 179.747 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 . . . . . 0 N--CA 1.472 0.627 0 CA-C-O 121.132 0.492 . . . . 0.0 111.721 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 m-70 -145.48 164.58 31.16 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.408 ' HG3' ' N ' ' G' ' 16' ' ' LYS . 64.5 tp60 -164.9 165.17 20.59 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.242 178.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG3' ' G' ' 15' ' ' GLN . 98.7 mttt -157.04 129.12 7.27 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -136.43 122.14 19.79 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.535 0.683 . . . . 0.0 110.999 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -123.44 129.55 74.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.566 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -128.81 134.89 48.51 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.803 0.335 . . . . 0.0 110.909 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 46.0 p90 -129.93 127.13 39.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.791 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.59 37.21 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 121.418 0.627 . . . . 0.0 111.372 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -174.48 98.72 0.09 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.545 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -152.63 114.7 4.4 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -28.99 122.55 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 113.9 -1.5 . . . . 0.0 113.358 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.44 -85.56 0.06 OUTLIER Glycine 0 CA--C 1.529 0.926 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.556 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.555 ' O ' ' O ' ' G' ' 27' ' ' ASN . 19.0 t -153.39 -173.59 4.63 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 119.462 1.631 . . . . 0.0 111.646 178.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.555 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.3 m-20 -20.52 156.57 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 113.58 -1.645 . . . . 0.0 112.903 177.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 58.5 tttm -168.44 102.83 0.43 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 118.732 -1.187 . . . . 0.0 113.739 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.43 ' O ' HG13 ' G' ' 31' ' ' ILE . . . -76.81 104.45 1.89 Allowed Glycine 0 CA--C 1.495 -1.205 0 CA-C-O 115.789 -2.673 . . . . 0.0 106.86 172.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.423 ' C ' HG13 ' G' ' 31' ' ' ILE . . . -74.75 143.15 44.23 Favored 'General case' 0 C--O 1.252 1.203 1 CA-C-N 124.22 4.01 . . . . 0.0 105.782 -178.126 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.43 HG13 ' O ' ' G' ' 29' ' ' GLY . 69.6 mt -156.75 115.29 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 112.883 -1.962 . . . . 0.0 108.509 -171.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' H' ' 32' ' ' ILE . 10.4 tt -141.01 131.01 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.427 0 CA-C-O 122.683 1.23 . . . . 0.0 110.523 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -148.98 154.27 25.7 Favored Glycine 0 CA--C 1.484 -1.871 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -145.04 140.68 28.28 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.691 -179.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 25.6 ttp -103.48 106.81 17.42 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.48 65.28 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -131.45 102.55 0.51 Allowed Glycine 0 C--N 1.369 2.374 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.13 173.42 41.66 Favored Glycine 0 CA--C 1.523 0.587 0 C-N-CA 120.385 -0.912 . . . . 0.0 111.894 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t . . . . . 0 N--CA 1.464 0.245 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.992 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 33.0 m . . . . . 0 N--CA 1.464 0.231 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -129.48 133.24 47.18 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.979 0.418 . . . . 0.0 111.948 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -140.9 163.81 31.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -157.59 177.5 11.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.355 0.598 . . . . 0.0 111.307 179.249 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -170.64 115.53 0.47 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.81 178.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . 0.501 ' N ' ' CD2' ' H' ' 17' ' ' LEU . 1.6 mm? -122.8 119.16 29.77 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -135.17 130.65 51.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.713 178.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -120.13 123.24 42.85 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.948 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.23 123.0 45.56 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.11 126.18 38.78 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.321 0.581 . . . . 0.0 110.48 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.419 ' O ' ' CG ' ' H' ' 23' ' ' ASP . 84.1 tt0 -138.94 131.12 28.2 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.146 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.2 m-20 -163.05 122.92 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.474 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 7.1 m . . . . . 0 C--N 1.318 -0.782 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.0 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 122.759 1.266 . . . . 0.0 110.266 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.7 124.99 24.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 113.084 -1.871 . . . . 0.0 111.55 -178.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.549 ' N ' ' SD ' ' B' ' 35' ' ' MET . 0.7 OUTLIER -114.52 117.29 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.195 178.054 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.428 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -118.38 109.3 1.75 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.4 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 15.5 mt -118.36 122.73 43.55 Favored 'General case' 0 CA--C 1.49 -1.333 0 N-CA-C 112.848 0.684 . . . . 0.0 112.848 -175.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.423 ' HE2' ' O ' ' B' ' 31' ' ' ILE . 2.1 ttm -114.56 106.1 13.87 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.63 71.81 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.23 111.72 3.71 Favored Glycine 0 C--N 1.365 2.148 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -45.37 160.18 0.17 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 40' ' ' VAL . 3.3 p -140.5 141.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.702 0.287 . . . . 0.0 110.314 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 39' ' ' VAL . 84.5 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.955 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.464 0.251 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -147.16 121.85 9.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.823 -179.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 87.7 m-70 -134.94 161.82 34.18 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -153.78 166.96 31.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.511 0.672 . . . . 0.0 111.576 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -156.91 127.32 6.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.352 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -128.8 125.73 38.4 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -128.86 126.82 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 116.691 -0.232 . . . . 0.0 111.189 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.615 ' CD1' ' CE1' ' J' ' 19' ' ' PHE . 31.4 m-85 -115.17 107.37 15.21 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -108.25 122.74 47.58 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 118.274 0.488 . . . . 0.0 110.795 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 138.93 34.44 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -152.29 121.87 6.88 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-O 118.972 -0.537 . . . . 0.0 111.752 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.589 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 63.7 m-20 -151.42 103.74 3.02 Favored 'General case' 0 C--N 1.362 1.115 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 176.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.8 t -31.87 142.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.616 1.567 . . . . 0.0 114.215 170.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -81.75 0.1 Allowed Glycine 0 CA--C 1.533 1.16 0 C-N-CA 119.187 -1.482 . . . . 0.0 114.779 174.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.54 ' O ' ' O ' ' I' ' 27' ' ' ASN . 91.5 p -132.61 -179.21 5.32 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.603 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 46.5 t-20 -40.23 167.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.603 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 70.7 tttt -72.3 110.6 6.84 Favored 'General case' 0 C--N 1.344 0.337 0 C-N-CA 114.268 -2.973 . . . . 0.0 111.316 178.286 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.68 94.69 1.66 Allowed Glycine 0 CA--C 1.491 -1.433 0 CA-C-O 115.406 -2.885 . . . . 0.0 106.399 167.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.14 142.29 49.43 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 123.892 3.846 . . . . 0.0 109.0 177.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.19 120.32 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 CA-C-N 111.54 -2.573 . . . . 0.0 109.261 -176.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.408 HD13 HG23 ' I' ' 32' ' ' ILE . 0.8 OUTLIER -110.53 114.27 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 121.333 0.587 . . . . 0.0 110.19 178.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.52 96.94 1.31 Allowed Glycine 0 CA--C 1.496 -1.099 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.437 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 31.9 tp -111.88 122.93 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -175.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.1 ttp -121.57 114.77 21.67 Favored 'General case' 0 CA--C 1.512 -0.514 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -131.89 72.22 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.284 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -37.77 -98.49 0.01 OUTLIER Glycine 0 C--N 1.358 1.765 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.07 -167.33 39.21 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -123.44 135.6 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.938 0.399 . . . . 0.0 110.405 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 28.5 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.448 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m . . . . . 0 N--CA 1.463 0.216 0 CA-C-O 121.35 0.595 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 12.0 t-80 -148.85 132.39 16.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.0 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.699 ' CD2' ' H ' ' J' ' 15' ' ' GLN . 11.3 t-80 -156.17 165.69 35.67 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.541 0.686 . . . . 0.0 109.523 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.699 ' H ' ' CD2' ' J' ' 14' ' ' HIS . 48.4 tt0 -165.0 168.89 17.01 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . 0.474 ' N ' ' CG ' ' J' ' 15' ' ' GLN . 88.5 tttt -153.7 132.63 12.45 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.449 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.43 127.23 47.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -126.08 127.93 71.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.834 0.35 . . . . 0.0 110.884 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.615 ' CE1' ' CD1' ' I' ' 19' ' ' PHE . 97.3 m-85 -113.52 109.56 18.84 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -120.03 122.83 41.98 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.733 0.271 . . . . 0.0 111.733 -176.91 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.22 132.21 41.23 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.498 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.583 ' OE2' ' CD1' ' J' ' 20' ' ' PHE . 18.6 mp0 -140.52 145.85 37.37 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 120.19 -0.604 . . . . 0.0 112.36 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 15.3 m-20 -167.33 124.24 1.18 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.5 0.666 . . . . 0.0 111.903 178.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.649 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 7.1 p -62.93 -116.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.762 -1.108 . . . . 0.0 110.834 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.649 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 60.72 -91.79 0.06 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 114.976 -1.011 . . . . 0.0 114.42 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.83 ' O ' ' O ' ' J' ' 27' ' ' ASN . 35.1 p -171.63 172.52 4.97 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 118.173 0.986 . . . . 0.0 110.834 -176.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.83 ' O ' ' O ' ' J' ' 26' ' ' SER . 80.3 m-20 15.58 -178.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 O-C-N 125.627 1.83 . . . . 0.0 114.738 -179.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.544 ' CA ' ' OD1' ' I' ' 27' ' ' ASN 0.255 80.4 tttt -148.49 109.92 4.41 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 118.359 -1.336 . . . . 0.0 113.906 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -73.73 94.13 0.75 Allowed Glycine 0 CA--C 1.489 -1.551 0 CA-C-O 116.172 -2.46 . . . . 0.0 107.683 169.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.48 146.52 50.79 Favored 'General case' 0 CA--C 1.481 -1.709 0 CA-C-N 123.116 3.458 . . . . 0.0 110.587 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.71 109.36 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 CA-C-N 110.906 -2.861 . . . . 0.0 105.629 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.502 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.1 tt -109.7 113.38 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 121.773 0.797 . . . . 0.0 108.9 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . 0.461 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -102.49 107.73 3.18 Favored Glycine 0 CA--C 1.507 -0.442 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 mt -110.62 111.36 22.53 Favored 'General case' 0 CA--C 1.507 -0.677 0 CA-C-O 121.247 0.546 . . . . 0.0 110.748 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.596 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 18.9 ttt -110.28 110.34 21.12 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 5.9 m -133.83 74.88 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.229 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.27 102.21 2.85 Favored Glycine 0 C--N 1.35 1.357 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -152.86 157.1 27.1 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.464 0.257 0 CA-C-O 120.795 0.331 . . . . 0.0 110.362 -179.661 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.657 0.265 . . . . 0.0 110.773 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.42 133.8 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.776 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 -128.16 121.58 29.87 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.51 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' NE2' ' L' ' 14' ' ' HIS . 96.6 m-70 -122.59 169.38 11.08 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.37 0.605 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 66.4 tp60 -155.36 169.98 22.97 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.164 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.61 125.32 0.48 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.553 0.216 . . . . 0.0 110.503 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -128.69 129.34 45.66 Favored 'General case' 0 N--CA 1.466 0.374 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -132.12 133.55 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.067 0.46 . . . . 0.0 111.504 -179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.437 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 37.7 m-85 -114.58 111.73 21.81 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.601 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 -109.13 114.43 28.15 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.353 -0.217 . . . . 0.0 111.252 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.32 121.27 38.27 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -121.68 130.87 53.77 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 16.4 p-10 179.25 102.25 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 114.936 -1.029 . . . . 0.0 109.415 176.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.423 ' CG2' ' N ' ' K' ' 25' ' ' GLY . 12.9 p -58.82 166.29 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.133 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.423 ' N ' ' CG2' ' K' ' 24' ' ' VAL . . . 88.23 81.6 1.26 Allowed Glycine 0 CA--C 1.53 0.969 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.463 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 34.0 p -47.9 166.78 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.611 ' ND2' ' ND2' ' J' ' 27' ' ' ASN . 9.6 t-20 -157.2 177.38 11.54 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.033 -0.667 . . . . 0.0 112.68 177.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.562 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 67.3 mmtt 2.31 -105.32 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.358 1.063 . . . . 0.0 113.265 178.626 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -140.92 97.66 0.22 Allowed Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.94 170.32 4.44 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -152.18 126.37 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 117.998 -1.481 . . . . 0.0 111.442 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.14 132.64 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.603 -178.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.76 116.34 2.97 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 12.6 mt -107.22 111.25 23.56 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' K' ' 35' ' ' MET . 0.0 OUTLIER -113.03 111.99 23.12 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 -178.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.09 81.79 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.16 100.88 1.8 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 178.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.82 161.43 34.97 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.644 -0.788 . . . . 0.0 111.455 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.464 0.231 0 CA-C-O 120.763 0.316 . . . . 0.0 110.558 179.918 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 7.9 m . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 121.255 0.55 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 69.5 t60 -140.14 125.14 18.5 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.415 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' ND1' ' K' ' 14' ' ' HIS . 23.6 p80 -157.38 170.97 21.24 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -148.75 174.2 12.44 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.48 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -152.86 139.5 18.81 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.457 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -134.34 122.38 22.54 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -126.12 132.82 70.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-O 121.079 0.466 . . . . 0.0 111.755 -178.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -112.62 112.01 23.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.565 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -120.73 119.45 32.82 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.31 0.576 . . . . 0.0 110.715 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.44 128.62 47.27 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' L' ' 22' ' ' GLU . 11.3 tm-20 -78.59 96.51 5.5 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.188 -178.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -152.55 113.57 4.19 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 31.9 m -98.62 130.51 47.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.281 -179.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.0 81.74 0.03 OUTLIER Glycine 0 C--N 1.336 0.581 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.748 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -62.16 -178.15 0.16 Allowed 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.773 0.797 . . . . 0.0 110.459 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.473 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 7.9 t-20 -80.63 178.46 8.33 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.393 -1.276 . . . . 0.0 112.449 -178.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.473 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 65.0 mttp -41.44 111.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.088 -0.96 . . . . 0.0 112.059 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . 83.71 -93.71 1.76 Allowed Glycine 0 N--CA 1.463 0.474 0 CA-C-N 113.951 -1.477 . . . . 0.0 112.982 179.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.48 ' C ' ' CG1' ' L' ' 31' ' ' ILE . . . 78.26 161.48 0.21 Allowed 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 100.636 -3.838 . . . . 0.0 100.636 -174.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.48 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -154.09 127.54 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 122.665 2.484 . . . . 0.0 111.961 -179.11 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 48.5 pt -122.64 141.54 42.63 Favored 'Isoleucine or valine' 0 C--N 1.339 0.134 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.063 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.88 121.21 3.33 Favored Glycine 0 N--CA 1.465 0.621 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.4 tp -124.42 123.02 39.26 Favored 'General case' 0 N--CA 1.465 0.278 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.578 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.1 ppp? -131.67 136.05 47.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.475 0.655 . . . . 0.0 110.651 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 37' ' ' GLY . 5.5 t -138.18 80.74 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.691 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 26.47 -104.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.09 0 O-C-N 123.419 0.45 . . . . 0.0 112.65 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 134.03 147.48 5.65 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -140.98 164.23 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.754 0.312 . . . . 0.0 110.734 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 28.4 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.379 179.891 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 . . . . . 0 N--CA 1.465 0.288 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.54 148.49 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 116.278 -0.419 . . . . 0.0 109.898 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -77.82 162.96 26.5 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.036 -178.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.554 ' ND1' ' N ' ' A' ' 14' ' ' HIS . 1.4 m-70 -104.12 172.98 6.5 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.167 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -151.11 173.03 14.85 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.006 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -155.25 132.39 10.9 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.666 0.27 . . . . 0.0 110.492 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 52.1 tp -131.96 126.66 34.58 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 121.194 0.521 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.2 m -128.17 132.83 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.767 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -135.14 131.23 36.57 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.973 0.416 . . . . 0.0 111.193 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -119.63 126.07 50.28 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.8 132.51 45.3 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.968 0.889 . . . . 0.0 112.647 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -140.77 96.44 3.02 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.592 -1.185 . . . . 0.0 109.217 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.433 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 2.1 m-20 . . . . . 0 C--N 1.325 -0.5 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.54 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 45.3 tttp . . . . . 0 CA--C 1.545 0.774 0 CA-C-O 121.381 0.61 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 59.63 92.09 0.01 OUTLIER Glycine 0 C--N 1.346 1.114 0 CA-C-O 118.089 -1.395 . . . . 0.0 114.766 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.06 142.2 40.3 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 116.645 -2.022 . . . . 0.0 109.227 174.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.418 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.9 OUTLIER -155.67 128.55 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 CA-C-N 111.603 -2.544 . . . . 0.0 109.499 -173.181 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' H' ' 35' ' ' MET . 24.4 mt -126.62 107.92 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.01 102.32 1.36 Allowed Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.021 -2.832 . . . . 0.0 106.021 177.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 75.7 mt -133.95 150.21 51.28 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 122.529 1.157 . . . . 0.0 112.802 -177.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 15.7 ttm -128.87 118.22 22.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 CA-C-N 113.048 -1.887 . . . . 0.0 107.14 177.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -109.01 71.03 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.066 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.158 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -37.54 -100.36 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.28 -171.76 40.68 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -122.3 135.97 60.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.01 0.433 . . . . 0.0 110.6 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.773 -179.796 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.68 144.13 42.7 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . 0.488 ' O ' ' NE2' ' C' ' 13' ' ' HIS . 96.3 mt-10 -61.96 129.9 43.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.98 0.419 . . . . 0.0 110.969 -179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.7 132.56 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.991 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -157.08 170.12 23.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.16 0.505 . . . . 0.0 111.382 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -134.14 169.56 16.98 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -155.01 165.0 38.1 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.128 179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -156.28 113.5 3.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.163 179.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.7 tp -118.79 121.03 39.09 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -125.56 124.3 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 110.575 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -121.79 119.02 30.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.06 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -120.19 120.0 34.87 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 126.92 35.49 Favored 'General case' 0 N--CA 1.474 0.753 0 CA-C-O 121.368 0.604 . . . . 0.0 111.684 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -153.26 145.1 23.55 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.561 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 23' ' ' ASP . 18.7 t70 . . . . . 0 N--CA 1.464 0.266 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.2 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.479 1.518 0 N-CA-C 114.064 0.386 . . . . 0.0 114.064 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.646 ' H ' ' HB1' ' C' ' 30' ' ' ALA . . . -140.03 151.39 45.4 Favored 'General case' 0 N--CA 1.425 -1.699 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 172.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.418 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 1.6 mt -137.63 105.09 3.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 118.672 -1.211 . . . . 0.0 108.262 -174.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.513 ' O ' ' SD ' ' I' ' 35' ' ' MET . 12.4 tt -126.18 123.59 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 118.984 -1.086 . . . . 0.0 112.211 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.601 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -114.9 104.94 1.42 Allowed Glycine 0 CA--C 1.503 -0.684 0 N-CA-C 106.975 -2.45 . . . . 0.0 106.975 177.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -122.62 125.94 46.67 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 122.605 1.193 . . . . 0.0 110.639 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.536 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 1.3 ttm -112.31 119.77 39.45 Favored 'General case' 0 N--CA 1.438 -1.068 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.538 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -123.31 70.95 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.875 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.635 -179.874 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -45.14 -99.06 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 178.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 138.02 165.47 10.35 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -135.41 161.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.644 -179.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 N--CA 1.468 0.448 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.488 ' NE2' ' O ' ' B' ' 11' ' ' GLU . 77.7 m80 -78.26 128.27 33.48 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.294 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.578 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 60.0 t-80 -151.64 163.88 38.12 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.578 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 80.9 mt-30 -157.43 175.58 13.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.284 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.46 115.7 0.49 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.069 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -120.03 125.58 48.7 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.889 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -131.65 124.68 54.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.43 112.85 22.92 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 175.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -118.6 130.4 55.86 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 -178.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . 0.465 ' O ' ' CB ' ' D' ' 21' ' ' ALA . . . -162.13 160.48 27.31 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 115.786 1.772 . . . . 0.0 115.786 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -118.1 118.74 32.72 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 113.695 -1.593 . . . . 0.0 111.059 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 47.9 t0 . . . . . 0 CA--C 1.531 0.227 0 CA-C-O 121.801 0.81 . . . . 0.0 112.086 177.886 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.453 -3.819 0 CA-C-O 125.317 2.621 . . . . 0.0 116.097 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . 0.646 ' HB1' ' H ' ' B' ' 30' ' ' ALA . . . -88.37 -130.87 0.07 Allowed 'General case' 2 N--CA 1.357 -5.093 2 N-CA-C 95.377 -5.786 . . . . 0.0 95.377 171.373 . . . . . . . . 4 3 . 1 . 006 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.47 HD13 ' HB ' ' D' ' 31' ' ' ILE . 7.8 tp -87.91 135.61 25.08 Favored 'Isoleucine or valine' 1 C--N 1.232 -4.504 0 N-CA-C 114.345 1.239 . . . . 0.0 114.345 -179.109 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.488 ' O ' ' CE ' ' J' ' 35' ' ' MET . 8.1 tt -120.77 112.98 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 175.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' C' ' 34' ' ' LEU . . . -122.36 122.84 5.21 Favored Glycine 0 CA--C 1.504 -0.636 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.447 -178.546 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.583 ' CD2' ' CZ ' ' D' ' 19' ' ' PHE . 6.6 mp -143.78 146.25 32.97 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 118.694 -1.202 . . . . 0.0 112.041 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.59 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 3.4 ttm -121.11 121.95 38.98 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 113.286 -1.779 . . . . 0.0 108.704 177.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.93 76.9 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.106 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -83.12 104.09 2.55 Favored Glycine 0 C--N 1.361 1.957 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.08 170.68 51.39 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.9 m -140.61 162.77 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 120.815 0.341 . . . . 0.0 110.756 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.428 179.676 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 121.275 0.559 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -132.87 138.71 47.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 29.3 t-80 -144.9 166.11 26.23 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 121.408 0.623 . . . . 0.0 110.083 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.552 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 52.7 tt0 -160.23 171.26 19.52 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.39 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.419 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 86.8 tttt -169.96 118.25 0.59 Allowed 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.452 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 tt -128.63 127.03 41.42 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -142.42 138.1 29.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.8 0.809 . . . . 0.0 113.095 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.583 ' CZ ' ' CD2' ' C' ' 34' ' ' LEU . 38.0 m-85 -113.36 117.94 33.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.036 177.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.566 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 22.6 t80 -127.59 124.55 38.38 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.745 0.307 . . . . 0.0 110.654 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . 0.465 ' CB ' ' O ' ' C' ' 21' ' ' ALA . . . -158.14 164.72 36.32 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.724 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -137.59 157.01 47.42 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.333 -1.303 . . . . 0.0 112.381 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 t0 . . . . . 0 C--N 1.331 -0.211 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.64 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.385 -3.718 1 N-CA-C 93.74 -6.393 . . . . 0.0 93.74 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.708 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 3.1 mp -103.42 122.51 56.08 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.134 0 C-N-CA 116.517 -2.073 . . . . 0.0 113.116 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -113.36 118.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.897 179.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.46 ' N ' ' CE ' ' J' ' 35' ' ' MET . . . -131.9 101.75 0.48 Allowed Glycine 0 N--CA 1.472 1.075 0 N-CA-C 106.792 -2.523 . . . . 0.0 106.792 177.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 mt -130.64 125.63 34.52 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-O 122.187 0.994 . . . . 0.0 111.793 -175.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -105.54 117.6 34.42 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 113.983 -1.462 . . . . 0.0 107.115 177.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -114.4 80.91 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 120.874 0.368 . . . . 0.0 110.49 -177.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.73 103.27 0.54 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.72 -163.0 6.88 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.41 133.94 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 121.09 0.472 . . . . 0.0 110.673 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.061 -0.971 . . . . 0.0 110.818 -179.861 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.7 144.57 43.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.96 0.41 . . . . 0.0 110.872 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -63.38 149.59 45.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.783 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.51 142.86 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 69.7 t60 -143.18 139.9 30.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.92 0.391 . . . . 0.0 110.696 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.528 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -135.92 170.12 16.5 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.528 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 43.7 tt0 -158.19 171.13 20.77 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.991 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.475 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -150.39 113.14 4.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.33 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -118.3 115.87 25.6 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -131.56 130.14 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.428 ' CG ' ' CE1' ' F' ' 19' ' ' PHE . 7.2 m-85 -113.05 111.2 21.74 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.488 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . 0.566 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 25.5 t80 -122.49 121.33 36.32 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 118.223 0.465 . . . . 0.0 111.292 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.34 136.88 33.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.951 0.405 . . . . 0.0 111.469 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -124.68 120.81 32.91 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' E' ' 23' ' ' ASP . 44.7 p-10 -163.75 101.77 0.9 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.602 -0.839 . . . . 0.0 113.251 177.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -59.49 166.74 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.164 -0.926 . . . . 0.0 112.353 177.025 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.9 81.62 1.24 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 115.336 0.894 . . . . 0.0 115.336 174.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.443 -0.782 0 CA-C-O 120.565 0.221 . . . . 0.0 110.795 175.969 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.595 ' H ' HD21 ' F' ' 27' ' ' ASN . . . . . . . . 0 C--O 1.238 0.473 0 CA-C-O 121.028 0.442 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.37 130.96 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.986 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -130.61 122.37 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 121.084 0.469 . . . . 0.0 110.959 -178.255 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.81 124.39 5.37 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . 0.478 ' CD1' ' N ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -126.94 128.27 46.16 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 120.891 0.377 . . . . 0.0 111.006 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.8 tpp -120.19 120.2 35.46 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.918 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' E' ' 37' ' ' GLY . 5.8 t -134.06 83.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 121.36 -0.136 . . . . 0.0 111.131 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -19.58 -94.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.162 0 O-C-N 123.461 0.475 . . . . 0.0 112.753 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.67 -167.58 35.26 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 p -138.76 145.67 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 120.802 0.334 . . . . 0.0 110.393 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.043 -0.979 . . . . 0.0 110.515 179.78 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -85.44 134.6 34.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.874 0.369 . . . . 0.0 110.696 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -138.39 131.01 29.23 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.202 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m -141.65 173.29 8.58 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 121.237 0.541 . . . . 0.0 110.965 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -80.45 144.03 32.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.425 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.544 ' O ' ' NE2' ' F' ' 15' ' ' GLN . 34.6 m80 -134.03 172.21 13.14 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.544 ' NE2' ' O ' ' F' ' 14' ' ' HIS . 99.3 mm-40 -144.54 178.3 8.05 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.41 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -169.23 116.19 0.61 Allowed 'General case' 0 CA--C 1.531 0.215 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.82 126.98 44.29 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.081 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.73 129.89 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 121.572 0.701 . . . . 0.0 112.247 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.428 ' CE1' ' CG ' ' E' ' 19' ' ' PHE . 4.0 m-85 -114.75 113.39 24.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.132 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . 0.486 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 35.4 t80 -127.06 120.98 30.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.502 0.668 . . . . 0.0 111.387 -179.08 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.1 135.66 46.6 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.094 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tp10 -78.02 120.79 23.36 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.231 -0.588 . . . . 0.0 110.215 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' F' ' 24' ' ' VAL . 19.7 t70 -169.0 121.71 0.79 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.655 -0.418 . . . . 0.0 112.045 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' F' ' 23' ' ' ASP . 4.5 m -63.06 -121.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.519 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -64.39 -86.05 0.06 OUTLIER Glycine 0 CA--C 1.519 0.304 0 N-CA-C 105.736 -2.946 . . . . 0.0 105.736 178.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.548 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 2.0 t 157.53 172.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 122.316 1.055 . . . . 0.0 112.087 174.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.595 HD21 ' H ' ' E' ' 30' ' ' ALA . 43.3 m-20 -44.69 174.76 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 112.947 -1.933 . . . . 0.0 111.298 176.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -70.28 111.38 5.84 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.25 -92.94 0.87 Allowed Glycine 0 C--N 1.313 -0.725 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 82.17 163.72 0.14 Allowed 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 100.451 -3.907 . . . . 0.0 100.451 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.563 ' CD1' ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -148.11 128.16 4.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 121.691 2.041 . . . . 0.0 110.653 179.297 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tt -123.95 136.82 59.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.602 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.77 117.93 2.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.2 tt -124.15 124.18 41.92 Favored 'General case' 0 N--CA 1.47 0.567 0 O-C-N 122.689 -0.301 . . . . 0.0 110.238 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 42.2 mmm -123.27 130.38 52.66 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 120.776 0.322 . . . . 0.0 110.745 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.16 81.02 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 CA-C-N 116.101 -0.499 . . . . 0.0 112.323 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -43.25 100.83 0.02 OUTLIER Glycine 0 C--N 1.341 0.839 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.854 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -128.77 163.75 22.1 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.21 135.19 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.838 0.352 . . . . 0.0 110.121 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.486 -179.994 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 39.7 p-80 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.789 0.328 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.485 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 33.9 p80 -77.46 171.33 15.07 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 48.5 tt0 -155.92 172.37 18.49 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.395 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . 0.46 ' HZ3' ' HZ3' ' H' ' 16' ' ' LYS . 71.7 mmtt -136.56 132.56 35.34 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -135.74 111.07 9.06 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.68 133.1 65.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -139.64 148.74 42.86 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -124.71 132.92 53.35 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 139.52 45.56 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.598 0.713 . . . . 0.0 112.104 -178.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -115.96 167.09 11.27 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.568 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.438 ' O ' ' CB ' ' G' ' 24' ' ' VAL . 44.1 t0 -46.3 142.96 2.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.454 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.438 ' CB ' ' O ' ' G' ' 23' ' ' ASP . 20.0 t 93.97 111.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 O-C-N 124.565 1.166 . . . . 0.0 111.48 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 49.35 91.64 0.01 OUTLIER Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.54 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 1.1 p 159.04 -179.57 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 122.187 0.994 . . . . 0.0 110.603 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' G' ' 28' ' ' LYS . 90.5 m-20 -58.93 172.05 0.6 Allowed 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 113.408 -1.724 . . . . 0.0 112.323 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.533 ' NZ ' ' OD2' ' I' ' 23' ' ' ASP . 84.5 tttt 52.75 105.53 0.01 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.13 -179.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.567 ' O ' ' CB ' ' G' ' 30' ' ' ALA . . . 107.51 103.71 2.89 Favored Glycine 1 CA--C 1.427 -5.413 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.102 -174.478 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.573 ' H ' ' CB ' ' H' ' 30' ' ' ALA . . . 87.66 -148.34 0.01 OUTLIER 'General case' 0 N--CA 1.384 -3.73 0 N-CA-C 103.138 -2.912 . . . . 0.0 103.138 -169.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.719 ' H ' ' CD1' ' G' ' 31' ' ' ILE 0.287 0.0 OUTLIER -109.54 114.79 47.93 Favored 'Isoleucine or valine' 0 C--N 1.252 -3.638 0 N-CA-C 118.043 2.608 . . . . 0.0 118.043 -174.012 . . . . . . . . 4 4 . 1 . 006 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 0.9 OUTLIER -112.36 116.37 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 173.421 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.51 121.3 4.33 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 49.0 mt -126.52 134.67 50.83 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 122.889 1.328 . . . . 0.0 111.302 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 20.1 ttt -98.02 110.91 23.4 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 112.494 -2.139 . . . . 0.0 107.081 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.44 64.77 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.517 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.919 -178.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.11 -106.45 0.41 Allowed Glycine 0 C--N 1.367 2.296 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -161.85 165.11 35.62 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 66.7 t . . . . . 0 N--CA 1.466 0.338 0 CA-C-O 120.833 0.349 . . . . 0.0 110.195 -179.893 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 24.4 m . . . . . 0 N--CA 1.468 0.457 0 CA-C-O 120.945 0.402 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -128.71 -175.42 3.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.208 179.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -80.61 168.52 18.79 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 122.153 0.978 . . . . 0.0 111.532 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -153.11 177.81 10.41 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.063 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . 0.46 ' HZ3' ' HZ3' ' G' ' 16' ' ' LYS . 51.4 mtmt -145.44 143.44 30.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.311 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -135.24 117.04 15.09 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . 0.406 ' CG1' ' CE2' ' H' ' 20' ' ' PHE . 70.2 t -126.87 134.03 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-O 120.872 0.368 . . . . 0.0 110.505 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 t80 -124.74 122.71 38.24 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.392 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.406 ' CE2' ' CG1' ' H' ' 18' ' ' VAL . 61.0 m-85 -115.2 125.66 53.65 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.155 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.67 120.96 40.27 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-N 118.222 0.464 . . . . 0.0 110.911 179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' H' ' 23' ' ' ASP . 81.6 tt0 -123.27 154.98 38.09 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.756 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.612 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 54.6 t0 49.38 114.22 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 CA-C-O 121.05 0.452 . . . . 0.0 110.715 -178.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 42.8 t . . . . . 0 C--N 1.314 -0.944 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.622 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.573 ' CB ' ' H ' ' G' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.397 -3.086 1 N-CA-C 95.715 -5.661 . . . . 0.0 95.715 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.721 ' CD1' ' N ' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -112.29 119.32 59.93 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 116.236 -2.186 . . . . 0.0 112.291 -178.403 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.536 ' C ' ' SD ' ' B' ' 35' ' ' MET . 5.5 tt -117.49 120.03 63.56 Favored 'Isoleucine or valine' 0 C--N 1.361 1.106 0 CA-C-N 114.34 -1.3 . . . . 0.0 110.445 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.536 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -114.77 116.9 3.89 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -124.18 125.84 45.13 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.681 0.753 . . . . 0.0 111.825 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 7.3 ttt -105.92 110.03 22.18 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 114.37 -1.286 . . . . 0.0 108.577 178.049 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.53 71.26 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.12 -179.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.53 -97.13 0.03 OUTLIER Glycine 0 C--N 1.359 1.822 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.21 -166.26 38.68 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -124.39 139.9 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.869 0.366 . . . . 0.0 111.09 -178.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.597 179.831 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 CA--C 1.521 -0.163 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.7 p80 -175.69 113.86 0.13 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.148 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 26.8 m-70 -82.19 165.9 20.09 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -148.34 173.01 13.5 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.279 0.562 . . . . 0.0 110.985 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -154.96 127.56 7.98 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.629 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -129.2 119.56 24.27 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -125.94 128.94 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.934 0.397 . . . . 0.0 111.754 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -113.18 103.8 11.71 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -114.84 130.05 56.81 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 111.751 0.278 . . . . 0.0 111.751 -177.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.0 135.82 29.68 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 121.277 0.561 . . . . 0.0 111.402 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 tm-20 -148.07 118.88 7.57 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.587 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.612 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 16.7 m-20 -158.64 110.5 2.2 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.828 0.823 . . . . 0.0 112.224 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 50.5 t -48.16 133.97 5.36 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.497 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 99.3 86.03 1.87 Allowed Glycine 0 CA--C 1.54 1.636 0 N-CA-C 120.316 2.886 . . . . 0.0 120.316 171.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.4 p 153.01 169.87 0.01 OUTLIER 'General case' 0 C--N 1.347 0.498 0 CA-C-O 122.635 1.207 . . . . 0.0 112.346 169.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' I' ' 28' ' ' LYS . 1.4 m120 -59.03 177.63 0.15 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.343 -1.299 . . . . 0.0 111.363 177.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.505 ' O ' ' O ' ' I' ' 27' ' ' ASN . 63.3 tttt -43.64 -100.86 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.223 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.027 172.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.761 ' O ' ' O ' ' I' ' 30' ' ' ALA . . . -170.59 106.33 0.24 Allowed Glycine 1 CA--C 1.42 -5.858 0 C-N-CA 119.061 -1.542 . . . . 0.0 116.527 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.761 ' O ' ' O ' ' I' ' 29' ' ' GLY 0.29 . . -0.46 -133.45 0.0 OUTLIER 'General case' 0 C--N 1.366 1.286 0 O-C-N 127.066 2.274 . . . . 0.0 108.333 170.579 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.54 ' CG2' ' SD ' ' C' ' 35' ' ' MET . 3.9 mp -122.52 132.82 70.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 117.269 2.322 . . . . 0.0 117.269 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.59 ' C ' ' SD ' ' C' ' 35' ' ' MET . 17.9 tt -116.27 120.8 65.99 Favored 'Isoleucine or valine' 0 C--N 1.371 1.531 0 CA-C-N 114.44 -1.255 . . . . 0.0 110.58 177.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.475 ' CA ' ' SD ' ' C' ' 35' ' ' MET . . . -102.77 112.19 4.21 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 107.157 -2.377 . . . . 0.0 107.157 177.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.511 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 32.8 tp -113.26 121.18 43.65 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-N 115.36 -0.42 . . . . 0.0 111.419 -177.339 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.513 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 19.1 ttt -118.69 112.56 19.94 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 176.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.31 71.45 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.208 0 CA-C-N 117.729 0.24 . . . . 0.0 111.273 -178.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -50.11 -97.97 0.01 OUTLIER Glycine 0 C--N 1.353 1.5 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.405 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.14 -162.65 28.63 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.05 138.67 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 120.894 0.378 . . . . 0.0 110.703 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.481 179.679 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . 0.498 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 60.0 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.498 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 2.9 p80 -66.58 134.11 51.69 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.196 0.522 . . . . 0.0 111.841 -178.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.436 ' NE2' ' O ' ' K' ' 12' ' ' VAL . 52.7 m170 -112.83 172.17 7.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -141.55 176.44 8.88 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.333 0.587 . . . . 0.0 111.479 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -174.01 124.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.105 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.85 132.35 40.28 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-O 121.303 0.573 . . . . 0.0 110.973 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.68 131.12 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.015 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.649 ' CD1' ' CZ ' ' K' ' 19' ' ' PHE . 20.1 m-85 -114.2 111.17 21.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.097 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -121.59 120.49 34.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.909 0.322 . . . . 0.0 110.155 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.51 132.64 29.67 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.136 0.494 . . . . 0.0 110.986 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.478 ' C ' ' OD1' ' J' ' 23' ' ' ASP . 73.6 mt-10 -144.78 127.45 16.18 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 119.84 -0.744 . . . . 0.0 112.472 -179.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' I' ' 23' ' ' ASP . 3.9 m-20 -159.68 110.98 2.0 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 118.938 -1.105 . . . . 0.0 113.353 176.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.0 t -37.8 128.65 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.464 172.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' I' ' 26' ' ' SER . . . 168.85 -83.64 0.09 OUTLIER Glycine 0 N--CA 1.467 0.709 0 C-N-CA 117.108 -2.472 . . . . 0.0 116.087 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.582 ' O ' ' O ' ' J' ' 27' ' ' ASN . 5.0 p -170.39 -178.55 2.75 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 118.825 -1.15 . . . . 0.0 113.081 -175.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.582 ' O ' ' O ' ' J' ' 26' ' ' SER . 63.6 t30 27.13 177.37 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 CA-C-N 112.113 -2.312 . . . . 0.0 115.565 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.569 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 96.7 mttt -119.71 -106.47 0.38 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 113.307 -1.769 . . . . 0.0 110.947 -176.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.688 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -66.13 96.6 0.28 Allowed Glycine 0 CA--C 1.48 -2.141 0 CA-C-O 123.654 1.697 . . . . 0.0 112.643 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.628 ' O ' ' C ' ' J' ' 29' ' ' GLY . . . -80.38 -145.12 0.05 OUTLIER 'General case' 0 C--N 1.293 -1.885 1 N-CA-C 93.921 -6.326 . . . . 0.0 93.921 170.407 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.463 ' H ' HG13 ' I' ' 31' ' ' ILE . 4.8 mm -100.89 115.34 42.32 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 1 CA-C-N 127.987 4.903 . . . . 0.0 111.035 -179.249 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CG2' ' J' ' 32' ' ' ILE . 0.6 OUTLIER -112.76 110.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.366 1.307 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.684 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.16 106.27 2.64 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.436 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 4.4 mt -104.78 106.87 17.55 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.488 ' CE ' ' O ' ' C' ' 32' ' ' ILE . 0.0 OUTLIER -106.09 113.2 26.59 Favored 'General case' 0 N--CA 1.444 -0.754 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 178.819 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.39 79.6 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.085 -177.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.55 103.48 1.63 Allowed Glycine 0 C--N 1.349 1.258 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 177.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.34 145.08 16.7 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 63.0 t . . . . . 0 N--CA 1.466 0.364 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 -179.873 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 . . . . . 0 C--O 1.231 0.089 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.436 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 8.8 m -150.58 145.75 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-O 121.408 0.623 . . . . 0.0 111.98 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' N ' ' K' ' 13' ' ' HIS . 0.7 OUTLIER -119.3 116.13 25.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.202 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.622 ' ND1' ' ND1' ' L' ' 13' ' ' HIS . 70.6 t60 -122.61 165.99 15.58 Favored 'General case' 0 CA--C 1.509 -0.616 0 CA-C-O 121.403 0.621 . . . . 0.0 110.025 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.453 ' N ' ' CG ' ' K' ' 14' ' ' HIS . 47.5 tt0 -163.39 166.95 22.32 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.453 178.386 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . 0.411 ' CE ' ' HE2' ' K' ' 14' ' ' HIS . 98.9 mttt -155.53 129.96 9.0 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -124.51 120.53 32.27 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . 0.413 ' CG1' ' CE2' ' K' ' 20' ' ' PHE . 57.9 t -132.94 127.03 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.935 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.649 ' CZ ' ' CD1' ' J' ' 19' ' ' PHE . 6.8 m-85 -117.28 112.81 21.27 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.413 ' CE2' ' CG1' ' K' ' 18' ' ' VAL . 47.6 m-85 -108.12 118.57 37.1 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 178.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 132.86 36.93 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.772 0.714 . . . . 0.0 112.775 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -113.58 122.77 48.23 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.465 178.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -178.73 110.87 0.06 Allowed 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.244 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 m -107.05 -123.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 31.49 85.51 0.01 OUTLIER Glycine 0 C--N 1.342 0.9 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.009 -178.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 24.1 p -50.1 158.82 0.5 Allowed 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.398 0.618 . . . . 0.0 111.754 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' OD1' ' J' ' 27' ' ' ASN . 0.0 OUTLIER -148.06 176.92 9.8 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.881 -1.054 . . . . 0.0 109.137 176.952 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.531 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.8 mttt -9.16 -103.27 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.664 0.603 . . . . 0.0 111.278 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.73 97.0 0.18 Allowed Glycine 0 CA--C 1.5 -0.896 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 176.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.688 ' CB ' ' O ' ' J' ' 29' ' ' GLY . . . -66.2 172.17 4.09 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 177.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.661 ' N ' ' O ' ' J' ' 29' ' ' GLY . 0.4 OUTLIER -147.58 123.46 2.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 CA-C-N 120.996 1.726 . . . . 0.0 111.858 -175.782 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -125.99 131.33 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.717 -1.128 . . . . 0.0 112.475 -178.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.71 119.96 3.17 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . 0.414 ' C ' ' CD2' ' K' ' 34' ' ' LEU . 5.5 tt -121.84 120.53 34.81 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 120.629 0.252 . . . . 0.0 110.765 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.542 ' SD ' ' O ' ' K' ' 35' ' ' MET . 5.6 ppp? -130.49 130.24 43.94 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.436 0.636 . . . . 0.0 111.058 178.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.534 ' O ' ' C ' ' K' ' 37' ' ' GLY . 3.2 p -158.11 79.98 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.869 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.534 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -1.37 -100.89 0.0 OUTLIER Glycine 0 C--N 1.348 1.214 0 O-C-N 123.311 0.382 . . . . 0.0 113.615 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.45 -172.5 41.73 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--N 1.33 -0.245 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.847 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.616 0.246 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.622 ' ND1' ' ND1' ' K' ' 14' ' ' HIS . 49.1 t-80 -90.45 176.68 6.62 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.607 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 27.5 t-80 -76.0 176.82 7.57 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.372 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.607 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 99.2 mm-40 -121.48 178.04 4.97 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.968 0.413 . . . . 0.0 111.004 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -165.98 113.48 0.92 Allowed 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.96 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 18.3 mt -128.71 124.92 36.85 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -140.1 135.03 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.436 ' CE1' ' CD1' ' J' ' 34' ' ' LEU . 7.3 m-85 -116.94 108.53 15.91 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 177.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -116.0 123.09 47.13 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-O 121.24 0.543 . . . . 0.0 110.867 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.68 134.01 45.47 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 81.0 tt0 -81.18 92.87 6.37 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.964 -0.694 . . . . 0.0 111.03 -178.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.585 ' O ' ' O ' ' L' ' 24' ' ' VAL . 70.7 m-20 -160.94 133.14 5.95 Favored 'General case' 0 C--O 1.226 -0.159 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.182 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.585 ' O ' ' O ' ' L' ' 23' ' ' ASP . 10.6 t -32.34 -110.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 124.003 0.815 . . . . 0.0 111.376 176.475 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -158.89 92.27 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.476 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 23.3 p -47.3 152.68 0.57 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.761 0.791 . . . . 0.0 111.443 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.488 ' O ' ' C ' ' L' ' 28' ' ' LYS . 31.8 m120 -157.42 -174.74 5.03 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.135 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 12.74 103.54 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 177.079 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.56 -101.48 0.81 Allowed Glycine 0 N--CA 1.47 0.961 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.5 171.48 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 117.287 0.543 . . . . 0.0 110.152 -178.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.42 148.56 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.854 -177.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 tt -133.53 126.75 52.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-N 114.018 -1.447 . . . . 0.0 109.191 178.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.17 119.44 4.38 Favored Glycine 0 N--CA 1.466 0.657 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 16.6 tp -126.09 120.75 31.01 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.857 0.328 . . . . 0.0 110.179 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.528 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.7 ppp? -132.86 133.06 42.81 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.872 0.844 . . . . 0.0 111.16 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 23.1 t -142.98 82.61 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.412 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' K' ' 37' ' ' GLY . . . -66.26 101.22 0.59 Allowed Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.31 168.58 35.93 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -129.53 160.03 40.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.884 0.373 . . . . 0.0 110.507 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.425 179.983 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 121.128 0.49 . . . . 0.0 111.337 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.8 t -133.3 158.42 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -142.44 134.28 27.01 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 120.539 -0.464 . . . . 0.0 111.384 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -155.11 166.87 32.22 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.368 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -155.83 175.73 13.55 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.898 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -153.37 115.57 4.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.926 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.92 121.63 23.13 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.06 0.457 . . . . 0.0 110.67 178.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.54 131.38 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 115.778 -0.647 . . . . 0.0 109.713 179.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -126.56 130.37 50.41 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.826 0.346 . . . . 0.0 110.627 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -126.24 126.92 44.81 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 133.03 46.65 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 121.017 0.437 . . . . 0.0 111.87 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -150.53 117.33 5.85 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.187 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 121.485 0.659 . . . . 0.0 111.928 -179.968 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.515 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 18.3 pttp . . . . . 0 CA--C 1.529 0.159 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.24 101.39 0.74 Allowed Glycine 0 CA--C 1.503 -0.674 0 N-CA-C 106.849 -2.5 . . . . 0.0 106.849 176.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.96 153.94 23.63 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 117.117 -1.833 . . . . 0.0 110.535 -175.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -146.34 115.59 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.498 -173.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.46 ' N ' ' HE3' ' H' ' 35' ' ' MET . 11.6 tt -127.55 108.78 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.24 122.61 4.69 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . 0.455 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.9 OUTLIER -178.13 -162.58 0.06 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 122.349 1.071 . . . . 0.0 111.228 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.457 ' SD ' ' HB ' ' H' ' 31' ' ' ILE . 1.1 ttp -149.89 157.6 43.34 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -111.71 75.68 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 C-N-CA 120.507 -0.477 . . . . 0.0 109.811 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.5 103.42 3.0 Favored Glycine 0 C--N 1.357 1.745 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.46 -172.1 47.54 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -132.93 161.68 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.048 0.451 . . . . 0.0 110.864 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.865 -1.064 . . . . 0.0 110.662 -179.951 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -147.8 157.82 43.73 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.686 0.279 . . . . 0.0 110.682 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 150.68 31.32 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.314 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.47 155.84 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.794 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -128.31 142.46 51.13 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -143.2 169.56 17.38 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -162.2 166.63 25.3 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.762 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -154.48 111.43 3.34 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 179.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 73.2 mt -121.84 117.49 26.65 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -131.13 129.03 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.338 0.59 . . . . 0.0 112.034 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -122.28 127.37 49.8 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.124 178.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.3 t80 -130.65 125.5 34.17 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.708 0.289 . . . . 0.0 110.949 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.97 129.71 42.47 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.868 0.366 . . . . 0.0 110.504 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -157.76 135.59 10.68 Favored 'General case' 0 C--O 1.226 -0.17 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.53 0.21 0 C-N-CA 120.724 -0.391 . . . . 0.0 111.218 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.487 -1.699 0 N-CA-C 106.605 -2.598 . . . . 0.0 106.605 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -91.08 149.14 21.94 Favored 'General case' 0 CA--C 1.498 -1.046 0 C-N-CA 115.357 -2.537 . . . . 0.0 106.434 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.445 ' O ' ' SD ' ' H' ' 35' ' ' MET . 2.6 mt -148.74 106.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 114.284 -1.326 . . . . 0.0 107.836 -174.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.7 tt -116.15 123.18 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-O 121.638 0.732 . . . . 0.0 110.955 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.727 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -116.53 115.31 3.27 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 106.008 -2.837 . . . . 0.0 106.008 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.537 ' O ' ' CB ' ' C' ' 34' ' ' LEU . 5.9 tp -144.12 144.33 31.54 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 -175.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.644 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 32.3 ttp -129.18 129.63 45.32 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.159 -1.382 . . . . 0.0 108.411 175.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -111.89 78.2 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.017 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.247 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 104.59 1.69 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.23 -179.14 36.84 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.751 -178.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -141.37 149.87 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.675 -179.851 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 66.1 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.944 0.402 . . . . 0.0 110.449 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -128.87 138.73 52.2 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.363 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 82.8 t60 -155.37 164.85 38.18 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 94.5 mt-30 -155.44 -179.36 8.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.308 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.05 112.97 1.01 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.53 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 67.8 tp -120.28 121.84 39.56 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.804 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -132.69 126.34 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -179.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -118.46 123.8 46.05 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 177.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.628 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 43.5 t80 -130.09 127.85 40.68 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.764 0.316 . . . . 0.0 111.373 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.48 138.97 45.14 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.299 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -143.82 151.81 40.4 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.408 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 . . . . . 0 N--CA 1.466 0.359 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.673 178.79 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.622 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.54 153.64 44.99 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 173.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.3 116.88 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 118.979 -1.089 . . . . 0.0 111.305 -172.367 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.571 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.6 pt -119.15 115.88 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 176.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.681 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -126.14 118.45 3.13 Favored Glycine 0 CA--C 1.501 -0.836 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -161.56 169.31 21.95 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 118.072 -1.451 . . . . 0.0 111.968 -177.513 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tmm? -141.37 137.26 32.18 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 113.538 -1.665 . . . . 0.0 109.654 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.04 73.09 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.564 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.75 103.84 3.02 Favored Glycine 0 C--N 1.37 2.437 0 N-CA-C 111.419 -0.673 . . . . 0.0 111.419 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.58 154.58 18.63 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -135.38 163.29 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.395 -179.889 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.7 t . . . . . 0 N--CA 1.463 0.21 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' E' ' 13' ' ' HIS . 23.1 p80 -155.01 158.84 39.76 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 119.035 -1.066 . . . . 0.0 112.841 -178.805 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.512 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 51.5 m-70 -147.27 169.62 19.02 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.512 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 97.4 mm-40 -148.9 168.82 22.0 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.154 179.288 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -153.31 106.97 3.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.995 179.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 51.7 mt -118.5 116.79 27.39 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.27 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -130.24 128.16 63.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.55 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 47.1 m-85 -121.02 111.8 17.93 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 177.004 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -120.21 132.1 55.23 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 118.251 0.478 . . . . 0.0 111.919 -178.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 122.31 24.79 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.51 0.671 . . . . 0.0 111.176 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.447 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 80.9 tt0 -111.18 89.82 3.16 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.071 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.457 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 4.9 p30 . . . . . 0 C--N 1.322 -0.59 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.446 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.592 ' H ' ' CB ' ' E' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.412 -2.33 0 N-CA-C 100.355 -3.943 . . . . 0.0 100.355 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.445 ' N ' HD13 ' D' ' 31' ' ' ILE . 4.6 mp -131.99 134.58 59.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 115.074 -2.65 . . . . 0.0 117.751 -174.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.9 tt -126.77 123.91 63.83 Favored 'Isoleucine or valine' 0 C--N 1.367 1.334 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.459 177.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.655 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -124.18 106.22 0.94 Allowed Glycine 0 C--O 1.237 0.29 0 N-CA-C 106.882 -2.487 . . . . 0.0 106.882 176.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . 0.48 ' CD1' ' CE1' ' E' ' 19' ' ' PHE . 10.0 tt -126.72 132.95 51.0 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-O 122.039 0.923 . . . . 0.0 112.431 -177.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.541 ' SD ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -122.1 126.66 48.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 114.32 -1.309 . . . . 0.0 109.865 178.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.457 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -113.3 79.77 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.49 -178.182 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -25.8 -95.74 0.01 OUTLIER Glycine 0 C--N 1.358 1.759 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.89 -162.03 29.25 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.583 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 40' ' ' VAL . 56.0 t -115.2 136.06 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.932 0.396 . . . . 0.0 110.266 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 39' ' ' VAL . 70.9 t . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.445 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -109.11 136.13 49.11 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 110.463 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . 0.521 ' OE2' ' NE2' ' E' ' 13' ' ' HIS . 81.4 tt0 -64.69 136.27 56.77 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.645 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.91 134.6 59.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-O 121.959 0.885 . . . . 0.0 112.596 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' D' ' 13' ' ' HIS . 46.8 m170 -121.17 138.88 54.0 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 114.066 -1.425 . . . . 0.0 108.559 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.585 ' CG ' ' H ' ' E' ' 15' ' ' GLN . 85.4 t60 -152.47 171.49 18.0 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 121.61 0.719 . . . . 0.0 110.742 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.585 ' H ' ' CG ' ' E' ' 14' ' ' HIS . 53.6 tt0 -154.01 173.27 16.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.774 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.57 113.34 0.61 Allowed 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.568 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 tt -123.65 123.44 40.56 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.98 122.3 45.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.222 0.534 . . . . 0.0 112.173 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' D' ' 19' ' ' PHE . 7.5 m-85 -113.88 117.54 31.69 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.58 131.94 53.46 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 145.94 28.4 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.42 128.47 44.81 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.802 -0.635 . . . . 0.0 111.18 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' O ' ' F' ' 22' ' ' GLU . 67.3 t0 -147.1 112.33 5.51 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.238 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . 0.618 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 12.1 p -101.8 -121.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.248 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.618 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . 34.2 -84.93 0.01 OUTLIER Glycine 0 N--CA 1.473 1.143 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -177.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.572 ' N ' ' O ' ' E' ' 24' ' ' VAL . 1.4 p . . . . . 0 N--CA 1.447 -0.582 0 CA-C-O 121.673 0.749 . . . . 0.0 109.913 175.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.592 ' CB ' ' H ' ' D' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.474 -1.947 0 CA-C-O 122.451 1.12 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -151.49 137.54 11.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 112.477 -2.147 . . . . 0.0 112.041 -171.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.549 ' CD1' ' N ' ' E' ' 32' ' ' ILE . 2.8 mp -122.41 118.01 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 114.275 -1.33 . . . . 0.0 110.35 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -120.2 116.29 3.2 Favored Glycine 0 N--CA 1.476 1.32 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 178.338 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 39.6 mt -119.36 117.39 28.38 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -120.27 126.35 50.36 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.08 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 89.1 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.01 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -69.3 94.69 0.4 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.22 -171.79 18.73 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -178.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -132.73 161.81 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.654 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 C--O 1.221 -0.423 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.753 -179.942 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -103.33 129.75 50.45 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.004 0.43 . . . . 0.0 110.47 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -92.9 145.58 24.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.856 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 t -105.85 130.04 57.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.133 0.492 . . . . 0.0 110.689 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 14.5 t60 -154.19 139.7 17.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -149.74 170.61 18.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.427 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 50.8 tt0 -155.09 171.15 20.25 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.525 -0.762 . . . . 0.0 109.591 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . 0.427 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 62.1 tttm -170.08 106.39 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.156 -0.617 . . . . 0.0 111.676 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -117.42 125.47 51.01 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.1 141.44 16.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -117.0 122.0 42.97 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 113.637 -1.62 . . . . 0.0 107.377 177.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -127.04 142.29 51.57 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 121.749 0.785 . . . . 0.0 111.317 -179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.25 146.5 23.82 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.54 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.476 ' O ' ' O ' ' E' ' 23' ' ' ASP . 97.6 mt-10 -89.48 98.86 12.01 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.845 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' F' ' 24' ' ' VAL . 6.2 t70 -120.47 110.87 17.01 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 120.601 0.238 . . . . 0.0 110.758 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.6 m -60.42 -133.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.696 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' F' ' 26' ' ' SER . . . -76.91 85.72 0.99 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 119.784 -0.453 . . . . 0.0 112.797 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' F' ' 25' ' ' GLY . 5.9 p -34.97 170.09 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.144 0 CA-C-O 121.191 0.52 . . . . 0.0 111.292 178.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.524 ' CG ' ' H ' ' F' ' 28' ' ' LYS . 8.0 t-20 -140.19 -178.96 5.71 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.151 177.376 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.524 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 62.8 mttp 26.37 -107.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.003 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.39 94.46 0.15 Allowed Glycine 0 C--N 1.338 0.674 0 CA-C-O 119.269 -0.74 . . . . 0.0 111.988 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.403 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -67.4 178.99 1.38 Allowed 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 103.876 -2.639 . . . . 0.0 103.876 174.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' H ' ' L' ' 38' ' ' GLY . 0.2 OUTLIER -146.87 118.79 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-N 121.651 2.023 . . . . 0.0 111.03 -178.763 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 45.9 pt -118.56 140.91 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.462 -178.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -145.05 125.14 2.29 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 178.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 4.9 mp -116.88 127.86 54.68 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.473 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 2.9 tmm? -129.16 127.97 42.47 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 121.564 0.697 . . . . 0.0 112.876 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.473 ' N ' ' SD ' ' F' ' 35' ' ' MET . 3.6 p -156.15 82.02 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.719 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.233 179.079 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.23 101.39 0.96 Allowed Glycine 0 CA--C 1.53 0.988 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.475 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -144.04 165.01 27.45 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -119.6 135.96 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.024 0.44 . . . . 0.0 110.331 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.728 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.514 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 81.5 t60 . . . . . 0 N--CA 1.465 0.307 0 CA-C-O 120.863 0.364 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.514 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 8.1 p-80 -96.81 172.25 8.0 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.099 0.476 . . . . 0.0 109.804 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -148.4 177.52 9.37 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.054 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -143.95 145.82 32.52 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.97 115.43 18.52 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.613 0.72 . . . . 0.0 110.306 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -125.82 121.98 61.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.127 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -153.24 158.23 41.38 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.611 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -132.56 150.16 52.2 Favored 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.415 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.6 135.1 44.03 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.86 0.838 . . . . 0.0 112.283 -179.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -143.38 151.9 40.96 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.802 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.475 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 57.5 t0 60.68 114.91 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.261 0.553 . . . . 0.0 111.965 179.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.556 ' O ' ' O ' ' G' ' 26' ' ' SER . 0.3 OUTLIER -147.32 112.81 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.524 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 36.82 -91.35 0.01 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.383 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.556 ' O ' ' O ' ' G' ' 24' ' ' VAL . 10.8 p -89.33 -178.86 5.72 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -60.31 166.05 3.21 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 115.87 -2.332 . . . . 0.0 107.564 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.558 ' NZ ' ' O ' ' I' ' 23' ' ' ASP . 29.6 tttm -53.69 107.35 0.25 Allowed 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 118.365 -1.334 . . . . 0.0 113.734 -177.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.51 100.81 2.71 Favored Glycine 0 N--CA 1.469 0.854 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 169.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 148.09 28.66 Favored 'General case' 0 C--O 1.248 0.985 1 CA-C-N 125.131 4.465 . . . . 0.0 109.378 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -162.71 107.36 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 112.47 -2.15 . . . . 0.0 106.96 -175.318 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.42 ' O ' ' O ' ' H' ' 33' ' ' GLY . 42.7 mm -108.8 104.73 17.54 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 C-N-CA 119.074 -1.051 . . . . 0.0 108.673 177.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.54 100.08 1.38 Allowed Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 104.336 -3.506 . . . . 0.0 104.336 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tp -147.32 149.07 32.11 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 123.321 1.534 . . . . 0.0 112.948 -177.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -111.92 135.61 52.33 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 112.476 -2.147 . . . . 0.0 110.579 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -135.54 66.4 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.11 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . 0.409 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -53.1 -103.06 0.01 OUTLIER Glycine 0 C--N 1.358 1.783 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.55 -177.89 47.93 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 121.013 0.435 . . . . 0.0 110.729 -179.446 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 51.6 t . . . . . 0 N--CA 1.464 0.259 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.643 ' NE2' ' CD2' ' I' ' 13' ' ' HIS . 19.3 p80 -167.96 156.65 9.23 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.568 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -144.44 170.4 16.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -144.97 172.51 12.94 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.951 0.405 . . . . 0.0 110.671 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -176.13 126.02 0.2 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.664 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -136.38 122.54 20.37 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.665 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 34.2 m -123.79 129.45 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 121.352 0.596 . . . . 0.0 110.344 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' H' ' 19' ' ' PHE . 5.0 m-85 -113.11 116.39 29.79 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.847 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -110.65 117.53 33.75 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.02 129.84 51.59 Favored 'General case' 0 N--CA 1.475 0.814 0 O-C-N 121.269 -0.895 . . . . 0.0 112.884 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -171.08 145.28 2.24 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.549 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.475 ' CB ' ' H ' ' G' ' 23' ' ' ASP . 29.7 t70 -172.0 105.97 0.2 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.942 1.46 . . . . 0.0 114.942 178.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' H' ' 23' ' ' ASP . 58.5 t . . . . . 0 N--CA 1.476 0.875 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.303 173.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.379 0 CA-C-O 124.038 1.875 . . . . 0.0 112.777 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.457 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.8 OUTLIER -152.95 128.27 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 111.519 -2.582 . . . . 0.0 109.797 -177.427 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 2.1 tt -119.45 116.12 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -121.28 115.17 2.77 Favored Glycine 0 C--O 1.24 0.526 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -138.23 150.75 47.01 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 122.971 1.367 . . . . 0.0 112.924 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.727 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 34.1 ttp -121.65 127.1 50.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.065 -1.425 . . . . 0.0 109.765 178.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.15 72.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 120.619 -0.433 . . . . 0.0 110.035 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.98 110.58 3.08 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.75 163.44 8.07 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.5 m -137.66 159.33 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.077 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.697 -179.781 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . 0.473 ' C ' ' ND1' ' I' ' 13' ' ' HIS . 27.1 m . . . . . 0 N--CA 1.469 0.512 0 CA-C-O 121.339 0.59 . . . . 0.0 110.869 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.643 ' CD2' ' NE2' ' H' ' 13' ' ' HIS . 12.9 m80 -139.78 140.92 36.79 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.185 -178.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' I' ' 15' ' ' GLN . 59.4 t-80 -153.48 162.12 41.58 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 178.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.592 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 49.8 tt0 -162.17 172.24 16.11 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.376 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . 0.455 ' H ' ' CG ' ' I' ' 15' ' ' GLN . 88.0 tttt -172.59 128.65 0.53 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.734 179.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 tt -130.27 121.47 26.18 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -120.34 126.53 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 122.256 -0.277 . . . . 0.0 111.709 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -103.98 101.26 11.04 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 176.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -113.27 117.85 33.01 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.22 124.87 35.61 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.442 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 14.4 pt-20 -127.09 75.41 1.58 Allowed 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.707 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.558 ' O ' ' NZ ' ' G' ' 28' ' ' LYS . 0.0 OUTLIER 164.03 115.0 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 114.198 -1.364 . . . . 0.0 109.872 176.158 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.486 ' H ' ' CG ' ' J' ' 23' ' ' ASP . 39.5 t -148.57 107.47 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 118.976 -1.089 . . . . 0.0 108.726 173.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' I' ' 24' ' ' VAL . . . -39.62 -93.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.406 0 CA-C-O 123.984 1.88 . . . . 0.0 109.929 171.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.408 ' O ' ' O ' ' I' ' 25' ' ' GLY . 79.5 p 47.28 -178.59 0.01 OUTLIER 'General case' 0 CA--C 1.481 -1.703 0 CA-C-N 110.276 -2.962 . . . . 0.0 111.025 177.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' I' ' 28' ' ' LYS . 29.4 m120 -126.47 164.4 21.22 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.25 -1.795 . . . . 0.0 107.292 172.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' I' ' 27' ' ' ASN 0.263 45.1 mttm -27.85 112.56 0.06 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 114.984 1.476 . . . . 0.0 114.984 174.809 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.35 92.64 2.24 Favored Glycine 0 N--CA 1.48 1.577 0 C-N-CA 124.602 1.096 . . . . 0.0 115.169 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.498 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -87.64 179.71 6.47 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 173.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.416 ' CG1' ' C ' ' I' ' 30' ' ' ALA . 0.4 OUTLIER -141.83 124.65 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 C-N-CA 116.517 -2.073 . . . . 0.0 111.471 -176.902 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 9.1 tt -125.89 127.24 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.213 0.53 . . . . 0.0 111.778 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . 0.644 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.81 117.46 3.04 Favored Glycine 0 C--O 1.24 0.482 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 16.9 tp -137.84 135.36 36.13 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-O 121.611 0.719 . . . . 0.0 111.744 -178.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.681 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 54.9 ttp -105.21 125.3 50.83 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.75 176.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.79 72.09 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.135 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.58 111.3 3.5 Favored Glycine 0 C--N 1.364 2.128 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 177.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -71.99 160.51 54.07 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -136.79 162.01 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.805 0.336 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.552 -179.879 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 121.268 0.556 . . . . 0.0 111.416 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 68.9 m80 -139.11 134.74 33.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.675 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . 0.642 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 4.8 t60 -148.56 158.11 43.91 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.759 0.79 . . . . 0.0 110.464 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.642 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 83.2 mt-30 -150.59 174.46 12.95 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.546 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 54.0 tttp -175.82 127.3 0.23 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.193 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -130.4 129.96 43.73 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' K' ' 18' ' ' VAL . 1.4 p -144.99 140.62 23.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -178.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.4 ' N ' ' CD1' ' J' ' 19' ' ' PHE . 0.6 OUTLIER -114.26 120.37 40.2 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.69 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.72 117.53 29.16 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.44 120.34 36.54 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 121.487 0.66 . . . . 0.0 111.653 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -159.69 104.45 1.58 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.486 ' CG ' ' H ' ' I' ' 24' ' ' VAL . 60.2 t0 -82.93 -133.52 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 175.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.54 ' O ' ' O ' ' J' ' 25' ' ' GLY . 21.9 t -92.2 112.17 25.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 N-CA-C 101.05 -3.685 . . . . 0.0 101.05 172.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . 0.54 ' O ' ' O ' ' J' ' 24' ' ' VAL . . . 42.38 90.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.01 -2.436 . . . . 0.0 107.01 -173.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.547 ' CB ' ' O ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -61.65 -179.82 0.2 Allowed 'General case' 0 N--CA 1.438 -1.034 0 C-N-CA 118.784 -1.167 . . . . 0.0 109.638 -174.865 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.466 ' N ' ' OG ' ' J' ' 26' ' ' SER . 1.6 m-20 -80.48 173.61 12.43 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 116.825 2.157 . . . . 0.0 116.825 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.552 ' O ' ' N ' ' J' ' 30' ' ' ALA 0.369 48.2 tttp -48.06 111.81 0.49 Allowed 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 109.221 -3.627 . . . . 0.0 116.782 173.499 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -68.34 99.19 0.56 Allowed Glycine 1 CA--C 1.446 -4.275 2 CA-C-O 128.699 4.5 . . . . 0.0 102.799 -176.331 . . . . . . . . 4 3 . 1 . 007 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -77.08 -132.78 0.01 OUTLIER 'General case' 1 N--CA 1.339 -6.005 3 CA-C-N 97.435 -9.383 . . . . 0.0 107.55 -167.012 . . . . . . . . 4 3 . 1 . 007 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.698 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 0.1 OUTLIER -90.02 108.94 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.692 0 CA-C-N 114.57 -1.195 . . . . 0.0 110.467 -175.592 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.541 ' O ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -106.58 111.05 33.78 Favored 'Isoleucine or valine' 0 C--N 1.363 1.169 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.699 179.486 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.89 103.85 1.67 Allowed Glycine 0 CA--C 1.505 -0.545 0 N-CA-C 107.819 -2.112 . . . . 0.0 107.819 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.461 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 66.9 mt -126.03 121.72 33.8 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.951 0.881 . . . . 0.0 112.514 -177.253 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 6.1 ttt -102.94 120.37 40.51 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 114.252 -1.34 . . . . 0.0 108.391 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t -137.23 66.86 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.327 -178.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.28 -102.63 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.13 154.88 30.65 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 50.5 t . . . . . 0 N--CA 1.465 0.289 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.495 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 . . . . . 0 N--CA 1.464 0.237 0 CA-C-O 120.878 0.37 . . . . 0.0 111.347 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 74.1 t -126.58 134.72 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' L' ' 13' ' ' HIS . 44.3 t60 -116.41 123.48 47.64 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 117.845 0.293 . . . . 0.0 111.309 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -114.86 158.95 21.23 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.418 ' O ' ' CG ' ' K' ' 16' ' ' LYS . 53.4 tt0 -170.05 161.58 8.71 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.226 177.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 95.5 mttt -163.03 132.23 4.12 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 tp -122.9 119.21 29.81 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 96.6 t -136.42 133.74 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.604 ' CZ ' ' CD2' ' L' ' 19' ' ' PHE . 23.4 p90 -145.62 130.4 18.1 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.296 177.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.638 ' N ' ' CD1' ' K' ' 20' ' ' PHE . 0.0 OUTLIER -149.35 163.77 36.78 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -178.475 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 141.67 38.89 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.328 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . 0.547 ' O ' ' CB ' ' J' ' 26' ' ' SER . 78.1 tt0 -89.71 156.59 18.45 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -178.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.52 ' OD2' ' N ' ' J' ' 28' ' ' LYS . 58.6 t0 176.11 130.79 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 123.465 0.706 . . . . 0.0 110.522 178.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.43 ' CG2' ' H ' ' K' ' 25' ' ' GLY . 5.3 m -87.53 -112.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.084 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 26' ' ' SER . . . -48.75 92.11 0.01 OUTLIER Glycine 0 CA--C 1.531 1.062 0 N-CA-C 114.838 0.695 . . . . 0.0 114.838 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.53 ' O ' ' O ' ' K' ' 25' ' ' GLY . 8.6 t -35.46 170.32 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.611 0.719 . . . . 0.0 111.368 176.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.481 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER -139.22 -177.15 4.78 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.946 177.751 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . 0.481 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 98.9 mttt -17.84 -104.87 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 113.242 0.83 . . . . 0.0 113.242 -178.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -150.44 95.34 0.16 Allowed Glycine 0 C--N 1.346 1.089 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.692 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' J' ' 29' ' ' GLY . . . -67.82 -173.13 0.32 Allowed 'General case' 0 C--O 1.237 0.444 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 175.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.77 130.03 14.06 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-O 122.212 1.006 . . . . 0.0 110.22 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 11.1 mm -114.84 122.5 69.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 114.164 -1.38 . . . . 0.0 110.485 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.434 ' H ' HG21 ' J' ' 32' ' ' ILE . . . -127.98 119.72 3.22 Favored Glycine 0 N--CA 1.473 1.121 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.722 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -129.39 122.25 29.05 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 114.524 -0.838 . . . . 0.0 110.211 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 38.8 ttp -105.96 119.62 39.64 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.88 178.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' K' ' 36' ' ' VAL . 54.7 t -139.8 71.06 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 119.415 -0.326 . . . . 0.0 110.53 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -53.88 -97.87 0.01 OUTLIER Glycine 0 C--N 1.342 0.897 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.32 163.83 35.86 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 C--N 1.328 -0.361 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.626 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' K' ' 13' ' ' HIS . 15.5 m80 -81.58 145.95 30.37 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.191 0.52 . . . . 0.0 111.047 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -83.45 177.78 8.31 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.196 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -110.73 178.69 4.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.813 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -146.24 140.85 26.83 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.045 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -125.33 119.99 29.89 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 7.3 t -141.45 131.9 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.643 0.735 . . . . 0.0 112.026 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.604 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 8.0 p90 -147.5 144.58 28.66 Favored 'General case' 0 C--N 1.322 -0.597 0 O-C-N 121.363 -0.835 . . . . 0.0 110.926 178.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' L' ' 19' ' ' PHE . 60.2 m-85 -157.77 157.35 33.21 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.52 1.152 . . . . 0.0 113.958 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.35 139.42 52.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.868 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -74.48 101.71 4.24 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.786 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 35.6 p-10 -171.4 113.76 0.37 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.778 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' L' ' 26' ' ' SER . 73.7 t -64.99 131.71 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.861 -178.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.51 83.76 0.01 OUTLIER Glycine 0 N--CA 1.466 0.655 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.518 ' N ' ' O ' ' L' ' 24' ' ' VAL . 15.4 m -67.52 -171.1 0.17 Allowed 'General case' 0 N--CA 1.437 -1.124 0 CA-C-O 122.541 1.163 . . . . 0.0 112.488 -177.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.515 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 54.3 t30 -80.51 179.39 7.76 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.788 -177.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.515 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.4 mttt -36.41 104.4 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.577 -178.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 168.09 -100.36 0.16 Allowed Glycine 0 C--O 1.22 -0.774 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -175.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.413 ' C ' ' CG1' ' L' ' 31' ' ' ILE . . . -51.35 172.13 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.682 1.741 . . . . 0.0 108.054 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . 0.413 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -152.53 149.41 13.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 C-N-CA 118.144 -1.423 . . . . 0.0 111.253 -176.44 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 38.5 pt -125.89 143.63 38.77 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.153 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.27 114.73 1.51 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.6 mt -119.09 120.31 36.77 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttp -111.75 123.99 51.39 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 120.204 -0.599 . . . . 0.0 111.47 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' L' ' 37' ' ' GLY . 4.9 t -133.91 69.68 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -27.17 -105.69 0.0 OUTLIER Glycine 0 CA--C 1.533 1.187 0 CA-C-O 121.344 0.413 . . . . 0.0 114.064 -179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . 0.46 ' H ' ' CD1' ' F' ' 31' ' ' ILE . . . -38.09 156.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 115.312 -0.444 . . . . 0.0 112.459 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.79 159.32 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.189 -0.505 . . . . 0.0 110.06 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.828 -179.721 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.873 0.368 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.15 146.93 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.729 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 14' ' ' HIS . 37.5 p-80 -91.12 -178.63 5.22 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.451 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 13' ' ' HIS . 24.8 m-70 -74.26 172.5 11.72 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -145.36 176.73 9.35 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.504 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -150.01 112.09 4.61 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.26 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -124.45 115.46 20.95 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 121.424 0.631 . . . . 0.0 110.261 179.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -123.6 128.96 74.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.403 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -128.76 124.13 34.7 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.9 p90 -128.04 125.63 39.71 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.94 0.4 . . . . 0.0 110.253 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.12 119.03 35.04 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -164.2 120.27 1.59 Allowed 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 38.7 t0 . . . . . 0 C--N 1.322 -0.619 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.561 -178.923 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.471 ' CB ' ' OD2' ' B' ' 23' ' ' ASP 0.442 74.5 tttt . . . . . 0 CA--C 1.538 0.495 0 CA-C-O 121.133 0.492 . . . . 0.0 111.576 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.66 104.03 1.23 Allowed Glycine 0 C--N 1.302 -1.317 0 CA-C-O 127.334 3.741 . . . . 0.0 112.02 -169.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . 0.545 ' O ' ' N ' ' A' ' 32' ' ' ILE . . . -69.81 -122.2 0.0 OUTLIER 'General case' 0 CA--C 1.479 -1.778 3 CA-C-N 103.478 -6.361 . . . . 0.0 96.052 -179.563 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.644 ' CD1' ' O ' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -51.16 99.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.587 2.401 0 CA-C-N 124.89 3.495 . . . . 0.0 107.895 175.942 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' ALA . 4.9 tt -128.78 113.44 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 119.419 -2.051 . . . . 0.0 109.387 178.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.516 ' HA2' ' O ' ' B' ' 33' ' ' GLY . . . -129.36 126.06 5.04 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 106.617 -2.593 . . . . 0.0 106.617 178.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 36.8 tp -133.67 135.22 43.96 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 122.529 1.157 . . . . 0.0 111.641 -178.251 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttm -104.66 110.54 22.9 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 113.752 -1.567 . . . . 0.0 107.198 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.15 72.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.7 110.83 3.12 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.15 165.74 11.95 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -95.01 135.98 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 110.711 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.62 179.797 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -102.92 134.93 45.52 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -141.21 130.35 23.42 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.952 0.406 . . . . 0.0 110.834 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.17 146.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.627 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 t60 -154.83 104.68 2.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.038 0.447 . . . . 0.0 111.16 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' ND1' ' C' ' 14' ' ' HIS . 31.3 m170 -119.35 164.51 15.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -154.47 173.03 16.81 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.01 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -153.67 114.11 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.809 178.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -128.39 114.49 16.91 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.92 133.73 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-O 121.101 0.477 . . . . 0.0 111.064 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -119.46 129.61 54.83 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.997 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -124.65 129.07 49.84 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.691 -0.231 . . . . 0.0 110.468 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.13 128.34 43.27 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 111.859 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.8 tt0 -136.79 149.36 47.73 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' CB ' ' A' ' 28' ' ' LYS . 81.3 m-20 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.812 0.339 . . . . 0.0 111.344 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.62 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.419 -5.908 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.62 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 119.44 -112.39 0.0 OUTLIER 'General case' 0 N--CA 1.391 -3.425 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 -173.213 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.464 ' H ' HD12 ' B' ' 31' ' ' ILE . 2.3 mp -79.79 113.29 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.037 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.507 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 tt -124.85 109.35 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.629 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -130.06 120.37 3.07 Favored Glycine 0 N--CA 1.468 0.815 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.433 ' O ' ' CD1' ' C' ' 34' ' ' LEU . 7.4 mp -136.5 160.34 39.07 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 123.219 1.485 . . . . 0.0 113.67 -178.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.6 ttm -127.5 112.33 14.82 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 112.791 -2.004 . . . . 0.0 107.677 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -119.6 74.07 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -179.583 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -31.89 -97.99 0.01 OUTLIER Glycine 0 C--N 1.357 1.749 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.48 -173.09 24.59 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.0 p -141.35 141.8 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.95 0.405 . . . . 0.0 110.511 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.945 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 52.2 t . . . . . 0 N--CA 1.467 0.416 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 17.2 p-80 -155.63 143.0 19.42 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 121.13 0.491 . . . . 0.0 111.241 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.632 ' ND1' ' CD2' ' B' ' 14' ' ' HIS . 6.1 m80 -140.91 167.38 22.33 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.11 0.481 . . . . 0.0 109.931 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -150.99 169.88 20.7 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.964 178.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -156.96 117.9 3.66 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.55 123.79 40.86 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.648 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -133.54 133.28 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -116.82 107.4 14.58 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 105.287 -2.116 . . . . 0.0 105.287 175.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 24.3 t80 -122.48 134.84 54.56 Favored 'General case' 0 N--CA 1.477 0.878 0 O-C-N 122.312 -0.242 . . . . 0.0 110.532 -177.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . 0.426 ' CB ' ' NZ ' ' A' ' 28' ' ' LYS . . . -145.61 144.11 30.27 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -142.61 110.73 5.99 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 114.147 -1.388 . . . . 0.0 109.642 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 4.1 m-20 . . . . . 0 C--O 1.215 -0.723 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.593 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.95 155.8 49.72 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.492 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -141.5 117.39 6.5 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 112.295 -2.23 . . . . 0.0 109.204 -170.592 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 5.4 mt -105.5 111.64 35.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . 0.499 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -122.11 104.39 0.91 Allowed Glycine 0 CA--C 1.506 -0.499 0 N-CA-C 106.273 -2.731 . . . . 0.0 106.273 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.433 ' CD1' ' O ' ' B' ' 34' ' ' LEU . 54.6 tp -132.59 141.05 48.52 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 123.3 1.524 . . . . 0.0 113.806 -176.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.543 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 8.3 ttm -115.56 118.43 33.11 Favored 'General case' 0 CA--C 1.505 -0.774 0 CA-C-N 112.4 -2.182 . . . . 0.0 109.262 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.3 m -128.57 74.12 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.1 105.68 3.08 Favored Glycine 0 C--N 1.354 1.545 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -129.76 148.29 18.34 Favored Glycine 0 N--CA 1.466 0.685 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 m -134.05 159.8 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.944 0.402 . . . . 0.0 110.834 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.914 179.816 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t . . . . . 0 CA--C 1.516 -0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.8 p-80 -157.8 148.74 21.14 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.632 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.565 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 56.7 t-80 -144.98 158.83 43.69 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . 0.565 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 67.7 mt-30 -156.22 172.15 18.96 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.106 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -155.63 122.3 5.29 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.709 179.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.7 tp -117.39 123.1 45.63 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 39.1 t -130.53 131.22 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -112.73 108.88 18.06 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.0 t80 -123.35 123.76 41.43 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 120.93 0.395 . . . . 0.0 112.026 -176.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.61 127.32 30.96 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.253 178.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -140.46 114.29 8.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.771 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . 0.517 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.2 OUTLIER . . . . . 0 N--CA 1.454 -0.242 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.971 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.487 -1.452 0 N-CA-C 101.352 -3.574 . . . . 0.0 101.352 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.418 ' C ' ' SD ' ' J' ' 35' ' ' MET . 0.0 OUTLIER -136.27 122.59 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.647 -171.33 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CE ' ' K' ' 35' ' ' MET . 78.4 mt -116.36 123.27 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.055 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.57 109.19 1.08 Allowed Glycine 0 N--CA 1.463 0.461 0 N-CA-C 107.609 -2.196 . . . . 0.0 107.609 175.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 14.7 tp -122.09 124.53 44.12 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 121.541 0.686 . . . . 0.0 112.243 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.508 ' SD ' ' N ' ' J' ' 32' ' ' ILE . 13.5 ttm -102.86 113.6 27.18 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.01 72.85 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.809 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.14 111.53 3.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 178.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.73 135.47 7.22 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -124.27 135.95 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.797 0.332 . . . . 0.0 110.309 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.588 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.49 148.25 33.56 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.788 0.328 . . . . 0.0 110.237 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -57.45 136.36 56.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.296 -0.411 . . . . 0.0 109.951 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -135.33 142.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -109.85 -178.89 3.65 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 118.179 0.445 . . . . 0.0 110.959 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CD2' ' F' ' 13' ' ' HIS . 93.8 m-70 -142.41 -178.66 5.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.751 0.786 . . . . 0.0 110.149 -179.078 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -88.46 168.0 12.99 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.661 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.42 143.38 33.88 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.273 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -131.22 124.35 30.4 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.146 0.498 . . . . 0.0 111.671 -178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -128.3 129.39 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.854 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -117.99 120.85 39.05 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -128.59 127.66 42.71 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 117.927 0.331 . . . . 0.0 111.124 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.3 131.55 43.89 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 122.381 1.086 . . . . 0.0 113.058 -179.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -138.27 85.73 2.11 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.069 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -93.97 -130.71 0.14 Allowed 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 82.9 t -106.2 112.32 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 N-CA-C 104.747 -2.316 . . . . 0.0 104.747 175.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 31.76 88.08 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 113.904 -1.498 . . . . 0.0 112.977 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.482 ' N ' ' HB2' ' F' ' 23' ' ' ASP . 35.3 p . . . . . 0 C--N 1.35 0.597 0 CA-C-N 119.262 1.531 . . . . 0.0 108.718 173.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.886 1 N-CA-C 93.028 -6.656 . . . . 0.0 93.028 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.5 OUTLIER -85.09 114.91 26.0 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 1 CA-C-N 127.789 4.813 . . . . 0.0 109.163 176.935 . . . . . . . . 4 4 . 1 . 008 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' K' ' 35' ' ' MET . 16.1 tt -136.69 134.94 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-O 121.719 0.771 . . . . 0.0 112.452 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -131.9 127.36 4.95 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 23.9 tp -121.03 124.26 44.41 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.637 -0.282 . . . . 0.0 111.679 -178.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.1 tpp -115.99 114.6 24.82 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.86 88.51 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.62 -178.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.58 95.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 119.67 -1.253 . . . . 0.0 110.342 178.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -159.28 162.56 32.86 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.56 162.77 34.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.311 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -148.26 159.59 43.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.016 0.436 . . . . 0.0 111.256 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -67.25 137.9 56.5 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.985 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -127.16 132.38 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.326 0.584 . . . . 0.0 110.999 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' NE2' ' E' ' 14' ' ' HIS . 27.2 t-80 -156.07 100.95 2.06 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.888 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -147.23 173.3 12.68 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -145.03 174.65 10.85 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.319 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -145.99 112.71 5.98 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.032 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 35.8 mt -125.07 110.2 13.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 m -145.93 147.12 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 118.682 -1.207 . . . . 0.0 114.244 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 73.0 m-85 -126.7 128.3 46.48 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 113.967 -1.469 . . . . 0.0 108.431 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -138.36 146.48 42.35 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.12 0.486 . . . . 0.0 111.458 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.55 146.48 32.39 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.956 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -88.07 127.47 35.4 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.482 ' HB2' ' N ' ' E' ' 26' ' ' SER . 67.1 t0 178.1 114.36 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 79.6 t -65.39 132.44 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . 71.68 -85.08 0.45 Allowed Glycine 0 N--CA 1.47 0.958 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 26' ' ' SER . . . . . 0.551 ' CB ' ' O ' ' F' ' 25' ' ' GLY . 2.8 t 140.23 165.4 0.0 OUTLIER 'General case' 0 C--N 1.352 0.703 0 CA-C-O 122.577 1.18 . . . . 0.0 112.905 174.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.504 ' N ' ' OD1' ' F' ' 27' ' ' ASN . 0.5 OUTLIER -46.48 171.93 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.44 175.535 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -69.93 111.53 5.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 170.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.88 -92.88 0.93 Allowed Glycine 0 N--CA 1.475 1.257 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.861 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.5 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . 83.38 160.28 0.12 Allowed 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 100.439 -3.911 . . . . 0.0 100.439 -174.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.5 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.2 OUTLIER -151.67 127.87 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 122.45 2.386 . . . . 0.0 111.039 -176.286 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -121.43 132.77 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-N 114.151 -1.386 . . . . 0.0 114.254 -175.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -130.22 115.12 1.78 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 mt -118.45 127.49 53.71 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CA ' ' L' ' 33' ' ' GLY . 1.8 ttt -132.09 126.7 34.41 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.539 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -143.33 82.52 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.442 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.23 100.37 0.04 OUTLIER Glycine 0 C--N 1.337 0.61 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.674 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.11 163.09 35.76 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -121.45 132.94 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.924 0.393 . . . . 0.0 110.315 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.897 -179.566 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 t60 . . . . . 0 C--O 1.225 -0.191 0 CA-C-O 120.88 0.372 . . . . 0.0 110.675 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 14.8 t60 -147.84 163.56 36.38 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 85.3 mt-30 -151.64 178.17 9.61 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.326 0.584 . . . . 0.0 110.871 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 25.5 pttm -167.72 133.57 2.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.266 179.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -133.57 125.05 28.0 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.95 138.14 49.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.248 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -134.77 137.25 43.24 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . 0.483 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 54.3 p90 -135.18 129.05 33.16 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.142 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.38 134.75 50.96 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -157.21 124.66 5.28 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.359 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.558 ' O ' ' O ' ' G' ' 24' ' ' VAL . 12.0 m-20 -154.13 122.71 6.21 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 120.827 -0.349 . . . . 0.0 111.849 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.558 ' O ' ' O ' ' G' ' 23' ' ' ASP . 11.8 m -43.67 -122.1 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 O-C-N 124.273 0.983 . . . . 0.0 111.621 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.49 -90.79 1.35 Allowed Glycine 0 CA--C 1.528 0.886 0 CA-C-O 119.52 -0.6 . . . . 0.0 113.023 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' G' ' 27' ' ' ASN . 1.3 p 173.76 -170.58 0.04 OUTLIER 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 117.587 0.694 . . . . 0.0 109.625 -177.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' G' ' 26' ' ' SER . 16.4 t-20 -16.98 158.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 O-C-N 125.149 1.53 . . . . 0.0 113.49 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.531 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 28.6 tttt -161.56 108.54 1.4 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.58 98.1 0.66 Allowed Glycine 0 N--CA 1.467 0.746 0 CA-C-O 116.221 -2.433 . . . . 0.0 107.935 172.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.08 154.24 19.95 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 123.627 3.714 . . . . 0.0 110.552 -176.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -153.82 114.55 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 112.528 -2.124 . . . . 0.0 109.75 -173.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 6.0 tt -122.78 113.79 39.61 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 176.355 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.68 137.61 9.52 Favored Glycine 0 CA--C 1.502 -0.731 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -153.26 146.81 25.01 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 122.447 1.117 . . . . 0.0 112.024 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.402 ' CE ' ' O ' ' A' ' 31' ' ' ILE . 31.0 mtp -105.19 119.15 38.34 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 113.257 -1.792 . . . . 0.0 107.878 178.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.76 65.72 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.297 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.283 178.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.95 102.42 0.56 Allowed Glycine 0 C--N 1.376 2.754 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 177.08 170.3 39.35 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-O 120.93 0.395 . . . . 0.0 110.258 179.321 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t . . . . . 0 CA--C 1.522 -0.103 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . 0.62 ' ND1' ' NE2' ' I' ' 13' ' ' HIS . 40.7 m80 -137.18 145.78 44.13 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.953 0.406 . . . . 0.0 111.396 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.531 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 99.1 m-70 -147.09 155.96 42.61 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.4 mm-40 -148.73 168.29 23.3 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.41 178.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -163.6 128.63 2.96 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.46 -0.791 . . . . 0.0 108.983 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 tt -127.46 118.11 23.4 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 72.8 t -122.2 129.48 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.202 -179.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -126.25 122.87 36.78 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -126.84 127.66 45.33 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.702 0.286 . . . . 0.0 111.374 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.36 125.61 50.38 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 120.981 0.42 . . . . 0.0 111.525 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' O ' ' I' ' 22' ' ' GLU . 52.7 tp10 -132.67 157.4 44.94 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.664 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -158.64 142.03 14.98 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--N 1.321 -0.658 0 CA-C-O 122.344 1.068 . . . . 0.0 110.391 -177.878 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.082 0 CA-C-O 123.279 1.514 . . . . 0.0 107.546 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.414 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -140.03 121.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-N 112.404 -2.18 . . . . 0.0 110.529 -173.474 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.513 ' N ' ' SD ' ' B' ' 35' ' ' MET . 8.7 tt -111.33 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 CA-C-O 121.613 0.72 . . . . 0.0 110.112 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.37 94.85 0.76 Allowed Glycine 0 N--CA 1.461 0.366 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 35.6 mt -117.0 129.25 55.9 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.273 1.035 . . . . 0.0 111.551 -178.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.629 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 21.9 ttp -116.27 115.52 26.1 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.312 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.89 71.15 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.897 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.61 112.41 3.61 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -50.64 152.52 4.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.84 162.02 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.297 179.901 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.553 0.692 . . . . 0.0 111.757 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.62 ' NE2' ' ND1' ' H' ' 13' ' ' HIS . 71.2 m80 -150.07 101.85 3.05 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.134 178.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 84.9 t60 -121.23 162.91 19.39 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.853 0.835 . . . . 0.0 111.376 -178.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.546 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 84.3 mt-30 -148.47 177.73 9.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.098 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -171.01 125.28 0.66 Allowed 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.4 mt -126.71 123.34 37.28 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' J' ' 18' ' ' VAL . 12.6 p -136.41 133.32 49.44 Favored 'Isoleucine or valine' 0 C--N 1.351 0.663 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -115.68 126.06 53.63 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.649 177.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -129.38 121.85 28.26 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 118.327 0.512 . . . . 0.0 111.03 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.31 128.46 51.08 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.077 0.465 . . . . 0.0 111.224 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' H' ' 22' ' ' GLU . 82.1 tt0 -149.02 124.67 10.43 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.311 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -157.11 103.97 2.05 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 118.909 -1.116 . . . . 0.0 113.799 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 2.2 p -31.78 147.67 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.525 -1.216 . . . . 0.0 113.07 175.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . 0.4 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 168.52 -79.42 0.1 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.282 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 1.001 ' O ' ' O ' ' I' ' 27' ' ' ASN . 2.1 p 161.66 179.86 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 1.001 ' O ' ' O ' ' I' ' 26' ' ' SER . 8.2 m120 10.52 -178.74 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.112 0 O-C-N 124.841 1.338 . . . . 0.0 113.251 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.497 ' O ' ' N ' ' J' ' 29' ' ' GLY . 12.7 tttt -149.15 109.77 4.24 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 116.202 -2.199 . . . . 0.0 114.646 177.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.96 94.65 0.79 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 106.248 -2.741 . . . . 0.0 106.248 168.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.43 144.4 51.06 Favored 'General case' 0 CA--C 1.476 -1.882 0 CA-C-N 122.543 3.171 . . . . 0.0 107.094 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.516 ' CG2' ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -144.15 125.24 9.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 113.09 -1.868 . . . . 0.0 109.504 -175.189 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.543 ' N ' ' SD ' ' C' ' 35' ' ' MET . 0.8 OUTLIER -105.22 110.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.064 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.69 101.73 1.24 Allowed Glycine 0 CA--C 1.494 -1.243 0 N-CA-C 104.817 -3.313 . . . . 0.0 104.817 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.578 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 17.0 tp -136.82 137.55 39.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-O 122.11 0.957 . . . . 0.0 112.508 -175.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 31.1 ttp -122.86 123.42 40.94 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 113.74 -1.573 . . . . 0.0 110.164 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.35 71.56 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.84 113.1 5.03 Favored Glycine 0 C--N 1.358 1.779 0 N-CA-C 110.531 -1.027 . . . . 0.0 110.531 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.16 147.81 41.66 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 64.3 t -130.87 137.29 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.44 179.815 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.473 0.686 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.9 OUTLIER -131.31 155.98 46.25 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 121.19 0.519 . . . . 0.0 110.943 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -152.4 160.18 43.32 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -154.67 172.25 18.2 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.219 -0.592 . . . . 0.0 110.634 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -155.75 127.96 7.65 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.747 178.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 87.4 mt -120.47 120.12 34.98 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' I' ' 18' ' ' VAL . 2.0 p -143.06 137.92 26.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -177.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.83 127.9 13.7 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 119.684 -0.806 . . . . 0.0 111.403 176.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -147.77 160.82 42.31 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.443 1.116 . . . . 0.0 113.752 -178.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 140.17 43.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 113.934 -1.484 . . . . 0.0 109.946 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.17 149.44 39.74 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.968 -178.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 33.7 t70 -173.49 126.46 0.41 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.08 0.467 . . . . 0.0 111.293 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 m -62.61 -116.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.516 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.47 -92.22 0.06 OUTLIER Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.603 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.831 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.3 t -171.24 170.05 6.17 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 117.535 0.668 . . . . 0.0 109.986 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.831 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.8 m120 10.85 -179.16 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 125.763 1.914 . . . . 0.0 115.567 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.547 ' H ' ' N ' ' K' ' 27' ' ' ASN . 15.8 pttt -149.4 110.76 4.44 Favored 'General case' 0 CA--C 1.558 1.25 0 O-C-N 120.635 -1.29 . . . . 0.0 114.284 178.263 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -61.48 93.22 0.07 OUTLIER Glycine 0 N--CA 1.479 1.517 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 172.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.39 149.33 49.3 Favored 'General case' 0 CA--C 1.486 -1.489 0 CA-C-N 121.677 2.739 . . . . 0.0 111.069 -178.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.487 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.0 OUTLIER -148.33 114.42 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.816 0 CA-C-N 108.989 -3.732 . . . . 0.0 107.612 -174.968 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.508 ' N ' ' SD ' ' D' ' 35' ' ' MET . 3.1 mt -105.56 118.74 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 CA-C-O 120.749 0.309 . . . . 0.0 110.429 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.96 100.78 0.91 Allowed Glycine 0 C--O 1.239 0.421 0 N-CA-C 106.9 -2.48 . . . . 0.0 106.9 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.627 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 55.7 tp -129.58 135.39 48.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.003 0.906 . . . . 0.0 112.415 -177.39 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.418 ' SD ' ' C ' ' D' ' 31' ' ' ILE . 48.9 ttp -117.87 117.07 28.28 Favored 'General case' 0 CA--C 1.502 -0.881 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.55 175.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.26 72.2 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 178.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.51 111.87 4.5 Favored Glycine 0 C--N 1.36 1.861 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 178.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.36 -151.58 3.07 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -179.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.9 m . . . . . 0 N--CA 1.467 0.386 0 CA-C-O 121.097 0.475 . . . . 0.0 110.74 179.994 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 . . . . . 0 N--CA 1.466 0.328 0 CA-C-O 120.676 0.274 . . . . 0.0 110.702 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.5 m -118.88 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.099 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . 0.631 ' CE1' ' NE2' ' L' ' 14' ' ' HIS . 1.8 p80 -161.7 168.87 22.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.475 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.537 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 39.4 t-80 -138.71 165.67 26.36 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.548 0.69 . . . . 0.0 110.901 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.537 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 87.4 mt-30 -148.42 178.69 8.38 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.966 -1.015 . . . . 0.0 110.091 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -172.76 123.41 0.44 Allowed 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 118.419 -0.8 . . . . 0.0 111.45 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . 0.943 ' O ' ' C ' ' L' ' 17' ' ' LEU . 9.4 mp -110.73 119.07 37.92 Favored 'General case' 0 C--N 1.379 1.85 0 CA-C-O 123.836 1.779 . . . . 0.0 111.111 177.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 7.1 p -138.25 112.07 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 O-C-N 120.675 -1.266 . . . . 0.0 111.432 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 1.7 p90 -134.51 139.62 45.59 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 176.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.47 ' CB ' ' O ' ' L' ' 20' ' ' PHE . 30.3 p90 -154.77 162.9 40.94 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -176.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.35 130.61 48.0 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.412 178.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.31 137.13 50.83 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.158 0.504 . . . . 0.0 111.965 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 56.6 t0 -159.56 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.323 178.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' K' ' 26' ' ' SER . 55.9 t -123.88 123.02 66.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 179.047 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.476 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 32.0 -84.35 0.0 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' K' ' 24' ' ' VAL . 8.1 t 154.31 172.0 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 121.748 0.785 . . . . 0.0 111.235 174.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.547 ' N ' ' H ' ' J' ' 28' ' ' LYS . 43.1 p-10 -53.63 179.94 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.43 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.72 112.09 1.88 Allowed 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.51 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . 75.4 -91.74 0.85 Allowed Glycine 0 CA--C 1.532 1.145 0 C-N-CA 121.285 -0.483 . . . . 0.0 112.083 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.51 ' CB ' ' O ' ' K' ' 29' ' ' GLY . . . 106.48 161.13 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 104.562 -2.384 . . . . 0.0 104.562 -178.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.88 132.15 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 118.027 -1.469 . . . . 0.0 112.796 -178.269 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -124.42 123.68 66.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.3 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 114.93 2.94 Favored Glycine 0 N--CA 1.473 1.126 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 46.0 mt -122.42 127.31 49.51 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 56.8 ttp -119.83 121.29 38.77 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.234 177.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.4 88.17 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.23 96.06 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.85 162.19 31.51 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.468 0.428 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.77 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.467 0.413 0 CA-C-O 121.116 0.484 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -99.45 176.79 5.38 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.276 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CE1' ' K' ' 13' ' ' HIS . 0.4 OUTLIER -92.36 165.76 12.91 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.302 0.573 . . . . 0.0 110.04 -179.614 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -168.19 168.58 11.54 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.548 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.52 108.71 2.98 Favored 'General case' 0 C--O 1.171 -3.049 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . 0.943 ' C ' ' O ' ' K' ' 17' ' ' LEU . 2.7 mm? -73.09 160.73 31.56 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 119.654 -1.903 . . . . 0.0 107.622 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 14.3 m -99.89 -121.06 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -173.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.627 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 7.7 p90 -147.6 162.11 39.78 Favored 'General case' 0 N--CA 1.47 0.551 0 O-C-N 121.618 -0.676 . . . . 0.0 112.588 -177.178 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . 0.47 ' O ' ' CB ' ' K' ' 20' ' ' PHE . 93.6 m-85 -144.72 151.48 38.96 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 121.718 0.77 . . . . 0.0 112.087 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.64 138.27 39.3 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -69.79 95.08 0.87 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.128 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -164.06 121.57 1.75 Allowed 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.589 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' L' ' 26' ' ' SER . 13.5 t -88.53 123.56 40.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.61 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.3 0.01 OUTLIER Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.578 ' N ' ' O ' ' L' ' 24' ' ' VAL . 12.8 t -68.13 -171.59 0.25 Allowed 'General case' 0 N--CA 1.441 -0.921 0 CA-C-O 122.593 1.187 . . . . 0.0 112.333 -177.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.415 ' O ' ' C ' ' L' ' 28' ' ' LYS . 35.4 p-10 -81.0 179.29 7.93 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 112.547 -2.115 . . . . 0.0 109.814 178.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' L' ' 27' ' ' ASN . 70.1 tttt -37.17 104.15 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 167.84 -100.42 0.16 Allowed Glycine 0 C--O 1.22 -0.726 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -49.55 169.37 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.137 1.469 . . . . 0.0 108.734 -178.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.37 133.2 3.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.454 -177.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 83.7 mt -120.41 128.91 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 114.43 -1.259 . . . . 0.0 108.921 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . 0.428 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -125.7 124.82 5.36 Favored Glycine 0 N--CA 1.468 0.808 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.2 tp -126.99 120.04 28.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 36.8 ttp -110.34 126.67 54.48 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.0 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.2 t -130.28 81.73 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.83 101.43 0.3 Allowed Glycine 0 N--CA 1.439 -1.161 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.16 169.28 41.36 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 57.6 t -122.73 135.84 61.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 120.742 0.306 . . . . 0.0 110.218 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.446 -179.919 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' CE1' ' B' ' 13' ' ' HIS . 42.6 tp10 . . . . . 0 C--O 1.232 0.143 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.2 160.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.445 0.641 . . . . 0.0 111.386 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.0 m80 -89.0 -170.17 2.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.905 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -80.49 168.64 18.7 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 121.357 0.599 . . . . 0.0 110.002 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -157.21 -179.86 8.6 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.878 -1.055 . . . . 0.0 108.993 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -155.22 129.32 8.82 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.695 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 72.9 mt -129.28 118.95 23.13 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.597 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -130.17 131.19 65.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -127.65 131.53 49.84 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.009 0.433 . . . . 0.0 110.712 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -132.53 125.94 31.74 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.94 137.16 44.69 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-O 121.778 0.799 . . . . 0.0 112.955 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -126.8 126.77 43.94 Favored 'General case' 0 CA--C 1.528 0.12 0 CA-C-N 114.625 -1.17 . . . . 0.0 108.449 178.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 20.7 t70 . . . . . 0 C--N 1.325 -0.457 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.527 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.4 tttt . . . . . 0 C--O 1.217 -0.624 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.16 102.9 0.98 Allowed Glycine 0 N--CA 1.467 0.706 0 N-CA-C 103.622 -3.791 . . . . 0.0 103.622 170.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -97.35 144.11 27.43 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 123.311 3.555 . . . . 0.0 115.527 -172.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' G' ' 35' ' ' MET . 1.7 pt -159.82 105.56 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.421 -1.907 1 CA-C-N 107.016 -4.629 . . . . 0.0 106.245 -173.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.475 ' O ' ' CG2' ' A' ' 32' ' ' ILE . 8.1 tt -108.45 114.53 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 CA-C-N 120.524 1.511 . . . . 0.0 108.107 178.236 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -121.58 124.72 5.89 Favored Glycine 0 CA--C 1.508 -0.351 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -148.83 140.4 23.47 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 122.806 1.288 . . . . 0.0 113.002 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' MET . . . . . 0.586 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 3.7 ttm -109.82 117.65 34.42 Favored 'General case' 0 CA--C 1.505 -0.786 0 CA-C-N 113.038 -1.892 . . . . 0.0 108.094 177.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -111.12 68.04 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -120.79 101.53 0.81 Allowed Glycine 0 C--N 1.359 1.842 0 N-CA-C 110.404 -1.079 . . . . 0.0 110.404 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.39 165.73 35.2 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.329 -0.709 . . . . 0.0 111.329 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.96 156.24 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.663 0.268 . . . . 0.0 110.385 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.129 179.261 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.86 145.37 42.92 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.6 0.238 . . . . 0.0 110.447 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -68.04 126.87 30.86 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.279 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m -137.08 164.1 30.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.092 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.538 ' CE1' ' OE1' ' A' ' 11' ' ' GLU . 59.4 m80 -91.36 98.14 11.52 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.546 -0.461 . . . . 0.0 109.971 179.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 3.7 m-70 -134.51 166.83 21.98 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -154.57 175.11 14.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.059 179.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -154.46 117.04 4.35 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.495 179.2 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.03 119.5 29.69 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.454 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 t -122.33 127.68 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.961 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 83.0 t80 -130.22 126.26 36.93 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.834 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -128.48 132.59 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.63 132.35 38.89 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 121.126 0.489 . . . . 0.0 111.114 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -147.88 168.0 23.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.227 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 121.153 0.502 . . . . 0.0 111.245 -179.788 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.592 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.417 -6.093 0 CA-C-O 115.111 -3.05 . . . . 0.0 111.33 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.592 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 76.0 -135.22 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.71 2 C-N-CA 108.667 -5.213 . . . . 0.0 99.248 -174.351 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.769 ' CD1' ' N ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -75.47 122.65 29.74 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -179.325 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.433 HD13 HG21 ' B' ' 32' ' ' ILE . 83.3 mt -121.73 122.16 66.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 175.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . 0.474 ' O ' ' HA2' ' A' ' 33' ' ' GLY . . . -132.47 111.07 0.99 Allowed Glycine 0 N--CA 1.473 1.119 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.075 179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . 0.488 ' CD2' ' CZ ' ' C' ' 19' ' ' PHE . 6.4 mp -138.31 144.85 40.61 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 123.47 1.605 . . . . 0.0 113.168 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.506 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 19.6 ttm -119.07 115.85 25.16 Favored 'General case' 0 CA--C 1.499 -0.999 0 CA-C-N 113.002 -1.908 . . . . 0.0 107.41 177.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.26 70.62 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.096 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.3 112.5 3.46 Favored Glycine 0 C--N 1.363 2.057 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 -179.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' C' ' 37' ' ' GLY . . . -73.04 147.73 40.07 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -139.49 161.34 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.807 0.337 . . . . 0.0 110.424 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.026 -0.987 . . . . 0.0 110.518 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 121.3 0.571 . . . . 0.0 111.364 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -118.8 138.29 52.8 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.877 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 28.8 t-80 -152.38 165.45 34.97 Favored 'General case' 0 CA--C 1.513 -0.463 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . 0.583 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 75.8 mt-30 -156.44 170.35 22.51 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.025 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -158.87 111.59 2.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.829 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -121.96 122.07 38.52 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -126.67 124.52 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.128 0.49 . . . . 0.0 111.831 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' B' ' 34' ' ' LEU . 1.0 OUTLIER -116.54 110.75 18.99 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 105.89 -1.893 . . . . 0.0 105.89 177.456 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -115.36 121.02 41.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.87 130.59 53.06 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.697 0.761 . . . . 0.0 111.673 -179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -121.18 91.53 3.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.994 178.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.551 1.007 0 C-N-CA 118.816 -1.154 . . . . 0.0 113.129 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.873 0 N-CA-C 112.342 -0.303 . . . . 0.0 112.342 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.48 165.74 34.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 175.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . 0.453 ' HB ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -139.94 121.29 15.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 118.481 -1.287 . . . . 0.0 111.237 -173.687 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . 0.458 ' O ' ' CE ' ' I' ' 35' ' ' MET . 12.1 tt -116.72 122.35 69.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-O 121.487 0.661 . . . . 0.0 111.039 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.61 117.36 4.62 Favored Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.483 ' CD2' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -146.2 138.23 25.07 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.861 1.315 . . . . 0.0 113.006 -178.099 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 15.0 ttm -129.09 127.37 41.35 Favored 'General case' 0 CA--C 1.505 -0.753 0 CA-C-N 113.446 -1.707 . . . . 0.0 109.449 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.91 78.06 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' B' ' 38' ' ' GLY . . . -69.64 104.78 1.37 Allowed Glycine 0 C--N 1.351 1.399 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.56 -179.33 52.2 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.89 144.21 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.939 0.399 . . . . 0.0 110.771 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.561 179.943 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.466 0.337 0 CA-C-O 120.922 0.392 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.435 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 9.5 m80 -123.44 154.81 38.55 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.685 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.435 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 47.2 m80 -151.02 164.99 35.13 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.158 0.504 . . . . 0.0 110.06 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -158.99 169.51 24.14 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.553 178.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . 0.505 ' NZ ' ' HE2' ' C' ' 14' ' ' HIS . 60.0 mttp -159.43 117.13 2.73 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.316 178.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 mp -119.34 123.78 45.01 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -126.29 127.05 70.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . 0.447 ' CZ ' ' CD1' ' C' ' 34' ' ' LEU . 1.8 t80 -125.39 113.5 17.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -122.8 131.55 53.82 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -176.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 109.77 16.7 Favored 'General case' 0 C--O 1.249 1.079 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 177.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' E' ' 22' ' ' GLU . 87.2 tt0 -165.23 91.46 0.53 Allowed 'General case' 0 C--N 1.347 0.487 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 34.1 t70 . . . . . 0 C--N 1.324 -0.531 0 N-CA-C 102.915 -2.995 . . . . 0.0 102.915 173.259 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . . . . . . 1 N--CA 1.372 -4.338 1 N-CA-C 97.485 -5.006 . . . . 0.0 97.485 . . . . . . . . . 3 2 . 1 . 009 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.786 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 1.0 OUTLIER -74.74 111.88 11.29 Favored 'Isoleucine or valine' 1 C--N 1.243 -4.029 0 CA-C-N 123.176 2.716 . . . . 0.0 111.714 -176.013 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . 0.517 ' C ' ' SD ' ' J' ' 35' ' ' MET . 0.2 OUTLIER -110.92 115.51 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 178.126 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . 0.551 ' CA ' ' SD ' ' J' ' 35' ' ' MET . . . -113.72 98.67 0.93 Allowed Glycine 0 CA--C 1.503 -0.689 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 61.7 mt -128.31 128.46 44.64 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -176.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 35' ' ' MET . . . . . 0.508 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -123.5 128.85 50.37 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.068 177.214 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.457 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -122.9 80.36 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.457 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -23.36 -95.45 0.01 OUTLIER Glycine 0 C--N 1.361 1.955 0 O-C-N 123.0 0.187 . . . . 0.0 112.639 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 125.84 -178.28 16.73 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 40' ' ' VAL . 34.3 m -123.27 137.1 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 39' ' ' VAL . 11.2 t . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.392 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -116.89 140.12 49.82 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.789 0.328 . . . . 0.0 110.716 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -63.88 145.17 56.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.692 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.53 127.93 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.029 0.442 . . . . 0.0 110.029 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' CB ' ' F' ' 13' ' ' HIS . 43.7 p-80 -164.38 157.74 17.81 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.945 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 73.4 m80 -135.54 167.78 20.46 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -155.29 167.83 29.06 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.362 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -148.19 117.37 6.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.123 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -114.66 122.17 45.63 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 177.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.28 136.35 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-O 122.125 0.964 . . . . 0.0 113.578 -177.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . 0.478 ' CB ' ' CE1' ' F' ' 19' ' ' PHE . 0.6 OUTLIER -121.37 126.05 48.48 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 113.832 -1.531 . . . . 0.0 109.091 178.783 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -127.22 129.85 48.56 Favored 'General case' 0 N--CA 1.481 1.076 0 O-C-N 122.079 -0.388 . . . . 0.0 110.663 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.12 125.68 16.8 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.002 0.43 . . . . 0.0 110.749 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 93.9 mt-10 -93.25 156.32 16.9 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.494 -0.882 . . . . 0.0 113.313 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -133.02 141.39 48.24 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.201 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.35 111.08 34.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . 0.543 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 34.6 90.81 0.01 OUTLIER Glycine 0 N--CA 1.472 1.049 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 26' ' ' SER . . . . . 0.543 ' O ' ' O ' ' E' ' 25' ' ' GLY . 11.6 p . . . . . 0 N--CA 1.447 -0.592 0 CA-C-O 122.232 1.015 . . . . 0.0 113.179 -179.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.241 0.608 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.442 ' O ' ' O ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -149.62 120.28 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 117.972 -1.491 . . . . 0.0 109.168 -176.685 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -117.69 126.56 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.569 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.14 110.63 1.82 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 60.7 mt -121.14 123.22 41.78 Favored 'General case' 0 N--CA 1.467 0.375 0 O-C-N 122.756 -0.261 . . . . 0.0 110.742 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.7 ttt -135.46 131.21 35.88 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 119.678 -0.809 . . . . 0.0 112.46 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -158.11 81.36 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.85 178.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.13 101.64 1.61 Allowed Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.98 154.89 21.36 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.43 145.1 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.404 -179.661 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -111.0 133.41 53.41 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.779 0.323 . . . . 0.0 110.572 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 71.3 mm-40 -70.71 142.2 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.195 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.31 176.0 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 121.082 0.467 . . . . 0.0 110.552 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.553 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 56.8 p-80 -99.37 159.88 14.68 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.64 179.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -153.48 178.37 9.89 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . 0.471 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 42.7 tt0 -148.92 166.64 27.99 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . 0.471 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 68.5 mttm -142.68 131.54 22.86 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.295 0.569 . . . . 0.0 111.608 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 56.1 tp -121.75 123.45 41.86 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.72 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.34 127.43 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 121.553 0.692 . . . . 0.0 111.14 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . 0.478 ' CE1' ' CB ' ' E' ' 19' ' ' PHE . 0.5 OUTLIER -122.13 114.48 20.94 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.9 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -120.41 117.3 27.36 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-O 121.313 0.578 . . . . 0.0 110.358 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.97 136.87 46.33 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . 0.487 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 70.5 mm-40 -70.18 122.1 18.81 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.07 -1.052 . . . . 0.0 111.524 -178.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 1.8 p-10 108.6 131.94 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.888 1.675 . . . . 0.0 109.33 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' F' ' 25' ' ' GLY . 2.4 m -110.22 113.44 44.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . 32.28 87.72 0.01 OUTLIER Glycine 0 CA--C 1.527 0.797 0 N-CA-C 111.838 -0.505 . . . . 0.0 111.838 178.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 62.7 m -65.17 -174.6 0.17 Allowed 'General case' 0 N--CA 1.438 -1.028 0 CA-C-O 121.448 0.642 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.432 ' O ' ' C ' ' F' ' 28' ' ' LYS . 96.5 m-20 -81.06 178.24 8.54 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.289 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.432 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.3 tttt -38.15 103.93 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.02 -100.54 0.17 Allowed Glycine 0 C--O 1.219 -0.796 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -176.008 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . 0.414 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -53.75 168.54 0.19 Allowed 'General case' 0 CA--C 1.509 -0.61 0 CA-C-N 118.038 0.919 . . . . 0.0 108.953 -178.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . 0.414 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.1 OUTLIER -150.91 128.1 2.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 C-N-CA 119.331 -0.947 . . . . 0.0 109.309 -174.586 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 17.2 tt -128.2 138.86 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-O 120.909 0.385 . . . . 0.0 111.873 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.41 124.27 3.64 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.2 tp -119.11 122.57 42.37 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.6 tpt -118.54 121.28 39.86 Favored 'General case' 0 N--CA 1.478 0.966 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' F' ' 37' ' ' GLY . 2.9 m -141.84 80.63 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 177.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . 18.1 -104.86 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 CA-C-N 117.516 0.144 . . . . 0.0 113.169 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.64 -161.29 22.82 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -134.37 161.45 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.387 179.939 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 . . . . . 0 N--CA 1.464 0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.528 ' CB ' ' CE1' ' H' ' 14' ' ' HIS . 12.9 p80 -81.99 174.58 11.12 Favored 'General case' 0 N--CA 1.442 -0.866 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -143.93 179.47 7.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.089 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -152.71 135.19 15.17 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -136.24 117.85 14.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.421 0.629 . . . . 0.0 110.539 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.81 136.31 55.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.619 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -136.09 131.81 35.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-O 121.369 0.604 . . . . 0.0 111.319 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -125.95 130.67 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.61 148.26 45.69 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 122.316 1.055 . . . . 0.0 113.207 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -101.93 -177.67 3.48 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 113.406 -1.724 . . . . 0.0 108.901 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' G' ' 26' ' ' SER . 67.3 t0 -58.45 123.86 17.62 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.203 -0.599 . . . . 0.0 110.184 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' G' ' 26' ' ' SER . 23.0 m -95.56 120.59 45.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.926 -179.042 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.93 -88.73 0.01 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 116.111 -0.495 . . . . 0.0 112.607 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.474 ' N ' ' O ' ' G' ' 24' ' ' VAL . 72.2 m -67.52 -171.6 0.2 Allowed 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.564 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 14.7 t-20 -78.79 178.77 7.66 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.186 -178.388 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.564 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 83.9 tttt -44.17 -110.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.143 0.794 . . . . 0.0 113.143 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 54.33 91.88 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 161.9 13.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 C-N-CA 116.696 -2.002 . . . . 0.0 108.628 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . 0.505 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.1 OUTLIER -152.36 110.06 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.023 -174.829 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . 0.586 ' N ' ' SD ' ' A' ' 35' ' ' MET . 97.3 mt -108.36 110.21 31.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.197 0.523 . . . . 0.0 110.241 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 92.49 0.62 Allowed Glycine 0 CA--C 1.502 -0.761 0 N-CA-C 105.648 -2.981 . . . . 0.0 105.648 175.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . 0.432 ' O ' ' CD1' ' H' ' 34' ' ' LEU . 16.7 mt -130.93 134.19 46.53 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.725 1.726 . . . . 0.0 111.984 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 0.0 OUTLIER -108.4 117.96 35.53 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 112.678 -2.055 . . . . 0.0 109.019 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.35 66.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 N-CA-C 109.244 -0.651 . . . . 0.0 109.244 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.22 -103.52 0.59 Allowed Glycine 0 C--N 1.363 2.063 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.84 162.61 25.23 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.562 179.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.464 0.248 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 -179.82 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t . . . . . 0 N--CA 1.464 0.262 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 82.8 t60 -147.26 107.83 4.12 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.683 -0.407 . . . . 0.0 109.99 178.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.618 ' CG ' ' CE1' ' I' ' 14' ' ' HIS . 15.0 p-80 -146.73 171.17 15.56 Favored 'General case' 0 N--CA 1.447 -0.586 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.283 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -144.35 177.25 8.76 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.13 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -152.8 131.22 12.13 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.9 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -129.36 118.56 22.42 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.934 0.397 . . . . 0.0 110.414 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -128.34 131.32 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.93 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -126.1 128.99 48.22 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.601 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 0.9 OUTLIER -134.76 128.03 32.07 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.605 -0.27 . . . . 0.0 110.389 -179.187 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.52 123.54 40.33 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.858 0.361 . . . . 0.0 110.226 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . 0.551 ' OE2' ' CE1' ' H' ' 20' ' ' PHE . 9.7 pt-20 -168.42 130.05 1.35 Allowed 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 119.897 -0.721 . . . . 0.0 112.157 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t70 178.83 114.72 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.389 0.614 . . . . 0.0 112.376 177.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 114.724 -1.126 . . . . 0.0 112.364 176.582 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.378 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.55 123.1 18.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 119.512 -0.875 . . . . 0.0 109.457 -176.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.506 ' N ' ' SD ' ' B' ' 35' ' ' MET . 1.7 mt -115.45 119.09 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.974 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.89 103.69 1.14 Allowed Glycine 0 C--O 1.241 0.588 0 N-CA-C 105.769 -2.932 . . . . 0.0 105.769 175.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . 0.432 ' CD1' ' O ' ' G' ' 34' ' ' LEU . 5.9 tp -133.74 144.13 48.89 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 122.919 1.342 . . . . 0.0 114.01 -176.16 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 tpt -122.25 115.58 22.62 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 113.448 -1.706 . . . . 0.0 108.873 178.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.47 65.11 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.19 103.86 0.64 Allowed Glycine 0 C--N 1.353 1.504 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -90.24 176.41 41.95 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -137.24 161.45 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 120.929 0.395 . . . . 0.0 110.634 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.957 -1.02 . . . . 0.0 110.424 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 N--CA 1.468 0.448 0 CA-C-O 120.88 0.372 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . 0.42 ' CD2' ' N ' ' I' ' 13' ' ' HIS . 3.3 m-70 -142.09 156.97 45.4 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.125 -178.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' H' ' 14' ' ' HIS . 16.9 p-80 -156.66 167.53 30.17 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 177.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.449 ' CG ' ' N ' ' I' ' 16' ' ' LYS . 52.1 tt0 -150.98 166.66 29.99 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.629 0.728 . . . . 0.0 111.519 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . 0.525 ' NZ ' ' CG2' ' I' ' 18' ' ' VAL . 65.9 tttm -154.41 127.57 8.37 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.85 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 59.3 tp -124.36 121.77 35.86 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . 0.525 ' CG2' ' NZ ' ' I' ' 16' ' ' LYS . 47.8 t -122.95 125.54 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.832 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -114.2 105.86 13.68 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 176.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 1.4 t80 -117.76 126.53 52.62 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 132.97 39.92 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.141 0.496 . . . . 0.0 111.813 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -159.35 114.47 2.45 Favored 'General case' 0 C--N 1.348 0.52 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' I' ' 23' ' ' ASP . 9.4 t0 -171.9 111.02 0.29 Allowed 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 114.435 1.272 . . . . 0.0 114.435 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 p -31.99 131.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 CA-C-N 112.611 -2.086 . . . . 0.0 115.425 174.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -84.22 0.09 OUTLIER Glycine 0 CA--C 1.543 1.841 0 C-N-CA 119.605 -1.283 . . . . 0.0 115.157 174.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.3 m -96.76 175.41 6.37 Favored 'General case' 0 CA--C 1.5 -0.944 0 CA-C-N 120.401 2.1 . . . . 0.0 108.916 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.45 ' O ' ' O ' ' I' ' 28' ' ' LYS . 8.9 m120 -62.52 175.62 0.76 Allowed 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' I' ' 27' ' ' ASN . 53.4 tttt -45.1 -107.88 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 122.301 1.048 . . . . 0.0 113.796 178.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . 87.73 -100.01 2.56 Favored Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 62.81 143.6 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.083 0 O-C-N 121.498 -1.001 . . . . 0.0 109.135 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . 0.429 ' CD1' ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -145.26 114.47 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.373 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 1.2 tt -108.19 112.38 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.97 113.86 2.56 Favored Glycine 0 CA--C 1.493 -1.288 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -162.06 160.73 27.83 Favored 'General case' 0 C--O 1.249 1.041 0 CA-C-O 123.304 1.526 . . . . 0.0 112.695 178.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 35' ' ' MET . . . . . 0.458 ' CE ' ' O ' ' C' ' 32' ' ' ILE . 33.2 ttm -127.71 136.6 51.77 Favored 'General case' 0 CA--C 1.503 -0.827 0 CA-C-N 112.351 -2.204 . . . . 0.0 111.052 -177.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.99 70.63 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.186 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.98 106.37 3.28 Favored Glycine 0 C--N 1.364 2.098 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.7 172.01 55.16 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.214 -0.755 . . . . 0.0 111.214 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -144.36 149.01 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.408 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 5.5 p . . . . . 0 C--O 1.238 0.449 0 CA-C-O 121.981 0.896 . . . . 0.0 112.591 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . 0.431 ' CD2' HE21 ' J' ' 15' ' ' GLN . 17.3 t-160 -150.9 105.62 3.28 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 114.08 -1.418 . . . . 0.0 109.548 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -149.27 166.8 27.86 Favored 'General case' 0 CA--C 1.508 -0.643 0 O-C-N 121.641 -0.662 . . . . 0.0 110.598 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . 0.431 HE21 ' CD2' ' J' ' 13' ' ' HIS . 13.3 mp0 -146.68 169.97 17.93 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.675 0.75 . . . . 0.0 111.414 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -143.71 135.88 26.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.152 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -133.87 124.61 26.75 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.65 133.69 61.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 CA-C-O 121.289 0.566 . . . . 0.0 112.078 -178.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 91.7 m-85 -112.02 113.84 26.37 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.45 ' CD1' ' CZ ' ' I' ' 20' ' ' PHE . 5.7 t80 -122.16 123.15 40.84 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 118.518 0.599 . . . . 0.0 112.592 -178.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.24 131.52 38.59 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 122.047 -0.408 . . . . 0.0 110.873 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 18.2 pt-20 -151.88 168.44 25.13 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.461 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.482 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 6.7 p30 150.94 164.12 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.149 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' J' ' 23' ' ' ASP . 48.8 t -35.83 101.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.44 93.36 0.5 Allowed Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.227 -0.897 . . . . 0.0 114.87 -175.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.751 ' O ' ' O ' ' J' ' 27' ' ' ASN . 39.3 p -102.79 160.63 14.43 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 175.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.751 ' O ' ' O ' ' J' ' 26' ' ' SER . 92.2 m-20 38.17 -179.22 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -174.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.677 ' N ' ' ND2' ' K' ' 27' ' ' ASN . 88.0 tttt -148.95 108.37 3.96 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 114.968 -2.693 . . . . 0.0 115.747 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -76.23 95.07 1.05 Allowed Glycine 0 CA--C 1.493 -1.285 0 CA-C-O 114.938 -3.146 . . . . 0.0 108.65 166.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' I' ' 29' ' ' GLY . . . -137.32 142.7 41.85 Favored 'General case' 0 CA--C 1.463 -2.381 1 CA-C-N 124.891 4.346 . . . . 0.0 108.061 176.136 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.91 106.12 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.357 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . 0.508 ' O ' ' CE ' ' D' ' 35' ' ' MET . 0.1 OUTLIER -105.32 116.7 49.63 Favored 'Isoleucine or valine' 0 C--N 1.359 0.993 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.677 -178.356 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.38 96.45 0.72 Allowed Glycine 0 C--O 1.24 0.49 0 N-CA-C 106.447 -2.661 . . . . 0.0 106.447 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.417 HD13 ' N ' ' J' ' 35' ' ' MET . 8.2 tp -134.25 124.87 26.63 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-O 122.695 1.236 . . . . 0.0 111.975 -177.19 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 35' ' ' MET . . . . . 0.551 ' SD ' ' CA ' ' D' ' 33' ' ' GLY . 4.3 ttt -119.87 126.96 52.21 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 113.345 -1.752 . . . . 0.0 109.176 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.58 73.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.187 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.66 112.46 0.4 Allowed Glycine 0 C--N 1.354 1.543 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.49 -139.86 0.33 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.583 -0.607 . . . . 0.0 111.583 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 54.5 t . . . . . 0 N--CA 1.464 0.254 0 CA-C-O 120.972 0.415 . . . . 0.0 110.089 -179.472 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . 0.491 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 54.9 mp0 . . . . . 0 C--O 1.225 -0.192 0 N-CA-C 110.678 -0.119 . . . . 0.0 110.678 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.71 131.0 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -114.49 117.23 30.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.775 0.321 . . . . 0.0 111.403 -179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 55.6 t-80 -135.33 164.39 27.85 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.42 0.629 . . . . 0.0 109.846 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . 0.527 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 86.0 mt-30 -157.05 172.49 18.58 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.634 178.468 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.5 tttm -155.92 122.77 5.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.36 179.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.6 mt -125.13 120.42 31.33 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 4.2 m -136.38 134.17 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-O 121.538 0.685 . . . . 0.0 112.654 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.623 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 87.5 m-85 -115.31 110.7 19.79 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -114.01 124.11 51.33 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -177.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 127.05 34.21 Favored 'General case' 0 N--CA 1.474 0.739 0 O-C-N 121.758 -0.589 . . . . 0.0 110.57 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.18 127.61 47.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.583 -179.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' K' ' 24' ' ' VAL . 3.6 t70 174.96 146.69 0.07 Allowed 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.474 ' O ' ' O ' ' K' ' 23' ' ' ASP . 2.8 m -21.89 -101.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 123.487 0.492 . . . . 0.0 111.712 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.412 ' H ' HG21 ' K' ' 24' ' ' VAL . . . 159.84 -91.36 0.11 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.807 177.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.683 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 75.3 m -54.23 160.8 1.5 Allowed 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 118.147 0.974 . . . . 0.0 108.381 178.185 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' O ' ' K' ' 26' ' ' SER . 23.2 p30 132.52 171.04 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 O-C-N 125.083 1.49 . . . . 0.0 111.715 176.129 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -30.27 104.92 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.8 -100.6 2.09 Favored Glycine 0 C--O 1.215 -1.056 0 N-CA-C 115.737 1.055 . . . . 0.0 115.737 170.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.431 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 60.77 145.29 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 106.436 -1.691 . . . . 0.0 106.436 -178.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . 0.431 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -160.85 134.41 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 121.614 2.006 . . . . 0.0 113.219 -179.253 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.41 HD13 HG23 ' K' ' 32' ' ' ILE . 98.0 mt -124.98 121.23 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.766 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.452 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -119.26 115.53 3.07 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 38.1 tp -124.98 121.62 34.96 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.149 -0.525 . . . . 0.0 111.271 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mmm -131.33 133.01 44.91 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.348 178.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.22 82.58 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.444 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.6 101.33 0.9 Allowed Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' L' ' 37' ' ' GLY . . . -158.4 155.62 26.63 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 N--CA 1.469 0.499 0 CA-C-O 120.859 0.361 . . . . 0.0 110.836 -179.588 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.464 0.26 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -116.24 171.15 8.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 120.961 0.41 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -78.34 176.28 9.47 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.646 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . 0.412 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 93.4 mt-30 -138.37 175.32 9.67 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -146.07 142.31 28.43 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.324 0.583 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -126.17 113.01 16.46 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -130.35 128.45 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.329 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-30 -109.06 109.03 19.95 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.436 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -112.53 114.03 26.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.392 0.615 . . . . 0.0 110.637 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . 0.422 ' O ' ' OD2' ' L' ' 23' ' ' ASP . . . -126.74 133.93 50.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' K' ' 24' ' ' VAL . 84.3 tt0 -60.68 105.48 0.45 Allowed 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.308 -177.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.422 ' OD2' ' O ' ' L' ' 21' ' ' ALA . 7.0 m-20 -154.46 136.21 14.44 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.329 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 22.5 m -109.99 111.74 37.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 119.862 -0.735 . . . . 0.0 110.566 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 26' ' ' SER . . . 31.84 -91.3 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-N 115.194 -0.912 . . . . 0.0 114.438 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' L' ' 25' ' ' GLY . 3.9 m 47.23 171.91 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.033 -1.083 . . . . 0.0 110.965 -176.635 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.526 ' O ' ' O ' ' L' ' 28' ' ' LYS . 72.3 m-80 -140.09 -177.88 5.2 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.365 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.526 ' O ' ' O ' ' L' ' 27' ' ' ASN . 99.2 mttt 26.5 102.13 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.068 0 O-C-N 123.716 0.635 . . . . 0.0 112.196 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.39 -101.57 0.21 Allowed Glycine 0 CA--C 1.493 -1.283 0 C-N-CA 119.913 -1.137 . . . . 0.0 111.791 -176.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -52.29 161.11 0.69 Allowed 'General case' 0 CA--C 1.514 -0.404 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.375 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -136.04 121.79 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.641 -177.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -129.03 138.46 54.46 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.279 0 CA-C-N 115.637 -0.711 . . . . 0.0 111.626 -178.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.97 120.99 3.25 Favored Glycine 0 N--CA 1.46 0.253 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 pp -126.12 122.24 35.16 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 38.2 mtp -134.81 143.49 47.08 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 122.147 0.975 . . . . 0.0 112.681 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -131.25 80.73 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 113.642 -1.617 . . . . 0.0 110.159 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' K' ' 38' ' ' GLY . . . -55.31 102.47 0.16 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.53 28.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.32 134.19 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.871 0.367 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.588 -179.843 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.932 0.396 . . . . 0.0 110.061 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -136.28 145.11 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.634 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 72.9 m80 -114.72 106.35 14.11 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 11.6 t-160 -135.55 159.72 40.73 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 109.767 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.692 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 98.1 mm-40 -157.64 -178.93 7.69 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.847 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -147.8 122.54 9.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.6 mt -129.64 117.25 20.07 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.062 0.458 . . . . 0.0 110.659 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.5 131.05 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.098 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -123.25 134.17 54.12 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.6 p90 -137.12 124.84 22.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.898 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.24 128.21 45.67 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-O 120.733 0.302 . . . . 0.0 111.253 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -147.39 146.66 29.7 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.248 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 22.7 t0 . . . . . 0 N--CA 1.463 0.176 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 177.272 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.521 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 33.1 pttt . . . . . 0 N--CA 1.462 0.137 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.53 100.61 0.62 Allowed Glycine 0 CA--C 1.496 -1.151 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 174.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.37 151.89 20.57 Favored 'General case' 0 C--O 1.251 1.169 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.005 -176.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ILE . . . . . 0.472 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -143.77 107.36 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.781 0 CA-C-N 110.443 -3.071 . . . . 0.0 108.449 -173.284 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ILE . . . . . 0.443 ' C ' ' SD ' ' G' ' 35' ' ' MET . 10.6 mt -103.43 111.0 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.035 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.72 92.48 0.58 Allowed Glycine 0 CA--C 1.501 -0.805 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 177.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tp -138.03 135.02 35.49 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 122.704 1.24 . . . . 0.0 111.169 -178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 3.1 ptm -111.04 123.31 49.94 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.3 -1.773 . . . . 0.0 108.403 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -116.14 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.92 -100.39 0.5 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.8 -170.74 34.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.07 162.07 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.863 0.364 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 81.2 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.379 179.749 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -110.57 134.34 52.48 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -138.79 142.76 38.75 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.17 161.02 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 13' ' ' HIS . . . . . 0.543 ' ND1' ' O ' ' A' ' 13' ' ' HIS . 2.1 t60 -130.29 129.03 42.72 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 14' ' ' HIS . . . . . 0.629 ' NE2' ' CG ' ' C' ' 13' ' ' HIS . 72.6 m80 -133.48 167.08 21.1 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.309 0.576 . . . . 0.0 109.678 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 46.2 tt0 -168.93 169.56 9.61 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.495 178.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -155.02 125.77 7.0 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 66.3 mt -122.22 110.97 16.37 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.058 0.456 . . . . 0.0 109.796 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -119.94 126.93 75.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.94 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -125.81 120.37 30.35 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.608 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 20' ' ' PHE . . . . . 0.4 ' HB2' ' CZ ' ' C' ' 20' ' ' PHE . 3.7 t80 -125.63 129.15 49.03 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.92 155.93 39.07 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 116.767 2.136 . . . . 0.0 116.767 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -162.75 78.34 0.47 Allowed 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 111.145 -2.752 . . . . 0.0 106.1 177.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 t0 . . . . . 0 N--CA 1.465 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.887 -176.384 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 29' ' ' GLY . . . . . 0.557 ' C ' ' O ' ' B' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.49 -1.518 0 CA-C-O 127.632 3.907 . . . . 0.0 109.401 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 30' ' ' ALA . . . . . 0.557 ' O ' ' C ' ' B' ' 29' ' ' GLY . . . -79.31 -125.07 0.01 OUTLIER 'General case' 1 N--CA 1.37 -4.446 3 N-CA-C 87.399 -8.741 . . . . 0.0 87.399 166.239 . . . . . . . . 4 3 . 1 . 010 nuclear orig core ' B' B ' 31' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' H' ' 35' ' ' MET . 0.2 OUTLIER -72.9 115.62 13.94 Favored 'Isoleucine or valine' 1 C--N 1.226 -4.792 0 CA-C-N 125.138 3.608 . . . . 0.0 111.128 176.465 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' B' B ' 32' ' ' ILE . . . . . 0.565 ' N ' ' SD ' ' H' ' 35' ' ' MET . 0.1 OUTLIER -109.41 115.48 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.774 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.7 90.94 0.58 Allowed Glycine 0 C--O 1.24 0.473 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 177.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 74.4 mt -121.27 137.0 54.88 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.422 1.106 . . . . 0.0 112.06 -177.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 35' ' ' MET . . . . . 0.736 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 34.2 ttp -126.25 117.3 22.77 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.864 -179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.36 71.49 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.066 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.1 -101.72 2.28 Favored Glycine 0 C--N 1.353 1.523 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.4 166.78 41.41 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -134.46 142.0 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.759 0.314 . . . . 0.0 110.306 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.398 179.801 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 120.993 0.425 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 13' ' ' HIS . . . . . 0.629 ' CG ' ' NE2' ' B' ' 14' ' ' HIS . 29.7 m-70 -133.32 145.12 50.14 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -84.48 -179.46 7.16 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-O 121.32 0.581 . . . . 0.0 110.272 -178.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -90.91 175.23 7.05 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.994 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -130.01 134.46 47.43 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.363 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -131.55 121.46 24.46 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.257 0.551 . . . . 0.0 112.412 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 18.0 m -132.04 127.26 57.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 CA-C-O 121.989 0.9 . . . . 0.0 110.734 177.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.13 119.49 36.59 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 114.716 -1.129 . . . . 0.0 108.97 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 20' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 20' ' ' PHE . 53.2 p90 -147.37 150.81 35.43 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 118.615 -1.234 . . . . 0.0 112.512 177.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.14 150.19 32.29 Favored 'General case' 0 C--O 1.241 0.634 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -119.01 117.15 28.0 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.307 -1.77 . . . . 0.0 107.673 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 23' ' ' ASP . . . . . 0.521 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 57.3 m-20 . . . . . 0 CA--C 1.51 -0.595 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.964 -177.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.13 0 N-CA-C 114.495 0.558 . . . . 0.0 114.495 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.41 176.71 8.11 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 101.411 -3.552 . . . . 0.0 101.411 172.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.97 111.72 2.76 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.248 -175.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.4 mt -98.75 111.17 27.71 Favored 'Isoleucine or valine' 0 C--N 1.349 0.569 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.41 99.64 1.13 Allowed Glycine 0 CA--C 1.505 -0.581 0 N-CA-C 106.048 -2.821 . . . . 0.0 106.048 175.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 34' ' ' LEU . . . . . 0.482 HD13 ' N ' ' C' ' 35' ' ' MET . 19.6 tp -135.83 133.17 37.54 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 123.056 1.408 . . . . 0.0 112.419 -176.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 35' ' ' MET . . . . . 0.492 ' HE2' ' N ' ' H' ' 32' ' ' ILE . 41.2 ttp -110.49 122.06 46.82 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 113.269 -1.787 . . . . 0.0 109.532 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.61 66.76 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.59 -102.81 0.01 OUTLIER Glycine 0 C--N 1.362 1.99 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.88 158.03 26.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -134.4 162.74 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.438 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.851 -179.897 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t . . . . . 0 N--CA 1.465 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' D' ' 14' ' ' HIS . 84.3 t60 -89.67 130.18 35.99 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.0 0.428 . . . . 0.0 111.864 -178.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 14' ' ' HIS . . . . . 0.449 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.8 m-70 -82.84 178.16 8.31 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -96.42 178.4 5.37 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.548 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -142.29 137.69 30.81 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.825 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 41.7 tp -120.82 115.06 22.53 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.618 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.3 127.08 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.408 -0.517 . . . . 0.0 112.153 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -118.12 114.46 23.12 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 20' ' ' PHE . . . . . 0.532 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 21.5 t80 -127.6 119.08 25.15 Favored 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.179 0.514 . . . . 0.0 110.328 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 21' ' ' ALA . . . . . 0.428 ' O ' ' OE1' ' E' ' 22' ' ' GLU . . . -132.19 133.31 44.04 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-O 121.928 0.87 . . . . 0.0 112.629 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -91.4 133.61 35.32 Favored 'General case' 0 C--N 1.339 0.112 0 CA-C-N 114.677 -1.147 . . . . 0.0 108.627 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t0 . . . . . 0 C--N 1.327 -0.378 0 CA-C-O 121.203 0.525 . . . . 0.0 110.191 -178.934 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' D' D ' 30' ' ' ALA . . . . . 0.462 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . . . . . . 0 CA--C 1.498 -1.051 1 N-CA-C 96.892 -5.225 . . . . 0.0 96.892 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 31' ' ' ILE . . . . . 0.654 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 0.1 OUTLIER -97.51 102.12 13.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 1 CA-C-N 127.292 4.587 . . . . 0.0 109.907 178.45 . . . . . . . . 4 4 . 1 . 010 nuclear orig core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.0 tt -112.97 121.94 66.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.612 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.849 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.46 100.1 1.1 Allowed Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 107.064 -2.414 . . . . 0.0 107.064 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tp -117.19 120.7 39.07 Favored 'General case' 0 CA--C 1.508 -0.64 0 CA-C-O 121.702 0.763 . . . . 0.0 110.492 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 4.9 tmm? -104.26 115.91 31.24 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -118.19 71.43 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.18 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' D' D ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.24 -101.12 0.01 OUTLIER Glycine 0 C--N 1.366 2.228 0 N-CA-C 111.86 -0.496 . . . . 0.0 111.86 178.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.48 -179.81 43.02 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.61 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -125.34 135.76 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.454 -0.373 . . . . 0.0 110.086 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.593 179.951 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -103.91 135.35 45.61 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.916 0.388 . . . . 0.0 110.21 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -106.8 151.39 25.24 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 m -131.09 156.94 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.969 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.75 174.28 7.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.798 0.332 . . . . 0.0 110.329 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 14' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.2 OUTLIER -78.32 174.04 11.67 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -179.374 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' E' E ' 15' ' ' GLN . . . . . 0.401 ' HG2' ' H ' ' E' ' 16' ' ' LYS . 44.1 tt0 -122.63 172.15 8.61 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.614 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 16' ' ' LYS . . . . . 0.401 ' H ' ' HG2' ' E' ' 15' ' ' GLN . 65.7 mttp -153.82 119.07 5.12 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.6 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.8 mt -126.31 116.43 21.21 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 5.6 p -143.16 147.56 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -120.04 124.33 45.61 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 114.227 -1.351 . . . . 0.0 109.747 179.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -121.39 126.81 50.29 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 122.373 -0.205 . . . . 0.0 110.529 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.06 137.57 37.92 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 -179.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 22' ' ' GLU . . . . . 0.532 ' OE2' ' CZ ' ' D' ' 20' ' ' PHE . 58.0 mp0 -113.22 137.84 50.87 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -150.0 132.46 15.68 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.383 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 30.1 m -74.59 113.08 12.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.071 179.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.08 92.18 0.01 OUTLIER Glycine 0 CA--C 1.527 0.824 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.447 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 74.0 m . . . . . 0 N--CA 1.443 -0.798 0 CA-C-N 115.693 -0.253 . . . . 0.0 111.518 178.877 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' E' E ' 30' ' ' ALA . . . . . 0.466 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.255 1.356 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 31' ' ' ILE . . . . . 0.466 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.1 OUTLIER -158.23 134.48 2.0 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 C-N-CA 118.669 -1.212 . . . . 0.0 110.734 -174.341 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -128.57 121.45 55.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 CA-C-O 121.4 0.619 . . . . 0.0 110.769 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 33' ' ' GLY . . . . . 0.546 ' CA ' ' SD ' ' K' ' 35' ' ' MET . . . -114.64 117.02 3.94 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -118.72 120.15 36.56 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.479 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 15.5 ttp -116.61 115.54 25.9 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.401 -0.52 . . . . 0.0 109.884 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 36' ' ' VAL . . . . . 0.475 ' O ' ' C ' ' E' ' 37' ' ' GLY . 2.8 p -144.03 83.77 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.52 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 37' ' ' GLY . . . . . 0.475 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -18.95 -94.49 0.01 OUTLIER Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.663 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.12 -164.05 37.24 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.07 161.01 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 120.847 0.356 . . . . 0.0 110.707 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.433 179.828 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -112.28 149.66 32.06 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.81 0.338 . . . . 0.0 110.387 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -54.01 149.14 9.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.132 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 65.3 t -114.34 130.84 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 110.948 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 13' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 31.1 p-80 -154.07 134.61 13.53 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.532 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 93.9 m-70 -155.23 170.03 22.8 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 121.303 0.573 . . . . 0.0 109.602 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -143.96 173.81 11.39 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.431 -0.804 . . . . 0.0 108.884 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -152.44 129.85 11.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.1 tp -121.08 117.9 28.38 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.51 133.14 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -118.48 114.73 23.3 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.902 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -134.18 144.86 48.73 Favored 'General case' 0 N--CA 1.477 0.885 0 CA-C-O 122.282 1.039 . . . . 0.0 112.086 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.43 148.35 30.2 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.128 178.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.52 136.83 39.32 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.712 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -149.62 134.03 17.46 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.418 0.628 . . . . 0.0 111.086 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' F' ' 25' ' ' GLY . 12.9 t -93.71 112.55 26.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.292 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 25' ' ' GLY . . . . . 0.463 ' O ' ' ND2' ' F' ' 27' ' ' ASN . . . 42.64 91.42 0.01 OUTLIER Glycine 0 N--CA 1.472 1.063 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.393 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 85.7 p -45.2 152.16 0.29 Allowed 'General case' 0 N--CA 1.439 -1.022 0 CA-C-O 123.066 1.412 . . . . 0.0 111.989 -176.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 69.0 m-80 -156.84 -170.9 3.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 111.679 -2.51 . . . . 0.0 106.304 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.7 mttt 19.19 110.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 121.797 0.808 . . . . 0.0 113.166 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.19 96.62 2.23 Favored Glycine 0 CA--C 1.492 -1.395 0 CA-C-O 123.412 1.562 . . . . 0.0 111.877 -174.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -63.94 -171.15 0.05 OUTLIER 'General case' 0 CA--C 1.489 -1.376 0 CA-C-N 110.989 -2.606 . . . . 0.0 107.537 -179.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.74 133.76 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 117.261 -1.776 . . . . 0.0 113.191 -176.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 tt -126.71 132.41 70.17 Favored 'Isoleucine or valine' 0 C--N 1.345 0.386 0 CA-C-N 113.747 -1.57 . . . . 0.0 112.202 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.7 115.54 2.74 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -119.47 119.51 34.09 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 35' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 30.8 ttp -114.03 118.61 34.58 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 121.267 -0.173 . . . . 0.0 111.196 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 36' ' ' VAL . . . . . 0.514 ' O ' ' C ' ' F' ' 37' ' ' GLY . 5.0 t -139.11 83.05 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-O 119.295 -0.384 . . . . 0.0 110.686 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 37' ' ' GLY . . . . . 0.514 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . -15.73 -95.66 0.01 OUTLIER Glycine 0 C--N 1.351 1.367 0 O-C-N 123.063 0.227 . . . . 0.0 112.886 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 127.92 163.05 11.26 Favored Glycine 0 N--CA 1.466 0.695 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 28.6 m -140.31 160.38 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.825 0.345 . . . . 0.0 110.655 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.532 -179.968 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' G' G ' 13' ' ' HIS . . . . . 0.475 ' ND1' ' N ' ' G' ' 13' ' ' HIS . 2.5 p-80 . . . . . 0 N--CA 1.463 0.192 0 CA-C-O 120.905 0.383 . . . . 0.0 110.995 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 14' ' ' HIS . . . . . 0.534 ' CD2' ' H ' ' H' ' 14' ' ' HIS . 89.0 m-70 -132.83 178.26 7.0 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -129.09 -179.13 4.94 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.086 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 89.2 tttt -99.23 142.53 30.6 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.643 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 74.7 mt -125.68 118.79 26.38 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -136.28 138.67 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.204 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.753 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -119.64 126.36 50.96 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.211 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -122.5 120.76 34.82 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.08 127.61 44.94 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.105 0.479 . . . . 0.0 111.806 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -160.83 87.27 0.73 Allowed 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.685 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -178.37 123.13 0.1 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.925 0.393 . . . . 0.0 110.628 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.8 t -38.93 114.34 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.185 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 25' ' ' GLY . . . . . 0.443 ' H ' ' CG2' ' H' ' 24' ' ' VAL . . . -98.14 -86.41 1.84 Allowed Glycine 0 N--CA 1.47 0.907 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 26' ' ' SER . . . . . 0.747 ' O ' ' O ' ' G' ' 27' ' ' ASN . 17.0 m -151.58 -173.06 4.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 27' ' ' ASN . . . . . 0.747 ' O ' ' O ' ' G' ' 26' ' ' SER . 97.0 m-20 -22.79 170.0 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 O-C-N 124.313 1.008 . . . . 0.0 113.235 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 28' ' ' LYS . . . . . 0.557 ' NZ ' ' O ' ' I' ' 26' ' ' SER . 32.4 tttt -102.03 -112.82 0.21 Allowed 'General case' 0 N--CA 1.476 0.828 0 O-C-N 121.606 -0.684 . . . . 0.0 112.265 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 29' ' ' GLY . . . . . 0.472 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 47.98 91.57 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . -106.18 162.37 13.7 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 123.85 1.786 . . . . 0.0 111.127 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -160.29 121.94 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 110.547 -3.024 . . . . 0.0 106.84 -172.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -139.64 122.73 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.249 178.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.7 117.41 5.86 Favored Glycine 0 CA--C 1.506 -0.519 0 N-CA-C 106.821 -2.511 . . . . 0.0 106.821 177.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 70.9 mt -113.59 120.17 40.02 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-O 121.562 0.696 . . . . 0.0 111.931 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' C ' ' A' ' 31' ' ' ILE . 3.8 ttm -120.84 108.02 13.43 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 177.046 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.72 71.56 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -178.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.11 -98.31 0.85 Allowed Glycine 0 C--N 1.361 1.921 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.6 -173.63 43.26 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 120.809 0.337 . . . . 0.0 110.102 -179.597 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.465 0.314 0 N-CA-C 110.494 -0.187 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -121.61 124.07 43.45 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.69 0.281 . . . . 0.0 110.664 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 14' ' ' HIS . . . . . 0.534 ' H ' ' CD2' ' G' ' 14' ' ' HIS . 37.1 m-70 -144.58 166.18 25.91 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.345 0.593 . . . . 0.0 110.277 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.6 tp60 -160.81 161.15 31.9 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.795 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -158.83 118.06 3.05 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.54 110.5 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 18' ' ' VAL . . . . . 0.408 ' CG1' ' CE2' ' H' ' 20' ' ' PHE . 72.4 t -124.29 130.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 120.551 -0.46 . . . . 0.0 111.045 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.39 114.25 22.05 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.973 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG1' ' H' ' 18' ' ' VAL . 52.4 m-85 -110.1 117.28 33.3 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.1 134.44 38.36 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 119.558 -0.857 . . . . 0.0 112.867 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -152.02 89.65 1.47 Allowed 'General case' 0 C--O 1.224 -0.261 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 23' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 26.5 p-10 169.85 -121.23 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.366 0.416 . . . . 0.0 110.073 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 24' ' ' VAL . . . . . 0.443 ' CG2' ' H ' ' G' ' 25' ' ' GLY . 1.5 m . . . . . 0 N--CA 1.446 -0.661 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 179.025 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 30' ' ' ALA . . . . . 0.746 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.434 -1.229 0 CA-C-O 124.967 2.318 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 31' ' ' ILE . . . . . 0.59 HD11 ' H ' ' H' ' 31' ' ' ILE . 4.1 mp -67.4 107.98 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.314 0 CA-C-N 109.966 -3.288 . . . . 0.0 109.796 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 32' ' ' ILE . . . . . 0.492 ' N ' ' HE2' ' C' ' 35' ' ' MET . 10.3 tt -122.47 120.44 61.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 122.246 1.022 . . . . 0.0 109.789 174.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 33' ' ' GLY . . . . . 0.736 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -98.87 117.96 6.02 Favored Glycine 0 CA--C 1.497 -1.075 0 N-CA-C 106.304 -2.718 . . . . 0.0 106.304 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 56.0 tp -120.04 119.66 34.03 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 113.836 1.051 . . . . 0.0 113.836 -175.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 35' ' ' MET . . . . . 0.565 ' SD ' ' N ' ' B' ' 32' ' ' ILE . 17.6 ttm -124.8 115.31 20.49 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 175.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.32 71.25 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.16 -100.81 2.66 Favored Glycine 0 C--N 1.358 1.8 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.54 166.17 19.21 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.04 156.62 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-O 120.686 0.279 . . . . 0.0 110.357 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.636 -179.826 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.466 0.358 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 75.7 m80 -129.61 131.96 46.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.84 0.352 . . . . 0.0 111.514 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 86.3 t60 -154.18 165.76 35.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 177.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 15' ' ' GLN . . . . . 0.52 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 76.0 mt-30 -158.76 171.22 20.49 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.502 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -151.05 121.48 7.36 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.071 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -127.67 123.82 36.44 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.7 t -134.44 130.29 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 45.4 m-85 -111.35 108.45 18.05 Favored 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 176.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -116.47 119.53 35.9 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.184 -0.323 . . . . 0.0 111.109 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.78 127.5 27.17 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -138.49 109.17 6.62 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.732 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 42.0 p-10 -161.69 125.14 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.96 179.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 24' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.8 m -89.82 -112.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.595 -0.442 . . . . 0.0 109.971 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.98 -92.02 0.01 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.0 p -129.19 170.27 13.77 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' I' ' 26' ' ' SER . 73.5 m-80 31.98 172.58 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 28' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' J' ' 23' ' ' ASP . 23.3 pttt 148.55 95.36 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 123.344 0.658 . . . . 0.0 111.571 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 29' ' ' GLY . . . . . 0.746 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 58.46 -112.59 4.12 Favored Glycine 1 CA--C 1.433 -5.059 0 CA-C-O 114.948 -3.14 . . . . 0.0 111.849 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' I' I ' 30' ' ' ALA . . . . . 0.619 ' CB ' ' O ' ' I' ' 29' ' ' GLY 0.529 . . 97.96 -125.45 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.513 1 C-N-CA 109.781 -4.768 . . . . 0.0 113.355 179.294 . . . . . . . . 4 3 . 1 . 010 nuclear orig core ' I' I ' 31' ' ' ILE . . . . . . . . . . . . 0.426 3.0 mt -64.05 110.74 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.402 -2.852 1 CA-C-N 106.479 -4.873 . . . . 0.0 109.967 173.924 . . . . . . . . 3 2 . 1 . 010 nuclear orig core ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 10.6 tt -135.36 126.15 44.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-O 122.333 1.064 . . . . 0.0 112.496 178.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.7 119.49 5.8 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 177.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 34' ' ' LEU . . . . . 0.486 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 13.7 tp -114.68 125.72 54.06 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.638 0.733 . . . . 0.0 112.277 -178.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 12.6 tpp -123.77 111.0 15.61 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.784 175.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.03 68.28 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.11 -101.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.625 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.01 160.02 23.54 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.73 135.95 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.519 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 120.836 0.351 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -137.59 103.78 5.14 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.759 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 65.5 m170 -117.7 164.66 14.64 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -157.77 172.83 17.78 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.217 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -155.41 115.64 3.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.526 178.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.27 124.15 41.78 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -134.07 132.43 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 19' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 14.8 m-85 -114.16 107.11 15.19 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 20' ' ' PHE . . . . . 0.57 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 35.4 t80 -120.92 117.55 27.63 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -166.96 175.68 7.47 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -178.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -88.22 138.83 31.09 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 113.134 -1.848 . . . . 0.0 109.032 177.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 23' ' ' ASP . . . . . 0.512 ' HA ' ' O ' ' I' ' 28' ' ' LYS . 74.0 m-20 -117.61 -161.0 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 121.384 0.611 . . . . 0.0 111.575 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 24' ' ' VAL . . . . . 0.449 HG11 ' H ' ' J' ' 29' ' ' GLY . 76.4 t 52.77 103.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 116.56 2.059 . . . . 0.0 116.56 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.59 -92.63 0.03 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 172.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' J' ' 27' ' ' ASN . 13.9 p -124.63 166.31 16.35 Favored 'General case' 0 CA--C 1.51 -0.57 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 175.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.9 m120 47.84 174.23 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 28' ' ' LYS . . . . . 0.504 ' HZ1' ' CB ' ' K' ' 30' ' ' ALA . 86.2 tttt -73.06 110.91 7.71 Favored 'General case' 0 C--N 1.35 0.626 1 C-N-CA 111.064 -4.254 . . . . 0.0 106.046 178.279 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' J' J ' 29' ' ' GLY . . . . . 0.449 ' H ' HG11 ' J' ' 24' ' ' VAL . . . -86.27 93.4 1.86 Allowed Glycine 0 CA--C 1.485 -1.807 0 CA-C-O 117.518 -1.712 . . . . 0.0 112.255 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 30' ' ' ALA . . . . . 0.454 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -163.16 140.21 7.49 Favored 'General case' 0 C--N 1.281 -2.406 0 CA-C-N 121.194 2.497 . . . . 0.0 108.348 171.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 31' ' ' ILE . . . . . 0.454 ' CG1' ' C ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -158.39 116.54 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 CA-C-N 112.249 -2.25 . . . . 0.0 107.08 -173.32 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 15.6 tt -124.87 117.33 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.896 0.855 . . . . 0.0 110.994 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.62 118.95 6.24 Favored Glycine 0 CA--C 1.505 -0.569 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 34' ' ' LEU . . . . . 0.492 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 50.8 mt -113.54 107.29 15.6 Favored 'General case' 0 CA--C 1.505 -0.783 0 CA-C-O 121.322 0.582 . . . . 0.0 111.125 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.0 tpt -111.5 112.0 23.42 Favored 'General case' 0 CA--C 1.514 -0.421 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.297 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -131.63 74.71 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.668 -177.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.23 106.23 2.97 Favored Glycine 0 C--N 1.355 1.6 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.77 169.39 52.15 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.644 0.259 . . . . 0.0 110.524 -179.558 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 . . . . . 0 N--CA 1.464 0.241 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' K' K ' 12' ' ' VAL . . . . . 0.557 ' CG2' ' NE2' ' K' ' 14' ' ' HIS . 2.6 m -140.24 -171.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -92.44 132.05 37.1 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.807 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' CG2' ' K' ' 12' ' ' VAL . 80.0 m-70 -148.03 169.75 19.25 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -157.27 178.96 9.73 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.805 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -160.57 121.5 2.96 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.173 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -126.62 125.09 41.33 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.68 129.61 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.927 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 19' ' ' PHE . . . . . 0.486 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 19.8 m-85 -113.45 108.89 17.82 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 20' ' ' PHE . . . . . 0.57 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.1 t80 -118.51 121.13 39.51 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.141 0.428 . . . . 0.0 110.855 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.03 139.84 45.13 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.71 167.53 26.18 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.781 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -166.38 -136.42 0.02 OUTLIER 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.144 177.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' K' ' 25' ' ' GLY . 18.7 t -110.62 110.36 31.9 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 25' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 32.54 91.44 0.01 OUTLIER Glycine 0 CA--C 1.53 0.981 0 N-CA-C 112.156 -0.377 . . . . 0.0 112.156 177.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 26' ' ' SER . . . . . 0.413 ' OG ' ' CG ' ' L' ' 23' ' ' ASP . 5.8 p -47.5 154.71 0.42 Allowed 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 m120 -119.15 172.58 7.48 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 122.239 1.018 . . . . 0.0 113.166 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -32.8 110.75 0.09 Allowed 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 116.248 1.944 . . . . 0.0 116.248 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.59 93.42 0.44 Allowed Glycine 0 N--CA 1.475 1.286 0 N-CA-C 116.386 1.314 . . . . 0.0 116.386 172.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 30' ' ' ALA . . . . . 0.504 ' CB ' ' HZ1' ' J' ' 28' ' ' LYS . . . -101.11 165.71 11.16 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 101.628 -3.471 . . . . 0.0 101.628 170.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.29 122.77 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 116.926 -1.91 . . . . 0.0 111.854 -178.224 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 32' ' ' ILE . . . . . 0.438 ' O ' ' SD ' ' F' ' 35' ' ' MET . 76.0 mt -131.96 130.92 61.63 Favored 'Isoleucine or valine' 0 C--N 1.352 0.686 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.443 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -122.47 122.22 4.96 Favored Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.371 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 mt -114.7 114.95 26.32 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.266 0.533 . . . . 0.0 111.8 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 35' ' ' MET . . . . . 0.546 ' SD ' ' CA ' ' E' ' 33' ' ' GLY . 8.1 ttt -128.36 120.89 27.88 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 177.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.08 81.61 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.05 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.41 102.05 0.63 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.75 152.64 24.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.6 m . . . . . 0 N--CA 1.464 0.267 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.846 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' L' L ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG2' ' K' ' 12' ' ' VAL . 66.9 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 121.922 0.868 . . . . 0.0 111.389 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 13' ' ' HIS . . . . . 0.493 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 4.4 m-70 -117.66 110.79 18.31 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.699 178.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -138.78 173.63 11.38 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -144.93 177.09 9.0 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.179 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -149.36 126.1 11.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.752 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.29 125.92 37.87 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -123.63 128.63 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-O 120.94 0.4 . . . . 0.0 110.425 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 19' ' ' PHE . . . . . 0.492 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 70.7 m-85 -113.81 112.3 23.18 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -133.49 127.72 33.85 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 121.696 0.76 . . . . 0.0 112.689 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.57 137.61 42.15 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.644 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -80.44 109.19 14.7 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 119.953 -0.699 . . . . 0.0 112.302 -178.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 23' ' ' ASP . . . . . 0.413 ' CG ' ' OG ' ' K' ' 26' ' ' SER . 37.0 t0 178.91 113.28 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.711 178.731 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 63.3 t -59.16 130.55 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.607 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -68.39 85.29 0.19 Allowed Glycine 0 CA--C 1.526 0.757 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.847 178.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 49.2 m -65.6 -175.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' O ' ' L' ' 28' ' ' LYS . 2.7 m120 -91.13 178.9 5.86 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 28' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 28.03 102.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.023 0 O-C-N 123.42 0.45 . . . . 0.0 111.69 177.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.85 -101.71 0.22 Allowed Glycine 0 N--CA 1.467 0.702 0 C-N-CA 119.251 -1.452 . . . . 0.0 112.556 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 30' ' ' ALA . . . . . 0.4 ' HA ' ' H ' ' K' ' 30' ' ' ALA . . . -53.65 161.72 1.01 Allowed 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.135 -177.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.12 127.14 2.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.438 -176.108 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -127.01 129.36 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.33 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 33' ' ' GLY . . . . . 0.623 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -122.11 132.74 9.0 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.244 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -120.44 121.82 39.34 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.07 0.435 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.2 123.16 35.97 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.14 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' L' ' 37' ' ' GLY . 16.7 m -145.41 78.92 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -3.63 -101.22 0.0 OUTLIER Glycine 0 C--N 1.359 1.814 0 C-N-CA 122.948 0.309 . . . . 0.0 113.284 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.6 162.74 21.49 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -132.39 156.08 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.868 0.366 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.936 -1.031 . . . . 0.0 111.076 -179.534 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -127.41 139.63 52.71 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.828 0.347 . . . . 0.0 110.404 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -61.61 135.92 57.82 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.2 t -126.01 133.77 68.15 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.018 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -106.24 165.87 10.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.467 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.414 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 8.2 p80 -92.34 169.58 10.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.385 0.612 . . . . 0.0 110.249 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 96.2 mm-40 -151.71 -179.96 7.88 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.008 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -126.04 126.71 44.69 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.904 0.383 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.2 mt -128.39 127.73 43.16 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.978 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -135.66 138.57 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.272 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -130.96 135.73 47.9 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.52 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.0 p90 -123.48 128.97 50.55 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.97 130.96 52.27 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 122.13 0.967 . . . . 0.0 112.788 -178.514 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -125.5 167.5 14.92 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -128.3 122.46 31.65 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 118.289 0.495 . . . . 0.0 112.119 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.538 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 m -94.25 -113.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 41.85 -90.98 0.01 OUTLIER Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.345 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.951 ' O ' ' O ' ' A' ' 27' ' ' ASN . 41.2 t -170.97 170.52 6.26 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.951 ' O ' ' O ' ' A' ' 26' ' ' SER . 4.0 m120 13.38 -179.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 124.839 1.337 . . . . 0.0 113.626 -176.482 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -150.05 105.5 3.39 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 119.586 -1.946 . . . . 0.0 114.683 177.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -77.53 101.4 1.64 Allowed Glycine 0 CA--C 1.507 -0.461 0 CA-C-O 114.823 -3.209 . . . . 0.0 105.505 168.648 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 147.73 25.98 Favored 'General case' 0 C--N 1.355 0.838 1 CA-C-N 125.483 4.642 . . . . 0.0 108.621 -178.407 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.521 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -152.73 112.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.397 -171.704 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.4 HD13 HG21 ' A' ' 32' ' ' ILE . 56.5 mt -121.93 103.48 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 176.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.65 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -116.55 107.49 1.63 Allowed Glycine 0 CA--C 1.505 -0.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 177.272 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.51 ' H ' HD22 ' B' ' 34' ' ' LEU . 70.2 mt -142.66 153.66 43.63 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 123.295 1.521 . . . . 0.0 113.085 -177.122 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.469 ' SD ' ' C ' ' G' ' 31' ' ' ILE . 28.5 ttm -119.96 119.58 33.86 Favored 'General case' 0 CA--C 1.5 -0.949 0 CA-C-N 112.643 -2.071 . . . . 0.0 108.433 178.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.53 66.91 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.09 -102.13 0.01 OUTLIER Glycine 0 C--N 1.356 1.65 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.75 171.99 38.71 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.6 t -131.56 139.16 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.838 0.351 . . . . 0.0 110.415 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.357 179.811 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.36 158.54 44.01 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.683 0.277 . . . . 0.0 110.37 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.51 ' OE2' ' NE2' ' B' ' 13' ' ' HIS . 81.2 tt0 -146.56 146.26 30.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.272 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.1 m -136.88 159.68 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.163 0.506 . . . . 0.0 111.283 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.51 ' NE2' ' OE2' ' B' ' 11' ' ' GLU . 96.0 m-70 -149.83 163.52 37.81 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.067 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -115.04 178.39 4.3 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -97.2 175.09 6.41 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.775 -179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -117.49 138.67 51.71 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.73 127.27 40.1 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-O 121.051 0.453 . . . . 0.0 111.589 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -126.85 130.49 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.097 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -124.23 134.01 53.37 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.395 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -136.2 123.48 21.85 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.727 -0.215 . . . . 0.0 111.031 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . 0.433 ' O ' ' CG ' ' B' ' 22' ' ' GLU . . . -126.86 117.55 22.82 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 120.946 0.403 . . . . 0.0 111.067 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.433 ' CG ' ' O ' ' B' ' 21' ' ' ALA . 83.3 mt-10 -165.47 133.8 3.16 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.617 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -170.27 111.03 0.41 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 72.8 t -30.72 132.1 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 113.943 -1.48 . . . . 0.0 111.942 174.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.19 -82.93 0.09 OUTLIER Glycine 0 CA--C 1.53 1.007 0 C-N-CA 119.627 -1.273 . . . . 0.0 113.405 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.588 ' O ' ' O ' ' B' ' 27' ' ' ASN . 0.4 OUTLIER -170.54 -179.2 2.88 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 119.476 1.638 . . . . 0.0 112.279 -178.909 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.588 ' O ' ' O ' ' B' ' 26' ' ' SER . 64.0 t30 27.22 -171.51 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 112.341 -2.208 . . . . 0.0 113.531 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.572 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 64.4 tttt -145.35 -103.81 0.1 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.164 -177.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 38.2 95.91 0.01 OUTLIER Glycine 0 C--N 1.35 1.355 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 -178.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.91 152.29 29.49 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.535 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -143.28 118.35 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 113.914 -1.494 . . . . 0.0 109.059 -175.126 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.1 tt -122.65 114.74 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.686 0.755 . . . . 0.0 109.705 179.976 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -117.5 116.9 3.62 Favored Glycine 0 N--CA 1.463 0.498 0 N-CA-C 107.877 -2.089 . . . . 0.0 107.877 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.51 HD22 ' H ' ' A' ' 34' ' ' LEU . 79.6 mt -134.62 147.0 50.09 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 114.444 1.276 . . . . 0.0 114.444 -176.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.464 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 3.2 ttm -122.48 118.35 28.11 Favored 'General case' 0 CA--C 1.505 -0.779 0 CA-C-N 113.469 -1.696 . . . . 0.0 109.366 177.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.09 70.16 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.18 112.18 3.46 Favored Glycine 0 C--N 1.358 1.785 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.43 147.94 12.74 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.628 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -127.82 136.3 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.572 179.704 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -109.91 139.14 45.33 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mp0 -63.11 132.4 51.73 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.5 t -129.24 131.53 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.692 -0.231 . . . . 0.0 110.425 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.572 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 80.0 m-70 -152.12 119.26 5.88 Favored 'General case' 0 N--CA 1.463 0.219 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.35 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -136.61 164.78 27.42 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -155.88 178.63 10.04 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.873 0.368 . . . . 0.0 110.557 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -167.72 106.92 0.54 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.208 178.664 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mt -122.12 121.15 36.24 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -129.26 125.97 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 CA-C-O 121.027 0.442 . . . . 0.0 111.971 -179.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -120.52 113.94 21.03 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -116.92 132.96 56.57 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.185 0.194 . . . . 0.0 110.641 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.91 138.1 25.37 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 85.1 tt0 -161.88 144.1 11.49 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.474 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.465 ' O ' ' O ' ' C' ' 24' ' ' VAL . 20.3 t0 -168.7 120.56 0.79 Allowed 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.187 178.233 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' C' ' 23' ' ' ASP . 12.7 m -49.15 -122.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.142 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.18 -91.13 1.01 Allowed Glycine 0 CA--C 1.536 1.391 0 CA-C-N 114.945 -1.025 . . . . 0.0 115.54 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' C' ' 27' ' ' ASN . 81.5 p -170.23 -179.01 2.96 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 118.385 1.092 . . . . 0.0 110.98 -175.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' C' ' 26' ' ' SER . 96.6 m-20 27.26 -169.61 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 114.862 -1.063 . . . . 0.0 112.629 -179.191 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.443 ' CD ' ' H ' ' D' ' 29' ' ' GLY . 42.9 tttt -138.37 -106.3 0.18 Allowed 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -176.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.529 ' H ' ' HA3' ' D' ' 29' ' ' GLY . . . 45.45 93.31 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -175.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.424 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -106.37 157.87 17.3 Favored 'General case' 0 CA--C 1.482 -1.665 0 N-CA-C 101.764 -3.421 . . . . 0.0 101.764 175.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.424 ' CG1' ' C ' ' C' ' 30' ' ' ALA . 2.0 mt -140.02 122.65 16.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 117.94 -1.504 . . . . 0.0 111.74 -173.209 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.4 HG23 HD11 ' C' ' 32' ' ' ILE . 1.1 mt -117.75 112.59 39.31 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.14 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.78 102.81 0.87 Allowed Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.427 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 7.0 tt -134.73 138.52 44.44 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.654 1.216 . . . . 0.0 113.29 -175.042 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 25.9 ttm -117.99 120.5 38.0 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 113.705 -1.588 . . . . 0.0 108.724 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.423 ' CG1' ' O ' ' C' ' 36' ' ' VAL . 4.0 p -125.36 71.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.39 -100.86 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.437 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.51 -157.83 29.8 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -133.9 160.24 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.004 0.43 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.831 179.986 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' D' ' 10' ' ' TYR . 18.0 p90 -147.75 156.12 42.42 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.945 0.402 . . . . 0.0 110.788 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -75.25 155.94 36.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.777 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 m -146.49 -164.47 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.062 -178.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.572 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 80.9 m-70 -78.4 124.63 28.33 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.145 -0.622 . . . . 0.0 111.727 -179.06 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 82.8 m-70 -148.45 167.97 23.91 Favored 'General case' 0 C--N 1.342 0.28 0 CA-C-O 121.244 0.545 . . . . 0.0 109.985 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.63 177.69 10.67 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.591 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.61 114.09 0.62 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.21 0.528 . . . . 0.0 111.779 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 35.5 tp -123.72 121.59 35.87 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.215 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -126.62 125.48 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.465 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 35.8 m-85 -117.21 120.87 39.58 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.187 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -128.34 122.41 31.48 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.828 0.347 . . . . 0.0 111.175 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.65 135.55 40.26 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.166 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.7 mt-10 -117.57 124.39 48.55 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.111 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 77.8 m-20 -146.38 122.58 10.85 Favored 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 112.852 0.686 . . . . 0.0 112.852 -179.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.402 ' H ' ' HZ2' ' B' ' 28' ' ' LYS . 11.8 t -101.98 -111.48 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.817 0.818 . . . . 0.0 111.638 179.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.21 -92.34 0.01 OUTLIER Glycine 0 CA--C 1.547 2.036 0 C-N-CA 126.727 2.108 . . . . 0.0 118.353 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 58.8 m -90.78 -178.4 5.24 Favored 'General case' 0 CA--C 1.501 -0.938 0 CA-C-N 118.532 1.166 . . . . 0.0 110.413 -174.865 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 69.3 m-80 -58.84 162.8 3.81 Favored 'General case' 0 CA--C 1.506 -0.721 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.755 ' HZ1' ' H ' ' E' ' 24' ' ' VAL . 76.6 mttt -56.32 111.25 0.92 Allowed 'General case' 0 N--CA 1.438 -1.052 0 C-N-CA 115.944 -2.302 . . . . 0.0 112.398 -174.017 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.529 ' HA3' ' H ' ' C' ' 29' ' ' GLY . . . -91.41 93.1 1.8 Allowed Glycine 0 CA--C 1.498 -1.001 0 CA-C-O 116.195 -2.447 . . . . 0.0 109.711 169.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.04 144.54 31.68 Favored 'General case' 0 CA--C 1.473 -2.0 0 CA-C-N 123.227 3.514 . . . . 0.0 108.923 175.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -143.36 108.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 CA-C-N 113.535 -1.666 . . . . 0.0 107.955 -176.561 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.53 121.89 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.087 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.626 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -125.94 103.22 0.68 Allowed Glycine 0 C--N 1.311 -0.813 0 N-CA-C 105.526 -3.03 . . . . 0.0 105.526 175.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.573 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.4 tt -127.78 131.33 49.62 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-O 122.171 0.986 . . . . 0.0 111.747 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.487 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 17.0 ttm -112.05 121.81 46.02 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 113.985 -1.462 . . . . 0.0 110.011 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.437 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -110.95 75.43 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.803 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -31.85 -96.24 0.01 OUTLIER Glycine 0 C--N 1.353 1.502 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.9 175.29 17.49 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 10.0 p -139.7 141.51 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.92 0.39 . . . . 0.0 110.608 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.563 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . 0.514 ' CE1' ' N ' ' F' ' 9' ' ' GLY . 88.1 m-85 -107.89 135.04 49.95 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.832 0.348 . . . . 0.0 110.211 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.52 138.63 58.51 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.186 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 72.6 t -122.38 131.28 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.619 179.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 96.1 m-70 -121.41 114.99 22.08 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.385 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' O ' ' E' ' 13' ' ' HIS . 2.7 m80 -142.46 168.31 20.03 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.641 0.734 . . . . 0.0 110.124 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -151.63 168.95 23.35 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.079 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -146.36 111.36 5.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 31.9 mt -122.99 121.81 37.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 14.3 p -140.16 135.87 37.22 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 CA-C-O 121.944 0.878 . . . . 0.0 112.883 -179.085 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.573 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 36.7 m-85 -117.72 117.23 28.77 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 114.327 -1.306 . . . . 0.0 109.927 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 38.3 m-85 -113.3 119.56 38.12 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.699 0.285 . . . . 0.0 111.105 -179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.6 137.86 53.38 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 120.972 0.415 . . . . 0.0 110.01 178.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -79.47 73.83 6.11 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 118.309 -1.356 . . . . 0.0 111.158 -177.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.608 ' O ' ' O ' ' E' ' 24' ' ' VAL . 1.3 p30 -171.49 109.92 0.29 Allowed 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.663 176.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.755 ' H ' ' HZ1' ' D' ' 28' ' ' LYS . 2.8 t -45.27 -132.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.698 1.237 . . . . 0.0 112.582 177.404 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.526 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . -138.76 80.99 0.27 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.613 ' O ' ' N ' ' F' ' 30' ' ' ALA . 28.6 m -68.94 -169.85 0.2 Allowed 'General case' 0 C--O 1.214 -0.808 0 CA-C-O 121.294 0.568 . . . . 0.0 110.734 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.528 ' O ' ' C ' ' E' ' 28' ' ' LYS . 39.8 m-20 -81.46 -175.53 5.55 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.012 179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.528 ' C ' ' O ' ' E' ' 27' ' ' ASN . 87.0 tttt -28.24 104.41 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -177.889 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.509 ' O ' ' CG1' ' E' ' 31' ' ' ILE . . . 168.16 -101.33 0.17 Allowed Glycine 0 C--O 1.211 -1.33 0 CA-C-O 117.586 -1.674 . . . . 0.0 111.231 -171.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -53.46 153.39 4.15 Favored 'General case' 0 C--O 1.246 0.893 0 CA-C-N 121.289 2.545 . . . . 0.0 110.251 -175.586 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.509 ' CG1' ' O ' ' E' ' 29' ' ' GLY . 1.1 mt -148.57 126.09 2.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.946 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' L' ' 35' ' ' MET . 89.3 mt -128.99 128.15 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 120.901 0.381 . . . . 0.0 111.946 -178.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 121.34 4.69 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 47.9 tp -127.93 124.67 37.91 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.499 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 8.9 ttt -129.84 126.27 37.64 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 120.31 -0.556 . . . . 0.0 111.547 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 51.3 t -109.94 86.84 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.425 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -75.0 96.9 0.99 Allowed Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.2 170.8 43.1 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -128.45 135.06 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-O 120.911 0.386 . . . . 0.0 109.999 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.795 -179.791 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . 0.514 ' N ' ' CE1' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 79.8 t80 -84.66 130.82 34.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.529 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 98.3 mt-10 -59.08 154.13 16.44 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.514 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 t -96.25 132.82 39.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.773 0.32 . . . . 0.0 110.703 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -153.13 113.98 4.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.204 0.526 . . . . 0.0 111.867 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -155.1 173.72 16.19 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -151.92 175.65 12.27 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.855 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -132.17 114.48 14.54 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.745 179.773 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 49.0 tp -122.68 118.77 28.89 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 77.2 t -133.35 130.0 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -113.64 111.82 22.47 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 175.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -141.81 152.86 44.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.005 0.907 . . . . 0.0 112.244 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -150.46 149.14 29.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.291 -179.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -136.79 144.39 43.7 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -178.147 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.571 ' CG ' ' H ' ' F' ' 24' ' ' VAL . 62.2 t0 177.75 -118.48 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.863 177.66 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.571 ' H ' ' CG ' ' F' ' 23' ' ' ASP . 13.2 p -102.18 126.41 56.23 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.568 0 CA-C-O 121.124 0.488 . . . . 0.0 110.659 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -31.4 -83.15 0.01 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.007 177.252 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 13.2 t 73.08 179.96 0.22 Allowed 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 124.456 1.102 . . . . 0.0 110.183 -176.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.418 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 88.8 m-20 -89.42 172.7 8.82 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 118.544 2.794 . . . . 0.0 118.544 -173.854 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -39.09 106.33 0.05 Allowed 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 109.268 -3.605 . . . . 0.0 119.894 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.61 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . 148.02 -97.22 0.18 Allowed Glycine 0 N--CA 1.483 1.8 0 C-N-CA 120.492 -0.861 . . . . 0.0 115.224 171.315 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.613 ' N ' ' O ' ' E' ' 26' ' ' SER . . . 56.2 166.02 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 103.186 -2.894 . . . . 0.0 103.186 -173.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.444 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 1.6 mt -140.08 119.37 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 124.098 3.135 . . . . 0.0 111.447 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . 0.4 HD12 HG23 ' F' ' 32' ' ' ILE . 57.7 mt -123.87 136.23 60.92 Favored 'Isoleucine or valine' 0 C--N 1.347 0.483 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.512 -176.438 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.44 125.16 5.16 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 46.9 tp -118.64 120.8 38.51 Favored 'General case' 0 N--CA 1.47 0.54 0 O-C-N 122.642 -0.328 . . . . 0.0 110.229 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -118.37 119.38 34.45 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 116.952 -0.113 . . . . 0.0 111.098 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 p -153.21 82.47 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.763 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 179.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.531 ' H ' ' CD1' ' L' ' 31' ' ' ILE . . . -71.4 101.11 0.94 Allowed Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.26 161.51 34.51 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -141.86 143.7 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 110.604 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 t . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.4 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -103.79 133.08 49.38 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.855 0.36 . . . . 0.0 110.449 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -112.98 152.42 29.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.803 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 134.02 57.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.935 0.397 . . . . 0.0 110.091 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.449 ' ND1' ' N ' ' G' ' 13' ' ' HIS . 6.3 p-80 -133.41 -177.95 4.76 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.311 -179.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 8.2 m80 -81.72 167.92 18.63 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-O 121.126 0.489 . . . . 0.0 109.961 -179.207 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.447 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 51.0 tp60 -163.17 172.32 15.0 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.563 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.447 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 99.7 mttt -138.72 139.81 38.5 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -138.83 120.68 15.41 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.213 0.53 . . . . 0.0 110.902 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.41 134.36 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.767 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -129.2 125.31 36.7 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 120.939 0.4 . . . . 0.0 110.592 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.402 ' CD1' ' C ' ' G' ' 20' ' ' PHE . 19.5 t80 -113.46 123.26 49.61 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.17 131.81 53.16 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 121.805 0.812 . . . . 0.0 112.472 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' G' ' 23' ' ' ASP . 18.6 pt-20 -102.48 -173.08 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.771 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.483 ' N ' ' CB ' ' H' ' 23' ' ' ASP . 19.3 t70 -23.83 132.96 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' G' ' 26' ' ' SER . 11.7 t -89.33 113.56 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 114.197 -1.365 . . . . 0.0 108.162 177.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . -44.92 91.55 0.01 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.402 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.552 ' O ' ' O ' ' G' ' 27' ' ' ASN . 16.1 m 138.92 172.34 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.577 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.552 ' O ' ' O ' ' G' ' 26' ' ' SER . 90.9 m-20 -43.07 -178.67 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 O-C-N 123.429 0.456 . . . . 0.0 111.066 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.466 ' CD ' ' O ' ' H' ' 26' ' ' SER . 68.5 tttt -72.07 -114.7 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.767 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 50.32 91.33 0.01 OUTLIER Glycine 0 C--N 1.344 0.974 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.0 163.26 12.32 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 117.326 -1.75 . . . . 0.0 108.629 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.469 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -152.56 109.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 CA-C-N 112.966 -1.924 . . . . 0.0 109.618 -172.806 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.418 ' N ' ' SD ' ' A' ' 35' ' ' MET . 5.1 mt -100.95 111.05 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.25 99.0 0.68 Allowed Glycine 0 CA--C 1.503 -0.661 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.407 ' H ' HD23 ' H' ' 34' ' ' LEU . 12.0 mt -138.65 141.58 39.06 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-O 122.965 1.364 . . . . 0.0 111.572 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.65 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 38.0 ttp -109.66 114.96 29.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 112.957 -1.928 . . . . 0.0 107.158 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.41 66.03 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.78 110.92 4.02 Favored Glycine 0 C--N 1.359 1.828 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.63 178.99 0.11 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.8 m -137.6 161.05 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.782 0.325 . . . . 0.0 110.749 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.066 -0.968 . . . . 0.0 110.325 179.69 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -106.67 140.84 38.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.945 0.402 . . . . 0.0 110.472 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -139.12 164.74 28.99 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.542 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 78.2 t -82.47 133.54 28.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.881 -179.99 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' I' ' 13' ' ' HIS . 3.5 t60 -140.06 100.23 3.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.894 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 13.9 t-80 -141.88 159.07 42.97 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.631 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 71.1 mt-30 -162.0 178.52 8.78 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.966 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -130.51 132.4 45.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 69.0 mt -120.9 111.74 17.91 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.54 127.22 74.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.143 0.497 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -117.1 112.94 21.59 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.381 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.24 121.2 44.66 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.37 132.39 48.55 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.256 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -164.58 125.73 2.13 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 119.857 -0.737 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.483 ' CB ' ' N ' ' G' ' 23' ' ' ASP . 0.9 OUTLIER -176.64 109.36 0.08 Allowed 'General case' 0 CA--C 1.544 0.723 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.6 t -37.9 135.35 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.285 173.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.05 -81.79 0.04 OUTLIER Glycine 0 CA--C 1.533 1.201 0 C-N-CA 118.941 -1.599 . . . . 0.0 112.54 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.742 ' O ' ' O ' ' H' ' 27' ' ' ASN . 49.5 p -171.01 179.88 2.96 Favored 'General case' 0 C--O 1.211 -0.922 0 CA-C-N 118.42 1.11 . . . . 0.0 109.823 178.467 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.742 ' O ' ' O ' ' H' ' 26' ' ' SER . 57.3 m-80 26.35 -177.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 177.349 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.426 ' HZ3' ' CG2' ' J' ' 24' ' ' VAL . 70.1 mmtt -119.6 -110.51 0.34 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.547 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 43.8 92.48 0.01 OUTLIER Glycine 0 N--CA 1.468 0.781 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.277 178.976 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.47 152.78 48.63 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.728 -1.952 . . . . 0.0 105.728 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -146.2 129.6 9.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 118.735 -1.186 . . . . 0.0 112.429 -172.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.464 ' C ' ' SD ' ' B' ' 35' ' ' MET . 67.3 mt -112.64 117.63 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.351 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 102.06 0.91 Allowed Glycine 0 N--CA 1.466 0.648 0 N-CA-C 108.017 -2.033 . . . . 0.0 108.017 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.407 HD23 ' H ' ' G' ' 34' ' ' LEU . 89.7 mt -131.96 131.37 42.55 Favored 'General case' 0 CA--C 1.498 -1.025 0 CA-C-O 122.005 0.907 . . . . 0.0 112.791 -177.647 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 42.1 ttp -108.61 116.86 32.78 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.193 -1.367 . . . . 0.0 107.546 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.17 67.5 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.218 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 38' ' ' GLY . . . -94.04 110.91 4.06 Favored Glycine 0 C--N 1.372 2.568 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 37' ' ' GLY . . . 31.59 -159.57 0.0 OUTLIER Glycine 0 CA--C 1.524 0.616 0 CA-C-O 121.777 0.654 . . . . 0.0 113.06 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -138.97 159.55 29.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.74 -0.73 . . . . 0.0 109.385 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.633 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.87 132.11 50.44 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.78 0.324 . . . . 0.0 110.538 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -105.78 157.38 17.49 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.751 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.546 ' O ' ' CG ' ' I' ' 13' ' ' HIS . 41.0 t -100.39 173.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.38 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.571 ' HE2' ' CB ' ' J' ' 11' ' ' GLU . 71.6 m80 -159.39 173.12 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.979 0.419 . . . . 0.0 111.092 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 -179.44 4.66 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.547 ' OE1' ' N ' ' H' ' 15' ' ' GLN . 8.9 mm-40 -95.83 173.88 7.24 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-O 121.328 0.585 . . . . 0.0 111.741 -178.354 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -114.33 139.29 49.58 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -119.49 122.78 42.44 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 121.188 0.518 . . . . 0.0 111.706 -179.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -130.96 122.2 51.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.957 178.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -111.24 107.18 16.4 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.301 -1.741 . . . . 0.0 106.301 176.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -115.63 127.42 55.19 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 120.75 0.309 . . . . 0.0 111.04 -177.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.37 128.54 25.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 122.112 0.958 . . . . 0.0 112.796 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -108.88 164.75 12.12 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 175.94 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 27.3 t70 60.71 -110.64 0.45 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 116.83 -1.948 . . . . 0.0 108.653 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 69.5 t -45.63 132.1 2.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 122.743 1.259 . . . . 0.0 112.581 -175.894 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.67 82.84 0.76 Allowed Glycine 0 CA--C 1.519 0.322 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.022 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 5.3 p -99.07 172.52 7.34 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-O 121.547 0.689 . . . . 0.0 110.269 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.851 HD21 ' H ' ' I' ' 27' ' ' ASN . 0.5 OUTLIER -62.12 171.02 1.93 Allowed 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.037 175.56 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' J' ' 26' ' ' SER . 89.6 mttt 55.37 110.69 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.475 ' H ' ' CA ' ' J' ' 30' ' ' ALA . . . 67.53 92.37 0.05 OUTLIER Glycine 0 N--CA 1.474 1.168 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -173.86 156.11 2.74 Favored 'General case' 0 C--N 1.271 -2.816 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 177.1 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.458 ' C ' ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -142.09 117.75 5.87 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 C-N-CA 117.14 -1.824 . . . . 0.0 109.982 -174.448 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.601 ' N ' ' SD ' ' C' ' 35' ' ' MET . 16.1 tt -115.08 121.0 66.2 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-O 122.114 0.959 . . . . 0.0 111.174 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.31 99.38 1.11 Allowed Glycine 0 CA--C 1.505 -0.576 0 N-CA-C 105.819 -2.913 . . . . 0.0 105.819 176.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 7.1 tt -123.37 127.63 48.75 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 122.545 1.164 . . . . 0.0 111.245 -177.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 2.8 ttm -108.87 118.9 37.98 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 114.227 -1.352 . . . . 0.0 111.195 -179.422 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.463 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.14 67.43 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 177.383 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -42.67 -103.26 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.67 -162.44 14.56 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -115.93 135.52 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.01 0.433 . . . . 0.0 110.48 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.784 -179.984 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . 0.426 ' O ' ' OE1' ' J' ' 11' ' ' GLU . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 78.7 t80 -93.4 129.76 39.43 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . 0.571 ' CB ' ' HE2' ' I' ' 13' ' ' HIS . 57.5 mp0 -132.47 146.57 52.03 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.15 0.5 . . . . 0.0 111.104 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.572 ' H ' ' CD2' ' K' ' 13' ' ' HIS . 0.1 OUTLIER -130.57 -165.38 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-N 115.519 -0.764 . . . . 0.0 108.992 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.511 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 27.7 m170 -61.98 118.32 7.12 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 119.964 -0.694 . . . . 0.0 110.565 -179.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 2.7 t-80 -135.75 164.04 28.81 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 83.2 mt-30 -155.81 177.01 11.89 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.269 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -172.27 128.24 0.56 Allowed 'General case' 0 C--O 1.239 0.522 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.521 178.758 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 11.3 mp -117.76 123.27 45.6 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.75 -179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -127.45 126.55 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.623 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -120.97 106.8 11.94 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -114.8 128.04 56.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.575 -0.703 . . . . 0.0 112.184 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.43 123.64 36.58 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-O 121.97 0.891 . . . . 0.0 111.617 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.452 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 81.2 mm-40 -128.11 113.08 15.3 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 114.414 -1.266 . . . . 0.0 110.479 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' J' ' 24' ' ' VAL . 30.9 t0 -174.79 138.31 0.48 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.816 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' J' ' 23' ' ' ASP . 3.7 m -16.95 -110.22 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -166.83 92.3 0.1 Allowed Glycine 0 CA--C 1.534 1.246 0 C-N-CA 119.83 -1.176 . . . . 0.0 113.892 -173.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' J' ' 27' ' ' ASN . 0.4 OUTLIER -63.26 -173.22 0.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.101 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' J' ' 26' ' ' SER . 77.5 m-20 -77.88 172.8 12.91 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 116.602 2.075 . . . . 0.0 116.602 -172.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.413 ' CE ' ' O ' ' K' ' 28' ' ' LYS . 6.5 mmtm -44.12 111.85 0.34 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 110.959 -2.837 . . . . 0.0 118.154 -177.628 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.84 94.42 1.56 Allowed Glycine 0 CA--C 1.501 -0.783 0 CA-C-N 114.209 -1.36 . . . . 0.0 114.501 176.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.475 ' CA ' ' H ' ' I' ' 29' ' ' GLY . . . -84.49 170.17 13.75 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 102.057 -3.312 . . . . 0.0 102.057 173.1 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.443 ' CG2' ' SD ' ' D' ' 35' ' ' MET . 0.4 OUTLIER -150.45 123.22 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 CA-C-N 120.985 1.72 . . . . 0.0 111.752 -177.294 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.492 ' CG1' ' CZ ' ' L' ' 20' ' ' PHE . 97.4 mt -109.89 117.27 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.385 178.717 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.14 102.08 1.17 Allowed Glycine 0 C--O 1.238 0.38 0 N-CA-C 106.282 -2.727 . . . . 0.0 106.282 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.438 ' CD1' ' CZ ' ' L' ' 19' ' ' PHE . 7.9 tt -132.74 139.18 47.48 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-O 121.675 0.75 . . . . 0.0 112.562 -176.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.8 ttp -123.7 125.74 45.3 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 114.734 -1.121 . . . . 0.0 112.6 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' J' ' 37' ' ' GLY . 0.0 OUTLIER -123.63 70.05 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.287 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -44.6 -100.78 0.01 OUTLIER Glycine 0 C--N 1.357 1.716 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.98 150.8 8.16 Favored Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -158.39 148.01 8.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.856 0.36 . . . . 0.0 110.224 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 71.3 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.379 179.861 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.74 143.86 47.57 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.724 0.297 . . . . 0.0 110.492 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -110.64 144.64 39.23 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.278 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 48.3 t -141.06 166.25 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.983 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.572 ' CD2' ' H ' ' J' ' 12' ' ' VAL . 1.2 m-70 -115.89 161.93 18.08 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.9 174.75 4.14 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-O 121.23 0.538 . . . . 0.0 109.868 -178.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -142.03 176.67 8.77 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.017 -179.226 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -149.42 135.47 18.93 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.051 0.453 . . . . 0.0 110.822 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -127.72 111.34 13.58 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 78.9 t -134.66 127.27 49.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.624 ' O ' ' HA ' ' L' ' 20' ' ' PHE . 3.4 m-30 -113.31 141.37 47.11 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.539 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.484 ' HA ' ' HA ' ' L' ' 20' ' ' PHE . 77.9 t80 -136.4 117.87 14.77 Favored 'General case' 0 N--CA 1.505 2.311 0 CA-C-N 120.858 1.663 . . . . 0.0 114.128 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . 0.797 ' H ' ' H ' ' L' ' 21' ' ' ALA . . . -121.91 126.17 48.06 Favored 'General case' 0 C--N 1.398 2.707 0 CA-C-O 123.13 1.443 . . . . 0.0 112.061 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.567 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 82.5 tt0 -89.63 124.7 34.81 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.249 -178.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -123.87 131.81 53.64 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.063 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.42 113.64 11.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.175 179.404 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' K' ' 26' ' ' SER . . . 59.41 91.35 0.01 OUTLIER Glycine 0 CA--C 1.529 0.954 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.861 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' CB ' ' K' ' 27' ' ' ASN . 3.7 p -43.67 170.27 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.553 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.654 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER 157.49 -179.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 122.891 1.329 . . . . 0.0 114.007 178.873 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.654 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 52.4 mttp -29.62 112.49 0.08 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 119.365 3.098 . . . . 0.0 119.365 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 83.01 91.62 0.65 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 119.814 2.686 . . . . 0.0 119.814 173.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.465 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -143.62 155.22 44.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 101.916 -3.364 . . . . 0.0 101.916 170.555 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.481 HG22 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -145.96 121.39 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 118.553 -1.259 . . . . 0.0 111.158 -176.563 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' E' ' 35' ' ' MET . 96.7 mt -120.74 127.64 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.488 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.55 110.64 1.88 Allowed Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 178.361 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -121.63 118.65 29.71 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.224 -0.488 . . . . 0.0 110.637 -179.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.447 ' SD ' ' C ' ' K' ' 35' ' ' MET . 6.2 tmm? -118.99 117.51 29.01 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.867 178.241 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 1.4 t -113.29 79.69 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 120.981 0.42 . . . . 0.0 110.162 178.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.29 100.58 2.59 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 178.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.72 172.78 42.64 Favored Glycine 0 CA--C 1.524 0.608 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.463 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -131.46 141.76 45.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.37 179.9 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.209 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -104.1 132.33 50.45 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -149.12 135.57 19.37 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.976 0.417 . . . . 0.0 110.944 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -128.96 134.61 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.008 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -158.0 107.39 2.08 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 120.872 0.368 . . . . 0.0 111.388 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 54.6 t-80 -153.81 166.95 31.29 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.522 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 84.5 mt-30 -152.7 178.88 9.14 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.129 0.49 . . . . 0.0 110.991 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -154.84 125.36 6.91 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.352 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -120.78 115.59 23.59 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.507 -0.121 . . . . 0.0 110.773 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -125.66 126.71 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.438 ' CZ ' ' CD1' ' J' ' 34' ' ' LEU . 5.0 m-30 -99.09 125.35 44.59 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.71 ' HB2' ' N ' ' K' ' 21' ' ' ALA . 1.6 p90 -32.47 159.9 0.0 OUTLIER 'General case' 0 C--O 1.158 -3.758 0 N-CA-C 121.05 3.722 . . . . 0.0 121.05 -172.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.797 ' H ' ' H ' ' K' ' 21' ' ' ALA . . . -78.62 157.14 28.77 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.068 174.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.456 ' OE1' ' O ' ' L' ' 20' ' ' PHE . 0.0 OUTLIER 178.67 -169.41 0.09 Allowed 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -177.114 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.562 ' OD1' ' N ' ' K' ' 27' ' ' ASN . 20.8 t0 -62.97 106.09 0.77 Allowed 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.161 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 87.0 t -36.16 142.84 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -178.423 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -98.75 82.94 0.61 Allowed Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 178.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 67.6 m -69.15 -171.69 0.35 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' L' ' 28' ' ' LYS . 96.3 m-20 -81.13 177.41 9.05 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.313 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.546 ' O ' ' O ' ' L' ' 27' ' ' ASN . 86.2 tttt 39.81 104.16 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 178.957 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.19 -101.19 1.85 Allowed Glycine 0 N--CA 1.467 0.715 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -177.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.465 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -61.88 170.0 2.29 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 118.222 1.011 . . . . 0.0 108.652 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.531 ' CD1' ' H ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -166.11 153.41 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 118.642 -1.223 . . . . 0.0 112.413 -177.885 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.7 mt -125.31 128.01 72.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.063 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.35 121.38 5.03 Favored Glycine 0 N--CA 1.469 0.853 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -119.77 118.62 31.35 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.518 ' SD ' ' O ' ' E' ' 32' ' ' ILE . 3.9 ttp -117.36 119.94 36.64 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.474 ' O ' ' C ' ' L' ' 37' ' ' GLY . 35.8 m -130.46 76.29 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.643 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.474 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 23.9 -112.63 0.01 OUTLIER Glycine 0 C--N 1.352 1.428 0 N-CA-C 112.234 -0.346 . . . . 0.0 112.234 178.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.76 -150.56 15.97 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.51 158.29 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.816 0.341 . . . . 0.0 110.35 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.676 -179.636 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -102.11 138.38 39.14 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.838 0.352 . . . . 0.0 110.387 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -119.63 143.05 47.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.429 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 m -121.9 132.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -151.83 166.79 30.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.411 ' CD2' ' CE1' ' B' ' 13' ' ' HIS . 93.0 m-70 -132.13 179.5 6.06 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -95.25 177.43 5.86 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.587 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -116.37 145.31 43.32 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.893 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.7 tp -128.22 123.0 33.12 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 121.268 0.556 . . . . 0.0 111.872 -179.152 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.54 131.43 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.335 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -137.52 132.7 33.61 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.133 0.492 . . . . 0.0 111.599 -179.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.3 p90 -133.14 129.94 38.56 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.24 158.12 39.77 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.446 ' CB ' ' O ' ' B' ' 22' ' ' GLU . 22.5 pt-20 -143.88 150.65 38.75 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.915 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -94.09 -146.54 0.25 Allowed 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.706 -0.797 . . . . 0.0 111.202 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' A' ' 26' ' ' SER . 15.2 t -103.34 107.27 21.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -34.62 92.52 0.01 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 121.536 -0.364 . . . . 0.0 112.914 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.685 ' O ' ' O ' ' A' ' 27' ' ' ASN . 2.2 t 170.05 177.51 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.685 ' O ' ' O ' ' A' ' 26' ' ' SER . 15.9 t-20 -29.19 179.15 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.59 1.181 . . . . 0.0 112.641 177.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.557 ' CG ' ' O ' ' A' ' 27' ' ' ASN . 0.0 OUTLIER 128.45 103.57 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 175.794 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.05 101.06 0.27 Allowed Glycine 0 CA--C 1.484 -1.891 0 N-CA-C 106.962 -2.455 . . . . 0.0 106.962 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.635 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . -83.33 151.79 25.4 Favored 'General case' 0 N--CA 1.438 -1.039 0 C-N-CA 114.861 -2.736 . . . . 0.0 108.78 -175.089 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' G' ' 35' ' ' MET 0.3 0.3 OUTLIER -166.34 108.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.41 -2.475 0 CA-C-N 109.253 -3.612 . . . . 0.0 104.97 -168.806 . . . . . . . . 4 4 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.465 ' N ' ' HE3' ' H' ' 35' ' ' MET . 17.8 tt -119.58 123.46 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 121.56 0.695 . . . . 0.0 110.032 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.573 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -124.3 116.8 2.91 Favored Glycine 0 CA--C 1.507 -0.468 0 N-CA-C 108.144 -1.982 . . . . 0.0 108.144 178.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 35.0 mt -136.21 148.15 47.97 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 122.905 1.336 . . . . 0.0 111.572 -179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.449 ' SD ' ' C ' ' G' ' 32' ' ' ILE . 12.0 ttm -121.18 124.0 43.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 112.475 -2.148 . . . . 0.0 109.362 -179.076 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.6 71.9 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.99 -96.47 0.01 OUTLIER Glycine 0 C--N 1.357 1.721 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 178.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.59 -162.76 36.55 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -131.0 160.76 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.855 0.359 . . . . 0.0 110.273 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.466 -179.662 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.04 140.71 47.61 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -110.57 137.65 47.98 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.909 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 27.8 m -135.7 159.95 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.815 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.589 ' HE2' HE21 ' B' ' 15' ' ' GLN . 79.9 t60 -140.64 124.02 16.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.37 -0.377 . . . . 0.0 109.999 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 p-80 -149.32 166.74 28.08 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 121.239 0.543 . . . . 0.0 109.846 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.589 HE21 ' HE2' ' B' ' 13' ' ' HIS . 76.9 mt-30 -153.84 179.72 8.62 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.592 -179.876 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -163.71 109.12 1.06 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.059 179.125 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -130.31 118.72 21.72 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.77 131.36 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.347 0.594 . . . . 0.0 110.866 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.91 131.14 55.13 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.1 t80 -128.37 119.95 26.02 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 132.68 53.21 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.863 -179.451 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 22' ' ' GLU . 81.8 tt0 -155.15 133.37 11.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.295 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -113.95 133.3 55.56 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 t -81.98 113.12 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.596 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 51.78 90.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.819 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.74 177.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.8 t 170.19 178.2 0.05 OUTLIER 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 178.314 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' B' ' 26' ' ' SER . 4.7 m120 -28.75 170.65 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.646 1.216 . . . . 0.0 111.473 177.337 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.596 ' NZ ' ' O ' ' D' ' 24' ' ' VAL . 98.2 mttt -151.43 104.17 3.05 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 123.032 1.396 . . . . 0.0 112.558 179.116 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.67 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . 50.64 -102.69 0.07 OUTLIER Glycine 1 CA--C 1.388 -7.855 0 C-N-CA 127.463 2.459 . . . . 0.0 114.279 179.457 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.67 ' CB ' ' O ' ' B' ' 29' ' ' GLY 0.451 . . 113.93 -131.84 0.0 OUTLIER 'General case' 1 N--CA 1.366 -4.645 0 C-N-CA 114.019 -3.072 . . . . 0.0 106.355 -175.777 . . . . . . . . 4 3 . 1 . 002 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.57 ' CD1' ' N ' ' B' ' 31' ' ' ILE 0.366 2.2 mp -70.07 120.92 18.65 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.877 0 CA-C-N 109.245 -3.616 . . . . 0.0 113.458 175.045 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 16.9 tt -125.83 118.28 51.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 175.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.676 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -124.65 119.37 3.64 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 96.4 mt -136.61 131.25 33.48 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 122.901 1.334 . . . . 0.0 113.277 -176.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.45 ' HE2' ' SD ' ' C' ' 35' ' ' MET . 33.7 tpp -113.34 118.23 33.99 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.545 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -122.53 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.3 103.6 2.49 Favored Glycine 0 C--N 1.358 1.753 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.72 162.63 19.5 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.9 t -133.99 138.18 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 120.699 0.285 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.349 -179.976 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.74 135.31 49.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.892 0.377 . . . . 0.0 110.451 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -110.62 134.56 52.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.498 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 50.2 t -124.19 133.62 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.795 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -149.93 129.35 12.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.003 0.43 . . . . 0.0 111.005 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.558 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 71.8 t60 -138.47 166.21 24.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.558 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 83.4 mt-30 -156.18 169.64 24.06 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.915 178.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -157.81 108.49 2.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.727 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.5 tp -125.77 118.89 26.52 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -129.01 126.19 64.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.278 0.561 . . . . 0.0 112.029 -179.185 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.05 104.74 12.43 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -116.86 126.17 52.62 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.24 141.13 23.71 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-O 123.446 1.594 . . . . 0.0 115.09 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.457 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 93.5 mt-10 -137.5 73.75 1.46 Allowed 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.65 -2.523 . . . . 0.0 104.269 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.548 ' OD2' ' N ' ' C' ' 24' ' ' VAL . 25.1 t70 141.93 -115.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -175.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.548 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 28.0 t -40.88 121.98 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.493 ' H ' ' HA2' ' B' ' 29' ' ' GLY . . . 93.74 -90.37 1.37 Allowed Glycine 0 CA--C 1.538 1.475 0 CA-C-O 122.186 0.881 . . . . 0.0 111.275 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.506 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 52.6 m -60.89 -177.23 0.07 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -177.254 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.506 ' OD1' ' O ' ' C' ' 26' ' ' SER . 0.9 OUTLIER 95.02 165.43 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 111.443 -2.617 . . . . 0.0 115.324 177.755 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -37.02 111.47 0.15 Allowed 'General case' 0 C--N 1.349 0.545 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.672 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.12 91.24 0.26 Allowed Glycine 0 CA--C 1.457 -3.556 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.498 ' CB ' ' O ' ' B' ' 30' ' ' ALA . . . -153.23 162.81 40.89 Favored 'General case' 0 N--CA 1.38 -3.959 0 N-CA-C 101.618 -3.475 . . . . 0.0 101.618 177.16 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . 0.273 3.0 mp -126.63 115.95 43.47 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.283 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.448 -174.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.502 ' O ' ' SD ' ' J' ' 35' ' ' MET . 4.9 mt -101.37 110.38 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.022 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.61 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -121.81 109.15 1.41 Allowed Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 105.869 -2.892 . . . . 0.0 105.869 176.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.43 ' HG ' ' N ' ' C' ' 35' ' ' MET . 0.6 OUTLIER -147.42 147.66 30.48 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 123.493 1.616 . . . . 0.0 113.178 -177.061 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.621 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 29.6 ttm -122.9 128.02 49.75 Favored 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 112.0 -2.364 . . . . 0.0 109.101 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.436 ' CG1' ' O ' ' C' ' 36' ' ' VAL . 4.9 p -132.45 71.55 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.31 112.93 4.23 Favored Glycine 0 C--N 1.361 1.948 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.601 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.77 -144.34 0.07 OUTLIER Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.0 141.69 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 m . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 117.907 -1.044 . . . . 0.0 110.738 -179.824 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -111.19 136.91 49.58 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -151.1 143.24 24.04 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.015 0.436 . . . . 0.0 111.216 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m -139.09 163.4 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.176 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.54 -179.16 4.37 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.091 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.51 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 77.0 t60 -77.07 169.48 18.26 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.732 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.441 ' H ' ' CG ' ' D' ' 14' ' ' HIS . 87.5 mt-30 -146.3 176.91 9.41 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.529 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -151.42 113.88 4.6 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 120.477 -0.489 . . . . 0.0 112.053 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.0 117.6 22.82 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.176 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -142.71 149.22 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 -178.483 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 2.5 m-30 -118.89 120.61 37.82 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.749 -1.569 . . . . 0.0 108.894 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -117.5 118.94 33.56 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 118.39 0.541 . . . . 0.0 109.988 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.64 121.6 35.96 Favored 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.887 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -164.83 106.34 0.83 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -170.24 105.63 0.31 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 174.506 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.596 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 8.1 p -27.26 140.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 114.37 -1.287 . . . . 0.0 113.205 173.556 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.88 -81.26 0.05 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 119.309 -1.424 . . . . 0.0 113.361 177.924 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.758 ' O ' ' O ' ' D' ' 27' ' ' ASN . 88.5 p -170.86 179.59 3.11 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 120.146 1.973 . . . . 0.0 110.535 178.779 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.758 ' O ' ' O ' ' D' ' 26' ' ' SER . 37.1 t30 25.58 -178.96 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 O-C-N 124.722 1.264 . . . . 0.0 113.431 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.495 ' NZ ' ' O ' ' E' ' 25' ' ' GLY . 83.9 tttt -119.19 -111.18 0.34 Allowed 'General case' 0 N--CA 1.466 0.37 0 O-C-N 121.542 -0.724 . . . . 0.0 109.61 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 41.69 91.52 0.01 OUTLIER Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.1 159.77 39.82 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 102.341 -3.207 . . . . 0.0 102.341 175.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -146.61 123.59 3.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 117.865 -1.534 . . . . 0.0 112.351 -170.427 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 1.5 mt -111.32 119.46 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-O 121.315 0.578 . . . . 0.0 110.129 178.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.699 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -127.01 100.48 0.55 Allowed Glycine 0 C--N 1.311 -0.817 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.869 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.433 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.5 tt -124.92 130.58 52.65 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.04 0.924 . . . . 0.0 111.964 -177.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.54 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.4 ttt -112.89 123.32 50.04 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 114.056 -1.429 . . . . 0.0 110.365 179.38 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.82 78.15 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-N 116.262 -0.426 . . . . 0.0 109.987 179.706 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.1 105.13 0.08 OUTLIER Glycine 0 C--N 1.348 1.211 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.24 -154.1 2.66 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.17 143.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.09 0.472 . . . . 0.0 110.329 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.473 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -140.97 150.49 43.15 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.409 ' OE1' ' C ' ' F' ' 11' ' ' GLU . 79.4 mm-40 -142.3 140.03 32.04 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.204 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 59.4 t -128.79 133.58 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.315 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -78.34 -168.67 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.437 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 37.8 p-80 -146.73 177.32 9.18 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 120.988 0.423 . . . . 0.0 110.087 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -100.26 169.68 8.96 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.24 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.79 120.75 13.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.613 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -122.2 121.83 37.76 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.667 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -130.49 126.83 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 120.562 -0.455 . . . . 0.0 112.192 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE2' ' CD2' ' D' ' 19' ' ' PHE . 10.8 m-85 -115.88 115.6 26.51 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 176.909 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.516 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 66.3 t80 -123.74 124.97 43.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.666 -177.913 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.9 139.74 41.83 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-O 121.114 0.483 . . . . 0.0 111.218 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.516 ' OE2' ' CZ ' ' E' ' 20' ' ' PHE . 8.6 mm-40 -108.49 119.88 40.79 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -166.81 101.18 0.56 Allowed 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.345 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -73.35 -158.84 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.711 0.767 . . . . 0.0 112.084 -178.371 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.495 ' O ' ' NZ ' ' D' ' 28' ' ' LYS . . . 62.17 79.61 0.13 Allowed Glycine 0 CA--C 1.526 0.776 0 CA-C-N 114.233 -1.349 . . . . 0.0 111.842 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.566 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 26.3 t -61.25 171.88 1.24 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.335 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' E' ' 26' ' ' SER . 9.6 p-10 102.9 177.26 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 O-C-N 124.772 1.295 . . . . 0.0 112.377 176.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.436 ' C ' ' O ' ' E' ' 27' ' ' ASN . 99.4 mttt -21.85 103.8 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 114.84 -1.073 . . . . 0.0 111.736 177.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.427 ' O ' ' CG1' ' E' ' 31' ' ' ILE . . . 166.4 -101.71 0.18 Allowed Glycine 0 CA--C 1.493 -1.337 0 C-N-CA 117.92 -2.086 . . . . 0.0 115.435 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -55.06 155.44 4.61 Favored 'General case' 0 C--O 1.245 0.832 0 C-N-CA 117.792 -1.563 . . . . 0.0 110.39 -174.767 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.428 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 1.0 OUTLIER -147.16 124.29 3.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.302 -1.317 . . . . 0.0 107.819 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 77.9 mt -123.19 130.24 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-O 120.958 0.409 . . . . 0.0 112.048 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.31 121.1 3.23 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 18.6 tp -125.7 123.36 38.72 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.629 -0.285 . . . . 0.0 110.812 -179.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 12.8 ttt -117.86 117.81 30.3 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.219 178.302 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.6 t -122.54 83.81 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.133 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -16.34 -95.19 0.01 OUTLIER Glycine 0 N--CA 1.471 1.03 0 O-C-N 123.404 0.44 . . . . 0.0 112.833 -179.118 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.33 176.57 18.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 m -100.53 142.61 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 0.0 110.245 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.478 -179.865 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -82.88 137.47 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.704 0.288 . . . . 0.0 110.624 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . 0.409 ' C ' ' OE1' ' E' ' 11' ' ' GLU . 82.4 tt0 -159.03 159.85 35.2 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.467 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -80.93 131.07 34.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -85.36 146.69 26.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.837 0.351 . . . . 0.0 111.364 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 83.5 m-70 -94.88 179.49 5.22 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -79.82 166.25 21.91 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 120.12 -0.632 . . . . 0.0 110.767 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -135.96 118.8 16.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 22.7 mt -122.5 120.45 33.91 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.28 130.9 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.209 0.528 . . . . 0.0 112.266 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 26.2 m-85 -119.64 123.83 44.81 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.001 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -139.69 130.93 26.64 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.589 0.709 . . . . 0.0 112.025 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.23 133.96 51.35 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.554 178.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.44 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 81.0 tt0 -76.65 90.48 3.38 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.937 -178.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' E' ' 26' ' ' SER . 15.7 t70 173.87 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.632 178.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 m -58.85 130.72 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.379 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.85 85.31 0.16 Allowed Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.419 -0.896 . . . . 0.0 111.709 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.9 p -64.67 -174.45 0.14 Allowed 'General case' 0 N--CA 1.442 -0.829 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.084 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.443 ' O ' ' O ' ' F' ' 28' ' ' LYS . 21.2 m120 -90.7 178.59 6.03 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 119.876 -0.73 . . . . 0.0 109.61 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.3 mttt 27.95 102.12 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 113.099 0.778 . . . . 0.0 113.099 177.517 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.72 -101.62 0.24 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 120.134 -1.032 . . . . 0.0 113.662 177.591 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.81 167.47 0.77 Allowed 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.08 126.86 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 118.105 -1.438 . . . . 0.0 111.416 -176.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 5.1 mp -127.39 133.01 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.193 -178.693 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.7 131.8 6.33 Favored Glycine 0 N--CA 1.469 0.893 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -127.23 125.48 41.07 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 24.4 ttt -128.37 126.68 41.17 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.818 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -118.17 81.15 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.438 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -45.29 100.9 0.02 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.873 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.82 162.01 35.78 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -136.14 145.96 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 120.788 0.327 . . . . 0.0 110.454 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.875 -1.059 . . . . 0.0 110.68 -179.647 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -118.11 148.69 42.06 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.816 0.341 . . . . 0.0 110.99 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -53.32 163.86 0.53 Allowed 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.012 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -119.62 130.43 74.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.897 0.379 . . . . 0.0 111.11 -179.177 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -159.77 156.09 26.98 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.463 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.424 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 22.8 m80 -97.55 178.65 5.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -118.26 -177.08 3.2 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.23 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.59 154.44 17.92 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.174 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.1 tp -131.15 118.23 20.19 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.088 0.47 . . . . 0.0 110.439 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -124.94 131.03 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.752 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 t80 -129.98 127.96 41.09 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.036 0.446 . . . . 0.0 110.304 179.74 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.523 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -130.3 128.59 41.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.89 123.04 46.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.981 0.42 . . . . 0.0 110.505 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' G' ' 23' ' ' ASP . 43.6 tt0 -141.06 142.28 34.19 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.913 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.48 ' O ' ' O ' ' G' ' 22' ' ' GLU . 97.5 m-20 50.54 113.88 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.937 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.545 ' N ' ' OD2' ' H' ' 23' ' ' ASP . 70.0 t -149.34 112.84 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.283 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.21 -91.02 0.01 OUTLIER Glycine 0 CA--C 1.529 0.924 0 CA-C-O 121.466 0.481 . . . . 0.0 112.898 177.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.78 ' O ' ' O ' ' G' ' 27' ' ' ASN . 21.2 p -161.76 174.57 13.03 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.78 ' O ' ' O ' ' G' ' 26' ' ' SER . 81.7 m-20 -9.42 160.03 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CB ' ' H' ' 26' ' ' SER . 17.1 pttp 179.26 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.1 100.93 0.68 Allowed Glycine 0 N--CA 1.469 0.898 0 N-CA-C 107.061 -2.416 . . . . 0.0 107.061 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.42 157.43 22.48 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 123.473 1.606 . . . . 0.0 113.301 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.83 111.61 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 CA-C-N 111.766 -2.47 . . . . 0.0 108.671 -178.197 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.449 ' C ' ' SD ' ' A' ' 35' ' ' MET . 1.9 mt -99.1 109.25 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.889 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.59 105.75 1.04 Allowed Glycine 0 CA--C 1.504 -0.645 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 18.1 mt -139.46 145.32 38.67 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 123.061 1.41 . . . . 0.0 112.709 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 48.4 ttp -113.87 114.24 25.98 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.538 -1.664 . . . . 0.0 106.803 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.1 71.0 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -157.1 95.98 0.15 Allowed Glycine 0 C--N 1.355 1.604 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 179.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -138.16 -176.87 14.78 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.84 159.21 43.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 51.4 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.558 -179.745 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 99.0 m-85 -106.91 133.34 51.7 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.776 0.322 . . . . 0.0 110.609 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . 0.524 ' N ' ' OE1' ' H' ' 11' ' ' GLU . 56.0 mp0 -111.89 132.7 54.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.848 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.75 162.31 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -152.57 97.67 2.28 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.429 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.424 ' CE1' ' O ' ' G' ' 14' ' ' HIS . 54.2 p-80 -108.1 166.45 10.72 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -152.54 168.9 24.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.778 0.799 . . . . 0.0 111.377 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -169.58 117.35 0.6 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.71 -179.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 11.0 mp -122.33 118.5 28.63 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.729 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 60.3 t -121.03 124.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.474 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 83.5 m-85 -119.7 106.55 12.24 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -116.41 124.65 50.55 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.455 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.98 130.04 49.28 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.813 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -159.33 114.78 2.49 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.823 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.545 ' OD2' ' N ' ' G' ' 24' ' ' VAL . 28.5 t0 -174.65 123.3 0.27 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 178.343 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' H' ' 23' ' ' ASP . 13.0 t -36.9 113.69 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.911 175.077 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.672 ' H ' ' CG2' ' I' ' 24' ' ' VAL . . . 169.37 -90.83 0.1 OUTLIER Glycine 0 CA--C 1.536 1.358 0 C-N-CA 118.854 -1.641 . . . . 0.0 115.188 -178.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.431 ' O ' ' O ' ' H' ' 25' ' ' GLY . 9.5 p -43.35 167.02 0.01 OUTLIER 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 118.374 1.087 . . . . 0.0 111.539 -174.055 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -109.57 171.75 7.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.8 -1.091 . . . . 0.0 113.361 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 51.7 mmtt -37.07 111.5 0.16 Allowed 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 114.3 -1.318 . . . . 0.0 113.944 177.079 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.43 93.8 1.73 Allowed Glycine 0 CA--C 1.491 -1.442 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.342 177.218 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.05 173.51 9.83 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 101.077 -3.675 . . . . 0.0 101.077 171.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -134.08 118.72 29.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 118.005 -1.478 . . . . 0.0 109.835 -178.295 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.428 HD11 HG23 ' H' ' 32' ' ' ILE . 1.3 mt -109.78 115.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.461 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.44 97.42 0.68 Allowed Glycine 0 CA--C 1.508 -0.345 0 N-CA-C 106.914 -2.475 . . . . 0.0 106.914 176.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 mp -127.02 133.51 50.51 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-O 122.552 1.168 . . . . 0.0 111.456 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.676 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 43.7 ttp -111.16 117.38 33.08 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-N 113.595 -1.639 . . . . 0.0 107.895 178.07 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -113.05 67.65 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.957 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.81 -101.62 0.01 OUTLIER Glycine 0 C--N 1.352 1.446 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.56 164.85 11.53 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.27 141.71 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.765 -179.936 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -99.48 132.22 44.96 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.774 0.321 . . . . 0.0 110.496 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.14 158.59 33.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.21 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.408 ' CG1' ' N ' ' I' ' 13' ' ' HIS . 43.1 t -130.43 164.85 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 120.977 0.418 . . . . 0.0 111.331 -179.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.693 ' CG ' ' H ' ' I' ' 14' ' ' HIS . 44.6 t-80 -125.82 -172.35 2.58 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.047 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.693 ' H ' ' CG ' ' I' ' 13' ' ' HIS . 0.1 OUTLIER -76.45 166.65 23.12 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.204 0.526 . . . . 0.0 109.795 -179.205 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -148.65 170.68 17.59 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.174 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -150.35 137.78 19.68 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 121.041 -0.264 . . . . 0.0 111.149 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 52.8 mt -130.99 124.5 31.09 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.33 137.83 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.474 ' CE2' ' CD2' ' H' ' 19' ' ' PHE . 60.8 m-85 -120.44 123.85 44.01 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.136 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.626 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 3.4 t80 -124.27 124.44 42.42 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.101 -177.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.83 126.05 42.7 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 122.49 1.138 . . . . 0.0 113.451 -178.991 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -154.28 82.83 1.12 Allowed 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.462 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.473 ' OD2' ' O ' ' H' ' 23' ' ' ASP . 13.1 t70 -105.79 -114.13 0.25 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.672 ' CG2' ' H ' ' H' ' 25' ' ' GLY . 58.2 t -85.45 130.69 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.933 0 N-CA-C 104.426 -2.435 . . . . 0.0 104.426 176.088 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.551 ' CA ' ' H ' ' J' ' 24' ' ' VAL . . . -42.98 82.66 0.0 OUTLIER Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.189 -1.005 . . . . 0.0 111.974 -176.117 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.667 ' N ' ' O ' ' I' ' 24' ' ' VAL . 11.4 p -65.63 -176.2 0.33 Allowed 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 177.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.492 ' O ' ' O ' ' I' ' 28' ' ' LYS . 0.2 OUTLIER -81.42 179.2 7.95 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.671 177.631 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' I' ' 27' ' ' ASN . 85.0 tttt -42.39 -106.42 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.984 0.897 . . . . 0.0 110.036 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.668 ' O ' ' N ' ' J' ' 31' ' ' ILE . . . -82.8 96.98 1.92 Allowed Glycine 0 CA--C 1.45 -3.973 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.562 ' O ' ' C ' ' I' ' 29' ' ' GLY . . . -68.73 -151.17 0.01 OUTLIER 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 101.899 -3.371 . . . . 0.0 101.899 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.708 ' CD1' ' N ' ' I' ' 31' ' ' ILE . 0.0 OUTLIER -102.62 104.01 15.89 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 CA-C-N 123.782 2.992 . . . . 0.0 109.964 -176.0 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.621 ' N ' ' SD ' ' C' ' 35' ' ' MET . 2.6 mt -107.11 114.2 45.48 Favored 'Isoleucine or valine' 0 C--N 1.362 1.131 0 CA-C-N 113.765 -1.561 . . . . 0.0 111.126 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.409 ' N ' ' CE ' ' B' ' 35' ' ' MET . . . -115.54 97.98 0.82 Allowed Glycine 0 C--O 1.242 0.641 0 N-CA-C 105.502 -3.039 . . . . 0.0 105.502 175.394 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.78 132.83 46.67 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-O 122.268 1.032 . . . . 0.0 111.077 -177.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.61 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.0 ttp -113.68 121.55 44.46 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.345 -178.887 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.51 70.03 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 177.126 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -41.12 -100.66 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.81 -160.59 33.68 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 54.7 t -122.46 134.94 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 120.859 0.361 . . . . 0.0 110.04 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 70.1 t . . . . . 0 C--O 1.218 -0.582 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.604 -179.984 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -104.15 131.58 51.3 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.868 0.366 . . . . 0.0 110.624 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -68.52 128.34 36.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.711 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -147.26 155.35 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.852 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -146.45 135.62 22.68 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.054 0.454 . . . . 0.0 111.523 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -152.43 155.94 38.53 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.595 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -153.38 173.64 15.38 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.441 0.639 . . . . 0.0 111.706 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -155.93 129.33 8.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.596 -1.184 . . . . 0.0 107.887 178.275 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.84 116.94 24.52 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.5 123.62 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.253 0.549 . . . . 0.0 110.896 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -120.88 109.06 14.67 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 179.276 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.626 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 3.7 p90 -148.94 151.36 34.48 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 117.772 -1.571 . . . . 0.0 114.649 -178.946 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.01 155.88 34.96 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.156 -1.384 . . . . 0.0 111.169 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -127.22 144.03 51.13 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -178.91 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.468 ' CG ' ' O ' ' I' ' 26' ' ' SER . 10.9 t0 -103.68 134.26 47.31 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.867 178.179 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.551 ' H ' ' CA ' ' I' ' 25' ' ' GLY . 57.4 t -110.43 111.78 37.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.661 179.495 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.23 90.37 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 N-CA-C 115.708 1.043 . . . . 0.0 115.708 174.96 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.613 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.8 p 170.68 174.83 0.06 Allowed 'General case' 0 C--N 1.343 0.324 0 CA-C-N 118.369 1.084 . . . . 0.0 111.379 176.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.8 m120 -28.04 -179.55 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.563 ' HZ2' ' CB ' ' K' ' 26' ' ' SER . 55.3 tttt -130.51 -107.31 0.27 Allowed 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.748 1.388 . . . . 0.0 114.748 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 41.61 91.81 0.01 OUTLIER Glycine 0 N--CA 1.481 1.677 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 -176.688 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.644 ' CB ' ' O ' ' I' ' 29' ' ' GLY . . . -140.61 157.73 45.02 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -177.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.668 ' N ' ' O ' ' I' ' 29' ' ' GLY . 0.1 OUTLIER -146.18 128.11 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.53 0 CA-C-O 121.461 0.648 . . . . 0.0 112.506 -178.286 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.54 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.3 tt -109.25 118.41 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.52 101.66 0.99 Allowed Glycine 0 N--CA 1.47 0.963 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 80.0 mt -127.05 131.68 50.88 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-O 121.431 0.634 . . . . 0.0 112.583 -177.751 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.699 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.2 ttp -113.82 120.6 41.3 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.015 178.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.74 67.46 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -49.97 121.4 9.58 Favored Glycine 0 C--N 1.355 1.593 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.54 -136.8 0.03 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -127.86 134.42 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.535 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 m . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.804 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.52 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -105.18 137.35 43.1 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 120.872 0.368 . . . . 0.0 110.617 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.72 131.8 29.75 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.797 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 m -139.83 134.21 37.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.156 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -124.3 119.17 28.52 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.315 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.89 162.55 24.15 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-O 121.485 0.66 . . . . 0.0 109.444 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' L' ' 15' ' ' GLN . 85.4 mt-30 -151.35 178.78 8.92 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.353 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -172.69 128.15 0.51 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -124.39 123.44 40.18 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.825 0.345 . . . . 0.0 110.117 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.48 125.38 65.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.74 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -115.77 114.92 25.44 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.047 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -122.05 123.64 42.09 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.01 128.08 39.62 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 121.49 0.662 . . . . 0.0 111.31 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -99.12 128.29 45.22 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 120.176 -0.609 . . . . 0.0 111.782 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.421 ' CG ' ' O ' ' L' ' 22' ' ' GLU . 9.2 p-10 -142.86 136.58 28.84 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.116 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 7.8 p -91.1 112.27 24.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.577 -176.973 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.69 91.5 0.01 OUTLIER Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.563 ' CB ' ' HZ2' ' J' ' 28' ' ' LYS . 5.4 t -42.32 154.63 0.05 Allowed 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.64 -0.78 . . . . 0.0 110.931 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.545 ' H ' ' CD ' ' J' ' 28' ' ' LYS . 84.7 m-20 -126.97 -179.86 5.05 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.746 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.401 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.7 mttt -30.12 107.29 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.473 1.286 . . . . 0.0 114.473 -177.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.36 -96.48 1.74 Allowed Glycine 0 N--CA 1.47 0.93 0 CA-C-N 113.996 -1.456 . . . . 0.0 116.208 172.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.535 ' CB ' ' HZ1' ' J' ' 28' ' ' LYS . . . 72.22 153.28 0.13 Allowed 'General case' 0 C--O 1.249 1.051 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 -174.44 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.425 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.2 OUTLIER -149.65 127.47 2.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 117.001 -1.88 . . . . 0.0 111.82 -176.98 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.504 ' O ' ' CE ' ' E' ' 35' ' ' MET . 82.7 mt -118.84 120.08 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.001 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -119.93 107.86 1.39 Allowed Glycine 0 N--CA 1.467 0.749 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 48.5 mt -121.43 120.6 35.45 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -117.97 124.78 49.03 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.188 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.05 80.77 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.799 178.338 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.8 102.87 0.61 Allowed Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.78 -146.79 18.03 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -121.74 138.2 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.661 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.789 179.449 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -90.33 136.75 32.86 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.686 0.279 . . . . 0.0 110.933 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -74.96 152.65 38.77 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -121.79 131.19 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.137 0.494 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -155.24 140.29 17.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.694 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -150.4 171.46 16.98 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 89.0 mt-30 -147.02 173.53 12.37 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.464 0.65 . . . . 0.0 111.228 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -155.55 130.26 9.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.494 179.157 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . 0.445 ' C ' ' CD2' ' L' ' 17' ' ' LEU . 7.6 tt -132.5 125.31 30.31 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -129.39 129.21 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 121.147 0.499 . . . . 0.0 111.835 -179.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 10.8 m-85 -113.43 114.27 26.34 Favored 'General case' 0 C--N 1.341 0.215 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.659 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -140.64 136.83 33.1 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 122.104 0.954 . . . . 0.0 112.249 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.16 151.84 30.58 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.386 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.421 ' O ' ' CG ' ' K' ' 23' ' ' ASP . 81.8 tt0 -75.11 95.15 3.02 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.991 -178.82 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' L' ' 24' ' ' VAL . 67.9 t0 -175.36 136.1 0.35 Allowed 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.981 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.522 ' N ' ' OD1' ' L' ' 23' ' ' ASP . 33.5 m -71.02 111.28 4.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.675 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.95 -91.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.007 0 CA-C-N 114.894 -1.048 . . . . 0.0 115.528 -176.095 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 10.0 p -71.24 176.67 4.36 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 122.967 1.365 . . . . 0.0 114.362 -175.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.541 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 4.9 t-20 85.89 178.65 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 111.412 -2.631 . . . . 0.0 114.486 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.541 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.1 mttt -40.99 104.49 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 116.61 2.078 . . . . 0.0 116.61 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.0 -101.24 0.3 Allowed Glycine 0 N--CA 1.473 1.161 0 N-CA-C 115.823 1.089 . . . . 0.0 115.823 173.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.506 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -58.37 172.8 0.43 Allowed 'General case' 0 CA--C 1.508 -0.636 0 CA-C-O 119.106 -0.474 . . . . 0.0 111.335 -177.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.602 ' CD1' ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -134.78 118.6 25.82 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 C-N-CA 118.405 -1.318 . . . . 0.0 111.148 179.661 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.62 133.23 68.75 Favored 'Isoleucine or valine' 0 C--O 1.23 0.072 0 CA-C-N 113.77 -1.559 . . . . 0.0 109.786 -178.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -131.3 118.88 2.49 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.381 -179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 10.6 mp -114.5 124.34 51.65 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 177.933 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.9 tmm? -117.51 120.53 38.37 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.616 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.72 81.13 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.549 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . 44.13 -101.39 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.875 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.53 -169.29 37.76 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.82 136.24 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.904 0.383 . . . . 0.0 110.672 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.813 179.726 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.333 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -115.26 138.57 50.8 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.983 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -141.85 156.52 45.53 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.51 133.55 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 120.952 0.406 . . . . 0.0 110.737 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -135.8 -175.7 4.05 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.067 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -80.03 164.79 23.16 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-O 121.23 0.538 . . . . 0.0 109.836 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -153.5 177.45 10.9 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.462 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -147.57 131.34 16.99 Favored 'General case' 0 N--CA 1.466 0.374 0 C-N-CA 121.118 -0.233 . . . . 0.0 110.809 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -133.4 115.44 14.84 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.326 0.584 . . . . 0.0 110.135 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.63 133.44 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.072 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -145.72 148.93 33.54 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.681 0.753 . . . . 0.0 111.511 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 p90 -135.92 149.3 48.9 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.717 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.81 136.54 27.24 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 122.275 1.035 . . . . 0.0 113.312 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' A' ' 23' ' ' ASP . 98.8 mt-10 -111.51 178.72 4.24 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.532 -1.667 . . . . 0.0 107.705 177.473 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.519 ' H ' ' CB ' ' B' ' 23' ' ' ASP . 95.7 m-20 58.54 132.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.489 ' N ' ' OD2' ' B' ' 23' ' ' ASP . 0.2 OUTLIER -71.88 113.09 8.18 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.181 -178.805 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -49.72 -91.11 0.01 OUTLIER Glycine 0 C--N 1.331 0.27 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.621 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 32.2 t -66.91 -170.1 0.1 Allowed 'General case' 0 N--CA 1.432 -1.371 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.037 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -78.77 177.73 8.45 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.699 0.762 . . . . 0.0 112.344 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.534 ' HZ3' ' H ' ' B' ' 26' ' ' SER . 8.9 mmtt -39.44 108.1 0.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.365 -1.289 . . . . 0.0 112.006 -178.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.3 99.2 2.59 Favored Glycine 0 CA--C 1.493 -1.289 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.205 -176.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.18 160.66 20.83 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.392 -176.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.519 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -146.74 111.79 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.775 -175.295 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 46.8 mt -121.29 104.88 15.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 177.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.641 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -113.96 114.2 3.26 Favored Glycine 0 CA--C 1.502 -0.78 0 N-CA-C 105.827 -2.909 . . . . 0.0 105.827 176.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 5.6 tp -146.04 144.93 30.37 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 122.754 1.264 . . . . 0.0 113.382 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.597 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 17.5 ttm -112.91 117.36 31.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.888 178.394 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.89 67.3 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 177.904 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.3 -101.71 0.01 OUTLIER Glycine 0 C--N 1.366 2.21 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.95 -166.13 39.21 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.97 158.08 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.836 0.35 . . . . 0.0 110.735 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.915 -1.04 . . . . 0.0 110.533 -179.866 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . 0.491 ' CD1' ' O ' ' C' ' 9' ' ' GLY . 91.9 m-85 -105.2 132.95 50.76 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -137.85 160.53 39.03 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.114 0.483 . . . . 0.0 111.14 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 50.9 t -122.41 134.45 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.893 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -109.07 114.83 28.9 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.985 0.421 . . . . 0.0 111.445 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.47 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 83.5 t60 -142.23 160.45 40.22 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.486 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.47 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 78.9 mt-30 -159.27 179.11 9.28 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.13 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -161.35 119.02 2.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.519 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -130.61 122.64 27.83 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.12 137.12 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 121.066 0.46 . . . . 0.0 110.582 178.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -128.87 138.33 51.96 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.879 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -123.15 131.49 53.71 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.21 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.48 125.71 29.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 120.673 -0.411 . . . . 0.0 111.86 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 82.5 tt0 -170.82 139.76 1.53 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.448 179.257 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.519 ' CB ' ' H ' ' A' ' 23' ' ' ASP . 14.3 p-10 -168.88 111.16 0.52 Allowed 'General case' 0 C--N 1.344 0.329 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.704 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 6.2 t -31.45 131.31 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.241 175.208 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.22 -83.31 0.09 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 118.815 -1.66 . . . . 0.0 114.849 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' B' ' 27' ' ' ASN . 6.2 p -170.53 -179.58 3.01 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 120.028 1.914 . . . . 0.0 113.125 -178.289 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' B' ' 26' ' ' SER . 89.2 m-20 26.77 -170.22 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 112.712 -2.04 . . . . 0.0 113.544 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.566 ' NZ ' ' O ' ' D' ' 23' ' ' ASP . 51.7 tttt -142.06 -104.52 0.14 Allowed 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 113.68 0.992 . . . . 0.0 113.68 -177.51 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.411 ' H ' ' HB3' ' B' ' 28' ' ' LYS . . . 40.24 95.59 0.01 OUTLIER Glycine 0 N--CA 1.477 1.429 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -177.816 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.445 ' O ' HG13 ' C' ' 31' ' ' ILE . . . -104.99 154.35 20.23 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 103.294 -2.854 . . . . 0.0 103.294 176.316 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . . . . . . . . . 2.0 mt -139.8 108.14 3.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.753 -173.677 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.435 ' O ' ' CG2' ' B' ' 32' ' ' ILE . 5.1 tt -122.37 116.55 49.4 Favored 'Isoleucine or valine' 0 C--O 1.241 0.646 0 CA-C-O 122.069 0.938 . . . . 0.0 109.619 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.667 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -127.99 117.92 2.72 Favored Glycine 0 N--CA 1.453 -0.188 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 7.0 mp -141.91 149.93 40.83 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-O 123.147 1.451 . . . . 0.0 113.214 -178.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 24.2 ttm -121.69 118.75 29.9 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 112.769 -2.014 . . . . 0.0 107.822 177.401 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -112.57 68.71 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -179.6 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.82 -101.5 0.12 Allowed Glycine 0 C--N 1.352 1.417 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.599 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.41 167.71 35.49 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.4 m -131.74 161.92 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.906 0.384 . . . . 0.0 110.242 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.648 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . 0.491 ' O ' ' CD1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -82.59 142.38 31.82 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' D' ' 11' ' ' GLU . 95.9 mt-10 -61.04 135.22 57.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.742 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m -137.13 136.79 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.009 179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -117.26 136.98 52.7 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 120.723 0.297 . . . . 0.0 111.57 -178.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 24.0 t-80 -141.37 163.2 33.6 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.663 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 83.0 mt-30 -156.03 169.74 23.77 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 121.183 0.516 . . . . 0.0 111.064 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -155.91 115.98 3.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.443 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 44.4 tp -121.5 124.09 43.6 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -133.38 127.28 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 113.466 0.913 . . . . 0.0 113.466 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 50.6 m-85 -117.47 119.29 34.61 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -122.46 126.37 47.75 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 117.827 0.285 . . . . 0.0 111.421 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.12 149.2 37.79 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 115.435 1.642 . . . . 0.0 115.435 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 28.0 mt-10 -154.45 138.69 16.59 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 114.398 -1.274 . . . . 0.0 110.857 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -156.13 112.24 3.05 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 114.504 1.298 . . . . 0.0 114.504 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 61.9 t -34.77 126.9 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 115.494 1.664 . . . . 0.0 115.494 175.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.85 -84.83 0.09 OUTLIER Glycine 0 CA--C 1.539 1.536 0 C-N-CA 119.325 -1.417 . . . . 0.0 115.07 173.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.73 ' O ' ' O ' ' C' ' 27' ' ' ASN . 36.7 p -172.06 163.56 6.05 Favored 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 118.852 1.326 . . . . 0.0 109.474 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.73 ' O ' ' O ' ' C' ' 26' ' ' SER . 14.6 m120 35.73 -178.68 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 O-C-N 124.015 0.822 . . . . 0.0 110.276 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.613 ' O ' ' O ' ' D' ' 29' ' ' GLY . 87.3 tttt -96.78 110.61 23.05 Favored 'General case' 0 C--O 1.218 -0.581 0 C-N-CA 117.231 -1.788 . . . . 0.0 109.461 177.413 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.451 ' H ' ' HD3' ' B' ' 28' ' ' LYS . . . -77.45 94.34 1.15 Allowed Glycine 0 CA--C 1.477 -2.308 0 CA-C-O 117.522 -1.71 . . . . 0.0 109.771 173.229 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.426 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -149.75 134.51 17.73 Favored 'General case' 0 CA--C 1.47 -2.113 0 C-N-CA 115.933 -2.307 . . . . 0.0 108.115 173.044 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.445 HG13 ' O ' ' B' ' 30' ' ' ALA 0.274 3.5 mt -138.78 102.22 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 CA-C-N 110.469 -3.059 . . . . 0.0 105.045 -175.837 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.515 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.9 mt -109.19 118.14 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-N 115.059 -0.973 . . . . 0.0 111.427 -176.679 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.708 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -129.92 99.08 0.44 Allowed Glycine 0 CA--C 1.5 -0.901 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.169 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.403 HD23 ' CZ ' ' D' ' 19' ' ' PHE . 3.7 mp -132.05 147.35 52.44 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 122.64 1.209 . . . . 0.0 111.924 -177.109 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.494 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 26.7 ttm -129.01 127.94 42.64 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.87 -1.968 . . . . 0.0 110.375 -179.098 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.75 72.24 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.9 102.76 2.39 Favored Glycine 0 C--N 1.364 2.102 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 -178.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.4 154.61 25.86 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.0 m -134.72 161.57 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-O 120.735 0.302 . . . . 0.0 110.477 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.256 179.664 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -106.56 132.01 53.06 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.843 0.354 . . . . 0.0 110.659 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' C' ' 11' ' ' GLU . 96.0 mt-10 -69.45 143.51 53.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.96 139.26 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.642 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -85.78 166.42 16.09 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.884 0.373 . . . . 0.0 110.097 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.563 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 43.7 p-80 -76.52 175.11 9.54 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.225 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -140.62 173.36 11.57 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.189 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -141.04 130.75 24.17 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.494 0.664 . . . . 0.0 112.258 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 49.5 tp -122.54 120.31 33.46 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.761 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 19.8 t -134.79 128.35 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.522 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 65.2 m-85 -125.46 115.32 20.06 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.771 177.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' D' ' 20' ' ' PHE . 0.0 OUTLIER -147.84 159.09 44.21 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 122.786 1.279 . . . . 0.0 113.949 179.129 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.74 156.33 38.91 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.867 -1.515 . . . . 0.0 112.013 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 33.1 mt-10 -148.24 141.71 25.35 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.685 -179.559 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.566 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 0.8 OUTLIER 168.09 103.68 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.447 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.56 ' O ' ' O ' ' D' ' 23' ' ' ASP . 3.4 t -27.57 158.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 C-N-CA 123.354 0.662 . . . . 0.0 112.044 176.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.97 -76.28 0.07 OUTLIER Glycine 0 CA--C 1.538 1.477 0 C-N-CA 119.454 -1.355 . . . . 0.0 114.192 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' D' ' 27' ' ' ASN . 0.1 OUTLIER 167.82 -167.26 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 -175.689 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' D' ' 26' ' ' SER . 19.6 t30 -44.79 166.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 118.074 -1.45 . . . . 0.0 109.682 -175.451 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.557 ' N ' ' OD1' ' D' ' 27' ' ' ASN . 24.7 tttp -69.86 111.5 5.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 115.205 1.558 . . . . 0.0 115.205 -176.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.613 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -81.26 93.45 1.54 Allowed Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 105.011 -3.236 . . . . 0.0 105.011 166.889 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.09 30.51 Favored 'General case' 0 CA--C 1.457 -2.597 0 CA-C-N 122.407 3.103 . . . . 0.0 109.429 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.98 99.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.062 0 CA-C-N 112.083 -2.326 . . . . 0.0 106.144 -176.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 mt -108.16 124.61 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.427 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.743 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.08 100.55 0.58 Allowed Glycine 0 C--N 1.309 -0.934 0 N-CA-C 105.331 -3.108 . . . . 0.0 105.331 174.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -121.79 120.7 35.37 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.524 0.678 . . . . 0.0 110.148 -177.68 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.471 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.5 ttt -112.99 115.43 28.37 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.682 -1.145 . . . . 0.0 108.068 178.064 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -112.43 77.31 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.495 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -4.12 -101.93 0.0 OUTLIER Glycine 0 C--N 1.368 2.324 0 O-C-N 123.608 0.568 . . . . 0.0 112.899 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.5 -170.62 39.72 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.59 159.73 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.436 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -139.82 123.67 17.52 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 120.744 0.306 . . . . 0.0 110.636 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -136.96 139.69 41.68 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.349 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -133.87 138.76 49.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 -139.74 126.86 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.37 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.576 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 45.4 t-80 -156.08 167.2 31.16 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.898 0.856 . . . . 0.0 110.952 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.576 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 47.5 tt0 -164.02 168.24 19.46 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.307 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.499 ' HZ3' ' CG2' ' E' ' 18' ' ' VAL . 53.8 tttm -135.44 120.19 18.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.465 178.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 36.1 mt -107.34 118.83 37.75 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . 0.499 ' CG2' ' HZ3' ' E' ' 16' ' ' LYS . 21.5 t -128.96 121.58 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -177.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 62.6 m-85 -115.62 115.76 26.97 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 176.342 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' F' ' 20' ' ' PHE . 25.3 t80 -142.21 149.09 39.2 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.078 1.51 . . . . 0.0 115.078 -175.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . 0.565 ' CB ' ' NZ ' ' C' ' 28' ' ' LYS . . . -149.73 138.63 21.06 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 81.5 tt0 -110.97 111.85 23.26 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.432 178.624 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' O ' ' C ' ' E' ' 24' ' ' VAL . 0.3 OUTLIER 176.37 122.52 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -178.049 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.456 ' C ' ' O ' ' E' ' 23' ' ' ASP . 41.5 t -37.32 117.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 121.595 0.712 . . . . 0.0 110.332 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.81 89.6 0.48 Allowed Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.919 -178.124 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.512 ' O ' ' OD1' ' D' ' 27' ' ' ASN . 46.7 t -87.09 -179.36 6.45 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 122.616 1.198 . . . . 0.0 111.765 -177.386 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.559 ' N ' HD21 ' E' ' 27' ' ' ASN . 0.6 OUTLIER -61.85 -178.45 0.15 Allowed 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 113.012 -1.903 . . . . 0.0 113.492 -178.508 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 78.1 tttt 68.1 -112.19 0.13 Allowed 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 178.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.33 91.7 0.25 Allowed Glycine 0 CA--C 1.532 1.105 0 N-CA-C 118.107 2.003 . . . . 0.0 118.107 -172.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.41 ' O ' HG22 ' E' ' 31' ' ' ILE . . . -163.98 147.86 9.96 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 105.575 -2.009 . . . . 0.0 105.575 170.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.461 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.1 OUTLIER -148.16 128.54 4.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 121.543 0.687 . . . . 0.0 111.086 -178.548 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 91.9 mt -128.19 128.59 68.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.109 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.4 124.58 5.64 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tt -130.17 121.71 26.79 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.513 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 9.4 ttt -123.15 125.37 45.01 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 121.065 -0.254 . . . . 0.0 111.477 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.3 t -127.59 78.64 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.496 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 13.77 -109.25 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 N-CA-C 114.107 0.403 . . . . 0.0 114.107 177.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -150.1 165.27 29.8 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -130.28 136.3 58.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' F' ' 39' ' ' VAL . 46.3 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.358 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -108.15 136.12 48.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.814 0.34 . . . . 0.0 110.609 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.23 133.83 47.7 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.245 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.71 135.27 51.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 31.3 p-80 -155.91 128.09 7.59 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.041 0.448 . . . . 0.0 111.593 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 62.5 m80 -151.09 171.58 17.13 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -151.1 171.16 17.78 Favored 'General case' 0 C--N 1.313 -1.015 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.331 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -141.71 127.2 18.89 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.67 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.57 126.78 54.65 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.74 119.76 52.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.13 0.49 . . . . 0.0 111.934 -178.633 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -113.7 105.93 13.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' E' ' 20' ' ' PHE . 5.7 m-85 -139.29 131.28 27.85 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 122.608 1.195 . . . . 0.0 112.558 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . 0.434 ' O ' ' OD1' ' F' ' 23' ' ' ASP . . . -148.94 163.16 38.29 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.357 178.818 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -71.15 85.03 0.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.818 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 11.1 p30 -165.3 112.77 0.98 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.844 178.37 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.58 ' O ' ' N ' ' F' ' 26' ' ' SER . 98.1 t -70.74 132.55 33.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.583 178.205 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.6 83.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.206 -1.558 . . . . 0.0 109.206 177.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.58 ' N ' ' O ' ' F' ' 24' ' ' VAL . 13.1 p -66.07 -174.18 0.23 Allowed 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 122.492 1.139 . . . . 0.0 112.276 -177.14 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -81.63 179.08 7.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 112.722 -2.036 . . . . 0.0 111.719 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -37.25 104.22 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.553 -0.748 . . . . 0.0 109.66 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.404 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 167.88 -100.67 0.17 Allowed Glycine 0 C--O 1.217 -0.956 0 N-CA-C 108.843 -1.703 . . . . 0.0 108.843 -174.854 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.24 166.02 0.08 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 119.674 1.737 . . . . 0.0 107.659 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.404 HG12 ' O ' ' F' ' 29' ' ' GLY . 0.1 OUTLIER -143.43 130.31 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 118.093 -1.443 . . . . 0.0 112.604 -175.123 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -128.98 122.87 57.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.909 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 122.34 5.41 Favored Glycine 0 N--CA 1.468 0.833 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 36.7 mt -119.66 120.37 36.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' L' ' 32' ' ' ILE . 19.9 ttt -130.88 134.53 46.87 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.873 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 1.5 p -156.96 89.41 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.742 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.39 94.83 0.23 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.757 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.81 167.77 29.91 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.706 -0.957 . . . . 0.0 110.706 -179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' E' ' 40' ' ' VAL . 30.9 m -132.08 157.12 43.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.893 0.378 . . . . 0.0 110.531 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.697 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -105.88 135.4 47.39 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.842 0.353 . . . . 0.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.538 ' N ' ' OE1' ' G' ' 11' ' ' GLU . 55.2 mp0 -94.14 141.75 28.18 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.547 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.23 132.69 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.086 0.47 . . . . 0.0 110.278 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -142.78 115.34 8.58 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.414 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' H' ' 14' ' ' HIS . 57.0 p-80 -152.93 169.98 21.52 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.39 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? -154.31 170.54 21.06 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.379 179.232 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.6 mttm -156.63 164.27 38.37 Favored 'General case' 0 C--O 1.222 -0.37 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.747 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 2.9 mp -146.71 175.93 10.24 Favored 'General case' 0 C--O 1.172 -3.02 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . 0.968 ' C ' ' O ' ' H' ' 18' ' ' VAL . 94.0 t -156.62 170.51 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 118.724 -2.485 . . . . 0.0 110.099 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.553 ' N ' ' O ' ' H' ' 18' ' ' VAL . 26.3 p90 -162.58 105.2 1.09 Allowed 'General case' 0 C--O 1.169 -3.169 0 O-C-N 121.375 -0.828 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.729 ' N ' ' H ' ' H' ' 20' ' ' PHE . 35.3 t80 -109.78 108.19 18.45 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.549 -1.344 . . . . 0.0 110.839 177.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . 0.566 ' N ' ' O ' ' H' ' 20' ' ' PHE . . . -82.42 103.12 11.74 Favored 'General case' 0 C--O 1.178 -2.684 0 C-N-CA 124.682 1.193 . . . . 0.0 111.012 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.546 ' H ' ' HA ' ' H' ' 21' ' ' ALA . 73.7 mt-10 -75.39 147.92 39.61 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 120.27 1.395 . . . . 0.0 111.86 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.445 ' CG ' ' N ' ' G' ' 24' ' ' VAL . 7.8 p-10 -156.02 -144.75 0.14 Allowed 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.159 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' G' ' 23' ' ' ASP . 18.3 t -29.58 103.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 114.988 -1.006 . . . . 0.0 112.501 178.412 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.39 -94.41 0.09 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.643 178.176 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.2 m -71.18 174.17 6.72 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 119.138 1.469 . . . . 0.0 110.388 -178.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -78.71 173.33 12.57 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.511 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.548 ' HZ2' ' CB ' ' I' ' 26' ' ' SER . 13.0 mmtt -46.04 111.77 0.4 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 174.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 94.29 1.74 Allowed Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -177.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.43 -179.92 7.08 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-O 122.349 1.071 . . . . 0.0 111.157 -178.397 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.462 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.12 109.18 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 CA-C-N 113.28 -1.782 . . . . 0.0 108.91 -177.924 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.597 ' N ' ' SD ' ' A' ' 35' ' ' MET . 2.4 mt -107.02 112.41 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.8 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.96 98.39 0.82 Allowed Glycine 0 CA--C 1.499 -0.927 0 N-CA-C 106.851 -2.5 . . . . 0.0 106.851 176.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 1.6 mm? -125.22 133.9 52.55 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 122.305 1.05 . . . . 0.0 110.475 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.641 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 42.7 ttp -109.93 120.08 41.35 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 113.8 -1.546 . . . . 0.0 108.973 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -134.5 70.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.762 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.32 106.09 2.9 Favored Glycine 0 C--N 1.365 2.139 0 N-CA-C 111.614 -0.594 . . . . 0.0 111.614 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.78 179.03 2.36 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 112.017 -0.433 . . . . 0.0 112.017 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 28.0 m -138.07 160.84 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.436 -0.382 . . . . 0.0 110.273 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.523 179.859 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -113.06 141.56 46.73 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -54.08 163.27 0.81 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.179 179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.2 t -111.87 127.48 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.383 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 p-80 -174.88 -172.35 0.61 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 111.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' G' ' 14' ' ' HIS . 82.4 m-70 -149.09 163.49 37.4 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.371 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 56.2 tt0 -160.25 167.44 27.56 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.427 179.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' G' ' 16' ' ' LYS . 73.1 mttt -156.57 151.67 26.31 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.373 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -134.16 123.57 24.6 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . 0.968 ' O ' ' C ' ' G' ' 18' ' ' VAL . 65.3 t -125.59 141.69 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 118.113 -1.435 . . . . 0.0 113.838 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 94.1 m-85 -118.62 115.01 23.66 Favored 'General case' 0 N--CA 1.472 0.644 0 O-C-N 120.723 -1.236 . . . . 0.0 109.722 179.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.729 ' H ' ' N ' ' G' ' 20' ' ' PHE . 8.2 t80 -109.89 106.89 16.63 Favored 'General case' 0 C--O 1.25 1.107 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 179.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . 0.546 ' HA ' ' H ' ' G' ' 22' ' ' GLU . . . -90.42 120.09 31.24 Favored 'General case' 0 C--N 1.36 1.052 0 O-C-N 124.864 1.352 . . . . 0.0 110.461 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.477 ' O ' ' CB ' ' H' ' 23' ' ' ASP . 82.4 tt0 -153.26 156.53 38.63 Favored 'General case' 0 C--N 1.359 1.022 0 C-N-CA 117.898 -1.521 . . . . 0.0 113.125 -177.678 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' H' ' 22' ' ' GLU . 0.9 OUTLIER 149.23 121.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.448 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 25.0 m -55.15 121.15 3.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 119.802 -0.759 . . . . 0.0 109.718 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.81 88.81 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.572 ' O ' ' O ' ' H' ' 27' ' ' ASN . 2.6 p 170.81 178.72 0.06 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.377 0.608 . . . . 0.0 110.219 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.572 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.8 m120 -27.89 172.85 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 113.776 -1.556 . . . . 0.0 114.841 -178.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.549 ' NZ ' ' O ' ' J' ' 22' ' ' GLU . 84.8 tttt 144.99 94.72 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.833 176.748 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' H' ' 30' ' ' ALA . . . 59.89 -117.08 10.12 Favored Glycine 1 CA--C 1.424 -5.625 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 179.773 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.494 ' CB ' ' O ' ' H' ' 29' ' ' GLY . . . 77.03 -124.52 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.678 1 N-CA-C 99.706 -4.183 . . . . 0.0 99.706 -176.617 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.696 ' CD1' ' N ' ' H' ' 31' ' ' ILE . 1.9 mp -82.02 103.74 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.344 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.287 174.822 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' B' ' 35' ' ' MET . 18.6 tt -121.32 121.34 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 CA-C-O 121.614 0.721 . . . . 0.0 111.009 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.82 116.59 2.39 Favored Glycine 0 C--O 1.244 0.74 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -130.83 128.8 41.38 Favored 'General case' 0 C--O 1.244 0.813 0 CA-C-O 121.785 0.802 . . . . 0.0 110.785 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.667 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 40.1 ttp -106.09 115.88 30.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.423 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.421 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -120.2 70.54 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.209 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.637 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.77 -100.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.02 -159.71 24.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.3 142.56 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.852 0.358 . . . . 0.0 110.781 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.671 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -144.89 156.4 43.98 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.701 0.286 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -133.94 135.59 43.65 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.157 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.55 152.59 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-O 121.863 0.839 . . . . 0.0 111.852 -179.725 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.546 ' O ' ' CG ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -149.27 109.04 4.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.658 179.034 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.1 m170 -114.17 162.49 16.45 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.641 0.734 . . . . 0.0 110.673 -179.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -153.0 172.8 16.27 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.495 178.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -172.11 132.95 0.68 Allowed 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.838 -179.746 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 6.7 tt -124.99 125.92 44.64 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.288 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 52.7 t -124.46 126.58 72.09 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.543 -178.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -108.2 103.5 12.7 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 175.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.492 ' CE1' ' CZ ' ' H' ' 20' ' ' PHE . 25.7 t80 -117.32 131.06 56.88 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.864 0.302 . . . . 0.0 110.643 -178.3 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.29 145.94 31.45 Favored 'General case' 0 C--O 1.243 0.714 0 CA-C-O 122.043 0.925 . . . . 0.0 113.338 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -137.61 135.29 36.46 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.81 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.464 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 48.0 t0 -139.5 137.84 35.86 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -92.12 113.19 26.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 C-N-CA 118.685 -1.206 . . . . 0.0 111.806 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.91 86.97 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 CA-C-N 113.744 -1.571 . . . . 0.0 115.255 176.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.615 ' HG ' ' H ' ' I' ' 27' ' ' ASN . 30.9 t -140.68 169.95 16.69 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-N 118.487 1.144 . . . . 0.0 109.147 175.544 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.615 ' H ' ' HG ' ' I' ' 26' ' ' SER . 89.7 m-20 -30.51 170.79 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 O-C-N 124.009 0.818 . . . . 0.0 112.896 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' K' ' 25' ' ' GLY . 86.3 mttt -108.37 -112.23 0.3 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 173.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.86 90.73 0.01 OUTLIER Glycine 0 N--CA 1.466 0.66 0 CA-C-N 116.09 -0.505 . . . . 0.0 112.155 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -140.01 161.9 36.5 Favored 'General case' 0 C--O 1.248 1.005 0 CA-C-O 122.221 1.01 . . . . 0.0 108.35 177.029 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.478 ' CD1' ' N ' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -139.69 133.07 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 CA-C-N 113.455 -1.702 . . . . 0.0 110.089 -175.957 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.494 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.1 mt -113.39 114.85 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 178.472 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.26 96.06 1.05 Allowed Glycine 0 CA--C 1.497 -1.058 0 N-CA-C 105.231 -3.148 . . . . 0.0 105.231 175.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 6.6 tp -114.05 125.91 54.52 Favored 'General case' 0 CA--C 1.502 -0.87 0 CA-C-O 121.738 0.78 . . . . 0.0 112.026 -177.127 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.708 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 4.6 ttp -119.14 109.92 16.45 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.914 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.2 75.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.141 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -26.72 -98.37 0.01 OUTLIER Glycine 0 C--N 1.363 2.08 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 178.698 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -151.03 19.39 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -124.59 138.92 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.82 0.343 . . . . 0.0 110.358 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.603 -179.47 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . 0.506 ' O ' ' CD1' ' J' ' 10' ' ' TYR . 30.5 p90 -104.06 126.22 51.01 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -148.54 141.11 24.4 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.123 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t -127.85 133.54 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 6.2 t-80 -148.93 143.15 26.0 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.252 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' J' ' 13' ' ' HIS . 46.9 m-70 -141.28 163.66 32.35 Favored 'General case' 0 CA--C 1.51 -0.576 0 CA-C-O 121.482 0.658 . . . . 0.0 110.052 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.418 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 50.9 tt0 -156.02 170.76 21.41 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.06 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . 0.418 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 54.2 mtmt -157.01 134.52 10.68 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -123.83 124.51 42.82 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -140.94 141.69 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 118.768 -1.173 . . . . 0.0 113.867 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.637 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 5.5 m-85 -111.45 110.01 20.24 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.03 120.89 42.14 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.455 0.571 . . . . 0.0 111.429 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . 0.461 ' CB ' HD21 ' J' ' 27' ' ' ASN . . . -125.51 117.58 23.93 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.549 ' O ' ' NZ ' ' H' ' 28' ' ' LYS . 97.2 mt-10 -120.12 142.37 48.98 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.834 -178.143 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 4.3 t70 146.31 159.21 0.0 OUTLIER 'General case' 0 C--N 1.345 0.407 0 O-C-N 124.373 1.046 . . . . 0.0 109.201 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 2.4 m -62.97 -110.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.8 93.04 0.14 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.957 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.841 ' O ' ' O ' ' J' ' 27' ' ' ASN . 15.4 p -153.91 -170.61 3.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.841 ' O ' ' O ' ' J' ' 26' ' ' SER . 50.2 m-20 -19.65 178.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 125.049 1.468 . . . . 0.0 114.258 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.588 ' O ' ' N ' ' J' ' 30' ' ' ALA . 58.0 tttp 138.88 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.246 -177.005 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' J' ' 28' ' ' LYS . . . -45.31 101.46 0.03 OUTLIER Glycine 0 N--CA 1.481 1.68 1 CA-C-O 128.54 4.411 . . . . 0.0 108.384 -174.271 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.588 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -99.51 -124.17 0.16 Allowed 'General case' 1 N--CA 1.368 -4.569 4 N-CA-C 89.89 -7.818 . . . . 0.0 89.89 177.972 . . . . . . . . 4 3 . 1 . 003 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.752 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 1.2 mp -76.99 102.89 3.82 Favored 'Isoleucine or valine' 0 C--N 1.257 -3.422 0 C-N-CA 115.006 -2.678 . . . . 0.0 109.583 176.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.471 ' C ' ' SD ' ' D' ' 35' ' ' MET . 14.2 tt -115.08 121.39 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-O 121.322 0.582 . . . . 0.0 109.476 178.181 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.58 113.83 2.09 Favored Glycine 0 N--CA 1.466 0.681 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.48 ' CD2' ' CZ ' ' L' ' 19' ' ' PHE . 0.0 OUTLIER -125.16 128.11 47.89 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 122.019 0.914 . . . . 0.0 111.702 -178.4 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.743 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 32.7 ttp -107.63 119.26 38.93 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.329 -1.305 . . . . 0.0 109.445 178.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.02 72.83 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 -179.443 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 38' ' ' GLY . . . -56.71 113.21 4.06 Favored Glycine 0 C--N 1.36 1.898 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -56.99 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' J' ' 40' ' ' VAL . 77.8 t -105.38 133.62 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.955 0.407 . . . . 0.0 111.003 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' J' ' 39' ' ' VAL . 62.1 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.951 -1.023 . . . . 0.0 111.172 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -104.97 127.45 52.84 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-O 121.168 0.509 . . . . 0.0 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -113.46 126.82 55.75 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.192 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 56.9 t -123.94 133.13 70.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -146.96 147.87 31.17 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.389 -0.524 . . . . 0.0 111.39 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 54.5 m80 -146.9 164.35 33.18 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.716 0.769 . . . . 0.0 110.593 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 80.8 mt-30 -154.57 179.1 9.36 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.388 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -169.79 131.79 1.11 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.562 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.97 120.53 36.64 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.28 124.93 65.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 121.032 0.444 . . . . 0.0 111.793 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.637 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 41.0 m-85 -115.75 110.25 18.84 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.067 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -120.98 127.36 51.72 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -177.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.21 137.68 36.2 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.582 0.706 . . . . 0.0 112.49 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -105.98 123.7 48.41 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 116.189 -0.459 . . . . 0.0 112.22 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' J' ' 26' ' ' SER . 49.3 t0 -172.37 114.68 0.31 Allowed 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.459 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 8.5 p -79.58 131.34 34.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.244 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.563 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . 58.82 82.38 0.06 OUTLIER Glycine 0 N--CA 1.467 0.7 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.07 178.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p -67.32 -172.08 0.2 Allowed 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.541 0.686 . . . . 0.0 110.172 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.495 ' C ' ' ND2' ' L' ' 27' ' ' ASN . 30.6 p-10 -79.63 179.28 7.59 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.47 ' O ' ' O ' ' K' ' 27' ' ' ASN . 81.2 tttt -43.65 -110.11 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.569 -0.742 . . . . 0.0 112.596 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.4 94.15 1.69 Allowed Glycine 0 N--CA 1.471 1.006 0 CA-C-O 119.992 -0.338 . . . . 0.0 112.859 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.02 173.48 11.73 Favored 'General case' 0 C--O 1.24 0.554 0 N-CA-C 104.317 -2.475 . . . . 0.0 104.317 176.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -151.72 136.93 10.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 C-N-CA 117.35 -1.74 . . . . 0.0 112.116 -174.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.415 HG21 HD11 ' K' ' 32' ' ' ILE . 89.7 mt -122.71 117.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.632 179.716 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.513 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -118.08 107.93 1.56 Allowed Glycine 0 C--N 1.334 0.467 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 178.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 51.9 tp -119.99 121.84 39.83 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 110.464 -0.198 . . . . 0.0 110.464 -178.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.402 ' SD ' ' C ' ' K' ' 35' ' ' MET . 6.3 tmm? -120.34 120.25 35.47 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.704 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.509 ' O ' ' C ' ' K' ' 37' ' ' GLY . 96.1 t -133.68 82.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.509 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -7.87 -97.81 0.0 OUTLIER Glycine 0 C--N 1.349 1.276 0 O-C-N 123.504 0.502 . . . . 0.0 113.703 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.25 -168.85 38.85 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.53 159.57 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.386 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.489 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.413 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -99.69 134.02 43.19 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.737 0.303 . . . . 0.0 110.329 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -144.73 135.07 24.3 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.753 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -134.74 132.31 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.88 179.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 31.8 p-80 -159.67 154.11 23.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 0.0 111.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -151.54 169.29 22.44 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.024 179.63 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -157.58 178.21 10.53 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.995 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -143.4 138.38 29.33 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.498 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 mt -121.68 119.43 31.77 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 m -143.01 135.91 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.48 ' CZ ' ' CD2' ' J' ' 34' ' ' LEU . 4.0 m-30 -116.33 127.91 55.09 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.999 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -141.55 139.44 33.19 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.777 0.798 . . . . 0.0 111.893 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 142.95 34.63 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.78 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.43 100.96 6.18 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.974 -179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -173.84 133.4 0.45 Allowed 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.9 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 113.75 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 54.39 -91.21 0.01 OUTLIER Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -178.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.5 p 152.5 176.71 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 122.006 0.908 . . . . 0.0 110.058 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.495 ' ND2' ' C ' ' K' ' 27' ' ' ASN . 18.4 m-20 -51.74 -179.45 0.01 OUTLIER 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 113.892 -1.504 . . . . 0.0 111.664 178.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -60.58 111.66 1.69 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.923 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.45 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . 81.07 -93.19 1.5 Allowed Glycine 0 N--CA 1.468 0.787 0 CA-C-N 114.993 -1.003 . . . . 0.0 112.22 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.45 ' CB ' ' O ' ' L' ' 29' ' ' GLY . . . 79.11 165.56 0.2 Allowed 'General case' 0 CA--C 1.507 -0.684 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 -175.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.576 ' CD1' ' N ' ' L' ' 31' ' ' ILE . 0.0 OUTLIER -149.87 131.93 5.87 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 CA-C-N 122.07 2.214 . . . . 0.0 111.583 178.038 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' F' ' 35' ' ' MET . 15.4 pt -124.46 142.08 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.115 -178.277 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.75 120.43 2.52 Favored Glycine 0 N--CA 1.463 0.457 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 20.0 mt -115.62 118.66 33.74 Favored 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 4.6 ttt -111.01 117.46 33.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.175 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -145.1 81.41 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.97 102.08 0.22 Allowed Glycine 0 C--N 1.337 0.621 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.072 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.65 178.95 34.17 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.3 136.59 59.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 120.842 0.353 . . . . 0.0 110.325 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.616 -179.698 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -110.33 132.72 53.93 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.785 0.326 . . . . 0.0 110.382 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -131.02 132.12 44.76 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.902 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -144.14 141.94 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.879 0.371 . . . . 0.0 110.668 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -141.75 -168.97 2.8 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.828 -179.387 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 73.7 m-70 -75.92 168.77 19.41 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 121.295 0.569 . . . . 0.0 110.087 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HG2' ' H ' ' A' ' 16' ' ' LYS . 48.5 tt0 -158.33 173.98 15.85 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.361 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.404 ' H ' ' HG2' ' A' ' 15' ' ' GLN . 88.9 tttt -144.27 126.35 15.51 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.621 0.248 . . . . 0.0 110.886 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.21 120.82 22.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.978 0.418 . . . . 0.0 110.046 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.32 136.9 50.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.795 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -129.67 132.01 46.56 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 111.396 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -114.84 123.06 48.23 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.9 123.44 42.52 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.385 0.612 . . . . 0.0 111.249 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -141.78 124.68 16.13 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.73 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 24' ' ' VAL . 62.3 t0 -65.22 140.69 58.76 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.287 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.489 ' N ' ' OD1' ' A' ' 23' ' ' ASP . 2.8 m -108.5 110.98 34.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.751 0.786 . . . . 0.0 109.804 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.57 90.19 0.01 OUTLIER Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.706 -1.133 . . . . 0.0 113.134 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.729 ' O ' ' O ' ' A' ' 27' ' ' ASN . 1.8 t 169.97 176.54 0.05 Allowed 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 176.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.729 ' O ' ' O ' ' A' ' 26' ' ' SER . 19.6 p30 -28.25 -179.13 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 O-C-N 124.792 1.308 . . . . 0.0 112.916 177.02 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.531 ' NZ ' ' O ' ' B' ' 26' ' ' SER . 78.3 tttt -128.86 -108.02 0.29 Allowed 'General case' 0 N--CA 1.469 0.5 0 O-C-N 121.523 -0.736 . . . . 0.0 110.111 175.366 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 28' ' ' LYS . . . 45.39 92.98 0.01 OUTLIER Glycine 0 N--CA 1.468 0.829 0 CA-C-O 118.191 -1.338 . . . . 0.0 110.261 178.194 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.04 160.36 15.1 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 116.627 -2.029 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -152.22 117.87 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 111.836 -2.438 . . . . 0.0 108.958 -171.736 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.472 ' CG2' ' O ' ' A' ' 32' ' ' ILE . 12.6 tt -128.85 109.28 18.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.032 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.613 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -122.31 119.86 4.13 Favored Glycine 0 CA--C 1.51 -0.263 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 178.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 8.4 tt -164.86 162.69 21.01 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.321 -176.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 5.1 ttp -135.45 143.24 45.79 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.244 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 m -121.89 71.53 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.764 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -47.05 -97.46 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.2 -168.85 30.83 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.43 134.35 66.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.635 -179.707 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -109.89 135.06 51.36 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.939 0.4 . . . . 0.0 110.708 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.94 161.29 28.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.1 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 m -131.04 160.85 41.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.46 ' N ' ' CD2' ' B' ' 13' ' ' HIS . 2.8 m-70 -127.74 124.27 37.38 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.711 0.291 . . . . 0.0 110.628 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.495 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 55.2 t60 -153.92 162.58 41.11 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.495 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 73.5 mt-30 -159.22 175.91 12.85 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.792 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -153.94 126.9 8.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.149 178.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 mt -124.7 114.46 19.35 Favored 'General case' 0 C--O 1.233 0.214 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.122 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -124.48 128.99 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.812 0.339 . . . . 0.0 110.344 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 88.7 t80 -125.7 123.32 38.63 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.036 -179.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -118.16 125.56 50.46 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.0 131.93 41.29 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.415 179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.47 ' CB ' ' O ' ' C' ' 22' ' ' GLU . 16.6 pt-20 -158.39 154.88 27.68 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 120.185 -0.606 . . . . 0.0 112.561 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.516 ' O ' ' O ' ' B' ' 24' ' ' VAL . 1.0 OUTLIER -164.52 114.25 1.17 Allowed 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.439 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.516 ' O ' ' O ' ' B' ' 23' ' ' ASP . 28.3 m -48.31 -131.07 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-O 121.658 0.742 . . . . 0.0 112.943 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.42 -85.87 0.72 Allowed Glycine 0 CA--C 1.537 1.439 0 CA-C-N 115.735 -0.666 . . . . 0.0 113.301 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.715 ' O ' ' O ' ' B' ' 27' ' ' ASN . 77.4 p 172.13 -170.75 0.03 OUTLIER 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.715 ' O ' ' O ' ' B' ' 26' ' ' SER . 22.0 t-20 -17.86 158.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 O-C-N 124.847 1.342 . . . . 0.0 112.473 179.107 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.518 ' O ' ' CG ' ' B' ' 28' ' ' LYS . 32.6 pttt -161.54 111.04 1.58 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 118.269 -1.373 . . . . 0.0 114.595 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.88 93.64 0.33 Allowed Glycine 0 CA--C 1.495 -1.202 0 N-CA-C 105.864 -2.894 . . . . 0.0 105.864 174.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.08 161.61 15.03 Favored 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.469 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -141.62 121.11 10.92 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.294 -172.346 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 1.6 mt -110.53 115.11 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.953 178.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.428 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -120.04 93.65 0.54 Allowed Glycine 0 CA--C 1.507 -0.443 0 N-CA-C 104.198 -3.561 . . . . 0.0 104.198 174.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 57.3 mt -122.58 140.22 53.04 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 122.958 1.361 . . . . 0.0 113.054 -176.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 12.1 ttt -127.7 123.3 35.12 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 113.789 -1.55 . . . . 0.0 111.027 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.71 72.98 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.962 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.085 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -98.2 103.34 2.79 Favored Glycine 0 C--N 1.354 1.549 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.28 172.13 34.53 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -154.23 147.42 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 110.949 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.372 179.668 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.46 146.41 34.58 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.265 -0.272 . . . . 0.0 110.265 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -60.67 130.67 47.69 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.742 -0.383 . . . . 0.0 110.465 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 23.7 m -139.95 159.44 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.104 0.478 . . . . 0.0 110.494 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -124.69 131.26 53.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.375 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 84.0 m-70 -143.49 168.55 19.58 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.402 0.62 . . . . 0.0 109.878 -179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 48.0 tt0 -159.53 172.99 16.85 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.625 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -166.61 114.75 0.87 Allowed 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 179.127 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 tp -121.74 121.72 37.92 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -130.03 124.99 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -114.48 106.36 14.19 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.131 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -113.26 127.14 56.06 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.15 0.5 . . . . 0.0 111.564 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.66 125.25 44.46 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.952 178.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' B' ' 22' ' ' GLU . 97.2 mt-10 -143.57 158.76 43.41 Favored 'General case' 0 C--O 1.222 -0.345 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.988 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.531 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 22.4 t0 177.58 120.99 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.284 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 m -57.79 120.63 4.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.525 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 74.66 90.08 0.19 Allowed Glycine 0 CA--C 1.532 1.14 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.958 177.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.525 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.8 m 162.21 160.16 0.02 OUTLIER 'General case' 0 C--N 1.341 0.23 0 CA-C-O 122.246 1.022 . . . . 0.0 111.022 175.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.677 HD21 ' N ' ' C' ' 27' ' ' ASN . 1.1 m120 -31.62 170.54 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.084 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.524 ' CG ' ' H ' ' C' ' 29' ' ' GLY . 26.1 pttt -108.37 -111.2 0.31 Allowed 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 171.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.579 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . -71.5 94.91 0.59 Allowed Glycine 1 CA--C 1.424 -5.626 0 N-CA-C 104.601 -3.4 . . . . 0.0 104.601 173.027 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.507 ' O ' ' C ' ' C' ' 29' ' ' GLY . . . -79.55 -140.47 0.03 OUTLIER 'General case' 0 N--CA 1.388 -3.564 1 N-CA-C 97.605 -4.961 . . . . 0.0 97.605 177.877 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.662 ' N ' ' CD1' ' C' ' 31' ' ' ILE . 1.0 OUTLIER -81.17 106.56 12.47 Favored 'Isoleucine or valine' 0 C--N 1.246 -3.904 0 C-N-CA 114.451 -2.9 . . . . 0.0 110.153 -177.751 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.498 ' O ' ' CE ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -108.68 122.52 63.37 Favored 'Isoleucine or valine' 0 C--N 1.363 1.161 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.766 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -138.76 113.23 0.93 Allowed Glycine 0 C--N 1.314 -0.666 0 N-CA-C 106.871 -2.492 . . . . 0.0 106.871 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.479 ' CD2' ' CE2' ' D' ' 19' ' ' PHE . 0.0 OUTLIER -140.65 158.55 43.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 123.115 1.436 . . . . 0.0 111.842 -176.673 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.479 ' CE ' ' O ' ' I' ' 32' ' ' ILE . 24.4 tpp -129.35 124.22 33.73 Favored 'General case' 0 CA--C 1.491 -1.289 0 CA-C-N 112.613 -2.085 . . . . 0.0 107.167 178.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . 0.445 ' O ' ' O ' ' C' ' 37' ' ' GLY . 48.7 t -116.9 70.98 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.049 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.32 -101.09 0.01 OUTLIER Glycine 0 C--N 1.377 2.829 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.086 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.83 -158.82 30.41 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -134.59 161.53 40.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.83 0.347 . . . . 0.0 110.341 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.662 -179.576 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -84.92 137.73 32.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.823 0.344 . . . . 0.0 110.598 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . 0.473 ' OE2' ' CE1' ' D' ' 13' ' ' HIS . 80.5 tt0 -71.79 147.44 47.26 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.67 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 54.2 t -120.92 131.82 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.473 ' CE1' ' OE2' ' D' ' 11' ' ' GLU . 33.0 m-70 -118.38 106.08 12.36 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.59 -178.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.429 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 60.8 m170 -108.67 166.51 10.74 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -152.82 172.51 16.62 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.03 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -157.08 114.5 3.11 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 60.3 mt -119.81 115.4 23.77 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -129.82 127.07 63.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.479 ' CE2' ' CD2' ' C' ' 34' ' ' LEU . 7.9 m-85 -116.07 117.76 30.98 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -132.9 128.56 36.82 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.944 -177.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 130.36 45.12 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.537 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 79.7 tt0 -141.81 107.91 5.21 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 119.945 -0.702 . . . . 0.0 112.777 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 71.8 m-20 -166.28 127.27 1.75 Allowed 'General case' 0 CA--C 1.534 0.327 0 O-C-N 123.872 0.732 . . . . 0.0 110.158 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 82.9 t -45.5 111.92 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.416 ' H ' ' HB2' ' E' ' 23' ' ' ASP . . . -127.71 86.21 0.33 Allowed Glycine 0 CA--C 1.538 1.48 0 N-CA-C 115.397 0.919 . . . . 0.0 115.397 -178.016 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 17.3 p -88.04 175.91 7.54 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 104.609 -2.367 . . . . 0.0 104.609 175.038 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.605 ' O ' ' HG3' ' D' ' 28' ' ' LYS . 1.8 m120 63.45 -171.76 0.17 Allowed 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 116.727 -1.989 . . . . 0.0 108.261 178.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.605 ' HG3' ' O ' ' D' ' 27' ' ' ASN . 0.2 OUTLIER 46.0 112.85 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 117.98 2.585 . . . . 0.0 117.98 177.876 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.61 94.61 1.54 Allowed Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 174.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.579 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . -81.03 175.17 10.91 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -174.87 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.459 ' CG1' ' C ' ' D' ' 30' ' ' ALA . 0.2 OUTLIER -150.92 125.07 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 116.683 -2.007 . . . . 0.0 111.846 -172.27 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.457 ' O ' ' CG2' ' D' ' 32' ' ' ILE . 3.7 tt -116.31 116.99 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.502 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.83 119.39 3.31 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 178.756 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.438 HD12 ' N ' ' D' ' 35' ' ' MET . 14.8 tp -138.84 126.46 21.96 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.161 0.981 . . . . 0.0 112.026 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.588 ' SD ' ' CA ' ' J' ' 33' ' ' GLY . 20.8 ttt -106.35 119.84 40.3 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.191 177.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.461 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -107.99 76.75 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.144 -178.579 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -26.43 -97.42 0.01 OUTLIER Glycine 0 C--N 1.354 1.552 0 N-CA-C 112.004 -0.438 . . . . 0.0 112.004 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.31 165.63 33.71 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.32 161.43 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.825 0.345 . . . . 0.0 110.474 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.3 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.492 179.689 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -103.58 131.17 50.95 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.862 0.363 . . . . 0.0 110.367 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -143.67 148.92 36.48 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.218 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.436 ' CG2' ' H ' ' F' ' 12' ' ' VAL . 0.2 OUTLIER -148.12 -153.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.462 -179.382 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.424 ' ND1' ' C ' ' E' ' 13' ' ' HIS . 7.2 t-80 -70.77 142.25 51.4 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 121.464 0.65 . . . . 0.0 112.68 -177.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -146.03 169.7 18.14 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 50.4 tt0 -155.39 168.01 28.51 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.924 -0.71 . . . . 0.0 112.233 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -148.75 123.48 9.88 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.614 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 34.0 tp -120.8 114.21 21.29 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.43 129.02 68.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 121.381 0.61 . . . . 0.0 111.999 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -124.07 123.93 41.42 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.619 ' CE1' ' CD1' ' F' ' 20' ' ' PHE . 2.0 t80 -133.64 130.14 37.85 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.718 0.294 . . . . 0.0 110.768 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.72 130.35 34.04 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.23 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -122.96 141.09 52.32 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 19.5 p-10 -165.49 113.74 0.99 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.563 177.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.09 131.0 31.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.196 -178.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 72.78 84.51 0.24 Allowed Glycine 0 CA--C 1.532 1.12 0 CA-C-N 116.007 -0.542 . . . . 0.0 114.12 177.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' E' ' 25' ' ' GLY . 88.7 p -34.61 170.72 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.666 0.786 . . . . 0.0 111.765 177.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.59 ' ND2' ' NZ ' ' D' ' 28' ' ' LYS . 18.1 p30 -138.88 -178.61 5.4 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.259 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.431 ' C ' ' O ' ' E' ' 27' ' ' ASN . 70.1 mmtt -18.88 -103.85 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.087 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.459 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -140.15 97.62 0.23 Allowed Glycine 0 CA--C 1.496 -1.096 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.389 179.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -67.72 172.06 5.72 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 176.075 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.417 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.3 OUTLIER -147.38 124.66 3.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 118.402 -1.319 . . . . 0.0 109.553 -178.151 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 66.1 mt -123.73 124.47 69.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.705 -176.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.416 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -127.27 110.31 1.18 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 177.704 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 43.5 mt -119.02 128.9 54.8 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -179.735 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.3 ttt -133.3 131.16 39.85 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 119.781 -0.768 . . . . 0.0 112.222 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.512 ' O ' ' C ' ' E' ' 37' ' ' GLY . 40.1 t -130.65 81.73 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.576 179.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 19.02 -102.7 0.01 OUTLIER Glycine 0 C--N 1.352 1.472 0 CA-C-N 117.848 0.294 . . . . 0.0 112.84 179.112 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.02 -174.51 46.79 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -135.69 161.71 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.798 0.332 . . . . 0.0 110.677 -179.523 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.5 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -147.23 155.78 42.38 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.099 0.476 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -101.72 143.89 31.1 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.957 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . 0.436 ' H ' ' CG2' ' E' ' 12' ' ' VAL . 55.5 t -118.84 129.59 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.404 0.621 . . . . 0.0 110.54 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -154.49 130.12 9.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.045 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -145.74 170.38 16.63 Favored 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.652 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -148.28 175.22 11.25 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.221 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.13 131.86 31.1 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -121.87 120.82 35.64 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.1 t -131.7 125.82 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.985 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -117.48 115.68 25.64 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE1' ' E' ' 20' ' ' PHE . 34.7 t80 -128.3 123.19 33.4 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.967 0.413 . . . . 0.0 110.084 179.209 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.84 134.33 36.82 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.494 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 80.1 tt0 -92.2 75.66 5.36 Favored 'General case' 0 N--CA 1.463 0.21 0 C-N-CA 119.888 -0.725 . . . . 0.0 112.066 -178.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.499 ' CG ' ' NZ ' ' C' ' 28' ' ' LYS . 19.3 m-20 -142.81 107.93 4.96 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 175.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 85.6 t -45.69 140.79 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.066 -177.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.85 83.61 1.63 Allowed Glycine 0 C--N 1.333 0.392 0 N-CA-C 107.865 -2.094 . . . . 0.0 107.865 177.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -68.63 -170.79 0.23 Allowed 'General case' 0 N--CA 1.434 -1.266 0 CA-C-O 122.393 1.092 . . . . 0.0 111.805 -177.582 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.438 ' O ' ' C ' ' F' ' 28' ' ' LYS . 49.9 p30 -80.23 179.19 7.78 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 113.014 -1.903 . . . . 0.0 108.781 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.438 ' C ' ' O ' ' F' ' 27' ' ' ASN . 98.8 mttt -36.82 104.16 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 122.072 0.939 . . . . 0.0 109.445 -178.793 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . 0.46 ' O ' HG13 ' F' ' 31' ' ' ILE . . . 168.07 -100.71 0.17 Allowed Glycine 0 C--O 1.209 -1.412 0 CA-C-O 117.308 -1.829 . . . . 0.0 109.28 -173.959 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.48 164.06 0.55 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.51 2.655 . . . . 0.0 106.808 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.483 ' CD1' ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -146.25 131.18 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 118.119 -1.433 . . . . 0.0 112.175 -177.148 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 13.4 mm -115.5 125.54 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.51 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 125.24 4.49 Favored Glycine 0 N--CA 1.473 1.151 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.106 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 mt -124.68 128.02 48.19 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -130.81 127.63 39.04 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 121.699 0.761 . . . . 0.0 112.571 -179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 48.8 t -147.38 86.66 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.813 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.45 96.79 1.28 Allowed Glycine 0 C--N 1.339 0.698 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.071 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.21 163.57 31.54 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.656 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 62.2 t -123.88 135.61 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.307 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -146.3 156.58 43.46 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.955 0.407 . . . . 0.0 110.801 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -145.4 131.14 18.99 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.437 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -140.26 158.52 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.302 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 75.8 m80 -120.26 166.6 13.27 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 120.92 0.39 . . . . 0.0 111.704 -179.554 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.434 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 94.3 m-70 -107.72 179.14 4.32 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.668 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.427 HE21 ' CD ' ' H' ' 16' ' ' LYS . 52.3 tt0 -100.07 172.66 7.06 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.714 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.4 mttm -149.19 165.58 31.41 Favored 'General case' 0 C--O 1.217 -0.639 0 CA-C-O 121.193 0.521 . . . . 0.0 111.419 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 7.0 tt -145.14 161.84 38.49 Favored 'General case' 0 C--O 1.171 -3.039 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . 0.958 ' C ' ' O ' ' H' ' 18' ' ' VAL . 86.3 t -156.07 170.77 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 118.701 -2.499 . . . . 0.0 110.529 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . 0.562 ' CD2' ' O ' ' G' ' 19' ' ' PHE . 31.2 p90 -158.86 108.32 1.96 Allowed 'General case' 0 C--O 1.165 -3.344 0 CA-C-O 118.373 -0.823 . . . . 0.0 109.803 -178.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.748 ' N ' ' H ' ' H' ' 20' ' ' PHE . 43.6 t80 -119.52 106.27 12.05 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 121.471 1.941 . . . . 0.0 112.026 178.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . 0.738 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -114.74 113.0 23.71 Favored 'General case' 0 C--O 1.174 -2.887 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.256 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' H' ' 22' ' ' GLU . 94.9 mt-10 -75.01 144.41 43.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 118.898 0.772 . . . . 0.0 112.032 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 33.4 m-20 -140.62 -142.24 0.14 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.975 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' G' ' 23' ' ' ASP . 13.7 t -27.44 103.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.318 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.455 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 172.0 92.77 0.08 OUTLIER Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 86.66 179.9 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.793 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -63.73 170.88 3.01 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.309 0.576 . . . . 0.0 111.459 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.804 ' NZ ' ' H ' ' H' ' 26' ' ' SER . 0.0 OUTLIER -47.85 112.07 0.51 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.106 176.986 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.52 94.31 2.35 Favored Glycine 0 CA--C 1.486 -1.75 0 CA-C-O 122.493 1.052 . . . . 0.0 110.841 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -74.31 -179.05 3.72 Favored 'General case' 0 N--CA 1.421 -1.922 0 CA-C-N 112.795 -1.702 . . . . 0.0 110.607 -179.373 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.608 ' CD1' ' N ' ' G' ' 31' ' ' ILE . 0.0 OUTLIER -141.62 112.65 3.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 113.335 -1.757 . . . . 0.0 106.41 179.415 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 18.5 tt -117.31 117.65 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-O 121.708 0.766 . . . . 0.0 110.414 179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.16 106.41 2.35 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 105.904 -2.878 . . . . 0.0 105.904 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.504 ' H ' HD21 ' H' ' 34' ' ' LEU . 13.2 tp -132.81 130.52 39.96 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 122.604 1.192 . . . . 0.0 111.535 -177.774 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.613 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 24.7 ttp -102.81 124.19 47.87 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.16 179.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.9 70.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.98 -100.53 1.47 Allowed Glycine 0 C--N 1.354 1.572 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.7 170.25 24.04 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . 0.405 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 27.4 m -141.24 163.68 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.832 0.348 . . . . 0.0 110.708 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . 0.405 ' OXT' ' O ' ' G' ' 39' ' ' VAL . 7.8 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.572 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . 0.524 ' CD1' ' O ' ' I' ' 9' ' ' GLY . 91.8 m-85 -105.06 138.99 40.42 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.012 0.434 . . . . 0.0 110.737 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -59.39 133.7 56.34 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.604 0.716 . . . . 0.0 111.14 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.09 132.74 70.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.037 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.613 ' CD2' ' ND1' ' I' ' 13' ' ' HIS . 7.3 p-80 -158.68 152.01 22.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.672 0.749 . . . . 0.0 111.785 -179.484 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.509 ' HE2' ' CG1' ' I' ' 12' ' ' VAL . 15.9 m80 -144.64 162.27 37.07 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.232 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.2 mm-40 -152.96 172.91 16.09 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.313 0.578 . . . . 0.0 110.087 178.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' G' ' 16' ' ' LYS . 76.7 tttt -176.04 136.86 0.31 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.026 -0.988 . . . . 0.0 108.467 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 77.0 mt -141.07 132.3 26.51 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.169 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . 0.958 ' O ' ' C ' ' G' ' 18' ' ' VAL . 76.8 t -124.6 146.07 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 C-N-CA 118.184 -1.407 . . . . 0.0 113.385 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 63.2 m-85 -125.19 119.33 28.21 Favored 'General case' 0 N--CA 1.478 0.949 0 O-C-N 120.141 -1.6 . . . . 0.0 111.479 -179.042 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.748 ' H ' ' N ' ' G' ' 20' ' ' PHE . 50.3 t80 -105.69 111.82 24.65 Favored 'General case' 0 C--O 1.248 0.981 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.698 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . 0.738 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -93.97 113.44 25.44 Favored 'General case' 0 C--N 1.352 0.717 0 CA-C-O 118.631 -0.7 . . . . 0.0 112.734 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.64 ' H ' ' CB ' ' G' ' 21' ' ' ALA . 48.6 tt0 -149.02 124.85 10.55 Favored 'General case' 0 C--N 1.379 1.884 0 C-N-CA 117.899 -1.52 . . . . 0.0 112.094 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.501 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 66.5 t0 -125.07 114.69 19.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.484 0.659 . . . . 0.0 110.252 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 40.1 t -38.72 122.88 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.39 -88.71 0.52 Allowed Glycine 0 CA--C 1.538 1.505 0 N-CA-C 115.802 1.081 . . . . 0.0 115.802 176.6 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.804 ' H ' ' NZ ' ' G' ' 28' ' ' LYS . 83.7 p -65.94 -172.48 0.14 Allowed 'General case' 0 CA--C 1.502 -0.896 0 CA-C-O 122.234 1.016 . . . . 0.0 113.008 -175.075 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.423 ' N ' ' OG ' ' I' ' 26' ' ' SER . 4.7 p30 -81.17 179.88 7.66 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 113.136 -1.847 . . . . 0.0 114.895 -176.988 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.401 ' NZ ' ' OG ' ' J' ' 26' ' ' SER . 86.2 mttt -41.42 -104.11 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 112.189 -2.278 . . . . 0.0 109.662 176.281 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.575 ' O ' ' CB ' ' I' ' 30' ' ' ALA . . . -82.01 100.62 2.12 Favored Glycine 0 CA--C 1.465 -3.058 0 CA-C-O 123.208 1.449 . . . . 0.0 111.011 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.569 ' O ' ' C ' ' H' ' 29' ' ' GLY . . . -73.73 -134.15 0.01 OUTLIER 'General case' 0 CA--C 1.477 -1.834 2 N-CA-C 93.853 -6.351 . . . . 0.0 93.853 170.076 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.571 ' CD1' ' N ' ' H' ' 31' ' ' ILE . 0.9 OUTLIER -94.43 110.69 24.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 CA-C-N 124.149 3.159 . . . . 0.0 108.602 177.09 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.558 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -112.86 110.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.361 1.075 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.686 -179.582 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.439 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -120.24 102.34 0.87 Allowed Glycine 0 N--CA 1.462 0.401 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.504 HD21 ' H ' ' G' ' 34' ' ' LEU . 2.6 mt -136.84 149.46 47.73 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-O 122.508 1.147 . . . . 0.0 112.844 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.469 ' SD ' ' O ' ' B' ' 31' ' ' ILE . 28.7 ttp -111.9 126.02 54.66 Favored 'General case' 0 CA--C 1.505 -0.772 0 CA-C-N 113.236 -1.802 . . . . 0.0 110.467 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -125.27 65.57 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.2 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.285 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -51.65 -104.6 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.81 -141.8 5.09 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -122.82 135.98 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.768 0.318 . . . . 0.0 110.288 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.495 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' H' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . 0.508 ' CZ ' ' O ' ' K' ' 9' ' ' GLY . 97.6 m-85 -115.06 152.22 32.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -60.01 134.83 57.42 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.182 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.509 ' CG1' ' HE2' ' H' ' 14' ' ' HIS . 77.3 t -124.31 133.33 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-O 120.804 0.335 . . . . 0.0 110.173 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.631 ' HE2' ' NE2' ' I' ' 15' ' ' GLN . 75.4 t60 -150.86 104.75 3.19 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.864 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.526 ' NE2' ' O ' ' J' ' 12' ' ' VAL . 64.7 m170 -112.6 160.12 18.18 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.37 0.605 . . . . 0.0 110.205 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.631 ' NE2' ' HE2' ' I' ' 13' ' ' HIS . 84.0 mt-30 -154.06 167.56 29.38 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.401 178.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . 0.432 ' CG ' ' O ' ' I' ' 15' ' ' GLN . 95.2 mttt -164.69 128.46 2.47 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 108.993 -0.744 . . . . 0.0 108.993 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.2 mt -126.97 126.14 42.69 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 19.8 t -125.0 129.92 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.414 ' CE1' ' CD1' ' H' ' 34' ' ' LEU . 0.5 OUTLIER -133.57 108.64 8.72 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.185 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.422 ' CG ' ' CZ ' ' J' ' 20' ' ' PHE . 4.0 p90 -143.57 153.82 42.95 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 118.624 -1.23 . . . . 0.0 112.797 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.46 141.48 51.87 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.964 -1.016 . . . . 0.0 112.962 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -150.99 99.86 2.74 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.072 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.553 ' OD1' ' O ' ' H' ' 26' ' ' SER . 3.1 t70 -103.05 120.24 40.31 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.11 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 27.5 m -59.21 121.36 6.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 179.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 81.97 90.31 0.61 Allowed Glycine 0 CA--C 1.535 1.305 0 N-CA-C 116.918 1.527 . . . . 0.0 116.918 174.769 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.523 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.4 p 137.43 167.3 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 124.902 1.281 . . . . 0.0 110.707 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.535 ' OD1' ' ND2' ' J' ' 27' ' ' ASN . 16.2 m-20 -49.84 178.15 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 115.841 1.793 . . . . 0.0 115.841 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . . . . . . . . . 12.9 tttt -61.82 -111.24 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.052 0 CA-C-N 113.177 -1.829 . . . . 0.0 114.912 172.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.609 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -79.59 96.3 1.52 Allowed Glycine 0 CA--C 1.458 -3.492 0 CA-C-N 110.762 -2.927 . . . . 0.0 114.677 -175.271 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.575 ' CB ' ' O ' ' H' ' 29' ' ' GLY . . . -76.61 -136.45 0.02 OUTLIER 'General case' 0 N--CA 1.412 -2.329 1 N-CA-C 93.992 -6.299 . . . . 0.0 93.992 169.066 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.699 ' N ' ' CD1' ' I' ' 31' ' ' ILE . 0.4 OUTLIER -98.46 121.91 49.55 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 1 CA-C-N 127.308 4.594 . . . . 0.0 111.412 -176.631 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.479 ' O ' ' CE ' ' C' ' 35' ' ' MET . 7.7 mt -112.09 112.26 39.74 Favored 'Isoleucine or valine' 0 C--N 1.359 1.022 0 CA-C-N 114.83 -1.077 . . . . 0.0 108.276 177.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.91 104.94 1.72 Allowed Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 107.295 -2.322 . . . . 0.0 107.295 177.217 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 65.0 mt -137.39 133.2 34.53 Favored 'General case' 0 C--O 1.24 0.561 0 CA-C-O 122.751 1.262 . . . . 0.0 113.549 -176.702 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 57.0 ttp -113.47 122.68 48.04 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-N 113.649 -1.614 . . . . 0.0 109.153 178.257 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.7 70.69 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -118.46 -103.57 2.15 Favored Glycine 0 C--N 1.36 1.881 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 178.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.49 -174.17 31.95 Favored Glycine 0 CA--C 1.522 0.501 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.113 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -132.82 161.9 40.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 CA-C-O 121.15 0.5 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 32.1 m . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.438 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -145.97 153.18 40.51 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.763 0.316 . . . . 0.0 110.686 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -145.07 159.22 43.31 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.251 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.526 ' O ' ' NE2' ' I' ' 14' ' ' HIS . 19.3 m -138.67 -166.74 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 -177.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -84.4 114.43 21.89 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.993 -0.283 . . . . 0.0 110.66 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.489 ' NE2' ' CG2' ' J' ' 12' ' ' VAL . 49.6 m170 -134.78 165.2 25.83 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-O 121.827 0.822 . . . . 0.0 110.641 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.41 HE21 HD12 ' J' ' 17' ' ' LEU . 37.5 tt0 -161.84 166.81 25.82 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.823 178.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -156.98 135.33 11.31 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . 0.41 HD12 HE21 ' J' ' 15' ' ' GLN . 11.0 mp -122.16 120.41 34.14 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.389 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -125.92 130.12 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -140.3 126.81 20.19 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.71 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.657 ' CG ' ' CZ ' ' K' ' 20' ' ' PHE . 51.2 p90 -158.75 160.53 36.45 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.619 1.711 . . . . 0.0 115.619 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.1 119.02 32.11 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 114.071 -1.422 . . . . 0.0 108.279 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -157.08 157.16 34.04 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-O 122.116 0.96 . . . . 0.0 113.494 -177.476 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.498 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 51.8 p-10 -157.54 -131.41 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 178.092 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.498 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 3.7 p -108.38 112.33 39.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.967 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.512 ' N ' ' OE1' ' K' ' 22' ' ' GLU . . . 32.02 87.94 0.01 OUTLIER Glycine 0 C--N 1.342 0.896 0 CA-C-O 118.218 -1.323 . . . . 0.0 110.781 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.572 ' O ' ' N ' ' K' ' 24' ' ' VAL . 82.8 p -96.57 168.35 10.59 Favored 'General case' 0 CA--C 1.497 -1.079 0 CA-C-N 120.772 2.286 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.535 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 84.3 m-20 -61.91 179.07 0.29 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 116.501 2.037 . . . . 0.0 116.501 175.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . 0.472 53.1 tttt -59.02 106.98 0.47 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 110.424 -3.08 . . . . 0.0 116.321 170.749 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.69 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -63.08 109.6 2.81 Favored Glycine 1 CA--C 1.435 -4.967 0 CA-C-O 125.192 2.551 . . . . 0.0 108.826 -173.994 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.69 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . -52.79 -124.69 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.518 2 CA-C-N 104.888 -5.656 . . . . 0.0 97.823 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.785 ' N ' ' CD1' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -93.43 115.25 31.8 Favored 'Isoleucine or valine' 0 C--N 1.263 -3.186 1 CA-C-N 126.896 4.407 . . . . 0.0 114.63 -173.485 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.507 ' C ' ' SD ' ' D' ' 35' ' ' MET . 16.1 tt -122.27 115.4 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.725 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . 0.588 ' CA ' ' SD ' ' D' ' 35' ' ' MET . . . -118.01 118.55 4.1 Favored Glycine 0 N--CA 1.464 0.51 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.409 HD22 ' CE2' ' K' ' 19' ' ' PHE . 2.2 mt -134.91 127.45 30.66 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.502 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 63.8 ttp -109.2 122.01 46.39 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.711 176.978 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.55 70.99 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.378 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.784 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.69 106.91 3.47 Favored Glycine 0 C--N 1.361 1.933 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 178.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -110.39 149.88 17.6 Favored Glycine 0 N--CA 1.464 0.552 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 8.2 p -145.23 143.77 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.631 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 40.0 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.472 179.73 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . 0.508 ' O ' ' CZ ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -115.58 143.23 45.63 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.851 0.358 . . . . 0.0 110.568 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.52 133.93 48.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.432 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.447 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 42.8 t -126.25 130.8 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-O 121.024 0.44 . . . . 0.0 110.542 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 69.2 m-70 -103.57 129.0 50.72 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.244 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.556 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 49.4 t60 -136.44 165.19 26.4 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 178.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.556 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 81.7 mt-30 -157.37 176.45 12.66 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.403 178.699 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -173.05 133.82 0.54 Allowed 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -125.89 122.4 35.93 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -127.97 129.29 69.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-O 120.908 0.385 . . . . 0.0 110.437 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.409 ' CE2' HD22 ' J' ' 34' ' ' LEU . 1.9 t80 -131.25 123.89 29.39 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.657 ' CZ ' ' CG ' ' J' ' 20' ' ' PHE . 52.4 p90 -144.77 151.39 38.78 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.67 138.17 30.43 Favored 'General case' 0 CA--C 1.543 0.7 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.244 -178.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' J' ' 25' ' ' GLY . 36.2 tt0 -89.5 134.09 34.26 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.654 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' J' ' 29' ' ' GLY . 13.8 m-20 -148.97 119.59 7.48 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' J' ' 26' ' ' SER . 6.0 p -120.37 121.61 66.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.37 84.87 0.01 OUTLIER Glycine 0 N--CA 1.484 1.854 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 12.8 p -46.22 165.28 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -179.393 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -109.22 170.57 7.97 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 112.733 -2.03 . . . . 0.0 107.151 171.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -38.37 111.08 0.15 Allowed 'General case' 0 CA--C 1.551 1.015 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 175.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 91.93 0.36 Allowed Glycine 0 N--CA 1.483 1.824 0 N-CA-C 117.832 1.893 . . . . 0.0 117.832 171.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.19 157.54 43.56 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 173.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.411 ' O ' ' O ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -146.92 137.26 17.44 Favored 'Isoleucine or valine' 0 C--O 1.242 0.698 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.848 -176.77 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.88 126.2 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.428 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.98 122.27 4.92 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.601 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 21.7 tp -120.6 121.07 37.57 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 114.91 -0.645 . . . . 0.0 110.257 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.416 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 15.9 ttt -117.14 116.6 27.62 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 2.3 p -139.91 79.76 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -178.852 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 38' ' ' GLY . . . -52.93 104.17 0.17 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.183 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 37' ' ' GLY . . . -55.35 -165.72 0.03 OUTLIER Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.18 156.54 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 120.967 0.413 . . . . 0.0 110.382 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.22 -179.89 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -84.35 137.75 33.25 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.777 0.323 . . . . 0.0 110.468 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -121.87 139.26 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.453 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m -131.81 158.63 43.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.377 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -95.76 151.97 18.9 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.108 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 62.3 m80 -80.7 177.51 8.98 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -129.98 177.57 7.18 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.656 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -147.7 150.32 34.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -127.25 124.61 39.27 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.116 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -124.52 130.48 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 120.903 0.382 . . . . 0.0 110.496 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 17.0 t80 -133.31 120.49 21.1 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.549 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -144.68 140.13 28.43 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.56 135.83 38.76 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.1 mt-10 -85.17 76.1 10.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 119.099 -1.04 . . . . 0.0 112.528 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -118.2 122.07 42.08 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 120.929 0.395 . . . . 0.0 111.127 178.445 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' L' ' 26' ' ' SER . 18.0 t -88.96 123.2 41.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.581 ' N ' ' O ' ' L' ' 24' ' ' VAL . 88.2 p -63.14 -178.33 0.23 Allowed 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 121.403 0.621 . . . . 0.0 109.882 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -81.82 177.51 8.84 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.588 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -38.8 103.99 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.284 177.973 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 165.73 -100.78 0.18 Allowed Glycine 0 C--O 1.22 -0.763 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.671 -177.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.39 170.87 0.2 Allowed 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.416 HG22 HD13 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -153.97 145.87 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 118.099 -1.44 . . . . 0.0 112.427 -176.553 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 13.6 tt -138.2 137.46 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.78 123.91 4.65 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 mt -117.36 119.78 36.17 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.76 119.82 36.65 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -129.32 81.66 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.655 -0.248 . . . . 0.0 110.88 -178.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.56 101.64 0.22 Allowed Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.01 168.99 33.06 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -131.18 159.12 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 120.699 0.285 . . . . 0.0 110.396 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.781 -179.63 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 57.0 t80 -82.47 130.54 35.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.854 0.359 . . . . 0.0 110.395 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.42 146.21 54.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.59 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.6 t -121.21 134.62 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.418 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -96.72 -176.53 3.62 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.144 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -81.02 171.26 15.19 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.419 ' HG3' ' N ' ' A' ' 16' ' ' LYS . 61.8 tp60 -152.48 171.63 17.79 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.498 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . 0.419 ' N ' ' HG3' ' A' ' 15' ' ' GLN . 99.4 mttt -145.58 119.74 9.49 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.49 0.186 . . . . 0.0 111.104 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -132.03 120.32 22.25 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 120.91 0.386 . . . . 0.0 110.061 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -142.23 139.28 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.662 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -135.87 140.2 43.95 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.386 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -139.75 135.44 33.11 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.072 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.39 124.27 47.29 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.648 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -172.75 99.91 0.14 Allowed 'General case' 0 CA--C 1.527 0.093 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 24' ' ' VAL . 49.2 t0 -146.12 113.85 6.43 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.403 ' C ' ' O ' ' A' ' 23' ' ' ASP . 61.6 t -28.5 125.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.152 -0.931 . . . . 0.0 112.06 177.079 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . 0.403 ' C ' ' HG ' ' A' ' 26' ' ' SER . . . -171.48 -83.34 0.05 OUTLIER Glycine 0 CA--C 1.527 0.824 0 C-N-CA 119.895 -1.145 . . . . 0.0 112.106 178.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 27' ' ' ASN . 1.5 p 170.66 179.53 0.05 Allowed 'General case' 0 N--CA 1.447 -0.588 0 CA-C-N 118.224 1.012 . . . . 0.0 110.711 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.533 ' O ' ' O ' ' A' ' 26' ' ' SER . 0.6 OUTLIER -28.38 159.58 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 113.76 -1.564 . . . . 0.0 112.28 179.095 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.519 ' CG ' ' O ' ' A' ' 28' ' ' LYS . 0.1 OUTLIER 179.37 101.91 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.739 0 CA-C-O 121.881 0.848 . . . . 0.0 112.19 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.8 101.52 0.8 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 176.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.33 153.57 24.53 Favored 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 116.528 -2.069 . . . . 0.0 111.035 -175.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.54 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -142.55 111.93 2.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 111.674 -2.512 . . . . 0.0 107.869 -173.449 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 7.8 mt -109.32 107.7 23.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -126.27 102.62 0.65 Allowed Glycine 0 CA--C 1.508 -0.4 0 N-CA-C 107.074 -2.411 . . . . 0.0 107.074 178.285 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 mt -138.36 149.12 45.27 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 122.666 1.222 . . . . 0.0 113.76 -177.135 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.428 ' SD ' ' HA3' ' H' ' 33' ' ' GLY . 97.7 mmm -109.65 107.25 17.24 Favored 'General case' 0 CA--C 1.498 -1.043 0 CA-C-N 112.684 -2.053 . . . . 0.0 106.507 175.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -98.04 71.91 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.76 102.73 2.4 Favored Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.08 146.62 14.01 Favored Glycine 0 CA--C 1.526 0.781 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.463 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.4 p -144.59 144.35 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.778 0.323 . . . . 0.0 110.649 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.102 -0.952 . . . . 0.0 110.537 179.967 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . 0.499 ' CZ ' ' OH ' ' D' ' 10' ' ' TYR . 65.7 m-85 -118.62 140.88 49.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -61.57 134.11 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.572 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 4.6 p -143.13 143.89 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.904 -179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -124.77 146.67 49.09 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 120.487 0.184 . . . . 0.0 110.661 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.528 ' O ' ' NE2' ' B' ' 15' ' ' GLN . 98.5 m-70 -153.89 162.07 41.51 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.589 0.709 . . . . 0.0 110.842 178.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.5 mm-40 -158.16 174.21 15.54 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.476 177.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -157.85 125.57 5.26 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 52.9 tp -130.99 122.58 27.09 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.993 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.44 133.06 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.899 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -131.06 130.07 42.76 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.391 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -132.23 125.73 31.81 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.288 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.38 125.97 45.96 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -168.37 117.76 0.74 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 178.525 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -148.35 106.93 3.78 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -28.74 140.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-N 114.998 -1.001 . . . . 0.0 113.077 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.25 -80.83 0.1 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' B' ' 27' ' ' ASN . 2.9 p 170.29 170.78 0.06 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' B' ' 26' ' ' SER . 52.4 p30 -18.0 158.16 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 O-C-N 124.593 1.183 . . . . 0.0 113.194 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.426 ' H ' ' CB ' ' C' ' 26' ' ' SER . 0.0 OUTLIER -161.78 110.71 1.51 Allowed 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 119.506 -0.877 . . . . 0.0 112.573 176.249 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.97 95.14 0.39 Allowed Glycine 0 CA--C 1.482 -1.988 0 N-CA-C 104.897 -3.281 . . . . 0.0 104.897 176.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 161.73 14.18 Favored 'General case' 0 CA--C 1.483 -1.623 0 C-N-CA 116.293 -2.163 . . . . 0.0 108.608 -175.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.423 ' O ' ' HE2' ' H' ' 35' ' ' MET . 0.0 OUTLIER -145.31 127.64 9.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 112.572 -2.104 . . . . 0.0 108.14 -173.74 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.444 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.6 OUTLIER -121.59 115.99 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 CA-C-O 121.044 0.45 . . . . 0.0 109.993 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.57 99.74 0.63 Allowed Glycine 0 N--CA 1.462 0.368 0 N-CA-C 105.622 -2.991 . . . . 0.0 105.622 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 75.1 mt -124.94 137.91 54.25 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.328 1.061 . . . . 0.0 112.903 -175.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.549 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.3 ttm -119.38 115.08 23.36 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 114.012 -1.449 . . . . 0.0 107.604 178.192 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.472 ' O ' ' CG1' ' B' ' 36' ' ' VAL . 3.3 p -126.84 66.88 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -54.65 -102.57 0.01 OUTLIER Glycine 0 C--N 1.357 1.726 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.55 152.55 15.91 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -130.88 135.62 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.833 0.349 . . . . 0.0 110.189 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.206 179.502 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -112.01 133.17 54.35 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.953 0.406 . . . . 0.0 110.749 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -87.15 136.9 32.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.047 179.599 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.3 t -116.82 130.59 71.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' D' ' 13' ' ' HIS . 51.3 p-80 -161.87 141.74 10.13 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.618 -0.833 . . . . 0.0 112.085 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.51 ' H ' ' CE1' ' B' ' 14' ' ' HIS . 17.1 m80 -121.39 163.21 19.08 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.413 ' CG ' ' N ' ' C' ' 16' ' ' LYS . 57.1 tt0 -168.62 169.23 10.37 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . 0.413 ' N ' ' CG ' ' C' ' 15' ' ' GLN . 62.8 pttt -158.61 132.91 7.94 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.877 0.846 . . . . 0.0 111.396 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 tt -120.31 125.23 47.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.279 -1.328 . . . . 0.0 108.01 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 20.5 t -127.47 123.3 61.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.187 0.518 . . . . 0.0 112.133 -178.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CB ' ' CE1' ' D' ' 19' ' ' PHE . 2.1 m-85 -112.95 110.6 20.77 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.494 ' CE2' ' CD2' ' D' ' 20' ' ' PHE . 7.4 t80 -116.25 118.11 31.87 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.228 -178.428 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.56 129.33 55.28 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 121.038 0.447 . . . . 0.0 111.469 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -158.56 101.85 1.69 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.972 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' D' ' 24' ' ' VAL . 17.8 m-20 -127.5 -134.62 0.24 Allowed 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.4 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' C' ' 26' ' ' SER . 12.7 t -90.55 112.49 25.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.396 -0.522 . . . . 0.0 111.336 179.538 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.6 91.69 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 177.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.525 ' N ' ' O ' ' C' ' 24' ' ' VAL . 4.5 p -65.16 -173.93 0.14 Allowed 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -78.64 171.78 14.65 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.957 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.485 ' NZ ' ' CB ' ' D' ' 28' ' ' LYS 0.454 5.1 tttp -45.43 114.19 0.71 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 179.317 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.12 91.5 2.02 Favored Glycine 0 CA--C 1.489 -1.535 0 C-N-CA 126.363 1.935 . . . . 0.0 116.727 -178.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -100.43 173.36 6.61 Favored 'General case' 0 N--CA 1.42 -1.961 1 N-CA-C 99.988 -4.079 . . . . 0.0 99.988 166.663 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.26 111.4 3.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 117.923 -1.511 . . . . 0.0 111.44 -177.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.596 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.0 OUTLIER -108.97 121.87 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.493 178.492 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -128.43 119.47 3.08 Favored Glycine 0 C--O 1.237 0.335 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.414 ' CD1' ' CZ ' ' D' ' 19' ' ' PHE . 3.6 tt -142.61 142.88 32.19 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 122.481 1.134 . . . . 0.0 112.935 -177.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.408 ' CE ' ' SD ' ' D' ' 35' ' ' MET . 0.1 OUTLIER -113.89 118.26 33.71 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.909 178.907 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.04 73.83 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.49 106.05 3.14 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 111.196 -0.761 . . . . 0.0 111.196 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.51 161.08 20.47 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -130.66 135.75 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.75 0.309 . . . . 0.0 110.641 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.598 179.377 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . 0.499 ' OH ' ' CZ ' ' B' ' 10' ' ' TYR . 85.3 m-85 -107.08 133.65 51.39 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.894 0.378 . . . . 0.0 110.48 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 79.6 tt0 -150.1 133.0 16.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.701 -179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m -99.65 166.34 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.076 179.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.501 ' CD2' ' CD2' ' C' ' 14' ' ' HIS . 46.7 t60 -153.84 148.93 26.84 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.227 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -99.79 -178.68 3.94 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.337 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 44.0 tt0 -84.55 167.91 15.88 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.716 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.502 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 95.5 mttt -119.86 139.23 52.7 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.6 mt -122.52 121.99 37.84 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.544 0.211 . . . . 0.0 110.462 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -129.84 128.02 64.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.092 0.472 . . . . 0.0 111.586 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.488 ' CE1' ' CB ' ' C' ' 19' ' ' PHE . 7.9 m-85 -122.86 119.8 31.6 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.065 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 13.7 t80 -112.87 118.67 35.55 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.75 111.59 22.87 Favored 'General case' 0 C--O 1.251 1.184 0 CA-C-O 122.552 1.168 . . . . 0.0 111.92 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.436 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 66.4 tt0 -139.31 178.25 7.33 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.48 ' O ' ' C ' ' D' ' 24' ' ' VAL . 19.8 p30 -179.93 126.13 0.08 Allowed 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.395 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.566 ' N ' ' O ' ' C' ' 23' ' ' ASP . 57.8 t -41.2 115.26 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-O 122.563 1.173 . . . . 0.0 108.094 -176.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.53 92.55 1.17 Allowed Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 105.336 -3.106 . . . . 0.0 105.336 -174.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.481 ' O ' ' CB ' ' D' ' 27' ' ' ASN . 11.0 p -44.46 169.83 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.369 -0.415 . . . . 0.0 110.872 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.533 ' CG ' ' N ' ' D' ' 28' ' ' LYS . 5.4 t-20 156.72 162.04 0.01 OUTLIER 'General case' 0 CA--C 1.561 1.377 0 CA-C-O 124.34 2.019 . . . . 0.0 114.669 174.541 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.585 ' N ' ' OD1' ' E' ' 23' ' ' ASP 0.827 13.5 tttt -29.6 112.08 0.07 Allowed 'General case' 0 C--N 1.323 -0.584 1 N-CA-C 127.623 6.157 . . . . 0.0 127.623 177.18 . . . . . . . . 4 3 . 1 . 005 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.07 100.16 1.6 Allowed Glycine 0 CA--C 1.461 -3.309 2 N-CA-C 100.274 -5.13 . . . . 0.0 100.274 176.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.448 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . -73.6 -128.78 0.01 OUTLIER 'General case' 1 N--CA 1.348 -5.569 4 CA-C-N 100.45 -7.875 . . . . 0.0 100.162 -174.909 . . . . . . . . 4 3 . 1 . 005 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.777 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 1.2 mp -76.78 113.87 16.4 Favored 'Isoleucine or valine' 0 C--N 1.255 -3.509 0 CA-C-N 123.247 2.749 . . . . 0.0 113.913 -174.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.482 ' O ' ' CG2' ' D' ' 32' ' ' ILE . 2.6 tt -121.32 112.65 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 175.622 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.95 110.89 1.71 Allowed Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 178.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.412 HD23 ' H ' ' C' ' 34' ' ' LEU . 21.2 mt -133.5 132.94 41.59 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 119.408 -0.917 . . . . 0.0 112.493 -176.916 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.502 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.9 ttm -109.78 126.64 53.98 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.153 178.187 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.2 t -121.41 79.27 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 CA-C-N 116.671 -0.241 . . . . 0.0 110.989 -178.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -44.34 103.18 0.04 OUTLIER Glycine 0 C--N 1.357 1.72 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 177.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.12 -166.63 29.05 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -122.47 136.21 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 121.021 0.439 . . . . 0.0 110.35 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.2 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.953 -1.023 . . . . 0.0 110.419 179.94 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . 0.419 ' O ' ' O ' ' D' ' 10' ' ' TYR . 98.8 m-85 -114.1 134.71 54.7 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.913 0.387 . . . . 0.0 110.807 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -119.34 148.13 43.53 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.311 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . 0.468 ' CG1' ' CE1' ' E' ' 14' ' ' HIS . 72.8 t -123.79 134.09 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.176 0.512 . . . . 0.0 110.398 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -118.99 101.99 8.43 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.118 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.468 ' CE1' ' CG1' ' E' ' 12' ' ' VAL . 50.6 m170 -130.02 169.1 15.71 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-O 121.609 0.718 . . . . 0.0 110.264 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -149.22 174.73 12.06 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.632 -1.167 . . . . 0.0 108.314 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -154.34 112.02 3.47 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.493 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.8 tp -121.45 117.1 26.03 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -130.93 127.76 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.459 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -118.53 115.98 25.71 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.06 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 36.1 t80 -114.98 122.88 47.61 Favored 'General case' 0 N--CA 1.471 0.609 0 O-C-N 122.385 -0.197 . . . . 0.0 111.171 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.56 132.72 42.87 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.999 -0.28 . . . . 0.0 110.633 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.14 136.64 39.73 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.615 -0.834 . . . . 0.0 112.94 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.585 ' OD1' ' N ' ' D' ' 28' ' ' LYS . 46.3 t0 -138.1 131.47 30.59 Favored 'General case' 0 C--N 1.368 1.382 0 CA-C-O 121.353 0.597 . . . . 0.0 112.559 178.201 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.416 ' CG2' ' OG ' ' D' ' 26' ' ' SER . 37.8 t -111.44 113.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.606 177.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . 32.74 88.77 0.01 OUTLIER Glycine 0 CA--C 1.534 1.258 0 CA-C-O 121.794 0.663 . . . . 0.0 112.297 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.491 ' OG ' ' OG ' ' F' ' 26' ' ' SER . 3.4 p -46.67 170.9 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.449 ' H ' ' NZ ' ' C' ' 28' ' ' LYS . 0.3 OUTLIER -129.14 -179.21 5.0 Favored 'General case' 0 CA--C 1.552 1.034 0 CA-C-N 112.94 -1.936 . . . . 0.0 107.996 173.775 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -29.58 107.88 0.04 OUTLIER 'General case' 0 CA--C 1.564 1.508 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 -177.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.439 ' O ' ' HA ' ' F' ' 30' ' ' ALA . . . 81.55 -96.62 1.77 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 118.129 2.011 . . . . 0.0 118.129 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.458 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . 75.28 149.56 0.1 Allowed 'General case' 0 C--O 1.252 1.219 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -175.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.458 ' CG1' ' C ' ' E' ' 30' ' ' ALA . 0.0 OUTLIER -154.33 122.82 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 117.147 -1.821 . . . . 0.0 110.442 -175.152 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 93.5 mt -121.58 127.13 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.255 -177.777 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.94 118.99 1.94 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 48.4 mt -123.87 123.64 40.89 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.807 -0.696 . . . . 0.0 109.951 -179.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -120.01 122.88 42.12 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.147 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 t -114.17 86.51 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.722 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.91 97.35 0.22 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.09 168.86 38.74 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.5 t -123.5 135.97 61.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.219 -0.532 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.385 -179.807 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -114.77 135.78 53.8 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.811 0.339 . . . . 0.0 110.779 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -85.6 159.86 19.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 81.1 t -94.78 133.68 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.194 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.658 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 p-80 -139.97 125.95 19.68 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.335 0.588 . . . . 0.0 110.722 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.65 ' CG ' ' H ' ' F' ' 15' ' ' GLN . 82.7 t60 -156.97 177.25 11.72 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.65 ' H ' ' CG ' ' F' ' 14' ' ' HIS . 86.9 mt-30 -144.21 173.87 11.38 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -148.94 112.43 5.02 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.277 0.561 . . . . 0.0 111.605 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -124.68 120.47 31.93 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -127.53 128.67 70.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-O 121.817 0.818 . . . . 0.0 112.704 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 8.7 m-85 -115.09 104.98 12.41 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.403 ' CE2' ' OE2' ' F' ' 22' ' ' GLU . 18.7 t80 -114.94 120.71 40.83 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 -177.932 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.27 129.54 33.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' CE2' ' F' ' 20' ' ' PHE . 73.5 mm-40 -92.6 92.4 8.0 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.507 -178.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 25.5 t0 -147.41 107.98 4.13 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 120.791 0.329 . . . . 0.0 111.5 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 m -77.49 -131.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.31 0.576 . . . . 0.0 110.147 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.15 85.44 0.01 OUTLIER Glycine 0 CA--C 1.528 0.879 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.927 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.491 ' OG ' ' OG ' ' E' ' 26' ' ' SER . 3.7 t -61.82 -178.39 0.15 Allowed 'General case' 0 N--CA 1.44 -0.95 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.417 ' N ' ' OG ' ' E' ' 26' ' ' SER . 59.5 t30 -80.16 172.78 13.32 Favored 'General case' 0 C--N 1.316 -0.866 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.228 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -45.45 110.73 0.27 Allowed 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.153 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.0 92.95 0.32 Allowed Glycine 0 N--CA 1.463 0.48 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.503 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.439 ' HA ' ' O ' ' E' ' 29' ' ' GLY . . . -120.84 162.5 19.71 Favored 'General case' 0 CA--C 1.489 -1.396 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 173.283 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.48 116.47 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 115.625 -2.43 . . . . 0.0 112.728 -175.903 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 tt -125.95 135.55 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.029 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.31 128.02 4.37 Favored Glycine 0 CA--C 1.531 1.043 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.022 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -119.66 124.37 46.13 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 0.4 OUTLIER -130.64 129.63 42.92 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.36 0.6 . . . . 0.0 112.363 -178.885 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.556 ' N ' ' SD ' ' F' ' 35' ' ' MET . 7.7 p -152.95 81.89 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.702 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.56 101.51 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.249 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -151.19 160.46 28.69 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 12.7 p -137.46 141.62 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 120.837 0.351 . . . . 0.0 110.907 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.629 179.747 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -113.69 135.94 53.38 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.897 0.379 . . . . 0.0 110.359 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 tp10 -68.69 135.85 51.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.135 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -144.49 151.06 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.476 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -130.87 122.02 26.29 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 121.132 0.492 . . . . 0.0 111.721 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 m-70 -145.48 164.58 31.16 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.408 ' HG3' ' N ' ' G' ' 16' ' ' LYS . 64.5 tp60 -164.9 165.17 20.59 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.242 178.758 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.408 ' N ' ' HG3' ' G' ' 15' ' ' GLN . 98.7 mttt -157.04 129.12 7.27 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -136.43 122.14 19.79 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.535 0.683 . . . . 0.0 110.999 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 71.4 t -123.44 129.55 74.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.566 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -128.81 134.89 48.51 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.803 0.335 . . . . 0.0 110.909 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 46.0 p90 -129.93 127.13 39.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.791 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.59 37.21 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 121.418 0.627 . . . . 0.0 111.372 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -174.48 98.72 0.09 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.545 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -152.63 114.7 4.4 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -28.99 122.55 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 113.9 -1.5 . . . . 0.0 113.358 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.44 -85.56 0.06 OUTLIER Glycine 0 CA--C 1.529 0.926 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.556 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.555 ' O ' ' O ' ' G' ' 27' ' ' ASN . 19.0 t -153.39 -173.59 4.63 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 119.462 1.631 . . . . 0.0 111.646 178.5 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.555 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.3 m-20 -20.52 156.57 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 113.58 -1.645 . . . . 0.0 112.903 177.873 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 58.5 tttm -168.44 102.83 0.43 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 118.732 -1.187 . . . . 0.0 113.739 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.43 ' O ' HG13 ' G' ' 31' ' ' ILE . . . -76.81 104.45 1.89 Allowed Glycine 0 CA--C 1.495 -1.205 0 CA-C-O 115.789 -2.673 . . . . 0.0 106.86 172.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.423 ' C ' HG13 ' G' ' 31' ' ' ILE . . . -74.75 143.15 44.23 Favored 'General case' 0 C--O 1.252 1.203 1 CA-C-N 124.22 4.01 . . . . 0.0 105.782 -178.126 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.43 HG13 ' O ' ' G' ' 29' ' ' GLY . 69.6 mt -156.75 115.29 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 112.883 -1.962 . . . . 0.0 108.509 -171.826 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.413 ' O ' ' HA ' ' H' ' 32' ' ' ILE . 10.4 tt -141.01 131.01 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.427 0 CA-C-O 122.683 1.23 . . . . 0.0 110.523 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -148.98 154.27 25.7 Favored Glycine 0 CA--C 1.484 -1.871 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 176.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -145.04 140.68 28.28 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.691 -179.183 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 25.6 ttp -103.48 106.81 17.42 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.862 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.48 65.28 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -131.45 102.55 0.51 Allowed Glycine 0 C--N 1.369 2.374 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.13 173.42 41.66 Favored Glycine 0 CA--C 1.523 0.587 0 C-N-CA 120.385 -0.912 . . . . 0.0 111.894 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -123.32 136.24 60.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 34.8 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.402 179.608 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -85.18 158.13 20.45 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -52.58 151.07 4.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.835 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.42 159.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.877 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -129.48 133.24 47.18 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.979 0.418 . . . . 0.0 111.948 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -140.9 163.81 31.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -157.59 177.5 11.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.355 0.598 . . . . 0.0 111.307 179.249 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 45.0 tttp -170.64 115.53 0.47 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.81 178.419 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . 0.501 ' N ' ' CD2' ' H' ' 17' ' ' LEU . 1.6 mm? -122.8 119.16 29.77 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 3.0 p -135.17 130.65 51.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.713 178.29 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -120.13 123.24 42.85 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.948 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.23 123.0 45.56 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.11 126.18 38.78 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.321 0.581 . . . . 0.0 110.48 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.419 ' O ' ' CG ' ' H' ' 23' ' ' ASP . 84.1 tt0 -138.94 131.12 28.2 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.146 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.2 m-20 -163.05 122.92 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.474 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.478 ' CG2' ' H ' ' H' ' 25' ' ' GLY . 7.1 m -93.51 -113.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.478 ' H ' ' CG2' ' H' ' 24' ' ' VAL . . . 42.74 -91.37 0.01 OUTLIER Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.068 -0.587 . . . . 0.0 114.086 176.064 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.446 ' N ' ' O ' ' H' ' 24' ' ' VAL . 25.6 p -73.58 170.74 14.56 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.587 1.184 . . . . 0.0 113.606 -174.547 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 23.3 m120 -46.97 179.97 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 112.597 -2.092 . . . . 0.0 113.564 -176.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 82.4 tttt -119.29 -110.25 0.35 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 114.16 -1.382 . . . . 0.0 112.0 -176.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 47.61 92.44 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.163 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -178.012 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.04 159.59 15.94 Favored 'General case' 0 C--O 1.25 1.118 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.266 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -138.7 124.99 24.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 113.084 -1.871 . . . . 0.0 111.55 -178.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.549 ' N ' ' SD ' ' B' ' 35' ' ' MET . 0.7 OUTLIER -114.52 117.29 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.195 178.054 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.428 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -118.38 109.3 1.75 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.4 ' CD2' ' CE1' ' J' ' 19' ' ' PHE . 15.5 mt -118.36 122.73 43.55 Favored 'General case' 0 CA--C 1.49 -1.333 0 N-CA-C 112.848 0.684 . . . . 0.0 112.848 -175.393 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.423 ' HE2' ' O ' ' B' ' 31' ' ' ILE . 2.1 ttm -114.56 106.1 13.87 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.495 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.63 71.81 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.402 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.23 111.72 3.71 Favored Glycine 0 C--N 1.365 2.148 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -45.37 160.18 0.17 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 40' ' ' VAL . 3.3 p -140.5 141.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.702 0.287 . . . . 0.0 110.314 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 39' ' ' VAL . 84.5 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.955 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -113.86 138.68 49.97 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -140.14 159.26 42.59 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.27 0.557 . . . . 0.0 111.445 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 75.1 t -121.69 131.74 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.018 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -147.16 121.85 9.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.823 -179.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 87.7 m-70 -134.94 161.82 34.18 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -153.78 166.96 31.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.511 0.672 . . . . 0.0 111.576 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -156.91 127.32 6.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.352 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -128.8 125.73 38.4 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -128.86 126.82 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 116.691 -0.232 . . . . 0.0 111.189 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.615 ' CD1' ' CE1' ' J' ' 19' ' ' PHE . 31.4 m-85 -115.17 107.37 15.21 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -108.25 122.74 47.58 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 118.274 0.488 . . . . 0.0 110.795 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 138.93 34.44 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -152.29 121.87 6.88 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-O 118.972 -0.537 . . . . 0.0 111.752 -179.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.589 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 63.7 m-20 -151.42 103.74 3.02 Favored 'General case' 0 C--N 1.362 1.115 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 176.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 59.8 t -31.87 142.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.616 1.567 . . . . 0.0 114.215 170.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -81.75 0.1 Allowed Glycine 0 CA--C 1.533 1.16 0 C-N-CA 119.187 -1.482 . . . . 0.0 114.779 174.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.54 ' O ' ' O ' ' I' ' 27' ' ' ASN . 91.5 p -132.61 -179.21 5.32 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.603 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 46.5 t-20 -40.23 167.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.603 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 70.7 tttt -72.3 110.6 6.84 Favored 'General case' 0 C--N 1.344 0.337 0 C-N-CA 114.268 -2.973 . . . . 0.0 111.316 178.286 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.68 94.69 1.66 Allowed Glycine 0 CA--C 1.491 -1.433 0 CA-C-O 115.406 -2.885 . . . . 0.0 106.399 167.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.14 142.29 49.43 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 123.892 3.846 . . . . 0.0 109.0 177.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.19 120.32 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 CA-C-N 111.54 -2.573 . . . . 0.0 109.261 -176.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.408 HD13 HG23 ' I' ' 32' ' ' ILE . 0.8 OUTLIER -110.53 114.27 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 121.333 0.587 . . . . 0.0 110.19 178.968 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.52 96.94 1.31 Allowed Glycine 0 CA--C 1.496 -1.099 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.437 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 31.9 tp -111.88 122.93 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -175.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.1 ttp -121.57 114.77 21.67 Favored 'General case' 0 CA--C 1.512 -0.514 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . 0.459 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -131.89 72.22 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.284 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -37.77 -98.49 0.01 OUTLIER Glycine 0 C--N 1.358 1.765 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.07 -167.33 39.21 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -123.44 135.6 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.938 0.399 . . . . 0.0 110.405 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 28.5 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.448 179.971 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -129.26 141.34 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -88.01 130.32 35.0 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.047 0.451 . . . . 0.0 110.151 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -137.09 144.46 31.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.35 0.595 . . . . 0.0 110.796 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 12.0 t-80 -148.85 132.39 16.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.0 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.699 ' CD2' ' H ' ' J' ' 15' ' ' GLN . 11.3 t-80 -156.17 165.69 35.67 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.541 0.686 . . . . 0.0 109.523 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.699 ' H ' ' CD2' ' J' ' 14' ' ' HIS . 48.4 tt0 -165.0 168.89 17.01 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . 0.474 ' N ' ' CG ' ' J' ' 15' ' ' GLN . 88.5 tttt -153.7 132.63 12.45 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.449 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.43 127.23 47.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -126.08 127.93 71.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.834 0.35 . . . . 0.0 110.884 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.615 ' CE1' ' CD1' ' I' ' 19' ' ' PHE . 97.3 m-85 -113.52 109.56 18.84 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -120.03 122.83 41.98 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.733 0.271 . . . . 0.0 111.733 -176.91 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.22 132.21 41.23 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.498 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.583 ' OE2' ' CD1' ' J' ' 20' ' ' PHE . 18.6 mp0 -140.52 145.85 37.37 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 120.19 -0.604 . . . . 0.0 112.36 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 15.3 m-20 -167.33 124.24 1.18 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.5 0.666 . . . . 0.0 111.903 178.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.649 ' CG1' ' H ' ' J' ' 25' ' ' GLY . 7.1 p -62.93 -116.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.762 -1.108 . . . . 0.0 110.834 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.649 ' H ' ' CG1' ' J' ' 24' ' ' VAL . . . 60.72 -91.79 0.06 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 114.976 -1.011 . . . . 0.0 114.42 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.83 ' O ' ' O ' ' J' ' 27' ' ' ASN . 35.1 p -171.63 172.52 4.97 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 118.173 0.986 . . . . 0.0 110.834 -176.921 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.83 ' O ' ' O ' ' J' ' 26' ' ' SER . 80.3 m-20 15.58 -178.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 O-C-N 125.627 1.83 . . . . 0.0 114.738 -179.486 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.544 ' CA ' ' OD1' ' I' ' 27' ' ' ASN 0.255 80.4 tttt -148.49 109.92 4.41 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 118.359 -1.336 . . . . 0.0 113.906 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -73.73 94.13 0.75 Allowed Glycine 0 CA--C 1.489 -1.551 0 CA-C-O 116.172 -2.46 . . . . 0.0 107.683 169.782 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.48 146.52 50.79 Favored 'General case' 0 CA--C 1.481 -1.709 0 CA-C-N 123.116 3.458 . . . . 0.0 110.587 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.71 109.36 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 CA-C-N 110.906 -2.861 . . . . 0.0 105.629 -178.141 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.502 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.1 tt -109.7 113.38 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 121.773 0.797 . . . . 0.0 108.9 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . 0.461 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -102.49 107.73 3.18 Favored Glycine 0 CA--C 1.507 -0.442 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . . . . . . . . . 6.4 mt -110.62 111.36 22.53 Favored 'General case' 0 CA--C 1.507 -0.677 0 CA-C-O 121.247 0.546 . . . . 0.0 110.748 -177.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.596 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 18.9 ttt -110.28 110.34 21.12 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 5.9 m -133.83 74.88 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.229 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.27 102.21 2.85 Favored Glycine 0 C--N 1.35 1.357 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -152.86 157.1 27.1 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -136.95 146.75 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.795 0.331 . . . . 0.0 110.362 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 t . . . . . 0 C--O 1.221 -0.426 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.57 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -105.29 137.63 42.77 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -156.22 129.81 8.32 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.773 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.42 133.8 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.776 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 -128.16 121.58 29.87 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.51 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' NE2' ' L' ' 14' ' ' HIS . 96.6 m-70 -122.59 169.38 11.08 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.37 0.605 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 66.4 tp60 -155.36 169.98 22.97 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.164 179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -172.61 125.32 0.48 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.553 0.216 . . . . 0.0 110.503 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -128.69 129.34 45.66 Favored 'General case' 0 N--CA 1.466 0.374 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.079 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 40.6 t -132.12 133.55 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.067 0.46 . . . . 0.0 111.504 -179.531 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.437 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 37.7 m-85 -114.58 111.73 21.81 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.601 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 54.8 m-85 -109.13 114.43 28.15 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.353 -0.217 . . . . 0.0 111.252 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.32 121.27 38.27 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.958 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -121.68 130.87 53.77 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.145 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 16.4 p-10 179.25 102.25 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 114.936 -1.029 . . . . 0.0 109.415 176.93 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.423 ' CG2' ' N ' ' K' ' 25' ' ' GLY . 12.9 p -58.82 166.29 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.133 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.423 ' N ' ' CG2' ' K' ' 24' ' ' VAL . . . 88.23 81.6 1.26 Allowed Glycine 0 CA--C 1.53 0.969 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.463 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 34.0 p -47.9 166.78 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.611 ' ND2' ' ND2' ' J' ' 27' ' ' ASN . 9.6 t-20 -157.2 177.38 11.54 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.033 -0.667 . . . . 0.0 112.68 177.576 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.562 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 67.3 mmtt 2.31 -105.32 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.358 1.063 . . . . 0.0 113.265 178.626 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -140.92 97.66 0.22 Allowed Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.94 170.32 4.44 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -152.18 126.37 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 117.998 -1.481 . . . . 0.0 111.442 -178.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 96.6 mt -126.14 132.64 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.603 -178.416 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.76 116.34 2.97 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 12.6 mt -107.22 111.25 23.56 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.456 ' SD ' ' C ' ' K' ' 35' ' ' MET . 0.0 OUTLIER -113.03 111.99 23.12 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 -178.943 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.09 81.79 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.16 100.88 1.8 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 178.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.82 161.43 34.97 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.644 -0.788 . . . . 0.0 111.455 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.9 m -139.28 162.47 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-O 120.763 0.316 . . . . 0.0 110.558 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.4 179.77 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . 0.441 ' H ' ' H ' ' L' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . 0.441 ' H ' ' H ' ' L' ' 9' ' ' GLY . 97.1 m-85 -120.74 140.85 51.07 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.883 0.373 . . . . 0.0 110.615 -179.747 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -59.19 141.3 54.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.4 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 7.9 m -121.62 133.74 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 121.255 0.55 . . . . 0.0 110.876 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 69.5 t60 -140.14 125.14 18.5 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.415 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' ND1' ' K' ' 14' ' ' HIS . 23.6 p80 -157.38 170.97 21.24 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -148.75 174.2 12.44 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.48 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -152.86 139.5 18.81 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.457 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -134.34 122.38 22.54 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -126.12 132.82 70.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-O 121.079 0.466 . . . . 0.0 111.755 -178.523 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -112.62 112.01 23.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.565 178.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -120.73 119.45 32.82 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.31 0.576 . . . . 0.0 110.715 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.44 128.62 47.27 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' L' ' 22' ' ' GLU . 11.3 tm-20 -78.59 96.51 5.5 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.188 -178.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -152.55 113.57 4.19 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 31.9 m -98.62 130.51 47.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.281 -179.467 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.0 81.74 0.03 OUTLIER Glycine 0 C--N 1.336 0.581 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.748 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -62.16 -178.15 0.16 Allowed 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.773 0.797 . . . . 0.0 110.459 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.473 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 7.9 t-20 -80.63 178.46 8.33 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.393 -1.276 . . . . 0.0 112.449 -178.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.473 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 65.0 mttp -41.44 111.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.088 -0.96 . . . . 0.0 112.059 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . 0.446 ' O ' ' CB ' ' L' ' 30' ' ' ALA . . . 83.71 -93.71 1.76 Allowed Glycine 0 N--CA 1.463 0.474 0 CA-C-N 113.951 -1.477 . . . . 0.0 112.982 179.513 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.48 ' C ' ' CG1' ' L' ' 31' ' ' ILE . . . 78.26 161.48 0.21 Allowed 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 100.636 -3.838 . . . . 0.0 100.636 -174.477 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.48 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -154.09 127.54 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 122.665 2.484 . . . . 0.0 111.961 -179.11 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 48.5 pt -122.64 141.54 42.63 Favored 'Isoleucine or valine' 0 C--N 1.339 0.134 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.063 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.88 121.21 3.33 Favored Glycine 0 N--CA 1.465 0.621 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.4 tp -124.42 123.02 39.26 Favored 'General case' 0 N--CA 1.465 0.278 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.578 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.1 ppp? -131.67 136.05 47.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.475 0.655 . . . . 0.0 110.651 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 37' ' ' GLY . 5.5 t -138.18 80.74 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.691 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.444 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 26.47 -104.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.09 0 O-C-N 123.419 0.45 . . . . 0.0 112.65 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 134.03 147.48 5.65 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -140.98 164.23 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.754 0.312 . . . . 0.0 110.734 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 28.4 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.379 179.891 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -114.63 139.67 49.44 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.769 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -128.99 160.75 31.73 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.018 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.54 148.49 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 116.278 -0.419 . . . . 0.0 109.898 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -77.82 162.96 26.5 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.036 -178.514 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.554 ' ND1' ' N ' ' A' ' 14' ' ' HIS . 1.4 m-70 -104.12 172.98 6.5 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.167 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 51.6 tt0 -151.11 173.03 14.85 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.006 179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -155.25 132.39 10.9 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.666 0.27 . . . . 0.0 110.492 -179.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 52.1 tp -131.96 126.66 34.58 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 121.194 0.521 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.2 m -128.17 132.83 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.767 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -135.14 131.23 36.57 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.973 0.416 . . . . 0.0 111.193 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -119.63 126.07 50.28 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.8 132.51 45.3 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.968 0.889 . . . . 0.0 112.647 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -140.77 96.44 3.02 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.592 -1.185 . . . . 0.0 109.217 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.433 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 2.1 m-20 -59.81 143.53 50.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.54 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.72 110.65 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 122.126 0.965 . . . . 0.0 108.465 -178.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.53 -92.7 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 113.452 -1.704 . . . . 0.0 113.16 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.7 t 61.66 179.33 0.12 Allowed 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' A' ' 28' ' ' LYS . 65.4 t30 -82.0 178.31 8.36 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 173.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.655 ' HZ3' ' HG ' ' B' ' 26' ' ' SER . 45.3 tttp -49.01 -110.98 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.774 0 CA-C-N 119.62 1.1 . . . . 0.0 110.508 176.273 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 59.63 92.09 0.01 OUTLIER Glycine 0 C--N 1.346 1.114 0 CA-C-O 118.089 -1.395 . . . . 0.0 114.766 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.06 142.2 40.3 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 116.645 -2.022 . . . . 0.0 109.227 174.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.418 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.9 OUTLIER -155.67 128.55 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 CA-C-N 111.603 -2.544 . . . . 0.0 109.499 -173.181 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' H' ' 35' ' ' MET . 24.4 mt -126.62 107.92 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.032 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.01 102.32 1.36 Allowed Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.021 -2.832 . . . . 0.0 106.021 177.379 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 75.7 mt -133.95 150.21 51.28 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 122.529 1.157 . . . . 0.0 112.802 -177.135 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 15.7 ttm -128.87 118.22 22.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 CA-C-N 113.048 -1.887 . . . . 0.0 107.14 177.962 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -109.01 71.03 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.066 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.158 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -37.54 -100.36 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.28 -171.76 40.68 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -122.3 135.97 60.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.01 0.433 . . . . 0.0 110.6 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.773 -179.796 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.68 144.13 42.7 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.488 ' O ' ' NE2' ' C' ' 13' ' ' HIS . 96.3 mt-10 -61.96 129.9 43.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.98 0.419 . . . . 0.0 110.969 -179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.7 132.56 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.991 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -157.08 170.12 23.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.16 0.505 . . . . 0.0 111.382 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -134.14 169.56 16.98 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -155.01 165.0 38.1 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.128 179.003 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -156.28 113.5 3.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.163 179.377 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.7 tp -118.79 121.03 39.09 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -125.56 124.3 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 110.575 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -121.79 119.02 30.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.06 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -120.19 120.0 34.87 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 126.92 35.49 Favored 'General case' 0 N--CA 1.474 0.753 0 CA-C-O 121.368 0.604 . . . . 0.0 111.684 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -153.26 145.1 23.55 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.561 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.445 ' O ' ' C ' ' B' ' 24' ' ' VAL . 18.7 t70 -146.5 115.28 6.86 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.2 178.802 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.445 ' C ' ' O ' ' B' ' 23' ' ' ASP . 2.8 t 25.75 -124.1 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.594 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.22 83.18 0.16 Allowed Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 178.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.655 ' HG ' ' HZ3' ' A' ' 28' ' ' LYS . 4.9 p -93.49 179.95 5.23 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.579 ' O ' ' NZ ' ' A' ' 28' ' ' LYS . 77.3 m-20 -59.6 -176.61 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.379 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.565 ' O ' ' CE ' ' A' ' 28' ' ' LYS . 13.8 tttp -63.22 -113.35 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.449 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 45.27 90.88 0.01 OUTLIER Glycine 0 N--CA 1.479 1.518 0 N-CA-C 114.064 0.386 . . . . 0.0 114.064 176.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.646 ' H ' ' HB1' ' C' ' 30' ' ' ALA . . . -140.03 151.39 45.4 Favored 'General case' 0 N--CA 1.425 -1.699 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 172.364 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.418 ' O ' ' HA ' ' A' ' 31' ' ' ILE . 1.6 mt -137.63 105.09 3.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 118.672 -1.211 . . . . 0.0 108.262 -174.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.513 ' O ' ' SD ' ' I' ' 35' ' ' MET . 12.4 tt -126.18 123.59 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 118.984 -1.086 . . . . 0.0 112.211 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.601 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -114.9 104.94 1.42 Allowed Glycine 0 CA--C 1.503 -0.684 0 N-CA-C 106.975 -2.45 . . . . 0.0 106.975 177.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -122.62 125.94 46.67 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 122.605 1.193 . . . . 0.0 110.639 -179.027 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.536 ' SD ' ' CA ' ' H' ' 33' ' ' GLY . 1.3 ttm -112.31 119.77 39.45 Favored 'General case' 0 N--CA 1.438 -1.068 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.538 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -123.31 70.95 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.875 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.635 -179.874 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -45.14 -99.06 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 178.771 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 138.02 165.47 10.35 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -135.41 161.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.644 -179.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -116.08 144.28 44.35 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -73.35 137.1 44.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.436 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 m -140.12 177.63 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.374 -178.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.488 ' NE2' ' O ' ' B' ' 11' ' ' GLU . 77.7 m80 -78.26 128.27 33.48 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.294 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.578 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 60.0 t-80 -151.64 163.88 38.12 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.578 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 80.9 mt-30 -157.43 175.58 13.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.284 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.46 115.7 0.49 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.069 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -120.03 125.58 48.7 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.889 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -131.65 124.68 54.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.43 112.85 22.92 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 175.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -118.6 130.4 55.86 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 -178.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . 0.494 ' CB ' ' OG ' ' C' ' 26' ' ' SER . . . -162.13 160.48 27.31 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 115.786 1.772 . . . . 0.0 115.786 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -118.1 118.74 32.72 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 113.695 -1.593 . . . . 0.0 111.059 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.563 ' CG ' ' H ' ' C' ' 24' ' ' VAL . 47.9 t0 49.61 -123.41 1.91 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.801 0.81 . . . . 0.0 112.086 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.563 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 12.1 t -30.96 112.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 114.153 -1.385 . . . . 0.0 114.121 -176.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.92 -93.33 0.71 Allowed Glycine 0 CA--C 1.53 0.98 0 CA-C-N 113.729 -1.578 . . . . 0.0 114.091 175.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.494 ' OG ' ' CB ' ' C' ' 21' ' ' ALA . 0.0 OUTLIER -80.36 172.0 14.33 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.243 1.02 . . . . 0.0 113.662 -178.47 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.553 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 37.5 t30 83.08 -178.82 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 112.399 -2.182 . . . . 0.0 113.673 176.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.553 ' H ' ' CG ' ' C' ' 27' ' ' ASN . 34.7 mtmt -38.65 -101.5 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 113.671 -1.604 . . . . 0.0 109.463 175.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 81.39 -110.58 3.18 Favored Glycine 0 CA--C 1.453 -3.819 0 CA-C-O 125.317 2.621 . . . . 0.0 116.097 176.343 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . 0.646 ' HB1' ' H ' ' B' ' 30' ' ' ALA . . . -88.37 -130.87 0.07 Allowed 'General case' 2 N--CA 1.357 -5.093 2 N-CA-C 95.377 -5.786 . . . . 0.0 95.377 171.373 . . . . . . . . 4 3 . 1 . 006 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.47 HD13 ' HB ' ' D' ' 31' ' ' ILE . 7.8 tp -87.91 135.61 25.08 Favored 'Isoleucine or valine' 1 C--N 1.232 -4.504 0 N-CA-C 114.345 1.239 . . . . 0.0 114.345 -179.109 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.488 ' O ' ' CE ' ' J' ' 35' ' ' MET . 8.1 tt -120.77 112.98 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 175.609 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.4 ' C ' ' CD1' ' C' ' 34' ' ' LEU . . . -122.36 122.84 5.21 Favored Glycine 0 CA--C 1.504 -0.636 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.447 -178.546 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.583 ' CD2' ' CZ ' ' D' ' 19' ' ' PHE . 6.6 mp -143.78 146.25 32.97 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 118.694 -1.202 . . . . 0.0 112.041 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.59 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 3.4 ttm -121.11 121.95 38.98 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 113.286 -1.779 . . . . 0.0 108.704 177.665 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.93 76.9 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.106 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -83.12 104.09 2.55 Favored Glycine 0 C--N 1.361 1.957 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.08 170.68 51.39 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.9 m -140.61 162.77 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 120.815 0.341 . . . . 0.0 110.756 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.428 179.676 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -91.77 135.34 33.98 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.83 0.348 . . . . 0.0 110.542 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -83.05 131.01 35.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.311 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -140.58 139.06 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-O 121.275 0.559 . . . . 0.0 110.889 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -132.87 138.71 47.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 29.3 t-80 -144.9 166.11 26.23 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 121.408 0.623 . . . . 0.0 110.083 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.552 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 52.7 tt0 -160.23 171.26 19.52 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.39 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.419 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 86.8 tttt -169.96 118.25 0.59 Allowed 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.452 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 tt -128.63 127.03 41.42 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -142.42 138.1 29.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.8 0.809 . . . . 0.0 113.095 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.583 ' CZ ' ' CD2' ' C' ' 34' ' ' LEU . 38.0 m-85 -113.36 117.94 33.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.036 177.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.566 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 22.6 t80 -127.59 124.55 38.38 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.745 0.307 . . . . 0.0 110.654 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . 0.465 ' CB ' ' O ' ' C' ' 21' ' ' ALA . . . -158.14 164.72 36.32 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.724 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -137.59 157.01 47.42 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.333 -1.303 . . . . 0.0 112.381 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -141.77 142.12 33.23 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 7.3 p -90.88 112.68 25.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 122.712 1.244 . . . . 0.0 110.015 -177.09 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 41.29 86.83 0.01 OUTLIER Glycine 0 CA--C 1.525 0.696 0 CA-C-N 112.976 -1.92 . . . . 0.0 113.01 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.585 ' N ' ' O ' ' E' ' 24' ' ' VAL . 36.8 t -140.55 170.14 16.34 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 117.218 0.509 . . . . 0.0 109.71 175.892 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.52 ' O ' ' O ' ' D' ' 26' ' ' SER . 4.5 m-20 -31.55 173.79 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 178.296 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.529 ' O ' ' CB ' ' E' ' 30' ' ' ALA . 87.9 tttt -86.33 112.1 21.1 Favored 'General case' 0 C--O 1.209 -1.073 0 CA-C-N 114.477 -1.238 . . . . 0.0 107.905 171.849 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.56 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 73.24 -93.39 0.69 Allowed Glycine 1 CA--C 1.446 -4.246 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.994 179.125 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.64 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . 113.55 -150.12 0.0 OUTLIER 'General case' 0 N--CA 1.385 -3.718 1 N-CA-C 93.74 -6.393 . . . . 0.0 93.74 -168.681 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.708 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 3.1 mp -103.42 122.51 56.08 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.134 0 C-N-CA 116.517 -2.073 . . . . 0.0 113.116 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -113.36 118.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.897 179.107 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.46 ' N ' ' CE ' ' J' ' 35' ' ' MET . . . -131.9 101.75 0.48 Allowed Glycine 0 N--CA 1.472 1.075 0 N-CA-C 106.792 -2.523 . . . . 0.0 106.792 177.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 10.0 mt -130.64 125.63 34.52 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-O 122.187 0.994 . . . . 0.0 111.793 -175.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -105.54 117.6 34.42 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 113.983 -1.462 . . . . 0.0 107.115 177.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -114.4 80.91 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 120.874 0.368 . . . . 0.0 110.49 -177.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.73 103.27 0.54 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.72 -163.0 6.88 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.352 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.41 133.94 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 121.09 0.472 . . . . 0.0 110.673 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.061 -0.971 . . . . 0.0 110.818 -179.861 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.7 144.57 43.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.96 0.41 . . . . 0.0 110.872 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -63.38 149.59 45.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.783 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.51 142.86 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 69.7 t60 -143.18 139.9 30.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.92 0.391 . . . . 0.0 110.696 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.528 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -135.92 170.12 16.5 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.528 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 43.7 tt0 -158.19 171.13 20.77 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.991 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.475 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -150.39 113.14 4.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.33 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -118.3 115.87 25.6 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -131.56 130.14 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.428 ' CG ' ' CE1' ' F' ' 19' ' ' PHE . 7.2 m-85 -113.05 111.2 21.74 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.488 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . 0.566 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 25.5 t80 -122.49 121.33 36.32 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 118.223 0.465 . . . . 0.0 111.292 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.34 136.88 33.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.951 0.405 . . . . 0.0 111.469 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -124.68 120.81 32.91 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.448 ' OD1' ' O ' ' E' ' 23' ' ' ASP . 44.7 p-10 -163.75 101.77 0.9 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.602 -0.839 . . . . 0.0 113.251 177.828 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.585 ' O ' ' N ' ' D' ' 26' ' ' SER . 21.2 t -59.49 166.74 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.164 -0.926 . . . . 0.0 112.353 177.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 87.9 81.62 1.24 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 115.336 0.894 . . . . 0.0 115.336 174.393 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -51.15 161.1 0.44 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 120.565 0.221 . . . . 0.0 110.795 175.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.495 ' O ' ' C ' ' E' ' 28' ' ' LYS . 62.5 t30 -148.11 175.78 10.74 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.825 175.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.495 ' C ' ' O ' ' E' ' 27' ' ' ASN . 67.6 mmtt -9.4 -103.8 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 178.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -150.77 96.39 0.17 Allowed Glycine 0 C--N 1.349 1.273 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.595 ' H ' HD21 ' F' ' 27' ' ' ASN . . . -67.22 176.29 2.28 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 117.99 0.895 . . . . 0.0 111.095 178.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.37 130.96 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.986 -179.601 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -130.61 122.37 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 121.084 0.469 . . . . 0.0 110.959 -178.255 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.81 124.39 5.37 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . 0.478 ' CD1' ' N ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -126.94 128.27 46.16 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 120.891 0.377 . . . . 0.0 111.006 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.8 tpp -120.19 120.2 35.46 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.918 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' E' ' 37' ' ' GLY . 5.8 t -134.06 83.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 121.36 -0.136 . . . . 0.0 111.131 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -19.58 -94.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.162 0 O-C-N 123.461 0.475 . . . . 0.0 112.753 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.67 -167.58 35.26 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 p -138.76 145.67 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 120.802 0.334 . . . . 0.0 110.393 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.043 -0.979 . . . . 0.0 110.515 179.78 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -85.44 134.6 34.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.874 0.369 . . . . 0.0 110.696 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -138.39 131.01 29.23 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.202 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m -141.65 173.29 8.58 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 121.237 0.541 . . . . 0.0 110.965 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -80.45 144.03 32.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.425 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.544 ' O ' ' NE2' ' F' ' 15' ' ' GLN . 34.6 m80 -134.03 172.21 13.14 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.544 ' NE2' ' O ' ' F' ' 14' ' ' HIS . 99.3 mm-40 -144.54 178.3 8.05 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.41 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -169.23 116.19 0.61 Allowed 'General case' 0 CA--C 1.531 0.215 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 2.0 mp -126.82 126.98 44.29 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.081 -179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.73 129.89 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 121.572 0.701 . . . . 0.0 112.247 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.428 ' CE1' ' CG ' ' E' ' 19' ' ' PHE . 4.0 m-85 -114.75 113.39 24.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.132 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . 0.486 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 35.4 t80 -127.06 120.98 30.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.502 0.668 . . . . 0.0 111.387 -179.08 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.1 135.66 46.6 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.094 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tp10 -78.02 120.79 23.36 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.231 -0.588 . . . . 0.0 110.215 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' F' ' 24' ' ' VAL . 19.7 t70 -169.0 121.71 0.79 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.655 -0.418 . . . . 0.0 112.045 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' F' ' 23' ' ' ASP . 4.5 m -63.06 -121.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.519 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -64.39 -86.05 0.06 OUTLIER Glycine 0 CA--C 1.519 0.304 0 N-CA-C 105.736 -2.946 . . . . 0.0 105.736 178.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.548 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 2.0 t 157.53 172.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 122.316 1.055 . . . . 0.0 112.087 174.176 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.595 HD21 ' H ' ' E' ' 30' ' ' ALA . 43.3 m-20 -44.69 174.76 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 112.947 -1.933 . . . . 0.0 111.298 176.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -70.28 111.38 5.84 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.25 -92.94 0.87 Allowed Glycine 0 C--N 1.313 -0.725 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 -178.841 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . 82.17 163.72 0.14 Allowed 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 100.451 -3.907 . . . . 0.0 100.451 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.563 ' CD1' ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -148.11 128.16 4.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 121.691 2.041 . . . . 0.0 110.653 179.297 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tt -123.95 136.82 59.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.602 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.77 117.93 2.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.2 tt -124.15 124.18 41.92 Favored 'General case' 0 N--CA 1.47 0.567 0 O-C-N 122.689 -0.301 . . . . 0.0 110.238 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 42.2 mmm -123.27 130.38 52.66 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 120.776 0.322 . . . . 0.0 110.745 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.16 81.02 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 CA-C-N 116.101 -0.499 . . . . 0.0 112.323 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -43.25 100.83 0.02 OUTLIER Glycine 0 C--N 1.341 0.839 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.854 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -128.77 163.75 22.1 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.21 135.19 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.838 0.352 . . . . 0.0 110.121 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.486 -179.994 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -114.53 145.61 41.72 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.231 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -132.21 143.26 49.82 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.89 132.82 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 121.117 0.484 . . . . 0.0 110.075 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 39.7 p-80 -109.24 -169.64 1.52 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.25 -179.633 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.485 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 33.9 p80 -77.46 171.33 15.07 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 48.5 tt0 -155.92 172.37 18.49 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.395 179.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . 0.46 ' HZ3' ' HZ3' ' H' ' 16' ' ' LYS . 71.7 mmtt -136.56 132.56 35.34 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.583 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -135.74 111.07 9.06 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.68 133.1 65.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -139.64 148.74 42.86 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -124.71 132.92 53.35 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 139.52 45.56 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.598 0.713 . . . . 0.0 112.104 -178.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -115.96 167.09 11.27 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.568 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.564 ' CG ' ' H ' ' H' ' 25' ' ' GLY . 44.1 t0 -46.3 142.96 2.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.454 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.438 ' CB ' ' O ' ' G' ' 23' ' ' ASP . 20.0 t 93.97 111.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 O-C-N 124.565 1.166 . . . . 0.0 111.48 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 49.35 91.64 0.01 OUTLIER Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.54 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 1.1 p 159.04 -179.57 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 122.187 0.994 . . . . 0.0 110.603 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' G' ' 28' ' ' LYS . 90.5 m-20 -58.93 172.05 0.6 Allowed 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 113.408 -1.724 . . . . 0.0 112.323 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.533 ' NZ ' ' OD2' ' I' ' 23' ' ' ASP . 84.5 tttt 52.75 105.53 0.01 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.13 -179.703 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.567 ' O ' ' CB ' ' G' ' 30' ' ' ALA . . . 107.51 103.71 2.89 Favored Glycine 1 CA--C 1.427 -5.413 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.102 -174.478 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.573 ' H ' ' CB ' ' H' ' 30' ' ' ALA . . . 87.66 -148.34 0.01 OUTLIER 'General case' 0 N--CA 1.384 -3.73 0 N-CA-C 103.138 -2.912 . . . . 0.0 103.138 -169.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.719 ' H ' ' CD1' ' G' ' 31' ' ' ILE 0.287 0.0 OUTLIER -109.54 114.79 47.93 Favored 'Isoleucine or valine' 0 C--N 1.252 -3.638 0 N-CA-C 118.043 2.608 . . . . 0.0 118.043 -174.012 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.441 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 0.9 OUTLIER -112.36 116.37 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 173.421 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.51 121.3 4.33 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 49.0 mt -126.52 134.67 50.83 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 122.889 1.328 . . . . 0.0 111.302 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 20.1 ttt -98.02 110.91 23.4 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 112.494 -2.139 . . . . 0.0 107.081 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.44 64.77 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.517 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.919 -178.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.11 -106.45 0.41 Allowed Glycine 0 C--N 1.367 2.296 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -161.85 165.11 35.62 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 66.7 t -127.93 134.26 65.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.833 0.349 . . . . 0.0 110.195 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.634 -179.936 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.17 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -83.2 137.69 33.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.605 0.24 . . . . 0.0 110.368 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -68.91 137.29 53.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.718 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 24.4 m -136.23 160.1 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.945 0.402 . . . . 0.0 110.932 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -128.71 -175.42 3.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.208 179.627 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -80.61 168.52 18.79 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 122.153 0.978 . . . . 0.0 111.532 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -153.11 177.81 10.41 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.063 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . 0.46 ' HZ3' ' HZ3' ' G' ' 16' ' ' LYS . 51.4 mtmt -145.44 143.44 30.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.311 179.925 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -135.24 117.04 15.09 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . 0.406 ' CG1' ' CE2' ' H' ' 20' ' ' PHE . 70.2 t -126.87 134.03 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-O 120.872 0.368 . . . . 0.0 110.505 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 45.7 t80 -124.74 122.71 38.24 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.392 179.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.406 ' CE2' ' CG1' ' H' ' 18' ' ' VAL . 61.0 m-85 -115.2 125.66 53.65 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.155 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.67 120.96 40.27 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-N 118.222 0.464 . . . . 0.0 110.911 179.211 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' H' ' 23' ' ' ASP . 81.6 tt0 -123.27 154.98 38.09 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.756 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.612 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 54.6 t0 49.38 114.22 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 CA-C-O 121.05 0.452 . . . . 0.0 110.715 -178.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' H' ' 25' ' ' GLY . 42.8 t -126.8 121.28 57.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.564 ' H ' ' CG ' ' G' ' 23' ' ' ASP . . . -28.21 -87.11 0.01 OUTLIER Glycine 0 N--CA 1.469 0.858 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 176.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.3 t -128.58 170.61 13.02 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.705 -1.221 . . . . 0.0 107.705 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' H' ' 26' ' ' SER . 62.2 t30 33.95 179.47 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 122.138 0.97 . . . . 0.0 113.348 -178.301 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.496 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 84.0 tttt -119.98 -105.45 0.39 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.636 -176.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.709 ' O ' ' CB ' ' I' ' 30' ' ' ALA . . . -64.62 98.62 0.29 Allowed Glycine 1 CA--C 1.428 -5.35 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -178.476 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.573 ' CB ' ' H ' ' G' ' 30' ' ' ALA . . . -82.23 -136.58 0.04 OUTLIER 'General case' 0 N--CA 1.397 -3.086 1 N-CA-C 95.715 -5.661 . . . . 0.0 95.715 174.038 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.721 ' CD1' ' N ' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -112.29 119.32 59.93 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 116.236 -2.186 . . . . 0.0 112.291 -178.403 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.536 ' C ' ' SD ' ' B' ' 35' ' ' MET . 5.5 tt -117.49 120.03 63.56 Favored 'Isoleucine or valine' 0 C--N 1.361 1.106 0 CA-C-N 114.34 -1.3 . . . . 0.0 110.445 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.536 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -114.77 116.9 3.89 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -124.18 125.84 45.13 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.681 0.753 . . . . 0.0 111.825 -179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 7.3 ttt -105.92 110.03 22.18 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 114.37 -1.286 . . . . 0.0 108.577 178.049 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -131.53 71.26 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.12 -179.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.53 -97.13 0.03 OUTLIER Glycine 0 C--N 1.359 1.822 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.21 -166.26 38.68 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -124.39 139.9 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.869 0.366 . . . . 0.0 111.09 -178.694 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.597 179.831 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -145.48 157.16 44.05 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -133.59 138.81 46.18 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.914 0.388 . . . . 0.0 110.844 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 22.3 t -128.11 129.55 69.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.7 p80 -175.69 113.86 0.13 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.148 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 26.8 m-70 -82.19 165.9 20.09 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.001 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -148.34 173.01 13.5 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.279 0.562 . . . . 0.0 110.985 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -154.96 127.56 7.98 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.629 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -129.2 119.56 24.27 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.619 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 48.1 t -125.94 128.94 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.934 0.397 . . . . 0.0 111.754 -179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -113.18 103.8 11.71 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -114.84 130.05 56.81 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 111.751 0.278 . . . . 0.0 111.751 -177.564 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.0 135.82 29.68 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 121.277 0.561 . . . . 0.0 111.402 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 tm-20 -148.07 118.88 7.57 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.587 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.612 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 16.7 m-20 -158.64 110.5 2.2 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.828 0.823 . . . . 0.0 112.224 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 50.5 t -48.16 133.97 5.36 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.497 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 99.3 86.03 1.87 Allowed Glycine 0 CA--C 1.54 1.636 0 N-CA-C 120.316 2.886 . . . . 0.0 120.316 171.948 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.4 p 153.01 169.87 0.01 OUTLIER 'General case' 0 C--N 1.347 0.498 0 CA-C-O 122.635 1.207 . . . . 0.0 112.346 169.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' I' ' 28' ' ' LYS . 1.4 m120 -59.03 177.63 0.15 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.343 -1.299 . . . . 0.0 111.363 177.679 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.505 ' O ' ' O ' ' I' ' 27' ' ' ASN . 63.3 tttt -43.64 -100.86 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.223 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.027 172.731 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.761 ' O ' ' O ' ' I' ' 30' ' ' ALA . . . -170.59 106.33 0.24 Allowed Glycine 1 CA--C 1.42 -5.858 0 C-N-CA 119.061 -1.542 . . . . 0.0 116.527 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.761 ' O ' ' O ' ' I' ' 29' ' ' GLY 0.29 . . -0.46 -133.45 0.0 OUTLIER 'General case' 0 C--N 1.366 1.286 0 O-C-N 127.066 2.274 . . . . 0.0 108.333 170.579 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.54 ' CG2' ' SD ' ' C' ' 35' ' ' MET . 3.9 mp -122.52 132.82 70.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 117.269 2.322 . . . . 0.0 117.269 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.59 ' C ' ' SD ' ' C' ' 35' ' ' MET . 17.9 tt -116.27 120.8 65.99 Favored 'Isoleucine or valine' 0 C--N 1.371 1.531 0 CA-C-N 114.44 -1.255 . . . . 0.0 110.58 177.698 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.475 ' CA ' ' SD ' ' C' ' 35' ' ' MET . . . -102.77 112.19 4.21 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 107.157 -2.377 . . . . 0.0 107.157 177.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.511 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 32.8 tp -113.26 121.18 43.65 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-N 115.36 -0.42 . . . . 0.0 111.419 -177.339 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.513 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 19.1 ttt -118.69 112.56 19.94 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 176.019 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.31 71.45 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.208 0 CA-C-N 117.729 0.24 . . . . 0.0 111.273 -178.126 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -50.11 -97.97 0.01 OUTLIER Glycine 0 C--N 1.353 1.5 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.405 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.14 -162.65 28.63 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.05 138.67 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 120.894 0.378 . . . . 0.0 110.703 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.481 179.679 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -108.95 134.09 52.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.95 0.405 . . . . 0.0 110.708 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -143.35 167.53 21.94 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.192 -179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . 0.498 ' CG1' ' N ' ' J' ' 13' ' ' HIS . 60.0 t -127.66 164.98 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.058 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.498 ' N ' ' CG1' ' J' ' 12' ' ' VAL . 2.9 p80 -66.58 134.11 51.69 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.196 0.522 . . . . 0.0 111.841 -178.292 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.436 ' NE2' ' O ' ' K' ' 12' ' ' VAL . 52.7 m170 -112.83 172.17 7.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -141.55 176.44 8.88 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.333 0.587 . . . . 0.0 111.479 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -174.01 124.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.105 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.85 132.35 40.28 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-O 121.303 0.573 . . . . 0.0 110.973 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.68 131.12 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.015 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.649 ' CD1' ' CZ ' ' K' ' 19' ' ' PHE . 20.1 m-85 -114.2 111.17 21.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.097 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -121.59 120.49 34.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.909 0.322 . . . . 0.0 110.155 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . 0.471 ' CB ' ' HZ1' ' H' ' 28' ' ' LYS . . . -139.51 132.64 29.67 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.136 0.494 . . . . 0.0 110.986 -179.603 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.478 ' C ' ' OD1' ' J' ' 23' ' ' ASP . 73.6 mt-10 -144.78 127.45 16.18 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 119.84 -0.744 . . . . 0.0 112.472 -179.277 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.606 ' OD2' ' N ' ' I' ' 23' ' ' ASP . 3.9 m-20 -159.68 110.98 2.0 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 118.938 -1.105 . . . . 0.0 113.353 176.741 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.0 t -37.8 128.65 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.464 172.32 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' I' ' 26' ' ' SER . . . 168.85 -83.64 0.09 OUTLIER Glycine 0 N--CA 1.467 0.709 0 C-N-CA 117.108 -2.472 . . . . 0.0 116.087 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.582 ' O ' ' O ' ' J' ' 27' ' ' ASN . 5.0 p -170.39 -178.55 2.75 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 118.825 -1.15 . . . . 0.0 113.081 -175.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.582 ' O ' ' O ' ' J' ' 26' ' ' SER . 63.6 t30 27.13 177.37 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 CA-C-N 112.113 -2.312 . . . . 0.0 115.565 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.569 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 96.7 mttt -119.71 -106.47 0.38 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 113.307 -1.769 . . . . 0.0 110.947 -176.775 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.688 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -66.13 96.6 0.28 Allowed Glycine 0 CA--C 1.48 -2.141 0 CA-C-O 123.654 1.697 . . . . 0.0 112.643 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.628 ' O ' ' C ' ' J' ' 29' ' ' GLY . . . -80.38 -145.12 0.05 OUTLIER 'General case' 0 C--N 1.293 -1.885 1 N-CA-C 93.921 -6.326 . . . . 0.0 93.921 170.407 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.463 ' H ' HG13 ' I' ' 31' ' ' ILE . 4.8 mm -100.89 115.34 42.32 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 1 CA-C-N 127.987 4.903 . . . . 0.0 111.035 -179.249 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CG2' ' J' ' 32' ' ' ILE . 0.6 OUTLIER -112.76 110.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.366 1.307 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.684 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.16 106.27 2.64 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.436 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 4.4 mt -104.78 106.87 17.55 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.488 ' CE ' ' O ' ' C' ' 32' ' ' ILE . 0.0 OUTLIER -106.09 113.2 26.59 Favored 'General case' 0 N--CA 1.444 -0.754 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 178.819 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.39 79.6 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.085 -177.661 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.55 103.48 1.63 Allowed Glycine 0 C--N 1.349 1.258 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 177.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.34 145.08 16.7 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 63.0 t -136.85 139.42 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 89.5 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.189 179.365 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -107.41 140.28 40.59 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.781 0.324 . . . . 0.0 110.614 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -56.73 137.88 53.75 Favored 'General case' 0 C--O 1.231 0.089 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.289 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.436 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 8.8 m -150.58 145.75 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-O 121.408 0.623 . . . . 0.0 111.98 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.538 ' ND1' ' N ' ' K' ' 13' ' ' HIS . 0.7 OUTLIER -119.3 116.13 25.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.202 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.622 ' ND1' ' ND1' ' L' ' 13' ' ' HIS . 70.6 t60 -122.61 165.99 15.58 Favored 'General case' 0 CA--C 1.509 -0.616 0 CA-C-O 121.403 0.621 . . . . 0.0 110.025 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.453 ' N ' ' CG ' ' K' ' 14' ' ' HIS . 47.5 tt0 -163.39 166.95 22.32 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.453 178.386 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . 0.411 ' CE ' ' HE2' ' K' ' 14' ' ' HIS . 98.9 mttt -155.53 129.96 9.0 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 26.9 tp -124.51 120.53 32.27 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . 0.413 ' CG1' ' CE2' ' K' ' 20' ' ' PHE . 57.9 t -132.94 127.03 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.935 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.649 ' CZ ' ' CD1' ' J' ' 19' ' ' PHE . 6.8 m-85 -117.28 112.81 21.27 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.033 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.413 ' CE2' ' CG1' ' K' ' 18' ' ' VAL . 47.6 m-85 -108.12 118.57 37.1 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 178.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 132.86 36.93 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.772 0.714 . . . . 0.0 112.775 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -113.58 122.77 48.23 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.465 178.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -178.73 110.87 0.06 Allowed 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.244 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 m -107.05 -123.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 31.49 85.51 0.01 OUTLIER Glycine 0 C--N 1.342 0.9 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.009 -178.127 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 24.1 p -50.1 158.82 0.5 Allowed 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.398 0.618 . . . . 0.0 111.754 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' OD1' ' J' ' 27' ' ' ASN . 0.0 OUTLIER -148.06 176.92 9.8 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.881 -1.054 . . . . 0.0 109.137 176.952 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.531 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.8 mttt -9.16 -103.27 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.664 0.603 . . . . 0.0 111.278 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.73 97.0 0.18 Allowed Glycine 0 CA--C 1.5 -0.896 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 176.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.688 ' CB ' ' O ' ' J' ' 29' ' ' GLY . . . -66.2 172.17 4.09 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 177.423 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.661 ' N ' ' O ' ' J' ' 29' ' ' GLY . 0.4 OUTLIER -147.58 123.46 2.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 CA-C-N 120.996 1.726 . . . . 0.0 111.858 -175.782 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 91.1 mt -125.99 131.33 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.717 -1.128 . . . . 0.0 112.475 -178.348 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.71 119.96 3.17 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . 0.414 ' C ' ' CD2' ' K' ' 34' ' ' LEU . 5.5 tt -121.84 120.53 34.81 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 120.629 0.252 . . . . 0.0 110.765 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.542 ' SD ' ' O ' ' K' ' 35' ' ' MET . 5.6 ppp? -130.49 130.24 43.94 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.436 0.636 . . . . 0.0 111.058 178.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.534 ' O ' ' C ' ' K' ' 37' ' ' GLY . 3.2 p -158.11 79.98 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.869 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.534 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -1.37 -100.89 0.0 OUTLIER Glycine 0 C--N 1.348 1.214 0 O-C-N 123.311 0.382 . . . . 0.0 113.615 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.45 -172.5 41.73 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m -133.86 161.56 40.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.306 179.901 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -119.69 140.58 50.45 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-O 120.855 0.36 . . . . 0.0 110.904 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -126.04 134.21 51.49 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -135.66 161.86 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.411 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.622 ' ND1' ' ND1' ' K' ' 14' ' ' HIS . 49.1 t-80 -90.45 176.68 6.62 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.607 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 27.5 t-80 -76.0 176.82 7.57 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.372 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.607 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 99.2 mm-40 -121.48 178.04 4.97 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.968 0.413 . . . . 0.0 111.004 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -165.98 113.48 0.92 Allowed 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.96 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 18.3 mt -128.71 124.92 36.85 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -140.1 135.03 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.436 ' CE1' ' CD1' ' J' ' 34' ' ' LEU . 7.3 m-85 -116.94 108.53 15.91 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 177.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -116.0 123.09 47.13 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-O 121.24 0.543 . . . . 0.0 110.867 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.68 134.01 45.47 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 81.0 tt0 -81.18 92.87 6.37 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.964 -0.694 . . . . 0.0 111.03 -178.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.585 ' O ' ' O ' ' L' ' 24' ' ' VAL . 70.7 m-20 -160.94 133.14 5.95 Favored 'General case' 0 C--O 1.226 -0.159 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.182 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.585 ' O ' ' O ' ' L' ' 23' ' ' ASP . 10.6 t -32.34 -110.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 124.003 0.815 . . . . 0.0 111.376 176.475 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -158.89 92.27 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.476 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 23.3 p -47.3 152.68 0.57 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.761 0.791 . . . . 0.0 111.443 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.488 ' O ' ' C ' ' L' ' 28' ' ' LYS . 31.8 m120 -157.42 -174.74 5.03 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.135 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 12.74 103.54 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 177.079 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.56 -101.48 0.81 Allowed Glycine 0 N--CA 1.47 0.961 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.5 171.48 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 117.287 0.543 . . . . 0.0 110.152 -178.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.42 148.56 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.854 -177.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 18.7 tt -133.53 126.75 52.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-N 114.018 -1.447 . . . . 0.0 109.191 178.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.17 119.44 4.38 Favored Glycine 0 N--CA 1.466 0.657 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 16.6 tp -126.09 120.75 31.01 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.857 0.328 . . . . 0.0 110.179 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.528 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.7 ppp? -132.86 133.06 42.81 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.872 0.844 . . . . 0.0 111.16 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 23.1 t -142.98 82.61 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.412 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' K' ' 37' ' ' GLY . . . -66.26 101.22 0.59 Allowed Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.31 168.58 35.93 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -129.53 160.03 40.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.884 0.373 . . . . 0.0 110.507 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.425 179.983 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -83.96 139.25 32.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.7 0.286 . . . . 0.0 110.599 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -148.44 137.9 22.03 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-O 121.128 0.49 . . . . 0.0 111.337 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 45.8 t -133.3 158.42 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 79.2 m80 -142.44 134.28 27.01 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 120.539 -0.464 . . . . 0.0 111.384 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -155.11 166.87 32.22 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.368 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -155.83 175.73 13.55 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.898 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -153.37 115.57 4.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.926 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.92 121.63 23.13 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.06 0.457 . . . . 0.0 110.67 178.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.54 131.38 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 115.778 -0.647 . . . . 0.0 109.713 179.371 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -126.56 130.37 50.41 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.826 0.346 . . . . 0.0 110.627 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -126.24 126.92 44.81 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 133.03 46.65 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 121.017 0.437 . . . . 0.0 111.87 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -150.53 117.33 5.85 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.187 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -128.01 120.16 26.94 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.485 0.659 . . . . 0.0 111.928 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 m -63.81 -121.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.19 178.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.51 -89.44 0.04 OUTLIER Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.62 -0.718 . . . . 0.0 113.353 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.782 ' O ' ' O ' ' A' ' 27' ' ' ASN . 2.1 t 174.04 -172.98 0.06 Allowed 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -178.952 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.782 ' O ' ' O ' ' A' ' 26' ' ' SER . 67.5 m-80 -10.33 159.71 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 O-C-N 125.032 1.458 . . . . 0.0 113.873 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.515 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 18.3 pttp 178.99 101.98 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 178.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.24 101.39 0.74 Allowed Glycine 0 CA--C 1.503 -0.674 0 N-CA-C 106.849 -2.5 . . . . 0.0 106.849 176.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.96 153.94 23.63 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 117.117 -1.833 . . . . 0.0 110.535 -175.957 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -146.34 115.59 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.498 -173.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.46 ' N ' ' HE3' ' H' ' 35' ' ' MET . 11.6 tt -127.55 108.78 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.24 122.61 4.69 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.14 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . 0.455 ' O ' ' HA ' ' B' ' 34' ' ' LEU . 0.9 OUTLIER -178.13 -162.58 0.06 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 122.349 1.071 . . . . 0.0 111.228 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.457 ' SD ' ' HB ' ' H' ' 31' ' ' ILE . 1.1 ttp -149.89 157.6 43.34 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -111.71 75.68 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 C-N-CA 120.507 -0.477 . . . . 0.0 109.811 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.5 103.42 3.0 Favored Glycine 0 C--N 1.357 1.745 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.46 -172.1 47.54 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -132.93 161.68 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.048 0.451 . . . . 0.0 110.864 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.865 -1.064 . . . . 0.0 110.662 -179.951 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -147.8 157.82 43.73 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.686 0.279 . . . . 0.0 110.682 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 150.68 31.32 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.314 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -137.47 155.84 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.794 -179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 5.7 m-70 -128.31 142.46 51.13 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -143.2 169.56 17.38 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -162.2 166.63 25.3 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.762 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -154.48 111.43 3.34 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 179.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 73.2 mt -121.84 117.49 26.65 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -131.13 129.03 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.338 0.59 . . . . 0.0 112.034 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -122.28 127.37 49.8 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.124 178.735 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.3 t80 -130.65 125.5 34.17 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.708 0.289 . . . . 0.0 110.949 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.97 129.71 42.47 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.868 0.366 . . . . 0.0 110.504 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -157.76 135.59 10.68 Favored 'General case' 0 C--O 1.226 -0.17 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.523 ' O ' ' O ' ' B' ' 24' ' ' VAL . 0.5 OUTLIER -171.24 121.53 0.53 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.724 -0.391 . . . . 0.0 111.218 -179.892 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' B' ' 23' ' ' ASP . 3.0 t -49.18 -122.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.229 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 -90.57 0.81 Allowed Glycine 0 CA--C 1.532 1.096 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.857 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.749 ' O ' ' O ' ' B' ' 27' ' ' ASN . 2.8 p 174.39 -171.71 0.05 Allowed 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 117.362 0.581 . . . . 0.0 109.588 -177.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.749 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.2 m-80 -10.04 160.53 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 O-C-N 125.406 1.691 . . . . 0.0 114.513 179.532 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . . . . . . . . . 16.2 tttt 179.54 101.63 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 121.288 0.566 . . . . 0.0 111.607 178.817 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.2 102.03 0.88 Allowed Glycine 0 CA--C 1.487 -1.699 0 N-CA-C 106.605 -2.598 . . . . 0.0 106.605 174.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -91.08 149.14 21.94 Favored 'General case' 0 CA--C 1.498 -1.046 0 C-N-CA 115.357 -2.537 . . . . 0.0 106.434 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.445 ' O ' ' SD ' ' H' ' 35' ' ' MET . 2.6 mt -148.74 106.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 114.284 -1.326 . . . . 0.0 107.836 -174.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 15.7 tt -116.15 123.18 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-O 121.638 0.732 . . . . 0.0 110.955 179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.727 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -116.53 115.31 3.27 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 106.008 -2.837 . . . . 0.0 106.008 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.537 ' O ' ' CB ' ' C' ' 34' ' ' LEU . 5.9 tp -144.12 144.33 31.54 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 -175.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.644 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 32.3 ttp -129.18 129.63 45.32 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.159 -1.382 . . . . 0.0 108.411 175.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -111.89 78.2 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.017 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.247 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -74.36 104.59 1.69 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.158 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.23 -179.14 36.84 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.751 -178.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -141.37 149.87 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.675 -179.851 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -110.2 128.25 55.39 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.62 0.248 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.477 ' CD ' ' NE2' ' C' ' 13' ' ' HIS . 82.6 tt0 -133.13 148.22 52.11 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.302 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.68 133.02 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.944 0.402 . . . . 0.0 110.449 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.477 ' NE2' ' CD ' ' C' ' 11' ' ' GLU . 60.2 m80 -128.87 138.73 52.2 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.363 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 82.8 t60 -155.37 164.85 38.18 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 94.5 mt-30 -155.44 -179.36 8.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.308 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.05 112.97 1.01 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.53 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 67.8 tp -120.28 121.84 39.56 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.804 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -132.69 126.34 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -179.101 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -118.46 123.8 46.05 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 177.179 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.628 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 43.5 t80 -130.09 127.85 40.68 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.764 0.316 . . . . 0.0 111.373 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.48 138.97 45.14 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.299 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -143.82 151.81 40.4 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.408 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.498 ' CG ' ' H ' ' C' ' 24' ' ' VAL . 16.7 t70 -151.72 -132.91 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.673 178.79 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' C' ' 26' ' ' SER . 63.2 t -122.91 112.02 32.26 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.454 ' C ' ' O ' ' C' ' 24' ' ' VAL . . . -28.95 89.5 0.01 OUTLIER Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 175.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.773 ' O ' ' O ' ' C' ' 27' ' ' ASN . 46.9 t -151.91 -170.8 3.75 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 -177.044 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.773 ' O ' ' O ' ' C' ' 26' ' ' SER . 28.7 t-20 -21.53 170.54 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.237 0 O-C-N 124.829 1.331 . . . . 0.0 113.622 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.454 ' N ' ' CG ' ' C' ' 27' ' ' ASN . 57.9 tttp -101.34 -113.49 0.19 Allowed 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 41.65 90.8 0.01 OUTLIER Glycine 0 C--N 1.338 0.692 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 179.645 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.54 153.64 44.99 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 173.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.3 116.88 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 118.979 -1.089 . . . . 0.0 111.305 -172.367 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.571 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.6 pt -119.15 115.88 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 176.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.681 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -126.14 118.45 3.13 Favored Glycine 0 CA--C 1.501 -0.836 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -161.56 169.31 21.95 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 118.072 -1.451 . . . . 0.0 111.968 -177.513 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 5.6 tmm? -141.37 137.26 32.18 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 113.538 -1.665 . . . . 0.0 109.654 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.04 73.09 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.564 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.75 103.84 3.02 Favored Glycine 0 C--N 1.37 2.437 0 N-CA-C 111.419 -0.673 . . . . 0.0 111.419 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.58 154.58 18.63 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -135.38 163.29 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.395 -179.889 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -108.84 131.73 54.71 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.874 0.369 . . . . 0.0 110.507 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -133.49 131.09 39.42 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.26 0.552 . . . . 0.0 111.024 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.7 t -120.21 135.41 60.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.128 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' E' ' 13' ' ' HIS . 23.1 p80 -155.01 158.84 39.76 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 119.035 -1.066 . . . . 0.0 112.841 -178.805 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.512 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 51.5 m-70 -147.27 169.62 19.02 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.016 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.512 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 97.4 mm-40 -148.9 168.82 22.0 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.154 179.288 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -153.31 106.97 3.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.995 179.024 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 51.7 mt -118.5 116.79 27.39 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.27 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -130.24 128.16 63.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.112 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.55 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 47.1 m-85 -121.02 111.8 17.93 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 177.004 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -120.21 132.1 55.23 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 118.251 0.478 . . . . 0.0 111.919 -178.587 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 122.31 24.79 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.51 0.671 . . . . 0.0 111.176 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.447 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 80.9 tt0 -111.18 89.82 3.16 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.071 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.461 ' O ' ' C ' ' D' ' 24' ' ' VAL . 4.9 p30 154.48 124.6 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.446 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.461 ' C ' ' O ' ' D' ' 23' ' ' ASP . 18.4 m -29.44 111.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 O-C-N 123.559 0.537 . . . . 0.0 111.499 179.107 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.455 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . -177.45 -91.1 0.08 OUTLIER Glycine 0 C--O 1.215 -1.059 0 C-N-CA 118.568 -1.777 . . . . 0.0 114.871 179.405 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.435 ' O ' ' CB ' ' D' ' 27' ' ' ASN . 80.9 p -72.84 168.94 17.85 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 118.884 1.342 . . . . 0.0 113.697 -175.179 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.435 ' CB ' ' O ' ' D' ' 26' ' ' SER . 5.5 t-20 84.42 -178.32 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.234 177.011 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.42 ' C ' ' O ' ' D' ' 27' ' ' ASN . 85.0 tttt -38.05 106.15 0.05 OUTLIER 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 175.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.53 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 109.25 102.21 2.74 Favored Glycine 0 CA--C 1.466 -2.997 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.07 -171.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.592 ' H ' ' CB ' ' E' ' 30' ' ' ALA . . . 86.99 -160.92 0.01 OUTLIER 'General case' 0 N--CA 1.412 -2.33 0 N-CA-C 100.355 -3.943 . . . . 0.0 100.355 -169.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.445 ' N ' HD13 ' D' ' 31' ' ' ILE . 4.6 mp -131.99 134.58 59.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 115.074 -2.65 . . . . 0.0 117.751 -174.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.9 tt -126.77 123.91 63.83 Favored 'Isoleucine or valine' 0 C--N 1.367 1.334 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.459 177.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.655 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -124.18 106.22 0.94 Allowed Glycine 0 C--O 1.237 0.29 0 N-CA-C 106.882 -2.487 . . . . 0.0 106.882 176.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . 0.48 ' CD1' ' CE1' ' E' ' 19' ' ' PHE . 10.0 tt -126.72 132.95 51.0 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-O 122.039 0.923 . . . . 0.0 112.431 -177.511 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.541 ' SD ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -122.1 126.66 48.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 114.32 -1.309 . . . . 0.0 109.865 178.887 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.457 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -113.3 79.77 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.49 -178.182 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -25.8 -95.74 0.01 OUTLIER Glycine 0 C--N 1.358 1.759 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.89 -162.03 29.25 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.583 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 40' ' ' VAL . 56.0 t -115.2 136.06 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.932 0.396 . . . . 0.0 110.266 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 39' ' ' VAL . 70.9 t . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.445 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -109.11 136.13 49.11 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 110.463 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . 0.521 ' OE2' ' NE2' ' E' ' 13' ' ' HIS . 81.4 tt0 -64.69 136.27 56.77 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.645 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.91 134.6 59.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-O 121.959 0.885 . . . . 0.0 112.596 -179.689 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' D' ' 13' ' ' HIS . 46.8 m170 -121.17 138.88 54.0 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 114.066 -1.425 . . . . 0.0 108.559 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.585 ' CG ' ' H ' ' E' ' 15' ' ' GLN . 85.4 t60 -152.47 171.49 18.0 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 121.61 0.719 . . . . 0.0 110.742 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.585 ' H ' ' CG ' ' E' ' 14' ' ' HIS . 53.6 tt0 -154.01 173.27 16.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.774 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.57 113.34 0.61 Allowed 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.568 -179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 tt -123.65 123.44 40.56 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.98 122.3 45.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.222 0.534 . . . . 0.0 112.173 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' D' ' 19' ' ' PHE . 7.5 m-85 -113.88 117.54 31.69 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 90.4 t80 -124.58 131.94 53.46 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.866 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 145.94 28.4 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.42 128.47 44.81 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.802 -0.635 . . . . 0.0 111.18 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' O ' ' F' ' 22' ' ' GLU . 67.3 t0 -147.1 112.33 5.51 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.238 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.618 ' CG1' ' H ' ' E' ' 25' ' ' GLY . 12.1 p -101.8 -121.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.248 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.618 ' H ' ' CG1' ' E' ' 24' ' ' VAL . . . 34.2 -84.93 0.01 OUTLIER Glycine 0 N--CA 1.473 1.143 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -177.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.572 ' N ' ' O ' ' E' ' 24' ' ' VAL . 1.4 p 161.95 160.31 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.673 0.749 . . . . 0.0 109.913 175.733 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.412 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.8 m120 -29.87 159.65 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 114.277 -1.329 . . . . 0.0 113.896 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.483 ' O ' ' O ' ' E' ' 29' ' ' GLY . 87.4 tttt 178.19 102.94 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 41.8 93.43 0.01 OUTLIER Glycine 0 N--CA 1.477 1.395 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.592 ' CB ' ' H ' ' D' ' 30' ' ' ALA . . . -156.52 147.39 21.91 Favored 'General case' 0 CA--C 1.474 -1.947 0 C-N-CA 117.847 -1.541 . . . . 0.0 109.319 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -151.49 137.54 11.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 112.477 -2.147 . . . . 0.0 112.041 -171.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.549 ' CD1' ' N ' ' E' ' 32' ' ' ILE . 2.8 mp -122.41 118.01 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 114.275 -1.33 . . . . 0.0 110.35 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -120.2 116.29 3.2 Favored Glycine 0 N--CA 1.476 1.32 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 178.338 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 39.6 mt -119.36 117.39 28.38 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.515 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -120.27 126.35 50.36 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.08 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 2.6 t -115.44 89.1 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.01 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' D' ' 37' ' ' GLY . . . -69.3 94.69 0.4 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.22 -171.79 18.73 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -178.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -132.73 161.81 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.654 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 C--O 1.221 -0.423 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.753 -179.942 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -103.33 129.75 50.45 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.004 0.43 . . . . 0.0 110.47 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -92.9 145.58 24.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.856 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 t -105.85 130.04 57.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.133 0.492 . . . . 0.0 110.689 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 14.5 t60 -154.19 139.7 17.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -149.74 170.61 18.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.427 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 50.8 tt0 -155.09 171.15 20.25 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.525 -0.762 . . . . 0.0 109.591 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . 0.427 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 62.1 tttm -170.08 106.39 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.156 -0.617 . . . . 0.0 111.676 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 6.1 mp -117.42 125.47 51.01 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.757 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.1 141.44 16.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 96.4 m-85 -117.0 122.0 42.97 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 113.637 -1.62 . . . . 0.0 107.377 177.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 47.7 m-85 -127.04 142.29 51.57 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 121.749 0.785 . . . . 0.0 111.317 -179.497 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.25 146.5 23.82 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.54 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.476 ' O ' ' O ' ' E' ' 23' ' ' ASP . 97.6 mt-10 -89.48 98.86 12.01 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.845 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' F' ' 24' ' ' VAL . 6.2 t70 -120.47 110.87 17.01 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 120.601 0.238 . . . . 0.0 110.758 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.6 m -60.42 -133.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.696 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' F' ' 26' ' ' SER . . . -76.91 85.72 0.99 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 119.784 -0.453 . . . . 0.0 112.797 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' F' ' 25' ' ' GLY . 5.9 p -34.97 170.09 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.144 0 CA-C-O 121.191 0.52 . . . . 0.0 111.292 178.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.524 ' CG ' ' H ' ' F' ' 28' ' ' LYS . 8.0 t-20 -140.19 -178.96 5.71 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.151 177.376 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.524 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 62.8 mttp 26.37 -107.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.003 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.39 94.46 0.15 Allowed Glycine 0 C--N 1.338 0.674 0 CA-C-O 119.269 -0.74 . . . . 0.0 111.988 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.403 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -67.4 178.99 1.38 Allowed 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 103.876 -2.639 . . . . 0.0 103.876 174.654 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.46 ' CD1' ' H ' ' L' ' 38' ' ' GLY . 0.2 OUTLIER -146.87 118.79 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-N 121.651 2.023 . . . . 0.0 111.03 -178.763 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 45.9 pt -118.56 140.91 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.462 -178.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -145.05 125.14 2.29 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 178.937 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 4.9 mp -116.88 127.86 54.68 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.473 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 2.9 tmm? -129.16 127.97 42.47 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 121.564 0.697 . . . . 0.0 112.876 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.473 ' N ' ' SD ' ' F' ' 35' ' ' MET . 3.6 p -156.15 82.02 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.719 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.233 179.079 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -71.23 101.39 0.96 Allowed Glycine 0 CA--C 1.53 0.988 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.475 -179.019 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -144.04 165.01 27.45 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -119.6 135.96 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.024 0.44 . . . . 0.0 110.331 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.728 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -83.32 141.46 31.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.601 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -55.71 142.33 34.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.842 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 8.0 m -121.24 132.86 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.847 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.514 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 81.5 t60 -146.45 160.62 41.85 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.609 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.514 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 8.1 p-80 -96.81 172.25 8.0 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.099 0.476 . . . . 0.0 109.804 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -148.4 177.52 9.37 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.054 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -143.95 145.82 32.52 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.97 115.43 18.52 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.613 0.72 . . . . 0.0 110.306 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -125.82 121.98 61.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.127 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -153.24 158.23 41.38 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.611 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -132.56 150.16 52.2 Favored 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.415 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.6 135.1 44.03 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.86 0.838 . . . . 0.0 112.283 -179.22 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -143.38 151.9 40.96 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.802 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.475 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 57.5 t0 60.68 114.91 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.261 0.553 . . . . 0.0 111.965 179.401 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.556 ' O ' ' O ' ' G' ' 26' ' ' SER . 0.3 OUTLIER -147.32 112.81 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.524 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 36.82 -91.35 0.01 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.383 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.556 ' O ' ' O ' ' G' ' 24' ' ' VAL . 10.8 p -89.33 -178.86 5.72 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.494 ' ND2' ' HG ' ' H' ' 26' ' ' SER . 33.1 m-80 -60.31 166.05 3.21 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 115.87 -2.332 . . . . 0.0 107.564 -177.392 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.558 ' NZ ' ' O ' ' I' ' 23' ' ' ASP . 29.6 tttm -53.69 107.35 0.25 Allowed 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 118.365 -1.334 . . . . 0.0 113.734 -177.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.51 100.81 2.71 Favored Glycine 0 N--CA 1.469 0.854 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 169.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 148.09 28.66 Favored 'General case' 0 C--O 1.248 0.985 1 CA-C-N 125.131 4.465 . . . . 0.0 109.378 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -162.71 107.36 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 112.47 -2.15 . . . . 0.0 106.96 -175.318 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.42 ' O ' ' O ' ' H' ' 33' ' ' GLY . 42.7 mm -108.8 104.73 17.54 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 C-N-CA 119.074 -1.051 . . . . 0.0 108.673 177.227 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.54 100.08 1.38 Allowed Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 104.336 -3.506 . . . . 0.0 104.336 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tp -147.32 149.07 32.11 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 123.321 1.534 . . . . 0.0 112.948 -177.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -111.92 135.61 52.33 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 112.476 -2.147 . . . . 0.0 110.579 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -135.54 66.4 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.11 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . 0.409 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -53.1 -103.06 0.01 OUTLIER Glycine 0 C--N 1.358 1.783 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.55 -177.89 47.93 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.41 144.66 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.013 0.435 . . . . 0.0 110.729 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.221 -0.402 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.705 -179.847 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -140.94 153.17 45.52 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.796 0.332 . . . . 0.0 110.164 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -128.54 129.95 46.73 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.358 -179.581 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 51.6 t -131.11 130.98 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.62 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.643 ' NE2' ' CD2' ' I' ' 13' ' ' HIS . 19.3 p80 -167.96 156.65 9.23 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.568 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -144.44 170.4 16.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -144.97 172.51 12.94 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.951 0.405 . . . . 0.0 110.671 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -176.13 126.02 0.2 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.664 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -136.38 122.54 20.37 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.665 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 34.2 m -123.79 129.45 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 121.352 0.596 . . . . 0.0 110.344 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . 0.426 ' CD1' ' N ' ' H' ' 19' ' ' PHE . 5.0 m-85 -113.11 116.39 29.79 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.847 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -110.65 117.53 33.75 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.02 129.84 51.59 Favored 'General case' 0 N--CA 1.475 0.814 0 O-C-N 121.269 -0.895 . . . . 0.0 112.884 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -171.08 145.28 2.24 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.549 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.475 ' CB ' ' H ' ' G' ' 23' ' ' ASP . 29.7 t70 -172.0 105.97 0.2 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.942 1.46 . . . . 0.0 114.942 178.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' H' ' 23' ' ' ASP . 58.5 t -29.17 141.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.303 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.414 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 169.4 -80.42 0.1 OUTLIER Glycine 0 CA--C 1.532 1.146 0 C-N-CA 118.833 -1.651 . . . . 0.0 114.448 179.425 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.522 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.3 OUTLIER 170.73 -179.11 0.05 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 118.299 1.05 . . . . 0.0 109.557 -177.091 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.522 ' O ' ' O ' ' H' ' 26' ' ' SER . 76.8 m-20 -27.76 157.49 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.955 -1.021 . . . . 0.0 112.802 -176.426 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.805 ' HZ1' ' N ' ' I' ' 25' ' ' GLY . 3.4 pttp 179.18 101.71 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.531 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.5 101.63 0.79 Allowed Glycine 0 N--CA 1.477 1.396 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 178.895 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.41 153.03 23.65 Favored 'General case' 0 C--O 1.255 1.379 0 CA-C-O 124.038 1.875 . . . . 0.0 112.777 -176.589 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.457 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.8 OUTLIER -152.95 128.27 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 111.519 -2.582 . . . . 0.0 109.797 -177.427 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . . . . . . . . . 2.1 tt -119.45 116.12 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -121.28 115.17 2.77 Favored Glycine 0 C--O 1.24 0.526 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -138.23 150.75 47.01 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 122.971 1.367 . . . . 0.0 112.924 -178.251 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.727 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 34.1 ttp -121.65 127.1 50.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.065 -1.425 . . . . 0.0 109.765 178.987 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -132.15 72.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 120.619 -0.433 . . . . 0.0 110.035 179.515 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.98 110.58 3.08 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 178.46 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.75 163.44 8.07 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.5 m -137.66 159.33 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.077 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.697 -179.781 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.39 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.93 160.17 43.52 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.503 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 53.6 mp0 -137.01 131.45 32.9 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.677 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . 0.473 ' C ' ' ND1' ' I' ' 13' ' ' HIS . 27.1 m -136.33 152.12 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 121.339 0.59 . . . . 0.0 110.869 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.643 ' CD2' ' NE2' ' H' ' 13' ' ' HIS . 12.9 m80 -139.78 140.92 36.79 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.185 -178.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' I' ' 15' ' ' GLN . 59.4 t-80 -153.48 162.12 41.58 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 178.48 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.592 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 49.8 tt0 -162.17 172.24 16.11 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.376 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . 0.455 ' H ' ' CG ' ' I' ' 15' ' ' GLN . 88.0 tttt -172.59 128.65 0.53 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.734 179.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 tt -130.27 121.47 26.18 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 39.6 t -120.34 126.53 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 122.256 -0.277 . . . . 0.0 111.709 -179.271 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 73.3 m-85 -103.98 101.26 11.04 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 176.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -113.27 117.85 33.01 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.22 124.87 35.61 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.15 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.442 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 14.4 pt-20 -127.09 75.41 1.58 Allowed 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.707 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.558 ' O ' ' NZ ' ' G' ' 28' ' ' LYS . 0.0 OUTLIER 164.03 115.0 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 114.198 -1.364 . . . . 0.0 109.872 176.158 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.586 ' C ' ' HZ1' ' H' ' 28' ' ' LYS . 39.5 t -148.57 107.47 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 118.976 -1.089 . . . . 0.0 108.726 173.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.805 ' N ' ' HZ1' ' H' ' 28' ' ' LYS . . . -39.62 -93.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.406 0 CA-C-O 123.984 1.88 . . . . 0.0 109.929 171.395 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.413 ' H ' ' H ' ' H' ' 28' ' ' LYS . 79.5 p 47.28 -178.59 0.01 OUTLIER 'General case' 0 CA--C 1.481 -1.703 0 CA-C-N 110.276 -2.962 . . . . 0.0 111.025 177.244 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' I' ' 28' ' ' LYS . 29.4 m120 -126.47 164.4 21.22 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.25 -1.795 . . . . 0.0 107.292 172.508 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' I' ' 27' ' ' ASN 0.263 45.1 mttm -27.85 112.56 0.06 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 114.984 1.476 . . . . 0.0 114.984 174.809 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 103.35 92.64 2.24 Favored Glycine 0 N--CA 1.48 1.577 0 C-N-CA 124.602 1.096 . . . . 0.0 115.169 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.498 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -87.64 179.71 6.47 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 173.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.416 ' CG1' ' C ' ' I' ' 30' ' ' ALA . 0.4 OUTLIER -141.83 124.65 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 C-N-CA 116.517 -2.073 . . . . 0.0 111.471 -176.902 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 9.1 tt -125.89 127.24 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.213 0.53 . . . . 0.0 111.778 -179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . 0.644 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.81 117.46 3.04 Favored Glycine 0 C--O 1.24 0.482 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 16.9 tp -137.84 135.36 36.13 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-O 121.611 0.719 . . . . 0.0 111.744 -178.982 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.681 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 54.9 ttp -105.21 125.3 50.83 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.75 176.409 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.79 72.09 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.135 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.58 111.3 3.5 Favored Glycine 0 C--N 1.364 2.128 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 177.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -71.99 160.51 54.07 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -136.79 162.01 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.805 0.336 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.552 -179.879 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -108.23 138.04 45.19 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.715 0.293 . . . . 0.0 110.329 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -75.95 128.18 34.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.016 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 23.4 m -140.97 161.14 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-O 121.268 0.556 . . . . 0.0 111.416 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 68.9 m80 -139.11 134.74 33.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.675 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . 0.642 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 4.8 t60 -148.56 158.11 43.91 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.759 0.79 . . . . 0.0 110.464 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.642 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 83.2 mt-30 -150.59 174.46 12.95 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.546 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 54.0 tttp -175.82 127.3 0.23 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.193 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -130.4 129.96 43.73 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . 0.461 ' HA ' ' O ' ' K' ' 18' ' ' VAL . 1.4 p -144.99 140.62 23.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -178.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.4 ' N ' ' CD1' ' J' ' 19' ' ' PHE . 0.6 OUTLIER -114.26 120.37 40.2 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.69 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.72 117.53 29.16 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.44 120.34 36.54 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 121.487 0.66 . . . . 0.0 111.653 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -159.69 104.45 1.58 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.486 ' CG ' ' H ' ' I' ' 24' ' ' VAL . 60.2 t0 -82.93 -133.52 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 175.424 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.54 ' O ' ' O ' ' J' ' 25' ' ' GLY . 21.9 t -92.2 112.17 25.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 N-CA-C 101.05 -3.685 . . . . 0.0 101.05 172.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . 0.54 ' O ' ' O ' ' J' ' 24' ' ' VAL . . . 42.38 90.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.01 -2.436 . . . . 0.0 107.01 -173.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.547 ' CB ' ' O ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -61.65 -179.82 0.2 Allowed 'General case' 0 N--CA 1.438 -1.034 0 C-N-CA 118.784 -1.167 . . . . 0.0 109.638 -174.865 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.466 ' N ' ' OG ' ' J' ' 26' ' ' SER . 1.6 m-20 -80.48 173.61 12.43 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 116.825 2.157 . . . . 0.0 116.825 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.552 ' O ' ' N ' ' J' ' 30' ' ' ALA 0.369 48.2 tttp -48.06 111.81 0.49 Allowed 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 109.221 -3.627 . . . . 0.0 116.782 173.499 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -68.34 99.19 0.56 Allowed Glycine 1 CA--C 1.446 -4.275 2 CA-C-O 128.699 4.5 . . . . 0.0 102.799 -176.331 . . . . . . . . 4 3 . 1 . 007 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -77.08 -132.78 0.01 OUTLIER 'General case' 1 N--CA 1.339 -6.005 3 CA-C-N 97.435 -9.383 . . . . 0.0 107.55 -167.012 . . . . . . . . 4 3 . 1 . 007 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.698 ' CD1' ' N ' ' J' ' 31' ' ' ILE . 0.1 OUTLIER -90.02 108.94 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.692 0 CA-C-N 114.57 -1.195 . . . . 0.0 110.467 -175.592 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.541 ' O ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -106.58 111.05 33.78 Favored 'Isoleucine or valine' 0 C--N 1.363 1.169 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.699 179.486 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.89 103.85 1.67 Allowed Glycine 0 CA--C 1.505 -0.545 0 N-CA-C 107.819 -2.112 . . . . 0.0 107.819 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.461 ' CD1' ' CE1' ' L' ' 19' ' ' PHE . 66.9 mt -126.03 121.72 33.8 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.951 0.881 . . . . 0.0 112.514 -177.253 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 6.1 ttt -102.94 120.37 40.51 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 114.252 -1.34 . . . . 0.0 108.391 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 3.6 t -137.23 66.86 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.327 -178.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.28 -102.63 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.13 154.88 30.65 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 50.5 t -130.67 136.57 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 32.7 t . . . . . 0 N--CA 1.468 0.457 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.29 179.591 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . 0.43 ' CD1' ' N ' ' K' ' 10' ' ' TYR . 11.6 p90 -133.68 152.12 51.81 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -91.97 138.79 31.25 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.347 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 74.1 t -126.58 134.72 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' L' ' 13' ' ' HIS . 44.3 t60 -116.41 123.48 47.64 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 117.845 0.293 . . . . 0.0 111.309 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -114.86 158.95 21.23 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.137 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.418 ' O ' ' CG ' ' K' ' 16' ' ' LYS . 53.4 tt0 -170.05 161.58 8.71 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.226 177.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 95.5 mttt -163.03 132.23 4.12 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.662 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 15.5 tp -122.9 119.21 29.81 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.221 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 96.6 t -136.42 133.74 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.604 ' CZ ' ' CD2' ' L' ' 19' ' ' PHE . 23.4 p90 -145.62 130.4 18.1 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.296 177.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.638 ' N ' ' CD1' ' K' ' 20' ' ' PHE . 0.0 OUTLIER -149.35 163.77 36.78 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -178.475 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 141.67 38.89 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.328 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . 0.547 ' O ' ' CB ' ' J' ' 26' ' ' SER . 78.1 tt0 -89.71 156.59 18.45 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -178.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.52 ' OD2' ' N ' ' J' ' 28' ' ' LYS . 58.6 t0 176.11 130.79 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 123.465 0.706 . . . . 0.0 110.522 178.589 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.43 ' CG2' ' H ' ' K' ' 25' ' ' GLY . 5.3 m -87.53 -112.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.084 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 26' ' ' SER . . . -48.75 92.11 0.01 OUTLIER Glycine 0 CA--C 1.531 1.062 0 N-CA-C 114.838 0.695 . . . . 0.0 114.838 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.53 ' O ' ' O ' ' K' ' 25' ' ' GLY . 8.6 t -35.46 170.32 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.611 0.719 . . . . 0.0 111.368 176.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.481 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER -139.22 -177.15 4.78 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.946 177.751 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . 0.481 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 98.9 mttt -17.84 -104.87 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 113.242 0.83 . . . . 0.0 113.242 -178.304 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -150.44 95.34 0.16 Allowed Glycine 0 C--N 1.346 1.089 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.692 -179.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' J' ' 29' ' ' GLY . . . -67.82 -173.13 0.32 Allowed 'General case' 0 C--O 1.237 0.444 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 175.135 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.77 130.03 14.06 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-O 122.212 1.006 . . . . 0.0 110.22 -179.465 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 11.1 mm -114.84 122.5 69.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 114.164 -1.38 . . . . 0.0 110.485 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.434 ' H ' HG21 ' J' ' 32' ' ' ILE . . . -127.98 119.72 3.22 Favored Glycine 0 N--CA 1.473 1.121 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.722 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -129.39 122.25 29.05 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 114.524 -0.838 . . . . 0.0 110.211 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 38.8 ttp -105.96 119.62 39.64 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.88 178.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . 0.484 ' CG1' ' O ' ' K' ' 36' ' ' VAL . 54.7 t -139.8 71.06 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 119.415 -0.326 . . . . 0.0 110.53 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' K' ' 36' ' ' VAL . . . -53.88 -97.87 0.01 OUTLIER Glycine 0 C--N 1.342 0.897 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.802 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.32 163.83 35.86 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.01 162.5 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 7.2 p . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.575 179.946 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -104.53 132.46 50.75 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.653 0.264 . . . . 0.0 110.395 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -80.84 131.29 35.38 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t -133.56 137.87 52.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.405 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' K' ' 13' ' ' HIS . 15.5 m80 -81.58 145.95 30.37 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.191 0.52 . . . . 0.0 111.047 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -83.45 177.78 8.31 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.196 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -110.73 178.69 4.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.813 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -146.24 140.85 26.83 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.045 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 28.6 tp -125.33 119.99 29.89 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . 0.475 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 7.3 t -141.45 131.9 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.643 0.735 . . . . 0.0 112.026 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.604 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 8.0 p90 -147.5 144.58 28.66 Favored 'General case' 0 C--N 1.322 -0.597 0 O-C-N 121.363 -0.835 . . . . 0.0 110.926 178.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' L' ' 19' ' ' PHE . 60.2 m-85 -157.77 157.35 33.21 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.52 1.152 . . . . 0.0 113.958 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.35 139.42 52.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.868 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -74.48 101.71 4.24 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.786 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 35.6 p-10 -171.4 113.76 0.37 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.778 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' L' ' 26' ' ' SER . 73.7 t -64.99 131.71 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.861 -178.41 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.51 83.76 0.01 OUTLIER Glycine 0 N--CA 1.466 0.655 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.518 ' N ' ' O ' ' L' ' 24' ' ' VAL . 15.4 m -67.52 -171.1 0.17 Allowed 'General case' 0 N--CA 1.437 -1.124 0 CA-C-O 122.541 1.163 . . . . 0.0 112.488 -177.309 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.515 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 54.3 t30 -80.51 179.39 7.76 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.788 -177.857 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.515 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.4 mttt -36.41 104.4 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.577 -178.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 168.09 -100.36 0.16 Allowed Glycine 0 C--O 1.22 -0.774 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -175.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.413 ' C ' ' CG1' ' L' ' 31' ' ' ILE . . . -51.35 172.13 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.682 1.741 . . . . 0.0 108.054 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . 0.413 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -152.53 149.41 13.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 C-N-CA 118.144 -1.423 . . . . 0.0 111.253 -176.44 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 38.5 pt -125.89 143.63 38.77 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.153 -179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.27 114.73 1.51 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.6 mt -119.09 120.31 36.77 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttp -111.75 123.99 51.39 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 120.204 -0.599 . . . . 0.0 111.47 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' L' ' 37' ' ' GLY . 4.9 t -133.91 69.68 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 36' ' ' VAL . . . -27.17 -105.69 0.0 OUTLIER Glycine 0 CA--C 1.533 1.187 0 CA-C-O 121.344 0.413 . . . . 0.0 114.064 -179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . 0.46 ' H ' ' CD1' ' F' ' 31' ' ' ILE . . . -38.09 156.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 115.312 -0.444 . . . . 0.0 112.459 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.79 159.32 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.189 -0.505 . . . . 0.0 110.06 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.828 -179.721 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . 0.414 ' H ' ' H ' ' A' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.414 ' H ' ' H ' ' A' ' 9' ' ' GLY . 97.7 m-85 -110.25 133.94 52.74 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.807 0.337 . . . . 0.0 110.259 179.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -62.45 130.8 46.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.197 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 9.9 p -146.15 146.93 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.729 -179.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 14' ' ' HIS . 37.5 p-80 -91.12 -178.63 5.22 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.451 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 13' ' ' HIS . 24.8 m-70 -74.26 172.5 11.72 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -145.36 176.73 9.35 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.504 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -150.01 112.09 4.61 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.26 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -124.45 115.46 20.95 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 121.424 0.631 . . . . 0.0 110.261 179.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -123.6 128.96 74.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.403 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -128.76 124.13 34.7 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.9 p90 -128.04 125.63 39.71 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.94 0.4 . . . . 0.0 110.253 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.12 119.03 35.04 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -164.2 120.27 1.59 Allowed 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.503 ' CG ' ' H ' ' A' ' 24' ' ' VAL . 38.7 t0 65.42 -136.22 0.21 Allowed 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.561 -178.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.503 ' H ' ' CG ' ' A' ' 23' ' ' ASP . 12.1 m -29.49 104.39 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.427 1.269 . . . . 0.0 114.427 -178.267 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 130.54 -101.22 0.49 Allowed Glycine 0 N--CA 1.468 0.799 0 CA-C-N 113.15 -1.841 . . . . 0.0 110.675 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.3 t -129.79 140.43 51.04 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 120.115 1.957 . . . . 0.0 111.99 174.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 -57.22 179.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.471 ' CB ' ' OD2' ' B' ' 23' ' ' ASP 0.442 74.5 tttt -59.76 110.62 1.2 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 112.073 -2.331 . . . . 0.0 111.576 169.135 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.66 104.03 1.23 Allowed Glycine 0 C--N 1.302 -1.317 0 CA-C-O 127.334 3.741 . . . . 0.0 112.02 -169.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . 0.545 ' O ' ' N ' ' A' ' 32' ' ' ILE . . . -69.81 -122.2 0.0 OUTLIER 'General case' 0 CA--C 1.479 -1.778 3 CA-C-N 103.478 -6.361 . . . . 0.0 96.052 -179.563 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.644 ' CD1' ' O ' ' A' ' 31' ' ' ILE . 0.0 OUTLIER -51.16 99.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.587 2.401 0 CA-C-N 124.89 3.495 . . . . 0.0 107.895 175.942 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' ALA . 4.9 tt -128.78 113.44 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 119.419 -2.051 . . . . 0.0 109.387 178.541 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.516 ' HA2' ' O ' ' B' ' 33' ' ' GLY . . . -129.36 126.06 5.04 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 106.617 -2.593 . . . . 0.0 106.617 178.027 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 36.8 tp -133.67 135.22 43.96 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 122.529 1.157 . . . . 0.0 111.641 -178.251 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 12.5 ttm -104.66 110.54 22.9 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 113.752 -1.567 . . . . 0.0 107.198 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.15 72.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.7 110.83 3.12 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.15 165.74 11.95 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -95.01 135.98 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 110.711 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.62 179.797 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -102.92 134.93 45.52 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -141.21 130.35 23.42 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.952 0.406 . . . . 0.0 110.834 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.17 146.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.627 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 t60 -154.83 104.68 2.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.038 0.447 . . . . 0.0 111.16 179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' ND1' ' C' ' 14' ' ' HIS . 31.3 m170 -119.35 164.51 15.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -154.47 173.03 16.81 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.01 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -153.67 114.11 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.809 178.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -128.39 114.49 16.91 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.92 133.73 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-O 121.101 0.477 . . . . 0.0 111.064 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -119.46 129.61 54.83 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.997 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -124.65 129.07 49.84 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.691 -0.231 . . . . 0.0 110.468 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.13 128.34 43.27 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 111.859 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.8 tt0 -136.79 149.36 47.73 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' CB ' ' A' ' 28' ' ' LYS . 81.3 m-20 -137.99 145.78 42.32 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.812 0.339 . . . . 0.0 111.344 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 1.6 m -107.33 110.59 32.35 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.575 ' H ' ' CG2' ' C' ' 24' ' ' VAL . . . 34.41 90.89 0.01 OUTLIER Glycine 0 N--CA 1.471 0.977 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.793 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.9 t 152.41 171.79 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.793 ' O ' ' O ' ' B' ' 26' ' ' SER . 1.3 t-20 20.51 179.79 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 177.806 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.461 ' CB ' ' O ' ' B' ' 27' ' ' ASN . 82.0 tttt 151.28 92.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 122.472 1.13 . . . . 0.0 110.27 -175.186 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.62 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . 31.54 -128.7 0.21 Allowed Glycine 1 CA--C 1.419 -5.908 0 CA-C-N 113.362 -1.745 . . . . 0.0 109.918 -178.814 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.62 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 119.44 -112.39 0.0 OUTLIER 'General case' 0 N--CA 1.391 -3.425 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 -173.213 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.464 ' H ' HD12 ' B' ' 31' ' ' ILE . 2.3 mp -79.79 113.29 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.037 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.507 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 14.7 tt -124.85 109.35 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.25 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.629 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -130.06 120.37 3.07 Favored Glycine 0 N--CA 1.468 0.815 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.433 ' O ' ' CD1' ' C' ' 34' ' ' LEU . 7.4 mp -136.5 160.34 39.07 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 123.219 1.485 . . . . 0.0 113.67 -178.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.6 ttm -127.5 112.33 14.82 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 112.791 -2.004 . . . . 0.0 107.677 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . 0.464 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -119.6 74.07 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -179.583 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -31.89 -97.99 0.01 OUTLIER Glycine 0 C--N 1.357 1.749 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.48 -173.09 24.59 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.0 p -141.35 141.8 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.95 0.405 . . . . 0.0 110.511 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.945 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -146.27 156.24 43.23 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.871 0.367 . . . . 0.0 110.787 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -116.32 137.87 51.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.21 132.25 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.156 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 17.2 p-80 -155.63 143.0 19.42 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 121.13 0.491 . . . . 0.0 111.241 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.632 ' ND1' ' CD2' ' B' ' 14' ' ' HIS . 6.1 m80 -140.91 167.38 22.33 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.11 0.481 . . . . 0.0 109.931 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -150.99 169.88 20.7 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.964 178.277 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -156.96 117.9 3.66 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.55 123.79 40.86 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.648 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -133.54 133.28 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -116.82 107.4 14.58 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 105.287 -2.116 . . . . 0.0 105.287 175.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 24.3 t80 -122.48 134.84 54.56 Favored 'General case' 0 N--CA 1.477 0.878 0 O-C-N 122.312 -0.242 . . . . 0.0 110.532 -177.883 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . 0.426 ' CB ' ' NZ ' ' A' ' 28' ' ' LYS . . . -145.61 144.11 30.27 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -142.61 110.73 5.99 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 114.147 -1.388 . . . . 0.0 109.642 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' C' ' 24' ' ' VAL . 4.1 m-20 -118.8 133.24 55.98 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.575 ' CG2' ' H ' ' B' ' 25' ' ' GLY . 4.9 t -28.81 -112.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -144.09 90.54 0.16 Allowed Glycine 0 CA--C 1.533 1.201 0 O-C-N 122.114 -0.366 . . . . 0.0 113.358 -176.05 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.57 ' O ' ' O ' ' C' ' 27' ' ' ASN . 33.4 p -140.4 170.61 15.47 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 117.83 0.815 . . . . 0.0 109.483 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.57 ' O ' ' O ' ' C' ' 26' ' ' SER . 33.3 m120 -30.21 170.81 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 64.4 tttt -108.6 -111.7 0.31 Allowed 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.105 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 43.13 91.24 0.01 OUTLIER Glycine 0 CA--C 1.489 -1.593 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.95 155.8 49.72 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.492 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -141.5 117.39 6.5 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 112.295 -2.23 . . . . 0.0 109.204 -170.592 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 5.4 mt -105.5 111.64 35.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . 0.499 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -122.11 104.39 0.91 Allowed Glycine 0 CA--C 1.506 -0.499 0 N-CA-C 106.273 -2.731 . . . . 0.0 106.273 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.433 ' CD1' ' O ' ' B' ' 34' ' ' LEU . 54.6 tp -132.59 141.05 48.52 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 123.3 1.524 . . . . 0.0 113.806 -176.589 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.543 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 8.3 ttm -115.56 118.43 33.11 Favored 'General case' 0 CA--C 1.505 -0.774 0 CA-C-N 112.4 -2.182 . . . . 0.0 109.262 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 1.3 m -128.57 74.12 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.19 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.1 105.68 3.08 Favored Glycine 0 C--N 1.354 1.545 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -129.76 148.29 18.34 Favored Glycine 0 N--CA 1.466 0.685 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 m -134.05 159.8 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.944 0.402 . . . . 0.0 110.834 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.914 179.816 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.15 129.93 54.77 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.867 0.365 . . . . 0.0 110.529 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 15.1 pt-20 -72.76 150.85 42.47 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.166 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 t -103.57 126.86 57.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.8 p-80 -157.8 148.74 21.14 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.632 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.565 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 56.7 t-80 -144.98 158.83 43.69 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.253 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . 0.565 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 67.7 mt-30 -156.22 172.15 18.96 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.106 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -155.63 122.3 5.29 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.709 179.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 47.7 tp -117.39 123.1 45.63 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 39.1 t -130.53 131.22 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -112.73 108.88 18.06 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 175.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.0 t80 -123.35 123.76 41.43 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 120.93 0.395 . . . . 0.0 112.026 -176.809 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.61 127.32 30.96 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.253 178.694 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -140.46 114.29 8.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.771 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.517 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.2 OUTLIER 178.65 117.85 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.971 179.875 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -43.52 120.88 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 176.94 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' D' ' 26' ' ' SER . . . -109.43 -82.43 1.37 Allowed Glycine 0 CA--C 1.53 1.004 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.175 179.405 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.862 ' O ' ' O ' ' D' ' 27' ' ' ASN . 2.9 p 151.74 171.41 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 -178.717 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.862 ' O ' ' O ' ' D' ' 26' ' ' SER . 68.7 m-80 22.09 -178.18 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 123.919 0.762 . . . . 0.0 113.005 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.534 ' NZ ' ' OD1' ' F' ' 27' ' ' ASN . 73.3 mttt -119.17 -111.19 0.34 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.477 -1.39 . . . . 0.0 112.518 -177.079 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' D' ' 28' ' ' LYS . . . 41.78 91.29 0.01 OUTLIER Glycine 0 N--CA 1.477 1.405 0 C-N-CA 120.293 -0.956 . . . . 0.0 110.747 -179.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.5 156.21 48.91 Favored 'General case' 0 CA--C 1.487 -1.452 0 N-CA-C 101.352 -3.574 . . . . 0.0 101.352 175.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.418 ' C ' ' SD ' ' J' ' 35' ' ' MET . 0.0 OUTLIER -136.27 122.59 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.647 -171.33 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CE ' ' K' ' 35' ' ' MET . 78.4 mt -116.36 123.27 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.055 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.57 109.19 1.08 Allowed Glycine 0 N--CA 1.463 0.461 0 N-CA-C 107.609 -2.196 . . . . 0.0 107.609 175.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 14.7 tp -122.09 124.53 44.12 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 121.541 0.686 . . . . 0.0 112.243 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.508 ' SD ' ' N ' ' J' ' 32' ' ' ILE . 13.5 ttm -102.86 113.6 27.18 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.01 72.85 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.809 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.14 111.53 3.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 178.91 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.73 135.47 7.22 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -124.27 135.95 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.797 0.332 . . . . 0.0 110.309 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.588 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.49 148.25 33.56 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.788 0.328 . . . . 0.0 110.237 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 59.9 mm-40 -57.45 136.36 56.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.296 -0.411 . . . . 0.0 109.951 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -135.33 142.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -109.85 -178.89 3.65 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 118.179 0.445 . . . . 0.0 110.959 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CD2' ' F' ' 13' ' ' HIS . 93.8 m-70 -142.41 -178.66 5.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.751 0.786 . . . . 0.0 110.149 -179.078 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -88.46 168.0 12.99 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.661 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.42 143.38 33.88 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.273 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -131.22 124.35 30.4 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.146 0.498 . . . . 0.0 111.671 -178.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -128.3 129.39 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.854 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 35.9 m-85 -117.99 120.85 39.05 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.801 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -128.59 127.66 42.71 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 117.927 0.331 . . . . 0.0 111.124 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.3 131.55 43.89 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 122.381 1.086 . . . . 0.0 113.058 -179.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -138.27 85.73 2.11 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.069 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -93.97 -130.71 0.14 Allowed 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.415 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . 0.456 HG21 ' H ' ' D' ' 25' ' ' GLY . 82.9 t -106.2 112.32 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 N-CA-C 104.747 -2.316 . . . . 0.0 104.747 175.301 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 31.76 88.08 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 113.904 -1.498 . . . . 0.0 112.977 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.482 ' N ' ' HB2' ' F' ' 23' ' ' ASP . 35.3 p -128.24 141.51 51.43 Favored 'General case' 0 C--N 1.35 0.597 0 CA-C-N 119.262 1.531 . . . . 0.0 108.718 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.862 ' ND2' ' H ' ' E' ' 28' ' ' LYS . 1.8 t-20 -58.21 178.91 0.08 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 178.98 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.862 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 98.1 mttt -50.19 -105.24 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 111.528 -2.578 . . . . 0.0 105.626 168.109 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.644 ' C ' ' O ' ' E' ' 30' ' ' ALA . . . -80.9 99.26 1.88 Allowed Glycine 0 CA--C 1.476 -2.396 0 CA-C-N 113.611 -1.631 . . . . 0.0 110.88 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.644 ' O ' ' C ' ' E' ' 29' ' ' GLY . . . -76.38 -136.84 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.886 1 N-CA-C 93.028 -6.656 . . . . 0.0 93.028 168.326 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.5 OUTLIER -85.09 114.91 26.0 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 1 CA-C-N 127.789 4.813 . . . . 0.0 109.163 176.935 . . . . . . . . 4 4 . 1 . 008 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' K' ' 35' ' ' MET . 16.1 tt -136.69 134.94 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-O 121.719 0.771 . . . . 0.0 112.452 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -131.9 127.36 4.95 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 23.9 tp -121.03 124.26 44.41 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.637 -0.282 . . . . 0.0 111.679 -178.369 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.1 tpp -115.99 114.6 24.82 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.86 88.51 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.62 -178.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.58 95.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 119.67 -1.253 . . . . 0.0 110.342 178.154 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -159.28 162.56 32.86 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.56 162.77 34.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.311 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -148.26 159.59 43.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.016 0.436 . . . . 0.0 111.256 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -67.25 137.9 56.5 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.985 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -127.16 132.38 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.326 0.584 . . . . 0.0 110.999 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' NE2' ' E' ' 14' ' ' HIS . 27.2 t-80 -156.07 100.95 2.06 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.888 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -147.23 173.3 12.68 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -145.03 174.65 10.85 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.319 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -145.99 112.71 5.98 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.032 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 35.8 mt -125.07 110.2 13.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 m -145.93 147.12 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 118.682 -1.207 . . . . 0.0 114.244 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 73.0 m-85 -126.7 128.3 46.48 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 113.967 -1.469 . . . . 0.0 108.431 177.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -138.36 146.48 42.35 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.12 0.486 . . . . 0.0 111.458 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.55 146.48 32.39 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.956 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -88.07 127.47 35.4 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.482 ' HB2' ' N ' ' E' ' 26' ' ' SER . 67.1 t0 178.1 114.36 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 79.6 t -65.39 132.44 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.173 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . 71.68 -85.08 0.45 Allowed Glycine 0 N--CA 1.47 0.958 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.877 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 26' ' ' SER . . . . . 0.551 ' CB ' ' O ' ' F' ' 25' ' ' GLY . 2.8 t 140.23 165.4 0.0 OUTLIER 'General case' 0 C--N 1.352 0.703 0 CA-C-O 122.577 1.18 . . . . 0.0 112.905 174.46 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.534 ' OD1' ' NZ ' ' D' ' 28' ' ' LYS . 0.5 OUTLIER -46.48 171.93 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.44 175.535 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -69.93 111.53 5.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 170.31 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 75.88 -92.88 0.93 Allowed Glycine 0 N--CA 1.475 1.257 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.861 179.07 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.5 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . 83.38 160.28 0.12 Allowed 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 100.439 -3.911 . . . . 0.0 100.439 -174.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.5 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.2 OUTLIER -151.67 127.87 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 122.45 2.386 . . . . 0.0 111.039 -176.286 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -121.43 132.77 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-N 114.151 -1.386 . . . . 0.0 114.254 -175.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -130.22 115.12 1.78 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 mt -118.45 127.49 53.71 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.428 ' SD ' ' CA ' ' L' ' 33' ' ' GLY . 1.8 ttt -132.09 126.7 34.41 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.539 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -143.33 82.52 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.442 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.23 100.37 0.04 OUTLIER Glycine 0 C--N 1.337 0.61 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.674 -179.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.11 163.09 35.76 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -121.45 132.94 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.924 0.393 . . . . 0.0 110.315 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.897 -179.566 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.386 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.63 129.36 53.89 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -147.29 147.73 30.69 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-O 121.126 0.488 . . . . 0.0 110.475 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.6 m -133.85 163.48 37.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.239 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -157.71 149.02 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.675 179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 14.8 t60 -147.84 163.56 36.38 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 85.3 mt-30 -151.64 178.17 9.61 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.326 0.584 . . . . 0.0 110.871 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 25.5 pttm -167.72 133.57 2.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.266 179.262 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -133.57 125.05 28.0 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.95 138.14 49.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.248 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -134.77 137.25 43.24 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . 0.483 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 54.3 p90 -135.18 129.05 33.16 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.142 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.38 134.75 50.96 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -157.21 124.66 5.28 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.359 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.558 ' O ' ' O ' ' G' ' 24' ' ' VAL . 12.0 m-20 -154.13 122.71 6.21 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 120.827 -0.349 . . . . 0.0 111.849 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.558 ' O ' ' O ' ' G' ' 23' ' ' ASP . 11.8 m -43.67 -122.1 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 O-C-N 124.273 0.983 . . . . 0.0 111.621 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.49 -90.79 1.35 Allowed Glycine 0 CA--C 1.528 0.886 0 CA-C-O 119.52 -0.6 . . . . 0.0 113.023 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' G' ' 27' ' ' ASN . 1.3 p 173.76 -170.58 0.04 OUTLIER 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 117.587 0.694 . . . . 0.0 109.625 -177.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' G' ' 26' ' ' SER . 16.4 t-20 -16.98 158.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 O-C-N 125.149 1.53 . . . . 0.0 113.49 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.531 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 28.6 tttt -161.56 108.54 1.4 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.58 98.1 0.66 Allowed Glycine 0 N--CA 1.467 0.746 0 CA-C-O 116.221 -2.433 . . . . 0.0 107.935 172.804 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -90.08 154.24 19.95 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 123.627 3.714 . . . . 0.0 110.552 -176.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -153.82 114.55 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 112.528 -2.124 . . . . 0.0 109.75 -173.626 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 6.0 tt -122.78 113.79 39.61 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 176.355 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.68 137.61 9.52 Favored Glycine 0 CA--C 1.502 -0.731 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.123 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -153.26 146.81 25.01 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 122.447 1.117 . . . . 0.0 112.024 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.402 ' CE ' ' O ' ' A' ' 31' ' ' ILE . 31.0 mtp -105.19 119.15 38.34 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 113.257 -1.792 . . . . 0.0 107.878 178.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.76 65.72 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.297 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.283 178.912 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.95 102.42 0.56 Allowed Glycine 0 C--N 1.376 2.754 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 177.08 170.3 39.35 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m -139.73 142.94 31.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.93 0.395 . . . . 0.0 110.258 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.022 -0.99 . . . . 0.0 110.736 -179.863 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -83.63 136.41 34.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.979 0.419 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -80.45 164.48 23.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.83 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 54.3 t -86.9 132.57 32.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.838 179.83 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.62 ' ND1' ' NE2' ' I' ' 13' ' ' HIS . 40.7 m80 -137.18 145.78 44.13 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.953 0.406 . . . . 0.0 111.396 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.531 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 99.1 m-70 -147.09 155.96 42.61 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.4 mm-40 -148.73 168.29 23.3 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.41 178.716 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -163.6 128.63 2.96 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.46 -0.791 . . . . 0.0 108.983 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 5.6 tt -127.46 118.11 23.4 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 72.8 t -122.2 129.48 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.202 -179.249 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -126.25 122.87 36.78 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.489 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -126.84 127.66 45.33 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.702 0.286 . . . . 0.0 111.374 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.36 125.61 50.38 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 120.981 0.42 . . . . 0.0 111.525 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' O ' ' I' ' 22' ' ' GLU . 52.7 tp10 -132.67 157.4 44.94 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.664 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -158.64 142.03 14.98 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.42 112.72 25.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 122.344 1.068 . . . . 0.0 110.391 -177.878 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . 0.561 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . 41.1 86.92 0.01 OUTLIER Glycine 0 CA--C 1.521 0.417 0 CA-C-N 113.177 -1.828 . . . . 0.0 114.122 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.769 ' O ' ' O ' ' H' ' 27' ' ' ASN . 82.9 p -152.94 170.95 19.14 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.673 175.022 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.769 ' O ' ' O ' ' H' ' 26' ' ' SER . 63.3 t30 -19.67 -173.71 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.167 0 O-C-N 125.293 1.621 . . . . 0.0 115.293 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.604 ' H ' ' CG ' ' H' ' 27' ' ' ASN . 15.2 mmtt -138.12 -104.64 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 115.14 -0.936 . . . . 0.0 108.995 174.927 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 40.61 95.3 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 C-N-CA 120.239 -0.981 . . . . 0.0 110.749 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.11 145.41 51.29 Favored 'General case' 0 CA--C 1.497 -1.082 0 CA-C-O 123.279 1.514 . . . . 0.0 107.546 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.414 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -140.03 121.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-N 112.404 -2.18 . . . . 0.0 110.529 -173.474 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.513 ' N ' ' SD ' ' B' ' 35' ' ' MET . 8.7 tt -111.33 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 CA-C-O 121.613 0.72 . . . . 0.0 110.112 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.37 94.85 0.76 Allowed Glycine 0 N--CA 1.461 0.366 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 179.577 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 35.6 mt -117.0 129.25 55.9 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.273 1.035 . . . . 0.0 111.551 -178.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.629 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 21.9 ttp -116.27 115.52 26.1 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.312 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.89 71.15 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.897 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.61 112.41 3.61 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -50.64 152.52 4.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.84 162.02 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.297 179.901 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.29 125.89 50.17 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.666 0.269 . . . . 0.0 110.336 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -88.12 121.9 31.06 Favored 'General case' 0 C--O 1.236 0.391 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 16.3 m -137.8 161.7 32.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-O 121.553 0.692 . . . . 0.0 111.757 -179.164 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.62 ' NE2' ' ND1' ' H' ' 13' ' ' HIS . 71.2 m80 -150.07 101.85 3.05 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.134 178.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 84.9 t60 -121.23 162.91 19.39 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.853 0.835 . . . . 0.0 111.376 -178.808 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.546 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 84.3 mt-30 -148.47 177.73 9.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.098 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -171.01 125.28 0.66 Allowed 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.4 mt -126.71 123.34 37.28 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.095 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' J' ' 18' ' ' VAL . 12.6 p -136.41 133.32 49.44 Favored 'Isoleucine or valine' 0 C--N 1.351 0.663 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -115.68 126.06 53.63 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.649 177.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -129.38 121.85 28.26 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 118.327 0.512 . . . . 0.0 111.03 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.31 128.46 51.08 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.077 0.465 . . . . 0.0 111.224 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' H' ' 22' ' ' GLU . 82.1 tt0 -149.02 124.67 10.43 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.311 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -157.11 103.97 2.05 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 118.909 -1.116 . . . . 0.0 113.799 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.561 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 2.2 p -31.78 147.67 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.525 -1.216 . . . . 0.0 113.07 175.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . 0.4 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 168.52 -79.42 0.1 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.282 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 1.001 ' O ' ' O ' ' I' ' 27' ' ' ASN . 2.1 p 161.66 179.86 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 1.001 ' O ' ' O ' ' I' ' 26' ' ' SER . 8.2 m120 10.52 -178.74 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.112 0 O-C-N 124.841 1.338 . . . . 0.0 113.251 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.497 ' O ' ' N ' ' J' ' 29' ' ' GLY . 12.7 tttt -149.15 109.77 4.24 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 116.202 -2.199 . . . . 0.0 114.646 177.625 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.96 94.65 0.79 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 106.248 -2.741 . . . . 0.0 106.248 168.194 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.43 144.4 51.06 Favored 'General case' 0 CA--C 1.476 -1.882 0 CA-C-N 122.543 3.171 . . . . 0.0 107.094 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.516 ' CG2' ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -144.15 125.24 9.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 113.09 -1.868 . . . . 0.0 109.504 -175.189 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.543 ' N ' ' SD ' ' C' ' 35' ' ' MET . 0.8 OUTLIER -105.22 110.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.064 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.69 101.73 1.24 Allowed Glycine 0 CA--C 1.494 -1.243 0 N-CA-C 104.817 -3.313 . . . . 0.0 104.817 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.578 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 17.0 tp -136.82 137.55 39.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-O 122.11 0.957 . . . . 0.0 112.508 -175.085 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 31.1 ttp -122.86 123.42 40.94 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 113.74 -1.573 . . . . 0.0 110.164 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.35 71.56 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.826 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.84 113.1 5.03 Favored Glycine 0 C--N 1.358 1.779 0 N-CA-C 110.531 -1.027 . . . . 0.0 110.531 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.16 147.81 41.66 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 64.3 t -130.87 137.29 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 30.4 m . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.44 179.815 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.379 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -82.96 138.94 33.6 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.846 0.355 . . . . 0.0 110.362 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -81.28 135.22 35.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.642 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.19 144.97 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 CA-C-N 116.348 -0.387 . . . . 0.0 109.998 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.9 OUTLIER -131.31 155.98 46.25 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 121.19 0.519 . . . . 0.0 110.943 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -152.4 160.18 43.32 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -154.67 172.25 18.2 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.219 -0.592 . . . . 0.0 110.634 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -155.75 127.96 7.65 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.747 178.527 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 87.4 mt -120.47 120.12 34.98 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.486 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . 0.459 ' O ' ' HA ' ' I' ' 18' ' ' VAL . 2.0 p -143.06 137.92 26.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -177.898 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.83 127.9 13.7 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 119.684 -0.806 . . . . 0.0 111.403 176.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -147.77 160.82 42.31 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.443 1.116 . . . . 0.0 113.752 -178.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 140.17 43.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 113.934 -1.484 . . . . 0.0 109.946 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.17 149.44 39.74 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.968 -178.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 33.7 t70 -173.49 126.46 0.41 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.08 0.467 . . . . 0.0 111.293 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 5.4 m -62.61 -116.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.516 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.47 -92.22 0.06 OUTLIER Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.603 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.831 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.3 t -171.24 170.05 6.17 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 117.535 0.668 . . . . 0.0 109.986 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.831 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.8 m120 10.85 -179.16 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 125.763 1.914 . . . . 0.0 115.567 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.547 ' H ' ' N ' ' K' ' 27' ' ' ASN . 15.8 pttt -149.4 110.76 4.44 Favored 'General case' 0 CA--C 1.558 1.25 0 O-C-N 120.635 -1.29 . . . . 0.0 114.284 178.263 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -61.48 93.22 0.07 OUTLIER Glycine 0 N--CA 1.479 1.517 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 172.077 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -126.39 149.33 49.3 Favored 'General case' 0 CA--C 1.486 -1.489 0 CA-C-N 121.677 2.739 . . . . 0.0 111.069 -178.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.487 ' C ' ' SD ' ' D' ' 35' ' ' MET . 0.0 OUTLIER -148.33 114.42 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.816 0 CA-C-N 108.989 -3.732 . . . . 0.0 107.612 -174.968 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.508 ' N ' ' SD ' ' D' ' 35' ' ' MET . 3.1 mt -105.56 118.74 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 CA-C-O 120.749 0.309 . . . . 0.0 110.429 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.96 100.78 0.91 Allowed Glycine 0 C--O 1.239 0.421 0 N-CA-C 106.9 -2.48 . . . . 0.0 106.9 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.627 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 55.7 tp -129.58 135.39 48.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.003 0.906 . . . . 0.0 112.415 -177.39 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.418 ' SD ' ' C ' ' D' ' 31' ' ' ILE . 48.9 ttp -117.87 117.07 28.28 Favored 'General case' 0 CA--C 1.502 -0.881 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.55 175.981 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.26 72.2 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 178.608 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.51 111.87 4.5 Favored Glycine 0 C--N 1.36 1.861 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 178.503 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.36 -151.58 3.07 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -179.199 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.9 m -133.26 158.07 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.097 0.475 . . . . 0.0 110.74 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 4.3 p . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.626 -179.852 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -97.48 131.37 44.17 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.797 0.332 . . . . 0.0 110.144 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -97.21 148.06 23.47 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.702 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.5 m -118.88 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.099 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . 0.631 ' CE1' ' NE2' ' L' ' 14' ' ' HIS . 1.8 p80 -161.7 168.87 22.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.475 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.537 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 39.4 t-80 -138.71 165.67 26.36 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.548 0.69 . . . . 0.0 110.901 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.537 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 87.4 mt-30 -148.42 178.69 8.38 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.966 -1.015 . . . . 0.0 110.091 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 38.2 ttmt -172.76 123.41 0.44 Allowed 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 118.419 -0.8 . . . . 0.0 111.45 -178.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . 0.943 ' O ' ' C ' ' L' ' 17' ' ' LEU . 9.4 mp -110.73 119.07 37.92 Favored 'General case' 0 C--N 1.379 1.85 0 CA-C-O 123.836 1.779 . . . . 0.0 111.111 177.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 7.1 p -138.25 112.07 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 O-C-N 120.675 -1.266 . . . . 0.0 111.432 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 1.7 p90 -134.51 139.62 45.59 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 176.383 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.47 ' CB ' ' O ' ' L' ' 20' ' ' PHE . 30.3 p90 -154.77 162.9 40.94 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -176.553 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.35 130.61 48.0 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.412 178.628 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.31 137.13 50.83 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.158 0.504 . . . . 0.0 111.965 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 56.6 t0 -159.56 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.323 178.96 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' K' ' 26' ' ' SER . 55.9 t -123.88 123.02 66.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 179.047 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.476 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 32.0 -84.35 0.0 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' K' ' 24' ' ' VAL . 8.1 t 154.31 172.0 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 121.748 0.785 . . . . 0.0 111.235 174.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.547 ' N ' ' H ' ' J' ' 28' ' ' LYS . 43.1 p-10 -53.63 179.94 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.43 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.72 112.09 1.88 Allowed 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.176 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.51 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . 75.4 -91.74 0.85 Allowed Glycine 0 CA--C 1.532 1.145 0 C-N-CA 121.285 -0.483 . . . . 0.0 112.083 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.51 ' CB ' ' O ' ' K' ' 29' ' ' GLY . . . 106.48 161.13 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 104.562 -2.384 . . . . 0.0 104.562 -178.436 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -144.88 132.15 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 118.027 -1.469 . . . . 0.0 112.796 -178.269 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -124.42 123.68 66.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.3 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 114.93 2.94 Favored Glycine 0 N--CA 1.473 1.126 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 46.0 mt -122.42 127.31 49.51 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 56.8 ttp -119.83 121.29 38.77 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.234 177.758 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 60.0 t -115.4 88.17 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.23 96.06 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.85 162.19 31.51 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -124.9 137.05 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 23.3 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.448 -179.564 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -82.05 131.19 35.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.359 . . . . 0.0 110.406 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -77.93 155.0 31.13 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.098 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -110.39 131.81 60.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.116 0.484 . . . . 0.0 110.368 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -99.45 176.79 5.38 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.276 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CE1' ' K' ' 13' ' ' HIS . 0.4 OUTLIER -92.36 165.76 12.91 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.302 0.573 . . . . 0.0 110.04 -179.614 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -168.19 168.58 11.54 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.548 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.52 108.71 2.98 Favored 'General case' 0 C--O 1.171 -3.049 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . 0.943 ' C ' ' O ' ' K' ' 17' ' ' LEU . 2.7 mm? -73.09 160.73 31.56 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 119.654 -1.903 . . . . 0.0 107.622 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . 0.493 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 14.3 m -99.89 -121.06 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -173.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.627 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 7.7 p90 -147.6 162.11 39.78 Favored 'General case' 0 N--CA 1.47 0.551 0 O-C-N 121.618 -0.676 . . . . 0.0 112.588 -177.178 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . 0.47 ' O ' ' CB ' ' K' ' 20' ' ' PHE . 93.6 m-85 -144.72 151.48 38.96 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 121.718 0.77 . . . . 0.0 112.087 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.64 138.27 39.3 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -69.79 95.08 0.87 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.128 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -164.06 121.57 1.75 Allowed 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.589 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' L' ' 26' ' ' SER . 13.5 t -88.53 123.56 40.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.61 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.3 0.01 OUTLIER Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.578 ' N ' ' O ' ' L' ' 24' ' ' VAL . 12.8 t -68.13 -171.59 0.25 Allowed 'General case' 0 N--CA 1.441 -0.921 0 CA-C-O 122.593 1.187 . . . . 0.0 112.333 -177.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.415 ' O ' ' C ' ' L' ' 28' ' ' LYS . 35.4 p-10 -81.0 179.29 7.93 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 112.547 -2.115 . . . . 0.0 109.814 178.924 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' L' ' 27' ' ' ASN . 70.1 tttt -37.17 104.15 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 167.84 -100.42 0.16 Allowed Glycine 0 C--O 1.22 -0.726 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -49.55 169.37 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.137 1.469 . . . . 0.0 108.734 -178.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -153.37 133.2 3.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.454 -177.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 83.7 mt -120.41 128.91 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 114.43 -1.259 . . . . 0.0 108.921 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . 0.428 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -125.7 124.82 5.36 Favored Glycine 0 N--CA 1.468 0.808 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.2 tp -126.99 120.04 28.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 36.8 ttp -110.34 126.67 54.48 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.0 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.2 t -130.28 81.73 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.056 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.83 101.43 0.3 Allowed Glycine 0 N--CA 1.439 -1.161 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.857 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.16 169.28 41.36 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 57.6 t -122.73 135.84 61.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 120.742 0.306 . . . . 0.0 110.218 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.446 -179.919 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.15 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -113.83 143.89 43.91 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.804 0.335 . . . . 0.0 110.645 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' CE1' ' B' ' 13' ' ' HIS . 42.6 tp10 -56.69 144.22 33.28 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.2 160.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.445 0.641 . . . . 0.0 111.386 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.0 m80 -89.0 -170.17 2.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.905 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -80.49 168.64 18.7 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 121.357 0.599 . . . . 0.0 110.002 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -157.21 -179.86 8.6 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.878 -1.055 . . . . 0.0 108.993 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -155.22 129.32 8.82 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.695 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 72.9 mt -129.28 118.95 23.13 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.597 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -130.17 131.19 65.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -127.65 131.53 49.84 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.009 0.433 . . . . 0.0 110.712 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -132.53 125.94 31.74 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.94 137.16 44.69 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-O 121.778 0.799 . . . . 0.0 112.955 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -126.8 126.77 43.94 Favored 'General case' 0 CA--C 1.528 0.12 0 CA-C-N 114.625 -1.17 . . . . 0.0 108.449 178.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 24' ' ' VAL . 20.7 t70 -85.81 107.86 17.84 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.447 ' C ' ' O ' ' A' ' 23' ' ' ASP . 6.7 p -32.97 141.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 O-C-N 123.423 0.452 . . . . 0.0 109.849 178.718 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.24 82.75 1.65 Allowed Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.729 -176.393 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 27' ' ' ASN . 74.8 m -141.19 170.87 14.9 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 176.057 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.541 ' O ' ' O ' ' A' ' 26' ' ' SER . 34.8 m120 -29.47 158.47 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 118.958 -0.544 . . . . 0.0 110.941 177.447 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.47 ' O ' ' CG ' ' B' ' 27' ' ' ASN . 64.4 tttt 179.44 101.12 0.03 OUTLIER 'General case' 0 C--O 1.217 -0.624 0 C-N-CA 119.154 -1.018 . . . . 0.0 113.568 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.16 102.9 0.98 Allowed Glycine 0 N--CA 1.467 0.706 0 N-CA-C 103.622 -3.791 . . . . 0.0 103.622 170.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -97.35 144.11 27.43 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 123.311 3.555 . . . . 0.0 115.527 -172.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' G' ' 35' ' ' MET . 1.7 pt -159.82 105.56 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.421 -1.907 1 CA-C-N 107.016 -4.629 . . . . 0.0 106.245 -173.895 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.475 ' O ' ' CG2' ' A' ' 32' ' ' ILE . 8.1 tt -108.45 114.53 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 CA-C-N 120.524 1.511 . . . . 0.0 108.107 178.236 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -121.58 124.72 5.89 Favored Glycine 0 CA--C 1.508 -0.351 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -148.83 140.4 23.47 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 122.806 1.288 . . . . 0.0 113.002 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' MET . . . . . 0.586 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 3.7 ttm -109.82 117.65 34.42 Favored 'General case' 0 CA--C 1.505 -0.786 0 CA-C-N 113.038 -1.892 . . . . 0.0 108.094 177.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -111.12 68.04 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -120.79 101.53 0.81 Allowed Glycine 0 C--N 1.359 1.842 0 N-CA-C 110.404 -1.079 . . . . 0.0 110.404 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.39 165.73 35.2 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.329 -0.709 . . . . 0.0 111.329 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 31.4 m -135.96 156.24 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.663 0.268 . . . . 0.0 110.385 179.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.129 179.261 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.86 145.37 42.92 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.6 0.238 . . . . 0.0 110.447 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -68.04 126.87 30.86 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.279 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m -137.08 164.1 30.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.092 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.538 ' CE1' ' OE1' ' A' ' 11' ' ' GLU . 59.4 m80 -91.36 98.14 11.52 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.546 -0.461 . . . . 0.0 109.971 179.254 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.538 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 3.7 m-70 -134.51 166.83 21.98 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -154.57 175.11 14.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.059 179.017 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -154.46 117.04 4.35 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.495 179.2 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.03 119.5 29.69 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.454 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 t -122.33 127.68 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.961 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 83.0 t80 -130.22 126.26 36.93 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.834 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -128.48 132.59 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.63 132.35 38.89 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 121.126 0.489 . . . . 0.0 111.114 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -147.88 168.0 23.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.227 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -140.27 123.2 16.55 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.153 0.502 . . . . 0.0 111.245 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 75.9 t -94.39 121.7 45.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.552 179.693 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . 0.405 ' O ' ' CB ' ' B' ' 26' ' ' SER . . . 45.74 85.53 0.01 OUTLIER Glycine 0 CA--C 1.53 1.023 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.853 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.714 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.9 t 162.12 161.0 0.02 OUTLIER 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 178.65 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.714 ' O ' ' O ' ' B' ' 26' ' ' SER . 11.9 m120 -30.13 171.99 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.515 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.464 ' CG ' ' O ' ' B' ' 27' ' ' ASN . 95.7 mttt -159.6 103.89 1.58 Allowed 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -178.064 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.592 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . 69.42 -105.32 1.48 Allowed Glycine 1 CA--C 1.417 -6.093 0 CA-C-O 115.111 -3.05 . . . . 0.0 111.33 -178.689 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.592 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 76.0 -135.22 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.71 2 C-N-CA 108.667 -5.213 . . . . 0.0 99.248 -174.351 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.769 ' CD1' ' N ' ' B' ' 31' ' ' ILE . 0.0 OUTLIER -75.47 122.65 29.74 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -179.325 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.433 HD13 HG21 ' B' ' 32' ' ' ILE . 83.3 mt -121.73 122.16 66.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 175.322 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . 0.474 ' O ' ' HA2' ' A' ' 33' ' ' GLY . . . -132.47 111.07 0.99 Allowed Glycine 0 N--CA 1.473 1.119 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.075 179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . 0.488 ' CD2' ' CZ ' ' C' ' 19' ' ' PHE . 6.4 mp -138.31 144.85 40.61 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 123.47 1.605 . . . . 0.0 113.168 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.506 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 19.6 ttm -119.07 115.85 25.16 Favored 'General case' 0 CA--C 1.499 -0.999 0 CA-C-N 113.002 -1.908 . . . . 0.0 107.41 177.777 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.26 70.62 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.096 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.3 112.5 3.46 Favored Glycine 0 C--N 1.363 2.057 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 -179.105 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' C' ' 37' ' ' GLY . . . -73.04 147.73 40.07 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -139.49 161.34 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.807 0.337 . . . . 0.0 110.424 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.026 -0.987 . . . . 0.0 110.518 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -81.71 128.13 33.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.798 0.332 . . . . 0.0 110.413 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -148.96 132.04 16.3 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.157 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m -140.76 162.69 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 121.3 0.571 . . . . 0.0 111.364 -179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -118.8 138.29 52.8 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.877 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . 0.583 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 28.8 t-80 -152.38 165.45 34.97 Favored 'General case' 0 CA--C 1.513 -0.463 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . 0.583 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 75.8 mt-30 -156.44 170.35 22.51 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.025 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -158.87 111.59 2.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.829 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -121.96 122.07 38.52 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -126.67 124.52 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.128 0.49 . . . . 0.0 111.831 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' B' ' 34' ' ' LEU . 1.0 OUTLIER -116.54 110.75 18.99 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 105.89 -1.893 . . . . 0.0 105.89 177.456 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -115.36 121.02 41.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.87 130.59 53.06 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.697 0.761 . . . . 0.0 111.673 -179.253 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -121.18 91.53 3.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.994 178.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -169.86 123.67 0.75 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.816 -1.154 . . . . 0.0 113.129 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.449 ' N ' ' HB3' ' B' ' 28' ' ' LYS . 11.5 t -146.89 106.9 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 174.922 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . 0.409 ' O ' ' O ' ' C' ' 24' ' ' VAL . . . -38.33 -94.97 0.01 OUTLIER Glycine 0 N--CA 1.482 1.729 0 CA-C-O 122.201 0.89 . . . . 0.0 112.828 -177.929 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' C' ' 27' ' ' ASN . 25.5 p -150.57 170.0 20.2 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 103.968 -2.605 . . . . 0.0 103.968 176.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' C' ' 26' ' ' SER . 5.5 t-20 43.18 -179.37 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.999 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.721 ' HZ2' ' N ' ' E' ' 27' ' ' ASN . 81.6 mttt -86.67 -117.69 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.719 0 O-C-N 120.94 -1.1 . . . . 0.0 109.87 179.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 43.6 89.69 0.01 OUTLIER Glycine 0 N--CA 1.469 0.873 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.342 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -157.48 165.74 34.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 175.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . 0.453 ' HB ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -139.94 121.29 15.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 118.481 -1.287 . . . . 0.0 111.237 -173.687 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . 0.458 ' O ' ' CE ' ' I' ' 35' ' ' MET . 12.1 tt -116.72 122.35 69.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-O 121.487 0.661 . . . . 0.0 111.039 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.61 117.36 4.62 Favored Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.483 ' CD2' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -146.2 138.23 25.07 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.861 1.315 . . . . 0.0 113.006 -178.099 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 15.0 ttm -129.09 127.37 41.35 Favored 'General case' 0 CA--C 1.505 -0.753 0 CA-C-N 113.446 -1.707 . . . . 0.0 109.449 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.91 78.06 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' B' ' 38' ' ' GLY . . . -69.64 104.78 1.37 Allowed Glycine 0 C--N 1.351 1.399 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.56 -179.33 52.2 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.89 144.21 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.939 0.399 . . . . 0.0 110.771 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.561 179.943 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -106.05 136.68 45.3 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.938 0.399 . . . . 0.0 110.571 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.16 148.53 28.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.365 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 m -134.56 160.98 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.405 179.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.435 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 9.5 m80 -123.44 154.81 38.55 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.685 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.435 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 47.2 m80 -151.02 164.99 35.13 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.158 0.504 . . . . 0.0 110.06 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -158.99 169.51 24.14 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.553 178.41 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . 0.505 ' NZ ' ' HE2' ' C' ' 14' ' ' HIS . 60.0 mttp -159.43 117.13 2.73 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.316 178.432 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.9 mp -119.34 123.78 45.01 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.147 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -126.29 127.05 70.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . 0.447 ' CZ ' ' CD1' ' C' ' 34' ' ' LEU . 1.8 t80 -125.39 113.5 17.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -122.8 131.55 53.82 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -176.026 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 109.77 16.7 Favored 'General case' 0 C--O 1.249 1.079 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 177.687 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' E' ' 22' ' ' GLU . 87.2 tt0 -165.23 91.46 0.53 Allowed 'General case' 0 C--N 1.347 0.487 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -76.06 -131.34 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 102.915 -2.995 . . . . 0.0 102.915 173.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' D' ' 25' ' ' GLY . 57.1 t -90.98 112.35 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.591 0 N-CA-C 101.089 -3.671 . . . . 0.0 101.089 173.792 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 41.32 89.69 0.01 OUTLIER Glycine 0 CA--C 1.535 1.294 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -173.883 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.434 ' O ' ' O ' ' E' ' 22' ' ' GLU . 4.0 m -69.95 164.54 23.63 Favored 'General case' 0 CA--C 1.498 -1.028 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.854 -178.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . 0.444 ' O ' ' O ' ' E' ' 22' ' ' GLU . 51.1 p-10 -79.2 174.39 11.61 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 123.875 1.798 . . . . 0.0 115.495 178.184 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' D' ' 30' ' ' ALA 0.319 21.6 tttt -49.02 111.17 0.44 Allowed 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 109.624 -3.444 . . . . 0.0 116.797 172.1 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' D' ' 30' ' ' ALA . . . -72.22 100.57 0.96 Allowed Glycine 0 CA--C 1.45 -3.998 1 N-CA-C 102.656 -4.178 . . . . 0.0 102.656 -178.344 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' D' ' 28' ' ' LYS . . . -70.56 -130.8 0.0 OUTLIER 'General case' 1 N--CA 1.372 -4.338 4 CA-C-N 101.161 -7.519 . . . . 0.0 97.485 -176.469 . . . . . . . . 4 3 . 1 . 009 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.786 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 1.0 OUTLIER -74.74 111.88 11.29 Favored 'Isoleucine or valine' 1 C--N 1.243 -4.029 0 CA-C-N 123.176 2.716 . . . . 0.0 111.714 -176.013 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . 0.517 ' C ' ' SD ' ' J' ' 35' ' ' MET . 0.2 OUTLIER -110.92 115.51 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 178.126 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . 0.551 ' CA ' ' SD ' ' J' ' 35' ' ' MET . . . -113.72 98.67 0.93 Allowed Glycine 0 CA--C 1.503 -0.689 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 61.7 mt -128.31 128.46 44.64 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -176.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 35' ' ' MET . . . . . 0.508 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -123.5 128.85 50.37 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.068 177.214 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.457 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -122.9 80.36 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.457 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -23.36 -95.45 0.01 OUTLIER Glycine 0 C--N 1.361 1.955 0 O-C-N 123.0 0.187 . . . . 0.0 112.639 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 125.84 -178.28 16.73 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 40' ' ' VAL . 34.3 m -123.27 137.1 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 39' ' ' VAL . 11.2 t . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.392 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -116.89 140.12 49.82 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.789 0.328 . . . . 0.0 110.716 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -63.88 145.17 56.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.692 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.53 127.93 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.029 0.442 . . . . 0.0 110.029 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' CB ' ' F' ' 13' ' ' HIS . 43.7 p-80 -164.38 157.74 17.81 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.945 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 73.4 m80 -135.54 167.78 20.46 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -155.29 167.83 29.06 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.362 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -148.19 117.37 6.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.123 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.5 mt -114.66 122.17 45.63 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 177.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.28 136.35 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-O 122.125 0.964 . . . . 0.0 113.578 -177.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . 0.478 ' CB ' ' CE1' ' F' ' 19' ' ' PHE . 0.6 OUTLIER -121.37 126.05 48.48 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 113.832 -1.531 . . . . 0.0 109.091 178.783 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -127.22 129.85 48.56 Favored 'General case' 0 N--CA 1.481 1.076 0 O-C-N 122.079 -0.388 . . . . 0.0 110.663 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.12 125.68 16.8 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.002 0.43 . . . . 0.0 110.749 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 93.9 mt-10 -93.25 156.32 16.9 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.494 -0.882 . . . . 0.0 113.313 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -133.02 141.39 48.24 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.201 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.35 111.08 34.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . 0.543 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 34.6 90.81 0.01 OUTLIER Glycine 0 N--CA 1.472 1.049 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 26' ' ' SER . . . . . 0.543 ' O ' ' O ' ' E' ' 25' ' ' GLY . 11.6 p -32.9 170.53 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 122.232 1.015 . . . . 0.0 113.179 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.721 ' N ' ' HZ2' ' C' ' 28' ' ' LYS . 19.6 m120 -158.52 178.15 10.46 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.466 177.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . 0.472 ' C ' ' O ' ' E' ' 27' ' ' ASN . 64.4 mttp 4.78 -106.36 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.994 0.918 . . . . 0.0 113.437 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.0 95.57 0.17 Allowed Glycine 0 C--N 1.346 1.114 0 C-N-CA 120.592 -0.813 . . . . 0.0 113.275 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -66.63 177.62 1.53 Allowed 'General case' 0 C--O 1.241 0.608 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 175.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.442 ' O ' ' O ' ' D' ' 30' ' ' ALA . 0.3 OUTLIER -149.62 120.28 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 117.972 -1.491 . . . . 0.0 109.168 -176.685 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 97.0 mt -117.69 126.56 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.569 -176.489 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.14 110.63 1.82 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 60.7 mt -121.14 123.22 41.78 Favored 'General case' 0 N--CA 1.467 0.375 0 O-C-N 122.756 -0.261 . . . . 0.0 110.742 -179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.7 ttt -135.46 131.21 35.88 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 119.678 -0.809 . . . . 0.0 112.46 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -158.11 81.36 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.85 178.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.13 101.64 1.61 Allowed Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.98 154.89 21.36 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.43 145.1 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.404 -179.661 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -111.0 133.41 53.41 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.779 0.323 . . . . 0.0 110.572 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 71.3 mm-40 -70.71 142.2 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.195 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.31 176.0 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 121.082 0.467 . . . . 0.0 110.552 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.553 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 56.8 p-80 -99.37 159.88 14.68 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.64 179.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -153.48 178.37 9.89 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . 0.471 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 42.7 tt0 -148.92 166.64 27.99 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.281 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . 0.471 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 68.5 mttm -142.68 131.54 22.86 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.295 0.569 . . . . 0.0 111.608 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 56.1 tp -121.75 123.45 41.86 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.72 178.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.34 127.43 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 121.553 0.692 . . . . 0.0 111.14 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . 0.478 ' CE1' ' CB ' ' E' ' 19' ' ' PHE . 0.5 OUTLIER -122.13 114.48 20.94 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.9 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -120.41 117.3 27.36 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-O 121.313 0.578 . . . . 0.0 110.358 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.97 136.87 46.33 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . 0.487 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 70.5 mm-40 -70.18 122.1 18.81 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.07 -1.052 . . . . 0.0 111.524 -178.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 1.8 p-10 108.6 131.94 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.888 1.675 . . . . 0.0 109.33 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' F' ' 25' ' ' GLY . 2.4 m -110.22 113.44 44.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . 32.28 87.72 0.01 OUTLIER Glycine 0 CA--C 1.527 0.797 0 N-CA-C 111.838 -0.505 . . . . 0.0 111.838 178.953 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 62.7 m -65.17 -174.6 0.17 Allowed 'General case' 0 N--CA 1.438 -1.028 0 CA-C-O 121.448 0.642 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.432 ' O ' ' C ' ' F' ' 28' ' ' LYS . 96.5 m-20 -81.06 178.24 8.54 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.289 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.432 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.3 tttt -38.15 103.93 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 166.02 -100.54 0.17 Allowed Glycine 0 C--O 1.219 -0.796 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -176.008 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.414 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -53.75 168.54 0.19 Allowed 'General case' 0 CA--C 1.509 -0.61 0 CA-C-N 118.038 0.919 . . . . 0.0 108.953 -178.56 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . 0.414 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.1 OUTLIER -150.91 128.1 2.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 C-N-CA 119.331 -0.947 . . . . 0.0 109.309 -174.586 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 17.2 tt -128.2 138.86 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-O 120.909 0.385 . . . . 0.0 111.873 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.41 124.27 3.64 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.2 tp -119.11 122.57 42.37 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.6 tpt -118.54 121.28 39.86 Favored 'General case' 0 N--CA 1.478 0.966 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' F' ' 37' ' ' GLY . 2.9 m -141.84 80.63 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 177.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . 18.1 -104.86 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 CA-C-N 117.516 0.144 . . . . 0.0 113.169 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.64 -161.29 22.82 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -134.37 161.45 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.387 179.939 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -121.16 139.04 53.89 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.652 0.263 . . . . 0.0 110.607 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -69.11 157.2 37.33 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.902 0.382 . . . . 0.0 110.717 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . 0.415 ' CG1' ' ND1' ' H' ' 13' ' ' HIS . 55.3 t -118.12 134.48 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.265 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -112.26 157.98 20.27 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.533 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.528 ' CB ' ' CE1' ' H' ' 14' ' ' HIS . 12.9 p80 -81.99 174.58 11.12 Favored 'General case' 0 N--CA 1.442 -0.866 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -143.93 179.47 7.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.089 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -152.71 135.19 15.17 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -136.24 117.85 14.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.421 0.629 . . . . 0.0 110.539 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.81 136.31 55.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.619 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -136.09 131.81 35.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-O 121.369 0.604 . . . . 0.0 111.319 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -125.95 130.67 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.61 148.26 45.69 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 122.316 1.055 . . . . 0.0 113.207 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -101.93 -177.67 3.48 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 113.406 -1.724 . . . . 0.0 108.901 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' G' ' 26' ' ' SER . 67.3 t0 -58.45 123.86 17.62 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.203 -0.599 . . . . 0.0 110.184 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . 0.474 ' O ' ' N ' ' G' ' 26' ' ' SER . 23.0 m -95.56 120.59 45.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.926 -179.042 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.93 -88.73 0.01 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 116.111 -0.495 . . . . 0.0 112.607 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.474 ' N ' ' O ' ' G' ' 24' ' ' VAL . 72.2 m -67.52 -171.6 0.2 Allowed 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.564 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 14.7 t-20 -78.79 178.77 7.66 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.186 -178.388 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.564 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 83.9 tttt -44.17 -110.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.143 0.794 . . . . 0.0 113.143 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 54.33 91.88 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -102.62 161.9 13.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 C-N-CA 116.696 -2.002 . . . . 0.0 108.628 179.032 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . 0.505 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.1 OUTLIER -152.36 110.06 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.023 -174.829 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . 0.586 ' N ' ' SD ' ' A' ' 35' ' ' MET . 97.3 mt -108.36 110.21 31.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.197 0.523 . . . . 0.0 110.241 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 92.49 0.62 Allowed Glycine 0 CA--C 1.502 -0.761 0 N-CA-C 105.648 -2.981 . . . . 0.0 105.648 175.984 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . 0.432 ' O ' ' CD1' ' H' ' 34' ' ' LEU . 16.7 mt -130.93 134.19 46.53 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.725 1.726 . . . . 0.0 111.984 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 0.0 OUTLIER -108.4 117.96 35.53 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 112.678 -2.055 . . . . 0.0 109.019 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.35 66.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 N-CA-C 109.244 -0.651 . . . . 0.0 109.244 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.22 -103.52 0.59 Allowed Glycine 0 C--N 1.363 2.063 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.84 162.61 25.23 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.562 179.002 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.21 147.87 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.826 -179.741 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.102 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -113.21 142.59 45.62 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.853 0.358 . . . . 0.0 110.519 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -77.44 127.35 32.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.605 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -137.27 139.35 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.036 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . 0.415 ' ND1' ' CG1' ' G' ' 12' ' ' VAL . 82.8 t60 -147.26 107.83 4.12 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.683 -0.407 . . . . 0.0 109.99 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.618 ' CG ' ' CE1' ' I' ' 14' ' ' HIS . 15.0 p-80 -146.73 171.17 15.56 Favored 'General case' 0 N--CA 1.447 -0.586 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.283 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -144.35 177.25 8.76 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.13 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -152.8 131.22 12.13 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.9 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -129.36 118.56 22.42 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.934 0.397 . . . . 0.0 110.414 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -128.34 131.32 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.93 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -126.1 128.99 48.22 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.601 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 0.9 OUTLIER -134.76 128.03 32.07 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.605 -0.27 . . . . 0.0 110.389 -179.187 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.52 123.54 40.33 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.858 0.361 . . . . 0.0 110.226 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . 0.551 ' OE2' ' CE1' ' H' ' 20' ' ' PHE . 9.7 pt-20 -168.42 130.05 1.35 Allowed 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 119.897 -0.721 . . . . 0.0 112.157 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 20.0 t70 178.83 114.72 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.389 0.614 . . . . 0.0 112.376 177.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t -28.89 122.86 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 114.724 -1.126 . . . . 0.0 112.364 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.48 -84.78 0.06 OUTLIER Glycine 0 CA--C 1.526 0.763 0 C-N-CA 119.959 -1.115 . . . . 0.0 112.098 178.513 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 26' ' ' SER . . . . . 0.545 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.4 OUTLIER -170.77 -179.96 3.02 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 119.001 1.401 . . . . 0.0 112.276 179.42 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.545 ' O ' ' O ' ' H' ' 26' ' ' SER . 11.4 m120 26.62 -170.79 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 112.426 -2.17 . . . . 0.0 115.216 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.408 ' O ' ' O ' ' H' ' 29' ' ' GLY . 86.3 tttt -143.7 -103.98 0.12 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.601 -1.181 . . . . 0.0 111.776 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.408 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 39.94 95.43 0.01 OUTLIER Glycine 0 CA--C 1.494 -1.278 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -177.578 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.92 153.14 27.16 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 178.276 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -139.55 123.1 18.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 119.512 -0.875 . . . . 0.0 109.457 -176.356 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.506 ' N ' ' SD ' ' B' ' 35' ' ' MET . 1.7 mt -115.45 119.09 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.974 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.89 103.69 1.14 Allowed Glycine 0 C--O 1.241 0.588 0 N-CA-C 105.769 -2.932 . . . . 0.0 105.769 175.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . 0.432 ' CD1' ' O ' ' G' ' 34' ' ' LEU . 5.9 tp -133.74 144.13 48.89 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 122.919 1.342 . . . . 0.0 114.01 -176.16 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 5.8 tpt -122.25 115.58 22.62 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 113.448 -1.706 . . . . 0.0 108.873 178.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.47 65.11 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.19 103.86 0.64 Allowed Glycine 0 C--N 1.353 1.504 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -90.24 176.41 41.95 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 40.5 t -137.24 161.45 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 120.929 0.395 . . . . 0.0 110.634 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.957 -1.02 . . . . 0.0 110.424 179.799 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -90.73 125.03 35.56 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . 0.494 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 96.9 mt-10 -82.48 164.48 20.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.935 -179.498 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m -93.26 135.14 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.528 -179.876 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . 0.494 ' CD2' ' O ' ' I' ' 11' ' ' GLU . 3.3 m-70 -142.09 156.97 45.4 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.125 -178.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' H' ' 14' ' ' HIS . 16.9 p-80 -156.66 167.53 30.17 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 177.413 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.449 ' CG ' ' N ' ' I' ' 16' ' ' LYS . 52.1 tt0 -150.98 166.66 29.99 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.629 0.728 . . . . 0.0 111.519 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . 0.525 ' NZ ' ' CG2' ' I' ' 18' ' ' VAL . 65.9 tttm -154.41 127.57 8.37 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.85 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 59.3 tp -124.36 121.77 35.86 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . 0.525 ' CG2' ' NZ ' ' I' ' 16' ' ' LYS . 47.8 t -122.95 125.54 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.832 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 60.5 m-85 -114.2 105.86 13.68 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 176.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 1.4 t80 -117.76 126.53 52.62 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 132.97 39.92 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.141 0.496 . . . . 0.0 111.813 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -159.35 114.47 2.45 Favored 'General case' 0 C--N 1.348 0.52 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' I' ' 23' ' ' ASP . 9.4 t0 -171.9 111.02 0.29 Allowed 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 114.435 1.272 . . . . 0.0 114.435 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 12.4 p -31.99 131.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 CA-C-N 112.611 -2.086 . . . . 0.0 115.425 174.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -84.22 0.09 OUTLIER Glycine 0 CA--C 1.543 1.841 0 C-N-CA 119.605 -1.283 . . . . 0.0 115.157 174.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.3 m -96.76 175.41 6.37 Favored 'General case' 0 CA--C 1.5 -0.944 0 CA-C-N 120.401 2.1 . . . . 0.0 108.916 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.45 ' O ' ' O ' ' I' ' 28' ' ' LYS . 8.9 m120 -62.52 175.62 0.76 Allowed 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' I' ' 27' ' ' ASN . 53.4 tttt -45.1 -107.88 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 122.301 1.048 . . . . 0.0 113.796 178.078 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . 87.73 -100.01 2.56 Favored Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.472 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 62.81 143.6 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.083 0 O-C-N 121.498 -1.001 . . . . 0.0 109.135 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . 0.429 ' CD1' ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -145.26 114.47 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.373 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . 0.455 ' O ' ' CG2' ' I' ' 32' ' ' ILE . 1.2 tt -108.19 112.38 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.97 113.86 2.56 Favored Glycine 0 CA--C 1.493 -1.288 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -162.06 160.73 27.83 Favored 'General case' 0 C--O 1.249 1.041 0 CA-C-O 123.304 1.526 . . . . 0.0 112.695 178.69 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 35' ' ' MET . . . . . 0.458 ' CE ' ' O ' ' C' ' 32' ' ' ILE . 33.2 ttm -127.71 136.6 51.77 Favored 'General case' 0 CA--C 1.503 -0.827 0 CA-C-N 112.351 -2.204 . . . . 0.0 111.052 -177.925 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.99 70.63 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.186 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.98 106.37 3.28 Favored Glycine 0 C--N 1.364 2.098 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.7 172.01 55.16 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.214 -0.755 . . . . 0.0 111.214 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -144.36 149.01 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.408 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -144.96 155.72 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -103.78 144.07 31.97 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.922 0.392 . . . . 0.0 111.252 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 5.5 p -136.91 150.79 26.86 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.981 0.896 . . . . 0.0 112.591 -178.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . 0.431 ' CD2' HE21 ' J' ' 15' ' ' GLN . 17.3 t-160 -150.9 105.62 3.28 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 114.08 -1.418 . . . . 0.0 109.548 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -149.27 166.8 27.86 Favored 'General case' 0 CA--C 1.508 -0.643 0 O-C-N 121.641 -0.662 . . . . 0.0 110.598 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . 0.431 HE21 ' CD2' ' J' ' 13' ' ' HIS . 13.3 mp0 -146.68 169.97 17.93 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.675 0.75 . . . . 0.0 111.414 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -143.71 135.88 26.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.152 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -133.87 124.61 26.75 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.65 133.69 61.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 CA-C-O 121.289 0.566 . . . . 0.0 112.078 -178.701 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 91.7 m-85 -112.02 113.84 26.37 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.39 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.45 ' CD1' ' CZ ' ' I' ' 20' ' ' PHE . 5.7 t80 -122.16 123.15 40.84 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 118.518 0.599 . . . . 0.0 112.592 -178.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.24 131.52 38.59 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 122.047 -0.408 . . . . 0.0 110.873 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 18.2 pt-20 -151.88 168.44 25.13 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.461 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.482 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 6.7 p30 150.94 164.12 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.149 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' J' ' 23' ' ' ASP . 48.8 t -35.83 101.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.44 93.36 0.5 Allowed Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.227 -0.897 . . . . 0.0 114.87 -175.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.751 ' O ' ' O ' ' J' ' 27' ' ' ASN . 39.3 p -102.79 160.63 14.43 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 175.95 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.751 ' O ' ' O ' ' J' ' 26' ' ' SER . 92.2 m-20 38.17 -179.22 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -174.035 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.677 ' N ' ' ND2' ' K' ' 27' ' ' ASN . 88.0 tttt -148.95 108.37 3.96 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 114.968 -2.693 . . . . 0.0 115.747 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -76.23 95.07 1.05 Allowed Glycine 0 CA--C 1.493 -1.285 0 CA-C-O 114.938 -3.146 . . . . 0.0 108.65 166.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.498 ' HA ' ' O ' ' I' ' 29' ' ' GLY . . . -137.32 142.7 41.85 Favored 'General case' 0 CA--C 1.463 -2.381 1 CA-C-N 124.891 4.346 . . . . 0.0 108.061 176.136 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -142.91 106.12 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.357 -177.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . 0.508 ' O ' ' CE ' ' D' ' 35' ' ' MET . 0.1 OUTLIER -105.32 116.7 49.63 Favored 'Isoleucine or valine' 0 C--N 1.359 0.993 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.677 -178.356 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.38 96.45 0.72 Allowed Glycine 0 C--O 1.24 0.49 0 N-CA-C 106.447 -2.661 . . . . 0.0 106.447 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.417 HD13 ' N ' ' J' ' 35' ' ' MET . 8.2 tp -134.25 124.87 26.63 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-O 122.695 1.236 . . . . 0.0 111.975 -177.19 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 35' ' ' MET . . . . . 0.551 ' SD ' ' CA ' ' D' ' 33' ' ' GLY . 4.3 ttt -119.87 126.96 52.21 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 113.345 -1.752 . . . . 0.0 109.176 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -113.58 73.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.187 -178.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.66 112.46 0.4 Allowed Glycine 0 C--N 1.354 1.543 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.49 -139.86 0.33 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.583 -0.607 . . . . 0.0 111.583 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 54.5 t -109.42 133.66 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.972 0.415 . . . . 0.0 110.089 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.07 -0.967 . . . . 0.0 110.928 -179.542 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -112.54 145.64 39.94 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.836 0.35 . . . . 0.0 110.618 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . 0.491 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 54.9 mp0 -84.5 134.43 34.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.678 -179.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.71 131.0 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -114.49 117.23 30.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.775 0.321 . . . . 0.0 111.403 -179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 55.6 t-80 -135.33 164.39 27.85 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.42 0.629 . . . . 0.0 109.846 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . 0.527 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 86.0 mt-30 -157.05 172.49 18.58 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.634 178.468 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.5 tttm -155.92 122.77 5.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.36 179.217 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.6 mt -125.13 120.42 31.33 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 4.2 m -136.38 134.17 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-O 121.538 0.685 . . . . 0.0 112.654 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.623 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 87.5 m-85 -115.31 110.7 19.79 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 7.8 m-85 -114.01 124.11 51.33 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -177.818 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 127.05 34.21 Favored 'General case' 0 N--CA 1.474 0.739 0 O-C-N 121.758 -0.589 . . . . 0.0 110.57 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.18 127.61 47.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.583 -179.055 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' K' ' 24' ' ' VAL . 3.6 t70 174.96 146.69 0.07 Allowed 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.474 ' O ' ' O ' ' K' ' 23' ' ' ASP . 2.8 m -21.89 -101.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 123.487 0.492 . . . . 0.0 111.712 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.412 ' H ' HG21 ' K' ' 24' ' ' VAL . . . 159.84 -91.36 0.11 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.807 177.706 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.683 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 75.3 m -54.23 160.8 1.5 Allowed 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 118.147 0.974 . . . . 0.0 108.381 178.185 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' O ' ' K' ' 26' ' ' SER . 23.2 p30 132.52 171.04 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 O-C-N 125.083 1.49 . . . . 0.0 111.715 176.129 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -30.27 104.92 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . 0.435 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.8 -100.6 2.09 Favored Glycine 0 C--O 1.215 -1.056 0 N-CA-C 115.737 1.055 . . . . 0.0 115.737 170.28 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.431 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 60.77 145.29 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 106.436 -1.691 . . . . 0.0 106.436 -178.72 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . 0.431 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -160.85 134.41 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 121.614 2.006 . . . . 0.0 113.219 -179.253 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.41 HD13 HG23 ' K' ' 32' ' ' ILE . 98.0 mt -124.98 121.23 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.766 179.727 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.452 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -119.26 115.53 3.07 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 38.1 tp -124.98 121.62 34.96 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.149 -0.525 . . . . 0.0 111.271 -179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mmm -131.33 133.01 44.91 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.348 178.683 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 15.0 t -123.22 82.58 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.444 179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.6 101.33 0.9 Allowed Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.502 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' L' ' 37' ' ' GLY . . . -158.4 155.62 26.63 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -135.74 146.85 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-O 120.859 0.361 . . . . 0.0 110.836 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.1 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.408 179.893 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -149.16 159.34 44.33 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.625 0.25 . . . . 0.0 110.608 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' K' ' 11' ' ' GLU . 80.7 tt0 -102.99 154.24 19.43 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.105 0.479 . . . . 0.0 110.439 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -138.94 151.96 23.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -116.24 171.15 8.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 120.961 0.41 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -78.34 176.28 9.47 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.646 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . 0.412 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 93.4 mt-30 -138.37 175.32 9.67 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -146.07 142.31 28.43 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.324 0.583 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -126.17 113.01 16.46 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -130.35 128.45 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.329 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . . . . . . . . . 9.3 m-30 -109.06 109.03 19.95 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.436 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 33.7 t80 -112.53 114.03 26.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.392 0.615 . . . . 0.0 110.637 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . 0.422 ' O ' ' OD2' ' L' ' 23' ' ' ASP . . . -126.74 133.93 50.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.354 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' K' ' 24' ' ' VAL . 84.3 tt0 -60.68 105.48 0.45 Allowed 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.308 -177.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.422 ' OD2' ' O ' ' L' ' 21' ' ' ALA . 7.0 m-20 -154.46 136.21 14.44 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.329 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 22.5 m -109.99 111.74 37.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 119.862 -0.735 . . . . 0.0 110.566 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 26' ' ' SER . . . 31.84 -91.3 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-N 115.194 -0.912 . . . . 0.0 114.438 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' L' ' 25' ' ' GLY . 3.9 m 47.23 171.91 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.033 -1.083 . . . . 0.0 110.965 -176.635 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.526 ' O ' ' O ' ' L' ' 28' ' ' LYS . 72.3 m-80 -140.09 -177.88 5.2 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.365 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.526 ' O ' ' O ' ' L' ' 27' ' ' ASN . 99.2 mttt 26.5 102.13 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.068 0 O-C-N 123.716 0.635 . . . . 0.0 112.196 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.39 -101.57 0.21 Allowed Glycine 0 CA--C 1.493 -1.283 0 C-N-CA 119.913 -1.137 . . . . 0.0 111.791 -176.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.435 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -52.29 161.11 0.69 Allowed 'General case' 0 CA--C 1.514 -0.404 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.375 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -136.04 121.79 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.641 -177.331 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -129.03 138.46 54.46 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.279 0 CA-C-N 115.637 -0.711 . . . . 0.0 111.626 -178.263 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.97 120.99 3.25 Favored Glycine 0 N--CA 1.46 0.253 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 2.9 pp -126.12 122.24 35.16 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 38.2 mtp -134.81 143.49 47.08 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 122.147 0.975 . . . . 0.0 112.681 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -131.25 80.73 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 113.642 -1.617 . . . . 0.0 110.159 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' K' ' 38' ' ' GLY . . . -55.31 102.47 0.16 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.53 28.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.32 134.19 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.871 0.367 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.588 -179.843 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -103.72 131.54 50.8 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.803 0.335 . . . . 0.0 110.427 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -136.92 133.11 35.34 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.932 0.396 . . . . 0.0 110.061 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 p -136.28 145.11 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.634 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' HIS . . . . . 0.543 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 72.9 m80 -114.72 106.35 14.11 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' HIS . . . . . 0.692 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 11.6 t-160 -135.55 159.72 40.73 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 109.767 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.692 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 98.1 mm-40 -157.64 -178.93 7.69 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.847 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -147.8 122.54 9.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.6 mt -129.64 117.25 20.07 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.062 0.458 . . . . 0.0 110.659 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.5 131.05 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.098 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -123.25 134.17 54.12 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.6 p90 -137.12 124.84 22.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.898 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.24 128.21 45.67 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-O 120.733 0.302 . . . . 0.0 111.253 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -147.39 146.66 29.7 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.248 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.531 ' CG ' ' H ' ' A' ' 24' ' ' VAL . 22.7 t0 -152.09 -141.21 0.1 Allowed 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 177.272 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.531 ' H ' ' CG ' ' A' ' 23' ' ' ASP . 80.3 t -90.26 111.28 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 C-N-CA 119.248 -0.981 . . . . 0.0 109.72 179.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.65 91.47 0.01 OUTLIER Glycine 0 CA--C 1.536 1.346 0 CA-C-O 118.943 -0.92 . . . . 0.0 113.208 177.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 27' ' ' ASN . 88.2 p -141.22 169.99 16.58 Favored 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 119.419 1.61 . . . . 0.0 108.985 175.578 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' A' ' 26' ' ' SER . 99.8 m-20 -29.52 157.62 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 O-C-N 123.799 0.687 . . . . 0.0 111.296 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.521 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 33.1 pttt 178.83 102.03 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 175.533 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.53 100.61 0.62 Allowed Glycine 0 CA--C 1.496 -1.151 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 174.145 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -99.37 151.89 20.57 Favored 'General case' 0 C--O 1.251 1.169 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.005 -176.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ILE . . . . . 0.472 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -143.77 107.36 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.781 0 CA-C-N 110.443 -3.071 . . . . 0.0 108.449 -173.284 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ILE . . . . . 0.443 ' C ' ' SD ' ' G' ' 35' ' ' MET . 10.6 mt -103.43 111.0 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.035 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.72 92.48 0.58 Allowed Glycine 0 CA--C 1.501 -0.805 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 177.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tp -138.03 135.02 35.49 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 122.704 1.24 . . . . 0.0 111.169 -178.82 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 3.1 ptm -111.04 123.31 49.94 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.3 -1.773 . . . . 0.0 108.403 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -116.14 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.92 -100.39 0.5 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.8 -170.74 34.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.07 162.07 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.863 0.364 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 81.2 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.379 179.749 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -110.57 134.34 52.48 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 11' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' C' ' 11' ' ' GLU . 94.8 mt-10 -138.79 142.76 38.75 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.17 161.02 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 13' ' ' HIS . . . . . 0.543 ' ND1' ' O ' ' A' ' 13' ' ' HIS . 2.1 t60 -130.29 129.03 42.72 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 14' ' ' HIS . . . . . 0.629 ' NE2' ' CG ' ' C' ' 13' ' ' HIS . 72.6 m80 -133.48 167.08 21.1 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.309 0.576 . . . . 0.0 109.678 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 46.2 tt0 -168.93 169.56 9.61 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.495 178.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -155.02 125.77 7.0 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 66.3 mt -122.22 110.97 16.37 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.058 0.456 . . . . 0.0 109.796 179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -119.94 126.93 75.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.94 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -125.81 120.37 30.35 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.608 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 20' ' ' PHE . . . . . 0.4 ' HB2' ' CZ ' ' C' ' 20' ' ' PHE . 3.7 t80 -125.63 129.15 49.03 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.92 155.93 39.07 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 116.767 2.136 . . . . 0.0 116.767 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -162.75 78.34 0.47 Allowed 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 111.145 -2.752 . . . . 0.0 106.1 177.702 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 23' ' ' ASP . . . . . 0.405 ' O ' ' C ' ' B' ' 24' ' ' VAL . 67.2 t0 -170.33 131.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.887 -176.384 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 24' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' B' ' 23' ' ' ASP . 2.5 t -35.13 111.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 121.555 0.693 . . . . 0.0 111.795 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 121.11 -93.12 0.52 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 108.576 -1.81 . . . . 0.0 108.576 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 26' ' ' SER . . . . . 0.544 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 4.4 m -60.9 171.91 1.1 Allowed 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 175.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 27' ' ' ASN . . . . . 0.576 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 0.9 OUTLIER 100.07 -170.88 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 CA-C-O 122.16 0.981 . . . . 0.0 113.506 178.441 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 28' ' ' LYS . . . . . 0.576 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 86.7 tttt -29.26 111.07 0.06 Allowed 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 113.349 -1.751 . . . . 0.0 113.016 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 29' ' ' GLY . . . . . 0.557 ' C ' ' O ' ' B' ' 30' ' ' ALA . . . -80.99 100.91 2.02 Favored Glycine 0 CA--C 1.49 -1.518 0 CA-C-O 127.632 3.907 . . . . 0.0 109.401 -176.86 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 30' ' ' ALA . . . . . 0.557 ' O ' ' C ' ' B' ' 29' ' ' GLY . . . -79.31 -125.07 0.01 OUTLIER 'General case' 1 N--CA 1.37 -4.446 3 N-CA-C 87.399 -8.741 . . . . 0.0 87.399 166.239 . . . . . . . . 4 3 . 1 . 010 nuclear orig full ' B' B ' 31' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' H' ' 35' ' ' MET . 0.2 OUTLIER -72.9 115.62 13.94 Favored 'Isoleucine or valine' 1 C--N 1.226 -4.792 0 CA-C-N 125.138 3.608 . . . . 0.0 111.128 176.465 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' B' B ' 32' ' ' ILE . . . . . 0.565 ' N ' ' SD ' ' H' ' 35' ' ' MET . 0.1 OUTLIER -109.41 115.48 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.774 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.7 90.94 0.58 Allowed Glycine 0 C--O 1.24 0.473 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 177.274 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 34' ' ' LEU . . . . . . . . . . . . . 74.4 mt -121.27 137.0 54.88 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.422 1.106 . . . . 0.0 112.06 -177.074 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 35' ' ' MET . . . . . 0.736 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 34.2 ttp -126.25 117.3 22.77 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.864 -179.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 34.0 m -123.36 71.49 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.066 179.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.1 -101.72 2.28 Favored Glycine 0 C--N 1.353 1.523 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.4 166.78 41.41 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -134.46 142.0 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.759 0.314 . . . . 0.0 110.306 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.398 179.801 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -123.74 141.47 51.99 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.989 0.424 . . . . 0.0 110.958 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 11' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' B' ' 11' ' ' GLU . 80.7 tt0 -111.2 137.15 49.27 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.782 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 m -146.56 167.2 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 CA-C-O 120.993 0.425 . . . . 0.0 111.643 -179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 13' ' ' HIS . . . . . 0.629 ' CG ' ' NE2' ' B' ' 14' ' ' HIS . 29.7 m-70 -133.32 145.12 50.14 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -84.48 -179.46 7.16 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-O 121.32 0.581 . . . . 0.0 110.272 -178.883 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -90.91 175.23 7.05 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.994 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -130.01 134.46 47.43 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.363 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -131.55 121.46 24.46 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.257 0.551 . . . . 0.0 112.412 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 18.0 m -132.04 127.26 57.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 CA-C-O 121.989 0.9 . . . . 0.0 110.734 177.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.13 119.49 36.59 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 114.716 -1.129 . . . . 0.0 108.97 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 20' ' ' PHE . . . . . 0.4 ' CZ ' ' HB2' ' B' ' 20' ' ' PHE . 53.2 p90 -147.37 150.81 35.43 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 118.615 -1.234 . . . . 0.0 112.512 177.534 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.14 150.19 32.29 Favored 'General case' 0 C--O 1.241 0.634 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -119.01 117.15 28.0 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.307 -1.77 . . . . 0.0 107.673 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 23' ' ' ASP . . . . . 0.581 ' O ' ' O ' ' C' ' 24' ' ' VAL . 57.3 m-20 -147.45 135.88 21.71 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.964 -177.579 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 24' ' ' VAL . . . . . 0.581 ' O ' ' O ' ' C' ' 23' ' ' ASP . 8.5 t -29.4 -110.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 O-C-N 124.54 1.15 . . . . 0.0 111.283 178.132 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.7 91.88 0.12 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.886 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 12.3 p -62.8 -176.98 0.13 Allowed 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 27' ' ' ASN . . . . . 0.468 ' CG ' ' H ' ' C' ' 28' ' ' LYS . 50.8 t30 -79.49 170.56 16.4 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 118.842 -1.143 . . . . 0.0 112.632 -178.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 28' ' ' LYS . . . . . 0.683 ' NZ ' HD22 ' E' ' 27' ' ' ASN . 29.1 mmtt -46.24 111.9 0.42 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 115.712 1.745 . . . . 0.0 115.712 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 29' ' ' GLY . . . . . 0.458 ' H ' ' HA3' ' D' ' 25' ' ' GLY . . . 92.69 93.78 1.45 Allowed Glycine 0 N--CA 1.473 1.13 0 CA-C-N 115.378 -0.828 . . . . 0.0 114.495 177.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -85.41 176.71 8.11 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 101.411 -3.552 . . . . 0.0 101.411 172.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -141.97 111.72 2.76 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.248 -175.62 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.4 mt -98.75 111.17 27.71 Favored 'Isoleucine or valine' 0 C--N 1.349 0.569 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.41 99.64 1.13 Allowed Glycine 0 CA--C 1.505 -0.581 0 N-CA-C 106.048 -2.821 . . . . 0.0 106.048 175.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 34' ' ' LEU . . . . . 0.482 HD13 ' N ' ' C' ' 35' ' ' MET . 19.6 tp -135.83 133.17 37.54 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 123.056 1.408 . . . . 0.0 112.419 -176.901 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 35' ' ' MET . . . . . 0.492 ' HE2' ' N ' ' H' ' 32' ' ' ILE . 41.2 ttp -110.49 122.06 46.82 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 113.269 -1.787 . . . . 0.0 109.532 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -109.61 66.76 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.618 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.59 -102.81 0.01 OUTLIER Glycine 0 C--N 1.362 1.99 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.88 158.03 26.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -134.4 162.74 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.438 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.851 -179.897 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -85.37 133.81 34.11 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -129.79 130.64 45.6 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.306 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -112.73 131.07 65.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.948 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' D' ' 14' ' ' HIS . 84.3 t60 -89.67 130.18 35.99 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.0 0.428 . . . . 0.0 111.864 -178.388 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 14' ' ' HIS . . . . . 0.449 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.8 m-70 -82.84 178.16 8.31 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -96.42 178.4 5.37 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.548 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -142.29 137.69 30.81 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.825 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 41.7 tp -120.82 115.06 22.53 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.618 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.3 127.08 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.408 -0.517 . . . . 0.0 112.153 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -118.12 114.46 23.12 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 20' ' ' PHE . . . . . 0.532 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 21.5 t80 -127.6 119.08 25.15 Favored 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.179 0.514 . . . . 0.0 110.328 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 21' ' ' ALA . . . . . 0.428 ' O ' ' OE1' ' E' ' 22' ' ' GLU . . . -132.19 133.31 44.04 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-O 121.928 0.87 . . . . 0.0 112.629 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -91.4 133.61 35.32 Favored 'General case' 0 C--N 1.339 0.112 0 CA-C-N 114.677 -1.147 . . . . 0.0 108.627 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 23' ' ' ASP . . . . . 0.458 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 5.8 t0 71.55 103.54 0.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.203 0.525 . . . . 0.0 110.191 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 24' ' ' VAL . . . . . 0.543 ' O ' ' C ' ' D' ' 25' ' ' GLY . 8.4 p -134.83 135.15 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 N-CA-C 105.747 -1.946 . . . . 0.0 105.747 -178.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 25' ' ' GLY . . . . . 0.543 ' C ' ' O ' ' D' ' 24' ' ' VAL . . . -24.39 -82.51 0.01 OUTLIER Glycine 0 N--CA 1.48 1.62 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.648 -174.696 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 26' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' E' ' 27' ' ' ASN . 5.5 p -166.8 176.22 7.25 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 120.698 2.249 . . . . 0.0 113.037 174.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 48.28 178.2 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 113.074 -1.875 . . . . 0.0 113.057 174.611 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -71.66 111.55 7.04 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 174.782 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 29' ' ' GLY . . . . . 0.613 ' C ' ' O ' ' D' ' 30' ' ' ALA . . . 84.87 94.49 0.73 Allowed Glycine 0 CA--C 1.482 -2.019 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.811 -177.807 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 30' ' ' ALA . . . . . 0.613 ' O ' ' C ' ' D' ' 29' ' ' GLY . . . -75.46 -149.84 0.03 OUTLIER 'General case' 0 CA--C 1.498 -1.051 1 N-CA-C 96.892 -5.225 . . . . 0.0 96.892 168.435 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 31' ' ' ILE . . . . . 0.654 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 0.1 OUTLIER -97.51 102.12 13.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 1 CA-C-N 127.292 4.587 . . . . 0.0 109.907 178.45 . . . . . . . . 4 4 . 1 . 010 nuclear orig full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.0 tt -112.97 121.94 66.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.612 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.849 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.46 100.1 1.1 Allowed Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 107.064 -2.414 . . . . 0.0 107.064 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tp -117.19 120.7 39.07 Favored 'General case' 0 CA--C 1.508 -0.64 0 CA-C-O 121.702 0.763 . . . . 0.0 110.492 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 4.9 tmm? -104.26 115.91 31.24 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -118.19 71.43 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.18 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.0 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' D' D ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.24 -101.12 0.01 OUTLIER Glycine 0 C--N 1.366 2.228 0 N-CA-C 111.86 -0.496 . . . . 0.0 111.86 178.766 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.48 -179.81 43.02 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.61 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -125.34 135.76 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.454 -0.373 . . . . 0.0 110.086 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.593 179.951 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -103.91 135.35 45.61 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.916 0.388 . . . . 0.0 110.21 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -106.8 151.39 25.24 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 m -131.09 156.94 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.969 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.75 174.28 7.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.798 0.332 . . . . 0.0 110.329 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 14' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.2 OUTLIER -78.32 174.04 11.67 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -179.374 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' E' E ' 15' ' ' GLN . . . . . 0.401 ' HG2' ' H ' ' E' ' 16' ' ' LYS . 44.1 tt0 -122.63 172.15 8.61 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.614 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 16' ' ' LYS . . . . . 0.401 ' H ' ' HG2' ' E' ' 15' ' ' GLN . 65.7 mttp -153.82 119.07 5.12 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.6 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.8 mt -126.31 116.43 21.21 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 5.6 p -143.16 147.56 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.182 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -120.04 124.33 45.61 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 114.227 -1.351 . . . . 0.0 109.747 179.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 31.9 m-85 -121.39 126.81 50.29 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 122.373 -0.205 . . . . 0.0 110.529 179.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.06 137.57 37.92 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 -179.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 22' ' ' GLU . . . . . 0.532 ' OE2' ' CZ ' ' D' ' 20' ' ' PHE . 58.0 mp0 -113.22 137.84 50.87 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 23' ' ' ASP . . . . . 0.477 ' OD1' ' O ' ' D' ' 25' ' ' GLY . 27.4 t70 -150.0 132.46 15.68 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.383 178.434 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 30.1 m -74.59 113.08 12.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.071 179.3 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.08 92.18 0.01 OUTLIER Glycine 0 CA--C 1.527 0.824 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.447 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 74.0 m -47.81 151.63 0.86 Allowed 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.693 -0.253 . . . . 0.0 111.518 178.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 27' ' ' ASN . . . . . 0.683 HD22 ' NZ ' ' C' ' 28' ' ' LYS . 10.3 p30 -157.35 178.43 10.32 Favored 'General case' 0 CA--C 1.55 0.957 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 173.682 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 1.63 104.4 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 119.236 3.051 . . . . 0.0 119.236 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 29' ' ' GLY . . . . . 0.501 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . 90.43 -100.63 2.7 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 116.404 1.322 . . . . 0.0 116.404 167.881 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 30' ' ' ALA . . . . . 0.578 ' CB ' ' O ' ' D' ' 29' ' ' GLY . . . 56.86 149.78 0.01 OUTLIER 'General case' 0 C--O 1.255 1.356 0 CA-C-N 112.138 -2.031 . . . . 0.0 106.645 -177.407 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 31' ' ' ILE . . . . . 0.603 ' N ' ' O ' ' D' ' 29' ' ' GLY . 0.1 OUTLIER -158.23 134.48 2.0 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 C-N-CA 118.669 -1.212 . . . . 0.0 110.734 -174.341 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -128.57 121.45 55.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 CA-C-O 121.4 0.619 . . . . 0.0 110.769 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 33' ' ' GLY . . . . . 0.546 ' CA ' ' SD ' ' K' ' 35' ' ' MET . . . -114.64 117.02 3.94 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -118.72 120.15 36.56 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.479 -178.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 15.5 ttp -116.61 115.54 25.9 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.401 -0.52 . . . . 0.0 109.884 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 36' ' ' VAL . . . . . 0.475 ' O ' ' C ' ' E' ' 37' ' ' GLY . 2.8 p -144.03 83.77 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.52 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 37' ' ' GLY . . . . . 0.475 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -18.95 -94.49 0.01 OUTLIER Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.663 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.12 -164.05 37.24 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.07 161.01 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 120.847 0.356 . . . . 0.0 110.707 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.433 179.828 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -112.28 149.66 32.06 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.81 0.338 . . . . 0.0 110.387 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -54.01 149.14 9.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.132 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 65.3 t -114.34 130.84 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 110.948 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 13' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 31.1 p-80 -154.07 134.61 13.53 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.532 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 93.9 m-70 -155.23 170.03 22.8 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 121.303 0.573 . . . . 0.0 109.602 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -143.96 173.81 11.39 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.431 -0.804 . . . . 0.0 108.884 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -152.44 129.85 11.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.1 tp -121.08 117.9 28.38 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.51 133.14 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 19' ' ' PHE . . . . . . . . . . . . . 86.2 m-85 -118.48 114.73 23.3 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.902 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -134.18 144.86 48.73 Favored 'General case' 0 N--CA 1.477 0.885 0 CA-C-O 122.282 1.039 . . . . 0.0 112.086 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.43 148.35 30.2 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.128 178.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.52 136.83 39.32 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.712 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -149.62 134.03 17.46 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.418 0.628 . . . . 0.0 111.086 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' F' ' 25' ' ' GLY . 12.9 t -93.71 112.55 26.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.292 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 25' ' ' GLY . . . . . 0.463 ' O ' ' ND2' ' F' ' 27' ' ' ASN . . . 42.64 91.42 0.01 OUTLIER Glycine 0 N--CA 1.472 1.063 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.393 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 85.7 p -45.2 152.16 0.29 Allowed 'General case' 0 N--CA 1.439 -1.022 0 CA-C-O 123.066 1.412 . . . . 0.0 111.989 -176.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 69.0 m-80 -156.84 -170.9 3.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 111.679 -2.51 . . . . 0.0 106.304 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.7 mttt 19.19 110.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 121.797 0.808 . . . . 0.0 113.166 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.19 96.62 2.23 Favored Glycine 0 CA--C 1.492 -1.395 0 CA-C-O 123.412 1.562 . . . . 0.0 111.877 -174.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 30' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' E' ' 29' ' ' GLY . . . -63.94 -171.15 0.05 OUTLIER 'General case' 0 CA--C 1.489 -1.376 0 CA-C-N 110.989 -2.606 . . . . 0.0 107.537 -179.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -132.74 133.76 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 117.261 -1.776 . . . . 0.0 113.191 -176.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 14.9 tt -126.71 132.41 70.17 Favored 'Isoleucine or valine' 0 C--N 1.345 0.386 0 CA-C-N 113.747 -1.57 . . . . 0.0 112.202 -177.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.7 115.54 2.74 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -119.47 119.51 34.09 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 35' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 30.8 ttp -114.03 118.61 34.58 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 121.267 -0.173 . . . . 0.0 111.196 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 36' ' ' VAL . . . . . 0.514 ' O ' ' C ' ' F' ' 37' ' ' GLY . 5.0 t -139.11 83.05 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-O 119.295 -0.384 . . . . 0.0 110.686 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 37' ' ' GLY . . . . . 0.514 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . -15.73 -95.66 0.01 OUTLIER Glycine 0 C--N 1.351 1.367 0 O-C-N 123.063 0.227 . . . . 0.0 112.886 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 127.92 163.05 11.26 Favored Glycine 0 N--CA 1.466 0.695 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 28.6 m -140.31 160.38 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.825 0.345 . . . . 0.0 110.655 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.532 -179.968 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -106.03 135.37 47.62 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.907 0.385 . . . . 0.0 110.724 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 11' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' H' ' 9' ' ' GLY . 73.1 mm-40 -84.28 142.6 30.11 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.53 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 12.0 p -127.09 136.84 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.725 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 13' ' ' HIS . . . . . 0.475 ' ND1' ' N ' ' G' ' 13' ' ' HIS . 2.5 p-80 -149.23 168.49 23.14 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.995 -179.137 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 14' ' ' HIS . . . . . 0.534 ' CD2' ' H ' ' H' ' 14' ' ' HIS . 89.0 m-70 -132.83 178.26 7.0 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -129.09 -179.13 4.94 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.086 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 89.2 tttt -99.23 142.53 30.6 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.643 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 74.7 mt -125.68 118.79 26.38 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -136.28 138.67 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.204 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.753 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -119.64 126.36 50.96 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.211 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -122.5 120.76 34.82 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.08 127.61 44.94 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.105 0.479 . . . . 0.0 111.806 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -160.83 87.27 0.73 Allowed 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.685 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -178.37 123.13 0.1 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.925 0.393 . . . . 0.0 110.628 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.8 t -38.93 114.34 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.185 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 25' ' ' GLY . . . . . 0.443 ' H ' ' CG2' ' H' ' 24' ' ' VAL . . . -98.14 -86.41 1.84 Allowed Glycine 0 N--CA 1.47 0.907 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 26' ' ' SER . . . . . 0.747 ' O ' ' O ' ' G' ' 27' ' ' ASN . 17.0 m -151.58 -173.06 4.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.536 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 27' ' ' ASN . . . . . 0.747 ' O ' ' O ' ' G' ' 26' ' ' SER . 97.0 m-20 -22.79 170.0 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 O-C-N 124.313 1.008 . . . . 0.0 113.235 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 28' ' ' LYS . . . . . 0.557 ' NZ ' ' O ' ' I' ' 26' ' ' SER . 32.4 tttt -102.03 -112.82 0.21 Allowed 'General case' 0 N--CA 1.476 0.828 0 O-C-N 121.606 -0.684 . . . . 0.0 112.265 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 29' ' ' GLY . . . . . 0.472 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 47.98 91.57 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 30' ' ' ALA . . . . . 0.522 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . -106.18 162.37 13.7 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 123.85 1.786 . . . . 0.0 111.127 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -160.29 121.94 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 110.547 -3.024 . . . . 0.0 106.84 -172.733 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -139.64 122.73 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.249 178.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.7 117.41 5.86 Favored Glycine 0 CA--C 1.506 -0.519 0 N-CA-C 106.821 -2.511 . . . . 0.0 106.821 177.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 70.9 mt -113.59 120.17 40.02 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-O 121.562 0.696 . . . . 0.0 111.931 -177.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' C ' ' A' ' 31' ' ' ILE . 3.8 ttm -120.84 108.02 13.43 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 177.046 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.72 71.56 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -178.933 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.11 -98.31 0.85 Allowed Glycine 0 C--N 1.361 1.921 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.6 -173.63 43.26 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -126.83 136.14 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.809 0.337 . . . . 0.0 110.102 -179.597 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.98 -1.01 . . . . 0.0 110.789 -179.809 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' H' H ' 9' ' ' GLY . . . . . 0.426 ' O ' ' OE2' ' G' ' 11' ' ' GLU . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 79.6 t80 -105.06 129.0 53.59 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.334 -0.247 . . . . 0.0 110.334 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -67.06 131.07 45.08 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.671 -0.412 . . . . 0.0 110.452 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.67 148.73 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.494 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -121.61 124.07 43.45 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.69 0.281 . . . . 0.0 110.664 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 14' ' ' HIS . . . . . 0.534 ' H ' ' CD2' ' G' ' 14' ' ' HIS . 37.1 m-70 -144.58 166.18 25.91 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.345 0.593 . . . . 0.0 110.277 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.6 tp60 -160.81 161.15 31.9 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.795 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -158.83 118.06 3.05 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.54 110.5 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 18' ' ' VAL . . . . . 0.408 ' CG1' ' CE2' ' H' ' 20' ' ' PHE . 72.4 t -124.29 130.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 120.551 -0.46 . . . . 0.0 111.045 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.39 114.25 22.05 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.973 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 20' ' ' PHE . . . . . 0.408 ' CE2' ' CG1' ' H' ' 18' ' ' VAL . 52.4 m-85 -110.1 117.28 33.3 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.53 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.1 134.44 38.36 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 119.558 -0.857 . . . . 0.0 112.867 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -152.02 89.65 1.47 Allowed 'General case' 0 C--O 1.224 -0.261 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 23' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 26.5 p-10 169.85 -121.23 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.366 0.416 . . . . 0.0 110.073 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 24' ' ' VAL . . . . . 0.443 ' CG2' ' H ' ' G' ' 25' ' ' GLY . 1.5 m -85.28 122.41 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 50.65 84.25 0.03 OUTLIER Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -178.902 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 26' ' ' SER . . . . . . . . . . . . . 22.0 p -68.95 -168.54 0.14 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 178.412 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' H' ' 28' ' ' LYS . 89.5 m-20 -80.2 175.91 10.23 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 28' ' ' LYS . . . . . 0.613 ' O ' ' O ' ' H' ' 27' ' ' ASN . 29.7 tttt 35.34 100.49 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -172.121 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 29' ' ' GLY . . . . . 0.615 ' O ' ' C ' ' H' ' 30' ' ' ALA . . . -98.3 110.31 3.99 Favored Glycine 1 CA--C 1.445 -4.315 1 CA-C-O 112.742 -4.366 . . . . 0.0 120.858 -176.647 . . . . . . . . 4 3 . 1 . 010 nuclear orig full ' H' H ' 30' ' ' ALA . . . . . 0.746 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 53.43 -122.32 2.0 Allowed 'General case' 0 C--N 1.39 2.342 2 C-N-CA 107.778 -5.569 . . . . 0.0 109.505 161.431 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' H' H ' 31' ' ' ILE . . . . . 0.59 HD11 ' H ' ' H' ' 31' ' ' ILE . 4.1 mp -67.4 107.98 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.314 0 CA-C-N 109.966 -3.288 . . . . 0.0 109.796 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 32' ' ' ILE . . . . . 0.492 ' N ' ' HE2' ' C' ' 35' ' ' MET . 10.3 tt -122.47 120.44 61.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 122.246 1.022 . . . . 0.0 109.789 174.816 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 33' ' ' GLY . . . . . 0.736 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -98.87 117.96 6.02 Favored Glycine 0 CA--C 1.497 -1.075 0 N-CA-C 106.304 -2.718 . . . . 0.0 106.304 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 56.0 tp -120.04 119.66 34.03 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 113.836 1.051 . . . . 0.0 113.836 -175.663 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 35' ' ' MET . . . . . 0.565 ' SD ' ' N ' ' B' ' 32' ' ' ILE . 17.6 ttm -124.8 115.31 20.49 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 175.517 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.32 71.25 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.85 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.16 -100.81 2.66 Favored Glycine 0 C--N 1.358 1.8 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 110.54 166.17 19.21 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.04 156.62 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-O 120.686 0.279 . . . . 0.0 110.357 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.636 -179.826 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -97.29 135.01 39.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.74 0.305 . . . . 0.0 110.278 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -143.18 160.1 41.07 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.222 0.534 . . . . 0.0 111.487 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t -120.61 133.63 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.253 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 75.7 m80 -129.61 131.96 46.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.84 0.352 . . . . 0.0 111.514 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 86.3 t60 -154.18 165.76 35.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 177.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 15' ' ' GLN . . . . . 0.52 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 76.0 mt-30 -158.76 171.22 20.49 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.502 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -151.05 121.48 7.36 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.071 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -127.67 123.82 36.44 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.7 t -134.44 130.29 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CZ ' ' J' ' 19' ' ' PHE . 45.4 m-85 -111.35 108.45 18.05 Favored 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 176.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -116.47 119.53 35.9 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.184 -0.323 . . . . 0.0 111.109 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 21' ' ' ALA . . . . . 0.468 ' HB1' ' N ' ' H' ' 27' ' ' ASN . . . -136.78 127.5 27.17 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 -178.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -138.49 109.17 6.62 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.732 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 42.0 p-10 -161.69 125.14 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.96 179.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 24' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.8 m -89.82 -112.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.595 -0.442 . . . . 0.0 109.971 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.98 -92.02 0.01 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.0 p -129.19 170.27 13.77 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' I' ' 26' ' ' SER . 73.5 m-80 31.98 172.58 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 28' ' ' LYS . . . . . 0.512 ' O ' ' HA ' ' J' ' 23' ' ' ASP . 23.3 pttt 148.55 95.36 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 123.344 0.658 . . . . 0.0 111.571 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 29' ' ' GLY . . . . . 0.746 ' O ' ' O ' ' H' ' 30' ' ' ALA . . . 58.46 -112.59 4.12 Favored Glycine 1 CA--C 1.433 -5.059 0 CA-C-O 114.948 -3.14 . . . . 0.0 111.849 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' I' I ' 30' ' ' ALA . . . . . 0.619 ' CB ' ' O ' ' I' ' 29' ' ' GLY 0.529 . . 97.96 -125.45 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.513 1 C-N-CA 109.781 -4.768 . . . . 0.0 113.355 179.294 . . . . . . . . 4 3 . 1 . 010 nuclear orig full ' I' I ' 31' ' ' ILE . . . . . . . . . . . . 0.426 3.0 mt -64.05 110.74 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.402 -2.852 1 CA-C-N 106.479 -4.873 . . . . 0.0 109.967 173.924 . . . . . . . . 3 2 . 1 . 010 nuclear orig full ' I' I ' 32' ' ' ILE . . . . . . . . . . . . . 10.6 tt -135.36 126.15 44.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-O 122.333 1.064 . . . . 0.0 112.496 178.158 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.7 119.49 5.8 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 177.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 34' ' ' LEU . . . . . 0.486 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 13.7 tp -114.68 125.72 54.06 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.638 0.733 . . . . 0.0 112.277 -178.887 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 35' ' ' MET . . . . . . . . . . . . . 12.6 tpp -123.77 111.0 15.61 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.784 175.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -128.03 68.28 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.374 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.11 -101.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.625 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.01 160.02 23.54 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.73 135.95 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.519 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.11 154.65 28.54 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -51.01 139.26 17.88 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.004 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -129.47 140.7 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.607 -179.128 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -137.59 103.78 5.14 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.759 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 65.5 m170 -117.7 164.66 14.64 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -157.77 172.83 17.78 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.217 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -155.41 115.64 3.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.526 178.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.27 124.15 41.78 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -134.07 132.43 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 19' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 14.8 m-85 -114.16 107.11 15.19 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.219 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 20' ' ' PHE . . . . . 0.57 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 35.4 t80 -120.92 117.55 27.63 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -166.96 175.68 7.47 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -178.389 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -88.22 138.83 31.09 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 113.134 -1.848 . . . . 0.0 109.032 177.861 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 23' ' ' ASP . . . . . 0.512 ' HA ' ' O ' ' I' ' 28' ' ' LYS . 74.0 m-20 -117.61 -161.0 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 121.384 0.611 . . . . 0.0 111.575 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 24' ' ' VAL . . . . . 0.449 HG11 ' H ' ' J' ' 29' ' ' GLY . 76.4 t 52.77 103.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 116.56 2.059 . . . . 0.0 116.56 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.59 -92.63 0.03 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 172.32 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' J' ' 27' ' ' ASN . 13.9 p -124.63 166.31 16.35 Favored 'General case' 0 CA--C 1.51 -0.57 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 175.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.9 m120 47.84 174.23 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 28' ' ' LYS . . . . . 0.504 ' HZ1' ' CB ' ' K' ' 30' ' ' ALA . 86.2 tttt -73.06 110.91 7.71 Favored 'General case' 0 C--N 1.35 0.626 1 C-N-CA 111.064 -4.254 . . . . 0.0 106.046 178.279 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' J' J ' 29' ' ' GLY . . . . . 0.449 ' H ' HG11 ' J' ' 24' ' ' VAL . . . -86.27 93.4 1.86 Allowed Glycine 0 CA--C 1.485 -1.807 0 CA-C-O 117.518 -1.712 . . . . 0.0 112.255 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 30' ' ' ALA . . . . . 0.454 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -163.16 140.21 7.49 Favored 'General case' 0 C--N 1.281 -2.406 0 CA-C-N 121.194 2.497 . . . . 0.0 108.348 171.193 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 31' ' ' ILE . . . . . 0.454 ' CG1' ' C ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -158.39 116.54 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 CA-C-N 112.249 -2.25 . . . . 0.0 107.08 -173.32 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' J' J ' 32' ' ' ILE . . . . . . . . . . . . . 15.6 tt -124.87 117.33 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.896 0.855 . . . . 0.0 110.994 179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.62 118.95 6.24 Favored Glycine 0 CA--C 1.505 -0.569 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 34' ' ' LEU . . . . . 0.492 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 50.8 mt -113.54 107.29 15.6 Favored 'General case' 0 CA--C 1.505 -0.783 0 CA-C-O 121.322 0.582 . . . . 0.0 111.125 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.0 tpt -111.5 112.0 23.42 Favored 'General case' 0 CA--C 1.514 -0.421 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.297 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -131.63 74.71 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.668 -177.72 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.23 106.23 2.97 Favored Glycine 0 C--N 1.355 1.6 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.77 169.39 52.15 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 70.0 t -133.94 138.57 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 120.644 0.259 . . . . 0.0 110.524 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.758 179.754 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -111.11 134.75 52.47 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.8 0.333 . . . . 0.0 110.478 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -110.94 148.89 31.51 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 12' ' ' VAL . . . . . 0.557 ' CG2' ' NE2' ' K' ' 14' ' ' HIS . 2.6 m -140.24 -171.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -92.44 132.05 37.1 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.807 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' CG2' ' K' ' 12' ' ' VAL . 80.0 m-70 -148.03 169.75 19.25 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -157.27 178.96 9.73 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.805 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -160.57 121.5 2.96 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.173 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -126.62 125.09 41.33 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.68 129.61 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.927 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 19' ' ' PHE . . . . . 0.486 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 19.8 m-85 -113.45 108.89 17.82 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 20' ' ' PHE . . . . . 0.57 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.1 t80 -118.51 121.13 39.51 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.141 0.428 . . . . 0.0 110.855 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.03 139.84 45.13 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.71 167.53 26.18 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.781 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -166.38 -136.42 0.02 OUTLIER 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.144 177.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' K' ' 25' ' ' GLY . 18.7 t -110.62 110.36 31.9 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 25' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 32.54 91.44 0.01 OUTLIER Glycine 0 CA--C 1.53 0.981 0 N-CA-C 112.156 -0.377 . . . . 0.0 112.156 177.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 26' ' ' SER . . . . . 0.413 ' OG ' ' CG ' ' L' ' 23' ' ' ASP . 5.8 p -47.5 154.71 0.42 Allowed 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 m120 -119.15 172.58 7.48 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 122.239 1.018 . . . . 0.0 113.166 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -32.8 110.75 0.09 Allowed 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 116.248 1.944 . . . . 0.0 116.248 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.59 93.42 0.44 Allowed Glycine 0 N--CA 1.475 1.286 0 N-CA-C 116.386 1.314 . . . . 0.0 116.386 172.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 30' ' ' ALA . . . . . 0.504 ' CB ' ' HZ1' ' J' ' 28' ' ' LYS . . . -101.11 165.71 11.16 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 101.628 -3.471 . . . . 0.0 101.628 170.096 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 31' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.29 122.77 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 116.926 -1.91 . . . . 0.0 111.854 -178.224 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 32' ' ' ILE . . . . . 0.438 ' O ' ' SD ' ' F' ' 35' ' ' MET . 76.0 mt -131.96 130.92 61.63 Favored 'Isoleucine or valine' 0 C--N 1.352 0.686 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.443 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -122.47 122.22 4.96 Favored Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.371 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 mt -114.7 114.95 26.32 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.266 0.533 . . . . 0.0 111.8 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 35' ' ' MET . . . . . 0.546 ' SD ' ' CA ' ' E' ' 33' ' ' GLY . 8.1 ttt -128.36 120.89 27.88 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 177.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.08 81.61 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.05 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -65.41 102.05 0.63 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.75 152.64 24.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.6 m -130.61 157.71 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.702 -179.663 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -110.29 146.83 35.01 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.756 0.312 . . . . 0.0 110.646 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -58.36 145.54 37.81 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.521 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG2' ' K' ' 12' ' ' VAL . 66.9 t -128.28 130.13 69.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.922 0.868 . . . . 0.0 111.389 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 13' ' ' HIS . . . . . 0.493 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 4.4 m-70 -117.66 110.79 18.31 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.699 178.685 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -138.78 173.63 11.38 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -144.93 177.09 9.0 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.179 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -149.36 126.1 11.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.752 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.29 125.92 37.87 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -123.63 128.63 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-O 120.94 0.4 . . . . 0.0 110.425 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 19' ' ' PHE . . . . . 0.492 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 70.7 m-85 -113.81 112.3 23.18 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -133.49 127.72 33.85 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 121.696 0.76 . . . . 0.0 112.689 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.57 137.61 42.15 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.644 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -80.44 109.19 14.7 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 119.953 -0.699 . . . . 0.0 112.302 -178.073 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 23' ' ' ASP . . . . . 0.413 ' CG ' ' OG ' ' K' ' 26' ' ' SER . 37.0 t0 178.91 113.28 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.711 178.731 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 63.3 t -59.16 130.55 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.607 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -68.39 85.29 0.19 Allowed Glycine 0 CA--C 1.526 0.757 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.847 178.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 49.2 m -65.6 -175.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.083 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' O ' ' L' ' 28' ' ' LYS . 2.7 m120 -91.13 178.9 5.86 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 28' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 28.03 102.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.023 0 O-C-N 123.42 0.45 . . . . 0.0 111.69 177.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.85 -101.71 0.22 Allowed Glycine 0 N--CA 1.467 0.702 0 C-N-CA 119.251 -1.452 . . . . 0.0 112.556 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 30' ' ' ALA . . . . . 0.4 ' HA ' ' H ' ' K' ' 30' ' ' ALA . . . -53.65 161.72 1.01 Allowed 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.135 -177.206 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -150.12 127.14 2.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.438 -176.108 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -127.01 129.36 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.33 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 33' ' ' GLY . . . . . 0.623 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -122.11 132.74 9.0 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.244 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -120.44 121.82 39.34 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.07 0.435 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.2 123.16 35.97 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.14 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 36' ' ' VAL . . . . . 0.515 ' O ' ' C ' ' L' ' 37' ' ' GLY . 16.7 m -145.41 78.92 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -3.63 -101.22 0.0 OUTLIER Glycine 0 C--N 1.359 1.814 0 C-N-CA 122.948 0.309 . . . . 0.0 113.284 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.6 162.74 21.49 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -132.39 156.08 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.868 0.366 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.936 -1.031 . . . . 0.0 111.076 -179.534 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 N--CA 1.456 -0.162 0 CA-C-O 120.712 0.291 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.2 t -126.01 133.77 68.15 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.018 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -106.24 165.87 10.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.467 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.414 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 8.2 p80 -92.34 169.58 10.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.385 0.612 . . . . 0.0 110.249 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 96.2 mm-40 -151.71 -179.96 7.88 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.008 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -126.04 126.71 44.69 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.904 0.383 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.2 mt -128.39 127.73 43.16 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.978 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -135.66 138.57 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.272 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -130.96 135.73 47.9 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.52 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.0 p90 -123.48 128.97 50.55 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.97 130.96 52.27 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 122.13 0.967 . . . . 0.0 112.788 -178.514 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -125.5 167.5 14.92 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 64.6 t0 . . . . . 0 N--CA 1.474 0.749 0 CA-C-N 118.289 0.495 . . . . 0.0 112.119 -178.83 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 74.1 tttt . . . . . 0 N--CA 1.464 0.242 0 N-CA-C 114.683 1.364 . . . . 0.0 114.683 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -77.53 101.4 1.64 Allowed Glycine 0 CA--C 1.507 -0.461 0 CA-C-O 114.823 -3.209 . . . . 0.0 105.505 168.648 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 147.73 25.98 Favored 'General case' 0 C--N 1.355 0.838 1 CA-C-N 125.483 4.642 . . . . 0.0 108.621 -178.407 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.591 HG22 ' CE ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -152.73 112.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.397 -171.704 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 56.5 mt -121.93 103.48 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.65 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -116.55 107.49 1.63 Allowed Glycine 0 CA--C 1.505 -0.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 177.272 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.501 ' H ' HD23 ' B' ' 34' ' ' LEU . 70.2 mt -142.66 153.66 43.63 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 123.295 1.521 . . . . 0.0 113.085 -177.122 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.469 ' SD ' ' C ' ' G' ' 31' ' ' ILE . 28.5 ttm -119.96 119.58 33.86 Favored 'General case' 0 CA--C 1.5 -0.949 0 CA-C-N 112.643 -2.071 . . . . 0.0 108.433 178.57 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.53 66.91 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.09 -102.13 0.01 OUTLIER Glycine 0 C--N 1.356 1.65 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.75 171.99 38.71 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.6 t -131.56 139.16 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.838 0.351 . . . . 0.0 110.415 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.357 179.811 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.36 158.54 44.01 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.683 0.277 . . . . 0.0 110.37 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.51 ' OE2' ' NE2' ' B' ' 13' ' ' HIS . 81.2 tt0 -146.56 146.26 30.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.272 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.1 m -136.88 159.68 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.163 0.506 . . . . 0.0 111.283 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.51 ' NE2' ' OE2' ' B' ' 11' ' ' GLU . 96.0 m-70 -149.83 163.52 37.81 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.067 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -115.04 178.39 4.3 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -97.2 175.09 6.41 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.775 -179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -117.49 138.67 51.71 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.73 127.27 40.1 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-O 121.051 0.453 . . . . 0.0 111.589 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -126.85 130.49 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.097 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -124.23 134.01 53.37 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.395 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -136.2 123.48 21.85 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.727 -0.215 . . . . 0.0 111.031 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.433 ' O ' ' CG ' ' B' ' 22' ' ' GLU . . . -126.86 117.55 22.82 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 120.946 0.403 . . . . 0.0 111.067 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.433 ' CG ' ' O ' ' B' ' 21' ' ' ALA . 83.3 mt-10 -165.47 133.8 3.16 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.617 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.9 t70 . . . . . 0 N--CA 1.471 0.605 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 177.238 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.275 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.91 152.29 29.49 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.645 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.28 118.35 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 113.914 -1.494 . . . . 0.0 109.059 -175.126 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.447 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.1 tt -122.65 114.74 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.686 0.755 . . . . 0.0 109.705 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -117.5 116.9 3.62 Favored Glycine 0 N--CA 1.463 0.498 0 N-CA-C 107.877 -2.089 . . . . 0.0 107.877 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.501 HD23 ' H ' ' A' ' 34' ' ' LEU . 79.6 mt -134.62 147.0 50.09 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 114.444 1.276 . . . . 0.0 114.444 -176.44 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.464 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 3.2 ttm -122.48 118.35 28.11 Favored 'General case' 0 CA--C 1.505 -0.779 0 CA-C-N 113.469 -1.696 . . . . 0.0 109.366 177.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.09 70.16 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.18 112.18 3.46 Favored Glycine 0 C--N 1.358 1.785 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.43 147.94 12.74 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.628 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -127.82 136.3 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.572 179.704 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.5 t . . . . . 0 N--CA 1.466 0.364 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -152.12 119.26 5.88 Favored 'General case' 0 N--CA 1.463 0.219 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.35 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -136.61 164.78 27.42 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -155.88 178.63 10.04 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.873 0.368 . . . . 0.0 110.557 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -167.72 106.92 0.54 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.208 178.664 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mt -122.12 121.15 36.24 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -129.26 125.97 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 CA-C-O 121.027 0.442 . . . . 0.0 111.971 -179.16 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -120.52 113.94 21.03 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -116.92 132.96 56.57 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.185 0.194 . . . . 0.0 110.641 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.91 138.1 25.37 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 85.1 tt0 -161.88 144.1 11.49 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.474 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 20.3 t0 . . . . . 0 CA--C 1.543 0.685 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.187 178.233 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.192 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.43 ' O ' HG13 ' D' ' 31' ' ' ILE . . . -106.37 157.87 17.3 Favored 'General case' 0 CA--C 1.482 -1.665 0 N-CA-C 101.764 -3.421 . . . . 0.0 101.764 175.586 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.645 HD12 ' CG2' ' B' ' 31' ' ' ILE . 2.0 mt -140.02 122.65 16.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 117.94 -1.504 . . . . 0.0 111.74 -173.209 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.469 HG22 ' O ' ' C' ' 32' ' ' ILE . 1.1 mt -117.75 112.59 39.31 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.14 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.78 102.81 0.87 Allowed Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.427 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 7.0 tt -134.73 138.52 44.44 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.654 1.216 . . . . 0.0 113.29 -175.042 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 25.9 ttm -117.99 120.5 38.0 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 113.705 -1.588 . . . . 0.0 108.724 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.652 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.0 p -125.36 71.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.39 -100.86 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.437 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.51 -157.83 29.8 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -133.9 160.24 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.004 0.43 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.831 179.986 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.604 HG21 ' HB ' ' E' ' 12' ' ' VAL . 9.9 m . . . . . 0 CA--C 1.536 0.439 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 63.0 m80 -78.4 124.63 28.33 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.145 -0.622 . . . . 0.0 111.727 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.507 ' CD2' HG23 ' D' ' 12' ' ' VAL . 82.8 m-70 -148.45 167.97 23.91 Favored 'General case' 0 C--N 1.342 0.28 0 CA-C-O 121.244 0.545 . . . . 0.0 109.985 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.63 177.69 10.67 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.591 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.61 114.09 0.62 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.21 0.528 . . . . 0.0 111.779 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 35.5 tp -123.72 121.59 35.87 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.215 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -126.62 125.48 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.465 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 35.8 m-85 -117.21 120.87 39.58 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.187 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -128.34 122.41 31.48 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.828 0.347 . . . . 0.0 111.175 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.65 135.55 40.26 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.166 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.7 mt-10 -117.57 124.39 48.55 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.111 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 77.8 m-20 . . . . . 0 CA--C 1.548 0.889 0 N-CA-C 112.852 0.686 . . . . 0.0 112.852 -179.255 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.473 -2.0 0 CA-C-O 122.086 0.946 . . . . 0.0 108.923 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -143.36 108.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 CA-C-N 113.535 -1.666 . . . . 0.0 107.955 -176.561 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.53 121.89 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.087 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.626 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -125.94 103.22 0.68 Allowed Glycine 0 C--N 1.311 -0.813 0 N-CA-C 105.526 -3.03 . . . . 0.0 105.526 175.301 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.573 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.4 tt -127.78 131.33 49.62 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-O 122.171 0.986 . . . . 0.0 111.747 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.944 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.0 ttm -112.05 121.81 46.02 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 113.985 -1.462 . . . . 0.0 110.011 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.466 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -110.95 75.43 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.803 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -31.85 -96.24 0.01 OUTLIER Glycine 0 C--N 1.353 1.502 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.9 175.29 17.49 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 10.0 p -139.7 141.51 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.92 0.39 . . . . 0.0 110.608 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.563 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' E' E ' 10' ' ' TYR . . . . . 0.514 ' CE1' ' N ' ' F' ' 9' ' ' GLY . 88.1 m-85 -107.89 135.04 49.95 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.832 0.348 . . . . 0.0 110.211 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.52 138.63 58.51 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.186 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.604 ' HB ' HG21 ' D' ' 12' ' ' VAL . 72.6 t -122.38 131.28 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.619 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 96.1 m-70 -121.41 114.99 22.08 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.385 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' O ' ' E' ' 13' ' ' HIS . 2.7 m80 -142.46 168.31 20.03 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.641 0.734 . . . . 0.0 110.124 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -151.63 168.95 23.35 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.079 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -146.36 111.36 5.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 31.9 mt -122.99 121.81 37.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 18' ' ' VAL . . . . . 0.523 HG21 ' CE2' ' E' ' 20' ' ' PHE . 14.3 p -140.16 135.87 37.22 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 CA-C-O 121.944 0.878 . . . . 0.0 112.883 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.573 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 36.7 m-85 -117.72 117.23 28.77 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 114.327 -1.306 . . . . 0.0 109.927 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.523 ' CE2' HG21 ' E' ' 18' ' ' VAL . 38.3 m-85 -113.3 119.56 38.12 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.699 0.285 . . . . 0.0 111.105 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -126.6 137.86 53.38 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 120.972 0.415 . . . . 0.0 110.01 178.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -79.47 73.83 6.11 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 118.309 -1.356 . . . . 0.0 111.158 -177.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.608 ' O ' ' O ' ' E' ' 24' ' ' VAL . 1.3 p30 -171.49 109.92 0.29 Allowed 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.663 176.011 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.608 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.8 t -45.27 -132.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.698 1.237 . . . . 0.0 112.582 177.404 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.648 ' C ' ' HB2' ' F' ' 30' ' ' ALA . . . -138.76 80.99 0.27 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.613 ' O ' ' N ' ' F' ' 30' ' ' ALA . 28.6 m . . . . . 0 C--O 1.214 -0.808 0 CA-C-O 121.294 0.568 . . . . 0.0 110.734 -179.089 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.246 0.893 0 CA-C-O 121.473 0.654 . . . . 0.0 110.251 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.532 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.1 mt -148.57 126.09 2.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.946 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' L' ' 35' ' ' MET . 89.3 mt -128.99 128.15 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 120.901 0.381 . . . . 0.0 111.946 -178.47 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 121.34 4.69 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.54 HD13 ' CZ ' ' F' ' 19' ' ' PHE . 47.9 tp -127.93 124.67 37.91 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.219 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.499 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 8.9 ttt -129.84 126.27 37.64 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 120.31 -0.556 . . . . 0.0 111.547 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' D' ' 36' ' ' VAL . 51.3 t -109.94 86.84 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.425 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.643 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -75.0 96.9 0.99 Allowed Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.2 170.8 43.1 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -128.45 135.06 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-O 120.911 0.386 . . . . 0.0 109.999 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.795 -179.791 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' F' F ' 9' ' ' GLY . . . . . 0.514 ' N ' ' CE1' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 10' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 79.8 t80 -84.66 130.82 34.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 11' ' ' GLU . . . . . 0.529 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 98.3 mt-10 -59.08 154.13 16.44 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.514 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 t -96.25 132.82 39.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.773 0.32 . . . . 0.0 110.703 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -153.13 113.98 4.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.204 0.526 . . . . 0.0 111.867 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -155.1 173.72 16.19 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -151.92 175.65 12.27 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.855 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -132.17 114.48 14.54 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.745 179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 49.0 tp -122.68 118.77 28.89 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 77.2 t -133.35 130.0 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.54 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 55.0 m-85 -113.64 111.82 22.47 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 175.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -141.81 152.86 44.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.005 0.907 . . . . 0.0 112.244 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.414 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -150.46 149.14 29.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.291 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -136.79 144.39 43.7 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -178.147 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' F' ' 24' ' ' VAL . 62.2 t0 177.75 -118.48 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.863 177.66 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 13.2 p -102.18 126.41 56.23 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.568 0 CA-C-O 121.124 0.488 . . . . 0.0 110.659 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -31.4 -83.15 0.01 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.007 177.252 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 13.2 t 73.08 179.96 0.22 Allowed 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 124.456 1.102 . . . . 0.0 110.183 -176.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -89.42 172.7 8.82 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 118.544 2.794 . . . . 0.0 118.544 -173.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -39.09 106.33 0.05 Allowed 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 109.268 -3.605 . . . . 0.0 119.894 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.61 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . 148.02 -97.22 0.18 Allowed Glycine 0 N--CA 1.483 1.8 0 C-N-CA 120.492 -0.861 . . . . 0.0 115.224 171.315 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.648 ' HB2' ' C ' ' E' ' 25' ' ' GLY . . . 56.2 166.02 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 103.186 -2.894 . . . . 0.0 103.186 -173.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.444 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 1.6 mt -140.08 119.37 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 124.098 3.135 . . . . 0.0 111.447 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 57.7 mt -123.87 136.23 60.92 Favored 'Isoleucine or valine' 0 C--N 1.347 0.483 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.512 -176.438 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.44 125.16 5.16 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 46.9 tp -118.64 120.8 38.51 Favored 'General case' 0 N--CA 1.47 0.54 0 O-C-N 122.642 -0.328 . . . . 0.0 110.229 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -118.37 119.38 34.45 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 116.952 -0.113 . . . . 0.0 111.098 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.49 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.4 p -153.21 82.47 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.763 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.898 ' H ' HD13 ' L' ' 31' ' ' ILE . . . -71.4 101.11 0.94 Allowed Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.26 161.51 34.51 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -141.86 143.7 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 110.604 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 t . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.4 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.505 ' N ' ' HD1' ' G' ' 13' ' ' HIS . 6.3 p-80 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 120.666 0.269 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 8.2 m80 -81.72 167.92 18.63 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-O 121.126 0.489 . . . . 0.0 109.961 -179.207 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.45 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 51.0 tp60 -163.17 172.32 15.0 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.563 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.45 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 99.7 mttt -138.72 139.81 38.5 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -138.83 120.68 15.41 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.213 0.53 . . . . 0.0 110.902 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.41 134.36 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.767 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -129.2 125.31 36.7 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 120.939 0.4 . . . . 0.0 110.592 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.402 ' CD1' ' C ' ' G' ' 20' ' ' PHE . 19.5 t80 -113.46 123.26 49.61 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.17 131.81 53.16 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 121.805 0.812 . . . . 0.0 112.472 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' G' ' 23' ' ' ASP . 18.6 pt-20 -102.48 -173.08 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.771 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.483 ' N ' ' CB ' ' H' ' 23' ' ' ASP . 19.3 t70 -23.83 132.96 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' G' ' 26' ' ' SER . 11.7 t -89.33 113.56 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 114.197 -1.365 . . . . 0.0 108.162 177.913 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . -44.92 91.55 0.01 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.402 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.552 ' O ' ' O ' ' G' ' 27' ' ' ASN . 16.1 m 138.92 172.34 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.577 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.552 ' O ' ' O ' ' G' ' 26' ' ' SER . 90.9 m-20 -43.07 -178.67 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 O-C-N 123.429 0.456 . . . . 0.0 111.066 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.573 ' CE ' HG22 ' I' ' 24' ' ' VAL . 68.5 tttt -72.07 -114.7 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.767 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 50.32 91.33 0.01 OUTLIER Glycine 0 C--N 1.344 0.974 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.0 163.26 12.32 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 117.326 -1.75 . . . . 0.0 108.629 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.469 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -152.56 109.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 CA-C-N 112.966 -1.924 . . . . 0.0 109.618 -172.806 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.522 ' CG2' HD21 ' H' ' 34' ' ' LEU . 5.1 mt -100.95 111.05 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.25 99.0 0.68 Allowed Glycine 0 CA--C 1.503 -0.661 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.419 ' H ' HD23 ' H' ' 34' ' ' LEU . 12.0 mt -138.65 141.58 39.06 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-O 122.965 1.364 . . . . 0.0 111.572 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.65 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 38.0 ttp -109.66 114.96 29.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 112.957 -1.928 . . . . 0.0 107.158 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.41 66.03 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.78 110.92 4.02 Favored Glycine 0 C--N 1.359 1.828 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.63 178.99 0.11 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.8 m . . . . . 0 N--CA 1.467 0.422 0 CA-C-O 120.782 0.325 . . . . 0.0 110.749 179.781 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.431 HG13 ' ND1' ' I' ' 13' ' ' HIS . 78.2 t . . . . . 0 CA--C 1.521 -0.156 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' I' ' 13' ' ' HIS . 3.5 t60 -140.06 100.23 3.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.894 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 13.9 t-80 -141.88 159.07 42.97 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.631 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 71.1 mt-30 -162.0 178.52 8.78 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.966 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -130.51 132.4 45.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 69.0 mt -120.9 111.74 17.91 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.54 127.22 74.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.143 0.497 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -117.1 112.94 21.59 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.381 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.24 121.2 44.66 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.37 132.39 48.55 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.256 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -164.58 125.73 2.13 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 119.857 -0.737 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.483 ' CB ' ' N ' ' G' ' 23' ' ' ASP . 0.9 OUTLIER -176.64 109.36 0.08 Allowed 'General case' 0 CA--C 1.544 0.723 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.6 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.285 173.818 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.092 0 N-CA-C 105.728 -1.952 . . . . 0.0 105.728 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.401 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -146.2 129.6 9.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 118.735 -1.186 . . . . 0.0 112.429 -172.378 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.464 ' C ' ' SD ' ' B' ' 35' ' ' MET . 67.3 mt -112.64 117.63 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.351 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 102.06 0.91 Allowed Glycine 0 N--CA 1.466 0.648 0 N-CA-C 108.017 -2.033 . . . . 0.0 108.017 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.522 HD21 ' CG2' ' G' ' 32' ' ' ILE . 89.7 mt -131.96 131.37 42.55 Favored 'General case' 0 CA--C 1.498 -1.025 0 CA-C-O 122.005 0.907 . . . . 0.0 112.791 -177.647 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 42.1 ttp -108.61 116.86 32.78 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.193 -1.367 . . . . 0.0 107.546 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.17 67.5 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.218 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 38' ' ' GLY . . . -94.04 110.91 4.06 Favored Glycine 0 C--N 1.372 2.568 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 37' ' ' GLY . . . 31.59 -159.57 0.0 OUTLIER Glycine 0 CA--C 1.524 0.616 0 CA-C-O 121.777 0.654 . . . . 0.0 113.06 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -138.97 159.55 29.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.74 -0.73 . . . . 0.0 109.385 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.633 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.659 HG12 ' N ' ' I' ' 13' ' ' HIS . 41.0 t . . . . . 0 N--CA 1.466 0.342 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.659 ' N ' HG12 ' I' ' 12' ' ' VAL . 71.6 m80 -159.39 173.12 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.979 0.419 . . . . 0.0 111.092 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 -179.44 4.66 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.547 ' OE1' ' N ' ' H' ' 15' ' ' GLN . 8.9 mm-40 -95.83 173.88 7.24 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-O 121.328 0.585 . . . . 0.0 111.741 -178.354 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -114.33 139.29 49.58 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -119.49 122.78 42.44 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 121.188 0.518 . . . . 0.0 111.706 -179.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -130.96 122.2 51.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.957 178.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -111.24 107.18 16.4 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.301 -1.741 . . . . 0.0 106.301 176.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -115.63 127.42 55.19 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 120.75 0.309 . . . . 0.0 111.04 -177.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.37 128.54 25.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 122.112 0.958 . . . . 0.0 112.796 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -108.88 164.75 12.12 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 175.94 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 27.3 t70 60.71 -110.64 0.45 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 116.83 -1.948 . . . . 0.0 108.653 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.573 HG22 ' CE ' ' G' ' 28' ' ' LYS . 69.5 t -45.63 132.1 2.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 122.743 1.259 . . . . 0.0 112.581 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.67 82.84 0.76 Allowed Glycine 0 CA--C 1.519 0.322 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.022 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 5.3 p -99.07 172.52 7.34 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-O 121.547 0.689 . . . . 0.0 110.269 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.869 ' H ' HD22 ' I' ' 27' ' ' ASN . 0.5 OUTLIER -62.12 171.02 1.93 Allowed 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.037 175.56 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' J' ' 26' ' ' SER . 89.6 mttt 55.37 110.69 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.526 ' H ' ' CA ' ' J' ' 30' ' ' ALA . . . 67.53 92.37 0.05 OUTLIER Glycine 0 N--CA 1.474 1.168 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.435 ' C ' HG12 ' I' ' 31' ' ' ILE . . . -173.86 156.11 2.74 Favored 'General case' 0 C--N 1.271 -2.816 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 177.1 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.586 ' CG2' HD12 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 117.75 5.87 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 C-N-CA 117.14 -1.824 . . . . 0.0 109.982 -174.448 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.601 ' N ' ' SD ' ' C' ' 35' ' ' MET . 16.1 tt -115.08 121.0 66.2 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-O 122.114 0.959 . . . . 0.0 111.174 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.31 99.38 1.11 Allowed Glycine 0 CA--C 1.505 -0.576 0 N-CA-C 105.819 -2.913 . . . . 0.0 105.819 176.484 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.661 HD13 ' CZ ' ' K' ' 19' ' ' PHE . 7.1 tt -123.37 127.63 48.75 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 122.545 1.164 . . . . 0.0 111.245 -177.625 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.425 ' HE2' ' O ' ' C' ' 31' ' ' ILE . 2.8 ttm -108.87 118.9 37.98 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 114.227 -1.352 . . . . 0.0 111.195 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.559 HG23 HG13 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -127.14 67.43 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 177.383 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -42.67 -103.26 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.67 -162.44 14.56 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -115.93 135.52 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.01 0.433 . . . . 0.0 110.48 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.427 ' OXT' HG22 ' I' ' 40' ' ' VAL . 8.2 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.784 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -61.98 118.32 7.12 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 119.964 -0.694 . . . . 0.0 110.565 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 2.7 t-80 -135.75 164.04 28.81 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 83.2 mt-30 -155.81 177.01 11.89 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.269 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.611 ' C ' HD12 ' J' ' 17' ' ' LEU . 86.6 tttt -172.27 128.24 0.56 Allowed 'General case' 0 C--O 1.239 0.522 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.521 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.611 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.3 mp -117.76 123.27 45.6 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.75 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -127.45 126.55 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.623 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -120.97 106.8 11.94 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -114.8 128.04 56.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.575 -0.703 . . . . 0.0 112.184 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.43 123.64 36.58 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-O 121.97 0.891 . . . . 0.0 111.617 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.452 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 81.2 mm-40 -128.11 113.08 15.3 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 114.414 -1.266 . . . . 0.0 110.479 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' J' ' 24' ' ' VAL . 30.9 t0 -174.79 138.31 0.48 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.816 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' J' ' 23' ' ' ASP . 3.7 m -16.95 -110.22 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.401 ' H ' HG23 ' J' ' 24' ' ' VAL . . . -166.83 92.3 0.1 Allowed Glycine 0 CA--C 1.534 1.246 0 C-N-CA 119.83 -1.176 . . . . 0.0 113.892 -173.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' J' ' 27' ' ' ASN . 0.4 OUTLIER -63.26 -173.22 0.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.101 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' J' ' 26' ' ' SER . 77.5 m-20 -77.88 172.8 12.91 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 116.602 2.075 . . . . 0.0 116.602 -172.554 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.413 ' CE ' ' O ' ' K' ' 28' ' ' LYS . 6.5 mmtm -44.12 111.85 0.34 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 110.959 -2.837 . . . . 0.0 118.154 -177.628 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' I' ' 29' ' ' GLY . . . 93.84 94.42 1.56 Allowed Glycine 0 CA--C 1.501 -0.783 0 CA-C-N 114.209 -1.36 . . . . 0.0 114.501 176.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.526 ' CA ' ' H ' ' I' ' 29' ' ' GLY . . . -84.49 170.17 13.75 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 102.057 -3.312 . . . . 0.0 102.057 173.1 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.944 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.4 OUTLIER -150.45 123.22 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 CA-C-N 120.985 1.72 . . . . 0.0 111.752 -177.294 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.647 HD12 HG12 ' K' ' 32' ' ' ILE . 97.4 mt -109.89 117.27 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.385 178.717 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.14 102.08 1.17 Allowed Glycine 0 C--O 1.238 0.38 0 N-CA-C 106.282 -2.727 . . . . 0.0 106.282 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.927 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 7.9 tt -132.74 139.18 47.48 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-O 121.675 0.75 . . . . 0.0 112.562 -176.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.784 ' N ' HD23 ' J' ' 34' ' ' LEU . 33.8 ttp -123.7 125.74 45.3 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 114.734 -1.121 . . . . 0.0 112.6 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.559 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -123.63 70.05 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.287 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -44.6 -100.78 0.01 OUTLIER Glycine 0 C--N 1.357 1.716 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.98 150.8 8.16 Favored Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.327 -0.37 0 CA-C-O 120.856 0.36 . . . . 0.0 110.224 179.912 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 N--CA 1.465 0.323 0 CA-C-O 120.717 0.294 . . . . 0.0 110.278 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.571 HG12 ' N ' ' K' ' 13' ' ' HIS . 48.3 t -141.06 166.25 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.983 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.571 ' N ' HG12 ' K' ' 12' ' ' VAL . 1.2 m-70 -115.89 161.93 18.08 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.477 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.9 174.75 4.14 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-O 121.23 0.538 . . . . 0.0 109.868 -178.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -142.03 176.67 8.77 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.017 -179.226 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -149.42 135.47 18.93 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.051 0.453 . . . . 0.0 110.822 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -127.72 111.34 13.58 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 78.9 t -134.66 127.27 49.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.661 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.4 m-30 -113.31 141.37 47.11 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.539 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.463 ' HA ' ' HA ' ' L' ' 20' ' ' PHE . 77.9 t80 -136.4 117.87 14.77 Favored 'General case' 0 N--CA 1.505 2.311 0 CA-C-N 120.858 1.663 . . . . 0.0 114.128 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.894 ' HB3' ' O ' ' L' ' 21' ' ' ALA . . . -121.91 126.17 48.06 Favored 'General case' 0 C--N 1.398 2.707 0 CA-C-O 123.13 1.443 . . . . 0.0 112.061 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.567 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 82.5 tt0 -89.63 124.7 34.81 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.249 -178.88 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -123.87 131.81 53.64 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.063 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.42 113.64 11.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.175 179.404 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' K' ' 26' ' ' SER . . . 59.41 91.35 0.01 OUTLIER Glycine 0 CA--C 1.529 0.954 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.861 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' CB ' ' K' ' 27' ' ' ASN . 3.7 p -43.67 170.27 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.553 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.654 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER 157.49 -179.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 122.891 1.329 . . . . 0.0 114.007 178.873 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.654 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 52.4 mttp -29.62 112.49 0.08 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 119.365 3.098 . . . . 0.0 119.365 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' L' ' 30' ' ' ALA . . . 83.01 91.62 0.65 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 119.814 2.686 . . . . 0.0 119.814 173.265 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.548 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -143.62 155.22 44.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 101.916 -3.364 . . . . 0.0 101.916 170.555 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.679 HG13 HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.96 121.39 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 118.553 -1.259 . . . . 0.0 111.158 -176.563 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.647 HG12 HD12 ' J' ' 32' ' ' ILE . 96.7 mt -120.74 127.64 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.488 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.55 110.64 1.88 Allowed Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 178.361 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.516 HD12 ' N ' ' K' ' 35' ' ' MET . 6.3 tp -121.63 118.65 29.71 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.224 -0.488 . . . . 0.0 110.637 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.516 ' N ' HD12 ' K' ' 34' ' ' LEU . 6.2 tmm? -118.99 117.51 29.01 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.867 178.241 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.431 HG22 HD11 ' K' ' 34' ' ' LEU . 1.4 t -113.29 79.69 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 120.981 0.42 . . . . 0.0 110.162 178.523 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.532 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -87.29 100.58 2.59 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 178.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.72 172.78 42.64 Favored Glycine 0 CA--C 1.524 0.608 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.463 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.465 0.317 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.589 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t . . . . . 0 N--CA 1.467 0.382 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -158.0 107.39 2.08 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 120.872 0.368 . . . . 0.0 111.388 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 54.6 t-80 -153.81 166.95 31.29 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.522 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 84.5 mt-30 -152.7 178.88 9.14 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.129 0.49 . . . . 0.0 110.991 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -154.84 125.36 6.91 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.352 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -120.78 115.59 23.59 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.507 -0.121 . . . . 0.0 110.773 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -125.66 126.71 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' J' ' 34' ' ' LEU . 5.0 m-30 -99.09 125.35 44.59 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.768 ' HB2' ' N ' ' K' ' 21' ' ' ALA . 1.6 p90 -32.47 159.9 0.0 OUTLIER 'General case' 0 C--O 1.158 -3.758 0 N-CA-C 121.05 3.722 . . . . 0.0 121.05 -172.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.894 ' O ' ' HB3' ' K' ' 21' ' ' ALA . . . -78.62 157.14 28.77 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.068 174.269 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.456 ' OE1' ' O ' ' L' ' 20' ' ' PHE . 0.0 OUTLIER 178.67 -169.41 0.09 Allowed 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -177.114 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.562 ' OD1' ' N ' ' K' ' 27' ' ' ASN . 20.8 t0 -62.97 106.09 0.77 Allowed 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.161 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.453 HG23 ' HB2' ' K' ' 26' ' ' SER . 87.0 t -36.16 142.84 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -98.75 82.94 0.61 Allowed Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 178.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 67.6 m -69.15 -171.69 0.35 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' L' ' 28' ' ' LYS . 96.3 m-20 -81.13 177.41 9.05 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.313 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.546 ' O ' ' O ' ' L' ' 27' ' ' ASN . 86.2 tttt 39.81 104.16 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 178.957 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.19 -101.19 1.85 Allowed Glycine 0 N--CA 1.467 0.715 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -177.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.548 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -61.88 170.0 2.29 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 118.222 1.011 . . . . 0.0 108.652 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.898 HD13 ' H ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -166.11 153.41 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 118.642 -1.223 . . . . 0.0 112.413 -177.885 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.7 mt -125.31 128.01 72.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.063 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.35 121.38 5.03 Favored Glycine 0 N--CA 1.469 0.853 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -119.77 118.62 31.35 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.522 ' CE ' HG22 ' E' ' 31' ' ' ILE . 3.9 ttp -117.36 119.94 36.64 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.58 ' O ' HG23 ' L' ' 36' ' ' VAL . 35.8 m -130.46 76.29 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.643 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.474 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 23.9 -112.63 0.01 OUTLIER Glycine 0 C--N 1.352 1.428 0 N-CA-C 112.234 -0.346 . . . . 0.0 112.234 178.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.76 -150.56 15.97 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.51 158.29 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.816 0.341 . . . . 0.0 110.35 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.676 -179.636 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 . . . . . 0 N--CA 1.466 0.348 0 CA-C-O 120.853 0.359 . . . . 0.0 110.429 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.499 HG23 ' O ' ' B' ' 12' ' ' VAL . 2.5 m -121.9 132.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -151.83 166.79 30.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.411 ' CD2' ' CE1' ' B' ' 13' ' ' HIS . 93.0 m-70 -132.13 179.5 6.06 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -95.25 177.43 5.86 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.587 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -116.37 145.31 43.32 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.893 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.7 tp -128.22 123.0 33.12 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 121.268 0.556 . . . . 0.0 111.872 -179.152 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.54 131.43 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.335 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -137.52 132.7 33.61 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.133 0.492 . . . . 0.0 111.599 -179.225 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.3 p90 -133.14 129.94 38.56 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.24 158.12 39.77 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.446 ' CB ' ' O ' ' B' ' 22' ' ' GLU . 22.5 pt-20 -143.88 150.65 38.75 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.915 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 . . . . . 0 N--CA 1.466 0.35 0 C-N-CA 119.706 -0.797 . . . . 0.0 111.202 -178.63 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.383 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.05 101.06 0.27 Allowed Glycine 0 CA--C 1.484 -1.891 0 N-CA-C 106.962 -2.455 . . . . 0.0 106.962 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . -83.33 151.79 25.4 Favored 'General case' 0 N--CA 1.438 -1.039 0 C-N-CA 114.861 -2.736 . . . . 0.0 108.78 -175.089 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' G' ' 35' ' ' MET 0.3 0.3 OUTLIER -166.34 108.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.41 -2.475 0 CA-C-N 109.253 -3.612 . . . . 0.0 104.97 -168.806 . . . . . . . . 4 4 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.495 ' N ' ' HE1' ' H' ' 35' ' ' MET . 17.8 tt -119.58 123.46 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 121.56 0.695 . . . . 0.0 110.032 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.573 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -124.3 116.8 2.91 Favored Glycine 0 CA--C 1.507 -0.468 0 N-CA-C 108.144 -1.982 . . . . 0.0 108.144 178.96 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 35.0 mt -136.21 148.15 47.97 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 122.905 1.336 . . . . 0.0 111.572 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.449 ' SD ' ' C ' ' G' ' 32' ' ' ILE . 12.0 ttm -121.18 124.0 43.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 112.475 -2.148 . . . . 0.0 109.362 -179.076 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.6 71.9 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.99 -96.47 0.01 OUTLIER Glycine 0 C--N 1.357 1.721 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 178.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.59 -162.76 36.55 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -131.0 160.76 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.855 0.359 . . . . 0.0 110.273 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.466 -179.662 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.04 140.71 47.61 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -110.57 137.65 47.98 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.909 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.499 ' O ' HG23 ' A' ' 12' ' ' VAL . 27.8 m -135.7 159.95 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.815 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.411 ' CE1' ' CD2' ' A' ' 14' ' ' HIS . 79.9 t60 -140.64 124.02 16.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.37 -0.377 . . . . 0.0 109.999 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 p-80 -149.32 166.74 28.08 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 121.239 0.543 . . . . 0.0 109.846 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.84 179.72 8.62 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.592 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -163.71 109.12 1.06 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.059 179.125 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -130.31 118.72 21.72 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.77 131.36 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.347 0.594 . . . . 0.0 110.866 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.91 131.14 55.13 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.1 t80 -128.37 119.95 26.02 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 132.68 53.21 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.863 -179.451 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 22' ' ' GLU . 81.8 tt0 -155.15 133.37 11.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.295 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 60.6 t0 . . . . . 0 N--CA 1.469 0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.518 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.784 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.388 -7.855 0 CA-C-O 117.675 -1.625 . . . . 0.0 114.279 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' B' ' 29' ' ' GLY 0.451 . . 113.93 -131.84 0.0 OUTLIER 'General case' 1 N--CA 1.366 -4.645 0 C-N-CA 114.019 -3.072 . . . . 0.0 106.355 -175.777 . . . . . . . . 4 3 . 1 . 002 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.725 HD12 ' N ' ' B' ' 31' ' ' ILE 0.366 2.2 mp -70.07 120.92 18.65 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.877 0 CA-C-N 109.245 -3.616 . . . . 0.0 113.458 175.045 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' B' ' 32' ' ' ILE . 16.9 tt -125.83 118.28 51.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.676 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -124.65 119.37 3.64 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.416 ' CD2' ' HB2' ' A' ' 34' ' ' LEU . 96.4 mt -136.61 131.25 33.48 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 122.901 1.334 . . . . 0.0 113.277 -176.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.485 ' HE1' ' SD ' ' C' ' 35' ' ' MET . 33.7 tpp -113.34 118.23 33.99 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.545 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.425 ' CG2' HG23 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -122.53 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.789 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.3 103.6 2.49 Favored Glycine 0 C--N 1.358 1.753 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.606 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.72 162.63 19.5 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.9 t -133.99 138.18 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 120.699 0.285 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.349 -179.976 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 50.2 t . . . . . 0 N--CA 1.466 0.352 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -149.93 129.35 12.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.003 0.43 . . . . 0.0 111.005 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.558 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 71.8 t60 -138.47 166.21 24.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.558 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 83.4 mt-30 -156.18 169.64 24.06 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.915 178.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -157.81 108.49 2.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.727 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.5 tp -125.77 118.89 26.52 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -129.01 126.19 64.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.278 0.561 . . . . 0.0 112.029 -179.185 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.05 104.74 12.43 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -116.86 126.17 52.62 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.24 141.13 23.71 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-O 123.446 1.594 . . . . 0.0 115.09 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.457 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 93.5 mt-10 -137.5 73.75 1.46 Allowed 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.65 -2.523 . . . . 0.0 104.269 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.495 ' O ' ' CA ' ' B' ' 29' ' ' GLY . 25.1 t70 . . . . . 0 N--CA 1.467 0.402 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -175.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.457 -3.556 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.654 ' HB1' ' O ' ' B' ' 30' ' ' ALA . . . -153.23 162.81 40.89 Favored 'General case' 0 N--CA 1.38 -3.959 0 N-CA-C 101.618 -3.475 . . . . 0.0 101.618 177.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.653 HG23 HD12 ' D' ' 31' ' ' ILE 0.273 3.0 mp -126.63 115.95 43.47 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.283 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.448 -174.397 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.502 ' O ' ' SD ' ' J' ' 35' ' ' MET . 4.9 mt -101.37 110.38 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.022 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.61 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -121.81 109.15 1.41 Allowed Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 105.869 -2.892 . . . . 0.0 105.869 176.18 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.469 ' HG ' ' N ' ' C' ' 35' ' ' MET . 0.6 OUTLIER -147.42 147.66 30.48 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 123.493 1.616 . . . . 0.0 113.178 -177.061 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.621 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 29.6 ttm -122.9 128.02 49.75 Favored 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 112.0 -2.364 . . . . 0.0 109.101 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.686 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.9 p -132.45 71.55 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.31 112.93 4.23 Favored Glycine 0 C--N 1.361 1.948 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.601 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.77 -144.34 0.07 OUTLIER Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.0 141.69 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' C' C ' 40' ' ' VAL . . . . . 0.423 HG22 ' H ' ' C' ' 40' ' ' VAL . 12.6 m . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 117.907 -1.044 . . . . 0.0 110.738 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 121.26 0.553 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.54 -179.16 4.37 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.091 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.51 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 77.0 t60 -77.07 169.48 18.26 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.732 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.434 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 87.5 mt-30 -146.3 176.91 9.41 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.529 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -151.42 113.88 4.6 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 120.477 -0.489 . . . . 0.0 112.053 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.0 117.6 22.82 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.176 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -142.71 149.22 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 -178.483 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 2.5 m-30 -118.89 120.61 37.82 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.749 -1.569 . . . . 0.0 108.894 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -117.5 118.94 33.56 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 118.39 0.541 . . . . 0.0 109.988 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.64 121.6 35.96 Favored 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.887 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -164.83 106.34 0.83 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 59.5 t0 . . . . . 0 CA--C 1.545 0.76 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 174.506 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.428 0 N-CA-C 102.341 -3.207 . . . . 0.0 102.341 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.653 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.61 123.59 3.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 117.865 -1.534 . . . . 0.0 112.351 -170.427 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.419 ' O ' HG22 ' D' ' 32' ' ' ILE . 1.5 mt -111.32 119.46 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-O 121.315 0.578 . . . . 0.0 110.129 178.366 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.699 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -127.01 100.48 0.55 Allowed Glycine 0 C--N 1.311 -0.817 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.869 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.537 HD21 HG13 ' D' ' 36' ' ' VAL . 10.5 tt -124.92 130.58 52.65 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.04 0.924 . . . . 0.0 111.964 -177.157 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.54 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.4 ttt -112.89 123.32 50.04 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 114.056 -1.429 . . . . 0.0 110.365 179.38 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.537 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.82 78.15 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-N 116.262 -0.426 . . . . 0.0 109.987 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.1 105.13 0.08 OUTLIER Glycine 0 C--N 1.348 1.211 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.24 -154.1 2.66 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.17 143.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.09 0.472 . . . . 0.0 110.329 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.473 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -140.97 150.49 43.15 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.409 ' OE1' ' C ' ' F' ' 11' ' ' GLU . 79.4 mm-40 -142.3 140.03 32.04 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.204 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG22 ' F' ' 12' ' ' VAL . 59.4 t -128.79 133.58 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.315 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -78.34 -168.67 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.437 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 37.8 p-80 -146.73 177.32 9.18 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 120.988 0.423 . . . . 0.0 110.087 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -100.26 169.68 8.96 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.24 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.79 120.75 13.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.613 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -122.2 121.83 37.76 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.667 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -130.49 126.83 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 120.562 -0.455 . . . . 0.0 112.192 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE2' ' CD2' ' D' ' 19' ' ' PHE . 10.8 m-85 -115.88 115.6 26.51 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 176.909 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.516 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 66.3 t80 -123.74 124.97 43.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.666 -177.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.9 139.74 41.83 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-O 121.114 0.483 . . . . 0.0 111.218 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.516 ' OE2' ' CZ ' ' E' ' 20' ' ' PHE . 8.6 mm-40 -108.49 119.88 40.79 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -166.81 101.18 0.56 Allowed 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.345 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -73.35 -158.84 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.711 0.767 . . . . 0.0 112.084 -178.371 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 62.17 79.61 0.13 Allowed Glycine 0 CA--C 1.526 0.776 0 CA-C-N 114.233 -1.349 . . . . 0.0 111.842 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.566 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 26.3 t . . . . . 0 N--CA 1.441 -0.89 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.335 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.245 0.832 0 CA-C-O 122.108 0.956 . . . . 0.0 110.39 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.686 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.0 OUTLIER -147.16 124.29 3.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.302 -1.317 . . . . 0.0 107.819 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 77.9 mt -123.19 130.24 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-O 120.958 0.409 . . . . 0.0 112.048 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.31 121.1 3.23 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.674 HD22 ' CE1' ' F' ' 19' ' ' PHE . 18.6 tp -125.7 123.36 38.72 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.629 -0.285 . . . . 0.0 110.812 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 12.8 ttt -117.86 117.81 30.3 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.219 178.302 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.6 t -122.54 83.81 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.133 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -16.34 -95.19 0.01 OUTLIER Glycine 0 N--CA 1.471 1.03 0 O-C-N 123.404 0.44 . . . . 0.0 112.833 -179.118 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.33 176.57 18.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 m -100.53 142.61 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 0.0 110.245 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.478 -179.865 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -82.88 137.47 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.704 0.288 . . . . 0.0 110.624 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 11' ' ' GLU . . . . . 0.409 ' C ' ' OE1' ' E' ' 11' ' ' GLU . 82.4 tt0 -159.03 159.85 35.2 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.467 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.434 HG22 ' H ' ' E' ' 12' ' ' VAL . 55.8 t -80.93 131.07 34.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -85.36 146.69 26.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.837 0.351 . . . . 0.0 111.364 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 83.5 m-70 -94.88 179.49 5.22 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -79.82 166.25 21.91 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 120.12 -0.632 . . . . 0.0 110.767 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -135.96 118.8 16.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 22.7 mt -122.5 120.45 33.91 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.28 130.9 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.209 0.528 . . . . 0.0 112.266 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.674 ' CE1' HD22 ' E' ' 34' ' ' LEU . 26.2 m-85 -119.64 123.83 44.81 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.001 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -139.69 130.93 26.64 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.589 0.709 . . . . 0.0 112.025 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.23 133.96 51.35 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.554 178.462 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.44 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 81.0 tt0 -76.65 90.48 3.38 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.937 -178.35 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' E' ' 26' ' ' SER . 15.7 t70 173.87 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.632 178.585 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 m -58.85 130.72 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.379 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.85 85.31 0.16 Allowed Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.419 -0.896 . . . . 0.0 111.709 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.9 p -64.67 -174.45 0.14 Allowed 'General case' 0 N--CA 1.442 -0.829 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.084 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.443 ' O ' ' O ' ' F' ' 28' ' ' LYS . 88.1 m-20 -90.7 178.59 6.03 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 119.876 -0.73 . . . . 0.0 109.61 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.3 mttt 27.95 102.12 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 113.099 0.778 . . . . 0.0 113.099 177.517 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.72 -101.62 0.24 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 120.134 -1.032 . . . . 0.0 113.662 177.591 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.81 167.47 0.77 Allowed 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.591 HG21 ' HA2' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -150.08 126.86 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 118.105 -1.438 . . . . 0.0 111.416 -176.939 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 5.1 mp -127.39 133.01 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.193 -178.693 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.7 131.8 6.33 Favored Glycine 0 N--CA 1.469 0.893 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -127.23 125.48 41.07 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 24.4 ttt -128.37 126.68 41.17 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.818 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -118.17 81.15 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.438 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.596 ' CA ' HG21 ' L' ' 31' ' ' ILE . . . -45.29 100.9 0.02 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.873 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.82 162.01 35.78 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -136.14 145.96 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 120.788 0.327 . . . . 0.0 110.454 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.875 -1.059 . . . . 0.0 110.68 -179.647 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 . . . . . 0 CA--C 1.527 0.075 0 CA-C-O 120.691 0.282 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.424 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 22.8 m80 -97.55 178.65 5.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -118.26 -177.08 3.2 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.23 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.59 154.44 17.92 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.174 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.1 tp -131.15 118.23 20.19 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.088 0.47 . . . . 0.0 110.439 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -124.94 131.03 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.752 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 t80 -129.98 127.96 41.09 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.036 0.446 . . . . 0.0 110.304 179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.523 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -130.3 128.59 41.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.89 123.04 46.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.981 0.42 . . . . 0.0 110.505 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' G' ' 23' ' ' ASP . 43.6 tt0 -141.06 142.28 34.19 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.913 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.48 ' O ' ' O ' ' G' ' 22' ' ' GLU . 97.5 m-20 50.54 113.88 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.937 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.545 ' N ' ' OD2' ' H' ' 23' ' ' ASP . 70.0 t -149.34 112.84 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.283 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.21 -91.02 0.01 OUTLIER Glycine 0 CA--C 1.529 0.924 0 CA-C-O 121.466 0.481 . . . . 0.0 112.898 177.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.78 ' O ' ' O ' ' G' ' 27' ' ' ASN . 21.2 p -161.76 174.57 13.03 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.78 ' O ' ' O ' ' G' ' 26' ' ' SER . 81.7 m-20 -9.42 160.03 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 17.1 pttp 179.26 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.1 100.93 0.68 Allowed Glycine 0 N--CA 1.469 0.898 0 N-CA-C 107.061 -2.416 . . . . 0.0 107.061 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.42 157.43 22.48 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 123.473 1.606 . . . . 0.0 113.301 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.415 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.83 111.61 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 CA-C-N 111.766 -2.47 . . . . 0.0 108.671 -178.197 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.449 ' C ' ' SD ' ' A' ' 35' ' ' MET . 1.9 mt -99.1 109.25 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.889 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.59 105.75 1.04 Allowed Glycine 0 CA--C 1.504 -0.645 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 18.1 mt -139.46 145.32 38.67 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 123.061 1.41 . . . . 0.0 112.709 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 48.4 ttp -113.87 114.24 25.98 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.538 -1.664 . . . . 0.0 106.803 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.1 71.0 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.495 ' O ' HG21 ' A' ' 31' ' ' ILE . . . -157.1 95.98 0.15 Allowed Glycine 0 C--N 1.355 1.604 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -138.16 -176.87 14.78 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m . . . . . 0 N--CA 1.464 0.271 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.907 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 N--CA 1.465 0.29 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -152.57 97.67 2.28 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.429 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.424 ' CE1' ' O ' ' G' ' 14' ' ' HIS . 54.2 p-80 -108.1 166.45 10.72 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -152.54 168.9 24.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.778 0.799 . . . . 0.0 111.377 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.675 ' C ' HD12 ' H' ' 17' ' ' LEU . 64.8 tttm -169.58 117.35 0.6 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.71 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.675 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.0 mp -122.33 118.5 28.63 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.729 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.51 HG21 ' HZ1' ' H' ' 16' ' ' LYS . 60.3 t -121.03 124.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.252 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.474 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 83.5 m-85 -119.7 106.55 12.24 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -116.41 124.65 50.55 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.455 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.98 130.04 49.28 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.813 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -159.33 114.78 2.49 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.823 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.545 ' OD2' ' N ' ' G' ' 24' ' ' VAL . 28.5 t0 -174.65 123.3 0.27 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 178.343 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' H' ' 23' ' ' ASP . 13.0 t . . . . . 0 N--CA 1.465 0.307 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.911 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.323 0 N-CA-C 101.077 -3.675 . . . . 0.0 101.077 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.421 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -134.08 118.72 29.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 118.005 -1.478 . . . . 0.0 109.835 -178.295 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.43 HG22 ' O ' ' H' ' 32' ' ' ILE . 1.3 mt -109.78 115.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.461 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.44 97.42 0.68 Allowed Glycine 0 CA--C 1.508 -0.345 0 N-CA-C 106.914 -2.475 . . . . 0.0 106.914 176.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.488 HD21 ' CZ ' ' I' ' 19' ' ' PHE . 2.9 mp -127.02 133.51 50.51 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-O 122.552 1.168 . . . . 0.0 111.456 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.676 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 43.7 ttp -111.16 117.38 33.08 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-N 113.595 -1.639 . . . . 0.0 107.895 178.07 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -113.05 67.65 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.957 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.81 -101.62 0.01 OUTLIER Glycine 0 C--N 1.352 1.446 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.56 164.85 11.53 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.27 141.71 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.765 -179.936 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.566 HG12 ' N ' ' I' ' 13' ' ' HIS . 43.1 t . . . . . 0 N--CA 1.468 0.455 0 CA-C-O 120.977 0.418 . . . . 0.0 111.331 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.666 ' CG ' ' H ' ' I' ' 14' ' ' HIS . 44.6 t-80 -125.82 -172.35 2.58 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.047 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.666 ' H ' ' CG ' ' I' ' 13' ' ' HIS . 0.1 OUTLIER -76.45 166.65 23.12 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.204 0.526 . . . . 0.0 109.795 -179.205 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -148.65 170.68 17.59 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.174 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -150.35 137.78 19.68 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 121.041 -0.264 . . . . 0.0 111.149 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 52.8 mt -130.99 124.5 31.09 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.33 137.83 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.488 ' CZ ' HD21 ' H' ' 34' ' ' LEU . 60.8 m-85 -120.44 123.85 44.01 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.136 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.626 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 3.4 t80 -124.27 124.44 42.42 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.101 -177.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.83 126.05 42.7 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 122.49 1.138 . . . . 0.0 113.451 -178.991 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -154.28 82.83 1.12 Allowed 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.462 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.473 ' OD2' ' O ' ' H' ' 23' ' ' ASP . 13.1 t70 -105.79 -114.13 0.25 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.667 ' O ' ' N ' ' I' ' 26' ' ' SER . 58.2 t -85.45 130.69 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.933 0 N-CA-C 104.426 -2.435 . . . . 0.0 104.426 176.088 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.607 ' CA ' ' H ' ' J' ' 24' ' ' VAL . . . -42.98 82.66 0.0 OUTLIER Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.189 -1.005 . . . . 0.0 111.974 -176.117 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.667 ' N ' ' O ' ' I' ' 24' ' ' VAL . 11.4 p -65.63 -176.2 0.33 Allowed 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 177.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.492 ' O ' ' O ' ' I' ' 28' ' ' LYS . 9.7 p30 -81.42 179.2 7.95 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.671 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' I' ' 27' ' ' ASN . 85.0 tttt -42.39 -106.42 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.984 0.897 . . . . 0.0 110.036 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.899 ' C ' ' HB1' ' J' ' 30' ' ' ALA . . . -82.8 96.98 1.92 Allowed Glycine 0 CA--C 1.45 -3.973 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.792 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -68.73 -151.17 0.01 OUTLIER 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 101.899 -3.371 . . . . 0.0 101.899 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.9 ' N ' HD13 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -102.62 104.01 15.89 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 CA-C-N 123.782 2.992 . . . . 0.0 109.964 -176.0 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.621 ' N ' ' SD ' ' C' ' 35' ' ' MET . 2.6 mt -107.11 114.2 45.48 Favored 'Isoleucine or valine' 0 C--N 1.362 1.131 0 CA-C-N 113.765 -1.561 . . . . 0.0 111.126 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.409 ' N ' ' CE ' ' B' ' 35' ' ' MET . . . -115.54 97.98 0.82 Allowed Glycine 0 C--O 1.242 0.641 0 N-CA-C 105.502 -3.039 . . . . 0.0 105.502 175.394 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.523 HD11 ' CZ ' ' J' ' 19' ' ' PHE . 0.2 OUTLIER -129.78 132.83 46.67 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-O 122.268 1.032 . . . . 0.0 111.077 -177.462 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.61 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.0 ttp -113.68 121.55 44.46 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.345 -178.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.51 70.03 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 177.126 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -41.12 -100.66 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.81 -160.59 33.68 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 54.7 t -122.46 134.94 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 120.859 0.361 . . . . 0.0 110.04 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 70.1 t . . . . . 0 C--O 1.218 -0.582 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.604 -179.984 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.463 0.199 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -146.45 135.62 22.68 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.054 0.454 . . . . 0.0 111.523 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -152.43 155.94 38.53 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.595 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -153.38 173.64 15.38 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.441 0.639 . . . . 0.0 111.706 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -155.93 129.33 8.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.596 -1.184 . . . . 0.0 107.887 178.275 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.84 116.94 24.52 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.5 123.62 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.253 0.549 . . . . 0.0 110.896 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.523 ' CZ ' HD11 ' I' ' 34' ' ' LEU . 3.9 m-85 -120.88 109.06 14.67 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 179.276 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.626 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 3.7 p90 -148.94 151.36 34.48 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 117.772 -1.571 . . . . 0.0 114.649 -178.946 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.01 155.88 34.96 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.156 -1.384 . . . . 0.0 111.169 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -127.22 144.03 51.13 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -178.91 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.468 ' CG ' ' O ' ' I' ' 26' ' ' SER . 10.9 t0 -103.68 134.26 47.31 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.867 178.179 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.607 ' H ' ' CA ' ' I' ' 25' ' ' GLY . 57.4 t -110.43 111.78 37.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.661 179.495 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.23 90.37 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 N-CA-C 115.708 1.043 . . . . 0.0 115.708 174.96 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.613 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.8 p 170.68 174.83 0.06 Allowed 'General case' 0 C--N 1.343 0.324 0 CA-C-N 118.369 1.084 . . . . 0.0 111.379 176.003 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' J' ' 26' ' ' SER . 13.6 m-20 -28.04 -179.55 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.59 ' CD ' ' H ' ' K' ' 27' ' ' ASN . 55.3 tttt -130.51 -107.31 0.27 Allowed 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.748 1.388 . . . . 0.0 114.748 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 41.61 91.81 0.01 OUTLIER Glycine 0 N--CA 1.481 1.677 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 -176.688 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.899 ' HB1' ' C ' ' I' ' 29' ' ' GLY . . . -140.61 157.73 45.02 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -177.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.82 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -146.18 128.11 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.53 0 CA-C-O 121.461 0.648 . . . . 0.0 112.506 -178.286 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.54 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.3 tt -109.25 118.41 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.52 101.66 0.99 Allowed Glycine 0 N--CA 1.47 0.963 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' I' ' 32' ' ' ILE . 80.0 mt -127.05 131.68 50.88 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-O 121.431 0.634 . . . . 0.0 112.583 -177.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.699 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.2 ttp -113.82 120.6 41.3 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.015 178.003 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.74 67.46 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.433 ' HA3' HD13 ' D' ' 31' ' ' ILE . . . -49.97 121.4 9.58 Favored Glycine 0 C--N 1.355 1.593 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.663 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.54 -136.8 0.03 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 N--CA 1.466 0.366 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.535 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 . . . . . 0 N--CA 1.464 0.271 0 CA-C-O 120.695 0.284 . . . . 0.0 110.797 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 m -139.83 134.21 37.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.156 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -124.3 119.17 28.52 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.315 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.89 162.55 24.15 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-O 121.485 0.66 . . . . 0.0 109.444 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' L' ' 15' ' ' GLN . 85.4 mt-30 -151.35 178.78 8.92 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.353 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -172.69 128.15 0.51 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -124.39 123.44 40.18 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.825 0.345 . . . . 0.0 110.117 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.48 125.38 65.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.74 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.413 ' HB2' ' CD1' ' L' ' 19' ' ' PHE . 17.3 m-85 -115.77 114.92 25.44 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -122.05 123.64 42.09 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.01 128.08 39.62 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 121.49 0.662 . . . . 0.0 111.31 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -99.12 128.29 45.22 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 120.176 -0.609 . . . . 0.0 111.782 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 9.2 p-10 -142.86 136.58 28.84 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.116 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.546 HG13 ' O ' ' K' ' 24' ' ' VAL . 7.8 p -91.1 112.27 24.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.577 -176.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.69 91.5 0.01 OUTLIER Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.586 ' HB2' ' HZ1' ' J' ' 28' ' ' LYS . 5.4 t -42.32 154.63 0.05 Allowed 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.64 -0.78 . . . . 0.0 110.931 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.59 ' H ' ' CD ' ' J' ' 28' ' ' LYS . 84.7 m-20 -126.97 -179.86 5.05 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.746 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.401 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.7 mttt -30.12 107.29 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.473 1.286 . . . . 0.0 114.473 -177.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.36 -96.48 1.74 Allowed Glycine 0 N--CA 1.47 0.93 0 CA-C-N 113.996 -1.456 . . . . 0.0 116.208 172.595 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.425 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 72.22 153.28 0.13 Allowed 'General case' 0 C--O 1.249 1.051 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 -174.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.715 HG23 HG12 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -149.65 127.47 2.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 117.001 -1.88 . . . . 0.0 111.82 -176.98 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.504 ' O ' ' CE ' ' E' ' 35' ' ' MET . 82.7 mt -118.84 120.08 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.001 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -119.93 107.86 1.39 Allowed Glycine 0 N--CA 1.467 0.749 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.422 HD13 ' CD2' ' L' ' 19' ' ' PHE . 48.5 mt -121.43 120.6 35.45 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -117.97 124.78 49.03 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.188 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.05 80.77 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.799 178.338 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.686 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -63.8 102.87 0.61 Allowed Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.78 -146.79 18.03 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.661 -179.913 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t . . . . . 0 N--CA 1.465 0.294 0 CA-C-O 121.137 0.494 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -155.24 140.29 17.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.694 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -150.4 171.46 16.98 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 89.0 mt-30 -147.02 173.53 12.37 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.464 0.65 . . . . 0.0 111.228 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -155.55 130.26 9.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.494 179.157 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.69 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.6 tt -132.5 125.31 30.31 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 18' ' ' VAL . . . . . 0.496 ' N ' HD23 ' L' ' 17' ' ' LEU . 73.8 t -129.39 129.21 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 121.147 0.499 . . . . 0.0 111.835 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.508 ' CD2' HD21 ' L' ' 17' ' ' LEU . 10.8 m-85 -113.43 114.27 26.34 Favored 'General case' 0 C--N 1.341 0.215 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -140.64 136.83 33.1 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 122.104 0.954 . . . . 0.0 112.249 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.16 151.84 30.58 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.386 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 81.8 tt0 -75.11 95.15 3.02 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.991 -178.82 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' L' ' 24' ' ' VAL . 67.9 t0 -175.36 136.1 0.35 Allowed 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.981 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.543 HG23 ' O ' ' L' ' 24' ' ' VAL . 33.5 m -71.02 111.28 4.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.675 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.95 -91.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.007 0 CA-C-N 114.894 -1.048 . . . . 0.0 115.528 -176.095 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 10.0 p -71.24 176.67 4.36 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 122.967 1.365 . . . . 0.0 114.362 -175.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 4.9 t-20 85.89 178.65 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 111.412 -2.631 . . . . 0.0 114.486 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.1 mttt -40.99 104.49 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 116.61 2.078 . . . . 0.0 116.61 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.0 -101.24 0.3 Allowed Glycine 0 N--CA 1.473 1.161 0 N-CA-C 115.823 1.089 . . . . 0.0 115.823 173.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.587 ' C ' HD13 ' L' ' 31' ' ' ILE . . . -58.37 172.8 0.43 Allowed 'General case' 0 CA--C 1.508 -0.636 0 CA-C-O 119.106 -0.474 . . . . 0.0 111.335 -177.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.845 ' N ' HD13 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -134.78 118.6 25.82 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 C-N-CA 118.405 -1.318 . . . . 0.0 111.148 179.661 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.62 133.23 68.75 Favored 'Isoleucine or valine' 0 C--O 1.23 0.072 0 CA-C-N 113.77 -1.559 . . . . 0.0 109.786 -178.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.521 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -131.3 118.88 2.49 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.381 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.521 HD12 ' C ' ' L' ' 33' ' ' GLY . 10.6 mp -114.5 124.34 51.65 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.9 tmm? -117.51 120.53 38.37 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.616 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.72 81.13 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.549 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.591 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . 44.13 -101.39 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.53 -169.29 37.76 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.82 136.24 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.904 0.383 . . . . 0.0 110.672 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.813 179.726 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 N--CA 1.466 0.327 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.51 133.55 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 120.952 0.406 . . . . 0.0 110.737 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -135.8 -175.7 4.05 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.067 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -80.03 164.79 23.16 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-O 121.23 0.538 . . . . 0.0 109.836 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -153.5 177.45 10.9 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.462 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -147.57 131.34 16.99 Favored 'General case' 0 N--CA 1.466 0.374 0 C-N-CA 121.118 -0.233 . . . . 0.0 110.809 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -133.4 115.44 14.84 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.326 0.584 . . . . 0.0 110.135 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.63 133.44 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.072 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -145.72 148.93 33.54 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.681 0.753 . . . . 0.0 111.511 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 p90 -135.92 149.3 48.9 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.717 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.81 136.54 27.24 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 122.275 1.035 . . . . 0.0 113.312 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' A' ' 23' ' ' ASP . 98.8 mt-10 -111.51 178.72 4.24 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.532 -1.667 . . . . 0.0 107.705 177.473 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.529 ' H ' ' CB ' ' B' ' 23' ' ' ASP . 95.7 m-20 . . . . . 0 C--N 1.33 -0.256 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 122.016 0.912 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.3 99.2 2.59 Favored Glycine 0 CA--C 1.493 -1.289 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.205 -176.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.18 160.66 20.83 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.392 -176.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.519 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -146.74 111.79 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.775 -175.295 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.581 HG22 HD11 ' B' ' 34' ' ' LEU . 46.8 mt -121.29 104.88 15.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.641 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -113.96 114.2 3.26 Favored Glycine 0 CA--C 1.502 -0.78 0 N-CA-C 105.827 -2.909 . . . . 0.0 105.827 176.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 5.6 tp -146.04 144.93 30.37 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 122.754 1.264 . . . . 0.0 113.382 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.597 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 17.5 ttm -112.91 117.36 31.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.888 178.394 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.89 67.3 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 177.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.3 -101.71 0.01 OUTLIER Glycine 0 C--N 1.366 2.21 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.95 -166.13 39.21 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.97 158.08 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.836 0.35 . . . . 0.0 110.735 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.915 -1.04 . . . . 0.0 110.533 -179.866 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -105.2 132.95 50.76 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -137.85 160.53 39.03 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.114 0.483 . . . . 0.0 111.14 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 50.9 t -122.41 134.45 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.893 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -109.07 114.83 28.9 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.985 0.421 . . . . 0.0 111.445 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.47 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 83.5 t60 -142.23 160.45 40.22 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.47 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 78.9 mt-30 -159.27 179.11 9.28 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.13 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -161.35 119.02 2.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.519 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -130.61 122.64 27.83 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.12 137.12 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 121.066 0.46 . . . . 0.0 110.582 178.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -128.87 138.33 51.96 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.879 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -123.15 131.49 53.71 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.21 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.48 125.71 29.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 120.673 -0.411 . . . . 0.0 111.86 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 82.5 tt0 -170.82 139.76 1.53 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.448 179.257 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.529 ' CB ' ' H ' ' A' ' 23' ' ' ASP . 14.3 p-10 . . . . . 0 C--N 1.344 0.329 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.429 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.452 ' O ' HG13 ' C' ' 31' ' ' ILE . . . -104.99 154.35 20.23 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 103.294 -2.854 . . . . 0.0 103.294 176.316 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.448 HD12 HG23 ' A' ' 31' ' ' ILE . 2.0 mt -139.8 108.14 3.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.753 -173.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.483 HG23 ' O ' ' B' ' 32' ' ' ILE . 5.1 tt -122.37 116.55 49.4 Favored 'Isoleucine or valine' 0 C--O 1.241 0.646 0 CA-C-O 122.069 0.938 . . . . 0.0 109.619 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.781 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -127.99 117.92 2.72 Favored Glycine 0 N--CA 1.453 -0.188 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.781 HD12 ' C ' ' B' ' 33' ' ' GLY . 7.0 mp -141.91 149.93 40.83 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-O 123.147 1.451 . . . . 0.0 113.214 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 24.2 ttm -121.69 118.75 29.9 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 112.769 -2.014 . . . . 0.0 107.822 177.401 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -112.57 68.71 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -179.6 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.82 -101.5 0.12 Allowed Glycine 0 C--N 1.352 1.417 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.599 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.41 167.71 35.49 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.4 m -131.74 161.92 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.906 0.384 . . . . 0.0 110.242 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.648 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.466 0.337 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -117.26 136.98 52.7 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 120.723 0.297 . . . . 0.0 111.57 -178.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 24.0 t-80 -141.37 163.2 33.6 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.663 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 33.6 mt-30 -156.03 169.74 23.77 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 121.183 0.516 . . . . 0.0 111.064 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -155.91 115.98 3.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.443 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 44.4 tp -121.5 124.09 43.6 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -133.38 127.28 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 113.466 0.913 . . . . 0.0 113.466 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 50.6 m-85 -117.47 119.29 34.61 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -122.46 126.37 47.75 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 117.827 0.285 . . . . 0.0 111.421 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.12 149.2 37.79 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 115.435 1.642 . . . . 0.0 115.435 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 28.0 mt-10 -154.45 138.69 16.59 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 114.398 -1.274 . . . . 0.0 110.857 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 26.2 t0 . . . . . 0 N--CA 1.484 1.273 0 N-CA-C 114.504 1.298 . . . . 0.0 114.504 176.782 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.477 -2.308 0 CA-C-O 117.522 -1.71 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.426 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -149.75 134.51 17.73 Favored 'General case' 0 CA--C 1.47 -2.113 0 C-N-CA 115.933 -2.307 . . . . 0.0 108.115 173.044 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.452 HG13 ' O ' ' B' ' 30' ' ' ALA 0.274 3.5 mt -138.78 102.22 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 CA-C-N 110.469 -3.059 . . . . 0.0 105.045 -175.837 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.515 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.9 mt -109.19 118.14 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-N 115.059 -0.973 . . . . 0.0 111.427 -176.679 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.708 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -129.92 99.08 0.44 Allowed Glycine 0 CA--C 1.5 -0.901 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.169 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.475 ' HG ' ' H ' ' B' ' 34' ' ' LEU . 3.7 mp -132.05 147.35 52.44 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 122.64 1.209 . . . . 0.0 111.924 -177.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.494 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 26.7 ttm -129.01 127.94 42.64 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.87 -1.968 . . . . 0.0 110.375 -179.098 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.75 72.24 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.9 102.76 2.39 Favored Glycine 0 C--N 1.364 2.102 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 -178.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.4 154.61 25.86 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.0 m -134.72 161.57 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-O 120.735 0.302 . . . . 0.0 110.477 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.256 179.664 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -85.78 166.42 16.09 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.884 0.373 . . . . 0.0 110.097 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 43.7 p-80 -76.52 175.11 9.54 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.225 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -140.62 173.36 11.57 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.189 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -141.04 130.75 24.17 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.494 0.664 . . . . 0.0 112.258 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 49.5 tp -122.54 120.31 33.46 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.761 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 18' ' ' VAL . . . . . 0.516 HG11 ' CE2' ' D' ' 20' ' ' PHE . 19.8 t -134.79 128.35 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.522 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 65.2 m-85 -125.46 115.32 20.06 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.771 177.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.53 ' N ' ' CD1' ' D' ' 20' ' ' PHE . 0.0 OUTLIER -147.84 159.09 44.21 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 122.786 1.279 . . . . 0.0 113.949 179.129 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.74 156.33 38.91 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.867 -1.515 . . . . 0.0 112.013 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 33.1 mt-10 -148.24 141.71 25.35 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.685 -179.559 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.514 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.8 OUTLIER . . . . . 0 N--CA 1.476 0.867 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.447 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.457 -2.597 0 CA-C-O 122.819 1.295 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.98 99.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.062 0 CA-C-N 112.083 -2.326 . . . . 0.0 106.144 -176.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 mt -108.16 124.61 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.427 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.743 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.08 100.55 0.58 Allowed Glycine 0 C--N 1.309 -0.934 0 N-CA-C 105.331 -3.108 . . . . 0.0 105.331 174.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.624 HD21 ' CZ ' ' E' ' 19' ' ' PHE . 0.1 OUTLIER -121.79 120.7 35.37 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.524 0.678 . . . . 0.0 110.148 -177.68 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.518 ' N ' HD13 ' D' ' 34' ' ' LEU . 3.5 ttt -112.99 115.43 28.37 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.682 -1.145 . . . . 0.0 108.068 178.064 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -112.43 77.31 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.495 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -4.12 -101.93 0.0 OUTLIER Glycine 0 C--N 1.368 2.324 0 O-C-N 123.608 0.568 . . . . 0.0 112.899 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.5 -170.62 39.72 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.59 159.73 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.436 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -139.82 123.67 17.52 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 120.744 0.306 . . . . 0.0 110.636 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -136.96 139.69 41.68 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.349 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -133.87 138.76 49.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 -139.74 126.86 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.37 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.576 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 45.4 t-80 -156.08 167.2 31.16 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.898 0.856 . . . . 0.0 110.952 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.576 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 47.5 tt0 -164.02 168.24 19.46 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.307 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 53.8 tttm -135.44 120.19 18.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.465 178.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 36.1 mt -107.34 118.83 37.75 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.96 121.58 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD21 ' D' ' 34' ' ' LEU . 62.6 m-85 -115.62 115.76 26.97 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 176.342 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' F' ' 20' ' ' PHE . 25.3 t80 -142.21 149.09 39.2 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.078 1.51 . . . . 0.0 115.078 -175.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 21' ' ' ALA . . . . . 0.426 ' N ' ' CD1' ' E' ' 20' ' ' PHE . . . -149.73 138.63 21.06 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.415 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 81.5 tt0 -110.97 111.85 23.26 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.432 178.624 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' O ' ' C ' ' E' ' 24' ' ' VAL . 0.3 OUTLIER 176.37 122.52 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -178.049 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.456 ' C ' ' O ' ' E' ' 23' ' ' ASP . 41.5 t -37.32 117.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 121.595 0.712 . . . . 0.0 110.332 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.81 89.6 0.48 Allowed Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.919 -178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 46.7 t . . . . . 0 N--CA 1.447 -0.624 0 CA-C-O 122.616 1.198 . . . . 0.0 111.765 -177.386 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.508 ' C ' HD13 ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.239 0.516 0 N-CA-C 105.575 -2.009 . . . . 0.0 105.575 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.668 ' N ' HD13 ' E' ' 31' ' ' ILE . 0.1 OUTLIER -148.16 128.54 4.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 121.543 0.687 . . . . 0.0 111.086 -178.548 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 91.9 mt -128.19 128.59 68.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.109 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.4 124.58 5.64 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.54 HD23 ' N ' ' E' ' 35' ' ' MET . 4.1 tt -130.17 121.71 26.79 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.54 ' N ' HD23 ' E' ' 34' ' ' LEU . 9.4 ttt -123.15 125.37 45.01 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 121.065 -0.254 . . . . 0.0 111.477 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.3 t -127.59 78.64 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.545 ' HA2' HG21 ' K' ' 31' ' ' ILE . . . 13.77 -109.25 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 N-CA-C 114.107 0.403 . . . . 0.0 114.107 177.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -150.1 165.27 29.8 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.436 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 55.3 t -130.28 136.3 58.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' E' E ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' F' ' 39' ' ' VAL . 46.3 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.358 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -108.15 136.12 48.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.814 0.34 . . . . 0.0 110.609 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.23 133.83 47.7 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.245 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.71 135.27 51.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 24.7 p80 -155.91 128.09 7.59 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.041 0.448 . . . . 0.0 111.593 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 62.5 m80 -151.09 171.58 17.13 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -151.1 171.16 17.78 Favored 'General case' 0 C--N 1.313 -1.015 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.331 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -141.71 127.2 18.89 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.67 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.57 126.78 54.65 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.74 119.76 52.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.13 0.49 . . . . 0.0 111.934 -178.633 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.42 ' CE1' HD11 ' E' ' 34' ' ' LEU . 4.0 m-85 -113.7 105.93 13.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.827 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' E' ' 20' ' ' PHE . 5.7 m-85 -139.29 131.28 27.85 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 122.608 1.195 . . . . 0.0 112.558 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 21' ' ' ALA . . . . . 0.434 ' O ' ' OD1' ' F' ' 23' ' ' ASP . . . -148.94 163.16 38.29 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.357 178.818 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -71.15 85.03 0.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.818 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.477 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 11.1 p30 -165.3 112.77 0.98 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.844 178.37 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.58 ' O ' ' N ' ' F' ' 26' ' ' SER . 98.1 t -70.74 132.55 33.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.583 178.205 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.6 83.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.206 -1.558 . . . . 0.0 109.206 177.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 26' ' ' SER . . . . . 0.58 ' N ' ' O ' ' F' ' 24' ' ' VAL . 13.1 p -66.07 -174.18 0.23 Allowed 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 122.492 1.139 . . . . 0.0 112.276 -177.14 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -81.63 179.08 7.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 112.722 -2.036 . . . . 0.0 111.719 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -37.25 104.22 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.553 -0.748 . . . . 0.0 109.66 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.448 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 167.88 -100.67 0.17 Allowed Glycine 0 C--O 1.217 -0.956 0 N-CA-C 108.843 -1.703 . . . . 0.0 108.843 -174.854 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.24 166.02 0.08 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 119.674 1.737 . . . . 0.0 107.659 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.652 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -143.43 130.31 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 118.093 -1.443 . . . . 0.0 112.604 -175.123 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -128.98 122.87 57.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.909 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 122.34 5.41 Favored Glycine 0 N--CA 1.468 0.833 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 36.7 mt -119.66 120.37 36.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' L' ' 32' ' ' ILE . 19.9 ttt -130.88 134.53 46.87 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.873 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.481 ' O ' HG22 ' F' ' 36' ' ' VAL . 1.5 p -156.96 89.41 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.742 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.39 94.83 0.23 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.757 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' F' F ' 38' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -149.81 167.77 29.91 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.706 -0.957 . . . . 0.0 110.706 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' E' ' 40' ' ' VAL . 30.9 m -132.08 157.12 43.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.893 0.378 . . . . 0.0 110.531 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.697 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.601 0.239 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' H' ' 14' ' ' HIS . 57.0 p-80 -152.93 169.98 21.52 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.39 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? -154.31 170.54 21.06 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.379 179.232 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.6 mttm -156.63 164.27 38.37 Favored 'General case' 0 C--O 1.222 -0.37 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.747 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 2.9 mp -146.71 175.93 10.24 Favored 'General case' 0 C--O 1.172 -3.02 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.968 ' C ' ' O ' ' H' ' 18' ' ' VAL . 94.0 t -156.62 170.51 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 118.724 -2.485 . . . . 0.0 110.099 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.654 ' N ' HG12 ' G' ' 18' ' ' VAL . 26.3 p90 -162.58 105.2 1.09 Allowed 'General case' 0 C--O 1.169 -3.169 0 O-C-N 121.375 -0.828 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.695 ' C ' ' O ' ' H' ' 20' ' ' PHE . 35.3 t80 -109.78 108.19 18.45 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.549 -1.344 . . . . 0.0 110.839 177.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -82.42 103.12 11.74 Favored 'General case' 0 C--O 1.178 -2.684 0 C-N-CA 124.682 1.193 . . . . 0.0 111.012 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.551 ' H ' ' HA ' ' H' ' 21' ' ' ALA . 73.7 mt-10 -75.39 147.92 39.61 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 120.27 1.395 . . . . 0.0 111.86 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.445 ' CG ' ' N ' ' G' ' 24' ' ' VAL . 7.8 p-10 -156.02 -144.75 0.14 Allowed 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.159 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' G' ' 23' ' ' ASP . 18.3 t -29.58 103.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 114.988 -1.006 . . . . 0.0 112.501 178.412 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.39 -94.41 0.09 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.643 178.176 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.2 m -71.18 174.17 6.72 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 119.138 1.469 . . . . 0.0 110.388 -178.659 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -78.71 173.33 12.57 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.511 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.461 ' HZ2' ' CB ' ' I' ' 26' ' ' SER . 13.0 mmtt -46.04 111.77 0.4 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 174.733 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 94.29 1.74 Allowed Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -177.928 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.43 -179.92 7.08 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-O 122.349 1.071 . . . . 0.0 111.157 -178.397 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.462 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.12 109.18 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 CA-C-N 113.28 -1.782 . . . . 0.0 108.91 -177.924 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.597 ' N ' ' SD ' ' A' ' 35' ' ' MET . 2.4 mt -107.02 112.41 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.8 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.612 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -115.96 98.39 0.82 Allowed Glycine 0 CA--C 1.499 -0.927 0 N-CA-C 106.851 -2.5 . . . . 0.0 106.851 176.816 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.612 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.6 mm? -125.22 133.9 52.55 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 122.305 1.05 . . . . 0.0 110.475 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.641 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 42.7 ttp -109.93 120.08 41.35 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 113.8 -1.546 . . . . 0.0 108.973 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.468 HG23 HG13 ' H' ' 36' ' ' VAL . 0.9 OUTLIER -134.5 70.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.762 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.32 106.09 2.9 Favored Glycine 0 C--N 1.365 2.139 0 N-CA-C 111.614 -0.594 . . . . 0.0 111.614 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.78 179.03 2.36 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 112.017 -0.433 . . . . 0.0 112.017 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 28.0 m . . . . . 0 N--CA 1.464 0.228 0 CA-C-N 115.436 -0.382 . . . . 0.0 110.273 179.783 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.2 t . . . . . 0 N--CA 1.466 0.329 0 N-CA-C 110.383 -0.229 . . . . 0.0 110.383 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 p-80 -174.88 -172.35 0.61 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 111.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' G' ' 14' ' ' HIS . 82.4 m-70 -149.09 163.49 37.4 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.371 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.415 ' HG2' ' N ' ' H' ' 16' ' ' LYS . 56.2 tt0 -160.25 167.44 27.56 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.427 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' G' ' 16' ' ' LYS . 73.1 mttt -156.57 151.67 26.31 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.373 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -134.16 123.57 24.6 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.968 ' O ' ' C ' ' G' ' 18' ' ' VAL . 65.3 t -125.59 141.69 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 118.113 -1.435 . . . . 0.0 113.838 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 94.1 m-85 -118.62 115.01 23.66 Favored 'General case' 0 N--CA 1.472 0.644 0 O-C-N 120.723 -1.236 . . . . 0.0 109.722 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.695 ' O ' ' C ' ' G' ' 20' ' ' PHE . 8.2 t80 -109.89 106.89 16.63 Favored 'General case' 0 C--O 1.25 1.107 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 179.005 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -90.42 120.09 31.24 Favored 'General case' 0 C--N 1.36 1.052 0 O-C-N 124.864 1.352 . . . . 0.0 110.461 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.477 ' O ' ' CB ' ' H' ' 23' ' ' ASP . 82.4 tt0 -153.26 156.53 38.63 Favored 'General case' 0 C--N 1.359 1.022 0 C-N-CA 117.898 -1.521 . . . . 0.0 113.125 -177.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' H' ' 22' ' ' GLU . 0.9 OUTLIER 149.23 121.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.448 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.507 HG23 ' O ' ' H' ' 24' ' ' VAL . 25.0 m . . . . . 0 C--N 1.328 -0.343 0 C-N-CA 119.802 -0.759 . . . . 0.0 109.718 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.418 ' C ' HD12 ' H' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.405 -2.678 1 N-CA-C 99.706 -4.183 . . . . 0.0 99.706 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.904 ' N ' HD12 ' H' ' 31' ' ' ILE . 1.9 mp -82.02 103.74 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.344 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.287 174.822 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' B' ' 35' ' ' MET . 18.6 tt -121.32 121.34 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 CA-C-O 121.614 0.721 . . . . 0.0 111.009 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.82 116.59 2.39 Favored Glycine 0 C--O 1.244 0.74 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -130.83 128.8 41.38 Favored 'General case' 0 C--O 1.244 0.813 0 CA-C-O 121.785 0.802 . . . . 0.0 110.785 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.667 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 40.1 ttp -106.09 115.88 30.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.423 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.468 HG13 HG23 ' G' ' 36' ' ' VAL . 0.0 OUTLIER -120.2 70.54 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.209 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.637 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.77 -100.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.02 -159.71 24.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.068 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.3 142.56 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.852 0.358 . . . . 0.0 110.781 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.671 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 121.863 0.839 . . . . 0.0 111.852 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.546 ' O ' ' CG ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -149.27 109.04 4.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.658 179.034 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.1 m170 -114.17 162.49 16.45 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.641 0.734 . . . . 0.0 110.673 -179.325 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' I' ' 16' ' ' LYS . 43.4 tt0 -153.0 172.8 16.27 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.495 178.59 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' I' ' 15' ' ' GLN . 88.3 tttt -172.11 132.95 0.68 Allowed 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.838 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 18' ' ' VAL . 6.7 tt -124.99 125.92 44.64 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.709 ' HB ' HG22 ' H' ' 18' ' ' VAL . 52.7 t -124.46 126.58 72.09 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.543 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -108.2 103.5 12.7 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 175.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.492 ' CE1' ' CZ ' ' H' ' 20' ' ' PHE . 25.7 t80 -117.32 131.06 56.88 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.864 0.302 . . . . 0.0 110.643 -178.3 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.29 145.94 31.45 Favored 'General case' 0 C--O 1.243 0.714 0 CA-C-O 122.043 0.925 . . . . 0.0 113.338 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -137.61 135.29 36.46 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.81 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.464 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 48.0 t0 -139.5 137.84 35.86 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -92.12 113.19 26.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 C-N-CA 118.685 -1.206 . . . . 0.0 111.806 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.91 86.97 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 CA-C-N 113.744 -1.571 . . . . 0.0 115.255 176.304 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.57 ' O ' ' O ' ' I' ' 27' ' ' ASN . 30.9 t -140.68 169.95 16.69 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-N 118.487 1.144 . . . . 0.0 109.147 175.544 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.57 ' O ' ' O ' ' I' ' 26' ' ' SER . 89.7 m-20 -30.51 170.79 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 O-C-N 124.009 0.818 . . . . 0.0 112.896 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' K' ' 25' ' ' GLY . 86.3 mttt -108.37 -112.23 0.3 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 173.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.86 90.73 0.01 OUTLIER Glycine 0 N--CA 1.466 0.66 0 CA-C-N 116.09 -0.505 . . . . 0.0 112.155 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.418 ' HA ' HD13 ' I' ' 31' ' ' ILE . . . -140.01 161.9 36.5 Favored 'General case' 0 C--O 1.248 1.005 0 CA-C-O 122.221 1.01 . . . . 0.0 108.35 177.029 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.697 HG22 ' HB ' ' J' ' 31' ' ' ILE . 0.1 OUTLIER -139.69 133.07 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 CA-C-N 113.455 -1.702 . . . . 0.0 110.089 -175.957 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.494 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.1 mt -113.39 114.85 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 178.472 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.26 96.06 1.05 Allowed Glycine 0 CA--C 1.497 -1.058 0 N-CA-C 105.231 -3.148 . . . . 0.0 105.231 175.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.578 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 6.6 tp -114.05 125.91 54.52 Favored 'General case' 0 CA--C 1.502 -0.87 0 CA-C-O 121.738 0.78 . . . . 0.0 112.026 -177.127 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.708 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 4.6 ttp -119.14 109.92 16.45 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.914 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.2 75.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.141 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -26.72 -98.37 0.01 OUTLIER Glycine 0 C--N 1.363 2.08 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 178.698 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -151.03 19.39 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -124.59 138.92 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.82 0.343 . . . . 0.0 110.358 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.603 -179.47 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t . . . . . 0 N--CA 1.467 0.401 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 6.2 t-80 -148.93 143.15 26.0 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.252 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' J' ' 13' ' ' HIS . 46.9 m-70 -141.28 163.66 32.35 Favored 'General case' 0 CA--C 1.51 -0.576 0 CA-C-O 121.482 0.658 . . . . 0.0 110.052 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.448 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 50.9 tt0 -156.02 170.76 21.41 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.06 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.448 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 54.2 mtmt -157.01 134.52 10.68 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -123.83 124.51 42.82 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -140.94 141.69 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 118.768 -1.173 . . . . 0.0 113.867 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.637 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 5.5 m-85 -111.45 110.01 20.24 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.763 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.03 120.89 42.14 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.455 0.571 . . . . 0.0 111.429 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.51 117.58 23.93 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.011 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.499 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 97.2 mt-10 -120.12 142.37 48.98 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.834 -178.143 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 4.3 t70 146.31 159.21 0.0 OUTLIER 'General case' 0 C--N 1.345 0.407 0 O-C-N 124.373 1.046 . . . . 0.0 109.201 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 2.4 m -62.97 -110.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.8 93.04 0.14 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.957 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.841 ' O ' ' O ' ' J' ' 27' ' ' ASN . 15.4 p -153.91 -170.61 3.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.841 ' O ' ' O ' ' J' ' 26' ' ' SER . 2.9 m120 -19.65 178.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 125.049 1.468 . . . . 0.0 114.258 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.588 ' O ' ' N ' ' J' ' 30' ' ' ALA . 58.0 tttp 138.88 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.246 -177.005 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' J' ' 28' ' ' LYS . . . -45.31 101.46 0.03 OUTLIER Glycine 0 N--CA 1.481 1.68 1 CA-C-O 128.54 4.411 . . . . 0.0 108.384 -174.271 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.588 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -99.51 -124.17 0.16 Allowed 'General case' 1 N--CA 1.368 -4.569 4 N-CA-C 89.89 -7.818 . . . . 0.0 89.89 177.972 . . . . . . . . 4 3 . 1 . 003 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.867 HD12 ' N ' ' J' ' 31' ' ' ILE . 1.2 mp -76.99 102.89 3.82 Favored 'Isoleucine or valine' 0 C--N 1.257 -3.422 0 C-N-CA 115.006 -2.678 . . . . 0.0 109.583 176.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.673 HD11 HD21 ' J' ' 34' ' ' LEU . 14.2 tt -115.08 121.39 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-O 121.322 0.582 . . . . 0.0 109.476 178.181 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.58 113.83 2.09 Favored Glycine 0 N--CA 1.466 0.681 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.989 HD22 ' CZ ' ' L' ' 19' ' ' PHE . 0.0 OUTLIER -125.16 128.11 47.89 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 122.019 0.914 . . . . 0.0 111.702 -178.4 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.743 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 32.7 ttp -107.63 119.26 38.93 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.329 -1.305 . . . . 0.0 109.445 178.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.519 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.02 72.83 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 -179.443 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 38' ' ' GLY . . . -56.71 113.21 4.06 Favored Glycine 0 C--N 1.36 1.898 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.648 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 38' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -56.99 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 N--CA 1.466 0.347 0 CA-C-O 120.955 0.407 . . . . 0.0 111.003 -179.444 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 N--CA 1.463 0.193 0 CA-C-O 120.837 0.351 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 56.9 t -123.94 133.13 70.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -146.96 147.87 31.17 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.389 -0.524 . . . . 0.0 111.39 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 54.5 m80 -146.9 164.35 33.18 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.716 0.769 . . . . 0.0 110.593 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 80.8 mt-30 -154.57 179.1 9.36 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.388 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -169.79 131.79 1.11 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.562 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.97 120.53 36.64 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.28 124.93 65.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 121.032 0.444 . . . . 0.0 111.793 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.637 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 41.0 m-85 -115.75 110.25 18.84 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.067 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -120.98 127.36 51.72 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -177.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.21 137.68 36.2 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.582 0.706 . . . . 0.0 112.49 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -105.98 123.7 48.41 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 116.189 -0.459 . . . . 0.0 112.22 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' J' ' 26' ' ' SER . 49.3 t0 -172.37 114.68 0.31 Allowed 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.459 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 8.5 p -79.58 131.34 34.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.244 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.563 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . 58.82 82.38 0.06 OUTLIER Glycine 0 N--CA 1.467 0.7 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.07 178.537 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p -67.32 -172.08 0.2 Allowed 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.541 0.686 . . . . 0.0 110.172 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' K' ' 28' ' ' LYS . 30.6 p-10 -79.63 179.28 7.59 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.47 ' O ' ' O ' ' K' ' 27' ' ' ASN . 81.2 tttt -43.65 -110.11 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.569 -0.742 . . . . 0.0 112.596 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.4 94.15 1.69 Allowed Glycine 0 N--CA 1.471 1.006 0 CA-C-O 119.992 -0.338 . . . . 0.0 112.859 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.02 173.48 11.73 Favored 'General case' 0 C--O 1.24 0.554 0 N-CA-C 104.317 -2.475 . . . . 0.0 104.317 176.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.572 HG23 HD13 ' L' ' 31' ' ' ILE . 0.1 OUTLIER -151.72 136.93 10.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 C-N-CA 117.35 -1.74 . . . . 0.0 112.116 -174.644 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.71 117.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.632 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.513 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -118.08 107.93 1.56 Allowed Glycine 0 C--N 1.334 0.467 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 178.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.428 HD11 HG21 ' J' ' 36' ' ' VAL . 51.9 tp -119.99 121.84 39.83 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 110.464 -0.198 . . . . 0.0 110.464 -178.802 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.402 ' C ' ' SD ' ' K' ' 35' ' ' MET . 6.3 tmm? -120.34 120.25 35.47 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.704 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.519 HG22 HG23 ' J' ' 36' ' ' VAL . 96.1 t -133.68 82.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.544 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -7.87 -97.81 0.0 OUTLIER Glycine 0 C--N 1.349 1.276 0 O-C-N 123.504 0.502 . . . . 0.0 113.703 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.25 -168.85 38.85 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.386 -179.758 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.464 0.241 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 31.8 p-80 -159.67 154.11 23.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 0.0 111.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -151.54 169.29 22.44 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.024 179.63 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -157.58 178.21 10.53 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.995 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -143.4 138.38 29.33 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.498 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 mt -121.68 119.43 31.77 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 m -143.01 135.91 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.989 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 4.0 m-30 -116.33 127.91 55.09 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -141.55 139.44 33.19 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.777 0.798 . . . . 0.0 111.893 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 142.95 34.63 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.78 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.43 100.96 6.18 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.974 -179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -173.84 133.4 0.45 Allowed 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.9 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 113.75 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 54.39 -91.21 0.01 OUTLIER Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -178.463 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.5 p 152.5 176.71 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 122.006 0.908 . . . . 0.0 110.058 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -51.74 -179.45 0.01 OUTLIER 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 113.892 -1.504 . . . . 0.0 111.664 178.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -60.58 111.66 1.69 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.923 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.597 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 81.07 -93.19 1.5 Allowed Glycine 0 N--CA 1.468 0.787 0 CA-C-N 114.993 -1.003 . . . . 0.0 112.22 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.597 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 79.11 165.56 0.2 Allowed 'General case' 0 CA--C 1.507 -0.684 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 -175.611 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.849 ' N ' HD12 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -149.87 131.93 5.87 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 CA-C-N 122.07 2.214 . . . . 0.0 111.583 178.038 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' F' ' 35' ' ' MET . 15.4 pt -124.46 142.08 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.115 -178.277 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.75 120.43 2.52 Favored Glycine 0 N--CA 1.463 0.457 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 20.0 mt -115.62 118.66 33.74 Favored 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 4.6 ttt -111.01 117.46 33.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.175 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -145.1 81.41 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.652 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -57.97 102.08 0.22 Allowed Glycine 0 C--N 1.337 0.621 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.072 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.65 178.95 34.17 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.3 136.59 59.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 120.842 0.353 . . . . 0.0 110.325 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.616 -179.698 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 . . . . . 0 N--CA 1.466 0.343 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -144.14 141.94 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.879 0.371 . . . . 0.0 110.668 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -141.75 -168.97 2.8 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.828 -179.387 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 73.7 m-70 -75.92 168.77 19.41 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 121.295 0.569 . . . . 0.0 110.087 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' A' ' 16' ' ' LYS . 48.5 tt0 -158.33 173.98 15.85 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.361 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' A' ' 15' ' ' GLN . 88.9 tttt -144.27 126.35 15.51 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.621 0.248 . . . . 0.0 110.886 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.21 120.82 22.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.978 0.418 . . . . 0.0 110.046 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.32 136.9 50.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.795 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -129.67 132.01 46.56 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 111.396 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -114.84 123.06 48.23 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.9 123.44 42.52 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.385 0.612 . . . . 0.0 111.249 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -141.78 124.68 16.13 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.73 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.3 t0 . . . . . 0 C--N 1.327 -0.389 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.287 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 29' ' ' GLY . 78.3 tttt . . . . . 0 N--CA 1.469 0.5 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 28' ' ' LYS . . . 45.39 92.98 0.01 OUTLIER Glycine 0 N--CA 1.468 0.829 0 CA-C-O 118.191 -1.338 . . . . 0.0 110.261 178.194 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.04 160.36 15.1 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 116.627 -2.029 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -152.22 117.87 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 111.836 -2.438 . . . . 0.0 108.958 -171.736 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 32' ' ' ILE . 12.6 tt -128.85 109.28 18.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.032 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.613 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -122.31 119.86 4.13 Favored Glycine 0 CA--C 1.51 -0.263 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 178.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 35' ' ' MET . 8.4 tt -164.86 162.69 21.01 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.321 -176.858 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 5.1 ttp -135.45 143.24 45.79 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.244 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 m -121.89 71.53 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.764 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.548 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -47.05 -97.46 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.2 -168.85 30.83 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.43 134.35 66.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.635 -179.707 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -109.89 135.06 51.36 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.939 0.4 . . . . 0.0 110.708 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.94 161.29 28.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.1 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 m -131.04 160.85 41.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.46 ' CD2' ' N ' ' B' ' 13' ' ' HIS . 2.8 m-70 -127.74 124.27 37.38 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.711 0.291 . . . . 0.0 110.628 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.772 ' HD1' ' HB2' ' C' ' 14' ' ' HIS . 55.2 t60 -153.92 162.58 41.11 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.495 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 73.5 mt-30 -159.22 175.91 12.85 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.792 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -153.94 126.9 8.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.149 178.554 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 mt -124.7 114.46 19.35 Favored 'General case' 0 C--O 1.233 0.214 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.122 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -124.48 128.99 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.812 0.339 . . . . 0.0 110.344 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 19' ' ' PHE . . . . . 0.497 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 88.7 t80 -125.7 123.32 38.63 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.036 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -118.16 125.56 50.46 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 21' ' ' ALA . . . . . 0.497 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -133.0 131.93 41.29 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.415 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.47 ' CB ' ' O ' ' C' ' 22' ' ' GLU . 16.6 pt-20 -158.39 154.88 27.68 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 120.185 -0.606 . . . . 0.0 112.561 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' B' ' 23' ' ' ASP . 1.0 OUTLIER . . . . . 0 CA--C 1.535 0.378 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.439 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.202 0 N-CA-C 105.864 -2.894 . . . . 0.0 105.864 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.08 161.61 15.03 Favored 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.469 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -141.62 121.11 10.92 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.294 -172.346 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.467 HG22 ' O ' ' B' ' 32' ' ' ILE . 1.6 mt -110.53 115.11 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.953 178.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.428 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -120.04 93.65 0.54 Allowed Glycine 0 CA--C 1.507 -0.443 0 N-CA-C 104.198 -3.561 . . . . 0.0 104.198 174.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.549 HD23 ' O ' ' A' ' 34' ' ' LEU . 57.3 mt -122.58 140.22 53.04 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 122.958 1.361 . . . . 0.0 113.054 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 12.1 ttt -127.7 123.3 35.12 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 113.789 -1.55 . . . . 0.0 111.027 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.416 HG23 HG22 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -117.71 72.98 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.962 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.085 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -98.2 103.34 2.79 Favored Glycine 0 C--N 1.354 1.549 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.28 172.13 34.53 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -154.23 147.42 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 110.949 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.372 179.668 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 N--CA 1.463 0.224 0 CA-C-O 121.104 0.478 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -124.69 131.26 53.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.375 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.772 ' HB2' ' HD1' ' B' ' 14' ' ' HIS . 84.0 m-70 -143.49 168.55 19.58 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.402 0.62 . . . . 0.0 109.878 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.402 ' HG2' ' H ' ' C' ' 16' ' ' LYS . 48.0 tt0 -159.53 172.99 16.85 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.625 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.402 ' H ' ' HG2' ' C' ' 15' ' ' GLN . 88.6 tttt -166.61 114.75 0.87 Allowed 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 tp -121.74 121.72 37.92 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -130.03 124.99 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -114.48 106.36 14.19 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.131 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -113.26 127.14 56.06 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.15 0.5 . . . . 0.0 111.564 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.66 125.25 44.46 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.952 178.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 22' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' B' ' 22' ' ' GLU . 97.2 mt-10 -143.57 158.76 43.41 Favored 'General case' 0 C--O 1.222 -0.345 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.988 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 22.4 t0 . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.284 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 1.104 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.424 -5.626 0 N-CA-C 104.601 -3.4 . . . . 0.0 104.601 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.507 ' O ' ' C ' ' C' ' 29' ' ' GLY . . . -79.55 -140.47 0.03 OUTLIER 'General case' 0 N--CA 1.388 -3.564 1 N-CA-C 97.605 -4.961 . . . . 0.0 97.605 177.877 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.662 ' CD1' ' N ' ' C' ' 31' ' ' ILE . 1.0 OUTLIER -81.17 106.56 12.47 Favored 'Isoleucine or valine' 0 C--N 1.246 -3.904 0 C-N-CA 114.451 -2.9 . . . . 0.0 110.153 -177.751 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.498 ' O ' ' CE ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -108.68 122.52 63.37 Favored 'Isoleucine or valine' 0 C--N 1.363 1.161 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.766 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -138.76 113.23 0.93 Allowed Glycine 0 C--N 1.314 -0.666 0 N-CA-C 106.871 -2.492 . . . . 0.0 106.871 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.517 ' O ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -140.65 158.55 43.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 123.115 1.436 . . . . 0.0 111.842 -176.673 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.479 ' CE ' ' O ' ' I' ' 32' ' ' ILE . 24.4 tpp -129.35 124.22 33.73 Favored 'General case' 0 CA--C 1.491 -1.289 0 CA-C-N 112.613 -2.085 . . . . 0.0 107.167 178.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.495 HG23 HD11 ' D' ' 34' ' ' LEU . 48.7 t -116.9 70.98 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.049 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.32 -101.09 0.01 OUTLIER Glycine 0 C--N 1.377 2.829 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.086 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.83 -158.82 30.41 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -134.59 161.53 40.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.83 0.347 . . . . 0.0 110.341 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.662 -179.576 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 54.2 t . . . . . 0 N--CA 1.465 0.313 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 33.0 m-70 -118.38 106.08 12.36 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.59 -178.993 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.429 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 60.8 m170 -108.67 166.51 10.74 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -152.82 172.51 16.62 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.03 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -157.08 114.5 3.11 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 60.3 mt -119.81 115.4 23.77 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -129.82 127.07 63.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.479 ' CE2' ' CD2' ' C' ' 34' ' ' LEU . 7.9 m-85 -116.07 117.76 30.98 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -132.9 128.56 36.82 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.944 -177.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 130.36 45.12 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.651 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.537 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 79.7 tt0 -141.81 107.91 5.21 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 119.945 -0.702 . . . . 0.0 112.777 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 71.8 m-20 . . . . . 0 CA--C 1.534 0.327 0 O-C-N 123.872 0.732 . . . . 0.0 110.158 178.248 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 1.104 ' HB1' ' O ' ' C' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.432 -1.364 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.632 HG22 ' CE ' ' K' ' 35' ' ' MET . 0.2 OUTLIER -150.92 125.07 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 116.683 -2.007 . . . . 0.0 111.846 -172.27 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.722 ' CG2' HG23 ' E' ' 32' ' ' ILE . 3.7 tt -116.31 116.99 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.502 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.83 119.39 3.31 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 178.756 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.591 HD23 ' CZ ' ' F' ' 19' ' ' PHE . 14.8 tp -138.84 126.46 21.96 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.161 0.981 . . . . 0.0 112.026 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.588 ' SD ' ' CA ' ' J' ' 33' ' ' GLY . 20.8 ttt -106.35 119.84 40.3 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.191 177.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.499 ' CG2' HG22 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -107.99 76.75 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.144 -178.579 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -26.43 -97.42 0.01 OUTLIER Glycine 0 C--N 1.354 1.552 0 N-CA-C 112.004 -0.438 . . . . 0.0 112.004 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.31 165.63 33.71 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.32 161.43 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.825 0.345 . . . . 0.0 110.474 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.3 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.492 179.689 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -103.58 131.17 50.95 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.862 0.363 . . . . 0.0 110.367 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -143.67 148.92 36.48 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.218 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.481 ' CG2' ' H ' ' F' ' 12' ' ' VAL . 0.2 OUTLIER -148.12 -153.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.462 -179.382 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.424 ' ND1' ' C ' ' E' ' 13' ' ' HIS . 7.2 t-80 -70.77 142.25 51.4 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 121.464 0.65 . . . . 0.0 112.68 -177.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -146.03 169.7 18.14 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 50.4 tt0 -155.39 168.01 28.51 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.924 -0.71 . . . . 0.0 112.233 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -148.75 123.48 9.88 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.614 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 34.0 tp -120.8 114.21 21.29 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.43 129.02 68.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 121.381 0.61 . . . . 0.0 111.999 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -124.07 123.93 41.42 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.619 ' CE1' ' CD1' ' F' ' 20' ' ' PHE . 2.0 t80 -133.64 130.14 37.85 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.718 0.294 . . . . 0.0 110.768 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.72 130.35 34.04 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.23 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -122.96 141.09 52.32 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 19.5 p-10 -165.49 113.74 0.99 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.563 177.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.09 131.0 31.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.196 -178.995 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 72.78 84.51 0.24 Allowed Glycine 0 CA--C 1.532 1.12 0 CA-C-N 116.007 -0.542 . . . . 0.0 114.12 177.722 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' E' ' 25' ' ' GLY . 88.7 p . . . . . 0 N--CA 1.453 -0.284 0 C-N-CA 123.666 0.786 . . . . 0.0 111.765 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.439 -0.985 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.825 HG23 HD13 ' F' ' 31' ' ' ILE . 0.3 OUTLIER -147.38 124.66 3.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 118.402 -1.319 . . . . 0.0 109.553 -178.151 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' F' ' 32' ' ' ILE . 66.1 mt -123.73 124.47 69.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.705 -176.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.416 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -127.27 110.31 1.18 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 177.704 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CE2' ' F' ' 19' ' ' PHE . 43.5 mt -119.02 128.9 54.8 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.3 ttt -133.3 131.16 39.85 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 119.781 -0.768 . . . . 0.0 112.222 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.512 ' O ' ' C ' ' E' ' 37' ' ' GLY . 40.1 t -130.65 81.73 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.576 179.074 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 19.02 -102.7 0.01 OUTLIER Glycine 0 C--N 1.352 1.472 0 CA-C-N 117.848 0.294 . . . . 0.0 112.84 179.112 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.02 -174.51 46.79 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' E' E ' 39' ' ' VAL . . . . . 0.439 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 30.3 m -135.69 161.71 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.798 0.332 . . . . 0.0 110.677 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.5 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -147.23 155.78 42.38 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.099 0.476 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -101.72 143.89 31.1 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.957 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 12' ' ' VAL . . . . . 0.481 ' H ' ' CG2' ' E' ' 12' ' ' VAL . 55.5 t -118.84 129.59 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.404 0.621 . . . . 0.0 110.54 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -154.49 130.12 9.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.045 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -145.74 170.38 16.63 Favored 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.652 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -148.28 175.22 11.25 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.221 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.13 131.86 31.1 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' F' ' 17' ' ' LEU . 5.2 mp -121.87 120.82 35.64 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.1 t -131.7 125.82 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.985 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CE2' HD22 ' E' ' 34' ' ' LEU . 35.9 m-85 -117.48 115.68 25.64 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 177.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE1' ' E' ' 20' ' ' PHE . 34.7 t80 -128.3 123.19 33.4 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.967 0.413 . . . . 0.0 110.084 179.209 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.84 134.33 36.82 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.494 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 80.1 tt0 -92.2 75.66 5.36 Favored 'General case' 0 N--CA 1.463 0.21 0 C-N-CA 119.888 -0.725 . . . . 0.0 112.066 -178.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 19.3 m-20 -142.81 107.93 4.96 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 175.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HB3' ' E' ' 26' ' ' SER . 85.6 t -45.69 140.79 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.066 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.85 83.61 1.63 Allowed Glycine 0 C--N 1.333 0.392 0 N-CA-C 107.865 -2.094 . . . . 0.0 107.865 177.743 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -68.63 -170.79 0.23 Allowed 'General case' 0 N--CA 1.434 -1.266 0 CA-C-O 122.393 1.092 . . . . 0.0 111.805 -177.582 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.438 ' O ' ' C ' ' F' ' 28' ' ' LYS . 49.9 p30 -80.23 179.19 7.78 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 113.014 -1.903 . . . . 0.0 108.781 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.438 ' C ' ' O ' ' F' ' 27' ' ' ASN . 98.8 mttt -36.82 104.16 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 122.072 0.939 . . . . 0.0 109.445 -178.793 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.492 ' O ' HG13 ' F' ' 31' ' ' ILE . . . 168.07 -100.71 0.17 Allowed Glycine 0 C--O 1.209 -1.412 0 CA-C-O 117.308 -1.829 . . . . 0.0 109.28 -173.959 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.48 164.06 0.55 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.51 2.655 . . . . 0.0 106.808 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.825 HD13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -146.25 131.18 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 118.119 -1.433 . . . . 0.0 112.175 -177.148 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' E' ' 32' ' ' ILE . 13.4 mm -115.5 125.54 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.51 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 125.24 4.49 Favored Glycine 0 N--CA 1.473 1.151 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.106 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 mt -124.68 128.02 48.19 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -130.81 127.63 39.04 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 121.699 0.761 . . . . 0.0 112.571 -179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 48.8 t -147.38 86.66 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.813 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.45 96.79 1.28 Allowed Glycine 0 C--N 1.339 0.698 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.071 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 38' ' ' GLY . . . . . 0.439 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -155.21 163.57 31.54 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 62.2 t -123.88 135.61 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.307 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 75.8 m80 . . . . . 0 N--CA 1.475 0.78 0 CA-C-O 120.92 0.39 . . . . 0.0 111.704 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -107.72 179.14 4.32 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.668 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.426 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 6.6 tt0 -100.07 172.66 7.06 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.714 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.4 mttm -149.19 165.58 31.41 Favored 'General case' 0 C--O 1.217 -0.639 0 CA-C-O 121.193 0.521 . . . . 0.0 111.419 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 7.0 tt -145.14 161.84 38.49 Favored 'General case' 0 C--O 1.171 -3.039 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.958 ' C ' ' O ' ' H' ' 18' ' ' VAL . 86.3 t -156.07 170.77 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 118.701 -2.499 . . . . 0.0 110.529 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 19' ' ' PHE . . . . . 0.641 ' N ' HG12 ' G' ' 18' ' ' VAL . 31.2 p90 -158.86 108.32 1.96 Allowed 'General case' 0 C--O 1.165 -3.344 0 CA-C-O 118.373 -0.823 . . . . 0.0 109.803 -178.428 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.713 ' C ' ' O ' ' H' ' 20' ' ' PHE . 43.6 t80 -119.52 106.27 12.05 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 121.471 1.941 . . . . 0.0 112.026 178.41 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -114.74 113.0 23.71 Favored 'General case' 0 C--O 1.174 -2.887 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.256 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 22' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' H' ' 22' ' ' GLU . 94.9 mt-10 -75.01 144.41 43.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 118.898 0.772 . . . . 0.0 112.032 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 33.4 m-20 -140.62 -142.24 0.14 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.975 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' G' ' 23' ' ' ASP . 13.7 t -27.44 103.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.318 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.455 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 172.0 92.77 0.08 OUTLIER Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 86.66 179.9 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.793 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -63.73 170.88 3.01 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.309 0.576 . . . . 0.0 111.459 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.85 112.07 0.51 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.106 176.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.52 94.31 2.35 Favored Glycine 0 CA--C 1.486 -1.75 0 CA-C-O 122.493 1.052 . . . . 0.0 110.841 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.504 ' C ' HD13 ' G' ' 31' ' ' ILE . . . -74.31 -179.05 3.72 Favored 'General case' 0 N--CA 1.421 -1.922 0 CA-C-N 112.795 -1.702 . . . . 0.0 110.607 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.856 ' N ' HD13 ' G' ' 31' ' ' ILE . 0.0 OUTLIER -141.62 112.65 3.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 113.335 -1.757 . . . . 0.0 106.41 179.415 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.413 HG23 HD21 ' H' ' 34' ' ' LEU . 18.5 tt -117.31 117.65 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-O 121.708 0.766 . . . . 0.0 110.414 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.16 106.41 2.35 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 105.904 -2.878 . . . . 0.0 105.904 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.688 ' HB3' HD22 ' H' ' 34' ' ' LEU . 13.2 tp -132.81 130.52 39.96 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 122.604 1.192 . . . . 0.0 111.535 -177.774 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.613 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 24.7 ttp -102.81 124.19 47.87 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.16 179.59 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.9 70.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.98 -100.53 1.47 Allowed Glycine 0 C--N 1.354 1.572 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.7 170.25 24.04 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.33 -0.243 0 CA-C-O 120.832 0.348 . . . . 0.0 110.708 -179.796 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t . . . . . 0 N--CA 1.461 0.116 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.67 ' CD2' ' N ' ' H' ' 13' ' ' HIS . 2.2 p80 -158.68 152.01 22.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.672 0.749 . . . . 0.0 111.785 -179.484 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.461 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 15.9 m80 -144.64 162.27 37.07 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.232 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 mm100 -152.96 172.91 16.09 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.313 0.578 . . . . 0.0 110.087 178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' G' ' 16' ' ' LYS . 76.7 tttt -176.04 136.86 0.31 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.026 -0.988 . . . . 0.0 108.467 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 77.0 mt -141.07 132.3 26.51 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.169 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.958 ' O ' ' C ' ' G' ' 18' ' ' VAL . 76.8 t -124.6 146.07 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 C-N-CA 118.184 -1.407 . . . . 0.0 113.385 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.414 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 63.2 m-85 -125.19 119.33 28.21 Favored 'General case' 0 N--CA 1.478 0.949 0 O-C-N 120.141 -1.6 . . . . 0.0 111.479 -179.042 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.713 ' O ' ' C ' ' G' ' 20' ' ' PHE . 50.3 t80 -105.69 111.82 24.65 Favored 'General case' 0 C--O 1.248 0.981 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.698 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -93.97 113.44 25.44 Favored 'General case' 0 C--N 1.352 0.717 0 CA-C-O 118.631 -0.7 . . . . 0.0 112.734 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.627 ' H ' ' HB1' ' G' ' 21' ' ' ALA . 48.6 tt0 -149.02 124.85 10.55 Favored 'General case' 0 C--N 1.379 1.884 0 C-N-CA 117.899 -1.52 . . . . 0.0 112.094 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.501 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 66.5 t0 -125.07 114.69 19.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.484 0.659 . . . . 0.0 110.252 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.406 ' H ' HG23 ' H' ' 24' ' ' VAL . 40.1 t . . . . . 0 C--N 1.316 -0.879 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.807 ' C ' HD13 ' H' ' 31' ' ' ILE . . . . . . . . 0 CA--C 1.477 -1.834 1 N-CA-C 93.853 -6.351 . . . . 0.0 93.853 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.807 HD13 ' C ' ' H' ' 30' ' ' ALA . 0.9 OUTLIER -94.43 110.69 24.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 CA-C-N 124.149 3.159 . . . . 0.0 108.602 177.09 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.558 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -112.86 110.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.361 1.075 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.686 -179.582 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.931 ' O ' HD23 ' H' ' 34' ' ' LEU . . . -120.24 102.34 0.87 Allowed Glycine 0 N--CA 1.462 0.401 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.931 HD23 ' O ' ' H' ' 33' ' ' GLY . 2.6 mt -136.84 149.46 47.73 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-O 122.508 1.147 . . . . 0.0 112.844 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.469 ' SD ' ' O ' ' B' ' 31' ' ' ILE . 28.7 ttp -111.9 126.02 54.66 Favored 'General case' 0 CA--C 1.505 -0.772 0 CA-C-N 113.236 -1.802 . . . . 0.0 110.467 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -125.27 65.57 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.2 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.285 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -51.65 -104.6 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.81 -141.8 5.09 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -122.82 135.98 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.768 0.318 . . . . 0.0 110.288 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.495 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 77.3 t . . . . . 0 N--CA 1.471 0.614 0 CA-C-O 120.804 0.335 . . . . 0.0 110.173 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.596 ' ND1' ' CE1' ' H' ' 13' ' ' HIS . 75.4 t60 -150.86 104.75 3.19 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.864 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.526 ' NE2' ' O ' ' J' ' 12' ' ' VAL . 64.7 m170 -112.6 160.12 18.18 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.37 0.605 . . . . 0.0 110.205 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.432 ' O ' ' CG ' ' I' ' 16' ' ' LYS . 27.1 mt-30 -154.06 167.56 29.38 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.401 178.143 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.432 ' CG ' ' O ' ' I' ' 15' ' ' GLN . 95.2 mttt -164.69 128.46 2.47 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 108.993 -0.744 . . . . 0.0 108.993 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.2 mt -126.97 126.14 42.69 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.668 ' HB ' HG22 ' H' ' 18' ' ' VAL . 19.8 t -125.0 129.92 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.7 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.5 OUTLIER -133.57 108.64 8.72 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.185 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.422 ' CG ' ' CZ ' ' J' ' 20' ' ' PHE . 4.0 p90 -143.57 153.82 42.95 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 118.624 -1.23 . . . . 0.0 112.797 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.46 141.48 51.87 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.964 -1.016 . . . . 0.0 112.962 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -150.99 99.86 2.74 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.072 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' H' ' 23' ' ' ASP . 3.1 t70 -103.05 120.24 40.31 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.11 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.447 ' O ' HG23 ' I' ' 24' ' ' VAL . 27.5 m -59.21 121.36 6.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 81.97 90.31 0.61 Allowed Glycine 0 CA--C 1.535 1.305 0 N-CA-C 116.918 1.527 . . . . 0.0 116.918 174.769 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.523 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.4 p 137.43 167.3 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 124.902 1.281 . . . . 0.0 110.707 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.535 ' OD1' ' ND2' ' J' ' 27' ' ' ASN . 16.2 m-20 -49.84 178.15 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 115.841 1.793 . . . . 0.0 115.841 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.504 ' CE ' ' HB1' ' K' ' 21' ' ' ALA . 12.9 tttt -61.82 -111.24 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.052 0 CA-C-N 113.177 -1.829 . . . . 0.0 114.912 172.794 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.908 ' O ' ' HB3' ' J' ' 30' ' ' ALA . . . -79.59 96.3 1.52 Allowed Glycine 0 CA--C 1.458 -3.492 0 CA-C-N 110.762 -2.927 . . . . 0.0 114.677 -175.271 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.688 ' C ' HD12 ' I' ' 31' ' ' ILE . . . -76.61 -136.45 0.02 OUTLIER 'General case' 0 N--CA 1.412 -2.329 1 N-CA-C 93.992 -6.299 . . . . 0.0 93.992 169.066 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.749 HD12 ' N ' ' I' ' 31' ' ' ILE . 0.4 OUTLIER -98.46 121.91 49.55 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 1 CA-C-N 127.308 4.594 . . . . 0.0 111.412 -176.631 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.479 ' O ' ' CE ' ' C' ' 35' ' ' MET . 7.7 mt -112.09 112.26 39.74 Favored 'Isoleucine or valine' 0 C--N 1.359 1.022 0 CA-C-N 114.83 -1.077 . . . . 0.0 108.276 177.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.91 104.94 1.72 Allowed Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 107.295 -2.322 . . . . 0.0 107.295 177.217 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 65.0 mt -137.39 133.2 34.53 Favored 'General case' 0 C--O 1.24 0.561 0 CA-C-O 122.751 1.262 . . . . 0.0 113.549 -176.702 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 57.0 ttp -113.47 122.68 48.04 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-N 113.649 -1.614 . . . . 0.0 109.153 178.257 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.7 70.69 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -118.46 -103.57 2.15 Favored Glycine 0 C--N 1.36 1.881 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 178.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.49 -174.17 31.95 Favored Glycine 0 CA--C 1.522 0.501 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.113 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -132.82 161.9 40.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 CA-C-O 121.15 0.5 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 32.1 m . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.438 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.68 ' CG2' ' CE1' ' J' ' 14' ' ' HIS . 19.3 m . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 120.231 0.062 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -84.4 114.43 21.89 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.993 -0.283 . . . . 0.0 110.66 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.68 ' CE1' ' CG2' ' J' ' 12' ' ' VAL . 8.2 m-70 -134.78 165.2 25.83 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-O 121.827 0.822 . . . . 0.0 110.641 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -161.84 166.81 25.82 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.823 178.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.583 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.7 mttt -156.98 135.33 11.31 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.583 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.0 mp -122.16 120.41 34.14 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.389 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -125.92 130.12 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.532 ' HZ ' HD12 ' H' ' 34' ' ' LEU . 0.4 OUTLIER -140.3 126.81 20.19 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.657 ' CG ' ' CZ ' ' K' ' 20' ' ' PHE . 51.2 p90 -158.75 160.53 36.45 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.619 1.711 . . . . 0.0 115.619 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.1 119.02 32.11 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 114.071 -1.422 . . . . 0.0 108.279 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.406 ' HG2' ' N ' ' J' ' 23' ' ' ASP . 80.5 tt0 -157.08 157.16 34.04 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-O 122.116 0.96 . . . . 0.0 113.494 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.498 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 51.8 p-10 -157.54 -131.41 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 178.092 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.537 HG13 ' O ' ' J' ' 24' ' ' VAL . 3.7 p -108.38 112.33 39.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.967 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.512 ' N ' ' OE1' ' K' ' 22' ' ' GLU . . . 32.02 87.94 0.01 OUTLIER Glycine 0 C--N 1.342 0.896 0 CA-C-O 118.218 -1.323 . . . . 0.0 110.781 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.572 ' O ' ' N ' ' K' ' 24' ' ' VAL . 82.8 p -96.57 168.35 10.59 Favored 'General case' 0 CA--C 1.497 -1.079 0 CA-C-N 120.772 2.286 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.535 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 84.3 m-20 -61.91 179.07 0.29 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 116.501 2.037 . . . . 0.0 116.501 175.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . 0.472 53.1 tttt -59.02 106.98 0.47 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 110.424 -3.08 . . . . 0.0 116.321 170.749 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.69 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -63.08 109.6 2.81 Favored Glycine 1 CA--C 1.435 -4.967 0 CA-C-O 125.192 2.551 . . . . 0.0 108.826 -173.994 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -52.79 -124.69 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.518 2 CA-C-N 104.888 -5.656 . . . . 0.0 97.823 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.979 HD12 ' N ' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -93.43 115.25 31.8 Favored 'Isoleucine or valine' 0 C--N 1.263 -3.186 1 CA-C-N 126.896 4.407 . . . . 0.0 114.63 -173.485 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.507 ' C ' ' SD ' ' D' ' 35' ' ' MET . 16.1 tt -122.27 115.4 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.725 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.588 ' CA ' ' SD ' ' D' ' 35' ' ' MET . . . -118.01 118.55 4.1 Favored Glycine 0 N--CA 1.464 0.51 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.527 HD11 ' CZ ' ' K' ' 19' ' ' PHE . 2.2 mt -134.91 127.45 30.66 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.502 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 63.8 ttp -109.2 122.01 46.39 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.711 176.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.55 70.99 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.378 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.784 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 37' ' ' GLY . . . . . 0.422 ' HA3' HG21 ' D' ' 31' ' ' ILE . . . -94.69 106.91 3.47 Favored Glycine 0 C--N 1.361 1.933 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -110.39 149.88 17.6 Favored Glycine 0 N--CA 1.464 0.552 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.631 -179.674 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.703 0.287 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.447 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 42.8 t -126.25 130.8 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-O 121.024 0.44 . . . . 0.0 110.542 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 69.2 m-70 -103.57 129.0 50.72 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.244 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.556 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 49.4 t60 -136.44 165.19 26.4 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 178.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.556 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 81.7 mt-30 -157.37 176.45 12.66 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.403 178.699 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -173.05 133.82 0.54 Allowed 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -125.89 122.4 35.93 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -127.97 129.29 69.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-O 120.908 0.385 . . . . 0.0 110.437 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.527 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 1.9 t80 -131.25 123.89 29.39 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.657 ' CZ ' ' CG ' ' J' ' 20' ' ' PHE . 52.4 p90 -144.77 151.39 38.78 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' CE ' ' I' ' 28' ' ' LYS . . . -142.67 138.17 30.43 Favored 'General case' 0 CA--C 1.543 0.7 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.244 -178.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' J' ' 25' ' ' GLY . 36.2 tt0 -89.5 134.09 34.26 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.654 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' J' ' 29' ' ' GLY . 13.8 m-20 -148.97 119.59 7.48 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' J' ' 26' ' ' SER . 6.0 p -120.37 121.61 66.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.37 84.87 0.01 OUTLIER Glycine 0 N--CA 1.484 1.854 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 12.8 p -46.22 165.28 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -179.393 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -109.22 170.57 7.97 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 112.733 -2.03 . . . . 0.0 107.151 171.113 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -38.37 111.08 0.15 Allowed 'General case' 0 CA--C 1.551 1.015 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 175.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 91.93 0.36 Allowed Glycine 0 N--CA 1.483 1.824 0 N-CA-C 117.832 1.893 . . . . 0.0 117.832 171.329 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.19 157.54 43.56 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 173.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.411 ' O ' ' O ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -146.92 137.26 17.44 Favored 'Isoleucine or valine' 0 C--O 1.242 0.698 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.848 -176.77 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.88 126.2 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.428 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.98 122.27 4.92 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.601 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.638 HD22 ' CD1' ' L' ' 19' ' ' PHE . 21.7 tp -120.6 121.07 37.57 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 114.91 -0.645 . . . . 0.0 110.257 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.632 ' CE ' HG22 ' D' ' 31' ' ' ILE . 15.9 ttt -117.14 116.6 27.62 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.62 HG13 HG12 ' L' ' 36' ' ' VAL . 2.3 p -139.91 79.76 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -178.852 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.734 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -52.93 104.17 0.17 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.183 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 37' ' ' GLY . . . -55.35 -165.72 0.03 OUTLIER Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.467 0.395 0 CA-C-O 120.967 0.413 . . . . 0.0 110.382 -179.736 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.466 0.33 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -95.76 151.97 18.9 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.108 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 62.3 m80 -80.7 177.51 8.98 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -129.98 177.57 7.18 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.656 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -147.7 150.32 34.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -127.25 124.61 39.27 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.116 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -124.52 130.48 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 120.903 0.382 . . . . 0.0 110.496 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.638 ' CD1' HD22 ' K' ' 34' ' ' LEU . 17.0 t80 -133.31 120.49 21.1 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -144.68 140.13 28.43 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.56 135.83 38.76 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.957 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.1 mt-10 -85.17 76.1 10.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 119.099 -1.04 . . . . 0.0 112.528 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -118.2 122.07 42.08 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 120.929 0.395 . . . . 0.0 111.127 178.445 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' L' ' 26' ' ' SER . 18.0 t -88.96 123.2 41.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.581 ' N ' ' O ' ' L' ' 24' ' ' VAL . 88.2 p -63.14 -178.33 0.23 Allowed 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 121.403 0.621 . . . . 0.0 109.882 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -81.82 177.51 8.84 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.588 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -38.8 103.99 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.284 177.973 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.417 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 165.73 -100.78 0.18 Allowed Glycine 0 C--O 1.22 -0.763 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.671 -177.876 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.39 170.87 0.2 Allowed 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.417 HG12 ' O ' ' L' ' 29' ' ' GLY . 0.0 OUTLIER -153.97 145.87 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 118.099 -1.44 . . . . 0.0 112.427 -176.553 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 13.6 tt -138.2 137.46 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.78 123.91 4.65 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 mt -117.36 119.78 36.17 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.76 119.82 36.65 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.62 HG12 HG13 ' K' ' 36' ' ' VAL . 3.2 m -129.32 81.66 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.655 -0.248 . . . . 0.0 110.88 -178.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.743 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . -58.56 101.64 0.22 Allowed Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.01 168.99 33.06 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -131.18 159.12 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 120.699 0.285 . . . . 0.0 110.396 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.781 -179.63 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.679 0.276 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.6 t -121.21 134.62 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.418 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -96.72 -176.53 3.62 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.144 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -81.02 171.26 15.19 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.433 ' HG3' ' N ' ' A' ' 16' ' ' LYS . 61.8 tp60 -152.48 171.63 17.79 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.498 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.433 ' N ' ' HG3' ' A' ' 15' ' ' GLN . 99.4 mttt -145.58 119.74 9.49 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.49 0.186 . . . . 0.0 111.104 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -132.03 120.32 22.25 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 120.91 0.386 . . . . 0.0 110.061 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -142.23 139.28 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.662 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -135.87 140.2 43.95 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.386 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -139.75 135.44 33.11 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.072 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.39 124.27 47.29 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.648 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -172.75 99.91 0.14 Allowed 'General case' 0 CA--C 1.527 0.093 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.2 t0 . . . . . 0 N--CA 1.469 0.476 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -179.594 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' CG ' ' A' ' 28' ' ' LYS . 0.1 OUTLIER . . . . . 0 CA--C 1.544 0.739 0 CA-C-O 121.881 0.848 . . . . 0.0 112.19 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.8 101.52 0.8 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 176.665 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.33 153.57 24.53 Favored 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 116.528 -2.069 . . . . 0.0 111.035 -175.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.654 HD13 ' O ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -142.55 111.93 2.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 111.674 -2.512 . . . . 0.0 107.869 -173.449 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.481 ' CG2' HD21 ' B' ' 34' ' ' LEU . 7.8 mt -109.32 107.7 23.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -126.27 102.62 0.65 Allowed Glycine 0 CA--C 1.508 -0.4 0 N-CA-C 107.074 -2.411 . . . . 0.0 107.074 178.285 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 mt -138.36 149.12 45.27 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 122.666 1.222 . . . . 0.0 113.76 -177.135 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.438 ' SD ' ' HA3' ' H' ' 33' ' ' GLY . 97.7 mmm -109.65 107.25 17.24 Favored 'General case' 0 CA--C 1.498 -1.043 0 CA-C-N 112.684 -2.053 . . . . 0.0 106.507 175.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -98.04 71.91 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.76 102.73 2.4 Favored Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.08 146.62 14.01 Favored Glycine 0 CA--C 1.526 0.781 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.463 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.4 p -144.59 144.35 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.778 0.323 . . . . 0.0 110.649 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.102 -0.952 . . . . 0.0 110.537 179.967 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -118.62 140.88 49.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -61.57 134.11 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.572 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.439 HG22 ' NE2' ' B' ' 14' ' ' HIS . 4.6 p -143.13 143.89 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.904 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -124.77 146.67 49.09 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 120.487 0.184 . . . . 0.0 110.661 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.566 ' CE1' ' H ' ' C' ' 14' ' ' HIS . 98.5 m-70 -153.89 162.07 41.51 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.589 0.709 . . . . 0.0 110.842 178.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.5 mm-40 -158.16 174.21 15.54 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.476 177.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -157.85 125.57 5.26 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 52.9 tp -130.99 122.58 27.09 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.993 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.44 133.06 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.899 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -131.06 130.07 42.76 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.391 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -132.23 125.73 31.81 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.288 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.38 125.97 45.96 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -168.37 117.76 0.74 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 178.525 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 50.3 t0 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -179.699 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.482 -1.988 0 N-CA-C 104.897 -3.281 . . . . 0.0 104.897 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 161.73 14.18 Favored 'General case' 0 CA--C 1.483 -1.623 0 C-N-CA 116.293 -2.163 . . . . 0.0 108.608 -175.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.634 HG22 ' CE ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -145.31 127.64 9.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 112.572 -2.104 . . . . 0.0 108.14 -173.74 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.455 HG22 ' O ' ' B' ' 32' ' ' ILE . 0.6 OUTLIER -121.59 115.99 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 CA-C-O 121.044 0.45 . . . . 0.0 109.993 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.57 99.74 0.63 Allowed Glycine 0 N--CA 1.462 0.368 0 N-CA-C 105.622 -2.991 . . . . 0.0 105.622 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.481 HD21 ' CG2' ' A' ' 32' ' ' ILE . 75.1 mt -124.94 137.91 54.25 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.328 1.061 . . . . 0.0 112.903 -175.637 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.549 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.3 ttm -119.38 115.08 23.36 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 114.012 -1.449 . . . . 0.0 107.604 178.192 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.713 ' O ' HG13 ' B' ' 36' ' ' VAL . 3.3 p -126.84 66.88 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -54.65 -102.57 0.01 OUTLIER Glycine 0 C--N 1.357 1.726 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.55 152.55 15.91 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -130.88 135.62 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.833 0.349 . . . . 0.0 110.189 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.206 179.502 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.3 t . . . . . 0 CA--C 1.513 -0.452 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' D' ' 13' ' ' HIS . 51.3 p-80 -161.87 141.74 10.13 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.618 -0.833 . . . . 0.0 112.085 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.566 ' H ' ' CE1' ' B' ' 14' ' ' HIS . 17.1 m80 -121.39 163.21 19.08 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 57.1 tt0 -168.62 169.23 10.37 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 62.8 pttt -158.61 132.91 7.94 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.877 0.846 . . . . 0.0 111.396 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 tt -120.31 125.23 47.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.279 -1.328 . . . . 0.0 108.01 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 20.5 t -127.47 123.3 61.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.187 0.518 . . . . 0.0 112.133 -178.271 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CB ' ' CE1' ' D' ' 19' ' ' PHE . 2.1 m-85 -112.95 110.6 20.77 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.494 ' CE2' ' CD2' ' D' ' 20' ' ' PHE . 7.4 t80 -116.25 118.11 31.87 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.228 -178.428 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.56 129.33 55.28 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 121.038 0.447 . . . . 0.0 111.469 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -158.56 101.85 1.69 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.972 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 . . . . . 0 N--CA 1.465 0.323 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.4 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.652 ' HA2' ' HB1' ' D' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.489 -1.535 0 CA-C-O 124.054 1.919 . . . . 0.0 116.727 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.418 ' C ' HG12 ' C' ' 31' ' ' ILE . . . -100.43 173.36 6.61 Favored 'General case' 0 N--CA 1.42 -1.961 1 N-CA-C 99.988 -4.079 . . . . 0.0 99.988 166.663 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.517 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -141.26 111.4 3.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 117.923 -1.511 . . . . 0.0 111.44 -177.109 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.596 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.0 OUTLIER -108.97 121.87 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.493 178.492 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -128.43 119.47 3.08 Favored Glycine 0 C--O 1.237 0.335 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.732 ' H ' HD23 ' D' ' 34' ' ' LEU . 3.6 tt -142.61 142.88 32.19 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 122.481 1.134 . . . . 0.0 112.935 -177.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 0.1 OUTLIER -113.89 118.26 33.71 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.909 178.907 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.04 73.83 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.49 106.05 3.14 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 111.196 -0.761 . . . . 0.0 111.196 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.51 161.08 20.47 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -130.66 135.75 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.75 0.309 . . . . 0.0 110.641 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.598 179.377 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m . . . . . 0 N--CA 1.465 0.279 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' C' ' 13' ' ' HIS . 18.9 t-80 -153.84 148.93 26.84 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.227 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -99.79 -178.68 3.94 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.337 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 44.0 tt0 -84.55 167.91 15.88 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.716 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.502 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 95.5 mttt -119.86 139.23 52.7 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.6 mt -122.52 121.99 37.84 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.544 0.211 . . . . 0.0 110.462 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -129.84 128.02 64.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.092 0.472 . . . . 0.0 111.586 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.488 ' CE1' ' CB ' ' C' ' 19' ' ' PHE . 7.9 m-85 -122.86 119.8 31.6 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.065 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 13.7 t80 -112.87 118.67 35.55 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.75 111.59 22.87 Favored 'General case' 0 C--O 1.251 1.184 0 CA-C-O 122.552 1.168 . . . . 0.0 111.92 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.468 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 66.4 tt0 -139.31 178.25 7.33 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.468 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 19.8 p30 . . . . . 0 C--N 1.318 -0.788 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.652 ' HB1' ' HA2' ' C' ' 29' ' ' GLY . . . . . . . . 1 N--CA 1.348 -5.569 1 N-CA-C 100.162 -4.014 . . . . 0.0 100.162 . . . . . . . . . 3 2 . 1 . 005 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.963 ' N ' HD12 ' D' ' 31' ' ' ILE . 1.2 mp -76.78 113.87 16.4 Favored 'Isoleucine or valine' 0 C--N 1.255 -3.509 0 CA-C-N 123.247 2.749 . . . . 0.0 113.913 -174.404 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' E' ' 32' ' ' ILE . 2.6 tt -121.32 112.65 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 175.622 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.635 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -121.95 110.89 1.71 Allowed Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.732 HD23 ' H ' ' C' ' 34' ' ' LEU . 21.2 mt -133.5 132.94 41.59 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 119.408 -0.917 . . . . 0.0 112.493 -176.916 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.502 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.9 ttm -109.78 126.64 53.98 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.153 178.187 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.2 t -121.41 79.27 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 CA-C-N 116.671 -0.241 . . . . 0.0 110.989 -178.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -44.34 103.18 0.04 OUTLIER Glycine 0 C--N 1.357 1.72 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 177.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.12 -166.63 29.05 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -122.47 136.21 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 121.021 0.439 . . . . 0.0 110.35 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.2 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.953 -1.023 . . . . 0.0 110.419 179.94 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -114.1 134.71 54.7 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.913 0.387 . . . . 0.0 110.807 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -119.34 148.13 43.53 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.311 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.405 ' CG1' ' CD2' ' E' ' 14' ' ' HIS . 72.8 t -123.79 134.09 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.176 0.512 . . . . 0.0 110.398 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -118.99 101.99 8.43 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.118 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.405 ' CD2' ' CG1' ' E' ' 12' ' ' VAL . 8.2 m-70 -130.02 169.1 15.71 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-O 121.609 0.718 . . . . 0.0 110.264 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -149.22 174.73 12.06 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.632 -1.167 . . . . 0.0 108.314 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -154.34 112.02 3.47 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.493 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.8 tp -121.45 117.1 26.03 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -130.93 127.76 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.459 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 3.1 m-85 -118.53 115.98 25.71 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 36.1 t80 -114.98 122.88 47.61 Favored 'General case' 0 N--CA 1.471 0.609 0 O-C-N 122.385 -0.197 . . . . 0.0 111.171 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.56 132.72 42.87 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.999 -0.28 . . . . 0.0 110.633 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.14 136.64 39.73 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.615 -0.834 . . . . 0.0 112.94 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.436 ' OD2' ' OD1' ' F' ' 23' ' ' ASP . 46.3 t0 -138.1 131.47 30.59 Favored 'General case' 0 C--N 1.368 1.382 0 CA-C-O 121.353 0.597 . . . . 0.0 112.559 178.201 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' E' ' 25' ' ' GLY . 37.8 t -111.44 113.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.606 177.491 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . 32.74 88.77 0.01 OUTLIER Glycine 0 CA--C 1.534 1.258 0 CA-C-O 121.794 0.663 . . . . 0.0 112.297 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.644 ' HG ' ' H ' ' F' ' 27' ' ' ASN . 3.4 p . . . . . 0 N--CA 1.445 -0.696 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.458 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.252 1.219 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.647 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -154.33 122.82 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 117.147 -1.821 . . . . 0.0 110.442 -175.152 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.562 HG23 ' CG2' ' D' ' 32' ' ' ILE . 93.5 mt -121.58 127.13 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.255 -177.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.94 118.99 1.94 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.751 HD13 ' CD2' ' F' ' 19' ' ' PHE . 48.4 mt -123.87 123.64 40.89 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.807 -0.696 . . . . 0.0 109.951 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -120.01 122.88 42.12 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.147 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 t -114.17 86.51 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.722 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.648 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -63.91 97.35 0.22 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.09 168.86 38.74 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.5 t -123.5 135.97 61.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.219 -0.532 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.385 -179.807 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -114.77 135.78 53.8 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.811 0.339 . . . . 0.0 110.779 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -85.6 159.86 19.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 81.1 t -94.78 133.68 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.194 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.658 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 p-80 -139.97 125.95 19.68 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.335 0.588 . . . . 0.0 110.722 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.614 ' CG ' ' H ' ' F' ' 15' ' ' GLN . 82.7 t60 -156.97 177.25 11.72 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.614 ' H ' ' CG ' ' F' ' 14' ' ' HIS . 86.9 mt-30 -144.21 173.87 11.38 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -148.94 112.43 5.02 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.277 0.561 . . . . 0.0 111.605 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -124.68 120.47 31.93 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -127.53 128.67 70.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-O 121.817 0.818 . . . . 0.0 112.704 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.751 ' CD2' HD13 ' E' ' 34' ' ' LEU . 8.7 m-85 -115.09 104.98 12.41 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.963 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.403 ' CE2' ' OE2' ' F' ' 22' ' ' GLU . 18.7 t80 -114.94 120.71 40.83 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 -177.932 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.27 129.54 33.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.776 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' CE2' ' F' ' 20' ' ' PHE . 73.5 mm-40 -92.6 92.4 8.0 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.507 -178.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 25.5 t0 -147.41 107.98 4.13 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 120.791 0.329 . . . . 0.0 111.5 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 m -77.49 -131.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.31 0.576 . . . . 0.0 110.147 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.15 85.44 0.01 OUTLIER Glycine 0 CA--C 1.528 0.879 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.927 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 26' ' ' SER . . . . . 0.481 ' OG ' ' OG ' ' E' ' 26' ' ' SER . 3.7 t -61.82 -178.39 0.15 Allowed 'General case' 0 N--CA 1.44 -0.95 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.644 ' H ' ' HG ' ' E' ' 26' ' ' SER . 59.5 t30 -80.16 172.78 13.32 Favored 'General case' 0 C--N 1.316 -0.866 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.228 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -45.45 110.73 0.27 Allowed 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.153 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.0 92.95 0.32 Allowed Glycine 0 N--CA 1.463 0.48 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.503 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 162.5 19.71 Favored 'General case' 0 CA--C 1.489 -1.396 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 173.283 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.46 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -144.48 116.47 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 115.625 -2.43 . . . . 0.0 112.728 -175.903 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 tt -125.95 135.55 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.029 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.31 128.02 4.37 Favored Glycine 0 CA--C 1.531 1.043 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.022 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -119.66 124.37 46.13 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 0.4 OUTLIER -130.64 129.63 42.92 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.36 0.6 . . . . 0.0 112.363 -178.885 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.586 HG13 ' O ' ' F' ' 36' ' ' VAL . 7.7 p -152.95 81.89 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.702 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.56 101.51 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.249 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -151.19 160.46 28.69 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 12.7 p -137.46 141.62 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 120.837 0.351 . . . . 0.0 110.907 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.629 179.747 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 53.5 m80 . . . . . 0 N--CA 1.472 0.627 0 CA-C-O 121.132 0.492 . . . . 0.0 111.721 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 m-70 -145.48 164.58 31.16 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.416 ' HG3' ' N ' ' G' ' 16' ' ' LYS . 64.5 tp60 -164.9 165.17 20.59 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.242 178.758 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.416 ' N ' ' HG3' ' G' ' 15' ' ' GLN . 98.7 mttt -157.04 129.12 7.27 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -136.43 122.14 19.79 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.535 0.683 . . . . 0.0 110.999 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 18' ' ' VAL . . . . . 0.452 HG22 ' CG1' ' H' ' 18' ' ' VAL . 71.4 t -123.44 129.55 74.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.566 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -128.81 134.89 48.51 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.803 0.335 . . . . 0.0 110.909 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 46.0 p90 -129.93 127.13 39.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.791 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.59 37.21 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 121.418 0.627 . . . . 0.0 111.372 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -174.48 98.72 0.09 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.545 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -152.63 114.7 4.4 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -28.99 122.55 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 113.9 -1.5 . . . . 0.0 113.358 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.44 -85.56 0.06 OUTLIER Glycine 0 CA--C 1.529 0.926 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.556 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.555 ' O ' ' O ' ' G' ' 27' ' ' ASN . 19.0 t -153.39 -173.59 4.63 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 119.462 1.631 . . . . 0.0 111.646 178.5 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.555 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.3 m-20 -20.52 156.57 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 113.58 -1.645 . . . . 0.0 112.903 177.873 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 58.5 tttm -168.44 102.83 0.43 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 118.732 -1.187 . . . . 0.0 113.739 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.445 ' O ' HG13 ' G' ' 31' ' ' ILE . . . -76.81 104.45 1.89 Allowed Glycine 0 CA--C 1.495 -1.205 0 CA-C-O 115.789 -2.673 . . . . 0.0 106.86 172.985 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.469 ' C ' HG13 ' G' ' 31' ' ' ILE . . . -74.75 143.15 44.23 Favored 'General case' 0 C--O 1.252 1.203 1 CA-C-N 124.22 4.01 . . . . 0.0 105.782 -178.126 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.469 HG13 ' C ' ' G' ' 30' ' ' ALA . 69.6 mt -156.75 115.29 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 112.883 -1.962 . . . . 0.0 108.509 -171.826 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' H' ' 32' ' ' ILE . 10.4 tt -141.01 131.01 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.427 0 CA-C-O 122.683 1.23 . . . . 0.0 110.523 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.413 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -148.98 154.27 25.7 Favored Glycine 0 CA--C 1.484 -1.871 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 176.657 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -145.04 140.68 28.28 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.691 -179.183 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 25.6 ttp -103.48 106.81 17.42 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.48 65.28 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.654 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -131.45 102.55 0.51 Allowed Glycine 0 C--N 1.369 2.374 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.13 173.42 41.66 Favored Glycine 0 CA--C 1.523 0.587 0 C-N-CA 120.385 -0.912 . . . . 0.0 111.894 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t . . . . . 0 N--CA 1.464 0.245 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.992 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 33.0 m . . . . . 0 N--CA 1.464 0.231 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -129.48 133.24 47.18 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.979 0.418 . . . . 0.0 111.948 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -140.9 163.81 31.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -157.59 177.5 11.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.355 0.598 . . . . 0.0 111.307 179.249 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 16' ' ' LYS . . . . . 0.617 ' C ' HD22 ' H' ' 17' ' ' LEU . 45.0 tttp -170.64 115.53 0.47 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.81 178.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.744 ' N ' HD22 ' H' ' 17' ' ' LEU . 1.6 mm? -122.8 119.16 29.77 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.452 ' CG1' HG22 ' G' ' 18' ' ' VAL . 3.0 p -135.17 130.65 51.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.713 178.29 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -120.13 123.24 42.85 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.948 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.23 123.0 45.56 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.11 126.18 38.78 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.321 0.581 . . . . 0.0 110.48 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.419 ' O ' ' CG ' ' H' ' 23' ' ' ASP . 84.1 tt0 -138.94 131.12 28.2 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.146 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.2 m-20 -163.05 122.92 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.474 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' I' ' 24' ' ' VAL . 7.1 m . . . . . 0 C--N 1.318 -0.782 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 122.759 1.266 . . . . 0.0 110.266 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.41 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -138.7 124.99 24.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 113.084 -1.871 . . . . 0.0 111.55 -178.745 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.549 ' N ' ' SD ' ' B' ' 35' ' ' MET . 0.7 OUTLIER -114.52 117.29 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.195 178.054 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.438 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -118.38 109.3 1.75 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.756 HD13 ' CZ ' ' J' ' 19' ' ' PHE . 15.5 mt -118.36 122.73 43.55 Favored 'General case' 0 CA--C 1.49 -1.333 0 N-CA-C 112.848 0.684 . . . . 0.0 112.848 -175.393 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.1 ttm -114.56 106.1 13.87 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.63 71.81 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.402 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.23 111.72 3.71 Favored Glycine 0 C--N 1.365 2.148 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -45.37 160.18 0.17 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 40' ' ' VAL . 3.3 p -140.5 141.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.702 0.287 . . . . 0.0 110.314 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 39' ' ' VAL . 84.5 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.955 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.464 0.251 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -147.16 121.85 9.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.823 -179.36 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 87.7 m-70 -134.94 161.82 34.18 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -153.78 166.96 31.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.511 0.672 . . . . 0.0 111.576 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -156.91 127.32 6.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.352 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -128.8 125.73 38.4 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.244 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -128.86 126.82 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 116.691 -0.232 . . . . 0.0 111.189 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.615 ' CD1' ' CE1' ' J' ' 19' ' ' PHE . 31.4 m-85 -115.17 107.37 15.21 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -108.25 122.74 47.58 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 118.274 0.488 . . . . 0.0 110.795 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 138.93 34.44 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.455 ' HG2' ' H ' ' J' ' 22' ' ' GLU . 72.7 mt-10 -152.29 121.87 6.88 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-O 118.972 -0.537 . . . . 0.0 111.752 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.589 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 63.7 m-20 -151.42 103.74 3.02 Favored 'General case' 0 C--N 1.362 1.115 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 176.587 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.548 ' CG2' HG12 ' H' ' 24' ' ' VAL . 59.8 t -31.87 142.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.616 1.567 . . . . 0.0 114.215 170.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -81.75 0.1 Allowed Glycine 0 CA--C 1.533 1.16 0 C-N-CA 119.187 -1.482 . . . . 0.0 114.779 174.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.54 ' O ' ' O ' ' I' ' 27' ' ' ASN . 91.5 p -132.61 -179.21 5.32 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.603 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 46.5 t-20 -40.23 167.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.603 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 70.7 tttt -72.3 110.6 6.84 Favored 'General case' 0 C--N 1.344 0.337 0 C-N-CA 114.268 -2.973 . . . . 0.0 111.316 178.286 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.68 94.69 1.66 Allowed Glycine 0 CA--C 1.491 -1.433 0 CA-C-O 115.406 -2.885 . . . . 0.0 106.399 167.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.14 142.29 49.43 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 123.892 3.846 . . . . 0.0 109.0 177.572 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.512 HG23 HG13 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -139.19 120.32 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 CA-C-N 111.54 -2.573 . . . . 0.0 109.261 -176.529 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.478 HG22 ' O ' ' I' ' 32' ' ' ILE . 0.8 OUTLIER -110.53 114.27 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 121.333 0.587 . . . . 0.0 110.19 178.968 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.52 96.94 1.31 Allowed Glycine 0 CA--C 1.496 -1.099 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.687 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 31.9 tp -111.88 122.93 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -175.784 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.1 ttp -121.57 114.77 21.67 Favored 'General case' 0 CA--C 1.512 -0.514 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.478 HG11 HD22 ' K' ' 17' ' ' LEU . 0.0 OUTLIER -131.89 72.22 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.284 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' I' I ' 37' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -37.77 -98.49 0.01 OUTLIER Glycine 0 C--N 1.358 1.765 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.07 -167.33 39.21 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -123.44 135.6 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.938 0.399 . . . . 0.0 110.405 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.412 HG22 ' H ' ' I' ' 40' ' ' VAL . 28.5 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.448 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m . . . . . 0 N--CA 1.463 0.216 0 CA-C-O 121.35 0.595 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 12.0 t-80 -148.85 132.39 16.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.0 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.542 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 36.1 t60 -156.17 165.69 35.67 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.541 0.686 . . . . 0.0 109.523 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.547 ' HB3' HE22 ' K' ' 15' ' ' GLN . 48.4 tt0 -165.0 168.89 17.01 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 16' ' ' LYS . . . . . 0.474 ' N ' ' CG ' ' J' ' 15' ' ' GLN . 88.5 tttt -153.7 132.63 12.45 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.449 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.43 127.23 47.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.219 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -126.08 127.93 71.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.834 0.35 . . . . 0.0 110.884 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 97.3 m-85 -113.52 109.56 18.84 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -120.03 122.83 41.98 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.733 0.271 . . . . 0.0 111.733 -176.91 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.22 132.21 41.23 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.498 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.583 ' OE2' ' CD1' ' J' ' 20' ' ' PHE . 18.6 mp0 -140.52 145.85 37.37 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 120.19 -0.604 . . . . 0.0 112.36 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 15.3 m-20 -167.33 124.24 1.18 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.5 0.666 . . . . 0.0 111.903 178.106 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.804 HG13 ' H ' ' J' ' 25' ' ' GLY . 7.1 p -62.93 -116.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.762 -1.108 . . . . 0.0 110.834 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.804 ' H ' HG13 ' J' ' 24' ' ' VAL . . . 60.72 -91.79 0.06 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 114.976 -1.011 . . . . 0.0 114.42 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.83 ' O ' ' O ' ' J' ' 27' ' ' ASN . 35.1 p -171.63 172.52 4.97 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 118.173 0.986 . . . . 0.0 110.834 -176.921 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.83 ' O ' ' O ' ' J' ' 26' ' ' SER . 4.8 m120 15.58 -178.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 O-C-N 125.627 1.83 . . . . 0.0 114.738 -179.486 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.544 ' CA ' ' OD1' ' I' ' 27' ' ' ASN 0.255 80.4 tttt -148.49 109.92 4.41 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 118.359 -1.336 . . . . 0.0 113.906 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -73.73 94.13 0.75 Allowed Glycine 0 CA--C 1.489 -1.551 0 CA-C-O 116.172 -2.46 . . . . 0.0 107.683 169.782 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.48 146.52 50.79 Favored 'General case' 0 CA--C 1.481 -1.709 0 CA-C-N 123.116 3.458 . . . . 0.0 110.587 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.53 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.1 OUTLIER -149.71 109.36 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 CA-C-N 110.906 -2.861 . . . . 0.0 105.629 -178.141 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.537 HG22 HG23 ' K' ' 32' ' ' ILE . 1.1 tt -109.7 113.38 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 121.773 0.797 . . . . 0.0 108.9 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 33' ' ' GLY . . . . . 0.461 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -102.49 107.73 3.18 Favored Glycine 0 CA--C 1.507 -0.442 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.794 HD22 ' CE1' ' L' ' 19' ' ' PHE . 6.4 mt -110.62 111.36 22.53 Favored 'General case' 0 CA--C 1.507 -0.677 0 CA-C-O 121.247 0.546 . . . . 0.0 110.748 -177.385 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.596 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 18.9 ttt -110.28 110.34 21.12 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.105 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 5.9 m -133.83 74.88 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.229 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.27 102.21 2.85 Favored Glycine 0 C--N 1.35 1.357 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -152.86 157.1 27.1 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.464 0.257 0 CA-C-O 120.795 0.331 . . . . 0.0 110.362 -179.661 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.657 0.265 . . . . 0.0 110.773 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.42 133.8 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.776 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 -128.16 121.58 29.87 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.51 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' NE2' ' L' ' 14' ' ' HIS . 96.6 m-70 -122.59 169.38 11.08 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.37 0.605 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.547 HE22 ' HB3' ' J' ' 15' ' ' GLN . 11.1 tp-100 -155.36 169.98 22.97 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.164 179.272 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG3' ' K' ' 15' ' ' GLN . 88.4 tttt -172.61 125.32 0.48 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.553 0.216 . . . . 0.0 110.503 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.478 HD22 HG11 ' I' ' 36' ' ' VAL . 5.1 mp -128.69 129.34 45.66 Favored 'General case' 0 N--CA 1.466 0.374 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.501 HG11 ' CE2' ' K' ' 20' ' ' PHE . 40.6 t -132.12 133.55 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.067 0.46 . . . . 0.0 111.504 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.687 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 37.7 m-85 -114.58 111.73 21.81 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.601 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.501 ' CE2' HG11 ' K' ' 18' ' ' VAL . 54.8 m-85 -109.13 114.43 28.15 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.353 -0.217 . . . . 0.0 111.252 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.32 121.27 38.27 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.958 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -121.68 130.87 53.77 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.145 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 16.4 p-10 179.25 102.25 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 114.936 -1.029 . . . . 0.0 109.415 176.93 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.607 HG22 ' N ' ' K' ' 25' ' ' GLY . 12.9 p -58.82 166.29 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.133 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.607 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 88.23 81.6 1.26 Allowed Glycine 0 CA--C 1.53 0.969 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.463 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 34.0 p -47.9 166.78 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.513 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 60.2 t30 -157.2 177.38 11.54 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.033 -0.667 . . . . 0.0 112.68 177.576 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.513 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 67.3 mmtt 2.31 -105.32 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.358 1.063 . . . . 0.0 113.265 178.626 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -140.92 97.66 0.22 Allowed Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.94 170.32 4.44 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.648 HG21 ' CA ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -152.18 126.37 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 117.998 -1.481 . . . . 0.0 111.442 -178.687 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.537 HG23 HG22 ' J' ' 32' ' ' ILE . 96.6 mt -126.14 132.64 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.603 -178.416 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.76 116.34 2.97 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 12.6 mt -107.22 111.25 23.56 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.456 ' C ' ' SD ' ' K' ' 35' ' ' MET . 0.0 OUTLIER -113.03 111.99 23.12 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 -178.943 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.09 81.79 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.647 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -79.16 100.88 1.8 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 178.164 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.82 161.43 34.97 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.644 -0.788 . . . . 0.0 111.455 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.464 0.231 0 CA-C-O 120.763 0.316 . . . . 0.0 110.558 179.918 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 7.9 m . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 121.255 0.55 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 69.5 t60 -140.14 125.14 18.5 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.415 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' ND1' ' K' ' 14' ' ' HIS . 23.6 p80 -157.38 170.97 21.24 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -148.75 174.2 12.44 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.48 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -152.86 139.5 18.81 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.457 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -134.34 122.38 22.54 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -126.12 132.82 70.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-O 121.079 0.466 . . . . 0.0 111.755 -178.523 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.794 ' CE1' HD22 ' J' ' 34' ' ' LEU . 88.1 m-85 -112.62 112.01 23.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.565 178.691 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -120.73 119.45 32.82 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.31 0.576 . . . . 0.0 110.715 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.44 128.62 47.27 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' L' ' 22' ' ' GLU . 11.3 tm-20 -78.59 96.51 5.5 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.188 -178.21 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -152.55 113.57 4.19 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.409 ' O ' HG23 ' L' ' 24' ' ' VAL . 31.9 m -98.62 130.51 47.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.281 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.0 81.74 0.03 OUTLIER Glycine 0 C--N 1.336 0.581 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.748 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -62.16 -178.15 0.16 Allowed 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.773 0.797 . . . . 0.0 110.459 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 7.9 t-20 -80.63 178.46 8.33 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.393 -1.276 . . . . 0.0 112.449 -178.213 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 65.0 mttp -41.44 111.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.088 -0.96 . . . . 0.0 112.059 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.71 -93.71 1.76 Allowed Glycine 0 N--CA 1.463 0.474 0 CA-C-N 113.951 -1.477 . . . . 0.0 112.982 179.513 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 78.26 161.48 0.21 Allowed 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 100.636 -3.838 . . . . 0.0 100.636 -174.477 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.48 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -154.09 127.54 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 122.665 2.484 . . . . 0.0 111.961 -179.11 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 48.5 pt -122.64 141.54 42.63 Favored 'Isoleucine or valine' 0 C--N 1.339 0.134 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.063 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.88 121.21 3.33 Favored Glycine 0 N--CA 1.465 0.621 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.4 tp -124.42 123.02 39.26 Favored 'General case' 0 N--CA 1.465 0.278 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.578 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.1 ppp? -131.67 136.05 47.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.475 0.655 . . . . 0.0 110.651 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 37' ' ' GLY . 5.5 t -138.18 80.74 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.691 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.46 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . 26.47 -104.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.09 0 O-C-N 123.419 0.45 . . . . 0.0 112.65 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 134.03 147.48 5.65 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -140.98 164.23 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.754 0.312 . . . . 0.0 110.734 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 28.4 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.379 179.891 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 . . . . . 0 N--CA 1.465 0.288 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.54 148.49 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 116.278 -0.419 . . . . 0.0 109.898 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -77.82 162.96 26.5 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.036 -178.514 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.554 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.4 m-70 -104.12 172.98 6.5 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.167 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.6 tt0 -151.11 173.03 14.85 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.006 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LYS . . . . . 0.404 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 88.0 tttt -155.25 132.39 10.9 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.666 0.27 . . . . 0.0 110.492 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 52.1 tp -131.96 126.66 34.58 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 121.194 0.521 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.2 m -128.17 132.83 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.767 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -135.14 131.23 36.57 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.973 0.416 . . . . 0.0 111.193 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -119.63 126.07 50.28 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.8 132.51 45.3 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.968 0.889 . . . . 0.0 112.647 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -140.77 96.44 3.02 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.592 -1.185 . . . . 0.0 109.217 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.433 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 2.1 m-20 . . . . . 0 C--N 1.325 -0.5 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.54 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 45.3 tttp . . . . . 0 CA--C 1.545 0.774 0 CA-C-O 121.381 0.61 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 59.63 92.09 0.01 OUTLIER Glycine 0 C--N 1.346 1.114 0 CA-C-O 118.089 -1.395 . . . . 0.0 114.766 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.06 142.2 40.3 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 116.645 -2.022 . . . . 0.0 109.227 174.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.9 OUTLIER -155.67 128.55 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 CA-C-N 111.603 -2.544 . . . . 0.0 109.499 -173.181 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' H' ' 35' ' ' MET . 24.4 mt -126.62 107.92 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.032 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.01 102.32 1.36 Allowed Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.021 -2.832 . . . . 0.0 106.021 177.379 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 75.7 mt -133.95 150.21 51.28 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 122.529 1.157 . . . . 0.0 112.802 -177.135 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 15.7 ttm -128.87 118.22 22.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 CA-C-N 113.048 -1.887 . . . . 0.0 107.14 177.962 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -109.01 71.03 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.066 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.158 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -37.54 -100.36 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.28 -171.76 40.68 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -122.3 135.97 60.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.01 0.433 . . . . 0.0 110.6 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.773 -179.796 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.68 144.13 42.7 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 11' ' ' GLU . . . . . 0.488 ' O ' ' NE2' ' C' ' 13' ' ' HIS . 96.3 mt-10 -61.96 129.9 43.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.98 0.419 . . . . 0.0 110.969 -179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.7 132.56 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.991 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -157.08 170.12 23.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.16 0.505 . . . . 0.0 111.382 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -134.14 169.56 16.98 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -155.01 165.0 38.1 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.128 179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -156.28 113.5 3.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.163 179.377 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.7 tp -118.79 121.03 39.09 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -125.56 124.3 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 110.575 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -121.79 119.02 30.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.06 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -120.19 120.0 34.87 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 126.92 35.49 Favored 'General case' 0 N--CA 1.474 0.753 0 CA-C-O 121.368 0.604 . . . . 0.0 111.684 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -153.26 145.1 23.55 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.561 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 23' ' ' ASP . 18.7 t70 . . . . . 0 N--CA 1.464 0.266 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.2 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.733 ' HA2' ' HB2' ' C' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.479 1.518 0 N-CA-C 114.064 0.386 . . . . 0.0 114.064 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.936 ' O ' ' HB3' ' C' ' 30' ' ' ALA . . . -140.03 151.39 45.4 Favored 'General case' 0 N--CA 1.425 -1.699 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 172.364 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.661 HG23 ' CG2' ' C' ' 31' ' ' ILE . 1.6 mt -137.63 105.09 3.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 118.672 -1.211 . . . . 0.0 108.262 -174.256 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.588 HD11 HD12 ' B' ' 34' ' ' LEU . 12.4 tt -126.18 123.59 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 118.984 -1.086 . . . . 0.0 112.211 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.601 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -114.9 104.94 1.42 Allowed Glycine 0 CA--C 1.503 -0.684 0 N-CA-C 106.975 -2.45 . . . . 0.0 106.975 177.023 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.624 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.0 OUTLIER -122.62 125.94 46.67 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 122.605 1.193 . . . . 0.0 110.639 -179.027 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.536 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 1.3 ttm -112.31 119.77 39.45 Favored 'General case' 0 N--CA 1.438 -1.068 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.538 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -123.31 70.95 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.875 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.635 -179.874 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -45.14 -99.06 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 178.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 138.02 165.47 10.35 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -135.41 161.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 40' ' ' VAL . . . . . 0.404 ' H ' HG13 ' B' ' 40' ' ' VAL . 7.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.644 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 N--CA 1.468 0.448 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.488 ' NE2' ' O ' ' B' ' 11' ' ' GLU . 77.7 m80 -78.26 128.27 33.48 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.294 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.578 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 60.0 t-80 -151.64 163.88 38.12 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.578 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 80.9 mt-30 -157.43 175.58 13.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.284 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.46 115.7 0.49 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.069 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -120.03 125.58 48.7 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.889 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -131.65 124.68 54.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD11 ' B' ' 34' ' ' LEU . 2.9 m-85 -115.43 112.85 22.92 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 175.608 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -118.6 130.4 55.86 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 -178.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.504 ' O ' ' HB1' ' D' ' 21' ' ' ALA . . . -162.13 160.48 27.31 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 115.786 1.772 . . . . 0.0 115.786 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -118.1 118.74 32.72 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 113.695 -1.593 . . . . 0.0 111.059 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 47.9 t0 . . . . . 0 CA--C 1.531 0.227 0 CA-C-O 121.801 0.81 . . . . 0.0 112.086 177.886 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' C' C ' 29' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.453 -3.819 0 CA-C-O 125.317 2.621 . . . . 0.0 116.097 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.936 ' HB3' ' O ' ' B' ' 30' ' ' ALA . . . -88.37 -130.87 0.07 Allowed 'General case' 2 N--CA 1.357 -5.093 2 N-CA-C 95.377 -5.786 . . . . 0.0 95.377 171.373 . . . . . . . . 4 3 . 1 . 006 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.684 HD11 ' CE ' ' J' ' 35' ' ' MET . 7.8 tp -87.91 135.61 25.08 Favored 'Isoleucine or valine' 1 C--N 1.232 -4.504 0 N-CA-C 114.345 1.239 . . . . 0.0 114.345 -179.109 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.488 ' O ' ' CE ' ' J' ' 35' ' ' MET . 8.1 tt -120.77 112.98 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 175.609 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -122.36 122.84 5.21 Favored Glycine 0 CA--C 1.504 -0.636 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.447 -178.546 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -143.78 146.25 32.97 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 118.694 -1.202 . . . . 0.0 112.041 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.59 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 3.4 ttm -121.11 121.95 38.98 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 113.286 -1.779 . . . . 0.0 108.704 177.665 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.93 76.9 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.106 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -83.12 104.09 2.55 Favored Glycine 0 C--N 1.361 1.957 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.08 170.68 51.39 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.9 m -140.61 162.77 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 120.815 0.341 . . . . 0.0 110.756 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.428 179.676 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 121.275 0.559 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -132.87 138.71 47.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 29.3 t-80 -144.9 166.11 26.23 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 121.408 0.623 . . . . 0.0 110.083 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.552 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 52.7 tt0 -160.23 171.26 19.52 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.39 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 16' ' ' LYS . . . . . 0.419 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 86.8 tttt -169.96 118.25 0.59 Allowed 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.452 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 tt -128.63 127.03 41.42 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -142.42 138.1 29.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.8 0.809 . . . . 0.0 113.095 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.583 ' CZ ' ' CD2' ' C' ' 34' ' ' LEU . 38.0 m-85 -113.36 117.94 33.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.036 177.403 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.566 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 22.6 t80 -127.59 124.55 38.38 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.745 0.307 . . . . 0.0 110.654 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' C' ' 21' ' ' ALA . . . -158.14 164.72 36.32 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.724 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -137.59 157.01 47.42 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.333 -1.303 . . . . 0.0 112.381 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 t0 . . . . . 0 C--N 1.331 -0.211 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.64 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.385 -3.718 1 N-CA-C 93.74 -6.393 . . . . 0.0 93.74 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.901 HD12 ' N ' ' D' ' 31' ' ' ILE . 3.1 mp -103.42 122.51 56.08 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.134 0 C-N-CA 116.517 -2.073 . . . . 0.0 113.116 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.429 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -113.36 118.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.897 179.107 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.46 ' N ' ' CE ' ' J' ' 35' ' ' MET . . . -131.9 101.75 0.48 Allowed Glycine 0 N--CA 1.472 1.075 0 N-CA-C 106.792 -2.523 . . . . 0.0 106.792 177.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.442 HD23 ' H ' ' C' ' 34' ' ' LEU . 10.0 mt -130.64 125.63 34.52 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-O 122.187 0.994 . . . . 0.0 111.793 -175.979 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -105.54 117.6 34.42 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 113.983 -1.462 . . . . 0.0 107.115 177.486 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -114.4 80.91 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 120.874 0.368 . . . . 0.0 110.49 -177.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.73 103.27 0.54 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.72 -163.0 6.88 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.352 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.41 133.94 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 121.09 0.472 . . . . 0.0 110.673 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.061 -0.971 . . . . 0.0 110.818 -179.861 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.7 144.57 43.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.96 0.41 . . . . 0.0 110.872 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -63.38 149.59 45.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.783 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.51 142.86 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 69.7 t60 -143.18 139.9 30.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.92 0.391 . . . . 0.0 110.696 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.528 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -135.92 170.12 16.5 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.528 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 11.0 tt0 -158.19 171.13 20.77 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.991 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.475 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -150.39 113.14 4.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.33 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -118.3 115.87 25.6 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -131.56 130.14 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 7.2 m-85 -113.05 111.2 21.74 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.488 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.566 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 25.5 t80 -122.49 121.33 36.32 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 118.223 0.465 . . . . 0.0 111.292 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.34 136.88 33.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.951 0.405 . . . . 0.0 111.469 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -124.68 120.81 32.91 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.448 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 44.7 p-10 -163.75 101.77 0.9 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.602 -0.839 . . . . 0.0 113.251 177.828 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.588 HG12 ' N ' ' E' ' 25' ' ' GLY . 21.2 t -59.49 166.74 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.164 -0.926 . . . . 0.0 112.353 177.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.588 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 87.9 81.62 1.24 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 115.336 0.894 . . . . 0.0 115.336 174.393 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.443 -0.782 0 CA-C-O 120.565 0.221 . . . . 0.0 110.795 175.969 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.556 ' HB1' ' O ' ' D' ' 30' ' ' ALA . . . . . . . . 0 C--O 1.238 0.473 0 CA-C-O 121.028 0.442 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.601 ' CG2' HD13 ' F' ' 31' ' ' ILE . 0.0 OUTLIER -144.37 130.96 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.986 -179.601 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.655 ' CG1' HD11 ' E' ' 34' ' ' LEU . 0.1 OUTLIER -130.61 122.37 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 121.084 0.469 . . . . 0.0 110.959 -178.255 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.81 124.39 5.37 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.681 HD12 ' N ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -126.94 128.27 46.16 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 120.891 0.377 . . . . 0.0 111.006 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.8 tpp -120.19 120.2 35.46 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.918 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' E' ' 37' ' ' GLY . 5.8 t -134.06 83.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 121.36 -0.136 . . . . 0.0 111.131 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -19.58 -94.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.162 0 O-C-N 123.461 0.475 . . . . 0.0 112.753 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.67 -167.58 35.26 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 p -138.76 145.67 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 120.802 0.334 . . . . 0.0 110.393 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.043 -0.979 . . . . 0.0 110.515 179.78 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -85.44 134.6 34.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.874 0.369 . . . . 0.0 110.696 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -138.39 131.01 29.23 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.202 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m -141.65 173.29 8.58 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 121.237 0.541 . . . . 0.0 110.965 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -80.45 144.03 32.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.425 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.544 ' O ' ' NE2' ' F' ' 15' ' ' GLN . 34.6 m80 -134.03 172.21 13.14 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.544 ' NE2' ' O ' ' F' ' 14' ' ' HIS . 99.3 mm-40 -144.54 178.3 8.05 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.41 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -169.23 116.19 0.61 Allowed 'General case' 0 CA--C 1.531 0.215 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.404 HD12 ' N ' ' F' ' 17' ' ' LEU . 2.0 mp -126.82 126.98 44.29 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.081 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.73 129.89 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 121.572 0.701 . . . . 0.0 112.247 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' E' ' 34' ' ' LEU . 4.0 m-85 -114.75 113.39 24.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.132 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.486 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 35.4 t80 -127.06 120.98 30.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.502 0.668 . . . . 0.0 111.387 -179.08 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.1 135.66 46.6 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.094 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tp10 -78.02 120.79 23.36 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.231 -0.588 . . . . 0.0 110.215 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' F' ' 24' ' ' VAL . 19.7 t70 -169.0 121.71 0.79 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.655 -0.418 . . . . 0.0 112.045 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' F' ' 23' ' ' ASP . 4.5 m -63.06 -121.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.519 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -64.39 -86.05 0.06 OUTLIER Glycine 0 CA--C 1.519 0.304 0 N-CA-C 105.736 -2.946 . . . . 0.0 105.736 178.039 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 26' ' ' SER . . . . . 0.548 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 2.0 t 157.53 172.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 122.316 1.055 . . . . 0.0 112.087 174.176 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.548 ' N ' ' OG ' ' F' ' 26' ' ' SER . 43.3 m-20 -44.69 174.76 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 112.947 -1.933 . . . . 0.0 111.298 176.633 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -70.28 111.38 5.84 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.25 -92.94 0.87 Allowed Glycine 0 C--N 1.313 -0.725 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' F' ' 27' ' ' ASN . . . 82.17 163.72 0.14 Allowed 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 100.451 -3.907 . . . . 0.0 100.451 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.828 HD12 ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -148.11 128.16 4.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 121.691 2.041 . . . . 0.0 110.653 179.297 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tt -123.95 136.82 59.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.602 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.77 117.93 2.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.2 tt -124.15 124.18 41.92 Favored 'General case' 0 N--CA 1.47 0.567 0 O-C-N 122.689 -0.301 . . . . 0.0 110.238 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 42.2 mmm -123.27 130.38 52.66 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 120.776 0.322 . . . . 0.0 110.745 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.16 81.02 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 CA-C-N 116.101 -0.499 . . . . 0.0 112.323 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -43.25 100.83 0.02 OUTLIER Glycine 0 C--N 1.341 0.839 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.854 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -128.77 163.75 22.1 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.21 135.19 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.838 0.352 . . . . 0.0 110.121 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.486 -179.994 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 39.7 p-80 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.789 0.328 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.485 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 33.9 p80 -77.46 171.33 15.07 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' H ' ' G' ' 16' ' ' LYS . 48.5 tt0 -155.92 172.37 18.49 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.395 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 16' ' ' LYS . . . . . 0.403 ' H ' ' HG2' ' G' ' 15' ' ' GLN . 71.7 mmtt -136.56 132.56 35.34 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.583 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -135.74 111.07 9.06 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.68 133.1 65.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -139.64 148.74 42.86 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -124.71 132.92 53.35 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 139.52 45.56 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.598 0.713 . . . . 0.0 112.104 -178.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -115.96 167.09 11.27 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.568 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.445 ' O ' ' HB ' ' G' ' 24' ' ' VAL . 44.1 t0 -46.3 142.96 2.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.454 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' G' ' 23' ' ' ASP . 20.0 t 93.97 111.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 O-C-N 124.565 1.166 . . . . 0.0 111.48 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 49.35 91.64 0.01 OUTLIER Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.54 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 1.1 p 159.04 -179.57 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 122.187 0.994 . . . . 0.0 110.603 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' G' ' 28' ' ' LYS . 90.5 m-20 -58.93 172.05 0.6 Allowed 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 113.408 -1.724 . . . . 0.0 112.323 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.533 ' NZ ' ' OD2' ' I' ' 23' ' ' ASP . 84.5 tttt 52.75 105.53 0.01 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.13 -179.703 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.727 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . 107.51 103.71 2.89 Favored Glycine 1 CA--C 1.427 -5.413 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.102 -174.478 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.727 ' HB3' ' O ' ' G' ' 29' ' ' GLY . . . 87.66 -148.34 0.01 OUTLIER 'General case' 0 N--CA 1.384 -3.73 0 N-CA-C 103.138 -2.912 . . . . 0.0 103.138 -169.603 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.884 ' H ' HD12 ' G' ' 31' ' ' ILE 0.287 0.0 OUTLIER -109.54 114.79 47.93 Favored 'Isoleucine or valine' 0 C--N 1.252 -3.638 0 N-CA-C 118.043 2.608 . . . . 0.0 118.043 -174.012 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.543 HG23 ' O ' ' G' ' 32' ' ' ILE . 0.9 OUTLIER -112.36 116.37 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 173.421 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.51 121.3 4.33 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 49.0 mt -126.52 134.67 50.83 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 122.889 1.328 . . . . 0.0 111.302 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 20.1 ttt -98.02 110.91 23.4 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 112.494 -2.139 . . . . 0.0 107.081 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.44 64.77 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.517 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.919 -178.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.11 -106.45 0.41 Allowed Glycine 0 C--N 1.367 2.296 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -161.85 165.11 35.62 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 66.7 t . . . . . 0 N--CA 1.466 0.338 0 CA-C-O 120.833 0.349 . . . . 0.0 110.195 -179.893 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 24.4 m . . . . . 0 N--CA 1.468 0.457 0 CA-C-O 120.945 0.402 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -128.71 -175.42 3.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.208 179.627 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -80.61 168.52 18.79 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 122.153 0.978 . . . . 0.0 111.532 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -153.11 177.81 10.41 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.063 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -145.44 143.44 30.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.311 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -135.24 117.04 15.09 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.423 HG11 ' CE2' ' H' ' 20' ' ' PHE . 70.2 t -126.87 134.03 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-O 120.872 0.368 . . . . 0.0 110.505 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.415 ' CZ ' ' HB2' ' H' ' 21' ' ' ALA . 45.7 t80 -124.74 122.71 38.24 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.392 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.423 ' CE2' HG11 ' H' ' 18' ' ' VAL . 61.0 m-85 -115.2 125.66 53.65 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.155 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 21' ' ' ALA . . . . . 0.415 ' HB2' ' CZ ' ' H' ' 19' ' ' PHE . . . -116.67 120.96 40.27 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-N 118.222 0.464 . . . . 0.0 110.911 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' H' ' 23' ' ' ASP . 81.6 tt0 -123.27 154.98 38.09 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.756 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.612 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 54.6 t0 49.38 114.22 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 CA-C-O 121.05 0.452 . . . . 0.0 110.715 -178.57 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.415 HG23 ' OD2' ' I' ' 23' ' ' ASP . 42.8 t . . . . . 0 C--N 1.314 -0.944 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.601 ' C ' HD12 ' H' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.397 -3.086 1 N-CA-C 95.715 -5.661 . . . . 0.0 95.715 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.965 HD12 ' N ' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -112.29 119.32 59.93 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 116.236 -2.186 . . . . 0.0 112.291 -178.403 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.692 HG23 HG13 ' I' ' 32' ' ' ILE . 5.5 tt -117.49 120.03 63.56 Favored 'Isoleucine or valine' 0 C--N 1.361 1.106 0 CA-C-N 114.34 -1.3 . . . . 0.0 110.445 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.536 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -114.77 116.9 3.89 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.518 HD22 ' O ' ' H' ' 33' ' ' GLY . 0.9 OUTLIER -124.18 125.84 45.13 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.681 0.753 . . . . 0.0 111.825 -179.367 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 7.3 ttt -105.92 110.03 22.18 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 114.37 -1.286 . . . . 0.0 108.577 178.049 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.43 HG11 ' CD2' ' J' ' 17' ' ' LEU . 0.0 OUTLIER -131.53 71.26 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.12 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.53 -97.13 0.03 OUTLIER Glycine 0 C--N 1.359 1.822 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.21 -166.26 38.68 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -124.39 139.9 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.869 0.366 . . . . 0.0 111.09 -178.694 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.597 179.831 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 CA--C 1.521 -0.163 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.7 p80 -175.69 113.86 0.13 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.148 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 26.8 m-70 -82.19 165.9 20.09 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.001 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -148.34 173.01 13.5 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.279 0.562 . . . . 0.0 110.985 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -154.96 127.56 7.98 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.629 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.567 HD23 ' N ' ' I' ' 18' ' ' VAL . 0.9 OUTLIER -129.2 119.56 24.27 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.619 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.567 ' N ' HD23 ' I' ' 17' ' ' LEU . 48.1 t -125.94 128.94 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.934 0.397 . . . . 0.0 111.754 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -113.18 103.8 11.71 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -114.84 130.05 56.81 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 111.751 0.278 . . . . 0.0 111.751 -177.564 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.0 135.82 29.68 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 121.277 0.561 . . . . 0.0 111.402 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 tm-20 -148.07 118.88 7.57 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.587 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.612 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 16.7 m-20 -158.64 110.5 2.2 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.828 0.823 . . . . 0.0 112.224 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 50.5 t -48.16 133.97 5.36 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.497 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 99.3 86.03 1.87 Allowed Glycine 0 CA--C 1.54 1.636 0 N-CA-C 120.316 2.886 . . . . 0.0 120.316 171.948 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.4 p 153.01 169.87 0.01 OUTLIER 'General case' 0 C--N 1.347 0.498 0 CA-C-O 122.635 1.207 . . . . 0.0 112.346 169.717 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' I' ' 28' ' ' LYS . 1.4 m120 -59.03 177.63 0.15 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.343 -1.299 . . . . 0.0 111.363 177.679 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.505 ' O ' ' O ' ' I' ' 27' ' ' ASN . 63.3 tttt -43.64 -100.86 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.223 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.027 172.731 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.761 ' O ' ' O ' ' I' ' 30' ' ' ALA . . . -170.59 106.33 0.24 Allowed Glycine 1 CA--C 1.42 -5.858 0 C-N-CA 119.061 -1.542 . . . . 0.0 116.527 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.859 ' C ' HD12 ' I' ' 31' ' ' ILE 0.29 . . -0.46 -133.45 0.0 OUTLIER 'General case' 0 C--N 1.366 1.286 0 O-C-N 127.066 2.274 . . . . 0.0 108.333 170.579 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.859 HD12 ' C ' ' I' ' 30' ' ' ALA . 3.9 mp -122.52 132.82 70.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 117.269 2.322 . . . . 0.0 117.269 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.692 HG13 HG23 ' H' ' 32' ' ' ILE . 17.9 tt -116.27 120.8 65.99 Favored 'Isoleucine or valine' 0 C--N 1.371 1.531 0 CA-C-N 114.44 -1.255 . . . . 0.0 110.58 177.698 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.475 ' CA ' ' SD ' ' C' ' 35' ' ' MET . . . -102.77 112.19 4.21 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 107.157 -2.377 . . . . 0.0 107.157 177.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.859 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 32.8 tp -113.26 121.18 43.65 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-N 115.36 -0.42 . . . . 0.0 111.419 -177.339 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.513 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 19.1 ttt -118.69 112.56 19.94 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 176.019 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.594 HG11 HD13 ' K' ' 17' ' ' LEU . 0.1 OUTLIER -126.31 71.45 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.208 0 CA-C-N 117.729 0.24 . . . . 0.0 111.273 -178.126 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -50.11 -97.97 0.01 OUTLIER Glycine 0 C--N 1.353 1.5 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.405 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.14 -162.65 28.63 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.05 138.67 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 120.894 0.378 . . . . 0.0 110.703 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.481 179.679 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' J' J ' 12' ' ' VAL . . . . . 0.568 HG12 ' N ' ' J' ' 13' ' ' HIS . 60.0 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.568 ' N ' HG12 ' J' ' 12' ' ' VAL . 2.9 p80 -66.58 134.11 51.69 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.196 0.522 . . . . 0.0 111.841 -178.292 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.436 ' NE2' ' O ' ' K' ' 12' ' ' VAL . 52.7 m170 -112.83 172.17 7.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -141.55 176.44 8.88 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.333 0.587 . . . . 0.0 111.479 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -174.01 124.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.105 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG11 ' H' ' 36' ' ' VAL . 4.0 mp -133.85 132.35 40.28 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-O 121.303 0.573 . . . . 0.0 110.973 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.68 131.12 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.015 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.649 ' CD1' ' CZ ' ' K' ' 19' ' ' PHE . 20.1 m-85 -114.2 111.17 21.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.097 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -121.59 120.49 34.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.909 0.322 . . . . 0.0 110.155 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.51 132.64 29.67 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.136 0.494 . . . . 0.0 110.986 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.478 ' C ' ' OD1' ' J' ' 23' ' ' ASP . 73.6 mt-10 -144.78 127.45 16.18 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 119.84 -0.744 . . . . 0.0 112.472 -179.277 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' I' ' 23' ' ' ASP . 3.9 m-20 -159.68 110.98 2.0 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 118.938 -1.105 . . . . 0.0 113.353 176.741 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.0 t -37.8 128.65 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.464 172.32 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.453 ' HA3' ' O ' ' I' ' 26' ' ' SER . . . 168.85 -83.64 0.09 OUTLIER Glycine 0 N--CA 1.467 0.709 0 C-N-CA 117.108 -2.472 . . . . 0.0 116.087 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.582 ' O ' ' O ' ' J' ' 27' ' ' ASN . 5.0 p -170.39 -178.55 2.75 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 118.825 -1.15 . . . . 0.0 113.081 -175.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.584 ' CG ' ' H ' ' J' ' 28' ' ' LYS . 63.6 t30 27.13 177.37 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 CA-C-N 112.113 -2.312 . . . . 0.0 115.565 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.584 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 96.7 mttt -119.71 -106.47 0.38 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 113.307 -1.769 . . . . 0.0 110.947 -176.775 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.93 ' C ' ' HB1' ' K' ' 30' ' ' ALA . . . -66.13 96.6 0.28 Allowed Glycine 0 CA--C 1.48 -2.141 0 CA-C-O 123.654 1.697 . . . . 0.0 112.643 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.628 ' O ' ' C ' ' J' ' 29' ' ' GLY . . . -80.38 -145.12 0.05 OUTLIER 'General case' 0 C--N 1.293 -1.885 1 N-CA-C 93.921 -6.326 . . . . 0.0 93.921 170.407 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.567 ' H ' HG13 ' I' ' 31' ' ' ILE . 4.8 mm -100.89 115.34 42.32 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 1 CA-C-N 127.987 4.903 . . . . 0.0 111.035 -179.249 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.628 HG22 HG23 ' K' ' 32' ' ' ILE . 0.6 OUTLIER -112.76 110.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.366 1.307 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.684 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.16 106.27 2.64 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.817 HD13 ' CE1' ' L' ' 19' ' ' PHE . 4.4 mt -104.78 106.87 17.55 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.684 ' CE ' HD11 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -106.09 113.2 26.59 Favored 'General case' 0 N--CA 1.444 -0.754 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 178.819 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.451 ' O ' HG23 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.39 79.6 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.085 -177.661 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.55 103.48 1.63 Allowed Glycine 0 C--N 1.349 1.258 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 177.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.34 145.08 16.7 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 63.0 t . . . . . 0 N--CA 1.466 0.364 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 -179.873 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 . . . . . 0 C--O 1.231 0.089 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.436 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 8.8 m -150.58 145.75 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-O 121.408 0.623 . . . . 0.0 111.98 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.7 OUTLIER -119.3 116.13 25.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.202 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' L' ' 13' ' ' HIS . 70.6 t60 -122.61 165.99 15.58 Favored 'General case' 0 CA--C 1.509 -0.616 0 CA-C-O 121.403 0.621 . . . . 0.0 110.025 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.453 ' N ' ' CG ' ' K' ' 14' ' ' HIS . 19.5 tt0 -163.39 166.95 22.32 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.453 178.386 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' K' ' 15' ' ' GLN . 98.9 mttt -155.53 129.96 9.0 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.594 HD13 HG11 ' I' ' 36' ' ' VAL . 26.9 tp -124.51 120.53 32.27 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.518 HG11 ' CE2' ' K' ' 20' ' ' PHE . 57.9 t -132.94 127.03 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.935 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.859 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 6.8 m-85 -117.28 112.81 21.27 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.033 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.518 ' CE2' HG11 ' K' ' 18' ' ' VAL . 47.6 m-85 -108.12 118.57 37.1 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 178.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 132.86 36.93 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.772 0.714 . . . . 0.0 112.775 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -113.58 122.77 48.23 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.465 178.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -178.73 110.87 0.06 Allowed 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.244 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 m -107.05 -123.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 31.49 85.51 0.01 OUTLIER Glycine 0 C--N 1.342 0.9 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.009 -178.127 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 24.1 p -50.1 158.82 0.5 Allowed 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.398 0.618 . . . . 0.0 111.754 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.531 ' O ' ' C ' ' K' ' 28' ' ' LYS . 13.7 p-10 -148.06 176.92 9.8 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.881 -1.054 . . . . 0.0 109.137 176.952 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.531 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.8 mttt -9.16 -103.27 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.664 0.603 . . . . 0.0 111.278 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.73 97.0 0.18 Allowed Glycine 0 CA--C 1.5 -0.896 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 176.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.93 ' HB1' ' C ' ' J' ' 29' ' ' GLY . . . -66.2 172.17 4.09 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 177.423 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.661 ' N ' ' O ' ' J' ' 29' ' ' GLY . 0.4 OUTLIER -147.58 123.46 2.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 CA-C-N 120.996 1.726 . . . . 0.0 111.858 -175.782 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.628 HG23 HG22 ' J' ' 32' ' ' ILE . 91.1 mt -125.99 131.33 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.717 -1.128 . . . . 0.0 112.475 -178.348 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.71 119.96 3.17 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.626 HD23 ' N ' ' K' ' 35' ' ' MET . 5.5 tt -121.84 120.53 34.81 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 120.629 0.252 . . . . 0.0 110.765 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.626 ' N ' HD23 ' K' ' 34' ' ' LEU . 5.6 ppp? -130.49 130.24 43.94 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.436 0.636 . . . . 0.0 111.058 178.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.534 ' O ' ' C ' ' K' ' 37' ' ' GLY . 3.2 p -158.11 79.98 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.869 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.534 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -1.37 -100.89 0.0 OUTLIER Glycine 0 C--N 1.348 1.214 0 O-C-N 123.311 0.382 . . . . 0.0 113.615 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.45 -172.5 41.73 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--N 1.33 -0.245 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.847 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.616 0.246 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' K' ' 14' ' ' HIS . 49.1 t-80 -90.45 176.68 6.62 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.182 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 27.5 t-80 -76.0 176.82 7.57 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.372 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 15' ' ' GLN . . . . . 0.577 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 99.2 mm-40 -121.48 178.04 4.97 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.968 0.413 . . . . 0.0 111.004 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -165.98 113.48 0.92 Allowed 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.96 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 18.3 mt -128.71 124.92 36.85 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -140.1 135.03 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.817 ' CE1' HD13 ' J' ' 34' ' ' LEU . 7.3 m-85 -116.94 108.53 15.91 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 177.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -116.0 123.09 47.13 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-O 121.24 0.543 . . . . 0.0 110.867 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.68 134.01 45.47 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.583 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 81.0 tt0 -81.18 92.87 6.37 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.964 -0.694 . . . . 0.0 111.03 -178.4 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.585 ' O ' ' O ' ' L' ' 24' ' ' VAL . 70.7 m-20 -160.94 133.14 5.95 Favored 'General case' 0 C--O 1.226 -0.159 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.182 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.585 ' O ' ' O ' ' L' ' 23' ' ' ASP . 10.6 t -32.34 -110.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 124.003 0.815 . . . . 0.0 111.376 176.475 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -158.89 92.27 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.476 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 23.3 p -47.3 152.68 0.57 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.761 0.791 . . . . 0.0 111.443 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.488 ' O ' ' C ' ' L' ' 28' ' ' LYS . 31.8 m120 -157.42 -174.74 5.03 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.135 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 12.74 103.54 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 177.079 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.56 -101.48 0.81 Allowed Glycine 0 N--CA 1.47 0.961 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.5 171.48 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 117.287 0.543 . . . . 0.0 110.152 -178.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.652 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -141.42 148.56 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.854 -177.977 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.481 HG23 ' O ' ' L' ' 32' ' ' ILE . 18.7 tt -133.53 126.75 52.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-N 114.018 -1.447 . . . . 0.0 109.191 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.17 119.44 4.38 Favored Glycine 0 N--CA 1.466 0.657 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 16.6 tp -126.09 120.75 31.01 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.857 0.328 . . . . 0.0 110.179 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.528 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.7 ppp? -132.86 133.06 42.81 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.872 0.844 . . . . 0.0 111.16 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 23.1 t -142.98 82.61 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.412 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' K' ' 37' ' ' GLY . . . -66.26 101.22 0.59 Allowed Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.31 168.58 35.93 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -129.53 160.03 40.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.884 0.373 . . . . 0.0 110.507 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.425 179.983 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 121.128 0.49 . . . . 0.0 111.337 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 13' ' ' HIS . 45.8 t -133.3 158.42 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.409 ' N ' HG12 ' A' ' 12' ' ' VAL . 79.2 m80 -142.44 134.28 27.01 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 120.539 -0.464 . . . . 0.0 111.384 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -155.11 166.87 32.22 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.368 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -155.83 175.73 13.55 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.898 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -153.37 115.57 4.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.926 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.92 121.63 23.13 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.06 0.457 . . . . 0.0 110.67 178.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.54 131.38 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 115.778 -0.647 . . . . 0.0 109.713 179.371 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -126.56 130.37 50.41 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.826 0.346 . . . . 0.0 110.627 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -126.24 126.92 44.81 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 133.03 46.65 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 121.017 0.437 . . . . 0.0 111.87 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -150.53 117.33 5.85 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.187 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 121.485 0.659 . . . . 0.0 111.928 -179.968 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.515 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 18.3 pttp . . . . . 0 CA--C 1.529 0.159 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.24 101.39 0.74 Allowed Glycine 0 CA--C 1.503 -0.674 0 N-CA-C 106.849 -2.5 . . . . 0.0 106.849 176.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.96 153.94 23.63 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 117.117 -1.833 . . . . 0.0 110.535 -175.957 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.407 HG22 ' HE3' ' H' ' 35' ' ' MET . 0.4 OUTLIER -146.34 115.59 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.498 -173.873 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 32' ' ' ILE . 11.6 tt -127.55 108.78 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.24 122.61 4.69 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.14 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.656 ' O ' HD12 ' B' ' 34' ' ' LEU . 0.9 OUTLIER -178.13 -162.58 0.06 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 122.349 1.071 . . . . 0.0 111.228 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.462 ' SD ' ' HB ' ' H' ' 31' ' ' ILE . 1.1 ttp -149.89 157.6 43.34 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -111.71 75.68 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 C-N-CA 120.507 -0.477 . . . . 0.0 109.811 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.5 103.42 3.0 Favored Glycine 0 C--N 1.357 1.745 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.46 -172.1 47.54 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -132.93 161.68 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.048 0.451 . . . . 0.0 110.864 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.865 -1.064 . . . . 0.0 110.662 -179.951 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -147.8 157.82 43.73 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.686 0.279 . . . . 0.0 110.682 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 150.68 31.32 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.314 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.418 HG22 ' N ' ' B' ' 13' ' ' HIS . 3.0 p -137.47 155.84 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.794 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.418 ' N ' HG22 ' B' ' 12' ' ' VAL . 5.7 m-70 -128.31 142.46 51.13 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -143.2 169.56 17.38 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -162.2 166.63 25.3 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.762 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -154.48 111.43 3.34 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 179.243 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 73.2 mt -121.84 117.49 26.65 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -131.13 129.03 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.338 0.59 . . . . 0.0 112.034 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -122.28 127.37 49.8 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.124 178.735 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.3 t80 -130.65 125.5 34.17 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.708 0.289 . . . . 0.0 110.949 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.97 129.71 42.47 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.868 0.366 . . . . 0.0 110.504 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -157.76 135.59 10.68 Favored 'General case' 0 C--O 1.226 -0.17 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.53 0.21 0 C-N-CA 120.724 -0.391 . . . . 0.0 111.218 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.487 -1.699 0 N-CA-C 106.605 -2.598 . . . . 0.0 106.605 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -91.08 149.14 21.94 Favored 'General case' 0 CA--C 1.498 -1.046 0 C-N-CA 115.357 -2.537 . . . . 0.0 106.434 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.614 HG23 HD12 ' C' ' 31' ' ' ILE . 2.6 mt -148.74 106.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 114.284 -1.326 . . . . 0.0 107.836 -174.336 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.426 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.7 tt -116.15 123.18 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-O 121.638 0.732 . . . . 0.0 110.955 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.727 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -116.53 115.31 3.27 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 106.008 -2.837 . . . . 0.0 106.008 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.656 HD12 ' O ' ' A' ' 34' ' ' LEU . 5.9 tp -144.12 144.33 31.54 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 -175.649 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.644 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 32.3 ttp -129.18 129.63 45.32 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.159 -1.382 . . . . 0.0 108.411 175.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -111.89 78.2 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.017 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.247 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.632 ' HA3' HG21 ' H' ' 31' ' ' ILE . . . -74.36 104.59 1.69 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.23 -179.14 36.84 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.751 -178.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -141.37 149.87 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.675 -179.851 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 66.1 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.944 0.402 . . . . 0.0 110.449 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -128.87 138.73 52.2 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.363 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 82.8 t60 -155.37 164.85 38.18 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 30.6 mt-30 -155.44 -179.36 8.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.308 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.05 112.97 1.01 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.53 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 67.8 tp -120.28 121.84 39.56 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.804 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -132.69 126.34 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -179.101 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -118.46 123.8 46.05 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 177.179 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.628 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 43.5 t80 -130.09 127.85 40.68 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.764 0.316 . . . . 0.0 111.373 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.48 138.97 45.14 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.299 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -143.82 151.81 40.4 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.408 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 . . . . . 0 N--CA 1.466 0.359 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.673 178.79 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.622 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.54 153.64 44.99 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 173.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.614 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -150.3 116.88 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 118.979 -1.089 . . . . 0.0 111.305 -172.367 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.732 HD11 HD12 ' D' ' 32' ' ' ILE . 1.6 pt -119.15 115.88 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 176.183 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.681 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -126.14 118.45 3.13 Favored Glycine 0 CA--C 1.501 -0.836 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -161.56 169.31 21.95 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 118.072 -1.451 . . . . 0.0 111.968 -177.513 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.419 ' HE3' ' O ' ' I' ' 32' ' ' ILE . 5.6 tmm? -141.37 137.26 32.18 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 113.538 -1.665 . . . . 0.0 109.654 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.04 73.09 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.564 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.75 103.84 3.02 Favored Glycine 0 C--N 1.37 2.437 0 N-CA-C 111.419 -0.673 . . . . 0.0 111.419 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.58 154.58 18.63 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -135.38 163.29 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.395 -179.889 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' E' ' 12' ' ' VAL . 53.7 t . . . . . 0 N--CA 1.463 0.21 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' E' ' 13' ' ' HIS . 23.1 p80 -155.01 158.84 39.76 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 119.035 -1.066 . . . . 0.0 112.841 -178.805 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.512 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 51.5 m-70 -147.27 169.62 19.02 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.016 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.512 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 97.4 mm-40 -148.9 168.82 22.0 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.154 179.288 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -153.31 106.97 3.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.995 179.024 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 51.7 mt -118.5 116.79 27.39 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.27 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -130.24 128.16 63.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.112 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.55 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 47.1 m-85 -121.02 111.8 17.93 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 177.004 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -120.21 132.1 55.23 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 118.251 0.478 . . . . 0.0 111.919 -178.587 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 122.31 24.79 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.51 0.671 . . . . 0.0 111.176 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.447 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 80.9 tt0 -111.18 89.82 3.16 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.071 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' D' ' 23' ' ' ASP . 4.9 p30 . . . . . 0 C--N 1.322 -0.59 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.446 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.753 ' C ' HD12 ' D' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.412 -2.33 0 N-CA-C 100.355 -3.943 . . . . 0.0 100.355 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.753 HD12 ' C ' ' D' ' 30' ' ' ALA . 4.6 mp -131.99 134.58 59.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 115.074 -2.65 . . . . 0.0 117.751 -174.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.732 HD12 HD11 ' C' ' 32' ' ' ILE . 11.9 tt -126.77 123.91 63.83 Favored 'Isoleucine or valine' 0 C--N 1.367 1.334 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.459 177.698 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.655 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -124.18 106.22 0.94 Allowed Glycine 0 C--O 1.237 0.29 0 N-CA-C 106.882 -2.487 . . . . 0.0 106.882 176.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.553 HD23 ' C ' ' D' ' 34' ' ' LEU . 10.0 tt -126.72 132.95 51.0 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-O 122.039 0.923 . . . . 0.0 112.431 -177.511 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.541 ' SD ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -122.1 126.66 48.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 114.32 -1.309 . . . . 0.0 109.865 178.887 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.498 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.3 79.77 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.49 -178.182 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -25.8 -95.74 0.01 OUTLIER Glycine 0 C--N 1.358 1.759 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.89 -162.03 29.25 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.583 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 40' ' ' VAL . 56.0 t -115.2 136.06 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.932 0.396 . . . . 0.0 110.266 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 39' ' ' VAL . 70.9 t . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.445 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -109.11 136.13 49.11 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 110.463 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.521 ' OE2' ' NE2' ' E' ' 13' ' ' HIS . 81.4 tt0 -64.69 136.27 56.77 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.645 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' D' ' 12' ' ' VAL . 9.4 p -131.91 134.6 59.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-O 121.959 0.885 . . . . 0.0 112.596 -179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' D' ' 13' ' ' HIS . 46.8 m170 -121.17 138.88 54.0 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 114.066 -1.425 . . . . 0.0 108.559 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.572 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.4 t60 -152.47 171.49 18.0 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 121.61 0.719 . . . . 0.0 110.742 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 53.6 tt0 -154.01 173.27 16.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.774 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 87.7 tttt -168.57 113.34 0.61 Allowed 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.568 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 tt -123.65 123.44 40.56 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.98 122.3 45.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.222 0.534 . . . . 0.0 112.173 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' D' ' 19' ' ' PHE . 7.5 m-85 -113.88 117.54 31.69 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 90.4 t80 -124.58 131.94 53.46 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 145.94 28.4 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.42 128.47 44.81 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.802 -0.635 . . . . 0.0 111.18 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' O ' ' F' ' 22' ' ' GLU . 67.3 t0 -147.1 112.33 5.51 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.238 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.756 HG13 ' H ' ' E' ' 25' ' ' GLY . 12.1 p -101.8 -121.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.248 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.756 ' H ' HG13 ' E' ' 24' ' ' VAL . . . 34.2 -84.93 0.01 OUTLIER Glycine 0 N--CA 1.473 1.143 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -177.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.572 ' N ' ' O ' ' E' ' 24' ' ' VAL . 1.4 p . . . . . 0 N--CA 1.447 -0.582 0 CA-C-O 121.673 0.749 . . . . 0.0 109.913 175.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.474 -1.947 0 CA-C-O 122.451 1.12 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.754 HG21 ' HA3' ' K' ' 37' ' ' GLY . 0.6 OUTLIER -151.49 137.54 11.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 112.477 -2.147 . . . . 0.0 112.041 -171.693 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 1.031 HD13 HG22 ' F' ' 32' ' ' ILE . 2.8 mp -122.41 118.01 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 114.275 -1.33 . . . . 0.0 110.35 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -120.2 116.29 3.2 Favored Glycine 0 N--CA 1.476 1.32 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 178.338 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.754 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 39.6 mt -119.36 117.39 28.38 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -120.27 126.35 50.36 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.08 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.447 ' O ' HG23 ' F' ' 36' ' ' VAL . 2.6 t -115.44 89.1 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.01 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.716 ' HA3' HG21 ' K' ' 31' ' ' ILE . . . -69.3 94.69 0.4 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.22 -171.79 18.73 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -178.952 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -132.73 161.81 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.654 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 C--O 1.221 -0.423 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.753 -179.942 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -103.33 129.75 50.45 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.004 0.43 . . . . 0.0 110.47 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -92.9 145.58 24.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.856 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 t -105.85 130.04 57.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.133 0.492 . . . . 0.0 110.689 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 14.5 t60 -154.19 139.7 17.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -149.74 170.61 18.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.427 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 50.8 tt0 -155.09 171.15 20.25 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.525 -0.762 . . . . 0.0 109.591 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' F' ' 17' ' ' LEU . 62.1 tttm -170.08 106.39 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.156 -0.617 . . . . 0.0 111.676 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' F' ' 16' ' ' LYS . 6.1 mp -117.42 125.47 51.01 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.757 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.1 141.44 16.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 96.4 m-85 -117.0 122.0 42.97 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 113.637 -1.62 . . . . 0.0 107.377 177.197 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 20' ' ' PHE . . . . . 0.4 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 47.7 m-85 -127.04 142.29 51.57 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 121.749 0.785 . . . . 0.0 111.317 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.25 146.5 23.82 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.54 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.476 ' O ' ' O ' ' E' ' 23' ' ' ASP . 97.6 mt-10 -89.48 98.86 12.01 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.845 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' F' ' 24' ' ' VAL . 6.2 t70 -120.47 110.87 17.01 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 120.601 0.238 . . . . 0.0 110.758 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.6 m -60.42 -133.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.696 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' F' ' 26' ' ' SER . . . -76.91 85.72 0.99 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 119.784 -0.453 . . . . 0.0 112.797 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' F' ' 25' ' ' GLY . 5.9 p -34.97 170.09 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.144 0 CA-C-O 121.191 0.52 . . . . 0.0 111.292 178.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' F' ' 28' ' ' LYS . 8.0 t-20 -140.19 -178.96 5.71 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.151 177.376 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 62.8 mttp 26.37 -107.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.003 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.39 94.46 0.15 Allowed Glycine 0 C--N 1.338 0.674 0 CA-C-O 119.269 -0.74 . . . . 0.0 111.988 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.403 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -67.4 178.99 1.38 Allowed 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 103.876 -2.639 . . . . 0.0 103.876 174.654 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.533 HD13 ' N ' ' L' ' 38' ' ' GLY . 0.2 OUTLIER -146.87 118.79 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-N 121.651 2.023 . . . . 0.0 111.03 -178.763 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 1.031 HG22 HD13 ' E' ' 32' ' ' ILE . 45.9 pt -118.56 140.91 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.462 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -145.05 125.14 2.29 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 178.937 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 4.9 mp -116.88 127.86 54.68 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.473 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 2.9 tmm? -129.16 127.97 42.47 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 121.564 0.697 . . . . 0.0 112.876 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.473 ' N ' ' SD ' ' F' ' 35' ' ' MET . 3.6 p -156.15 82.02 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.719 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.233 179.079 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.447 ' O ' HD13 ' L' ' 31' ' ' ILE . . . -71.23 101.39 0.96 Allowed Glycine 0 CA--C 1.53 0.988 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.475 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -144.04 165.01 27.45 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -119.6 135.96 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.024 0.44 . . . . 0.0 110.331 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.728 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.403 ' CG ' ' N ' ' G' ' 14' ' ' HIS . 26.3 t-80 . . . . . 0 N--CA 1.465 0.307 0 CA-C-O 120.863 0.364 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.403 ' N ' ' CG ' ' G' ' 13' ' ' HIS . 8.1 p-80 -96.81 172.25 8.0 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.099 0.476 . . . . 0.0 109.804 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -148.4 177.52 9.37 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.054 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -143.95 145.82 32.52 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.97 115.43 18.52 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.613 0.72 . . . . 0.0 110.306 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -125.82 121.98 61.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.127 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -153.24 158.23 41.38 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.611 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -132.56 150.16 52.2 Favored 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.415 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.6 135.1 44.03 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.86 0.838 . . . . 0.0 112.283 -179.22 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -143.38 151.9 40.96 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.802 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.509 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 57.5 t0 60.68 114.91 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.261 0.553 . . . . 0.0 111.965 179.401 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.556 ' O ' ' O ' ' G' ' 26' ' ' SER . 0.3 OUTLIER -147.32 112.81 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.524 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 36.82 -91.35 0.01 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.383 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.556 ' O ' ' O ' ' G' ' 24' ' ' VAL . 10.8 p -89.33 -178.86 5.72 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -60.31 166.05 3.21 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 115.87 -2.332 . . . . 0.0 107.564 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.558 ' NZ ' ' O ' ' I' ' 23' ' ' ASP . 29.6 tttm -53.69 107.35 0.25 Allowed 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 118.365 -1.334 . . . . 0.0 113.734 -177.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.51 100.81 2.71 Favored Glycine 0 N--CA 1.469 0.854 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 169.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 148.09 28.66 Favored 'General case' 0 C--O 1.248 0.985 1 CA-C-N 125.131 4.465 . . . . 0.0 109.378 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -162.71 107.36 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 112.47 -2.15 . . . . 0.0 106.96 -175.318 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.42 ' O ' ' O ' ' H' ' 33' ' ' GLY . 42.7 mm -108.8 104.73 17.54 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 C-N-CA 119.074 -1.051 . . . . 0.0 108.673 177.227 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.54 100.08 1.38 Allowed Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 104.336 -3.506 . . . . 0.0 104.336 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tp -147.32 149.07 32.11 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 123.321 1.534 . . . . 0.0 112.948 -177.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -111.92 135.61 52.33 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 112.476 -2.147 . . . . 0.0 110.579 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 36' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -135.54 66.4 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.11 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' G' G ' 37' ' ' GLY . . . . . 0.409 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -53.1 -103.06 0.01 OUTLIER Glycine 0 C--N 1.358 1.783 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.55 -177.89 47.93 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 121.013 0.435 . . . . 0.0 110.729 -179.446 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 51.6 t . . . . . 0 N--CA 1.464 0.259 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.643 ' NE2' ' CD2' ' I' ' 13' ' ' HIS . 19.3 p80 -167.96 156.65 9.23 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.568 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -144.44 170.4 16.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -144.97 172.51 12.94 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.951 0.405 . . . . 0.0 110.671 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -176.13 126.02 0.2 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.664 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -136.38 122.54 20.37 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.665 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 34.2 m -123.79 129.45 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 121.352 0.596 . . . . 0.0 110.344 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 19' ' ' PHE . . . . . 0.426 ' N ' ' CD1' ' H' ' 19' ' ' PHE . 5.0 m-85 -113.11 116.39 29.79 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.847 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -110.65 117.53 33.75 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.02 129.84 51.59 Favored 'General case' 0 N--CA 1.475 0.814 0 O-C-N 121.269 -0.895 . . . . 0.0 112.884 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -171.08 145.28 2.24 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.549 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.509 ' CB ' ' H ' ' G' ' 23' ' ' ASP . 29.7 t70 -172.0 105.97 0.2 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.942 1.46 . . . . 0.0 114.942 178.372 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' H' ' 23' ' ' ASP . 58.5 t . . . . . 0 N--CA 1.476 0.875 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.303 173.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.379 0 CA-C-O 124.038 1.875 . . . . 0.0 112.777 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.632 HG21 ' HA3' ' B' ' 37' ' ' GLY . 0.8 OUTLIER -152.95 128.27 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 111.519 -2.582 . . . . 0.0 109.797 -177.427 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.55 HG21 HD12 ' I' ' 32' ' ' ILE . 2.1 tt -119.45 116.12 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -121.28 115.17 2.77 Favored Glycine 0 C--O 1.24 0.526 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.921 ' O ' HD12 ' I' ' 34' ' ' LEU . 0.5 OUTLIER -138.23 150.75 47.01 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 122.971 1.367 . . . . 0.0 112.924 -178.251 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.727 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 34.1 ttp -121.65 127.1 50.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.065 -1.425 . . . . 0.0 109.765 178.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.494 ' CG2' HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -132.15 72.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 120.619 -0.433 . . . . 0.0 110.035 179.515 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' H' H ' 37' ' ' GLY . . . . . 0.421 ' HA3' HG21 ' B' ' 31' ' ' ILE . . . -75.98 110.58 3.08 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.75 163.44 8.07 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.5 m -137.66 159.33 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.077 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.697 -179.781 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.473 ' C ' ' ND1' ' I' ' 13' ' ' HIS . 27.1 m . . . . . 0 N--CA 1.469 0.512 0 CA-C-O 121.339 0.59 . . . . 0.0 110.869 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.643 ' CD2' ' NE2' ' H' ' 13' ' ' HIS . 12.9 m80 -139.78 140.92 36.79 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.185 -178.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' I' ' 15' ' ' GLN . 59.4 t-80 -153.48 162.12 41.58 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 178.48 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.592 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 49.8 tt0 -162.17 172.24 16.11 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.376 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.451 ' N ' ' CG ' ' I' ' 15' ' ' GLN . 88.0 tttt -172.59 128.65 0.53 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.734 179.496 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.692 HD22 ' CE1' ' I' ' 19' ' ' PHE . 3.5 tt -130.27 121.47 26.18 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.66 ' N ' HD23 ' I' ' 17' ' ' LEU . 39.6 t -120.34 126.53 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 122.256 -0.277 . . . . 0.0 111.709 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.692 ' CE1' HD22 ' I' ' 17' ' ' LEU . 73.3 m-85 -103.98 101.26 11.04 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 176.16 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -113.27 117.85 33.01 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.22 124.87 35.61 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.15 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.442 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 14.4 pt-20 -127.09 75.41 1.58 Allowed 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.707 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.558 ' O ' ' NZ ' ' G' ' 28' ' ' LYS . 0.0 OUTLIER 164.03 115.0 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 114.198 -1.364 . . . . 0.0 109.872 176.158 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.498 ' H ' ' HB2' ' J' ' 23' ' ' ASP . 39.5 t -148.57 107.47 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 118.976 -1.089 . . . . 0.0 108.726 173.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' I' ' 24' ' ' VAL . . . -39.62 -93.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.406 0 CA-C-O 123.984 1.88 . . . . 0.0 109.929 171.395 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.408 ' O ' ' O ' ' I' ' 25' ' ' GLY . 79.5 p 47.28 -178.59 0.01 OUTLIER 'General case' 0 CA--C 1.481 -1.703 0 CA-C-N 110.276 -2.962 . . . . 0.0 111.025 177.244 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' I' ' 28' ' ' LYS . 29.4 m120 -126.47 164.4 21.22 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.25 -1.795 . . . . 0.0 107.292 172.508 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' I' ' 27' ' ' ASN 0.263 45.1 mttm -27.85 112.56 0.06 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 114.984 1.476 . . . . 0.0 114.984 174.809 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.467 ' HA2' ' HB2' ' J' ' 30' ' ' ALA . . . 103.35 92.64 2.24 Favored Glycine 0 N--CA 1.48 1.577 0 C-N-CA 124.602 1.096 . . . . 0.0 115.169 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.498 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -87.64 179.71 6.47 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 173.129 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.49 ' HB ' HG22 ' H' ' 31' ' ' ILE . 0.4 OUTLIER -141.83 124.65 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 C-N-CA 116.517 -2.073 . . . . 0.0 111.471 -176.902 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.55 HD12 HG21 ' H' ' 32' ' ' ILE . 9.1 tt -125.89 127.24 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.213 0.53 . . . . 0.0 111.778 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 33' ' ' GLY . . . . . 0.644 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.81 117.46 3.04 Favored Glycine 0 C--O 1.24 0.482 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.921 HD12 ' O ' ' H' ' 34' ' ' LEU . 16.9 tp -137.84 135.36 36.13 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-O 121.611 0.719 . . . . 0.0 111.744 -178.982 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.681 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 54.9 ttp -105.21 125.3 50.83 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.75 176.409 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.79 72.09 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.135 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.58 111.3 3.5 Favored Glycine 0 C--N 1.364 2.128 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 177.755 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -71.99 160.51 54.07 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -136.79 162.01 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.805 0.336 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.552 -179.879 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 121.268 0.556 . . . . 0.0 111.416 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 68.9 m80 -139.11 134.74 33.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.675 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 14' ' ' HIS . . . . . 0.544 ' CD2' ' HB2' ' K' ' 14' ' ' HIS . 3.1 t-80 -148.56 158.11 43.91 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.759 0.79 . . . . 0.0 110.464 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 15' ' ' GLN . . . . . 0.54 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 83.2 mt-30 -150.59 174.46 12.95 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.546 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 54.0 tttp -175.82 127.3 0.23 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.193 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -130.4 129.96 43.73 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 18' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' K' ' 18' ' ' VAL . 1.4 p -144.99 140.62 23.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -178.505 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.6 OUTLIER -114.26 120.37 40.2 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.69 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.72 117.53 29.16 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.44 120.34 36.54 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 121.487 0.66 . . . . 0.0 111.653 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -159.69 104.45 1.58 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.498 ' HB2' ' H ' ' I' ' 24' ' ' VAL . 60.2 t0 -82.93 -133.52 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 175.424 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.54 ' O ' ' O ' ' J' ' 25' ' ' GLY . 21.9 t -92.2 112.17 25.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 N-CA-C 101.05 -3.685 . . . . 0.0 101.05 172.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 25' ' ' GLY . . . . . 0.54 ' O ' ' O ' ' J' ' 24' ' ' VAL . . . 42.38 90.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.01 -2.436 . . . . 0.0 107.01 -173.305 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.547 ' CB ' ' O ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -61.65 -179.82 0.2 Allowed 'General case' 0 N--CA 1.438 -1.034 0 C-N-CA 118.784 -1.167 . . . . 0.0 109.638 -174.865 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.466 ' N ' ' OG ' ' J' ' 26' ' ' SER . 1.6 m-20 -80.48 173.61 12.43 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 116.825 2.157 . . . . 0.0 116.825 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.552 ' O ' ' N ' ' J' ' 30' ' ' ALA 0.369 48.2 tttp -48.06 111.81 0.49 Allowed 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 109.221 -3.627 . . . . 0.0 116.782 173.499 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -68.34 99.19 0.56 Allowed Glycine 1 CA--C 1.446 -4.275 2 CA-C-O 128.699 4.5 . . . . 0.0 102.799 -176.331 . . . . . . . . 4 3 . 1 . 007 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.783 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -77.08 -132.78 0.01 OUTLIER 'General case' 1 N--CA 1.339 -6.005 3 CA-C-N 97.435 -9.383 . . . . 0.0 107.55 -167.012 . . . . . . . . 4 3 . 1 . 007 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.861 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -90.02 108.94 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.692 0 CA-C-N 114.57 -1.195 . . . . 0.0 110.467 -175.592 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.541 ' O ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -106.58 111.05 33.78 Favored 'Isoleucine or valine' 0 C--N 1.363 1.169 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.699 179.486 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.89 103.85 1.67 Allowed Glycine 0 CA--C 1.505 -0.545 0 N-CA-C 107.819 -2.112 . . . . 0.0 107.819 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.58 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 66.9 mt -126.03 121.72 33.8 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.951 0.881 . . . . 0.0 112.514 -177.253 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 6.1 ttt -102.94 120.37 40.51 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 114.252 -1.34 . . . . 0.0 108.391 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.478 ' HB ' HG22 ' K' ' 36' ' ' VAL . 3.6 t -137.23 66.86 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.327 -178.336 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.28 -102.63 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.13 154.88 30.65 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 50.5 t . . . . . 0 N--CA 1.465 0.289 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.495 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 . . . . . 0 N--CA 1.464 0.237 0 CA-C-O 120.878 0.37 . . . . 0.0 111.347 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.44 HG13 ' ND1' ' L' ' 13' ' ' HIS . 74.1 t -126.58 134.72 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' L' ' 13' ' ' HIS . 44.3 t60 -116.41 123.48 47.64 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 117.845 0.293 . . . . 0.0 111.309 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.544 ' HB2' ' CD2' ' J' ' 14' ' ' HIS . 86.6 m-70 -114.86 158.95 21.23 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.418 ' O ' ' CG ' ' K' ' 16' ' ' LYS . 53.4 tt0 -170.05 161.58 8.71 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.226 177.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 95.5 mttt -163.03 132.23 4.12 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.416 HD23 HD13 ' L' ' 17' ' ' LEU . 15.5 tp -122.9 119.21 29.81 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.221 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 96.6 t -136.42 133.74 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.604 ' CZ ' ' CD2' ' L' ' 19' ' ' PHE . 23.4 p90 -145.62 130.4 18.1 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.296 177.1 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.638 ' N ' ' CD1' ' K' ' 20' ' ' PHE . 0.0 OUTLIER -149.35 163.77 36.78 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -178.475 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 141.67 38.89 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.328 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 22' ' ' GLU . . . . . 0.547 ' O ' ' CB ' ' J' ' 26' ' ' SER . 78.1 tt0 -89.71 156.59 18.45 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -178.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.52 ' OD2' ' N ' ' J' ' 28' ' ' LYS . 58.6 t0 176.11 130.79 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 123.465 0.706 . . . . 0.0 110.522 178.589 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.456 HG23 ' H ' ' K' ' 25' ' ' GLY . 5.3 m -87.53 -112.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.084 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 26' ' ' SER . . . -48.75 92.11 0.01 OUTLIER Glycine 0 CA--C 1.531 1.062 0 N-CA-C 114.838 0.695 . . . . 0.0 114.838 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.53 ' O ' ' O ' ' K' ' 25' ' ' GLY . 8.6 t -35.46 170.32 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.611 0.719 . . . . 0.0 111.368 176.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.481 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER -139.22 -177.15 4.78 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.946 177.751 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' K' K ' 28' ' ' LYS . . . . . 0.481 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 98.9 mttt -17.84 -104.87 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 113.242 0.83 . . . . 0.0 113.242 -178.304 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.552 ' HA2' ' HB2' ' L' ' 30' ' ' ALA . . . -150.44 95.34 0.16 Allowed Glycine 0 C--N 1.346 1.089 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.692 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.575 ' C ' HD13 ' K' ' 31' ' ' ILE . . . -67.82 -173.13 0.32 Allowed 'General case' 0 C--O 1.237 0.444 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 175.135 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.716 HG21 ' HA3' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -144.77 130.03 14.06 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-O 122.212 1.006 . . . . 0.0 110.22 -179.465 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 11.1 mm -114.84 122.5 69.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 114.164 -1.38 . . . . 0.0 110.485 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.482 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -127.98 119.72 3.22 Favored Glycine 0 N--CA 1.473 1.121 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.722 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -129.39 122.25 29.05 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 114.524 -0.838 . . . . 0.0 110.211 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 38.8 ttp -105.96 119.62 39.64 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.88 178.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.702 HG12 ' O ' ' K' ' 36' ' ' VAL . 54.7 t -139.8 71.06 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 119.415 -0.326 . . . . 0.0 110.53 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.754 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -53.88 -97.87 0.01 OUTLIER Glycine 0 C--N 1.342 0.897 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.802 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.32 163.83 35.86 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 C--N 1.328 -0.361 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.626 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' L' L ' 13' ' ' HIS . . . . . 0.44 ' ND1' HG13 ' K' ' 12' ' ' VAL . 15.5 m80 -81.58 145.95 30.37 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.191 0.52 . . . . 0.0 111.047 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -83.45 177.78 8.31 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.196 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -110.73 178.69 4.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.813 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -146.24 140.85 26.83 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.045 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.416 HD13 HD23 ' K' ' 17' ' ' LEU . 28.6 tp -125.33 119.99 29.89 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 18' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 7.3 t -141.45 131.9 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.643 0.735 . . . . 0.0 112.026 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.604 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 8.0 p90 -147.5 144.58 28.66 Favored 'General case' 0 C--N 1.322 -0.597 0 O-C-N 121.363 -0.835 . . . . 0.0 110.926 178.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' L' ' 19' ' ' PHE . 60.2 m-85 -157.77 157.35 33.21 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.52 1.152 . . . . 0.0 113.958 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.35 139.42 52.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.868 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -74.48 101.71 4.24 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.786 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 35.6 p-10 -171.4 113.76 0.37 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.778 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' L' ' 26' ' ' SER . 73.7 t -64.99 131.71 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.861 -178.41 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.51 83.76 0.01 OUTLIER Glycine 0 N--CA 1.466 0.655 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.518 ' N ' ' O ' ' L' ' 24' ' ' VAL . 15.4 m -67.52 -171.1 0.17 Allowed 'General case' 0 N--CA 1.437 -1.124 0 CA-C-O 122.541 1.163 . . . . 0.0 112.488 -177.309 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 54.3 t30 -80.51 179.39 7.76 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.788 -177.857 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.4 mttt -36.41 104.4 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.577 -178.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 168.09 -100.36 0.16 Allowed Glycine 0 C--O 1.22 -0.774 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.552 ' HB2' ' HA2' ' K' ' 29' ' ' GLY . . . -51.35 172.13 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.682 1.741 . . . . 0.0 108.054 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.447 HD13 ' O ' ' F' ' 37' ' ' GLY . 0.1 OUTLIER -152.53 149.41 13.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 C-N-CA 118.144 -1.423 . . . . 0.0 111.253 -176.44 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' L' L ' 32' ' ' ILE . . . . . 0.403 HG21 HD13 ' L' ' 32' ' ' ILE . 38.5 pt -125.89 143.63 38.77 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.153 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.27 114.73 1.51 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.6 mt -119.09 120.31 36.77 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttp -111.75 123.99 51.39 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 120.204 -0.599 . . . . 0.0 111.47 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' L' ' 37' ' ' GLY . 4.9 t -133.91 69.68 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.465 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -27.17 -105.69 0.0 OUTLIER Glycine 0 CA--C 1.533 1.187 0 CA-C-O 121.344 0.413 . . . . 0.0 114.064 -179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 38' ' ' GLY . . . . . 0.533 ' N ' HD13 ' F' ' 31' ' ' ILE . . . -38.09 156.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 115.312 -0.444 . . . . 0.0 112.459 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.79 159.32 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.189 -0.505 . . . . 0.0 110.06 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.828 -179.721 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.873 0.368 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.447 HG11 ' ND1' ' B' ' 13' ' ' HIS . 9.9 p -146.15 146.93 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.729 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 14' ' ' HIS . 37.5 p-80 -91.12 -178.63 5.22 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.451 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 13' ' ' HIS . 24.8 m-70 -74.26 172.5 11.72 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -145.36 176.73 9.35 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.504 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -150.01 112.09 4.61 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.26 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -124.45 115.46 20.95 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 121.424 0.631 . . . . 0.0 110.261 179.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -123.6 128.96 74.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.403 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -128.76 124.13 34.7 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.9 p90 -128.04 125.63 39.71 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.94 0.4 . . . . 0.0 110.253 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.12 119.03 35.04 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -164.2 120.27 1.59 Allowed 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 38.7 t0 . . . . . 0 C--N 1.322 -0.619 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.561 -178.923 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.471 ' CB ' ' OD2' ' B' ' 23' ' ' ASP 0.442 74.5 tttt . . . . . 0 CA--C 1.538 0.495 0 CA-C-O 121.133 0.492 . . . . 0.0 111.576 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.66 104.03 1.23 Allowed Glycine 0 C--N 1.302 -1.317 0 CA-C-O 127.334 3.741 . . . . 0.0 112.02 -169.246 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.545 ' O ' ' N ' ' A' ' 32' ' ' ILE . . . -69.81 -122.2 0.0 OUTLIER 'General case' 0 CA--C 1.479 -1.778 3 CA-C-N 103.478 -6.361 . . . . 0.0 96.052 -179.563 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.818 ' O ' HD13 ' A' ' 31' ' ' ILE . 0.0 OUTLIER -51.16 99.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.587 2.401 0 CA-C-N 124.89 3.495 . . . . 0.0 107.895 175.942 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' ALA . 4.9 tt -128.78 113.44 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 119.419 -2.051 . . . . 0.0 109.387 178.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' B' ' 33' ' ' GLY . . . -129.36 126.06 5.04 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 106.617 -2.593 . . . . 0.0 106.617 178.027 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' LEU . . . . . 0.498 ' H ' ' HG ' ' B' ' 34' ' ' LEU . 36.8 tp -133.67 135.22 43.96 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 122.529 1.157 . . . . 0.0 111.641 -178.251 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.409 ' HE1' ' O ' ' H' ' 31' ' ' ILE . 12.5 ttm -104.66 110.54 22.9 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 113.752 -1.567 . . . . 0.0 107.198 177.629 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.15 72.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.7 110.83 3.12 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.15 165.74 11.95 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -95.01 135.98 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 110.711 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.432 HG23 ' H ' ' A' ' 40' ' ' VAL . 11.5 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.62 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -102.92 134.93 45.52 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -141.21 130.35 23.42 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.952 0.406 . . . . 0.0 110.834 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.17 146.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.627 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.447 ' ND1' HG11 ' A' ' 12' ' ' VAL . 26.0 t60 -154.83 104.68 2.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.038 0.447 . . . . 0.0 111.16 179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' ND1' ' C' ' 14' ' ' HIS . 31.3 m170 -119.35 164.51 15.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -154.47 173.03 16.81 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.01 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -153.67 114.11 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.809 178.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.421 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.1 mp -128.39 114.49 16.91 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.92 133.73 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-O 121.101 0.477 . . . . 0.0 111.064 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -119.46 129.61 54.83 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.997 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -124.65 129.07 49.84 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.691 -0.231 . . . . 0.0 110.468 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.13 128.34 43.27 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 111.859 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.8 tt0 -136.79 149.36 47.73 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' CB ' ' A' ' 28' ' ' LYS . 81.3 m-20 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.812 0.339 . . . . 0.0 111.344 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.62 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.419 -5.908 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.62 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 119.44 -112.39 0.0 OUTLIER 'General case' 0 N--CA 1.391 -3.425 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 -173.213 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.783 ' H ' HD12 ' B' ' 31' ' ' ILE . 2.3 mp -79.79 113.29 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.037 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.507 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.447 HG23 ' O ' ' B' ' 32' ' ' ILE . 14.7 tt -124.85 109.35 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.25 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.833 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -130.06 120.37 3.07 Favored Glycine 0 N--CA 1.468 0.815 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.899 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.4 mp -136.5 160.34 39.07 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 123.219 1.485 . . . . 0.0 113.67 -178.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.6 ttm -127.5 112.33 14.82 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 112.791 -2.004 . . . . 0.0 107.677 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.749 ' CG2' HD11 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -119.6 74.07 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -179.583 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -31.89 -97.99 0.01 OUTLIER Glycine 0 C--N 1.357 1.749 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.48 -173.09 24.59 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.0 p -141.35 141.8 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.95 0.405 . . . . 0.0 110.511 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.945 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 52.2 t . . . . . 0 N--CA 1.467 0.416 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 17.2 p-80 -155.63 143.0 19.42 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 121.13 0.491 . . . . 0.0 111.241 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.632 ' ND1' ' CD2' ' B' ' 14' ' ' HIS . 6.1 m80 -140.91 167.38 22.33 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.11 0.481 . . . . 0.0 109.931 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -150.99 169.88 20.7 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.964 178.277 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -156.96 117.9 3.66 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.55 123.79 40.86 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.648 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -133.54 133.28 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -116.82 107.4 14.58 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 105.287 -2.116 . . . . 0.0 105.287 175.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 24.3 t80 -122.48 134.84 54.56 Favored 'General case' 0 N--CA 1.477 0.878 0 O-C-N 122.312 -0.242 . . . . 0.0 110.532 -177.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 21' ' ' ALA . . . . . 0.426 ' CB ' ' NZ ' ' A' ' 28' ' ' LYS . . . -145.61 144.11 30.27 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -142.61 110.73 5.99 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 114.147 -1.388 . . . . 0.0 109.642 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.417 ' H ' ' HB3' ' D' ' 23' ' ' ASP . 4.1 m-20 . . . . . 0 C--O 1.215 -0.723 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.593 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.95 155.8 49.72 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.492 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -141.5 117.39 6.5 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 112.295 -2.23 . . . . 0.0 109.204 -170.592 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.408 ' O ' HG22 ' C' ' 32' ' ' ILE . 5.4 mt -105.5 111.64 35.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.499 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -122.11 104.39 0.91 Allowed Glycine 0 CA--C 1.506 -0.499 0 N-CA-C 106.273 -2.731 . . . . 0.0 106.273 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.899 HD12 ' O ' ' B' ' 34' ' ' LEU . 54.6 tp -132.59 141.05 48.52 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 123.3 1.524 . . . . 0.0 113.806 -176.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.793 ' SD ' HG22 ' I' ' 31' ' ' ILE . 8.3 ttm -115.56 118.43 33.11 Favored 'General case' 0 CA--C 1.505 -0.774 0 CA-C-N 112.4 -2.182 . . . . 0.0 109.262 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.557 HG11 HD23 ' D' ' 17' ' ' LEU . 1.3 m -128.57 74.12 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.19 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.1 105.68 3.08 Favored Glycine 0 C--N 1.354 1.545 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -129.76 148.29 18.34 Favored Glycine 0 N--CA 1.466 0.685 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 m -134.05 159.8 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.944 0.402 . . . . 0.0 110.834 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.914 179.816 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 12' ' ' VAL . . . . . 0.591 HG22 ' O ' ' E' ' 11' ' ' GLU . 2.8 t . . . . . 0 CA--C 1.516 -0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.8 p-80 -157.8 148.74 21.14 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.632 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.565 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 56.7 t-80 -144.98 158.83 43.69 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.253 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 15' ' ' GLN . . . . . 0.565 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 67.7 mt-30 -156.22 172.15 18.96 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.106 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -155.63 122.3 5.29 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.709 179.346 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.557 HD23 HG11 ' C' ' 36' ' ' VAL . 47.7 tp -117.39 123.1 45.63 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 39.1 t -130.53 131.22 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.724 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 10.7 m-85 -112.73 108.88 18.06 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 175.743 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.0 t80 -123.35 123.76 41.43 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 120.93 0.395 . . . . 0.0 112.026 -176.809 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.61 127.32 30.96 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.253 178.694 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -140.46 114.29 8.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.771 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 23' ' ' ASP . . . . . 0.517 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.2 OUTLIER . . . . . 0 N--CA 1.454 -0.242 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.971 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.487 -1.452 0 N-CA-C 101.352 -3.574 . . . . 0.0 101.352 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.455 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -136.27 122.59 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.647 -171.33 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CE ' ' K' ' 35' ' ' MET . 78.4 mt -116.36 123.27 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.055 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.57 109.19 1.08 Allowed Glycine 0 N--CA 1.463 0.461 0 N-CA-C 107.609 -2.196 . . . . 0.0 107.609 175.174 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.419 HD13 ' CZ ' ' E' ' 19' ' ' PHE . 14.7 tp -122.09 124.53 44.12 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 121.541 0.686 . . . . 0.0 112.243 -178.708 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.508 ' SD ' ' N ' ' J' ' 32' ' ' ILE . 13.5 ttm -102.86 113.6 27.18 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.435 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.01 72.85 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.809 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.14 111.53 3.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 178.91 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.73 135.47 7.22 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -124.27 135.95 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.797 0.332 . . . . 0.0 110.309 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.588 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.49 148.25 33.56 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.788 0.328 . . . . 0.0 110.237 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 11' ' ' GLU . . . . . 0.591 ' O ' HG22 ' D' ' 12' ' ' VAL . 59.9 mm-40 -57.45 136.36 56.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.296 -0.411 . . . . 0.0 109.951 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -135.33 142.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -109.85 -178.89 3.65 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 118.179 0.445 . . . . 0.0 110.959 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CD2' ' F' ' 13' ' ' HIS . 93.8 m-70 -142.41 -178.66 5.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.751 0.786 . . . . 0.0 110.149 -179.078 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -88.46 168.0 12.99 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.661 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.42 143.38 33.88 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.273 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.529 HD13 ' CD2' ' F' ' 17' ' ' LEU . 5.2 mp -131.22 124.35 30.4 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.146 0.498 . . . . 0.0 111.671 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -128.3 129.39 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.854 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.438 ' HZ ' HD23 ' C' ' 34' ' ' LEU . 35.9 m-85 -117.99 120.85 39.05 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -128.59 127.66 42.71 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 117.927 0.331 . . . . 0.0 111.124 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.3 131.55 43.89 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 122.381 1.086 . . . . 0.0 113.058 -179.032 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -138.27 85.73 2.11 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.069 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -93.97 -130.71 0.14 Allowed 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.415 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 82.9 t -106.2 112.32 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 N-CA-C 104.747 -2.316 . . . . 0.0 104.747 175.301 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 31.76 88.08 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 113.904 -1.498 . . . . 0.0 112.977 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.509 ' N ' ' HB2' ' F' ' 23' ' ' ASP . 35.3 p . . . . . 0 C--N 1.35 0.597 0 CA-C-N 119.262 1.531 . . . . 0.0 108.718 173.992 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.886 1 N-CA-C 93.028 -6.656 . . . . 0.0 93.028 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.5 OUTLIER -85.09 114.91 26.0 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 1 CA-C-N 127.789 4.813 . . . . 0.0 109.163 176.935 . . . . . . . . 4 4 . 1 . 008 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' K' ' 35' ' ' MET . 16.1 tt -136.69 134.94 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-O 121.719 0.771 . . . . 0.0 112.452 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -131.9 127.36 4.95 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.512 HD13 ' CE1' ' F' ' 19' ' ' PHE . 23.9 tp -121.03 124.26 44.41 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.637 -0.282 . . . . 0.0 111.679 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.1 tpp -115.99 114.6 24.82 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.86 88.51 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.62 -178.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.58 95.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 119.67 -1.253 . . . . 0.0 110.342 178.154 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -159.28 162.56 32.86 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.56 162.77 34.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.311 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -148.26 159.59 43.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.016 0.436 . . . . 0.0 111.256 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -67.25 137.9 56.5 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.985 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -127.16 132.38 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.326 0.584 . . . . 0.0 110.999 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' NE2' ' E' ' 14' ' ' HIS . 27.2 t-80 -156.07 100.95 2.06 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.888 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -147.23 173.3 12.68 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -145.03 174.65 10.85 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.319 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -145.99 112.71 5.98 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.032 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.529 ' CD2' HD13 ' E' ' 17' ' ' LEU . 35.8 mt -125.07 110.2 13.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 m -145.93 147.12 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 118.682 -1.207 . . . . 0.0 114.244 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.512 ' CE1' HD13 ' E' ' 34' ' ' LEU . 73.0 m-85 -126.7 128.3 46.48 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 113.967 -1.469 . . . . 0.0 108.431 177.822 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -138.36 146.48 42.35 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.12 0.486 . . . . 0.0 111.458 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.55 146.48 32.39 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.956 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -88.07 127.47 35.4 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.866 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.509 ' HB2' ' N ' ' E' ' 26' ' ' SER . 67.1 t0 178.1 114.36 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 79.6 t -65.39 132.44 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.173 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . 71.68 -85.08 0.45 Allowed Glycine 0 N--CA 1.47 0.958 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 26' ' ' SER . . . . . 0.551 ' CB ' ' O ' ' F' ' 25' ' ' GLY . 2.8 t 140.23 165.4 0.0 OUTLIER 'General case' 0 C--N 1.352 0.703 0 CA-C-O 122.577 1.18 . . . . 0.0 112.905 174.46 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.504 ' N ' ' OD1' ' F' ' 27' ' ' ASN . 0.5 OUTLIER -46.48 171.93 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.44 175.535 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -69.93 111.53 5.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 170.31 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.88 -92.88 0.93 Allowed Glycine 0 N--CA 1.475 1.257 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.861 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.5 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . 83.38 160.28 0.12 Allowed 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 100.439 -3.911 . . . . 0.0 100.439 -174.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.5 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.2 OUTLIER -151.67 127.87 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 122.45 2.386 . . . . 0.0 111.039 -176.286 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -121.43 132.77 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-N 114.151 -1.386 . . . . 0.0 114.254 -175.524 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -130.22 115.12 1.78 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 mt -118.45 127.49 53.71 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.534 ' CE ' HG22 ' L' ' 31' ' ' ILE . 1.8 ttt -132.09 126.7 34.41 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.539 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -143.33 82.52 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.442 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.666 ' HA3' HD13 ' L' ' 31' ' ' ILE . . . -51.23 100.37 0.04 OUTLIER Glycine 0 C--N 1.337 0.61 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.674 -179.209 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.11 163.09 35.76 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -121.45 132.94 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.924 0.393 . . . . 0.0 110.315 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.897 -179.566 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 t60 . . . . . 0 C--O 1.225 -0.191 0 CA-C-O 120.88 0.372 . . . . 0.0 110.675 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 14.8 t60 -147.84 163.56 36.38 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 85.3 mt-30 -151.64 178.17 9.61 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.326 0.584 . . . . 0.0 110.871 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 25.5 pttm -167.72 133.57 2.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.266 179.262 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -133.57 125.05 28.0 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.95 138.14 49.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.248 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -134.77 137.25 43.24 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 20' ' ' PHE . . . . . 0.483 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 54.3 p90 -135.18 129.05 33.16 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.142 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.38 134.75 50.96 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -157.21 124.66 5.28 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.359 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.558 ' O ' ' O ' ' G' ' 24' ' ' VAL . 12.0 m-20 -154.13 122.71 6.21 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 120.827 -0.349 . . . . 0.0 111.849 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.558 ' O ' ' O ' ' G' ' 23' ' ' ASP . 11.8 m -43.67 -122.1 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 O-C-N 124.273 0.983 . . . . 0.0 111.621 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.49 -90.79 1.35 Allowed Glycine 0 CA--C 1.528 0.886 0 CA-C-O 119.52 -0.6 . . . . 0.0 113.023 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' G' ' 27' ' ' ASN . 1.3 p 173.76 -170.58 0.04 OUTLIER 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 117.587 0.694 . . . . 0.0 109.625 -177.694 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' G' ' 26' ' ' SER . 16.4 t-20 -16.98 158.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 O-C-N 125.149 1.53 . . . . 0.0 113.49 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.531 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 28.6 tttt -161.56 108.54 1.4 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.58 98.1 0.66 Allowed Glycine 0 N--CA 1.467 0.746 0 CA-C-O 116.221 -2.433 . . . . 0.0 107.935 172.804 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.406 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -90.08 154.24 19.95 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 123.627 3.714 . . . . 0.0 110.552 -176.706 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.4 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -153.82 114.55 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 112.528 -2.124 . . . . 0.0 109.75 -173.626 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 6.0 tt -122.78 113.79 39.61 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 176.355 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 33' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' H' ' 33' ' ' GLY . . . -132.68 137.61 9.52 Favored Glycine 0 CA--C 1.502 -0.731 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -153.26 146.81 25.01 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 122.447 1.117 . . . . 0.0 112.024 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.402 ' CE ' ' O ' ' A' ' 31' ' ' ILE . 31.0 mtp -105.19 119.15 38.34 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 113.257 -1.792 . . . . 0.0 107.878 178.286 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.76 65.72 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.297 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.283 178.912 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.95 102.42 0.56 Allowed Glycine 0 C--N 1.376 2.754 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 177.08 170.3 39.35 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-O 120.93 0.395 . . . . 0.0 110.258 179.321 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 12' ' ' VAL . . . . . 0.405 HG13 ' CG2' ' I' ' 12' ' ' VAL . 54.3 t . . . . . 0 CA--C 1.522 -0.103 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 13' ' ' HIS . . . . . 0.904 ' HD1' ' CD2' ' I' ' 13' ' ' HIS . 40.7 m80 -137.18 145.78 44.13 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.953 0.406 . . . . 0.0 111.396 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.531 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 99.1 m-70 -147.09 155.96 42.61 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.4 mm-40 -148.73 168.29 23.3 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.41 178.716 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -163.6 128.63 2.96 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.46 -0.791 . . . . 0.0 108.983 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 17' ' ' LEU . . . . . 0.597 HD23 ' C ' ' H' ' 17' ' ' LEU . 5.6 tt -127.46 118.11 23.4 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.58 ' N ' HD23 ' H' ' 17' ' ' LEU . 72.8 t -122.2 129.48 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.202 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -126.25 122.87 36.78 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.489 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -126.84 127.66 45.33 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.702 0.286 . . . . 0.0 111.374 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.36 125.61 50.38 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 120.981 0.42 . . . . 0.0 111.525 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' O ' ' I' ' 22' ' ' GLU . 52.7 tp10 -132.67 157.4 44.94 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.664 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -158.64 142.03 14.98 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--N 1.321 -0.658 0 CA-C-O 122.344 1.068 . . . . 0.0 110.391 -177.878 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.082 0 CA-C-O 123.279 1.514 . . . . 0.0 107.546 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.554 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -140.03 121.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-N 112.404 -2.18 . . . . 0.0 110.529 -173.474 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.513 ' N ' ' SD ' ' B' ' 35' ' ' MET . 8.7 tt -111.33 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 CA-C-O 121.613 0.72 . . . . 0.0 110.112 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' G' ' 33' ' ' GLY . . . -112.37 94.85 0.76 Allowed Glycine 0 N--CA 1.461 0.366 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' I' ' 34' ' ' LEU . 35.6 mt -117.0 129.25 55.9 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.273 1.035 . . . . 0.0 111.551 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.629 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 21.9 ttp -116.27 115.52 26.1 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.312 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.89 71.15 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.897 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.61 112.41 3.61 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -50.64 152.52 4.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.84 162.02 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.297 179.901 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' I' I ' 12' ' ' VAL . . . . . 0.405 ' CG2' HG13 ' H' ' 12' ' ' VAL . 16.3 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.553 0.692 . . . . 0.0 111.757 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.904 ' CD2' ' HD1' ' H' ' 13' ' ' HIS . 71.2 m80 -150.07 101.85 3.05 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.134 178.811 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 84.9 t60 -121.23 162.91 19.39 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.853 0.835 . . . . 0.0 111.376 -178.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.546 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 84.3 mt-30 -148.47 177.73 9.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.098 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -171.01 125.28 0.66 Allowed 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.4 mt -126.71 123.34 37.28 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.095 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' J' ' 18' ' ' VAL . 12.6 p -136.41 133.32 49.44 Favored 'Isoleucine or valine' 0 C--N 1.351 0.663 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -115.68 126.06 53.63 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.649 177.782 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -129.38 121.85 28.26 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 118.327 0.512 . . . . 0.0 111.03 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.31 128.46 51.08 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.077 0.465 . . . . 0.0 111.224 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' H' ' 22' ' ' GLU . 82.1 tt0 -149.02 124.67 10.43 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.311 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -157.11 103.97 2.05 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 118.909 -1.116 . . . . 0.0 113.799 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 2.2 p -31.78 147.67 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.525 -1.216 . . . . 0.0 113.07 175.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.4 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 168.52 -79.42 0.1 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.282 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 26' ' ' SER . . . . . 1.001 ' O ' ' O ' ' I' ' 27' ' ' ASN . 2.1 p 161.66 179.86 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 1.001 ' O ' ' O ' ' I' ' 26' ' ' SER . 8.2 m120 10.52 -178.74 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.112 0 O-C-N 124.841 1.338 . . . . 0.0 113.251 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.497 ' O ' ' N ' ' J' ' 29' ' ' GLY . 12.7 tttt -149.15 109.77 4.24 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 116.202 -2.199 . . . . 0.0 114.646 177.625 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.96 94.65 0.79 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 106.248 -2.741 . . . . 0.0 106.248 168.194 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.43 144.4 51.06 Favored 'General case' 0 CA--C 1.476 -1.882 0 CA-C-N 122.543 3.171 . . . . 0.0 107.094 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.793 HG22 ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -144.15 125.24 9.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 113.09 -1.868 . . . . 0.0 109.504 -175.189 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.543 ' N ' ' SD ' ' C' ' 35' ' ' MET . 0.8 OUTLIER -105.22 110.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.064 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.69 101.73 1.24 Allowed Glycine 0 CA--C 1.494 -1.243 0 N-CA-C 104.817 -3.313 . . . . 0.0 104.817 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' H' ' 34' ' ' LEU . 17.0 tp -136.82 137.55 39.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-O 122.11 0.957 . . . . 0.0 112.508 -175.085 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 31.1 ttp -122.86 123.42 40.94 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 113.74 -1.573 . . . . 0.0 110.164 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.559 ' CG2' HD11 ' J' ' 34' ' ' LEU . 0.1 OUTLIER -126.35 71.56 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.826 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.84 113.1 5.03 Favored Glycine 0 C--N 1.358 1.779 0 N-CA-C 110.531 -1.027 . . . . 0.0 110.531 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.16 147.81 41.66 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 64.3 t -130.87 137.29 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' I' I ' 40' ' ' VAL . . . . . 0.402 ' O ' HG23 ' I' ' 40' ' ' VAL . 30.4 m . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.44 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.473 0.686 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' J' J ' 13' ' ' HIS . . . . . 0.498 ' CD2' ' HB2' ' I' ' 13' ' ' HIS . 0.4 OUTLIER -131.31 155.98 46.25 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 121.19 0.519 . . . . 0.0 110.943 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -152.4 160.18 43.32 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -154.67 172.25 18.2 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.219 -0.592 . . . . 0.0 110.634 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -155.75 127.96 7.65 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.747 178.527 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 17' ' ' LEU . . . . . 0.427 HD12 HD11 ' K' ' 17' ' ' LEU . 87.4 mt -120.47 120.12 34.98 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 18' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' I' ' 18' ' ' VAL . 2.0 p -143.06 137.92 26.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -177.898 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.83 127.9 13.7 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 119.684 -0.806 . . . . 0.0 111.403 176.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -147.77 160.82 42.31 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.443 1.116 . . . . 0.0 113.752 -178.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 140.17 43.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 113.934 -1.484 . . . . 0.0 109.946 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.17 149.44 39.74 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.968 -178.926 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 33.7 t70 -173.49 126.46 0.41 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.08 0.467 . . . . 0.0 111.293 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.444 ' H ' HG22 ' J' ' 24' ' ' VAL . 5.4 m -62.61 -116.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.516 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.47 -92.22 0.06 OUTLIER Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.603 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.831 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.3 t -171.24 170.05 6.17 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 117.535 0.668 . . . . 0.0 109.986 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.831 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.8 m120 10.85 -179.16 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 125.763 1.914 . . . . 0.0 115.567 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.595 ' H ' ' N ' ' K' ' 27' ' ' ASN . 15.8 pttt -149.4 110.76 4.44 Favored 'General case' 0 CA--C 1.558 1.25 0 O-C-N 120.635 -1.29 . . . . 0.0 114.284 178.263 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -61.48 93.22 0.07 OUTLIER Glycine 0 N--CA 1.479 1.517 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 172.077 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.487 ' HB2' ' HG3' ' J' ' 28' ' ' LYS . . . -126.39 149.33 49.3 Favored 'General case' 0 CA--C 1.486 -1.489 0 CA-C-N 121.677 2.739 . . . . 0.0 111.069 -178.707 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.736 HG13 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.33 114.42 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.816 0 CA-C-N 108.989 -3.732 . . . . 0.0 107.612 -174.968 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.508 ' N ' ' SD ' ' D' ' 35' ' ' MET . 3.1 mt -105.56 118.74 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 CA-C-O 120.749 0.309 . . . . 0.0 110.429 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.96 100.78 0.91 Allowed Glycine 0 C--O 1.239 0.421 0 N-CA-C 106.9 -2.48 . . . . 0.0 106.9 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.627 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 55.7 tp -129.58 135.39 48.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.003 0.906 . . . . 0.0 112.415 -177.39 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.418 ' SD ' ' C ' ' D' ' 31' ' ' ILE . 48.9 ttp -117.87 117.07 28.28 Favored 'General case' 0 CA--C 1.502 -0.881 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.55 175.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.506 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -120.26 72.2 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 178.608 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.51 111.87 4.5 Favored Glycine 0 C--N 1.36 1.861 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 178.503 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.36 -151.58 3.07 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -179.199 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.9 m . . . . . 0 N--CA 1.467 0.386 0 CA-C-O 121.097 0.475 . . . . 0.0 110.74 179.994 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 . . . . . 0 N--CA 1.466 0.328 0 CA-C-O 120.676 0.274 . . . . 0.0 110.702 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.5 m -118.88 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.099 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 13' ' ' HIS . . . . . 0.631 ' CE1' ' NE2' ' L' ' 14' ' ' HIS . 1.8 p80 -161.7 168.87 22.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.475 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.537 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 39.4 t-80 -138.71 165.67 26.36 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.548 0.69 . . . . 0.0 110.901 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.537 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 87.4 mt-30 -148.42 178.69 8.38 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.966 -1.015 . . . . 0.0 110.091 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 16' ' ' LYS . . . . . 0.433 ' C ' HD12 ' K' ' 17' ' ' LEU . 38.2 ttmt -172.76 123.41 0.44 Allowed 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 118.419 -0.8 . . . . 0.0 111.45 -178.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 17' ' ' LEU . . . . . 0.943 ' O ' ' C ' ' L' ' 17' ' ' LEU . 9.4 mp -110.73 119.07 37.92 Favored 'General case' 0 C--N 1.379 1.85 0 CA-C-O 123.836 1.779 . . . . 0.0 111.111 177.354 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 18' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 7.1 p -138.25 112.07 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 O-C-N 120.675 -1.266 . . . . 0.0 111.432 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 1.7 p90 -134.51 139.62 45.59 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 176.383 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.47 ' CB ' ' O ' ' L' ' 20' ' ' PHE . 30.3 p90 -154.77 162.9 40.94 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -176.553 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.35 130.61 48.0 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.412 178.628 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.31 137.13 50.83 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.158 0.504 . . . . 0.0 111.965 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 56.6 t0 -159.56 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.323 178.96 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' K' ' 26' ' ' SER . 55.9 t -123.88 123.02 66.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 179.047 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.476 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 32.0 -84.35 0.0 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' K' ' 24' ' ' VAL . 8.1 t 154.31 172.0 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 121.748 0.785 . . . . 0.0 111.235 174.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.595 ' N ' ' H ' ' J' ' 28' ' ' LYS . 43.1 p-10 -53.63 179.94 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.43 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.72 112.09 1.88 Allowed 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.176 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.617 ' O ' ' HB2' ' L' ' 30' ' ' ALA . . . 75.4 -91.74 0.85 Allowed Glycine 0 CA--C 1.532 1.145 0 C-N-CA 121.285 -0.483 . . . . 0.0 112.083 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.519 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 106.48 161.13 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 104.562 -2.384 . . . . 0.0 104.562 -178.436 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.519 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -144.88 132.15 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 118.027 -1.469 . . . . 0.0 112.796 -178.269 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -124.42 123.68 66.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.3 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 114.93 2.94 Favored Glycine 0 N--CA 1.473 1.126 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 46.0 mt -122.42 127.31 49.51 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 56.8 ttp -119.83 121.29 38.77 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.234 177.758 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.506 HG22 HG23 ' J' ' 36' ' ' VAL . 60.0 t -115.4 88.17 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.23 96.06 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.85 162.19 31.51 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.468 0.428 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.77 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.467 0.413 0 CA-C-O 121.116 0.484 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -99.45 176.79 5.38 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.276 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CE1' ' K' ' 13' ' ' HIS . 0.4 OUTLIER -92.36 165.76 12.91 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.302 0.573 . . . . 0.0 110.04 -179.614 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -168.19 168.58 11.54 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.548 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.52 108.71 2.98 Favored 'General case' 0 C--O 1.171 -3.049 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 17' ' ' LEU . . . . . 0.943 ' C ' ' O ' ' K' ' 17' ' ' LEU . 2.7 mm? -73.09 160.73 31.56 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 119.654 -1.903 . . . . 0.0 107.622 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 18' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 14.3 m -99.89 -121.06 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -173.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.627 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 7.7 p90 -147.6 162.11 39.78 Favored 'General case' 0 N--CA 1.47 0.551 0 O-C-N 121.618 -0.676 . . . . 0.0 112.588 -177.178 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.47 ' O ' ' CB ' ' K' ' 20' ' ' PHE . 93.6 m-85 -144.72 151.48 38.96 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 121.718 0.77 . . . . 0.0 112.087 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.64 138.27 39.3 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -69.79 95.08 0.87 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.128 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -164.06 121.57 1.75 Allowed 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.589 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' L' ' 26' ' ' SER . 13.5 t -88.53 123.56 40.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.61 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.3 0.01 OUTLIER Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.578 ' N ' ' O ' ' L' ' 24' ' ' VAL . 12.8 t -68.13 -171.59 0.25 Allowed 'General case' 0 N--CA 1.441 -0.921 0 CA-C-O 122.593 1.187 . . . . 0.0 112.333 -177.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.415 ' O ' ' C ' ' L' ' 28' ' ' LYS . 35.4 p-10 -81.0 179.29 7.93 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 112.547 -2.115 . . . . 0.0 109.814 178.924 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' L' ' 27' ' ' ASN . 70.1 tttt -37.17 104.15 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 29' ' ' GLY . . . . . 0.402 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 167.84 -100.42 0.16 Allowed Glycine 0 C--O 1.22 -0.726 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.617 ' HB2' ' O ' ' K' ' 29' ' ' GLY . . . -49.55 169.37 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.137 1.469 . . . . 0.0 108.734 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.666 HD13 ' HA3' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -153.37 133.2 3.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.454 -177.659 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 83.7 mt -120.41 128.91 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 114.43 -1.259 . . . . 0.0 108.921 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.428 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -125.7 124.82 5.36 Favored Glycine 0 N--CA 1.468 0.808 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.2 tp -126.99 120.04 28.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 36.8 ttp -110.34 126.67 54.48 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.0 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.2 t -130.28 81.73 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.056 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.489 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -60.83 101.43 0.3 Allowed Glycine 0 N--CA 1.439 -1.161 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.16 169.28 41.36 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 57.6 t -122.73 135.84 61.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 120.742 0.306 . . . . 0.0 110.218 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.446 -179.919 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' CE1' ' B' ' 13' ' ' HIS . 42.6 tp10 . . . . . 0 C--O 1.232 0.143 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.2 160.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.445 0.641 . . . . 0.0 111.386 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.0 m80 -89.0 -170.17 2.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.905 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -80.49 168.64 18.7 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 121.357 0.599 . . . . 0.0 110.002 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -157.21 -179.86 8.6 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.878 -1.055 . . . . 0.0 108.993 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -155.22 129.32 8.82 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.695 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 72.9 mt -129.28 118.95 23.13 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.597 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -130.17 131.19 65.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -127.65 131.53 49.84 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.009 0.433 . . . . 0.0 110.712 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -132.53 125.94 31.74 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.94 137.16 44.69 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-O 121.778 0.799 . . . . 0.0 112.955 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -126.8 126.77 43.94 Favored 'General case' 0 CA--C 1.528 0.12 0 CA-C-N 114.625 -1.17 . . . . 0.0 108.449 178.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 20.7 t70 . . . . . 0 C--N 1.325 -0.457 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.527 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.4 tttt . . . . . 0 C--O 1.217 -0.624 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.16 102.9 0.98 Allowed Glycine 0 N--CA 1.467 0.706 0 N-CA-C 103.622 -3.791 . . . . 0.0 103.622 170.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -97.35 144.11 27.43 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 123.311 3.555 . . . . 0.0 115.527 -172.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' G' ' 35' ' ' MET . 1.7 pt -159.82 105.56 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.421 -1.907 1 CA-C-N 107.016 -4.629 . . . . 0.0 106.245 -173.895 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.554 HG23 HD11 ' B' ' 34' ' ' LEU . 8.1 tt -108.45 114.53 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 CA-C-N 120.524 1.511 . . . . 0.0 108.107 178.236 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -121.58 124.72 5.89 Favored Glycine 0 CA--C 1.508 -0.351 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -148.83 140.4 23.47 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 122.806 1.288 . . . . 0.0 113.002 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' MET . . . . . 0.586 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 3.7 ttm -109.82 117.65 34.42 Favored 'General case' 0 CA--C 1.505 -0.786 0 CA-C-N 113.038 -1.892 . . . . 0.0 108.094 177.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -111.12 68.04 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -120.79 101.53 0.81 Allowed Glycine 0 C--N 1.359 1.842 0 N-CA-C 110.404 -1.079 . . . . 0.0 110.404 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.39 165.73 35.2 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.329 -0.709 . . . . 0.0 111.329 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' VAL . . . . . 0.479 ' O ' HG13 ' A' ' 40' ' ' VAL . 31.4 m -135.96 156.24 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.663 0.268 . . . . 0.0 110.385 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' VAL . . . . . 0.479 HG13 ' O ' ' A' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.129 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.86 145.37 42.92 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.6 0.238 . . . . 0.0 110.447 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -68.04 126.87 30.86 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.279 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m -137.08 164.1 30.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.092 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.538 ' CE1' ' OE1' ' A' ' 11' ' ' GLU . 59.4 m80 -91.36 98.14 11.52 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.546 -0.461 . . . . 0.0 109.971 179.254 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.519 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 3.7 m-70 -134.51 166.83 21.98 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -154.57 175.11 14.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.059 179.017 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -154.46 117.04 4.35 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.495 179.2 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.03 119.5 29.69 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.454 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 t -122.33 127.68 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.961 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 83.0 t80 -130.22 126.26 36.93 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.834 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -128.48 132.59 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.63 132.35 38.89 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 121.126 0.489 . . . . 0.0 111.114 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -147.88 168.0 23.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.227 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 121.153 0.502 . . . . 0.0 111.245 -179.788 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.799 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.417 -6.093 0 CA-C-O 115.111 -3.05 . . . . 0.0 111.33 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.799 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . 76.0 -135.22 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.71 2 C-N-CA 108.667 -5.213 . . . . 0.0 99.248 -174.351 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.973 ' N ' HD13 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -75.47 122.65 29.74 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -179.325 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 83.3 mt -121.73 122.16 66.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 175.322 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 33' ' ' GLY . . . . . 0.701 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -132.47 111.07 0.99 Allowed Glycine 0 N--CA 1.473 1.119 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.075 179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.701 HD12 ' C ' ' B' ' 33' ' ' GLY . 6.4 mp -138.31 144.85 40.61 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 123.47 1.605 . . . . 0.0 113.168 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.506 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 19.6 ttm -119.07 115.85 25.16 Favored 'General case' 0 CA--C 1.499 -0.999 0 CA-C-N 113.002 -1.908 . . . . 0.0 107.41 177.777 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.26 70.62 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.096 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.3 112.5 3.46 Favored Glycine 0 C--N 1.363 2.057 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 -179.105 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 38' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' C' ' 37' ' ' GLY . . . -73.04 147.73 40.07 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -139.49 161.34 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.807 0.337 . . . . 0.0 110.424 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.026 -0.987 . . . . 0.0 110.518 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 121.3 0.571 . . . . 0.0 111.364 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -118.8 138.29 52.8 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.877 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 14' ' ' HIS . . . . . 0.783 ' HD1' ' N ' ' C' ' 15' ' ' GLN . 28.8 t-80 -152.38 165.45 34.97 Favored 'General case' 0 CA--C 1.513 -0.463 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.339 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 15' ' ' GLN . . . . . 0.783 ' N ' ' HD1' ' C' ' 14' ' ' HIS . 75.8 mt-30 -156.44 170.35 22.51 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.025 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -158.87 111.59 2.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.829 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -121.96 122.07 38.52 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -126.67 124.52 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.128 0.49 . . . . 0.0 111.831 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' B' ' 34' ' ' LEU . 1.0 OUTLIER -116.54 110.75 18.99 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 105.89 -1.893 . . . . 0.0 105.89 177.456 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -115.36 121.02 41.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.87 130.59 53.06 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.697 0.761 . . . . 0.0 111.673 -179.253 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -121.18 91.53 3.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.994 178.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.551 1.007 0 C-N-CA 118.816 -1.154 . . . . 0.0 113.129 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.873 0 N-CA-C 112.342 -0.303 . . . . 0.0 112.342 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.401 ' C ' HD13 ' C' ' 31' ' ' ILE . . . -157.48 165.74 34.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 175.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.498 HG22 ' HB ' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.94 121.29 15.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 118.481 -1.287 . . . . 0.0 111.237 -173.687 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 32' ' ' ILE . . . . . 0.458 ' O ' ' CE ' ' I' ' 35' ' ' MET . 12.1 tt -116.72 122.35 69.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-O 121.487 0.661 . . . . 0.0 111.039 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 33' ' ' GLY . . . . . 0.418 ' N ' ' HE1' ' H' ' 35' ' ' MET . . . -110.61 117.36 4.62 Favored Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.876 HD11 ' CZ ' ' D' ' 19' ' ' PHE . 0.4 OUTLIER -146.2 138.23 25.07 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.861 1.315 . . . . 0.0 113.006 -178.099 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 15.0 ttm -129.09 127.37 41.35 Favored 'General case' 0 CA--C 1.505 -0.753 0 CA-C-N 113.446 -1.707 . . . . 0.0 109.449 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.91 78.06 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' B' ' 38' ' ' GLY . . . -69.64 104.78 1.37 Allowed Glycine 0 C--N 1.351 1.399 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.56 -179.33 52.2 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.89 144.21 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.939 0.399 . . . . 0.0 110.771 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.561 179.943 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.466 0.337 0 CA-C-O 120.922 0.392 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 13' ' ' HIS . . . . . 0.435 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 9.5 m80 -123.44 154.81 38.55 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.685 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 14' ' ' HIS . . . . . 0.435 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 47.2 m80 -151.02 164.99 35.13 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.158 0.504 . . . . 0.0 110.06 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -158.99 169.51 24.14 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.553 178.41 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -159.43 117.13 2.73 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.316 178.432 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 17' ' ' LEU . . . . . 0.402 HD13 ' CD2' ' E' ' 17' ' ' LEU . 5.9 mp -119.34 123.78 45.01 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.147 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -126.29 127.05 70.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 19' ' ' PHE . . . . . 0.876 ' CZ ' HD11 ' C' ' 34' ' ' LEU . 1.8 t80 -125.39 113.5 17.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -122.8 131.55 53.82 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -176.026 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 109.77 16.7 Favored 'General case' 0 C--O 1.249 1.079 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 177.687 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' E' ' 22' ' ' GLU . 87.2 tt0 -165.23 91.46 0.53 Allowed 'General case' 0 C--N 1.347 0.487 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 34.1 t70 . . . . . 0 C--N 1.324 -0.531 0 N-CA-C 102.915 -2.995 . . . . 0.0 102.915 173.259 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . . . . . . 1 N--CA 1.372 -4.338 1 N-CA-C 97.485 -5.006 . . . . 0.0 97.485 . . . . . . . . . 3 2 . 1 . 009 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.786 ' N ' ' CD1' ' D' ' 31' ' ' ILE . 1.0 OUTLIER -74.74 111.88 11.29 Favored 'Isoleucine or valine' 1 C--N 1.243 -4.029 0 CA-C-N 123.176 2.716 . . . . 0.0 111.714 -176.013 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' D' D ' 32' ' ' ILE . . . . . 0.54 HG21 HG23 ' E' ' 32' ' ' ILE . 0.2 OUTLIER -110.92 115.51 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 178.126 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 33' ' ' GLY . . . . . 0.551 ' CA ' ' SD ' ' J' ' 35' ' ' MET . . . -113.72 98.67 0.93 Allowed Glycine 0 CA--C 1.503 -0.689 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 34' ' ' LEU . . . . . 0.426 HD22 ' CZ ' ' E' ' 19' ' ' PHE . 61.7 mt -128.31 128.46 44.64 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -176.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 35' ' ' MET . . . . . 0.508 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -123.5 128.85 50.37 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.068 177.214 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.521 ' O ' HG23 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -122.9 80.36 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.457 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -23.36 -95.45 0.01 OUTLIER Glycine 0 C--N 1.361 1.955 0 O-C-N 123.0 0.187 . . . . 0.0 112.639 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 125.84 -178.28 16.73 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' D' D ' 39' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 40' ' ' VAL . 34.3 m -123.27 137.1 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' D' D ' 40' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 39' ' ' VAL . 11.2 t . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.392 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -116.89 140.12 49.82 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.789 0.328 . . . . 0.0 110.716 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -63.88 145.17 56.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.692 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.53 127.93 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.029 0.442 . . . . 0.0 110.029 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 13' ' ' HIS . . . . . 0.479 ' CD2' ' HB3' ' F' ' 13' ' ' HIS . 22.9 p80 -164.38 157.74 17.81 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.945 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 73.4 m80 -135.54 167.78 20.46 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -155.29 167.83 29.06 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.362 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -148.19 117.37 6.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.123 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 17' ' ' LEU . . . . . 0.402 ' CD2' HD13 ' D' ' 17' ' ' LEU . 25.5 mt -114.66 122.17 45.63 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 177.914 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.28 136.35 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-O 122.125 0.964 . . . . 0.0 113.578 -177.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 19' ' ' PHE . . . . . 0.478 ' CB ' ' CE1' ' F' ' 19' ' ' PHE . 0.6 OUTLIER -121.37 126.05 48.48 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 113.832 -1.531 . . . . 0.0 109.091 178.783 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -127.22 129.85 48.56 Favored 'General case' 0 N--CA 1.481 1.076 0 O-C-N 122.079 -0.388 . . . . 0.0 110.663 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.12 125.68 16.8 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.002 0.43 . . . . 0.0 110.749 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 93.9 mt-10 -93.25 156.32 16.9 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.494 -0.882 . . . . 0.0 113.313 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -133.02 141.39 48.24 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.201 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.35 111.08 34.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 25' ' ' GLY . . . . . 0.543 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 34.6 90.81 0.01 OUTLIER Glycine 0 N--CA 1.472 1.049 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 26' ' ' SER . . . . . 0.543 ' O ' ' O ' ' E' ' 25' ' ' GLY . 11.6 p . . . . . 0 N--CA 1.447 -0.592 0 CA-C-O 122.232 1.015 . . . . 0.0 113.179 -179.095 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.241 0.608 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.601 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.3 OUTLIER -149.62 120.28 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 117.972 -1.491 . . . . 0.0 109.168 -176.685 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.54 HG23 HG21 ' D' ' 32' ' ' ILE . 97.0 mt -117.69 126.56 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.569 -176.489 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.14 110.63 1.82 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.588 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 60.7 mt -121.14 123.22 41.78 Favored 'General case' 0 N--CA 1.467 0.375 0 O-C-N 122.756 -0.261 . . . . 0.0 110.742 -179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.7 ttt -135.46 131.21 35.88 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 119.678 -0.809 . . . . 0.0 112.46 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.644 ' O ' HG22 ' E' ' 36' ' ' VAL . 0.6 OUTLIER -158.11 81.36 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.85 178.986 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.13 101.64 1.61 Allowed Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.98 154.89 21.36 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.43 145.1 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.404 -179.661 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -111.0 133.41 53.41 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.779 0.323 . . . . 0.0 110.572 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 71.3 mm-40 -70.71 142.2 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.195 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.31 176.0 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 121.082 0.467 . . . . 0.0 110.552 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.479 ' HB3' ' CD2' ' E' ' 13' ' ' HIS . 56.8 p-80 -99.37 159.88 14.68 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.64 179.256 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -153.48 178.37 9.89 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 15' ' ' GLN . . . . . 0.471 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 42.7 tt0 -148.92 166.64 27.99 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.281 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 16' ' ' LYS . . . . . 0.471 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 68.5 mttm -142.68 131.54 22.86 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.295 0.569 . . . . 0.0 111.608 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 17' ' ' LEU . . . . . 0.427 ' CD2' HG11 ' E' ' 36' ' ' VAL . 56.1 tp -121.75 123.45 41.86 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.72 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.34 127.43 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 121.553 0.692 . . . . 0.0 111.14 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.588 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 0.5 OUTLIER -122.13 114.48 20.94 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.9 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -120.41 117.3 27.36 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-O 121.313 0.578 . . . . 0.0 110.358 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.97 136.87 46.33 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 22' ' ' GLU . . . . . 0.487 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 70.5 mm-40 -70.18 122.1 18.81 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.07 -1.052 . . . . 0.0 111.524 -178.642 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 1.8 p-10 108.6 131.94 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.888 1.675 . . . . 0.0 109.33 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' F' ' 25' ' ' GLY . 2.4 m -110.22 113.44 44.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . 32.28 87.72 0.01 OUTLIER Glycine 0 CA--C 1.527 0.797 0 N-CA-C 111.838 -0.505 . . . . 0.0 111.838 178.953 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 62.7 m -65.17 -174.6 0.17 Allowed 'General case' 0 N--CA 1.438 -1.028 0 CA-C-O 121.448 0.642 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.432 ' O ' ' C ' ' F' ' 28' ' ' LYS . 96.5 m-20 -81.06 178.24 8.54 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.289 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.432 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.3 tttt -38.15 103.93 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 29' ' ' GLY . . . . . 0.44 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 166.02 -100.54 0.17 Allowed Glycine 0 C--O 1.219 -0.796 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -176.008 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.414 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -53.75 168.54 0.19 Allowed 'General case' 0 CA--C 1.509 -0.61 0 CA-C-N 118.038 0.919 . . . . 0.0 108.953 -178.56 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.547 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -150.91 128.1 2.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 C-N-CA 119.331 -0.947 . . . . 0.0 109.309 -174.586 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 17.2 tt -128.2 138.86 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-O 120.909 0.385 . . . . 0.0 111.873 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.41 124.27 3.64 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.2 tp -119.11 122.57 42.37 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.6 tpt -118.54 121.28 39.86 Favored 'General case' 0 N--CA 1.478 0.966 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' F' ' 37' ' ' GLY . 2.9 m -141.84 80.63 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 177.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . 18.1 -104.86 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 CA-C-N 117.516 0.144 . . . . 0.0 113.169 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.64 -161.29 22.82 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -134.37 161.45 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.387 179.939 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 . . . . . 0 N--CA 1.464 0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.514 ' HB2' ' CE1' ' H' ' 14' ' ' HIS . 45.1 p-80 -81.99 174.58 11.12 Favored 'General case' 0 N--CA 1.442 -0.866 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -143.93 179.47 7.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.089 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -152.71 135.19 15.17 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -136.24 117.85 14.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.421 0.629 . . . . 0.0 110.539 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.81 136.31 55.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.619 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -136.09 131.81 35.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-O 121.369 0.604 . . . . 0.0 111.319 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -125.95 130.67 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.61 148.26 45.69 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 122.316 1.055 . . . . 0.0 113.207 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -101.93 -177.67 3.48 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 113.406 -1.724 . . . . 0.0 108.901 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 23' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' G' ' 26' ' ' SER . 67.3 t0 -58.45 123.86 17.62 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.203 -0.599 . . . . 0.0 110.184 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 24' ' ' VAL . . . . . 0.53 ' O ' HG23 ' G' ' 24' ' ' VAL . 23.0 m -95.56 120.59 45.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.926 -179.042 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.93 -88.73 0.01 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 116.111 -0.495 . . . . 0.0 112.607 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.474 ' N ' ' O ' ' G' ' 24' ' ' VAL . 72.2 m -67.52 -171.6 0.2 Allowed 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.549 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 14.7 t-20 -78.79 178.77 7.66 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.186 -178.388 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.549 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 83.9 tttt -44.17 -110.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.143 0.794 . . . . 0.0 113.143 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 54.33 91.88 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.424 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -102.62 161.9 13.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 C-N-CA 116.696 -2.002 . . . . 0.0 108.628 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.505 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.1 OUTLIER -152.36 110.06 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.023 -174.829 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' G' G ' 32' ' ' ILE . . . . . 0.586 ' N ' ' SD ' ' A' ' 35' ' ' MET . 97.3 mt -108.36 110.21 31.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.197 0.523 . . . . 0.0 110.241 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 92.49 0.62 Allowed Glycine 0 CA--C 1.502 -0.761 0 N-CA-C 105.648 -2.981 . . . . 0.0 105.648 175.984 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.723 ' O ' HD12 ' H' ' 34' ' ' LEU . 16.7 mt -130.93 134.19 46.53 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.725 1.726 . . . . 0.0 111.984 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 0.0 OUTLIER -108.4 117.96 35.53 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 112.678 -2.055 . . . . 0.0 109.019 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.35 66.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 N-CA-C 109.244 -0.651 . . . . 0.0 109.244 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.22 -103.52 0.59 Allowed Glycine 0 C--N 1.363 2.063 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.84 162.61 25.23 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.562 179.002 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.464 0.248 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 -179.82 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t . . . . . 0 N--CA 1.464 0.262 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 82.8 t60 -147.26 107.83 4.12 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.683 -0.407 . . . . 0.0 109.99 178.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.618 ' CG ' ' CE1' ' I' ' 14' ' ' HIS . 27.6 p80 -146.73 171.17 15.56 Favored 'General case' 0 N--CA 1.447 -0.586 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.283 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -144.35 177.25 8.76 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.13 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -152.8 131.22 12.13 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.9 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -129.36 118.56 22.42 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.934 0.397 . . . . 0.0 110.414 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -128.34 131.32 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.93 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -126.1 128.99 48.22 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.601 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 0.9 OUTLIER -134.76 128.03 32.07 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.605 -0.27 . . . . 0.0 110.389 -179.187 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.52 123.54 40.33 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.858 0.361 . . . . 0.0 110.226 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 22' ' ' GLU . . . . . 0.551 ' OE2' ' CE1' ' H' ' 20' ' ' PHE . 9.7 pt-20 -168.42 130.05 1.35 Allowed 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 119.897 -0.721 . . . . 0.0 112.157 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 20.0 t70 178.83 114.72 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.389 0.614 . . . . 0.0 112.376 177.386 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 114.724 -1.126 . . . . 0.0 112.364 176.582 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.378 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.491 HG22 ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -139.55 123.1 18.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 119.512 -0.875 . . . . 0.0 109.457 -176.356 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.506 ' N ' ' SD ' ' B' ' 35' ' ' MET . 1.7 mt -115.45 119.09 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.974 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.89 103.69 1.14 Allowed Glycine 0 C--O 1.241 0.588 0 N-CA-C 105.769 -2.932 . . . . 0.0 105.769 175.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.723 HD12 ' O ' ' G' ' 34' ' ' LEU . 5.9 tp -133.74 144.13 48.89 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 122.919 1.342 . . . . 0.0 114.01 -176.16 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.418 ' HE1' ' N ' ' C' ' 33' ' ' GLY . 5.8 tpt -122.25 115.58 22.62 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 113.448 -1.706 . . . . 0.0 108.873 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.47 65.11 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.19 103.86 0.64 Allowed Glycine 0 C--N 1.353 1.504 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -90.24 176.41 41.95 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' H' H ' 39' ' ' VAL . . . . . 0.522 HG12 ' N ' ' H' ' 40' ' ' VAL . 40.5 t -137.24 161.45 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 120.929 0.395 . . . . 0.0 110.634 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' H' H ' 40' ' ' VAL . . . . . 0.522 ' N ' HG12 ' H' ' 39' ' ' VAL . 7.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.957 -1.02 . . . . 0.0 110.424 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 N--CA 1.468 0.448 0 CA-C-O 120.88 0.372 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' I' I ' 13' ' ' HIS . . . . . 0.42 ' CD2' ' N ' ' I' ' 13' ' ' HIS . 3.3 m-70 -142.09 156.97 45.4 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.125 -178.763 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' H' ' 14' ' ' HIS . 16.9 p-80 -156.66 167.53 30.17 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 177.413 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.449 ' CG ' ' N ' ' I' ' 16' ' ' LYS . 52.1 tt0 -150.98 166.66 29.99 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.629 0.728 . . . . 0.0 111.519 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 16' ' ' LYS . . . . . 0.525 ' NZ ' ' CG2' ' I' ' 18' ' ' VAL . 65.9 tttm -154.41 127.57 8.37 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.85 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 17' ' ' LEU . . . . . 0.41 HD21 ' CE2' ' I' ' 19' ' ' PHE . 59.3 tp -124.36 121.77 35.86 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 18' ' ' VAL . . . . . 0.525 ' CG2' ' NZ ' ' I' ' 16' ' ' LYS . 47.8 t -122.95 125.54 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.832 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CE2' HD21 ' I' ' 17' ' ' LEU . 60.5 m-85 -114.2 105.86 13.68 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 176.936 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 1.4 t80 -117.76 126.53 52.62 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 132.97 39.92 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.141 0.496 . . . . 0.0 111.813 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -159.35 114.47 2.45 Favored 'General case' 0 C--N 1.348 0.52 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 23' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' I' ' 23' ' ' ASP . 9.4 t0 -171.9 111.02 0.29 Allowed 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 114.435 1.272 . . . . 0.0 114.435 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.462 ' O ' HG13 ' I' ' 24' ' ' VAL . 12.4 p -31.99 131.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 CA-C-N 112.611 -2.086 . . . . 0.0 115.425 174.478 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -84.22 0.09 OUTLIER Glycine 0 CA--C 1.543 1.841 0 C-N-CA 119.605 -1.283 . . . . 0.0 115.157 174.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.3 m -96.76 175.41 6.37 Favored 'General case' 0 CA--C 1.5 -0.944 0 CA-C-N 120.401 2.1 . . . . 0.0 108.916 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.45 ' O ' ' O ' ' I' ' 28' ' ' LYS . 46.2 m-20 -62.52 175.62 0.76 Allowed 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' I' ' 27' ' ' ASN . 53.4 tttt -45.1 -107.88 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 122.301 1.048 . . . . 0.0 113.796 178.078 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . 87.73 -100.01 2.56 Favored Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.907 ' C ' HD13 ' I' ' 31' ' ' ILE . . . 62.81 143.6 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.083 0 O-C-N 121.498 -1.001 . . . . 0.0 109.135 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.907 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -145.26 114.47 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.373 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' I' ' 32' ' ' ILE . 1.2 tt -108.19 112.38 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.97 113.86 2.56 Favored Glycine 0 CA--C 1.493 -1.288 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 0.549 HD23 ' N ' ' I' ' 34' ' ' LEU . 2.0 pt? -162.06 160.73 27.83 Favored 'General case' 0 C--O 1.249 1.041 0 CA-C-O 123.304 1.526 . . . . 0.0 112.695 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.491 ' SD ' ' HB ' ' C' ' 31' ' ' ILE . 33.2 ttm -127.71 136.6 51.77 Favored 'General case' 0 CA--C 1.503 -0.827 0 CA-C-N 112.351 -2.204 . . . . 0.0 111.052 -177.925 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.99 70.63 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.186 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.98 106.37 3.28 Favored Glycine 0 C--N 1.364 2.098 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.7 172.01 55.16 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.214 -0.755 . . . . 0.0 111.214 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -144.36 149.01 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.408 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 5.5 p . . . . . 0 C--O 1.238 0.449 0 CA-C-O 121.981 0.896 . . . . 0.0 112.591 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -150.9 105.62 3.28 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 114.08 -1.418 . . . . 0.0 109.548 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -149.27 166.8 27.86 Favored 'General case' 0 CA--C 1.508 -0.643 0 O-C-N 121.641 -0.662 . . . . 0.0 110.598 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 13.3 mp0 -146.68 169.97 17.93 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.675 0.75 . . . . 0.0 111.414 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -143.71 135.88 26.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.152 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -133.87 124.61 26.75 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.65 133.69 61.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 CA-C-O 121.289 0.566 . . . . 0.0 112.078 -178.701 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 91.7 m-85 -112.02 113.84 26.37 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.39 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.45 ' CD1' ' CZ ' ' I' ' 20' ' ' PHE . 5.7 t80 -122.16 123.15 40.84 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 118.518 0.599 . . . . 0.0 112.592 -178.27 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.24 131.52 38.59 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 122.047 -0.408 . . . . 0.0 110.873 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 18.2 pt-20 -151.88 168.44 25.13 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.461 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.482 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 6.7 p30 150.94 164.12 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.149 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' J' ' 23' ' ' ASP . 48.8 t -35.83 101.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.44 93.36 0.5 Allowed Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.227 -0.897 . . . . 0.0 114.87 -175.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.751 ' O ' ' O ' ' J' ' 27' ' ' ASN . 39.3 p -102.79 160.63 14.43 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 175.95 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.751 ' O ' ' O ' ' J' ' 26' ' ' SER . 92.2 m-20 38.17 -179.22 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -174.035 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.677 ' N ' ' ND2' ' K' ' 27' ' ' ASN . 88.0 tttt -148.95 108.37 3.96 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 114.968 -2.693 . . . . 0.0 115.747 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -76.23 95.07 1.05 Allowed Glycine 0 CA--C 1.493 -1.285 0 CA-C-O 114.938 -3.146 . . . . 0.0 108.65 166.121 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' I' ' 29' ' ' GLY . . . -137.32 142.7 41.85 Favored 'General case' 0 CA--C 1.463 -2.381 1 CA-C-N 124.891 4.346 . . . . 0.0 108.061 176.136 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.621 HD12 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -142.91 106.12 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.357 -177.774 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.517 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -105.32 116.7 49.63 Favored 'Isoleucine or valine' 0 C--N 1.359 0.993 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.677 -178.356 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.38 96.45 0.72 Allowed Glycine 0 C--O 1.24 0.49 0 N-CA-C 106.447 -2.661 . . . . 0.0 106.447 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.803 HD23 ' CZ ' ' L' ' 19' ' ' PHE . 8.2 tp -134.25 124.87 26.63 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-O 122.695 1.236 . . . . 0.0 111.975 -177.19 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 35' ' ' MET . . . . . 0.562 ' N ' HD12 ' J' ' 34' ' ' LEU . 4.3 ttt -119.87 126.96 52.21 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 113.345 -1.752 . . . . 0.0 109.176 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' J' J ' 36' ' ' VAL . . . . . 0.557 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -113.58 73.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.187 -178.952 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.66 112.46 0.4 Allowed Glycine 0 C--N 1.354 1.543 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.49 -139.86 0.33 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.583 -0.607 . . . . 0.0 111.583 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 54.5 t . . . . . 0 N--CA 1.464 0.254 0 CA-C-O 120.972 0.415 . . . . 0.0 110.089 -179.472 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' K' K ' 11' ' ' GLU . . . . . 0.521 ' N ' ' OE1' ' K' ' 11' ' ' GLU . 54.9 mp0 . . . . . 0 C--O 1.225 -0.192 0 N-CA-C 110.678 -0.119 . . . . 0.0 110.678 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.71 131.0 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -114.49 117.23 30.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.775 0.321 . . . . 0.0 111.403 -179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 55.6 t-80 -135.33 164.39 27.85 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.42 0.629 . . . . 0.0 109.846 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 15' ' ' GLN . . . . . 0.527 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 86.0 mt-30 -157.05 172.49 18.58 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.634 178.468 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.5 tttm -155.92 122.77 5.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.36 179.217 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.6 mt -125.13 120.42 31.33 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 4.2 m -136.38 134.17 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-O 121.538 0.685 . . . . 0.0 112.654 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 0.623 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 87.5 m-85 -115.31 110.7 19.79 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' L' ' 20' ' ' PHE . 7.8 m-85 -114.01 124.11 51.33 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -177.818 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 127.05 34.21 Favored 'General case' 0 N--CA 1.474 0.739 0 O-C-N 121.758 -0.589 . . . . 0.0 110.57 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.18 127.61 47.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.583 -179.055 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 23' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' K' ' 24' ' ' VAL . 3.6 t70 174.96 146.69 0.07 Allowed 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.523 HG23 ' H ' ' K' ' 25' ' ' GLY . 2.8 m -21.89 -101.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 123.487 0.492 . . . . 0.0 111.712 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.523 ' H ' HG23 ' K' ' 24' ' ' VAL . . . 159.84 -91.36 0.11 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.807 177.706 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.683 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 75.3 m -54.23 160.8 1.5 Allowed 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 118.147 0.974 . . . . 0.0 108.381 178.185 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' O ' ' K' ' 26' ' ' SER . 23.2 p30 132.52 171.04 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 O-C-N 125.083 1.49 . . . . 0.0 111.715 176.129 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -30.27 104.92 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 29' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.8 -100.6 2.09 Favored Glycine 0 C--O 1.215 -1.056 0 N-CA-C 115.737 1.055 . . . . 0.0 115.737 170.28 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.431 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 60.77 145.29 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 106.436 -1.691 . . . . 0.0 106.436 -178.72 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.431 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -160.85 134.41 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 121.614 2.006 . . . . 0.0 113.219 -179.253 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 98.0 mt -124.98 121.23 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.766 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.517 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -119.26 115.53 3.07 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 34' ' ' LEU . . . . . 0.423 HD11 ' CG2' ' J' ' 36' ' ' VAL . 38.1 tp -124.98 121.62 34.96 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.149 -0.525 . . . . 0.0 111.271 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mmm -131.33 133.01 44.91 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.348 178.683 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' K' K ' 36' ' ' VAL . . . . . 0.557 HG22 HG23 ' J' ' 36' ' ' VAL . 15.0 t -123.22 82.58 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.444 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.601 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -70.6 101.33 0.9 Allowed Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' L' ' 37' ' ' GLY . . . -158.4 155.62 26.63 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 N--CA 1.469 0.499 0 CA-C-O 120.859 0.361 . . . . 0.0 110.836 -179.588 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.464 0.26 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -116.24 171.15 8.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 120.961 0.41 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -78.34 176.28 9.47 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.646 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -138.37 175.32 9.67 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -146.07 142.31 28.43 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.324 0.583 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -126.17 113.01 16.46 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -130.35 128.45 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.329 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.803 ' CZ ' HD23 ' J' ' 34' ' ' LEU . 9.3 m-30 -109.06 109.03 19.95 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 20' ' ' PHE . . . . . 0.409 ' O ' ' HA ' ' K' ' 20' ' ' PHE . 33.7 t80 -112.53 114.03 26.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.392 0.615 . . . . 0.0 110.637 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 21' ' ' ALA . . . . . 0.422 ' O ' ' OD2' ' L' ' 23' ' ' ASP . . . -126.74 133.93 50.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.354 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' K' ' 24' ' ' VAL . 84.3 tt0 -60.68 105.48 0.45 Allowed 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.308 -177.669 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.422 ' OD2' ' O ' ' L' ' 21' ' ' ALA . 7.0 m-20 -154.46 136.21 14.44 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.329 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 24' ' ' VAL . . . . . 0.624 ' O ' HG23 ' L' ' 24' ' ' VAL . 22.5 m -109.99 111.74 37.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 119.862 -0.735 . . . . 0.0 110.566 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 25' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 26' ' ' SER . . . 31.84 -91.3 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-N 115.194 -0.912 . . . . 0.0 114.438 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' L' ' 25' ' ' GLY . 3.9 m 47.23 171.91 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.033 -1.083 . . . . 0.0 110.965 -176.635 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.526 ' O ' ' O ' ' L' ' 28' ' ' LYS . 72.3 m-80 -140.09 -177.88 5.2 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.365 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.526 ' O ' ' O ' ' L' ' 27' ' ' ASN . 99.2 mttt 26.5 102.13 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.068 0 O-C-N 123.716 0.635 . . . . 0.0 112.196 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.39 -101.57 0.21 Allowed Glycine 0 CA--C 1.493 -1.283 0 C-N-CA 119.913 -1.137 . . . . 0.0 111.791 -176.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 30' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -52.29 161.11 0.69 Allowed 'General case' 0 CA--C 1.514 -0.404 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.375 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -136.04 121.79 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.641 -177.331 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -129.03 138.46 54.46 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.279 0 CA-C-N 115.637 -0.711 . . . . 0.0 111.626 -178.263 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.97 120.99 3.25 Favored Glycine 0 N--CA 1.46 0.253 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 34' ' ' LEU . . . . . 0.435 HD12 ' O ' ' L' ' 34' ' ' LEU . 2.9 pp -126.12 122.24 35.16 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 38.2 mtp -134.81 143.49 47.08 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 122.147 0.975 . . . . 0.0 112.681 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -131.25 80.73 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 113.642 -1.617 . . . . 0.0 110.159 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.547 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -55.31 102.47 0.16 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.53 28.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.32 134.19 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.871 0.367 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.588 -179.843 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.932 0.396 . . . . 0.0 110.061 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' B' ' 12' ' ' VAL . 2.4 p -136.28 145.11 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.634 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 72.9 m80 -114.72 106.35 14.11 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' HIS . . . . . 0.44 ' CE1' ' O ' ' A' ' 15' ' ' GLN . 14.8 t60 -135.55 159.72 40.73 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 109.767 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.44 ' O ' ' CE1' ' A' ' 14' ' ' HIS . 28.7 mm100 -157.64 -178.93 7.69 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.847 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -147.8 122.54 9.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.6 mt -129.64 117.25 20.07 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.062 0.458 . . . . 0.0 110.659 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.5 131.05 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.098 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -123.25 134.17 54.12 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.6 p90 -137.12 124.84 22.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.898 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.24 128.21 45.67 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-O 120.733 0.302 . . . . 0.0 111.253 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -147.39 146.66 29.7 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.248 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 22.7 t0 . . . . . 0 N--CA 1.463 0.176 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 177.272 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.479 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 33.1 pttt . . . . . 0 N--CA 1.462 0.137 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.53 100.61 0.62 Allowed Glycine 0 CA--C 1.496 -1.151 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 174.145 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ALA . . . . . 0.574 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . -99.37 151.89 20.57 Favored 'General case' 0 C--O 1.251 1.169 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.005 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ILE . . . . . 0.472 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -143.77 107.36 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.781 0 CA-C-N 110.443 -3.071 . . . . 0.0 108.449 -173.284 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ILE . . . . . 0.598 ' CG2' HD21 ' B' ' 34' ' ' LEU . 10.6 mt -103.43 111.0 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.035 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.72 92.48 0.58 Allowed Glycine 0 CA--C 1.501 -0.805 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 177.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tp -138.03 135.02 35.49 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 122.704 1.24 . . . . 0.0 111.169 -178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 3.1 ptm -111.04 123.31 49.94 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.3 -1.773 . . . . 0.0 108.403 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -116.14 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.649 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -82.92 -100.39 0.5 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.8 -170.74 34.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.07 162.07 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.863 0.364 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 81.2 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.379 179.749 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -110.57 134.34 52.48 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -138.79 142.76 38.75 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' A' ' 12' ' ' VAL . 19.8 m -131.17 161.02 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' O ' ' C' ' 13' ' ' HIS . 2.1 t60 -130.29 129.03 42.72 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 14' ' ' HIS . . . . . 0.629 ' NE2' ' CG ' ' C' ' 13' ' ' HIS . 72.6 m80 -133.48 167.08 21.1 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.309 0.576 . . . . 0.0 109.678 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 15' ' ' GLN . . . . . 0.477 HE21 HD21 ' B' ' 17' ' ' LEU . 46.2 tt0 -168.93 169.56 9.61 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.495 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -155.02 125.77 7.0 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 17' ' ' LEU . . . . . 0.477 HD21 HE21 ' B' ' 15' ' ' GLN . 66.3 mt -122.22 110.97 16.37 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.058 0.456 . . . . 0.0 109.796 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -119.94 126.93 75.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.94 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -125.81 120.37 30.35 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.608 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' HB2' ' CZ ' ' C' ' 20' ' ' PHE . 3.7 t80 -125.63 129.15 49.03 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.92 155.93 39.07 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 116.767 2.136 . . . . 0.0 116.767 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -162.75 78.34 0.47 Allowed 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 111.145 -2.752 . . . . 0.0 106.1 177.702 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 t0 . . . . . 0 N--CA 1.465 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.887 -176.384 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB1' ' C' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.49 -1.518 0 CA-C-O 127.632 3.907 . . . . 0.0 109.401 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 30' ' ' ALA . . . . . 0.574 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -79.31 -125.07 0.01 OUTLIER 'General case' 1 N--CA 1.37 -4.446 3 N-CA-C 87.399 -8.741 . . . . 0.0 87.399 166.239 . . . . . . . . 4 3 . 1 . 010 nuclear build core ' B' B ' 31' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' H' ' 35' ' ' MET . 0.2 OUTLIER -72.9 115.62 13.94 Favored 'Isoleucine or valine' 1 C--N 1.226 -4.792 0 CA-C-N 125.138 3.608 . . . . 0.0 111.128 176.465 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' B' B ' 32' ' ' ILE . . . . . 0.565 ' N ' ' SD ' ' H' ' 35' ' ' MET . 0.1 OUTLIER -109.41 115.48 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.774 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.7 90.94 0.58 Allowed Glycine 0 C--O 1.24 0.473 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 177.274 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 34' ' ' LEU . . . . . 0.598 HD21 ' CG2' ' A' ' 32' ' ' ILE . 74.4 mt -121.27 137.0 54.88 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.422 1.106 . . . . 0.0 112.06 -177.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 35' ' ' MET . . . . . 0.736 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 34.2 ttp -126.25 117.3 22.77 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.864 -179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 36' ' ' VAL . . . . . 0.616 HG22 HD11 ' C' ' 34' ' ' LEU . 34.0 m -123.36 71.49 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.066 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.1 -101.72 2.28 Favored Glycine 0 C--N 1.353 1.523 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.4 166.78 41.41 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -134.46 142.0 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.759 0.314 . . . . 0.0 110.306 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.398 179.801 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 120.993 0.425 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 13' ' ' HIS . . . . . 0.629 ' CG ' ' NE2' ' B' ' 14' ' ' HIS . 29.7 m-70 -133.32 145.12 50.14 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -84.48 -179.46 7.16 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-O 121.32 0.581 . . . . 0.0 110.272 -178.883 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -90.91 175.23 7.05 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.994 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -130.01 134.46 47.43 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.363 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -131.55 121.46 24.46 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.257 0.551 . . . . 0.0 112.412 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 18.0 m -132.04 127.26 57.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 CA-C-O 121.989 0.9 . . . . 0.0 110.734 177.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.13 119.49 36.59 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 114.716 -1.129 . . . . 0.0 108.97 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' HB2' ' B' ' 20' ' ' PHE . 53.2 p90 -147.37 150.81 35.43 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 118.615 -1.234 . . . . 0.0 112.512 177.534 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.14 150.19 32.29 Favored 'General case' 0 C--O 1.241 0.634 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -119.01 117.15 28.0 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.307 -1.77 . . . . 0.0 107.673 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 23' ' ' ASP . . . . . 0.479 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 57.3 m-20 . . . . . 0 CA--C 1.51 -0.595 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.964 -177.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.13 0 N-CA-C 114.495 0.558 . . . . 0.0 114.495 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' C' C ' 30' ' ' ALA . . . . . 0.598 ' HB1' ' O ' ' B' ' 29' ' ' GLY . . . -85.41 176.71 8.11 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 101.411 -3.552 . . . . 0.0 101.411 172.199 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 31' ' ' ILE . . . . . 0.438 HG12 ' C ' ' C' ' 30' ' ' ALA . 0.0 OUTLIER -141.97 111.72 2.76 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.248 -175.62 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.4 mt -98.75 111.17 27.71 Favored 'Isoleucine or valine' 0 C--N 1.349 0.569 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.41 99.64 1.13 Allowed Glycine 0 CA--C 1.505 -0.581 0 N-CA-C 106.048 -2.821 . . . . 0.0 106.048 175.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 34' ' ' LEU . . . . . 0.616 HD11 HG22 ' B' ' 36' ' ' VAL . 19.6 tp -135.83 133.17 37.54 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 123.056 1.408 . . . . 0.0 112.419 -176.901 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 35' ' ' MET . . . . . 0.774 ' SD ' HG22 ' I' ' 31' ' ' ILE . 41.2 ttp -110.49 122.06 46.82 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 113.269 -1.787 . . . . 0.0 109.532 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' C' C ' 36' ' ' VAL . . . . . 0.416 HG13 ' CG2' ' B' ' 36' ' ' VAL . 0.0 OUTLIER -109.61 66.76 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.618 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.59 -102.81 0.01 OUTLIER Glycine 0 C--N 1.362 1.99 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.88 158.03 26.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -134.4 162.74 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.438 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.851 -179.897 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t . . . . . 0 N--CA 1.465 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -89.67 130.18 35.99 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.0 0.428 . . . . 0.0 111.864 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -82.84 178.16 8.31 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -96.42 178.4 5.37 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.548 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -142.29 137.69 30.81 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.825 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 41.7 tp -120.82 115.06 22.53 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.618 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.3 127.08 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.408 -0.517 . . . . 0.0 112.153 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -118.12 114.46 23.12 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 20' ' ' PHE . . . . . 0.532 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 21.5 t80 -127.6 119.08 25.15 Favored 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.179 0.514 . . . . 0.0 110.328 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 21' ' ' ALA . . . . . 0.428 ' O ' ' OE1' ' E' ' 22' ' ' GLU . . . -132.19 133.31 44.04 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-O 121.928 0.87 . . . . 0.0 112.629 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -91.4 133.61 35.32 Favored 'General case' 0 C--N 1.339 0.112 0 CA-C-N 114.677 -1.147 . . . . 0.0 108.627 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t0 . . . . . 0 C--N 1.327 -0.378 0 CA-C-O 121.203 0.525 . . . . 0.0 110.191 -178.934 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' D' D ' 30' ' ' ALA . . . . . 0.811 ' C ' HD13 ' D' ' 31' ' ' ILE . . . . . . . . 0 CA--C 1.498 -1.051 1 N-CA-C 96.892 -5.225 . . . . 0.0 96.892 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 31' ' ' ILE . . . . . 0.87 ' N ' HD13 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -97.51 102.12 13.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 1 CA-C-N 127.292 4.587 . . . . 0.0 109.907 178.45 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.0 tt -112.97 121.94 66.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.612 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.849 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.46 100.1 1.1 Allowed Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 107.064 -2.414 . . . . 0.0 107.064 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tp -117.19 120.7 39.07 Favored 'General case' 0 CA--C 1.508 -0.64 0 CA-C-O 121.702 0.763 . . . . 0.0 110.492 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 4.9 tmm? -104.26 115.91 31.24 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.687 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -118.19 71.43 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.18 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.0 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' D' D ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.24 -101.12 0.01 OUTLIER Glycine 0 C--N 1.366 2.228 0 N-CA-C 111.86 -0.496 . . . . 0.0 111.86 178.766 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.48 -179.81 43.02 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.61 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -125.34 135.76 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.454 -0.373 . . . . 0.0 110.086 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.593 179.951 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -103.91 135.35 45.61 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.916 0.388 . . . . 0.0 110.21 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -106.8 151.39 25.24 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 m -131.09 156.94 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.969 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.75 174.28 7.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.798 0.332 . . . . 0.0 110.329 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 14' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.2 OUTLIER -78.32 174.04 11.67 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -179.374 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 15' ' ' GLN . . . . . 0.405 ' HG2' ' H ' ' E' ' 16' ' ' LYS . 44.1 tt0 -122.63 172.15 8.61 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.614 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 16' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' E' ' 15' ' ' GLN . 65.7 mttp -153.82 119.07 5.12 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.6 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.8 mt -126.31 116.43 21.21 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 18' ' ' VAL . . . . . 0.533 HG21 ' CE2' ' E' ' 20' ' ' PHE . 5.6 p -143.16 147.56 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.182 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -120.04 124.33 45.61 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 114.227 -1.351 . . . . 0.0 109.747 179.003 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 20' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' E' ' 18' ' ' VAL . 31.9 m-85 -121.39 126.81 50.29 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 122.373 -0.205 . . . . 0.0 110.529 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.06 137.57 37.92 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 -179.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 22' ' ' GLU . . . . . 0.532 ' OE2' ' CZ ' ' D' ' 20' ' ' PHE . 58.0 mp0 -113.22 137.84 50.87 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -150.0 132.46 15.68 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.383 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 24' ' ' VAL . . . . . 0.527 HG23 ' O ' ' E' ' 24' ' ' VAL . 30.1 m -74.59 113.08 12.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.071 179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.08 92.18 0.01 OUTLIER Glycine 0 CA--C 1.527 0.824 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.447 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 74.0 m . . . . . 0 N--CA 1.443 -0.798 0 CA-C-N 115.693 -0.253 . . . . 0.0 111.518 178.877 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' E' E ' 30' ' ' ALA . . . . . 0.466 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.255 1.356 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 31' ' ' ILE . . . . . 0.721 HG23 HG12 ' F' ' 31' ' ' ILE . 0.1 OUTLIER -158.23 134.48 2.0 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 C-N-CA 118.669 -1.212 . . . . 0.0 110.734 -174.341 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 32' ' ' ILE . . . . . 0.534 HD11 HD11 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -128.57 121.45 55.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 CA-C-O 121.4 0.619 . . . . 0.0 110.769 179.705 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' E' E ' 33' ' ' GLY . . . . . 0.546 ' CA ' ' SD ' ' K' ' 35' ' ' MET . . . -114.64 117.02 3.94 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 34' ' ' LEU . . . . . 0.74 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 22.9 mt -118.72 120.15 36.56 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.479 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 15.5 ttp -116.61 115.54 25.9 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.401 -0.52 . . . . 0.0 109.884 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 36' ' ' VAL . . . . . 0.654 HG13 HG22 ' F' ' 36' ' ' VAL . 2.8 p -144.03 83.77 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.52 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 37' ' ' GLY . . . . . 0.475 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -18.95 -94.49 0.01 OUTLIER Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.663 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.12 -164.05 37.24 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.07 161.01 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 120.847 0.356 . . . . 0.0 110.707 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.433 179.828 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -112.28 149.66 32.06 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.81 0.338 . . . . 0.0 110.387 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -54.01 149.14 9.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.132 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 65.3 t -114.34 130.84 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 110.948 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 13' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 31.1 p-80 -154.07 134.61 13.53 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.532 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 93.9 m-70 -155.23 170.03 22.8 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 121.303 0.573 . . . . 0.0 109.602 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -143.96 173.81 11.39 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.431 -0.804 . . . . 0.0 108.884 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -152.44 129.85 11.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.1 tp -121.08 117.9 28.38 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.177 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.51 133.14 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -177.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 19' ' ' PHE . . . . . 0.74 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 86.2 m-85 -118.48 114.73 23.3 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.902 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -134.18 144.86 48.73 Favored 'General case' 0 N--CA 1.477 0.885 0 CA-C-O 122.282 1.039 . . . . 0.0 112.086 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.43 148.35 30.2 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.128 178.164 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.52 136.83 39.32 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.712 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -149.62 134.03 17.46 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.418 0.628 . . . . 0.0 111.086 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' F' ' 25' ' ' GLY . 12.9 t -93.71 112.55 26.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.292 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 25' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' F' ' 24' ' ' VAL . . . 42.64 91.42 0.01 OUTLIER Glycine 0 N--CA 1.472 1.063 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.393 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 85.7 p -45.2 152.16 0.29 Allowed 'General case' 0 N--CA 1.439 -1.022 0 CA-C-O 123.066 1.412 . . . . 0.0 111.989 -176.142 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 28.6 m120 -156.84 -170.9 3.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 111.679 -2.51 . . . . 0.0 106.304 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.7 mttt 19.19 110.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 121.797 0.808 . . . . 0.0 113.166 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.19 96.62 2.23 Favored Glycine 0 CA--C 1.492 -1.395 0 CA-C-O 123.412 1.562 . . . . 0.0 111.877 -174.456 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 30' ' ' ALA . . . . . 0.459 ' C ' HD13 ' F' ' 31' ' ' ILE . . . -63.94 -171.15 0.05 OUTLIER 'General case' 0 CA--C 1.489 -1.376 0 CA-C-N 110.989 -2.606 . . . . 0.0 107.537 -179.033 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 31' ' ' ILE . . . . . 0.721 HG12 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -132.74 133.76 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 117.261 -1.776 . . . . 0.0 113.191 -176.283 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' F' F ' 32' ' ' ILE . . . . . 0.444 HG23 ' O ' ' F' ' 32' ' ' ILE . 14.9 tt -126.71 132.41 70.17 Favored 'Isoleucine or valine' 0 C--N 1.345 0.386 0 CA-C-N 113.747 -1.57 . . . . 0.0 112.202 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.7 115.54 2.74 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -119.47 119.51 34.09 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 35' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 30.8 ttp -114.03 118.61 34.58 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 121.267 -0.173 . . . . 0.0 111.196 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 36' ' ' VAL . . . . . 0.654 HG22 HG13 ' E' ' 36' ' ' VAL . 5.0 t -139.11 83.05 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-O 119.295 -0.384 . . . . 0.0 110.686 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 37' ' ' GLY . . . . . 0.514 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . -15.73 -95.66 0.01 OUTLIER Glycine 0 C--N 1.351 1.367 0 O-C-N 123.063 0.227 . . . . 0.0 112.886 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 127.92 163.05 11.26 Favored Glycine 0 N--CA 1.466 0.695 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 28.6 m -140.31 160.38 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.825 0.345 . . . . 0.0 110.655 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.532 -179.968 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' G' G ' 13' ' ' HIS . . . . . 0.579 ' N ' ' HD1' ' G' ' 13' ' ' HIS . 2.5 p-80 . . . . . 0 N--CA 1.463 0.192 0 CA-C-O 120.905 0.383 . . . . 0.0 110.995 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 14' ' ' HIS . . . . . 0.571 ' CD2' ' H ' ' H' ' 14' ' ' HIS . 89.0 m-70 -132.83 178.26 7.0 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -129.09 -179.13 4.94 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.086 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 89.2 tttt -99.23 142.53 30.6 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.643 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 74.7 mt -125.68 118.79 26.38 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -136.28 138.67 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.204 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.753 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -119.64 126.36 50.96 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.211 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -122.5 120.76 34.82 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.08 127.61 44.94 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.105 0.479 . . . . 0.0 111.806 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -160.83 87.27 0.73 Allowed 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.685 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -178.37 123.13 0.1 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.925 0.393 . . . . 0.0 110.628 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.8 t -38.93 114.34 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.185 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 25' ' ' GLY . . . . . 0.808 ' H ' HG21 ' H' ' 24' ' ' VAL . . . -98.14 -86.41 1.84 Allowed Glycine 0 N--CA 1.47 0.907 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 26' ' ' SER . . . . . 0.747 ' O ' ' O ' ' G' ' 27' ' ' ASN . 17.0 m -151.58 -173.06 4.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.536 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 27' ' ' ASN . . . . . 0.747 ' O ' ' O ' ' G' ' 26' ' ' SER . 97.0 m-20 -22.79 170.0 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 O-C-N 124.313 1.008 . . . . 0.0 113.235 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 28' ' ' LYS . . . . . 0.498 ' NZ ' ' O ' ' I' ' 26' ' ' SER . 32.4 tttt -102.03 -112.82 0.21 Allowed 'General case' 0 N--CA 1.476 0.828 0 O-C-N 121.606 -0.684 . . . . 0.0 112.265 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 29' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' G' ' 28' ' ' LYS . . . 47.98 91.57 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 30' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . -106.18 162.37 13.7 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 123.85 1.786 . . . . 0.0 111.127 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 31' ' ' ILE . . . . . 0.649 HG21 ' HA3' ' A' ' 37' ' ' GLY . 1.0 OUTLIER -160.29 121.94 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 110.547 -3.024 . . . . 0.0 106.84 -172.733 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -139.64 122.73 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.249 178.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.7 117.41 5.86 Favored Glycine 0 CA--C 1.506 -0.519 0 N-CA-C 106.821 -2.511 . . . . 0.0 106.821 177.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 34' ' ' LEU . . . . . 0.678 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 70.9 mt -113.59 120.17 40.02 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-O 121.562 0.696 . . . . 0.0 111.931 -177.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' C ' ' A' ' 31' ' ' ILE . 3.8 ttm -120.84 108.02 13.43 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 177.046 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.72 71.56 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -178.933 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.11 -98.31 0.85 Allowed Glycine 0 C--N 1.361 1.921 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.6 -173.63 43.26 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 120.809 0.337 . . . . 0.0 110.102 -179.597 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.465 0.314 0 N-CA-C 110.494 -0.187 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -121.61 124.07 43.45 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.69 0.281 . . . . 0.0 110.664 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' G' ' 14' ' ' HIS . 37.1 m-70 -144.58 166.18 25.91 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.345 0.593 . . . . 0.0 110.277 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.6 tp60 -160.81 161.15 31.9 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.795 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -158.83 118.06 3.05 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.54 110.5 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 18' ' ' VAL . . . . . 0.485 HG11 ' CE2' ' H' ' 20' ' ' PHE . 72.4 t -124.29 130.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 120.551 -0.46 . . . . 0.0 111.045 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.39 114.25 22.05 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.973 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 20' ' ' PHE . . . . . 0.485 ' CE2' HG11 ' H' ' 18' ' ' VAL . 52.4 m-85 -110.1 117.28 33.3 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.53 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.1 134.44 38.36 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 119.558 -0.857 . . . . 0.0 112.867 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -152.02 89.65 1.47 Allowed 'General case' 0 C--O 1.224 -0.261 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 23' ' ' ASP . . . . . 0.444 ' N ' ' OD1' ' H' ' 23' ' ' ASP . 26.5 p-10 169.85 -121.23 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.366 0.416 . . . . 0.0 110.073 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 24' ' ' VAL . . . . . 0.808 HG21 ' H ' ' G' ' 25' ' ' GLY . 1.5 m . . . . . 0 N--CA 1.446 -0.661 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 179.025 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 30' ' ' ALA . . . . . 0.746 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.434 -1.229 0 CA-C-O 124.967 2.318 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 31' ' ' ILE . . . . . 0.894 HD12 ' H ' ' H' ' 31' ' ' ILE . 4.1 mp -67.4 107.98 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.314 0 CA-C-N 109.966 -3.288 . . . . 0.0 109.796 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 32' ' ' ILE . . . . . 0.508 ' N ' ' HE1' ' C' ' 35' ' ' MET . 10.3 tt -122.47 120.44 61.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 122.246 1.022 . . . . 0.0 109.789 174.816 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 33' ' ' GLY . . . . . 0.736 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -98.87 117.96 6.02 Favored Glycine 0 CA--C 1.497 -1.075 0 N-CA-C 106.304 -2.718 . . . . 0.0 106.304 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 34' ' ' LEU . . . . . 0.424 HD11 HG22 ' H' ' 36' ' ' VAL . 56.0 tp -120.04 119.66 34.03 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 113.836 1.051 . . . . 0.0 113.836 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 35' ' ' MET . . . . . 0.565 ' SD ' ' N ' ' B' ' 32' ' ' ILE . 17.6 ttm -124.8 115.31 20.49 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 175.517 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 36' ' ' VAL . . . . . 0.444 ' O ' HG12 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -129.32 71.25 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.16 -100.81 2.66 Favored Glycine 0 C--N 1.358 1.8 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 38' ' ' GLY . . . . . 0.422 ' H ' HD13 ' B' ' 31' ' ' ILE . . . 110.54 166.17 19.21 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.04 156.62 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-O 120.686 0.279 . . . . 0.0 110.357 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.636 -179.826 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.466 0.358 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 75.7 m80 -129.61 131.96 46.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.84 0.352 . . . . 0.0 111.514 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 86.3 t60 -154.18 165.76 35.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 177.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 15' ' ' GLN . . . . . 0.52 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 76.0 mt-30 -158.76 171.22 20.49 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.502 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -151.05 121.48 7.36 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.071 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -127.67 123.82 36.44 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.7 t -134.44 130.29 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 19' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' G' ' 34' ' ' LEU . 45.4 m-85 -111.35 108.45 18.05 Favored 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 176.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -116.47 119.53 35.9 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.184 -0.323 . . . . 0.0 111.109 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.78 127.5 27.17 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -138.49 109.17 6.62 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.732 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 42.0 p-10 -161.69 125.14 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.96 179.554 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 24' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.8 m -89.82 -112.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.595 -0.442 . . . . 0.0 109.971 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 25' ' ' GLY . . . . . 0.407 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 43.98 -92.02 0.01 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.622 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.0 p -129.19 170.27 13.77 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' I' ' 26' ' ' SER . 35.7 m120 31.98 172.58 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 28' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' J' ' 23' ' ' ASP . 23.3 pttt 148.55 95.36 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 123.344 0.658 . . . . 0.0 111.571 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 29' ' ' GLY . . . . . 0.801 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . 58.46 -112.59 4.12 Favored Glycine 1 CA--C 1.433 -5.059 0 CA-C-O 114.948 -3.14 . . . . 0.0 111.849 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 30' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' I' ' 29' ' ' GLY 0.529 . . 97.96 -125.45 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.513 1 C-N-CA 109.781 -4.768 . . . . 0.0 113.355 179.294 . . . . . . . . 4 3 . 1 . 010 nuclear build core ' I' I ' 31' ' ' ILE . . . . . 0.774 HG22 ' SD ' ' C' ' 35' ' ' MET 0.426 3.0 mt -64.05 110.74 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.402 -2.852 1 CA-C-N 106.479 -4.873 . . . . 0.0 109.967 173.924 . . . . . . . . 4 3 . 1 . 010 nuclear build core ' I' I ' 32' ' ' ILE . . . . . 0.659 HG23 HG13 ' J' ' 32' ' ' ILE . 10.6 tt -135.36 126.15 44.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-O 122.333 1.064 . . . . 0.0 112.496 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.7 119.49 5.8 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 177.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 34' ' ' LEU . . . . . 1.0 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 13.7 tp -114.68 125.72 54.06 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.638 0.733 . . . . 0.0 112.277 -178.887 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 35' ' ' MET . . . . . 0.421 ' N ' HD12 ' I' ' 34' ' ' LEU . 12.6 tpp -123.77 111.0 15.61 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.784 175.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' I' I ' 36' ' ' VAL . . . . . 0.734 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -128.03 68.28 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.374 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.11 -101.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.625 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.01 160.02 23.54 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.73 135.95 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.519 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 120.836 0.351 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -137.59 103.78 5.14 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.759 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 65.5 m170 -117.7 164.66 14.64 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -157.77 172.83 17.78 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.217 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -155.41 115.64 3.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.526 178.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.27 124.15 41.78 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -134.07 132.43 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 19' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 14.8 m-85 -114.16 107.11 15.19 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.219 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 20' ' ' PHE . . . . . 0.57 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 35.4 t80 -120.92 117.55 27.63 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -166.96 175.68 7.47 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -178.389 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -88.22 138.83 31.09 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 113.134 -1.848 . . . . 0.0 109.032 177.861 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 23' ' ' ASP . . . . . 0.548 ' HA ' ' O ' ' I' ' 28' ' ' LYS . 74.0 m-20 -117.61 -161.0 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 121.384 0.611 . . . . 0.0 111.575 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 24' ' ' VAL . . . . . 0.554 HG13 ' H ' ' J' ' 29' ' ' GLY . 76.4 t 52.77 103.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 116.56 2.059 . . . . 0.0 116.56 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.59 -92.63 0.03 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 172.32 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' J' ' 27' ' ' ASN . 13.9 p -124.63 166.31 16.35 Favored 'General case' 0 CA--C 1.51 -0.57 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 175.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' J' ' 26' ' ' SER . 97.1 m-20 47.84 174.23 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 28' ' ' LYS . . . . . 0.745 ' NZ ' ' HB2' ' K' ' 30' ' ' ALA . 86.2 tttt -73.06 110.91 7.71 Favored 'General case' 0 C--N 1.35 0.626 1 C-N-CA 111.064 -4.254 . . . . 0.0 106.046 178.279 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 29' ' ' GLY . . . . . 0.554 ' H ' HG13 ' J' ' 24' ' ' VAL . . . -86.27 93.4 1.86 Allowed Glycine 0 CA--C 1.485 -1.807 0 CA-C-O 117.518 -1.712 . . . . 0.0 112.255 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 30' ' ' ALA . . . . . 0.454 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -163.16 140.21 7.49 Favored 'General case' 0 C--N 1.281 -2.406 0 CA-C-N 121.194 2.497 . . . . 0.0 108.348 171.193 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 31' ' ' ILE . . . . . 0.508 HG23 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -158.39 116.54 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 CA-C-N 112.249 -2.25 . . . . 0.0 107.08 -173.32 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' J' J ' 32' ' ' ILE . . . . . 0.659 HG13 HG23 ' I' ' 32' ' ' ILE . 15.6 tt -124.87 117.33 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.896 0.855 . . . . 0.0 110.994 179.489 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.62 118.95 6.24 Favored Glycine 0 CA--C 1.505 -0.569 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 34' ' ' LEU . . . . . 0.773 HD22 ' CE1' ' L' ' 19' ' ' PHE . 50.8 mt -113.54 107.29 15.6 Favored 'General case' 0 CA--C 1.505 -0.783 0 CA-C-O 121.322 0.582 . . . . 0.0 111.125 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.0 tpt -111.5 112.0 23.42 Favored 'General case' 0 CA--C 1.514 -0.421 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.297 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -131.63 74.71 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.668 -177.72 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.23 106.23 2.97 Favored Glycine 0 C--N 1.355 1.6 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.77 169.39 52.15 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.644 0.259 . . . . 0.0 110.524 -179.558 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 . . . . . 0 N--CA 1.464 0.241 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' K' K ' 12' ' ' VAL . . . . . 0.557 ' CG2' ' NE2' ' K' ' 14' ' ' HIS . 2.6 m -140.24 -171.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -92.44 132.05 37.1 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.807 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' CG2' ' K' ' 12' ' ' VAL . 80.0 m-70 -148.03 169.75 19.25 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -157.27 178.96 9.73 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.805 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -160.57 121.5 2.96 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.173 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -126.62 125.09 41.33 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.68 129.61 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.927 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 19' ' ' PHE . . . . . 1.0 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 19.8 m-85 -113.45 108.89 17.82 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 20' ' ' PHE . . . . . 0.57 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.1 t80 -118.51 121.13 39.51 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.141 0.428 . . . . 0.0 110.855 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.03 139.84 45.13 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.71 167.53 26.18 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.781 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -166.38 -136.42 0.02 OUTLIER 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.144 177.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' K' ' 25' ' ' GLY . 18.7 t -110.62 110.36 31.9 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 25' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 32.54 91.44 0.01 OUTLIER Glycine 0 CA--C 1.53 0.981 0 N-CA-C 112.156 -0.377 . . . . 0.0 112.156 177.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 26' ' ' SER . . . . . 0.413 ' OG ' ' CG ' ' L' ' 23' ' ' ASP . 5.8 p -47.5 154.71 0.42 Allowed 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 m120 -119.15 172.58 7.48 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 122.239 1.018 . . . . 0.0 113.166 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -32.8 110.75 0.09 Allowed 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 116.248 1.944 . . . . 0.0 116.248 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.59 93.42 0.44 Allowed Glycine 0 N--CA 1.475 1.286 0 N-CA-C 116.386 1.314 . . . . 0.0 116.386 172.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 30' ' ' ALA . . . . . 0.745 ' HB2' ' NZ ' ' J' ' 28' ' ' LYS . . . -101.11 165.71 11.16 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 101.628 -3.471 . . . . 0.0 101.628 170.096 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 31' ' ' ILE . . . . . 0.508 HD12 HG23 ' J' ' 31' ' ' ILE . 0.2 OUTLIER -138.29 122.77 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 116.926 -1.91 . . . . 0.0 111.854 -178.224 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' K' K ' 32' ' ' ILE . . . . . 0.438 ' O ' ' SD ' ' F' ' 35' ' ' MET . 76.0 mt -131.96 130.92 61.63 Favored 'Isoleucine or valine' 0 C--N 1.352 0.686 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.443 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -122.47 122.22 4.96 Favored Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.371 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 mt -114.7 114.95 26.32 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.266 0.533 . . . . 0.0 111.8 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 35' ' ' MET . . . . . 0.546 ' SD ' ' CA ' ' E' ' 33' ' ' GLY . 8.1 ttt -128.36 120.89 27.88 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 177.794 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.08 81.61 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.05 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 37' ' ' GLY . . . . . 0.702 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -65.41 102.05 0.63 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.75 152.64 24.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.6 m . . . . . 0 N--CA 1.464 0.267 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.846 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' L' L ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG2' ' K' ' 12' ' ' VAL . 66.9 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 121.922 0.868 . . . . 0.0 111.389 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 3.0 m80 -117.66 110.79 18.31 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.699 178.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -138.78 173.63 11.38 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -144.93 177.09 9.0 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.179 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -149.36 126.1 11.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.752 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.29 125.92 37.87 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -123.63 128.63 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-O 120.94 0.4 . . . . 0.0 110.425 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 19' ' ' PHE . . . . . 0.773 ' CE1' HD22 ' J' ' 34' ' ' LEU . 70.7 m-85 -113.81 112.3 23.18 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -133.49 127.72 33.85 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 121.696 0.76 . . . . 0.0 112.689 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.57 137.61 42.15 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.644 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -80.44 109.19 14.7 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 119.953 -0.699 . . . . 0.0 112.302 -178.073 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 23' ' ' ASP . . . . . 0.413 ' CG ' ' OG ' ' K' ' 26' ' ' SER . 37.0 t0 178.91 113.28 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.711 178.731 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 63.3 t -59.16 130.55 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.607 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -68.39 85.29 0.19 Allowed Glycine 0 CA--C 1.526 0.757 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.847 178.512 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 49.2 m -65.6 -175.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.083 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' O ' ' L' ' 28' ' ' LYS . 13.6 m-20 -91.13 178.9 5.86 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.509 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 28' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 28.03 102.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.023 0 O-C-N 123.42 0.45 . . . . 0.0 111.69 177.143 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.85 -101.71 0.22 Allowed Glycine 0 N--CA 1.467 0.702 0 C-N-CA 119.251 -1.452 . . . . 0.0 112.556 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.65 161.72 1.01 Allowed 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.135 -177.206 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 31' ' ' ILE . . . . . 0.415 HG21 ' CA ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -150.12 127.14 2.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.438 -176.108 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -127.01 129.36 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.33 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 33' ' ' GLY . . . . . 0.623 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -122.11 132.74 9.0 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.244 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -120.44 121.82 39.34 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.07 0.435 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.2 123.16 35.97 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.14 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 36' ' ' VAL . . . . . 0.73 HG23 ' O ' ' L' ' 36' ' ' VAL . 16.7 m -145.41 78.92 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -3.63 -101.22 0.0 OUTLIER Glycine 0 C--N 1.359 1.814 0 C-N-CA 122.948 0.309 . . . . 0.0 113.284 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.6 162.74 21.49 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -132.39 156.08 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.868 0.366 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.936 -1.031 . . . . 0.0 111.076 -179.534 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -127.41 139.63 52.71 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.828 0.347 . . . . 0.0 110.404 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -61.61 135.92 57.82 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.2 t -126.01 133.77 68.15 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.018 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -106.24 165.87 10.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.467 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.414 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 8.2 p80 -92.34 169.58 10.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.385 0.612 . . . . 0.0 110.249 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 96.2 mm-40 -151.71 -179.96 7.88 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.008 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -126.04 126.71 44.69 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.904 0.383 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.2 mt -128.39 127.73 43.16 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.978 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -135.66 138.57 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.272 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -130.96 135.73 47.9 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.52 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.0 p90 -123.48 128.97 50.55 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.97 130.96 52.27 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 122.13 0.967 . . . . 0.0 112.788 -178.514 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -125.5 167.5 14.92 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -128.3 122.46 31.65 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 118.289 0.495 . . . . 0.0 112.119 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.538 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 m -94.25 -113.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 41.85 -90.98 0.01 OUTLIER Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.345 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.951 ' O ' ' O ' ' A' ' 27' ' ' ASN . 41.2 t -170.97 170.52 6.26 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.951 ' O ' ' O ' ' A' ' 26' ' ' SER . 32.8 m-20 13.38 -179.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 124.839 1.337 . . . . 0.0 113.626 -176.482 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -150.05 105.5 3.39 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 119.586 -1.946 . . . . 0.0 114.683 177.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -77.53 101.4 1.64 Allowed Glycine 0 CA--C 1.507 -0.461 0 CA-C-O 114.823 -3.209 . . . . 0.0 105.505 168.648 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 147.73 25.98 Favored 'General case' 0 C--N 1.355 0.838 1 CA-C-N 125.483 4.642 . . . . 0.0 108.621 -178.407 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.591 HG22 ' CE ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -152.73 112.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.397 -171.704 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 56.5 mt -121.93 103.48 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.65 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -116.55 107.49 1.63 Allowed Glycine 0 CA--C 1.505 -0.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 177.272 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.501 ' H ' HD23 ' B' ' 34' ' ' LEU . 70.2 mt -142.66 153.66 43.63 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 123.295 1.521 . . . . 0.0 113.085 -177.122 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.469 ' SD ' ' C ' ' G' ' 31' ' ' ILE . 28.5 ttm -119.96 119.58 33.86 Favored 'General case' 0 CA--C 1.5 -0.949 0 CA-C-N 112.643 -2.071 . . . . 0.0 108.433 178.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.53 66.91 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.09 -102.13 0.01 OUTLIER Glycine 0 C--N 1.356 1.65 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.75 171.99 38.71 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.6 t -131.56 139.16 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.838 0.351 . . . . 0.0 110.415 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.357 179.811 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.36 158.54 44.01 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.683 0.277 . . . . 0.0 110.37 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.51 ' OE2' ' NE2' ' B' ' 13' ' ' HIS . 81.2 tt0 -146.56 146.26 30.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.272 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.1 m -136.88 159.68 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.163 0.506 . . . . 0.0 111.283 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.51 ' NE2' ' OE2' ' B' ' 11' ' ' GLU . 96.0 m-70 -149.83 163.52 37.81 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.067 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -115.04 178.39 4.3 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -97.2 175.09 6.41 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.775 -179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -117.49 138.67 51.71 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.73 127.27 40.1 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-O 121.051 0.453 . . . . 0.0 111.589 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -126.85 130.49 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.097 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -124.23 134.01 53.37 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.395 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -136.2 123.48 21.85 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.727 -0.215 . . . . 0.0 111.031 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.433 ' O ' ' CG ' ' B' ' 22' ' ' GLU . . . -126.86 117.55 22.82 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 120.946 0.403 . . . . 0.0 111.067 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.433 ' CG ' ' O ' ' B' ' 21' ' ' ALA . 83.3 mt-10 -165.47 133.8 3.16 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.617 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -170.27 111.03 0.41 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 72.8 t -30.72 132.1 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 113.943 -1.48 . . . . 0.0 111.942 174.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.19 -82.93 0.09 OUTLIER Glycine 0 CA--C 1.53 1.007 0 C-N-CA 119.627 -1.273 . . . . 0.0 113.405 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.588 ' O ' ' O ' ' B' ' 27' ' ' ASN . 0.4 OUTLIER -170.54 -179.2 2.88 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 119.476 1.638 . . . . 0.0 112.279 -178.909 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.588 ' O ' ' O ' ' B' ' 26' ' ' SER . 64.0 t30 27.22 -171.51 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 112.341 -2.208 . . . . 0.0 113.531 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.561 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 64.4 tttt -145.35 -103.81 0.1 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.164 -177.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 38.2 95.91 0.01 OUTLIER Glycine 0 C--N 1.35 1.355 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 -178.647 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.91 152.29 29.49 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.645 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.28 118.35 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 113.914 -1.494 . . . . 0.0 109.059 -175.126 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.447 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.1 tt -122.65 114.74 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.686 0.755 . . . . 0.0 109.705 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -117.5 116.9 3.62 Favored Glycine 0 N--CA 1.463 0.498 0 N-CA-C 107.877 -2.089 . . . . 0.0 107.877 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.501 HD23 ' H ' ' A' ' 34' ' ' LEU . 79.6 mt -134.62 147.0 50.09 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 114.444 1.276 . . . . 0.0 114.444 -176.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.464 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 3.2 ttm -122.48 118.35 28.11 Favored 'General case' 0 CA--C 1.505 -0.779 0 CA-C-N 113.469 -1.696 . . . . 0.0 109.366 177.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.09 70.16 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.18 112.18 3.46 Favored Glycine 0 C--N 1.358 1.785 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.43 147.94 12.74 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.628 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -127.82 136.3 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.572 179.704 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -109.91 139.14 45.33 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mp0 -63.11 132.4 51.73 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.5 t -129.24 131.53 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.692 -0.231 . . . . 0.0 110.425 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 79.1 m80 -152.12 119.26 5.88 Favored 'General case' 0 N--CA 1.463 0.219 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.35 179.964 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -136.61 164.78 27.42 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -155.88 178.63 10.04 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.873 0.368 . . . . 0.0 110.557 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -167.72 106.92 0.54 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.208 178.664 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mt -122.12 121.15 36.24 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -129.26 125.97 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 CA-C-O 121.027 0.442 . . . . 0.0 111.971 -179.16 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -120.52 113.94 21.03 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -116.92 132.96 56.57 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.185 0.194 . . . . 0.0 110.641 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.91 138.1 25.37 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 85.1 tt0 -161.88 144.1 11.49 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.474 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.465 ' O ' ' O ' ' C' ' 24' ' ' VAL . 20.3 t0 -168.7 120.56 0.79 Allowed 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.187 178.233 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' C' ' 23' ' ' ASP . 12.7 m -49.15 -122.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.142 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.18 -91.13 1.01 Allowed Glycine 0 CA--C 1.536 1.391 0 CA-C-N 114.945 -1.025 . . . . 0.0 115.54 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' C' ' 27' ' ' ASN . 81.5 p -170.23 -179.01 2.96 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 118.385 1.092 . . . . 0.0 110.98 -175.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' C' ' 26' ' ' SER . 96.6 m-20 27.26 -169.61 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 114.862 -1.063 . . . . 0.0 112.629 -179.191 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.428 ' CD ' ' H ' ' D' ' 29' ' ' GLY . 42.9 tttt -138.37 -106.3 0.18 Allowed 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -176.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.647 ' H ' ' HA3' ' D' ' 29' ' ' GLY . . . 45.45 93.31 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -175.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.43 ' O ' HG13 ' D' ' 31' ' ' ILE . . . -106.37 157.87 17.3 Favored 'General case' 0 CA--C 1.482 -1.665 0 N-CA-C 101.764 -3.421 . . . . 0.0 101.764 175.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.645 HD12 ' CG2' ' B' ' 31' ' ' ILE . 2.0 mt -140.02 122.65 16.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 117.94 -1.504 . . . . 0.0 111.74 -173.209 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.469 HG22 ' O ' ' C' ' 32' ' ' ILE . 1.1 mt -117.75 112.59 39.31 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.14 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.78 102.81 0.87 Allowed Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.427 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 7.0 tt -134.73 138.52 44.44 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.654 1.216 . . . . 0.0 113.29 -175.042 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 25.9 ttm -117.99 120.5 38.0 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 113.705 -1.588 . . . . 0.0 108.724 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.652 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.0 p -125.36 71.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.39 -100.86 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.437 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.51 -157.83 29.8 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -133.9 160.24 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.004 0.43 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.831 179.986 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' D' D ' 10' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' D' ' 10' ' ' TYR . 18.0 p90 -147.75 156.12 42.42 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.945 0.402 . . . . 0.0 110.788 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -75.25 155.94 36.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.777 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.604 HG21 ' HB ' ' E' ' 12' ' ' VAL . 9.9 m -146.49 -164.47 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.062 -178.58 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 63.0 m80 -78.4 124.63 28.33 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.145 -0.622 . . . . 0.0 111.727 -179.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.507 ' CD2' HG23 ' D' ' 12' ' ' VAL . 82.8 m-70 -148.45 167.97 23.91 Favored 'General case' 0 C--N 1.342 0.28 0 CA-C-O 121.244 0.545 . . . . 0.0 109.985 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.63 177.69 10.67 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.591 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.61 114.09 0.62 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.21 0.528 . . . . 0.0 111.779 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 35.5 tp -123.72 121.59 35.87 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.215 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -126.62 125.48 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.465 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 35.8 m-85 -117.21 120.87 39.58 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.187 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -128.34 122.41 31.48 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.828 0.347 . . . . 0.0 111.175 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.65 135.55 40.26 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.166 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.7 mt-10 -117.57 124.39 48.55 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.111 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 77.8 m-20 -146.38 122.58 10.85 Favored 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 112.852 0.686 . . . . 0.0 112.852 -179.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.98 -111.48 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.817 0.818 . . . . 0.0 111.638 179.534 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.21 -92.34 0.01 OUTLIER Glycine 0 CA--C 1.547 2.036 0 C-N-CA 126.727 2.108 . . . . 0.0 118.353 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 58.8 m -90.78 -178.4 5.24 Favored 'General case' 0 CA--C 1.501 -0.938 0 CA-C-N 118.532 1.166 . . . . 0.0 110.413 -174.865 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 69.3 m-80 -58.84 162.8 3.81 Favored 'General case' 0 CA--C 1.506 -0.721 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.784 ' HZ3' ' H ' ' E' ' 24' ' ' VAL . 76.6 mttt -56.32 111.25 0.92 Allowed 'General case' 0 N--CA 1.438 -1.052 0 C-N-CA 115.944 -2.302 . . . . 0.0 112.398 -174.017 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.647 ' HA3' ' H ' ' C' ' 29' ' ' GLY . . . -91.41 93.1 1.8 Allowed Glycine 0 CA--C 1.498 -1.001 0 CA-C-O 116.195 -2.447 . . . . 0.0 109.711 169.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.04 144.54 31.68 Favored 'General case' 0 CA--C 1.473 -2.0 0 CA-C-N 123.227 3.514 . . . . 0.0 108.923 175.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -143.36 108.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 CA-C-N 113.535 -1.666 . . . . 0.0 107.955 -176.561 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.53 121.89 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.087 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.626 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -125.94 103.22 0.68 Allowed Glycine 0 C--N 1.311 -0.813 0 N-CA-C 105.526 -3.03 . . . . 0.0 105.526 175.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.573 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.4 tt -127.78 131.33 49.62 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-O 122.171 0.986 . . . . 0.0 111.747 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.944 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.0 ttm -112.05 121.81 46.02 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 113.985 -1.462 . . . . 0.0 110.011 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.466 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -110.95 75.43 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.803 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -31.85 -96.24 0.01 OUTLIER Glycine 0 C--N 1.353 1.502 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.9 175.29 17.49 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 10.0 p -139.7 141.51 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.92 0.39 . . . . 0.0 110.608 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.563 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' E' E ' 10' ' ' TYR . . . . . 0.514 ' CE1' ' N ' ' F' ' 9' ' ' GLY . 88.1 m-85 -107.89 135.04 49.95 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.832 0.348 . . . . 0.0 110.211 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.52 138.63 58.51 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.186 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.604 ' HB ' HG21 ' D' ' 12' ' ' VAL . 72.6 t -122.38 131.28 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.619 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 96.1 m-70 -121.41 114.99 22.08 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.385 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' O ' ' E' ' 13' ' ' HIS . 2.7 m80 -142.46 168.31 20.03 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.641 0.734 . . . . 0.0 110.124 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -151.63 168.95 23.35 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.079 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -146.36 111.36 5.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 31.9 mt -122.99 121.81 37.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 18' ' ' VAL . . . . . 0.523 HG21 ' CE2' ' E' ' 20' ' ' PHE . 14.3 p -140.16 135.87 37.22 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 CA-C-O 121.944 0.878 . . . . 0.0 112.883 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.573 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 36.7 m-85 -117.72 117.23 28.77 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 114.327 -1.306 . . . . 0.0 109.927 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.523 ' CE2' HG21 ' E' ' 18' ' ' VAL . 38.3 m-85 -113.3 119.56 38.12 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.699 0.285 . . . . 0.0 111.105 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -126.6 137.86 53.38 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 120.972 0.415 . . . . 0.0 110.01 178.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -79.47 73.83 6.11 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 118.309 -1.356 . . . . 0.0 111.158 -177.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.608 ' O ' ' O ' ' E' ' 24' ' ' VAL . 1.3 p30 -171.49 109.92 0.29 Allowed 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.663 176.011 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.784 ' H ' ' HZ3' ' D' ' 28' ' ' LYS . 2.8 t -45.27 -132.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.698 1.237 . . . . 0.0 112.582 177.404 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.648 ' C ' ' HB2' ' F' ' 30' ' ' ALA . . . -138.76 80.99 0.27 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.613 ' O ' ' N ' ' F' ' 30' ' ' ALA . 28.6 m -68.94 -169.85 0.2 Allowed 'General case' 0 C--O 1.214 -0.808 0 CA-C-O 121.294 0.568 . . . . 0.0 110.734 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.528 ' O ' ' C ' ' E' ' 28' ' ' LYS . 39.8 m-20 -81.46 -175.53 5.55 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.012 179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.528 ' C ' ' O ' ' E' ' 27' ' ' ASN . 87.0 tttt -28.24 104.41 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -177.889 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.509 ' O ' ' CG1' ' E' ' 31' ' ' ILE . . . 168.16 -101.33 0.17 Allowed Glycine 0 C--O 1.211 -1.33 0 CA-C-O 117.586 -1.674 . . . . 0.0 111.231 -171.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -53.46 153.39 4.15 Favored 'General case' 0 C--O 1.246 0.893 0 CA-C-N 121.289 2.545 . . . . 0.0 110.251 -175.586 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.532 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.1 mt -148.57 126.09 2.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.946 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' L' ' 35' ' ' MET . 89.3 mt -128.99 128.15 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 120.901 0.381 . . . . 0.0 111.946 -178.47 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 121.34 4.69 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.54 HD13 ' CZ ' ' F' ' 19' ' ' PHE . 47.9 tp -127.93 124.67 37.91 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.219 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.499 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 8.9 ttt -129.84 126.27 37.64 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 120.31 -0.556 . . . . 0.0 111.547 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' D' ' 36' ' ' VAL . 51.3 t -109.94 86.84 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.425 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.643 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -75.0 96.9 0.99 Allowed Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.2 170.8 43.1 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -128.45 135.06 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-O 120.911 0.386 . . . . 0.0 109.999 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.795 -179.791 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' F' F ' 9' ' ' GLY . . . . . 0.514 ' N ' ' CE1' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 10' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 79.8 t80 -84.66 130.82 34.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.529 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 98.3 mt-10 -59.08 154.13 16.44 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.514 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 t -96.25 132.82 39.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.773 0.32 . . . . 0.0 110.703 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -153.13 113.98 4.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.204 0.526 . . . . 0.0 111.867 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -155.1 173.72 16.19 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -151.92 175.65 12.27 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.855 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -132.17 114.48 14.54 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.745 179.773 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 49.0 tp -122.68 118.77 28.89 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 77.2 t -133.35 130.0 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.54 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 55.0 m-85 -113.64 111.82 22.47 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 175.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -141.81 152.86 44.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.005 0.907 . . . . 0.0 112.244 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.414 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -150.46 149.14 29.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.291 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -136.79 144.39 43.7 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -178.147 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' F' ' 24' ' ' VAL . 62.2 t0 177.75 -118.48 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.863 177.66 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 13.2 p -102.18 126.41 56.23 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.568 0 CA-C-O 121.124 0.488 . . . . 0.0 110.659 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -31.4 -83.15 0.01 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.007 177.252 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 13.2 t 73.08 179.96 0.22 Allowed 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 124.456 1.102 . . . . 0.0 110.183 -176.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.418 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 88.8 m-20 -89.42 172.7 8.82 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 118.544 2.794 . . . . 0.0 118.544 -173.854 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -39.09 106.33 0.05 Allowed 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 109.268 -3.605 . . . . 0.0 119.894 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.61 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . 148.02 -97.22 0.18 Allowed Glycine 0 N--CA 1.483 1.8 0 C-N-CA 120.492 -0.861 . . . . 0.0 115.224 171.315 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.648 ' HB2' ' C ' ' E' ' 25' ' ' GLY . . . 56.2 166.02 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 103.186 -2.894 . . . . 0.0 103.186 -173.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.444 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 1.6 mt -140.08 119.37 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 124.098 3.135 . . . . 0.0 111.447 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 57.7 mt -123.87 136.23 60.92 Favored 'Isoleucine or valine' 0 C--N 1.347 0.483 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.512 -176.438 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.44 125.16 5.16 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 46.9 tp -118.64 120.8 38.51 Favored 'General case' 0 N--CA 1.47 0.54 0 O-C-N 122.642 -0.328 . . . . 0.0 110.229 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -118.37 119.38 34.45 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 116.952 -0.113 . . . . 0.0 111.098 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.49 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.4 p -153.21 82.47 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.763 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.898 ' H ' HD13 ' L' ' 31' ' ' ILE . . . -71.4 101.11 0.94 Allowed Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.26 161.51 34.51 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -141.86 143.7 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 110.604 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 t . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.4 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -103.79 133.08 49.38 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.855 0.36 . . . . 0.0 110.449 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -112.98 152.42 29.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.803 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 134.02 57.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.935 0.397 . . . . 0.0 110.091 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.449 ' N ' ' ND1' ' G' ' 13' ' ' HIS . 6.3 p-80 -133.41 -177.95 4.76 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.311 -179.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 8.2 m80 -81.72 167.92 18.63 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-O 121.126 0.489 . . . . 0.0 109.961 -179.207 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.45 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 51.0 tp60 -163.17 172.32 15.0 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.563 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.45 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 99.7 mttt -138.72 139.81 38.5 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -138.83 120.68 15.41 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.213 0.53 . . . . 0.0 110.902 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.41 134.36 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.767 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -129.2 125.31 36.7 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 120.939 0.4 . . . . 0.0 110.592 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.402 ' CD1' ' C ' ' G' ' 20' ' ' PHE . 19.5 t80 -113.46 123.26 49.61 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.17 131.81 53.16 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 121.805 0.812 . . . . 0.0 112.472 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' G' ' 23' ' ' ASP . 18.6 pt-20 -102.48 -173.08 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.771 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.483 ' N ' ' CB ' ' H' ' 23' ' ' ASP . 19.3 t70 -23.83 132.96 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' G' ' 26' ' ' SER . 11.7 t -89.33 113.56 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 114.197 -1.365 . . . . 0.0 108.162 177.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . -44.92 91.55 0.01 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.402 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.552 ' O ' ' O ' ' G' ' 27' ' ' ASN . 16.1 m 138.92 172.34 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.577 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.552 ' O ' ' O ' ' G' ' 26' ' ' SER . 90.9 m-20 -43.07 -178.67 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 O-C-N 123.429 0.456 . . . . 0.0 111.066 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.573 ' CE ' HG22 ' I' ' 24' ' ' VAL . 68.5 tttt -72.07 -114.7 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.767 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 50.32 91.33 0.01 OUTLIER Glycine 0 C--N 1.344 0.974 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.0 163.26 12.32 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 117.326 -1.75 . . . . 0.0 108.629 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.469 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -152.56 109.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 CA-C-N 112.966 -1.924 . . . . 0.0 109.618 -172.806 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.522 ' CG2' HD21 ' H' ' 34' ' ' LEU . 5.1 mt -100.95 111.05 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.25 99.0 0.68 Allowed Glycine 0 CA--C 1.503 -0.661 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.419 ' H ' HD23 ' H' ' 34' ' ' LEU . 12.0 mt -138.65 141.58 39.06 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-O 122.965 1.364 . . . . 0.0 111.572 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.65 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 38.0 ttp -109.66 114.96 29.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 112.957 -1.928 . . . . 0.0 107.158 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.41 66.03 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.78 110.92 4.02 Favored Glycine 0 C--N 1.359 1.828 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.63 178.99 0.11 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.8 m -137.6 161.05 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.782 0.325 . . . . 0.0 110.749 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.066 -0.968 . . . . 0.0 110.325 179.69 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -106.67 140.84 38.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.945 0.402 . . . . 0.0 110.472 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -139.12 164.74 28.99 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.542 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.639 HG13 ' HD1' ' I' ' 13' ' ' HIS . 78.2 t -82.47 133.54 28.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.881 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' I' ' 13' ' ' HIS . 3.5 t60 -140.06 100.23 3.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.894 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 13.9 t-80 -141.88 159.07 42.97 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.631 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 71.1 mt-30 -162.0 178.52 8.78 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.966 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -130.51 132.4 45.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 69.0 mt -120.9 111.74 17.91 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.54 127.22 74.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.143 0.497 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -117.1 112.94 21.59 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.381 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.24 121.2 44.66 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.37 132.39 48.55 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.256 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -164.58 125.73 2.13 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 119.857 -0.737 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.483 ' CB ' ' N ' ' G' ' 23' ' ' ASP . 0.9 OUTLIER -176.64 109.36 0.08 Allowed 'General case' 0 CA--C 1.544 0.723 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.6 t -37.9 135.35 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.285 173.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.05 -81.79 0.04 OUTLIER Glycine 0 CA--C 1.533 1.201 0 C-N-CA 118.941 -1.599 . . . . 0.0 112.54 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.742 ' O ' ' O ' ' H' ' 27' ' ' ASN . 49.5 p -171.01 179.88 2.96 Favored 'General case' 0 C--O 1.211 -0.922 0 CA-C-N 118.42 1.11 . . . . 0.0 109.823 178.467 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.742 ' O ' ' O ' ' H' ' 26' ' ' SER . 57.3 m-80 26.35 -177.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 177.349 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' H' ' 29' ' ' GLY . 70.1 mmtt -119.6 -110.51 0.34 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.547 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 43.8 92.48 0.01 OUTLIER Glycine 0 N--CA 1.468 0.781 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.277 178.976 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.47 152.78 48.63 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.728 -1.952 . . . . 0.0 105.728 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.401 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -146.2 129.6 9.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 118.735 -1.186 . . . . 0.0 112.429 -172.378 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.464 ' C ' ' SD ' ' B' ' 35' ' ' MET . 67.3 mt -112.64 117.63 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.351 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 102.06 0.91 Allowed Glycine 0 N--CA 1.466 0.648 0 N-CA-C 108.017 -2.033 . . . . 0.0 108.017 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.522 HD21 ' CG2' ' G' ' 32' ' ' ILE . 89.7 mt -131.96 131.37 42.55 Favored 'General case' 0 CA--C 1.498 -1.025 0 CA-C-O 122.005 0.907 . . . . 0.0 112.791 -177.647 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 42.1 ttp -108.61 116.86 32.78 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.193 -1.367 . . . . 0.0 107.546 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.17 67.5 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.218 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 38' ' ' GLY . . . -94.04 110.91 4.06 Favored Glycine 0 C--N 1.372 2.568 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 37' ' ' GLY . . . 31.59 -159.57 0.0 OUTLIER Glycine 0 CA--C 1.524 0.616 0 CA-C-O 121.777 0.654 . . . . 0.0 113.06 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -138.97 159.55 29.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.74 -0.73 . . . . 0.0 109.385 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.633 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.87 132.11 50.44 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.78 0.324 . . . . 0.0 110.538 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -105.78 157.38 17.49 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.751 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.659 HG12 ' N ' ' I' ' 13' ' ' HIS . 41.0 t -100.39 173.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.38 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.659 ' N ' HG12 ' I' ' 12' ' ' VAL . 71.6 m80 -159.39 173.12 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.979 0.419 . . . . 0.0 111.092 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 -179.44 4.66 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.547 ' OE1' ' N ' ' H' ' 15' ' ' GLN . 8.9 mm-40 -95.83 173.88 7.24 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-O 121.328 0.585 . . . . 0.0 111.741 -178.354 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -114.33 139.29 49.58 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -119.49 122.78 42.44 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 121.188 0.518 . . . . 0.0 111.706 -179.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -130.96 122.2 51.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.957 178.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -111.24 107.18 16.4 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.301 -1.741 . . . . 0.0 106.301 176.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -115.63 127.42 55.19 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 120.75 0.309 . . . . 0.0 111.04 -177.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.37 128.54 25.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 122.112 0.958 . . . . 0.0 112.796 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -108.88 164.75 12.12 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 175.94 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 27.3 t70 60.71 -110.64 0.45 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 116.83 -1.948 . . . . 0.0 108.653 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.573 HG22 ' CE ' ' G' ' 28' ' ' LYS . 69.5 t -45.63 132.1 2.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 122.743 1.259 . . . . 0.0 112.581 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.67 82.84 0.76 Allowed Glycine 0 CA--C 1.519 0.322 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.022 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 5.3 p -99.07 172.52 7.34 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-O 121.547 0.689 . . . . 0.0 110.269 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.869 ' H ' HD22 ' I' ' 27' ' ' ASN . 0.5 OUTLIER -62.12 171.02 1.93 Allowed 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.037 175.56 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' J' ' 26' ' ' SER . 89.6 mttt 55.37 110.69 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.526 ' H ' ' CA ' ' J' ' 30' ' ' ALA . . . 67.53 92.37 0.05 OUTLIER Glycine 0 N--CA 1.474 1.168 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.435 ' C ' HG12 ' I' ' 31' ' ' ILE . . . -173.86 156.11 2.74 Favored 'General case' 0 C--N 1.271 -2.816 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 177.1 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.586 ' CG2' HD12 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 117.75 5.87 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 C-N-CA 117.14 -1.824 . . . . 0.0 109.982 -174.448 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.601 ' N ' ' SD ' ' C' ' 35' ' ' MET . 16.1 tt -115.08 121.0 66.2 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-O 122.114 0.959 . . . . 0.0 111.174 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.31 99.38 1.11 Allowed Glycine 0 CA--C 1.505 -0.576 0 N-CA-C 105.819 -2.913 . . . . 0.0 105.819 176.484 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.661 HD13 ' CZ ' ' K' ' 19' ' ' PHE . 7.1 tt -123.37 127.63 48.75 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 122.545 1.164 . . . . 0.0 111.245 -177.625 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.425 ' HE2' ' O ' ' C' ' 31' ' ' ILE . 2.8 ttm -108.87 118.9 37.98 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 114.227 -1.352 . . . . 0.0 111.195 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.559 HG23 HG13 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -127.14 67.43 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 177.383 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -42.67 -103.26 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.67 -162.44 14.56 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -115.93 135.52 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.01 0.433 . . . . 0.0 110.48 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.427 ' OXT' HG22 ' I' ' 40' ' ' VAL . 8.2 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.784 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 9' ' ' GLY . . . . . 0.426 ' O ' ' OE1' ' J' ' 11' ' ' GLU . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 78.7 t80 -93.4 129.76 39.43 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.533 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 57.5 mp0 -132.47 146.57 52.03 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.15 0.5 . . . . 0.0 111.104 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.459 HG23 ' CE1' ' K' ' 13' ' ' HIS . 0.1 OUTLIER -130.57 -165.38 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-N 115.519 -0.764 . . . . 0.0 108.992 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -61.98 118.32 7.12 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 119.964 -0.694 . . . . 0.0 110.565 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 2.7 t-80 -135.75 164.04 28.81 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 83.2 mt-30 -155.81 177.01 11.89 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.269 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.611 ' C ' HD12 ' J' ' 17' ' ' LEU . 86.6 tttt -172.27 128.24 0.56 Allowed 'General case' 0 C--O 1.239 0.522 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.521 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.611 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.3 mp -117.76 123.27 45.6 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.75 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -127.45 126.55 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.623 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -120.97 106.8 11.94 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -114.8 128.04 56.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.575 -0.703 . . . . 0.0 112.184 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.43 123.64 36.58 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-O 121.97 0.891 . . . . 0.0 111.617 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.452 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 81.2 mm-40 -128.11 113.08 15.3 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 114.414 -1.266 . . . . 0.0 110.479 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' J' ' 24' ' ' VAL . 30.9 t0 -174.79 138.31 0.48 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.816 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' J' ' 23' ' ' ASP . 3.7 m -16.95 -110.22 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.401 ' H ' HG23 ' J' ' 24' ' ' VAL . . . -166.83 92.3 0.1 Allowed Glycine 0 CA--C 1.534 1.246 0 C-N-CA 119.83 -1.176 . . . . 0.0 113.892 -173.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' J' ' 27' ' ' ASN . 0.4 OUTLIER -63.26 -173.22 0.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.101 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' J' ' 26' ' ' SER . 77.5 m-20 -77.88 172.8 12.91 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 116.602 2.075 . . . . 0.0 116.602 -172.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.413 ' CE ' ' O ' ' K' ' 28' ' ' LYS . 6.5 mmtm -44.12 111.85 0.34 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 110.959 -2.837 . . . . 0.0 118.154 -177.628 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' I' ' 29' ' ' GLY . . . 93.84 94.42 1.56 Allowed Glycine 0 CA--C 1.501 -0.783 0 CA-C-N 114.209 -1.36 . . . . 0.0 114.501 176.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.526 ' CA ' ' H ' ' I' ' 29' ' ' GLY . . . -84.49 170.17 13.75 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 102.057 -3.312 . . . . 0.0 102.057 173.1 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.944 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.4 OUTLIER -150.45 123.22 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 CA-C-N 120.985 1.72 . . . . 0.0 111.752 -177.294 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.647 HD12 HG12 ' K' ' 32' ' ' ILE . 97.4 mt -109.89 117.27 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.385 178.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.14 102.08 1.17 Allowed Glycine 0 C--O 1.238 0.38 0 N-CA-C 106.282 -2.727 . . . . 0.0 106.282 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.927 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 7.9 tt -132.74 139.18 47.48 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-O 121.675 0.75 . . . . 0.0 112.562 -176.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.784 ' N ' HD23 ' J' ' 34' ' ' LEU . 33.8 ttp -123.7 125.74 45.3 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 114.734 -1.121 . . . . 0.0 112.6 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.559 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -123.63 70.05 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.287 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -44.6 -100.78 0.01 OUTLIER Glycine 0 C--N 1.357 1.716 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.98 150.8 8.16 Favored Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -158.39 148.01 8.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.856 0.36 . . . . 0.0 110.224 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 71.3 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.379 179.861 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.74 143.86 47.57 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.724 0.297 . . . . 0.0 110.492 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -110.64 144.64 39.23 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.278 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.571 HG12 ' N ' ' K' ' 13' ' ' HIS . 48.3 t -141.06 166.25 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.983 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.571 ' N ' HG12 ' K' ' 12' ' ' VAL . 3.1 m170 -115.89 161.93 18.08 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.9 174.75 4.14 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-O 121.23 0.538 . . . . 0.0 109.868 -178.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -142.03 176.67 8.77 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.017 -179.226 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -149.42 135.47 18.93 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.051 0.453 . . . . 0.0 110.822 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -127.72 111.34 13.58 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 78.9 t -134.66 127.27 49.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.661 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.4 m-30 -113.31 141.37 47.11 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.539 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.463 ' HA ' ' HA ' ' L' ' 20' ' ' PHE . 77.9 t80 -136.4 117.87 14.77 Favored 'General case' 0 N--CA 1.505 2.311 0 CA-C-N 120.858 1.663 . . . . 0.0 114.128 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.894 ' HB3' ' O ' ' L' ' 21' ' ' ALA . . . -121.91 126.17 48.06 Favored 'General case' 0 C--N 1.398 2.707 0 CA-C-O 123.13 1.443 . . . . 0.0 112.061 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.567 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 82.5 tt0 -89.63 124.7 34.81 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.249 -178.88 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -123.87 131.81 53.64 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.063 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.42 113.64 11.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.175 179.404 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' K' ' 26' ' ' SER . . . 59.41 91.35 0.01 OUTLIER Glycine 0 CA--C 1.529 0.954 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.861 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' CB ' ' K' ' 27' ' ' ASN . 3.7 p -43.67 170.27 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.553 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.654 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER 157.49 -179.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 122.891 1.329 . . . . 0.0 114.007 178.873 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.654 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 52.4 mttp -29.62 112.49 0.08 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 119.365 3.098 . . . . 0.0 119.365 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' L' ' 30' ' ' ALA . . . 83.01 91.62 0.65 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 119.814 2.686 . . . . 0.0 119.814 173.265 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.548 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -143.62 155.22 44.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 101.916 -3.364 . . . . 0.0 101.916 170.555 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.679 HG13 HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.96 121.39 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 118.553 -1.259 . . . . 0.0 111.158 -176.563 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.647 HG12 HD12 ' J' ' 32' ' ' ILE . 96.7 mt -120.74 127.64 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.488 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.55 110.64 1.88 Allowed Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 178.361 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.516 HD12 ' N ' ' K' ' 35' ' ' MET . 6.3 tp -121.63 118.65 29.71 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.224 -0.488 . . . . 0.0 110.637 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.516 ' N ' HD12 ' K' ' 34' ' ' LEU . 6.2 tmm? -118.99 117.51 29.01 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.867 178.241 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.431 HG22 HD11 ' K' ' 34' ' ' LEU . 1.4 t -113.29 79.69 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 120.981 0.42 . . . . 0.0 110.162 178.523 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.532 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -87.29 100.58 2.59 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 178.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.72 172.78 42.64 Favored Glycine 0 CA--C 1.524 0.608 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.463 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -131.46 141.76 45.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.37 179.9 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.209 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -104.1 132.33 50.45 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -149.12 135.57 19.37 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.976 0.417 . . . . 0.0 110.944 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -128.96 134.61 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.008 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -158.0 107.39 2.08 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 120.872 0.368 . . . . 0.0 111.388 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 54.6 t-80 -153.81 166.95 31.29 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.522 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 84.5 mt-30 -152.7 178.88 9.14 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.129 0.49 . . . . 0.0 110.991 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -154.84 125.36 6.91 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.352 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -120.78 115.59 23.59 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.507 -0.121 . . . . 0.0 110.773 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -125.66 126.71 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' J' ' 34' ' ' LEU . 5.0 m-30 -99.09 125.35 44.59 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.768 ' HB2' ' N ' ' K' ' 21' ' ' ALA . 1.6 p90 -32.47 159.9 0.0 OUTLIER 'General case' 0 C--O 1.158 -3.758 0 N-CA-C 121.05 3.722 . . . . 0.0 121.05 -172.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.894 ' O ' ' HB3' ' K' ' 21' ' ' ALA . . . -78.62 157.14 28.77 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.068 174.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.456 ' OE1' ' O ' ' L' ' 20' ' ' PHE . 0.0 OUTLIER 178.67 -169.41 0.09 Allowed 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -177.114 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.562 ' OD1' ' N ' ' K' ' 27' ' ' ASN . 20.8 t0 -62.97 106.09 0.77 Allowed 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.161 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.453 HG23 ' HB2' ' K' ' 26' ' ' SER . 87.0 t -36.16 142.84 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -98.75 82.94 0.61 Allowed Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 178.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 67.6 m -69.15 -171.69 0.35 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' L' ' 28' ' ' LYS . 96.3 m-20 -81.13 177.41 9.05 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.313 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.546 ' O ' ' O ' ' L' ' 27' ' ' ASN . 86.2 tttt 39.81 104.16 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 178.957 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.19 -101.19 1.85 Allowed Glycine 0 N--CA 1.467 0.715 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -177.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.548 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -61.88 170.0 2.29 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 118.222 1.011 . . . . 0.0 108.652 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.898 HD13 ' H ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -166.11 153.41 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 118.642 -1.223 . . . . 0.0 112.413 -177.885 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.7 mt -125.31 128.01 72.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.063 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.35 121.38 5.03 Favored Glycine 0 N--CA 1.469 0.853 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -119.77 118.62 31.35 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.522 ' CE ' HG22 ' E' ' 31' ' ' ILE . 3.9 ttp -117.36 119.94 36.64 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.58 ' O ' HG23 ' L' ' 36' ' ' VAL . 35.8 m -130.46 76.29 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.643 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.474 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 23.9 -112.63 0.01 OUTLIER Glycine 0 C--N 1.352 1.428 0 N-CA-C 112.234 -0.346 . . . . 0.0 112.234 178.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.76 -150.56 15.97 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.51 158.29 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.816 0.341 . . . . 0.0 110.35 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.676 -179.636 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -102.11 138.38 39.14 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.838 0.352 . . . . 0.0 110.387 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -119.63 143.05 47.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.429 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.499 HG23 ' O ' ' B' ' 12' ' ' VAL . 2.5 m -121.9 132.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -151.83 166.79 30.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.411 ' CD2' ' CE1' ' B' ' 13' ' ' HIS . 93.0 m-70 -132.13 179.5 6.06 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -95.25 177.43 5.86 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.587 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -116.37 145.31 43.32 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.893 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.7 tp -128.22 123.0 33.12 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 121.268 0.556 . . . . 0.0 111.872 -179.152 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.54 131.43 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.335 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -137.52 132.7 33.61 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.133 0.492 . . . . 0.0 111.599 -179.225 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.3 p90 -133.14 129.94 38.56 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.24 158.12 39.77 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.446 ' CB ' ' O ' ' B' ' 22' ' ' GLU . 22.5 pt-20 -143.88 150.65 38.75 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.915 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -94.09 -146.54 0.25 Allowed 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.706 -0.797 . . . . 0.0 111.202 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' A' ' 26' ' ' SER . 15.2 t -103.34 107.27 21.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -34.62 92.52 0.01 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 121.536 -0.364 . . . . 0.0 112.914 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.685 ' O ' ' O ' ' A' ' 27' ' ' ASN . 2.2 t 170.05 177.51 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.685 ' O ' ' O ' ' A' ' 26' ' ' SER . 15.9 t-20 -29.19 179.15 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.59 1.181 . . . . 0.0 112.641 177.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.557 ' CG ' ' O ' ' A' ' 27' ' ' ASN . 0.0 OUTLIER 128.45 103.57 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 175.794 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.05 101.06 0.27 Allowed Glycine 0 CA--C 1.484 -1.891 0 N-CA-C 106.962 -2.455 . . . . 0.0 106.962 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . -83.33 151.79 25.4 Favored 'General case' 0 N--CA 1.438 -1.039 0 C-N-CA 114.861 -2.736 . . . . 0.0 108.78 -175.089 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' G' ' 35' ' ' MET 0.3 0.3 OUTLIER -166.34 108.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.41 -2.475 0 CA-C-N 109.253 -3.612 . . . . 0.0 104.97 -168.806 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.495 ' N ' ' HE1' ' H' ' 35' ' ' MET . 17.8 tt -119.58 123.46 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 121.56 0.695 . . . . 0.0 110.032 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.573 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -124.3 116.8 2.91 Favored Glycine 0 CA--C 1.507 -0.468 0 N-CA-C 108.144 -1.982 . . . . 0.0 108.144 178.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 35.0 mt -136.21 148.15 47.97 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 122.905 1.336 . . . . 0.0 111.572 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.449 ' SD ' ' C ' ' G' ' 32' ' ' ILE . 12.0 ttm -121.18 124.0 43.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 112.475 -2.148 . . . . 0.0 109.362 -179.076 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.6 71.9 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.99 -96.47 0.01 OUTLIER Glycine 0 C--N 1.357 1.721 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 178.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.59 -162.76 36.55 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -131.0 160.76 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.855 0.359 . . . . 0.0 110.273 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.466 -179.662 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.04 140.71 47.61 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -110.57 137.65 47.98 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.909 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.499 ' O ' HG23 ' A' ' 12' ' ' VAL . 27.8 m -135.7 159.95 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.815 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.411 ' CE1' ' CD2' ' A' ' 14' ' ' HIS . 79.9 t60 -140.64 124.02 16.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.37 -0.377 . . . . 0.0 109.999 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 p-80 -149.32 166.74 28.08 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 121.239 0.543 . . . . 0.0 109.846 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.84 179.72 8.62 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.592 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -163.71 109.12 1.06 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.059 179.125 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -130.31 118.72 21.72 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.77 131.36 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.347 0.594 . . . . 0.0 110.866 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.91 131.14 55.13 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.1 t80 -128.37 119.95 26.02 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 132.68 53.21 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.863 -179.451 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 22' ' ' GLU . 81.8 tt0 -155.15 133.37 11.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.295 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -113.95 133.3 55.56 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 t -81.98 113.12 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.596 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 51.78 90.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.819 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.74 177.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.8 t 170.19 178.2 0.05 OUTLIER 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 178.314 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' B' ' 26' ' ' SER . 4.7 m120 -28.75 170.65 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.646 1.216 . . . . 0.0 111.473 177.337 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.573 ' NZ ' ' O ' ' D' ' 24' ' ' VAL . 98.2 mttt -151.43 104.17 3.05 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 123.032 1.396 . . . . 0.0 112.558 179.116 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.784 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . 50.64 -102.69 0.07 OUTLIER Glycine 1 CA--C 1.388 -7.855 0 C-N-CA 127.463 2.459 . . . . 0.0 114.279 179.457 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' B' ' 29' ' ' GLY 0.451 . . 113.93 -131.84 0.0 OUTLIER 'General case' 1 N--CA 1.366 -4.645 0 C-N-CA 114.019 -3.072 . . . . 0.0 106.355 -175.777 . . . . . . . . 4 3 . 1 . 002 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.725 HD12 ' N ' ' B' ' 31' ' ' ILE 0.366 2.2 mp -70.07 120.92 18.65 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.877 0 CA-C-N 109.245 -3.616 . . . . 0.0 113.458 175.045 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' B' ' 32' ' ' ILE . 16.9 tt -125.83 118.28 51.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.676 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -124.65 119.37 3.64 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.416 ' CD2' ' HB2' ' A' ' 34' ' ' LEU . 96.4 mt -136.61 131.25 33.48 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 122.901 1.334 . . . . 0.0 113.277 -176.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.485 ' HE1' ' SD ' ' C' ' 35' ' ' MET . 33.7 tpp -113.34 118.23 33.99 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.545 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.425 ' CG2' HG23 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -122.53 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.789 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.3 103.6 2.49 Favored Glycine 0 C--N 1.358 1.753 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.72 162.63 19.5 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.9 t -133.99 138.18 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 120.699 0.285 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.349 -179.976 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.74 135.31 49.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.892 0.377 . . . . 0.0 110.451 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -110.62 134.56 52.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.498 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 50.2 t -124.19 133.62 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.795 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -149.93 129.35 12.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.003 0.43 . . . . 0.0 111.005 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.558 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 71.8 t60 -138.47 166.21 24.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.558 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 83.4 mt-30 -156.18 169.64 24.06 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.915 178.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -157.81 108.49 2.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.727 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.5 tp -125.77 118.89 26.52 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -129.01 126.19 64.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.278 0.561 . . . . 0.0 112.029 -179.185 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.05 104.74 12.43 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -116.86 126.17 52.62 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.24 141.13 23.71 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-O 123.446 1.594 . . . . 0.0 115.09 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.457 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 93.5 mt-10 -137.5 73.75 1.46 Allowed 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.65 -2.523 . . . . 0.0 104.269 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.548 ' OD2' ' N ' ' C' ' 24' ' ' VAL . 25.1 t70 141.93 -115.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -175.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.548 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 28.0 t -40.88 121.98 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.517 ' H ' ' HA2' ' B' ' 29' ' ' GLY . . . 93.74 -90.37 1.37 Allowed Glycine 0 CA--C 1.538 1.475 0 CA-C-O 122.186 0.881 . . . . 0.0 111.275 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.506 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 52.6 m -60.89 -177.23 0.07 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -177.254 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.506 ' OD1' ' O ' ' C' ' 26' ' ' SER . 0.9 OUTLIER 95.02 165.43 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 111.443 -2.617 . . . . 0.0 115.324 177.755 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -37.02 111.47 0.15 Allowed 'General case' 0 C--N 1.349 0.545 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.672 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.12 91.24 0.26 Allowed Glycine 0 CA--C 1.457 -3.556 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.654 ' HB1' ' O ' ' B' ' 30' ' ' ALA . . . -153.23 162.81 40.89 Favored 'General case' 0 N--CA 1.38 -3.959 0 N-CA-C 101.618 -3.475 . . . . 0.0 101.618 177.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.653 HG23 HD12 ' D' ' 31' ' ' ILE 0.273 3.0 mp -126.63 115.95 43.47 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.283 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.448 -174.397 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.502 ' O ' ' SD ' ' J' ' 35' ' ' MET . 4.9 mt -101.37 110.38 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.022 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.61 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -121.81 109.15 1.41 Allowed Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 105.869 -2.892 . . . . 0.0 105.869 176.18 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.469 ' HG ' ' N ' ' C' ' 35' ' ' MET . 0.6 OUTLIER -147.42 147.66 30.48 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 123.493 1.616 . . . . 0.0 113.178 -177.061 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.621 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 29.6 ttm -122.9 128.02 49.75 Favored 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 112.0 -2.364 . . . . 0.0 109.101 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.686 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.9 p -132.45 71.55 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.31 112.93 4.23 Favored Glycine 0 C--N 1.361 1.948 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.601 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.77 -144.34 0.07 OUTLIER Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.0 141.69 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' C' C ' 40' ' ' VAL . . . . . 0.423 HG22 ' H ' ' C' ' 40' ' ' VAL . 12.6 m . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 117.907 -1.044 . . . . 0.0 110.738 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -111.19 136.91 49.58 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -151.1 143.24 24.04 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.015 0.436 . . . . 0.0 111.216 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m -139.09 163.4 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.176 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.54 -179.16 4.37 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.091 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.51 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 77.0 t60 -77.07 169.48 18.26 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.732 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.434 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 87.5 mt-30 -146.3 176.91 9.41 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.529 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -151.42 113.88 4.6 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 120.477 -0.489 . . . . 0.0 112.053 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.0 117.6 22.82 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.176 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -142.71 149.22 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 -178.483 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 2.5 m-30 -118.89 120.61 37.82 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.749 -1.569 . . . . 0.0 108.894 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -117.5 118.94 33.56 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 118.39 0.541 . . . . 0.0 109.988 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.407 ' HB1' ' HB3' ' C' ' 26' ' ' SER . . . -123.64 121.6 35.96 Favored 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.887 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -164.83 106.34 0.83 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -170.24 105.63 0.31 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 174.506 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.573 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 8.1 p -27.26 140.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 114.37 -1.287 . . . . 0.0 113.205 173.556 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.88 -81.26 0.05 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 119.309 -1.424 . . . . 0.0 113.361 177.924 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.758 ' O ' ' O ' ' D' ' 27' ' ' ASN . 88.5 p -170.86 179.59 3.11 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 120.146 1.973 . . . . 0.0 110.535 178.779 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.758 ' O ' ' O ' ' D' ' 26' ' ' SER . 37.1 t30 25.58 -178.96 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 O-C-N 124.722 1.264 . . . . 0.0 113.431 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.444 ' H ' ' CG ' ' D' ' 27' ' ' ASN . 83.9 tttt -119.19 -111.18 0.34 Allowed 'General case' 0 N--CA 1.466 0.37 0 O-C-N 121.542 -0.724 . . . . 0.0 109.61 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 41.69 91.52 0.01 OUTLIER Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.1 159.77 39.82 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 102.341 -3.207 . . . . 0.0 102.341 175.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.653 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.61 123.59 3.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 117.865 -1.534 . . . . 0.0 112.351 -170.427 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.419 ' O ' HG22 ' D' ' 32' ' ' ILE . 1.5 mt -111.32 119.46 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-O 121.315 0.578 . . . . 0.0 110.129 178.366 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.699 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -127.01 100.48 0.55 Allowed Glycine 0 C--N 1.311 -0.817 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.869 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.537 HD21 HG13 ' D' ' 36' ' ' VAL . 10.5 tt -124.92 130.58 52.65 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.04 0.924 . . . . 0.0 111.964 -177.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.54 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.4 ttt -112.89 123.32 50.04 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 114.056 -1.429 . . . . 0.0 110.365 179.38 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.537 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.82 78.15 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-N 116.262 -0.426 . . . . 0.0 109.987 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.1 105.13 0.08 OUTLIER Glycine 0 C--N 1.348 1.211 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.24 -154.1 2.66 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.17 143.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.09 0.472 . . . . 0.0 110.329 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.473 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -140.97 150.49 43.15 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.409 ' OE1' ' C ' ' F' ' 11' ' ' GLU . 79.4 mm-40 -142.3 140.03 32.04 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.204 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG22 ' F' ' 12' ' ' VAL . 59.4 t -128.79 133.58 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.315 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -78.34 -168.67 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.437 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 37.8 p-80 -146.73 177.32 9.18 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 120.988 0.423 . . . . 0.0 110.087 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -100.26 169.68 8.96 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.24 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.79 120.75 13.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.613 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -122.2 121.83 37.76 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.667 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -130.49 126.83 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 120.562 -0.455 . . . . 0.0 112.192 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE2' ' CD2' ' D' ' 19' ' ' PHE . 10.8 m-85 -115.88 115.6 26.51 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 176.909 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.516 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 66.3 t80 -123.74 124.97 43.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.666 -177.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.9 139.74 41.83 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-O 121.114 0.483 . . . . 0.0 111.218 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.516 ' OE2' ' CZ ' ' E' ' 20' ' ' PHE . 8.6 mm-40 -108.49 119.88 40.79 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -166.81 101.18 0.56 Allowed 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.345 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -73.35 -158.84 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.711 0.767 . . . . 0.0 112.084 -178.371 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 62.17 79.61 0.13 Allowed Glycine 0 CA--C 1.526 0.776 0 CA-C-N 114.233 -1.349 . . . . 0.0 111.842 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.566 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 26.3 t -61.25 171.88 1.24 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.335 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' E' ' 26' ' ' SER . 9.6 p-10 102.9 177.26 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 O-C-N 124.772 1.295 . . . . 0.0 112.377 176.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.436 ' C ' ' O ' ' E' ' 27' ' ' ASN . 99.4 mttt -21.85 103.8 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 114.84 -1.073 . . . . 0.0 111.736 177.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.427 ' O ' ' CG1' ' E' ' 31' ' ' ILE . . . 166.4 -101.71 0.18 Allowed Glycine 0 CA--C 1.493 -1.337 0 C-N-CA 117.92 -2.086 . . . . 0.0 115.435 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -55.06 155.44 4.61 Favored 'General case' 0 C--O 1.245 0.832 0 C-N-CA 117.792 -1.563 . . . . 0.0 110.39 -174.767 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.686 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.0 OUTLIER -147.16 124.29 3.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.302 -1.317 . . . . 0.0 107.819 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 77.9 mt -123.19 130.24 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-O 120.958 0.409 . . . . 0.0 112.048 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.31 121.1 3.23 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.674 HD22 ' CE1' ' F' ' 19' ' ' PHE . 18.6 tp -125.7 123.36 38.72 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.629 -0.285 . . . . 0.0 110.812 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 12.8 ttt -117.86 117.81 30.3 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.219 178.302 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.6 t -122.54 83.81 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.133 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -16.34 -95.19 0.01 OUTLIER Glycine 0 N--CA 1.471 1.03 0 O-C-N 123.404 0.44 . . . . 0.0 112.833 -179.118 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.33 176.57 18.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 m -100.53 142.61 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 0.0 110.245 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.478 -179.865 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -82.88 137.47 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.704 0.288 . . . . 0.0 110.624 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 11' ' ' GLU . . . . . 0.409 ' C ' ' OE1' ' E' ' 11' ' ' GLU . 82.4 tt0 -159.03 159.85 35.2 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.467 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.434 HG22 ' H ' ' E' ' 12' ' ' VAL . 55.8 t -80.93 131.07 34.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -85.36 146.69 26.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.837 0.351 . . . . 0.0 111.364 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 83.5 m-70 -94.88 179.49 5.22 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -79.82 166.25 21.91 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 120.12 -0.632 . . . . 0.0 110.767 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -135.96 118.8 16.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 22.7 mt -122.5 120.45 33.91 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.28 130.9 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.209 0.528 . . . . 0.0 112.266 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.674 ' CE1' HD22 ' E' ' 34' ' ' LEU . 26.2 m-85 -119.64 123.83 44.81 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.001 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -139.69 130.93 26.64 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.589 0.709 . . . . 0.0 112.025 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.23 133.96 51.35 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.554 178.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.44 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 81.0 tt0 -76.65 90.48 3.38 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.937 -178.35 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' E' ' 26' ' ' SER . 15.7 t70 173.87 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.632 178.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 m -58.85 130.72 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.379 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.85 85.31 0.16 Allowed Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.419 -0.896 . . . . 0.0 111.709 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.9 p -64.67 -174.45 0.14 Allowed 'General case' 0 N--CA 1.442 -0.829 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.084 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.443 ' O ' ' O ' ' F' ' 28' ' ' LYS . 88.1 m-20 -90.7 178.59 6.03 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 119.876 -0.73 . . . . 0.0 109.61 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.3 mttt 27.95 102.12 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 113.099 0.778 . . . . 0.0 113.099 177.517 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.72 -101.62 0.24 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 120.134 -1.032 . . . . 0.0 113.662 177.591 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.81 167.47 0.77 Allowed 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.591 HG21 ' HA2' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -150.08 126.86 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 118.105 -1.438 . . . . 0.0 111.416 -176.939 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 5.1 mp -127.39 133.01 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.193 -178.693 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.7 131.8 6.33 Favored Glycine 0 N--CA 1.469 0.893 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -127.23 125.48 41.07 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 24.4 ttt -128.37 126.68 41.17 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.818 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -118.17 81.15 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.438 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.596 ' CA ' HG21 ' L' ' 31' ' ' ILE . . . -45.29 100.9 0.02 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.873 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.82 162.01 35.78 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -136.14 145.96 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 120.788 0.327 . . . . 0.0 110.454 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.875 -1.059 . . . . 0.0 110.68 -179.647 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -118.11 148.69 42.06 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.816 0.341 . . . . 0.0 110.99 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -53.32 163.86 0.53 Allowed 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.012 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.418 ' O ' HG13 ' G' ' 12' ' ' VAL . 9.9 p -119.62 130.43 74.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.897 0.379 . . . . 0.0 111.11 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -159.77 156.09 26.98 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.463 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.424 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 22.8 m80 -97.55 178.65 5.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -118.26 -177.08 3.2 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.23 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.59 154.44 17.92 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.174 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.1 tp -131.15 118.23 20.19 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.088 0.47 . . . . 0.0 110.439 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -124.94 131.03 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.752 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 t80 -129.98 127.96 41.09 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.036 0.446 . . . . 0.0 110.304 179.74 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.523 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -130.3 128.59 41.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.89 123.04 46.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.981 0.42 . . . . 0.0 110.505 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' G' ' 23' ' ' ASP . 43.6 tt0 -141.06 142.28 34.19 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.913 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.48 ' O ' ' O ' ' G' ' 22' ' ' GLU . 97.5 m-20 50.54 113.88 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.937 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.545 ' N ' ' OD2' ' H' ' 23' ' ' ASP . 70.0 t -149.34 112.84 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.283 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.21 -91.02 0.01 OUTLIER Glycine 0 CA--C 1.529 0.924 0 CA-C-O 121.466 0.481 . . . . 0.0 112.898 177.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.78 ' O ' ' O ' ' G' ' 27' ' ' ASN . 21.2 p -161.76 174.57 13.03 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.78 ' O ' ' O ' ' G' ' 26' ' ' SER . 81.7 m-20 -9.42 160.03 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CB ' ' H' ' 26' ' ' SER . 17.1 pttp 179.26 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.1 100.93 0.68 Allowed Glycine 0 N--CA 1.469 0.898 0 N-CA-C 107.061 -2.416 . . . . 0.0 107.061 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.42 157.43 22.48 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 123.473 1.606 . . . . 0.0 113.301 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.415 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.83 111.61 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 CA-C-N 111.766 -2.47 . . . . 0.0 108.671 -178.197 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.449 ' C ' ' SD ' ' A' ' 35' ' ' MET . 1.9 mt -99.1 109.25 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.889 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.59 105.75 1.04 Allowed Glycine 0 CA--C 1.504 -0.645 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 18.1 mt -139.46 145.32 38.67 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 123.061 1.41 . . . . 0.0 112.709 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 48.4 ttp -113.87 114.24 25.98 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.538 -1.664 . . . . 0.0 106.803 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.1 71.0 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.495 ' O ' HG21 ' A' ' 31' ' ' ILE . . . -157.1 95.98 0.15 Allowed Glycine 0 C--N 1.355 1.604 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -138.16 -176.87 14.78 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.84 159.21 43.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 51.4 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.558 -179.745 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 99.0 m-85 -106.91 133.34 51.7 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.776 0.322 . . . . 0.0 110.609 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' H' ' 11' ' ' GLU . 56.0 mp0 -111.89 132.7 54.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.848 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.75 162.31 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -152.57 97.67 2.28 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.429 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.424 ' CE1' ' O ' ' G' ' 14' ' ' HIS . 54.2 p-80 -108.1 166.45 10.72 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -152.54 168.9 24.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.778 0.799 . . . . 0.0 111.377 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.675 ' C ' HD12 ' H' ' 17' ' ' LEU . 64.8 tttm -169.58 117.35 0.6 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.71 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.675 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.0 mp -122.33 118.5 28.63 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.729 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.51 HG21 ' HZ1' ' H' ' 16' ' ' LYS . 60.3 t -121.03 124.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.252 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.474 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 83.5 m-85 -119.7 106.55 12.24 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -116.41 124.65 50.55 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.455 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.98 130.04 49.28 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.813 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -159.33 114.78 2.49 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.823 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.545 ' OD2' ' N ' ' G' ' 24' ' ' VAL . 28.5 t0 -174.65 123.3 0.27 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 178.343 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' H' ' 23' ' ' ASP . 13.0 t -36.9 113.69 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.911 175.077 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.726 ' H ' ' CG2' ' I' ' 24' ' ' VAL . . . 169.37 -90.83 0.1 OUTLIER Glycine 0 CA--C 1.536 1.358 0 C-N-CA 118.854 -1.641 . . . . 0.0 115.188 -178.435 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.431 ' O ' ' O ' ' H' ' 25' ' ' GLY . 9.5 p -43.35 167.02 0.01 OUTLIER 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 118.374 1.087 . . . . 0.0 111.539 -174.055 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -109.57 171.75 7.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.8 -1.091 . . . . 0.0 113.361 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 51.7 mmtt -37.07 111.5 0.16 Allowed 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 114.3 -1.318 . . . . 0.0 113.944 177.079 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.43 93.8 1.73 Allowed Glycine 0 CA--C 1.491 -1.442 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.342 177.218 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.05 173.51 9.83 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 101.077 -3.675 . . . . 0.0 101.077 171.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.421 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -134.08 118.72 29.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 118.005 -1.478 . . . . 0.0 109.835 -178.295 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.43 HG22 ' O ' ' H' ' 32' ' ' ILE . 1.3 mt -109.78 115.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.461 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.44 97.42 0.68 Allowed Glycine 0 CA--C 1.508 -0.345 0 N-CA-C 106.914 -2.475 . . . . 0.0 106.914 176.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.488 HD21 ' CZ ' ' I' ' 19' ' ' PHE . 2.9 mp -127.02 133.51 50.51 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-O 122.552 1.168 . . . . 0.0 111.456 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.676 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 43.7 ttp -111.16 117.38 33.08 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-N 113.595 -1.639 . . . . 0.0 107.895 178.07 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -113.05 67.65 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.957 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.81 -101.62 0.01 OUTLIER Glycine 0 C--N 1.352 1.446 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.56 164.85 11.53 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.27 141.71 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.765 -179.936 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -99.48 132.22 44.96 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.774 0.321 . . . . 0.0 110.496 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.14 158.59 33.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.21 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.566 HG12 ' N ' ' I' ' 13' ' ' HIS . 43.1 t -130.43 164.85 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 120.977 0.418 . . . . 0.0 111.331 -179.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.666 ' CG ' ' H ' ' I' ' 14' ' ' HIS . 44.6 t-80 -125.82 -172.35 2.58 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.047 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.666 ' H ' ' CG ' ' I' ' 13' ' ' HIS . 0.1 OUTLIER -76.45 166.65 23.12 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.204 0.526 . . . . 0.0 109.795 -179.205 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -148.65 170.68 17.59 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.174 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -150.35 137.78 19.68 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 121.041 -0.264 . . . . 0.0 111.149 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 52.8 mt -130.99 124.5 31.09 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.33 137.83 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.488 ' CZ ' HD21 ' H' ' 34' ' ' LEU . 60.8 m-85 -120.44 123.85 44.01 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.136 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.626 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 3.4 t80 -124.27 124.44 42.42 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.101 -177.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.83 126.05 42.7 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 122.49 1.138 . . . . 0.0 113.451 -178.991 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -154.28 82.83 1.12 Allowed 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.462 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.473 ' OD2' ' O ' ' H' ' 23' ' ' ASP . 13.1 t70 -105.79 -114.13 0.25 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.726 ' CG2' ' H ' ' H' ' 25' ' ' GLY . 58.2 t -85.45 130.69 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.933 0 N-CA-C 104.426 -2.435 . . . . 0.0 104.426 176.088 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.607 ' CA ' ' H ' ' J' ' 24' ' ' VAL . . . -42.98 82.66 0.0 OUTLIER Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.189 -1.005 . . . . 0.0 111.974 -176.117 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.667 ' N ' ' O ' ' I' ' 24' ' ' VAL . 11.4 p -65.63 -176.2 0.33 Allowed 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 177.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.492 ' O ' ' O ' ' I' ' 28' ' ' LYS . 9.7 p30 -81.42 179.2 7.95 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.671 177.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' I' ' 27' ' ' ASN . 85.0 tttt -42.39 -106.42 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.984 0.897 . . . . 0.0 110.036 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.899 ' C ' ' HB1' ' J' ' 30' ' ' ALA . . . -82.8 96.98 1.92 Allowed Glycine 0 CA--C 1.45 -3.973 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.792 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -68.73 -151.17 0.01 OUTLIER 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 101.899 -3.371 . . . . 0.0 101.899 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.9 ' N ' HD13 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -102.62 104.01 15.89 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 CA-C-N 123.782 2.992 . . . . 0.0 109.964 -176.0 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.621 ' N ' ' SD ' ' C' ' 35' ' ' MET . 2.6 mt -107.11 114.2 45.48 Favored 'Isoleucine or valine' 0 C--N 1.362 1.131 0 CA-C-N 113.765 -1.561 . . . . 0.0 111.126 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.409 ' N ' ' CE ' ' B' ' 35' ' ' MET . . . -115.54 97.98 0.82 Allowed Glycine 0 C--O 1.242 0.641 0 N-CA-C 105.502 -3.039 . . . . 0.0 105.502 175.394 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.523 HD11 ' CZ ' ' J' ' 19' ' ' PHE . 0.2 OUTLIER -129.78 132.83 46.67 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-O 122.268 1.032 . . . . 0.0 111.077 -177.462 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.61 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.0 ttp -113.68 121.55 44.46 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.345 -178.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.51 70.03 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 177.126 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -41.12 -100.66 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.81 -160.59 33.68 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 54.7 t -122.46 134.94 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 120.859 0.361 . . . . 0.0 110.04 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 70.1 t . . . . . 0 C--O 1.218 -0.582 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.604 -179.984 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -104.15 131.58 51.3 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.868 0.366 . . . . 0.0 110.624 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -68.52 128.34 36.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.711 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -147.26 155.35 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.852 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -146.45 135.62 22.68 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.054 0.454 . . . . 0.0 111.523 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -152.43 155.94 38.53 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.595 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -153.38 173.64 15.38 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.441 0.639 . . . . 0.0 111.706 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -155.93 129.33 8.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.596 -1.184 . . . . 0.0 107.887 178.275 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.84 116.94 24.52 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.5 123.62 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.253 0.549 . . . . 0.0 110.896 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.523 ' CZ ' HD11 ' I' ' 34' ' ' LEU . 3.9 m-85 -120.88 109.06 14.67 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 179.276 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.626 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 3.7 p90 -148.94 151.36 34.48 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 117.772 -1.571 . . . . 0.0 114.649 -178.946 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.01 155.88 34.96 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.156 -1.384 . . . . 0.0 111.169 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -127.22 144.03 51.13 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -178.91 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.468 ' CG ' ' O ' ' I' ' 26' ' ' SER . 10.9 t0 -103.68 134.26 47.31 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.867 178.179 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.607 ' H ' ' CA ' ' I' ' 25' ' ' GLY . 57.4 t -110.43 111.78 37.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.661 179.495 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.23 90.37 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 N-CA-C 115.708 1.043 . . . . 0.0 115.708 174.96 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.613 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.8 p 170.68 174.83 0.06 Allowed 'General case' 0 C--N 1.343 0.324 0 CA-C-N 118.369 1.084 . . . . 0.0 111.379 176.003 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' J' ' 26' ' ' SER . 13.6 m-20 -28.04 -179.55 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.59 ' CD ' ' H ' ' K' ' 27' ' ' ASN . 55.3 tttt -130.51 -107.31 0.27 Allowed 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.748 1.388 . . . . 0.0 114.748 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 41.61 91.81 0.01 OUTLIER Glycine 0 N--CA 1.481 1.677 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 -176.688 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.899 ' HB1' ' C ' ' I' ' 29' ' ' GLY . . . -140.61 157.73 45.02 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -177.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.82 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -146.18 128.11 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.53 0 CA-C-O 121.461 0.648 . . . . 0.0 112.506 -178.286 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.54 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.3 tt -109.25 118.41 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.52 101.66 0.99 Allowed Glycine 0 N--CA 1.47 0.963 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' I' ' 32' ' ' ILE . 80.0 mt -127.05 131.68 50.88 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-O 121.431 0.634 . . . . 0.0 112.583 -177.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.699 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.2 ttp -113.82 120.6 41.3 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.015 178.003 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.74 67.46 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.433 ' HA3' HD13 ' D' ' 31' ' ' ILE . . . -49.97 121.4 9.58 Favored Glycine 0 C--N 1.355 1.593 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.663 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.54 -136.8 0.03 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -127.86 134.42 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.535 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 m . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.804 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.52 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -105.18 137.35 43.1 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 120.872 0.368 . . . . 0.0 110.617 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.72 131.8 29.75 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.797 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 m -139.83 134.21 37.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.156 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -124.3 119.17 28.52 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.315 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.89 162.55 24.15 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-O 121.485 0.66 . . . . 0.0 109.444 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' L' ' 15' ' ' GLN . 85.4 mt-30 -151.35 178.78 8.92 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.353 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -172.69 128.15 0.51 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -124.39 123.44 40.18 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.825 0.345 . . . . 0.0 110.117 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.48 125.38 65.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.74 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.413 ' HB2' ' CD1' ' L' ' 19' ' ' PHE . 17.3 m-85 -115.77 114.92 25.44 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -122.05 123.64 42.09 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.01 128.08 39.62 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 121.49 0.662 . . . . 0.0 111.31 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -99.12 128.29 45.22 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 120.176 -0.609 . . . . 0.0 111.782 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 9.2 p-10 -142.86 136.58 28.84 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.116 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.546 HG13 ' O ' ' K' ' 24' ' ' VAL . 7.8 p -91.1 112.27 24.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.577 -176.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.69 91.5 0.01 OUTLIER Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.586 ' HB2' ' HZ1' ' J' ' 28' ' ' LYS . 5.4 t -42.32 154.63 0.05 Allowed 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.64 -0.78 . . . . 0.0 110.931 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.59 ' H ' ' CD ' ' J' ' 28' ' ' LYS . 84.7 m-20 -126.97 -179.86 5.05 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.746 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.401 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.7 mttt -30.12 107.29 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.473 1.286 . . . . 0.0 114.473 -177.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.36 -96.48 1.74 Allowed Glycine 0 N--CA 1.47 0.93 0 CA-C-N 113.996 -1.456 . . . . 0.0 116.208 172.595 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.425 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 72.22 153.28 0.13 Allowed 'General case' 0 C--O 1.249 1.051 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 -174.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.715 HG23 HG12 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -149.65 127.47 2.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 117.001 -1.88 . . . . 0.0 111.82 -176.98 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.504 ' O ' ' CE ' ' E' ' 35' ' ' MET . 82.7 mt -118.84 120.08 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.001 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -119.93 107.86 1.39 Allowed Glycine 0 N--CA 1.467 0.749 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.422 HD13 ' CD2' ' L' ' 19' ' ' PHE . 48.5 mt -121.43 120.6 35.45 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -117.97 124.78 49.03 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.188 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.05 80.77 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.799 178.338 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.686 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -63.8 102.87 0.61 Allowed Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.78 -146.79 18.03 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -121.74 138.2 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.661 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.789 179.449 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -90.33 136.75 32.86 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.686 0.279 . . . . 0.0 110.933 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -74.96 152.65 38.77 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -121.79 131.19 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.137 0.494 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -155.24 140.29 17.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.694 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -150.4 171.46 16.98 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 89.0 mt-30 -147.02 173.53 12.37 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.464 0.65 . . . . 0.0 111.228 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -155.55 130.26 9.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.494 179.157 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.69 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.6 tt -132.5 125.31 30.31 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 18' ' ' VAL . . . . . 0.496 ' N ' HD23 ' L' ' 17' ' ' LEU . 73.8 t -129.39 129.21 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 121.147 0.499 . . . . 0.0 111.835 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.508 ' CD2' HD21 ' L' ' 17' ' ' LEU . 10.8 m-85 -113.43 114.27 26.34 Favored 'General case' 0 C--N 1.341 0.215 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -140.64 136.83 33.1 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 122.104 0.954 . . . . 0.0 112.249 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.16 151.84 30.58 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.386 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 81.8 tt0 -75.11 95.15 3.02 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.991 -178.82 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' L' ' 24' ' ' VAL . 67.9 t0 -175.36 136.1 0.35 Allowed 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.981 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.543 HG23 ' O ' ' L' ' 24' ' ' VAL . 33.5 m -71.02 111.28 4.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.675 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.95 -91.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.007 0 CA-C-N 114.894 -1.048 . . . . 0.0 115.528 -176.095 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 10.0 p -71.24 176.67 4.36 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 122.967 1.365 . . . . 0.0 114.362 -175.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 4.9 t-20 85.89 178.65 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 111.412 -2.631 . . . . 0.0 114.486 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.1 mttt -40.99 104.49 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 116.61 2.078 . . . . 0.0 116.61 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.0 -101.24 0.3 Allowed Glycine 0 N--CA 1.473 1.161 0 N-CA-C 115.823 1.089 . . . . 0.0 115.823 173.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.587 ' C ' HD13 ' L' ' 31' ' ' ILE . . . -58.37 172.8 0.43 Allowed 'General case' 0 CA--C 1.508 -0.636 0 CA-C-O 119.106 -0.474 . . . . 0.0 111.335 -177.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.845 ' N ' HD13 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -134.78 118.6 25.82 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 C-N-CA 118.405 -1.318 . . . . 0.0 111.148 179.661 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.62 133.23 68.75 Favored 'Isoleucine or valine' 0 C--O 1.23 0.072 0 CA-C-N 113.77 -1.559 . . . . 0.0 109.786 -178.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.521 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -131.3 118.88 2.49 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.381 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.521 HD12 ' C ' ' L' ' 33' ' ' GLY . 10.6 mp -114.5 124.34 51.65 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.9 tmm? -117.51 120.53 38.37 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.616 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.72 81.13 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.549 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.591 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . 44.13 -101.39 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.53 -169.29 37.76 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.82 136.24 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.904 0.383 . . . . 0.0 110.672 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.813 179.726 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.333 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -115.26 138.57 50.8 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.983 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -141.85 156.52 45.53 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.51 133.55 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 120.952 0.406 . . . . 0.0 110.737 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -135.8 -175.7 4.05 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.067 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -80.03 164.79 23.16 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-O 121.23 0.538 . . . . 0.0 109.836 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -153.5 177.45 10.9 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.462 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -147.57 131.34 16.99 Favored 'General case' 0 N--CA 1.466 0.374 0 C-N-CA 121.118 -0.233 . . . . 0.0 110.809 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -133.4 115.44 14.84 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.326 0.584 . . . . 0.0 110.135 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.63 133.44 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.072 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -145.72 148.93 33.54 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.681 0.753 . . . . 0.0 111.511 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 p90 -135.92 149.3 48.9 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.717 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.81 136.54 27.24 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 122.275 1.035 . . . . 0.0 113.312 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' A' ' 23' ' ' ASP . 98.8 mt-10 -111.51 178.72 4.24 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.532 -1.667 . . . . 0.0 107.705 177.473 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.529 ' H ' ' CB ' ' B' ' 23' ' ' ASP . 95.7 m-20 58.54 132.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.489 ' N ' ' OD2' ' B' ' 23' ' ' ASP . 0.2 OUTLIER -71.88 113.09 8.18 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.181 -178.805 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -49.72 -91.11 0.01 OUTLIER Glycine 0 C--N 1.331 0.27 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.621 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.586 ' OG ' HD11 ' A' ' 31' ' ' ILE . 32.2 t -66.91 -170.1 0.1 Allowed 'General case' 0 N--CA 1.432 -1.371 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -78.77 177.73 8.45 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.699 0.762 . . . . 0.0 112.344 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -39.44 108.1 0.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.365 -1.289 . . . . 0.0 112.006 -178.604 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.3 99.2 2.59 Favored Glycine 0 CA--C 1.493 -1.289 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.205 -176.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.18 160.66 20.83 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.392 -176.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.586 HD11 ' OG ' ' A' ' 26' ' ' SER . 0.0 OUTLIER -146.74 111.79 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.775 -175.295 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.581 HG22 HD11 ' B' ' 34' ' ' LEU . 46.8 mt -121.29 104.88 15.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.641 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -113.96 114.2 3.26 Favored Glycine 0 CA--C 1.502 -0.78 0 N-CA-C 105.827 -2.909 . . . . 0.0 105.827 176.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 5.6 tp -146.04 144.93 30.37 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 122.754 1.264 . . . . 0.0 113.382 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.597 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 17.5 ttm -112.91 117.36 31.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.888 178.394 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.89 67.3 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 177.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.3 -101.71 0.01 OUTLIER Glycine 0 C--N 1.366 2.21 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.95 -166.13 39.21 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.97 158.08 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.836 0.35 . . . . 0.0 110.735 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.915 -1.04 . . . . 0.0 110.533 -179.866 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 10' ' ' TYR . . . . . 0.491 ' CD1' ' O ' ' C' ' 9' ' ' GLY . 91.9 m-85 -105.2 132.95 50.76 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -137.85 160.53 39.03 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.114 0.483 . . . . 0.0 111.14 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 50.9 t -122.41 134.45 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.893 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -109.07 114.83 28.9 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.985 0.421 . . . . 0.0 111.445 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.47 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 83.5 t60 -142.23 160.45 40.22 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.486 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.47 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 78.9 mt-30 -159.27 179.11 9.28 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.13 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -161.35 119.02 2.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.519 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -130.61 122.64 27.83 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.12 137.12 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 121.066 0.46 . . . . 0.0 110.582 178.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -128.87 138.33 51.96 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.879 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -123.15 131.49 53.71 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.21 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.48 125.71 29.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 120.673 -0.411 . . . . 0.0 111.86 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 82.5 tt0 -170.82 139.76 1.53 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.448 179.257 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.529 ' CB ' ' H ' ' A' ' 23' ' ' ASP . 14.3 p-10 -168.88 111.16 0.52 Allowed 'General case' 0 C--N 1.344 0.329 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.406 HG23 ' H ' ' B' ' 24' ' ' VAL . 6.2 t -31.45 131.31 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.241 175.208 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.22 -83.31 0.09 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 118.815 -1.66 . . . . 0.0 114.849 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' B' ' 27' ' ' ASN . 6.2 p -170.53 -179.58 3.01 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 120.028 1.914 . . . . 0.0 113.125 -178.289 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' B' ' 26' ' ' SER . 89.2 m-20 26.77 -170.22 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 112.712 -2.04 . . . . 0.0 113.544 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.566 ' NZ ' ' O ' ' D' ' 23' ' ' ASP . 51.7 tttt -142.06 -104.52 0.14 Allowed 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 113.68 0.992 . . . . 0.0 113.68 -177.51 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.24 95.59 0.01 OUTLIER Glycine 0 N--CA 1.477 1.429 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.452 ' O ' HG13 ' C' ' 31' ' ' ILE . . . -104.99 154.35 20.23 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 103.294 -2.854 . . . . 0.0 103.294 176.316 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.448 HD12 HG23 ' A' ' 31' ' ' ILE . 2.0 mt -139.8 108.14 3.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.753 -173.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.483 ' O ' HG23 ' B' ' 32' ' ' ILE . 5.1 tt -122.37 116.55 49.4 Favored 'Isoleucine or valine' 0 C--O 1.241 0.646 0 CA-C-O 122.069 0.938 . . . . 0.0 109.619 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.781 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -127.99 117.92 2.72 Favored Glycine 0 N--CA 1.453 -0.188 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.781 HD12 ' C ' ' B' ' 33' ' ' GLY . 7.0 mp -141.91 149.93 40.83 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-O 123.147 1.451 . . . . 0.0 113.214 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 24.2 ttm -121.69 118.75 29.9 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 112.769 -2.014 . . . . 0.0 107.822 177.401 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -112.57 68.71 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -179.6 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.82 -101.5 0.12 Allowed Glycine 0 C--N 1.352 1.417 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.599 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.41 167.71 35.49 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.4 m -131.74 161.92 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.906 0.384 . . . . 0.0 110.242 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.648 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' C' C ' 9' ' ' GLY . . . . . 0.491 ' O ' ' CD1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -82.59 142.38 31.82 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' D' ' 11' ' ' GLU . 95.9 mt-10 -61.04 135.22 57.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.742 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m -137.13 136.79 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.009 179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -117.26 136.98 52.7 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 120.723 0.297 . . . . 0.0 111.57 -178.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 24.0 t-80 -141.37 163.2 33.6 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.663 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 33.6 mt-30 -156.03 169.74 23.77 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 121.183 0.516 . . . . 0.0 111.064 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -155.91 115.98 3.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.443 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 44.4 tp -121.5 124.09 43.6 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -133.38 127.28 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 113.466 0.913 . . . . 0.0 113.466 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 50.6 m-85 -117.47 119.29 34.61 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -122.46 126.37 47.75 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 117.827 0.285 . . . . 0.0 111.421 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.12 149.2 37.79 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 115.435 1.642 . . . . 0.0 115.435 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 28.0 mt-10 -154.45 138.69 16.59 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 114.398 -1.274 . . . . 0.0 110.857 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -156.13 112.24 3.05 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 114.504 1.298 . . . . 0.0 114.504 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.408 HG23 ' H ' ' C' ' 24' ' ' VAL . 61.9 t -34.77 126.9 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 115.494 1.664 . . . . 0.0 115.494 175.132 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.85 -84.83 0.09 OUTLIER Glycine 0 CA--C 1.539 1.536 0 C-N-CA 119.325 -1.417 . . . . 0.0 115.07 173.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.73 ' O ' ' O ' ' C' ' 27' ' ' ASN . 36.7 p -172.06 163.56 6.05 Favored 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 118.852 1.326 . . . . 0.0 109.474 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.73 ' O ' ' O ' ' C' ' 26' ' ' SER . 26.8 m-80 35.73 -178.68 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 O-C-N 124.015 0.822 . . . . 0.0 110.276 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.613 ' O ' ' O ' ' D' ' 29' ' ' GLY . 87.3 tttt -96.78 110.61 23.05 Favored 'General case' 0 C--O 1.218 -0.581 0 C-N-CA 117.231 -1.788 . . . . 0.0 109.461 177.413 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.528 ' H ' ' HD3' ' B' ' 28' ' ' LYS . . . -77.45 94.34 1.15 Allowed Glycine 0 CA--C 1.477 -2.308 0 CA-C-O 117.522 -1.71 . . . . 0.0 109.771 173.229 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.426 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -149.75 134.51 17.73 Favored 'General case' 0 CA--C 1.47 -2.113 0 C-N-CA 115.933 -2.307 . . . . 0.0 108.115 173.044 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.452 HG13 ' O ' ' B' ' 30' ' ' ALA 0.274 3.5 mt -138.78 102.22 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 CA-C-N 110.469 -3.059 . . . . 0.0 105.045 -175.837 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.515 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.9 mt -109.19 118.14 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-N 115.059 -0.973 . . . . 0.0 111.427 -176.679 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.708 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -129.92 99.08 0.44 Allowed Glycine 0 CA--C 1.5 -0.901 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.169 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.475 ' HG ' ' H ' ' B' ' 34' ' ' LEU . 3.7 mp -132.05 147.35 52.44 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 122.64 1.209 . . . . 0.0 111.924 -177.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.494 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 26.7 ttm -129.01 127.94 42.64 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.87 -1.968 . . . . 0.0 110.375 -179.098 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.75 72.24 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.9 102.76 2.39 Favored Glycine 0 C--N 1.364 2.102 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 -178.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.4 154.61 25.86 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.0 m -134.72 161.57 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-O 120.735 0.302 . . . . 0.0 110.477 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.256 179.664 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -106.56 132.01 53.06 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.843 0.354 . . . . 0.0 110.659 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' C' ' 11' ' ' GLU . 96.0 mt-10 -69.45 143.51 53.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.96 139.26 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.642 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -85.78 166.42 16.09 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.884 0.373 . . . . 0.0 110.097 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 43.7 p-80 -76.52 175.11 9.54 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.225 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -140.62 173.36 11.57 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.189 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -141.04 130.75 24.17 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.494 0.664 . . . . 0.0 112.258 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 49.5 tp -122.54 120.31 33.46 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.761 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 18' ' ' VAL . . . . . 0.516 HG11 ' CE2' ' D' ' 20' ' ' PHE . 19.8 t -134.79 128.35 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.522 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 65.2 m-85 -125.46 115.32 20.06 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.771 177.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' D' ' 20' ' ' PHE . 0.0 OUTLIER -147.84 159.09 44.21 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 122.786 1.279 . . . . 0.0 113.949 179.129 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.74 156.33 38.91 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.867 -1.515 . . . . 0.0 112.013 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 33.1 mt-10 -148.24 141.71 25.35 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.685 -179.559 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.566 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 0.8 OUTLIER 168.09 103.68 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.447 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.56 ' O ' ' O ' ' D' ' 23' ' ' ASP . 3.4 t -27.57 158.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 C-N-CA 123.354 0.662 . . . . 0.0 112.044 176.527 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.97 -76.28 0.07 OUTLIER Glycine 0 CA--C 1.538 1.477 0 C-N-CA 119.454 -1.355 . . . . 0.0 114.192 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' D' ' 27' ' ' ASN . 0.1 OUTLIER 167.82 -167.26 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 -175.689 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' D' ' 26' ' ' SER . 19.6 t30 -44.79 166.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 118.074 -1.45 . . . . 0.0 109.682 -175.451 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.564 ' HZ1' ' HB1' ' F' ' 21' ' ' ALA . 24.7 tttp -69.86 111.5 5.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 115.205 1.558 . . . . 0.0 115.205 -176.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.613 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -81.26 93.45 1.54 Allowed Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 105.011 -3.236 . . . . 0.0 105.011 166.889 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.09 30.51 Favored 'General case' 0 CA--C 1.457 -2.597 0 CA-C-N 122.407 3.103 . . . . 0.0 109.429 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.98 99.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.062 0 CA-C-N 112.083 -2.326 . . . . 0.0 106.144 -176.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 mt -108.16 124.61 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.427 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.743 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.08 100.55 0.58 Allowed Glycine 0 C--N 1.309 -0.934 0 N-CA-C 105.331 -3.108 . . . . 0.0 105.331 174.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.624 HD21 ' CZ ' ' E' ' 19' ' ' PHE . 0.1 OUTLIER -121.79 120.7 35.37 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.524 0.678 . . . . 0.0 110.148 -177.68 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.518 ' N ' HD13 ' D' ' 34' ' ' LEU . 3.5 ttt -112.99 115.43 28.37 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.682 -1.145 . . . . 0.0 108.068 178.064 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -112.43 77.31 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.495 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -4.12 -101.93 0.0 OUTLIER Glycine 0 C--N 1.368 2.324 0 O-C-N 123.608 0.568 . . . . 0.0 112.899 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.5 -170.62 39.72 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.59 159.73 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.436 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -139.82 123.67 17.52 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 120.744 0.306 . . . . 0.0 110.636 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -136.96 139.69 41.68 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.349 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -133.87 138.76 49.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 -139.74 126.86 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.37 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.576 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 45.4 t-80 -156.08 167.2 31.16 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.898 0.856 . . . . 0.0 110.952 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.576 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 47.5 tt0 -164.02 168.24 19.46 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.307 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 53.8 tttm -135.44 120.19 18.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.465 178.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 36.1 mt -107.34 118.83 37.75 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.96 121.58 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD21 ' D' ' 34' ' ' LEU . 62.6 m-85 -115.62 115.76 26.97 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 176.342 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' F' ' 20' ' ' PHE . 25.3 t80 -142.21 149.09 39.2 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.078 1.51 . . . . 0.0 115.078 -175.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.565 ' CB ' ' NZ ' ' C' ' 28' ' ' LYS . . . -149.73 138.63 21.06 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.415 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 81.5 tt0 -110.97 111.85 23.26 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.432 178.624 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' O ' ' C ' ' E' ' 24' ' ' VAL . 0.3 OUTLIER 176.37 122.52 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -178.049 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.456 ' C ' ' O ' ' E' ' 23' ' ' ASP . 41.5 t -37.32 117.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 121.595 0.712 . . . . 0.0 110.332 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.81 89.6 0.48 Allowed Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.919 -178.124 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.512 ' O ' ' OD1' ' D' ' 27' ' ' ASN . 46.7 t -87.09 -179.36 6.45 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 122.616 1.198 . . . . 0.0 111.765 -177.386 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.452 ' N ' ' OG ' ' E' ' 26' ' ' SER . 1.4 m-20 -61.85 -178.45 0.15 Allowed 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 113.012 -1.903 . . . . 0.0 113.492 -178.508 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 78.1 tttt 68.1 -112.19 0.13 Allowed 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 178.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.33 91.7 0.25 Allowed Glycine 0 CA--C 1.532 1.105 0 N-CA-C 118.107 2.003 . . . . 0.0 118.107 -172.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.508 ' C ' HD13 ' E' ' 31' ' ' ILE . . . -163.98 147.86 9.96 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 105.575 -2.009 . . . . 0.0 105.575 170.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.668 ' N ' HD13 ' E' ' 31' ' ' ILE . 0.1 OUTLIER -148.16 128.54 4.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 121.543 0.687 . . . . 0.0 111.086 -178.548 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 91.9 mt -128.19 128.59 68.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.109 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.4 124.58 5.64 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.54 HD23 ' N ' ' E' ' 35' ' ' MET . 4.1 tt -130.17 121.71 26.79 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.54 ' N ' HD23 ' E' ' 34' ' ' LEU . 9.4 ttt -123.15 125.37 45.01 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 121.065 -0.254 . . . . 0.0 111.477 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.3 t -127.59 78.64 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.545 ' HA2' HG21 ' K' ' 31' ' ' ILE . . . 13.77 -109.25 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 N-CA-C 114.107 0.403 . . . . 0.0 114.107 177.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -150.1 165.27 29.8 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.436 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 55.3 t -130.28 136.3 58.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' E' E ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' F' ' 39' ' ' VAL . 46.3 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.358 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -108.15 136.12 48.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.814 0.34 . . . . 0.0 110.609 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.23 133.83 47.7 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.245 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.71 135.27 51.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 24.7 p80 -155.91 128.09 7.59 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.041 0.448 . . . . 0.0 111.593 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 62.5 m80 -151.09 171.58 17.13 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -151.1 171.16 17.78 Favored 'General case' 0 C--N 1.313 -1.015 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.331 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -141.71 127.2 18.89 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.67 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.57 126.78 54.65 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.74 119.76 52.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.13 0.49 . . . . 0.0 111.934 -178.633 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.42 ' CE1' HD11 ' E' ' 34' ' ' LEU . 4.0 m-85 -113.7 105.93 13.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.827 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' E' ' 20' ' ' PHE . 5.7 m-85 -139.29 131.28 27.85 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 122.608 1.195 . . . . 0.0 112.558 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.564 ' HB1' ' HZ1' ' D' ' 28' ' ' LYS . . . -148.94 163.16 38.29 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.357 178.818 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -71.15 85.03 0.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.818 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 11.1 p30 -165.3 112.77 0.98 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.844 178.37 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.58 ' O ' ' N ' ' F' ' 26' ' ' SER . 98.1 t -70.74 132.55 33.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.583 178.205 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.6 83.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.206 -1.558 . . . . 0.0 109.206 177.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.58 ' N ' ' O ' ' F' ' 24' ' ' VAL . 13.1 p -66.07 -174.18 0.23 Allowed 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 122.492 1.139 . . . . 0.0 112.276 -177.14 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -81.63 179.08 7.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 112.722 -2.036 . . . . 0.0 111.719 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -37.25 104.22 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.553 -0.748 . . . . 0.0 109.66 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.448 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 167.88 -100.67 0.17 Allowed Glycine 0 C--O 1.217 -0.956 0 N-CA-C 108.843 -1.703 . . . . 0.0 108.843 -174.854 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.24 166.02 0.08 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 119.674 1.737 . . . . 0.0 107.659 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.652 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -143.43 130.31 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 118.093 -1.443 . . . . 0.0 112.604 -175.123 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -128.98 122.87 57.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.909 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 122.34 5.41 Favored Glycine 0 N--CA 1.468 0.833 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 36.7 mt -119.66 120.37 36.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' L' ' 32' ' ' ILE . 19.9 ttt -130.88 134.53 46.87 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.873 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.481 HG22 ' O ' ' F' ' 36' ' ' VAL . 1.5 p -156.96 89.41 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.742 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.39 94.83 0.23 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.757 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' F' F ' 38' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -149.81 167.77 29.91 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.706 -0.957 . . . . 0.0 110.706 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' E' ' 40' ' ' VAL . 30.9 m -132.08 157.12 43.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.893 0.378 . . . . 0.0 110.531 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.697 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -105.88 135.4 47.39 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.842 0.353 . . . . 0.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 55.2 mp0 -94.14 141.75 28.18 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.547 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.23 132.69 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.086 0.47 . . . . 0.0 110.278 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -142.78 115.34 8.58 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.414 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' H' ' 14' ' ' HIS . 57.0 p-80 -152.93 169.98 21.52 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.39 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? -154.31 170.54 21.06 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.379 179.232 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.6 mttm -156.63 164.27 38.37 Favored 'General case' 0 C--O 1.222 -0.37 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.747 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 2.9 mp -146.71 175.93 10.24 Favored 'General case' 0 C--O 1.172 -3.02 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.968 ' C ' ' O ' ' H' ' 18' ' ' VAL . 94.0 t -156.62 170.51 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 118.724 -2.485 . . . . 0.0 110.099 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.654 ' N ' HG12 ' G' ' 18' ' ' VAL . 26.3 p90 -162.58 105.2 1.09 Allowed 'General case' 0 C--O 1.169 -3.169 0 O-C-N 121.375 -0.828 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.695 ' C ' ' O ' ' H' ' 20' ' ' PHE . 35.3 t80 -109.78 108.19 18.45 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.549 -1.344 . . . . 0.0 110.839 177.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -82.42 103.12 11.74 Favored 'General case' 0 C--O 1.178 -2.684 0 C-N-CA 124.682 1.193 . . . . 0.0 111.012 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.551 ' H ' ' HA ' ' H' ' 21' ' ' ALA . 73.7 mt-10 -75.39 147.92 39.61 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 120.27 1.395 . . . . 0.0 111.86 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.445 ' CG ' ' N ' ' G' ' 24' ' ' VAL . 7.8 p-10 -156.02 -144.75 0.14 Allowed 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.159 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' G' ' 23' ' ' ASP . 18.3 t -29.58 103.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 114.988 -1.006 . . . . 0.0 112.501 178.412 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.39 -94.41 0.09 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.643 178.176 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.2 m -71.18 174.17 6.72 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 119.138 1.469 . . . . 0.0 110.388 -178.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -78.71 173.33 12.57 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.511 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.592 ' HZ2' ' CB ' ' I' ' 26' ' ' SER . 13.0 mmtt -46.04 111.77 0.4 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 174.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 94.29 1.74 Allowed Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -177.928 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.43 -179.92 7.08 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-O 122.349 1.071 . . . . 0.0 111.157 -178.397 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.462 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.12 109.18 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 CA-C-N 113.28 -1.782 . . . . 0.0 108.91 -177.924 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.597 ' N ' ' SD ' ' A' ' 35' ' ' MET . 2.4 mt -107.02 112.41 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.8 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.612 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -115.96 98.39 0.82 Allowed Glycine 0 CA--C 1.499 -0.927 0 N-CA-C 106.851 -2.5 . . . . 0.0 106.851 176.816 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.612 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.6 mm? -125.22 133.9 52.55 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 122.305 1.05 . . . . 0.0 110.475 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.641 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 42.7 ttp -109.93 120.08 41.35 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 113.8 -1.546 . . . . 0.0 108.973 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.468 HG23 HG13 ' H' ' 36' ' ' VAL . 0.9 OUTLIER -134.5 70.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.762 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.32 106.09 2.9 Favored Glycine 0 C--N 1.365 2.139 0 N-CA-C 111.614 -0.594 . . . . 0.0 111.614 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.78 179.03 2.36 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 112.017 -0.433 . . . . 0.0 112.017 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 28.0 m -138.07 160.84 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.436 -0.382 . . . . 0.0 110.273 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.523 179.859 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -113.06 141.56 46.73 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -54.08 163.27 0.81 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.179 179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.2 t -111.87 127.48 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.383 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 p-80 -174.88 -172.35 0.61 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 111.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' G' ' 14' ' ' HIS . 82.4 m-70 -149.09 163.49 37.4 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.371 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.415 ' HG2' ' N ' ' H' ' 16' ' ' LYS . 56.2 tt0 -160.25 167.44 27.56 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.427 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' G' ' 16' ' ' LYS . 73.1 mttt -156.57 151.67 26.31 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.373 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -134.16 123.57 24.6 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.968 ' O ' ' C ' ' G' ' 18' ' ' VAL . 65.3 t -125.59 141.69 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 118.113 -1.435 . . . . 0.0 113.838 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 94.1 m-85 -118.62 115.01 23.66 Favored 'General case' 0 N--CA 1.472 0.644 0 O-C-N 120.723 -1.236 . . . . 0.0 109.722 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.695 ' O ' ' C ' ' G' ' 20' ' ' PHE . 8.2 t80 -109.89 106.89 16.63 Favored 'General case' 0 C--O 1.25 1.107 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 179.005 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -90.42 120.09 31.24 Favored 'General case' 0 C--N 1.36 1.052 0 O-C-N 124.864 1.352 . . . . 0.0 110.461 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.477 ' O ' ' CB ' ' H' ' 23' ' ' ASP . 82.4 tt0 -153.26 156.53 38.63 Favored 'General case' 0 C--N 1.359 1.022 0 C-N-CA 117.898 -1.521 . . . . 0.0 113.125 -177.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' H' ' 22' ' ' GLU . 0.9 OUTLIER 149.23 121.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.448 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.507 ' O ' HG23 ' H' ' 24' ' ' VAL . 25.0 m -55.15 121.15 3.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 119.802 -0.759 . . . . 0.0 109.718 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.81 88.81 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.572 ' O ' ' O ' ' H' ' 27' ' ' ASN . 2.6 p 170.81 178.72 0.06 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.377 0.608 . . . . 0.0 110.219 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.572 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.8 m120 -27.89 172.85 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 113.776 -1.556 . . . . 0.0 114.841 -178.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.549 ' NZ ' ' O ' ' J' ' 22' ' ' GLU . 84.8 tttt 144.99 94.72 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.833 176.748 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.697 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . 59.89 -117.08 10.12 Favored Glycine 1 CA--C 1.424 -5.625 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 179.773 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.697 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . 77.03 -124.52 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.678 1 N-CA-C 99.706 -4.183 . . . . 0.0 99.706 -176.617 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.904 HD12 ' N ' ' H' ' 31' ' ' ILE . 1.9 mp -82.02 103.74 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.344 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.287 174.822 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' B' ' 35' ' ' MET . 18.6 tt -121.32 121.34 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 CA-C-O 121.614 0.721 . . . . 0.0 111.009 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.82 116.59 2.39 Favored Glycine 0 C--O 1.244 0.74 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -130.83 128.8 41.38 Favored 'General case' 0 C--O 1.244 0.813 0 CA-C-O 121.785 0.802 . . . . 0.0 110.785 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.667 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 40.1 ttp -106.09 115.88 30.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.423 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.468 HG13 HG23 ' G' ' 36' ' ' VAL . 0.0 OUTLIER -120.2 70.54 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.209 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.637 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.77 -100.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.02 -159.71 24.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.3 142.56 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.852 0.358 . . . . 0.0 110.781 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.671 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -144.89 156.4 43.98 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.701 0.286 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -133.94 135.59 43.65 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.157 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.55 152.59 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-O 121.863 0.839 . . . . 0.0 111.852 -179.725 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.546 ' O ' ' CG ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -149.27 109.04 4.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.658 179.034 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.1 m170 -114.17 162.49 16.45 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.641 0.734 . . . . 0.0 110.673 -179.325 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' I' ' 16' ' ' LYS . 43.4 tt0 -153.0 172.8 16.27 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.495 178.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' I' ' 15' ' ' GLN . 88.3 tttt -172.11 132.95 0.68 Allowed 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.838 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 18' ' ' VAL . 6.7 tt -124.99 125.92 44.64 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.709 ' HB ' HG22 ' H' ' 18' ' ' VAL . 52.7 t -124.46 126.58 72.09 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.543 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -108.2 103.5 12.7 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 175.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.492 ' CE1' ' CZ ' ' H' ' 20' ' ' PHE . 25.7 t80 -117.32 131.06 56.88 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.864 0.302 . . . . 0.0 110.643 -178.3 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.29 145.94 31.45 Favored 'General case' 0 C--O 1.243 0.714 0 CA-C-O 122.043 0.925 . . . . 0.0 113.338 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -137.61 135.29 36.46 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.81 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.464 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 48.0 t0 -139.5 137.84 35.86 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -92.12 113.19 26.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 C-N-CA 118.685 -1.206 . . . . 0.0 111.806 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.91 86.97 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 CA-C-N 113.744 -1.571 . . . . 0.0 115.255 176.304 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.592 ' CB ' ' HZ2' ' G' ' 28' ' ' LYS . 30.9 t -140.68 169.95 16.69 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-N 118.487 1.144 . . . . 0.0 109.147 175.544 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.57 ' O ' ' O ' ' I' ' 26' ' ' SER . 89.7 m-20 -30.51 170.79 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 O-C-N 124.009 0.818 . . . . 0.0 112.896 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' K' ' 25' ' ' GLY . 86.3 mttt -108.37 -112.23 0.3 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 173.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.86 90.73 0.01 OUTLIER Glycine 0 N--CA 1.466 0.66 0 CA-C-N 116.09 -0.505 . . . . 0.0 112.155 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.418 ' HA ' HD13 ' I' ' 31' ' ' ILE . . . -140.01 161.9 36.5 Favored 'General case' 0 C--O 1.248 1.005 0 CA-C-O 122.221 1.01 . . . . 0.0 108.35 177.029 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.697 HG22 ' HB ' ' J' ' 31' ' ' ILE . 0.1 OUTLIER -139.69 133.07 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 CA-C-N 113.455 -1.702 . . . . 0.0 110.089 -175.957 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.494 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.1 mt -113.39 114.85 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 178.472 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.26 96.06 1.05 Allowed Glycine 0 CA--C 1.497 -1.058 0 N-CA-C 105.231 -3.148 . . . . 0.0 105.231 175.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.578 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 6.6 tp -114.05 125.91 54.52 Favored 'General case' 0 CA--C 1.502 -0.87 0 CA-C-O 121.738 0.78 . . . . 0.0 112.026 -177.127 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.708 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 4.6 ttp -119.14 109.92 16.45 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.914 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.2 75.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.141 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -26.72 -98.37 0.01 OUTLIER Glycine 0 C--N 1.363 2.08 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 178.698 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -151.03 19.39 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -124.59 138.92 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.82 0.343 . . . . 0.0 110.358 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.603 -179.47 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' J' J ' 10' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' J' ' 10' ' ' TYR . 30.5 p90 -104.06 126.22 51.01 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -148.54 141.11 24.4 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.123 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t -127.85 133.54 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 6.2 t-80 -148.93 143.15 26.0 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.252 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' J' ' 13' ' ' HIS . 46.9 m-70 -141.28 163.66 32.35 Favored 'General case' 0 CA--C 1.51 -0.576 0 CA-C-O 121.482 0.658 . . . . 0.0 110.052 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.448 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 50.9 tt0 -156.02 170.76 21.41 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.06 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.448 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 54.2 mtmt -157.01 134.52 10.68 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -123.83 124.51 42.82 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -140.94 141.69 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 118.768 -1.173 . . . . 0.0 113.867 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.637 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 5.5 m-85 -111.45 110.01 20.24 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.763 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.03 120.89 42.14 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.455 0.571 . . . . 0.0 111.429 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.51 117.58 23.93 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.549 ' O ' ' NZ ' ' H' ' 28' ' ' LYS . 97.2 mt-10 -120.12 142.37 48.98 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.834 -178.143 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.504 ' HB3' ' NZ ' ' H' ' 28' ' ' LYS . 4.3 t70 146.31 159.21 0.0 OUTLIER 'General case' 0 C--N 1.345 0.407 0 O-C-N 124.373 1.046 . . . . 0.0 109.201 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 2.4 m -62.97 -110.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.8 93.04 0.14 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.957 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.841 ' O ' ' O ' ' J' ' 27' ' ' ASN . 15.4 p -153.91 -170.61 3.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.841 ' O ' ' O ' ' J' ' 26' ' ' SER . 2.9 m120 -19.65 178.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 125.049 1.468 . . . . 0.0 114.258 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.588 ' O ' ' N ' ' J' ' 30' ' ' ALA . 58.0 tttp 138.88 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.246 -177.005 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' J' ' 28' ' ' LYS . . . -45.31 101.46 0.03 OUTLIER Glycine 0 N--CA 1.481 1.68 1 CA-C-O 128.54 4.411 . . . . 0.0 108.384 -174.271 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.588 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -99.51 -124.17 0.16 Allowed 'General case' 1 N--CA 1.368 -4.569 4 N-CA-C 89.89 -7.818 . . . . 0.0 89.89 177.972 . . . . . . . . 4 3 . 1 . 003 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.867 HD12 ' N ' ' J' ' 31' ' ' ILE . 1.2 mp -76.99 102.89 3.82 Favored 'Isoleucine or valine' 0 C--N 1.257 -3.422 0 C-N-CA 115.006 -2.678 . . . . 0.0 109.583 176.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.673 HD11 HD21 ' J' ' 34' ' ' LEU . 14.2 tt -115.08 121.39 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-O 121.322 0.582 . . . . 0.0 109.476 178.181 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.58 113.83 2.09 Favored Glycine 0 N--CA 1.466 0.681 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.989 HD22 ' CZ ' ' L' ' 19' ' ' PHE . 0.0 OUTLIER -125.16 128.11 47.89 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 122.019 0.914 . . . . 0.0 111.702 -178.4 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.743 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 32.7 ttp -107.63 119.26 38.93 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.329 -1.305 . . . . 0.0 109.445 178.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.519 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.02 72.83 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 -179.443 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 38' ' ' GLY . . . -56.71 113.21 4.06 Favored Glycine 0 C--N 1.36 1.898 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.648 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 38' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -56.99 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 39' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' J' ' 40' ' ' VAL . 77.8 t -105.38 133.62 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.955 0.407 . . . . 0.0 111.003 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' J' ' 39' ' ' VAL . 62.1 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.951 -1.023 . . . . 0.0 111.172 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -104.97 127.45 52.84 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-O 121.168 0.509 . . . . 0.0 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -113.46 126.82 55.75 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.192 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 56.9 t -123.94 133.13 70.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -146.96 147.87 31.17 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.389 -0.524 . . . . 0.0 111.39 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 54.5 m80 -146.9 164.35 33.18 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.716 0.769 . . . . 0.0 110.593 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 80.8 mt-30 -154.57 179.1 9.36 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.388 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -169.79 131.79 1.11 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.562 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.97 120.53 36.64 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.28 124.93 65.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 121.032 0.444 . . . . 0.0 111.793 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.637 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 41.0 m-85 -115.75 110.25 18.84 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.067 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -120.98 127.36 51.72 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -177.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.21 137.68 36.2 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.582 0.706 . . . . 0.0 112.49 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -105.98 123.7 48.41 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 116.189 -0.459 . . . . 0.0 112.22 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' J' ' 26' ' ' SER . 49.3 t0 -172.37 114.68 0.31 Allowed 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.459 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 8.5 p -79.58 131.34 34.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.244 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.563 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . 58.82 82.38 0.06 OUTLIER Glycine 0 N--CA 1.467 0.7 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.07 178.537 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p -67.32 -172.08 0.2 Allowed 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.541 0.686 . . . . 0.0 110.172 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.47 ' O ' ' O ' ' K' ' 28' ' ' LYS . 30.6 p-10 -79.63 179.28 7.59 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.47 ' O ' ' O ' ' K' ' 27' ' ' ASN . 81.2 tttt -43.65 -110.11 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.569 -0.742 . . . . 0.0 112.596 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.4 94.15 1.69 Allowed Glycine 0 N--CA 1.471 1.006 0 CA-C-O 119.992 -0.338 . . . . 0.0 112.859 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.02 173.48 11.73 Favored 'General case' 0 C--O 1.24 0.554 0 N-CA-C 104.317 -2.475 . . . . 0.0 104.317 176.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.572 HG23 HD13 ' L' ' 31' ' ' ILE . 0.1 OUTLIER -151.72 136.93 10.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 C-N-CA 117.35 -1.74 . . . . 0.0 112.116 -174.644 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.71 117.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.632 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.513 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -118.08 107.93 1.56 Allowed Glycine 0 C--N 1.334 0.467 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 178.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.428 HD11 HG21 ' J' ' 36' ' ' VAL . 51.9 tp -119.99 121.84 39.83 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 110.464 -0.198 . . . . 0.0 110.464 -178.802 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.402 ' C ' ' SD ' ' K' ' 35' ' ' MET . 6.3 tmm? -120.34 120.25 35.47 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.704 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.519 HG22 HG23 ' J' ' 36' ' ' VAL . 96.1 t -133.68 82.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.544 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -7.87 -97.81 0.0 OUTLIER Glycine 0 C--N 1.349 1.276 0 O-C-N 123.504 0.502 . . . . 0.0 113.703 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.25 -168.85 38.85 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.53 159.57 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.386 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.489 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.413 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -99.69 134.02 43.19 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.737 0.303 . . . . 0.0 110.329 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -144.73 135.07 24.3 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.753 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -134.74 132.31 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.88 179.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 31.8 p-80 -159.67 154.11 23.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 0.0 111.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -151.54 169.29 22.44 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.024 179.63 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -157.58 178.21 10.53 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.995 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -143.4 138.38 29.33 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.498 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 mt -121.68 119.43 31.77 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 m -143.01 135.91 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.989 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 4.0 m-30 -116.33 127.91 55.09 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -141.55 139.44 33.19 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.777 0.798 . . . . 0.0 111.893 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 142.95 34.63 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.78 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.43 100.96 6.18 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.974 -179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -173.84 133.4 0.45 Allowed 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.9 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 113.75 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 54.39 -91.21 0.01 OUTLIER Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -178.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.5 p 152.5 176.71 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 122.006 0.908 . . . . 0.0 110.058 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -51.74 -179.45 0.01 OUTLIER 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 113.892 -1.504 . . . . 0.0 111.664 178.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -60.58 111.66 1.69 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.923 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.597 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 81.07 -93.19 1.5 Allowed Glycine 0 N--CA 1.468 0.787 0 CA-C-N 114.993 -1.003 . . . . 0.0 112.22 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.597 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 79.11 165.56 0.2 Allowed 'General case' 0 CA--C 1.507 -0.684 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 -175.611 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.849 ' N ' HD12 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -149.87 131.93 5.87 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 CA-C-N 122.07 2.214 . . . . 0.0 111.583 178.038 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' F' ' 35' ' ' MET . 15.4 pt -124.46 142.08 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.115 -178.277 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.75 120.43 2.52 Favored Glycine 0 N--CA 1.463 0.457 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 20.0 mt -115.62 118.66 33.74 Favored 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 4.6 ttt -111.01 117.46 33.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.175 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -145.1 81.41 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.652 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -57.97 102.08 0.22 Allowed Glycine 0 C--N 1.337 0.621 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.072 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.65 178.95 34.17 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.3 136.59 59.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 120.842 0.353 . . . . 0.0 110.325 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.616 -179.698 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -110.33 132.72 53.93 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.785 0.326 . . . . 0.0 110.382 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -131.02 132.12 44.76 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.902 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -144.14 141.94 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.879 0.371 . . . . 0.0 110.668 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -141.75 -168.97 2.8 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.828 -179.387 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 73.7 m-70 -75.92 168.77 19.41 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 121.295 0.569 . . . . 0.0 110.087 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' A' ' 16' ' ' LYS . 48.5 tt0 -158.33 173.98 15.85 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.361 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' A' ' 15' ' ' GLN . 88.9 tttt -144.27 126.35 15.51 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.621 0.248 . . . . 0.0 110.886 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.21 120.82 22.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.978 0.418 . . . . 0.0 110.046 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.32 136.9 50.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.795 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -129.67 132.01 46.56 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 111.396 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -114.84 123.06 48.23 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.9 123.44 42.52 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.385 0.612 . . . . 0.0 111.249 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -141.78 124.68 16.13 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.73 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 24' ' ' VAL . 62.3 t0 -65.22 140.69 58.76 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.287 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.489 ' N ' ' OD1' ' A' ' 23' ' ' ASP . 2.8 m -108.5 110.98 34.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.751 0.786 . . . . 0.0 109.804 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.57 90.19 0.01 OUTLIER Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.706 -1.133 . . . . 0.0 113.134 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.729 ' O ' ' O ' ' A' ' 27' ' ' ASN . 1.8 t 169.97 176.54 0.05 Allowed 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 176.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.729 ' O ' ' O ' ' A' ' 26' ' ' SER . 19.6 p30 -28.25 -179.13 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 O-C-N 124.792 1.308 . . . . 0.0 112.916 177.02 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.531 ' NZ ' ' O ' ' B' ' 26' ' ' SER . 78.3 tttt -128.86 -108.02 0.29 Allowed 'General case' 0 N--CA 1.469 0.5 0 O-C-N 121.523 -0.736 . . . . 0.0 110.111 175.366 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 28' ' ' LYS . . . 45.39 92.98 0.01 OUTLIER Glycine 0 N--CA 1.468 0.829 0 CA-C-O 118.191 -1.338 . . . . 0.0 110.261 178.194 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.04 160.36 15.1 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 116.627 -2.029 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -152.22 117.87 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 111.836 -2.438 . . . . 0.0 108.958 -171.736 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 32' ' ' ILE . 12.6 tt -128.85 109.28 18.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.032 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.613 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -122.31 119.86 4.13 Favored Glycine 0 CA--C 1.51 -0.263 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 178.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 35' ' ' MET . 8.4 tt -164.86 162.69 21.01 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.321 -176.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 5.1 ttp -135.45 143.24 45.79 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.244 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 m -121.89 71.53 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.764 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.548 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -47.05 -97.46 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.2 -168.85 30.83 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.43 134.35 66.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.635 -179.707 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -109.89 135.06 51.36 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.939 0.4 . . . . 0.0 110.708 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.94 161.29 28.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.1 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 m -131.04 160.85 41.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.46 ' CD2' ' N ' ' B' ' 13' ' ' HIS . 2.8 m-70 -127.74 124.27 37.38 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.711 0.291 . . . . 0.0 110.628 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.772 ' HD1' ' HB2' ' C' ' 14' ' ' HIS . 55.2 t60 -153.92 162.58 41.11 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.495 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 73.5 mt-30 -159.22 175.91 12.85 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.792 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -153.94 126.9 8.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.149 178.554 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 mt -124.7 114.46 19.35 Favored 'General case' 0 C--O 1.233 0.214 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.122 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -124.48 128.99 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.812 0.339 . . . . 0.0 110.344 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 19' ' ' PHE . . . . . 0.497 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 88.7 t80 -125.7 123.32 38.63 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.036 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -118.16 125.56 50.46 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 21' ' ' ALA . . . . . 0.497 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -133.0 131.93 41.29 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.415 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.47 ' CB ' ' O ' ' C' ' 22' ' ' GLU . 16.6 pt-20 -158.39 154.88 27.68 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 120.185 -0.606 . . . . 0.0 112.561 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.516 ' O ' ' O ' ' B' ' 24' ' ' VAL . 1.0 OUTLIER -164.52 114.25 1.17 Allowed 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.439 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.516 ' O ' ' O ' ' B' ' 23' ' ' ASP . 28.3 m -48.31 -131.07 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-O 121.658 0.742 . . . . 0.0 112.943 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.42 -85.87 0.72 Allowed Glycine 0 CA--C 1.537 1.439 0 CA-C-N 115.735 -0.666 . . . . 0.0 113.301 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.715 ' O ' ' O ' ' B' ' 27' ' ' ASN . 77.4 p 172.13 -170.75 0.03 OUTLIER 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.715 ' O ' ' O ' ' B' ' 26' ' ' SER . 22.0 t-20 -17.86 158.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 O-C-N 124.847 1.342 . . . . 0.0 112.473 179.107 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.518 ' O ' ' CG ' ' B' ' 28' ' ' LYS . 32.6 pttt -161.54 111.04 1.58 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 118.269 -1.373 . . . . 0.0 114.595 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.88 93.64 0.33 Allowed Glycine 0 CA--C 1.495 -1.202 0 N-CA-C 105.864 -2.894 . . . . 0.0 105.864 174.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.08 161.61 15.03 Favored 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.469 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -141.62 121.11 10.92 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.294 -172.346 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.467 HG22 ' O ' ' B' ' 32' ' ' ILE . 1.6 mt -110.53 115.11 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.953 178.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.428 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -120.04 93.65 0.54 Allowed Glycine 0 CA--C 1.507 -0.443 0 N-CA-C 104.198 -3.561 . . . . 0.0 104.198 174.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.549 HD23 ' O ' ' A' ' 34' ' ' LEU . 57.3 mt -122.58 140.22 53.04 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 122.958 1.361 . . . . 0.0 113.054 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 12.1 ttt -127.7 123.3 35.12 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 113.789 -1.55 . . . . 0.0 111.027 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.416 HG23 HG22 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -117.71 72.98 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.962 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.085 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -98.2 103.34 2.79 Favored Glycine 0 C--N 1.354 1.549 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.28 172.13 34.53 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -154.23 147.42 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 110.949 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.372 179.668 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.46 146.41 34.58 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.265 -0.272 . . . . 0.0 110.265 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -60.67 130.67 47.69 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.742 -0.383 . . . . 0.0 110.465 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 23.7 m -139.95 159.44 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.104 0.478 . . . . 0.0 110.494 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -124.69 131.26 53.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.375 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.772 ' HB2' ' HD1' ' B' ' 14' ' ' HIS . 84.0 m-70 -143.49 168.55 19.58 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.402 0.62 . . . . 0.0 109.878 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.402 ' HG2' ' H ' ' C' ' 16' ' ' LYS . 48.0 tt0 -159.53 172.99 16.85 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.625 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.402 ' H ' ' HG2' ' C' ' 15' ' ' GLN . 88.6 tttt -166.61 114.75 0.87 Allowed 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 tp -121.74 121.72 37.92 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -130.03 124.99 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -114.48 106.36 14.19 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.131 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -113.26 127.14 56.06 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.15 0.5 . . . . 0.0 111.564 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.66 125.25 44.46 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.952 178.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 22' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' B' ' 22' ' ' GLU . 97.2 mt-10 -143.57 158.76 43.41 Favored 'General case' 0 C--O 1.222 -0.345 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.988 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 22.4 t0 177.58 120.99 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.284 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 m -57.79 120.63 4.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.479 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 74.66 90.08 0.19 Allowed Glycine 0 CA--C 1.532 1.14 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.958 177.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.8 m 162.21 160.16 0.02 OUTLIER 'General case' 0 C--N 1.341 0.23 0 CA-C-O 122.246 1.022 . . . . 0.0 111.022 175.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.429 ' O ' ' O ' ' C' ' 26' ' ' SER . 3.8 m-20 -31.62 170.54 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.084 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.499 ' NZ ' ' CG ' ' F' ' 23' ' ' ASP . 26.1 pttt -108.37 -111.2 0.31 Allowed 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 171.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 1.104 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . -71.5 94.91 0.59 Allowed Glycine 1 CA--C 1.424 -5.626 0 N-CA-C 104.601 -3.4 . . . . 0.0 104.601 173.027 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.507 ' O ' ' C ' ' C' ' 29' ' ' GLY . . . -79.55 -140.47 0.03 OUTLIER 'General case' 0 N--CA 1.388 -3.564 1 N-CA-C 97.605 -4.961 . . . . 0.0 97.605 177.877 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.662 ' CD1' ' N ' ' C' ' 31' ' ' ILE . 1.0 OUTLIER -81.17 106.56 12.47 Favored 'Isoleucine or valine' 0 C--N 1.246 -3.904 0 C-N-CA 114.451 -2.9 . . . . 0.0 110.153 -177.751 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.498 ' O ' ' CE ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -108.68 122.52 63.37 Favored 'Isoleucine or valine' 0 C--N 1.363 1.161 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.766 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -138.76 113.23 0.93 Allowed Glycine 0 C--N 1.314 -0.666 0 N-CA-C 106.871 -2.492 . . . . 0.0 106.871 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.517 ' O ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -140.65 158.55 43.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 123.115 1.436 . . . . 0.0 111.842 -176.673 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.479 ' CE ' ' O ' ' I' ' 32' ' ' ILE . 24.4 tpp -129.35 124.22 33.73 Favored 'General case' 0 CA--C 1.491 -1.289 0 CA-C-N 112.613 -2.085 . . . . 0.0 107.167 178.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.495 HG23 HD11 ' D' ' 34' ' ' LEU . 48.7 t -116.9 70.98 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.049 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.32 -101.09 0.01 OUTLIER Glycine 0 C--N 1.377 2.829 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.086 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.83 -158.82 30.41 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -134.59 161.53 40.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.83 0.347 . . . . 0.0 110.341 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.662 -179.576 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -84.92 137.73 32.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.823 0.344 . . . . 0.0 110.598 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.473 ' OE2' ' CE1' ' D' ' 13' ' ' HIS . 80.5 tt0 -71.79 147.44 47.26 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.67 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 54.2 t -120.92 131.82 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.473 ' CE1' ' OE2' ' D' ' 11' ' ' GLU . 33.0 m-70 -118.38 106.08 12.36 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.59 -178.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.429 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 60.8 m170 -108.67 166.51 10.74 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -152.82 172.51 16.62 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.03 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -157.08 114.5 3.11 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 60.3 mt -119.81 115.4 23.77 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -129.82 127.07 63.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.479 ' CE2' ' CD2' ' C' ' 34' ' ' LEU . 7.9 m-85 -116.07 117.76 30.98 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -132.9 128.56 36.82 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.944 -177.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 130.36 45.12 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.537 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 79.7 tt0 -141.81 107.91 5.21 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 119.945 -0.702 . . . . 0.0 112.777 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 71.8 m-20 -166.28 127.27 1.75 Allowed 'General case' 0 CA--C 1.534 0.327 0 O-C-N 123.872 0.732 . . . . 0.0 110.158 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 82.9 t -45.5 111.92 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.509 ' H ' ' HB2' ' E' ' 23' ' ' ASP . . . -127.71 86.21 0.33 Allowed Glycine 0 CA--C 1.538 1.48 0 N-CA-C 115.397 0.919 . . . . 0.0 115.397 -178.016 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 17.3 p -88.04 175.91 7.54 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 104.609 -2.367 . . . . 0.0 104.609 175.038 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.645 ' O ' ' HG3' ' D' ' 28' ' ' LYS . 1.8 m120 63.45 -171.76 0.17 Allowed 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 116.727 -1.989 . . . . 0.0 108.261 178.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.666 ' CD ' ' HB2' ' D' ' 30' ' ' ALA . 0.2 OUTLIER 46.0 112.85 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 117.98 2.585 . . . . 0.0 117.98 177.876 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.61 94.61 1.54 Allowed Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 174.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 1.104 ' HB1' ' O ' ' C' ' 29' ' ' GLY . . . -81.03 175.17 10.91 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -174.87 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.632 HG22 ' CE ' ' K' ' 35' ' ' MET . 0.2 OUTLIER -150.92 125.07 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 116.683 -2.007 . . . . 0.0 111.846 -172.27 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.722 ' CG2' HG23 ' E' ' 32' ' ' ILE . 3.7 tt -116.31 116.99 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.502 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.83 119.39 3.31 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 178.756 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.591 HD23 ' CZ ' ' F' ' 19' ' ' PHE . 14.8 tp -138.84 126.46 21.96 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.161 0.981 . . . . 0.0 112.026 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.588 ' SD ' ' CA ' ' J' ' 33' ' ' GLY . 20.8 ttt -106.35 119.84 40.3 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.191 177.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.499 ' CG2' HG22 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -107.99 76.75 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.144 -178.579 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -26.43 -97.42 0.01 OUTLIER Glycine 0 C--N 1.354 1.552 0 N-CA-C 112.004 -0.438 . . . . 0.0 112.004 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.31 165.63 33.71 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.32 161.43 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.825 0.345 . . . . 0.0 110.474 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.3 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.492 179.689 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -103.58 131.17 50.95 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.862 0.363 . . . . 0.0 110.367 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -143.67 148.92 36.48 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.218 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.481 ' CG2' ' H ' ' F' ' 12' ' ' VAL . 0.2 OUTLIER -148.12 -153.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.462 -179.382 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.424 ' ND1' ' C ' ' E' ' 13' ' ' HIS . 7.2 t-80 -70.77 142.25 51.4 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 121.464 0.65 . . . . 0.0 112.68 -177.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -146.03 169.7 18.14 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 50.4 tt0 -155.39 168.01 28.51 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.924 -0.71 . . . . 0.0 112.233 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -148.75 123.48 9.88 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.614 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 34.0 tp -120.8 114.21 21.29 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.43 129.02 68.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 121.381 0.61 . . . . 0.0 111.999 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -124.07 123.93 41.42 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.619 ' CE1' ' CD1' ' F' ' 20' ' ' PHE . 2.0 t80 -133.64 130.14 37.85 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.718 0.294 . . . . 0.0 110.768 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.72 130.35 34.04 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.23 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -122.96 141.09 52.32 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.509 ' HB2' ' H ' ' D' ' 25' ' ' GLY . 19.5 p-10 -165.49 113.74 0.99 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.563 177.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.09 131.0 31.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.196 -178.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 72.78 84.51 0.24 Allowed Glycine 0 CA--C 1.532 1.12 0 CA-C-N 116.007 -0.542 . . . . 0.0 114.12 177.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' E' ' 25' ' ' GLY . 88.7 p -34.61 170.72 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.666 0.786 . . . . 0.0 111.765 177.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.475 ' CB ' ' O ' ' D' ' 27' ' ' ASN . 0.8 OUTLIER -138.88 -178.61 5.4 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.259 179.628 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.431 ' C ' ' O ' ' E' ' 27' ' ' ASN . 70.1 mmtt -18.88 -103.85 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.087 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.459 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.503 ' HA2' ' HB2' ' F' ' 30' ' ' ALA . . . -140.15 97.62 0.23 Allowed Glycine 0 CA--C 1.496 -1.096 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.389 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -67.72 172.06 5.72 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 176.075 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.825 HG23 HD13 ' F' ' 31' ' ' ILE . 0.3 OUTLIER -147.38 124.66 3.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 118.402 -1.319 . . . . 0.0 109.553 -178.151 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' F' ' 32' ' ' ILE . 66.1 mt -123.73 124.47 69.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.705 -176.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.416 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -127.27 110.31 1.18 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 177.704 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CE2' ' F' ' 19' ' ' PHE . 43.5 mt -119.02 128.9 54.8 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.3 ttt -133.3 131.16 39.85 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 119.781 -0.768 . . . . 0.0 112.222 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.512 ' O ' ' C ' ' E' ' 37' ' ' GLY . 40.1 t -130.65 81.73 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.576 179.074 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 19.02 -102.7 0.01 OUTLIER Glycine 0 C--N 1.352 1.472 0 CA-C-N 117.848 0.294 . . . . 0.0 112.84 179.112 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.02 -174.51 46.79 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' E' E ' 39' ' ' VAL . . . . . 0.439 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 30.3 m -135.69 161.71 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.798 0.332 . . . . 0.0 110.677 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.5 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -147.23 155.78 42.38 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.099 0.476 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -101.72 143.89 31.1 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.957 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 12' ' ' VAL . . . . . 0.481 ' H ' ' CG2' ' E' ' 12' ' ' VAL . 55.5 t -118.84 129.59 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.404 0.621 . . . . 0.0 110.54 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -154.49 130.12 9.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.045 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -145.74 170.38 16.63 Favored 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.652 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -148.28 175.22 11.25 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.221 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.13 131.86 31.1 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' F' ' 17' ' ' LEU . 5.2 mp -121.87 120.82 35.64 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.1 t -131.7 125.82 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.985 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CE2' HD22 ' E' ' 34' ' ' LEU . 35.9 m-85 -117.48 115.68 25.64 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 177.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE1' ' E' ' 20' ' ' PHE . 34.7 t80 -128.3 123.19 33.4 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.967 0.413 . . . . 0.0 110.084 179.209 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.84 134.33 36.82 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.494 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 80.1 tt0 -92.2 75.66 5.36 Favored 'General case' 0 N--CA 1.463 0.21 0 C-N-CA 119.888 -0.725 . . . . 0.0 112.066 -178.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.499 ' CG ' ' NZ ' ' C' ' 28' ' ' LYS . 19.3 m-20 -142.81 107.93 4.96 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 175.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HB3' ' E' ' 26' ' ' SER . 85.6 t -45.69 140.79 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.066 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.85 83.61 1.63 Allowed Glycine 0 C--N 1.333 0.392 0 N-CA-C 107.865 -2.094 . . . . 0.0 107.865 177.743 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -68.63 -170.79 0.23 Allowed 'General case' 0 N--CA 1.434 -1.266 0 CA-C-O 122.393 1.092 . . . . 0.0 111.805 -177.582 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.438 ' O ' ' C ' ' F' ' 28' ' ' LYS . 49.9 p30 -80.23 179.19 7.78 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 113.014 -1.903 . . . . 0.0 108.781 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.438 ' C ' ' O ' ' F' ' 27' ' ' ASN . 98.8 mttt -36.82 104.16 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 122.072 0.939 . . . . 0.0 109.445 -178.793 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.492 ' O ' HG13 ' F' ' 31' ' ' ILE . . . 168.07 -100.71 0.17 Allowed Glycine 0 C--O 1.209 -1.412 0 CA-C-O 117.308 -1.829 . . . . 0.0 109.28 -173.959 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.503 ' HB2' ' HA2' ' E' ' 29' ' ' GLY . . . -53.48 164.06 0.55 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.51 2.655 . . . . 0.0 106.808 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.825 HD13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -146.25 131.18 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 118.119 -1.433 . . . . 0.0 112.175 -177.148 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' E' ' 32' ' ' ILE . 13.4 mm -115.5 125.54 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.51 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 125.24 4.49 Favored Glycine 0 N--CA 1.473 1.151 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.106 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 mt -124.68 128.02 48.19 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -130.81 127.63 39.04 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 121.699 0.761 . . . . 0.0 112.571 -179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 48.8 t -147.38 86.66 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.813 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.45 96.79 1.28 Allowed Glycine 0 C--N 1.339 0.698 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.071 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 38' ' ' GLY . . . . . 0.439 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -155.21 163.57 31.54 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 62.2 t -123.88 135.61 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.307 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -146.3 156.58 43.46 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.955 0.407 . . . . 0.0 110.801 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -145.4 131.14 18.99 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.437 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.434 HG22 ' N ' ' G' ' 13' ' ' HIS . 2.6 p -140.26 158.52 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.302 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.434 ' N ' HG22 ' G' ' 12' ' ' VAL . 75.8 m80 -120.26 166.6 13.27 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 120.92 0.39 . . . . 0.0 111.704 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 94.3 m-70 -107.72 179.14 4.32 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.668 -179.82 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.426 ' HG2' ' N ' ' G' ' 16' ' ' LYS . 6.6 tt0 -100.07 172.66 7.06 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.714 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.4 mttm -149.19 165.58 31.41 Favored 'General case' 0 C--O 1.217 -0.639 0 CA-C-O 121.193 0.521 . . . . 0.0 111.419 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 7.0 tt -145.14 161.84 38.49 Favored 'General case' 0 C--O 1.171 -3.039 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.958 ' C ' ' O ' ' H' ' 18' ' ' VAL . 86.3 t -156.07 170.77 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 118.701 -2.499 . . . . 0.0 110.529 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 19' ' ' PHE . . . . . 0.641 ' N ' HG12 ' G' ' 18' ' ' VAL . 31.2 p90 -158.86 108.32 1.96 Allowed 'General case' 0 C--O 1.165 -3.344 0 CA-C-O 118.373 -0.823 . . . . 0.0 109.803 -178.428 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.713 ' C ' ' O ' ' H' ' 20' ' ' PHE . 43.6 t80 -119.52 106.27 12.05 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 121.471 1.941 . . . . 0.0 112.026 178.41 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -114.74 113.0 23.71 Favored 'General case' 0 C--O 1.174 -2.887 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.256 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 22' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' H' ' 22' ' ' GLU . 94.9 mt-10 -75.01 144.41 43.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 118.898 0.772 . . . . 0.0 112.032 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 33.4 m-20 -140.62 -142.24 0.14 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.975 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' G' ' 23' ' ' ASP . 13.7 t -27.44 103.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.318 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.455 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 172.0 92.77 0.08 OUTLIER Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 86.66 179.9 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.793 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -63.73 170.88 3.01 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.309 0.576 . . . . 0.0 111.459 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.966 ' HZ2' ' H ' ' H' ' 26' ' ' SER . 0.0 OUTLIER -47.85 112.07 0.51 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.106 176.986 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.52 94.31 2.35 Favored Glycine 0 CA--C 1.486 -1.75 0 CA-C-O 122.493 1.052 . . . . 0.0 110.841 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.504 ' C ' HD13 ' G' ' 31' ' ' ILE . . . -74.31 -179.05 3.72 Favored 'General case' 0 N--CA 1.421 -1.922 0 CA-C-N 112.795 -1.702 . . . . 0.0 110.607 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.856 ' N ' HD13 ' G' ' 31' ' ' ILE . 0.0 OUTLIER -141.62 112.65 3.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 113.335 -1.757 . . . . 0.0 106.41 179.415 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.413 HG23 HD21 ' H' ' 34' ' ' LEU . 18.5 tt -117.31 117.65 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-O 121.708 0.766 . . . . 0.0 110.414 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.16 106.41 2.35 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 105.904 -2.878 . . . . 0.0 105.904 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.688 ' HB3' HD22 ' H' ' 34' ' ' LEU . 13.2 tp -132.81 130.52 39.96 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 122.604 1.192 . . . . 0.0 111.535 -177.774 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.613 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 24.7 ttp -102.81 124.19 47.87 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.16 179.59 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.9 70.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.98 -100.53 1.47 Allowed Glycine 0 C--N 1.354 1.572 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.7 170.25 24.04 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' G' G ' 39' ' ' VAL . . . . . 0.405 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 27.4 m -141.24 163.68 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.832 0.348 . . . . 0.0 110.708 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' G' G ' 40' ' ' VAL . . . . . 0.405 ' OXT' ' O ' ' G' ' 39' ' ' VAL . 7.8 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.572 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' H' H ' 10' ' ' TYR . . . . . 0.524 ' CD1' ' O ' ' I' ' 9' ' ' GLY . 91.8 m-85 -105.06 138.99 40.42 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.012 0.434 . . . . 0.0 110.737 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -59.39 133.7 56.34 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.604 0.716 . . . . 0.0 111.14 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.09 132.74 70.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.037 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.67 ' CD2' ' N ' ' H' ' 13' ' ' HIS . 2.2 p80 -158.68 152.01 22.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.672 0.749 . . . . 0.0 111.785 -179.484 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.461 ' CD2' ' O ' ' H' ' 13' ' ' HIS . 15.9 m80 -144.64 162.27 37.07 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.232 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 30.4 mm100 -152.96 172.91 16.09 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.313 0.578 . . . . 0.0 110.087 178.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' G' ' 16' ' ' LYS . 76.7 tttt -176.04 136.86 0.31 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.026 -0.988 . . . . 0.0 108.467 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 77.0 mt -141.07 132.3 26.51 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.169 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.958 ' O ' ' C ' ' G' ' 18' ' ' VAL . 76.8 t -124.6 146.07 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 C-N-CA 118.184 -1.407 . . . . 0.0 113.385 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.414 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 63.2 m-85 -125.19 119.33 28.21 Favored 'General case' 0 N--CA 1.478 0.949 0 O-C-N 120.141 -1.6 . . . . 0.0 111.479 -179.042 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.713 ' O ' ' C ' ' G' ' 20' ' ' PHE . 50.3 t80 -105.69 111.82 24.65 Favored 'General case' 0 C--O 1.248 0.981 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.698 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -93.97 113.44 25.44 Favored 'General case' 0 C--N 1.352 0.717 0 CA-C-O 118.631 -0.7 . . . . 0.0 112.734 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.627 ' H ' ' HB1' ' G' ' 21' ' ' ALA . 48.6 tt0 -149.02 124.85 10.55 Favored 'General case' 0 C--N 1.379 1.884 0 C-N-CA 117.899 -1.52 . . . . 0.0 112.094 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.501 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 66.5 t0 -125.07 114.69 19.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.484 0.659 . . . . 0.0 110.252 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.406 ' H ' HG23 ' H' ' 24' ' ' VAL . 40.1 t -38.72 122.88 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 179.223 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.39 -88.71 0.52 Allowed Glycine 0 CA--C 1.538 1.505 0 N-CA-C 115.802 1.081 . . . . 0.0 115.802 176.6 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.966 ' H ' ' HZ2' ' G' ' 28' ' ' LYS . 83.7 p -65.94 -172.48 0.14 Allowed 'General case' 0 CA--C 1.502 -0.896 0 CA-C-O 122.234 1.016 . . . . 0.0 113.008 -175.075 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.643 ' ND2' ' HB2' ' I' ' 30' ' ' ALA . 4.7 p30 -81.17 179.88 7.66 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 113.136 -1.847 . . . . 0.0 114.895 -176.988 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 86.2 mttt -41.42 -104.11 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 112.189 -2.278 . . . . 0.0 109.662 176.281 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.966 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . -82.01 100.62 2.12 Favored Glycine 0 CA--C 1.465 -3.058 0 CA-C-O 123.208 1.449 . . . . 0.0 111.011 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.807 ' C ' HD13 ' H' ' 31' ' ' ILE . . . -73.73 -134.15 0.01 OUTLIER 'General case' 0 CA--C 1.477 -1.834 2 N-CA-C 93.853 -6.351 . . . . 0.0 93.853 170.076 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.807 HD13 ' C ' ' H' ' 30' ' ' ALA . 0.9 OUTLIER -94.43 110.69 24.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 CA-C-N 124.149 3.159 . . . . 0.0 108.602 177.09 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.558 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -112.86 110.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.361 1.075 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.686 -179.582 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.931 ' O ' HD23 ' H' ' 34' ' ' LEU . . . -120.24 102.34 0.87 Allowed Glycine 0 N--CA 1.462 0.401 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.931 HD23 ' O ' ' H' ' 33' ' ' GLY . 2.6 mt -136.84 149.46 47.73 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-O 122.508 1.147 . . . . 0.0 112.844 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.469 ' SD ' ' O ' ' B' ' 31' ' ' ILE . 28.7 ttp -111.9 126.02 54.66 Favored 'General case' 0 CA--C 1.505 -0.772 0 CA-C-N 113.236 -1.802 . . . . 0.0 110.467 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -125.27 65.57 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.2 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.285 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -51.65 -104.6 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.81 -141.8 5.09 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -122.82 135.98 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.768 0.318 . . . . 0.0 110.288 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.495 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' I' I ' 9' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' H' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 10' ' ' TYR . . . . . 0.508 ' CZ ' ' O ' ' K' ' 9' ' ' GLY . 97.6 m-85 -115.06 152.22 32.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -60.01 134.83 57.42 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.182 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.416 ' O ' ' CD2' ' H' ' 13' ' ' HIS . 77.3 t -124.31 133.33 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-O 120.804 0.335 . . . . 0.0 110.173 -179.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.596 ' ND1' ' CE1' ' H' ' 13' ' ' HIS . 75.4 t60 -150.86 104.75 3.19 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.864 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.526 ' NE2' ' O ' ' J' ' 12' ' ' VAL . 64.7 m170 -112.6 160.12 18.18 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.37 0.605 . . . . 0.0 110.205 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.432 ' O ' ' CG ' ' I' ' 16' ' ' LYS . 27.1 mt-30 -154.06 167.56 29.38 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.401 178.143 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.432 ' CG ' ' O ' ' I' ' 15' ' ' GLN . 95.2 mttt -164.69 128.46 2.47 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 108.993 -0.744 . . . . 0.0 108.993 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.2 mt -126.97 126.14 42.69 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.668 ' HB ' HG22 ' H' ' 18' ' ' VAL . 19.8 t -125.0 129.92 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.7 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.5 OUTLIER -133.57 108.64 8.72 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.185 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.422 ' CG ' ' CZ ' ' J' ' 20' ' ' PHE . 4.0 p90 -143.57 153.82 42.95 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 118.624 -1.23 . . . . 0.0 112.797 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.46 141.48 51.87 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.964 -1.016 . . . . 0.0 112.962 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -150.99 99.86 2.74 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.072 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.553 ' OD1' ' O ' ' H' ' 26' ' ' SER . 3.1 t70 -103.05 120.24 40.31 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.11 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.447 ' O ' HG23 ' I' ' 24' ' ' VAL . 27.5 m -59.21 121.36 6.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 81.97 90.31 0.61 Allowed Glycine 0 CA--C 1.535 1.305 0 N-CA-C 116.918 1.527 . . . . 0.0 116.918 174.769 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.523 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.4 p 137.43 167.3 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 124.902 1.281 . . . . 0.0 110.707 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.535 ' OD1' ' ND2' ' J' ' 27' ' ' ASN . 16.2 m-20 -49.84 178.15 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 115.841 1.793 . . . . 0.0 115.841 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.504 ' CE ' ' HB1' ' K' ' 21' ' ' ALA . 12.9 tttt -61.82 -111.24 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.052 0 CA-C-N 113.177 -1.829 . . . . 0.0 114.912 172.794 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.908 ' O ' ' HB3' ' J' ' 30' ' ' ALA . . . -79.59 96.3 1.52 Allowed Glycine 0 CA--C 1.458 -3.492 0 CA-C-N 110.762 -2.927 . . . . 0.0 114.677 -175.271 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.966 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -76.61 -136.45 0.02 OUTLIER 'General case' 0 N--CA 1.412 -2.329 1 N-CA-C 93.992 -6.299 . . . . 0.0 93.992 169.066 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.749 HD12 ' N ' ' I' ' 31' ' ' ILE . 0.4 OUTLIER -98.46 121.91 49.55 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 1 CA-C-N 127.308 4.594 . . . . 0.0 111.412 -176.631 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.479 ' O ' ' CE ' ' C' ' 35' ' ' MET . 7.7 mt -112.09 112.26 39.74 Favored 'Isoleucine or valine' 0 C--N 1.359 1.022 0 CA-C-N 114.83 -1.077 . . . . 0.0 108.276 177.926 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.91 104.94 1.72 Allowed Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 107.295 -2.322 . . . . 0.0 107.295 177.217 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 65.0 mt -137.39 133.2 34.53 Favored 'General case' 0 C--O 1.24 0.561 0 CA-C-O 122.751 1.262 . . . . 0.0 113.549 -176.702 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 57.0 ttp -113.47 122.68 48.04 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-N 113.649 -1.614 . . . . 0.0 109.153 178.257 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.7 70.69 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -118.46 -103.57 2.15 Favored Glycine 0 C--N 1.36 1.881 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 178.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.49 -174.17 31.95 Favored Glycine 0 CA--C 1.522 0.501 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.113 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -132.82 161.9 40.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 CA-C-O 121.15 0.5 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 32.1 m . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.438 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -145.97 153.18 40.51 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.763 0.316 . . . . 0.0 110.686 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -145.07 159.22 43.31 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.251 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.68 ' CG2' ' CE1' ' J' ' 14' ' ' HIS . 19.3 m -138.67 -166.74 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 -177.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -84.4 114.43 21.89 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.993 -0.283 . . . . 0.0 110.66 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.68 ' CE1' ' CG2' ' J' ' 12' ' ' VAL . 8.2 m-70 -134.78 165.2 25.83 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-O 121.827 0.822 . . . . 0.0 110.641 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -161.84 166.81 25.82 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.823 178.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.583 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.7 mttt -156.98 135.33 11.31 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.583 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.0 mp -122.16 120.41 34.14 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.389 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -125.92 130.12 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.532 ' HZ ' HD12 ' H' ' 34' ' ' LEU . 0.4 OUTLIER -140.3 126.81 20.19 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.657 ' CG ' ' CZ ' ' K' ' 20' ' ' PHE . 51.2 p90 -158.75 160.53 36.45 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.619 1.711 . . . . 0.0 115.619 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.1 119.02 32.11 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 114.071 -1.422 . . . . 0.0 108.279 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.406 ' HG2' ' N ' ' J' ' 23' ' ' ASP . 80.5 tt0 -157.08 157.16 34.04 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-O 122.116 0.96 . . . . 0.0 113.494 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.498 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 51.8 p-10 -157.54 -131.41 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 178.092 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.537 HG13 ' O ' ' J' ' 24' ' ' VAL . 3.7 p -108.38 112.33 39.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.967 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.512 ' N ' ' OE1' ' K' ' 22' ' ' GLU . . . 32.02 87.94 0.01 OUTLIER Glycine 0 C--N 1.342 0.896 0 CA-C-O 118.218 -1.323 . . . . 0.0 110.781 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.572 ' O ' ' N ' ' K' ' 24' ' ' VAL . 82.8 p -96.57 168.35 10.59 Favored 'General case' 0 CA--C 1.497 -1.079 0 CA-C-N 120.772 2.286 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.535 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 84.3 m-20 -61.91 179.07 0.29 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 116.501 2.037 . . . . 0.0 116.501 175.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . 0.472 53.1 tttt -59.02 106.98 0.47 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 110.424 -3.08 . . . . 0.0 116.321 170.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.69 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -63.08 109.6 2.81 Favored Glycine 1 CA--C 1.435 -4.967 0 CA-C-O 125.192 2.551 . . . . 0.0 108.826 -173.994 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -52.79 -124.69 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.518 2 CA-C-N 104.888 -5.656 . . . . 0.0 97.823 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.979 HD12 ' N ' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -93.43 115.25 31.8 Favored 'Isoleucine or valine' 0 C--N 1.263 -3.186 1 CA-C-N 126.896 4.407 . . . . 0.0 114.63 -173.485 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.507 ' C ' ' SD ' ' D' ' 35' ' ' MET . 16.1 tt -122.27 115.4 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.588 ' CA ' ' SD ' ' D' ' 35' ' ' MET . . . -118.01 118.55 4.1 Favored Glycine 0 N--CA 1.464 0.51 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.527 HD11 ' CZ ' ' K' ' 19' ' ' PHE . 2.2 mt -134.91 127.45 30.66 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.502 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 63.8 ttp -109.2 122.01 46.39 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.711 176.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.55 70.99 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.378 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.784 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 37' ' ' GLY . . . . . 0.422 ' HA3' HG21 ' D' ' 31' ' ' ILE . . . -94.69 106.91 3.47 Favored Glycine 0 C--N 1.361 1.933 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -110.39 149.88 17.6 Favored Glycine 0 N--CA 1.464 0.552 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 8.2 p -145.23 143.77 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.631 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 40.0 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.472 179.73 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' K' K ' 9' ' ' GLY . . . . . 0.508 ' O ' ' CZ ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -115.58 143.23 45.63 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.851 0.358 . . . . 0.0 110.568 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.52 133.93 48.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.432 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.447 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 42.8 t -126.25 130.8 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-O 121.024 0.44 . . . . 0.0 110.542 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 69.2 m-70 -103.57 129.0 50.72 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.244 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.556 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 49.4 t60 -136.44 165.19 26.4 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 178.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.556 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 81.7 mt-30 -157.37 176.45 12.66 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.403 178.699 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -173.05 133.82 0.54 Allowed 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -125.89 122.4 35.93 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -127.97 129.29 69.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-O 120.908 0.385 . . . . 0.0 110.437 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.527 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 1.9 t80 -131.25 123.89 29.39 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.657 ' CZ ' ' CG ' ' J' ' 20' ' ' PHE . 52.4 p90 -144.77 151.39 38.78 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' CE ' ' I' ' 28' ' ' LYS . . . -142.67 138.17 30.43 Favored 'General case' 0 CA--C 1.543 0.7 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.244 -178.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' J' ' 25' ' ' GLY . 36.2 tt0 -89.5 134.09 34.26 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.654 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' J' ' 29' ' ' GLY . 13.8 m-20 -148.97 119.59 7.48 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' J' ' 26' ' ' SER . 6.0 p -120.37 121.61 66.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.37 84.87 0.01 OUTLIER Glycine 0 N--CA 1.484 1.854 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 12.8 p -46.22 165.28 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -179.393 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 84.6 m-20 -109.22 170.57 7.97 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 112.733 -2.03 . . . . 0.0 107.151 171.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -38.37 111.08 0.15 Allowed 'General case' 0 CA--C 1.551 1.015 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 175.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 91.93 0.36 Allowed Glycine 0 N--CA 1.483 1.824 0 N-CA-C 117.832 1.893 . . . . 0.0 117.832 171.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.19 157.54 43.56 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 173.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.411 ' O ' ' O ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -146.92 137.26 17.44 Favored 'Isoleucine or valine' 0 C--O 1.242 0.698 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.848 -176.77 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.88 126.2 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.428 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.98 122.27 4.92 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.601 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.638 HD22 ' CD1' ' L' ' 19' ' ' PHE . 21.7 tp -120.6 121.07 37.57 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 114.91 -0.645 . . . . 0.0 110.257 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.632 ' CE ' HG22 ' D' ' 31' ' ' ILE . 15.9 ttt -117.14 116.6 27.62 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.62 HG13 HG12 ' L' ' 36' ' ' VAL . 2.3 p -139.91 79.76 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -178.852 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.734 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -52.93 104.17 0.17 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.183 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 37' ' ' GLY . . . -55.35 -165.72 0.03 OUTLIER Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.18 156.54 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 120.967 0.413 . . . . 0.0 110.382 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.22 -179.89 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -84.35 137.75 33.25 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.777 0.323 . . . . 0.0 110.468 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -121.87 139.26 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.453 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m -131.81 158.63 43.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.377 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -95.76 151.97 18.9 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.108 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 62.3 m80 -80.7 177.51 8.98 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -129.98 177.57 7.18 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.656 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -147.7 150.32 34.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -127.25 124.61 39.27 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.116 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -124.52 130.48 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 120.903 0.382 . . . . 0.0 110.496 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.638 ' CD1' HD22 ' K' ' 34' ' ' LEU . 17.0 t80 -133.31 120.49 21.1 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -144.68 140.13 28.43 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.56 135.83 38.76 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.1 mt-10 -85.17 76.1 10.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 119.099 -1.04 . . . . 0.0 112.528 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -118.2 122.07 42.08 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 120.929 0.395 . . . . 0.0 111.127 178.445 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' L' ' 26' ' ' SER . 18.0 t -88.96 123.2 41.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.581 ' N ' ' O ' ' L' ' 24' ' ' VAL . 88.2 p -63.14 -178.33 0.23 Allowed 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 121.403 0.621 . . . . 0.0 109.882 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -81.82 177.51 8.84 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.588 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -38.8 103.99 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.284 177.973 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.417 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 165.73 -100.78 0.18 Allowed Glycine 0 C--O 1.22 -0.763 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.671 -177.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.39 170.87 0.2 Allowed 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.417 HG12 ' O ' ' L' ' 29' ' ' GLY . 0.0 OUTLIER -153.97 145.87 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 118.099 -1.44 . . . . 0.0 112.427 -176.553 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 13.6 tt -138.2 137.46 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.78 123.91 4.65 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 mt -117.36 119.78 36.17 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.76 119.82 36.65 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.62 HG12 HG13 ' K' ' 36' ' ' VAL . 3.2 m -129.32 81.66 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.655 -0.248 . . . . 0.0 110.88 -178.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.743 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . -58.56 101.64 0.22 Allowed Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.01 168.99 33.06 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -131.18 159.12 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 120.699 0.285 . . . . 0.0 110.396 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.781 -179.63 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 57.0 t80 -82.47 130.54 35.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.854 0.359 . . . . 0.0 110.395 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.42 146.21 54.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.59 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.6 t -121.21 134.62 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.418 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -96.72 -176.53 3.62 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.144 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -81.02 171.26 15.19 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.433 ' HG3' ' N ' ' A' ' 16' ' ' LYS . 61.8 tp60 -152.48 171.63 17.79 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.498 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.433 ' N ' ' HG3' ' A' ' 15' ' ' GLN . 99.4 mttt -145.58 119.74 9.49 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.49 0.186 . . . . 0.0 111.104 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -132.03 120.32 22.25 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 120.91 0.386 . . . . 0.0 110.061 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -142.23 139.28 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.662 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -135.87 140.2 43.95 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.386 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -139.75 135.44 33.11 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.072 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.39 124.27 47.29 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.648 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -172.75 99.91 0.14 Allowed 'General case' 0 CA--C 1.527 0.093 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 24' ' ' VAL . 49.2 t0 -146.12 113.85 6.43 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.403 ' C ' ' O ' ' A' ' 23' ' ' ASP . 61.6 t -28.5 125.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.152 -0.931 . . . . 0.0 112.06 177.079 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.48 -83.34 0.05 OUTLIER Glycine 0 CA--C 1.527 0.824 0 C-N-CA 119.895 -1.145 . . . . 0.0 112.106 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 27' ' ' ASN . 1.5 p 170.66 179.53 0.05 Allowed 'General case' 0 N--CA 1.447 -0.588 0 CA-C-N 118.224 1.012 . . . . 0.0 110.711 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.533 ' O ' ' O ' ' A' ' 26' ' ' SER . 0.6 OUTLIER -28.38 159.58 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 113.76 -1.564 . . . . 0.0 112.28 179.095 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' CG ' ' A' ' 28' ' ' LYS . 0.1 OUTLIER 179.37 101.91 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.739 0 CA-C-O 121.881 0.848 . . . . 0.0 112.19 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.8 101.52 0.8 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 176.665 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.33 153.57 24.53 Favored 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 116.528 -2.069 . . . . 0.0 111.035 -175.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.654 HD13 ' O ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -142.55 111.93 2.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 111.674 -2.512 . . . . 0.0 107.869 -173.449 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.481 ' CG2' HD21 ' B' ' 34' ' ' LEU . 7.8 mt -109.32 107.7 23.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -126.27 102.62 0.65 Allowed Glycine 0 CA--C 1.508 -0.4 0 N-CA-C 107.074 -2.411 . . . . 0.0 107.074 178.285 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 mt -138.36 149.12 45.27 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 122.666 1.222 . . . . 0.0 113.76 -177.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.438 ' SD ' ' HA3' ' H' ' 33' ' ' GLY . 97.7 mmm -109.65 107.25 17.24 Favored 'General case' 0 CA--C 1.498 -1.043 0 CA-C-N 112.684 -2.053 . . . . 0.0 106.507 175.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -98.04 71.91 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.76 102.73 2.4 Favored Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.08 146.62 14.01 Favored Glycine 0 CA--C 1.526 0.781 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.463 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.4 p -144.59 144.35 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.778 0.323 . . . . 0.0 110.649 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.102 -0.952 . . . . 0.0 110.537 179.967 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 10' ' ' TYR . . . . . 0.489 ' CZ ' ' OH ' ' D' ' 10' ' ' TYR . 65.7 m-85 -118.62 140.88 49.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -61.57 134.11 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.572 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.439 HG22 ' NE2' ' B' ' 14' ' ' HIS . 4.6 p -143.13 143.89 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.904 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -124.77 146.67 49.09 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 120.487 0.184 . . . . 0.0 110.661 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.566 ' CE1' ' H ' ' C' ' 14' ' ' HIS . 98.5 m-70 -153.89 162.07 41.51 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.589 0.709 . . . . 0.0 110.842 178.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.5 mm-40 -158.16 174.21 15.54 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.476 177.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -157.85 125.57 5.26 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 52.9 tp -130.99 122.58 27.09 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.993 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.44 133.06 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.899 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -131.06 130.07 42.76 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.391 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -132.23 125.73 31.81 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.288 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.38 125.97 45.96 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -168.37 117.76 0.74 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 178.525 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -148.35 106.93 3.78 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -28.74 140.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-N 114.998 -1.001 . . . . 0.0 113.077 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.25 -80.83 0.1 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' B' ' 27' ' ' ASN . 2.9 p 170.29 170.78 0.06 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' B' ' 26' ' ' SER . 52.4 p30 -18.0 158.16 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 O-C-N 124.593 1.183 . . . . 0.0 113.194 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.478 ' H ' ' HB3' ' C' ' 26' ' ' SER . 0.0 OUTLIER -161.78 110.71 1.51 Allowed 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 119.506 -0.877 . . . . 0.0 112.573 176.249 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.97 95.14 0.39 Allowed Glycine 0 CA--C 1.482 -1.988 0 N-CA-C 104.897 -3.281 . . . . 0.0 104.897 176.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 161.73 14.18 Favored 'General case' 0 CA--C 1.483 -1.623 0 C-N-CA 116.293 -2.163 . . . . 0.0 108.608 -175.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.634 HG22 ' CE ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -145.31 127.64 9.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 112.572 -2.104 . . . . 0.0 108.14 -173.74 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.455 HG22 ' O ' ' B' ' 32' ' ' ILE . 0.6 OUTLIER -121.59 115.99 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 CA-C-O 121.044 0.45 . . . . 0.0 109.993 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.57 99.74 0.63 Allowed Glycine 0 N--CA 1.462 0.368 0 N-CA-C 105.622 -2.991 . . . . 0.0 105.622 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.481 HD21 ' CG2' ' A' ' 32' ' ' ILE . 75.1 mt -124.94 137.91 54.25 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.328 1.061 . . . . 0.0 112.903 -175.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.549 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.3 ttm -119.38 115.08 23.36 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 114.012 -1.449 . . . . 0.0 107.604 178.192 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.713 ' O ' HG13 ' B' ' 36' ' ' VAL . 3.3 p -126.84 66.88 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -54.65 -102.57 0.01 OUTLIER Glycine 0 C--N 1.357 1.726 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.55 152.55 15.91 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -130.88 135.62 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.833 0.349 . . . . 0.0 110.189 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.206 179.502 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -112.01 133.17 54.35 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.953 0.406 . . . . 0.0 110.749 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.442 ' O ' HG12 ' D' ' 12' ' ' VAL . 98.3 mt-10 -87.15 136.9 32.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.047 179.599 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.526 HG22 ' O ' ' D' ' 11' ' ' GLU . 48.3 t -116.82 130.59 71.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' D' ' 13' ' ' HIS . 51.3 p-80 -161.87 141.74 10.13 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.618 -0.833 . . . . 0.0 112.085 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.566 ' H ' ' CE1' ' B' ' 14' ' ' HIS . 17.1 m80 -121.39 163.21 19.08 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 57.1 tt0 -168.62 169.23 10.37 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 62.8 pttt -158.61 132.91 7.94 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.877 0.846 . . . . 0.0 111.396 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 tt -120.31 125.23 47.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.279 -1.328 . . . . 0.0 108.01 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 20.5 t -127.47 123.3 61.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.187 0.518 . . . . 0.0 112.133 -178.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CB ' ' CE1' ' D' ' 19' ' ' PHE . 2.1 m-85 -112.95 110.6 20.77 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.494 ' CE2' ' CD2' ' D' ' 20' ' ' PHE . 7.4 t80 -116.25 118.11 31.87 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.228 -178.428 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.56 129.33 55.28 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 121.038 0.447 . . . . 0.0 111.469 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -158.56 101.85 1.69 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.972 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' D' ' 24' ' ' VAL . 17.8 m-20 -127.5 -134.62 0.24 Allowed 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.4 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' C' ' 26' ' ' SER . 12.7 t -90.55 112.49 25.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.396 -0.522 . . . . 0.0 111.336 179.538 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.6 91.69 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 177.419 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.525 ' N ' ' O ' ' C' ' 24' ' ' VAL . 4.5 p -65.16 -173.93 0.14 Allowed 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -78.64 171.78 14.65 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.957 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.504 ' NZ ' ' H ' ' E' ' 27' ' ' ASN 0.454 5.1 tttp -45.43 114.19 0.71 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 179.317 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.652 ' HA2' ' HB1' ' D' ' 30' ' ' ALA . . . 99.12 91.5 2.02 Favored Glycine 0 CA--C 1.489 -1.535 0 C-N-CA 126.363 1.935 . . . . 0.0 116.727 -178.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.418 ' C ' HG12 ' C' ' 31' ' ' ILE . . . -100.43 173.36 6.61 Favored 'General case' 0 N--CA 1.42 -1.961 1 N-CA-C 99.988 -4.079 . . . . 0.0 99.988 166.663 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.517 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -141.26 111.4 3.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 117.923 -1.511 . . . . 0.0 111.44 -177.109 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.596 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.0 OUTLIER -108.97 121.87 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.493 178.492 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -128.43 119.47 3.08 Favored Glycine 0 C--O 1.237 0.335 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.732 ' H ' HD23 ' D' ' 34' ' ' LEU . 3.6 tt -142.61 142.88 32.19 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 122.481 1.134 . . . . 0.0 112.935 -177.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 0.1 OUTLIER -113.89 118.26 33.71 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.909 178.907 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.04 73.83 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.49 106.05 3.14 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 111.196 -0.761 . . . . 0.0 111.196 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.51 161.08 20.47 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -130.66 135.75 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.75 0.309 . . . . 0.0 110.641 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.598 179.377 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' D' D ' 10' ' ' TYR . . . . . 0.489 ' OH ' ' CZ ' ' B' ' 10' ' ' TYR . 85.3 m-85 -107.08 133.65 51.39 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.894 0.378 . . . . 0.0 110.48 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.526 ' O ' HG22 ' C' ' 12' ' ' VAL . 79.6 tt0 -150.1 133.0 16.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.701 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.442 HG12 ' O ' ' C' ' 11' ' ' GLU . 29.2 m -99.65 166.34 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.076 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' C' ' 13' ' ' HIS . 18.9 t-80 -153.84 148.93 26.84 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.227 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -99.79 -178.68 3.94 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.337 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 44.0 tt0 -84.55 167.91 15.88 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.716 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.502 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 95.5 mttt -119.86 139.23 52.7 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.6 mt -122.52 121.99 37.84 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.544 0.211 . . . . 0.0 110.462 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -129.84 128.02 64.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.092 0.472 . . . . 0.0 111.586 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.488 ' CE1' ' CB ' ' C' ' 19' ' ' PHE . 7.9 m-85 -122.86 119.8 31.6 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.065 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 13.7 t80 -112.87 118.67 35.55 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.75 111.59 22.87 Favored 'General case' 0 C--O 1.251 1.184 0 CA-C-O 122.552 1.168 . . . . 0.0 111.92 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.468 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 66.4 tt0 -139.31 178.25 7.33 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.48 ' O ' ' C ' ' D' ' 24' ' ' VAL . 19.8 p30 -179.93 126.13 0.08 Allowed 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.395 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.566 ' N ' ' O ' ' C' ' 23' ' ' ASP . 57.8 t -41.2 115.26 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-O 122.563 1.173 . . . . 0.0 108.094 -176.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.53 92.55 1.17 Allowed Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 105.336 -3.106 . . . . 0.0 105.336 -174.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.481 ' O ' ' CB ' ' D' ' 27' ' ' ASN . 11.0 p -44.46 169.83 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.369 -0.415 . . . . 0.0 110.872 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.533 ' CG ' ' N ' ' D' ' 28' ' ' LYS . 1.6 t30 156.72 162.04 0.01 OUTLIER 'General case' 0 CA--C 1.561 1.377 0 CA-C-O 124.34 2.019 . . . . 0.0 114.669 174.541 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.585 ' N ' ' OD1' ' E' ' 23' ' ' ASP 0.827 13.5 tttt -29.6 112.08 0.07 Allowed 'General case' 0 C--N 1.323 -0.584 1 N-CA-C 127.623 6.157 . . . . 0.0 127.623 177.18 . . . . . . . . 4 3 . 1 . 005 nuclear build full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.07 100.16 1.6 Allowed Glycine 0 CA--C 1.461 -3.309 2 N-CA-C 100.274 -5.13 . . . . 0.0 100.274 176.048 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.652 ' HB1' ' HA2' ' C' ' 29' ' ' GLY . . . -73.6 -128.78 0.01 OUTLIER 'General case' 1 N--CA 1.348 -5.569 4 CA-C-N 100.45 -7.875 . . . . 0.0 100.162 -174.909 . . . . . . . . 4 3 . 1 . 005 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.963 HD12 ' N ' ' D' ' 31' ' ' ILE . 1.2 mp -76.78 113.87 16.4 Favored 'Isoleucine or valine' 0 C--N 1.255 -3.509 0 CA-C-N 123.247 2.749 . . . . 0.0 113.913 -174.404 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' E' ' 32' ' ' ILE . 2.6 tt -121.32 112.65 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 175.622 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.635 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -121.95 110.89 1.71 Allowed Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.732 HD23 ' H ' ' C' ' 34' ' ' LEU . 21.2 mt -133.5 132.94 41.59 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 119.408 -0.917 . . . . 0.0 112.493 -176.916 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.502 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.9 ttm -109.78 126.64 53.98 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.153 178.187 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.2 t -121.41 79.27 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 CA-C-N 116.671 -0.241 . . . . 0.0 110.989 -178.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -44.34 103.18 0.04 OUTLIER Glycine 0 C--N 1.357 1.72 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 177.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.12 -166.63 29.05 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -122.47 136.21 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 121.021 0.439 . . . . 0.0 110.35 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.2 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.953 -1.023 . . . . 0.0 110.419 179.94 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' E' E ' 10' ' ' TYR . . . . . 0.419 ' O ' ' O ' ' D' ' 10' ' ' TYR . 98.8 m-85 -114.1 134.71 54.7 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.913 0.387 . . . . 0.0 110.807 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -119.34 148.13 43.53 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.311 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.405 ' CG1' ' CD2' ' E' ' 14' ' ' HIS . 72.8 t -123.79 134.09 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.176 0.512 . . . . 0.0 110.398 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -118.99 101.99 8.43 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.118 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.405 ' CD2' ' CG1' ' E' ' 12' ' ' VAL . 8.2 m-70 -130.02 169.1 15.71 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-O 121.609 0.718 . . . . 0.0 110.264 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -149.22 174.73 12.06 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.632 -1.167 . . . . 0.0 108.314 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -154.34 112.02 3.47 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.493 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.8 tp -121.45 117.1 26.03 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -130.93 127.76 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.459 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 3.1 m-85 -118.53 115.98 25.71 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 36.1 t80 -114.98 122.88 47.61 Favored 'General case' 0 N--CA 1.471 0.609 0 O-C-N 122.385 -0.197 . . . . 0.0 111.171 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.56 132.72 42.87 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.999 -0.28 . . . . 0.0 110.633 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.14 136.64 39.73 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.615 -0.834 . . . . 0.0 112.94 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.585 ' OD1' ' N ' ' D' ' 28' ' ' LYS . 46.3 t0 -138.1 131.47 30.59 Favored 'General case' 0 C--N 1.368 1.382 0 CA-C-O 121.353 0.597 . . . . 0.0 112.559 178.201 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.416 ' CG2' ' OG ' ' D' ' 26' ' ' SER . 37.8 t -111.44 113.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.606 177.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . 32.74 88.77 0.01 OUTLIER Glycine 0 CA--C 1.534 1.258 0 CA-C-O 121.794 0.663 . . . . 0.0 112.297 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.527 ' CB ' ' HG ' ' F' ' 26' ' ' SER . 3.4 p -46.67 170.9 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.504 ' H ' ' NZ ' ' C' ' 28' ' ' LYS . 0.3 OUTLIER -129.14 -179.21 5.0 Favored 'General case' 0 CA--C 1.552 1.034 0 CA-C-N 112.94 -1.936 . . . . 0.0 107.996 173.775 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -29.58 107.88 0.04 OUTLIER 'General case' 0 CA--C 1.564 1.508 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 -177.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.581 ' O ' ' HB3' ' E' ' 30' ' ' ALA . . . 81.55 -96.62 1.77 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 118.129 2.011 . . . . 0.0 118.129 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.581 ' HB3' ' O ' ' E' ' 29' ' ' GLY . . . 75.28 149.56 0.1 Allowed 'General case' 0 C--O 1.252 1.219 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -175.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.647 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -154.33 122.82 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 117.147 -1.821 . . . . 0.0 110.442 -175.152 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.562 HG23 ' CG2' ' D' ' 32' ' ' ILE . 93.5 mt -121.58 127.13 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.255 -177.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.94 118.99 1.94 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.751 HD13 ' CD2' ' F' ' 19' ' ' PHE . 48.4 mt -123.87 123.64 40.89 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.807 -0.696 . . . . 0.0 109.951 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -120.01 122.88 42.12 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.147 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 t -114.17 86.51 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.722 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.648 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -63.91 97.35 0.22 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.09 168.86 38.74 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.5 t -123.5 135.97 61.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.219 -0.532 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.385 -179.807 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -114.77 135.78 53.8 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.811 0.339 . . . . 0.0 110.779 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -85.6 159.86 19.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 81.1 t -94.78 133.68 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.194 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.658 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 p-80 -139.97 125.95 19.68 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.335 0.588 . . . . 0.0 110.722 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.614 ' CG ' ' H ' ' F' ' 15' ' ' GLN . 82.7 t60 -156.97 177.25 11.72 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.614 ' H ' ' CG ' ' F' ' 14' ' ' HIS . 86.9 mt-30 -144.21 173.87 11.38 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -148.94 112.43 5.02 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.277 0.561 . . . . 0.0 111.605 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -124.68 120.47 31.93 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -127.53 128.67 70.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-O 121.817 0.818 . . . . 0.0 112.704 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.751 ' CD2' HD13 ' E' ' 34' ' ' LEU . 8.7 m-85 -115.09 104.98 12.41 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.963 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.403 ' CE2' ' OE2' ' F' ' 22' ' ' GLU . 18.7 t80 -114.94 120.71 40.83 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 -177.932 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.27 129.54 33.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' CE2' ' F' ' 20' ' ' PHE . 73.5 mm-40 -92.6 92.4 8.0 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.507 -178.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 25.5 t0 -147.41 107.98 4.13 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 120.791 0.329 . . . . 0.0 111.5 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 m -77.49 -131.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.31 0.576 . . . . 0.0 110.147 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.15 85.44 0.01 OUTLIER Glycine 0 CA--C 1.528 0.879 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.927 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.527 ' HG ' ' CB ' ' E' ' 26' ' ' SER . 3.7 t -61.82 -178.39 0.15 Allowed 'General case' 0 N--CA 1.44 -0.95 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.417 ' N ' ' OG ' ' E' ' 26' ' ' SER . 59.5 t30 -80.16 172.78 13.32 Favored 'General case' 0 C--N 1.316 -0.866 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.228 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -45.45 110.73 0.27 Allowed 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.153 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.0 92.95 0.32 Allowed Glycine 0 N--CA 1.463 0.48 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.503 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.56 ' HB1' ' HZ3' ' D' ' 28' ' ' LYS . . . -120.84 162.5 19.71 Favored 'General case' 0 CA--C 1.489 -1.396 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 173.283 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.46 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -144.48 116.47 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 115.625 -2.43 . . . . 0.0 112.728 -175.903 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 tt -125.95 135.55 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.029 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.31 128.02 4.37 Favored Glycine 0 CA--C 1.531 1.043 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.022 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -119.66 124.37 46.13 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 0.4 OUTLIER -130.64 129.63 42.92 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.36 0.6 . . . . 0.0 112.363 -178.885 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.586 ' O ' HG13 ' F' ' 36' ' ' VAL . 7.7 p -152.95 81.89 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.702 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.56 101.51 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.249 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -151.19 160.46 28.69 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 12.7 p -137.46 141.62 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 120.837 0.351 . . . . 0.0 110.907 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.629 179.747 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -113.69 135.94 53.38 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.897 0.379 . . . . 0.0 110.359 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 tp10 -68.69 135.85 51.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.135 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -144.49 151.06 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.476 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 53.5 m80 -130.87 122.02 26.29 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 121.132 0.492 . . . . 0.0 111.721 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 m-70 -145.48 164.58 31.16 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.416 ' HG3' ' N ' ' G' ' 16' ' ' LYS . 64.5 tp60 -164.9 165.17 20.59 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.242 178.758 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.416 ' N ' ' HG3' ' G' ' 15' ' ' GLN . 98.7 mttt -157.04 129.12 7.27 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -136.43 122.14 19.79 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.535 0.683 . . . . 0.0 110.999 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 18' ' ' VAL . . . . . 0.452 HG22 ' CG1' ' H' ' 18' ' ' VAL . 71.4 t -123.44 129.55 74.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.566 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -128.81 134.89 48.51 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.803 0.335 . . . . 0.0 110.909 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 46.0 p90 -129.93 127.13 39.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.791 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.59 37.21 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 121.418 0.627 . . . . 0.0 111.372 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -174.48 98.72 0.09 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.545 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -152.63 114.7 4.4 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -28.99 122.55 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 113.9 -1.5 . . . . 0.0 113.358 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.44 -85.56 0.06 OUTLIER Glycine 0 CA--C 1.529 0.926 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.556 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.555 ' O ' ' O ' ' G' ' 27' ' ' ASN . 19.0 t -153.39 -173.59 4.63 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 119.462 1.631 . . . . 0.0 111.646 178.5 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.555 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.3 m-20 -20.52 156.57 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 113.58 -1.645 . . . . 0.0 112.903 177.873 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 58.5 tttm -168.44 102.83 0.43 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 118.732 -1.187 . . . . 0.0 113.739 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.445 ' O ' HG13 ' G' ' 31' ' ' ILE . . . -76.81 104.45 1.89 Allowed Glycine 0 CA--C 1.495 -1.205 0 CA-C-O 115.789 -2.673 . . . . 0.0 106.86 172.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.469 ' C ' HG13 ' G' ' 31' ' ' ILE . . . -74.75 143.15 44.23 Favored 'General case' 0 C--O 1.252 1.203 1 CA-C-N 124.22 4.01 . . . . 0.0 105.782 -178.126 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.469 HG13 ' C ' ' G' ' 30' ' ' ALA . 69.6 mt -156.75 115.29 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 112.883 -1.962 . . . . 0.0 108.509 -171.826 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' H' ' 32' ' ' ILE . 10.4 tt -141.01 131.01 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.427 0 CA-C-O 122.683 1.23 . . . . 0.0 110.523 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.413 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -148.98 154.27 25.7 Favored Glycine 0 CA--C 1.484 -1.871 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 176.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -145.04 140.68 28.28 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.691 -179.183 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 25.6 ttp -103.48 106.81 17.42 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.48 65.28 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.654 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -131.45 102.55 0.51 Allowed Glycine 0 C--N 1.369 2.374 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.13 173.42 41.66 Favored Glycine 0 CA--C 1.523 0.587 0 C-N-CA 120.385 -0.912 . . . . 0.0 111.894 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -123.32 136.24 60.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 34.8 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.402 179.608 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -85.18 158.13 20.45 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -52.58 151.07 4.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.835 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.42 159.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.877 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -129.48 133.24 47.18 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.979 0.418 . . . . 0.0 111.948 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -140.9 163.81 31.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -157.59 177.5 11.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.355 0.598 . . . . 0.0 111.307 179.249 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 16' ' ' LYS . . . . . 0.617 ' C ' HD22 ' H' ' 17' ' ' LEU . 45.0 tttp -170.64 115.53 0.47 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.81 178.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.744 HD22 ' N ' ' H' ' 17' ' ' LEU . 1.6 mm? -122.8 119.16 29.77 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.452 ' CG1' HG22 ' G' ' 18' ' ' VAL . 3.0 p -135.17 130.65 51.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.713 178.29 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -120.13 123.24 42.85 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.948 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.23 123.0 45.56 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.11 126.18 38.78 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.321 0.581 . . . . 0.0 110.48 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.419 ' O ' ' CG ' ' H' ' 23' ' ' ASP . 84.1 tt0 -138.94 131.12 28.2 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.146 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.2 m-20 -163.05 122.92 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.474 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' I' ' 24' ' ' VAL . 7.1 m -93.51 -113.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.507 ' N ' HG23 ' H' ' 24' ' ' VAL . . . 42.74 -91.37 0.01 OUTLIER Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.068 -0.587 . . . . 0.0 114.086 176.064 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.446 ' N ' ' O ' ' H' ' 24' ' ' VAL . 25.6 p -73.58 170.74 14.56 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.587 1.184 . . . . 0.0 113.606 -174.547 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 23.3 m120 -46.97 179.97 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 112.597 -2.092 . . . . 0.0 113.564 -176.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.492 ' HZ1' ' HB2' ' J' ' 23' ' ' ASP . 82.4 tttt -119.29 -110.25 0.35 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 114.16 -1.382 . . . . 0.0 112.0 -176.24 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 47.61 92.44 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.163 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -178.012 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.04 159.59 15.94 Favored 'General case' 0 C--O 1.25 1.118 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.266 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.41 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -138.7 124.99 24.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 113.084 -1.871 . . . . 0.0 111.55 -178.745 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.549 ' N ' ' SD ' ' B' ' 35' ' ' MET . 0.7 OUTLIER -114.52 117.29 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.195 178.054 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.438 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -118.38 109.3 1.75 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.756 HD13 ' CZ ' ' J' ' 19' ' ' PHE . 15.5 mt -118.36 122.73 43.55 Favored 'General case' 0 CA--C 1.49 -1.333 0 N-CA-C 112.848 0.684 . . . . 0.0 112.848 -175.393 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.1 ttm -114.56 106.1 13.87 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.63 71.81 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.402 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.23 111.72 3.71 Favored Glycine 0 C--N 1.365 2.148 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -45.37 160.18 0.17 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 40' ' ' VAL . 3.3 p -140.5 141.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.702 0.287 . . . . 0.0 110.314 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 39' ' ' VAL . 84.5 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.955 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -113.86 138.68 49.97 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -140.14 159.26 42.59 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.27 0.557 . . . . 0.0 111.445 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 75.1 t -121.69 131.74 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.018 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -147.16 121.85 9.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.823 -179.36 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 87.7 m-70 -134.94 161.82 34.18 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -153.78 166.96 31.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.511 0.672 . . . . 0.0 111.576 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -156.91 127.32 6.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.352 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -128.8 125.73 38.4 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.244 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -128.86 126.82 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 116.691 -0.232 . . . . 0.0 111.189 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.615 ' CD1' ' CE1' ' J' ' 19' ' ' PHE . 31.4 m-85 -115.17 107.37 15.21 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -108.25 122.74 47.58 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 118.274 0.488 . . . . 0.0 110.795 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 138.93 34.44 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.455 ' HG2' ' H ' ' J' ' 22' ' ' GLU . 72.7 mt-10 -152.29 121.87 6.88 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-O 118.972 -0.537 . . . . 0.0 111.752 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.589 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 63.7 m-20 -151.42 103.74 3.02 Favored 'General case' 0 C--N 1.362 1.115 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 176.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.548 ' CG2' HG12 ' H' ' 24' ' ' VAL . 59.8 t -31.87 142.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.616 1.567 . . . . 0.0 114.215 170.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -81.75 0.1 Allowed Glycine 0 CA--C 1.533 1.16 0 C-N-CA 119.187 -1.482 . . . . 0.0 114.779 174.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.54 ' O ' ' O ' ' I' ' 27' ' ' ASN . 91.5 p -132.61 -179.21 5.32 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.603 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 46.5 t-20 -40.23 167.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.603 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 70.7 tttt -72.3 110.6 6.84 Favored 'General case' 0 C--N 1.344 0.337 0 C-N-CA 114.268 -2.973 . . . . 0.0 111.316 178.286 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.68 94.69 1.66 Allowed Glycine 0 CA--C 1.491 -1.433 0 CA-C-O 115.406 -2.885 . . . . 0.0 106.399 167.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.14 142.29 49.43 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 123.892 3.846 . . . . 0.0 109.0 177.572 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.512 HG23 HG13 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -139.19 120.32 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 CA-C-N 111.54 -2.573 . . . . 0.0 109.261 -176.529 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.478 HG22 ' O ' ' I' ' 32' ' ' ILE . 0.8 OUTLIER -110.53 114.27 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 121.333 0.587 . . . . 0.0 110.19 178.968 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.52 96.94 1.31 Allowed Glycine 0 CA--C 1.496 -1.099 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.687 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 31.9 tp -111.88 122.93 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -175.784 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.1 ttp -121.57 114.77 21.67 Favored 'General case' 0 CA--C 1.512 -0.514 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.478 HG11 HD22 ' K' ' 17' ' ' LEU . 0.0 OUTLIER -131.89 72.22 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.284 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' I' I ' 37' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -37.77 -98.49 0.01 OUTLIER Glycine 0 C--N 1.358 1.765 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.07 -167.33 39.21 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -123.44 135.6 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.938 0.399 . . . . 0.0 110.405 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.412 HG22 ' H ' ' I' ' 40' ' ' VAL . 28.5 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.448 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -129.26 141.34 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -88.01 130.32 35.0 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.047 0.451 . . . . 0.0 110.151 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -137.09 144.46 31.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.35 0.595 . . . . 0.0 110.796 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 12.0 t-80 -148.85 132.39 16.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.0 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.542 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 36.1 t60 -156.17 165.69 35.67 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.541 0.686 . . . . 0.0 109.523 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.547 ' HB3' HE22 ' K' ' 15' ' ' GLN . 48.4 tt0 -165.0 168.89 17.01 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 16' ' ' LYS . . . . . 0.474 ' N ' ' CG ' ' J' ' 15' ' ' GLN . 88.5 tttt -153.7 132.63 12.45 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.449 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.43 127.23 47.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.219 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -126.08 127.93 71.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.834 0.35 . . . . 0.0 110.884 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 97.3 m-85 -113.52 109.56 18.84 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -120.03 122.83 41.98 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.733 0.271 . . . . 0.0 111.733 -176.91 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.22 132.21 41.23 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.498 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.583 ' OE2' ' CD1' ' J' ' 20' ' ' PHE . 18.6 mp0 -140.52 145.85 37.37 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 120.19 -0.604 . . . . 0.0 112.36 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 15.3 m-20 -167.33 124.24 1.18 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.5 0.666 . . . . 0.0 111.903 178.106 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.804 HG13 ' H ' ' J' ' 25' ' ' GLY . 7.1 p -62.93 -116.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.762 -1.108 . . . . 0.0 110.834 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.804 ' H ' HG13 ' J' ' 24' ' ' VAL . . . 60.72 -91.79 0.06 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 114.976 -1.011 . . . . 0.0 114.42 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.83 ' O ' ' O ' ' J' ' 27' ' ' ASN . 35.1 p -171.63 172.52 4.97 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 118.173 0.986 . . . . 0.0 110.834 -176.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.83 ' O ' ' O ' ' J' ' 26' ' ' SER . 4.8 m120 15.58 -178.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 O-C-N 125.627 1.83 . . . . 0.0 114.738 -179.486 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.544 ' CA ' ' OD1' ' I' ' 27' ' ' ASN 0.255 80.4 tttt -148.49 109.92 4.41 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 118.359 -1.336 . . . . 0.0 113.906 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -73.73 94.13 0.75 Allowed Glycine 0 CA--C 1.489 -1.551 0 CA-C-O 116.172 -2.46 . . . . 0.0 107.683 169.782 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.48 146.52 50.79 Favored 'General case' 0 CA--C 1.481 -1.709 0 CA-C-N 123.116 3.458 . . . . 0.0 110.587 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.53 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.1 OUTLIER -149.71 109.36 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 CA-C-N 110.906 -2.861 . . . . 0.0 105.629 -178.141 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.537 HG22 HG23 ' K' ' 32' ' ' ILE . 1.1 tt -109.7 113.38 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 121.773 0.797 . . . . 0.0 108.9 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 33' ' ' GLY . . . . . 0.461 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -102.49 107.73 3.18 Favored Glycine 0 CA--C 1.507 -0.442 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.794 HD22 ' CE1' ' L' ' 19' ' ' PHE . 6.4 mt -110.62 111.36 22.53 Favored 'General case' 0 CA--C 1.507 -0.677 0 CA-C-O 121.247 0.546 . . . . 0.0 110.748 -177.385 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.596 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 18.9 ttt -110.28 110.34 21.12 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.105 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 5.9 m -133.83 74.88 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.229 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.27 102.21 2.85 Favored Glycine 0 C--N 1.35 1.357 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -152.86 157.1 27.1 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -136.95 146.75 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.795 0.331 . . . . 0.0 110.362 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 t . . . . . 0 C--O 1.221 -0.426 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.57 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -105.29 137.63 42.77 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -156.22 129.81 8.32 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.773 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.42 133.8 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.776 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 -128.16 121.58 29.87 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.51 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' NE2' ' L' ' 14' ' ' HIS . 96.6 m-70 -122.59 169.38 11.08 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.37 0.605 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.547 HE22 ' HB3' ' J' ' 15' ' ' GLN . 11.1 tp-100 -155.36 169.98 22.97 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.164 179.272 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG3' ' K' ' 15' ' ' GLN . 88.4 tttt -172.61 125.32 0.48 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.553 0.216 . . . . 0.0 110.503 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.478 HD22 HG11 ' I' ' 36' ' ' VAL . 5.1 mp -128.69 129.34 45.66 Favored 'General case' 0 N--CA 1.466 0.374 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.501 HG11 ' CE2' ' K' ' 20' ' ' PHE . 40.6 t -132.12 133.55 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.067 0.46 . . . . 0.0 111.504 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.687 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 37.7 m-85 -114.58 111.73 21.81 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.601 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.501 ' CE2' HG11 ' K' ' 18' ' ' VAL . 54.8 m-85 -109.13 114.43 28.15 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.353 -0.217 . . . . 0.0 111.252 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.32 121.27 38.27 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.958 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -121.68 130.87 53.77 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.145 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 16.4 p-10 179.25 102.25 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 114.936 -1.029 . . . . 0.0 109.415 176.93 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.607 HG22 ' N ' ' K' ' 25' ' ' GLY . 12.9 p -58.82 166.29 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.133 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.607 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 88.23 81.6 1.26 Allowed Glycine 0 CA--C 1.53 0.969 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.463 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 34.0 p -47.9 166.78 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.513 ' CG ' ' H ' ' K' ' 28' ' ' LYS . 60.2 t30 -157.2 177.38 11.54 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.033 -0.667 . . . . 0.0 112.68 177.576 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.513 ' H ' ' CG ' ' K' ' 27' ' ' ASN . 67.3 mmtt 2.31 -105.32 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.358 1.063 . . . . 0.0 113.265 178.626 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -140.92 97.66 0.22 Allowed Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.94 170.32 4.44 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.648 HG21 ' CA ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -152.18 126.37 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 117.998 -1.481 . . . . 0.0 111.442 -178.687 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.537 HG23 HG22 ' J' ' 32' ' ' ILE . 96.6 mt -126.14 132.64 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.603 -178.416 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.76 116.34 2.97 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 12.6 mt -107.22 111.25 23.56 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.456 ' C ' ' SD ' ' K' ' 35' ' ' MET . 0.0 OUTLIER -113.03 111.99 23.12 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 -178.943 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.09 81.79 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.647 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -79.16 100.88 1.8 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 178.164 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.82 161.43 34.97 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.644 -0.788 . . . . 0.0 111.455 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.9 m -139.28 162.47 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-O 120.763 0.316 . . . . 0.0 110.558 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.4 179.77 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.74 140.85 51.07 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.883 0.373 . . . . 0.0 110.615 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -59.19 141.3 54.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.4 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 7.9 m -121.62 133.74 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 121.255 0.55 . . . . 0.0 110.876 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 69.5 t60 -140.14 125.14 18.5 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.415 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' ND1' ' K' ' 14' ' ' HIS . 23.6 p80 -157.38 170.97 21.24 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -148.75 174.2 12.44 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.48 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -152.86 139.5 18.81 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.457 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -134.34 122.38 22.54 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -126.12 132.82 70.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-O 121.079 0.466 . . . . 0.0 111.755 -178.523 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.794 ' CE1' HD22 ' J' ' 34' ' ' LEU . 88.1 m-85 -112.62 112.01 23.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.565 178.691 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -120.73 119.45 32.82 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.31 0.576 . . . . 0.0 110.715 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.44 128.62 47.27 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' L' ' 22' ' ' GLU . 11.3 tm-20 -78.59 96.51 5.5 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.188 -178.21 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -152.55 113.57 4.19 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.409 HG23 ' O ' ' L' ' 24' ' ' VAL . 31.9 m -98.62 130.51 47.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.281 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.0 81.74 0.03 OUTLIER Glycine 0 C--N 1.336 0.581 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.748 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -62.16 -178.15 0.16 Allowed 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.773 0.797 . . . . 0.0 110.459 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 7.9 t-20 -80.63 178.46 8.33 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.393 -1.276 . . . . 0.0 112.449 -178.213 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 65.0 mttp -41.44 111.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.088 -0.96 . . . . 0.0 112.059 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.71 -93.71 1.76 Allowed Glycine 0 N--CA 1.463 0.474 0 CA-C-N 113.951 -1.477 . . . . 0.0 112.982 179.513 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 78.26 161.48 0.21 Allowed 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 100.636 -3.838 . . . . 0.0 100.636 -174.477 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.48 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -154.09 127.54 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 122.665 2.484 . . . . 0.0 111.961 -179.11 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 48.5 pt -122.64 141.54 42.63 Favored 'Isoleucine or valine' 0 C--N 1.339 0.134 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.063 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.88 121.21 3.33 Favored Glycine 0 N--CA 1.465 0.621 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.4 tp -124.42 123.02 39.26 Favored 'General case' 0 N--CA 1.465 0.278 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.578 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.1 ppp? -131.67 136.05 47.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.475 0.655 . . . . 0.0 110.651 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 37' ' ' GLY . 5.5 t -138.18 80.74 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.691 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.46 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . 26.47 -104.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.09 0 O-C-N 123.419 0.45 . . . . 0.0 112.65 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 134.03 147.48 5.65 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -140.98 164.23 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.754 0.312 . . . . 0.0 110.734 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 28.4 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.379 179.891 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -114.63 139.67 49.44 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.769 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -128.99 160.75 31.73 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.018 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.54 148.49 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 116.278 -0.419 . . . . 0.0 109.898 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -77.82 162.96 26.5 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.036 -178.514 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.554 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.4 m-70 -104.12 172.98 6.5 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.167 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.6 tt0 -151.11 173.03 14.85 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.006 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LYS . . . . . 0.404 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 88.0 tttt -155.25 132.39 10.9 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.666 0.27 . . . . 0.0 110.492 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 52.1 tp -131.96 126.66 34.58 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 121.194 0.521 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.2 m -128.17 132.83 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.767 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -135.14 131.23 36.57 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.973 0.416 . . . . 0.0 111.193 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -119.63 126.07 50.28 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.8 132.51 45.3 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.968 0.889 . . . . 0.0 112.647 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -140.77 96.44 3.02 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.592 -1.185 . . . . 0.0 109.217 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.433 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 2.1 m-20 -59.81 143.53 50.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.54 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.72 110.65 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 122.126 0.965 . . . . 0.0 108.465 -178.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.53 -92.7 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 113.452 -1.704 . . . . 0.0 113.16 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.7 t 61.66 179.33 0.12 Allowed 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' A' ' 28' ' ' LYS . 65.4 t30 -82.0 178.31 8.36 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 173.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.623 ' O ' ' O ' ' A' ' 27' ' ' ASN . 45.3 tttp -49.01 -110.98 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.774 0 CA-C-N 119.62 1.1 . . . . 0.0 110.508 176.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 59.63 92.09 0.01 OUTLIER Glycine 0 C--N 1.346 1.114 0 CA-C-O 118.089 -1.395 . . . . 0.0 114.766 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.569 ' HB1' ' HA2' ' C' ' 25' ' ' GLY . . . -138.06 142.2 40.3 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 116.645 -2.022 . . . . 0.0 109.227 174.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.9 OUTLIER -155.67 128.55 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 CA-C-N 111.603 -2.544 . . . . 0.0 109.499 -173.181 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' H' ' 35' ' ' MET . 24.4 mt -126.62 107.92 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.032 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.01 102.32 1.36 Allowed Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.021 -2.832 . . . . 0.0 106.021 177.379 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 75.7 mt -133.95 150.21 51.28 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 122.529 1.157 . . . . 0.0 112.802 -177.135 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 15.7 ttm -128.87 118.22 22.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 CA-C-N 113.048 -1.887 . . . . 0.0 107.14 177.962 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -109.01 71.03 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.066 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.158 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -37.54 -100.36 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.28 -171.76 40.68 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -122.3 135.97 60.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.01 0.433 . . . . 0.0 110.6 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.773 -179.796 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.68 144.13 42.7 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.488 ' O ' ' NE2' ' C' ' 13' ' ' HIS . 96.3 mt-10 -61.96 129.9 43.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.98 0.419 . . . . 0.0 110.969 -179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.7 132.56 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.991 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -157.08 170.12 23.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.16 0.505 . . . . 0.0 111.382 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -134.14 169.56 16.98 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -155.01 165.0 38.1 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.128 179.003 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -156.28 113.5 3.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.163 179.377 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.7 tp -118.79 121.03 39.09 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -125.56 124.3 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 110.575 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -121.79 119.02 30.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.06 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -120.19 120.0 34.87 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 126.92 35.49 Favored 'General case' 0 N--CA 1.474 0.753 0 CA-C-O 121.368 0.604 . . . . 0.0 111.684 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -153.26 145.1 23.55 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.561 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.445 ' O ' ' C ' ' B' ' 24' ' ' VAL . 18.7 t70 -146.5 115.28 6.86 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.2 178.802 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.445 ' C ' ' O ' ' B' ' 23' ' ' ASP . 2.8 t 25.75 -124.1 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.594 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.22 83.18 0.16 Allowed Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 178.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.523 ' OG ' ' NZ ' ' A' ' 28' ' ' LYS . 4.9 p -93.49 179.95 5.23 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.524 ' O ' ' NZ ' ' A' ' 28' ' ' LYS . 77.3 m-20 -59.6 -176.61 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.379 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.565 ' O ' ' CE ' ' A' ' 28' ' ' LYS . 13.8 tttp -63.22 -113.35 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.449 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.733 ' HA2' ' HB2' ' C' ' 30' ' ' ALA . . . 45.27 90.88 0.01 OUTLIER Glycine 0 N--CA 1.479 1.518 0 N-CA-C 114.064 0.386 . . . . 0.0 114.064 176.463 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.936 ' O ' ' HB3' ' C' ' 30' ' ' ALA . . . -140.03 151.39 45.4 Favored 'General case' 0 N--CA 1.425 -1.699 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 172.364 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.661 HG23 ' CG2' ' C' ' 31' ' ' ILE . 1.6 mt -137.63 105.09 3.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 118.672 -1.211 . . . . 0.0 108.262 -174.256 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.588 HD11 HD12 ' B' ' 34' ' ' LEU . 12.4 tt -126.18 123.59 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 118.984 -1.086 . . . . 0.0 112.211 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.601 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -114.9 104.94 1.42 Allowed Glycine 0 CA--C 1.503 -0.684 0 N-CA-C 106.975 -2.45 . . . . 0.0 106.975 177.023 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.624 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.0 OUTLIER -122.62 125.94 46.67 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 122.605 1.193 . . . . 0.0 110.639 -179.027 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.536 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 1.3 ttm -112.31 119.77 39.45 Favored 'General case' 0 N--CA 1.438 -1.068 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.538 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -123.31 70.95 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.875 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.635 -179.874 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -45.14 -99.06 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 178.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 138.02 165.47 10.35 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -135.41 161.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 40' ' ' VAL . . . . . 0.404 ' H ' HG13 ' B' ' 40' ' ' VAL . 7.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.644 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -116.08 144.28 44.35 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -73.35 137.1 44.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.436 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 m -140.12 177.63 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.374 -178.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.488 ' NE2' ' O ' ' B' ' 11' ' ' GLU . 77.7 m80 -78.26 128.27 33.48 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.294 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.578 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 60.0 t-80 -151.64 163.88 38.12 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.578 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 80.9 mt-30 -157.43 175.58 13.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.284 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.46 115.7 0.49 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.069 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -120.03 125.58 48.7 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.889 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -131.65 124.68 54.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD11 ' B' ' 34' ' ' LEU . 2.9 m-85 -115.43 112.85 22.92 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 175.608 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -118.6 130.4 55.86 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 -178.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.504 ' O ' ' HB1' ' D' ' 21' ' ' ALA . . . -162.13 160.48 27.31 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 115.786 1.772 . . . . 0.0 115.786 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -118.1 118.74 32.72 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 113.695 -1.593 . . . . 0.0 111.059 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.511 ' CG ' ' H ' ' C' ' 24' ' ' VAL . 47.9 t0 49.61 -123.41 1.91 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.801 0.81 . . . . 0.0 112.086 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.511 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 12.1 t -30.96 112.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 114.153 -1.385 . . . . 0.0 114.121 -176.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.569 ' HA2' ' HB1' ' A' ' 30' ' ' ALA . . . 110.92 -93.33 0.71 Allowed Glycine 0 CA--C 1.53 0.98 0 CA-C-N 113.729 -1.578 . . . . 0.0 114.091 175.811 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.494 ' OG ' ' CB ' ' C' ' 21' ' ' ALA . 0.0 OUTLIER -80.36 172.0 14.33 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.243 1.02 . . . . 0.0 113.662 -178.47 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' C' ' 28' ' ' LYS . 37.5 t30 83.08 -178.82 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 112.399 -2.182 . . . . 0.0 113.673 176.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' C' ' 27' ' ' ASN . 34.7 mtmt -38.65 -101.5 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 113.671 -1.604 . . . . 0.0 109.463 175.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 81.39 -110.58 3.18 Favored Glycine 0 CA--C 1.453 -3.819 0 CA-C-O 125.317 2.621 . . . . 0.0 116.097 176.343 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.936 ' HB3' ' O ' ' B' ' 30' ' ' ALA . . . -88.37 -130.87 0.07 Allowed 'General case' 2 N--CA 1.357 -5.093 2 N-CA-C 95.377 -5.786 . . . . 0.0 95.377 171.373 . . . . . . . . 4 3 . 1 . 006 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.684 HD11 ' CE ' ' J' ' 35' ' ' MET . 7.8 tp -87.91 135.61 25.08 Favored 'Isoleucine or valine' 1 C--N 1.232 -4.504 0 N-CA-C 114.345 1.239 . . . . 0.0 114.345 -179.109 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.488 ' O ' ' CE ' ' J' ' 35' ' ' MET . 8.1 tt -120.77 112.98 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 175.609 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -122.36 122.84 5.21 Favored Glycine 0 CA--C 1.504 -0.636 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.447 -178.546 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -143.78 146.25 32.97 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 118.694 -1.202 . . . . 0.0 112.041 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.59 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 3.4 ttm -121.11 121.95 38.98 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 113.286 -1.779 . . . . 0.0 108.704 177.665 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.93 76.9 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.106 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -83.12 104.09 2.55 Favored Glycine 0 C--N 1.361 1.957 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.08 170.68 51.39 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.9 m -140.61 162.77 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 120.815 0.341 . . . . 0.0 110.756 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.428 179.676 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -91.77 135.34 33.98 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.83 0.348 . . . . 0.0 110.542 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -83.05 131.01 35.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.311 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -140.58 139.06 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-O 121.275 0.559 . . . . 0.0 110.889 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -132.87 138.71 47.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 29.3 t-80 -144.9 166.11 26.23 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 121.408 0.623 . . . . 0.0 110.083 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.552 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 52.7 tt0 -160.23 171.26 19.52 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.39 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 16' ' ' LYS . . . . . 0.419 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 86.8 tttt -169.96 118.25 0.59 Allowed 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.452 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 tt -128.63 127.03 41.42 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -142.42 138.1 29.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.8 0.809 . . . . 0.0 113.095 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.583 ' CZ ' ' CD2' ' C' ' 34' ' ' LEU . 38.0 m-85 -113.36 117.94 33.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.036 177.403 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.566 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 22.6 t80 -127.59 124.55 38.38 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.745 0.307 . . . . 0.0 110.654 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' C' ' 21' ' ' ALA . . . -158.14 164.72 36.32 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.724 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -137.59 157.01 47.42 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.333 -1.303 . . . . 0.0 112.381 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -141.77 142.12 33.23 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.517 HG13 ' O ' ' D' ' 24' ' ' VAL . 7.3 p -90.88 112.68 25.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 122.712 1.244 . . . . 0.0 110.015 -177.09 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 41.29 86.83 0.01 OUTLIER Glycine 0 CA--C 1.525 0.696 0 CA-C-N 112.976 -1.92 . . . . 0.0 113.01 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.585 ' N ' ' O ' ' E' ' 24' ' ' VAL . 36.8 t -140.55 170.14 16.34 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 117.218 0.509 . . . . 0.0 109.71 175.892 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.52 ' O ' ' O ' ' D' ' 26' ' ' SER . 4.5 m-20 -31.55 173.79 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 178.296 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.529 ' O ' ' CB ' ' E' ' 30' ' ' ALA . 87.9 tttt -86.33 112.1 21.1 Favored 'General case' 0 C--O 1.209 -1.073 0 CA-C-N 114.477 -1.238 . . . . 0.0 107.905 171.849 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.56 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 73.24 -93.39 0.69 Allowed Glycine 1 CA--C 1.446 -4.246 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.994 179.125 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.64 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . 113.55 -150.12 0.0 OUTLIER 'General case' 0 N--CA 1.385 -3.718 1 N-CA-C 93.74 -6.393 . . . . 0.0 93.74 -168.681 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.901 HD12 ' N ' ' D' ' 31' ' ' ILE . 3.1 mp -103.42 122.51 56.08 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.134 0 C-N-CA 116.517 -2.073 . . . . 0.0 113.116 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.429 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -113.36 118.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.897 179.107 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.46 ' N ' ' CE ' ' J' ' 35' ' ' MET . . . -131.9 101.75 0.48 Allowed Glycine 0 N--CA 1.472 1.075 0 N-CA-C 106.792 -2.523 . . . . 0.0 106.792 177.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.442 HD23 ' H ' ' C' ' 34' ' ' LEU . 10.0 mt -130.64 125.63 34.52 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-O 122.187 0.994 . . . . 0.0 111.793 -175.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -105.54 117.6 34.42 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 113.983 -1.462 . . . . 0.0 107.115 177.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -114.4 80.91 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 120.874 0.368 . . . . 0.0 110.49 -177.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.73 103.27 0.54 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.72 -163.0 6.88 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.352 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.41 133.94 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 121.09 0.472 . . . . 0.0 110.673 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.061 -0.971 . . . . 0.0 110.818 -179.861 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.7 144.57 43.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.96 0.41 . . . . 0.0 110.872 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -63.38 149.59 45.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.783 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.51 142.86 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 69.7 t60 -143.18 139.9 30.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.92 0.391 . . . . 0.0 110.696 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.528 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -135.92 170.12 16.5 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.528 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 11.0 tt0 -158.19 171.13 20.77 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.991 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.475 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -150.39 113.14 4.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.33 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -118.3 115.87 25.6 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -131.56 130.14 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 7.2 m-85 -113.05 111.2 21.74 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.488 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.566 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 25.5 t80 -122.49 121.33 36.32 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 118.223 0.465 . . . . 0.0 111.292 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.34 136.88 33.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.951 0.405 . . . . 0.0 111.469 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -124.68 120.81 32.91 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.448 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 44.7 p-10 -163.75 101.77 0.9 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.602 -0.839 . . . . 0.0 113.251 177.828 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.588 HG12 ' N ' ' E' ' 25' ' ' GLY . 21.2 t -59.49 166.74 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.164 -0.926 . . . . 0.0 112.353 177.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.588 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 87.9 81.62 1.24 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 115.336 0.894 . . . . 0.0 115.336 174.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -51.15 161.1 0.44 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 120.565 0.221 . . . . 0.0 110.795 175.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.522 ' ND2' ' H ' ' E' ' 28' ' ' LYS . 7.3 t-20 -148.11 175.78 10.74 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.825 175.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.522 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 67.6 mmtt -9.4 -103.8 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 178.297 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -150.77 96.39 0.17 Allowed Glycine 0 C--N 1.349 1.273 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.673 ' H ' HD22 ' F' ' 27' ' ' ASN . . . -67.22 176.29 2.28 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 117.99 0.895 . . . . 0.0 111.095 178.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.601 ' CG2' HD13 ' F' ' 31' ' ' ILE . 0.0 OUTLIER -144.37 130.96 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.986 -179.601 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.655 ' CG1' HD11 ' E' ' 34' ' ' LEU . 0.1 OUTLIER -130.61 122.37 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 121.084 0.469 . . . . 0.0 110.959 -178.255 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.81 124.39 5.37 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.681 HD12 ' N ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -126.94 128.27 46.16 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 120.891 0.377 . . . . 0.0 111.006 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.8 tpp -120.19 120.2 35.46 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.918 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' E' ' 37' ' ' GLY . 5.8 t -134.06 83.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 121.36 -0.136 . . . . 0.0 111.131 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -19.58 -94.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.162 0 O-C-N 123.461 0.475 . . . . 0.0 112.753 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.67 -167.58 35.26 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 p -138.76 145.67 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 120.802 0.334 . . . . 0.0 110.393 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.043 -0.979 . . . . 0.0 110.515 179.78 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -85.44 134.6 34.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.874 0.369 . . . . 0.0 110.696 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -138.39 131.01 29.23 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.202 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m -141.65 173.29 8.58 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 121.237 0.541 . . . . 0.0 110.965 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -80.45 144.03 32.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.425 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.544 ' O ' ' NE2' ' F' ' 15' ' ' GLN . 34.6 m80 -134.03 172.21 13.14 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.544 ' NE2' ' O ' ' F' ' 14' ' ' HIS . 99.3 mm-40 -144.54 178.3 8.05 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.41 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -169.23 116.19 0.61 Allowed 'General case' 0 CA--C 1.531 0.215 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.404 HD12 ' N ' ' F' ' 17' ' ' LEU . 2.0 mp -126.82 126.98 44.29 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.081 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.73 129.89 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 121.572 0.701 . . . . 0.0 112.247 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' E' ' 34' ' ' LEU . 4.0 m-85 -114.75 113.39 24.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.132 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.486 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 35.4 t80 -127.06 120.98 30.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.502 0.668 . . . . 0.0 111.387 -179.08 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.1 135.66 46.6 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.094 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tp10 -78.02 120.79 23.36 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.231 -0.588 . . . . 0.0 110.215 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' F' ' 24' ' ' VAL . 19.7 t70 -169.0 121.71 0.79 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.655 -0.418 . . . . 0.0 112.045 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' F' ' 23' ' ' ASP . 4.5 m -63.06 -121.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.519 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -64.39 -86.05 0.06 OUTLIER Glycine 0 CA--C 1.519 0.304 0 N-CA-C 105.736 -2.946 . . . . 0.0 105.736 178.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.548 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 2.0 t 157.53 172.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 122.316 1.055 . . . . 0.0 112.087 174.176 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.673 HD22 ' H ' ' E' ' 30' ' ' ALA . 43.3 m-20 -44.69 174.76 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 112.947 -1.933 . . . . 0.0 111.298 176.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -70.28 111.38 5.84 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.25 -92.94 0.87 Allowed Glycine 0 C--N 1.313 -0.725 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' F' ' 27' ' ' ASN . . . 82.17 163.72 0.14 Allowed 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 100.451 -3.907 . . . . 0.0 100.451 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.828 HD12 ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -148.11 128.16 4.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 121.691 2.041 . . . . 0.0 110.653 179.297 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tt -123.95 136.82 59.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.602 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.77 117.93 2.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.2 tt -124.15 124.18 41.92 Favored 'General case' 0 N--CA 1.47 0.567 0 O-C-N 122.689 -0.301 . . . . 0.0 110.238 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 42.2 mmm -123.27 130.38 52.66 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 120.776 0.322 . . . . 0.0 110.745 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.16 81.02 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 CA-C-N 116.101 -0.499 . . . . 0.0 112.323 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -43.25 100.83 0.02 OUTLIER Glycine 0 C--N 1.341 0.839 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.854 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -128.77 163.75 22.1 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.21 135.19 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.838 0.352 . . . . 0.0 110.121 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.486 -179.994 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -114.53 145.61 41.72 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.231 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -132.21 143.26 49.82 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.89 132.82 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 121.117 0.484 . . . . 0.0 110.075 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 39.7 p-80 -109.24 -169.64 1.52 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.25 -179.633 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.485 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 33.9 p80 -77.46 171.33 15.07 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' H ' ' G' ' 16' ' ' LYS . 48.5 tt0 -155.92 172.37 18.49 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.395 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 16' ' ' LYS . . . . . 0.403 ' H ' ' HG2' ' G' ' 15' ' ' GLN . 71.7 mmtt -136.56 132.56 35.34 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.583 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -135.74 111.07 9.06 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.68 133.1 65.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -139.64 148.74 42.86 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -124.71 132.92 53.35 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 139.52 45.56 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.598 0.713 . . . . 0.0 112.104 -178.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -115.96 167.09 11.27 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.568 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.664 ' CG ' ' H ' ' H' ' 25' ' ' GLY . 44.1 t0 -46.3 142.96 2.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.454 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' G' ' 23' ' ' ASP . 20.0 t 93.97 111.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 O-C-N 124.565 1.166 . . . . 0.0 111.48 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 49.35 91.64 0.01 OUTLIER Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.54 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 1.1 p 159.04 -179.57 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 122.187 0.994 . . . . 0.0 110.603 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' G' ' 28' ' ' LYS . 90.5 m-20 -58.93 172.05 0.6 Allowed 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 113.408 -1.724 . . . . 0.0 112.323 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.533 ' NZ ' ' OD2' ' I' ' 23' ' ' ASP . 84.5 tttt 52.75 105.53 0.01 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.13 -179.703 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.727 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . 107.51 103.71 2.89 Favored Glycine 1 CA--C 1.427 -5.413 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.102 -174.478 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.727 ' HB3' ' O ' ' G' ' 29' ' ' GLY . . . 87.66 -148.34 0.01 OUTLIER 'General case' 0 N--CA 1.384 -3.73 0 N-CA-C 103.138 -2.912 . . . . 0.0 103.138 -169.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.884 ' H ' HD12 ' G' ' 31' ' ' ILE 0.287 0.0 OUTLIER -109.54 114.79 47.93 Favored 'Isoleucine or valine' 0 C--N 1.252 -3.638 0 N-CA-C 118.043 2.608 . . . . 0.0 118.043 -174.012 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.543 HG23 ' O ' ' G' ' 32' ' ' ILE . 0.9 OUTLIER -112.36 116.37 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 173.421 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.51 121.3 4.33 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 49.0 mt -126.52 134.67 50.83 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 122.889 1.328 . . . . 0.0 111.302 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 20.1 ttt -98.02 110.91 23.4 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 112.494 -2.139 . . . . 0.0 107.081 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.44 64.77 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.517 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.919 -178.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.11 -106.45 0.41 Allowed Glycine 0 C--N 1.367 2.296 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -161.85 165.11 35.62 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 66.7 t -127.93 134.26 65.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.833 0.349 . . . . 0.0 110.195 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.634 -179.936 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.17 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -83.2 137.69 33.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.605 0.24 . . . . 0.0 110.368 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -68.91 137.29 53.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.718 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 24.4 m -136.23 160.1 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.945 0.402 . . . . 0.0 110.932 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -128.71 -175.42 3.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.208 179.627 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -80.61 168.52 18.79 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 122.153 0.978 . . . . 0.0 111.532 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -153.11 177.81 10.41 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.063 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -145.44 143.44 30.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.311 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -135.24 117.04 15.09 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.423 HG11 ' CE2' ' H' ' 20' ' ' PHE . 70.2 t -126.87 134.03 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-O 120.872 0.368 . . . . 0.0 110.505 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.415 ' CZ ' ' HB2' ' H' ' 21' ' ' ALA . 45.7 t80 -124.74 122.71 38.24 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.392 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.423 ' CE2' HG11 ' H' ' 18' ' ' VAL . 61.0 m-85 -115.2 125.66 53.65 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.155 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.415 ' HB2' ' CZ ' ' H' ' 19' ' ' PHE . . . -116.67 120.96 40.27 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-N 118.222 0.464 . . . . 0.0 110.911 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' H' ' 23' ' ' ASP . 81.6 tt0 -123.27 154.98 38.09 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.756 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.612 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 54.6 t0 49.38 114.22 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 CA-C-O 121.05 0.452 . . . . 0.0 110.715 -178.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' H' ' 25' ' ' GLY . 42.8 t -126.8 121.28 57.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.664 ' H ' ' CG ' ' G' ' 23' ' ' ASP . . . -28.21 -87.11 0.01 OUTLIER Glycine 0 N--CA 1.469 0.858 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 176.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.3 t -128.58 170.61 13.02 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.705 -1.221 . . . . 0.0 107.705 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' H' ' 26' ' ' SER . 62.2 t30 33.95 179.47 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 122.138 0.97 . . . . 0.0 113.348 -178.301 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.823 ' NZ ' ' HB1' ' J' ' 21' ' ' ALA . 84.0 tttt -119.98 -105.45 0.39 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.636 -176.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.88 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . -64.62 98.62 0.29 Allowed Glycine 1 CA--C 1.428 -5.35 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -178.476 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.601 ' C ' HD12 ' H' ' 31' ' ' ILE . . . -82.23 -136.58 0.04 OUTLIER 'General case' 0 N--CA 1.397 -3.086 1 N-CA-C 95.715 -5.661 . . . . 0.0 95.715 174.038 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.965 HD12 ' N ' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -112.29 119.32 59.93 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 116.236 -2.186 . . . . 0.0 112.291 -178.403 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.692 HG23 HG13 ' I' ' 32' ' ' ILE . 5.5 tt -117.49 120.03 63.56 Favored 'Isoleucine or valine' 0 C--N 1.361 1.106 0 CA-C-N 114.34 -1.3 . . . . 0.0 110.445 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.536 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -114.77 116.9 3.89 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.518 HD22 ' O ' ' H' ' 33' ' ' GLY . 0.9 OUTLIER -124.18 125.84 45.13 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.681 0.753 . . . . 0.0 111.825 -179.367 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 7.3 ttt -105.92 110.03 22.18 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 114.37 -1.286 . . . . 0.0 108.577 178.049 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.43 HG11 ' CD2' ' J' ' 17' ' ' LEU . 0.0 OUTLIER -131.53 71.26 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.12 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.53 -97.13 0.03 OUTLIER Glycine 0 C--N 1.359 1.822 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.21 -166.26 38.68 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -124.39 139.9 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.869 0.366 . . . . 0.0 111.09 -178.694 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.597 179.831 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -145.48 157.16 44.05 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -133.59 138.81 46.18 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.914 0.388 . . . . 0.0 110.844 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.48 HG22 ' O ' ' J' ' 11' ' ' GLU . 22.3 t -128.11 129.55 69.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.7 p80 -175.69 113.86 0.13 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.148 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 26.8 m-70 -82.19 165.9 20.09 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.001 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -148.34 173.01 13.5 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.279 0.562 . . . . 0.0 110.985 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -154.96 127.56 7.98 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.629 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.567 HD23 ' N ' ' I' ' 18' ' ' VAL . 0.9 OUTLIER -129.2 119.56 24.27 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.619 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.567 ' N ' HD23 ' I' ' 17' ' ' LEU . 48.1 t -125.94 128.94 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.934 0.397 . . . . 0.0 111.754 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -113.18 103.8 11.71 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -114.84 130.05 56.81 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 111.751 0.278 . . . . 0.0 111.751 -177.564 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.0 135.82 29.68 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 121.277 0.561 . . . . 0.0 111.402 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 tm-20 -148.07 118.88 7.57 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.587 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.612 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 16.7 m-20 -158.64 110.5 2.2 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.828 0.823 . . . . 0.0 112.224 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 50.5 t -48.16 133.97 5.36 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.497 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 99.3 86.03 1.87 Allowed Glycine 0 CA--C 1.54 1.636 0 N-CA-C 120.316 2.886 . . . . 0.0 120.316 171.948 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.4 p 153.01 169.87 0.01 OUTLIER 'General case' 0 C--N 1.347 0.498 0 CA-C-O 122.635 1.207 . . . . 0.0 112.346 169.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' I' ' 28' ' ' LYS . 1.4 m120 -59.03 177.63 0.15 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.343 -1.299 . . . . 0.0 111.363 177.679 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.505 ' O ' ' O ' ' I' ' 27' ' ' ASN . 63.3 tttt -43.64 -100.86 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.223 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.027 172.731 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.761 ' O ' ' O ' ' I' ' 30' ' ' ALA . . . -170.59 106.33 0.24 Allowed Glycine 1 CA--C 1.42 -5.858 0 C-N-CA 119.061 -1.542 . . . . 0.0 116.527 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.88 ' HB3' ' O ' ' H' ' 29' ' ' GLY 0.29 . . -0.46 -133.45 0.0 OUTLIER 'General case' 0 C--N 1.366 1.286 0 O-C-N 127.066 2.274 . . . . 0.0 108.333 170.579 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.859 HD12 ' C ' ' I' ' 30' ' ' ALA . 3.9 mp -122.52 132.82 70.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 117.269 2.322 . . . . 0.0 117.269 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.692 HG13 HG23 ' H' ' 32' ' ' ILE . 17.9 tt -116.27 120.8 65.99 Favored 'Isoleucine or valine' 0 C--N 1.371 1.531 0 CA-C-N 114.44 -1.255 . . . . 0.0 110.58 177.698 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.475 ' CA ' ' SD ' ' C' ' 35' ' ' MET . . . -102.77 112.19 4.21 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 107.157 -2.377 . . . . 0.0 107.157 177.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.859 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 32.8 tp -113.26 121.18 43.65 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-N 115.36 -0.42 . . . . 0.0 111.419 -177.339 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.513 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 19.1 ttt -118.69 112.56 19.94 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 176.019 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.594 HG11 HD13 ' K' ' 17' ' ' LEU . 0.1 OUTLIER -126.31 71.45 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.208 0 CA-C-N 117.729 0.24 . . . . 0.0 111.273 -178.126 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -50.11 -97.97 0.01 OUTLIER Glycine 0 C--N 1.353 1.5 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.405 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.14 -162.65 28.63 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.05 138.67 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 120.894 0.378 . . . . 0.0 110.703 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.481 179.679 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -108.95 134.09 52.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.95 0.405 . . . . 0.0 110.708 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 11' ' ' GLU . . . . . 0.48 ' O ' HG22 ' I' ' 12' ' ' VAL . 98.2 mt-10 -143.35 167.53 21.94 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.192 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.568 HG12 ' N ' ' J' ' 13' ' ' HIS . 60.0 t -127.66 164.98 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.058 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.568 ' N ' HG12 ' J' ' 12' ' ' VAL . 2.9 p80 -66.58 134.11 51.69 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.196 0.522 . . . . 0.0 111.841 -178.292 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.436 ' NE2' ' O ' ' K' ' 12' ' ' VAL . 52.7 m170 -112.83 172.17 7.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -141.55 176.44 8.88 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.333 0.587 . . . . 0.0 111.479 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -174.01 124.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.105 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG11 ' H' ' 36' ' ' VAL . 4.0 mp -133.85 132.35 40.28 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-O 121.303 0.573 . . . . 0.0 110.973 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.68 131.12 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.015 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.649 ' CD1' ' CZ ' ' K' ' 19' ' ' PHE . 20.1 m-85 -114.2 111.17 21.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.097 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -121.59 120.49 34.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.909 0.322 . . . . 0.0 110.155 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 21' ' ' ALA . . . . . 0.823 ' HB1' ' NZ ' ' H' ' 28' ' ' LYS . . . -139.51 132.64 29.67 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.136 0.494 . . . . 0.0 110.986 -179.603 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.478 ' C ' ' OD1' ' J' ' 23' ' ' ASP . 73.6 mt-10 -144.78 127.45 16.18 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 119.84 -0.744 . . . . 0.0 112.472 -179.277 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' I' ' 23' ' ' ASP . 3.9 m-20 -159.68 110.98 2.0 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 118.938 -1.105 . . . . 0.0 113.353 176.741 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.0 t -37.8 128.65 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.464 172.32 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.453 ' HA3' ' O ' ' I' ' 26' ' ' SER . . . 168.85 -83.64 0.09 OUTLIER Glycine 0 N--CA 1.467 0.709 0 C-N-CA 117.108 -2.472 . . . . 0.0 116.087 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.582 ' O ' ' O ' ' J' ' 27' ' ' ASN . 5.0 p -170.39 -178.55 2.75 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 118.825 -1.15 . . . . 0.0 113.081 -175.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.584 ' CG ' ' H ' ' J' ' 28' ' ' LYS . 63.6 t30 27.13 177.37 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 CA-C-N 112.113 -2.312 . . . . 0.0 115.565 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.584 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 96.7 mttt -119.71 -106.47 0.38 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 113.307 -1.769 . . . . 0.0 110.947 -176.775 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.93 ' C ' ' HB1' ' K' ' 30' ' ' ALA . . . -66.13 96.6 0.28 Allowed Glycine 0 CA--C 1.48 -2.141 0 CA-C-O 123.654 1.697 . . . . 0.0 112.643 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.628 ' O ' ' C ' ' J' ' 29' ' ' GLY . . . -80.38 -145.12 0.05 OUTLIER 'General case' 0 C--N 1.293 -1.885 1 N-CA-C 93.921 -6.326 . . . . 0.0 93.921 170.407 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.567 ' H ' HG13 ' I' ' 31' ' ' ILE . 4.8 mm -100.89 115.34 42.32 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 1 CA-C-N 127.987 4.903 . . . . 0.0 111.035 -179.249 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.628 HG22 HG23 ' K' ' 32' ' ' ILE . 0.6 OUTLIER -112.76 110.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.366 1.307 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.684 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.16 106.27 2.64 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.817 HD13 ' CE1' ' L' ' 19' ' ' PHE . 4.4 mt -104.78 106.87 17.55 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.684 ' CE ' HD11 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -106.09 113.2 26.59 Favored 'General case' 0 N--CA 1.444 -0.754 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 178.819 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.451 ' O ' HG23 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.39 79.6 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.085 -177.661 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.55 103.48 1.63 Allowed Glycine 0 C--N 1.349 1.258 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 177.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.34 145.08 16.7 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 63.0 t -136.85 139.42 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 89.5 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.189 179.365 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -107.41 140.28 40.59 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.781 0.324 . . . . 0.0 110.614 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -56.73 137.88 53.75 Favored 'General case' 0 C--O 1.231 0.089 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.289 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.436 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 8.8 m -150.58 145.75 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-O 121.408 0.623 . . . . 0.0 111.98 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.7 OUTLIER -119.3 116.13 25.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.202 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' L' ' 13' ' ' HIS . 70.6 t60 -122.61 165.99 15.58 Favored 'General case' 0 CA--C 1.509 -0.616 0 CA-C-O 121.403 0.621 . . . . 0.0 110.025 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.453 ' N ' ' CG ' ' K' ' 14' ' ' HIS . 19.5 tt0 -163.39 166.95 22.32 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.453 178.386 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' K' ' 15' ' ' GLN . 98.9 mttt -155.53 129.96 9.0 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.594 HD13 HG11 ' I' ' 36' ' ' VAL . 26.9 tp -124.51 120.53 32.27 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.518 HG11 ' CE2' ' K' ' 20' ' ' PHE . 57.9 t -132.94 127.03 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.935 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.859 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 6.8 m-85 -117.28 112.81 21.27 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.033 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.518 ' CE2' HG11 ' K' ' 18' ' ' VAL . 47.6 m-85 -108.12 118.57 37.1 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 178.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 132.86 36.93 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.772 0.714 . . . . 0.0 112.775 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -113.58 122.77 48.23 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.465 178.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -178.73 110.87 0.06 Allowed 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.244 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 m -107.05 -123.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 31.49 85.51 0.01 OUTLIER Glycine 0 C--N 1.342 0.9 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.009 -178.127 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 24.1 p -50.1 158.82 0.5 Allowed 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.398 0.618 . . . . 0.0 111.754 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.531 ' O ' ' C ' ' K' ' 28' ' ' LYS . 13.7 p-10 -148.06 176.92 9.8 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.881 -1.054 . . . . 0.0 109.137 176.952 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.531 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.8 mttt -9.16 -103.27 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.664 0.603 . . . . 0.0 111.278 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.73 97.0 0.18 Allowed Glycine 0 CA--C 1.5 -0.896 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 176.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.93 ' HB1' ' C ' ' J' ' 29' ' ' GLY . . . -66.2 172.17 4.09 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 177.423 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.661 ' N ' ' O ' ' J' ' 29' ' ' GLY . 0.4 OUTLIER -147.58 123.46 2.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 CA-C-N 120.996 1.726 . . . . 0.0 111.858 -175.782 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.628 HG23 HG22 ' J' ' 32' ' ' ILE . 91.1 mt -125.99 131.33 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.717 -1.128 . . . . 0.0 112.475 -178.348 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.71 119.96 3.17 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.626 HD23 ' N ' ' K' ' 35' ' ' MET . 5.5 tt -121.84 120.53 34.81 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 120.629 0.252 . . . . 0.0 110.765 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.626 ' N ' HD23 ' K' ' 34' ' ' LEU . 5.6 ppp? -130.49 130.24 43.94 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.436 0.636 . . . . 0.0 111.058 178.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.534 ' O ' ' C ' ' K' ' 37' ' ' GLY . 3.2 p -158.11 79.98 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.869 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.534 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -1.37 -100.89 0.0 OUTLIER Glycine 0 C--N 1.348 1.214 0 O-C-N 123.311 0.382 . . . . 0.0 113.615 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.45 -172.5 41.73 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m -133.86 161.56 40.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.306 179.901 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -119.69 140.58 50.45 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-O 120.855 0.36 . . . . 0.0 110.904 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -126.04 134.21 51.49 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -135.66 161.86 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.411 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' K' ' 14' ' ' HIS . 49.1 t-80 -90.45 176.68 6.62 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.182 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 27.5 t-80 -76.0 176.82 7.57 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.372 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 15' ' ' GLN . . . . . 0.577 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 99.2 mm-40 -121.48 178.04 4.97 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.968 0.413 . . . . 0.0 111.004 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -165.98 113.48 0.92 Allowed 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.96 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 18.3 mt -128.71 124.92 36.85 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -140.1 135.03 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.817 ' CE1' HD13 ' J' ' 34' ' ' LEU . 7.3 m-85 -116.94 108.53 15.91 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 177.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -116.0 123.09 47.13 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-O 121.24 0.543 . . . . 0.0 110.867 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.68 134.01 45.47 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 81.0 tt0 -81.18 92.87 6.37 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.964 -0.694 . . . . 0.0 111.03 -178.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.585 ' O ' ' O ' ' L' ' 24' ' ' VAL . 70.7 m-20 -160.94 133.14 5.95 Favored 'General case' 0 C--O 1.226 -0.159 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.182 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.585 ' O ' ' O ' ' L' ' 23' ' ' ASP . 10.6 t -32.34 -110.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 124.003 0.815 . . . . 0.0 111.376 176.475 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -158.89 92.27 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.476 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 23.3 p -47.3 152.68 0.57 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.761 0.791 . . . . 0.0 111.443 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.488 ' O ' ' C ' ' L' ' 28' ' ' LYS . 31.8 m120 -157.42 -174.74 5.03 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.135 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 12.74 103.54 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 177.079 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.56 -101.48 0.81 Allowed Glycine 0 N--CA 1.47 0.961 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.5 171.48 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 117.287 0.543 . . . . 0.0 110.152 -178.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.652 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -141.42 148.56 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.854 -177.977 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.481 HG23 ' O ' ' L' ' 32' ' ' ILE . 18.7 tt -133.53 126.75 52.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-N 114.018 -1.447 . . . . 0.0 109.191 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.17 119.44 4.38 Favored Glycine 0 N--CA 1.466 0.657 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 16.6 tp -126.09 120.75 31.01 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.857 0.328 . . . . 0.0 110.179 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.528 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.7 ppp? -132.86 133.06 42.81 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.872 0.844 . . . . 0.0 111.16 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 23.1 t -142.98 82.61 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.412 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' K' ' 37' ' ' GLY . . . -66.26 101.22 0.59 Allowed Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.31 168.58 35.93 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -129.53 160.03 40.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.884 0.373 . . . . 0.0 110.507 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.425 179.983 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -83.96 139.25 32.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.7 0.286 . . . . 0.0 110.599 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -148.44 137.9 22.03 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-O 121.128 0.49 . . . . 0.0 111.337 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 13' ' ' HIS . 45.8 t -133.3 158.42 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.409 ' N ' HG12 ' A' ' 12' ' ' VAL . 79.2 m80 -142.44 134.28 27.01 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 120.539 -0.464 . . . . 0.0 111.384 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -155.11 166.87 32.22 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.368 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -155.83 175.73 13.55 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.898 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -153.37 115.57 4.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.926 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.92 121.63 23.13 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.06 0.457 . . . . 0.0 110.67 178.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.54 131.38 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 115.778 -0.647 . . . . 0.0 109.713 179.371 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -126.56 130.37 50.41 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.826 0.346 . . . . 0.0 110.627 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -126.24 126.92 44.81 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 133.03 46.65 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 121.017 0.437 . . . . 0.0 111.87 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -150.53 117.33 5.85 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.187 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -128.01 120.16 26.94 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.485 0.659 . . . . 0.0 111.928 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 m -63.81 -121.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.19 178.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.51 -89.44 0.04 OUTLIER Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.62 -0.718 . . . . 0.0 113.353 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.782 ' O ' ' O ' ' A' ' 27' ' ' ASN . 2.1 t 174.04 -172.98 0.06 Allowed 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -178.952 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.782 ' O ' ' O ' ' A' ' 26' ' ' SER . 67.5 m-80 -10.33 159.71 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 O-C-N 125.032 1.458 . . . . 0.0 113.873 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.515 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 18.3 pttp 178.99 101.98 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 178.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.24 101.39 0.74 Allowed Glycine 0 CA--C 1.503 -0.674 0 N-CA-C 106.849 -2.5 . . . . 0.0 106.849 176.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.96 153.94 23.63 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 117.117 -1.833 . . . . 0.0 110.535 -175.957 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.407 HG22 ' HE3' ' H' ' 35' ' ' MET . 0.4 OUTLIER -146.34 115.59 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.498 -173.873 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 32' ' ' ILE . 11.6 tt -127.55 108.78 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.24 122.61 4.69 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.14 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.656 ' O ' HD12 ' B' ' 34' ' ' LEU . 0.9 OUTLIER -178.13 -162.58 0.06 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 122.349 1.071 . . . . 0.0 111.228 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.462 ' SD ' ' HB ' ' H' ' 31' ' ' ILE . 1.1 ttp -149.89 157.6 43.34 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -111.71 75.68 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 C-N-CA 120.507 -0.477 . . . . 0.0 109.811 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.5 103.42 3.0 Favored Glycine 0 C--N 1.357 1.745 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.46 -172.1 47.54 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -132.93 161.68 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.048 0.451 . . . . 0.0 110.864 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.865 -1.064 . . . . 0.0 110.662 -179.951 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -147.8 157.82 43.73 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.686 0.279 . . . . 0.0 110.682 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 150.68 31.32 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.314 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.418 HG22 ' N ' ' B' ' 13' ' ' HIS . 3.0 p -137.47 155.84 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.794 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.418 ' N ' HG22 ' B' ' 12' ' ' VAL . 5.7 m-70 -128.31 142.46 51.13 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -143.2 169.56 17.38 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -162.2 166.63 25.3 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.762 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -154.48 111.43 3.34 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 179.243 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 73.2 mt -121.84 117.49 26.65 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -131.13 129.03 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.338 0.59 . . . . 0.0 112.034 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -122.28 127.37 49.8 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.124 178.735 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.3 t80 -130.65 125.5 34.17 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.708 0.289 . . . . 0.0 110.949 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.97 129.71 42.47 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.868 0.366 . . . . 0.0 110.504 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -157.76 135.59 10.68 Favored 'General case' 0 C--O 1.226 -0.17 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.523 ' O ' ' O ' ' B' ' 24' ' ' VAL . 0.5 OUTLIER -171.24 121.53 0.53 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.724 -0.391 . . . . 0.0 111.218 -179.892 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' B' ' 23' ' ' ASP . 3.0 t -49.18 -122.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.229 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 -90.57 0.81 Allowed Glycine 0 CA--C 1.532 1.096 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.857 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.749 ' O ' ' O ' ' B' ' 27' ' ' ASN . 2.8 p 174.39 -171.71 0.05 Allowed 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 117.362 0.581 . . . . 0.0 109.588 -177.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.749 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.2 m-80 -10.04 160.53 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 O-C-N 125.406 1.691 . . . . 0.0 114.513 179.532 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.487 ' HE2' ' HB2' ' B' ' 30' ' ' ALA . 16.2 tttt 179.54 101.63 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 121.288 0.566 . . . . 0.0 111.607 178.817 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.2 102.03 0.88 Allowed Glycine 0 CA--C 1.487 -1.699 0 N-CA-C 106.605 -2.598 . . . . 0.0 106.605 174.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.487 ' HB2' ' HE2' ' B' ' 28' ' ' LYS . . . -91.08 149.14 21.94 Favored 'General case' 0 CA--C 1.498 -1.046 0 C-N-CA 115.357 -2.537 . . . . 0.0 106.434 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.614 HG23 HD12 ' C' ' 31' ' ' ILE . 2.6 mt -148.74 106.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 114.284 -1.326 . . . . 0.0 107.836 -174.336 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.426 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.7 tt -116.15 123.18 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-O 121.638 0.732 . . . . 0.0 110.955 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.727 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -116.53 115.31 3.27 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 106.008 -2.837 . . . . 0.0 106.008 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.656 HD12 ' O ' ' A' ' 34' ' ' LEU . 5.9 tp -144.12 144.33 31.54 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 -175.649 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.644 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 32.3 ttp -129.18 129.63 45.32 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.159 -1.382 . . . . 0.0 108.411 175.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -111.89 78.2 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.017 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.247 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.632 ' HA3' HG21 ' H' ' 31' ' ' ILE . . . -74.36 104.59 1.69 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.23 -179.14 36.84 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.751 -178.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -141.37 149.87 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.675 -179.851 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -110.2 128.25 55.39 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.62 0.248 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.477 ' CD ' ' NE2' ' C' ' 13' ' ' HIS . 82.6 tt0 -133.13 148.22 52.11 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.302 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.68 133.02 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.944 0.402 . . . . 0.0 110.449 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.477 ' NE2' ' CD ' ' C' ' 11' ' ' GLU . 60.2 m80 -128.87 138.73 52.2 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.363 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 82.8 t60 -155.37 164.85 38.18 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 30.6 mt-30 -155.44 -179.36 8.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.308 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.05 112.97 1.01 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.53 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 67.8 tp -120.28 121.84 39.56 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.804 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -132.69 126.34 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -179.101 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -118.46 123.8 46.05 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 177.179 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.628 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 43.5 t80 -130.09 127.85 40.68 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.764 0.316 . . . . 0.0 111.373 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.48 138.97 45.14 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.299 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -143.82 151.81 40.4 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.408 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.443 ' CG ' ' H ' ' C' ' 24' ' ' VAL . 16.7 t70 -151.72 -132.91 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.673 178.79 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' C' ' 26' ' ' SER . 63.2 t -122.91 112.02 32.26 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.454 ' C ' ' O ' ' C' ' 24' ' ' VAL . . . -28.95 89.5 0.01 OUTLIER Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 175.005 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.773 ' O ' ' O ' ' C' ' 27' ' ' ASN . 46.9 t -151.91 -170.8 3.75 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 -177.044 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.773 ' O ' ' O ' ' C' ' 26' ' ' SER . 28.7 t-20 -21.53 170.54 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.237 0 O-C-N 124.829 1.331 . . . . 0.0 113.622 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.454 ' N ' ' CG ' ' C' ' 27' ' ' ASN . 57.9 tttp -101.34 -113.49 0.19 Allowed 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 41.65 90.8 0.01 OUTLIER Glycine 0 C--N 1.338 0.692 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 179.645 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.54 153.64 44.99 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 173.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.614 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -150.3 116.88 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 118.979 -1.089 . . . . 0.0 111.305 -172.367 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.732 HD11 HD12 ' D' ' 32' ' ' ILE . 1.6 pt -119.15 115.88 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 176.183 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.681 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -126.14 118.45 3.13 Favored Glycine 0 CA--C 1.501 -0.836 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -161.56 169.31 21.95 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 118.072 -1.451 . . . . 0.0 111.968 -177.513 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.419 ' HE3' ' O ' ' I' ' 32' ' ' ILE . 5.6 tmm? -141.37 137.26 32.18 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 113.538 -1.665 . . . . 0.0 109.654 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.04 73.09 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.564 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.75 103.84 3.02 Favored Glycine 0 C--N 1.37 2.437 0 N-CA-C 111.419 -0.673 . . . . 0.0 111.419 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.58 154.58 18.63 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -135.38 163.29 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.395 -179.889 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -108.84 131.73 54.71 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.874 0.369 . . . . 0.0 110.507 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -133.49 131.09 39.42 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.26 0.552 . . . . 0.0 111.024 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' E' ' 12' ' ' VAL . 53.7 t -120.21 135.41 60.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' E' ' 13' ' ' HIS . 23.1 p80 -155.01 158.84 39.76 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 119.035 -1.066 . . . . 0.0 112.841 -178.805 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.512 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 51.5 m-70 -147.27 169.62 19.02 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.016 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.512 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 97.4 mm-40 -148.9 168.82 22.0 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.154 179.288 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -153.31 106.97 3.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.995 179.024 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 51.7 mt -118.5 116.79 27.39 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.27 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -130.24 128.16 63.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.112 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.55 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 47.1 m-85 -121.02 111.8 17.93 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 177.004 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -120.21 132.1 55.23 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 118.251 0.478 . . . . 0.0 111.919 -178.587 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 122.31 24.79 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.51 0.671 . . . . 0.0 111.176 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.447 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 80.9 tt0 -111.18 89.82 3.16 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.071 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.461 ' O ' ' C ' ' D' ' 24' ' ' VAL . 4.9 p30 154.48 124.6 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.446 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.461 ' C ' ' O ' ' D' ' 23' ' ' ASP . 18.4 m -29.44 111.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 O-C-N 123.559 0.537 . . . . 0.0 111.499 179.107 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.703 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . -177.45 -91.1 0.08 OUTLIER Glycine 0 C--O 1.215 -1.059 0 C-N-CA 118.568 -1.777 . . . . 0.0 114.871 179.405 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.435 ' O ' ' CB ' ' D' ' 27' ' ' ASN . 80.9 p -72.84 168.94 17.85 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 118.884 1.342 . . . . 0.0 113.697 -175.179 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.658 ' ND2' ' HB2' ' F' ' 21' ' ' ALA . 5.5 t-20 84.42 -178.32 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.234 177.011 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.497 ' HA ' HD11 ' E' ' 32' ' ' ILE . 85.0 tttt -38.05 106.15 0.05 OUTLIER 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 175.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.664 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . 109.25 102.21 2.74 Favored Glycine 0 CA--C 1.466 -2.997 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.07 -171.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.753 ' C ' HD12 ' D' ' 31' ' ' ILE . . . 86.99 -160.92 0.01 OUTLIER 'General case' 0 N--CA 1.412 -2.33 0 N-CA-C 100.355 -3.943 . . . . 0.0 100.355 -169.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.753 HD12 ' C ' ' D' ' 30' ' ' ALA . 4.6 mp -131.99 134.58 59.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 115.074 -2.65 . . . . 0.0 117.751 -174.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.732 HD12 HD11 ' C' ' 32' ' ' ILE . 11.9 tt -126.77 123.91 63.83 Favored 'Isoleucine or valine' 0 C--N 1.367 1.334 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.459 177.698 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.655 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -124.18 106.22 0.94 Allowed Glycine 0 C--O 1.237 0.29 0 N-CA-C 106.882 -2.487 . . . . 0.0 106.882 176.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.553 HD23 ' C ' ' D' ' 34' ' ' LEU . 10.0 tt -126.72 132.95 51.0 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-O 122.039 0.923 . . . . 0.0 112.431 -177.511 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.541 ' SD ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -122.1 126.66 48.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 114.32 -1.309 . . . . 0.0 109.865 178.887 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.498 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.3 79.77 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.49 -178.182 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -25.8 -95.74 0.01 OUTLIER Glycine 0 C--N 1.358 1.759 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.89 -162.03 29.25 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.583 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 40' ' ' VAL . 56.0 t -115.2 136.06 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.932 0.396 . . . . 0.0 110.266 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 39' ' ' VAL . 70.9 t . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.445 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -109.11 136.13 49.11 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 110.463 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.521 ' OE2' ' NE2' ' E' ' 13' ' ' HIS . 81.4 tt0 -64.69 136.27 56.77 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.645 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' D' ' 12' ' ' VAL . 9.4 p -131.91 134.6 59.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-O 121.959 0.885 . . . . 0.0 112.596 -179.689 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' D' ' 13' ' ' HIS . 46.8 m170 -121.17 138.88 54.0 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 114.066 -1.425 . . . . 0.0 108.559 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.572 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.4 t60 -152.47 171.49 18.0 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 121.61 0.719 . . . . 0.0 110.742 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 53.6 tt0 -154.01 173.27 16.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.774 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 87.7 tttt -168.57 113.34 0.61 Allowed 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.568 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 tt -123.65 123.44 40.56 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.98 122.3 45.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.222 0.534 . . . . 0.0 112.173 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' D' ' 19' ' ' PHE . 7.5 m-85 -113.88 117.54 31.69 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 90.4 t80 -124.58 131.94 53.46 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.5 ' HB3' ' HB2' ' D' ' 27' ' ' ASN . . . -148.27 145.94 28.4 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 179.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.42 128.47 44.81 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.802 -0.635 . . . . 0.0 111.18 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' O ' ' F' ' 22' ' ' GLU . 67.3 t0 -147.1 112.33 5.51 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.238 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.756 HG13 ' H ' ' E' ' 25' ' ' GLY . 12.1 p -101.8 -121.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.248 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.756 ' H ' HG13 ' E' ' 24' ' ' VAL . . . 34.2 -84.93 0.01 OUTLIER Glycine 0 N--CA 1.473 1.143 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -177.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.572 ' N ' ' O ' ' E' ' 24' ' ' VAL . 1.4 p 161.95 160.31 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.673 0.749 . . . . 0.0 109.913 175.733 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.412 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.8 m120 -29.87 159.65 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 114.277 -1.329 . . . . 0.0 113.896 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.483 ' O ' ' O ' ' E' ' 29' ' ' GLY . 87.4 tttt 178.19 102.94 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 41.8 93.43 0.01 OUTLIER Glycine 0 N--CA 1.477 1.395 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.701 ' HB2' ' H ' ' D' ' 30' ' ' ALA . . . -156.52 147.39 21.91 Favored 'General case' 0 CA--C 1.474 -1.947 0 C-N-CA 117.847 -1.541 . . . . 0.0 109.319 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.754 HG21 ' HA3' ' K' ' 37' ' ' GLY . 0.6 OUTLIER -151.49 137.54 11.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 112.477 -2.147 . . . . 0.0 112.041 -171.693 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 1.031 HD13 HG22 ' F' ' 32' ' ' ILE . 2.8 mp -122.41 118.01 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 114.275 -1.33 . . . . 0.0 110.35 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -120.2 116.29 3.2 Favored Glycine 0 N--CA 1.476 1.32 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 178.338 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.754 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 39.6 mt -119.36 117.39 28.38 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -120.27 126.35 50.36 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.08 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.447 ' O ' HG23 ' F' ' 36' ' ' VAL . 2.6 t -115.44 89.1 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.01 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.716 ' HA3' HG21 ' K' ' 31' ' ' ILE . . . -69.3 94.69 0.4 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.22 -171.79 18.73 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -178.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -132.73 161.81 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.654 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 C--O 1.221 -0.423 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.753 -179.942 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -103.33 129.75 50.45 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.004 0.43 . . . . 0.0 110.47 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -92.9 145.58 24.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.856 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 t -105.85 130.04 57.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.133 0.492 . . . . 0.0 110.689 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 14.5 t60 -154.19 139.7 17.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -149.74 170.61 18.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.427 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 50.8 tt0 -155.09 171.15 20.25 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.525 -0.762 . . . . 0.0 109.591 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' F' ' 17' ' ' LEU . 62.1 tttm -170.08 106.39 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.156 -0.617 . . . . 0.0 111.676 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' F' ' 16' ' ' LYS . 6.1 mp -117.42 125.47 51.01 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.757 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.1 141.44 16.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 96.4 m-85 -117.0 122.0 42.97 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 113.637 -1.62 . . . . 0.0 107.377 177.197 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 20' ' ' PHE . . . . . 0.4 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 47.7 m-85 -127.04 142.29 51.57 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 121.749 0.785 . . . . 0.0 111.317 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 21' ' ' ALA . . . . . 0.658 ' HB2' ' ND2' ' D' ' 27' ' ' ASN . . . -154.25 146.5 23.82 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.54 178.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.476 ' O ' ' O ' ' E' ' 23' ' ' ASP . 97.6 mt-10 -89.48 98.86 12.01 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.845 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' F' ' 24' ' ' VAL . 6.2 t70 -120.47 110.87 17.01 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 120.601 0.238 . . . . 0.0 110.758 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.6 m -60.42 -133.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.696 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' F' ' 26' ' ' SER . . . -76.91 85.72 0.99 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 119.784 -0.453 . . . . 0.0 112.797 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' F' ' 25' ' ' GLY . 5.9 p -34.97 170.09 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.144 0 CA-C-O 121.191 0.52 . . . . 0.0 111.292 178.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' F' ' 28' ' ' LYS . 8.0 t-20 -140.19 -178.96 5.71 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.151 177.376 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 62.8 mttp 26.37 -107.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.003 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.39 94.46 0.15 Allowed Glycine 0 C--N 1.338 0.674 0 CA-C-O 119.269 -0.74 . . . . 0.0 111.988 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.403 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -67.4 178.99 1.38 Allowed 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 103.876 -2.639 . . . . 0.0 103.876 174.654 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.533 HD13 ' N ' ' L' ' 38' ' ' GLY . 0.2 OUTLIER -146.87 118.79 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-N 121.651 2.023 . . . . 0.0 111.03 -178.763 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 1.031 HG22 HD13 ' E' ' 32' ' ' ILE . 45.9 pt -118.56 140.91 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.462 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -145.05 125.14 2.29 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 178.937 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 4.9 mp -116.88 127.86 54.68 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.473 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 2.9 tmm? -129.16 127.97 42.47 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 121.564 0.697 . . . . 0.0 112.876 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.473 ' N ' ' SD ' ' F' ' 35' ' ' MET . 3.6 p -156.15 82.02 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.719 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.233 179.079 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.447 ' O ' HD13 ' L' ' 31' ' ' ILE . . . -71.23 101.39 0.96 Allowed Glycine 0 CA--C 1.53 0.988 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.475 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -144.04 165.01 27.45 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -119.6 135.96 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.024 0.44 . . . . 0.0 110.331 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.728 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -83.32 141.46 31.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.601 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -55.71 142.33 34.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.842 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 8.0 m -121.24 132.86 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.847 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.403 ' CG ' ' N ' ' G' ' 14' ' ' HIS . 26.3 t-80 -146.45 160.62 41.85 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.609 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.403 ' N ' ' CG ' ' G' ' 13' ' ' HIS . 8.1 p-80 -96.81 172.25 8.0 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.099 0.476 . . . . 0.0 109.804 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -148.4 177.52 9.37 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.054 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -143.95 145.82 32.52 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.97 115.43 18.52 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.613 0.72 . . . . 0.0 110.306 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -125.82 121.98 61.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.127 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -153.24 158.23 41.38 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.611 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -132.56 150.16 52.2 Favored 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.415 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.6 135.1 44.03 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.86 0.838 . . . . 0.0 112.283 -179.22 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -143.38 151.9 40.96 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.802 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.509 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 57.5 t0 60.68 114.91 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.261 0.553 . . . . 0.0 111.965 179.401 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.556 ' O ' ' O ' ' G' ' 26' ' ' SER . 0.3 OUTLIER -147.32 112.81 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.524 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 36.82 -91.35 0.01 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.383 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.556 ' O ' ' O ' ' G' ' 24' ' ' VAL . 10.8 p -89.33 -178.86 5.72 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.411 ' CG ' ' OG ' ' H' ' 26' ' ' SER . 18.4 m120 -60.31 166.05 3.21 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 115.87 -2.332 . . . . 0.0 107.564 -177.392 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.558 ' NZ ' ' O ' ' I' ' 23' ' ' ASP . 29.6 tttm -53.69 107.35 0.25 Allowed 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 118.365 -1.334 . . . . 0.0 113.734 -177.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.51 100.81 2.71 Favored Glycine 0 N--CA 1.469 0.854 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 169.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 148.09 28.66 Favored 'General case' 0 C--O 1.248 0.985 1 CA-C-N 125.131 4.465 . . . . 0.0 109.378 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -162.71 107.36 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 112.47 -2.15 . . . . 0.0 106.96 -175.318 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.42 ' O ' ' O ' ' H' ' 33' ' ' GLY . 42.7 mm -108.8 104.73 17.54 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 C-N-CA 119.074 -1.051 . . . . 0.0 108.673 177.227 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.54 100.08 1.38 Allowed Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 104.336 -3.506 . . . . 0.0 104.336 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tp -147.32 149.07 32.11 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 123.321 1.534 . . . . 0.0 112.948 -177.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -111.92 135.61 52.33 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 112.476 -2.147 . . . . 0.0 110.579 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 36' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -135.54 66.4 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.11 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' G' G ' 37' ' ' GLY . . . . . 0.409 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -53.1 -103.06 0.01 OUTLIER Glycine 0 C--N 1.358 1.783 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.55 -177.89 47.93 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.41 144.66 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.013 0.435 . . . . 0.0 110.729 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.221 -0.402 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.705 -179.847 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -140.94 153.17 45.52 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.796 0.332 . . . . 0.0 110.164 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 11' ' ' GLU . . . . . 0.432 ' H ' ' HG3' ' I' ' 11' ' ' GLU . 95.7 mt-10 -128.54 129.95 46.73 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.358 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 51.6 t -131.11 130.98 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.62 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.643 ' NE2' ' CD2' ' I' ' 13' ' ' HIS . 19.3 p80 -167.96 156.65 9.23 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.568 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -144.44 170.4 16.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -144.97 172.51 12.94 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.951 0.405 . . . . 0.0 110.671 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -176.13 126.02 0.2 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.664 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -136.38 122.54 20.37 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.665 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 34.2 m -123.79 129.45 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 121.352 0.596 . . . . 0.0 110.344 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 19' ' ' PHE . . . . . 0.426 ' N ' ' CD1' ' H' ' 19' ' ' PHE . 5.0 m-85 -113.11 116.39 29.79 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.847 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -110.65 117.53 33.75 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.02 129.84 51.59 Favored 'General case' 0 N--CA 1.475 0.814 0 O-C-N 121.269 -0.895 . . . . 0.0 112.884 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -171.08 145.28 2.24 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.549 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.509 ' CB ' ' H ' ' G' ' 23' ' ' ASP . 29.7 t70 -172.0 105.97 0.2 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.942 1.46 . . . . 0.0 114.942 178.372 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' H' ' 23' ' ' ASP . 58.5 t -29.17 141.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.303 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.414 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 169.4 -80.42 0.1 OUTLIER Glycine 0 CA--C 1.532 1.146 0 C-N-CA 118.833 -1.651 . . . . 0.0 114.448 179.425 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.522 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.3 OUTLIER 170.73 -179.11 0.05 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 118.299 1.05 . . . . 0.0 109.557 -177.091 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.522 ' O ' ' O ' ' H' ' 26' ' ' SER . 76.8 m-20 -27.76 157.49 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.955 -1.021 . . . . 0.0 112.802 -176.426 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.89 ' HZ2' ' N ' ' I' ' 25' ' ' GLY . 3.4 pttp 179.18 101.71 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.531 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.5 101.63 0.79 Allowed Glycine 0 N--CA 1.477 1.396 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 178.895 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.41 153.03 23.65 Favored 'General case' 0 C--O 1.255 1.379 0 CA-C-O 124.038 1.875 . . . . 0.0 112.777 -176.589 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.632 HG21 ' HA3' ' B' ' 37' ' ' GLY . 0.8 OUTLIER -152.95 128.27 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 111.519 -2.582 . . . . 0.0 109.797 -177.427 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.55 HG21 HD12 ' I' ' 32' ' ' ILE . 2.1 tt -119.45 116.12 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -121.28 115.17 2.77 Favored Glycine 0 C--O 1.24 0.526 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.921 ' O ' HD12 ' I' ' 34' ' ' LEU . 0.5 OUTLIER -138.23 150.75 47.01 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 122.971 1.367 . . . . 0.0 112.924 -178.251 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.727 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 34.1 ttp -121.65 127.1 50.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.065 -1.425 . . . . 0.0 109.765 178.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.494 ' CG2' HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -132.15 72.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 120.619 -0.433 . . . . 0.0 110.035 179.515 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' H' H ' 37' ' ' GLY . . . . . 0.421 ' HA3' HG21 ' B' ' 31' ' ' ILE . . . -75.98 110.58 3.08 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.75 163.44 8.07 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.5 m -137.66 159.33 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.077 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.697 -179.781 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.39 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.93 160.17 43.52 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.503 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 53.6 mp0 -137.01 131.45 32.9 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.677 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.473 ' C ' ' ND1' ' I' ' 13' ' ' HIS . 27.1 m -136.33 152.12 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 121.339 0.59 . . . . 0.0 110.869 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.643 ' CD2' ' NE2' ' H' ' 13' ' ' HIS . 12.9 m80 -139.78 140.92 36.79 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.185 -178.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' I' ' 15' ' ' GLN . 59.4 t-80 -153.48 162.12 41.58 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 178.48 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.592 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 49.8 tt0 -162.17 172.24 16.11 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.376 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.451 ' N ' ' CG ' ' I' ' 15' ' ' GLN . 88.0 tttt -172.59 128.65 0.53 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.734 179.496 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.692 HD22 ' CE1' ' I' ' 19' ' ' PHE . 3.5 tt -130.27 121.47 26.18 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.66 ' N ' HD23 ' I' ' 17' ' ' LEU . 39.6 t -120.34 126.53 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 122.256 -0.277 . . . . 0.0 111.709 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.692 ' CE1' HD22 ' I' ' 17' ' ' LEU . 73.3 m-85 -103.98 101.26 11.04 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 176.16 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -113.27 117.85 33.01 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.22 124.87 35.61 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.15 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.442 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 14.4 pt-20 -127.09 75.41 1.58 Allowed 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.707 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.558 ' O ' ' NZ ' ' G' ' 28' ' ' LYS . 0.0 OUTLIER 164.03 115.0 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 114.198 -1.364 . . . . 0.0 109.872 176.158 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.687 ' C ' ' HZ2' ' H' ' 28' ' ' LYS . 39.5 t -148.57 107.47 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 118.976 -1.089 . . . . 0.0 108.726 173.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.89 ' N ' ' HZ2' ' H' ' 28' ' ' LYS . . . -39.62 -93.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.406 0 CA-C-O 123.984 1.88 . . . . 0.0 109.929 171.395 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.508 ' H ' ' H ' ' H' ' 28' ' ' LYS . 79.5 p 47.28 -178.59 0.01 OUTLIER 'General case' 0 CA--C 1.481 -1.703 0 CA-C-N 110.276 -2.962 . . . . 0.0 111.025 177.244 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' I' ' 28' ' ' LYS . 29.4 m120 -126.47 164.4 21.22 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.25 -1.795 . . . . 0.0 107.292 172.508 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' I' ' 27' ' ' ASN 0.263 45.1 mttm -27.85 112.56 0.06 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 114.984 1.476 . . . . 0.0 114.984 174.809 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.467 ' HA2' ' HB2' ' J' ' 30' ' ' ALA . . . 103.35 92.64 2.24 Favored Glycine 0 N--CA 1.48 1.577 0 C-N-CA 124.602 1.096 . . . . 0.0 115.169 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.498 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -87.64 179.71 6.47 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 173.129 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.49 ' HB ' HG22 ' H' ' 31' ' ' ILE . 0.4 OUTLIER -141.83 124.65 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 C-N-CA 116.517 -2.073 . . . . 0.0 111.471 -176.902 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.55 HD12 HG21 ' H' ' 32' ' ' ILE . 9.1 tt -125.89 127.24 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.213 0.53 . . . . 0.0 111.778 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 33' ' ' GLY . . . . . 0.644 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.81 117.46 3.04 Favored Glycine 0 C--O 1.24 0.482 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.921 HD12 ' O ' ' H' ' 34' ' ' LEU . 16.9 tp -137.84 135.36 36.13 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-O 121.611 0.719 . . . . 0.0 111.744 -178.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.681 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 54.9 ttp -105.21 125.3 50.83 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.75 176.409 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.79 72.09 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.135 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.58 111.3 3.5 Favored Glycine 0 C--N 1.364 2.128 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 177.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -71.99 160.51 54.07 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -136.79 162.01 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.805 0.336 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.552 -179.879 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -108.23 138.04 45.19 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.715 0.293 . . . . 0.0 110.329 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -75.95 128.18 34.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.016 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 23.4 m -140.97 161.14 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-O 121.268 0.556 . . . . 0.0 111.416 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 68.9 m80 -139.11 134.74 33.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.675 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 14' ' ' HIS . . . . . 0.544 ' CD2' ' HB2' ' K' ' 14' ' ' HIS . 3.1 t-80 -148.56 158.11 43.91 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.759 0.79 . . . . 0.0 110.464 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 15' ' ' GLN . . . . . 0.54 ' O ' ' CE1' ' J' ' 14' ' ' HIS . 83.2 mt-30 -150.59 174.46 12.95 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.546 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 54.0 tttp -175.82 127.3 0.23 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.193 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -130.4 129.96 43.73 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 18' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' K' ' 18' ' ' VAL . 1.4 p -144.99 140.62 23.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -178.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.6 OUTLIER -114.26 120.37 40.2 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.69 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.72 117.53 29.16 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.44 120.34 36.54 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 121.487 0.66 . . . . 0.0 111.653 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -159.69 104.45 1.58 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.498 ' HB2' ' H ' ' I' ' 24' ' ' VAL . 60.2 t0 -82.93 -133.52 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 175.424 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.54 ' O ' ' O ' ' J' ' 25' ' ' GLY . 21.9 t -92.2 112.17 25.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 N-CA-C 101.05 -3.685 . . . . 0.0 101.05 172.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 25' ' ' GLY . . . . . 0.54 ' O ' ' O ' ' J' ' 24' ' ' VAL . . . 42.38 90.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.01 -2.436 . . . . 0.0 107.01 -173.305 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.547 ' CB ' ' O ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -61.65 -179.82 0.2 Allowed 'General case' 0 N--CA 1.438 -1.034 0 C-N-CA 118.784 -1.167 . . . . 0.0 109.638 -174.865 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.466 ' N ' ' OG ' ' J' ' 26' ' ' SER . 1.6 m-20 -80.48 173.61 12.43 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 116.825 2.157 . . . . 0.0 116.825 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.552 ' O ' ' N ' ' J' ' 30' ' ' ALA 0.369 48.2 tttp -48.06 111.81 0.49 Allowed 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 109.221 -3.627 . . . . 0.0 116.782 173.499 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -68.34 99.19 0.56 Allowed Glycine 1 CA--C 1.446 -4.275 2 CA-C-O 128.699 4.5 . . . . 0.0 102.799 -176.331 . . . . . . . . 4 3 . 1 . 007 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.783 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -77.08 -132.78 0.01 OUTLIER 'General case' 1 N--CA 1.339 -6.005 3 CA-C-N 97.435 -9.383 . . . . 0.0 107.55 -167.012 . . . . . . . . 4 3 . 1 . 007 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.861 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -90.02 108.94 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.692 0 CA-C-N 114.57 -1.195 . . . . 0.0 110.467 -175.592 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.541 ' O ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -106.58 111.05 33.78 Favored 'Isoleucine or valine' 0 C--N 1.363 1.169 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.699 179.486 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.89 103.85 1.67 Allowed Glycine 0 CA--C 1.505 -0.545 0 N-CA-C 107.819 -2.112 . . . . 0.0 107.819 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.58 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 66.9 mt -126.03 121.72 33.8 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.951 0.881 . . . . 0.0 112.514 -177.253 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 6.1 ttt -102.94 120.37 40.51 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 114.252 -1.34 . . . . 0.0 108.391 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.478 ' HB ' HG22 ' K' ' 36' ' ' VAL . 3.6 t -137.23 66.86 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.327 -178.336 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.28 -102.63 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.13 154.88 30.65 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 50.5 t -130.67 136.57 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 32.7 t . . . . . 0 N--CA 1.468 0.457 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.29 179.591 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' K' K ' 10' ' ' TYR . . . . . 0.43 ' CD1' ' N ' ' K' ' 10' ' ' TYR . 11.6 p90 -133.68 152.12 51.81 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -91.97 138.79 31.25 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.347 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.44 HG13 ' ND1' ' L' ' 13' ' ' HIS . 74.1 t -126.58 134.72 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' L' ' 13' ' ' HIS . 44.3 t60 -116.41 123.48 47.64 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 117.845 0.293 . . . . 0.0 111.309 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.544 ' HB2' ' CD2' ' J' ' 14' ' ' HIS . 86.6 m-70 -114.86 158.95 21.23 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.137 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.418 ' O ' ' CG ' ' K' ' 16' ' ' LYS . 53.4 tt0 -170.05 161.58 8.71 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.226 177.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 95.5 mttt -163.03 132.23 4.12 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.662 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.416 HD23 HD13 ' L' ' 17' ' ' LEU . 15.5 tp -122.9 119.21 29.81 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.221 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 96.6 t -136.42 133.74 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.604 ' CZ ' ' CD2' ' L' ' 19' ' ' PHE . 23.4 p90 -145.62 130.4 18.1 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.296 177.1 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.638 ' N ' ' CD1' ' K' ' 20' ' ' PHE . 0.0 OUTLIER -149.35 163.77 36.78 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -178.475 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 141.67 38.89 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.328 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 22' ' ' GLU . . . . . 0.547 ' O ' ' CB ' ' J' ' 26' ' ' SER . 78.1 tt0 -89.71 156.59 18.45 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -178.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.52 ' OD2' ' N ' ' J' ' 28' ' ' LYS . 58.6 t0 176.11 130.79 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 123.465 0.706 . . . . 0.0 110.522 178.589 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.456 HG23 ' H ' ' K' ' 25' ' ' GLY . 5.3 m -87.53 -112.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.084 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 26' ' ' SER . . . -48.75 92.11 0.01 OUTLIER Glycine 0 CA--C 1.531 1.062 0 N-CA-C 114.838 0.695 . . . . 0.0 114.838 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.53 ' O ' ' O ' ' K' ' 25' ' ' GLY . 8.6 t -35.46 170.32 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.611 0.719 . . . . 0.0 111.368 176.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.481 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER -139.22 -177.15 4.78 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.946 177.751 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' K' K ' 28' ' ' LYS . . . . . 0.481 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 98.9 mttt -17.84 -104.87 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 113.242 0.83 . . . . 0.0 113.242 -178.304 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.552 ' HA2' ' HB2' ' L' ' 30' ' ' ALA . . . -150.44 95.34 0.16 Allowed Glycine 0 C--N 1.346 1.089 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.692 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.575 ' C ' HD13 ' K' ' 31' ' ' ILE . . . -67.82 -173.13 0.32 Allowed 'General case' 0 C--O 1.237 0.444 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 175.135 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.716 HG21 ' HA3' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -144.77 130.03 14.06 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-O 122.212 1.006 . . . . 0.0 110.22 -179.465 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 11.1 mm -114.84 122.5 69.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 114.164 -1.38 . . . . 0.0 110.485 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.482 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -127.98 119.72 3.22 Favored Glycine 0 N--CA 1.473 1.121 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.722 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -129.39 122.25 29.05 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 114.524 -0.838 . . . . 0.0 110.211 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 38.8 ttp -105.96 119.62 39.64 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.88 178.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.702 HG12 ' O ' ' K' ' 36' ' ' VAL . 54.7 t -139.8 71.06 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 119.415 -0.326 . . . . 0.0 110.53 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.754 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -53.88 -97.87 0.01 OUTLIER Glycine 0 C--N 1.342 0.897 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.802 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.32 163.83 35.86 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.01 162.5 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' K' K ' 40' ' ' VAL . . . . . 0.407 HG22 ' O ' ' K' ' 40' ' ' VAL . 7.2 p . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.575 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -104.53 132.46 50.75 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.653 0.264 . . . . 0.0 110.395 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -80.84 131.29 35.38 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t -133.56 137.87 52.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.405 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 13' ' ' HIS . . . . . 0.44 ' ND1' HG13 ' K' ' 12' ' ' VAL . 15.5 m80 -81.58 145.95 30.37 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.191 0.52 . . . . 0.0 111.047 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -83.45 177.78 8.31 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.196 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -110.73 178.69 4.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.813 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -146.24 140.85 26.83 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.045 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.416 HD13 HD23 ' K' ' 17' ' ' LEU . 28.6 tp -125.33 119.99 29.89 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 18' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 7.3 t -141.45 131.9 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.643 0.735 . . . . 0.0 112.026 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.604 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 8.0 p90 -147.5 144.58 28.66 Favored 'General case' 0 C--N 1.322 -0.597 0 O-C-N 121.363 -0.835 . . . . 0.0 110.926 178.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' L' ' 19' ' ' PHE . 60.2 m-85 -157.77 157.35 33.21 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.52 1.152 . . . . 0.0 113.958 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.35 139.42 52.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.868 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -74.48 101.71 4.24 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.786 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 35.6 p-10 -171.4 113.76 0.37 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.778 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' L' ' 26' ' ' SER . 73.7 t -64.99 131.71 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.861 -178.41 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.51 83.76 0.01 OUTLIER Glycine 0 N--CA 1.466 0.655 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.518 ' N ' ' O ' ' L' ' 24' ' ' VAL . 15.4 m -67.52 -171.1 0.17 Allowed 'General case' 0 N--CA 1.437 -1.124 0 CA-C-O 122.541 1.163 . . . . 0.0 112.488 -177.309 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 54.3 t30 -80.51 179.39 7.76 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.788 -177.857 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.4 mttt -36.41 104.4 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.577 -178.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 168.09 -100.36 0.16 Allowed Glycine 0 C--O 1.22 -0.774 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.552 ' HB2' ' HA2' ' K' ' 29' ' ' GLY . . . -51.35 172.13 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.682 1.741 . . . . 0.0 108.054 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.447 HD13 ' O ' ' F' ' 37' ' ' GLY . 0.1 OUTLIER -152.53 149.41 13.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 C-N-CA 118.144 -1.423 . . . . 0.0 111.253 -176.44 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' L' L ' 32' ' ' ILE . . . . . 0.403 HG21 HD13 ' L' ' 32' ' ' ILE . 38.5 pt -125.89 143.63 38.77 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.153 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.27 114.73 1.51 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.6 mt -119.09 120.31 36.77 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttp -111.75 123.99 51.39 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 120.204 -0.599 . . . . 0.0 111.47 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' L' ' 37' ' ' GLY . 4.9 t -133.91 69.68 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.465 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -27.17 -105.69 0.0 OUTLIER Glycine 0 CA--C 1.533 1.187 0 CA-C-O 121.344 0.413 . . . . 0.0 114.064 -179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 38' ' ' GLY . . . . . 0.533 ' N ' HD13 ' F' ' 31' ' ' ILE . . . -38.09 156.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 115.312 -0.444 . . . . 0.0 112.459 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.79 159.32 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.189 -0.505 . . . . 0.0 110.06 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.828 -179.721 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -110.25 133.94 52.74 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.807 0.337 . . . . 0.0 110.259 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -62.45 130.8 46.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.197 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.447 HG11 ' ND1' ' B' ' 13' ' ' HIS . 9.9 p -146.15 146.93 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.729 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 14' ' ' HIS . 37.5 p-80 -91.12 -178.63 5.22 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.451 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 13' ' ' HIS . 24.8 m-70 -74.26 172.5 11.72 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -145.36 176.73 9.35 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.504 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -150.01 112.09 4.61 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.26 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -124.45 115.46 20.95 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 121.424 0.631 . . . . 0.0 110.261 179.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -123.6 128.96 74.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.403 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -128.76 124.13 34.7 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.9 p90 -128.04 125.63 39.71 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.94 0.4 . . . . 0.0 110.253 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.12 119.03 35.04 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -164.2 120.27 1.59 Allowed 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.462 ' CG ' ' H ' ' A' ' 24' ' ' VAL . 38.7 t0 65.42 -136.22 0.21 Allowed 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.561 -178.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.462 ' H ' ' CG ' ' A' ' 23' ' ' ASP . 12.1 m -29.49 104.39 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.427 1.269 . . . . 0.0 114.427 -178.267 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 130.54 -101.22 0.49 Allowed Glycine 0 N--CA 1.468 0.799 0 CA-C-N 113.15 -1.841 . . . . 0.0 110.675 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.3 t -129.79 140.43 51.04 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 120.115 1.957 . . . . 0.0 111.99 174.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 -57.22 179.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.506 ' HG2' ' H ' ' B' ' 29' ' ' GLY 0.442 74.5 tttt -59.76 110.62 1.2 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 112.073 -2.331 . . . . 0.0 111.576 169.135 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.66 104.03 1.23 Allowed Glycine 0 C--N 1.302 -1.317 0 CA-C-O 127.334 3.741 . . . . 0.0 112.02 -169.246 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.545 ' O ' ' N ' ' A' ' 32' ' ' ILE . . . -69.81 -122.2 0.0 OUTLIER 'General case' 0 CA--C 1.479 -1.778 3 CA-C-N 103.478 -6.361 . . . . 0.0 96.052 -179.563 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.818 ' O ' HD13 ' A' ' 31' ' ' ILE . 0.0 OUTLIER -51.16 99.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.587 2.401 0 CA-C-N 124.89 3.495 . . . . 0.0 107.895 175.942 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' ALA . 4.9 tt -128.78 113.44 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 119.419 -2.051 . . . . 0.0 109.387 178.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' B' ' 33' ' ' GLY . . . -129.36 126.06 5.04 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 106.617 -2.593 . . . . 0.0 106.617 178.027 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' LEU . . . . . 0.498 ' H ' ' HG ' ' B' ' 34' ' ' LEU . 36.8 tp -133.67 135.22 43.96 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 122.529 1.157 . . . . 0.0 111.641 -178.251 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.409 ' HE1' ' O ' ' H' ' 31' ' ' ILE . 12.5 ttm -104.66 110.54 22.9 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 113.752 -1.567 . . . . 0.0 107.198 177.629 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.15 72.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.7 110.83 3.12 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.15 165.74 11.95 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -95.01 135.98 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 110.711 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 40' ' ' VAL . 11.5 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.62 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -102.92 134.93 45.52 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -141.21 130.35 23.42 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.952 0.406 . . . . 0.0 110.834 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.17 146.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.627 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.447 ' ND1' HG11 ' A' ' 12' ' ' VAL . 26.0 t60 -154.83 104.68 2.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.038 0.447 . . . . 0.0 111.16 179.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' ND1' ' C' ' 14' ' ' HIS . 31.3 m170 -119.35 164.51 15.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -154.47 173.03 16.81 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.01 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -153.67 114.11 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.809 178.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.421 HD12 ' N ' ' B' ' 17' ' ' LEU . 4.1 mp -128.39 114.49 16.91 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.92 133.73 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-O 121.101 0.477 . . . . 0.0 111.064 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -119.46 129.61 54.83 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.997 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -124.65 129.07 49.84 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.691 -0.231 . . . . 0.0 110.468 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.13 128.34 43.27 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 111.859 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.8 tt0 -136.79 149.36 47.73 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.552 ' O ' HG23 ' C' ' 24' ' ' VAL . 81.3 m-20 -137.99 145.78 42.32 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.812 0.339 . . . . 0.0 111.344 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 1.6 m -107.33 110.59 32.35 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.896 ' H ' HG21 ' C' ' 24' ' ' VAL . . . 34.41 90.89 0.01 OUTLIER Glycine 0 N--CA 1.471 0.977 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.793 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.9 t 152.41 171.79 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.793 ' O ' ' O ' ' B' ' 26' ' ' SER . 1.3 t-20 20.51 179.79 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 177.806 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.461 ' CB ' ' O ' ' B' ' 27' ' ' ASN . 82.0 tttt 151.28 92.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 122.472 1.13 . . . . 0.0 110.27 -175.186 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.62 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . 31.54 -128.7 0.21 Allowed Glycine 1 CA--C 1.419 -5.908 0 CA-C-N 113.362 -1.745 . . . . 0.0 109.918 -178.814 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.62 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 119.44 -112.39 0.0 OUTLIER 'General case' 0 N--CA 1.391 -3.425 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 -173.213 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.783 ' H ' HD12 ' B' ' 31' ' ' ILE . 2.3 mp -79.79 113.29 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.037 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.507 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.447 ' O ' HG23 ' B' ' 32' ' ' ILE . 14.7 tt -124.85 109.35 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.25 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.833 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -130.06 120.37 3.07 Favored Glycine 0 N--CA 1.468 0.815 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.899 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.4 mp -136.5 160.34 39.07 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 123.219 1.485 . . . . 0.0 113.67 -178.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.6 ttm -127.5 112.33 14.82 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 112.791 -2.004 . . . . 0.0 107.677 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.749 ' CG2' HD11 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -119.6 74.07 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -179.583 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -31.89 -97.99 0.01 OUTLIER Glycine 0 C--N 1.357 1.749 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.48 -173.09 24.59 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.0 p -141.35 141.8 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.95 0.405 . . . . 0.0 110.511 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.945 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -146.27 156.24 43.23 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.871 0.367 . . . . 0.0 110.787 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -116.32 137.87 51.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.21 132.25 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.156 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 17.2 p-80 -155.63 143.0 19.42 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 121.13 0.491 . . . . 0.0 111.241 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.632 ' ND1' ' CD2' ' B' ' 14' ' ' HIS . 6.1 m80 -140.91 167.38 22.33 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.11 0.481 . . . . 0.0 109.931 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -150.99 169.88 20.7 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.964 178.277 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -156.96 117.9 3.66 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.55 123.79 40.86 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.648 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -133.54 133.28 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -116.82 107.4 14.58 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 105.287 -2.116 . . . . 0.0 105.287 175.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 24.3 t80 -122.48 134.84 54.56 Favored 'General case' 0 N--CA 1.477 0.878 0 O-C-N 122.312 -0.242 . . . . 0.0 110.532 -177.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 21' ' ' ALA . . . . . 0.426 ' CB ' ' NZ ' ' A' ' 28' ' ' LYS . . . -145.61 144.11 30.27 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -142.61 110.73 5.99 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 114.147 -1.388 . . . . 0.0 109.642 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' C' ' 24' ' ' VAL . 4.1 m-20 -118.8 133.24 55.98 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.896 HG21 ' H ' ' B' ' 25' ' ' GLY . 4.9 t -28.81 -112.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -144.09 90.54 0.16 Allowed Glycine 0 CA--C 1.533 1.201 0 O-C-N 122.114 -0.366 . . . . 0.0 113.358 -176.05 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.57 ' O ' ' O ' ' C' ' 27' ' ' ASN . 33.4 p -140.4 170.61 15.47 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 117.83 0.815 . . . . 0.0 109.483 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.57 ' O ' ' O ' ' C' ' 26' ' ' SER . 33.3 m120 -30.21 170.81 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 64.4 tttt -108.6 -111.7 0.31 Allowed 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.105 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 43.13 91.24 0.01 OUTLIER Glycine 0 CA--C 1.489 -1.593 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.95 155.8 49.72 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.492 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -141.5 117.39 6.5 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 112.295 -2.23 . . . . 0.0 109.204 -170.592 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.408 ' O ' HG22 ' C' ' 32' ' ' ILE . 5.4 mt -105.5 111.64 35.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.499 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -122.11 104.39 0.91 Allowed Glycine 0 CA--C 1.506 -0.499 0 N-CA-C 106.273 -2.731 . . . . 0.0 106.273 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.899 HD12 ' O ' ' B' ' 34' ' ' LEU . 54.6 tp -132.59 141.05 48.52 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 123.3 1.524 . . . . 0.0 113.806 -176.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.793 ' SD ' HG22 ' I' ' 31' ' ' ILE . 8.3 ttm -115.56 118.43 33.11 Favored 'General case' 0 CA--C 1.505 -0.774 0 CA-C-N 112.4 -2.182 . . . . 0.0 109.262 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.557 HG11 HD23 ' D' ' 17' ' ' LEU . 1.3 m -128.57 74.12 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.19 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.1 105.68 3.08 Favored Glycine 0 C--N 1.354 1.545 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -129.76 148.29 18.34 Favored Glycine 0 N--CA 1.466 0.685 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 m -134.05 159.8 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.944 0.402 . . . . 0.0 110.834 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.914 179.816 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.15 129.93 54.77 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.867 0.365 . . . . 0.0 110.529 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 11' ' ' GLU . . . . . 0.507 ' O ' HG23 ' E' ' 12' ' ' VAL . 15.1 pt-20 -72.76 150.85 42.47 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.166 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.591 HG22 ' O ' ' E' ' 11' ' ' GLU . 2.8 t -103.57 126.86 57.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.8 p-80 -157.8 148.74 21.14 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.632 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.565 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 56.7 t-80 -144.98 158.83 43.69 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.253 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 15' ' ' GLN . . . . . 0.565 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 67.7 mt-30 -156.22 172.15 18.96 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.106 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -155.63 122.3 5.29 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.709 179.346 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.557 HD23 HG11 ' C' ' 36' ' ' VAL . 47.7 tp -117.39 123.1 45.63 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 39.1 t -130.53 131.22 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.724 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 10.7 m-85 -112.73 108.88 18.06 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 175.743 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.0 t80 -123.35 123.76 41.43 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 120.93 0.395 . . . . 0.0 112.026 -176.809 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.61 127.32 30.96 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.253 178.694 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -140.46 114.29 8.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.771 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' D' ' 23' ' ' ASP . 0.2 OUTLIER 178.65 117.85 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.971 179.875 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -43.52 120.88 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 176.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.497 ' H ' HG23 ' E' ' 24' ' ' VAL . . . -109.43 -82.43 1.37 Allowed Glycine 0 CA--C 1.53 1.004 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.175 179.405 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.862 ' O ' ' O ' ' D' ' 27' ' ' ASN . 2.9 p 151.74 171.41 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 -178.717 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.862 ' O ' ' O ' ' D' ' 26' ' ' SER . 68.7 m-80 22.09 -178.18 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 123.919 0.762 . . . . 0.0 113.005 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.482 ' HZ3' ' CG ' ' F' ' 27' ' ' ASN . 73.3 mttt -119.17 -111.19 0.34 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.477 -1.39 . . . . 0.0 112.518 -177.079 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' D' ' 28' ' ' LYS . . . 41.78 91.29 0.01 OUTLIER Glycine 0 N--CA 1.477 1.405 0 C-N-CA 120.293 -0.956 . . . . 0.0 110.747 -179.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.5 156.21 48.91 Favored 'General case' 0 CA--C 1.487 -1.452 0 N-CA-C 101.352 -3.574 . . . . 0.0 101.352 175.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.455 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -136.27 122.59 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.647 -171.33 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CE ' ' K' ' 35' ' ' MET . 78.4 mt -116.36 123.27 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.055 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.57 109.19 1.08 Allowed Glycine 0 N--CA 1.463 0.461 0 N-CA-C 107.609 -2.196 . . . . 0.0 107.609 175.174 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.419 HD13 ' CZ ' ' E' ' 19' ' ' PHE . 14.7 tp -122.09 124.53 44.12 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 121.541 0.686 . . . . 0.0 112.243 -178.708 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.508 ' SD ' ' N ' ' J' ' 32' ' ' ILE . 13.5 ttm -102.86 113.6 27.18 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.435 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.01 72.85 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.809 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.14 111.53 3.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 178.91 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.73 135.47 7.22 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -124.27 135.95 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.797 0.332 . . . . 0.0 110.309 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.588 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.49 148.25 33.56 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.788 0.328 . . . . 0.0 110.237 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 11' ' ' GLU . . . . . 0.591 ' O ' HG22 ' D' ' 12' ' ' VAL . 59.9 mm-40 -57.45 136.36 56.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.296 -0.411 . . . . 0.0 109.951 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 12' ' ' VAL . . . . . 0.507 HG23 ' O ' ' D' ' 11' ' ' GLU . 2.7 p -135.33 142.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -109.85 -178.89 3.65 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 118.179 0.445 . . . . 0.0 110.959 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CD2' ' F' ' 13' ' ' HIS . 93.8 m-70 -142.41 -178.66 5.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.751 0.786 . . . . 0.0 110.149 -179.078 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -88.46 168.0 12.99 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.661 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.42 143.38 33.88 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.273 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.529 HD13 ' CD2' ' F' ' 17' ' ' LEU . 5.2 mp -131.22 124.35 30.4 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.146 0.498 . . . . 0.0 111.671 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -128.3 129.39 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.854 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.438 ' HZ ' HD23 ' C' ' 34' ' ' LEU . 35.9 m-85 -117.99 120.85 39.05 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -128.59 127.66 42.71 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 117.927 0.331 . . . . 0.0 111.124 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.3 131.55 43.89 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 122.381 1.086 . . . . 0.0 113.058 -179.032 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -138.27 85.73 2.11 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.069 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -93.97 -130.71 0.14 Allowed 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.415 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.497 HG23 ' H ' ' D' ' 25' ' ' GLY . 82.9 t -106.2 112.32 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 N-CA-C 104.747 -2.316 . . . . 0.0 104.747 175.301 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 31.76 88.08 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 113.904 -1.498 . . . . 0.0 112.977 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.509 ' N ' ' HB2' ' F' ' 23' ' ' ASP . 35.3 p -128.24 141.51 51.43 Favored 'General case' 0 C--N 1.35 0.597 0 CA-C-N 119.262 1.531 . . . . 0.0 108.718 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.841 ' ND2' ' H ' ' E' ' 28' ' ' LYS . 1.8 t-20 -58.21 178.91 0.08 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 178.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.841 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 98.1 mttt -50.19 -105.24 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 111.528 -2.578 . . . . 0.0 105.626 168.109 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.846 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -80.9 99.26 1.88 Allowed Glycine 0 CA--C 1.476 -2.396 0 CA-C-N 113.611 -1.631 . . . . 0.0 110.88 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.644 ' O ' ' C ' ' E' ' 29' ' ' GLY . . . -76.38 -136.84 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.886 1 N-CA-C 93.028 -6.656 . . . . 0.0 93.028 168.326 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.5 OUTLIER -85.09 114.91 26.0 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 1 CA-C-N 127.789 4.813 . . . . 0.0 109.163 176.935 . . . . . . . . 4 4 . 1 . 008 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' K' ' 35' ' ' MET . 16.1 tt -136.69 134.94 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-O 121.719 0.771 . . . . 0.0 112.452 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -131.9 127.36 4.95 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.512 HD13 ' CE1' ' F' ' 19' ' ' PHE . 23.9 tp -121.03 124.26 44.41 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.637 -0.282 . . . . 0.0 111.679 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.1 tpp -115.99 114.6 24.82 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.86 88.51 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.62 -178.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.58 95.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 119.67 -1.253 . . . . 0.0 110.342 178.154 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -159.28 162.56 32.86 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.56 162.77 34.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.311 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -148.26 159.59 43.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.016 0.436 . . . . 0.0 111.256 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -67.25 137.9 56.5 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.985 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -127.16 132.38 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.326 0.584 . . . . 0.0 110.999 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' NE2' ' E' ' 14' ' ' HIS . 27.2 t-80 -156.07 100.95 2.06 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.888 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -147.23 173.3 12.68 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -145.03 174.65 10.85 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.319 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -145.99 112.71 5.98 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.032 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.529 ' CD2' HD13 ' E' ' 17' ' ' LEU . 35.8 mt -125.07 110.2 13.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 m -145.93 147.12 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 118.682 -1.207 . . . . 0.0 114.244 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.512 ' CE1' HD13 ' E' ' 34' ' ' LEU . 73.0 m-85 -126.7 128.3 46.48 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 113.967 -1.469 . . . . 0.0 108.431 177.822 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -138.36 146.48 42.35 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.12 0.486 . . . . 0.0 111.458 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.55 146.48 32.39 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.956 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -88.07 127.47 35.4 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.866 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.509 ' HB2' ' N ' ' E' ' 26' ' ' SER . 67.1 t0 178.1 114.36 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 79.6 t -65.39 132.44 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.173 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . 71.68 -85.08 0.45 Allowed Glycine 0 N--CA 1.47 0.958 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 26' ' ' SER . . . . . 0.551 ' CB ' ' O ' ' F' ' 25' ' ' GLY . 2.8 t 140.23 165.4 0.0 OUTLIER 'General case' 0 C--N 1.352 0.703 0 CA-C-O 122.577 1.18 . . . . 0.0 112.905 174.46 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.573 ' CG ' ' H ' ' E' ' 27' ' ' ASN . 0.5 OUTLIER -46.48 171.93 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.44 175.535 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -69.93 111.53 5.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 170.31 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.88 -92.88 0.93 Allowed Glycine 0 N--CA 1.475 1.257 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.861 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.846 ' HB1' ' O ' ' E' ' 29' ' ' GLY . . . 83.38 160.28 0.12 Allowed 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 100.439 -3.911 . . . . 0.0 100.439 -174.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.5 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.2 OUTLIER -151.67 127.87 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 122.45 2.386 . . . . 0.0 111.039 -176.286 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -121.43 132.77 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-N 114.151 -1.386 . . . . 0.0 114.254 -175.524 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -130.22 115.12 1.78 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 mt -118.45 127.49 53.71 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.534 ' CE ' HG22 ' L' ' 31' ' ' ILE . 1.8 ttt -132.09 126.7 34.41 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.539 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -143.33 82.52 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.442 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.666 ' HA3' HD13 ' L' ' 31' ' ' ILE . . . -51.23 100.37 0.04 OUTLIER Glycine 0 C--N 1.337 0.61 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.674 -179.209 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.11 163.09 35.76 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -121.45 132.94 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.924 0.393 . . . . 0.0 110.315 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.897 -179.566 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.386 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.63 129.36 53.89 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -147.29 147.73 30.69 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-O 121.126 0.488 . . . . 0.0 110.475 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.6 m -133.85 163.48 37.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.239 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -157.71 149.02 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.675 179.588 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 14.8 t60 -147.84 163.56 36.38 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 85.3 mt-30 -151.64 178.17 9.61 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.326 0.584 . . . . 0.0 110.871 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 25.5 pttm -167.72 133.57 2.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.266 179.262 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -133.57 125.05 28.0 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.95 138.14 49.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.248 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -134.77 137.25 43.24 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 20' ' ' PHE . . . . . 0.483 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 54.3 p90 -135.18 129.05 33.16 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.142 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.38 134.75 50.96 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -157.21 124.66 5.28 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.359 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.558 ' O ' ' O ' ' G' ' 24' ' ' VAL . 12.0 m-20 -154.13 122.71 6.21 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 120.827 -0.349 . . . . 0.0 111.849 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.558 ' O ' ' O ' ' G' ' 23' ' ' ASP . 11.8 m -43.67 -122.1 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 O-C-N 124.273 0.983 . . . . 0.0 111.621 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.49 -90.79 1.35 Allowed Glycine 0 CA--C 1.528 0.886 0 CA-C-O 119.52 -0.6 . . . . 0.0 113.023 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' G' ' 27' ' ' ASN . 1.3 p 173.76 -170.58 0.04 OUTLIER 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 117.587 0.694 . . . . 0.0 109.625 -177.694 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' G' ' 26' ' ' SER . 16.4 t-20 -16.98 158.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 O-C-N 125.149 1.53 . . . . 0.0 113.49 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.531 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 28.6 tttt -161.56 108.54 1.4 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.58 98.1 0.66 Allowed Glycine 0 N--CA 1.467 0.746 0 CA-C-O 116.221 -2.433 . . . . 0.0 107.935 172.804 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.406 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -90.08 154.24 19.95 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 123.627 3.714 . . . . 0.0 110.552 -176.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.4 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -153.82 114.55 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 112.528 -2.124 . . . . 0.0 109.75 -173.626 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 6.0 tt -122.78 113.79 39.61 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 176.355 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 33' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' H' ' 33' ' ' GLY . . . -132.68 137.61 9.52 Favored Glycine 0 CA--C 1.502 -0.731 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -153.26 146.81 25.01 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 122.447 1.117 . . . . 0.0 112.024 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.402 ' CE ' ' O ' ' A' ' 31' ' ' ILE . 31.0 mtp -105.19 119.15 38.34 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 113.257 -1.792 . . . . 0.0 107.878 178.286 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.76 65.72 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.297 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.283 178.912 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.95 102.42 0.56 Allowed Glycine 0 C--N 1.376 2.754 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 177.08 170.3 39.35 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m -139.73 142.94 31.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.93 0.395 . . . . 0.0 110.258 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.022 -0.99 . . . . 0.0 110.736 -179.863 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -83.63 136.41 34.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.979 0.419 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -80.45 164.48 23.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.83 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 12' ' ' VAL . . . . . 0.405 HG13 ' CG2' ' I' ' 12' ' ' VAL . 54.3 t -86.9 132.57 32.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.838 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.904 ' HD1' ' CD2' ' I' ' 13' ' ' HIS . 40.7 m80 -137.18 145.78 44.13 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.953 0.406 . . . . 0.0 111.396 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.531 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 99.1 m-70 -147.09 155.96 42.61 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.4 mm-40 -148.73 168.29 23.3 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.41 178.716 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -163.6 128.63 2.96 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.46 -0.791 . . . . 0.0 108.983 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 17' ' ' LEU . . . . . 0.597 ' C ' HD23 ' H' ' 17' ' ' LEU . 5.6 tt -127.46 118.11 23.4 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.58 ' N ' HD23 ' H' ' 17' ' ' LEU . 72.8 t -122.2 129.48 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.202 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -126.25 122.87 36.78 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.489 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -126.84 127.66 45.33 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.702 0.286 . . . . 0.0 111.374 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.36 125.61 50.38 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 120.981 0.42 . . . . 0.0 111.525 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' O ' ' I' ' 22' ' ' GLU . 52.7 tp10 -132.67 157.4 44.94 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.664 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -158.64 142.03 14.98 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.42 112.72 25.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 122.344 1.068 . . . . 0.0 110.391 -177.878 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 25' ' ' GLY . . . . . 0.641 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . 41.1 86.92 0.01 OUTLIER Glycine 0 CA--C 1.521 0.417 0 CA-C-N 113.177 -1.828 . . . . 0.0 114.122 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.769 ' O ' ' O ' ' H' ' 27' ' ' ASN . 82.9 p -152.94 170.95 19.14 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.673 175.022 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.769 ' O ' ' O ' ' H' ' 26' ' ' SER . 63.3 t30 -19.67 -173.71 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.167 0 O-C-N 125.293 1.621 . . . . 0.0 115.293 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.556 ' HZ1' ' HE3' ' I' ' 28' ' ' LYS . 15.2 mmtt -138.12 -104.64 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 115.14 -0.936 . . . . 0.0 108.995 174.927 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 40.61 95.3 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 C-N-CA 120.239 -0.981 . . . . 0.0 110.749 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.11 145.41 51.29 Favored 'General case' 0 CA--C 1.497 -1.082 0 CA-C-O 123.279 1.514 . . . . 0.0 107.546 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.554 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -140.03 121.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-N 112.404 -2.18 . . . . 0.0 110.529 -173.474 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.513 ' N ' ' SD ' ' B' ' 35' ' ' MET . 8.7 tt -111.33 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 CA-C-O 121.613 0.72 . . . . 0.0 110.112 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' G' ' 33' ' ' GLY . . . -112.37 94.85 0.76 Allowed Glycine 0 N--CA 1.461 0.366 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' I' ' 34' ' ' LEU . 35.6 mt -117.0 129.25 55.9 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.273 1.035 . . . . 0.0 111.551 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.629 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 21.9 ttp -116.27 115.52 26.1 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.312 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.89 71.15 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.897 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.61 112.41 3.61 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -50.64 152.52 4.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.84 162.02 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.297 179.901 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.29 125.89 50.17 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.666 0.269 . . . . 0.0 110.336 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -88.12 121.9 31.06 Favored 'General case' 0 C--O 1.236 0.391 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.405 ' CG2' HG13 ' H' ' 12' ' ' VAL . 16.3 m -137.8 161.7 32.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-O 121.553 0.692 . . . . 0.0 111.757 -179.164 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.904 ' CD2' ' HD1' ' H' ' 13' ' ' HIS . 71.2 m80 -150.07 101.85 3.05 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.134 178.811 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 84.9 t60 -121.23 162.91 19.39 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.853 0.835 . . . . 0.0 111.376 -178.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.546 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 84.3 mt-30 -148.47 177.73 9.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.098 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -171.01 125.28 0.66 Allowed 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.4 mt -126.71 123.34 37.28 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.095 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' J' ' 18' ' ' VAL . 12.6 p -136.41 133.32 49.44 Favored 'Isoleucine or valine' 0 C--N 1.351 0.663 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -115.68 126.06 53.63 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.649 177.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -129.38 121.85 28.26 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 118.327 0.512 . . . . 0.0 111.03 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.31 128.46 51.08 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.077 0.465 . . . . 0.0 111.224 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' H' ' 22' ' ' GLU . 82.1 tt0 -149.02 124.67 10.43 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.311 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -157.11 103.97 2.05 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 118.909 -1.116 . . . . 0.0 113.799 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.641 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 2.2 p -31.78 147.67 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.525 -1.216 . . . . 0.0 113.07 175.01 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.4 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 168.52 -79.42 0.1 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.282 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 26' ' ' SER . . . . . 1.001 ' O ' ' O ' ' I' ' 27' ' ' ASN . 2.1 p 161.66 179.86 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 1.001 ' O ' ' O ' ' I' ' 26' ' ' SER . 8.2 m120 10.52 -178.74 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.112 0 O-C-N 124.841 1.338 . . . . 0.0 113.251 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.556 ' HE3' ' HZ1' ' H' ' 28' ' ' LYS . 12.7 tttt -149.15 109.77 4.24 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 116.202 -2.199 . . . . 0.0 114.646 177.625 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.96 94.65 0.79 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 106.248 -2.741 . . . . 0.0 106.248 168.194 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.43 144.4 51.06 Favored 'General case' 0 CA--C 1.476 -1.882 0 CA-C-N 122.543 3.171 . . . . 0.0 107.094 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.793 HG22 ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -144.15 125.24 9.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 113.09 -1.868 . . . . 0.0 109.504 -175.189 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.543 ' N ' ' SD ' ' C' ' 35' ' ' MET . 0.8 OUTLIER -105.22 110.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.064 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.69 101.73 1.24 Allowed Glycine 0 CA--C 1.494 -1.243 0 N-CA-C 104.817 -3.313 . . . . 0.0 104.817 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' H' ' 34' ' ' LEU . 17.0 tp -136.82 137.55 39.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-O 122.11 0.957 . . . . 0.0 112.508 -175.085 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 31.1 ttp -122.86 123.42 40.94 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 113.74 -1.573 . . . . 0.0 110.164 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.559 ' CG2' HD11 ' J' ' 34' ' ' LEU . 0.1 OUTLIER -126.35 71.56 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.826 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.84 113.1 5.03 Favored Glycine 0 C--N 1.358 1.779 0 N-CA-C 110.531 -1.027 . . . . 0.0 110.531 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.16 147.81 41.66 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 64.3 t -130.87 137.29 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' I' I ' 40' ' ' VAL . . . . . 0.402 HG23 ' O ' ' I' ' 40' ' ' VAL . 30.4 m . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.44 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.379 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -82.96 138.94 33.6 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.846 0.355 . . . . 0.0 110.362 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -81.28 135.22 35.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.642 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.19 144.97 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 CA-C-N 116.348 -0.387 . . . . 0.0 109.998 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.9 OUTLIER -131.31 155.98 46.25 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 121.19 0.519 . . . . 0.0 110.943 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -152.4 160.18 43.32 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -154.67 172.25 18.2 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.219 -0.592 . . . . 0.0 110.634 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -155.75 127.96 7.65 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.747 178.527 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 17' ' ' LEU . . . . . 0.427 HD12 HD11 ' K' ' 17' ' ' LEU . 87.4 mt -120.47 120.12 34.98 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 18' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' I' ' 18' ' ' VAL . 2.0 p -143.06 137.92 26.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -177.898 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.83 127.9 13.7 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 119.684 -0.806 . . . . 0.0 111.403 176.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -147.77 160.82 42.31 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.443 1.116 . . . . 0.0 113.752 -178.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 140.17 43.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 113.934 -1.484 . . . . 0.0 109.946 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.17 149.44 39.74 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.968 -178.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 33.7 t70 -173.49 126.46 0.41 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.08 0.467 . . . . 0.0 111.293 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.444 HG22 ' H ' ' J' ' 24' ' ' VAL . 5.4 m -62.61 -116.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.516 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.47 -92.22 0.06 OUTLIER Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.603 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.831 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.3 t -171.24 170.05 6.17 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 117.535 0.668 . . . . 0.0 109.986 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.831 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.8 m120 10.85 -179.16 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 125.763 1.914 . . . . 0.0 115.567 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.595 ' H ' ' N ' ' K' ' 27' ' ' ASN . 15.8 pttt -149.4 110.76 4.44 Favored 'General case' 0 CA--C 1.558 1.25 0 O-C-N 120.635 -1.29 . . . . 0.0 114.284 178.263 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -61.48 93.22 0.07 OUTLIER Glycine 0 N--CA 1.479 1.517 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 172.077 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.487 ' HB2' ' HG3' ' J' ' 28' ' ' LYS . . . -126.39 149.33 49.3 Favored 'General case' 0 CA--C 1.486 -1.489 0 CA-C-N 121.677 2.739 . . . . 0.0 111.069 -178.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.736 HG13 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.33 114.42 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.816 0 CA-C-N 108.989 -3.732 . . . . 0.0 107.612 -174.968 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.508 ' N ' ' SD ' ' D' ' 35' ' ' MET . 3.1 mt -105.56 118.74 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 CA-C-O 120.749 0.309 . . . . 0.0 110.429 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.96 100.78 0.91 Allowed Glycine 0 C--O 1.239 0.421 0 N-CA-C 106.9 -2.48 . . . . 0.0 106.9 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.627 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 55.7 tp -129.58 135.39 48.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.003 0.906 . . . . 0.0 112.415 -177.39 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.418 ' SD ' ' C ' ' D' ' 31' ' ' ILE . 48.9 ttp -117.87 117.07 28.28 Favored 'General case' 0 CA--C 1.502 -0.881 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.55 175.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.506 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -120.26 72.2 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 178.608 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.51 111.87 4.5 Favored Glycine 0 C--N 1.36 1.861 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 178.503 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.36 -151.58 3.07 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -179.199 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.9 m -133.26 158.07 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.097 0.475 . . . . 0.0 110.74 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' J' J ' 40' ' ' VAL . . . . . 0.422 ' H ' HG12 ' J' ' 40' ' ' VAL . 4.3 p . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.626 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -97.48 131.37 44.17 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.797 0.332 . . . . 0.0 110.144 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -97.21 148.06 23.47 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.702 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.5 m -118.88 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.099 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 13' ' ' HIS . . . . . 0.631 ' CE1' ' NE2' ' L' ' 14' ' ' HIS . 1.8 p80 -161.7 168.87 22.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.475 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.537 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 39.4 t-80 -138.71 165.67 26.36 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.548 0.69 . . . . 0.0 110.901 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.537 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 87.4 mt-30 -148.42 178.69 8.38 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.966 -1.015 . . . . 0.0 110.091 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 16' ' ' LYS . . . . . 0.433 ' C ' HD12 ' K' ' 17' ' ' LEU . 38.2 ttmt -172.76 123.41 0.44 Allowed 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 118.419 -0.8 . . . . 0.0 111.45 -178.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 17' ' ' LEU . . . . . 0.943 ' O ' ' C ' ' L' ' 17' ' ' LEU . 9.4 mp -110.73 119.07 37.92 Favored 'General case' 0 C--N 1.379 1.85 0 CA-C-O 123.836 1.779 . . . . 0.0 111.111 177.354 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 18' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 7.1 p -138.25 112.07 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 O-C-N 120.675 -1.266 . . . . 0.0 111.432 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 1.7 p90 -134.51 139.62 45.59 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 176.383 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.47 ' CB ' ' O ' ' L' ' 20' ' ' PHE . 30.3 p90 -154.77 162.9 40.94 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -176.553 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.35 130.61 48.0 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.412 178.628 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.31 137.13 50.83 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.158 0.504 . . . . 0.0 111.965 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 56.6 t0 -159.56 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.323 178.96 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' K' ' 26' ' ' SER . 55.9 t -123.88 123.02 66.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 179.047 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.476 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 32.0 -84.35 0.0 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' K' ' 24' ' ' VAL . 8.1 t 154.31 172.0 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 121.748 0.785 . . . . 0.0 111.235 174.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.595 ' N ' ' H ' ' J' ' 28' ' ' LYS . 43.1 p-10 -53.63 179.94 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.43 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.72 112.09 1.88 Allowed 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.176 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.617 ' O ' ' HB2' ' L' ' 30' ' ' ALA . . . 75.4 -91.74 0.85 Allowed Glycine 0 CA--C 1.532 1.145 0 C-N-CA 121.285 -0.483 . . . . 0.0 112.083 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.519 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 106.48 161.13 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 104.562 -2.384 . . . . 0.0 104.562 -178.436 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.519 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -144.88 132.15 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 118.027 -1.469 . . . . 0.0 112.796 -178.269 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -124.42 123.68 66.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.3 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 114.93 2.94 Favored Glycine 0 N--CA 1.473 1.126 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 46.0 mt -122.42 127.31 49.51 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 56.8 ttp -119.83 121.29 38.77 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.234 177.758 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.506 HG22 HG23 ' J' ' 36' ' ' VAL . 60.0 t -115.4 88.17 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.23 96.06 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.85 162.19 31.51 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -124.9 137.05 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 23.3 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.448 -179.564 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -82.05 131.19 35.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.359 . . . . 0.0 110.406 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -77.93 155.0 31.13 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.098 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -110.39 131.81 60.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.116 0.484 . . . . 0.0 110.368 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -99.45 176.79 5.38 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.276 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CE1' ' K' ' 13' ' ' HIS . 0.4 OUTLIER -92.36 165.76 12.91 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.302 0.573 . . . . 0.0 110.04 -179.614 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -168.19 168.58 11.54 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.548 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.52 108.71 2.98 Favored 'General case' 0 C--O 1.171 -3.049 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 17' ' ' LEU . . . . . 0.943 ' C ' ' O ' ' K' ' 17' ' ' LEU . 2.7 mm? -73.09 160.73 31.56 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 119.654 -1.903 . . . . 0.0 107.622 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 18' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 14.3 m -99.89 -121.06 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -173.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.627 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 7.7 p90 -147.6 162.11 39.78 Favored 'General case' 0 N--CA 1.47 0.551 0 O-C-N 121.618 -0.676 . . . . 0.0 112.588 -177.178 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.47 ' O ' ' CB ' ' K' ' 20' ' ' PHE . 93.6 m-85 -144.72 151.48 38.96 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 121.718 0.77 . . . . 0.0 112.087 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.64 138.27 39.3 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -69.79 95.08 0.87 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.128 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -164.06 121.57 1.75 Allowed 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.589 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' L' ' 26' ' ' SER . 13.5 t -88.53 123.56 40.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.61 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.3 0.01 OUTLIER Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.578 ' N ' ' O ' ' L' ' 24' ' ' VAL . 12.8 t -68.13 -171.59 0.25 Allowed 'General case' 0 N--CA 1.441 -0.921 0 CA-C-O 122.593 1.187 . . . . 0.0 112.333 -177.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.415 ' O ' ' C ' ' L' ' 28' ' ' LYS . 35.4 p-10 -81.0 179.29 7.93 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 112.547 -2.115 . . . . 0.0 109.814 178.924 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' L' ' 27' ' ' ASN . 70.1 tttt -37.17 104.15 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 29' ' ' GLY . . . . . 0.402 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 167.84 -100.42 0.16 Allowed Glycine 0 C--O 1.22 -0.726 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.617 ' HB2' ' O ' ' K' ' 29' ' ' GLY . . . -49.55 169.37 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.137 1.469 . . . . 0.0 108.734 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.666 HD13 ' HA3' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -153.37 133.2 3.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.454 -177.659 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 83.7 mt -120.41 128.91 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 114.43 -1.259 . . . . 0.0 108.921 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.428 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -125.7 124.82 5.36 Favored Glycine 0 N--CA 1.468 0.808 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.2 tp -126.99 120.04 28.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 36.8 ttp -110.34 126.67 54.48 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.0 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.2 t -130.28 81.73 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.056 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.489 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -60.83 101.43 0.3 Allowed Glycine 0 N--CA 1.439 -1.161 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.16 169.28 41.36 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 57.6 t -122.73 135.84 61.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 120.742 0.306 . . . . 0.0 110.218 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.446 -179.919 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.15 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -113.83 143.89 43.91 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.804 0.335 . . . . 0.0 110.645 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' CE1' ' B' ' 13' ' ' HIS . 42.6 tp10 -56.69 144.22 33.28 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.2 160.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.445 0.641 . . . . 0.0 111.386 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.0 m80 -89.0 -170.17 2.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.905 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -80.49 168.64 18.7 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 121.357 0.599 . . . . 0.0 110.002 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -157.21 -179.86 8.6 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.878 -1.055 . . . . 0.0 108.993 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -155.22 129.32 8.82 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.695 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 72.9 mt -129.28 118.95 23.13 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.597 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -130.17 131.19 65.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -127.65 131.53 49.84 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.009 0.433 . . . . 0.0 110.712 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -132.53 125.94 31.74 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.94 137.16 44.69 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-O 121.778 0.799 . . . . 0.0 112.955 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . 0.418 ' OE2' HG21 ' B' ' 24' ' ' VAL . 78.2 tt0 -126.8 126.77 43.94 Favored 'General case' 0 CA--C 1.528 0.12 0 CA-C-N 114.625 -1.17 . . . . 0.0 108.449 178.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 24' ' ' VAL . 20.7 t70 -85.81 107.86 17.84 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.527 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.447 ' C ' ' O ' ' A' ' 23' ' ' ASP . 6.7 p -32.97 141.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 O-C-N 123.423 0.452 . . . . 0.0 109.849 178.718 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.24 82.75 1.65 Allowed Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.729 -176.393 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 27' ' ' ASN . 74.8 m -141.19 170.87 14.9 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 176.057 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.541 ' O ' ' O ' ' A' ' 26' ' ' SER . 34.8 m120 -29.47 158.47 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 118.958 -0.544 . . . . 0.0 110.941 177.447 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.47 ' O ' ' CG ' ' B' ' 27' ' ' ASN . 64.4 tttt 179.44 101.12 0.03 OUTLIER 'General case' 0 C--O 1.217 -0.624 0 C-N-CA 119.154 -1.018 . . . . 0.0 113.568 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.16 102.9 0.98 Allowed Glycine 0 N--CA 1.467 0.706 0 N-CA-C 103.622 -3.791 . . . . 0.0 103.622 170.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -97.35 144.11 27.43 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 123.311 3.555 . . . . 0.0 115.527 -172.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' G' ' 35' ' ' MET . 1.7 pt -159.82 105.56 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.421 -1.907 1 CA-C-N 107.016 -4.629 . . . . 0.0 106.245 -173.895 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.554 HG23 HD11 ' B' ' 34' ' ' LEU . 8.1 tt -108.45 114.53 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 CA-C-N 120.524 1.511 . . . . 0.0 108.107 178.236 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -121.58 124.72 5.89 Favored Glycine 0 CA--C 1.508 -0.351 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -148.83 140.4 23.47 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 122.806 1.288 . . . . 0.0 113.002 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' MET . . . . . 0.586 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 3.7 ttm -109.82 117.65 34.42 Favored 'General case' 0 CA--C 1.505 -0.786 0 CA-C-N 113.038 -1.892 . . . . 0.0 108.094 177.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -111.12 68.04 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -120.79 101.53 0.81 Allowed Glycine 0 C--N 1.359 1.842 0 N-CA-C 110.404 -1.079 . . . . 0.0 110.404 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.39 165.73 35.2 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.329 -0.709 . . . . 0.0 111.329 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' VAL . . . . . 0.479 ' O ' HG13 ' A' ' 40' ' ' VAL . 31.4 m -135.96 156.24 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.663 0.268 . . . . 0.0 110.385 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' VAL . . . . . 0.479 HG13 ' O ' ' A' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.129 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.86 145.37 42.92 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.6 0.238 . . . . 0.0 110.447 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -68.04 126.87 30.86 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.279 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m -137.08 164.1 30.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.092 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.538 ' CE1' ' OE1' ' A' ' 11' ' ' GLU . 59.4 m80 -91.36 98.14 11.52 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.546 -0.461 . . . . 0.0 109.971 179.254 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.519 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 3.7 m-70 -134.51 166.83 21.98 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -154.57 175.11 14.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.059 179.017 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -154.46 117.04 4.35 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.495 179.2 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.03 119.5 29.69 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.454 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 t -122.33 127.68 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.961 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 83.0 t80 -130.22 126.26 36.93 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.834 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -128.48 132.59 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.63 132.35 38.89 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 121.126 0.489 . . . . 0.0 111.114 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -147.88 168.0 23.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.227 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -140.27 123.2 16.55 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.153 0.502 . . . . 0.0 111.245 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.418 HG21 ' OE2' ' A' ' 22' ' ' GLU . 75.9 t -94.39 121.7 45.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.552 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 25' ' ' GLY . . . . . 0.405 ' O ' ' CB ' ' B' ' 26' ' ' SER . . . 45.74 85.53 0.01 OUTLIER Glycine 0 CA--C 1.53 1.023 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.853 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.714 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.9 t 162.12 161.0 0.02 OUTLIER 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 178.65 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.714 ' O ' ' O ' ' B' ' 26' ' ' SER . 11.9 m120 -30.13 171.99 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.515 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.494 ' HB3' ' N ' ' C' ' 24' ' ' VAL . 95.7 mttt -159.6 103.89 1.58 Allowed 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -178.064 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.799 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . 69.42 -105.32 1.48 Allowed Glycine 1 CA--C 1.417 -6.093 0 CA-C-O 115.111 -3.05 . . . . 0.0 111.33 -178.689 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.799 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . 76.0 -135.22 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.71 2 C-N-CA 108.667 -5.213 . . . . 0.0 99.248 -174.351 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.973 ' N ' HD13 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -75.47 122.65 29.74 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -179.325 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 83.3 mt -121.73 122.16 66.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 175.322 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 33' ' ' GLY . . . . . 0.701 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -132.47 111.07 0.99 Allowed Glycine 0 N--CA 1.473 1.119 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.075 179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.701 HD12 ' C ' ' B' ' 33' ' ' GLY . 6.4 mp -138.31 144.85 40.61 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 123.47 1.605 . . . . 0.0 113.168 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.506 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 19.6 ttm -119.07 115.85 25.16 Favored 'General case' 0 CA--C 1.499 -0.999 0 CA-C-N 113.002 -1.908 . . . . 0.0 107.41 177.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.26 70.62 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.096 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.3 112.5 3.46 Favored Glycine 0 C--N 1.363 2.057 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 -179.105 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 38' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' C' ' 37' ' ' GLY . . . -73.04 147.73 40.07 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -139.49 161.34 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.807 0.337 . . . . 0.0 110.424 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.026 -0.987 . . . . 0.0 110.518 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -81.71 128.13 33.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.798 0.332 . . . . 0.0 110.413 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -148.96 132.04 16.3 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.157 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 12' ' ' VAL . . . . . 0.432 HG12 ' H ' ' D' ' 12' ' ' VAL . 18.6 m -140.76 162.69 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 121.3 0.571 . . . . 0.0 111.364 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -118.8 138.29 52.8 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.877 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 14' ' ' HIS . . . . . 0.783 ' HD1' ' N ' ' C' ' 15' ' ' GLN . 28.8 t-80 -152.38 165.45 34.97 Favored 'General case' 0 CA--C 1.513 -0.463 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.339 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 15' ' ' GLN . . . . . 0.783 ' N ' ' HD1' ' C' ' 14' ' ' HIS . 75.8 mt-30 -156.44 170.35 22.51 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.025 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -158.87 111.59 2.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.829 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -121.96 122.07 38.52 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -126.67 124.52 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.128 0.49 . . . . 0.0 111.831 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' B' ' 34' ' ' LEU . 1.0 OUTLIER -116.54 110.75 18.99 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 105.89 -1.893 . . . . 0.0 105.89 177.456 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -115.36 121.02 41.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.87 130.59 53.06 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.697 0.761 . . . . 0.0 111.673 -179.253 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -121.18 91.53 3.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.994 178.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -169.86 123.67 0.75 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.816 -1.154 . . . . 0.0 113.129 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.494 ' N ' ' HB3' ' B' ' 28' ' ' LYS . 11.5 t -146.89 106.9 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 174.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 25' ' ' GLY . . . . . 0.444 ' N ' ' HB2' ' B' ' 28' ' ' LYS . . . -38.33 -94.97 0.01 OUTLIER Glycine 0 N--CA 1.482 1.729 0 CA-C-O 122.201 0.89 . . . . 0.0 112.828 -177.929 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' C' ' 27' ' ' ASN . 25.5 p -150.57 170.0 20.2 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 103.968 -2.605 . . . . 0.0 103.968 176.036 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' C' ' 26' ' ' SER . 63.4 t30 43.18 -179.37 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.999 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.61 ' HZ1' ' N ' ' E' ' 27' ' ' ASN . 81.6 mttt -86.67 -117.69 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.719 0 O-C-N 120.94 -1.1 . . . . 0.0 109.87 179.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 43.6 89.69 0.01 OUTLIER Glycine 0 N--CA 1.469 0.873 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.342 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.401 ' C ' HD13 ' C' ' 31' ' ' ILE . . . -157.48 165.74 34.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 175.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.498 HG22 ' HB ' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.94 121.29 15.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 118.481 -1.287 . . . . 0.0 111.237 -173.687 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 32' ' ' ILE . . . . . 0.458 ' O ' ' CE ' ' I' ' 35' ' ' MET . 12.1 tt -116.72 122.35 69.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-O 121.487 0.661 . . . . 0.0 111.039 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 33' ' ' GLY . . . . . 0.418 ' N ' ' HE1' ' H' ' 35' ' ' MET . . . -110.61 117.36 4.62 Favored Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.876 HD11 ' CZ ' ' D' ' 19' ' ' PHE . 0.4 OUTLIER -146.2 138.23 25.07 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.861 1.315 . . . . 0.0 113.006 -178.099 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 15.0 ttm -129.09 127.37 41.35 Favored 'General case' 0 CA--C 1.505 -0.753 0 CA-C-N 113.446 -1.707 . . . . 0.0 109.449 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.91 78.06 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' B' ' 38' ' ' GLY . . . -69.64 104.78 1.37 Allowed Glycine 0 C--N 1.351 1.399 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.56 -179.33 52.2 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.89 144.21 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.939 0.399 . . . . 0.0 110.771 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.561 179.943 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -106.05 136.68 45.3 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.938 0.399 . . . . 0.0 110.571 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.16 148.53 28.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.365 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 12' ' ' VAL . . . . . 0.432 ' H ' HG12 ' C' ' 12' ' ' VAL . 3.4 m -134.56 160.98 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.405 179.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 13' ' ' HIS . . . . . 0.435 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 9.5 m80 -123.44 154.81 38.55 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.685 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 14' ' ' HIS . . . . . 0.435 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 47.2 m80 -151.02 164.99 35.13 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.158 0.504 . . . . 0.0 110.06 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -158.99 169.51 24.14 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.553 178.41 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -159.43 117.13 2.73 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.316 178.432 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 17' ' ' LEU . . . . . 0.402 HD13 ' CD2' ' E' ' 17' ' ' LEU . 5.9 mp -119.34 123.78 45.01 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.147 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -126.29 127.05 70.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 19' ' ' PHE . . . . . 0.876 ' CZ ' HD11 ' C' ' 34' ' ' LEU . 1.8 t80 -125.39 113.5 17.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -122.8 131.55 53.82 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -176.026 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 109.77 16.7 Favored 'General case' 0 C--O 1.249 1.079 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 177.687 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' E' ' 22' ' ' GLU . 87.2 tt0 -165.23 91.46 0.53 Allowed 'General case' 0 C--N 1.347 0.487 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -76.06 -131.34 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 102.915 -2.995 . . . . 0.0 102.915 173.259 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' D' ' 25' ' ' GLY . 57.1 t -90.98 112.35 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.591 0 N-CA-C 101.089 -3.671 . . . . 0.0 101.089 173.792 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 41.32 89.69 0.01 OUTLIER Glycine 0 CA--C 1.535 1.294 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -173.883 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.434 ' O ' ' O ' ' E' ' 22' ' ' GLU . 4.0 m -69.95 164.54 23.63 Favored 'General case' 0 CA--C 1.498 -1.028 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.854 -178.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 27' ' ' ASN . . . . . 0.444 ' O ' ' O ' ' E' ' 22' ' ' GLU . 51.1 p-10 -79.2 174.39 11.61 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 123.875 1.798 . . . . 0.0 115.495 178.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 28' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' D' ' 30' ' ' ALA 0.319 21.6 tttt -49.02 111.17 0.44 Allowed 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 109.624 -3.444 . . . . 0.0 116.797 172.1 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' D' ' 30' ' ' ALA . . . -72.22 100.57 0.96 Allowed Glycine 0 CA--C 1.45 -3.998 1 N-CA-C 102.656 -4.178 . . . . 0.0 102.656 -178.344 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' D' ' 28' ' ' LYS . . . -70.56 -130.8 0.0 OUTLIER 'General case' 1 N--CA 1.372 -4.338 4 CA-C-N 101.161 -7.519 . . . . 0.0 97.485 -176.469 . . . . . . . . 4 3 . 1 . 009 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.786 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 1.0 OUTLIER -74.74 111.88 11.29 Favored 'Isoleucine or valine' 1 C--N 1.243 -4.029 0 CA-C-N 123.176 2.716 . . . . 0.0 111.714 -176.013 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' D' D ' 32' ' ' ILE . . . . . 0.54 HG21 HG23 ' E' ' 32' ' ' ILE . 0.2 OUTLIER -110.92 115.51 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 178.126 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 33' ' ' GLY . . . . . 0.551 ' CA ' ' SD ' ' J' ' 35' ' ' MET . . . -113.72 98.67 0.93 Allowed Glycine 0 CA--C 1.503 -0.689 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 34' ' ' LEU . . . . . 0.426 HD22 ' CZ ' ' E' ' 19' ' ' PHE . 61.7 mt -128.31 128.46 44.64 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -176.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 35' ' ' MET . . . . . 0.508 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -123.5 128.85 50.37 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.068 177.214 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.521 ' O ' HG23 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -122.9 80.36 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.457 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -23.36 -95.45 0.01 OUTLIER Glycine 0 C--N 1.361 1.955 0 O-C-N 123.0 0.187 . . . . 0.0 112.639 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 125.84 -178.28 16.73 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' D' D ' 39' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 40' ' ' VAL . 34.3 m -123.27 137.1 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' D' D ' 40' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 39' ' ' VAL . 11.2 t . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.392 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -116.89 140.12 49.82 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.789 0.328 . . . . 0.0 110.716 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -63.88 145.17 56.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.692 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.53 127.93 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.029 0.442 . . . . 0.0 110.029 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 13' ' ' HIS . . . . . 0.479 ' CD2' ' HB3' ' F' ' 13' ' ' HIS . 22.9 p80 -164.38 157.74 17.81 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.945 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 73.4 m80 -135.54 167.78 20.46 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -155.29 167.83 29.06 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.362 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -148.19 117.37 6.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.123 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 17' ' ' LEU . . . . . 0.402 ' CD2' HD13 ' D' ' 17' ' ' LEU . 25.5 mt -114.66 122.17 45.63 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 177.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.28 136.35 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-O 122.125 0.964 . . . . 0.0 113.578 -177.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 19' ' ' PHE . . . . . 0.478 ' CB ' ' CE1' ' F' ' 19' ' ' PHE . 0.6 OUTLIER -121.37 126.05 48.48 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 113.832 -1.531 . . . . 0.0 109.091 178.783 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -127.22 129.85 48.56 Favored 'General case' 0 N--CA 1.481 1.076 0 O-C-N 122.079 -0.388 . . . . 0.0 110.663 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.12 125.68 16.8 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.002 0.43 . . . . 0.0 110.749 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 93.9 mt-10 -93.25 156.32 16.9 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.494 -0.882 . . . . 0.0 113.313 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -133.02 141.39 48.24 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.201 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.35 111.08 34.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 25' ' ' GLY . . . . . 0.543 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 34.6 90.81 0.01 OUTLIER Glycine 0 N--CA 1.472 1.049 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 26' ' ' SER . . . . . 0.543 ' O ' ' O ' ' E' ' 25' ' ' GLY . 11.6 p -32.9 170.53 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 122.232 1.015 . . . . 0.0 113.179 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.61 ' N ' ' HZ1' ' C' ' 28' ' ' LYS . 19.6 m120 -158.52 178.15 10.46 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.466 177.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 28' ' ' LYS . . . . . 0.472 ' C ' ' O ' ' E' ' 27' ' ' ASN . 64.4 mttp 4.78 -106.36 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.994 0.918 . . . . 0.0 113.437 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.0 95.57 0.17 Allowed Glycine 0 C--N 1.346 1.114 0 C-N-CA 120.592 -0.813 . . . . 0.0 113.275 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -66.63 177.62 1.53 Allowed 'General case' 0 C--O 1.241 0.608 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 175.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.601 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.3 OUTLIER -149.62 120.28 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 117.972 -1.491 . . . . 0.0 109.168 -176.685 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.54 HG23 HG21 ' D' ' 32' ' ' ILE . 97.0 mt -117.69 126.56 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.569 -176.489 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.14 110.63 1.82 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.588 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 60.7 mt -121.14 123.22 41.78 Favored 'General case' 0 N--CA 1.467 0.375 0 O-C-N 122.756 -0.261 . . . . 0.0 110.742 -179.805 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.7 ttt -135.46 131.21 35.88 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 119.678 -0.809 . . . . 0.0 112.46 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.644 HG22 ' O ' ' E' ' 36' ' ' VAL . 0.6 OUTLIER -158.11 81.36 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.85 178.986 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.13 101.64 1.61 Allowed Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.98 154.89 21.36 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.43 145.1 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.404 -179.661 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -111.0 133.41 53.41 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.779 0.323 . . . . 0.0 110.572 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 71.3 mm-40 -70.71 142.2 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.195 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.31 176.0 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 121.082 0.467 . . . . 0.0 110.552 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.479 ' HB3' ' CD2' ' E' ' 13' ' ' HIS . 56.8 p-80 -99.37 159.88 14.68 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.64 179.256 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -153.48 178.37 9.89 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 15' ' ' GLN . . . . . 0.471 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 42.7 tt0 -148.92 166.64 27.99 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.281 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 16' ' ' LYS . . . . . 0.471 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 68.5 mttm -142.68 131.54 22.86 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.295 0.569 . . . . 0.0 111.608 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 17' ' ' LEU . . . . . 0.427 ' CD2' HG11 ' E' ' 36' ' ' VAL . 56.1 tp -121.75 123.45 41.86 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.72 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.34 127.43 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 121.553 0.692 . . . . 0.0 111.14 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.588 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 0.5 OUTLIER -122.13 114.48 20.94 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.9 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -120.41 117.3 27.36 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-O 121.313 0.578 . . . . 0.0 110.358 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.97 136.87 46.33 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 22' ' ' GLU . . . . . 0.487 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 70.5 mm-40 -70.18 122.1 18.81 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.07 -1.052 . . . . 0.0 111.524 -178.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 1.8 p-10 108.6 131.94 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.888 1.675 . . . . 0.0 109.33 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' F' ' 25' ' ' GLY . 2.4 m -110.22 113.44 44.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . 32.28 87.72 0.01 OUTLIER Glycine 0 CA--C 1.527 0.797 0 N-CA-C 111.838 -0.505 . . . . 0.0 111.838 178.953 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 62.7 m -65.17 -174.6 0.17 Allowed 'General case' 0 N--CA 1.438 -1.028 0 CA-C-O 121.448 0.642 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.432 ' O ' ' C ' ' F' ' 28' ' ' LYS . 96.5 m-20 -81.06 178.24 8.54 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.289 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.432 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.3 tttt -38.15 103.93 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 29' ' ' GLY . . . . . 0.44 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 166.02 -100.54 0.17 Allowed Glycine 0 C--O 1.219 -0.796 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -176.008 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.414 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -53.75 168.54 0.19 Allowed 'General case' 0 CA--C 1.509 -0.61 0 CA-C-N 118.038 0.919 . . . . 0.0 108.953 -178.56 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.547 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -150.91 128.1 2.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 C-N-CA 119.331 -0.947 . . . . 0.0 109.309 -174.586 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 17.2 tt -128.2 138.86 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-O 120.909 0.385 . . . . 0.0 111.873 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.41 124.27 3.64 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.2 tp -119.11 122.57 42.37 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.6 tpt -118.54 121.28 39.86 Favored 'General case' 0 N--CA 1.478 0.966 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' F' ' 37' ' ' GLY . 2.9 m -141.84 80.63 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 177.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . 18.1 -104.86 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 CA-C-N 117.516 0.144 . . . . 0.0 113.169 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.64 -161.29 22.82 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -134.37 161.45 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.387 179.939 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -121.16 139.04 53.89 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.652 0.263 . . . . 0.0 110.607 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -69.11 157.2 37.33 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.902 0.382 . . . . 0.0 110.717 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 12' ' ' VAL . . . . . 0.415 ' CG1' ' ND1' ' H' ' 13' ' ' HIS . 55.3 t -118.12 134.48 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.265 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -112.26 157.98 20.27 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.533 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.514 ' HB2' ' CE1' ' H' ' 14' ' ' HIS . 45.1 p-80 -81.99 174.58 11.12 Favored 'General case' 0 N--CA 1.442 -0.866 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -143.93 179.47 7.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.089 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -152.71 135.19 15.17 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -136.24 117.85 14.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.421 0.629 . . . . 0.0 110.539 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.81 136.31 55.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.619 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -136.09 131.81 35.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-O 121.369 0.604 . . . . 0.0 111.319 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -125.95 130.67 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.61 148.26 45.69 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 122.316 1.055 . . . . 0.0 113.207 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -101.93 -177.67 3.48 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 113.406 -1.724 . . . . 0.0 108.901 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 23' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' G' ' 26' ' ' SER . 67.3 t0 -58.45 123.86 17.62 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.203 -0.599 . . . . 0.0 110.184 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 24' ' ' VAL . . . . . 0.53 ' O ' HG23 ' G' ' 24' ' ' VAL . 23.0 m -95.56 120.59 45.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.926 -179.042 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.93 -88.73 0.01 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 116.111 -0.495 . . . . 0.0 112.607 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.474 ' N ' ' O ' ' G' ' 24' ' ' VAL . 72.2 m -67.52 -171.6 0.2 Allowed 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.549 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 52.8 t30 -78.79 178.77 7.66 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.186 -178.388 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.549 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 83.9 tttt -44.17 -110.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.143 0.794 . . . . 0.0 113.143 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 54.33 91.88 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.424 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -102.62 161.9 13.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 C-N-CA 116.696 -2.002 . . . . 0.0 108.628 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.505 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.1 OUTLIER -152.36 110.06 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.023 -174.829 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' G' G ' 32' ' ' ILE . . . . . 0.586 ' N ' ' SD ' ' A' ' 35' ' ' MET . 97.3 mt -108.36 110.21 31.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.197 0.523 . . . . 0.0 110.241 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 92.49 0.62 Allowed Glycine 0 CA--C 1.502 -0.761 0 N-CA-C 105.648 -2.981 . . . . 0.0 105.648 175.984 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.723 ' O ' HD12 ' H' ' 34' ' ' LEU . 16.7 mt -130.93 134.19 46.53 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.725 1.726 . . . . 0.0 111.984 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 0.0 OUTLIER -108.4 117.96 35.53 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 112.678 -2.055 . . . . 0.0 109.019 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.35 66.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 N-CA-C 109.244 -0.651 . . . . 0.0 109.244 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.22 -103.52 0.59 Allowed Glycine 0 C--N 1.363 2.063 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.84 162.61 25.23 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.562 179.002 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.21 147.87 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.826 -179.741 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.102 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -113.21 142.59 45.62 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.853 0.358 . . . . 0.0 110.519 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -77.44 127.35 32.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.605 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -137.27 139.35 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.036 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 13' ' ' HIS . . . . . 0.415 ' ND1' ' CG1' ' G' ' 12' ' ' VAL . 82.8 t60 -147.26 107.83 4.12 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.683 -0.407 . . . . 0.0 109.99 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.618 ' CG ' ' CE1' ' I' ' 14' ' ' HIS . 27.6 p80 -146.73 171.17 15.56 Favored 'General case' 0 N--CA 1.447 -0.586 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.283 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -144.35 177.25 8.76 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.13 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -152.8 131.22 12.13 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.9 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -129.36 118.56 22.42 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.934 0.397 . . . . 0.0 110.414 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -128.34 131.32 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.93 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -126.1 128.99 48.22 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.601 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 0.9 OUTLIER -134.76 128.03 32.07 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.605 -0.27 . . . . 0.0 110.389 -179.187 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.52 123.54 40.33 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.858 0.361 . . . . 0.0 110.226 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 22' ' ' GLU . . . . . 0.551 ' OE2' ' CE1' ' H' ' 20' ' ' PHE . 9.7 pt-20 -168.42 130.05 1.35 Allowed 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 119.897 -0.721 . . . . 0.0 112.157 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 20.0 t70 178.83 114.72 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.389 0.614 . . . . 0.0 112.376 177.386 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t -28.89 122.86 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 114.724 -1.126 . . . . 0.0 112.364 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.48 -84.78 0.06 OUTLIER Glycine 0 CA--C 1.526 0.763 0 C-N-CA 119.959 -1.115 . . . . 0.0 112.098 178.513 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.545 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.4 OUTLIER -170.77 -179.96 3.02 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 119.001 1.401 . . . . 0.0 112.276 179.42 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.545 ' O ' ' O ' ' H' ' 26' ' ' SER . 82.8 m-20 26.62 -170.79 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 112.426 -2.17 . . . . 0.0 115.216 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.408 ' O ' ' O ' ' H' ' 29' ' ' GLY . 86.3 tttt -143.7 -103.98 0.12 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.601 -1.181 . . . . 0.0 111.776 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.408 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 39.94 95.43 0.01 OUTLIER Glycine 0 CA--C 1.494 -1.278 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -177.578 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.92 153.14 27.16 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 178.276 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.491 HG22 ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -139.55 123.1 18.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 119.512 -0.875 . . . . 0.0 109.457 -176.356 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.506 ' N ' ' SD ' ' B' ' 35' ' ' MET . 1.7 mt -115.45 119.09 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.974 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.89 103.69 1.14 Allowed Glycine 0 C--O 1.241 0.588 0 N-CA-C 105.769 -2.932 . . . . 0.0 105.769 175.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.723 HD12 ' O ' ' G' ' 34' ' ' LEU . 5.9 tp -133.74 144.13 48.89 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 122.919 1.342 . . . . 0.0 114.01 -176.16 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.418 ' HE1' ' N ' ' C' ' 33' ' ' GLY . 5.8 tpt -122.25 115.58 22.62 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 113.448 -1.706 . . . . 0.0 108.873 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.47 65.11 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.19 103.86 0.64 Allowed Glycine 0 C--N 1.353 1.504 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -90.24 176.41 41.95 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' H' H ' 39' ' ' VAL . . . . . 0.522 HG12 ' N ' ' H' ' 40' ' ' VAL . 40.5 t -137.24 161.45 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 120.929 0.395 . . . . 0.0 110.634 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' H' H ' 40' ' ' VAL . . . . . 0.522 ' N ' HG12 ' H' ' 39' ' ' VAL . 7.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.957 -1.02 . . . . 0.0 110.424 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -90.73 125.03 35.56 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 11' ' ' GLU . . . . . 0.494 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 96.9 mt-10 -82.48 164.48 20.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.935 -179.498 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 12' ' ' VAL . . . . . 0.428 HG12 ' H ' ' J' ' 12' ' ' VAL . 34.4 m -93.26 135.14 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.528 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 13' ' ' HIS . . . . . 0.494 ' CD2' ' O ' ' I' ' 11' ' ' GLU . 3.3 m-70 -142.09 156.97 45.4 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.125 -178.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' H' ' 14' ' ' HIS . 16.9 p-80 -156.66 167.53 30.17 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 177.413 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.449 ' CG ' ' N ' ' I' ' 16' ' ' LYS . 52.1 tt0 -150.98 166.66 29.99 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.629 0.728 . . . . 0.0 111.519 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 16' ' ' LYS . . . . . 0.525 ' NZ ' ' CG2' ' I' ' 18' ' ' VAL . 65.9 tttm -154.41 127.57 8.37 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.85 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 17' ' ' LEU . . . . . 0.41 HD21 ' CE2' ' I' ' 19' ' ' PHE . 59.3 tp -124.36 121.77 35.86 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 18' ' ' VAL . . . . . 0.525 ' CG2' ' NZ ' ' I' ' 16' ' ' LYS . 47.8 t -122.95 125.54 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.832 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CE2' HD21 ' I' ' 17' ' ' LEU . 60.5 m-85 -114.2 105.86 13.68 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 176.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 1.4 t80 -117.76 126.53 52.62 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 132.97 39.92 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.141 0.496 . . . . 0.0 111.813 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -159.35 114.47 2.45 Favored 'General case' 0 C--N 1.348 0.52 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 23' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' I' ' 23' ' ' ASP . 9.4 t0 -171.9 111.02 0.29 Allowed 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 114.435 1.272 . . . . 0.0 114.435 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.462 HG13 ' O ' ' I' ' 24' ' ' VAL . 12.4 p -31.99 131.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 CA-C-N 112.611 -2.086 . . . . 0.0 115.425 174.478 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -84.22 0.09 OUTLIER Glycine 0 CA--C 1.543 1.841 0 C-N-CA 119.605 -1.283 . . . . 0.0 115.157 174.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.3 m -96.76 175.41 6.37 Favored 'General case' 0 CA--C 1.5 -0.944 0 CA-C-N 120.401 2.1 . . . . 0.0 108.916 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.45 ' O ' ' O ' ' I' ' 28' ' ' LYS . 46.2 m-20 -62.52 175.62 0.76 Allowed 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' I' ' 27' ' ' ASN . 53.4 tttt -45.1 -107.88 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 122.301 1.048 . . . . 0.0 113.796 178.078 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . 87.73 -100.01 2.56 Favored Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.907 ' C ' HD13 ' I' ' 31' ' ' ILE . . . 62.81 143.6 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.083 0 O-C-N 121.498 -1.001 . . . . 0.0 109.135 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.907 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -145.26 114.47 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.373 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' I' ' 32' ' ' ILE . 1.2 tt -108.19 112.38 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.97 113.86 2.56 Favored Glycine 0 CA--C 1.493 -1.288 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 0.549 HD23 ' N ' ' I' ' 34' ' ' LEU . 2.0 pt? -162.06 160.73 27.83 Favored 'General case' 0 C--O 1.249 1.041 0 CA-C-O 123.304 1.526 . . . . 0.0 112.695 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.491 ' SD ' ' HB ' ' C' ' 31' ' ' ILE . 33.2 ttm -127.71 136.6 51.77 Favored 'General case' 0 CA--C 1.503 -0.827 0 CA-C-N 112.351 -2.204 . . . . 0.0 111.052 -177.925 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.99 70.63 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.186 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.98 106.37 3.28 Favored Glycine 0 C--N 1.364 2.098 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.7 172.01 55.16 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.214 -0.755 . . . . 0.0 111.214 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -144.36 149.01 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.408 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -144.96 155.72 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -103.78 144.07 31.97 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.922 0.392 . . . . 0.0 111.252 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 12' ' ' VAL . . . . . 0.428 ' H ' HG12 ' I' ' 12' ' ' VAL . 5.5 p -136.91 150.79 26.86 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.981 0.896 . . . . 0.0 112.591 -178.739 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 0.8 OUTLIER -150.9 105.62 3.28 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 114.08 -1.418 . . . . 0.0 109.548 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -149.27 166.8 27.86 Favored 'General case' 0 CA--C 1.508 -0.643 0 O-C-N 121.641 -0.662 . . . . 0.0 110.598 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 13.3 mp0 -146.68 169.97 17.93 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.675 0.75 . . . . 0.0 111.414 179.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -143.71 135.88 26.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.152 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -133.87 124.61 26.75 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.65 133.69 61.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 CA-C-O 121.289 0.566 . . . . 0.0 112.078 -178.701 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 91.7 m-85 -112.02 113.84 26.37 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.39 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.45 ' CD1' ' CZ ' ' I' ' 20' ' ' PHE . 5.7 t80 -122.16 123.15 40.84 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 118.518 0.599 . . . . 0.0 112.592 -178.27 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.24 131.52 38.59 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 122.047 -0.408 . . . . 0.0 110.873 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 18.2 pt-20 -151.88 168.44 25.13 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.461 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.482 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 6.7 p30 150.94 164.12 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.149 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' J' ' 23' ' ' ASP . 48.8 t -35.83 101.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.44 93.36 0.5 Allowed Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.227 -0.897 . . . . 0.0 114.87 -175.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.751 ' O ' ' O ' ' J' ' 27' ' ' ASN . 39.3 p -102.79 160.63 14.43 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 175.95 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.751 ' O ' ' O ' ' J' ' 26' ' ' SER . 92.2 m-20 38.17 -179.22 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -174.035 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.677 ' N ' ' ND2' ' K' ' 27' ' ' ASN . 88.0 tttt -148.95 108.37 3.96 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 114.968 -2.693 . . . . 0.0 115.747 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -76.23 95.07 1.05 Allowed Glycine 0 CA--C 1.493 -1.285 0 CA-C-O 114.938 -3.146 . . . . 0.0 108.65 166.121 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' I' ' 29' ' ' GLY . . . -137.32 142.7 41.85 Favored 'General case' 0 CA--C 1.463 -2.381 1 CA-C-N 124.891 4.346 . . . . 0.0 108.061 176.136 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.621 HD12 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -142.91 106.12 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.357 -177.774 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.517 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -105.32 116.7 49.63 Favored 'Isoleucine or valine' 0 C--N 1.359 0.993 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.677 -178.356 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.38 96.45 0.72 Allowed Glycine 0 C--O 1.24 0.49 0 N-CA-C 106.447 -2.661 . . . . 0.0 106.447 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.803 HD23 ' CZ ' ' L' ' 19' ' ' PHE . 8.2 tp -134.25 124.87 26.63 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-O 122.695 1.236 . . . . 0.0 111.975 -177.19 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 35' ' ' MET . . . . . 0.562 ' N ' HD12 ' J' ' 34' ' ' LEU . 4.3 ttt -119.87 126.96 52.21 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 113.345 -1.752 . . . . 0.0 109.176 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' J' J ' 36' ' ' VAL . . . . . 0.557 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -113.58 73.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.187 -178.952 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.66 112.46 0.4 Allowed Glycine 0 C--N 1.354 1.543 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.49 -139.86 0.33 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.583 -0.607 . . . . 0.0 111.583 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 54.5 t -109.42 133.66 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.972 0.415 . . . . 0.0 110.089 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.07 -0.967 . . . . 0.0 110.928 -179.542 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -112.54 145.64 39.94 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.836 0.35 . . . . 0.0 110.618 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 11' ' ' GLU . . . . . 0.491 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 54.9 mp0 -84.5 134.43 34.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.678 -179.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.71 131.0 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -114.49 117.23 30.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.775 0.321 . . . . 0.0 111.403 -179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 55.6 t-80 -135.33 164.39 27.85 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.42 0.629 . . . . 0.0 109.846 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 15' ' ' GLN . . . . . 0.527 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 86.0 mt-30 -157.05 172.49 18.58 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.634 178.468 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.5 tttm -155.92 122.77 5.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.36 179.217 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.6 mt -125.13 120.42 31.33 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 4.2 m -136.38 134.17 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-O 121.538 0.685 . . . . 0.0 112.654 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 0.623 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 87.5 m-85 -115.31 110.7 19.79 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' L' ' 20' ' ' PHE . 7.8 m-85 -114.01 124.11 51.33 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -177.818 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 127.05 34.21 Favored 'General case' 0 N--CA 1.474 0.739 0 O-C-N 121.758 -0.589 . . . . 0.0 110.57 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.18 127.61 47.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.583 -179.055 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 23' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' K' ' 24' ' ' VAL . 3.6 t70 174.96 146.69 0.07 Allowed 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.523 HG23 ' H ' ' K' ' 25' ' ' GLY . 2.8 m -21.89 -101.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 123.487 0.492 . . . . 0.0 111.712 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.523 ' H ' HG23 ' K' ' 24' ' ' VAL . . . 159.84 -91.36 0.11 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.807 177.706 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.683 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 75.3 m -54.23 160.8 1.5 Allowed 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 118.147 0.974 . . . . 0.0 108.381 178.185 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' O ' ' K' ' 26' ' ' SER . 23.2 p30 132.52 171.04 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 O-C-N 125.083 1.49 . . . . 0.0 111.715 176.129 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -30.27 104.92 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 29' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.8 -100.6 2.09 Favored Glycine 0 C--O 1.215 -1.056 0 N-CA-C 115.737 1.055 . . . . 0.0 115.737 170.28 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.431 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 60.77 145.29 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 106.436 -1.691 . . . . 0.0 106.436 -178.72 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.431 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -160.85 134.41 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 121.614 2.006 . . . . 0.0 113.219 -179.253 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 98.0 mt -124.98 121.23 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.766 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.517 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -119.26 115.53 3.07 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 34' ' ' LEU . . . . . 0.423 HD11 ' CG2' ' J' ' 36' ' ' VAL . 38.1 tp -124.98 121.62 34.96 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.149 -0.525 . . . . 0.0 111.271 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mmm -131.33 133.01 44.91 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.348 178.683 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 36' ' ' VAL . . . . . 0.557 HG22 HG23 ' J' ' 36' ' ' VAL . 15.0 t -123.22 82.58 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.444 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.601 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -70.6 101.33 0.9 Allowed Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' L' ' 37' ' ' GLY . . . -158.4 155.62 26.63 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -135.74 146.85 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-O 120.859 0.361 . . . . 0.0 110.836 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.1 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.408 179.893 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -149.16 159.34 44.33 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.625 0.25 . . . . 0.0 110.608 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 11' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' K' ' 11' ' ' GLU . 80.7 tt0 -102.99 154.24 19.43 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.105 0.479 . . . . 0.0 110.439 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -138.94 151.96 23.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -116.24 171.15 8.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 120.961 0.41 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -78.34 176.28 9.47 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.646 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 23.3 mt-30 -138.37 175.32 9.67 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -146.07 142.31 28.43 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.324 0.583 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -126.17 113.01 16.46 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -130.35 128.45 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.329 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.803 ' CZ ' HD23 ' J' ' 34' ' ' LEU . 9.3 m-30 -109.06 109.03 19.95 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 20' ' ' PHE . . . . . 0.409 ' O ' ' HA ' ' K' ' 20' ' ' PHE . 33.7 t80 -112.53 114.03 26.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.392 0.615 . . . . 0.0 110.637 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 21' ' ' ALA . . . . . 0.422 ' O ' ' OD2' ' L' ' 23' ' ' ASP . . . -126.74 133.93 50.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.354 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' K' ' 24' ' ' VAL . 84.3 tt0 -60.68 105.48 0.45 Allowed 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.308 -177.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.422 ' OD2' ' O ' ' L' ' 21' ' ' ALA . 7.0 m-20 -154.46 136.21 14.44 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.329 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 24' ' ' VAL . . . . . 0.624 HG23 ' O ' ' L' ' 24' ' ' VAL . 22.5 m -109.99 111.74 37.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 119.862 -0.735 . . . . 0.0 110.566 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 25' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 26' ' ' SER . . . 31.84 -91.3 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-N 115.194 -0.912 . . . . 0.0 114.438 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' L' ' 25' ' ' GLY . 3.9 m 47.23 171.91 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.033 -1.083 . . . . 0.0 110.965 -176.635 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.526 ' O ' ' O ' ' L' ' 28' ' ' LYS . 72.3 m-80 -140.09 -177.88 5.2 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.365 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.526 ' O ' ' O ' ' L' ' 27' ' ' ASN . 99.2 mttt 26.5 102.13 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.068 0 O-C-N 123.716 0.635 . . . . 0.0 112.196 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.39 -101.57 0.21 Allowed Glycine 0 CA--C 1.493 -1.283 0 C-N-CA 119.913 -1.137 . . . . 0.0 111.791 -176.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 30' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -52.29 161.11 0.69 Allowed 'General case' 0 CA--C 1.514 -0.404 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.375 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -136.04 121.79 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.641 -177.331 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -129.03 138.46 54.46 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.279 0 CA-C-N 115.637 -0.711 . . . . 0.0 111.626 -178.263 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.97 120.99 3.25 Favored Glycine 0 N--CA 1.46 0.253 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 34' ' ' LEU . . . . . 0.435 ' O ' HD12 ' L' ' 34' ' ' LEU . 2.9 pp -126.12 122.24 35.16 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 38.2 mtp -134.81 143.49 47.08 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 122.147 0.975 . . . . 0.0 112.681 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -131.25 80.73 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 113.642 -1.617 . . . . 0.0 110.159 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.547 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -55.31 102.47 0.16 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.53 28.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.32 134.19 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.871 0.367 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.588 -179.843 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -103.72 131.54 50.8 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.803 0.335 . . . . 0.0 110.427 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -136.92 133.11 35.34 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.932 0.396 . . . . 0.0 110.061 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' B' ' 12' ' ' VAL . 2.4 p -136.28 145.11 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.634 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 72.9 m80 -114.72 106.35 14.11 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' HIS . . . . . 0.44 ' CE1' ' O ' ' A' ' 15' ' ' GLN . 14.8 t60 -135.55 159.72 40.73 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 109.767 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.44 ' O ' ' CE1' ' A' ' 14' ' ' HIS . 28.7 mm100 -157.64 -178.93 7.69 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.847 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -147.8 122.54 9.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.6 mt -129.64 117.25 20.07 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.062 0.458 . . . . 0.0 110.659 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.5 131.05 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.098 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -123.25 134.17 54.12 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.6 p90 -137.12 124.84 22.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.898 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.24 128.21 45.67 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-O 120.733 0.302 . . . . 0.0 111.253 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -147.39 146.66 29.7 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.248 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.497 ' CG ' ' H ' ' A' ' 24' ' ' VAL . 22.7 t0 -152.09 -141.21 0.1 Allowed 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 177.272 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.497 ' H ' ' CG ' ' A' ' 23' ' ' ASP . 80.3 t -90.26 111.28 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 C-N-CA 119.248 -0.981 . . . . 0.0 109.72 179.048 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.65 91.47 0.01 OUTLIER Glycine 0 CA--C 1.536 1.346 0 CA-C-O 118.943 -0.92 . . . . 0.0 113.208 177.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 27' ' ' ASN . 88.2 p -141.22 169.99 16.58 Favored 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 119.419 1.61 . . . . 0.0 108.985 175.578 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' A' ' 26' ' ' SER . 99.8 m-20 -29.52 157.62 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 O-C-N 123.799 0.687 . . . . 0.0 111.296 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.479 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 33.1 pttt 178.83 102.03 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 175.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.53 100.61 0.62 Allowed Glycine 0 CA--C 1.496 -1.151 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 174.145 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ALA . . . . . 0.574 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . -99.37 151.89 20.57 Favored 'General case' 0 C--O 1.251 1.169 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.005 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ILE . . . . . 0.472 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -143.77 107.36 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.781 0 CA-C-N 110.443 -3.071 . . . . 0.0 108.449 -173.284 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ILE . . . . . 0.598 ' CG2' HD21 ' B' ' 34' ' ' LEU . 10.6 mt -103.43 111.0 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.035 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.72 92.48 0.58 Allowed Glycine 0 CA--C 1.501 -0.805 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 177.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tp -138.03 135.02 35.49 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 122.704 1.24 . . . . 0.0 111.169 -178.82 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 3.1 ptm -111.04 123.31 49.94 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.3 -1.773 . . . . 0.0 108.403 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -116.14 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.649 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -82.92 -100.39 0.5 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.8 -170.74 34.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.07 162.07 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.863 0.364 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 81.2 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.379 179.749 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -110.57 134.34 52.48 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 11' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' C' ' 11' ' ' GLU . 94.8 mt-10 -138.79 142.76 38.75 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' A' ' 12' ' ' VAL . 19.8 m -131.17 161.02 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' O ' ' C' ' 13' ' ' HIS . 2.1 t60 -130.29 129.03 42.72 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 14' ' ' HIS . . . . . 0.629 ' NE2' ' CG ' ' C' ' 13' ' ' HIS . 72.6 m80 -133.48 167.08 21.1 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.309 0.576 . . . . 0.0 109.678 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 15' ' ' GLN . . . . . 0.477 HE21 HD21 ' B' ' 17' ' ' LEU . 46.2 tt0 -168.93 169.56 9.61 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.495 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -155.02 125.77 7.0 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 17' ' ' LEU . . . . . 0.477 HD21 HE21 ' B' ' 15' ' ' GLN . 66.3 mt -122.22 110.97 16.37 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.058 0.456 . . . . 0.0 109.796 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -119.94 126.93 75.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.94 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -125.81 120.37 30.35 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.608 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' HB2' ' CZ ' ' C' ' 20' ' ' PHE . 3.7 t80 -125.63 129.15 49.03 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.92 155.93 39.07 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 116.767 2.136 . . . . 0.0 116.767 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -162.75 78.34 0.47 Allowed 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 111.145 -2.752 . . . . 0.0 106.1 177.702 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 23' ' ' ASP . . . . . 0.405 ' O ' ' C ' ' B' ' 24' ' ' VAL . 67.2 t0 -170.33 131.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.887 -176.384 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 24' ' ' VAL . . . . . 0.451 HG23 ' H ' ' B' ' 24' ' ' VAL . 2.5 t -35.13 111.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 121.555 0.693 . . . . 0.0 111.795 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 121.11 -93.12 0.52 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 108.576 -1.81 . . . . 0.0 108.576 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 26' ' ' SER . . . . . 0.544 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 4.4 m -60.9 171.91 1.1 Allowed 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 175.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 27' ' ' ASN . . . . . 0.576 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 0.9 OUTLIER 100.07 -170.88 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 CA-C-O 122.16 0.981 . . . . 0.0 113.506 178.441 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 28' ' ' LYS . . . . . 0.576 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 86.7 tttt -29.26 111.07 0.06 Allowed 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 113.349 -1.751 . . . . 0.0 113.016 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB1' ' C' ' 30' ' ' ALA . . . -80.99 100.91 2.02 Favored Glycine 0 CA--C 1.49 -1.518 0 CA-C-O 127.632 3.907 . . . . 0.0 109.401 -176.86 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 30' ' ' ALA . . . . . 0.574 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -79.31 -125.07 0.01 OUTLIER 'General case' 1 N--CA 1.37 -4.446 3 N-CA-C 87.399 -8.741 . . . . 0.0 87.399 166.239 . . . . . . . . 4 3 . 1 . 010 nuclear build full ' B' B ' 31' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' H' ' 35' ' ' MET . 0.2 OUTLIER -72.9 115.62 13.94 Favored 'Isoleucine or valine' 1 C--N 1.226 -4.792 0 CA-C-N 125.138 3.608 . . . . 0.0 111.128 176.465 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' B' B ' 32' ' ' ILE . . . . . 0.565 ' N ' ' SD ' ' H' ' 35' ' ' MET . 0.1 OUTLIER -109.41 115.48 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.774 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.7 90.94 0.58 Allowed Glycine 0 C--O 1.24 0.473 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 177.274 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 34' ' ' LEU . . . . . 0.598 HD21 ' CG2' ' A' ' 32' ' ' ILE . 74.4 mt -121.27 137.0 54.88 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.422 1.106 . . . . 0.0 112.06 -177.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 35' ' ' MET . . . . . 0.736 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 34.2 ttp -126.25 117.3 22.77 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.864 -179.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 36' ' ' VAL . . . . . 0.616 HG22 HD11 ' C' ' 34' ' ' LEU . 34.0 m -123.36 71.49 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.066 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.1 -101.72 2.28 Favored Glycine 0 C--N 1.353 1.523 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.4 166.78 41.41 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -134.46 142.0 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.759 0.314 . . . . 0.0 110.306 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.398 179.801 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -123.74 141.47 51.99 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.989 0.424 . . . . 0.0 110.958 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 11' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' B' ' 11' ' ' GLU . 80.7 tt0 -111.2 137.15 49.27 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.782 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 m -146.56 167.2 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 CA-C-O 120.993 0.425 . . . . 0.0 111.643 -179.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 13' ' ' HIS . . . . . 0.629 ' CG ' ' NE2' ' B' ' 14' ' ' HIS . 29.7 m-70 -133.32 145.12 50.14 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -84.48 -179.46 7.16 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-O 121.32 0.581 . . . . 0.0 110.272 -178.883 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -90.91 175.23 7.05 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.994 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -130.01 134.46 47.43 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.363 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -131.55 121.46 24.46 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.257 0.551 . . . . 0.0 112.412 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 18.0 m -132.04 127.26 57.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 CA-C-O 121.989 0.9 . . . . 0.0 110.734 177.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.13 119.49 36.59 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 114.716 -1.129 . . . . 0.0 108.97 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' HB2' ' B' ' 20' ' ' PHE . 53.2 p90 -147.37 150.81 35.43 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 118.615 -1.234 . . . . 0.0 112.512 177.534 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.14 150.19 32.29 Favored 'General case' 0 C--O 1.241 0.634 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -119.01 117.15 28.0 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.307 -1.77 . . . . 0.0 107.673 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 23' ' ' ASP . . . . . 0.581 ' O ' ' O ' ' C' ' 24' ' ' VAL . 57.3 m-20 -147.45 135.88 21.71 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.964 -177.579 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 24' ' ' VAL . . . . . 0.581 ' O ' ' O ' ' C' ' 23' ' ' ASP . 8.5 t -29.4 -110.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 O-C-N 124.54 1.15 . . . . 0.0 111.283 178.132 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.7 91.88 0.12 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.886 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 12.3 p -62.8 -176.98 0.13 Allowed 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 27' ' ' ASN . . . . . 0.464 ' CG ' ' N ' ' C' ' 28' ' ' LYS . 50.8 t30 -79.49 170.56 16.4 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 118.842 -1.143 . . . . 0.0 112.632 -178.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 28' ' ' LYS . . . . . 0.464 ' N ' ' CG ' ' C' ' 27' ' ' ASN . 29.1 mmtt -46.24 111.9 0.42 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 115.712 1.745 . . . . 0.0 115.712 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 29' ' ' GLY . . . . . 0.551 ' H ' ' HA3' ' D' ' 25' ' ' GLY . . . 92.69 93.78 1.45 Allowed Glycine 0 N--CA 1.473 1.13 0 CA-C-N 115.378 -0.828 . . . . 0.0 114.495 177.332 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 30' ' ' ALA . . . . . 0.598 ' HB1' ' O ' ' B' ' 29' ' ' GLY . . . -85.41 176.71 8.11 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 101.411 -3.552 . . . . 0.0 101.411 172.199 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 31' ' ' ILE . . . . . 0.438 HG12 ' C ' ' C' ' 30' ' ' ALA . 0.0 OUTLIER -141.97 111.72 2.76 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.248 -175.62 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.4 mt -98.75 111.17 27.71 Favored 'Isoleucine or valine' 0 C--N 1.349 0.569 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.41 99.64 1.13 Allowed Glycine 0 CA--C 1.505 -0.581 0 N-CA-C 106.048 -2.821 . . . . 0.0 106.048 175.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 34' ' ' LEU . . . . . 0.616 HD11 HG22 ' B' ' 36' ' ' VAL . 19.6 tp -135.83 133.17 37.54 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 123.056 1.408 . . . . 0.0 112.419 -176.901 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 35' ' ' MET . . . . . 0.774 ' SD ' HG22 ' I' ' 31' ' ' ILE . 41.2 ttp -110.49 122.06 46.82 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 113.269 -1.787 . . . . 0.0 109.532 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' C' C ' 36' ' ' VAL . . . . . 0.416 HG13 ' CG2' ' B' ' 36' ' ' VAL . 0.0 OUTLIER -109.61 66.76 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.618 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.59 -102.81 0.01 OUTLIER Glycine 0 C--N 1.362 1.99 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.88 158.03 26.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -134.4 162.74 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.438 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.851 -179.897 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -85.37 133.81 34.11 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -129.79 130.64 45.6 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.306 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -112.73 131.07 65.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.948 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 -89.67 130.18 35.99 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.0 0.428 . . . . 0.0 111.864 -178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 2.8 m-70 -82.84 178.16 8.31 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -96.42 178.4 5.37 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.548 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -142.29 137.69 30.81 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.825 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 41.7 tp -120.82 115.06 22.53 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.618 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.3 127.08 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.408 -0.517 . . . . 0.0 112.153 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -118.12 114.46 23.12 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 20' ' ' PHE . . . . . 0.532 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 21.5 t80 -127.6 119.08 25.15 Favored 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.179 0.514 . . . . 0.0 110.328 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 21' ' ' ALA . . . . . 0.428 ' O ' ' OE1' ' E' ' 22' ' ' GLU . . . -132.19 133.31 44.04 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-O 121.928 0.87 . . . . 0.0 112.629 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -91.4 133.61 35.32 Favored 'General case' 0 C--N 1.339 0.112 0 CA-C-N 114.677 -1.147 . . . . 0.0 108.627 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 23' ' ' ASP . . . . . 0.458 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 5.8 t0 71.55 103.54 0.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.203 0.525 . . . . 0.0 110.191 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 24' ' ' VAL . . . . . 0.543 ' O ' ' C ' ' D' ' 25' ' ' GLY . 8.4 p -134.83 135.15 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 N-CA-C 105.747 -1.946 . . . . 0.0 105.747 -178.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 25' ' ' GLY . . . . . 0.551 ' HA3' ' H ' ' C' ' 29' ' ' GLY . . . -24.39 -82.51 0.01 OUTLIER Glycine 0 N--CA 1.48 1.62 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.648 -174.696 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 26' ' ' SER . . . . . 0.456 ' OG ' ' O ' ' E' ' 27' ' ' ASN . 5.5 p -166.8 176.22 7.25 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 120.698 2.249 . . . . 0.0 113.037 174.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 48.28 178.2 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 113.074 -1.875 . . . . 0.0 113.057 174.611 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -71.66 111.55 7.04 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 174.782 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 29' ' ' GLY . . . . . 0.942 ' O ' ' HB1' ' E' ' 30' ' ' ALA . . . 84.87 94.49 0.73 Allowed Glycine 0 CA--C 1.482 -2.019 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.811 -177.807 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 30' ' ' ALA . . . . . 0.811 ' C ' HD13 ' D' ' 31' ' ' ILE . . . -75.46 -149.84 0.03 OUTLIER 'General case' 0 CA--C 1.498 -1.051 1 N-CA-C 96.892 -5.225 . . . . 0.0 96.892 168.435 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 31' ' ' ILE . . . . . 0.87 ' N ' HD13 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -97.51 102.12 13.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 1 CA-C-N 127.292 4.587 . . . . 0.0 109.907 178.45 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.0 tt -112.97 121.94 66.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.612 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.849 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.46 100.1 1.1 Allowed Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 107.064 -2.414 . . . . 0.0 107.064 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tp -117.19 120.7 39.07 Favored 'General case' 0 CA--C 1.508 -0.64 0 CA-C-O 121.702 0.763 . . . . 0.0 110.492 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 4.9 tmm? -104.26 115.91 31.24 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -118.19 71.43 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.18 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.0 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' D' D ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.24 -101.12 0.01 OUTLIER Glycine 0 C--N 1.366 2.228 0 N-CA-C 111.86 -0.496 . . . . 0.0 111.86 178.766 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.48 -179.81 43.02 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.61 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -125.34 135.76 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.454 -0.373 . . . . 0.0 110.086 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.593 179.951 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -103.91 135.35 45.61 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.916 0.388 . . . . 0.0 110.21 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -106.8 151.39 25.24 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 m -131.09 156.94 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.969 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.75 174.28 7.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.798 0.332 . . . . 0.0 110.329 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 14' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.2 OUTLIER -78.32 174.04 11.67 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -179.374 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 15' ' ' GLN . . . . . 0.405 ' HG2' ' H ' ' E' ' 16' ' ' LYS . 44.1 tt0 -122.63 172.15 8.61 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.614 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 16' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' E' ' 15' ' ' GLN . 65.7 mttp -153.82 119.07 5.12 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.6 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.8 mt -126.31 116.43 21.21 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 18' ' ' VAL . . . . . 0.533 HG21 ' CE2' ' E' ' 20' ' ' PHE . 5.6 p -143.16 147.56 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.182 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -120.04 124.33 45.61 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 114.227 -1.351 . . . . 0.0 109.747 179.003 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 20' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' E' ' 18' ' ' VAL . 31.9 m-85 -121.39 126.81 50.29 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 122.373 -0.205 . . . . 0.0 110.529 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 21' ' ' ALA . . . . . 0.446 ' HB1' HG11 ' D' ' 24' ' ' VAL . . . -138.06 137.57 37.92 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 22' ' ' GLU . . . . . 0.532 ' OE2' ' CZ ' ' D' ' 20' ' ' PHE . 58.0 mp0 -113.22 137.84 50.87 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 23' ' ' ASP . . . . . 0.477 ' OD1' ' O ' ' D' ' 25' ' ' GLY . 27.4 t70 -150.0 132.46 15.68 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.383 178.434 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 24' ' ' VAL . . . . . 0.527 HG23 ' O ' ' E' ' 24' ' ' VAL . 30.1 m -74.59 113.08 12.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.071 179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.08 92.18 0.01 OUTLIER Glycine 0 CA--C 1.527 0.824 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.447 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 74.0 m -47.81 151.63 0.86 Allowed 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.693 -0.253 . . . . 0.0 111.518 178.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 27' ' ' ASN . . . . . 0.456 ' O ' ' OG ' ' D' ' 26' ' ' SER . 0.5 OUTLIER -157.35 178.43 10.32 Favored 'General case' 0 CA--C 1.55 0.957 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 173.682 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 1.63 104.4 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 119.236 3.051 . . . . 0.0 119.236 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 29' ' ' GLY . . . . . 0.501 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . 90.43 -100.63 2.7 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 116.404 1.322 . . . . 0.0 116.404 167.881 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 30' ' ' ALA . . . . . 0.942 ' HB1' ' O ' ' D' ' 29' ' ' GLY . . . 56.86 149.78 0.01 OUTLIER 'General case' 0 C--O 1.255 1.356 0 CA-C-N 112.138 -2.031 . . . . 0.0 106.645 -177.407 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 31' ' ' ILE . . . . . 0.721 HG23 HG12 ' F' ' 31' ' ' ILE . 0.1 OUTLIER -158.23 134.48 2.0 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 C-N-CA 118.669 -1.212 . . . . 0.0 110.734 -174.341 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 32' ' ' ILE . . . . . 0.534 HD11 HD11 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -128.57 121.45 55.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 CA-C-O 121.4 0.619 . . . . 0.0 110.769 179.705 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' E' E ' 33' ' ' GLY . . . . . 0.546 ' CA ' ' SD ' ' K' ' 35' ' ' MET . . . -114.64 117.02 3.94 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 34' ' ' LEU . . . . . 0.74 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 22.9 mt -118.72 120.15 36.56 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.479 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 15.5 ttp -116.61 115.54 25.9 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.401 -0.52 . . . . 0.0 109.884 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 36' ' ' VAL . . . . . 0.654 HG13 HG22 ' F' ' 36' ' ' VAL . 2.8 p -144.03 83.77 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.52 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 37' ' ' GLY . . . . . 0.475 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -18.95 -94.49 0.01 OUTLIER Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.663 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.12 -164.05 37.24 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.07 161.01 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 120.847 0.356 . . . . 0.0 110.707 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.433 179.828 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -112.28 149.66 32.06 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.81 0.338 . . . . 0.0 110.387 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -54.01 149.14 9.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.132 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 65.3 t -114.34 130.84 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 110.948 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 13' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 31.1 p-80 -154.07 134.61 13.53 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.532 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 93.9 m-70 -155.23 170.03 22.8 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 121.303 0.573 . . . . 0.0 109.602 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -143.96 173.81 11.39 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.431 -0.804 . . . . 0.0 108.884 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -152.44 129.85 11.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.1 tp -121.08 117.9 28.38 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.51 133.14 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -177.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 19' ' ' PHE . . . . . 0.74 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 86.2 m-85 -118.48 114.73 23.3 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.902 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -134.18 144.86 48.73 Favored 'General case' 0 N--CA 1.477 0.885 0 CA-C-O 122.282 1.039 . . . . 0.0 112.086 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.43 148.35 30.2 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.128 178.164 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.52 136.83 39.32 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.712 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -149.62 134.03 17.46 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.418 0.628 . . . . 0.0 111.086 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' F' ' 25' ' ' GLY . 12.9 t -93.71 112.55 26.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.292 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 25' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' F' ' 24' ' ' VAL . . . 42.64 91.42 0.01 OUTLIER Glycine 0 N--CA 1.472 1.063 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.393 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 85.7 p -45.2 152.16 0.29 Allowed 'General case' 0 N--CA 1.439 -1.022 0 CA-C-O 123.066 1.412 . . . . 0.0 111.989 -176.142 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 28.6 m120 -156.84 -170.9 3.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 111.679 -2.51 . . . . 0.0 106.304 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.7 mttt 19.19 110.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 121.797 0.808 . . . . 0.0 113.166 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.19 96.62 2.23 Favored Glycine 0 CA--C 1.492 -1.395 0 CA-C-O 123.412 1.562 . . . . 0.0 111.877 -174.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 30' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' E' ' 29' ' ' GLY . . . -63.94 -171.15 0.05 OUTLIER 'General case' 0 CA--C 1.489 -1.376 0 CA-C-N 110.989 -2.606 . . . . 0.0 107.537 -179.033 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 31' ' ' ILE . . . . . 0.721 HG12 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -132.74 133.76 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 117.261 -1.776 . . . . 0.0 113.191 -176.283 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' F' F ' 32' ' ' ILE . . . . . 0.444 HG23 ' O ' ' F' ' 32' ' ' ILE . 14.9 tt -126.71 132.41 70.17 Favored 'Isoleucine or valine' 0 C--N 1.345 0.386 0 CA-C-N 113.747 -1.57 . . . . 0.0 112.202 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.7 115.54 2.74 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -119.47 119.51 34.09 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 35' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 30.8 ttp -114.03 118.61 34.58 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 121.267 -0.173 . . . . 0.0 111.196 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 36' ' ' VAL . . . . . 0.654 HG22 HG13 ' E' ' 36' ' ' VAL . 5.0 t -139.11 83.05 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-O 119.295 -0.384 . . . . 0.0 110.686 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 37' ' ' GLY . . . . . 0.514 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . -15.73 -95.66 0.01 OUTLIER Glycine 0 C--N 1.351 1.367 0 O-C-N 123.063 0.227 . . . . 0.0 112.886 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 127.92 163.05 11.26 Favored Glycine 0 N--CA 1.466 0.695 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 28.6 m -140.31 160.38 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.825 0.345 . . . . 0.0 110.655 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.532 -179.968 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -106.03 135.37 47.62 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.907 0.385 . . . . 0.0 110.724 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 11' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' H' ' 9' ' ' GLY . 73.1 mm-40 -84.28 142.6 30.11 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.53 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 12.0 p -127.09 136.84 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.725 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 13' ' ' HIS . . . . . 0.475 ' ND1' ' N ' ' G' ' 13' ' ' HIS . 2.5 p-80 -149.23 168.49 23.14 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.995 -179.137 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 14' ' ' HIS . . . . . 0.571 ' CD2' ' H ' ' H' ' 14' ' ' HIS . 89.0 m-70 -132.83 178.26 7.0 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -129.09 -179.13 4.94 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.086 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 89.2 tttt -99.23 142.53 30.6 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.643 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 74.7 mt -125.68 118.79 26.38 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -136.28 138.67 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.204 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.753 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -119.64 126.36 50.96 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.211 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -122.5 120.76 34.82 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.08 127.61 44.94 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.105 0.479 . . . . 0.0 111.806 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -160.83 87.27 0.73 Allowed 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.685 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -178.37 123.13 0.1 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.925 0.393 . . . . 0.0 110.628 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.8 t -38.93 114.34 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.185 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 25' ' ' GLY . . . . . 0.808 ' H ' HG21 ' H' ' 24' ' ' VAL . . . -98.14 -86.41 1.84 Allowed Glycine 0 N--CA 1.47 0.907 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 26' ' ' SER . . . . . 0.747 ' O ' ' O ' ' G' ' 27' ' ' ASN . 17.0 m -151.58 -173.06 4.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.536 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 27' ' ' ASN . . . . . 0.747 ' O ' ' O ' ' G' ' 26' ' ' SER . 97.0 m-20 -22.79 170.0 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 O-C-N 124.313 1.008 . . . . 0.0 113.235 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 28' ' ' LYS . . . . . 0.498 ' NZ ' ' O ' ' I' ' 26' ' ' SER . 32.4 tttt -102.03 -112.82 0.21 Allowed 'General case' 0 N--CA 1.476 0.828 0 O-C-N 121.606 -0.684 . . . . 0.0 112.265 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 29' ' ' GLY . . . . . 0.404 ' O ' ' O ' ' G' ' 28' ' ' LYS . . . 47.98 91.57 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 30' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . -106.18 162.37 13.7 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 123.85 1.786 . . . . 0.0 111.127 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 31' ' ' ILE . . . . . 0.649 HG21 ' HA3' ' A' ' 37' ' ' GLY . 1.0 OUTLIER -160.29 121.94 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 110.547 -3.024 . . . . 0.0 106.84 -172.733 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -139.64 122.73 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.249 178.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.7 117.41 5.86 Favored Glycine 0 CA--C 1.506 -0.519 0 N-CA-C 106.821 -2.511 . . . . 0.0 106.821 177.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 34' ' ' LEU . . . . . 0.678 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 70.9 mt -113.59 120.17 40.02 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-O 121.562 0.696 . . . . 0.0 111.931 -177.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' C ' ' A' ' 31' ' ' ILE . 3.8 ttm -120.84 108.02 13.43 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 177.046 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.72 71.56 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -178.933 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.11 -98.31 0.85 Allowed Glycine 0 C--N 1.361 1.921 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.6 -173.63 43.26 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -126.83 136.14 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.809 0.337 . . . . 0.0 110.102 -179.597 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.98 -1.01 . . . . 0.0 110.789 -179.809 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' H' H ' 9' ' ' GLY . . . . . 0.426 ' O ' ' OE2' ' G' ' 11' ' ' GLU . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 79.6 t80 -105.06 129.0 53.59 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.334 -0.247 . . . . 0.0 110.334 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -67.06 131.07 45.08 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.671 -0.412 . . . . 0.0 110.452 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.67 148.73 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.494 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -121.61 124.07 43.45 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.69 0.281 . . . . 0.0 110.664 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' G' ' 14' ' ' HIS . 37.1 m-70 -144.58 166.18 25.91 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.345 0.593 . . . . 0.0 110.277 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.6 tp60 -160.81 161.15 31.9 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.795 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -158.83 118.06 3.05 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.54 110.5 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 18' ' ' VAL . . . . . 0.485 HG11 ' CE2' ' H' ' 20' ' ' PHE . 72.4 t -124.29 130.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 120.551 -0.46 . . . . 0.0 111.045 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.39 114.25 22.05 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.973 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 20' ' ' PHE . . . . . 0.485 ' CE2' HG11 ' H' ' 18' ' ' VAL . 52.4 m-85 -110.1 117.28 33.3 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.53 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 21' ' ' ALA . . . . . 0.401 ' HB3' ' H ' ' H' ' 27' ' ' ASN . . . -136.1 134.44 38.36 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 119.558 -0.857 . . . . 0.0 112.867 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -152.02 89.65 1.47 Allowed 'General case' 0 C--O 1.224 -0.261 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 23' ' ' ASP . . . . . 0.444 ' N ' ' OD1' ' H' ' 23' ' ' ASP . 26.5 p-10 169.85 -121.23 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.366 0.416 . . . . 0.0 110.073 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 24' ' ' VAL . . . . . 0.808 HG21 ' H ' ' G' ' 25' ' ' GLY . 1.5 m -85.28 122.41 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 50.65 84.25 0.03 OUTLIER Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -178.902 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 26' ' ' SER . . . . . 0.401 ' HB2' ' HB1' ' I' ' 21' ' ' ALA . 22.0 p -68.95 -168.54 0.14 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' H' ' 28' ' ' LYS . 19.6 m120 -80.2 175.91 10.23 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 28' ' ' LYS . . . . . 0.68 ' HA ' HD12 ' H' ' 32' ' ' ILE . 29.7 tttt 35.34 100.49 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -172.121 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 29' ' ' GLY . . . . . 0.615 ' O ' ' C ' ' H' ' 30' ' ' ALA . . . -98.3 110.31 3.99 Favored Glycine 1 CA--C 1.445 -4.315 1 CA-C-O 112.742 -4.366 . . . . 0.0 120.858 -176.647 . . . . . . . . 4 3 . 1 . 010 nuclear build full ' H' H ' 30' ' ' ALA . . . . . 0.746 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 53.43 -122.32 2.0 Allowed 'General case' 0 C--N 1.39 2.342 2 C-N-CA 107.778 -5.569 . . . . 0.0 109.505 161.431 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' H' H ' 31' ' ' ILE . . . . . 0.894 HD12 ' H ' ' H' ' 31' ' ' ILE . 4.1 mp -67.4 107.98 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.314 0 CA-C-N 109.966 -3.288 . . . . 0.0 109.796 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 32' ' ' ILE . . . . . 0.68 HD12 ' HA ' ' H' ' 28' ' ' LYS . 10.3 tt -122.47 120.44 61.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 122.246 1.022 . . . . 0.0 109.789 174.816 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 33' ' ' GLY . . . . . 0.736 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -98.87 117.96 6.02 Favored Glycine 0 CA--C 1.497 -1.075 0 N-CA-C 106.304 -2.718 . . . . 0.0 106.304 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 34' ' ' LEU . . . . . 0.424 HD11 HG22 ' H' ' 36' ' ' VAL . 56.0 tp -120.04 119.66 34.03 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 113.836 1.051 . . . . 0.0 113.836 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 35' ' ' MET . . . . . 0.565 ' SD ' ' N ' ' B' ' 32' ' ' ILE . 17.6 ttm -124.8 115.31 20.49 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 175.517 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 36' ' ' VAL . . . . . 0.444 ' O ' HG12 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -129.32 71.25 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.16 -100.81 2.66 Favored Glycine 0 C--N 1.358 1.8 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 38' ' ' GLY . . . . . 0.422 ' H ' HD13 ' B' ' 31' ' ' ILE . . . 110.54 166.17 19.21 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.04 156.62 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-O 120.686 0.279 . . . . 0.0 110.357 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.636 -179.826 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -97.29 135.01 39.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.74 0.305 . . . . 0.0 110.278 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -143.18 160.1 41.07 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.222 0.534 . . . . 0.0 111.487 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t -120.61 133.63 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.253 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 75.7 m80 -129.61 131.96 46.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.84 0.352 . . . . 0.0 111.514 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 86.3 t60 -154.18 165.76 35.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 177.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 15' ' ' GLN . . . . . 0.52 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 76.0 mt-30 -158.76 171.22 20.49 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.502 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -151.05 121.48 7.36 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.071 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -127.67 123.82 36.44 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.7 t -134.44 130.29 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 19' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' G' ' 34' ' ' LEU . 45.4 m-85 -111.35 108.45 18.05 Favored 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 176.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -116.47 119.53 35.9 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.184 -0.323 . . . . 0.0 111.109 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' HB2' ' H' ' 26' ' ' SER . . . -136.78 127.5 27.17 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 -178.568 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -138.49 109.17 6.62 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.732 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 42.0 p-10 -161.69 125.14 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.96 179.554 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 24' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.8 m -89.82 -112.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.595 -0.442 . . . . 0.0 109.971 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 25' ' ' GLY . . . . . 0.407 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 43.98 -92.02 0.01 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.622 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.0 p -129.19 170.27 13.77 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' I' ' 26' ' ' SER . 35.7 m120 31.98 172.58 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 28' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' J' ' 23' ' ' ASP . 23.3 pttt 148.55 95.36 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 123.344 0.658 . . . . 0.0 111.571 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 29' ' ' GLY . . . . . 0.801 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . 58.46 -112.59 4.12 Favored Glycine 1 CA--C 1.433 -5.059 0 CA-C-O 114.948 -3.14 . . . . 0.0 111.849 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 30' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' I' ' 29' ' ' GLY 0.529 . . 97.96 -125.45 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.513 1 C-N-CA 109.781 -4.768 . . . . 0.0 113.355 179.294 . . . . . . . . 4 3 . 1 . 010 nuclear build full ' I' I ' 31' ' ' ILE . . . . . 0.774 HG22 ' SD ' ' C' ' 35' ' ' MET 0.426 3.0 mt -64.05 110.74 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.402 -2.852 1 CA-C-N 106.479 -4.873 . . . . 0.0 109.967 173.924 . . . . . . . . 4 3 . 1 . 010 nuclear build full ' I' I ' 32' ' ' ILE . . . . . 0.659 HG23 HG13 ' J' ' 32' ' ' ILE . 10.6 tt -135.36 126.15 44.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-O 122.333 1.064 . . . . 0.0 112.496 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.7 119.49 5.8 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 177.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 34' ' ' LEU . . . . . 1.0 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 13.7 tp -114.68 125.72 54.06 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.638 0.733 . . . . 0.0 112.277 -178.887 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 35' ' ' MET . . . . . 0.421 ' N ' HD12 ' I' ' 34' ' ' LEU . 12.6 tpp -123.77 111.0 15.61 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.784 175.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' I' I ' 36' ' ' VAL . . . . . 0.734 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -128.03 68.28 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.374 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.11 -101.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.625 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.01 160.02 23.54 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.73 135.95 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.519 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.11 154.65 28.54 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -51.01 139.26 17.88 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.004 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -129.47 140.7 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.607 -179.128 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -137.59 103.78 5.14 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.759 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 65.5 m170 -117.7 164.66 14.64 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -157.77 172.83 17.78 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.217 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -155.41 115.64 3.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.526 178.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.27 124.15 41.78 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -134.07 132.43 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 19' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 14.8 m-85 -114.16 107.11 15.19 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.219 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 20' ' ' PHE . . . . . 0.57 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 35.4 t80 -120.92 117.55 27.63 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -166.96 175.68 7.47 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -178.389 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -88.22 138.83 31.09 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 113.134 -1.848 . . . . 0.0 109.032 177.861 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 23' ' ' ASP . . . . . 0.548 ' HA ' ' O ' ' I' ' 28' ' ' LYS . 74.0 m-20 -117.61 -161.0 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 121.384 0.611 . . . . 0.0 111.575 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 24' ' ' VAL . . . . . 0.554 HG13 ' H ' ' J' ' 29' ' ' GLY . 76.4 t 52.77 103.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 116.56 2.059 . . . . 0.0 116.56 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.59 -92.63 0.03 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 172.32 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' J' ' 27' ' ' ASN . 13.9 p -124.63 166.31 16.35 Favored 'General case' 0 CA--C 1.51 -0.57 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 175.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' J' ' 26' ' ' SER . 97.1 m-20 47.84 174.23 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 28' ' ' LYS . . . . . 0.745 ' NZ ' ' HB2' ' K' ' 30' ' ' ALA . 86.2 tttt -73.06 110.91 7.71 Favored 'General case' 0 C--N 1.35 0.626 1 C-N-CA 111.064 -4.254 . . . . 0.0 106.046 178.279 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 29' ' ' GLY . . . . . 0.554 ' H ' HG13 ' J' ' 24' ' ' VAL . . . -86.27 93.4 1.86 Allowed Glycine 0 CA--C 1.485 -1.807 0 CA-C-O 117.518 -1.712 . . . . 0.0 112.255 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 30' ' ' ALA . . . . . 0.454 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -163.16 140.21 7.49 Favored 'General case' 0 C--N 1.281 -2.406 0 CA-C-N 121.194 2.497 . . . . 0.0 108.348 171.193 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 31' ' ' ILE . . . . . 0.508 HG23 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -158.39 116.54 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 CA-C-N 112.249 -2.25 . . . . 0.0 107.08 -173.32 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' J' J ' 32' ' ' ILE . . . . . 0.659 HG13 HG23 ' I' ' 32' ' ' ILE . 15.6 tt -124.87 117.33 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.896 0.855 . . . . 0.0 110.994 179.489 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.62 118.95 6.24 Favored Glycine 0 CA--C 1.505 -0.569 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 34' ' ' LEU . . . . . 0.773 HD22 ' CE1' ' L' ' 19' ' ' PHE . 50.8 mt -113.54 107.29 15.6 Favored 'General case' 0 CA--C 1.505 -0.783 0 CA-C-O 121.322 0.582 . . . . 0.0 111.125 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.0 tpt -111.5 112.0 23.42 Favored 'General case' 0 CA--C 1.514 -0.421 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.297 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -131.63 74.71 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.668 -177.72 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.23 106.23 2.97 Favored Glycine 0 C--N 1.355 1.6 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.77 169.39 52.15 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 70.0 t -133.94 138.57 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 120.644 0.259 . . . . 0.0 110.524 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.758 179.754 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -111.11 134.75 52.47 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.8 0.333 . . . . 0.0 110.478 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -110.94 148.89 31.51 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 12' ' ' VAL . . . . . 0.557 ' CG2' ' NE2' ' K' ' 14' ' ' HIS . 2.6 m -140.24 -171.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -92.44 132.05 37.1 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.807 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' CG2' ' K' ' 12' ' ' VAL . 80.0 m-70 -148.03 169.75 19.25 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -157.27 178.96 9.73 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.805 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -160.57 121.5 2.96 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.173 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -126.62 125.09 41.33 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.68 129.61 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.927 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 19' ' ' PHE . . . . . 1.0 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 19.8 m-85 -113.45 108.89 17.82 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 20' ' ' PHE . . . . . 0.57 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.1 t80 -118.51 121.13 39.51 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.141 0.428 . . . . 0.0 110.855 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.03 139.84 45.13 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.71 167.53 26.18 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.781 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -166.38 -136.42 0.02 OUTLIER 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.144 177.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' K' ' 25' ' ' GLY . 18.7 t -110.62 110.36 31.9 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 25' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 32.54 91.44 0.01 OUTLIER Glycine 0 CA--C 1.53 0.981 0 N-CA-C 112.156 -0.377 . . . . 0.0 112.156 177.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 26' ' ' SER . . . . . 0.413 ' OG ' ' CG ' ' L' ' 23' ' ' ASP . 5.8 p -47.5 154.71 0.42 Allowed 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 m120 -119.15 172.58 7.48 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 122.239 1.018 . . . . 0.0 113.166 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -32.8 110.75 0.09 Allowed 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 116.248 1.944 . . . . 0.0 116.248 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.59 93.42 0.44 Allowed Glycine 0 N--CA 1.475 1.286 0 N-CA-C 116.386 1.314 . . . . 0.0 116.386 172.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 30' ' ' ALA . . . . . 0.745 ' HB2' ' NZ ' ' J' ' 28' ' ' LYS . . . -101.11 165.71 11.16 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 101.628 -3.471 . . . . 0.0 101.628 170.096 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 31' ' ' ILE . . . . . 0.508 HD12 HG23 ' J' ' 31' ' ' ILE . 0.2 OUTLIER -138.29 122.77 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 116.926 -1.91 . . . . 0.0 111.854 -178.224 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' K' K ' 32' ' ' ILE . . . . . 0.438 ' O ' ' SD ' ' F' ' 35' ' ' MET . 76.0 mt -131.96 130.92 61.63 Favored 'Isoleucine or valine' 0 C--N 1.352 0.686 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.443 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -122.47 122.22 4.96 Favored Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.371 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 mt -114.7 114.95 26.32 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.266 0.533 . . . . 0.0 111.8 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 35' ' ' MET . . . . . 0.546 ' SD ' ' CA ' ' E' ' 33' ' ' GLY . 8.1 ttt -128.36 120.89 27.88 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 177.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.08 81.61 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.05 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 37' ' ' GLY . . . . . 0.702 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -65.41 102.05 0.63 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.75 152.64 24.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.6 m -130.61 157.71 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.702 -179.663 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -110.29 146.83 35.01 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.756 0.312 . . . . 0.0 110.646 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -58.36 145.54 37.81 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.521 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG2' ' K' ' 12' ' ' VAL . 66.9 t -128.28 130.13 69.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.922 0.868 . . . . 0.0 111.389 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 3.0 m80 -117.66 110.79 18.31 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.699 178.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -138.78 173.63 11.38 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -144.93 177.09 9.0 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.179 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -149.36 126.1 11.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.752 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.29 125.92 37.87 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -123.63 128.63 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-O 120.94 0.4 . . . . 0.0 110.425 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 19' ' ' PHE . . . . . 0.773 ' CE1' HD22 ' J' ' 34' ' ' LEU . 70.7 m-85 -113.81 112.3 23.18 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -133.49 127.72 33.85 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 121.696 0.76 . . . . 0.0 112.689 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.57 137.61 42.15 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.644 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -80.44 109.19 14.7 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 119.953 -0.699 . . . . 0.0 112.302 -178.073 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 23' ' ' ASP . . . . . 0.413 ' CG ' ' OG ' ' K' ' 26' ' ' SER . 37.0 t0 178.91 113.28 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.711 178.731 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 63.3 t -59.16 130.55 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.607 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -68.39 85.29 0.19 Allowed Glycine 0 CA--C 1.526 0.757 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.847 178.512 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 49.2 m -65.6 -175.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.083 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' O ' ' L' ' 28' ' ' LYS . 13.6 m-20 -91.13 178.9 5.86 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.509 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 28' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 28.03 102.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.023 0 O-C-N 123.42 0.45 . . . . 0.0 111.69 177.143 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.85 -101.71 0.22 Allowed Glycine 0 N--CA 1.467 0.702 0 C-N-CA 119.251 -1.452 . . . . 0.0 112.556 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.65 161.72 1.01 Allowed 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.135 -177.206 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 31' ' ' ILE . . . . . 0.415 HG21 ' CA ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -150.12 127.14 2.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.438 -176.108 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -127.01 129.36 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.33 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 33' ' ' GLY . . . . . 0.623 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -122.11 132.74 9.0 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.244 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -120.44 121.82 39.34 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.07 0.435 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.2 123.16 35.97 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.14 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 36' ' ' VAL . . . . . 0.73 HG23 ' O ' ' L' ' 36' ' ' VAL . 16.7 m -145.41 78.92 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -3.63 -101.22 0.0 OUTLIER Glycine 0 C--N 1.359 1.814 0 C-N-CA 122.948 0.309 . . . . 0.0 113.284 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.6 162.74 21.49 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -132.39 156.08 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.868 0.366 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.936 -1.031 . . . . 0.0 111.076 -179.534 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 . . . . . 0 N--CA 1.456 -0.162 0 CA-C-O 120.712 0.291 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.2 t -126.01 133.77 68.15 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.018 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -106.24 165.87 10.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.467 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.414 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 8.2 p80 -92.34 169.58 10.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.385 0.612 . . . . 0.0 110.249 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 96.2 mm-40 -151.71 -179.96 7.88 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.008 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -126.04 126.71 44.69 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.904 0.383 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.2 mt -128.39 127.73 43.16 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.978 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -135.66 138.57 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.272 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -130.96 135.73 47.9 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.52 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.0 p90 -123.48 128.97 50.55 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.97 130.96 52.27 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 122.13 0.967 . . . . 0.0 112.788 -178.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -125.5 167.5 14.92 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 64.6 t0 . . . . . 0 N--CA 1.474 0.749 0 CA-C-N 118.289 0.495 . . . . 0.0 112.119 -178.83 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 74.1 tttt . . . . . 0 N--CA 1.464 0.242 0 N-CA-C 114.683 1.364 . . . . 0.0 114.683 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -77.53 101.4 1.64 Allowed Glycine 0 CA--C 1.507 -0.461 0 CA-C-O 114.823 -3.209 . . . . 0.0 105.505 168.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 147.73 25.98 Favored 'General case' 0 C--N 1.355 0.838 1 CA-C-N 125.483 4.642 . . . . 0.0 108.621 -178.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.591 HG22 ' CE ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -152.73 112.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.397 -171.704 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 56.5 mt -121.93 103.48 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.65 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -116.55 107.49 1.63 Allowed Glycine 0 CA--C 1.505 -0.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 177.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.501 ' H ' HD23 ' B' ' 34' ' ' LEU . 70.2 mt -142.66 153.66 43.63 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 123.295 1.521 . . . . 0.0 113.085 -177.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.469 ' SD ' ' C ' ' G' ' 31' ' ' ILE . 28.5 ttm -119.96 119.58 33.86 Favored 'General case' 0 CA--C 1.5 -0.949 0 CA-C-N 112.643 -2.071 . . . . 0.0 108.433 178.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.53 66.91 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.09 -102.13 0.01 OUTLIER Glycine 0 C--N 1.356 1.65 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.75 171.99 38.71 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.6 t -131.56 139.16 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.838 0.351 . . . . 0.0 110.415 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.357 179.811 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.36 158.54 44.01 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.683 0.277 . . . . 0.0 110.37 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.51 ' OE2' ' NE2' ' B' ' 13' ' ' HIS . 81.2 tt0 -146.56 146.26 30.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.272 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.1 m -136.88 159.68 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.163 0.506 . . . . 0.0 111.283 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.51 ' NE2' ' OE2' ' B' ' 11' ' ' GLU . 96.0 m-70 -149.83 163.52 37.81 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.067 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -115.04 178.39 4.3 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -97.2 175.09 6.41 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.775 -179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -117.49 138.67 51.71 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.73 127.27 40.1 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-O 121.051 0.453 . . . . 0.0 111.589 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -126.85 130.49 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.097 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -124.23 134.01 53.37 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.395 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -136.2 123.48 21.85 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.727 -0.215 . . . . 0.0 111.031 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.433 ' O ' ' CG ' ' B' ' 22' ' ' GLU . . . -126.86 117.55 22.82 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 120.946 0.403 . . . . 0.0 111.067 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.433 ' CG ' ' O ' ' B' ' 21' ' ' ALA . 83.3 mt-10 -165.47 133.8 3.16 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.617 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.9 t70 . . . . . 0 N--CA 1.471 0.605 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 177.238 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 1.275 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.91 152.29 29.49 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.645 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.28 118.35 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 113.914 -1.494 . . . . 0.0 109.059 -175.126 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.447 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.1 tt -122.65 114.74 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.686 0.755 . . . . 0.0 109.705 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -117.5 116.9 3.62 Favored Glycine 0 N--CA 1.463 0.498 0 N-CA-C 107.877 -2.089 . . . . 0.0 107.877 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.501 HD23 ' H ' ' A' ' 34' ' ' LEU . 79.6 mt -134.62 147.0 50.09 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 114.444 1.276 . . . . 0.0 114.444 -176.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.464 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 3.2 ttm -122.48 118.35 28.11 Favored 'General case' 0 CA--C 1.505 -0.779 0 CA-C-N 113.469 -1.696 . . . . 0.0 109.366 177.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.09 70.16 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.18 112.18 3.46 Favored Glycine 0 C--N 1.358 1.785 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.43 147.94 12.74 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.628 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -127.82 136.3 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.572 179.704 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.5 t . . . . . 0 N--CA 1.466 0.364 0 N-CA-C 110.425 -0.213 . . . . 0.0 110.425 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.572 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 80.0 m-70 -152.12 119.26 5.88 Favored 'General case' 0 N--CA 1.463 0.219 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.35 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -136.61 164.78 27.42 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -155.88 178.63 10.04 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.873 0.368 . . . . 0.0 110.557 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -167.72 106.92 0.54 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.208 178.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mt -122.12 121.15 36.24 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -129.26 125.97 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 CA-C-O 121.027 0.442 . . . . 0.0 111.971 -179.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -120.52 113.94 21.03 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -116.92 132.96 56.57 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.185 0.194 . . . . 0.0 110.641 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.91 138.1 25.37 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 85.1 tt0 -161.88 144.1 11.49 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.474 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 20.3 t0 . . . . . 0 CA--C 1.543 0.685 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.187 178.233 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.192 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.43 ' O ' HG13 ' D' ' 31' ' ' ILE . . . -106.37 157.87 17.3 Favored 'General case' 0 CA--C 1.482 -1.665 0 N-CA-C 101.764 -3.421 . . . . 0.0 101.764 175.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.645 HD12 ' CG2' ' B' ' 31' ' ' ILE . 2.0 mt -140.02 122.65 16.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 117.94 -1.504 . . . . 0.0 111.74 -173.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.469 HG22 ' O ' ' C' ' 32' ' ' ILE . 1.1 mt -117.75 112.59 39.31 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.14 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.78 102.81 0.87 Allowed Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.427 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 7.0 tt -134.73 138.52 44.44 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.654 1.216 . . . . 0.0 113.29 -175.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 25.9 ttm -117.99 120.5 38.0 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 113.705 -1.588 . . . . 0.0 108.724 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.652 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.0 p -125.36 71.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.39 -100.86 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.437 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.51 -157.83 29.8 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -133.9 160.24 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.004 0.43 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.831 179.986 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.604 HG21 ' HB ' ' E' ' 12' ' ' VAL . 9.9 m . . . . . 0 CA--C 1.536 0.439 0 N-CA-C 110.062 -0.348 . . . . 0.0 110.062 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.572 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 80.9 m-70 -78.4 124.63 28.33 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.145 -0.622 . . . . 0.0 111.727 -179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.507 ' CD2' HG23 ' D' ' 12' ' ' VAL . 82.8 m-70 -148.45 167.97 23.91 Favored 'General case' 0 C--N 1.342 0.28 0 CA-C-O 121.244 0.545 . . . . 0.0 109.985 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.63 177.69 10.67 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.591 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.61 114.09 0.62 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.21 0.528 . . . . 0.0 111.779 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 35.5 tp -123.72 121.59 35.87 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.215 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -126.62 125.48 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.465 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 35.8 m-85 -117.21 120.87 39.58 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.187 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -128.34 122.41 31.48 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.828 0.347 . . . . 0.0 111.175 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.65 135.55 40.26 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.166 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.7 mt-10 -117.57 124.39 48.55 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.111 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 77.8 m-20 . . . . . 0 CA--C 1.548 0.889 0 N-CA-C 112.852 0.686 . . . . 0.0 112.852 -179.255 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.473 -2.0 0 CA-C-O 122.086 0.946 . . . . 0.0 108.923 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -143.36 108.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 CA-C-N 113.535 -1.666 . . . . 0.0 107.955 -176.561 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.53 121.89 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.087 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.626 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -125.94 103.22 0.68 Allowed Glycine 0 C--N 1.311 -0.813 0 N-CA-C 105.526 -3.03 . . . . 0.0 105.526 175.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.573 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.4 tt -127.78 131.33 49.62 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-O 122.171 0.986 . . . . 0.0 111.747 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.944 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.0 ttm -112.05 121.81 46.02 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 113.985 -1.462 . . . . 0.0 110.011 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.466 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -110.95 75.43 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -31.85 -96.24 0.01 OUTLIER Glycine 0 C--N 1.353 1.502 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.9 175.29 17.49 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 10.0 p -139.7 141.51 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.92 0.39 . . . . 0.0 110.608 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.563 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . 0.514 ' CE1' ' N ' ' F' ' 9' ' ' GLY . 88.1 m-85 -107.89 135.04 49.95 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.832 0.348 . . . . 0.0 110.211 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.52 138.63 58.51 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.186 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.604 ' HB ' HG21 ' D' ' 12' ' ' VAL . 72.6 t -122.38 131.28 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.619 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 96.1 m-70 -121.41 114.99 22.08 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.385 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' O ' ' E' ' 13' ' ' HIS . 2.7 m80 -142.46 168.31 20.03 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.641 0.734 . . . . 0.0 110.124 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -151.63 168.95 23.35 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.079 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -146.36 111.36 5.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 31.9 mt -122.99 121.81 37.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . 0.523 HG21 ' CE2' ' E' ' 20' ' ' PHE . 14.3 p -140.16 135.87 37.22 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 CA-C-O 121.944 0.878 . . . . 0.0 112.883 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.573 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 36.7 m-85 -117.72 117.23 28.77 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 114.327 -1.306 . . . . 0.0 109.927 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.523 ' CE2' HG21 ' E' ' 18' ' ' VAL . 38.3 m-85 -113.3 119.56 38.12 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.699 0.285 . . . . 0.0 111.105 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -126.6 137.86 53.38 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 120.972 0.415 . . . . 0.0 110.01 178.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -79.47 73.83 6.11 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 118.309 -1.356 . . . . 0.0 111.158 -177.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.608 ' O ' ' O ' ' E' ' 24' ' ' VAL . 1.3 p30 -171.49 109.92 0.29 Allowed 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.663 176.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.608 ' O ' ' O ' ' E' ' 23' ' ' ASP . 2.8 t -45.27 -132.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.698 1.237 . . . . 0.0 112.582 177.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.648 ' C ' ' HB2' ' F' ' 30' ' ' ALA . . . -138.76 80.99 0.27 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.613 ' O ' ' N ' ' F' ' 30' ' ' ALA . 28.6 m . . . . . 0 C--O 1.214 -0.808 0 CA-C-O 121.294 0.568 . . . . 0.0 110.734 -179.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.246 0.893 0 CA-C-O 121.473 0.654 . . . . 0.0 110.251 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.532 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.1 mt -148.57 126.09 2.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.946 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' L' ' 35' ' ' MET . 89.3 mt -128.99 128.15 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 120.901 0.381 . . . . 0.0 111.946 -178.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 121.34 4.69 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.54 HD13 ' CZ ' ' F' ' 19' ' ' PHE . 47.9 tp -127.93 124.67 37.91 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.219 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.499 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 8.9 ttt -129.84 126.27 37.64 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 120.31 -0.556 . . . . 0.0 111.547 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' D' ' 36' ' ' VAL . 51.3 t -109.94 86.84 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.425 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.643 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -75.0 96.9 0.99 Allowed Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.2 170.8 43.1 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -128.45 135.06 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-O 120.911 0.386 . . . . 0.0 109.999 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.795 -179.791 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . 0.514 ' N ' ' CE1' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 79.8 t80 -84.66 130.82 34.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . 0.529 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 98.3 mt-10 -59.08 154.13 16.44 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.514 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 t -96.25 132.82 39.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.773 0.32 . . . . 0.0 110.703 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -153.13 113.98 4.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.204 0.526 . . . . 0.0 111.867 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -155.1 173.72 16.19 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -151.92 175.65 12.27 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.855 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -132.17 114.48 14.54 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.745 179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 49.0 tp -122.68 118.77 28.89 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 77.2 t -133.35 130.0 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.54 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 55.0 m-85 -113.64 111.82 22.47 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 175.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -141.81 152.86 44.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.005 0.907 . . . . 0.0 112.244 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.414 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -150.46 149.14 29.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.291 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -136.79 144.39 43.7 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -178.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' F' ' 24' ' ' VAL . 62.2 t0 177.75 -118.48 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.863 177.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 13.2 p -102.18 126.41 56.23 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.568 0 CA-C-O 121.124 0.488 . . . . 0.0 110.659 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -31.4 -83.15 0.01 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.007 177.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 13.2 t 73.08 179.96 0.22 Allowed 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 124.456 1.102 . . . . 0.0 110.183 -176.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 88.8 m-20 -89.42 172.7 8.82 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 118.544 2.794 . . . . 0.0 118.544 -173.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -39.09 106.33 0.05 Allowed 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 109.268 -3.605 . . . . 0.0 119.894 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.61 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . 148.02 -97.22 0.18 Allowed Glycine 0 N--CA 1.483 1.8 0 C-N-CA 120.492 -0.861 . . . . 0.0 115.224 171.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.648 ' HB2' ' C ' ' E' ' 25' ' ' GLY . . . 56.2 166.02 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 103.186 -2.894 . . . . 0.0 103.186 -173.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.444 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 1.6 mt -140.08 119.37 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 124.098 3.135 . . . . 0.0 111.447 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 57.7 mt -123.87 136.23 60.92 Favored 'Isoleucine or valine' 0 C--N 1.347 0.483 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.512 -176.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.44 125.16 5.16 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 46.9 tp -118.64 120.8 38.51 Favored 'General case' 0 N--CA 1.47 0.54 0 O-C-N 122.642 -0.328 . . . . 0.0 110.229 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -118.37 119.38 34.45 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 116.952 -0.113 . . . . 0.0 111.098 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.49 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.4 p -153.21 82.47 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.763 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.898 ' H ' HD13 ' L' ' 31' ' ' ILE . . . -71.4 101.11 0.94 Allowed Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.26 161.51 34.51 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -141.86 143.7 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 110.604 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 t . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.4 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.505 ' N ' ' HD1' ' G' ' 13' ' ' HIS . 6.3 p-80 . . . . . 0 N--CA 1.465 0.287 0 CA-C-O 120.666 0.269 . . . . 0.0 110.311 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 8.2 m80 -81.72 167.92 18.63 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-O 121.126 0.489 . . . . 0.0 109.961 -179.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.45 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 51.0 tp60 -163.17 172.32 15.0 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.563 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.45 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 99.7 mttt -138.72 139.81 38.5 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -138.83 120.68 15.41 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.213 0.53 . . . . 0.0 110.902 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.41 134.36 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.767 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -129.2 125.31 36.7 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 120.939 0.4 . . . . 0.0 110.592 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.402 ' CD1' ' C ' ' G' ' 20' ' ' PHE . 19.5 t80 -113.46 123.26 49.61 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.17 131.81 53.16 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 121.805 0.812 . . . . 0.0 112.472 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' G' ' 23' ' ' ASP . 18.6 pt-20 -102.48 -173.08 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.771 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.483 ' N ' ' CB ' ' H' ' 23' ' ' ASP . 19.3 t70 -23.83 132.96 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' G' ' 26' ' ' SER . 11.7 t -89.33 113.56 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 114.197 -1.365 . . . . 0.0 108.162 177.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . -44.92 91.55 0.01 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.402 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.552 ' O ' ' O ' ' G' ' 27' ' ' ASN . 16.1 m 138.92 172.34 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.577 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.552 ' O ' ' O ' ' G' ' 26' ' ' SER . 90.9 m-20 -43.07 -178.67 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 O-C-N 123.429 0.456 . . . . 0.0 111.066 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.573 ' CE ' HG22 ' I' ' 24' ' ' VAL . 68.5 tttt -72.07 -114.7 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.767 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 50.32 91.33 0.01 OUTLIER Glycine 0 C--N 1.344 0.974 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.0 163.26 12.32 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 117.326 -1.75 . . . . 0.0 108.629 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.469 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -152.56 109.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 CA-C-N 112.966 -1.924 . . . . 0.0 109.618 -172.806 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.522 ' CG2' HD21 ' H' ' 34' ' ' LEU . 5.1 mt -100.95 111.05 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.25 99.0 0.68 Allowed Glycine 0 CA--C 1.503 -0.661 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.419 ' H ' HD23 ' H' ' 34' ' ' LEU . 12.0 mt -138.65 141.58 39.06 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-O 122.965 1.364 . . . . 0.0 111.572 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.65 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 38.0 ttp -109.66 114.96 29.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 112.957 -1.928 . . . . 0.0 107.158 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.41 66.03 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.78 110.92 4.02 Favored Glycine 0 C--N 1.359 1.828 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.63 178.99 0.11 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.8 m . . . . . 0 N--CA 1.467 0.422 0 CA-C-O 120.782 0.325 . . . . 0.0 110.749 179.781 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.431 HG13 ' ND1' ' I' ' 13' ' ' HIS . 78.2 t . . . . . 0 CA--C 1.521 -0.156 0 N-CA-C 109.881 -0.414 . . . . 0.0 109.881 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' I' ' 13' ' ' HIS . 3.5 t60 -140.06 100.23 3.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.894 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 13.9 t-80 -141.88 159.07 42.97 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.631 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 71.1 mt-30 -162.0 178.52 8.78 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.966 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -130.51 132.4 45.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 69.0 mt -120.9 111.74 17.91 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.54 127.22 74.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.143 0.497 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -117.1 112.94 21.59 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.381 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.24 121.2 44.66 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.37 132.39 48.55 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.256 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -164.58 125.73 2.13 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 119.857 -0.737 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.483 ' CB ' ' N ' ' G' ' 23' ' ' ASP . 0.9 OUTLIER -176.64 109.36 0.08 Allowed 'General case' 0 CA--C 1.544 0.723 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.6 t . . . . . 0 N--CA 1.469 0.517 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.285 173.818 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.092 0 N-CA-C 105.728 -1.952 . . . . 0.0 105.728 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.401 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -146.2 129.6 9.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 118.735 -1.186 . . . . 0.0 112.429 -172.378 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.464 ' C ' ' SD ' ' B' ' 35' ' ' MET . 67.3 mt -112.64 117.63 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.351 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 102.06 0.91 Allowed Glycine 0 N--CA 1.466 0.648 0 N-CA-C 108.017 -2.033 . . . . 0.0 108.017 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.522 HD21 ' CG2' ' G' ' 32' ' ' ILE . 89.7 mt -131.96 131.37 42.55 Favored 'General case' 0 CA--C 1.498 -1.025 0 CA-C-O 122.005 0.907 . . . . 0.0 112.791 -177.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 42.1 ttp -108.61 116.86 32.78 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.193 -1.367 . . . . 0.0 107.546 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.17 67.5 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.218 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 38' ' ' GLY . . . -94.04 110.91 4.06 Favored Glycine 0 C--N 1.372 2.568 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 37' ' ' GLY . . . 31.59 -159.57 0.0 OUTLIER Glycine 0 CA--C 1.524 0.616 0 CA-C-O 121.777 0.654 . . . . 0.0 113.06 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -138.97 159.55 29.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.74 -0.73 . . . . 0.0 109.385 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.633 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.659 HG12 ' N ' ' I' ' 13' ' ' HIS . 41.0 t . . . . . 0 N--CA 1.466 0.342 0 N-CA-C 110.38 -0.23 . . . . 0.0 110.38 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.659 ' N ' HG12 ' I' ' 12' ' ' VAL . 71.6 m80 -159.39 173.12 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.979 0.419 . . . . 0.0 111.092 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 -179.44 4.66 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.547 ' OE1' ' N ' ' H' ' 15' ' ' GLN . 8.9 mm-40 -95.83 173.88 7.24 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-O 121.328 0.585 . . . . 0.0 111.741 -178.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -114.33 139.29 49.58 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -119.49 122.78 42.44 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 121.188 0.518 . . . . 0.0 111.706 -179.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -130.96 122.2 51.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.957 178.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -111.24 107.18 16.4 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.301 -1.741 . . . . 0.0 106.301 176.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -115.63 127.42 55.19 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 120.75 0.309 . . . . 0.0 111.04 -177.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.37 128.54 25.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 122.112 0.958 . . . . 0.0 112.796 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -108.88 164.75 12.12 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 175.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 27.3 t70 60.71 -110.64 0.45 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 116.83 -1.948 . . . . 0.0 108.653 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.573 HG22 ' CE ' ' G' ' 28' ' ' LYS . 69.5 t -45.63 132.1 2.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 122.743 1.259 . . . . 0.0 112.581 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.67 82.84 0.76 Allowed Glycine 0 CA--C 1.519 0.322 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.022 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 5.3 p -99.07 172.52 7.34 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-O 121.547 0.689 . . . . 0.0 110.269 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.869 ' H ' HD22 ' I' ' 27' ' ' ASN . 0.5 OUTLIER -62.12 171.02 1.93 Allowed 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.037 175.56 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' J' ' 26' ' ' SER . 89.6 mttt 55.37 110.69 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.526 ' H ' ' CA ' ' J' ' 30' ' ' ALA . . . 67.53 92.37 0.05 OUTLIER Glycine 0 N--CA 1.474 1.168 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.435 ' C ' HG12 ' I' ' 31' ' ' ILE . . . -173.86 156.11 2.74 Favored 'General case' 0 C--N 1.271 -2.816 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 177.1 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.586 ' CG2' HD12 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 117.75 5.87 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 C-N-CA 117.14 -1.824 . . . . 0.0 109.982 -174.448 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.601 ' N ' ' SD ' ' C' ' 35' ' ' MET . 16.1 tt -115.08 121.0 66.2 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-O 122.114 0.959 . . . . 0.0 111.174 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.31 99.38 1.11 Allowed Glycine 0 CA--C 1.505 -0.576 0 N-CA-C 105.819 -2.913 . . . . 0.0 105.819 176.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.661 HD13 ' CZ ' ' K' ' 19' ' ' PHE . 7.1 tt -123.37 127.63 48.75 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 122.545 1.164 . . . . 0.0 111.245 -177.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.425 ' HE2' ' O ' ' C' ' 31' ' ' ILE . 2.8 ttm -108.87 118.9 37.98 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 114.227 -1.352 . . . . 0.0 111.195 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.559 HG23 HG13 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -127.14 67.43 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 177.383 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -42.67 -103.26 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.67 -162.44 14.56 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -115.93 135.52 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.01 0.433 . . . . 0.0 110.48 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.427 ' OXT' HG22 ' I' ' 40' ' ' VAL . 8.2 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.784 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.47 0.551 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -61.98 118.32 7.12 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 119.964 -0.694 . . . . 0.0 110.565 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 2.7 t-80 -135.75 164.04 28.81 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 83.2 mt-30 -155.81 177.01 11.89 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.269 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.611 ' C ' HD12 ' J' ' 17' ' ' LEU . 86.6 tttt -172.27 128.24 0.56 Allowed 'General case' 0 C--O 1.239 0.522 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.521 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.611 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.3 mp -117.76 123.27 45.6 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.75 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -127.45 126.55 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.623 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -120.97 106.8 11.94 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -114.8 128.04 56.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.575 -0.703 . . . . 0.0 112.184 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.43 123.64 36.58 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-O 121.97 0.891 . . . . 0.0 111.617 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.452 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 81.2 mm-40 -128.11 113.08 15.3 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 114.414 -1.266 . . . . 0.0 110.479 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' J' ' 24' ' ' VAL . 30.9 t0 -174.79 138.31 0.48 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.816 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' J' ' 23' ' ' ASP . 3.7 m -16.95 -110.22 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.401 ' H ' HG23 ' J' ' 24' ' ' VAL . . . -166.83 92.3 0.1 Allowed Glycine 0 CA--C 1.534 1.246 0 C-N-CA 119.83 -1.176 . . . . 0.0 113.892 -173.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' J' ' 27' ' ' ASN . 0.4 OUTLIER -63.26 -173.22 0.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.101 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' J' ' 26' ' ' SER . 77.5 m-20 -77.88 172.8 12.91 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 116.602 2.075 . . . . 0.0 116.602 -172.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.413 ' CE ' ' O ' ' K' ' 28' ' ' LYS . 6.5 mmtm -44.12 111.85 0.34 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 110.959 -2.837 . . . . 0.0 118.154 -177.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' I' ' 29' ' ' GLY . . . 93.84 94.42 1.56 Allowed Glycine 0 CA--C 1.501 -0.783 0 CA-C-N 114.209 -1.36 . . . . 0.0 114.501 176.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.526 ' CA ' ' H ' ' I' ' 29' ' ' GLY . . . -84.49 170.17 13.75 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 102.057 -3.312 . . . . 0.0 102.057 173.1 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.944 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.4 OUTLIER -150.45 123.22 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 CA-C-N 120.985 1.72 . . . . 0.0 111.752 -177.294 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.647 HD12 HG12 ' K' ' 32' ' ' ILE . 97.4 mt -109.89 117.27 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.385 178.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.14 102.08 1.17 Allowed Glycine 0 C--O 1.238 0.38 0 N-CA-C 106.282 -2.727 . . . . 0.0 106.282 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.927 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 7.9 tt -132.74 139.18 47.48 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-O 121.675 0.75 . . . . 0.0 112.562 -176.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.784 ' N ' HD23 ' J' ' 34' ' ' LEU . 33.8 ttp -123.7 125.74 45.3 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 114.734 -1.121 . . . . 0.0 112.6 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.559 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -123.63 70.05 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.287 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -44.6 -100.78 0.01 OUTLIER Glycine 0 C--N 1.357 1.716 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.98 150.8 8.16 Favored Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p . . . . . 0 C--N 1.327 -0.37 0 CA-C-O 120.856 0.36 . . . . 0.0 110.224 179.912 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 N--CA 1.465 0.323 0 CA-C-O 120.717 0.294 . . . . 0.0 110.278 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.571 HG12 ' N ' ' K' ' 13' ' ' HIS . 48.3 t -141.06 166.25 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.983 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.571 ' N ' HG12 ' K' ' 12' ' ' VAL . 1.2 m-70 -115.89 161.93 18.08 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.9 174.75 4.14 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-O 121.23 0.538 . . . . 0.0 109.868 -178.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -142.03 176.67 8.77 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.017 -179.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -149.42 135.47 18.93 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.051 0.453 . . . . 0.0 110.822 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -127.72 111.34 13.58 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 78.9 t -134.66 127.27 49.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.661 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.4 m-30 -113.31 141.37 47.11 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.463 ' HA ' ' HA ' ' L' ' 20' ' ' PHE . 77.9 t80 -136.4 117.87 14.77 Favored 'General case' 0 N--CA 1.505 2.311 0 CA-C-N 120.858 1.663 . . . . 0.0 114.128 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.894 ' HB3' ' O ' ' L' ' 21' ' ' ALA . . . -121.91 126.17 48.06 Favored 'General case' 0 C--N 1.398 2.707 0 CA-C-O 123.13 1.443 . . . . 0.0 112.061 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.567 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 82.5 tt0 -89.63 124.7 34.81 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.249 -178.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -123.87 131.81 53.64 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.063 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.42 113.64 11.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.175 179.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' K' ' 26' ' ' SER . . . 59.41 91.35 0.01 OUTLIER Glycine 0 CA--C 1.529 0.954 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.861 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' CB ' ' K' ' 27' ' ' ASN . 3.7 p -43.67 170.27 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.654 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER 157.49 -179.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 122.891 1.329 . . . . 0.0 114.007 178.873 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.654 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 52.4 mttp -29.62 112.49 0.08 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 119.365 3.098 . . . . 0.0 119.365 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' L' ' 30' ' ' ALA . . . 83.01 91.62 0.65 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 119.814 2.686 . . . . 0.0 119.814 173.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.548 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -143.62 155.22 44.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 101.916 -3.364 . . . . 0.0 101.916 170.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.679 HG13 HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.96 121.39 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 118.553 -1.259 . . . . 0.0 111.158 -176.563 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.647 HG12 HD12 ' J' ' 32' ' ' ILE . 96.7 mt -120.74 127.64 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.488 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.55 110.64 1.88 Allowed Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 178.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.516 HD12 ' N ' ' K' ' 35' ' ' MET . 6.3 tp -121.63 118.65 29.71 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.224 -0.488 . . . . 0.0 110.637 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.516 ' N ' HD12 ' K' ' 34' ' ' LEU . 6.2 tmm? -118.99 117.51 29.01 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.867 178.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.431 HG22 HD11 ' K' ' 34' ' ' LEU . 1.4 t -113.29 79.69 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 120.981 0.42 . . . . 0.0 110.162 178.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.532 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -87.29 100.58 2.59 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 178.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.72 172.78 42.64 Favored Glycine 0 CA--C 1.524 0.608 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.463 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.465 0.317 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.589 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t . . . . . 0 N--CA 1.467 0.382 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -158.0 107.39 2.08 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 120.872 0.368 . . . . 0.0 111.388 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 54.6 t-80 -153.81 166.95 31.29 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.522 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 84.5 mt-30 -152.7 178.88 9.14 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.129 0.49 . . . . 0.0 110.991 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -154.84 125.36 6.91 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.352 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -120.78 115.59 23.59 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.507 -0.121 . . . . 0.0 110.773 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -125.66 126.71 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' J' ' 34' ' ' LEU . 5.0 m-30 -99.09 125.35 44.59 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.768 ' HB2' ' N ' ' K' ' 21' ' ' ALA . 1.6 p90 -32.47 159.9 0.0 OUTLIER 'General case' 0 C--O 1.158 -3.758 0 N-CA-C 121.05 3.722 . . . . 0.0 121.05 -172.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.894 ' O ' ' HB3' ' K' ' 21' ' ' ALA . . . -78.62 157.14 28.77 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.068 174.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.456 ' OE1' ' O ' ' L' ' 20' ' ' PHE . 0.0 OUTLIER 178.67 -169.41 0.09 Allowed 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -177.114 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.562 ' OD1' ' N ' ' K' ' 27' ' ' ASN . 20.8 t0 -62.97 106.09 0.77 Allowed 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.453 HG23 ' HB2' ' K' ' 26' ' ' SER . 87.0 t -36.16 142.84 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -98.75 82.94 0.61 Allowed Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 178.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 67.6 m -69.15 -171.69 0.35 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' L' ' 28' ' ' LYS . 96.3 m-20 -81.13 177.41 9.05 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.313 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.546 ' O ' ' O ' ' L' ' 27' ' ' ASN . 86.2 tttt 39.81 104.16 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 178.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.19 -101.19 1.85 Allowed Glycine 0 N--CA 1.467 0.715 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -177.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.548 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -61.88 170.0 2.29 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 118.222 1.011 . . . . 0.0 108.652 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.898 HD13 ' H ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -166.11 153.41 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 118.642 -1.223 . . . . 0.0 112.413 -177.885 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.7 mt -125.31 128.01 72.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.063 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.35 121.38 5.03 Favored Glycine 0 N--CA 1.469 0.853 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -119.77 118.62 31.35 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.522 ' CE ' HG22 ' E' ' 31' ' ' ILE . 3.9 ttp -117.36 119.94 36.64 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.58 ' O ' HG23 ' L' ' 36' ' ' VAL . 35.8 m -130.46 76.29 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.643 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.474 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 23.9 -112.63 0.01 OUTLIER Glycine 0 C--N 1.352 1.428 0 N-CA-C 112.234 -0.346 . . . . 0.0 112.234 178.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.76 -150.56 15.97 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.51 158.29 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.816 0.341 . . . . 0.0 110.35 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.676 -179.636 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 . . . . . 0 N--CA 1.466 0.348 0 CA-C-O 120.853 0.359 . . . . 0.0 110.429 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.499 HG23 ' O ' ' B' ' 12' ' ' VAL . 2.5 m -121.9 132.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -151.83 166.79 30.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.411 ' CD2' ' CE1' ' B' ' 13' ' ' HIS . 93.0 m-70 -132.13 179.5 6.06 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -95.25 177.43 5.86 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.587 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -116.37 145.31 43.32 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.893 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.7 tp -128.22 123.0 33.12 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 121.268 0.556 . . . . 0.0 111.872 -179.152 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.54 131.43 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.335 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -137.52 132.7 33.61 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.133 0.492 . . . . 0.0 111.599 -179.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.3 p90 -133.14 129.94 38.56 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.24 158.12 39.77 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.446 ' CB ' ' O ' ' B' ' 22' ' ' GLU . 22.5 pt-20 -143.88 150.65 38.75 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.915 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 . . . . . 0 N--CA 1.466 0.35 0 C-N-CA 119.706 -0.797 . . . . 0.0 111.202 -178.63 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.383 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.05 101.06 0.27 Allowed Glycine 0 CA--C 1.484 -1.891 0 N-CA-C 106.962 -2.455 . . . . 0.0 106.962 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . -83.33 151.79 25.4 Favored 'General case' 0 N--CA 1.438 -1.039 0 C-N-CA 114.861 -2.736 . . . . 0.0 108.78 -175.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' G' ' 35' ' ' MET 0.3 0.3 OUTLIER -166.34 108.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.41 -2.475 0 CA-C-N 109.253 -3.612 . . . . 0.0 104.97 -168.806 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.495 ' N ' ' HE1' ' H' ' 35' ' ' MET . 17.8 tt -119.58 123.46 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 121.56 0.695 . . . . 0.0 110.032 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.573 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -124.3 116.8 2.91 Favored Glycine 0 CA--C 1.507 -0.468 0 N-CA-C 108.144 -1.982 . . . . 0.0 108.144 178.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 35.0 mt -136.21 148.15 47.97 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 122.905 1.336 . . . . 0.0 111.572 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.449 ' SD ' ' C ' ' G' ' 32' ' ' ILE . 12.0 ttm -121.18 124.0 43.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 112.475 -2.148 . . . . 0.0 109.362 -179.076 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.6 71.9 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.99 -96.47 0.01 OUTLIER Glycine 0 C--N 1.357 1.721 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 178.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.59 -162.76 36.55 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -131.0 160.76 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.855 0.359 . . . . 0.0 110.273 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.466 -179.662 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.04 140.71 47.61 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -110.57 137.65 47.98 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.909 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.499 ' O ' HG23 ' A' ' 12' ' ' VAL . 27.8 m -135.7 159.95 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.815 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.411 ' CE1' ' CD2' ' A' ' 14' ' ' HIS . 79.9 t60 -140.64 124.02 16.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.37 -0.377 . . . . 0.0 109.999 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 p-80 -149.32 166.74 28.08 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 121.239 0.543 . . . . 0.0 109.846 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.84 179.72 8.62 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.592 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -163.71 109.12 1.06 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.059 179.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -130.31 118.72 21.72 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.77 131.36 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.347 0.594 . . . . 0.0 110.866 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.91 131.14 55.13 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.1 t80 -128.37 119.95 26.02 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 132.68 53.21 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.863 -179.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 22' ' ' GLU . 81.8 tt0 -155.15 133.37 11.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.295 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 60.6 t0 . . . . . 0 N--CA 1.469 0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.518 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.784 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.388 -7.855 0 CA-C-O 117.675 -1.625 . . . . 0.0 114.279 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' B' ' 29' ' ' GLY 0.451 . . 113.93 -131.84 0.0 OUTLIER 'General case' 1 N--CA 1.366 -4.645 0 C-N-CA 114.019 -3.072 . . . . 0.0 106.355 -175.777 . . . . . . . . 4 3 . 1 . 002 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.725 HD12 ' N ' ' B' ' 31' ' ' ILE 0.366 2.2 mp -70.07 120.92 18.65 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.877 0 CA-C-N 109.245 -3.616 . . . . 0.0 113.458 175.045 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' B' ' 32' ' ' ILE . 16.9 tt -125.83 118.28 51.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.676 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -124.65 119.37 3.64 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.416 ' CD2' ' HB2' ' A' ' 34' ' ' LEU . 96.4 mt -136.61 131.25 33.48 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 122.901 1.334 . . . . 0.0 113.277 -176.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.485 ' HE1' ' SD ' ' C' ' 35' ' ' MET . 33.7 tpp -113.34 118.23 33.99 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.545 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.425 ' CG2' HG23 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -122.53 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.789 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.3 103.6 2.49 Favored Glycine 0 C--N 1.358 1.753 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.72 162.63 19.5 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.9 t -133.99 138.18 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 120.699 0.285 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.349 -179.976 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 50.2 t . . . . . 0 N--CA 1.466 0.352 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -149.93 129.35 12.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.003 0.43 . . . . 0.0 111.005 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.558 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 71.8 t60 -138.47 166.21 24.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.558 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 83.4 mt-30 -156.18 169.64 24.06 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.915 178.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -157.81 108.49 2.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.727 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.5 tp -125.77 118.89 26.52 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -129.01 126.19 64.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.278 0.561 . . . . 0.0 112.029 -179.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.05 104.74 12.43 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -116.86 126.17 52.62 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.24 141.13 23.71 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-O 123.446 1.594 . . . . 0.0 115.09 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.457 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 93.5 mt-10 -137.5 73.75 1.46 Allowed 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.65 -2.523 . . . . 0.0 104.269 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.495 ' O ' ' CA ' ' B' ' 29' ' ' GLY . 25.1 t70 . . . . . 0 N--CA 1.467 0.402 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -175.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.457 -3.556 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.654 ' HB1' ' O ' ' B' ' 30' ' ' ALA . . . -153.23 162.81 40.89 Favored 'General case' 0 N--CA 1.38 -3.959 0 N-CA-C 101.618 -3.475 . . . . 0.0 101.618 177.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.653 HG23 HD12 ' D' ' 31' ' ' ILE 0.273 3.0 mp -126.63 115.95 43.47 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.283 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.448 -174.397 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.502 ' O ' ' SD ' ' J' ' 35' ' ' MET . 4.9 mt -101.37 110.38 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.022 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.61 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -121.81 109.15 1.41 Allowed Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 105.869 -2.892 . . . . 0.0 105.869 176.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.469 ' HG ' ' N ' ' C' ' 35' ' ' MET . 0.6 OUTLIER -147.42 147.66 30.48 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 123.493 1.616 . . . . 0.0 113.178 -177.061 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.621 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 29.6 ttm -122.9 128.02 49.75 Favored 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 112.0 -2.364 . . . . 0.0 109.101 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.686 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.9 p -132.45 71.55 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.31 112.93 4.23 Favored Glycine 0 C--N 1.361 1.948 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.601 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.77 -144.34 0.07 OUTLIER Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.0 141.69 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . 0.423 HG22 ' H ' ' C' ' 40' ' ' VAL . 12.6 m . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 117.907 -1.044 . . . . 0.0 110.738 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 121.26 0.553 . . . . 0.0 111.176 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.54 -179.16 4.37 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.091 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.51 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 77.0 t60 -77.07 169.48 18.26 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.732 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.434 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 87.5 mt-30 -146.3 176.91 9.41 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.529 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -151.42 113.88 4.6 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 120.477 -0.489 . . . . 0.0 112.053 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.0 117.6 22.82 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -142.71 149.22 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 -178.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 2.5 m-30 -118.89 120.61 37.82 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.749 -1.569 . . . . 0.0 108.894 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -117.5 118.94 33.56 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 118.39 0.541 . . . . 0.0 109.988 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.64 121.6 35.96 Favored 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.887 -179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -164.83 106.34 0.83 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 59.5 t0 . . . . . 0 CA--C 1.545 0.76 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 174.506 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.488 -1.428 0 N-CA-C 102.341 -3.207 . . . . 0.0 102.341 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.653 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.61 123.59 3.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 117.865 -1.534 . . . . 0.0 112.351 -170.427 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.419 ' O ' HG22 ' D' ' 32' ' ' ILE . 1.5 mt -111.32 119.46 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-O 121.315 0.578 . . . . 0.0 110.129 178.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.699 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -127.01 100.48 0.55 Allowed Glycine 0 C--N 1.311 -0.817 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.537 HD21 HG13 ' D' ' 36' ' ' VAL . 10.5 tt -124.92 130.58 52.65 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.04 0.924 . . . . 0.0 111.964 -177.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.54 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.4 ttt -112.89 123.32 50.04 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 114.056 -1.429 . . . . 0.0 110.365 179.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.537 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.82 78.15 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-N 116.262 -0.426 . . . . 0.0 109.987 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.1 105.13 0.08 OUTLIER Glycine 0 C--N 1.348 1.211 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.24 -154.1 2.66 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.17 143.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.09 0.472 . . . . 0.0 110.329 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.473 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -140.97 150.49 43.15 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.409 ' OE1' ' C ' ' F' ' 11' ' ' GLU . 79.4 mm-40 -142.3 140.03 32.04 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.204 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG22 ' F' ' 12' ' ' VAL . 59.4 t -128.79 133.58 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.315 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -78.34 -168.67 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.437 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 37.8 p-80 -146.73 177.32 9.18 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 120.988 0.423 . . . . 0.0 110.087 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -100.26 169.68 8.96 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.24 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.79 120.75 13.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.613 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -122.2 121.83 37.76 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.667 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -130.49 126.83 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 120.562 -0.455 . . . . 0.0 112.192 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE2' ' CD2' ' D' ' 19' ' ' PHE . 10.8 m-85 -115.88 115.6 26.51 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 176.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.516 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 66.3 t80 -123.74 124.97 43.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.666 -177.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.9 139.74 41.83 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-O 121.114 0.483 . . . . 0.0 111.218 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.516 ' OE2' ' CZ ' ' E' ' 20' ' ' PHE . 8.6 mm-40 -108.49 119.88 40.79 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -166.81 101.18 0.56 Allowed 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.345 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -73.35 -158.84 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.711 0.767 . . . . 0.0 112.084 -178.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 62.17 79.61 0.13 Allowed Glycine 0 CA--C 1.526 0.776 0 CA-C-N 114.233 -1.349 . . . . 0.0 111.842 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.566 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 26.3 t . . . . . 0 N--CA 1.441 -0.89 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.245 0.832 0 CA-C-O 122.108 0.956 . . . . 0.0 110.39 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.686 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.0 OUTLIER -147.16 124.29 3.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.302 -1.317 . . . . 0.0 107.819 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 77.9 mt -123.19 130.24 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-O 120.958 0.409 . . . . 0.0 112.048 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.31 121.1 3.23 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.674 HD22 ' CE1' ' F' ' 19' ' ' PHE . 18.6 tp -125.7 123.36 38.72 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.629 -0.285 . . . . 0.0 110.812 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 12.8 ttt -117.86 117.81 30.3 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.219 178.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.6 t -122.54 83.81 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -16.34 -95.19 0.01 OUTLIER Glycine 0 N--CA 1.471 1.03 0 O-C-N 123.404 0.44 . . . . 0.0 112.833 -179.118 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.33 176.57 18.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 m -100.53 142.61 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 0.0 110.245 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.478 -179.865 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -82.88 137.47 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.704 0.288 . . . . 0.0 110.624 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . 0.409 ' C ' ' OE1' ' E' ' 11' ' ' GLU . 82.4 tt0 -159.03 159.85 35.2 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.467 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.434 HG22 ' H ' ' E' ' 12' ' ' VAL . 55.8 t -80.93 131.07 34.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -85.36 146.69 26.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.837 0.351 . . . . 0.0 111.364 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 83.5 m-70 -94.88 179.49 5.22 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -79.82 166.25 21.91 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 120.12 -0.632 . . . . 0.0 110.767 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -135.96 118.8 16.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 22.7 mt -122.5 120.45 33.91 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.28 130.9 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.209 0.528 . . . . 0.0 112.266 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.674 ' CE1' HD22 ' E' ' 34' ' ' LEU . 26.2 m-85 -119.64 123.83 44.81 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.001 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -139.69 130.93 26.64 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.589 0.709 . . . . 0.0 112.025 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.23 133.96 51.35 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.554 178.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.44 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 81.0 tt0 -76.65 90.48 3.38 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.937 -178.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' E' ' 26' ' ' SER . 15.7 t70 173.87 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.632 178.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 m -58.85 130.72 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.379 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.85 85.31 0.16 Allowed Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.419 -0.896 . . . . 0.0 111.709 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.9 p -64.67 -174.45 0.14 Allowed 'General case' 0 N--CA 1.442 -0.829 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.443 ' O ' ' O ' ' F' ' 28' ' ' LYS . 21.2 m120 -90.7 178.59 6.03 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 119.876 -0.73 . . . . 0.0 109.61 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.3 mttt 27.95 102.12 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 113.099 0.778 . . . . 0.0 113.099 177.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.72 -101.62 0.24 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 120.134 -1.032 . . . . 0.0 113.662 177.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.81 167.47 0.77 Allowed 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.591 HG21 ' HA2' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -150.08 126.86 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 118.105 -1.438 . . . . 0.0 111.416 -176.939 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 5.1 mp -127.39 133.01 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.193 -178.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.7 131.8 6.33 Favored Glycine 0 N--CA 1.469 0.893 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -127.23 125.48 41.07 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 24.4 ttt -128.37 126.68 41.17 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.818 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -118.17 81.15 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.438 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.596 ' CA ' HG21 ' L' ' 31' ' ' ILE . . . -45.29 100.9 0.02 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.873 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.82 162.01 35.78 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -136.14 145.96 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 120.788 0.327 . . . . 0.0 110.454 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.875 -1.059 . . . . 0.0 110.68 -179.647 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 . . . . . 0 CA--C 1.527 0.075 0 CA-C-O 120.691 0.282 . . . . 0.0 110.463 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.424 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 22.8 m80 -97.55 178.65 5.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -118.26 -177.08 3.2 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.23 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.59 154.44 17.92 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.174 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.1 tp -131.15 118.23 20.19 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.088 0.47 . . . . 0.0 110.439 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -124.94 131.03 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.752 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 t80 -129.98 127.96 41.09 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.036 0.446 . . . . 0.0 110.304 179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.523 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -130.3 128.59 41.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.89 123.04 46.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.981 0.42 . . . . 0.0 110.505 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' G' ' 23' ' ' ASP . 43.6 tt0 -141.06 142.28 34.19 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.913 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.48 ' O ' ' O ' ' G' ' 22' ' ' GLU . 97.5 m-20 50.54 113.88 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.937 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.545 ' N ' ' OD2' ' H' ' 23' ' ' ASP . 70.0 t -149.34 112.84 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.283 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.21 -91.02 0.01 OUTLIER Glycine 0 CA--C 1.529 0.924 0 CA-C-O 121.466 0.481 . . . . 0.0 112.898 177.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.78 ' O ' ' O ' ' G' ' 27' ' ' ASN . 21.2 p -161.76 174.57 13.03 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.78 ' O ' ' O ' ' G' ' 26' ' ' SER . 81.7 m-20 -9.42 160.03 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 17.1 pttp 179.26 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 179.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.1 100.93 0.68 Allowed Glycine 0 N--CA 1.469 0.898 0 N-CA-C 107.061 -2.416 . . . . 0.0 107.061 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.42 157.43 22.48 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 123.473 1.606 . . . . 0.0 113.301 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.415 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.83 111.61 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 CA-C-N 111.766 -2.47 . . . . 0.0 108.671 -178.197 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.449 ' C ' ' SD ' ' A' ' 35' ' ' MET . 1.9 mt -99.1 109.25 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.59 105.75 1.04 Allowed Glycine 0 CA--C 1.504 -0.645 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 18.1 mt -139.46 145.32 38.67 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 123.061 1.41 . . . . 0.0 112.709 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 48.4 ttp -113.87 114.24 25.98 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.538 -1.664 . . . . 0.0 106.803 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.1 71.0 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.495 ' O ' HG21 ' A' ' 31' ' ' ILE . . . -157.1 95.98 0.15 Allowed Glycine 0 C--N 1.355 1.604 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -138.16 -176.87 14.78 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m . . . . . 0 N--CA 1.464 0.271 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.907 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 N--CA 1.465 0.29 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -152.57 97.67 2.28 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.429 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.424 ' CE1' ' O ' ' G' ' 14' ' ' HIS . 54.2 p-80 -108.1 166.45 10.72 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -152.54 168.9 24.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.778 0.799 . . . . 0.0 111.377 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.675 ' C ' HD12 ' H' ' 17' ' ' LEU . 64.8 tttm -169.58 117.35 0.6 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.71 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.675 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.0 mp -122.33 118.5 28.63 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.51 HG21 ' HZ1' ' H' ' 16' ' ' LYS . 60.3 t -121.03 124.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.474 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 83.5 m-85 -119.7 106.55 12.24 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -116.41 124.65 50.55 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.455 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.98 130.04 49.28 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.813 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -159.33 114.78 2.49 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.823 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.545 ' OD2' ' N ' ' G' ' 24' ' ' VAL . 28.5 t0 -174.65 123.3 0.27 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 178.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' H' ' 23' ' ' ASP . 13.0 t . . . . . 0 N--CA 1.465 0.307 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.911 175.077 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.323 0 N-CA-C 101.077 -3.675 . . . . 0.0 101.077 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.421 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -134.08 118.72 29.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 118.005 -1.478 . . . . 0.0 109.835 -178.295 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.43 HG22 ' O ' ' H' ' 32' ' ' ILE . 1.3 mt -109.78 115.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.461 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.44 97.42 0.68 Allowed Glycine 0 CA--C 1.508 -0.345 0 N-CA-C 106.914 -2.475 . . . . 0.0 106.914 176.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.488 HD21 ' CZ ' ' I' ' 19' ' ' PHE . 2.9 mp -127.02 133.51 50.51 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-O 122.552 1.168 . . . . 0.0 111.456 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.676 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 43.7 ttp -111.16 117.38 33.08 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-N 113.595 -1.639 . . . . 0.0 107.895 178.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -113.05 67.65 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.957 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.81 -101.62 0.01 OUTLIER Glycine 0 C--N 1.352 1.446 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.56 164.85 11.53 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.27 141.71 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.765 -179.936 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.566 HG12 ' N ' ' I' ' 13' ' ' HIS . 43.1 t . . . . . 0 N--CA 1.468 0.455 0 CA-C-O 120.977 0.418 . . . . 0.0 111.331 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.666 ' CG ' ' H ' ' I' ' 14' ' ' HIS . 44.6 t-80 -125.82 -172.35 2.58 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.047 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.666 ' H ' ' CG ' ' I' ' 13' ' ' HIS . 0.1 OUTLIER -76.45 166.65 23.12 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.204 0.526 . . . . 0.0 109.795 -179.205 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -148.65 170.68 17.59 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.174 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -150.35 137.78 19.68 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 121.041 -0.264 . . . . 0.0 111.149 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 52.8 mt -130.99 124.5 31.09 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.33 137.83 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.488 ' CZ ' HD21 ' H' ' 34' ' ' LEU . 60.8 m-85 -120.44 123.85 44.01 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.136 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.626 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 3.4 t80 -124.27 124.44 42.42 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.101 -177.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.83 126.05 42.7 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 122.49 1.138 . . . . 0.0 113.451 -178.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -154.28 82.83 1.12 Allowed 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.462 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.473 ' OD2' ' O ' ' H' ' 23' ' ' ASP . 13.1 t70 -105.79 -114.13 0.25 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.667 ' O ' ' N ' ' I' ' 26' ' ' SER . 58.2 t -85.45 130.69 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.933 0 N-CA-C 104.426 -2.435 . . . . 0.0 104.426 176.088 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.607 ' CA ' ' H ' ' J' ' 24' ' ' VAL . . . -42.98 82.66 0.0 OUTLIER Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.189 -1.005 . . . . 0.0 111.974 -176.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.667 ' N ' ' O ' ' I' ' 24' ' ' VAL . 11.4 p -65.63 -176.2 0.33 Allowed 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 177.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.51 HD22 ' C ' ' I' ' 27' ' ' ASN . 0.2 OUTLIER -81.42 179.2 7.95 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.671 177.631 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' I' ' 27' ' ' ASN . 85.0 tttt -42.39 -106.42 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.984 0.897 . . . . 0.0 110.036 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.899 ' C ' ' HB1' ' J' ' 30' ' ' ALA . . . -82.8 96.98 1.92 Allowed Glycine 0 CA--C 1.45 -3.973 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.792 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -68.73 -151.17 0.01 OUTLIER 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 101.899 -3.371 . . . . 0.0 101.899 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.9 ' N ' HD13 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -102.62 104.01 15.89 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 CA-C-N 123.782 2.992 . . . . 0.0 109.964 -176.0 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.621 ' N ' ' SD ' ' C' ' 35' ' ' MET . 2.6 mt -107.11 114.2 45.48 Favored 'Isoleucine or valine' 0 C--N 1.362 1.131 0 CA-C-N 113.765 -1.561 . . . . 0.0 111.126 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.409 ' N ' ' CE ' ' B' ' 35' ' ' MET . . . -115.54 97.98 0.82 Allowed Glycine 0 C--O 1.242 0.641 0 N-CA-C 105.502 -3.039 . . . . 0.0 105.502 175.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.523 HD11 ' CZ ' ' J' ' 19' ' ' PHE . 0.2 OUTLIER -129.78 132.83 46.67 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-O 122.268 1.032 . . . . 0.0 111.077 -177.462 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.61 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.0 ttp -113.68 121.55 44.46 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.345 -178.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.51 70.03 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 177.126 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -41.12 -100.66 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.81 -160.59 33.68 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 54.7 t -122.46 134.94 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 120.859 0.361 . . . . 0.0 110.04 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 70.1 t . . . . . 0 C--O 1.218 -0.582 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.604 -179.984 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p . . . . . 0 N--CA 1.463 0.199 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -146.45 135.62 22.68 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.054 0.454 . . . . 0.0 111.523 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -152.43 155.94 38.53 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -153.38 173.64 15.38 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.441 0.639 . . . . 0.0 111.706 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -155.93 129.33 8.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.596 -1.184 . . . . 0.0 107.887 178.275 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.84 116.94 24.52 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.5 123.62 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.253 0.549 . . . . 0.0 110.896 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.523 ' CZ ' HD11 ' I' ' 34' ' ' LEU . 3.9 m-85 -120.88 109.06 14.67 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 179.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.626 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 3.7 p90 -148.94 151.36 34.48 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 117.772 -1.571 . . . . 0.0 114.649 -178.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.01 155.88 34.96 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.156 -1.384 . . . . 0.0 111.169 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -127.22 144.03 51.13 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -178.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.468 ' CG ' ' O ' ' I' ' 26' ' ' SER . 10.9 t0 -103.68 134.26 47.31 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.867 178.179 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.607 ' H ' ' CA ' ' I' ' 25' ' ' GLY . 57.4 t -110.43 111.78 37.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.661 179.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.23 90.37 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 N-CA-C 115.708 1.043 . . . . 0.0 115.708 174.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.613 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.8 p 170.68 174.83 0.06 Allowed 'General case' 0 C--N 1.343 0.324 0 CA-C-N 118.369 1.084 . . . . 0.0 111.379 176.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.8 m120 -28.04 -179.55 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.59 ' CD ' ' H ' ' K' ' 27' ' ' ASN . 55.3 tttt -130.51 -107.31 0.27 Allowed 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.748 1.388 . . . . 0.0 114.748 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 41.61 91.81 0.01 OUTLIER Glycine 0 N--CA 1.481 1.677 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 -176.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.899 ' HB1' ' C ' ' I' ' 29' ' ' GLY . . . -140.61 157.73 45.02 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -177.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.82 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -146.18 128.11 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.53 0 CA-C-O 121.461 0.648 . . . . 0.0 112.506 -178.286 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.54 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.3 tt -109.25 118.41 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.52 101.66 0.99 Allowed Glycine 0 N--CA 1.47 0.963 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' I' ' 32' ' ' ILE . 80.0 mt -127.05 131.68 50.88 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-O 121.431 0.634 . . . . 0.0 112.583 -177.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.699 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.2 ttp -113.82 120.6 41.3 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.015 178.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.74 67.46 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.433 ' HA3' HD13 ' D' ' 31' ' ' ILE . . . -49.97 121.4 9.58 Favored Glycine 0 C--N 1.355 1.593 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.54 -136.8 0.03 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t . . . . . 0 N--CA 1.466 0.366 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.535 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 . . . . . 0 N--CA 1.464 0.271 0 CA-C-O 120.695 0.284 . . . . 0.0 110.797 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 m -139.83 134.21 37.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.156 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -124.3 119.17 28.52 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.315 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.89 162.55 24.15 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-O 121.485 0.66 . . . . 0.0 109.444 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' L' ' 15' ' ' GLN . 85.4 mt-30 -151.35 178.78 8.92 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.353 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -172.69 128.15 0.51 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -124.39 123.44 40.18 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.825 0.345 . . . . 0.0 110.117 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.48 125.38 65.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.74 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.413 ' HB2' ' CD1' ' L' ' 19' ' ' PHE . 17.3 m-85 -115.77 114.92 25.44 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -122.05 123.64 42.09 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.01 128.08 39.62 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 121.49 0.662 . . . . 0.0 111.31 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -99.12 128.29 45.22 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 120.176 -0.609 . . . . 0.0 111.782 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 9.2 p-10 -142.86 136.58 28.84 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.116 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.546 HG13 ' O ' ' K' ' 24' ' ' VAL . 7.8 p -91.1 112.27 24.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.577 -176.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.69 91.5 0.01 OUTLIER Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.586 ' HB2' ' HZ1' ' J' ' 28' ' ' LYS . 5.4 t -42.32 154.63 0.05 Allowed 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.64 -0.78 . . . . 0.0 110.931 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.59 ' H ' ' CD ' ' J' ' 28' ' ' LYS . 84.7 m-20 -126.97 -179.86 5.05 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.746 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.401 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.7 mttt -30.12 107.29 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.473 1.286 . . . . 0.0 114.473 -177.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.36 -96.48 1.74 Allowed Glycine 0 N--CA 1.47 0.93 0 CA-C-N 113.996 -1.456 . . . . 0.0 116.208 172.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.425 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 72.22 153.28 0.13 Allowed 'General case' 0 C--O 1.249 1.051 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 -174.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.715 HG23 HG12 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -149.65 127.47 2.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 117.001 -1.88 . . . . 0.0 111.82 -176.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.504 ' O ' ' CE ' ' E' ' 35' ' ' MET . 82.7 mt -118.84 120.08 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.001 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -119.93 107.86 1.39 Allowed Glycine 0 N--CA 1.467 0.749 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.422 HD13 ' CD2' ' L' ' 19' ' ' PHE . 48.5 mt -121.43 120.6 35.45 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -117.97 124.78 49.03 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.188 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.05 80.77 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.799 178.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.686 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -63.8 102.87 0.61 Allowed Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.78 -146.79 18.03 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.661 -179.913 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t . . . . . 0 N--CA 1.465 0.294 0 CA-C-O 121.137 0.494 . . . . 0.0 110.382 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -155.24 140.29 17.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.694 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -150.4 171.46 16.98 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 89.0 mt-30 -147.02 173.53 12.37 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.464 0.65 . . . . 0.0 111.228 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -155.55 130.26 9.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.494 179.157 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.69 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.6 tt -132.5 125.31 30.31 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . 0.496 ' N ' HD23 ' L' ' 17' ' ' LEU . 73.8 t -129.39 129.21 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 121.147 0.499 . . . . 0.0 111.835 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.508 ' CD2' HD21 ' L' ' 17' ' ' LEU . 10.8 m-85 -113.43 114.27 26.34 Favored 'General case' 0 C--N 1.341 0.215 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -140.64 136.83 33.1 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 122.104 0.954 . . . . 0.0 112.249 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.16 151.84 30.58 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.386 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 81.8 tt0 -75.11 95.15 3.02 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.991 -178.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' L' ' 24' ' ' VAL . 67.9 t0 -175.36 136.1 0.35 Allowed 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.981 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.543 HG23 ' O ' ' L' ' 24' ' ' VAL . 33.5 m -71.02 111.28 4.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.95 -91.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.007 0 CA-C-N 114.894 -1.048 . . . . 0.0 115.528 -176.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 10.0 p -71.24 176.67 4.36 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 122.967 1.365 . . . . 0.0 114.362 -175.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 4.9 t-20 85.89 178.65 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 111.412 -2.631 . . . . 0.0 114.486 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.1 mttt -40.99 104.49 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 116.61 2.078 . . . . 0.0 116.61 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.0 -101.24 0.3 Allowed Glycine 0 N--CA 1.473 1.161 0 N-CA-C 115.823 1.089 . . . . 0.0 115.823 173.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.587 ' C ' HD13 ' L' ' 31' ' ' ILE . . . -58.37 172.8 0.43 Allowed 'General case' 0 CA--C 1.508 -0.636 0 CA-C-O 119.106 -0.474 . . . . 0.0 111.335 -177.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.845 ' N ' HD13 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -134.78 118.6 25.82 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 C-N-CA 118.405 -1.318 . . . . 0.0 111.148 179.661 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.62 133.23 68.75 Favored 'Isoleucine or valine' 0 C--O 1.23 0.072 0 CA-C-N 113.77 -1.559 . . . . 0.0 109.786 -178.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.521 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -131.3 118.88 2.49 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.381 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.521 HD12 ' C ' ' L' ' 33' ' ' GLY . 10.6 mp -114.5 124.34 51.65 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.9 tmm? -117.51 120.53 38.37 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.616 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.72 81.13 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.549 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.591 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . 44.13 -101.39 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.53 -169.29 37.76 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.82 136.24 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.904 0.383 . . . . 0.0 110.672 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.813 179.726 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 . . . . . 0 N--CA 1.466 0.327 0 N-CA-C 110.089 -0.337 . . . . 0.0 110.089 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.51 133.55 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 120.952 0.406 . . . . 0.0 110.737 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -135.8 -175.7 4.05 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.067 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -80.03 164.79 23.16 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-O 121.23 0.538 . . . . 0.0 109.836 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -153.5 177.45 10.9 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.462 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -147.57 131.34 16.99 Favored 'General case' 0 N--CA 1.466 0.374 0 C-N-CA 121.118 -0.233 . . . . 0.0 110.809 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -133.4 115.44 14.84 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.326 0.584 . . . . 0.0 110.135 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.63 133.44 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.072 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -145.72 148.93 33.54 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.681 0.753 . . . . 0.0 111.511 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 p90 -135.92 149.3 48.9 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.717 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.81 136.54 27.24 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 122.275 1.035 . . . . 0.0 113.312 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' A' ' 23' ' ' ASP . 98.8 mt-10 -111.51 178.72 4.24 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.532 -1.667 . . . . 0.0 107.705 177.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.529 ' H ' ' CB ' ' B' ' 23' ' ' ASP . 95.7 m-20 . . . . . 0 C--N 1.33 -0.256 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.941 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 122.016 0.912 . . . . 0.0 112.006 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.3 99.2 2.59 Favored Glycine 0 CA--C 1.493 -1.289 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.205 -176.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.18 160.66 20.83 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.392 -176.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.519 ' O ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -146.74 111.79 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.775 -175.295 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.581 HG22 HD11 ' B' ' 34' ' ' LEU . 46.8 mt -121.29 104.88 15.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.641 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -113.96 114.2 3.26 Favored Glycine 0 CA--C 1.502 -0.78 0 N-CA-C 105.827 -2.909 . . . . 0.0 105.827 176.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 5.6 tp -146.04 144.93 30.37 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 122.754 1.264 . . . . 0.0 113.382 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.597 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 17.5 ttm -112.91 117.36 31.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.888 178.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.89 67.3 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 177.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.3 -101.71 0.01 OUTLIER Glycine 0 C--N 1.366 2.21 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.95 -166.13 39.21 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.97 158.08 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.836 0.35 . . . . 0.0 110.735 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.915 -1.04 . . . . 0.0 110.533 -179.866 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.9 m-85 -105.2 132.95 50.76 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -137.85 160.53 39.03 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.114 0.483 . . . . 0.0 111.14 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 50.9 t -122.41 134.45 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.893 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -109.07 114.83 28.9 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.985 0.421 . . . . 0.0 111.445 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.47 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 83.5 t60 -142.23 160.45 40.22 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.47 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 78.9 mt-30 -159.27 179.11 9.28 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.13 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -161.35 119.02 2.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.519 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -130.61 122.64 27.83 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.12 137.12 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 121.066 0.46 . . . . 0.0 110.582 178.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -128.87 138.33 51.96 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.879 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -123.15 131.49 53.71 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.21 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.48 125.71 29.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 120.673 -0.411 . . . . 0.0 111.86 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 82.5 tt0 -170.82 139.76 1.53 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.448 179.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.529 ' CB ' ' H ' ' A' ' 23' ' ' ASP . 14.3 p-10 . . . . . 0 C--N 1.344 0.329 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.477 1.429 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.452 ' O ' HG13 ' C' ' 31' ' ' ILE . . . -104.99 154.35 20.23 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 103.294 -2.854 . . . . 0.0 103.294 176.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.448 HD12 HG23 ' A' ' 31' ' ' ILE . 2.0 mt -139.8 108.14 3.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.753 -173.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.483 ' O ' HG23 ' B' ' 32' ' ' ILE . 5.1 tt -122.37 116.55 49.4 Favored 'Isoleucine or valine' 0 C--O 1.241 0.646 0 CA-C-O 122.069 0.938 . . . . 0.0 109.619 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.781 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -127.99 117.92 2.72 Favored Glycine 0 N--CA 1.453 -0.188 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.781 HD12 ' C ' ' B' ' 33' ' ' GLY . 7.0 mp -141.91 149.93 40.83 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-O 123.147 1.451 . . . . 0.0 113.214 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 24.2 ttm -121.69 118.75 29.9 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 112.769 -2.014 . . . . 0.0 107.822 177.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -112.57 68.71 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -179.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.82 -101.5 0.12 Allowed Glycine 0 C--N 1.352 1.417 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.599 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.41 167.71 35.49 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.4 m -131.74 161.92 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.906 0.384 . . . . 0.0 110.242 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.648 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m . . . . . 0 N--CA 1.466 0.337 0 N-CA-C 110.009 -0.367 . . . . 0.0 110.009 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -117.26 136.98 52.7 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 120.723 0.297 . . . . 0.0 111.57 -178.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 24.0 t-80 -141.37 163.2 33.6 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.663 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 83.0 mt-30 -156.03 169.74 23.77 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 121.183 0.516 . . . . 0.0 111.064 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -155.91 115.98 3.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.443 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 44.4 tp -121.5 124.09 43.6 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -133.38 127.28 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 113.466 0.913 . . . . 0.0 113.466 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 50.6 m-85 -117.47 119.29 34.61 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -122.46 126.37 47.75 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 117.827 0.285 . . . . 0.0 111.421 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.12 149.2 37.79 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 115.435 1.642 . . . . 0.0 115.435 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 28.0 mt-10 -154.45 138.69 16.59 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 114.398 -1.274 . . . . 0.0 110.857 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 26.2 t0 . . . . . 0 N--CA 1.484 1.273 0 N-CA-C 114.504 1.298 . . . . 0.0 114.504 176.782 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.477 -2.308 0 CA-C-O 117.522 -1.71 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.426 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -149.75 134.51 17.73 Favored 'General case' 0 CA--C 1.47 -2.113 0 C-N-CA 115.933 -2.307 . . . . 0.0 108.115 173.044 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.452 HG13 ' O ' ' B' ' 30' ' ' ALA 0.274 3.5 mt -138.78 102.22 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 CA-C-N 110.469 -3.059 . . . . 0.0 105.045 -175.837 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.515 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.9 mt -109.19 118.14 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-N 115.059 -0.973 . . . . 0.0 111.427 -176.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.708 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -129.92 99.08 0.44 Allowed Glycine 0 CA--C 1.5 -0.901 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.475 ' HG ' ' H ' ' B' ' 34' ' ' LEU . 3.7 mp -132.05 147.35 52.44 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 122.64 1.209 . . . . 0.0 111.924 -177.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.494 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 26.7 ttm -129.01 127.94 42.64 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.87 -1.968 . . . . 0.0 110.375 -179.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.75 72.24 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.9 102.76 2.39 Favored Glycine 0 C--N 1.364 2.102 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 -178.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.4 154.61 25.86 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.0 m -134.72 161.57 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-O 120.735 0.302 . . . . 0.0 110.477 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.256 179.664 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -85.78 166.42 16.09 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.884 0.373 . . . . 0.0 110.097 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 43.7 p-80 -76.52 175.11 9.54 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.225 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -140.62 173.36 11.57 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.189 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -141.04 130.75 24.17 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.494 0.664 . . . . 0.0 112.258 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 49.5 tp -122.54 120.31 33.46 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.761 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . 0.516 HG11 ' CE2' ' D' ' 20' ' ' PHE . 19.8 t -134.79 128.35 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.522 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 65.2 m-85 -125.46 115.32 20.06 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.771 177.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' D' ' 20' ' ' PHE . 0.0 OUTLIER -147.84 159.09 44.21 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 122.786 1.279 . . . . 0.0 113.949 179.129 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.74 156.33 38.91 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.867 -1.515 . . . . 0.0 112.013 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 33.1 mt-10 -148.24 141.71 25.35 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.685 -179.559 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' D' ' 23' ' ' ASP . 0.8 OUTLIER . . . . . 0 N--CA 1.476 0.867 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.447 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.457 -2.597 0 CA-C-O 122.819 1.295 . . . . 0.0 109.429 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.98 99.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.062 0 CA-C-N 112.083 -2.326 . . . . 0.0 106.144 -176.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 mt -108.16 124.61 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.427 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.743 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.08 100.55 0.58 Allowed Glycine 0 C--N 1.309 -0.934 0 N-CA-C 105.331 -3.108 . . . . 0.0 105.331 174.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.624 HD21 ' CZ ' ' E' ' 19' ' ' PHE . 0.1 OUTLIER -121.79 120.7 35.37 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.524 0.678 . . . . 0.0 110.148 -177.68 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.518 ' N ' HD13 ' D' ' 34' ' ' LEU . 3.5 ttt -112.99 115.43 28.37 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.682 -1.145 . . . . 0.0 108.068 178.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -112.43 77.31 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.495 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -4.12 -101.93 0.0 OUTLIER Glycine 0 C--N 1.368 2.324 0 O-C-N 123.608 0.568 . . . . 0.0 112.899 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.5 -170.62 39.72 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.59 159.73 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.436 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -139.82 123.67 17.52 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 120.744 0.306 . . . . 0.0 110.636 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -136.96 139.69 41.68 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.349 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -133.87 138.76 49.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 -139.74 126.86 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.37 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.576 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 45.4 t-80 -156.08 167.2 31.16 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.898 0.856 . . . . 0.0 110.952 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.576 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 47.5 tt0 -164.02 168.24 19.46 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.307 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 53.8 tttm -135.44 120.19 18.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.465 178.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 36.1 mt -107.34 118.83 37.75 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.96 121.58 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD21 ' D' ' 34' ' ' LEU . 62.6 m-85 -115.62 115.76 26.97 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 176.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' F' ' 20' ' ' PHE . 25.3 t80 -142.21 149.09 39.2 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.078 1.51 . . . . 0.0 115.078 -175.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . 0.426 ' N ' ' CD1' ' E' ' 20' ' ' PHE . . . -149.73 138.63 21.06 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.415 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 81.5 tt0 -110.97 111.85 23.26 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.432 178.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.456 ' O ' ' C ' ' E' ' 24' ' ' VAL . 0.3 OUTLIER 176.37 122.52 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -178.049 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.456 ' C ' ' O ' ' E' ' 23' ' ' ASP . 41.5 t -37.32 117.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 121.595 0.712 . . . . 0.0 110.332 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.81 89.6 0.48 Allowed Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.919 -178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 46.7 t . . . . . 0 N--CA 1.447 -0.624 0 CA-C-O 122.616 1.198 . . . . 0.0 111.765 -177.386 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.508 ' C ' HD13 ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.239 0.516 0 N-CA-C 105.575 -2.009 . . . . 0.0 105.575 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.668 ' N ' HD13 ' E' ' 31' ' ' ILE . 0.1 OUTLIER -148.16 128.54 4.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 121.543 0.687 . . . . 0.0 111.086 -178.548 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 91.9 mt -128.19 128.59 68.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.109 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.4 124.58 5.64 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.54 HD23 ' N ' ' E' ' 35' ' ' MET . 4.1 tt -130.17 121.71 26.79 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.54 ' N ' HD23 ' E' ' 34' ' ' LEU . 9.4 ttt -123.15 125.37 45.01 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 121.065 -0.254 . . . . 0.0 111.477 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.3 t -127.59 78.64 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.545 ' HA2' HG21 ' K' ' 31' ' ' ILE . . . 13.77 -109.25 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 N-CA-C 114.107 0.403 . . . . 0.0 114.107 177.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -150.1 165.27 29.8 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.436 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 55.3 t -130.28 136.3 58.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' F' ' 39' ' ' VAL . 46.3 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.358 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -108.15 136.12 48.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.814 0.34 . . . . 0.0 110.609 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.23 133.83 47.7 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.245 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.71 135.27 51.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 31.3 p-80 -155.91 128.09 7.59 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.041 0.448 . . . . 0.0 111.593 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 62.5 m80 -151.09 171.58 17.13 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -151.1 171.16 17.78 Favored 'General case' 0 C--N 1.313 -1.015 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.331 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -141.71 127.2 18.89 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.67 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.57 126.78 54.65 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.74 119.76 52.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.13 0.49 . . . . 0.0 111.934 -178.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.42 ' CE1' HD11 ' E' ' 34' ' ' LEU . 4.0 m-85 -113.7 105.93 13.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' E' ' 20' ' ' PHE . 5.7 m-85 -139.29 131.28 27.85 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 122.608 1.195 . . . . 0.0 112.558 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . 0.434 ' O ' ' OD1' ' F' ' 23' ' ' ASP . . . -148.94 163.16 38.29 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.357 178.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -71.15 85.03 0.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.818 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 11.1 p30 -165.3 112.77 0.98 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.844 178.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.58 ' O ' ' N ' ' F' ' 26' ' ' SER . 98.1 t -70.74 132.55 33.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.583 178.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.6 83.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.206 -1.558 . . . . 0.0 109.206 177.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . 0.58 ' N ' ' O ' ' F' ' 24' ' ' VAL . 13.1 p -66.07 -174.18 0.23 Allowed 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 122.492 1.139 . . . . 0.0 112.276 -177.14 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -81.63 179.08 7.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 112.722 -2.036 . . . . 0.0 111.719 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -37.25 104.22 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.553 -0.748 . . . . 0.0 109.66 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.448 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 167.88 -100.67 0.17 Allowed Glycine 0 C--O 1.217 -0.956 0 N-CA-C 108.843 -1.703 . . . . 0.0 108.843 -174.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.24 166.02 0.08 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 119.674 1.737 . . . . 0.0 107.659 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.652 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -143.43 130.31 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 118.093 -1.443 . . . . 0.0 112.604 -175.123 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -128.98 122.87 57.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.909 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 122.34 5.41 Favored Glycine 0 N--CA 1.468 0.833 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 36.7 mt -119.66 120.37 36.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' L' ' 32' ' ' ILE . 19.9 ttt -130.88 134.53 46.87 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.873 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.481 HG22 ' O ' ' F' ' 36' ' ' VAL . 1.5 p -156.96 89.41 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.742 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.39 94.83 0.23 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.757 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -149.81 167.77 29.91 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.706 -0.957 . . . . 0.0 110.706 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' E' ' 40' ' ' VAL . 30.9 m -132.08 157.12 43.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.893 0.378 . . . . 0.0 110.531 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.697 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.601 0.239 . . . . 0.0 110.414 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' H' ' 14' ' ' HIS . 57.0 p-80 -152.93 169.98 21.52 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? -154.31 170.54 21.06 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.379 179.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.6 mttm -156.63 164.27 38.37 Favored 'General case' 0 C--O 1.222 -0.37 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.747 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 2.9 mp -146.71 175.93 10.24 Favored 'General case' 0 C--O 1.172 -3.02 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.968 ' C ' ' O ' ' H' ' 18' ' ' VAL . 94.0 t -156.62 170.51 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 118.724 -2.485 . . . . 0.0 110.099 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.654 ' N ' HG12 ' G' ' 18' ' ' VAL . 26.3 p90 -162.58 105.2 1.09 Allowed 'General case' 0 C--O 1.169 -3.169 0 O-C-N 121.375 -0.828 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.695 ' C ' ' O ' ' H' ' 20' ' ' PHE . 35.3 t80 -109.78 108.19 18.45 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.549 -1.344 . . . . 0.0 110.839 177.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -82.42 103.12 11.74 Favored 'General case' 0 C--O 1.178 -2.684 0 C-N-CA 124.682 1.193 . . . . 0.0 111.012 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.551 ' H ' ' HA ' ' H' ' 21' ' ' ALA . 73.7 mt-10 -75.39 147.92 39.61 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 120.27 1.395 . . . . 0.0 111.86 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.445 ' CG ' ' N ' ' G' ' 24' ' ' VAL . 7.8 p-10 -156.02 -144.75 0.14 Allowed 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.159 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' G' ' 23' ' ' ASP . 18.3 t -29.58 103.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 114.988 -1.006 . . . . 0.0 112.501 178.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.39 -94.41 0.09 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.643 178.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.2 m -71.18 174.17 6.72 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 119.138 1.469 . . . . 0.0 110.388 -178.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -78.71 173.33 12.57 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.511 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.461 ' HZ2' ' CB ' ' I' ' 26' ' ' SER . 13.0 mmtt -46.04 111.77 0.4 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 174.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 94.29 1.74 Allowed Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -177.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.43 -179.92 7.08 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-O 122.349 1.071 . . . . 0.0 111.157 -178.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.462 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.12 109.18 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 CA-C-N 113.28 -1.782 . . . . 0.0 108.91 -177.924 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.597 ' N ' ' SD ' ' A' ' 35' ' ' MET . 2.4 mt -107.02 112.41 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.612 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -115.96 98.39 0.82 Allowed Glycine 0 CA--C 1.499 -0.927 0 N-CA-C 106.851 -2.5 . . . . 0.0 106.851 176.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.612 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.6 mm? -125.22 133.9 52.55 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 122.305 1.05 . . . . 0.0 110.475 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.641 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 42.7 ttp -109.93 120.08 41.35 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 113.8 -1.546 . . . . 0.0 108.973 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.468 HG23 HG13 ' H' ' 36' ' ' VAL . 0.9 OUTLIER -134.5 70.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.762 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.32 106.09 2.9 Favored Glycine 0 C--N 1.365 2.139 0 N-CA-C 111.614 -0.594 . . . . 0.0 111.614 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.78 179.03 2.36 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 112.017 -0.433 . . . . 0.0 112.017 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 28.0 m . . . . . 0 N--CA 1.464 0.228 0 CA-C-N 115.436 -0.382 . . . . 0.0 110.273 179.783 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.2 t . . . . . 0 N--CA 1.466 0.329 0 N-CA-C 110.383 -0.229 . . . . 0.0 110.383 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 p-80 -174.88 -172.35 0.61 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 111.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' G' ' 14' ' ' HIS . 82.4 m-70 -149.09 163.49 37.4 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.415 ' HG2' ' N ' ' H' ' 16' ' ' LYS . 56.2 tt0 -160.25 167.44 27.56 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.427 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' G' ' 16' ' ' LYS . 73.1 mttt -156.57 151.67 26.31 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -134.16 123.57 24.6 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.968 ' O ' ' C ' ' G' ' 18' ' ' VAL . 65.3 t -125.59 141.69 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 118.113 -1.435 . . . . 0.0 113.838 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 94.1 m-85 -118.62 115.01 23.66 Favored 'General case' 0 N--CA 1.472 0.644 0 O-C-N 120.723 -1.236 . . . . 0.0 109.722 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.695 ' O ' ' C ' ' G' ' 20' ' ' PHE . 8.2 t80 -109.89 106.89 16.63 Favored 'General case' 0 C--O 1.25 1.107 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 179.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -90.42 120.09 31.24 Favored 'General case' 0 C--N 1.36 1.052 0 O-C-N 124.864 1.352 . . . . 0.0 110.461 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.477 ' O ' ' CB ' ' H' ' 23' ' ' ASP . 82.4 tt0 -153.26 156.53 38.63 Favored 'General case' 0 C--N 1.359 1.022 0 C-N-CA 117.898 -1.521 . . . . 0.0 113.125 -177.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' H' ' 22' ' ' GLU . 0.9 OUTLIER 149.23 121.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.448 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.507 ' O ' HG23 ' H' ' 24' ' ' VAL . 25.0 m . . . . . 0 C--N 1.328 -0.343 0 C-N-CA 119.802 -0.759 . . . . 0.0 109.718 -179.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.418 ' C ' HD12 ' H' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.405 -2.678 1 N-CA-C 99.706 -4.183 . . . . 0.0 99.706 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.904 HD12 ' N ' ' H' ' 31' ' ' ILE . 1.9 mp -82.02 103.74 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.344 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.287 174.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' B' ' 35' ' ' MET . 18.6 tt -121.32 121.34 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 CA-C-O 121.614 0.721 . . . . 0.0 111.009 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.82 116.59 2.39 Favored Glycine 0 C--O 1.244 0.74 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -130.83 128.8 41.38 Favored 'General case' 0 C--O 1.244 0.813 0 CA-C-O 121.785 0.802 . . . . 0.0 110.785 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.667 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 40.1 ttp -106.09 115.88 30.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.423 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.468 HG13 HG23 ' G' ' 36' ' ' VAL . 0.0 OUTLIER -120.2 70.54 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.209 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.637 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.77 -100.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.02 -159.71 24.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.3 142.56 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.852 0.358 . . . . 0.0 110.781 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.671 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m . . . . . 0 N--CA 1.466 0.349 0 CA-C-O 121.863 0.839 . . . . 0.0 111.852 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.546 ' O ' ' CG ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -149.27 109.04 4.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.658 179.034 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.1 m170 -114.17 162.49 16.45 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.641 0.734 . . . . 0.0 110.673 -179.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' I' ' 16' ' ' LYS . 43.4 tt0 -153.0 172.8 16.27 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.495 178.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' I' ' 15' ' ' GLN . 88.3 tttt -172.11 132.95 0.68 Allowed 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.838 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 18' ' ' VAL . 6.7 tt -124.99 125.92 44.64 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.709 ' HB ' HG22 ' H' ' 18' ' ' VAL . 52.7 t -124.46 126.58 72.09 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.543 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -108.2 103.5 12.7 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 175.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.492 ' CE1' ' CZ ' ' H' ' 20' ' ' PHE . 25.7 t80 -117.32 131.06 56.88 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.864 0.302 . . . . 0.0 110.643 -178.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.29 145.94 31.45 Favored 'General case' 0 C--O 1.243 0.714 0 CA-C-O 122.043 0.925 . . . . 0.0 113.338 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -137.61 135.29 36.46 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.81 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.464 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 48.0 t0 -139.5 137.84 35.86 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -92.12 113.19 26.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 C-N-CA 118.685 -1.206 . . . . 0.0 111.806 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.91 86.97 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 CA-C-N 113.744 -1.571 . . . . 0.0 115.255 176.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.57 ' O ' ' O ' ' I' ' 27' ' ' ASN . 30.9 t -140.68 169.95 16.69 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-N 118.487 1.144 . . . . 0.0 109.147 175.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.57 ' O ' ' O ' ' I' ' 26' ' ' SER . 89.7 m-20 -30.51 170.79 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 O-C-N 124.009 0.818 . . . . 0.0 112.896 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' K' ' 25' ' ' GLY . 86.3 mttt -108.37 -112.23 0.3 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 173.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.86 90.73 0.01 OUTLIER Glycine 0 N--CA 1.466 0.66 0 CA-C-N 116.09 -0.505 . . . . 0.0 112.155 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.418 ' HA ' HD13 ' I' ' 31' ' ' ILE . . . -140.01 161.9 36.5 Favored 'General case' 0 C--O 1.248 1.005 0 CA-C-O 122.221 1.01 . . . . 0.0 108.35 177.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.697 HG22 ' HB ' ' J' ' 31' ' ' ILE . 0.1 OUTLIER -139.69 133.07 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 CA-C-N 113.455 -1.702 . . . . 0.0 110.089 -175.957 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.494 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.1 mt -113.39 114.85 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 178.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.26 96.06 1.05 Allowed Glycine 0 CA--C 1.497 -1.058 0 N-CA-C 105.231 -3.148 . . . . 0.0 105.231 175.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.578 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 6.6 tp -114.05 125.91 54.52 Favored 'General case' 0 CA--C 1.502 -0.87 0 CA-C-O 121.738 0.78 . . . . 0.0 112.026 -177.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.708 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 4.6 ttp -119.14 109.92 16.45 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.914 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.2 75.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.141 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -26.72 -98.37 0.01 OUTLIER Glycine 0 C--N 1.363 2.08 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 178.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -151.03 19.39 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -124.59 138.92 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.82 0.343 . . . . 0.0 110.358 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.603 -179.47 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t . . . . . 0 N--CA 1.467 0.401 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 6.2 t-80 -148.93 143.15 26.0 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.252 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' J' ' 13' ' ' HIS . 46.9 m-70 -141.28 163.66 32.35 Favored 'General case' 0 CA--C 1.51 -0.576 0 CA-C-O 121.482 0.658 . . . . 0.0 110.052 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.448 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 50.9 tt0 -156.02 170.76 21.41 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.06 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.448 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 54.2 mtmt -157.01 134.52 10.68 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -123.83 124.51 42.82 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -140.94 141.69 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 118.768 -1.173 . . . . 0.0 113.867 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.637 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 5.5 m-85 -111.45 110.01 20.24 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.03 120.89 42.14 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.455 0.571 . . . . 0.0 111.429 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . 0.581 ' HB2' HD22 ' J' ' 27' ' ' ASN . . . -125.51 117.58 23.93 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.499 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 97.2 mt-10 -120.12 142.37 48.98 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.834 -178.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.499 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 4.3 t70 146.31 159.21 0.0 OUTLIER 'General case' 0 C--N 1.345 0.407 0 O-C-N 124.373 1.046 . . . . 0.0 109.201 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 2.4 m -62.97 -110.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.8 93.04 0.14 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.957 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.841 ' O ' ' O ' ' J' ' 27' ' ' ASN . 15.4 p -153.91 -170.61 3.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.841 ' O ' ' O ' ' J' ' 26' ' ' SER . 50.2 m-20 -19.65 178.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 125.049 1.468 . . . . 0.0 114.258 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.588 ' O ' ' N ' ' J' ' 30' ' ' ALA . 58.0 tttp 138.88 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.246 -177.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' J' ' 28' ' ' LYS . . . -45.31 101.46 0.03 OUTLIER Glycine 0 N--CA 1.481 1.68 1 CA-C-O 128.54 4.411 . . . . 0.0 108.384 -174.271 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.588 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -99.51 -124.17 0.16 Allowed 'General case' 1 N--CA 1.368 -4.569 4 N-CA-C 89.89 -7.818 . . . . 0.0 89.89 177.972 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.867 HD12 ' N ' ' J' ' 31' ' ' ILE . 1.2 mp -76.99 102.89 3.82 Favored 'Isoleucine or valine' 0 C--N 1.257 -3.422 0 C-N-CA 115.006 -2.678 . . . . 0.0 109.583 176.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.673 HD11 HD21 ' J' ' 34' ' ' LEU . 14.2 tt -115.08 121.39 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-O 121.322 0.582 . . . . 0.0 109.476 178.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.58 113.83 2.09 Favored Glycine 0 N--CA 1.466 0.681 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.989 HD22 ' CZ ' ' L' ' 19' ' ' PHE . 0.0 OUTLIER -125.16 128.11 47.89 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 122.019 0.914 . . . . 0.0 111.702 -178.4 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.743 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 32.7 ttp -107.63 119.26 38.93 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.329 -1.305 . . . . 0.0 109.445 178.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.519 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.02 72.83 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 -179.443 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 38' ' ' GLY . . . -56.71 113.21 4.06 Favored Glycine 0 C--N 1.36 1.898 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -56.99 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 77.8 t . . . . . 0 N--CA 1.466 0.347 0 CA-C-O 120.955 0.407 . . . . 0.0 111.003 -179.444 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 N--CA 1.463 0.193 0 CA-C-O 120.837 0.351 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 56.9 t -123.94 133.13 70.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -146.96 147.87 31.17 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.389 -0.524 . . . . 0.0 111.39 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 54.5 m80 -146.9 164.35 33.18 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.716 0.769 . . . . 0.0 110.593 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 80.8 mt-30 -154.57 179.1 9.36 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.388 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -169.79 131.79 1.11 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.562 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.97 120.53 36.64 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.28 124.93 65.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 121.032 0.444 . . . . 0.0 111.793 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.637 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 41.0 m-85 -115.75 110.25 18.84 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.067 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -120.98 127.36 51.72 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -177.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.21 137.68 36.2 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.582 0.706 . . . . 0.0 112.49 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -105.98 123.7 48.41 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 116.189 -0.459 . . . . 0.0 112.22 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' J' ' 26' ' ' SER . 49.3 t0 -172.37 114.68 0.31 Allowed 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.459 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 8.5 p -79.58 131.34 34.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.244 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.563 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . 58.82 82.38 0.06 OUTLIER Glycine 0 N--CA 1.467 0.7 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.07 178.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p -67.32 -172.08 0.2 Allowed 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.541 0.686 . . . . 0.0 110.172 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.495 ' C ' ' ND2' ' L' ' 27' ' ' ASN . 30.6 p-10 -79.63 179.28 7.59 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.47 ' O ' ' O ' ' K' ' 27' ' ' ASN . 81.2 tttt -43.65 -110.11 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.569 -0.742 . . . . 0.0 112.596 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.4 94.15 1.69 Allowed Glycine 0 N--CA 1.471 1.006 0 CA-C-O 119.992 -0.338 . . . . 0.0 112.859 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.02 173.48 11.73 Favored 'General case' 0 C--O 1.24 0.554 0 N-CA-C 104.317 -2.475 . . . . 0.0 104.317 176.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.572 HG23 HD13 ' L' ' 31' ' ' ILE . 0.1 OUTLIER -151.72 136.93 10.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 C-N-CA 117.35 -1.74 . . . . 0.0 112.116 -174.644 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.71 117.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.632 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.513 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -118.08 107.93 1.56 Allowed Glycine 0 C--N 1.334 0.467 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 178.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.428 HD11 HG21 ' J' ' 36' ' ' VAL . 51.9 tp -119.99 121.84 39.83 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 110.464 -0.198 . . . . 0.0 110.464 -178.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.402 ' C ' ' SD ' ' K' ' 35' ' ' MET . 6.3 tmm? -120.34 120.25 35.47 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.704 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.519 HG22 HG23 ' J' ' 36' ' ' VAL . 96.1 t -133.68 82.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.544 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -7.87 -97.81 0.0 OUTLIER Glycine 0 C--N 1.349 1.276 0 O-C-N 123.504 0.502 . . . . 0.0 113.703 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.25 -168.85 38.85 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.386 -179.758 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m . . . . . 0 N--CA 1.464 0.241 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 31.8 p-80 -159.67 154.11 23.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 0.0 111.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -151.54 169.29 22.44 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.024 179.63 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -157.58 178.21 10.53 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.995 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -143.4 138.38 29.33 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.498 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 mt -121.68 119.43 31.77 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 m -143.01 135.91 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.989 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 4.0 m-30 -116.33 127.91 55.09 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -141.55 139.44 33.19 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.777 0.798 . . . . 0.0 111.893 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 142.95 34.63 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.78 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.43 100.96 6.18 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.974 -179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -173.84 133.4 0.45 Allowed 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.9 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 113.75 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 54.39 -91.21 0.01 OUTLIER Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -178.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.5 p 152.5 176.71 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 122.006 0.908 . . . . 0.0 110.058 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.495 ' ND2' ' C ' ' K' ' 27' ' ' ASN . 18.4 m-20 -51.74 -179.45 0.01 OUTLIER 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 113.892 -1.504 . . . . 0.0 111.664 178.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -60.58 111.66 1.69 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.923 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.597 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 81.07 -93.19 1.5 Allowed Glycine 0 N--CA 1.468 0.787 0 CA-C-N 114.993 -1.003 . . . . 0.0 112.22 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.597 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 79.11 165.56 0.2 Allowed 'General case' 0 CA--C 1.507 -0.684 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 -175.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.849 ' N ' HD12 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -149.87 131.93 5.87 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 CA-C-N 122.07 2.214 . . . . 0.0 111.583 178.038 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' F' ' 35' ' ' MET . 15.4 pt -124.46 142.08 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.115 -178.277 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.75 120.43 2.52 Favored Glycine 0 N--CA 1.463 0.457 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 20.0 mt -115.62 118.66 33.74 Favored 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 4.6 ttt -111.01 117.46 33.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.175 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -145.1 81.41 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.652 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -57.97 102.08 0.22 Allowed Glycine 0 C--N 1.337 0.621 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.072 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.65 178.95 34.17 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.3 136.59 59.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 120.842 0.353 . . . . 0.0 110.325 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.616 -179.698 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 . . . . . 0 N--CA 1.466 0.343 0 N-CA-C 109.902 -0.407 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -144.14 141.94 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.879 0.371 . . . . 0.0 110.668 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -141.75 -168.97 2.8 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.828 -179.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 73.7 m-70 -75.92 168.77 19.41 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 121.295 0.569 . . . . 0.0 110.087 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' A' ' 16' ' ' LYS . 48.5 tt0 -158.33 173.98 15.85 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.361 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' A' ' 15' ' ' GLN . 88.9 tttt -144.27 126.35 15.51 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.621 0.248 . . . . 0.0 110.886 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.21 120.82 22.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.978 0.418 . . . . 0.0 110.046 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.32 136.9 50.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.795 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -129.67 132.01 46.56 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 111.396 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -114.84 123.06 48.23 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.9 123.44 42.52 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.385 0.612 . . . . 0.0 111.249 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -141.78 124.68 16.13 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.73 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 62.3 t0 . . . . . 0 C--N 1.327 -0.389 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.287 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' A' ' 29' ' ' GLY . 78.3 tttt . . . . . 0 N--CA 1.469 0.5 0 N-CA-C 110.111 -0.329 . . . . 0.0 110.111 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 28' ' ' LYS . . . 45.39 92.98 0.01 OUTLIER Glycine 0 N--CA 1.468 0.829 0 CA-C-O 118.191 -1.338 . . . . 0.0 110.261 178.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.04 160.36 15.1 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 116.627 -2.029 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -152.22 117.87 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 111.836 -2.438 . . . . 0.0 108.958 -171.736 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 32' ' ' ILE . 12.6 tt -128.85 109.28 18.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.613 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -122.31 119.86 4.13 Favored Glycine 0 CA--C 1.51 -0.263 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 178.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 35' ' ' MET . 8.4 tt -164.86 162.69 21.01 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.321 -176.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 5.1 ttp -135.45 143.24 45.79 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.244 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 m -121.89 71.53 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.764 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.548 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -47.05 -97.46 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.2 -168.85 30.83 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.43 134.35 66.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.635 -179.707 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -109.89 135.06 51.36 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.939 0.4 . . . . 0.0 110.708 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.94 161.29 28.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.1 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 m -131.04 160.85 41.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.46 ' CD2' ' N ' ' B' ' 13' ' ' HIS . 2.8 m-70 -127.74 124.27 37.38 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.711 0.291 . . . . 0.0 110.628 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.772 ' HD1' ' HB2' ' C' ' 14' ' ' HIS . 55.2 t60 -153.92 162.58 41.11 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.495 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 73.5 mt-30 -159.22 175.91 12.85 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.792 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -153.94 126.9 8.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.149 178.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 mt -124.7 114.46 19.35 Favored 'General case' 0 C--O 1.233 0.214 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -124.48 128.99 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.812 0.339 . . . . 0.0 110.344 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . 0.497 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 88.7 t80 -125.7 123.32 38.63 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.036 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -118.16 125.56 50.46 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . 0.497 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -133.0 131.93 41.29 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.415 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.47 ' CB ' ' O ' ' C' ' 22' ' ' GLU . 16.6 pt-20 -158.39 154.88 27.68 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 120.185 -0.606 . . . . 0.0 112.561 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.47 ' OD1' ' N ' ' B' ' 23' ' ' ASP . 1.0 OUTLIER . . . . . 0 CA--C 1.535 0.378 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.439 179.555 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.495 -1.202 0 N-CA-C 105.864 -2.894 . . . . 0.0 105.864 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.08 161.61 15.03 Favored 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.469 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -141.62 121.11 10.92 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.294 -172.346 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.467 HG22 ' O ' ' B' ' 32' ' ' ILE . 1.6 mt -110.53 115.11 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.953 178.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.428 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -120.04 93.65 0.54 Allowed Glycine 0 CA--C 1.507 -0.443 0 N-CA-C 104.198 -3.561 . . . . 0.0 104.198 174.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.549 HD23 ' O ' ' A' ' 34' ' ' LEU . 57.3 mt -122.58 140.22 53.04 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 122.958 1.361 . . . . 0.0 113.054 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 12.1 ttt -127.7 123.3 35.12 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 113.789 -1.55 . . . . 0.0 111.027 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.416 HG23 HG22 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -117.71 72.98 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.962 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.085 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -98.2 103.34 2.79 Favored Glycine 0 C--N 1.354 1.549 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.28 172.13 34.53 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -154.23 147.42 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 110.949 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.372 179.668 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 N--CA 1.463 0.224 0 CA-C-O 121.104 0.478 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -124.69 131.26 53.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.375 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.772 ' HB2' ' HD1' ' B' ' 14' ' ' HIS . 84.0 m-70 -143.49 168.55 19.58 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.402 0.62 . . . . 0.0 109.878 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.402 ' HG2' ' H ' ' C' ' 16' ' ' LYS . 48.0 tt0 -159.53 172.99 16.85 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.625 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.402 ' H ' ' HG2' ' C' ' 15' ' ' GLN . 88.6 tttt -166.61 114.75 0.87 Allowed 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 tp -121.74 121.72 37.92 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -130.03 124.99 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -114.48 106.36 14.19 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -113.26 127.14 56.06 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.15 0.5 . . . . 0.0 111.564 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.66 125.25 44.46 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.952 178.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' B' ' 22' ' ' GLU . 97.2 mt-10 -143.57 158.76 43.41 Favored 'General case' 0 C--O 1.222 -0.345 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.988 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 22.4 t0 . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.284 179.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 1.104 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.424 -5.626 0 N-CA-C 104.601 -3.4 . . . . 0.0 104.601 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.507 ' O ' ' C ' ' C' ' 29' ' ' GLY . . . -79.55 -140.47 0.03 OUTLIER 'General case' 0 N--CA 1.388 -3.564 1 N-CA-C 97.605 -4.961 . . . . 0.0 97.605 177.877 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.662 ' CD1' ' N ' ' C' ' 31' ' ' ILE . 1.0 OUTLIER -81.17 106.56 12.47 Favored 'Isoleucine or valine' 0 C--N 1.246 -3.904 0 C-N-CA 114.451 -2.9 . . . . 0.0 110.153 -177.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.498 ' O ' ' CE ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -108.68 122.52 63.37 Favored 'Isoleucine or valine' 0 C--N 1.363 1.161 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.766 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -138.76 113.23 0.93 Allowed Glycine 0 C--N 1.314 -0.666 0 N-CA-C 106.871 -2.492 . . . . 0.0 106.871 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.517 ' O ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -140.65 158.55 43.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 123.115 1.436 . . . . 0.0 111.842 -176.673 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.479 ' CE ' ' O ' ' I' ' 32' ' ' ILE . 24.4 tpp -129.35 124.22 33.73 Favored 'General case' 0 CA--C 1.491 -1.289 0 CA-C-N 112.613 -2.085 . . . . 0.0 107.167 178.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.495 HG23 HD11 ' D' ' 34' ' ' LEU . 48.7 t -116.9 70.98 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.32 -101.09 0.01 OUTLIER Glycine 0 C--N 1.377 2.829 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.086 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.83 -158.82 30.41 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -134.59 161.53 40.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.83 0.347 . . . . 0.0 110.341 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.662 -179.576 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 54.2 t . . . . . 0 N--CA 1.465 0.313 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 33.0 m-70 -118.38 106.08 12.36 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.59 -178.993 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.429 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 60.8 m170 -108.67 166.51 10.74 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -152.82 172.51 16.62 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.03 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -157.08 114.5 3.11 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 60.3 mt -119.81 115.4 23.77 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -129.82 127.07 63.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.479 ' CE2' ' CD2' ' C' ' 34' ' ' LEU . 7.9 m-85 -116.07 117.76 30.98 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -132.9 128.56 36.82 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.944 -177.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 130.36 45.12 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.537 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 79.7 tt0 -141.81 107.91 5.21 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 119.945 -0.702 . . . . 0.0 112.777 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 71.8 m-20 . . . . . 0 CA--C 1.534 0.327 0 O-C-N 123.872 0.732 . . . . 0.0 110.158 178.248 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 1.104 ' HB1' ' O ' ' C' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.432 -1.364 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.632 HG22 ' CE ' ' K' ' 35' ' ' MET . 0.2 OUTLIER -150.92 125.07 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 116.683 -2.007 . . . . 0.0 111.846 -172.27 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.722 ' CG2' HG23 ' E' ' 32' ' ' ILE . 3.7 tt -116.31 116.99 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.502 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.83 119.39 3.31 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 178.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.591 HD23 ' CZ ' ' F' ' 19' ' ' PHE . 14.8 tp -138.84 126.46 21.96 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.161 0.981 . . . . 0.0 112.026 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.588 ' SD ' ' CA ' ' J' ' 33' ' ' GLY . 20.8 ttt -106.35 119.84 40.3 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.191 177.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.499 ' CG2' HG22 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -107.99 76.75 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.144 -178.579 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -26.43 -97.42 0.01 OUTLIER Glycine 0 C--N 1.354 1.552 0 N-CA-C 112.004 -0.438 . . . . 0.0 112.004 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.31 165.63 33.71 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.32 161.43 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.825 0.345 . . . . 0.0 110.474 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.3 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.492 179.689 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -103.58 131.17 50.95 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.862 0.363 . . . . 0.0 110.367 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -143.67 148.92 36.48 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.218 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.481 ' CG2' ' H ' ' F' ' 12' ' ' VAL . 0.2 OUTLIER -148.12 -153.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.462 -179.382 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.424 ' ND1' ' C ' ' E' ' 13' ' ' HIS . 7.2 t-80 -70.77 142.25 51.4 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 121.464 0.65 . . . . 0.0 112.68 -177.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -146.03 169.7 18.14 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 50.4 tt0 -155.39 168.01 28.51 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.924 -0.71 . . . . 0.0 112.233 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -148.75 123.48 9.88 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.614 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 34.0 tp -120.8 114.21 21.29 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.43 129.02 68.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 121.381 0.61 . . . . 0.0 111.999 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -124.07 123.93 41.42 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.619 ' CE1' ' CD1' ' F' ' 20' ' ' PHE . 2.0 t80 -133.64 130.14 37.85 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.718 0.294 . . . . 0.0 110.768 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.72 130.35 34.04 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.23 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -122.96 141.09 52.32 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 19.5 p-10 -165.49 113.74 0.99 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.563 177.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.09 131.0 31.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.196 -178.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 72.78 84.51 0.24 Allowed Glycine 0 CA--C 1.532 1.12 0 CA-C-N 116.007 -0.542 . . . . 0.0 114.12 177.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' E' ' 25' ' ' GLY . 88.7 p . . . . . 0 N--CA 1.453 -0.284 0 C-N-CA 123.666 0.786 . . . . 0.0 111.765 177.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.439 -0.985 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.825 HG23 HD13 ' F' ' 31' ' ' ILE . 0.3 OUTLIER -147.38 124.66 3.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 118.402 -1.319 . . . . 0.0 109.553 -178.151 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' F' ' 32' ' ' ILE . 66.1 mt -123.73 124.47 69.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.705 -176.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.416 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -127.27 110.31 1.18 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 177.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CE2' ' F' ' 19' ' ' PHE . 43.5 mt -119.02 128.9 54.8 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.3 ttt -133.3 131.16 39.85 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 119.781 -0.768 . . . . 0.0 112.222 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.512 ' O ' ' C ' ' E' ' 37' ' ' GLY . 40.1 t -130.65 81.73 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.576 179.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 19.02 -102.7 0.01 OUTLIER Glycine 0 C--N 1.352 1.472 0 CA-C-N 117.848 0.294 . . . . 0.0 112.84 179.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.02 -174.51 46.79 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . 0.439 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 30.3 m -135.69 161.71 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.798 0.332 . . . . 0.0 110.677 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.5 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -147.23 155.78 42.38 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.099 0.476 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -101.72 143.89 31.1 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.957 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . 0.481 ' H ' ' CG2' ' E' ' 12' ' ' VAL . 55.5 t -118.84 129.59 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.404 0.621 . . . . 0.0 110.54 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -154.49 130.12 9.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.045 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -145.74 170.38 16.63 Favored 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -148.28 175.22 11.25 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.221 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.13 131.86 31.1 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' F' ' 17' ' ' LEU . 5.2 mp -121.87 120.82 35.64 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.1 t -131.7 125.82 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.985 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CE2' HD22 ' E' ' 34' ' ' LEU . 35.9 m-85 -117.48 115.68 25.64 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 177.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE1' ' E' ' 20' ' ' PHE . 34.7 t80 -128.3 123.19 33.4 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.967 0.413 . . . . 0.0 110.084 179.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.84 134.33 36.82 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.494 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 80.1 tt0 -92.2 75.66 5.36 Favored 'General case' 0 N--CA 1.463 0.21 0 C-N-CA 119.888 -0.725 . . . . 0.0 112.066 -178.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.455 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 19.3 m-20 -142.81 107.93 4.96 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 175.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HB3' ' E' ' 26' ' ' SER . 85.6 t -45.69 140.79 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.066 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.85 83.61 1.63 Allowed Glycine 0 C--N 1.333 0.392 0 N-CA-C 107.865 -2.094 . . . . 0.0 107.865 177.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -68.63 -170.79 0.23 Allowed 'General case' 0 N--CA 1.434 -1.266 0 CA-C-O 122.393 1.092 . . . . 0.0 111.805 -177.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.438 ' O ' ' C ' ' F' ' 28' ' ' LYS . 49.9 p30 -80.23 179.19 7.78 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 113.014 -1.903 . . . . 0.0 108.781 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.438 ' C ' ' O ' ' F' ' 27' ' ' ASN . 98.8 mttt -36.82 104.16 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 122.072 0.939 . . . . 0.0 109.445 -178.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.492 ' O ' HG13 ' F' ' 31' ' ' ILE . . . 168.07 -100.71 0.17 Allowed Glycine 0 C--O 1.209 -1.412 0 CA-C-O 117.308 -1.829 . . . . 0.0 109.28 -173.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.48 164.06 0.55 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.51 2.655 . . . . 0.0 106.808 179.737 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.825 HD13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -146.25 131.18 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 118.119 -1.433 . . . . 0.0 112.175 -177.148 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' E' ' 32' ' ' ILE . 13.4 mm -115.5 125.54 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.51 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 125.24 4.49 Favored Glycine 0 N--CA 1.473 1.151 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.106 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 mt -124.68 128.02 48.19 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -130.81 127.63 39.04 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 121.699 0.761 . . . . 0.0 112.571 -179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 48.8 t -147.38 86.66 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.813 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.45 96.79 1.28 Allowed Glycine 0 C--N 1.339 0.698 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.071 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . 0.439 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -155.21 163.57 31.54 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 62.2 t -123.88 135.61 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.307 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 75.8 m80 . . . . . 0 N--CA 1.475 0.78 0 CA-C-O 120.92 0.39 . . . . 0.0 111.704 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.434 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 94.3 m-70 -107.72 179.14 4.32 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.668 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.459 HE21 ' CD ' ' H' ' 16' ' ' LYS . 52.3 tt0 -100.07 172.66 7.06 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.714 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.4 mttm -149.19 165.58 31.41 Favored 'General case' 0 C--O 1.217 -0.639 0 CA-C-O 121.193 0.521 . . . . 0.0 111.419 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 7.0 tt -145.14 161.84 38.49 Favored 'General case' 0 C--O 1.171 -3.039 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.958 ' C ' ' O ' ' H' ' 18' ' ' VAL . 86.3 t -156.07 170.77 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 118.701 -2.499 . . . . 0.0 110.529 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . 0.641 ' N ' HG12 ' G' ' 18' ' ' VAL . 31.2 p90 -158.86 108.32 1.96 Allowed 'General case' 0 C--O 1.165 -3.344 0 CA-C-O 118.373 -0.823 . . . . 0.0 109.803 -178.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.713 ' C ' ' O ' ' H' ' 20' ' ' PHE . 43.6 t80 -119.52 106.27 12.05 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 121.471 1.941 . . . . 0.0 112.026 178.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -114.74 113.0 23.71 Favored 'General case' 0 C--O 1.174 -2.887 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.256 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' H' ' 22' ' ' GLU . 94.9 mt-10 -75.01 144.41 43.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 118.898 0.772 . . . . 0.0 112.032 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 33.4 m-20 -140.62 -142.24 0.14 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.975 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' G' ' 23' ' ' ASP . 13.7 t -27.44 103.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.318 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.455 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 172.0 92.77 0.08 OUTLIER Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 86.66 179.9 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.793 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -63.73 170.88 3.01 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.309 0.576 . . . . 0.0 111.459 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.85 112.07 0.51 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.106 176.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.52 94.31 2.35 Favored Glycine 0 CA--C 1.486 -1.75 0 CA-C-O 122.493 1.052 . . . . 0.0 110.841 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.504 ' C ' HD13 ' G' ' 31' ' ' ILE . . . -74.31 -179.05 3.72 Favored 'General case' 0 N--CA 1.421 -1.922 0 CA-C-N 112.795 -1.702 . . . . 0.0 110.607 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.856 ' N ' HD13 ' G' ' 31' ' ' ILE . 0.0 OUTLIER -141.62 112.65 3.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 113.335 -1.757 . . . . 0.0 106.41 179.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.413 HG23 HD21 ' H' ' 34' ' ' LEU . 18.5 tt -117.31 117.65 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-O 121.708 0.766 . . . . 0.0 110.414 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.16 106.41 2.35 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 105.904 -2.878 . . . . 0.0 105.904 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.688 ' HB3' HD22 ' H' ' 34' ' ' LEU . 13.2 tp -132.81 130.52 39.96 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 122.604 1.192 . . . . 0.0 111.535 -177.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.613 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 24.7 ttp -102.81 124.19 47.87 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.16 179.59 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.9 70.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.98 -100.53 1.47 Allowed Glycine 0 C--N 1.354 1.572 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.7 170.25 24.04 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m . . . . . 0 C--N 1.33 -0.243 0 CA-C-O 120.832 0.348 . . . . 0.0 110.708 -179.796 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t . . . . . 0 N--CA 1.461 0.116 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.613 ' CD2' ' ND1' ' I' ' 13' ' ' HIS . 7.3 p-80 -158.68 152.01 22.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.672 0.749 . . . . 0.0 111.785 -179.484 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.509 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 15.9 m80 -144.64 162.27 37.07 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.2 mm-40 -152.96 172.91 16.09 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.313 0.578 . . . . 0.0 110.087 178.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.459 ' CD ' HE21 ' G' ' 15' ' ' GLN . 76.7 tttt -176.04 136.86 0.31 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.026 -0.988 . . . . 0.0 108.467 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 77.0 mt -141.07 132.3 26.51 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.958 ' O ' ' C ' ' G' ' 18' ' ' VAL . 76.8 t -124.6 146.07 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 C-N-CA 118.184 -1.407 . . . . 0.0 113.385 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.414 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 63.2 m-85 -125.19 119.33 28.21 Favored 'General case' 0 N--CA 1.478 0.949 0 O-C-N 120.141 -1.6 . . . . 0.0 111.479 -179.042 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.713 ' O ' ' C ' ' G' ' 20' ' ' PHE . 50.3 t80 -105.69 111.82 24.65 Favored 'General case' 0 C--O 1.248 0.981 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -93.97 113.44 25.44 Favored 'General case' 0 C--N 1.352 0.717 0 CA-C-O 118.631 -0.7 . . . . 0.0 112.734 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.627 ' H ' ' HB1' ' G' ' 21' ' ' ALA . 48.6 tt0 -149.02 124.85 10.55 Favored 'General case' 0 C--N 1.379 1.884 0 C-N-CA 117.899 -1.52 . . . . 0.0 112.094 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.501 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 66.5 t0 -125.07 114.69 19.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.484 0.659 . . . . 0.0 110.252 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.406 ' H ' HG23 ' H' ' 24' ' ' VAL . 40.1 t . . . . . 0 C--N 1.316 -0.879 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 179.223 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.807 ' C ' HD13 ' H' ' 31' ' ' ILE . . . . . . . . 0 CA--C 1.477 -1.834 1 N-CA-C 93.853 -6.351 . . . . 0.0 93.853 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.807 HD13 ' C ' ' H' ' 30' ' ' ALA . 0.9 OUTLIER -94.43 110.69 24.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 CA-C-N 124.149 3.159 . . . . 0.0 108.602 177.09 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.558 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -112.86 110.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.361 1.075 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.686 -179.582 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.931 ' O ' HD23 ' H' ' 34' ' ' LEU . . . -120.24 102.34 0.87 Allowed Glycine 0 N--CA 1.462 0.401 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.931 HD23 ' O ' ' H' ' 33' ' ' GLY . 2.6 mt -136.84 149.46 47.73 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-O 122.508 1.147 . . . . 0.0 112.844 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.469 ' SD ' ' O ' ' B' ' 31' ' ' ILE . 28.7 ttp -111.9 126.02 54.66 Favored 'General case' 0 CA--C 1.505 -0.772 0 CA-C-N 113.236 -1.802 . . . . 0.0 110.467 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -125.27 65.57 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.2 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.285 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -51.65 -104.6 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.81 -141.8 5.09 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -122.82 135.98 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.768 0.318 . . . . 0.0 110.288 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.495 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 77.3 t . . . . . 0 N--CA 1.471 0.614 0 CA-C-O 120.804 0.335 . . . . 0.0 110.173 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.66 ' HE2' ' NE2' ' I' ' 15' ' ' GLN . 75.4 t60 -150.86 104.75 3.19 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.864 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.526 ' NE2' ' O ' ' J' ' 12' ' ' VAL . 64.7 m170 -112.6 160.12 18.18 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.37 0.605 . . . . 0.0 110.205 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.66 ' NE2' ' HE2' ' I' ' 13' ' ' HIS . 84.0 mt-30 -154.06 167.56 29.38 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.401 178.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.432 ' CG ' ' O ' ' I' ' 15' ' ' GLN . 95.2 mttt -164.69 128.46 2.47 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 108.993 -0.744 . . . . 0.0 108.993 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.2 mt -126.97 126.14 42.69 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.668 ' HB ' HG22 ' H' ' 18' ' ' VAL . 19.8 t -125.0 129.92 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.7 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.5 OUTLIER -133.57 108.64 8.72 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.185 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.422 ' CG ' ' CZ ' ' J' ' 20' ' ' PHE . 4.0 p90 -143.57 153.82 42.95 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 118.624 -1.23 . . . . 0.0 112.797 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.46 141.48 51.87 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.964 -1.016 . . . . 0.0 112.962 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -150.99 99.86 2.74 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.072 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.501 ' OD1' ' O ' ' H' ' 23' ' ' ASP . 3.1 t70 -103.05 120.24 40.31 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.11 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.447 ' O ' HG23 ' I' ' 24' ' ' VAL . 27.5 m -59.21 121.36 6.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 81.97 90.31 0.61 Allowed Glycine 0 CA--C 1.535 1.305 0 N-CA-C 116.918 1.527 . . . . 0.0 116.918 174.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.523 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.4 p 137.43 167.3 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 124.902 1.281 . . . . 0.0 110.707 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.535 ' OD1' ' ND2' ' J' ' 27' ' ' ASN . 16.2 m-20 -49.84 178.15 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 115.841 1.793 . . . . 0.0 115.841 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.504 ' CE ' ' HB1' ' K' ' 21' ' ' ALA . 12.9 tttt -61.82 -111.24 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.052 0 CA-C-N 113.177 -1.829 . . . . 0.0 114.912 172.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.908 ' O ' ' HB3' ' J' ' 30' ' ' ALA . . . -79.59 96.3 1.52 Allowed Glycine 0 CA--C 1.458 -3.492 0 CA-C-N 110.762 -2.927 . . . . 0.0 114.677 -175.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.688 ' C ' HD12 ' I' ' 31' ' ' ILE . . . -76.61 -136.45 0.02 OUTLIER 'General case' 0 N--CA 1.412 -2.329 1 N-CA-C 93.992 -6.299 . . . . 0.0 93.992 169.066 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.749 HD12 ' N ' ' I' ' 31' ' ' ILE . 0.4 OUTLIER -98.46 121.91 49.55 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 1 CA-C-N 127.308 4.594 . . . . 0.0 111.412 -176.631 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.479 ' O ' ' CE ' ' C' ' 35' ' ' MET . 7.7 mt -112.09 112.26 39.74 Favored 'Isoleucine or valine' 0 C--N 1.359 1.022 0 CA-C-N 114.83 -1.077 . . . . 0.0 108.276 177.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.91 104.94 1.72 Allowed Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 107.295 -2.322 . . . . 0.0 107.295 177.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 65.0 mt -137.39 133.2 34.53 Favored 'General case' 0 C--O 1.24 0.561 0 CA-C-O 122.751 1.262 . . . . 0.0 113.549 -176.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 57.0 ttp -113.47 122.68 48.04 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-N 113.649 -1.614 . . . . 0.0 109.153 178.257 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.7 70.69 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -118.46 -103.57 2.15 Favored Glycine 0 C--N 1.36 1.881 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 178.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.49 -174.17 31.95 Favored Glycine 0 CA--C 1.522 0.501 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.113 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -132.82 161.9 40.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 CA-C-O 121.15 0.5 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 32.1 m . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.438 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.526 ' O ' ' NE2' ' I' ' 14' ' ' HIS . 19.3 m . . . . . 0 N--CA 1.47 0.557 0 CA-C-O 120.231 0.062 . . . . 0.0 111.091 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -84.4 114.43 21.89 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.993 -0.283 . . . . 0.0 110.66 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.489 ' NE2' ' CG2' ' J' ' 12' ' ' VAL . 49.6 m170 -134.78 165.2 25.83 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-O 121.827 0.822 . . . . 0.0 110.641 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -161.84 166.81 25.82 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.823 178.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.583 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.7 mttt -156.98 135.33 11.31 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.583 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.0 mp -122.16 120.41 34.14 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -125.92 130.12 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.532 ' HZ ' HD12 ' H' ' 34' ' ' LEU . 0.4 OUTLIER -140.3 126.81 20.19 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.657 ' CG ' ' CZ ' ' K' ' 20' ' ' PHE . 51.2 p90 -158.75 160.53 36.45 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.619 1.711 . . . . 0.0 115.619 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.1 119.02 32.11 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 114.071 -1.422 . . . . 0.0 108.279 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.406 ' HG2' ' N ' ' J' ' 23' ' ' ASP . 80.5 tt0 -157.08 157.16 34.04 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-O 122.116 0.96 . . . . 0.0 113.494 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.498 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 51.8 p-10 -157.54 -131.41 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 178.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.537 HG13 ' O ' ' J' ' 24' ' ' VAL . 3.7 p -108.38 112.33 39.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.512 ' N ' ' OE1' ' K' ' 22' ' ' GLU . . . 32.02 87.94 0.01 OUTLIER Glycine 0 C--N 1.342 0.896 0 CA-C-O 118.218 -1.323 . . . . 0.0 110.781 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.572 ' O ' ' N ' ' K' ' 24' ' ' VAL . 82.8 p -96.57 168.35 10.59 Favored 'General case' 0 CA--C 1.497 -1.079 0 CA-C-N 120.772 2.286 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.535 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 84.3 m-20 -61.91 179.07 0.29 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 116.501 2.037 . . . . 0.0 116.501 175.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . . . . . . . . 0.472 53.1 tttt -59.02 106.98 0.47 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 110.424 -3.08 . . . . 0.0 116.321 170.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.69 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -63.08 109.6 2.81 Favored Glycine 1 CA--C 1.435 -4.967 0 CA-C-O 125.192 2.551 . . . . 0.0 108.826 -173.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -52.79 -124.69 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.518 2 CA-C-N 104.888 -5.656 . . . . 0.0 97.823 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.979 HD12 ' N ' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -93.43 115.25 31.8 Favored 'Isoleucine or valine' 0 C--N 1.263 -3.186 1 CA-C-N 126.896 4.407 . . . . 0.0 114.63 -173.485 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.507 ' C ' ' SD ' ' D' ' 35' ' ' MET . 16.1 tt -122.27 115.4 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.588 ' CA ' ' SD ' ' D' ' 35' ' ' MET . . . -118.01 118.55 4.1 Favored Glycine 0 N--CA 1.464 0.51 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.527 HD11 ' CZ ' ' K' ' 19' ' ' PHE . 2.2 mt -134.91 127.45 30.66 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.502 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 63.8 ttp -109.2 122.01 46.39 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.711 176.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.55 70.99 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.378 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.784 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . 0.422 ' HA3' HG21 ' D' ' 31' ' ' ILE . . . -94.69 106.91 3.47 Favored Glycine 0 C--N 1.361 1.933 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -110.39 149.88 17.6 Favored Glycine 0 N--CA 1.464 0.552 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.631 -179.674 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 . . . . . 0 N--CA 1.457 -0.101 0 CA-C-O 120.703 0.287 . . . . 0.0 110.432 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.447 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 42.8 t -126.25 130.8 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-O 121.024 0.44 . . . . 0.0 110.542 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 69.2 m-70 -103.57 129.0 50.72 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.244 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.556 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 49.4 t60 -136.44 165.19 26.4 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 178.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.556 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 81.7 mt-30 -157.37 176.45 12.66 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.403 178.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -173.05 133.82 0.54 Allowed 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -125.89 122.4 35.93 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -127.97 129.29 69.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-O 120.908 0.385 . . . . 0.0 110.437 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.527 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 1.9 t80 -131.25 123.89 29.39 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.657 ' CZ ' ' CG ' ' J' ' 20' ' ' PHE . 52.4 p90 -144.77 151.39 38.78 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' CE ' ' I' ' 28' ' ' LYS . . . -142.67 138.17 30.43 Favored 'General case' 0 CA--C 1.543 0.7 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.244 -178.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' J' ' 25' ' ' GLY . 36.2 tt0 -89.5 134.09 34.26 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.654 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' J' ' 29' ' ' GLY . 13.8 m-20 -148.97 119.59 7.48 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' J' ' 26' ' ' SER . 6.0 p -120.37 121.61 66.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.37 84.87 0.01 OUTLIER Glycine 0 N--CA 1.484 1.854 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 12.8 p -46.22 165.28 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -179.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -109.22 170.57 7.97 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 112.733 -2.03 . . . . 0.0 107.151 171.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -38.37 111.08 0.15 Allowed 'General case' 0 CA--C 1.551 1.015 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 175.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 91.93 0.36 Allowed Glycine 0 N--CA 1.483 1.824 0 N-CA-C 117.832 1.893 . . . . 0.0 117.832 171.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.19 157.54 43.56 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 173.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.411 ' O ' ' O ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -146.92 137.26 17.44 Favored 'Isoleucine or valine' 0 C--O 1.242 0.698 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.848 -176.77 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.88 126.2 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.428 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.98 122.27 4.92 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.601 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.638 HD22 ' CD1' ' L' ' 19' ' ' PHE . 21.7 tp -120.6 121.07 37.57 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 114.91 -0.645 . . . . 0.0 110.257 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.632 ' CE ' HG22 ' D' ' 31' ' ' ILE . 15.9 ttt -117.14 116.6 27.62 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.62 HG13 HG12 ' L' ' 36' ' ' VAL . 2.3 p -139.91 79.76 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -178.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.734 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -52.93 104.17 0.17 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.183 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 37' ' ' GLY . . . -55.35 -165.72 0.03 OUTLIER Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m . . . . . 0 N--CA 1.467 0.395 0 CA-C-O 120.967 0.413 . . . . 0.0 110.382 -179.736 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m . . . . . 0 N--CA 1.466 0.33 0 N-CA-C 110.377 -0.231 . . . . 0.0 110.377 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -95.76 151.97 18.9 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.108 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 62.3 m80 -80.7 177.51 8.98 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -129.98 177.57 7.18 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.656 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -147.7 150.32 34.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -127.25 124.61 39.27 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -124.52 130.48 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 120.903 0.382 . . . . 0.0 110.496 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.638 ' CD1' HD22 ' K' ' 34' ' ' LEU . 17.0 t80 -133.31 120.49 21.1 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -144.68 140.13 28.43 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.56 135.83 38.76 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.1 mt-10 -85.17 76.1 10.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 119.099 -1.04 . . . . 0.0 112.528 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -118.2 122.07 42.08 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 120.929 0.395 . . . . 0.0 111.127 178.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' L' ' 26' ' ' SER . 18.0 t -88.96 123.2 41.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.581 ' N ' ' O ' ' L' ' 24' ' ' VAL . 88.2 p -63.14 -178.33 0.23 Allowed 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 121.403 0.621 . . . . 0.0 109.882 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -81.82 177.51 8.84 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.588 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -38.8 103.99 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.284 177.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.417 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 165.73 -100.78 0.18 Allowed Glycine 0 C--O 1.22 -0.763 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.671 -177.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.39 170.87 0.2 Allowed 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.417 HG12 ' O ' ' L' ' 29' ' ' GLY . 0.0 OUTLIER -153.97 145.87 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 118.099 -1.44 . . . . 0.0 112.427 -176.553 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 13.6 tt -138.2 137.46 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.78 123.91 4.65 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 mt -117.36 119.78 36.17 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.76 119.82 36.65 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.62 HG12 HG13 ' K' ' 36' ' ' VAL . 3.2 m -129.32 81.66 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.655 -0.248 . . . . 0.0 110.88 -178.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.743 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . -58.56 101.64 0.22 Allowed Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.01 168.99 33.06 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -131.18 159.12 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 120.699 0.285 . . . . 0.0 110.396 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.781 -179.63 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 120.679 0.276 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.6 t -121.21 134.62 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.418 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -96.72 -176.53 3.62 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.144 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -81.02 171.26 15.19 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.433 ' HG3' ' N ' ' A' ' 16' ' ' LYS . 61.8 tp60 -152.48 171.63 17.79 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.498 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.433 ' N ' ' HG3' ' A' ' 15' ' ' GLN . 99.4 mttt -145.58 119.74 9.49 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.49 0.186 . . . . 0.0 111.104 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -132.03 120.32 22.25 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 120.91 0.386 . . . . 0.0 110.061 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -142.23 139.28 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.662 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -135.87 140.2 43.95 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.386 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -139.75 135.44 33.11 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.072 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.39 124.27 47.29 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.648 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -172.75 99.91 0.14 Allowed 'General case' 0 CA--C 1.527 0.093 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.2 t0 . . . . . 0 N--CA 1.469 0.476 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -179.594 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' CG ' ' A' ' 28' ' ' LYS . 0.1 OUTLIER . . . . . 0 CA--C 1.544 0.739 0 CA-C-O 121.881 0.848 . . . . 0.0 112.19 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.8 101.52 0.8 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 176.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.33 153.57 24.53 Favored 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 116.528 -2.069 . . . . 0.0 111.035 -175.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.654 HD13 ' O ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -142.55 111.93 2.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 111.674 -2.512 . . . . 0.0 107.869 -173.449 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.481 ' CG2' HD21 ' B' ' 34' ' ' LEU . 7.8 mt -109.32 107.7 23.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -126.27 102.62 0.65 Allowed Glycine 0 CA--C 1.508 -0.4 0 N-CA-C 107.074 -2.411 . . . . 0.0 107.074 178.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 mt -138.36 149.12 45.27 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 122.666 1.222 . . . . 0.0 113.76 -177.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.438 ' SD ' ' HA3' ' H' ' 33' ' ' GLY . 97.7 mmm -109.65 107.25 17.24 Favored 'General case' 0 CA--C 1.498 -1.043 0 CA-C-N 112.684 -2.053 . . . . 0.0 106.507 175.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -98.04 71.91 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.76 102.73 2.4 Favored Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.08 146.62 14.01 Favored Glycine 0 CA--C 1.526 0.781 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.463 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.4 p -144.59 144.35 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.778 0.323 . . . . 0.0 110.649 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.102 -0.952 . . . . 0.0 110.537 179.967 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 65.7 m-85 -118.62 140.88 49.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.828 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -61.57 134.11 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.572 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.439 HG22 ' NE2' ' B' ' 14' ' ' HIS . 4.6 p -143.13 143.89 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.904 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -124.77 146.67 49.09 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 120.487 0.184 . . . . 0.0 110.661 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.566 ' CE1' ' H ' ' C' ' 14' ' ' HIS . 98.5 m-70 -153.89 162.07 41.51 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.589 0.709 . . . . 0.0 110.842 178.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.5 mm-40 -158.16 174.21 15.54 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.476 177.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -157.85 125.57 5.26 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 52.9 tp -130.99 122.58 27.09 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.993 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.44 133.06 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.899 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -131.06 130.07 42.76 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.391 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -132.23 125.73 31.81 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.288 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.38 125.97 45.96 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -168.37 117.76 0.74 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 178.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 50.3 t0 . . . . . 0 N--CA 1.475 0.8 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -179.699 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.482 -1.988 0 N-CA-C 104.897 -3.281 . . . . 0.0 104.897 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 161.73 14.18 Favored 'General case' 0 CA--C 1.483 -1.623 0 C-N-CA 116.293 -2.163 . . . . 0.0 108.608 -175.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.634 HG22 ' CE ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -145.31 127.64 9.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 112.572 -2.104 . . . . 0.0 108.14 -173.74 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.455 HG22 ' O ' ' B' ' 32' ' ' ILE . 0.6 OUTLIER -121.59 115.99 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 CA-C-O 121.044 0.45 . . . . 0.0 109.993 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.57 99.74 0.63 Allowed Glycine 0 N--CA 1.462 0.368 0 N-CA-C 105.622 -2.991 . . . . 0.0 105.622 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.481 HD21 ' CG2' ' A' ' 32' ' ' ILE . 75.1 mt -124.94 137.91 54.25 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.328 1.061 . . . . 0.0 112.903 -175.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.549 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.3 ttm -119.38 115.08 23.36 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 114.012 -1.449 . . . . 0.0 107.604 178.192 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.713 ' O ' HG13 ' B' ' 36' ' ' VAL . 3.3 p -126.84 66.88 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -54.65 -102.57 0.01 OUTLIER Glycine 0 C--N 1.357 1.726 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.55 152.55 15.91 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -130.88 135.62 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.833 0.349 . . . . 0.0 110.189 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.206 179.502 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 48.3 t . . . . . 0 CA--C 1.513 -0.452 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' D' ' 13' ' ' HIS . 51.3 p-80 -161.87 141.74 10.13 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.618 -0.833 . . . . 0.0 112.085 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.566 ' H ' ' CE1' ' B' ' 14' ' ' HIS . 17.1 m80 -121.39 163.21 19.08 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 57.1 tt0 -168.62 169.23 10.37 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 62.8 pttt -158.61 132.91 7.94 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.877 0.846 . . . . 0.0 111.396 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 tt -120.31 125.23 47.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.279 -1.328 . . . . 0.0 108.01 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 20.5 t -127.47 123.3 61.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.187 0.518 . . . . 0.0 112.133 -178.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CB ' ' CE1' ' D' ' 19' ' ' PHE . 2.1 m-85 -112.95 110.6 20.77 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.494 ' CE2' ' CD2' ' D' ' 20' ' ' PHE . 7.4 t80 -116.25 118.11 31.87 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.228 -178.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.56 129.33 55.28 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 121.038 0.447 . . . . 0.0 111.469 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -158.56 101.85 1.69 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.972 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 17.8 m-20 . . . . . 0 N--CA 1.465 0.323 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.4 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.652 ' HA2' ' HB1' ' D' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.489 -1.535 0 CA-C-O 124.054 1.919 . . . . 0.0 116.727 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.418 ' C ' HG12 ' C' ' 31' ' ' ILE . . . -100.43 173.36 6.61 Favored 'General case' 0 N--CA 1.42 -1.961 1 N-CA-C 99.988 -4.079 . . . . 0.0 99.988 166.663 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.517 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -141.26 111.4 3.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 117.923 -1.511 . . . . 0.0 111.44 -177.109 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.596 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.0 OUTLIER -108.97 121.87 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.493 178.492 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -128.43 119.47 3.08 Favored Glycine 0 C--O 1.237 0.335 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.732 ' H ' HD23 ' D' ' 34' ' ' LEU . 3.6 tt -142.61 142.88 32.19 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 122.481 1.134 . . . . 0.0 112.935 -177.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 0.1 OUTLIER -113.89 118.26 33.71 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.909 178.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.04 73.83 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.49 106.05 3.14 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 111.196 -0.761 . . . . 0.0 111.196 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.51 161.08 20.47 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -130.66 135.75 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.75 0.309 . . . . 0.0 110.641 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.598 179.377 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m . . . . . 0 N--CA 1.465 0.279 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.501 ' CD2' ' CD2' ' C' ' 14' ' ' HIS . 46.7 t60 -153.84 148.93 26.84 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.227 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -99.79 -178.68 3.94 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.337 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 44.0 tt0 -84.55 167.91 15.88 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.716 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.502 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 95.5 mttt -119.86 139.23 52.7 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.6 mt -122.52 121.99 37.84 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.544 0.211 . . . . 0.0 110.462 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -129.84 128.02 64.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.092 0.472 . . . . 0.0 111.586 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.488 ' CE1' ' CB ' ' C' ' 19' ' ' PHE . 7.9 m-85 -122.86 119.8 31.6 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 13.7 t80 -112.87 118.67 35.55 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.75 111.59 22.87 Favored 'General case' 0 C--O 1.251 1.184 0 CA-C-O 122.552 1.168 . . . . 0.0 111.92 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.468 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 66.4 tt0 -139.31 178.25 7.33 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.468 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 19.8 p30 . . . . . 0 C--N 1.318 -0.788 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.652 ' HB1' ' HA2' ' C' ' 29' ' ' GLY . . . . . . . . 1 N--CA 1.348 -5.569 1 N-CA-C 100.162 -4.014 . . . . 0.0 100.162 . . . . . . . . . 3 2 . 1 . 005 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.963 ' N ' HD12 ' D' ' 31' ' ' ILE . 1.2 mp -76.78 113.87 16.4 Favored 'Isoleucine or valine' 0 C--N 1.255 -3.509 0 CA-C-N 123.247 2.749 . . . . 0.0 113.913 -174.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' E' ' 32' ' ' ILE . 2.6 tt -121.32 112.65 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 175.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.635 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -121.95 110.89 1.71 Allowed Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.732 HD23 ' H ' ' C' ' 34' ' ' LEU . 21.2 mt -133.5 132.94 41.59 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 119.408 -0.917 . . . . 0.0 112.493 -176.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.502 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.9 ttm -109.78 126.64 53.98 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.153 178.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.2 t -121.41 79.27 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 CA-C-N 116.671 -0.241 . . . . 0.0 110.989 -178.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -44.34 103.18 0.04 OUTLIER Glycine 0 C--N 1.357 1.72 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 177.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.12 -166.63 29.05 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -122.47 136.21 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 121.021 0.439 . . . . 0.0 110.35 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.2 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.953 -1.023 . . . . 0.0 110.419 179.94 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 98.8 m-85 -114.1 134.71 54.7 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.913 0.387 . . . . 0.0 110.807 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -119.34 148.13 43.53 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.311 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.468 ' CG1' ' CE1' ' E' ' 14' ' ' HIS . 72.8 t -123.79 134.09 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.176 0.512 . . . . 0.0 110.398 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -118.99 101.99 8.43 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.118 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.468 ' CE1' ' CG1' ' E' ' 12' ' ' VAL . 50.6 m170 -130.02 169.1 15.71 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-O 121.609 0.718 . . . . 0.0 110.264 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -149.22 174.73 12.06 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.632 -1.167 . . . . 0.0 108.314 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -154.34 112.02 3.47 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.493 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.8 tp -121.45 117.1 26.03 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -130.93 127.76 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 3.1 m-85 -118.53 115.98 25.71 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 36.1 t80 -114.98 122.88 47.61 Favored 'General case' 0 N--CA 1.471 0.609 0 O-C-N 122.385 -0.197 . . . . 0.0 111.171 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.56 132.72 42.87 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.999 -0.28 . . . . 0.0 110.633 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.14 136.64 39.73 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.615 -0.834 . . . . 0.0 112.94 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.436 ' OD2' ' OD1' ' F' ' 23' ' ' ASP . 46.3 t0 -138.1 131.47 30.59 Favored 'General case' 0 C--N 1.368 1.382 0 CA-C-O 121.353 0.597 . . . . 0.0 112.559 178.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.401 ' O ' ' C ' ' E' ' 25' ' ' GLY . 37.8 t -111.44 113.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.606 177.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . 32.74 88.77 0.01 OUTLIER Glycine 0 CA--C 1.534 1.258 0 CA-C-O 121.794 0.663 . . . . 0.0 112.297 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.644 ' HG ' ' H ' ' F' ' 27' ' ' ASN . 3.4 p . . . . . 0 N--CA 1.445 -0.696 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 179.774 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.458 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.252 1.219 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.647 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -154.33 122.82 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 117.147 -1.821 . . . . 0.0 110.442 -175.152 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.562 HG23 ' CG2' ' D' ' 32' ' ' ILE . 93.5 mt -121.58 127.13 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.255 -177.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.94 118.99 1.94 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.751 HD13 ' CD2' ' F' ' 19' ' ' PHE . 48.4 mt -123.87 123.64 40.89 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.807 -0.696 . . . . 0.0 109.951 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -120.01 122.88 42.12 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.147 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 t -114.17 86.51 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.722 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.648 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -63.91 97.35 0.22 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.09 168.86 38.74 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.5 t -123.5 135.97 61.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.219 -0.532 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.385 -179.807 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -114.77 135.78 53.8 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.811 0.339 . . . . 0.0 110.779 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -85.6 159.86 19.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 81.1 t -94.78 133.68 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.194 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.658 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 p-80 -139.97 125.95 19.68 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.335 0.588 . . . . 0.0 110.722 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.614 ' CG ' ' H ' ' F' ' 15' ' ' GLN . 82.7 t60 -156.97 177.25 11.72 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.614 ' H ' ' CG ' ' F' ' 14' ' ' HIS . 86.9 mt-30 -144.21 173.87 11.38 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -148.94 112.43 5.02 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.277 0.561 . . . . 0.0 111.605 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -124.68 120.47 31.93 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -127.53 128.67 70.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-O 121.817 0.818 . . . . 0.0 112.704 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.751 ' CD2' HD13 ' E' ' 34' ' ' LEU . 8.7 m-85 -115.09 104.98 12.41 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.403 ' CE2' ' OE2' ' F' ' 22' ' ' GLU . 18.7 t80 -114.94 120.71 40.83 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 -177.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.27 129.54 33.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' CE2' ' F' ' 20' ' ' PHE . 73.5 mm-40 -92.6 92.4 8.0 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.507 -178.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 25.5 t0 -147.41 107.98 4.13 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 120.791 0.329 . . . . 0.0 111.5 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 m -77.49 -131.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.31 0.576 . . . . 0.0 110.147 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.15 85.44 0.01 OUTLIER Glycine 0 CA--C 1.528 0.879 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.927 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . 0.481 ' OG ' ' OG ' ' E' ' 26' ' ' SER . 3.7 t -61.82 -178.39 0.15 Allowed 'General case' 0 N--CA 1.44 -0.95 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.644 ' H ' ' HG ' ' E' ' 26' ' ' SER . 59.5 t30 -80.16 172.78 13.32 Favored 'General case' 0 C--N 1.316 -0.866 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.228 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -45.45 110.73 0.27 Allowed 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.153 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.0 92.95 0.32 Allowed Glycine 0 N--CA 1.463 0.48 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.503 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -120.84 162.5 19.71 Favored 'General case' 0 CA--C 1.489 -1.396 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 173.283 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.46 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -144.48 116.47 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 115.625 -2.43 . . . . 0.0 112.728 -175.903 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 tt -125.95 135.55 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.029 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.31 128.02 4.37 Favored Glycine 0 CA--C 1.531 1.043 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.022 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -119.66 124.37 46.13 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 0.4 OUTLIER -130.64 129.63 42.92 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.36 0.6 . . . . 0.0 112.363 -178.885 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.586 HG13 ' O ' ' F' ' 36' ' ' VAL . 7.7 p -152.95 81.89 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.702 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.56 101.51 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.249 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -151.19 160.46 28.69 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 12.7 p -137.46 141.62 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 120.837 0.351 . . . . 0.0 110.907 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.629 179.747 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 . . . . . 0 N--CA 1.472 0.627 0 CA-C-O 121.132 0.492 . . . . 0.0 111.721 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 m-70 -145.48 164.58 31.16 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.416 ' HG3' ' N ' ' G' ' 16' ' ' LYS . 64.5 tp60 -164.9 165.17 20.59 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.242 178.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.416 ' N ' ' HG3' ' G' ' 15' ' ' GLN . 98.7 mttt -157.04 129.12 7.27 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -136.43 122.14 19.79 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.535 0.683 . . . . 0.0 110.999 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . 0.452 HG22 ' CG1' ' H' ' 18' ' ' VAL . 71.4 t -123.44 129.55 74.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.566 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -128.81 134.89 48.51 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.803 0.335 . . . . 0.0 110.909 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.513 ' CD2' ' O ' ' G' ' 20' ' ' PHE . 46.0 p90 -129.93 127.13 39.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.791 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.59 37.21 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 121.418 0.627 . . . . 0.0 111.372 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -174.48 98.72 0.09 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.545 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -152.63 114.7 4.4 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -28.99 122.55 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 113.9 -1.5 . . . . 0.0 113.358 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.44 -85.56 0.06 OUTLIER Glycine 0 CA--C 1.529 0.926 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.556 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.555 ' O ' ' O ' ' G' ' 27' ' ' ASN . 19.0 t -153.39 -173.59 4.63 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 119.462 1.631 . . . . 0.0 111.646 178.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.555 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.3 m-20 -20.52 156.57 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 113.58 -1.645 . . . . 0.0 112.903 177.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 58.5 tttm -168.44 102.83 0.43 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 118.732 -1.187 . . . . 0.0 113.739 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.445 ' O ' HG13 ' G' ' 31' ' ' ILE . . . -76.81 104.45 1.89 Allowed Glycine 0 CA--C 1.495 -1.205 0 CA-C-O 115.789 -2.673 . . . . 0.0 106.86 172.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.469 ' C ' HG13 ' G' ' 31' ' ' ILE . . . -74.75 143.15 44.23 Favored 'General case' 0 C--O 1.252 1.203 1 CA-C-N 124.22 4.01 . . . . 0.0 105.782 -178.126 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.469 HG13 ' C ' ' G' ' 30' ' ' ALA . 69.6 mt -156.75 115.29 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 112.883 -1.962 . . . . 0.0 108.509 -171.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' H' ' 32' ' ' ILE . 10.4 tt -141.01 131.01 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.427 0 CA-C-O 122.683 1.23 . . . . 0.0 110.523 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.413 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -148.98 154.27 25.7 Favored Glycine 0 CA--C 1.484 -1.871 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 176.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -145.04 140.68 28.28 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.691 -179.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 25.6 ttp -103.48 106.81 17.42 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.48 65.28 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.654 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -131.45 102.55 0.51 Allowed Glycine 0 C--N 1.369 2.374 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.13 173.42 41.66 Favored Glycine 0 CA--C 1.523 0.587 0 C-N-CA 120.385 -0.912 . . . . 0.0 111.894 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t . . . . . 0 N--CA 1.464 0.245 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.992 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 33.0 m . . . . . 0 N--CA 1.464 0.231 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -129.48 133.24 47.18 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.979 0.418 . . . . 0.0 111.948 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -140.9 163.81 31.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -157.59 177.5 11.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.355 0.598 . . . . 0.0 111.307 179.249 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . 0.617 ' C ' HD22 ' H' ' 17' ' ' LEU . 45.0 tttp -170.64 115.53 0.47 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.81 178.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.744 ' N ' HD22 ' H' ' 17' ' ' LEU . 1.6 mm? -122.8 119.16 29.77 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.452 ' CG1' HG22 ' G' ' 18' ' ' VAL . 3.0 p -135.17 130.65 51.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.713 178.29 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -120.13 123.24 42.85 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.948 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.23 123.0 45.56 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.11 126.18 38.78 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.321 0.581 . . . . 0.0 110.48 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.419 ' O ' ' CG ' ' H' ' 23' ' ' ASP . 84.1 tt0 -138.94 131.12 28.2 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.146 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.2 m-20 -163.05 122.92 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.474 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' I' ' 24' ' ' VAL . 7.1 m . . . . . 0 C--N 1.318 -0.782 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.118 0 CA-C-O 122.759 1.266 . . . . 0.0 110.266 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.41 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -138.7 124.99 24.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 113.084 -1.871 . . . . 0.0 111.55 -178.745 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.549 ' N ' ' SD ' ' B' ' 35' ' ' MET . 0.7 OUTLIER -114.52 117.29 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.195 178.054 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.438 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -118.38 109.3 1.75 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.756 HD13 ' CZ ' ' J' ' 19' ' ' PHE . 15.5 mt -118.36 122.73 43.55 Favored 'General case' 0 CA--C 1.49 -1.333 0 N-CA-C 112.848 0.684 . . . . 0.0 112.848 -175.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.1 ttm -114.56 106.1 13.87 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.63 71.81 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.23 111.72 3.71 Favored Glycine 0 C--N 1.365 2.148 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -45.37 160.18 0.17 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 40' ' ' VAL . 3.3 p -140.5 141.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.702 0.287 . . . . 0.0 110.314 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 39' ' ' VAL . 84.5 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.955 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 75.1 t . . . . . 0 N--CA 1.464 0.251 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -147.16 121.85 9.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.823 -179.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 87.7 m-70 -134.94 161.82 34.18 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -153.78 166.96 31.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.511 0.672 . . . . 0.0 111.576 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -156.91 127.32 6.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.352 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -128.8 125.73 38.4 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -128.86 126.82 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 116.691 -0.232 . . . . 0.0 111.189 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.615 ' CD1' ' CE1' ' J' ' 19' ' ' PHE . 31.4 m-85 -115.17 107.37 15.21 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -108.25 122.74 47.58 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 118.274 0.488 . . . . 0.0 110.795 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 138.93 34.44 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.455 ' HG2' ' H ' ' J' ' 22' ' ' GLU . 72.7 mt-10 -152.29 121.87 6.88 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-O 118.972 -0.537 . . . . 0.0 111.752 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.589 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 63.7 m-20 -151.42 103.74 3.02 Favored 'General case' 0 C--N 1.362 1.115 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 176.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.548 ' CG2' HG12 ' H' ' 24' ' ' VAL . 59.8 t -31.87 142.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.616 1.567 . . . . 0.0 114.215 170.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -81.75 0.1 Allowed Glycine 0 CA--C 1.533 1.16 0 C-N-CA 119.187 -1.482 . . . . 0.0 114.779 174.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.54 ' O ' ' O ' ' I' ' 27' ' ' ASN . 91.5 p -132.61 -179.21 5.32 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.603 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 46.5 t-20 -40.23 167.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.603 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 70.7 tttt -72.3 110.6 6.84 Favored 'General case' 0 C--N 1.344 0.337 0 C-N-CA 114.268 -2.973 . . . . 0.0 111.316 178.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.68 94.69 1.66 Allowed Glycine 0 CA--C 1.491 -1.433 0 CA-C-O 115.406 -2.885 . . . . 0.0 106.399 167.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.14 142.29 49.43 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 123.892 3.846 . . . . 0.0 109.0 177.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.512 HG23 HG13 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -139.19 120.32 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 CA-C-N 111.54 -2.573 . . . . 0.0 109.261 -176.529 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.478 HG22 ' O ' ' I' ' 32' ' ' ILE . 0.8 OUTLIER -110.53 114.27 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 121.333 0.587 . . . . 0.0 110.19 178.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.52 96.94 1.31 Allowed Glycine 0 CA--C 1.496 -1.099 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.687 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 31.9 tp -111.88 122.93 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -175.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.1 ttp -121.57 114.77 21.67 Favored 'General case' 0 CA--C 1.512 -0.514 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.478 HG11 HD22 ' K' ' 17' ' ' LEU . 0.0 OUTLIER -131.89 72.22 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.284 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -37.77 -98.49 0.01 OUTLIER Glycine 0 C--N 1.358 1.765 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.07 -167.33 39.21 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -123.44 135.6 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.938 0.399 . . . . 0.0 110.405 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.412 HG22 ' H ' ' I' ' 40' ' ' VAL . 28.5 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.448 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m . . . . . 0 N--CA 1.463 0.216 0 CA-C-O 121.35 0.595 . . . . 0.0 110.796 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 12.0 t-80 -148.85 132.39 16.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.0 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.708 ' CD2' ' H ' ' J' ' 15' ' ' GLN . 11.3 t-80 -156.17 165.69 35.67 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.541 0.686 . . . . 0.0 109.523 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.708 ' H ' ' CD2' ' J' ' 14' ' ' HIS . 48.4 tt0 -165.0 168.89 17.01 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . 0.474 ' N ' ' CG ' ' J' ' 15' ' ' GLN . 88.5 tttt -153.7 132.63 12.45 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.449 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.43 127.23 47.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -126.08 127.93 71.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.834 0.35 . . . . 0.0 110.884 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 97.3 m-85 -113.52 109.56 18.84 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -120.03 122.83 41.98 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.733 0.271 . . . . 0.0 111.733 -176.91 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.22 132.21 41.23 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.498 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.583 ' OE2' ' CD1' ' J' ' 20' ' ' PHE . 18.6 mp0 -140.52 145.85 37.37 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 120.19 -0.604 . . . . 0.0 112.36 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 15.3 m-20 -167.33 124.24 1.18 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.5 0.666 . . . . 0.0 111.903 178.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.804 HG13 ' H ' ' J' ' 25' ' ' GLY . 7.1 p -62.93 -116.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.762 -1.108 . . . . 0.0 110.834 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.804 ' H ' HG13 ' J' ' 24' ' ' VAL . . . 60.72 -91.79 0.06 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 114.976 -1.011 . . . . 0.0 114.42 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.83 ' O ' ' O ' ' J' ' 27' ' ' ASN . 35.1 p -171.63 172.52 4.97 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 118.173 0.986 . . . . 0.0 110.834 -176.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.83 ' O ' ' O ' ' J' ' 26' ' ' SER . 80.3 m-20 15.58 -178.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 O-C-N 125.627 1.83 . . . . 0.0 114.738 -179.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.544 ' CA ' ' OD1' ' I' ' 27' ' ' ASN 0.255 80.4 tttt -148.49 109.92 4.41 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 118.359 -1.336 . . . . 0.0 113.906 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -73.73 94.13 0.75 Allowed Glycine 0 CA--C 1.489 -1.551 0 CA-C-O 116.172 -2.46 . . . . 0.0 107.683 169.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.48 146.52 50.79 Favored 'General case' 0 CA--C 1.481 -1.709 0 CA-C-N 123.116 3.458 . . . . 0.0 110.587 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.53 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.1 OUTLIER -149.71 109.36 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 CA-C-N 110.906 -2.861 . . . . 0.0 105.629 -178.141 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.537 HG22 HG23 ' K' ' 32' ' ' ILE . 1.1 tt -109.7 113.38 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 121.773 0.797 . . . . 0.0 108.9 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . 0.461 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -102.49 107.73 3.18 Favored Glycine 0 CA--C 1.507 -0.442 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.794 HD22 ' CE1' ' L' ' 19' ' ' PHE . 6.4 mt -110.62 111.36 22.53 Favored 'General case' 0 CA--C 1.507 -0.677 0 CA-C-O 121.247 0.546 . . . . 0.0 110.748 -177.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.596 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 18.9 ttt -110.28 110.34 21.12 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 5.9 m -133.83 74.88 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.229 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.27 102.21 2.85 Favored Glycine 0 C--N 1.35 1.357 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -152.86 157.1 27.1 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.464 0.257 0 CA-C-O 120.795 0.331 . . . . 0.0 110.362 -179.661 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 . . . . . 0 C--O 1.232 0.168 0 CA-C-O 120.657 0.265 . . . . 0.0 110.773 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.42 133.8 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.776 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 -128.16 121.58 29.87 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.51 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' NE2' ' L' ' 14' ' ' HIS . 96.6 m-70 -122.59 169.38 11.08 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.37 0.605 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.403 ' HG3' ' N ' ' K' ' 16' ' ' LYS . 66.4 tp60 -155.36 169.98 22.97 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.164 179.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG3' ' K' ' 15' ' ' GLN . 88.4 tttt -172.61 125.32 0.48 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.553 0.216 . . . . 0.0 110.503 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.478 HD22 HG11 ' I' ' 36' ' ' VAL . 5.1 mp -128.69 129.34 45.66 Favored 'General case' 0 N--CA 1.466 0.374 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.501 HG11 ' CE2' ' K' ' 20' ' ' PHE . 40.6 t -132.12 133.55 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.067 0.46 . . . . 0.0 111.504 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.687 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 37.7 m-85 -114.58 111.73 21.81 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.601 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.501 ' CE2' HG11 ' K' ' 18' ' ' VAL . 54.8 m-85 -109.13 114.43 28.15 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.353 -0.217 . . . . 0.0 111.252 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.32 121.27 38.27 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -121.68 130.87 53.77 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.51 ' N ' ' OD1' ' K' ' 23' ' ' ASP . 16.4 p-10 179.25 102.25 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 114.936 -1.029 . . . . 0.0 109.415 176.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.607 HG22 ' N ' ' K' ' 25' ' ' GLY . 12.9 p -58.82 166.29 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.133 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.607 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 88.23 81.6 1.26 Allowed Glycine 0 CA--C 1.53 0.969 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.463 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 34.0 p -47.9 166.78 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.611 ' ND2' ' ND2' ' J' ' 27' ' ' ASN . 9.6 t-20 -157.2 177.38 11.54 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.033 -0.667 . . . . 0.0 112.68 177.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.544 ' H ' ' ND2' ' K' ' 27' ' ' ASN . 67.3 mmtt 2.31 -105.32 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.358 1.063 . . . . 0.0 113.265 178.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -140.92 97.66 0.22 Allowed Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.94 170.32 4.44 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.648 HG21 ' CA ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -152.18 126.37 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 117.998 -1.481 . . . . 0.0 111.442 -178.687 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.537 HG23 HG22 ' J' ' 32' ' ' ILE . 96.6 mt -126.14 132.64 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.603 -178.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.76 116.34 2.97 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 12.6 mt -107.22 111.25 23.56 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.456 ' C ' ' SD ' ' K' ' 35' ' ' MET . 0.0 OUTLIER -113.03 111.99 23.12 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 -178.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.09 81.79 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.647 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -79.16 100.88 1.8 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 178.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.82 161.43 34.97 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.644 -0.788 . . . . 0.0 111.455 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 N--CA 1.464 0.231 0 CA-C-O 120.763 0.316 . . . . 0.0 110.558 179.918 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 7.9 m . . . . . 0 N--CA 1.469 0.517 0 CA-C-O 121.255 0.55 . . . . 0.0 110.876 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 69.5 t60 -140.14 125.14 18.5 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.415 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' ND1' ' K' ' 14' ' ' HIS . 23.6 p80 -157.38 170.97 21.24 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -148.75 174.2 12.44 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.48 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -152.86 139.5 18.81 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.457 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -134.34 122.38 22.54 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -126.12 132.82 70.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-O 121.079 0.466 . . . . 0.0 111.755 -178.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.794 ' CE1' HD22 ' J' ' 34' ' ' LEU . 88.1 m-85 -112.62 112.01 23.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.565 178.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -120.73 119.45 32.82 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.31 0.576 . . . . 0.0 110.715 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.44 128.62 47.27 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' L' ' 22' ' ' GLU . 11.3 tm-20 -78.59 96.51 5.5 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.188 -178.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -152.55 113.57 4.19 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.409 ' O ' HG23 ' L' ' 24' ' ' VAL . 31.9 m -98.62 130.51 47.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.281 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.0 81.74 0.03 OUTLIER Glycine 0 C--N 1.336 0.581 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.748 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -62.16 -178.15 0.16 Allowed 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.773 0.797 . . . . 0.0 110.459 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 7.9 t-20 -80.63 178.46 8.33 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.393 -1.276 . . . . 0.0 112.449 -178.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 65.0 mttp -41.44 111.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.088 -0.96 . . . . 0.0 112.059 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.71 -93.71 1.76 Allowed Glycine 0 N--CA 1.463 0.474 0 CA-C-N 113.951 -1.477 . . . . 0.0 112.982 179.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 78.26 161.48 0.21 Allowed 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 100.636 -3.838 . . . . 0.0 100.636 -174.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.48 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -154.09 127.54 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 122.665 2.484 . . . . 0.0 111.961 -179.11 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 48.5 pt -122.64 141.54 42.63 Favored 'Isoleucine or valine' 0 C--N 1.339 0.134 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.063 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.88 121.21 3.33 Favored Glycine 0 N--CA 1.465 0.621 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.4 tp -124.42 123.02 39.26 Favored 'General case' 0 N--CA 1.465 0.278 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.578 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.1 ppp? -131.67 136.05 47.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.475 0.655 . . . . 0.0 110.651 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 37' ' ' GLY . 5.5 t -138.18 80.74 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.691 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.46 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . 26.47 -104.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.09 0 O-C-N 123.419 0.45 . . . . 0.0 112.65 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 134.03 147.48 5.65 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -140.98 164.23 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.754 0.312 . . . . 0.0 110.734 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 28.4 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.379 179.891 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 . . . . . 0 N--CA 1.465 0.288 0 N-CA-C 110.018 -0.364 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.54 148.49 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 116.278 -0.419 . . . . 0.0 109.898 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -77.82 162.96 26.5 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.036 -178.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.554 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.4 m-70 -104.12 172.98 6.5 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.167 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.6 tt0 -151.11 173.03 14.85 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.006 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . 0.404 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 88.0 tttt -155.25 132.39 10.9 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.666 0.27 . . . . 0.0 110.492 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 52.1 tp -131.96 126.66 34.58 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 121.194 0.521 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.2 m -128.17 132.83 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.767 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -135.14 131.23 36.57 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.973 0.416 . . . . 0.0 111.193 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -119.63 126.07 50.28 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.8 132.51 45.3 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.968 0.889 . . . . 0.0 112.647 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -140.77 96.44 3.02 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.592 -1.185 . . . . 0.0 109.217 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.433 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 2.1 m-20 . . . . . 0 C--N 1.325 -0.5 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.54 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 45.3 tttp . . . . . 0 CA--C 1.545 0.774 0 CA-C-O 121.381 0.61 . . . . 0.0 110.508 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 59.63 92.09 0.01 OUTLIER Glycine 0 C--N 1.346 1.114 0 CA-C-O 118.089 -1.395 . . . . 0.0 114.766 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -138.06 142.2 40.3 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 116.645 -2.022 . . . . 0.0 109.227 174.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.9 OUTLIER -155.67 128.55 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 CA-C-N 111.603 -2.544 . . . . 0.0 109.499 -173.181 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' H' ' 35' ' ' MET . 24.4 mt -126.62 107.92 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.01 102.32 1.36 Allowed Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.021 -2.832 . . . . 0.0 106.021 177.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 75.7 mt -133.95 150.21 51.28 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 122.529 1.157 . . . . 0.0 112.802 -177.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 15.7 ttm -128.87 118.22 22.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 CA-C-N 113.048 -1.887 . . . . 0.0 107.14 177.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -109.01 71.03 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.066 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.158 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -37.54 -100.36 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.28 -171.76 40.68 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -122.3 135.97 60.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.01 0.433 . . . . 0.0 110.6 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.773 -179.796 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.68 144.13 42.7 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . 0.488 ' O ' ' NE2' ' C' ' 13' ' ' HIS . 96.3 mt-10 -61.96 129.9 43.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.98 0.419 . . . . 0.0 110.969 -179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.7 132.56 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.991 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -157.08 170.12 23.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.16 0.505 . . . . 0.0 111.382 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -134.14 169.56 16.98 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -155.01 165.0 38.1 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.128 179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -156.28 113.5 3.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.163 179.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.7 tp -118.79 121.03 39.09 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -125.56 124.3 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 110.575 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -121.79 119.02 30.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.06 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -120.19 120.0 34.87 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 126.92 35.49 Favored 'General case' 0 N--CA 1.474 0.753 0 CA-C-O 121.368 0.604 . . . . 0.0 111.684 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -153.26 145.1 23.55 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.561 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.433 ' OD1' ' O ' ' A' ' 23' ' ' ASP . 18.7 t70 . . . . . 0 N--CA 1.464 0.266 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.2 178.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.733 ' HA2' ' HB2' ' C' ' 30' ' ' ALA . . . . . . . . 0 N--CA 1.479 1.518 0 N-CA-C 114.064 0.386 . . . . 0.0 114.064 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.936 ' O ' ' HB3' ' C' ' 30' ' ' ALA . . . -140.03 151.39 45.4 Favored 'General case' 0 N--CA 1.425 -1.699 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 172.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.661 HG23 ' CG2' ' C' ' 31' ' ' ILE . 1.6 mt -137.63 105.09 3.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 118.672 -1.211 . . . . 0.0 108.262 -174.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.588 HD11 HD12 ' B' ' 34' ' ' LEU . 12.4 tt -126.18 123.59 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 118.984 -1.086 . . . . 0.0 112.211 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.601 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -114.9 104.94 1.42 Allowed Glycine 0 CA--C 1.503 -0.684 0 N-CA-C 106.975 -2.45 . . . . 0.0 106.975 177.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.624 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.0 OUTLIER -122.62 125.94 46.67 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 122.605 1.193 . . . . 0.0 110.639 -179.027 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.536 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 1.3 ttm -112.31 119.77 39.45 Favored 'General case' 0 N--CA 1.438 -1.068 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.538 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -123.31 70.95 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.875 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.635 -179.874 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -45.14 -99.06 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 178.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 138.02 165.47 10.35 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -135.41 161.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . 0.404 ' H ' HG13 ' B' ' 40' ' ' VAL . 7.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.644 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 m . . . . . 0 N--CA 1.468 0.448 0 N-CA-C 110.374 -0.232 . . . . 0.0 110.374 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.488 ' NE2' ' O ' ' B' ' 11' ' ' GLU . 77.7 m80 -78.26 128.27 33.48 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.294 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.578 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 60.0 t-80 -151.64 163.88 38.12 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.578 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 80.9 mt-30 -157.43 175.58 13.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.284 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.46 115.7 0.49 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.069 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -120.03 125.58 48.7 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.889 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -131.65 124.68 54.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD11 ' B' ' 34' ' ' LEU . 2.9 m-85 -115.43 112.85 22.92 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 175.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -118.6 130.4 55.86 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 -178.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.504 ' O ' ' HB1' ' D' ' 21' ' ' ALA . . . -162.13 160.48 27.31 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 115.786 1.772 . . . . 0.0 115.786 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -118.1 118.74 32.72 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 113.695 -1.593 . . . . 0.0 111.059 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 47.9 t0 . . . . . 0 CA--C 1.531 0.227 0 CA-C-O 121.801 0.81 . . . . 0.0 112.086 177.886 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.453 -3.819 0 CA-C-O 125.317 2.621 . . . . 0.0 116.097 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.936 ' HB3' ' O ' ' B' ' 30' ' ' ALA . . . -88.37 -130.87 0.07 Allowed 'General case' 2 N--CA 1.357 -5.093 2 N-CA-C 95.377 -5.786 . . . . 0.0 95.377 171.373 . . . . . . . . 4 3 . 1 . 006 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.684 HD11 ' CE ' ' J' ' 35' ' ' MET . 7.8 tp -87.91 135.61 25.08 Favored 'Isoleucine or valine' 1 C--N 1.232 -4.504 0 N-CA-C 114.345 1.239 . . . . 0.0 114.345 -179.109 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.488 ' O ' ' CE ' ' J' ' 35' ' ' MET . 8.1 tt -120.77 112.98 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 175.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -122.36 122.84 5.21 Favored Glycine 0 CA--C 1.504 -0.636 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.447 -178.546 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -143.78 146.25 32.97 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 118.694 -1.202 . . . . 0.0 112.041 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.59 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 3.4 ttm -121.11 121.95 38.98 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 113.286 -1.779 . . . . 0.0 108.704 177.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.93 76.9 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.106 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -83.12 104.09 2.55 Favored Glycine 0 C--N 1.361 1.957 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.08 170.68 51.39 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.9 m -140.61 162.77 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 120.815 0.341 . . . . 0.0 110.756 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.428 179.676 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t . . . . . 0 N--CA 1.467 0.399 0 CA-C-O 121.275 0.559 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -132.87 138.71 47.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 29.3 t-80 -144.9 166.11 26.23 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 121.408 0.623 . . . . 0.0 110.083 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.552 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 52.7 tt0 -160.23 171.26 19.52 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.39 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . 0.419 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 86.8 tttt -169.96 118.25 0.59 Allowed 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.452 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 tt -128.63 127.03 41.42 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -142.42 138.1 29.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.8 0.809 . . . . 0.0 113.095 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.583 ' CZ ' ' CD2' ' C' ' 34' ' ' LEU . 38.0 m-85 -113.36 117.94 33.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.036 177.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.566 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 22.6 t80 -127.59 124.55 38.38 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.745 0.307 . . . . 0.0 110.654 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' C' ' 21' ' ' ALA . . . -158.14 164.72 36.32 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.724 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -137.59 157.01 47.42 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.333 -1.303 . . . . 0.0 112.381 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 t0 . . . . . 0 C--N 1.331 -0.211 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 179.963 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.64 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.385 -3.718 1 N-CA-C 93.74 -6.393 . . . . 0.0 93.74 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.901 HD12 ' N ' ' D' ' 31' ' ' ILE . 3.1 mp -103.42 122.51 56.08 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.134 0 C-N-CA 116.517 -2.073 . . . . 0.0 113.116 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.429 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -113.36 118.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.897 179.107 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.46 ' N ' ' CE ' ' J' ' 35' ' ' MET . . . -131.9 101.75 0.48 Allowed Glycine 0 N--CA 1.472 1.075 0 N-CA-C 106.792 -2.523 . . . . 0.0 106.792 177.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.442 HD23 ' H ' ' C' ' 34' ' ' LEU . 10.0 mt -130.64 125.63 34.52 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-O 122.187 0.994 . . . . 0.0 111.793 -175.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -105.54 117.6 34.42 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 113.983 -1.462 . . . . 0.0 107.115 177.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -114.4 80.91 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 120.874 0.368 . . . . 0.0 110.49 -177.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.73 103.27 0.54 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.72 -163.0 6.88 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.41 133.94 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 121.09 0.472 . . . . 0.0 110.673 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.061 -0.971 . . . . 0.0 110.818 -179.861 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.7 144.57 43.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.96 0.41 . . . . 0.0 110.872 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -63.38 149.59 45.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.783 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.51 142.86 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 69.7 t60 -143.18 139.9 30.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.92 0.391 . . . . 0.0 110.696 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.528 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -135.92 170.12 16.5 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.528 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 43.7 tt0 -158.19 171.13 20.77 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.991 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.475 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -150.39 113.14 4.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.33 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -118.3 115.87 25.6 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -131.56 130.14 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 7.2 m-85 -113.05 111.2 21.74 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.488 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.566 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 25.5 t80 -122.49 121.33 36.32 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 118.223 0.465 . . . . 0.0 111.292 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.34 136.88 33.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.951 0.405 . . . . 0.0 111.469 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -124.68 120.81 32.91 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.448 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 44.7 p-10 -163.75 101.77 0.9 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.602 -0.839 . . . . 0.0 113.251 177.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.588 HG12 ' N ' ' E' ' 25' ' ' GLY . 21.2 t -59.49 166.74 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.164 -0.926 . . . . 0.0 112.353 177.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.588 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 87.9 81.62 1.24 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 115.336 0.894 . . . . 0.0 115.336 174.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p . . . . . 0 N--CA 1.443 -0.782 0 CA-C-O 120.565 0.221 . . . . 0.0 110.795 175.969 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.556 ' HB1' ' O ' ' D' ' 30' ' ' ALA . . . . . . . . 0 C--O 1.238 0.473 0 CA-C-O 121.028 0.442 . . . . 0.0 111.095 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.601 ' CG2' HD13 ' F' ' 31' ' ' ILE . 0.0 OUTLIER -144.37 130.96 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.986 -179.601 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.655 ' CG1' HD11 ' E' ' 34' ' ' LEU . 0.1 OUTLIER -130.61 122.37 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 121.084 0.469 . . . . 0.0 110.959 -178.255 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.81 124.39 5.37 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.681 HD12 ' N ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -126.94 128.27 46.16 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 120.891 0.377 . . . . 0.0 111.006 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.8 tpp -120.19 120.2 35.46 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.918 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' E' ' 37' ' ' GLY . 5.8 t -134.06 83.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 121.36 -0.136 . . . . 0.0 111.131 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -19.58 -94.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.162 0 O-C-N 123.461 0.475 . . . . 0.0 112.753 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.67 -167.58 35.26 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 p -138.76 145.67 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 120.802 0.334 . . . . 0.0 110.393 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.043 -0.979 . . . . 0.0 110.515 179.78 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -85.44 134.6 34.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.874 0.369 . . . . 0.0 110.696 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -138.39 131.01 29.23 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.202 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m -141.65 173.29 8.58 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 121.237 0.541 . . . . 0.0 110.965 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -80.45 144.03 32.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.425 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.544 ' O ' ' NE2' ' F' ' 15' ' ' GLN . 34.6 m80 -134.03 172.21 13.14 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.544 ' NE2' ' O ' ' F' ' 14' ' ' HIS . 99.3 mm-40 -144.54 178.3 8.05 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.41 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -169.23 116.19 0.61 Allowed 'General case' 0 CA--C 1.531 0.215 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.404 HD12 ' N ' ' F' ' 17' ' ' LEU . 2.0 mp -126.82 126.98 44.29 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.081 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.73 129.89 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 121.572 0.701 . . . . 0.0 112.247 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' E' ' 34' ' ' LEU . 4.0 m-85 -114.75 113.39 24.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.132 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.486 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 35.4 t80 -127.06 120.98 30.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.502 0.668 . . . . 0.0 111.387 -179.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.1 135.66 46.6 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.094 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tp10 -78.02 120.79 23.36 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.231 -0.588 . . . . 0.0 110.215 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' F' ' 24' ' ' VAL . 19.7 t70 -169.0 121.71 0.79 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.655 -0.418 . . . . 0.0 112.045 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' F' ' 23' ' ' ASP . 4.5 m -63.06 -121.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.519 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -64.39 -86.05 0.06 OUTLIER Glycine 0 CA--C 1.519 0.304 0 N-CA-C 105.736 -2.946 . . . . 0.0 105.736 178.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . 0.548 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 2.0 t 157.53 172.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 122.316 1.055 . . . . 0.0 112.087 174.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.548 ' N ' ' OG ' ' F' ' 26' ' ' SER . 43.3 m-20 -44.69 174.76 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 112.947 -1.933 . . . . 0.0 111.298 176.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -70.28 111.38 5.84 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.25 -92.94 0.87 Allowed Glycine 0 C--N 1.313 -0.725 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' F' ' 27' ' ' ASN . . . 82.17 163.72 0.14 Allowed 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 100.451 -3.907 . . . . 0.0 100.451 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.828 HD12 ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -148.11 128.16 4.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 121.691 2.041 . . . . 0.0 110.653 179.297 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tt -123.95 136.82 59.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.602 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.77 117.93 2.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.2 tt -124.15 124.18 41.92 Favored 'General case' 0 N--CA 1.47 0.567 0 O-C-N 122.689 -0.301 . . . . 0.0 110.238 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 42.2 mmm -123.27 130.38 52.66 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 120.776 0.322 . . . . 0.0 110.745 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.16 81.02 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 CA-C-N 116.101 -0.499 . . . . 0.0 112.323 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -43.25 100.83 0.02 OUTLIER Glycine 0 C--N 1.341 0.839 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.854 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -128.77 163.75 22.1 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.21 135.19 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.838 0.352 . . . . 0.0 110.121 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.486 -179.994 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 39.7 p-80 . . . . . 0 N--CA 1.465 0.306 0 CA-C-O 120.789 0.328 . . . . 0.0 110.25 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.485 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 33.9 p80 -77.46 171.33 15.07 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' H ' ' G' ' 16' ' ' LYS . 48.5 tt0 -155.92 172.37 18.49 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.395 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . 0.403 ' H ' ' HG2' ' G' ' 15' ' ' GLN . 71.7 mmtt -136.56 132.56 35.34 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -135.74 111.07 9.06 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.68 133.1 65.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -139.64 148.74 42.86 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -124.71 132.92 53.35 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 139.52 45.56 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.598 0.713 . . . . 0.0 112.104 -178.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -115.96 167.09 11.27 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.568 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.445 ' O ' ' HB ' ' G' ' 24' ' ' VAL . 44.1 t0 -46.3 142.96 2.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.454 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' G' ' 23' ' ' ASP . 20.0 t 93.97 111.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 O-C-N 124.565 1.166 . . . . 0.0 111.48 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 49.35 91.64 0.01 OUTLIER Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.54 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 1.1 p 159.04 -179.57 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 122.187 0.994 . . . . 0.0 110.603 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' G' ' 28' ' ' LYS . 90.5 m-20 -58.93 172.05 0.6 Allowed 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 113.408 -1.724 . . . . 0.0 112.323 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.533 ' NZ ' ' OD2' ' I' ' 23' ' ' ASP . 84.5 tttt 52.75 105.53 0.01 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.13 -179.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.727 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . 107.51 103.71 2.89 Favored Glycine 1 CA--C 1.427 -5.413 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.102 -174.478 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.727 ' HB3' ' O ' ' G' ' 29' ' ' GLY . . . 87.66 -148.34 0.01 OUTLIER 'General case' 0 N--CA 1.384 -3.73 0 N-CA-C 103.138 -2.912 . . . . 0.0 103.138 -169.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.884 ' H ' HD12 ' G' ' 31' ' ' ILE 0.287 0.0 OUTLIER -109.54 114.79 47.93 Favored 'Isoleucine or valine' 0 C--N 1.252 -3.638 0 N-CA-C 118.043 2.608 . . . . 0.0 118.043 -174.012 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.543 HG23 ' O ' ' G' ' 32' ' ' ILE . 0.9 OUTLIER -112.36 116.37 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 173.421 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.51 121.3 4.33 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 49.0 mt -126.52 134.67 50.83 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 122.889 1.328 . . . . 0.0 111.302 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 20.1 ttt -98.02 110.91 23.4 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 112.494 -2.139 . . . . 0.0 107.081 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.44 64.77 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.517 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.919 -178.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.11 -106.45 0.41 Allowed Glycine 0 C--N 1.367 2.296 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -161.85 165.11 35.62 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 66.7 t . . . . . 0 N--CA 1.466 0.338 0 CA-C-O 120.833 0.349 . . . . 0.0 110.195 -179.893 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 24.4 m . . . . . 0 N--CA 1.468 0.457 0 CA-C-O 120.945 0.402 . . . . 0.0 110.932 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -128.71 -175.42 3.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.208 179.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -80.61 168.52 18.79 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 122.153 0.978 . . . . 0.0 111.532 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -153.11 177.81 10.41 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.063 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -145.44 143.44 30.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.311 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -135.24 117.04 15.09 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.423 HG11 ' CE2' ' H' ' 20' ' ' PHE . 70.2 t -126.87 134.03 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-O 120.872 0.368 . . . . 0.0 110.505 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.415 ' CZ ' ' HB2' ' H' ' 21' ' ' ALA . 45.7 t80 -124.74 122.71 38.24 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.392 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.423 ' CE2' HG11 ' H' ' 18' ' ' VAL . 61.0 m-85 -115.2 125.66 53.65 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.155 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . 0.415 ' HB2' ' CZ ' ' H' ' 19' ' ' PHE . . . -116.67 120.96 40.27 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-N 118.222 0.464 . . . . 0.0 110.911 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' H' ' 23' ' ' ASP . 81.6 tt0 -123.27 154.98 38.09 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.756 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.612 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 54.6 t0 49.38 114.22 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 CA-C-O 121.05 0.452 . . . . 0.0 110.715 -178.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.415 HG23 ' OD2' ' I' ' 23' ' ' ASP . 42.8 t . . . . . 0 C--N 1.314 -0.944 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.622 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.601 ' C ' HD12 ' H' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.397 -3.086 1 N-CA-C 95.715 -5.661 . . . . 0.0 95.715 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.965 HD12 ' N ' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -112.29 119.32 59.93 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 116.236 -2.186 . . . . 0.0 112.291 -178.403 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.692 HG23 HG13 ' I' ' 32' ' ' ILE . 5.5 tt -117.49 120.03 63.56 Favored 'Isoleucine or valine' 0 C--N 1.361 1.106 0 CA-C-N 114.34 -1.3 . . . . 0.0 110.445 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.536 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -114.77 116.9 3.89 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.518 HD22 ' O ' ' H' ' 33' ' ' GLY . 0.9 OUTLIER -124.18 125.84 45.13 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.681 0.753 . . . . 0.0 111.825 -179.367 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 7.3 ttt -105.92 110.03 22.18 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 114.37 -1.286 . . . . 0.0 108.577 178.049 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.43 HG11 ' CD2' ' J' ' 17' ' ' LEU . 0.0 OUTLIER -131.53 71.26 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.12 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.53 -97.13 0.03 OUTLIER Glycine 0 C--N 1.359 1.822 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.21 -166.26 38.68 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -124.39 139.9 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.869 0.366 . . . . 0.0 111.09 -178.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.597 179.831 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 22.3 t . . . . . 0 CA--C 1.521 -0.163 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.7 p80 -175.69 113.86 0.13 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.148 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 26.8 m-70 -82.19 165.9 20.09 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -148.34 173.01 13.5 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.279 0.562 . . . . 0.0 110.985 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -154.96 127.56 7.98 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.629 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.567 HD23 ' N ' ' I' ' 18' ' ' VAL . 0.9 OUTLIER -129.2 119.56 24.27 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.619 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.567 ' N ' HD23 ' I' ' 17' ' ' LEU . 48.1 t -125.94 128.94 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.934 0.397 . . . . 0.0 111.754 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -113.18 103.8 11.71 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -114.84 130.05 56.81 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 111.751 0.278 . . . . 0.0 111.751 -177.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.0 135.82 29.68 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 121.277 0.561 . . . . 0.0 111.402 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 tm-20 -148.07 118.88 7.57 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.587 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.612 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 16.7 m-20 -158.64 110.5 2.2 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.828 0.823 . . . . 0.0 112.224 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 50.5 t -48.16 133.97 5.36 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.497 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 99.3 86.03 1.87 Allowed Glycine 0 CA--C 1.54 1.636 0 N-CA-C 120.316 2.886 . . . . 0.0 120.316 171.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.4 p 153.01 169.87 0.01 OUTLIER 'General case' 0 C--N 1.347 0.498 0 CA-C-O 122.635 1.207 . . . . 0.0 112.346 169.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' I' ' 28' ' ' LYS . 1.4 m120 -59.03 177.63 0.15 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.343 -1.299 . . . . 0.0 111.363 177.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.505 ' O ' ' O ' ' I' ' 27' ' ' ASN . 63.3 tttt -43.64 -100.86 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.223 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.027 172.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.761 ' O ' ' O ' ' I' ' 30' ' ' ALA . . . -170.59 106.33 0.24 Allowed Glycine 1 CA--C 1.42 -5.858 0 C-N-CA 119.061 -1.542 . . . . 0.0 116.527 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.859 ' C ' HD12 ' I' ' 31' ' ' ILE 0.29 . . -0.46 -133.45 0.0 OUTLIER 'General case' 0 C--N 1.366 1.286 0 O-C-N 127.066 2.274 . . . . 0.0 108.333 170.579 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.859 HD12 ' C ' ' I' ' 30' ' ' ALA . 3.9 mp -122.52 132.82 70.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 117.269 2.322 . . . . 0.0 117.269 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.692 HG13 HG23 ' H' ' 32' ' ' ILE . 17.9 tt -116.27 120.8 65.99 Favored 'Isoleucine or valine' 0 C--N 1.371 1.531 0 CA-C-N 114.44 -1.255 . . . . 0.0 110.58 177.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.475 ' CA ' ' SD ' ' C' ' 35' ' ' MET . . . -102.77 112.19 4.21 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 107.157 -2.377 . . . . 0.0 107.157 177.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.859 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 32.8 tp -113.26 121.18 43.65 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-N 115.36 -0.42 . . . . 0.0 111.419 -177.339 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.513 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 19.1 ttt -118.69 112.56 19.94 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 176.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.594 HG11 HD13 ' K' ' 17' ' ' LEU . 0.1 OUTLIER -126.31 71.45 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.208 0 CA-C-N 117.729 0.24 . . . . 0.0 111.273 -178.126 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -50.11 -97.97 0.01 OUTLIER Glycine 0 C--N 1.353 1.5 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.405 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.14 -162.65 28.63 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.05 138.67 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 120.894 0.378 . . . . 0.0 110.703 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.481 179.679 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . 0.568 HG12 ' N ' ' J' ' 13' ' ' HIS . 60.0 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.058 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.568 ' N ' HG12 ' J' ' 12' ' ' VAL . 2.9 p80 -66.58 134.11 51.69 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.196 0.522 . . . . 0.0 111.841 -178.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.436 ' NE2' ' O ' ' K' ' 12' ' ' VAL . 52.7 m170 -112.83 172.17 7.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -141.55 176.44 8.88 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.333 0.587 . . . . 0.0 111.479 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -174.01 124.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.105 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG11 ' H' ' 36' ' ' VAL . 4.0 mp -133.85 132.35 40.28 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-O 121.303 0.573 . . . . 0.0 110.973 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.68 131.12 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.015 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.649 ' CD1' ' CZ ' ' K' ' 19' ' ' PHE . 20.1 m-85 -114.2 111.17 21.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.097 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -121.59 120.49 34.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.909 0.322 . . . . 0.0 110.155 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.51 132.64 29.67 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.136 0.494 . . . . 0.0 110.986 -179.603 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.478 ' C ' ' OD1' ' J' ' 23' ' ' ASP . 73.6 mt-10 -144.78 127.45 16.18 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 119.84 -0.744 . . . . 0.0 112.472 -179.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' I' ' 23' ' ' ASP . 3.9 m-20 -159.68 110.98 2.0 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 118.938 -1.105 . . . . 0.0 113.353 176.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.0 t -37.8 128.65 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.464 172.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.453 ' HA3' ' O ' ' I' ' 26' ' ' SER . . . 168.85 -83.64 0.09 OUTLIER Glycine 0 N--CA 1.467 0.709 0 C-N-CA 117.108 -2.472 . . . . 0.0 116.087 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.582 ' O ' ' O ' ' J' ' 27' ' ' ASN . 5.0 p -170.39 -178.55 2.75 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 118.825 -1.15 . . . . 0.0 113.081 -175.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.584 ' CG ' ' H ' ' J' ' 28' ' ' LYS . 63.6 t30 27.13 177.37 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 CA-C-N 112.113 -2.312 . . . . 0.0 115.565 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.584 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 96.7 mttt -119.71 -106.47 0.38 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 113.307 -1.769 . . . . 0.0 110.947 -176.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.93 ' C ' ' HB1' ' K' ' 30' ' ' ALA . . . -66.13 96.6 0.28 Allowed Glycine 0 CA--C 1.48 -2.141 0 CA-C-O 123.654 1.697 . . . . 0.0 112.643 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.628 ' O ' ' C ' ' J' ' 29' ' ' GLY . . . -80.38 -145.12 0.05 OUTLIER 'General case' 0 C--N 1.293 -1.885 1 N-CA-C 93.921 -6.326 . . . . 0.0 93.921 170.407 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.567 ' H ' HG13 ' I' ' 31' ' ' ILE . 4.8 mm -100.89 115.34 42.32 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 1 CA-C-N 127.987 4.903 . . . . 0.0 111.035 -179.249 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.628 HG22 HG23 ' K' ' 32' ' ' ILE . 0.6 OUTLIER -112.76 110.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.366 1.307 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.684 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.16 106.27 2.64 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.817 HD13 ' CE1' ' L' ' 19' ' ' PHE . 4.4 mt -104.78 106.87 17.55 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.684 ' CE ' HD11 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -106.09 113.2 26.59 Favored 'General case' 0 N--CA 1.444 -0.754 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 178.819 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.451 ' O ' HG23 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.39 79.6 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.085 -177.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.55 103.48 1.63 Allowed Glycine 0 C--N 1.349 1.258 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 177.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.34 145.08 16.7 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 63.0 t . . . . . 0 N--CA 1.466 0.364 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 -179.873 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 . . . . . 0 C--O 1.231 0.089 0 N-CA-C 110.289 -0.263 . . . . 0.0 110.289 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.436 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 8.8 m -150.58 145.75 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-O 121.408 0.623 . . . . 0.0 111.98 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.7 OUTLIER -119.3 116.13 25.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.202 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' L' ' 13' ' ' HIS . 70.6 t60 -122.61 165.99 15.58 Favored 'General case' 0 CA--C 1.509 -0.616 0 CA-C-O 121.403 0.621 . . . . 0.0 110.025 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.453 ' N ' ' CG ' ' K' ' 14' ' ' HIS . 47.5 tt0 -163.39 166.95 22.32 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.453 178.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' K' ' 15' ' ' GLN . 98.9 mttt -155.53 129.96 9.0 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.594 HD13 HG11 ' I' ' 36' ' ' VAL . 26.9 tp -124.51 120.53 32.27 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.518 HG11 ' CE2' ' K' ' 20' ' ' PHE . 57.9 t -132.94 127.03 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.935 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.859 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 6.8 m-85 -117.28 112.81 21.27 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.518 ' CE2' HG11 ' K' ' 18' ' ' VAL . 47.6 m-85 -108.12 118.57 37.1 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 178.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 132.86 36.93 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.772 0.714 . . . . 0.0 112.775 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -113.58 122.77 48.23 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.465 178.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -178.73 110.87 0.06 Allowed 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.244 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 m -107.05 -123.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 31.49 85.51 0.01 OUTLIER Glycine 0 C--N 1.342 0.9 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.009 -178.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 24.1 p -50.1 158.82 0.5 Allowed 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.398 0.618 . . . . 0.0 111.754 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' OD1' ' J' ' 27' ' ' ASN . 0.0 OUTLIER -148.06 176.92 9.8 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.881 -1.054 . . . . 0.0 109.137 176.952 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.531 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.8 mttt -9.16 -103.27 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.664 0.603 . . . . 0.0 111.278 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.73 97.0 0.18 Allowed Glycine 0 CA--C 1.5 -0.896 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 176.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.93 ' HB1' ' C ' ' J' ' 29' ' ' GLY . . . -66.2 172.17 4.09 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 177.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.661 ' N ' ' O ' ' J' ' 29' ' ' GLY . 0.4 OUTLIER -147.58 123.46 2.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 CA-C-N 120.996 1.726 . . . . 0.0 111.858 -175.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.628 HG23 HG22 ' J' ' 32' ' ' ILE . 91.1 mt -125.99 131.33 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.717 -1.128 . . . . 0.0 112.475 -178.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.71 119.96 3.17 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.626 HD23 ' N ' ' K' ' 35' ' ' MET . 5.5 tt -121.84 120.53 34.81 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 120.629 0.252 . . . . 0.0 110.765 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.626 ' N ' HD23 ' K' ' 34' ' ' LEU . 5.6 ppp? -130.49 130.24 43.94 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.436 0.636 . . . . 0.0 111.058 178.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.534 ' O ' ' C ' ' K' ' 37' ' ' GLY . 3.2 p -158.11 79.98 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.869 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.534 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -1.37 -100.89 0.0 OUTLIER Glycine 0 C--N 1.348 1.214 0 O-C-N 123.311 0.382 . . . . 0.0 113.615 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.45 -172.5 41.73 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--N 1.33 -0.245 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.847 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.616 0.246 . . . . 0.0 110.411 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' K' ' 14' ' ' HIS . 49.1 t-80 -90.45 176.68 6.62 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 27.5 t-80 -76.0 176.82 7.57 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.372 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.577 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 99.2 mm-40 -121.48 178.04 4.97 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.968 0.413 . . . . 0.0 111.004 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -165.98 113.48 0.92 Allowed 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.96 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 18.3 mt -128.71 124.92 36.85 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -140.1 135.03 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.817 ' CE1' HD13 ' J' ' 34' ' ' LEU . 7.3 m-85 -116.94 108.53 15.91 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 177.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -116.0 123.09 47.13 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-O 121.24 0.543 . . . . 0.0 110.867 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.68 134.01 45.47 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 81.0 tt0 -81.18 92.87 6.37 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.964 -0.694 . . . . 0.0 111.03 -178.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.585 ' O ' ' O ' ' L' ' 24' ' ' VAL . 70.7 m-20 -160.94 133.14 5.95 Favored 'General case' 0 C--O 1.226 -0.159 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.182 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.585 ' O ' ' O ' ' L' ' 23' ' ' ASP . 10.6 t -32.34 -110.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 124.003 0.815 . . . . 0.0 111.376 176.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -158.89 92.27 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.476 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 23.3 p -47.3 152.68 0.57 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.761 0.791 . . . . 0.0 111.443 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.488 ' O ' ' C ' ' L' ' 28' ' ' LYS . 31.8 m120 -157.42 -174.74 5.03 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.135 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 12.74 103.54 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 177.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.56 -101.48 0.81 Allowed Glycine 0 N--CA 1.47 0.961 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.5 171.48 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 117.287 0.543 . . . . 0.0 110.152 -178.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.652 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -141.42 148.56 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.854 -177.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.481 HG23 ' O ' ' L' ' 32' ' ' ILE . 18.7 tt -133.53 126.75 52.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-N 114.018 -1.447 . . . . 0.0 109.191 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.17 119.44 4.38 Favored Glycine 0 N--CA 1.466 0.657 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 16.6 tp -126.09 120.75 31.01 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.857 0.328 . . . . 0.0 110.179 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.528 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.7 ppp? -132.86 133.06 42.81 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.872 0.844 . . . . 0.0 111.16 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 23.1 t -142.98 82.61 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.412 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' K' ' 37' ' ' GLY . . . -66.26 101.22 0.59 Allowed Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.31 168.58 35.93 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -129.53 160.03 40.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.884 0.373 . . . . 0.0 110.507 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.425 179.983 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 . . . . . 0 N--CA 1.463 0.195 0 CA-C-O 121.128 0.49 . . . . 0.0 111.337 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 13' ' ' HIS . 45.8 t -133.3 158.42 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.409 ' N ' HG12 ' A' ' 12' ' ' VAL . 79.2 m80 -142.44 134.28 27.01 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 120.539 -0.464 . . . . 0.0 111.384 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -155.11 166.87 32.22 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.368 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -155.83 175.73 13.55 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.898 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -153.37 115.57 4.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.926 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.92 121.63 23.13 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.06 0.457 . . . . 0.0 110.67 178.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.54 131.38 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 115.778 -0.647 . . . . 0.0 109.713 179.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -126.56 130.37 50.41 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.826 0.346 . . . . 0.0 110.627 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -126.24 126.92 44.81 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 133.03 46.65 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 121.017 0.437 . . . . 0.0 111.87 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -150.53 117.33 5.85 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.187 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 . . . . . 0 N--CA 1.47 0.56 0 CA-C-O 121.485 0.659 . . . . 0.0 111.928 -179.968 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.515 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 18.3 pttp . . . . . 0 CA--C 1.529 0.159 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.24 101.39 0.74 Allowed Glycine 0 CA--C 1.503 -0.674 0 N-CA-C 106.849 -2.5 . . . . 0.0 106.849 176.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.96 153.94 23.63 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 117.117 -1.833 . . . . 0.0 110.535 -175.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.407 HG22 ' HE3' ' H' ' 35' ' ' MET . 0.4 OUTLIER -146.34 115.59 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.498 -173.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 32' ' ' ILE . 11.6 tt -127.55 108.78 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.24 122.61 4.69 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.656 ' O ' HD12 ' B' ' 34' ' ' LEU . 0.9 OUTLIER -178.13 -162.58 0.06 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 122.349 1.071 . . . . 0.0 111.228 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.462 ' SD ' ' HB ' ' H' ' 31' ' ' ILE . 1.1 ttp -149.89 157.6 43.34 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -111.71 75.68 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 C-N-CA 120.507 -0.477 . . . . 0.0 109.811 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.5 103.42 3.0 Favored Glycine 0 C--N 1.357 1.745 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.46 -172.1 47.54 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -132.93 161.68 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.048 0.451 . . . . 0.0 110.864 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.865 -1.064 . . . . 0.0 110.662 -179.951 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -147.8 157.82 43.73 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.686 0.279 . . . . 0.0 110.682 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 150.68 31.32 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.314 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.418 HG22 ' N ' ' B' ' 13' ' ' HIS . 3.0 p -137.47 155.84 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.794 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.418 ' N ' HG22 ' B' ' 12' ' ' VAL . 5.7 m-70 -128.31 142.46 51.13 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -143.2 169.56 17.38 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -162.2 166.63 25.3 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.762 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -154.48 111.43 3.34 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 179.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 73.2 mt -121.84 117.49 26.65 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -131.13 129.03 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.338 0.59 . . . . 0.0 112.034 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -122.28 127.37 49.8 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.124 178.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.3 t80 -130.65 125.5 34.17 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.708 0.289 . . . . 0.0 110.949 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.97 129.71 42.47 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.868 0.366 . . . . 0.0 110.504 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -157.76 135.59 10.68 Favored 'General case' 0 C--O 1.226 -0.17 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.515 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 0.5 OUTLIER . . . . . 0 CA--C 1.53 0.21 0 C-N-CA 120.724 -0.391 . . . . 0.0 111.218 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.487 -1.699 0 N-CA-C 106.605 -2.598 . . . . 0.0 106.605 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' B' ' 31' ' ' ILE . . . -91.08 149.14 21.94 Favored 'General case' 0 CA--C 1.498 -1.046 0 C-N-CA 115.357 -2.537 . . . . 0.0 106.434 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.614 HG23 HD12 ' C' ' 31' ' ' ILE . 2.6 mt -148.74 106.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 114.284 -1.326 . . . . 0.0 107.836 -174.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.426 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.7 tt -116.15 123.18 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-O 121.638 0.732 . . . . 0.0 110.955 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.727 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -116.53 115.31 3.27 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 106.008 -2.837 . . . . 0.0 106.008 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.656 HD12 ' O ' ' A' ' 34' ' ' LEU . 5.9 tp -144.12 144.33 31.54 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 -175.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.644 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 32.3 ttp -129.18 129.63 45.32 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.159 -1.382 . . . . 0.0 108.411 175.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -111.89 78.2 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.017 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.247 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.632 ' HA3' HG21 ' H' ' 31' ' ' ILE . . . -74.36 104.59 1.69 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.23 -179.14 36.84 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.751 -178.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -141.37 149.87 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.675 -179.851 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 66.1 t . . . . . 0 N--CA 1.467 0.403 0 CA-C-O 120.944 0.402 . . . . 0.0 110.449 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 60.2 m80 -128.87 138.73 52.2 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.363 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 82.8 t60 -155.37 164.85 38.18 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 94.5 mt-30 -155.44 -179.36 8.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.308 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.05 112.97 1.01 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.53 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 67.8 tp -120.28 121.84 39.56 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.804 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -132.69 126.34 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -179.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -118.46 123.8 46.05 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 177.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.628 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 43.5 t80 -130.09 127.85 40.68 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.764 0.316 . . . . 0.0 111.373 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.48 138.97 45.14 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.299 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -143.82 151.81 40.4 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.408 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 16.7 t70 . . . . . 0 N--CA 1.466 0.359 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.673 178.79 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.622 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.54 153.64 44.99 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 173.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.614 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -150.3 116.88 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 118.979 -1.089 . . . . 0.0 111.305 -172.367 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.732 HD11 HD12 ' D' ' 32' ' ' ILE . 1.6 pt -119.15 115.88 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 176.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.681 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -126.14 118.45 3.13 Favored Glycine 0 CA--C 1.501 -0.836 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -161.56 169.31 21.95 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 118.072 -1.451 . . . . 0.0 111.968 -177.513 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.419 ' HE3' ' O ' ' I' ' 32' ' ' ILE . 5.6 tmm? -141.37 137.26 32.18 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 113.538 -1.665 . . . . 0.0 109.654 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.04 73.09 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.564 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.75 103.84 3.02 Favored Glycine 0 C--N 1.37 2.437 0 N-CA-C 111.419 -0.673 . . . . 0.0 111.419 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.58 154.58 18.63 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -135.38 163.29 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.395 -179.889 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' E' ' 12' ' ' VAL . 53.7 t . . . . . 0 N--CA 1.463 0.21 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' E' ' 13' ' ' HIS . 23.1 p80 -155.01 158.84 39.76 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 119.035 -1.066 . . . . 0.0 112.841 -178.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.512 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 51.5 m-70 -147.27 169.62 19.02 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.016 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.512 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 97.4 mm-40 -148.9 168.82 22.0 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.154 179.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -153.31 106.97 3.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.995 179.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 51.7 mt -118.5 116.79 27.39 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.27 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -130.24 128.16 63.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.55 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 47.1 m-85 -121.02 111.8 17.93 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 177.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -120.21 132.1 55.23 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 118.251 0.478 . . . . 0.0 111.919 -178.587 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 122.31 24.79 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.51 0.671 . . . . 0.0 111.176 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.447 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 80.9 tt0 -111.18 89.82 3.16 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.071 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.457 ' OD1' ' N ' ' D' ' 23' ' ' ASP . 4.9 p30 . . . . . 0 C--N 1.322 -0.59 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.446 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.753 ' C ' HD12 ' D' ' 31' ' ' ILE . . . . . . . . 0 N--CA 1.412 -2.33 0 N-CA-C 100.355 -3.943 . . . . 0.0 100.355 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.753 HD12 ' C ' ' D' ' 30' ' ' ALA . 4.6 mp -131.99 134.58 59.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 115.074 -2.65 . . . . 0.0 117.751 -174.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.732 HD12 HD11 ' C' ' 32' ' ' ILE . 11.9 tt -126.77 123.91 63.83 Favored 'Isoleucine or valine' 0 C--N 1.367 1.334 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.459 177.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.655 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -124.18 106.22 0.94 Allowed Glycine 0 C--O 1.237 0.29 0 N-CA-C 106.882 -2.487 . . . . 0.0 106.882 176.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.553 HD23 ' C ' ' D' ' 34' ' ' LEU . 10.0 tt -126.72 132.95 51.0 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-O 122.039 0.923 . . . . 0.0 112.431 -177.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.541 ' SD ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -122.1 126.66 48.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 114.32 -1.309 . . . . 0.0 109.865 178.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.498 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.3 79.77 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.49 -178.182 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -25.8 -95.74 0.01 OUTLIER Glycine 0 C--N 1.358 1.759 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.89 -162.03 29.25 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.583 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 40' ' ' VAL . 56.0 t -115.2 136.06 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.932 0.396 . . . . 0.0 110.266 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 39' ' ' VAL . 70.9 t . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.445 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -109.11 136.13 49.11 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 110.463 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.521 ' OE2' ' NE2' ' E' ' 13' ' ' HIS . 81.4 tt0 -64.69 136.27 56.77 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.645 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' D' ' 12' ' ' VAL . 9.4 p -131.91 134.6 59.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-O 121.959 0.885 . . . . 0.0 112.596 -179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' D' ' 13' ' ' HIS . 46.8 m170 -121.17 138.88 54.0 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 114.066 -1.425 . . . . 0.0 108.559 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.572 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.4 t60 -152.47 171.49 18.0 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 121.61 0.719 . . . . 0.0 110.742 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 53.6 tt0 -154.01 173.27 16.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.774 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 87.7 tttt -168.57 113.34 0.61 Allowed 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.568 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 tt -123.65 123.44 40.56 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.98 122.3 45.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.222 0.534 . . . . 0.0 112.173 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' D' ' 19' ' ' PHE . 7.5 m-85 -113.88 117.54 31.69 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 90.4 t80 -124.58 131.94 53.46 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.27 145.94 28.4 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 179.287 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.42 128.47 44.81 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.802 -0.635 . . . . 0.0 111.18 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' O ' ' F' ' 22' ' ' GLU . 67.3 t0 -147.1 112.33 5.51 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.238 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.756 HG13 ' H ' ' E' ' 25' ' ' GLY . 12.1 p -101.8 -121.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.248 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.756 ' H ' HG13 ' E' ' 24' ' ' VAL . . . 34.2 -84.93 0.01 OUTLIER Glycine 0 N--CA 1.473 1.143 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -177.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.572 ' N ' ' O ' ' E' ' 24' ' ' VAL . 1.4 p . . . . . 0 N--CA 1.447 -0.582 0 CA-C-O 121.673 0.749 . . . . 0.0 109.913 175.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.474 -1.947 0 CA-C-O 122.451 1.12 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.754 HG21 ' HA3' ' K' ' 37' ' ' GLY . 0.6 OUTLIER -151.49 137.54 11.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 112.477 -2.147 . . . . 0.0 112.041 -171.693 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 1.031 HD13 HG22 ' F' ' 32' ' ' ILE . 2.8 mp -122.41 118.01 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 114.275 -1.33 . . . . 0.0 110.35 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -120.2 116.29 3.2 Favored Glycine 0 N--CA 1.476 1.32 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 178.338 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.754 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 39.6 mt -119.36 117.39 28.38 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -120.27 126.35 50.36 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.08 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.447 ' O ' HG23 ' F' ' 36' ' ' VAL . 2.6 t -115.44 89.1 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.01 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.716 ' HA3' HG21 ' K' ' 31' ' ' ILE . . . -69.3 94.69 0.4 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.22 -171.79 18.73 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -178.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -132.73 161.81 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.654 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 C--O 1.221 -0.423 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.753 -179.942 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -103.33 129.75 50.45 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.004 0.43 . . . . 0.0 110.47 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -92.9 145.58 24.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.856 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 t -105.85 130.04 57.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.133 0.492 . . . . 0.0 110.689 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 14.5 t60 -154.19 139.7 17.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -149.74 170.61 18.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.427 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 50.8 tt0 -155.09 171.15 20.25 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.525 -0.762 . . . . 0.0 109.591 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' F' ' 17' ' ' LEU . 62.1 tttm -170.08 106.39 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.156 -0.617 . . . . 0.0 111.676 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' F' ' 16' ' ' LYS . 6.1 mp -117.42 125.47 51.01 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.1 141.44 16.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 96.4 m-85 -117.0 122.0 42.97 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 113.637 -1.62 . . . . 0.0 107.377 177.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . 0.4 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 47.7 m-85 -127.04 142.29 51.57 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 121.749 0.785 . . . . 0.0 111.317 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.25 146.5 23.82 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.54 178.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.476 ' O ' ' O ' ' E' ' 23' ' ' ASP . 97.6 mt-10 -89.48 98.86 12.01 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.845 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' F' ' 24' ' ' VAL . 6.2 t70 -120.47 110.87 17.01 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 120.601 0.238 . . . . 0.0 110.758 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.6 m -60.42 -133.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.696 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' F' ' 26' ' ' SER . . . -76.91 85.72 0.99 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 119.784 -0.453 . . . . 0.0 112.797 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' F' ' 25' ' ' GLY . 5.9 p -34.97 170.09 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.144 0 CA-C-O 121.191 0.52 . . . . 0.0 111.292 178.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' F' ' 28' ' ' LYS . 8.0 t-20 -140.19 -178.96 5.71 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.151 177.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 62.8 mttp 26.37 -107.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.003 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.39 94.46 0.15 Allowed Glycine 0 C--N 1.338 0.674 0 CA-C-O 119.269 -0.74 . . . . 0.0 111.988 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.403 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -67.4 178.99 1.38 Allowed 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 103.876 -2.639 . . . . 0.0 103.876 174.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.533 HD13 ' N ' ' L' ' 38' ' ' GLY . 0.2 OUTLIER -146.87 118.79 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-N 121.651 2.023 . . . . 0.0 111.03 -178.763 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 1.031 HG22 HD13 ' E' ' 32' ' ' ILE . 45.9 pt -118.56 140.91 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.462 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -145.05 125.14 2.29 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 178.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 4.9 mp -116.88 127.86 54.68 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.473 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 2.9 tmm? -129.16 127.97 42.47 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 121.564 0.697 . . . . 0.0 112.876 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.473 ' N ' ' SD ' ' F' ' 35' ' ' MET . 3.6 p -156.15 82.02 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.719 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.233 179.079 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.447 ' O ' HD13 ' L' ' 31' ' ' ILE . . . -71.23 101.39 0.96 Allowed Glycine 0 CA--C 1.53 0.988 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.475 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -144.04 165.01 27.45 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -119.6 135.96 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.024 0.44 . . . . 0.0 110.331 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.728 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.514 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 81.5 t60 . . . . . 0 N--CA 1.465 0.307 0 CA-C-O 120.863 0.364 . . . . 0.0 110.609 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.514 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 8.1 p-80 -96.81 172.25 8.0 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.099 0.476 . . . . 0.0 109.804 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -148.4 177.52 9.37 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.054 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -143.95 145.82 32.52 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.97 115.43 18.52 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.613 0.72 . . . . 0.0 110.306 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -125.82 121.98 61.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.127 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -153.24 158.23 41.38 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.611 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -132.56 150.16 52.2 Favored 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.415 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.6 135.1 44.03 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.86 0.838 . . . . 0.0 112.283 -179.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -143.38 151.9 40.96 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.802 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.509 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 57.5 t0 60.68 114.91 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.261 0.553 . . . . 0.0 111.965 179.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.556 ' O ' ' O ' ' G' ' 26' ' ' SER . 0.3 OUTLIER -147.32 112.81 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.524 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 36.82 -91.35 0.01 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.383 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.556 ' O ' ' O ' ' G' ' 24' ' ' VAL . 10.8 p -89.33 -178.86 5.72 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 33.1 m-80 -60.31 166.05 3.21 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 115.87 -2.332 . . . . 0.0 107.564 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.558 ' NZ ' ' O ' ' I' ' 23' ' ' ASP . 29.6 tttm -53.69 107.35 0.25 Allowed 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 118.365 -1.334 . . . . 0.0 113.734 -177.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.51 100.81 2.71 Favored Glycine 0 N--CA 1.469 0.854 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 169.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 148.09 28.66 Favored 'General case' 0 C--O 1.248 0.985 1 CA-C-N 125.131 4.465 . . . . 0.0 109.378 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -162.71 107.36 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 112.47 -2.15 . . . . 0.0 106.96 -175.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.42 ' O ' ' O ' ' H' ' 33' ' ' GLY . 42.7 mm -108.8 104.73 17.54 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 C-N-CA 119.074 -1.051 . . . . 0.0 108.673 177.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.54 100.08 1.38 Allowed Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 104.336 -3.506 . . . . 0.0 104.336 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tp -147.32 149.07 32.11 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 123.321 1.534 . . . . 0.0 112.948 -177.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -111.92 135.61 52.33 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 112.476 -2.147 . . . . 0.0 110.579 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -135.54 66.4 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.11 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . 0.409 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -53.1 -103.06 0.01 OUTLIER Glycine 0 C--N 1.358 1.783 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.55 -177.89 47.93 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p . . . . . 0 N--CA 1.468 0.431 0 CA-C-O 121.013 0.435 . . . . 0.0 110.729 -179.446 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 51.6 t . . . . . 0 N--CA 1.464 0.259 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.643 ' NE2' ' CD2' ' I' ' 13' ' ' HIS . 19.3 p80 -167.96 156.65 9.23 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.568 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -144.44 170.4 16.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -144.97 172.51 12.94 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.951 0.405 . . . . 0.0 110.671 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -176.13 126.02 0.2 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.664 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -136.38 122.54 20.37 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.665 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 34.2 m -123.79 129.45 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 121.352 0.596 . . . . 0.0 110.344 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . 0.426 ' N ' ' CD1' ' H' ' 19' ' ' PHE . 5.0 m-85 -113.11 116.39 29.79 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.847 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -110.65 117.53 33.75 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.02 129.84 51.59 Favored 'General case' 0 N--CA 1.475 0.814 0 O-C-N 121.269 -0.895 . . . . 0.0 112.884 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -171.08 145.28 2.24 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.549 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.509 ' CB ' ' H ' ' G' ' 23' ' ' ASP . 29.7 t70 -172.0 105.97 0.2 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.942 1.46 . . . . 0.0 114.942 178.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' H' ' 23' ' ' ASP . 58.5 t . . . . . 0 N--CA 1.476 0.875 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.303 173.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.255 1.379 0 CA-C-O 124.038 1.875 . . . . 0.0 112.777 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.632 HG21 ' HA3' ' B' ' 37' ' ' GLY . 0.8 OUTLIER -152.95 128.27 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 111.519 -2.582 . . . . 0.0 109.797 -177.427 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.55 HG21 HD12 ' I' ' 32' ' ' ILE . 2.1 tt -119.45 116.12 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -121.28 115.17 2.77 Favored Glycine 0 C--O 1.24 0.526 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.921 ' O ' HD12 ' I' ' 34' ' ' LEU . 0.5 OUTLIER -138.23 150.75 47.01 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 122.971 1.367 . . . . 0.0 112.924 -178.251 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.727 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 34.1 ttp -121.65 127.1 50.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.065 -1.425 . . . . 0.0 109.765 178.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.494 ' CG2' HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -132.15 72.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 120.619 -0.433 . . . . 0.0 110.035 179.515 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . 0.421 ' HA3' HG21 ' B' ' 31' ' ' ILE . . . -75.98 110.58 3.08 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.75 163.44 8.07 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.5 m -137.66 159.33 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.077 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.697 -179.781 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.473 ' C ' ' ND1' ' I' ' 13' ' ' HIS . 27.1 m . . . . . 0 N--CA 1.469 0.512 0 CA-C-O 121.339 0.59 . . . . 0.0 110.869 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.643 ' CD2' ' NE2' ' H' ' 13' ' ' HIS . 12.9 m80 -139.78 140.92 36.79 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.185 -178.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' I' ' 15' ' ' GLN . 59.4 t-80 -153.48 162.12 41.58 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 178.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.592 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 49.8 tt0 -162.17 172.24 16.11 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.376 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.451 ' N ' ' CG ' ' I' ' 15' ' ' GLN . 88.0 tttt -172.59 128.65 0.53 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.734 179.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.692 HD22 ' CE1' ' I' ' 19' ' ' PHE . 3.5 tt -130.27 121.47 26.18 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.66 ' N ' HD23 ' I' ' 17' ' ' LEU . 39.6 t -120.34 126.53 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 122.256 -0.277 . . . . 0.0 111.709 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.692 ' CE1' HD22 ' I' ' 17' ' ' LEU . 73.3 m-85 -103.98 101.26 11.04 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 176.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -113.27 117.85 33.01 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.22 124.87 35.61 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.442 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 14.4 pt-20 -127.09 75.41 1.58 Allowed 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.707 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.558 ' O ' ' NZ ' ' G' ' 28' ' ' LYS . 0.0 OUTLIER 164.03 115.0 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 114.198 -1.364 . . . . 0.0 109.872 176.158 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.498 ' H ' ' HB2' ' J' ' 23' ' ' ASP . 39.5 t -148.57 107.47 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 118.976 -1.089 . . . . 0.0 108.726 173.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.455 ' O ' ' O ' ' I' ' 24' ' ' VAL . . . -39.62 -93.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.406 0 CA-C-O 123.984 1.88 . . . . 0.0 109.929 171.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.408 ' O ' ' O ' ' I' ' 25' ' ' GLY . 79.5 p 47.28 -178.59 0.01 OUTLIER 'General case' 0 CA--C 1.481 -1.703 0 CA-C-N 110.276 -2.962 . . . . 0.0 111.025 177.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' I' ' 28' ' ' LYS . 29.4 m120 -126.47 164.4 21.22 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.25 -1.795 . . . . 0.0 107.292 172.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' I' ' 27' ' ' ASN 0.263 45.1 mttm -27.85 112.56 0.06 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 114.984 1.476 . . . . 0.0 114.984 174.809 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.467 ' HA2' ' HB2' ' J' ' 30' ' ' ALA . . . 103.35 92.64 2.24 Favored Glycine 0 N--CA 1.48 1.577 0 C-N-CA 124.602 1.096 . . . . 0.0 115.169 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.498 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -87.64 179.71 6.47 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 173.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.49 ' HB ' HG22 ' H' ' 31' ' ' ILE . 0.4 OUTLIER -141.83 124.65 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 C-N-CA 116.517 -2.073 . . . . 0.0 111.471 -176.902 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.55 HD12 HG21 ' H' ' 32' ' ' ILE . 9.1 tt -125.89 127.24 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.213 0.53 . . . . 0.0 111.778 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . 0.644 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.81 117.46 3.04 Favored Glycine 0 C--O 1.24 0.482 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.921 HD12 ' O ' ' H' ' 34' ' ' LEU . 16.9 tp -137.84 135.36 36.13 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-O 121.611 0.719 . . . . 0.0 111.744 -178.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.681 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 54.9 ttp -105.21 125.3 50.83 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.75 176.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.79 72.09 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.135 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.58 111.3 3.5 Favored Glycine 0 C--N 1.364 2.128 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 177.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -71.99 160.51 54.07 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -136.79 162.01 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.805 0.336 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.552 -179.879 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 N--CA 1.468 0.451 0 CA-C-O 121.268 0.556 . . . . 0.0 111.416 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 68.9 m80 -139.11 134.74 33.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.675 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . 0.642 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 4.8 t60 -148.56 158.11 43.91 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.759 0.79 . . . . 0.0 110.464 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.642 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 83.2 mt-30 -150.59 174.46 12.95 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.546 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 54.0 tttp -175.82 127.3 0.23 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.193 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -130.4 129.96 43.73 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' K' ' 18' ' ' VAL . 1.4 p -144.99 140.62 23.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -178.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.6 OUTLIER -114.26 120.37 40.2 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.69 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.72 117.53 29.16 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.44 120.34 36.54 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 121.487 0.66 . . . . 0.0 111.653 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -159.69 104.45 1.58 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.498 ' HB2' ' H ' ' I' ' 24' ' ' VAL . 60.2 t0 -82.93 -133.52 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 175.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.54 ' O ' ' O ' ' J' ' 25' ' ' GLY . 21.9 t -92.2 112.17 25.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 N-CA-C 101.05 -3.685 . . . . 0.0 101.05 172.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . 0.54 ' O ' ' O ' ' J' ' 24' ' ' VAL . . . 42.38 90.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.01 -2.436 . . . . 0.0 107.01 -173.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.547 ' CB ' ' O ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -61.65 -179.82 0.2 Allowed 'General case' 0 N--CA 1.438 -1.034 0 C-N-CA 118.784 -1.167 . . . . 0.0 109.638 -174.865 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.466 ' N ' ' OG ' ' J' ' 26' ' ' SER . 1.6 m-20 -80.48 173.61 12.43 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 116.825 2.157 . . . . 0.0 116.825 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.552 ' O ' ' N ' ' J' ' 30' ' ' ALA 0.369 48.2 tttp -48.06 111.81 0.49 Allowed 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 109.221 -3.627 . . . . 0.0 116.782 173.499 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -68.34 99.19 0.56 Allowed Glycine 1 CA--C 1.446 -4.275 2 CA-C-O 128.699 4.5 . . . . 0.0 102.799 -176.331 . . . . . . . . 4 3 . 1 . 007 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.783 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -77.08 -132.78 0.01 OUTLIER 'General case' 1 N--CA 1.339 -6.005 3 CA-C-N 97.435 -9.383 . . . . 0.0 107.55 -167.012 . . . . . . . . 4 3 . 1 . 007 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.861 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -90.02 108.94 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.692 0 CA-C-N 114.57 -1.195 . . . . 0.0 110.467 -175.592 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.541 ' O ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -106.58 111.05 33.78 Favored 'Isoleucine or valine' 0 C--N 1.363 1.169 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.699 179.486 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.89 103.85 1.67 Allowed Glycine 0 CA--C 1.505 -0.545 0 N-CA-C 107.819 -2.112 . . . . 0.0 107.819 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.58 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 66.9 mt -126.03 121.72 33.8 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.951 0.881 . . . . 0.0 112.514 -177.253 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 6.1 ttt -102.94 120.37 40.51 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 114.252 -1.34 . . . . 0.0 108.391 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.478 ' HB ' HG22 ' K' ' 36' ' ' VAL . 3.6 t -137.23 66.86 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.327 -178.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.28 -102.63 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.13 154.88 30.65 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 50.5 t . . . . . 0 N--CA 1.465 0.289 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.495 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 . . . . . 0 N--CA 1.464 0.237 0 CA-C-O 120.878 0.37 . . . . 0.0 111.347 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.44 HG13 ' ND1' ' L' ' 13' ' ' HIS . 74.1 t -126.58 134.72 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' L' ' 13' ' ' HIS . 44.3 t60 -116.41 123.48 47.64 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 117.845 0.293 . . . . 0.0 111.309 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -114.86 158.95 21.23 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.418 ' O ' ' CG ' ' K' ' 16' ' ' LYS . 53.4 tt0 -170.05 161.58 8.71 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.226 177.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 95.5 mttt -163.03 132.23 4.12 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.416 HD23 HD13 ' L' ' 17' ' ' LEU . 15.5 tp -122.9 119.21 29.81 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 96.6 t -136.42 133.74 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.604 ' CZ ' ' CD2' ' L' ' 19' ' ' PHE . 23.4 p90 -145.62 130.4 18.1 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.296 177.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.638 ' N ' ' CD1' ' K' ' 20' ' ' PHE . 0.0 OUTLIER -149.35 163.77 36.78 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -178.475 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 141.67 38.89 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.328 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . 0.547 ' O ' ' CB ' ' J' ' 26' ' ' SER . 78.1 tt0 -89.71 156.59 18.45 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -178.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.52 ' OD2' ' N ' ' J' ' 28' ' ' LYS . 58.6 t0 176.11 130.79 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 123.465 0.706 . . . . 0.0 110.522 178.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.456 HG23 ' H ' ' K' ' 25' ' ' GLY . 5.3 m -87.53 -112.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.084 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 26' ' ' SER . . . -48.75 92.11 0.01 OUTLIER Glycine 0 CA--C 1.531 1.062 0 N-CA-C 114.838 0.695 . . . . 0.0 114.838 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.53 ' O ' ' O ' ' K' ' 25' ' ' GLY . 8.6 t -35.46 170.32 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.611 0.719 . . . . 0.0 111.368 176.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.481 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER -139.22 -177.15 4.78 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.946 177.751 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . 0.481 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 98.9 mttt -17.84 -104.87 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 113.242 0.83 . . . . 0.0 113.242 -178.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.552 ' HA2' ' HB2' ' L' ' 30' ' ' ALA . . . -150.44 95.34 0.16 Allowed Glycine 0 C--N 1.346 1.089 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.692 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.575 ' C ' HD13 ' K' ' 31' ' ' ILE . . . -67.82 -173.13 0.32 Allowed 'General case' 0 C--O 1.237 0.444 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 175.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.716 HG21 ' HA3' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -144.77 130.03 14.06 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-O 122.212 1.006 . . . . 0.0 110.22 -179.465 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 11.1 mm -114.84 122.5 69.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 114.164 -1.38 . . . . 0.0 110.485 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.482 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -127.98 119.72 3.22 Favored Glycine 0 N--CA 1.473 1.121 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.722 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -129.39 122.25 29.05 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 114.524 -0.838 . . . . 0.0 110.211 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 38.8 ttp -105.96 119.62 39.64 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.88 178.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.702 HG12 ' O ' ' K' ' 36' ' ' VAL . 54.7 t -139.8 71.06 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 119.415 -0.326 . . . . 0.0 110.53 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.754 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -53.88 -97.87 0.01 OUTLIER Glycine 0 C--N 1.342 0.897 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.32 163.83 35.86 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 m . . . . . 0 C--N 1.328 -0.361 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.626 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.466 0.351 0 N-CA-C 110.405 -0.22 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.44 ' ND1' HG13 ' K' ' 12' ' ' VAL . 15.5 m80 -81.58 145.95 30.37 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.191 0.52 . . . . 0.0 111.047 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -83.45 177.78 8.31 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.196 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -110.73 178.69 4.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.813 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -146.24 140.85 26.83 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.045 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.416 HD13 HD23 ' K' ' 17' ' ' LEU . 28.6 tp -125.33 119.99 29.89 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 7.3 t -141.45 131.9 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.643 0.735 . . . . 0.0 112.026 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.604 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 8.0 p90 -147.5 144.58 28.66 Favored 'General case' 0 C--N 1.322 -0.597 0 O-C-N 121.363 -0.835 . . . . 0.0 110.926 178.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' L' ' 19' ' ' PHE . 60.2 m-85 -157.77 157.35 33.21 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.52 1.152 . . . . 0.0 113.958 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.35 139.42 52.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.868 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -74.48 101.71 4.24 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.786 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 35.6 p-10 -171.4 113.76 0.37 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.778 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' L' ' 26' ' ' SER . 73.7 t -64.99 131.71 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.861 -178.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.51 83.76 0.01 OUTLIER Glycine 0 N--CA 1.466 0.655 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.518 ' N ' ' O ' ' L' ' 24' ' ' VAL . 15.4 m -67.52 -171.1 0.17 Allowed 'General case' 0 N--CA 1.437 -1.124 0 CA-C-O 122.541 1.163 . . . . 0.0 112.488 -177.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 54.3 t30 -80.51 179.39 7.76 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.788 -177.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.4 mttt -36.41 104.4 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.577 -178.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 168.09 -100.36 0.16 Allowed Glycine 0 C--O 1.22 -0.774 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.552 ' HB2' ' HA2' ' K' ' 29' ' ' GLY . . . -51.35 172.13 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.682 1.741 . . . . 0.0 108.054 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.447 HD13 ' O ' ' F' ' 37' ' ' GLY . 0.1 OUTLIER -152.53 149.41 13.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 C-N-CA 118.144 -1.423 . . . . 0.0 111.253 -176.44 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . 0.403 HG21 HD13 ' L' ' 32' ' ' ILE . 38.5 pt -125.89 143.63 38.77 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.153 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.27 114.73 1.51 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.6 mt -119.09 120.31 36.77 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttp -111.75 123.99 51.39 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 120.204 -0.599 . . . . 0.0 111.47 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' L' ' 37' ' ' GLY . 4.9 t -133.91 69.68 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.465 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -27.17 -105.69 0.0 OUTLIER Glycine 0 CA--C 1.533 1.187 0 CA-C-O 121.344 0.413 . . . . 0.0 114.064 -179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . 0.533 ' N ' HD13 ' F' ' 31' ' ' ILE . . . -38.09 156.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 115.312 -0.444 . . . . 0.0 112.459 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.79 159.32 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.189 -0.505 . . . . 0.0 110.06 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.828 -179.721 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.873 0.368 . . . . 0.0 110.197 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.447 HG11 ' ND1' ' B' ' 13' ' ' HIS . 9.9 p -146.15 146.93 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.729 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 14' ' ' HIS . 37.5 p-80 -91.12 -178.63 5.22 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.451 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 13' ' ' HIS . 24.8 m-70 -74.26 172.5 11.72 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -145.36 176.73 9.35 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.504 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -150.01 112.09 4.61 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.26 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -124.45 115.46 20.95 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 121.424 0.631 . . . . 0.0 110.261 179.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -123.6 128.96 74.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.403 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -128.76 124.13 34.7 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.9 p90 -128.04 125.63 39.71 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.94 0.4 . . . . 0.0 110.253 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.12 119.03 35.04 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -164.2 120.27 1.59 Allowed 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 38.7 t0 . . . . . 0 C--N 1.322 -0.619 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.561 -178.923 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.471 ' CB ' ' OD2' ' B' ' 23' ' ' ASP 0.442 74.5 tttt . . . . . 0 CA--C 1.538 0.495 0 CA-C-O 121.133 0.492 . . . . 0.0 111.576 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.66 104.03 1.23 Allowed Glycine 0 C--N 1.302 -1.317 0 CA-C-O 127.334 3.741 . . . . 0.0 112.02 -169.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.545 ' O ' ' N ' ' A' ' 32' ' ' ILE . . . -69.81 -122.2 0.0 OUTLIER 'General case' 0 CA--C 1.479 -1.778 3 CA-C-N 103.478 -6.361 . . . . 0.0 96.052 -179.563 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.818 ' O ' HD13 ' A' ' 31' ' ' ILE . 0.0 OUTLIER -51.16 99.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.587 2.401 0 CA-C-N 124.89 3.495 . . . . 0.0 107.895 175.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' ALA . 4.9 tt -128.78 113.44 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 119.419 -2.051 . . . . 0.0 109.387 178.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' B' ' 33' ' ' GLY . . . -129.36 126.06 5.04 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 106.617 -2.593 . . . . 0.0 106.617 178.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . 0.498 ' H ' ' HG ' ' B' ' 34' ' ' LEU . 36.8 tp -133.67 135.22 43.96 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 122.529 1.157 . . . . 0.0 111.641 -178.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.409 ' HE1' ' O ' ' H' ' 31' ' ' ILE . 12.5 ttm -104.66 110.54 22.9 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 113.752 -1.567 . . . . 0.0 107.198 177.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.15 72.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.7 110.83 3.12 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.15 165.74 11.95 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -95.01 135.98 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 110.711 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.432 HG23 ' H ' ' A' ' 40' ' ' VAL . 11.5 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.62 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -102.92 134.93 45.52 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -141.21 130.35 23.42 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.952 0.406 . . . . 0.0 110.834 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.17 146.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.627 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.447 ' ND1' HG11 ' A' ' 12' ' ' VAL . 26.0 t60 -154.83 104.68 2.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.038 0.447 . . . . 0.0 111.16 179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' ND1' ' C' ' 14' ' ' HIS . 31.3 m170 -119.35 164.51 15.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -154.47 173.03 16.81 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.01 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -153.67 114.11 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.809 178.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.421 ' N ' HD12 ' B' ' 17' ' ' LEU . 4.1 mp -128.39 114.49 16.91 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.92 133.73 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-O 121.101 0.477 . . . . 0.0 111.064 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -119.46 129.61 54.83 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.997 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -124.65 129.07 49.84 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.691 -0.231 . . . . 0.0 110.468 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.13 128.34 43.27 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 111.859 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.8 tt0 -136.79 149.36 47.73 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . 0.471 ' OD2' ' CB ' ' A' ' 28' ' ' LYS . 81.3 m-20 . . . . . 0 N--CA 1.468 0.441 0 CA-C-O 120.812 0.339 . . . . 0.0 111.344 -178.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.62 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.419 -5.908 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.62 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 119.44 -112.39 0.0 OUTLIER 'General case' 0 N--CA 1.391 -3.425 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 -173.213 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.783 ' H ' HD12 ' B' ' 31' ' ' ILE . 2.3 mp -79.79 113.29 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.037 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.507 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.447 HG23 ' O ' ' B' ' 32' ' ' ILE . 14.7 tt -124.85 109.35 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.833 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -130.06 120.37 3.07 Favored Glycine 0 N--CA 1.468 0.815 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.899 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.4 mp -136.5 160.34 39.07 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 123.219 1.485 . . . . 0.0 113.67 -178.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.6 ttm -127.5 112.33 14.82 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 112.791 -2.004 . . . . 0.0 107.677 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.749 ' CG2' HD11 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -119.6 74.07 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -179.583 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -31.89 -97.99 0.01 OUTLIER Glycine 0 C--N 1.357 1.749 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.48 -173.09 24.59 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.0 p -141.35 141.8 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.95 0.405 . . . . 0.0 110.511 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.945 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 52.2 t . . . . . 0 N--CA 1.467 0.416 0 N-CA-C 110.156 -0.312 . . . . 0.0 110.156 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 17.2 p-80 -155.63 143.0 19.42 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 121.13 0.491 . . . . 0.0 111.241 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.632 ' ND1' ' CD2' ' B' ' 14' ' ' HIS . 6.1 m80 -140.91 167.38 22.33 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.11 0.481 . . . . 0.0 109.931 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -150.99 169.88 20.7 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.964 178.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -156.96 117.9 3.66 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.55 123.79 40.86 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.648 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -133.54 133.28 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -116.82 107.4 14.58 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 105.287 -2.116 . . . . 0.0 105.287 175.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 24.3 t80 -122.48 134.84 54.56 Favored 'General case' 0 N--CA 1.477 0.878 0 O-C-N 122.312 -0.242 . . . . 0.0 110.532 -177.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . 0.426 ' CB ' ' NZ ' ' A' ' 28' ' ' LYS . . . -145.61 144.11 30.27 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -142.61 110.73 5.99 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 114.147 -1.388 . . . . 0.0 109.642 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.417 ' H ' ' HB3' ' D' ' 23' ' ' ASP . 4.1 m-20 . . . . . 0 C--O 1.215 -0.723 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.489 -1.593 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.95 155.8 49.72 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.492 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -141.5 117.39 6.5 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 112.295 -2.23 . . . . 0.0 109.204 -170.592 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.408 ' O ' HG22 ' C' ' 32' ' ' ILE . 5.4 mt -105.5 111.64 35.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.499 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -122.11 104.39 0.91 Allowed Glycine 0 CA--C 1.506 -0.499 0 N-CA-C 106.273 -2.731 . . . . 0.0 106.273 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.899 HD12 ' O ' ' B' ' 34' ' ' LEU . 54.6 tp -132.59 141.05 48.52 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 123.3 1.524 . . . . 0.0 113.806 -176.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.793 ' SD ' HG22 ' I' ' 31' ' ' ILE . 8.3 ttm -115.56 118.43 33.11 Favored 'General case' 0 CA--C 1.505 -0.774 0 CA-C-N 112.4 -2.182 . . . . 0.0 109.262 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.557 HG11 HD23 ' D' ' 17' ' ' LEU . 1.3 m -128.57 74.12 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.1 105.68 3.08 Favored Glycine 0 C--N 1.354 1.545 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -129.76 148.29 18.34 Favored Glycine 0 N--CA 1.466 0.685 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 m -134.05 159.8 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.944 0.402 . . . . 0.0 110.834 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.914 179.816 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . 0.591 HG22 ' O ' ' E' ' 11' ' ' GLU . 2.8 t . . . . . 0 CA--C 1.516 -0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.8 p-80 -157.8 148.74 21.14 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.632 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.565 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 56.7 t-80 -144.98 158.83 43.69 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . 0.565 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 67.7 mt-30 -156.22 172.15 18.96 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.106 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -155.63 122.3 5.29 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.709 179.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.557 HD23 HG11 ' C' ' 36' ' ' VAL . 47.7 tp -117.39 123.1 45.63 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 39.1 t -130.53 131.22 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.724 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 10.7 m-85 -112.73 108.88 18.06 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 175.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.0 t80 -123.35 123.76 41.43 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 120.93 0.395 . . . . 0.0 112.026 -176.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.61 127.32 30.96 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.253 178.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -140.46 114.29 8.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.771 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . 0.517 ' N ' ' OD1' ' D' ' 23' ' ' ASP . 0.2 OUTLIER . . . . . 0 N--CA 1.454 -0.242 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.971 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.487 -1.452 0 N-CA-C 101.352 -3.574 . . . . 0.0 101.352 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.455 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -136.27 122.59 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.647 -171.33 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CE ' ' K' ' 35' ' ' MET . 78.4 mt -116.36 123.27 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.055 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.57 109.19 1.08 Allowed Glycine 0 N--CA 1.463 0.461 0 N-CA-C 107.609 -2.196 . . . . 0.0 107.609 175.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.419 HD13 ' CZ ' ' E' ' 19' ' ' PHE . 14.7 tp -122.09 124.53 44.12 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 121.541 0.686 . . . . 0.0 112.243 -178.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.508 ' SD ' ' N ' ' J' ' 32' ' ' ILE . 13.5 ttm -102.86 113.6 27.18 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.01 72.85 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.809 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.14 111.53 3.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 178.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.73 135.47 7.22 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -124.27 135.95 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.797 0.332 . . . . 0.0 110.309 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.588 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.49 148.25 33.56 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.788 0.328 . . . . 0.0 110.237 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . 0.591 ' O ' HG22 ' D' ' 12' ' ' VAL . 59.9 mm-40 -57.45 136.36 56.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.296 -0.411 . . . . 0.0 109.951 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 2.7 p -135.33 142.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -109.85 -178.89 3.65 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 118.179 0.445 . . . . 0.0 110.959 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CD2' ' F' ' 13' ' ' HIS . 93.8 m-70 -142.41 -178.66 5.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.751 0.786 . . . . 0.0 110.149 -179.078 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -88.46 168.0 12.99 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.661 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.42 143.38 33.88 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.273 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.529 HD13 ' CD2' ' F' ' 17' ' ' LEU . 5.2 mp -131.22 124.35 30.4 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.146 0.498 . . . . 0.0 111.671 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -128.3 129.39 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.854 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.438 ' HZ ' HD23 ' C' ' 34' ' ' LEU . 35.9 m-85 -117.99 120.85 39.05 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -128.59 127.66 42.71 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 117.927 0.331 . . . . 0.0 111.124 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.3 131.55 43.89 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 122.381 1.086 . . . . 0.0 113.058 -179.032 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -138.27 85.73 2.11 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.069 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -93.97 -130.71 0.14 Allowed 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 82.9 t -106.2 112.32 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 N-CA-C 104.747 -2.316 . . . . 0.0 104.747 175.301 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 31.76 88.08 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 113.904 -1.498 . . . . 0.0 112.977 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.509 ' N ' ' HB2' ' F' ' 23' ' ' ASP . 35.3 p . . . . . 0 C--N 1.35 0.597 0 CA-C-N 119.262 1.531 . . . . 0.0 108.718 173.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.421 -1.886 1 N-CA-C 93.028 -6.656 . . . . 0.0 93.028 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.5 OUTLIER -85.09 114.91 26.0 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 1 CA-C-N 127.789 4.813 . . . . 0.0 109.163 176.935 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' K' ' 35' ' ' MET . 16.1 tt -136.69 134.94 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-O 121.719 0.771 . . . . 0.0 112.452 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -131.9 127.36 4.95 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.512 HD13 ' CE1' ' F' ' 19' ' ' PHE . 23.9 tp -121.03 124.26 44.41 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.637 -0.282 . . . . 0.0 111.679 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.1 tpp -115.99 114.6 24.82 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.86 88.51 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.62 -178.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.58 95.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 119.67 -1.253 . . . . 0.0 110.342 178.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -159.28 162.56 32.86 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.56 162.77 34.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.311 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -148.26 159.59 43.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.016 0.436 . . . . 0.0 111.256 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -67.25 137.9 56.5 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.985 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -127.16 132.38 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.326 0.584 . . . . 0.0 110.999 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' NE2' ' E' ' 14' ' ' HIS . 27.2 t-80 -156.07 100.95 2.06 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.888 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -147.23 173.3 12.68 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -145.03 174.65 10.85 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.319 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -145.99 112.71 5.98 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.032 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.529 ' CD2' HD13 ' E' ' 17' ' ' LEU . 35.8 mt -125.07 110.2 13.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 m -145.93 147.12 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 118.682 -1.207 . . . . 0.0 114.244 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.512 ' CE1' HD13 ' E' ' 34' ' ' LEU . 73.0 m-85 -126.7 128.3 46.48 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 113.967 -1.469 . . . . 0.0 108.431 177.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -138.36 146.48 42.35 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.12 0.486 . . . . 0.0 111.458 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.55 146.48 32.39 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.956 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -88.07 127.47 35.4 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.509 ' HB2' ' N ' ' E' ' 26' ' ' SER . 67.1 t0 178.1 114.36 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 79.6 t -65.39 132.44 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . 71.68 -85.08 0.45 Allowed Glycine 0 N--CA 1.47 0.958 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . 0.551 ' CB ' ' O ' ' F' ' 25' ' ' GLY . 2.8 t 140.23 165.4 0.0 OUTLIER 'General case' 0 C--N 1.352 0.703 0 CA-C-O 122.577 1.18 . . . . 0.0 112.905 174.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.504 ' N ' ' OD1' ' F' ' 27' ' ' ASN . 0.5 OUTLIER -46.48 171.93 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.44 175.535 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -69.93 111.53 5.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 170.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.88 -92.88 0.93 Allowed Glycine 0 N--CA 1.475 1.257 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.861 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.5 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . 83.38 160.28 0.12 Allowed 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 100.439 -3.911 . . . . 0.0 100.439 -174.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.5 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.2 OUTLIER -151.67 127.87 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 122.45 2.386 . . . . 0.0 111.039 -176.286 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -121.43 132.77 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-N 114.151 -1.386 . . . . 0.0 114.254 -175.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -130.22 115.12 1.78 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 mt -118.45 127.49 53.71 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.534 ' CE ' HG22 ' L' ' 31' ' ' ILE . 1.8 ttt -132.09 126.7 34.41 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.539 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -143.33 82.52 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.442 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.666 ' HA3' HD13 ' L' ' 31' ' ' ILE . . . -51.23 100.37 0.04 OUTLIER Glycine 0 C--N 1.337 0.61 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.674 -179.209 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.11 163.09 35.76 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -121.45 132.94 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.924 0.393 . . . . 0.0 110.315 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.897 -179.566 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 t60 . . . . . 0 C--O 1.225 -0.191 0 CA-C-O 120.88 0.372 . . . . 0.0 110.675 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 14.8 t60 -147.84 163.56 36.38 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 85.3 mt-30 -151.64 178.17 9.61 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.326 0.584 . . . . 0.0 110.871 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 25.5 pttm -167.72 133.57 2.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.266 179.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -133.57 125.05 28.0 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.95 138.14 49.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.248 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -134.77 137.25 43.24 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . 0.483 ' CD1' ' O ' ' G' ' 20' ' ' PHE . 54.3 p90 -135.18 129.05 33.16 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.142 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.38 134.75 50.96 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -157.21 124.66 5.28 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.359 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.558 ' O ' ' O ' ' G' ' 24' ' ' VAL . 12.0 m-20 -154.13 122.71 6.21 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 120.827 -0.349 . . . . 0.0 111.849 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.558 ' O ' ' O ' ' G' ' 23' ' ' ASP . 11.8 m -43.67 -122.1 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 O-C-N 124.273 0.983 . . . . 0.0 111.621 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.49 -90.79 1.35 Allowed Glycine 0 CA--C 1.528 0.886 0 CA-C-O 119.52 -0.6 . . . . 0.0 113.023 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' G' ' 27' ' ' ASN . 1.3 p 173.76 -170.58 0.04 OUTLIER 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 117.587 0.694 . . . . 0.0 109.625 -177.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' G' ' 26' ' ' SER . 16.4 t-20 -16.98 158.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 O-C-N 125.149 1.53 . . . . 0.0 113.49 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.531 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 28.6 tttt -161.56 108.54 1.4 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.58 98.1 0.66 Allowed Glycine 0 N--CA 1.467 0.746 0 CA-C-O 116.221 -2.433 . . . . 0.0 107.935 172.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.406 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -90.08 154.24 19.95 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 123.627 3.714 . . . . 0.0 110.552 -176.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.4 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -153.82 114.55 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 112.528 -2.124 . . . . 0.0 109.75 -173.626 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 6.0 tt -122.78 113.79 39.61 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 176.355 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' H' ' 33' ' ' GLY . . . -132.68 137.61 9.52 Favored Glycine 0 CA--C 1.502 -0.731 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -153.26 146.81 25.01 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 122.447 1.117 . . . . 0.0 112.024 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.402 ' CE ' ' O ' ' A' ' 31' ' ' ILE . 31.0 mtp -105.19 119.15 38.34 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 113.257 -1.792 . . . . 0.0 107.878 178.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.76 65.72 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.297 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.283 178.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.95 102.42 0.56 Allowed Glycine 0 C--N 1.376 2.754 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 177.08 170.3 39.35 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-O 120.93 0.395 . . . . 0.0 110.258 179.321 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . 0.405 HG13 ' CG2' ' I' ' 12' ' ' VAL . 54.3 t . . . . . 0 CA--C 1.522 -0.103 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . 0.904 ' HD1' ' CD2' ' I' ' 13' ' ' HIS . 40.7 m80 -137.18 145.78 44.13 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.953 0.406 . . . . 0.0 111.396 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.531 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 99.1 m-70 -147.09 155.96 42.61 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.4 mm-40 -148.73 168.29 23.3 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.41 178.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -163.6 128.63 2.96 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.46 -0.791 . . . . 0.0 108.983 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . 0.597 HD23 ' C ' ' H' ' 17' ' ' LEU . 5.6 tt -127.46 118.11 23.4 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.58 ' N ' HD23 ' H' ' 17' ' ' LEU . 72.8 t -122.2 129.48 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.202 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -126.25 122.87 36.78 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -126.84 127.66 45.33 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.702 0.286 . . . . 0.0 111.374 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.36 125.61 50.38 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 120.981 0.42 . . . . 0.0 111.525 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' O ' ' I' ' 22' ' ' GLU . 52.7 tp10 -132.67 157.4 44.94 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.664 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -158.64 142.03 14.98 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t . . . . . 0 C--N 1.321 -0.658 0 CA-C-O 122.344 1.068 . . . . 0.0 110.391 -177.878 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.497 -1.082 0 CA-C-O 123.279 1.514 . . . . 0.0 107.546 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.554 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -140.03 121.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-N 112.404 -2.18 . . . . 0.0 110.529 -173.474 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.513 ' N ' ' SD ' ' B' ' 35' ' ' MET . 8.7 tt -111.33 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 CA-C-O 121.613 0.72 . . . . 0.0 110.112 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' G' ' 33' ' ' GLY . . . -112.37 94.85 0.76 Allowed Glycine 0 N--CA 1.461 0.366 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' I' ' 34' ' ' LEU . 35.6 mt -117.0 129.25 55.9 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.273 1.035 . . . . 0.0 111.551 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.629 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 21.9 ttp -116.27 115.52 26.1 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.312 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.89 71.15 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.897 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.61 112.41 3.61 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -50.64 152.52 4.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.84 162.02 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.297 179.901 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . 0.405 ' CG2' HG13 ' H' ' 12' ' ' VAL . 16.3 m . . . . . 0 C--O 1.232 0.138 0 CA-C-O 121.553 0.692 . . . . 0.0 111.757 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.904 ' CD2' ' HD1' ' H' ' 13' ' ' HIS . 71.2 m80 -150.07 101.85 3.05 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.134 178.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 84.9 t60 -121.23 162.91 19.39 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.853 0.835 . . . . 0.0 111.376 -178.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.546 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 84.3 mt-30 -148.47 177.73 9.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.098 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -171.01 125.28 0.66 Allowed 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.4 mt -126.71 123.34 37.28 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' J' ' 18' ' ' VAL . 12.6 p -136.41 133.32 49.44 Favored 'Isoleucine or valine' 0 C--N 1.351 0.663 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -115.68 126.06 53.63 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.649 177.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -129.38 121.85 28.26 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 118.327 0.512 . . . . 0.0 111.03 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.31 128.46 51.08 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.077 0.465 . . . . 0.0 111.224 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' H' ' 22' ' ' GLU . 82.1 tt0 -149.02 124.67 10.43 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.311 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -157.11 103.97 2.05 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 118.909 -1.116 . . . . 0.0 113.799 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 2.2 p -31.78 147.67 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.525 -1.216 . . . . 0.0 113.07 175.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.4 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 168.52 -79.42 0.1 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.282 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 1.001 ' O ' ' O ' ' I' ' 27' ' ' ASN . 2.1 p 161.66 179.86 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 1.001 ' O ' ' O ' ' I' ' 26' ' ' SER . 8.2 m120 10.52 -178.74 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.112 0 O-C-N 124.841 1.338 . . . . 0.0 113.251 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.497 ' O ' ' N ' ' J' ' 29' ' ' GLY . 12.7 tttt -149.15 109.77 4.24 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 116.202 -2.199 . . . . 0.0 114.646 177.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.96 94.65 0.79 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 106.248 -2.741 . . . . 0.0 106.248 168.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.43 144.4 51.06 Favored 'General case' 0 CA--C 1.476 -1.882 0 CA-C-N 122.543 3.171 . . . . 0.0 107.094 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.793 HG22 ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -144.15 125.24 9.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 113.09 -1.868 . . . . 0.0 109.504 -175.189 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.543 ' N ' ' SD ' ' C' ' 35' ' ' MET . 0.8 OUTLIER -105.22 110.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.064 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.69 101.73 1.24 Allowed Glycine 0 CA--C 1.494 -1.243 0 N-CA-C 104.817 -3.313 . . . . 0.0 104.817 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' H' ' 34' ' ' LEU . 17.0 tp -136.82 137.55 39.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-O 122.11 0.957 . . . . 0.0 112.508 -175.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 31.1 ttp -122.86 123.42 40.94 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 113.74 -1.573 . . . . 0.0 110.164 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.559 ' CG2' HD11 ' J' ' 34' ' ' LEU . 0.1 OUTLIER -126.35 71.56 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.826 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.84 113.1 5.03 Favored Glycine 0 C--N 1.358 1.779 0 N-CA-C 110.531 -1.027 . . . . 0.0 110.531 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.16 147.81 41.66 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 64.3 t -130.87 137.29 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . 0.402 ' O ' HG23 ' I' ' 40' ' ' VAL . 30.4 m . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.44 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p . . . . . 0 N--CA 1.473 0.686 0 N-CA-C 109.998 -0.371 . . . . 0.0 109.998 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.513 ' N ' ' CD2' ' J' ' 13' ' ' HIS . 0.9 OUTLIER -131.31 155.98 46.25 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 121.19 0.519 . . . . 0.0 110.943 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -152.4 160.18 43.32 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -154.67 172.25 18.2 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.219 -0.592 . . . . 0.0 110.634 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -155.75 127.96 7.65 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.747 178.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . 0.427 HD12 HD11 ' K' ' 17' ' ' LEU . 87.4 mt -120.47 120.12 34.98 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' I' ' 18' ' ' VAL . 2.0 p -143.06 137.92 26.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -177.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.83 127.9 13.7 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 119.684 -0.806 . . . . 0.0 111.403 176.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -147.77 160.82 42.31 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.443 1.116 . . . . 0.0 113.752 -178.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 140.17 43.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 113.934 -1.484 . . . . 0.0 109.946 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.17 149.44 39.74 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.968 -178.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 33.7 t70 -173.49 126.46 0.41 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.08 0.467 . . . . 0.0 111.293 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.444 ' H ' HG22 ' J' ' 24' ' ' VAL . 5.4 m -62.61 -116.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.516 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.47 -92.22 0.06 OUTLIER Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.603 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.831 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.3 t -171.24 170.05 6.17 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 117.535 0.668 . . . . 0.0 109.986 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.831 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.8 m120 10.85 -179.16 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 125.763 1.914 . . . . 0.0 115.567 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.595 ' H ' ' N ' ' K' ' 27' ' ' ASN . 15.8 pttt -149.4 110.76 4.44 Favored 'General case' 0 CA--C 1.558 1.25 0 O-C-N 120.635 -1.29 . . . . 0.0 114.284 178.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -61.48 93.22 0.07 OUTLIER Glycine 0 N--CA 1.479 1.517 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 172.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.487 ' HB2' ' HG3' ' J' ' 28' ' ' LYS . . . -126.39 149.33 49.3 Favored 'General case' 0 CA--C 1.486 -1.489 0 CA-C-N 121.677 2.739 . . . . 0.0 111.069 -178.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.736 HG13 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.33 114.42 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.816 0 CA-C-N 108.989 -3.732 . . . . 0.0 107.612 -174.968 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.508 ' N ' ' SD ' ' D' ' 35' ' ' MET . 3.1 mt -105.56 118.74 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 CA-C-O 120.749 0.309 . . . . 0.0 110.429 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.96 100.78 0.91 Allowed Glycine 0 C--O 1.239 0.421 0 N-CA-C 106.9 -2.48 . . . . 0.0 106.9 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.627 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 55.7 tp -129.58 135.39 48.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.003 0.906 . . . . 0.0 112.415 -177.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.418 ' SD ' ' C ' ' D' ' 31' ' ' ILE . 48.9 ttp -117.87 117.07 28.28 Favored 'General case' 0 CA--C 1.502 -0.881 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.55 175.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.506 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -120.26 72.2 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 178.608 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.51 111.87 4.5 Favored Glycine 0 C--N 1.36 1.861 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 178.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.36 -151.58 3.07 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -179.199 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.9 m . . . . . 0 N--CA 1.467 0.386 0 CA-C-O 121.097 0.475 . . . . 0.0 110.74 179.994 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 . . . . . 0 N--CA 1.466 0.328 0 CA-C-O 120.676 0.274 . . . . 0.0 110.702 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.5 m -118.88 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.099 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . 0.631 ' CE1' ' NE2' ' L' ' 14' ' ' HIS . 1.8 p80 -161.7 168.87 22.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.475 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.537 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 39.4 t-80 -138.71 165.67 26.36 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.548 0.69 . . . . 0.0 110.901 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.537 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 87.4 mt-30 -148.42 178.69 8.38 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.966 -1.015 . . . . 0.0 110.091 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . 0.433 ' C ' HD12 ' K' ' 17' ' ' LEU . 38.2 ttmt -172.76 123.41 0.44 Allowed 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 118.419 -0.8 . . . . 0.0 111.45 -178.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . 0.943 ' O ' ' C ' ' L' ' 17' ' ' LEU . 9.4 mp -110.73 119.07 37.92 Favored 'General case' 0 C--N 1.379 1.85 0 CA-C-O 123.836 1.779 . . . . 0.0 111.111 177.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 7.1 p -138.25 112.07 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 O-C-N 120.675 -1.266 . . . . 0.0 111.432 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 1.7 p90 -134.51 139.62 45.59 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 176.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.47 ' CB ' ' O ' ' L' ' 20' ' ' PHE . 30.3 p90 -154.77 162.9 40.94 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -176.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.35 130.61 48.0 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.412 178.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.31 137.13 50.83 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.158 0.504 . . . . 0.0 111.965 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 56.6 t0 -159.56 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.323 178.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' K' ' 26' ' ' SER . 55.9 t -123.88 123.02 66.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 179.047 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.476 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 32.0 -84.35 0.0 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' K' ' 24' ' ' VAL . 8.1 t 154.31 172.0 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 121.748 0.785 . . . . 0.0 111.235 174.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.595 ' N ' ' H ' ' J' ' 28' ' ' LYS . 43.1 p-10 -53.63 179.94 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.43 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.72 112.09 1.88 Allowed 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.617 ' O ' ' HB2' ' L' ' 30' ' ' ALA . . . 75.4 -91.74 0.85 Allowed Glycine 0 CA--C 1.532 1.145 0 C-N-CA 121.285 -0.483 . . . . 0.0 112.083 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.519 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 106.48 161.13 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 104.562 -2.384 . . . . 0.0 104.562 -178.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.519 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -144.88 132.15 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 118.027 -1.469 . . . . 0.0 112.796 -178.269 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -124.42 123.68 66.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.3 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 114.93 2.94 Favored Glycine 0 N--CA 1.473 1.126 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 46.0 mt -122.42 127.31 49.51 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 56.8 ttp -119.83 121.29 38.77 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.234 177.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.506 HG22 HG23 ' J' ' 36' ' ' VAL . 60.0 t -115.4 88.17 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.23 96.06 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.85 162.19 31.51 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t . . . . . 0 N--CA 1.468 0.428 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.77 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t . . . . . 0 N--CA 1.467 0.413 0 CA-C-O 121.116 0.484 . . . . 0.0 110.368 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -99.45 176.79 5.38 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.276 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CE1' ' K' ' 13' ' ' HIS . 0.4 OUTLIER -92.36 165.76 12.91 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.302 0.573 . . . . 0.0 110.04 -179.614 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -168.19 168.58 11.54 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.548 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.52 108.71 2.98 Favored 'General case' 0 C--O 1.171 -3.049 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . 0.943 ' C ' ' O ' ' K' ' 17' ' ' LEU . 2.7 mm? -73.09 160.73 31.56 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 119.654 -1.903 . . . . 0.0 107.622 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 14.3 m -99.89 -121.06 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -173.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.627 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 7.7 p90 -147.6 162.11 39.78 Favored 'General case' 0 N--CA 1.47 0.551 0 O-C-N 121.618 -0.676 . . . . 0.0 112.588 -177.178 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.47 ' O ' ' CB ' ' K' ' 20' ' ' PHE . 93.6 m-85 -144.72 151.48 38.96 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 121.718 0.77 . . . . 0.0 112.087 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.64 138.27 39.3 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -69.79 95.08 0.87 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.128 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -164.06 121.57 1.75 Allowed 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.589 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' L' ' 26' ' ' SER . 13.5 t -88.53 123.56 40.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.61 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.3 0.01 OUTLIER Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.578 ' N ' ' O ' ' L' ' 24' ' ' VAL . 12.8 t -68.13 -171.59 0.25 Allowed 'General case' 0 N--CA 1.441 -0.921 0 CA-C-O 122.593 1.187 . . . . 0.0 112.333 -177.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.415 ' O ' ' C ' ' L' ' 28' ' ' LYS . 35.4 p-10 -81.0 179.29 7.93 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 112.547 -2.115 . . . . 0.0 109.814 178.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' L' ' 27' ' ' ASN . 70.1 tttt -37.17 104.15 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . 0.402 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 167.84 -100.42 0.16 Allowed Glycine 0 C--O 1.22 -0.726 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.617 ' HB2' ' O ' ' K' ' 29' ' ' GLY . . . -49.55 169.37 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.137 1.469 . . . . 0.0 108.734 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.666 HD13 ' HA3' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -153.37 133.2 3.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.454 -177.659 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 83.7 mt -120.41 128.91 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 114.43 -1.259 . . . . 0.0 108.921 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.428 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -125.7 124.82 5.36 Favored Glycine 0 N--CA 1.468 0.808 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.2 tp -126.99 120.04 28.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 36.8 ttp -110.34 126.67 54.48 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.0 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.2 t -130.28 81.73 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.489 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -60.83 101.43 0.3 Allowed Glycine 0 N--CA 1.439 -1.161 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.16 169.28 41.36 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 57.6 t -122.73 135.84 61.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 120.742 0.306 . . . . 0.0 110.218 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.446 -179.919 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' CE1' ' B' ' 13' ' ' HIS . 42.6 tp10 . . . . . 0 C--O 1.232 0.143 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.2 160.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.445 0.641 . . . . 0.0 111.386 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.0 m80 -89.0 -170.17 2.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.905 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -80.49 168.64 18.7 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 121.357 0.599 . . . . 0.0 110.002 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -157.21 -179.86 8.6 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.878 -1.055 . . . . 0.0 108.993 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -155.22 129.32 8.82 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.695 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 72.9 mt -129.28 118.95 23.13 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.597 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -130.17 131.19 65.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -127.65 131.53 49.84 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.009 0.433 . . . . 0.0 110.712 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -132.53 125.94 31.74 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.94 137.16 44.69 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-O 121.778 0.799 . . . . 0.0 112.955 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 78.2 tt0 -126.8 126.77 43.94 Favored 'General case' 0 CA--C 1.528 0.12 0 CA-C-N 114.625 -1.17 . . . . 0.0 108.449 178.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 20.7 t70 . . . . . 0 C--N 1.325 -0.457 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.527 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 64.4 tttt . . . . . 0 C--O 1.217 -0.624 0 N-CA-C 113.568 0.951 . . . . 0.0 113.568 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.16 102.9 0.98 Allowed Glycine 0 N--CA 1.467 0.706 0 N-CA-C 103.622 -3.791 . . . . 0.0 103.622 170.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -97.35 144.11 27.43 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 123.311 3.555 . . . . 0.0 115.527 -172.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' G' ' 35' ' ' MET . 1.7 pt -159.82 105.56 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.421 -1.907 1 CA-C-N 107.016 -4.629 . . . . 0.0 106.245 -173.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.554 HG23 HD11 ' B' ' 34' ' ' LEU . 8.1 tt -108.45 114.53 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 CA-C-N 120.524 1.511 . . . . 0.0 108.107 178.236 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -121.58 124.72 5.89 Favored Glycine 0 CA--C 1.508 -0.351 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -148.83 140.4 23.47 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 122.806 1.288 . . . . 0.0 113.002 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . 0.586 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 3.7 ttm -109.82 117.65 34.42 Favored 'General case' 0 CA--C 1.505 -0.786 0 CA-C-N 113.038 -1.892 . . . . 0.0 108.094 177.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -111.12 68.04 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -120.79 101.53 0.81 Allowed Glycine 0 C--N 1.359 1.842 0 N-CA-C 110.404 -1.079 . . . . 0.0 110.404 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.39 165.73 35.2 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.329 -0.709 . . . . 0.0 111.329 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . 0.479 ' O ' HG13 ' A' ' 40' ' ' VAL . 31.4 m -135.96 156.24 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.663 0.268 . . . . 0.0 110.385 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . 0.479 HG13 ' O ' ' A' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.129 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.86 145.37 42.92 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.6 0.238 . . . . 0.0 110.447 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -68.04 126.87 30.86 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.279 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m -137.08 164.1 30.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.092 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.538 ' CE1' ' OE1' ' A' ' 11' ' ' GLU . 59.4 m80 -91.36 98.14 11.52 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.546 -0.461 . . . . 0.0 109.971 179.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.519 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 3.7 m-70 -134.51 166.83 21.98 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -154.57 175.11 14.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.059 179.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -154.46 117.04 4.35 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.495 179.2 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.03 119.5 29.69 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.454 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 t -122.33 127.68 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.961 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 83.0 t80 -130.22 126.26 36.93 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.834 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -128.48 132.59 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.63 132.35 38.89 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 121.126 0.489 . . . . 0.0 111.114 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -147.88 168.0 23.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.227 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 . . . . . 0 N--CA 1.468 0.439 0 CA-C-O 121.153 0.502 . . . . 0.0 111.245 -179.788 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.799 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . . . . . . 1 CA--C 1.417 -6.093 0 CA-C-O 115.111 -3.05 . . . . 0.0 111.33 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.799 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . 76.0 -135.22 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.71 2 C-N-CA 108.667 -5.213 . . . . 0.0 99.248 -174.351 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.973 ' N ' HD13 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -75.47 122.65 29.74 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -179.325 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 83.3 mt -121.73 122.16 66.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 175.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . 0.701 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -132.47 111.07 0.99 Allowed Glycine 0 N--CA 1.473 1.119 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.075 179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.701 HD12 ' C ' ' B' ' 33' ' ' GLY . 6.4 mp -138.31 144.85 40.61 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 123.47 1.605 . . . . 0.0 113.168 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.506 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 19.6 ttm -119.07 115.85 25.16 Favored 'General case' 0 CA--C 1.499 -0.999 0 CA-C-N 113.002 -1.908 . . . . 0.0 107.41 177.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.26 70.62 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.096 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.3 112.5 3.46 Favored Glycine 0 C--N 1.363 2.057 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 -179.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' C' ' 37' ' ' GLY . . . -73.04 147.73 40.07 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -139.49 161.34 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.807 0.337 . . . . 0.0 110.424 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.026 -0.987 . . . . 0.0 110.518 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 18.6 m . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 121.3 0.571 . . . . 0.0 111.364 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -118.8 138.29 52.8 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.877 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . 0.783 ' HD1' ' N ' ' C' ' 15' ' ' GLN . 28.8 t-80 -152.38 165.45 34.97 Favored 'General case' 0 CA--C 1.513 -0.463 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . 0.783 ' N ' ' HD1' ' C' ' 14' ' ' HIS . 75.8 mt-30 -156.44 170.35 22.51 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.025 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -158.87 111.59 2.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.829 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -121.96 122.07 38.52 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -126.67 124.52 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.128 0.49 . . . . 0.0 111.831 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' B' ' 34' ' ' LEU . 1.0 OUTLIER -116.54 110.75 18.99 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 105.89 -1.893 . . . . 0.0 105.89 177.456 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -115.36 121.02 41.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.87 130.59 53.06 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.697 0.761 . . . . 0.0 111.673 -179.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -121.18 91.53 3.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.994 178.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 CA--C 1.551 1.007 0 C-N-CA 118.816 -1.154 . . . . 0.0 113.129 -179.343 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.873 0 N-CA-C 112.342 -0.303 . . . . 0.0 112.342 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.401 ' C ' HD13 ' C' ' 31' ' ' ILE . . . -157.48 165.74 34.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 175.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.498 HG22 ' HB ' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.94 121.29 15.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 118.481 -1.287 . . . . 0.0 111.237 -173.687 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . 0.458 ' O ' ' CE ' ' I' ' 35' ' ' MET . 12.1 tt -116.72 122.35 69.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-O 121.487 0.661 . . . . 0.0 111.039 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . 0.418 ' N ' ' HE1' ' H' ' 35' ' ' MET . . . -110.61 117.36 4.62 Favored Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.876 HD11 ' CZ ' ' D' ' 19' ' ' PHE . 0.4 OUTLIER -146.2 138.23 25.07 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.861 1.315 . . . . 0.0 113.006 -178.099 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 15.0 ttm -129.09 127.37 41.35 Favored 'General case' 0 CA--C 1.505 -0.753 0 CA-C-N 113.446 -1.707 . . . . 0.0 109.449 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.91 78.06 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' B' ' 38' ' ' GLY . . . -69.64 104.78 1.37 Allowed Glycine 0 C--N 1.351 1.399 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.56 -179.33 52.2 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.89 144.21 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.939 0.399 . . . . 0.0 110.771 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.561 179.943 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 m . . . . . 0 N--CA 1.466 0.337 0 CA-C-O 120.922 0.392 . . . . 0.0 110.405 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.435 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 9.5 m80 -123.44 154.81 38.55 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.685 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.435 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 47.2 m80 -151.02 164.99 35.13 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.158 0.504 . . . . 0.0 110.06 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -158.99 169.51 24.14 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.553 178.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -159.43 117.13 2.73 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.316 178.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . 0.402 HD13 ' CD2' ' E' ' 17' ' ' LEU . 5.9 mp -119.34 123.78 45.01 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -126.29 127.05 70.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . 0.876 ' CZ ' HD11 ' C' ' 34' ' ' LEU . 1.8 t80 -125.39 113.5 17.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -122.8 131.55 53.82 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -176.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 109.77 16.7 Favored 'General case' 0 C--O 1.249 1.079 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 177.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' E' ' 22' ' ' GLU . 87.2 tt0 -165.23 91.46 0.53 Allowed 'General case' 0 C--N 1.347 0.487 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 34.1 t70 . . . . . 0 C--N 1.324 -0.531 0 N-CA-C 102.915 -2.995 . . . . 0.0 102.915 173.259 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.442 ' O ' ' O ' ' E' ' 31' ' ' ILE . . . . . . . . 1 N--CA 1.372 -4.338 1 N-CA-C 97.485 -5.006 . . . . 0.0 97.485 . . . . . . . . . 3 2 . 1 . 009 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.786 ' N ' ' CD1' ' D' ' 31' ' ' ILE . 1.0 OUTLIER -74.74 111.88 11.29 Favored 'Isoleucine or valine' 1 C--N 1.243 -4.029 0 CA-C-N 123.176 2.716 . . . . 0.0 111.714 -176.013 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . 0.54 HG21 HG23 ' E' ' 32' ' ' ILE . 0.2 OUTLIER -110.92 115.51 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 178.126 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . 0.551 ' CA ' ' SD ' ' J' ' 35' ' ' MET . . . -113.72 98.67 0.93 Allowed Glycine 0 CA--C 1.503 -0.689 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . 0.426 HD22 ' CZ ' ' E' ' 19' ' ' PHE . 61.7 mt -128.31 128.46 44.64 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -176.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . 0.508 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -123.5 128.85 50.37 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.068 177.214 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.521 ' O ' HG23 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -122.9 80.36 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.457 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -23.36 -95.45 0.01 OUTLIER Glycine 0 C--N 1.361 1.955 0 O-C-N 123.0 0.187 . . . . 0.0 112.639 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 125.84 -178.28 16.73 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 40' ' ' VAL . 34.3 m -123.27 137.1 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 39' ' ' VAL . 11.2 t . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.392 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -116.89 140.12 49.82 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.789 0.328 . . . . 0.0 110.716 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -63.88 145.17 56.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.692 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.53 127.93 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.029 0.442 . . . . 0.0 110.029 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' CB ' ' F' ' 13' ' ' HIS . 43.7 p-80 -164.38 157.74 17.81 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.945 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 73.4 m80 -135.54 167.78 20.46 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -155.29 167.83 29.06 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.362 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -148.19 117.37 6.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.123 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . 0.402 ' CD2' HD13 ' D' ' 17' ' ' LEU . 25.5 mt -114.66 122.17 45.63 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 177.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.28 136.35 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-O 122.125 0.964 . . . . 0.0 113.578 -177.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . 0.478 ' CB ' ' CE1' ' F' ' 19' ' ' PHE . 0.6 OUTLIER -121.37 126.05 48.48 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 113.832 -1.531 . . . . 0.0 109.091 178.783 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -127.22 129.85 48.56 Favored 'General case' 0 N--CA 1.481 1.076 0 O-C-N 122.079 -0.388 . . . . 0.0 110.663 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.12 125.68 16.8 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.002 0.43 . . . . 0.0 110.749 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 93.9 mt-10 -93.25 156.32 16.9 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.494 -0.882 . . . . 0.0 113.313 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -133.02 141.39 48.24 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.201 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.35 111.08 34.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . 0.543 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 34.6 90.81 0.01 OUTLIER Glycine 0 N--CA 1.472 1.049 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . 0.543 ' O ' ' O ' ' E' ' 25' ' ' GLY . 11.6 p . . . . . 0 N--CA 1.447 -0.592 0 CA-C-O 122.232 1.015 . . . . 0.0 113.179 -179.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.241 0.608 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.601 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.3 OUTLIER -149.62 120.28 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 117.972 -1.491 . . . . 0.0 109.168 -176.685 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.54 HG23 HG21 ' D' ' 32' ' ' ILE . 97.0 mt -117.69 126.56 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.569 -176.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.14 110.63 1.82 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.588 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 60.7 mt -121.14 123.22 41.78 Favored 'General case' 0 N--CA 1.467 0.375 0 O-C-N 122.756 -0.261 . . . . 0.0 110.742 -179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.7 ttt -135.46 131.21 35.88 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 119.678 -0.809 . . . . 0.0 112.46 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.644 ' O ' HG22 ' E' ' 36' ' ' VAL . 0.6 OUTLIER -158.11 81.36 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.85 178.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.13 101.64 1.61 Allowed Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.98 154.89 21.36 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.43 145.1 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.404 -179.661 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -111.0 133.41 53.41 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.779 0.323 . . . . 0.0 110.572 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 71.3 mm-40 -70.71 142.2 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.195 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.31 176.0 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 121.082 0.467 . . . . 0.0 110.552 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.553 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 56.8 p-80 -99.37 159.88 14.68 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.64 179.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -153.48 178.37 9.89 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . 0.471 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 42.7 tt0 -148.92 166.64 27.99 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . 0.471 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 68.5 mttm -142.68 131.54 22.86 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.295 0.569 . . . . 0.0 111.608 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . 0.427 ' CD2' HG11 ' E' ' 36' ' ' VAL . 56.1 tp -121.75 123.45 41.86 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.72 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.34 127.43 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 121.553 0.692 . . . . 0.0 111.14 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.588 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 0.5 OUTLIER -122.13 114.48 20.94 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.9 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -120.41 117.3 27.36 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-O 121.313 0.578 . . . . 0.0 110.358 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.97 136.87 46.33 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . 0.487 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 70.5 mm-40 -70.18 122.1 18.81 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.07 -1.052 . . . . 0.0 111.524 -178.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 1.8 p-10 108.6 131.94 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.888 1.675 . . . . 0.0 109.33 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' F' ' 25' ' ' GLY . 2.4 m -110.22 113.44 44.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . 32.28 87.72 0.01 OUTLIER Glycine 0 CA--C 1.527 0.797 0 N-CA-C 111.838 -0.505 . . . . 0.0 111.838 178.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 62.7 m -65.17 -174.6 0.17 Allowed 'General case' 0 N--CA 1.438 -1.028 0 CA-C-O 121.448 0.642 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.432 ' O ' ' C ' ' F' ' 28' ' ' LYS . 96.5 m-20 -81.06 178.24 8.54 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.289 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.432 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.3 tttt -38.15 103.93 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . 0.44 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 166.02 -100.54 0.17 Allowed Glycine 0 C--O 1.219 -0.796 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -176.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.414 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -53.75 168.54 0.19 Allowed 'General case' 0 CA--C 1.509 -0.61 0 CA-C-N 118.038 0.919 . . . . 0.0 108.953 -178.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.547 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -150.91 128.1 2.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 C-N-CA 119.331 -0.947 . . . . 0.0 109.309 -174.586 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 17.2 tt -128.2 138.86 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-O 120.909 0.385 . . . . 0.0 111.873 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.41 124.27 3.64 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.2 tp -119.11 122.57 42.37 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.6 tpt -118.54 121.28 39.86 Favored 'General case' 0 N--CA 1.478 0.966 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' F' ' 37' ' ' GLY . 2.9 m -141.84 80.63 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 177.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . 18.1 -104.86 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 CA-C-N 117.516 0.144 . . . . 0.0 113.169 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.64 -161.29 22.82 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -134.37 161.45 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.387 179.939 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 . . . . . 0 N--CA 1.464 0.26 0 CA-C-O 120.926 0.393 . . . . 0.0 110.533 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.528 ' CB ' ' CE1' ' H' ' 14' ' ' HIS . 12.9 p80 -81.99 174.58 11.12 Favored 'General case' 0 N--CA 1.442 -0.866 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -143.93 179.47 7.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.089 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -152.71 135.19 15.17 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -136.24 117.85 14.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.421 0.629 . . . . 0.0 110.539 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.81 136.31 55.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.619 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -136.09 131.81 35.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-O 121.369 0.604 . . . . 0.0 111.319 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -125.95 130.67 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.61 148.26 45.69 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 122.316 1.055 . . . . 0.0 113.207 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -101.93 -177.67 3.48 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 113.406 -1.724 . . . . 0.0 108.901 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' G' ' 26' ' ' SER . 67.3 t0 -58.45 123.86 17.62 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.203 -0.599 . . . . 0.0 110.184 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . 0.53 ' O ' HG23 ' G' ' 24' ' ' VAL . 23.0 m -95.56 120.59 45.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.926 -179.042 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.93 -88.73 0.01 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 116.111 -0.495 . . . . 0.0 112.607 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.474 ' N ' ' O ' ' G' ' 24' ' ' VAL . 72.2 m -67.52 -171.6 0.2 Allowed 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.549 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 14.7 t-20 -78.79 178.77 7.66 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.186 -178.388 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.549 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 83.9 tttt -44.17 -110.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.143 0.794 . . . . 0.0 113.143 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 54.33 91.88 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.424 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -102.62 161.9 13.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 C-N-CA 116.696 -2.002 . . . . 0.0 108.628 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.505 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.1 OUTLIER -152.36 110.06 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.023 -174.829 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . 0.586 ' N ' ' SD ' ' A' ' 35' ' ' MET . 97.3 mt -108.36 110.21 31.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.197 0.523 . . . . 0.0 110.241 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 92.49 0.62 Allowed Glycine 0 CA--C 1.502 -0.761 0 N-CA-C 105.648 -2.981 . . . . 0.0 105.648 175.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.723 ' O ' HD12 ' H' ' 34' ' ' LEU . 16.7 mt -130.93 134.19 46.53 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.725 1.726 . . . . 0.0 111.984 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 0.0 OUTLIER -108.4 117.96 35.53 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 112.678 -2.055 . . . . 0.0 109.019 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.35 66.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 N-CA-C 109.244 -0.651 . . . . 0.0 109.244 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.22 -103.52 0.59 Allowed Glycine 0 C--N 1.363 2.063 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.84 162.61 25.23 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.562 179.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p . . . . . 0 N--CA 1.464 0.248 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 -179.82 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t . . . . . 0 N--CA 1.464 0.262 0 N-CA-C 110.036 -0.357 . . . . 0.0 110.036 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 82.8 t60 -147.26 107.83 4.12 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.683 -0.407 . . . . 0.0 109.99 178.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.618 ' CG ' ' CE1' ' I' ' 14' ' ' HIS . 15.0 p-80 -146.73 171.17 15.56 Favored 'General case' 0 N--CA 1.447 -0.586 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.283 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -144.35 177.25 8.76 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.13 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -152.8 131.22 12.13 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.9 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -129.36 118.56 22.42 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.934 0.397 . . . . 0.0 110.414 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -128.34 131.32 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.93 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -126.1 128.99 48.22 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.601 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 0.9 OUTLIER -134.76 128.03 32.07 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.605 -0.27 . . . . 0.0 110.389 -179.187 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.52 123.54 40.33 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.858 0.361 . . . . 0.0 110.226 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . 0.551 ' OE2' ' CE1' ' H' ' 20' ' ' PHE . 9.7 pt-20 -168.42 130.05 1.35 Allowed 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 119.897 -0.721 . . . . 0.0 112.157 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 20.0 t70 178.83 114.72 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.389 0.614 . . . . 0.0 112.376 177.386 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 114.724 -1.126 . . . . 0.0 112.364 176.582 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.431 -1.378 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.491 HG22 ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -139.55 123.1 18.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 119.512 -0.875 . . . . 0.0 109.457 -176.356 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.506 ' N ' ' SD ' ' B' ' 35' ' ' MET . 1.7 mt -115.45 119.09 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.974 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.89 103.69 1.14 Allowed Glycine 0 C--O 1.241 0.588 0 N-CA-C 105.769 -2.932 . . . . 0.0 105.769 175.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.723 HD12 ' O ' ' G' ' 34' ' ' LEU . 5.9 tp -133.74 144.13 48.89 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 122.919 1.342 . . . . 0.0 114.01 -176.16 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.418 ' HE1' ' N ' ' C' ' 33' ' ' GLY . 5.8 tpt -122.25 115.58 22.62 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 113.448 -1.706 . . . . 0.0 108.873 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.47 65.11 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.19 103.86 0.64 Allowed Glycine 0 C--N 1.353 1.504 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -90.24 176.41 41.95 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . 0.522 HG12 ' N ' ' H' ' 40' ' ' VAL . 40.5 t -137.24 161.45 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 120.929 0.395 . . . . 0.0 110.634 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . 0.522 ' N ' HG12 ' H' ' 39' ' ' VAL . 7.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.957 -1.02 . . . . 0.0 110.424 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.4 m . . . . . 0 N--CA 1.468 0.448 0 CA-C-O 120.88 0.372 . . . . 0.0 110.528 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . 0.42 ' CD2' ' N ' ' I' ' 13' ' ' HIS . 3.3 m-70 -142.09 156.97 45.4 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.125 -178.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' H' ' 14' ' ' HIS . 16.9 p-80 -156.66 167.53 30.17 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 177.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.449 ' CG ' ' N ' ' I' ' 16' ' ' LYS . 52.1 tt0 -150.98 166.66 29.99 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.629 0.728 . . . . 0.0 111.519 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . 0.525 ' NZ ' ' CG2' ' I' ' 18' ' ' VAL . 65.9 tttm -154.41 127.57 8.37 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.85 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . 0.41 HD21 ' CE2' ' I' ' 19' ' ' PHE . 59.3 tp -124.36 121.77 35.86 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . 0.525 ' CG2' ' NZ ' ' I' ' 16' ' ' LYS . 47.8 t -122.95 125.54 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.832 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CE2' HD21 ' I' ' 17' ' ' LEU . 60.5 m-85 -114.2 105.86 13.68 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 176.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 1.4 t80 -117.76 126.53 52.62 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 132.97 39.92 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.141 0.496 . . . . 0.0 111.813 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -159.35 114.47 2.45 Favored 'General case' 0 C--N 1.348 0.52 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' I' ' 23' ' ' ASP . 9.4 t0 -171.9 111.02 0.29 Allowed 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 114.435 1.272 . . . . 0.0 114.435 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.462 ' O ' HG13 ' I' ' 24' ' ' VAL . 12.4 p -31.99 131.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 CA-C-N 112.611 -2.086 . . . . 0.0 115.425 174.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -84.22 0.09 OUTLIER Glycine 0 CA--C 1.543 1.841 0 C-N-CA 119.605 -1.283 . . . . 0.0 115.157 174.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.3 m -96.76 175.41 6.37 Favored 'General case' 0 CA--C 1.5 -0.944 0 CA-C-N 120.401 2.1 . . . . 0.0 108.916 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.45 ' O ' ' O ' ' I' ' 28' ' ' LYS . 8.9 m120 -62.52 175.62 0.76 Allowed 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' I' ' 27' ' ' ASN . 53.4 tttt -45.1 -107.88 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 122.301 1.048 . . . . 0.0 113.796 178.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . 87.73 -100.01 2.56 Favored Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.907 ' C ' HD13 ' I' ' 31' ' ' ILE . . . 62.81 143.6 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.083 0 O-C-N 121.498 -1.001 . . . . 0.0 109.135 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.907 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -145.26 114.47 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.373 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' I' ' 32' ' ' ILE . 1.2 tt -108.19 112.38 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.97 113.86 2.56 Favored Glycine 0 CA--C 1.493 -1.288 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 0.549 HD23 ' N ' ' I' ' 34' ' ' LEU . 2.0 pt? -162.06 160.73 27.83 Favored 'General case' 0 C--O 1.249 1.041 0 CA-C-O 123.304 1.526 . . . . 0.0 112.695 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.491 ' SD ' ' HB ' ' C' ' 31' ' ' ILE . 33.2 ttm -127.71 136.6 51.77 Favored 'General case' 0 CA--C 1.503 -0.827 0 CA-C-N 112.351 -2.204 . . . . 0.0 111.052 -177.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.99 70.63 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.186 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.98 106.37 3.28 Favored Glycine 0 C--N 1.364 2.098 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.7 172.01 55.16 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.214 -0.755 . . . . 0.0 111.214 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -144.36 149.01 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.408 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 5.5 p . . . . . 0 C--O 1.238 0.449 0 CA-C-O 121.981 0.896 . . . . 0.0 112.591 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . 0.445 ' CD2' HE21 ' J' ' 15' ' ' GLN . 17.3 t-160 -150.9 105.62 3.28 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 114.08 -1.418 . . . . 0.0 109.548 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -149.27 166.8 27.86 Favored 'General case' 0 CA--C 1.508 -0.643 0 O-C-N 121.641 -0.662 . . . . 0.0 110.598 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . 0.445 HE21 ' CD2' ' J' ' 13' ' ' HIS . 13.3 mp0 -146.68 169.97 17.93 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.675 0.75 . . . . 0.0 111.414 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -143.71 135.88 26.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.152 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -133.87 124.61 26.75 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.65 133.69 61.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 CA-C-O 121.289 0.566 . . . . 0.0 112.078 -178.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 91.7 m-85 -112.02 113.84 26.37 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.45 ' CD1' ' CZ ' ' I' ' 20' ' ' PHE . 5.7 t80 -122.16 123.15 40.84 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 118.518 0.599 . . . . 0.0 112.592 -178.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.24 131.52 38.59 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 122.047 -0.408 . . . . 0.0 110.873 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 18.2 pt-20 -151.88 168.44 25.13 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.461 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.482 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 6.7 p30 150.94 164.12 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.149 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' J' ' 23' ' ' ASP . 48.8 t -35.83 101.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.44 93.36 0.5 Allowed Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.227 -0.897 . . . . 0.0 114.87 -175.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.751 ' O ' ' O ' ' J' ' 27' ' ' ASN . 39.3 p -102.79 160.63 14.43 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 175.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.751 ' O ' ' O ' ' J' ' 26' ' ' SER . 92.2 m-20 38.17 -179.22 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -174.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.677 ' N ' ' ND2' ' K' ' 27' ' ' ASN . 88.0 tttt -148.95 108.37 3.96 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 114.968 -2.693 . . . . 0.0 115.747 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -76.23 95.07 1.05 Allowed Glycine 0 CA--C 1.493 -1.285 0 CA-C-O 114.938 -3.146 . . . . 0.0 108.65 166.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' I' ' 29' ' ' GLY . . . -137.32 142.7 41.85 Favored 'General case' 0 CA--C 1.463 -2.381 1 CA-C-N 124.891 4.346 . . . . 0.0 108.061 176.136 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.621 HD12 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -142.91 106.12 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.357 -177.774 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.517 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -105.32 116.7 49.63 Favored 'Isoleucine or valine' 0 C--N 1.359 0.993 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.677 -178.356 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.38 96.45 0.72 Allowed Glycine 0 C--O 1.24 0.49 0 N-CA-C 106.447 -2.661 . . . . 0.0 106.447 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.803 HD23 ' CZ ' ' L' ' 19' ' ' PHE . 8.2 tp -134.25 124.87 26.63 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-O 122.695 1.236 . . . . 0.0 111.975 -177.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . 0.562 ' N ' HD12 ' J' ' 34' ' ' LEU . 4.3 ttt -119.87 126.96 52.21 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 113.345 -1.752 . . . . 0.0 109.176 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . 0.557 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -113.58 73.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.187 -178.952 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.66 112.46 0.4 Allowed Glycine 0 C--N 1.354 1.543 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.49 -139.86 0.33 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.583 -0.607 . . . . 0.0 111.583 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 54.5 t . . . . . 0 N--CA 1.464 0.254 0 CA-C-O 120.972 0.415 . . . . 0.0 110.089 -179.472 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . 0.521 ' N ' ' OE1' ' K' ' 11' ' ' GLU . 54.9 mp0 . . . . . 0 C--O 1.225 -0.192 0 N-CA-C 110.678 -0.119 . . . . 0.0 110.678 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.71 131.0 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -114.49 117.23 30.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.775 0.321 . . . . 0.0 111.403 -179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 55.6 t-80 -135.33 164.39 27.85 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.42 0.629 . . . . 0.0 109.846 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . 0.527 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 86.0 mt-30 -157.05 172.49 18.58 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.634 178.468 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.5 tttm -155.92 122.77 5.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.36 179.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.6 mt -125.13 120.42 31.33 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 4.2 m -136.38 134.17 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-O 121.538 0.685 . . . . 0.0 112.654 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 0.623 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 87.5 m-85 -115.31 110.7 19.79 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' L' ' 20' ' ' PHE . 7.8 m-85 -114.01 124.11 51.33 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -177.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 127.05 34.21 Favored 'General case' 0 N--CA 1.474 0.739 0 O-C-N 121.758 -0.589 . . . . 0.0 110.57 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.18 127.61 47.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.583 -179.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' K' ' 24' ' ' VAL . 3.6 t70 174.96 146.69 0.07 Allowed 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.523 HG23 ' H ' ' K' ' 25' ' ' GLY . 2.8 m -21.89 -101.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 123.487 0.492 . . . . 0.0 111.712 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.523 ' H ' HG23 ' K' ' 24' ' ' VAL . . . 159.84 -91.36 0.11 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.807 177.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.683 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 75.3 m -54.23 160.8 1.5 Allowed 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 118.147 0.974 . . . . 0.0 108.381 178.185 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' O ' ' K' ' 26' ' ' SER . 23.2 p30 132.52 171.04 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 O-C-N 125.083 1.49 . . . . 0.0 111.715 176.129 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -30.27 104.92 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.8 -100.6 2.09 Favored Glycine 0 C--O 1.215 -1.056 0 N-CA-C 115.737 1.055 . . . . 0.0 115.737 170.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.431 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 60.77 145.29 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 106.436 -1.691 . . . . 0.0 106.436 -178.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.431 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -160.85 134.41 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 121.614 2.006 . . . . 0.0 113.219 -179.253 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 98.0 mt -124.98 121.23 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.766 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.517 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -119.26 115.53 3.07 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . 0.423 HD11 ' CG2' ' J' ' 36' ' ' VAL . 38.1 tp -124.98 121.62 34.96 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.149 -0.525 . . . . 0.0 111.271 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mmm -131.33 133.01 44.91 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.348 178.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . 0.557 HG22 HG23 ' J' ' 36' ' ' VAL . 15.0 t -123.22 82.58 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.444 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.601 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -70.6 101.33 0.9 Allowed Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' L' ' 37' ' ' GLY . . . -158.4 155.62 26.63 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p . . . . . 0 N--CA 1.469 0.499 0 CA-C-O 120.859 0.361 . . . . 0.0 110.836 -179.588 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p . . . . . 0 N--CA 1.464 0.26 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -116.24 171.15 8.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 120.961 0.41 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -78.34 176.28 9.47 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.646 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . 0.412 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 93.4 mt-30 -138.37 175.32 9.67 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -146.07 142.31 28.43 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.324 0.583 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -126.17 113.01 16.46 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -130.35 128.45 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.329 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.803 ' CZ ' HD23 ' J' ' 34' ' ' LEU . 9.3 m-30 -109.06 109.03 19.95 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . 0.409 ' O ' ' HA ' ' K' ' 20' ' ' PHE . 33.7 t80 -112.53 114.03 26.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.392 0.615 . . . . 0.0 110.637 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . 0.422 ' O ' ' OD2' ' L' ' 23' ' ' ASP . . . -126.74 133.93 50.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' K' ' 24' ' ' VAL . 84.3 tt0 -60.68 105.48 0.45 Allowed 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.308 -177.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.422 ' OD2' ' O ' ' L' ' 21' ' ' ALA . 7.0 m-20 -154.46 136.21 14.44 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.329 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . 0.624 ' O ' HG23 ' L' ' 24' ' ' VAL . 22.5 m -109.99 111.74 37.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 119.862 -0.735 . . . . 0.0 110.566 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 26' ' ' SER . . . 31.84 -91.3 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-N 115.194 -0.912 . . . . 0.0 114.438 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' L' ' 25' ' ' GLY . 3.9 m 47.23 171.91 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.033 -1.083 . . . . 0.0 110.965 -176.635 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.526 ' O ' ' O ' ' L' ' 28' ' ' LYS . 72.3 m-80 -140.09 -177.88 5.2 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.365 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.526 ' O ' ' O ' ' L' ' 27' ' ' ASN . 99.2 mttt 26.5 102.13 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.068 0 O-C-N 123.716 0.635 . . . . 0.0 112.196 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.39 -101.57 0.21 Allowed Glycine 0 CA--C 1.493 -1.283 0 C-N-CA 119.913 -1.137 . . . . 0.0 111.791 -176.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -52.29 161.11 0.69 Allowed 'General case' 0 CA--C 1.514 -0.404 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.375 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -136.04 121.79 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.641 -177.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -129.03 138.46 54.46 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.279 0 CA-C-N 115.637 -0.711 . . . . 0.0 111.626 -178.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.97 120.99 3.25 Favored Glycine 0 N--CA 1.46 0.253 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . 0.435 HD12 ' O ' ' L' ' 34' ' ' LEU . 2.9 pp -126.12 122.24 35.16 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 38.2 mtp -134.81 143.49 47.08 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 122.147 0.975 . . . . 0.0 112.681 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -131.25 80.73 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 113.642 -1.617 . . . . 0.0 110.159 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.547 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -55.31 102.47 0.16 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.53 28.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.32 134.19 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.871 0.367 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.588 -179.843 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 . . . . . 0 N--CA 1.464 0.268 0 CA-C-O 120.932 0.396 . . . . 0.0 110.061 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' B' ' 12' ' ' VAL . 2.4 p -136.28 145.11 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.634 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 72.9 m80 -114.72 106.35 14.11 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' HIS . . . . . 0.685 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 11.6 t-160 -135.55 159.72 40.73 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 109.767 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.685 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 98.1 mm-40 -157.64 -178.93 7.69 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.847 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -147.8 122.54 9.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.6 mt -129.64 117.25 20.07 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.062 0.458 . . . . 0.0 110.659 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.5 131.05 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.098 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -123.25 134.17 54.12 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.6 p90 -137.12 124.84 22.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.898 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.24 128.21 45.67 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-O 120.733 0.302 . . . . 0.0 111.253 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -147.39 146.66 29.7 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.248 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 22.7 t0 . . . . . 0 N--CA 1.463 0.176 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 177.272 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.479 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 33.1 pttt . . . . . 0 N--CA 1.462 0.137 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.53 100.61 0.62 Allowed Glycine 0 CA--C 1.496 -1.151 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 174.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ALA . . . . . 0.574 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . -99.37 151.89 20.57 Favored 'General case' 0 C--O 1.251 1.169 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.005 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ILE . . . . . 0.472 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -143.77 107.36 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.781 0 CA-C-N 110.443 -3.071 . . . . 0.0 108.449 -173.284 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ILE . . . . . 0.598 ' CG2' HD21 ' B' ' 34' ' ' LEU . 10.6 mt -103.43 111.0 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.035 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.72 92.48 0.58 Allowed Glycine 0 CA--C 1.501 -0.805 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 177.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tp -138.03 135.02 35.49 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 122.704 1.24 . . . . 0.0 111.169 -178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 3.1 ptm -111.04 123.31 49.94 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.3 -1.773 . . . . 0.0 108.403 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -116.14 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.649 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -82.92 -100.39 0.5 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.8 -170.74 34.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.07 162.07 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.863 0.364 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 81.2 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.379 179.749 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -110.57 134.34 52.48 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 94.8 mt-10 -138.79 142.76 38.75 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' A' ' 12' ' ' VAL . 19.8 m -131.17 161.02 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' O ' ' C' ' 13' ' ' HIS . 2.1 t60 -130.29 129.03 42.72 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 14' ' ' HIS . . . . . 0.629 ' NE2' ' CG ' ' C' ' 13' ' ' HIS . 72.6 m80 -133.48 167.08 21.1 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.309 0.576 . . . . 0.0 109.678 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 15' ' ' GLN . . . . . 0.477 HE21 HD21 ' B' ' 17' ' ' LEU . 46.2 tt0 -168.93 169.56 9.61 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.495 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -155.02 125.77 7.0 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 17' ' ' LEU . . . . . 0.477 HD21 HE21 ' B' ' 15' ' ' GLN . 66.3 mt -122.22 110.97 16.37 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.058 0.456 . . . . 0.0 109.796 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -119.94 126.93 75.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.94 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -125.81 120.37 30.35 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.608 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 20' ' ' PHE . . . . . 0.418 ' HB2' ' CZ ' ' C' ' 20' ' ' PHE . 3.7 t80 -125.63 129.15 49.03 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.92 155.93 39.07 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 116.767 2.136 . . . . 0.0 116.767 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -162.75 78.34 0.47 Allowed 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 111.145 -2.752 . . . . 0.0 106.1 177.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.2 t0 . . . . . 0 N--CA 1.465 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.887 -176.384 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB1' ' C' ' 30' ' ' ALA . . . . . . . . 0 CA--C 1.49 -1.518 0 CA-C-O 127.632 3.907 . . . . 0.0 109.401 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 30' ' ' ALA . . . . . 0.574 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -79.31 -125.07 0.01 OUTLIER 'General case' 1 N--CA 1.37 -4.446 3 N-CA-C 87.399 -8.741 . . . . 0.0 87.399 166.239 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild core ' B' B ' 31' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' H' ' 35' ' ' MET . 0.2 OUTLIER -72.9 115.62 13.94 Favored 'Isoleucine or valine' 1 C--N 1.226 -4.792 0 CA-C-N 125.138 3.608 . . . . 0.0 111.128 176.465 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' B' B ' 32' ' ' ILE . . . . . 0.565 ' N ' ' SD ' ' H' ' 35' ' ' MET . 0.1 OUTLIER -109.41 115.48 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.774 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.7 90.94 0.58 Allowed Glycine 0 C--O 1.24 0.473 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 177.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 34' ' ' LEU . . . . . 0.598 HD21 ' CG2' ' A' ' 32' ' ' ILE . 74.4 mt -121.27 137.0 54.88 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.422 1.106 . . . . 0.0 112.06 -177.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 35' ' ' MET . . . . . 0.736 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 34.2 ttp -126.25 117.3 22.77 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.864 -179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 36' ' ' VAL . . . . . 0.616 HG22 HD11 ' C' ' 34' ' ' LEU . 34.0 m -123.36 71.49 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.066 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.1 -101.72 2.28 Favored Glycine 0 C--N 1.353 1.523 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.4 166.78 41.41 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -134.46 142.0 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.759 0.314 . . . . 0.0 110.306 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.398 179.801 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 m . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 120.993 0.425 . . . . 0.0 111.643 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 13' ' ' HIS . . . . . 0.629 ' CG ' ' NE2' ' B' ' 14' ' ' HIS . 29.7 m-70 -133.32 145.12 50.14 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -84.48 -179.46 7.16 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-O 121.32 0.581 . . . . 0.0 110.272 -178.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -90.91 175.23 7.05 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.994 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -130.01 134.46 47.43 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.363 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -131.55 121.46 24.46 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.257 0.551 . . . . 0.0 112.412 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 18.0 m -132.04 127.26 57.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 CA-C-O 121.989 0.9 . . . . 0.0 110.734 177.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.13 119.49 36.59 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 114.716 -1.129 . . . . 0.0 108.97 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' HB2' ' B' ' 20' ' ' PHE . 53.2 p90 -147.37 150.81 35.43 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 118.615 -1.234 . . . . 0.0 112.512 177.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.14 150.19 32.29 Favored 'General case' 0 C--O 1.241 0.634 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -119.01 117.15 28.0 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.307 -1.77 . . . . 0.0 107.673 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 23' ' ' ASP . . . . . 0.479 ' OD1' ' NZ ' ' A' ' 28' ' ' LYS . 57.3 m-20 . . . . . 0 CA--C 1.51 -0.595 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.964 -177.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 1.13 0 N-CA-C 114.495 0.558 . . . . 0.0 114.495 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' C' C ' 30' ' ' ALA . . . . . 0.598 ' HB1' ' O ' ' B' ' 29' ' ' GLY . . . -85.41 176.71 8.11 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 101.411 -3.552 . . . . 0.0 101.411 172.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 31' ' ' ILE . . . . . 0.438 HG12 ' C ' ' C' ' 30' ' ' ALA . 0.0 OUTLIER -141.97 111.72 2.76 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.248 -175.62 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.4 mt -98.75 111.17 27.71 Favored 'Isoleucine or valine' 0 C--N 1.349 0.569 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.41 99.64 1.13 Allowed Glycine 0 CA--C 1.505 -0.581 0 N-CA-C 106.048 -2.821 . . . . 0.0 106.048 175.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 34' ' ' LEU . . . . . 0.616 HD11 HG22 ' B' ' 36' ' ' VAL . 19.6 tp -135.83 133.17 37.54 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 123.056 1.408 . . . . 0.0 112.419 -176.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 35' ' ' MET . . . . . 0.774 ' SD ' HG22 ' I' ' 31' ' ' ILE . 41.2 ttp -110.49 122.06 46.82 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 113.269 -1.787 . . . . 0.0 109.532 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' C' C ' 36' ' ' VAL . . . . . 0.416 HG13 ' CG2' ' B' ' 36' ' ' VAL . 0.0 OUTLIER -109.61 66.76 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.618 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.59 -102.81 0.01 OUTLIER Glycine 0 C--N 1.362 1.99 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.88 158.03 26.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -134.4 162.74 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.438 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.851 -179.897 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t . . . . . 0 N--CA 1.465 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' D' ' 14' ' ' HIS . 84.3 t60 -89.67 130.18 35.99 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.0 0.428 . . . . 0.0 111.864 -178.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 14' ' ' HIS . . . . . 0.449 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.8 m-70 -82.84 178.16 8.31 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -96.42 178.4 5.37 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.548 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -142.29 137.69 30.81 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.825 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 41.7 tp -120.82 115.06 22.53 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.618 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.3 127.08 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.408 -0.517 . . . . 0.0 112.153 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -118.12 114.46 23.12 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 20' ' ' PHE . . . . . 0.532 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 21.5 t80 -127.6 119.08 25.15 Favored 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.179 0.514 . . . . 0.0 110.328 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 21' ' ' ALA . . . . . 0.428 ' O ' ' OE1' ' E' ' 22' ' ' GLU . . . -132.19 133.31 44.04 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-O 121.928 0.87 . . . . 0.0 112.629 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -91.4 133.61 35.32 Favored 'General case' 0 C--N 1.339 0.112 0 CA-C-N 114.677 -1.147 . . . . 0.0 108.627 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 5.8 t0 . . . . . 0 C--N 1.327 -0.378 0 CA-C-O 121.203 0.525 . . . . 0.0 110.191 -178.934 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' D' D ' 30' ' ' ALA . . . . . 0.811 ' C ' HD13 ' D' ' 31' ' ' ILE . . . . . . . . 0 CA--C 1.498 -1.051 1 N-CA-C 96.892 -5.225 . . . . 0.0 96.892 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 31' ' ' ILE . . . . . 0.87 ' N ' HD13 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -97.51 102.12 13.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 1 CA-C-N 127.292 4.587 . . . . 0.0 109.907 178.45 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.0 tt -112.97 121.94 66.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.612 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.849 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.46 100.1 1.1 Allowed Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 107.064 -2.414 . . . . 0.0 107.064 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tp -117.19 120.7 39.07 Favored 'General case' 0 CA--C 1.508 -0.64 0 CA-C-O 121.702 0.763 . . . . 0.0 110.492 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 4.9 tmm? -104.26 115.91 31.24 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -118.19 71.43 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.18 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' D' D ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.24 -101.12 0.01 OUTLIER Glycine 0 C--N 1.366 2.228 0 N-CA-C 111.86 -0.496 . . . . 0.0 111.86 178.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.48 -179.81 43.02 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.61 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -125.34 135.76 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.454 -0.373 . . . . 0.0 110.086 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.593 179.951 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -103.91 135.35 45.61 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.916 0.388 . . . . 0.0 110.21 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -106.8 151.39 25.24 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 m -131.09 156.94 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.969 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.75 174.28 7.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.798 0.332 . . . . 0.0 110.329 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 14' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' E' ' 14' ' ' HIS . 0.2 OUTLIER -78.32 174.04 11.67 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -179.374 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 15' ' ' GLN . . . . . 0.405 ' HG2' ' H ' ' E' ' 16' ' ' LYS . 44.1 tt0 -122.63 172.15 8.61 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.614 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 16' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' E' ' 15' ' ' GLN . 65.7 mttp -153.82 119.07 5.12 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.6 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.8 mt -126.31 116.43 21.21 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 18' ' ' VAL . . . . . 0.533 HG21 ' CE2' ' E' ' 20' ' ' PHE . 5.6 p -143.16 147.56 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -120.04 124.33 45.61 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 114.227 -1.351 . . . . 0.0 109.747 179.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 20' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' E' ' 18' ' ' VAL . 31.9 m-85 -121.39 126.81 50.29 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 122.373 -0.205 . . . . 0.0 110.529 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.06 137.57 37.92 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 -179.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 22' ' ' GLU . . . . . 0.532 ' OE2' ' CZ ' ' D' ' 20' ' ' PHE . 58.0 mp0 -113.22 137.84 50.87 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -150.0 132.46 15.68 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.383 178.434 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 24' ' ' VAL . . . . . 0.527 HG23 ' O ' ' E' ' 24' ' ' VAL . 30.1 m -74.59 113.08 12.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.071 179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.08 92.18 0.01 OUTLIER Glycine 0 CA--C 1.527 0.824 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.447 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 74.0 m . . . . . 0 N--CA 1.443 -0.798 0 CA-C-N 115.693 -0.253 . . . . 0.0 111.518 178.877 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' E' E ' 30' ' ' ALA . . . . . 0.466 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . . . . . . 0 C--O 1.255 1.356 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 31' ' ' ILE . . . . . 0.721 HG23 HG12 ' F' ' 31' ' ' ILE . 0.1 OUTLIER -158.23 134.48 2.0 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 C-N-CA 118.669 -1.212 . . . . 0.0 110.734 -174.341 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 32' ' ' ILE . . . . . 0.534 HD11 HD11 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -128.57 121.45 55.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 CA-C-O 121.4 0.619 . . . . 0.0 110.769 179.705 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' E' E ' 33' ' ' GLY . . . . . 0.546 ' CA ' ' SD ' ' K' ' 35' ' ' MET . . . -114.64 117.02 3.94 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 34' ' ' LEU . . . . . 0.74 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 22.9 mt -118.72 120.15 36.56 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.479 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 15.5 ttp -116.61 115.54 25.9 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.401 -0.52 . . . . 0.0 109.884 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 36' ' ' VAL . . . . . 0.654 HG13 HG22 ' F' ' 36' ' ' VAL . 2.8 p -144.03 83.77 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.52 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 37' ' ' GLY . . . . . 0.475 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -18.95 -94.49 0.01 OUTLIER Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.663 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.12 -164.05 37.24 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.07 161.01 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 120.847 0.356 . . . . 0.0 110.707 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.433 179.828 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -112.28 149.66 32.06 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.81 0.338 . . . . 0.0 110.387 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -54.01 149.14 9.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.132 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 65.3 t -114.34 130.84 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 110.948 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 13' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 31.1 p-80 -154.07 134.61 13.53 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.532 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 93.9 m-70 -155.23 170.03 22.8 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 121.303 0.573 . . . . 0.0 109.602 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -143.96 173.81 11.39 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.431 -0.804 . . . . 0.0 108.884 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -152.44 129.85 11.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.1 tp -121.08 117.9 28.38 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.51 133.14 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -177.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 19' ' ' PHE . . . . . 0.74 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 86.2 m-85 -118.48 114.73 23.3 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.902 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -134.18 144.86 48.73 Favored 'General case' 0 N--CA 1.477 0.885 0 CA-C-O 122.282 1.039 . . . . 0.0 112.086 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.43 148.35 30.2 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.128 178.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.52 136.83 39.32 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.712 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -149.62 134.03 17.46 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.418 0.628 . . . . 0.0 111.086 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' F' ' 25' ' ' GLY . 12.9 t -93.71 112.55 26.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.292 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 25' ' ' GLY . . . . . 0.463 ' O ' ' ND2' ' F' ' 27' ' ' ASN . . . 42.64 91.42 0.01 OUTLIER Glycine 0 N--CA 1.472 1.063 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.393 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 85.7 p -45.2 152.16 0.29 Allowed 'General case' 0 N--CA 1.439 -1.022 0 CA-C-O 123.066 1.412 . . . . 0.0 111.989 -176.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 69.0 m-80 -156.84 -170.9 3.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 111.679 -2.51 . . . . 0.0 106.304 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.7 mttt 19.19 110.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 121.797 0.808 . . . . 0.0 113.166 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.19 96.62 2.23 Favored Glycine 0 CA--C 1.492 -1.395 0 CA-C-O 123.412 1.562 . . . . 0.0 111.877 -174.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 30' ' ' ALA . . . . . 0.459 ' C ' HD13 ' F' ' 31' ' ' ILE . . . -63.94 -171.15 0.05 OUTLIER 'General case' 0 CA--C 1.489 -1.376 0 CA-C-N 110.989 -2.606 . . . . 0.0 107.537 -179.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 31' ' ' ILE . . . . . 0.721 HG12 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -132.74 133.76 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 117.261 -1.776 . . . . 0.0 113.191 -176.283 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' F' F ' 32' ' ' ILE . . . . . 0.444 HG23 ' O ' ' F' ' 32' ' ' ILE . 14.9 tt -126.71 132.41 70.17 Favored 'Isoleucine or valine' 0 C--N 1.345 0.386 0 CA-C-N 113.747 -1.57 . . . . 0.0 112.202 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.7 115.54 2.74 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -119.47 119.51 34.09 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 35' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 30.8 ttp -114.03 118.61 34.58 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 121.267 -0.173 . . . . 0.0 111.196 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 36' ' ' VAL . . . . . 0.654 HG22 HG13 ' E' ' 36' ' ' VAL . 5.0 t -139.11 83.05 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-O 119.295 -0.384 . . . . 0.0 110.686 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 37' ' ' GLY . . . . . 0.514 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . -15.73 -95.66 0.01 OUTLIER Glycine 0 C--N 1.351 1.367 0 O-C-N 123.063 0.227 . . . . 0.0 112.886 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 127.92 163.05 11.26 Favored Glycine 0 N--CA 1.466 0.695 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 28.6 m -140.31 160.38 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.825 0.345 . . . . 0.0 110.655 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.532 -179.968 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' G' G ' 13' ' ' HIS . . . . . 0.579 ' N ' ' HD1' ' G' ' 13' ' ' HIS . 2.5 p-80 . . . . . 0 N--CA 1.463 0.192 0 CA-C-O 120.905 0.383 . . . . 0.0 110.995 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 14' ' ' HIS . . . . . 0.571 ' CD2' ' H ' ' H' ' 14' ' ' HIS . 89.0 m-70 -132.83 178.26 7.0 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -129.09 -179.13 4.94 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.086 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 89.2 tttt -99.23 142.53 30.6 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.643 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 74.7 mt -125.68 118.79 26.38 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -136.28 138.67 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.204 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.753 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -119.64 126.36 50.96 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.211 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -122.5 120.76 34.82 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.08 127.61 44.94 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.105 0.479 . . . . 0.0 111.806 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -160.83 87.27 0.73 Allowed 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.685 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -178.37 123.13 0.1 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.925 0.393 . . . . 0.0 110.628 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.8 t -38.93 114.34 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.185 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 25' ' ' GLY . . . . . 0.808 ' H ' HG21 ' H' ' 24' ' ' VAL . . . -98.14 -86.41 1.84 Allowed Glycine 0 N--CA 1.47 0.907 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 26' ' ' SER . . . . . 0.747 ' O ' ' O ' ' G' ' 27' ' ' ASN . 17.0 m -151.58 -173.06 4.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 27' ' ' ASN . . . . . 0.747 ' O ' ' O ' ' G' ' 26' ' ' SER . 97.0 m-20 -22.79 170.0 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 O-C-N 124.313 1.008 . . . . 0.0 113.235 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 28' ' ' LYS . . . . . 0.498 ' NZ ' ' O ' ' I' ' 26' ' ' SER . 32.4 tttt -102.03 -112.82 0.21 Allowed 'General case' 0 N--CA 1.476 0.828 0 O-C-N 121.606 -0.684 . . . . 0.0 112.265 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 29' ' ' GLY . . . . . 0.551 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 47.98 91.57 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 30' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . -106.18 162.37 13.7 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 123.85 1.786 . . . . 0.0 111.127 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 31' ' ' ILE . . . . . 0.649 HG21 ' HA3' ' A' ' 37' ' ' GLY . 1.0 OUTLIER -160.29 121.94 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 110.547 -3.024 . . . . 0.0 106.84 -172.733 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -139.64 122.73 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.249 178.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.7 117.41 5.86 Favored Glycine 0 CA--C 1.506 -0.519 0 N-CA-C 106.821 -2.511 . . . . 0.0 106.821 177.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 34' ' ' LEU . . . . . 0.678 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 70.9 mt -113.59 120.17 40.02 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-O 121.562 0.696 . . . . 0.0 111.931 -177.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' C ' ' A' ' 31' ' ' ILE . 3.8 ttm -120.84 108.02 13.43 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 177.046 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.72 71.56 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -178.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.11 -98.31 0.85 Allowed Glycine 0 C--N 1.361 1.921 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.6 -173.63 43.26 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t . . . . . 0 N--CA 1.468 0.428 0 CA-C-O 120.809 0.337 . . . . 0.0 110.102 -179.597 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p . . . . . 0 N--CA 1.465 0.314 0 N-CA-C 110.494 -0.187 . . . . 0.0 110.494 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -121.61 124.07 43.45 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.69 0.281 . . . . 0.0 110.664 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' G' ' 14' ' ' HIS . 37.1 m-70 -144.58 166.18 25.91 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.345 0.593 . . . . 0.0 110.277 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.6 tp60 -160.81 161.15 31.9 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.795 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -158.83 118.06 3.05 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.54 110.5 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 18' ' ' VAL . . . . . 0.485 HG11 ' CE2' ' H' ' 20' ' ' PHE . 72.4 t -124.29 130.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 120.551 -0.46 . . . . 0.0 111.045 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.39 114.25 22.05 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.973 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 20' ' ' PHE . . . . . 0.485 ' CE2' HG11 ' H' ' 18' ' ' VAL . 52.4 m-85 -110.1 117.28 33.3 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.1 134.44 38.36 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 119.558 -0.857 . . . . 0.0 112.867 -179.355 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -152.02 89.65 1.47 Allowed 'General case' 0 C--O 1.224 -0.261 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 23' ' ' ASP . . . . . 0.444 ' N ' ' OD1' ' H' ' 23' ' ' ASP . 26.5 p-10 169.85 -121.23 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.366 0.416 . . . . 0.0 110.073 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 24' ' ' VAL . . . . . 0.808 HG21 ' H ' ' G' ' 25' ' ' GLY . 1.5 m . . . . . 0 N--CA 1.446 -0.661 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 179.025 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 30' ' ' ALA . . . . . 0.746 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . . . . . . 0 N--CA 1.434 -1.229 0 CA-C-O 124.967 2.318 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 31' ' ' ILE . . . . . 0.894 HD12 ' H ' ' H' ' 31' ' ' ILE . 4.1 mp -67.4 107.98 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.314 0 CA-C-N 109.966 -3.288 . . . . 0.0 109.796 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 32' ' ' ILE . . . . . 0.508 ' N ' ' HE1' ' C' ' 35' ' ' MET . 10.3 tt -122.47 120.44 61.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 122.246 1.022 . . . . 0.0 109.789 174.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 33' ' ' GLY . . . . . 0.736 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -98.87 117.96 6.02 Favored Glycine 0 CA--C 1.497 -1.075 0 N-CA-C 106.304 -2.718 . . . . 0.0 106.304 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 34' ' ' LEU . . . . . 0.424 HD11 HG22 ' H' ' 36' ' ' VAL . 56.0 tp -120.04 119.66 34.03 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 113.836 1.051 . . . . 0.0 113.836 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 35' ' ' MET . . . . . 0.565 ' SD ' ' N ' ' B' ' 32' ' ' ILE . 17.6 ttm -124.8 115.31 20.49 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 175.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 36' ' ' VAL . . . . . 0.444 ' O ' HG12 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -129.32 71.25 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.16 -100.81 2.66 Favored Glycine 0 C--N 1.358 1.8 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 38' ' ' GLY . . . . . 0.422 ' H ' HD13 ' B' ' 31' ' ' ILE . . . 110.54 166.17 19.21 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.04 156.62 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-O 120.686 0.279 . . . . 0.0 110.357 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.636 -179.826 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t . . . . . 0 N--CA 1.466 0.358 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 75.7 m80 -129.61 131.96 46.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.84 0.352 . . . . 0.0 111.514 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 86.3 t60 -154.18 165.76 35.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 177.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 15' ' ' GLN . . . . . 0.52 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 76.0 mt-30 -158.76 171.22 20.49 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.502 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -151.05 121.48 7.36 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.071 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -127.67 123.82 36.44 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.7 t -134.44 130.29 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 19' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' G' ' 34' ' ' LEU . 45.4 m-85 -111.35 108.45 18.05 Favored 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 176.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -116.47 119.53 35.9 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.184 -0.323 . . . . 0.0 111.109 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.78 127.5 27.17 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 -178.568 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -138.49 109.17 6.62 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.732 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 42.0 p-10 -161.69 125.14 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.96 179.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 24' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.8 m -89.82 -112.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.595 -0.442 . . . . 0.0 109.971 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 25' ' ' GLY . . . . . 0.407 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 43.98 -92.02 0.01 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.0 p -129.19 170.27 13.77 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' I' ' 26' ' ' SER . 73.5 m-80 31.98 172.58 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 28' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' J' ' 23' ' ' ASP . 23.3 pttt 148.55 95.36 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 123.344 0.658 . . . . 0.0 111.571 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 29' ' ' GLY . . . . . 0.801 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . 58.46 -112.59 4.12 Favored Glycine 1 CA--C 1.433 -5.059 0 CA-C-O 114.948 -3.14 . . . . 0.0 111.849 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 30' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' I' ' 29' ' ' GLY 0.529 . . 97.96 -125.45 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.513 1 C-N-CA 109.781 -4.768 . . . . 0.0 113.355 179.294 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild core ' I' I ' 31' ' ' ILE . . . . . 0.774 HG22 ' SD ' ' C' ' 35' ' ' MET 0.426 3.0 mt -64.05 110.74 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.402 -2.852 1 CA-C-N 106.479 -4.873 . . . . 0.0 109.967 173.924 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild core ' I' I ' 32' ' ' ILE . . . . . 0.659 HG23 HG13 ' J' ' 32' ' ' ILE . 10.6 tt -135.36 126.15 44.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-O 122.333 1.064 . . . . 0.0 112.496 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.7 119.49 5.8 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 177.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 34' ' ' LEU . . . . . 1.0 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 13.7 tp -114.68 125.72 54.06 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.638 0.733 . . . . 0.0 112.277 -178.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 35' ' ' MET . . . . . 0.421 ' N ' HD12 ' I' ' 34' ' ' LEU . 12.6 tpp -123.77 111.0 15.61 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.784 175.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' I' I ' 36' ' ' VAL . . . . . 0.734 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -128.03 68.28 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.374 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.11 -101.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.625 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.01 160.02 23.54 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.73 135.95 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.519 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 120.836 0.351 . . . . 0.0 110.607 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -137.59 103.78 5.14 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.759 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 65.5 m170 -117.7 164.66 14.64 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -157.77 172.83 17.78 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.217 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -155.41 115.64 3.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.526 178.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.27 124.15 41.78 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -134.07 132.43 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 19' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 14.8 m-85 -114.16 107.11 15.19 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 20' ' ' PHE . . . . . 0.57 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 35.4 t80 -120.92 117.55 27.63 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -166.96 175.68 7.47 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -178.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -88.22 138.83 31.09 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 113.134 -1.848 . . . . 0.0 109.032 177.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 23' ' ' ASP . . . . . 0.548 ' HA ' ' O ' ' I' ' 28' ' ' LYS . 74.0 m-20 -117.61 -161.0 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 121.384 0.611 . . . . 0.0 111.575 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 24' ' ' VAL . . . . . 0.554 HG13 ' H ' ' J' ' 29' ' ' GLY . 76.4 t 52.77 103.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 116.56 2.059 . . . . 0.0 116.56 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.59 -92.63 0.03 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 172.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' J' ' 27' ' ' ASN . 13.9 p -124.63 166.31 16.35 Favored 'General case' 0 CA--C 1.51 -0.57 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 175.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.9 m120 47.84 174.23 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 28' ' ' LYS . . . . . 0.745 ' NZ ' ' HB2' ' K' ' 30' ' ' ALA . 86.2 tttt -73.06 110.91 7.71 Favored 'General case' 0 C--N 1.35 0.626 1 C-N-CA 111.064 -4.254 . . . . 0.0 106.046 178.279 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 29' ' ' GLY . . . . . 0.554 ' H ' HG13 ' J' ' 24' ' ' VAL . . . -86.27 93.4 1.86 Allowed Glycine 0 CA--C 1.485 -1.807 0 CA-C-O 117.518 -1.712 . . . . 0.0 112.255 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 30' ' ' ALA . . . . . 0.454 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -163.16 140.21 7.49 Favored 'General case' 0 C--N 1.281 -2.406 0 CA-C-N 121.194 2.497 . . . . 0.0 108.348 171.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 31' ' ' ILE . . . . . 0.508 HG23 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -158.39 116.54 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 CA-C-N 112.249 -2.25 . . . . 0.0 107.08 -173.32 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' J' J ' 32' ' ' ILE . . . . . 0.659 HG13 HG23 ' I' ' 32' ' ' ILE . 15.6 tt -124.87 117.33 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.896 0.855 . . . . 0.0 110.994 179.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.62 118.95 6.24 Favored Glycine 0 CA--C 1.505 -0.569 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 34' ' ' LEU . . . . . 0.773 HD22 ' CE1' ' L' ' 19' ' ' PHE . 50.8 mt -113.54 107.29 15.6 Favored 'General case' 0 CA--C 1.505 -0.783 0 CA-C-O 121.322 0.582 . . . . 0.0 111.125 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.0 tpt -111.5 112.0 23.42 Favored 'General case' 0 CA--C 1.514 -0.421 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.297 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -131.63 74.71 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.668 -177.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.23 106.23 2.97 Favored Glycine 0 C--N 1.355 1.6 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.77 169.39 52.15 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 70.0 t . . . . . 0 N--CA 1.467 0.391 0 CA-C-O 120.644 0.259 . . . . 0.0 110.524 -179.558 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 . . . . . 0 N--CA 1.464 0.241 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' K' K ' 12' ' ' VAL . . . . . 0.557 ' CG2' ' NE2' ' K' ' 14' ' ' HIS . 2.6 m -140.24 -171.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -92.44 132.05 37.1 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.807 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' CG2' ' K' ' 12' ' ' VAL . 80.0 m-70 -148.03 169.75 19.25 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -157.27 178.96 9.73 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.805 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -160.57 121.5 2.96 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.173 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -126.62 125.09 41.33 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.68 129.61 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.927 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 19' ' ' PHE . . . . . 1.0 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 19.8 m-85 -113.45 108.89 17.82 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 20' ' ' PHE . . . . . 0.57 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.1 t80 -118.51 121.13 39.51 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.141 0.428 . . . . 0.0 110.855 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.03 139.84 45.13 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.71 167.53 26.18 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.781 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -166.38 -136.42 0.02 OUTLIER 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.144 177.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' K' ' 25' ' ' GLY . 18.7 t -110.62 110.36 31.9 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 25' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 32.54 91.44 0.01 OUTLIER Glycine 0 CA--C 1.53 0.981 0 N-CA-C 112.156 -0.377 . . . . 0.0 112.156 177.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 26' ' ' SER . . . . . 0.413 ' OG ' ' CG ' ' L' ' 23' ' ' ASP . 5.8 p -47.5 154.71 0.42 Allowed 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 m120 -119.15 172.58 7.48 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 122.239 1.018 . . . . 0.0 113.166 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -32.8 110.75 0.09 Allowed 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 116.248 1.944 . . . . 0.0 116.248 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.59 93.42 0.44 Allowed Glycine 0 N--CA 1.475 1.286 0 N-CA-C 116.386 1.314 . . . . 0.0 116.386 172.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 30' ' ' ALA . . . . . 0.745 ' HB2' ' NZ ' ' J' ' 28' ' ' LYS . . . -101.11 165.71 11.16 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 101.628 -3.471 . . . . 0.0 101.628 170.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 31' ' ' ILE . . . . . 0.508 HD12 HG23 ' J' ' 31' ' ' ILE . 0.2 OUTLIER -138.29 122.77 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 116.926 -1.91 . . . . 0.0 111.854 -178.224 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' K' K ' 32' ' ' ILE . . . . . 0.438 ' O ' ' SD ' ' F' ' 35' ' ' MET . 76.0 mt -131.96 130.92 61.63 Favored 'Isoleucine or valine' 0 C--N 1.352 0.686 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.443 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -122.47 122.22 4.96 Favored Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.371 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 mt -114.7 114.95 26.32 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.266 0.533 . . . . 0.0 111.8 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 35' ' ' MET . . . . . 0.546 ' SD ' ' CA ' ' E' ' 33' ' ' GLY . 8.1 ttt -128.36 120.89 27.88 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 177.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.08 81.61 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.05 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 37' ' ' GLY . . . . . 0.702 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -65.41 102.05 0.63 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.75 152.64 24.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.6 m . . . . . 0 N--CA 1.464 0.267 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.846 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' L' L ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG2' ' K' ' 12' ' ' VAL . 66.9 t . . . . . 0 N--CA 1.467 0.414 0 CA-C-O 121.922 0.868 . . . . 0.0 111.389 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 13' ' ' HIS . . . . . 0.493 ' N ' ' CD2' ' L' ' 13' ' ' HIS . 4.4 m-70 -117.66 110.79 18.31 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.699 178.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -138.78 173.63 11.38 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -144.93 177.09 9.0 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.179 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -149.36 126.1 11.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.752 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.29 125.92 37.87 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -123.63 128.63 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-O 120.94 0.4 . . . . 0.0 110.425 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 19' ' ' PHE . . . . . 0.773 ' CE1' HD22 ' J' ' 34' ' ' LEU . 70.7 m-85 -113.81 112.3 23.18 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -133.49 127.72 33.85 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 121.696 0.76 . . . . 0.0 112.689 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.57 137.61 42.15 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.644 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -80.44 109.19 14.7 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 119.953 -0.699 . . . . 0.0 112.302 -178.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 23' ' ' ASP . . . . . 0.413 ' CG ' ' OG ' ' K' ' 26' ' ' SER . 37.0 t0 178.91 113.28 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.711 178.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 63.3 t -59.16 130.55 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.607 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -68.39 85.29 0.19 Allowed Glycine 0 CA--C 1.526 0.757 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.847 178.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 49.2 m -65.6 -175.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' O ' ' L' ' 28' ' ' LYS . 2.7 m120 -91.13 178.9 5.86 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 28' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 28.03 102.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.023 0 O-C-N 123.42 0.45 . . . . 0.0 111.69 177.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.85 -101.71 0.22 Allowed Glycine 0 N--CA 1.467 0.702 0 C-N-CA 119.251 -1.452 . . . . 0.0 112.556 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.65 161.72 1.01 Allowed 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.135 -177.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 31' ' ' ILE . . . . . 0.415 HG21 ' CA ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -150.12 127.14 2.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.438 -176.108 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -127.01 129.36 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.33 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 33' ' ' GLY . . . . . 0.623 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -122.11 132.74 9.0 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.244 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -120.44 121.82 39.34 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.07 0.435 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.2 123.16 35.97 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.14 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 36' ' ' VAL . . . . . 0.73 HG23 ' O ' ' L' ' 36' ' ' VAL . 16.7 m -145.41 78.92 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -3.63 -101.22 0.0 OUTLIER Glycine 0 C--N 1.359 1.814 0 C-N-CA 122.948 0.309 . . . . 0.0 113.284 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.6 162.74 21.49 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -132.39 156.08 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.868 0.366 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.936 -1.031 . . . . 0.0 111.076 -179.534 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.266 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -127.41 139.63 52.71 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.828 0.347 . . . . 0.0 110.404 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -61.61 135.92 57.82 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.306 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.2 t -126.01 133.77 68.15 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.213 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.018 -179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 95.1 m-70 -106.24 165.87 10.93 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.467 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.414 ' O ' ' NE2' ' A' ' 15' ' ' GLN . 8.2 p80 -92.34 169.58 10.46 Favored 'General case' 0 N--CA 1.449 -0.516 0 CA-C-O 121.385 0.612 . . . . 0.0 110.249 -179.107 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.414 ' NE2' ' O ' ' A' ' 14' ' ' HIS . 96.2 mm-40 -151.71 -179.96 7.88 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.008 179.244 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 83.9 tttt -126.04 126.71 44.69 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.904 0.383 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.2 mt -128.39 127.73 43.16 Favored 'General case' 0 C--O 1.235 0.312 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.978 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -135.66 138.57 47.79 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.223 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.272 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -130.96 135.73 47.9 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.877 -179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.52 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 52.0 p90 -123.48 128.97 50.55 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.97 130.96 52.27 Favored 'General case' 0 C--O 1.24 0.568 0 CA-C-O 122.13 0.967 . . . . 0.0 112.788 -178.514 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -125.5 167.5 14.92 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 107.611 -1.255 . . . . 0.0 107.611 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -128.3 122.46 31.65 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 118.289 0.495 . . . . 0.0 112.119 -178.83 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.538 ' O ' ' N ' ' A' ' 26' ' ' SER . 3.5 m -94.25 -113.23 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 N-CA-C 108.055 -1.091 . . . . 0.0 108.055 178.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 41.85 -90.98 0.01 OUTLIER Glycine 0 CA--C 1.527 0.791 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.345 178.082 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.951 ' O ' ' O ' ' A' ' 27' ' ' ASN . 41.2 t -170.97 170.52 6.26 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 106.139 -1.8 . . . . 0.0 106.139 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.951 ' O ' ' O ' ' A' ' 26' ' ' SER . 4.0 m120 13.38 -179.18 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 124.839 1.337 . . . . 0.0 113.626 -176.482 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 74.1 tttt -150.05 105.5 3.39 Favored 'General case' 0 N--CA 1.464 0.242 0 O-C-N 119.586 -1.946 . . . . 0.0 114.683 177.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -77.53 101.4 1.64 Allowed Glycine 0 CA--C 1.507 -0.461 0 CA-C-O 114.823 -3.209 . . . . 0.0 105.505 168.648 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.22 147.73 25.98 Favored 'General case' 0 C--N 1.355 0.838 1 CA-C-N 125.483 4.642 . . . . 0.0 108.621 -178.407 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.591 HG22 ' CE ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -152.73 112.44 0.4 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-N 113.117 -1.856 . . . . 0.0 109.397 -171.704 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . . . . . . . . . 56.5 mt -121.93 103.48 13.53 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 N-CA-C 108.267 -1.012 . . . . 0.0 108.267 176.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.65 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -116.55 107.49 1.63 Allowed Glycine 0 CA--C 1.505 -0.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 177.272 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.501 ' H ' HD23 ' B' ' 34' ' ' LEU . 70.2 mt -142.66 153.66 43.63 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-O 123.295 1.521 . . . . 0.0 113.085 -177.122 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.469 ' SD ' ' C ' ' G' ' 31' ' ' ILE . 28.5 ttm -119.96 119.58 33.86 Favored 'General case' 0 CA--C 1.5 -0.949 0 CA-C-N 112.643 -2.071 . . . . 0.0 108.433 178.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -117.53 66.91 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.846 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.09 -102.13 0.01 OUTLIER Glycine 0 C--N 1.356 1.65 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.75 171.99 38.71 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 179.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 54.6 t -131.56 139.16 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.838 0.351 . . . . 0.0 110.415 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 23.5 m . . . . . 0 C--O 1.221 -0.447 0 CA-C-O 117.894 -1.05 . . . . 0.0 110.357 179.811 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 53.4 p90 -147.36 158.54 44.01 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.683 0.277 . . . . 0.0 110.37 -179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.51 ' OE2' ' NE2' ' B' ' 13' ' ' HIS . 81.2 tt0 -146.56 146.26 30.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.272 179.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.1 m -136.88 159.68 36.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.163 0.506 . . . . 0.0 111.283 -179.824 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.51 ' NE2' ' OE2' ' B' ' 11' ' ' GLU . 96.0 m-70 -149.83 163.52 37.81 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.067 -179.883 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -115.04 178.39 4.3 Favored 'General case' 0 CA--C 1.51 -0.576 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 179.571 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 85.3 mt-30 -97.2 175.09 6.41 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.775 -179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -117.49 138.67 51.71 Favored 'General case' 0 N--CA 1.465 0.316 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -129.73 127.27 40.1 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-O 121.051 0.453 . . . . 0.0 111.589 -179.162 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 64.9 t -126.85 130.49 71.46 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.097 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -124.23 134.01 53.37 Favored 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.395 179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 30.6 t80 -136.2 123.48 21.85 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.727 -0.215 . . . . 0.0 111.031 -179.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.433 ' O ' ' CG ' ' B' ' 22' ' ' GLU . . . -126.86 117.55 22.82 Favored 'General case' 0 N--CA 1.479 0.986 0 CA-C-O 120.946 0.403 . . . . 0.0 111.067 179.273 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.433 ' CG ' ' O ' ' B' ' 21' ' ' ALA . 83.3 mt-10 -165.47 133.8 3.16 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.617 179.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -170.27 111.03 0.41 Allowed 'General case' 0 N--CA 1.471 0.605 0 N-CA-C 115.209 1.559 . . . . 0.0 115.209 177.238 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 72.8 t -30.72 132.1 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.32 0 CA-C-N 113.943 -1.48 . . . . 0.0 111.942 174.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.19 -82.93 0.09 OUTLIER Glycine 0 CA--C 1.53 1.007 0 C-N-CA 119.627 -1.273 . . . . 0.0 113.405 179.086 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.588 ' O ' ' O ' ' B' ' 27' ' ' ASN . 0.4 OUTLIER -170.54 -179.2 2.88 Favored 'General case' 0 N--CA 1.445 -0.712 0 CA-C-N 119.476 1.638 . . . . 0.0 112.279 -178.909 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.588 ' O ' ' O ' ' B' ' 26' ' ' SER . 64.0 t30 27.22 -171.51 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 112.341 -2.208 . . . . 0.0 113.531 -177.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.561 ' H ' ' CG ' ' B' ' 27' ' ' ASN . 64.4 tttt -145.35 -103.81 0.1 Allowed 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 115.985 -0.552 . . . . 0.0 112.164 -177.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' B' ' 28' ' ' LYS . . . 38.2 95.91 0.01 OUTLIER Glycine 0 C--N 1.35 1.355 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 -178.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -112.91 152.29 29.49 Favored 'General case' 0 CA--C 1.494 -1.183 0 N-CA-C 107.702 -1.222 . . . . 0.0 107.702 179.678 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.645 ' CG2' HD12 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -143.28 118.35 4.35 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.193 0 CA-C-N 113.914 -1.494 . . . . 0.0 109.059 -175.126 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.447 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.1 tt -122.65 114.74 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 121.686 0.755 . . . . 0.0 109.705 179.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -117.5 116.9 3.62 Favored Glycine 0 N--CA 1.463 0.498 0 N-CA-C 107.877 -2.089 . . . . 0.0 107.877 178.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.501 HD23 ' H ' ' A' ' 34' ' ' LEU . 79.6 mt -134.62 147.0 50.09 Favored 'General case' 0 CA--C 1.505 -0.75 0 N-CA-C 114.444 1.276 . . . . 0.0 114.444 -176.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.464 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 3.2 ttm -122.48 118.35 28.11 Favored 'General case' 0 CA--C 1.505 -0.779 0 CA-C-N 113.469 -1.696 . . . . 0.0 109.366 177.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.09 70.16 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.792 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.18 112.18 3.46 Favored Glycine 0 C--N 1.358 1.785 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 178.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -52.43 147.94 12.74 Favored Glycine 0 CA--C 1.525 0.668 0 C-N-CA 120.829 -0.701 . . . . 0.0 111.628 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -127.82 136.3 60.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 109.744 -0.465 . . . . 0.0 109.744 179.74 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 12.7 p . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.087 -0.958 . . . . 0.0 110.572 179.704 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.427 -1.469 . . . . 0.0 109.427 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -109.91 139.14 45.33 Favored 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 110.068 -0.345 . . . . 0.0 110.068 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 57.4 mp0 -63.11 132.4 51.73 Favored 'General case' 0 N--CA 1.462 0.136 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 72.5 t -129.24 131.53 67.59 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-N 116.692 -0.231 . . . . 0.0 110.425 -179.842 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.572 ' CD2' ' CE1' ' D' ' 13' ' ' HIS . 80.0 m-70 -152.12 119.26 5.88 Favored 'General case' 0 N--CA 1.463 0.219 0 C-N-CA 120.565 -0.454 . . . . 0.0 111.35 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 53.9 t-80 -136.61 164.78 27.42 Favored 'General case' 0 CA--C 1.511 -0.527 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -155.88 178.63 10.04 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 120.873 0.368 . . . . 0.0 110.557 -179.72 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 86.9 tttt -167.72 106.92 0.54 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.208 178.664 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 10.0 mt -122.12 121.15 36.24 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 179.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 41.4 t -129.26 125.97 63.09 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.582 0 CA-C-O 121.027 0.442 . . . . 0.0 111.971 -179.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 8.6 m-85 -120.52 113.94 21.03 Favored 'General case' 0 CA--C 1.545 0.751 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 178.05 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -116.92 132.96 56.57 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.185 0.194 . . . . 0.0 110.641 -179.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.91 138.1 25.37 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 -179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.459 ' OE1' ' OE1' ' D' ' 22' ' ' GLU . 85.1 tt0 -161.88 144.1 11.49 Favored 'General case' 0 N--CA 1.475 0.817 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.474 178.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.465 ' O ' ' O ' ' C' ' 24' ' ' VAL . 20.3 t0 -168.7 120.56 0.79 Allowed 'General case' 0 CA--C 1.543 0.685 0 C-N-CA 120.329 -0.548 . . . . 0.0 112.187 178.233 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.465 ' O ' ' O ' ' C' ' 23' ' ' ASP . 12.7 m -49.15 -122.04 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-N 115.327 -0.852 . . . . 0.0 112.142 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 77.18 -91.13 1.01 Allowed Glycine 0 CA--C 1.536 1.391 0 CA-C-N 114.945 -1.025 . . . . 0.0 115.54 179.427 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.661 ' O ' ' O ' ' C' ' 27' ' ' ASN . 81.5 p -170.23 -179.01 2.96 Favored 'General case' 0 CA--C 1.51 -0.571 0 CA-C-N 118.385 1.092 . . . . 0.0 110.98 -175.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.661 ' O ' ' O ' ' C' ' 26' ' ' SER . 96.6 m-20 27.26 -169.61 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 114.862 -1.063 . . . . 0.0 112.629 -179.191 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.428 ' CD ' ' H ' ' D' ' 29' ' ' GLY . 42.9 tttt -138.37 -106.3 0.18 Allowed 'General case' 0 N--CA 1.467 0.392 0 N-CA-C 112.71 0.633 . . . . 0.0 112.71 -176.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.647 ' H ' ' HA3' ' D' ' 29' ' ' GLY . . . 45.45 93.31 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 -175.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.43 ' O ' HG13 ' D' ' 31' ' ' ILE . . . -106.37 157.87 17.3 Favored 'General case' 0 CA--C 1.482 -1.665 0 N-CA-C 101.764 -3.421 . . . . 0.0 101.764 175.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.645 HD12 ' CG2' ' B' ' 31' ' ' ILE . 2.0 mt -140.02 122.65 16.72 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.15 0 C-N-CA 117.94 -1.504 . . . . 0.0 111.74 -173.209 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.469 HG22 ' O ' ' C' ' 32' ' ' ILE . 1.1 mt -117.75 112.59 39.31 Favored 'Isoleucine or valine' 0 C--N 1.348 0.532 0 CA-C-N 115.473 -0.785 . . . . 0.0 109.14 179.137 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.78 102.81 0.87 Allowed Glycine 0 CA--C 1.507 -0.461 0 N-CA-C 105.009 -3.236 . . . . 0.0 105.009 176.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.427 ' CD1' ' CE2' ' D' ' 19' ' ' PHE . 7.0 tt -134.73 138.52 44.44 Favored 'General case' 0 CA--C 1.513 -0.465 0 CA-C-O 122.654 1.216 . . . . 0.0 113.29 -175.042 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 25.9 ttm -117.99 120.5 38.0 Favored 'General case' 0 CA--C 1.504 -0.798 0 CA-C-N 113.705 -1.588 . . . . 0.0 108.724 178.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.652 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.0 p -125.36 71.52 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.032 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.465 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.405 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.39 -100.86 0.01 OUTLIER Glycine 0 C--N 1.362 2.012 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.437 -179.7 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.51 -157.83 29.8 Favored Glycine 0 CA--C 1.526 0.768 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 -178.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -133.9 160.24 42.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.004 0.43 . . . . 0.0 110.905 -179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 44.9 t . . . . . 0 C--O 1.22 -0.491 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.831 179.986 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.343 0 N-CA-C 109.443 -1.463 . . . . 0.0 109.443 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' D' ' 10' ' ' TYR . 18.0 p90 -147.75 156.12 42.42 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-O 120.945 0.402 . . . . 0.0 110.788 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 73.4 mm-40 -75.25 155.94 36.23 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.777 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.604 HG21 ' HB ' ' E' ' 12' ' ' VAL . 9.9 m -146.49 -164.47 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.062 -178.58 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.572 ' CE1' ' CD2' ' C' ' 13' ' ' HIS . 80.9 m-70 -78.4 124.63 28.33 Favored 'General case' 0 C--N 1.325 -0.458 0 C-N-CA 120.145 -0.622 . . . . 0.0 111.727 -179.06 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.507 ' CD2' HG23 ' D' ' 12' ' ' VAL . 82.8 m-70 -148.45 167.97 23.91 Favored 'General case' 0 C--N 1.342 0.28 0 CA-C-O 121.244 0.545 . . . . 0.0 109.985 179.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.63 177.69 10.67 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.2 -0.909 . . . . 0.0 109.591 178.882 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -168.61 114.09 0.62 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.21 0.528 . . . . 0.0 111.779 179.215 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 35.5 tp -123.72 121.59 35.87 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.215 179.825 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 47.0 t -126.62 125.48 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.465 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 35.8 m-85 -117.21 120.87 39.58 Favored 'General case' 0 N--CA 1.47 0.553 0 CA-C-N 115.595 -0.729 . . . . 0.0 109.187 177.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 4.3 t80 -128.34 122.41 31.48 Favored 'General case' 0 N--CA 1.474 0.74 0 CA-C-O 120.828 0.347 . . . . 0.0 111.175 -179.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.65 135.55 40.26 Favored 'General case' 0 N--CA 1.471 0.591 0 C-N-CA 121.083 -0.247 . . . . 0.0 111.166 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.49 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 89.7 mt-10 -117.57 124.39 48.55 Favored 'General case' 0 N--CA 1.482 1.167 0 C-N-CA 120.811 -0.355 . . . . 0.0 111.111 -179.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 77.8 m-20 -146.38 122.58 10.85 Favored 'General case' 0 CA--C 1.548 0.889 0 N-CA-C 112.852 0.686 . . . . 0.0 112.852 -179.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.98 -111.48 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.542 0.646 0 CA-C-O 121.817 0.818 . . . . 0.0 111.638 179.534 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 42.21 -92.34 0.01 OUTLIER Glycine 0 CA--C 1.547 2.036 0 C-N-CA 126.727 2.108 . . . . 0.0 118.353 -179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 58.8 m -90.78 -178.4 5.24 Favored 'General case' 0 CA--C 1.501 -0.938 0 CA-C-N 118.532 1.166 . . . . 0.0 110.413 -174.865 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 69.3 m-80 -58.84 162.8 3.81 Favored 'General case' 0 CA--C 1.506 -0.721 0 N-CA-C 105.933 -1.877 . . . . 0.0 105.933 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.784 ' HZ3' ' H ' ' E' ' 24' ' ' VAL . 76.6 mttt -56.32 111.25 0.92 Allowed 'General case' 0 N--CA 1.438 -1.052 0 C-N-CA 115.944 -2.302 . . . . 0.0 112.398 -174.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.647 ' HA3' ' H ' ' C' ' 29' ' ' GLY . . . -91.41 93.1 1.8 Allowed Glycine 0 CA--C 1.498 -1.001 0 CA-C-O 116.195 -2.447 . . . . 0.0 109.711 169.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.04 144.54 31.68 Favored 'General case' 0 CA--C 1.473 -2.0 0 CA-C-N 123.227 3.514 . . . . 0.0 108.923 175.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.499 ' O ' ' SD ' ' J' ' 35' ' ' MET . 0.1 OUTLIER -143.36 108.2 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 CA-C-N 113.535 -1.666 . . . . 0.0 107.955 -176.561 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 5.2 mt -110.53 121.89 64.11 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.087 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.626 -178.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -125.94 103.22 0.68 Allowed Glycine 0 C--N 1.311 -0.813 0 N-CA-C 105.526 -3.03 . . . . 0.0 105.526 175.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.573 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 10.4 tt -127.78 131.33 49.62 Favored 'General case' 0 C--O 1.241 0.653 0 CA-C-O 122.171 0.986 . . . . 0.0 111.747 -177.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.944 ' SD ' HG22 ' J' ' 31' ' ' ILE . 17.0 ttm -112.05 121.81 46.02 Favored 'General case' 0 CA--C 1.509 -0.604 0 CA-C-N 113.985 -1.462 . . . . 0.0 110.011 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.466 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -110.95 75.43 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.558 0 N-CA-C 108.586 -0.894 . . . . 0.0 108.586 178.803 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -31.85 -96.24 0.01 OUTLIER Glycine 0 C--N 1.353 1.502 0 N-CA-C 111.251 -0.74 . . . . 0.0 111.251 179.461 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 116.9 175.29 17.49 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 179.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 10.0 p -139.7 141.51 34.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.92 0.39 . . . . 0.0 110.608 -179.886 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 39.9 t . . . . . 0 C--O 1.22 -0.46 0 CA-C-O 118.077 -0.963 . . . . 0.0 110.563 179.962 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.254 0 N-CA-C 109.558 -1.417 . . . . 0.0 109.558 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . 0.514 ' CE1' ' N ' ' F' ' 9' ' ' GLY . 88.1 m-85 -107.89 135.04 49.95 Favored 'General case' 0 N--CA 1.464 0.227 0 CA-C-O 120.832 0.348 . . . . 0.0 110.211 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -64.52 138.63 58.51 Favored 'General case' 0 C--O 1.237 0.409 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.186 -179.42 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.604 ' HB ' HG21 ' D' ' 12' ' ' VAL . 72.6 t -122.38 131.28 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.237 0 CA-C-N 115.635 -0.712 . . . . 0.0 109.619 179.153 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.542 ' O ' ' ND1' ' E' ' 14' ' ' HIS . 96.1 m-70 -121.41 114.99 22.08 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.385 -179.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.542 ' ND1' ' O ' ' E' ' 13' ' ' HIS . 2.7 m80 -142.46 168.31 20.03 Favored 'General case' 0 CA--C 1.509 -0.603 0 CA-C-O 121.641 0.734 . . . . 0.0 110.124 -179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -151.63 168.95 23.35 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-N 114.599 -1.182 . . . . 0.0 109.079 178.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -146.36 111.36 5.33 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 179.483 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 31.9 mt -122.99 121.81 37.0 Favored 'General case' 0 C--O 1.235 0.292 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 179.365 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . 0.523 HG21 ' CE2' ' E' ' 20' ' ' PHE . 14.3 p -140.16 135.87 37.22 Favored 'Isoleucine or valine' 0 C--O 1.239 0.511 0 CA-C-O 121.944 0.878 . . . . 0.0 112.883 -179.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.573 ' CZ ' ' CD1' ' D' ' 34' ' ' LEU . 36.7 m-85 -117.72 117.23 28.77 Favored 'General case' 0 CA--C 1.532 0.261 0 CA-C-N 114.327 -1.306 . . . . 0.0 109.927 179.303 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.523 ' CE2' HG21 ' E' ' 18' ' ' VAL . 38.3 m-85 -113.3 119.56 38.12 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.699 0.285 . . . . 0.0 111.105 -179.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.414 ' O ' ' HA ' ' F' ' 21' ' ' ALA . . . -126.6 137.86 53.38 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-O 120.972 0.415 . . . . 0.0 110.01 178.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 77.5 tt0 -79.47 73.83 6.11 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 118.309 -1.356 . . . . 0.0 111.158 -177.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.608 ' O ' ' O ' ' E' ' 24' ' ' VAL . 1.3 p30 -171.49 109.92 0.29 Allowed 'General case' 0 CA--C 1.549 0.917 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.663 176.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.784 ' H ' ' HZ3' ' D' ' 28' ' ' LYS . 2.8 t -45.27 -132.23 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.481 1.077 0 CA-C-O 122.698 1.237 . . . . 0.0 112.582 177.404 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.648 ' C ' ' HB2' ' F' ' 30' ' ' ALA . . . -138.76 80.99 0.27 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.613 ' O ' ' N ' ' F' ' 30' ' ' ALA . 28.6 m -68.94 -169.85 0.2 Allowed 'General case' 0 C--O 1.214 -0.808 0 CA-C-O 121.294 0.568 . . . . 0.0 110.734 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.528 ' O ' ' C ' ' E' ' 28' ' ' LYS . 39.8 m-20 -81.46 -175.53 5.55 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 114.577 -1.192 . . . . 0.0 108.012 179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.528 ' C ' ' O ' ' E' ' 27' ' ' ASN . 87.0 tttt -28.24 104.41 0.02 OUTLIER 'General case' 0 N--CA 1.48 1.049 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 -177.889 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.509 ' O ' ' CG1' ' E' ' 31' ' ' ILE . . . 168.16 -101.33 0.17 Allowed Glycine 0 C--O 1.211 -1.33 0 CA-C-O 117.586 -1.674 . . . . 0.0 111.231 -171.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.421 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -53.46 153.39 4.15 Favored 'General case' 0 C--O 1.246 0.893 0 CA-C-N 121.289 2.545 . . . . 0.0 110.251 -175.586 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.532 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.1 mt -148.57 126.09 2.9 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.516 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.946 -175.127 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' L' ' 35' ' ' MET . 89.3 mt -128.99 128.15 66.92 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.711 0 CA-C-O 120.901 0.381 . . . . 0.0 111.946 -178.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.91 121.34 4.69 Favored Glycine 0 N--CA 1.469 0.871 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.095 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.54 HD13 ' CZ ' ' F' ' 19' ' ' PHE . 47.9 tp -127.93 124.67 37.91 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.219 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.499 ' SD ' ' O ' ' K' ' 32' ' ' ILE . 8.9 ttt -129.84 126.27 37.64 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 120.31 -0.556 . . . . 0.0 111.547 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.449 HG22 ' CG2' ' D' ' 36' ' ' VAL . 51.3 t -109.94 86.84 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 CA-C-N 115.826 -0.625 . . . . 0.0 110.425 179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.643 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -75.0 96.9 0.99 Allowed Glycine 0 N--CA 1.438 -1.174 0 N-CA-C 110.419 -1.072 . . . . 0.0 110.419 179.458 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.2 170.8 43.1 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 -179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -128.45 135.06 63.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-O 120.911 0.386 . . . . 0.0 109.999 178.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.0 p . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.795 -179.791 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . 0.514 ' N ' ' CE1' ' E' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.646 -1.382 . . . . 0.0 109.646 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' F' ' 11' ' ' GLU . 79.8 t80 -84.66 130.82 34.66 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.731 0.3 . . . . 0.0 110.94 -179.744 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.529 ' O ' ' CD2' ' F' ' 10' ' ' TYR . 98.3 mt-10 -59.08 154.13 16.44 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.514 179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 6.2 t -96.25 132.82 39.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.773 0.32 . . . . 0.0 110.703 -179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 82.1 t60 -153.13 113.98 4.1 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.204 0.526 . . . . 0.0 111.867 -178.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -155.1 173.72 16.19 Favored 'General case' 0 CA--C 1.511 -0.546 0 N-CA-C 107.25 -1.389 . . . . 0.0 107.25 179.183 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 12.5 pt20 -151.92 175.65 12.27 Favored 'General case' 0 C--N 1.316 -0.886 0 C-N-CA 119.936 -0.706 . . . . 0.0 111.855 -179.788 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -132.17 114.48 14.54 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.745 179.773 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 49.0 tp -122.68 118.77 28.89 Favored 'General case' 0 C--N 1.33 -0.252 0 N-CA-C 108.326 -0.991 . . . . 0.0 108.326 179.535 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 77.2 t -133.35 130.0 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 N-CA-C 113.528 0.936 . . . . 0.0 113.528 -178.324 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.54 ' CZ ' HD13 ' E' ' 34' ' ' LEU . 55.0 m-85 -113.64 111.82 22.47 Favored 'General case' 0 C--N 1.333 -0.151 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 175.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 10.3 t80 -141.81 152.86 44.09 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-O 122.005 0.907 . . . . 0.0 112.244 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.414 ' HA ' ' O ' ' E' ' 21' ' ' ALA . . . -150.46 149.14 29.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.055 -0.975 . . . . 0.0 110.291 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -136.79 144.39 43.7 Favored 'General case' 0 N--CA 1.478 0.936 0 N-CA-C 112.875 0.694 . . . . 0.0 112.875 -178.147 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.54 ' OD1' ' N ' ' F' ' 24' ' ' VAL . 62.2 t0 177.75 -118.48 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.863 177.66 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.54 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 13.2 p -102.18 126.41 56.23 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.568 0 CA-C-O 121.124 0.488 . . . . 0.0 110.659 -179.234 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -31.4 -83.15 0.01 OUTLIER Glycine 0 CA--C 1.531 1.092 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.007 177.252 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 13.2 t 73.08 179.96 0.22 Allowed 'General case' 0 N--CA 1.449 -0.522 0 C-N-CA 124.456 1.102 . . . . 0.0 110.183 -176.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.418 ' O ' ' OD1' ' E' ' 27' ' ' ASN . 88.8 m-20 -89.42 172.7 8.82 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 118.544 2.794 . . . . 0.0 118.544 -173.854 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -39.09 106.33 0.05 Allowed 'General case' 0 CA--C 1.546 0.806 0 CA-C-N 109.268 -3.605 . . . . 0.0 119.894 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.61 ' C ' ' O ' ' F' ' 30' ' ' ALA . . . 148.02 -97.22 0.18 Allowed Glycine 0 N--CA 1.483 1.8 0 C-N-CA 120.492 -0.861 . . . . 0.0 115.224 171.315 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.648 ' HB2' ' C ' ' E' ' 25' ' ' GLY . . . 56.2 166.02 0.02 OUTLIER 'General case' 0 N--CA 1.472 0.651 0 N-CA-C 103.186 -2.894 . . . . 0.0 103.186 -173.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.444 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 1.6 mt -140.08 119.37 12.23 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.906 0 CA-C-N 124.098 3.135 . . . . 0.0 111.447 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 57.7 mt -123.87 136.23 60.92 Favored 'Isoleucine or valine' 0 C--N 1.347 0.483 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.512 -176.438 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.44 125.16 5.16 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 178.532 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 46.9 tp -118.64 120.8 38.51 Favored 'General case' 0 N--CA 1.47 0.54 0 O-C-N 122.642 -0.328 . . . . 0.0 110.229 179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -118.37 119.38 34.45 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-N 116.952 -0.113 . . . . 0.0 111.098 -179.502 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.49 HG22 ' O ' ' F' ' 36' ' ' VAL . 2.4 p -153.21 82.47 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.545 0.763 0 CA-C-O 120.805 0.336 . . . . 0.0 110.912 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.898 ' H ' HD13 ' L' ' 31' ' ' ILE . . . -71.4 101.11 0.94 Allowed Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.891 -0.883 . . . . 0.0 110.891 179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.26 161.51 34.51 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -141.86 143.7 26.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.791 0.329 . . . . 0.0 110.604 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 t . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.4 179.769 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 76.3 m-85 -103.79 133.08 49.38 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 120.855 0.36 . . . . 0.0 110.449 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 79.9 mm-40 -112.98 152.42 29.43 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.803 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 39.6 t -113.38 134.02 57.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.324 0 CA-C-O 120.935 0.397 . . . . 0.0 110.091 -179.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.449 ' N ' ' ND1' ' G' ' 13' ' ' HIS . 6.3 p-80 -133.41 -177.95 4.76 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.311 -179.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 8.2 m80 -81.72 167.92 18.63 Favored 'General case' 0 N--CA 1.446 -0.648 0 CA-C-O 121.126 0.489 . . . . 0.0 109.961 -179.207 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.45 ' HG3' ' H ' ' G' ' 16' ' ' LYS . 51.0 tp60 -163.17 172.32 15.0 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.556 -0.747 . . . . 0.0 109.563 179.471 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.45 ' H ' ' HG3' ' G' ' 15' ' ' GLN . 99.7 mttt -138.72 139.81 38.5 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.408 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 47.1 tp -138.83 120.68 15.41 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 121.213 0.53 . . . . 0.0 110.902 179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 33.7 m -126.41 134.36 66.57 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.479 -0.782 . . . . 0.0 109.767 179.497 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 11.8 t80 -129.2 125.31 36.7 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 120.939 0.4 . . . . 0.0 110.592 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.402 ' CD1' ' C ' ' G' ' 20' ' ' PHE . 19.5 t80 -113.46 123.26 49.61 Favored 'General case' 0 N--CA 1.468 0.429 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.17 131.81 53.16 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-O 121.805 0.812 . . . . 0.0 112.472 -178.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.419 ' O ' ' C ' ' G' ' 23' ' ' ASP . 18.6 pt-20 -102.48 -173.08 2.25 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 114.302 -1.317 . . . . 0.0 110.771 179.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.483 ' N ' ' CB ' ' H' ' 23' ' ' ASP . 19.3 t70 -23.83 132.96 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 113.492 0.923 . . . . 0.0 113.492 -179.089 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.522 ' O ' ' N ' ' G' ' 26' ' ' SER . 11.7 t -89.33 113.56 26.0 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-N 114.197 -1.365 . . . . 0.0 108.162 177.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . -44.92 91.55 0.01 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.402 -178.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.552 ' O ' ' O ' ' G' ' 27' ' ' ASN . 16.1 m 138.92 172.34 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.577 0 N-CA-C 107.331 -1.359 . . . . 0.0 107.331 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.552 ' O ' ' O ' ' G' ' 26' ' ' SER . 90.9 m-20 -43.07 -178.67 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 O-C-N 123.429 0.456 . . . . 0.0 111.066 179.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.573 ' CE ' HG22 ' I' ' 24' ' ' VAL . 68.5 tttt -72.07 -114.7 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.515 0 C-N-CA 120.077 -0.649 . . . . 0.0 110.767 178.314 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 50.32 91.33 0.01 OUTLIER Glycine 0 C--N 1.344 0.974 0 N-CA-C 109.755 -1.338 . . . . 0.0 109.755 179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -103.0 163.26 12.32 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 117.326 -1.75 . . . . 0.0 108.629 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.469 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -152.56 109.5 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.198 0 CA-C-N 112.966 -1.924 . . . . 0.0 109.618 -172.806 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.522 ' CG2' HD21 ' H' ' 34' ' ' LEU . 5.1 mt -100.95 111.05 29.39 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 107.954 -1.128 . . . . 0.0 107.954 177.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.25 99.0 0.68 Allowed Glycine 0 CA--C 1.503 -0.661 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.419 ' H ' HD23 ' H' ' 34' ' ' LEU . 12.0 mt -138.65 141.58 39.06 Favored 'General case' 0 C--O 1.242 0.666 0 CA-C-O 122.965 1.364 . . . . 0.0 111.572 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.65 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 38.0 ttp -109.66 114.96 29.0 Favored 'General case' 0 N--CA 1.44 -0.971 0 CA-C-N 112.957 -1.928 . . . . 0.0 107.158 178.648 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -115.41 66.03 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.927 0 N-CA-C 109.679 -0.489 . . . . 0.0 109.679 -179.35 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -100.78 110.92 4.02 Favored Glycine 0 C--N 1.359 1.828 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 178.816 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 53.63 178.99 0.11 Allowed Glycine 0 CA--C 1.525 0.69 0 N-CA-C 110.943 -0.863 . . . . 0.0 110.943 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 23.8 m -137.6 161.05 34.26 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 CA-C-O 120.782 0.325 . . . . 0.0 110.749 179.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.471 0 CA-C-O 118.066 -0.968 . . . . 0.0 110.325 179.69 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -106.67 140.84 38.89 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-O 120.945 0.402 . . . . 0.0 110.472 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -139.12 164.74 28.99 Favored 'General case' 0 N--CA 1.463 0.223 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.542 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.639 HG13 ' HD1' ' I' ' 13' ' ' HIS . 78.2 t -82.47 133.54 28.92 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.881 -179.99 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.428 ' O ' ' O ' ' I' ' 13' ' ' HIS . 3.5 t60 -140.06 100.23 3.87 Favored 'General case' 0 C--N 1.33 -0.267 0 C-N-CA 120.816 -0.354 . . . . 0.0 110.894 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.631 ' ND1' ' N ' ' H' ' 15' ' ' GLN . 13.9 t-80 -141.88 159.07 42.97 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 178.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.631 ' N ' ' ND1' ' H' ' 14' ' ' HIS . 71.1 mt-30 -162.0 178.52 8.78 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.155 -0.93 . . . . 0.0 108.966 178.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -130.51 132.4 45.6 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 69.0 mt -120.9 111.74 17.91 Favored 'General case' 0 C--O 1.233 0.217 0 N-CA-C 109.287 -0.634 . . . . 0.0 109.287 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.54 127.22 74.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-O 121.143 0.497 . . . . 0.0 110.963 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 85.0 t80 -117.1 112.94 21.59 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.381 178.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 45.1 t80 -111.24 121.2 44.66 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 110.178 -0.304 . . . . 0.0 110.178 -179.563 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.37 132.39 48.55 Favored 'General case' 0 N--CA 1.476 0.867 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.256 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 80.9 tt0 -164.58 125.73 2.13 Favored 'General case' 0 N--CA 1.467 0.377 0 C-N-CA 119.857 -0.737 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.483 ' CB ' ' N ' ' G' ' 23' ' ' ASP . 0.9 OUTLIER -176.64 109.36 0.08 Allowed 'General case' 0 CA--C 1.544 0.723 0 N-CA-C 115.0 1.481 . . . . 0.0 115.0 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 95.6 t -37.9 135.35 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.285 173.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -160.05 -81.79 0.04 OUTLIER Glycine 0 CA--C 1.533 1.201 0 C-N-CA 118.941 -1.599 . . . . 0.0 112.54 176.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.742 ' O ' ' O ' ' H' ' 27' ' ' ASN . 49.5 p -171.01 179.88 2.96 Favored 'General case' 0 C--O 1.211 -0.922 0 CA-C-N 118.42 1.11 . . . . 0.0 109.823 178.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.742 ' O ' ' O ' ' H' ' 26' ' ' SER . 57.3 m-80 26.35 -177.88 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.961 0 N-CA-C 114.148 1.166 . . . . 0.0 114.148 177.349 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.415 ' O ' ' O ' ' H' ' 29' ' ' GLY . 70.1 mmtt -119.6 -110.51 0.34 Allowed 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.547 -179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 43.8 92.48 0.01 OUTLIER Glycine 0 N--CA 1.468 0.781 0 C-N-CA 119.712 -1.232 . . . . 0.0 111.277 178.976 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.47 152.78 48.63 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.728 -1.952 . . . . 0.0 105.728 178.826 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.401 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -146.2 129.6 9.87 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 118.735 -1.186 . . . . 0.0 112.429 -172.378 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.464 ' C ' ' SD ' ' B' ' 35' ' ' MET . 67.3 mt -112.64 117.63 55.8 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.767 0 CA-C-N 115.218 -0.901 . . . . 0.0 109.351 178.468 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 102.06 0.91 Allowed Glycine 0 N--CA 1.466 0.648 0 N-CA-C 108.017 -2.033 . . . . 0.0 108.017 177.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.522 HD21 ' CG2' ' G' ' 32' ' ' ILE . 89.7 mt -131.96 131.37 42.55 Favored 'General case' 0 CA--C 1.498 -1.025 0 CA-C-O 122.005 0.907 . . . . 0.0 112.791 -177.647 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 42.1 ttp -108.61 116.86 32.78 Favored 'General case' 0 N--CA 1.445 -0.696 0 CA-C-N 114.193 -1.367 . . . . 0.0 107.546 176.874 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.17 67.5 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.557 1.218 0 N-CA-C 108.427 -0.953 . . . . 0.0 108.427 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 38' ' ' GLY . . . -94.04 110.91 4.06 Favored Glycine 0 C--N 1.372 2.568 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.323 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.49 ' O ' ' O ' ' H' ' 37' ' ' GLY . . . 31.59 -159.57 0.0 OUTLIER Glycine 0 CA--C 1.524 0.616 0 CA-C-O 121.777 0.654 . . . . 0.0 113.06 178.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -138.97 159.55 29.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.74 -0.73 . . . . 0.0 109.385 179.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 30.7 m . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.633 -179.67 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -103.87 132.11 50.44 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 120.78 0.324 . . . . 0.0 110.538 -179.848 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 80.4 mm-40 -105.78 157.38 17.49 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.751 -179.902 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.659 HG12 ' N ' ' I' ' 13' ' ' HIS . 41.0 t -100.39 173.77 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.342 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.38 179.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.659 ' N ' HG12 ' I' ' 12' ' ' VAL . 71.6 m80 -159.39 173.12 16.73 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.979 0.419 . . . . 0.0 111.092 179.429 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 45.8 m-70 -125.75 -179.44 4.66 Favored 'General case' 0 CA--C 1.511 -0.535 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 179.108 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.547 ' OE1' ' N ' ' H' ' 15' ' ' GLN . 8.9 mm-40 -95.83 173.88 7.24 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-O 121.328 0.585 . . . . 0.0 111.741 -178.354 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -114.33 139.29 49.58 Favored 'General case' 0 N--CA 1.469 0.507 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 178.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 12.6 mt -119.49 122.78 42.44 Favored 'General case' 0 N--CA 1.473 0.676 0 CA-C-O 121.188 0.518 . . . . 0.0 111.706 -179.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 59.1 t -130.96 122.2 51.41 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.957 178.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 46.8 m-85 -111.24 107.18 16.4 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.301 -1.741 . . . . 0.0 106.301 176.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 14.4 t80 -115.63 127.42 55.19 Favored 'General case' 0 N--CA 1.47 0.563 0 CA-C-O 120.75 0.309 . . . . 0.0 111.04 -177.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.37 128.54 25.75 Favored 'General case' 0 C--O 1.234 0.278 0 CA-C-O 122.112 0.958 . . . . 0.0 112.796 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 -108.88 164.75 12.12 Favored 'General case' 0 CA--C 1.51 -0.571 0 N-CA-C 104.46 -2.422 . . . . 0.0 104.46 175.94 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 27.3 t70 60.71 -110.64 0.45 Allowed 'General case' 0 C--N 1.323 -0.556 0 C-N-CA 116.83 -1.948 . . . . 0.0 108.653 -179.368 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.573 HG22 ' CE ' ' G' ' 28' ' ' LYS . 69.5 t -45.63 132.1 2.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-O 122.743 1.259 . . . . 0.0 112.581 -175.894 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.67 82.84 0.76 Allowed Glycine 0 CA--C 1.519 0.322 0 CA-C-N 112.365 -2.198 . . . . 0.0 110.022 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 5.3 p -99.07 172.52 7.34 Favored 'General case' 0 CA--C 1.499 -0.986 0 CA-C-O 121.547 0.689 . . . . 0.0 110.269 177.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.869 ' H ' HD22 ' I' ' 27' ' ' ASN . 0.5 OUTLIER -62.12 171.02 1.93 Allowed 'General case' 0 C--N 1.304 -1.4 0 CA-C-N 114.488 -1.233 . . . . 0.0 109.037 175.56 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.459 ' O ' ' CB ' ' J' ' 26' ' ' SER . 89.6 mttt 55.37 110.69 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.47 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 178.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.526 ' H ' ' CA ' ' J' ' 30' ' ' ALA . . . 67.53 92.37 0.05 OUTLIER Glycine 0 N--CA 1.474 1.168 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 179.203 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.435 ' C ' HG12 ' I' ' 31' ' ' ILE . . . -173.86 156.11 2.74 Favored 'General case' 0 C--N 1.271 -2.816 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 177.1 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.586 ' CG2' HD12 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -142.09 117.75 5.87 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 C-N-CA 117.14 -1.824 . . . . 0.0 109.982 -174.448 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.601 ' N ' ' SD ' ' C' ' 35' ' ' MET . 16.1 tt -115.08 121.0 66.2 Favored 'Isoleucine or valine' 0 C--N 1.36 1.026 0 CA-C-O 122.114 0.959 . . . . 0.0 111.174 179.84 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.31 99.38 1.11 Allowed Glycine 0 CA--C 1.505 -0.576 0 N-CA-C 105.819 -2.913 . . . . 0.0 105.819 176.484 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.661 HD13 ' CZ ' ' K' ' 19' ' ' PHE . 7.1 tt -123.37 127.63 48.75 Favored 'General case' 0 C--O 1.238 0.481 0 CA-C-O 122.545 1.164 . . . . 0.0 111.245 -177.625 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.425 ' HE2' ' O ' ' C' ' 31' ' ' ILE . 2.8 ttm -108.87 118.9 37.98 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 114.227 -1.352 . . . . 0.0 111.195 -179.422 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.559 HG23 HG13 ' J' ' 36' ' ' VAL . 0.0 OUTLIER -127.14 67.43 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.74 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 177.383 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.463 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -42.67 -103.26 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 111.122 -0.791 . . . . 0.0 111.122 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -163.67 -162.44 14.56 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -115.93 135.52 55.79 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 CA-C-O 121.01 0.433 . . . . 0.0 110.48 -179.385 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.427 ' OXT' HG22 ' I' ' 40' ' ' VAL . 8.2 p . . . . . 0 C--O 1.219 -0.54 0 CA-C-O 118.011 -0.995 . . . . 0.0 110.784 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . 0.426 ' O ' ' OE1' ' J' ' 11' ' ' GLU . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.521 -1.432 . . . . 0.0 109.521 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 78.7 t80 -93.4 129.76 39.43 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 179.721 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.533 ' OE1' ' N ' ' J' ' 11' ' ' GLU . 57.5 mp0 -132.47 146.57 52.03 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-O 121.15 0.5 . . . . 0.0 111.104 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.589 ' H ' ' CD2' ' K' ' 13' ' ' HIS . 0.1 OUTLIER -130.57 -165.38 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.551 0 CA-C-N 115.519 -0.764 . . . . 0.0 108.992 -179.955 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 27.7 m170 -61.98 118.32 7.12 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 119.964 -0.694 . . . . 0.0 110.565 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.539 ' CG ' ' N ' ' J' ' 15' ' ' GLN . 2.7 t-80 -135.75 164.04 28.81 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 179.689 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.539 ' N ' ' CG ' ' J' ' 14' ' ' HIS . 83.2 mt-30 -155.81 177.01 11.89 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.269 179.569 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.611 ' C ' HD12 ' J' ' 17' ' ' LEU . 86.6 tttt -172.27 128.24 0.56 Allowed 'General case' 0 C--O 1.239 0.522 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.521 178.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.611 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.3 mp -117.76 123.27 45.6 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.75 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 73.6 t -127.45 126.55 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.658 0 C-N-CA 120.92 -0.312 . . . . 0.0 111.623 -179.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -120.97 106.8 11.94 Favored 'General case' 0 N--CA 1.473 0.722 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 178.743 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -114.8 128.04 56.07 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.575 -0.703 . . . . 0.0 112.184 -178.89 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.43 123.64 36.58 Favored 'General case' 0 C--O 1.248 0.997 0 CA-C-O 121.97 0.891 . . . . 0.0 111.617 179.123 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.452 ' OE1' ' OE1' ' K' ' 22' ' ' GLU . 81.2 mm-40 -128.11 113.08 15.3 Favored 'General case' 0 N--CA 1.471 0.59 0 CA-C-N 114.414 -1.266 . . . . 0.0 110.479 -179.163 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.437 ' O ' ' C ' ' J' ' 24' ' ' VAL . 30.9 t0 -174.79 138.31 0.48 Allowed 'General case' 0 C--N 1.333 -0.142 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.816 -178.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.437 ' C ' ' O ' ' J' ' 23' ' ' ASP . 3.7 m -16.95 -110.22 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.711 0 N-CA-C 113.863 1.06 . . . . 0.0 113.863 -178.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.401 ' H ' HG23 ' J' ' 24' ' ' VAL . . . -166.83 92.3 0.1 Allowed Glycine 0 CA--C 1.534 1.246 0 C-N-CA 119.83 -1.176 . . . . 0.0 113.892 -173.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' J' ' 27' ' ' ASN . 0.4 OUTLIER -63.26 -173.22 0.06 Allowed 'General case' 0 N--CA 1.449 -0.523 0 N-CA-C 108.307 -0.997 . . . . 0.0 108.307 -179.101 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' J' ' 26' ' ' SER . 77.5 m-20 -77.88 172.8 12.91 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 116.602 2.075 . . . . 0.0 116.602 -172.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.413 ' CE ' ' O ' ' K' ' 28' ' ' LYS . 6.5 mmtm -44.12 111.85 0.34 Allowed 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 110.959 -2.837 . . . . 0.0 118.154 -177.628 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.403 ' C ' ' H ' ' I' ' 29' ' ' GLY . . . 93.84 94.42 1.56 Allowed Glycine 0 CA--C 1.501 -0.783 0 CA-C-N 114.209 -1.36 . . . . 0.0 114.501 176.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.526 ' CA ' ' H ' ' I' ' 29' ' ' GLY . . . -84.49 170.17 13.75 Favored 'General case' 0 CA--C 1.506 -0.749 0 N-CA-C 102.057 -3.312 . . . . 0.0 102.057 173.1 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.944 HG22 ' SD ' ' D' ' 35' ' ' MET . 0.4 OUTLIER -150.45 123.22 1.33 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.861 0 CA-C-N 120.985 1.72 . . . . 0.0 111.752 -177.294 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.647 HD12 HG12 ' K' ' 32' ' ' ILE . 97.4 mt -109.89 117.27 54.29 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.297 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.385 178.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -114.14 102.08 1.17 Allowed Glycine 0 C--O 1.238 0.38 0 N-CA-C 106.282 -2.727 . . . . 0.0 106.282 175.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.927 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 7.9 tt -132.74 139.18 47.48 Favored 'General case' 0 C--O 1.245 0.819 0 CA-C-O 121.675 0.75 . . . . 0.0 112.562 -176.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.784 ' N ' HD23 ' J' ' 34' ' ' LEU . 33.8 ttp -123.7 125.74 45.3 Favored 'General case' 0 N--CA 1.469 0.52 0 CA-C-N 114.734 -1.121 . . . . 0.0 112.6 179.866 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.559 HG13 HG23 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -123.63 70.05 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.558 1.287 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 177.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' J' ' 36' ' ' VAL . . . -44.6 -100.78 0.01 OUTLIER Glycine 0 C--N 1.357 1.716 0 N-CA-C 110.811 -0.915 . . . . 0.0 110.811 178.668 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 122.98 150.8 8.16 Favored Glycine 0 N--CA 1.463 0.483 0 N-CA-C 110.841 -0.904 . . . . 0.0 110.841 179.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 14.6 p -158.39 148.01 8.63 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 120.856 0.36 . . . . 0.0 110.224 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 71.3 t . . . . . 0 C--O 1.221 -0.437 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.379 179.861 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -119.74 143.86 47.57 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.724 0.297 . . . . 0.0 110.492 -179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -110.64 144.64 39.23 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.278 179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.571 HG12 ' N ' ' K' ' 13' ' ' HIS . 48.3 t -141.06 166.25 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.983 -179.078 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.589 ' CD2' ' H ' ' J' ' 12' ' ' VAL . 1.2 m-70 -115.89 161.93 18.08 Favored 'General case' 0 N--CA 1.468 0.435 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 0.4 OUTLIER -68.9 174.75 4.14 Favored 'General case' 0 N--CA 1.442 -0.843 0 CA-C-O 121.23 0.538 . . . . 0.0 109.868 -178.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -142.03 176.67 8.77 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.017 -179.226 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -149.42 135.47 18.93 Favored 'General case' 0 C--O 1.236 0.381 0 CA-C-O 121.051 0.453 . . . . 0.0 110.822 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -127.72 111.34 13.58 Favored 'General case' 0 C--O 1.237 0.398 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 178.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 78.9 t -134.66 127.27 49.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 N-CA-C 112.933 0.716 . . . . 0.0 112.933 -178.316 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.661 ' CZ ' HD13 ' I' ' 34' ' ' LEU . 3.4 m-30 -113.31 141.37 47.11 Favored 'General case' 0 CA--C 1.536 0.442 0 N-CA-C 105.163 -2.162 . . . . 0.0 105.163 175.539 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.463 ' HA ' ' HA ' ' L' ' 20' ' ' PHE . 77.9 t80 -136.4 117.87 14.77 Favored 'General case' 0 N--CA 1.505 2.311 0 CA-C-N 120.858 1.663 . . . . 0.0 114.128 179.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.894 ' HB3' ' O ' ' L' ' 21' ' ' ALA . . . -121.91 126.17 48.06 Favored 'General case' 0 C--N 1.398 2.707 0 CA-C-O 123.13 1.443 . . . . 0.0 112.061 178.475 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.567 ' O ' ' ND2' ' I' ' 27' ' ' ASN . 82.5 tt0 -89.63 124.7 34.81 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 113.934 -1.485 . . . . 0.0 112.249 -178.88 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -123.87 131.81 53.64 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.063 179.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 5.2 t -73.42 113.64 11.67 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.53 0 C-N-CA 120.332 -0.547 . . . . 0.0 110.175 179.404 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.432 ' O ' ' O ' ' K' ' 26' ' ' SER . . . 59.41 91.35 0.01 OUTLIER Glycine 0 CA--C 1.529 0.954 0 CA-C-N 115.554 -0.748 . . . . 0.0 112.861 178.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.542 ' O ' ' CB ' ' K' ' 27' ' ' ASN . 3.7 p -43.67 170.27 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 177.553 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.654 ' CG ' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER 157.49 -179.19 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 CA-C-O 122.891 1.329 . . . . 0.0 114.007 178.873 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.654 ' N ' ' CG ' ' K' ' 27' ' ' ASN . 52.4 mttp -29.62 112.49 0.08 Allowed 'General case' 0 N--CA 1.478 0.952 0 N-CA-C 119.365 3.098 . . . . 0.0 119.365 -179.665 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.403 ' H ' ' HB2' ' L' ' 30' ' ' ALA . . . 83.01 91.62 0.65 Allowed Glycine 0 N--CA 1.48 1.598 0 N-CA-C 119.814 2.686 . . . . 0.0 119.814 173.265 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.548 ' H ' ' CB ' ' L' ' 30' ' ' ALA . . . -143.62 155.22 44.2 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 101.916 -3.364 . . . . 0.0 101.916 170.555 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.679 HG13 HG23 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -145.96 121.39 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 C-N-CA 118.553 -1.259 . . . . 0.0 111.158 -176.563 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.647 HG12 HD12 ' J' ' 32' ' ' ILE . 96.7 mt -120.74 127.64 75.95 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.488 -177.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.55 110.64 1.88 Allowed Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 178.361 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.516 HD12 ' N ' ' K' ' 35' ' ' MET . 6.3 tp -121.63 118.65 29.71 Favored 'General case' 0 C--O 1.238 0.453 0 CA-C-N 115.224 -0.488 . . . . 0.0 110.637 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.516 ' N ' HD12 ' K' ' 34' ' ' LEU . 6.2 tmm? -118.99 117.51 29.01 Favored 'General case' 0 N--CA 1.475 0.81 0 C-N-CA 120.105 -0.638 . . . . 0.0 110.867 178.241 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.431 HG22 HD11 ' K' ' 34' ' ' LEU . 1.4 t -113.29 79.69 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-O 120.981 0.42 . . . . 0.0 110.162 178.523 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.532 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -87.29 100.58 2.59 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 178.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -167.72 172.78 42.64 Favored Glycine 0 CA--C 1.524 0.608 0 C-N-CA 120.727 -0.749 . . . . 0.0 111.463 -179.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -131.46 141.76 45.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 N-CA-C 109.855 -0.424 . . . . 0.0 109.855 179.589 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 5.9 p . . . . . 0 C--O 1.219 -0.512 0 CA-C-O 117.966 -1.016 . . . . 0.0 110.37 179.9 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.209 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -104.1 132.33 50.45 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 45.9 tp10 -149.12 135.57 19.37 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.976 0.417 . . . . 0.0 110.944 -179.374 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 53.2 t -128.96 134.61 63.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.382 0 CA-C-N 115.804 -0.634 . . . . 0.0 110.008 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 53.2 t-80 -158.0 107.39 2.08 Favored 'General case' 0 CA--C 1.53 0.174 0 CA-C-O 120.872 0.368 . . . . 0.0 111.388 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.522 ' CE1' ' O ' ' L' ' 15' ' ' GLN . 54.6 t-80 -153.81 166.95 31.29 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 179.126 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.522 ' O ' ' CE1' ' L' ' 14' ' ' HIS . 84.5 mt-30 -152.7 178.88 9.14 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.129 0.49 . . . . 0.0 110.991 -179.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -154.84 125.36 6.91 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.471 -0.786 . . . . 0.0 109.352 179.29 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 14.0 mt -120.78 115.59 23.59 Favored 'General case' 0 N--CA 1.467 0.382 0 O-C-N 122.507 -0.121 . . . . 0.0 110.773 -179.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 67.5 t -125.66 126.71 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 178.526 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.927 ' CZ ' HD13 ' J' ' 34' ' ' LEU . 5.0 m-30 -99.09 125.35 44.59 Favored 'General case' 0 N--CA 1.469 0.506 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 -178.592 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.768 ' HB2' ' N ' ' K' ' 21' ' ' ALA . 1.6 p90 -32.47 159.9 0.0 OUTLIER 'General case' 0 C--O 1.158 -3.758 0 N-CA-C 121.05 3.722 . . . . 0.0 121.05 -172.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.894 ' O ' ' HB3' ' K' ' 21' ' ' ALA . . . -78.62 157.14 28.77 Favored 'General case' 0 N--CA 1.438 -1.039 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.068 174.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.456 ' OE1' ' O ' ' L' ' 20' ' ' PHE . 0.0 OUTLIER 178.67 -169.41 0.09 Allowed 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 -177.114 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.562 ' OD1' ' N ' ' K' ' 27' ' ' ASN . 20.8 t0 -62.97 106.09 0.77 Allowed 'General case' 0 CA--C 1.539 0.549 0 N-CA-C 107.663 -1.236 . . . . 0.0 107.663 178.161 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.453 HG23 ' HB2' ' K' ' 26' ' ' SER . 87.0 t -36.16 142.84 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 N-CA-C 111.865 0.32 . . . . 0.0 111.865 -178.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -98.75 82.94 0.61 Allowed Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 178.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 67.6 m -69.15 -171.69 0.35 Allowed 'General case' 0 N--CA 1.44 -0.927 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.546 ' O ' ' O ' ' L' ' 28' ' ' LYS . 96.3 m-20 -81.13 177.41 9.05 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-N 115.17 -0.923 . . . . 0.0 109.313 178.075 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.546 ' O ' ' O ' ' L' ' 27' ' ' ASN . 86.2 tttt 39.81 104.16 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 120.875 0.369 . . . . 0.0 111.265 178.957 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.19 -101.19 1.85 Allowed Glycine 0 N--CA 1.467 0.715 0 N-CA-C 110.302 -1.119 . . . . 0.0 110.302 -177.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.548 ' CB ' ' H ' ' K' ' 30' ' ' ALA . . . -61.88 170.0 2.29 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 118.222 1.011 . . . . 0.0 108.652 -179.168 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.898 HD13 ' H ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -166.11 153.41 1.71 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 C-N-CA 118.642 -1.223 . . . . 0.0 112.413 -177.885 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 86.7 mt -125.31 128.01 72.4 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.157 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.063 177.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.35 121.38 5.03 Favored Glycine 0 N--CA 1.469 0.853 0 N-CA-C 111.873 -0.491 . . . . 0.0 111.873 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 49.2 tp -119.77 118.62 31.35 Favored 'General case' 0 N--CA 1.463 0.22 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 178.952 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.522 ' CE ' HG22 ' E' ' 31' ' ' ILE . 3.9 ttp -117.36 119.94 36.64 Favored 'General case' 0 N--CA 1.472 0.657 0 C-N-CA 121.06 -0.256 . . . . 0.0 110.525 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.58 ' O ' HG23 ' L' ' 36' ' ' VAL . 35.8 m -130.46 76.29 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.643 0 N-CA-C 111.619 0.229 . . . . 0.0 111.619 179.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.474 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . 23.9 -112.63 0.01 OUTLIER Glycine 0 C--N 1.352 1.428 0 N-CA-C 112.234 -0.346 . . . . 0.0 112.234 178.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -107.76 -150.56 15.97 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.022 -1.231 . . . . 0.0 110.022 179.346 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.3 m -130.51 158.29 42.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-O 120.816 0.341 . . . . 0.0 110.35 179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 12.8 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.676 -179.636 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.329 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -102.11 138.38 39.14 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.838 0.352 . . . . 0.0 110.387 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -119.63 143.05 47.9 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.429 -179.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.499 HG23 ' O ' ' B' ' 12' ' ' VAL . 2.5 m -121.9 132.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.432 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 46.1 p-80 -151.83 166.79 30.33 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.929 -179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.411 ' CD2' ' CE1' ' B' ' 13' ' ' HIS . 93.0 m-70 -132.13 179.5 6.06 Favored 'General case' 0 N--CA 1.452 -0.343 0 N-CA-C 109.615 -0.513 . . . . 0.0 109.615 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 96.7 mm-40 -95.25 177.43 5.86 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 115.778 -0.646 . . . . 0.0 111.587 -179.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -116.37 145.31 43.32 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-N 115.532 -0.758 . . . . 0.0 109.893 -179.454 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 40.7 tp -128.22 123.0 33.12 Favored 'General case' 0 N--CA 1.475 0.783 0 CA-C-O 121.268 0.556 . . . . 0.0 111.872 -179.152 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.5 p -130.54 131.43 65.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-N 115.538 -0.756 . . . . 0.0 109.335 178.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 70.2 t80 -137.52 132.7 33.61 Favored 'General case' 0 N--CA 1.467 0.409 0 CA-C-O 121.133 0.492 . . . . 0.0 111.599 -179.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.3 p90 -133.14 129.94 38.56 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -154.24 158.12 39.77 Favored 'General case' 0 N--CA 1.471 0.62 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -178.334 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.446 ' CB ' ' O ' ' B' ' 22' ' ' GLU . 22.5 pt-20 -143.88 150.65 38.75 Favored 'General case' 0 CA--C 1.536 0.409 0 CA-C-N 113.459 -1.7 . . . . 0.0 107.915 179.014 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 71.4 m-20 -94.09 -146.54 0.25 Allowed 'General case' 0 N--CA 1.466 0.35 0 C-N-CA 119.706 -0.797 . . . . 0.0 111.202 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.43 ' O ' ' N ' ' A' ' 26' ' ' SER . 15.2 t -103.34 107.27 21.78 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 179.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' A' ' 24' ' ' VAL . . . -34.62 92.52 0.01 OUTLIER Glycine 0 CA--C 1.535 1.343 0 C-N-CA 121.536 -0.364 . . . . 0.0 112.914 178.911 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.685 ' O ' ' O ' ' A' ' 27' ' ' ASN . 2.2 t 170.05 177.51 0.05 OUTLIER 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 177.067 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.685 ' O ' ' O ' ' A' ' 26' ' ' SER . 15.9 t-20 -29.19 179.15 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.59 1.181 . . . . 0.0 112.641 177.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.557 ' CG ' ' O ' ' A' ' 27' ' ' ASN . 0.0 OUTLIER 128.45 103.57 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.383 0 N-CA-C 113.429 0.9 . . . . 0.0 113.429 175.794 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -61.05 101.06 0.27 Allowed Glycine 0 CA--C 1.484 -1.891 0 N-CA-C 106.962 -2.455 . . . . 0.0 106.962 176.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.784 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . -83.33 151.79 25.4 Favored 'General case' 0 N--CA 1.438 -1.039 0 C-N-CA 114.861 -2.736 . . . . 0.0 108.78 -175.089 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.518 ' O ' ' SD ' ' G' ' 35' ' ' MET 0.3 0.3 OUTLIER -166.34 108.3 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.41 -2.475 0 CA-C-N 109.253 -3.612 . . . . 0.0 104.97 -168.806 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.495 ' N ' ' HE1' ' H' ' 35' ' ' MET . 17.8 tt -119.58 123.46 71.12 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.969 0 CA-C-O 121.56 0.695 . . . . 0.0 110.032 179.716 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.573 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -124.3 116.8 2.91 Favored Glycine 0 CA--C 1.507 -0.468 0 N-CA-C 108.144 -1.982 . . . . 0.0 108.144 178.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.416 ' HB2' ' CD2' ' B' ' 34' ' ' LEU . 35.0 mt -136.21 148.15 47.97 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 122.905 1.336 . . . . 0.0 111.572 -179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.449 ' SD ' ' C ' ' G' ' 32' ' ' ILE . 12.0 ttm -121.18 124.0 43.64 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 112.475 -2.148 . . . . 0.0 109.362 -179.076 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -124.6 71.9 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.821 0 N-CA-C 109.787 -0.449 . . . . 0.0 109.787 179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -51.99 -96.47 0.01 OUTLIER Glycine 0 C--N 1.357 1.721 0 N-CA-C 110.39 -1.084 . . . . 0.0 110.39 178.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.59 -162.76 36.55 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.756 -0.938 . . . . 0.0 110.756 -179.76 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 33.6 m -131.0 160.76 42.01 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.26 0 CA-C-O 120.855 0.359 . . . . 0.0 110.273 -179.632 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.22 -0.47 0 CA-C-O 117.956 -1.021 . . . . 0.0 110.466 -179.662 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.736 -1.346 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -113.04 140.71 47.61 Favored 'General case' 0 N--CA 1.467 0.403 0 N-CA-C 110.174 -0.306 . . . . 0.0 110.174 179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -110.57 137.65 47.98 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.909 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.499 ' O ' HG23 ' A' ' 12' ' ' VAL . 27.8 m -135.7 159.95 39.64 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.815 179.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.411 ' CE1' ' CD2' ' A' ' 14' ' ' HIS . 79.9 t60 -140.64 124.02 16.82 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.37 -0.377 . . . . 0.0 109.999 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 52.9 p-80 -149.32 166.74 28.08 Favored 'General case' 0 N--CA 1.448 -0.559 0 CA-C-O 121.239 0.543 . . . . 0.0 109.846 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 76.9 mt-30 -153.84 179.72 8.62 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 115.305 -0.862 . . . . 0.0 109.592 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -163.71 109.12 1.06 Allowed 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.059 179.125 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 5.0 mp -130.31 118.72 21.72 Favored 'General case' 0 C--O 1.235 0.29 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 179.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.77 131.36 53.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 121.347 0.594 . . . . 0.0 110.866 179.55 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 90.4 m-85 -119.91 131.14 55.13 Favored 'General case' 0 C--O 1.232 0.143 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.239 -179.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 94.1 t80 -128.37 119.95 26.02 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -125.01 132.68 53.21 Favored 'General case' 0 N--CA 1.476 0.826 0 C-N-CA 120.522 -0.471 . . . . 0.0 111.863 -179.451 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.446 ' O ' ' CB ' ' A' ' 22' ' ' GLU . 81.8 tt0 -155.15 133.37 11.68 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.295 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 60.6 t0 -113.95 133.3 55.56 Favored 'General case' 0 N--CA 1.469 0.496 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 4.0 t -81.98 113.12 20.8 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 C-N-CA 120.346 -0.542 . . . . 0.0 110.596 -179.116 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 51.78 90.4 0.01 OUTLIER Glycine 0 CA--C 1.527 0.819 0 CA-C-N 115.697 -0.683 . . . . 0.0 112.74 177.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.8 t 170.19 178.2 0.05 OUTLIER 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 109.595 -0.52 . . . . 0.0 109.595 178.314 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' B' ' 26' ' ' SER . 4.7 m120 -28.75 170.65 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.974 0 O-C-N 124.646 1.216 . . . . 0.0 111.473 177.337 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.573 ' NZ ' ' O ' ' D' ' 24' ' ' VAL . 98.2 mttt -151.43 104.17 3.05 Favored 'General case' 0 CA--C 1.542 0.657 0 CA-C-O 123.032 1.396 . . . . 0.0 112.558 179.116 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.784 ' O ' ' HB3' ' A' ' 30' ' ' ALA . . . 50.64 -102.69 0.07 OUTLIER Glycine 1 CA--C 1.388 -7.855 0 C-N-CA 127.463 2.459 . . . . 0.0 114.279 179.457 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.743 ' HB3' ' O ' ' B' ' 29' ' ' GLY 0.451 . . 113.93 -131.84 0.0 OUTLIER 'General case' 1 N--CA 1.366 -4.645 0 C-N-CA 114.019 -3.072 . . . . 0.0 106.355 -175.777 . . . . . . . . 4 3 . 1 . 002 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.725 HD12 ' N ' ' B' ' 31' ' ' ILE 0.366 2.2 mp -70.07 120.92 18.65 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.877 0 CA-C-N 109.245 -3.616 . . . . 0.0 113.458 175.045 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.422 ' O ' HG23 ' B' ' 32' ' ' ILE . 16.9 tt -125.83 118.28 51.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 175.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.676 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -124.65 119.37 3.64 Favored Glycine 0 N--CA 1.469 0.897 0 N-CA-C 108.814 -1.714 . . . . 0.0 108.814 -179.428 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.416 ' CD2' ' HB2' ' A' ' 34' ' ' LEU . 96.4 mt -136.61 131.25 33.48 Favored 'General case' 0 CA--C 1.535 0.378 0 CA-C-O 122.901 1.334 . . . . 0.0 113.277 -176.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.485 ' HE1' ' SD ' ' C' ' 35' ' ' MET . 33.7 tpp -113.34 118.23 33.99 Favored 'General case' 0 CA--C 1.508 -0.669 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.545 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.425 ' CG2' HG23 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -122.53 71.34 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.789 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.3 103.6 2.49 Favored Glycine 0 C--N 1.358 1.753 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 178.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.72 162.63 19.5 Favored Glycine 0 CA--C 1.522 0.499 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 53.9 t -133.99 138.18 50.83 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-O 120.699 0.285 . . . . 0.0 110.331 -179.797 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 t . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.349 -179.976 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.631 -1.388 . . . . 0.0 109.631 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -107.74 135.31 49.38 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 120.892 0.377 . . . . 0.0 110.451 179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -110.62 134.56 52.31 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.498 179.882 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 50.2 t -124.19 133.62 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.352 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.795 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 71.7 m80 -149.93 129.35 12.97 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.003 0.43 . . . . 0.0 111.005 -179.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.558 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 71.8 t60 -138.47 166.21 24.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.558 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 83.4 mt-30 -156.18 169.64 24.06 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.915 178.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 30.3 mttt -157.81 108.49 2.2 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.965 -0.561 . . . . 0.0 109.727 179.301 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.5 tp -125.77 118.89 26.52 Favored 'General case' 0 N--CA 1.465 0.324 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 179.486 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.3 t -129.01 126.19 64.1 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-O 121.278 0.561 . . . . 0.0 112.029 -179.185 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -114.05 104.74 12.43 Favored 'General case' 0 CA--C 1.535 0.402 0 N-CA-C 105.111 -2.181 . . . . 0.0 105.111 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 5.7 t80 -116.86 126.17 52.62 Favored 'General case' 0 C--O 1.24 0.572 0 N-CA-C 109.545 -0.539 . . . . 0.0 109.545 -178.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.24 141.13 23.71 Favored 'General case' 0 C--O 1.244 0.769 0 CA-C-O 123.446 1.594 . . . . 0.0 115.09 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.457 ' O ' ' CB ' ' C' ' 23' ' ' ASP . 93.5 mt-10 -137.5 73.75 1.46 Allowed 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 111.65 -2.523 . . . . 0.0 104.269 176.032 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.548 ' OD2' ' N ' ' C' ' 24' ' ' VAL . 25.1 t70 141.93 -115.61 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 107.088 -1.449 . . . . 0.0 107.088 -175.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.548 ' N ' ' OD2' ' C' ' 23' ' ' ASP . 28.0 t -40.88 121.98 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 N-CA-C 109.852 -0.425 . . . . 0.0 109.852 -179.617 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.517 ' H ' ' HA2' ' B' ' 29' ' ' GLY . . . 93.74 -90.37 1.37 Allowed Glycine 0 CA--C 1.538 1.475 0 CA-C-O 122.186 0.881 . . . . 0.0 111.275 -178.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.506 ' O ' ' OD1' ' C' ' 27' ' ' ASN . 52.6 m -60.89 -177.23 0.07 Allowed 'General case' 0 C--N 1.319 -0.742 0 N-CA-C 115.953 1.834 . . . . 0.0 115.953 -177.254 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.506 ' OD1' ' O ' ' C' ' 26' ' ' SER . 0.9 OUTLIER 95.02 165.43 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.48 0 CA-C-N 111.443 -2.617 . . . . 0.0 115.324 177.755 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 18.1 mttm -37.02 111.47 0.15 Allowed 'General case' 0 C--N 1.349 0.545 0 CA-C-N 113.279 -1.782 . . . . 0.0 111.672 178.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 77.12 91.24 0.26 Allowed Glycine 0 CA--C 1.457 -3.556 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 178.056 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.654 ' HB1' ' O ' ' B' ' 30' ' ' ALA . . . -153.23 162.81 40.89 Favored 'General case' 0 N--CA 1.38 -3.959 0 N-CA-C 101.618 -3.475 . . . . 0.0 101.618 177.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.653 HG23 HD12 ' D' ' 31' ' ' ILE 0.273 3.0 mp -126.63 115.95 43.47 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.283 0 CA-C-N 114.767 -1.106 . . . . 0.0 108.448 -174.397 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.502 ' O ' ' SD ' ' J' ' 35' ' ' MET . 4.9 mt -101.37 110.38 28.08 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.94 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.022 -178.324 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.61 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -121.81 109.15 1.41 Allowed Glycine 0 CA--C 1.503 -0.701 0 N-CA-C 105.869 -2.892 . . . . 0.0 105.869 176.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.469 ' HG ' ' N ' ' C' ' 35' ' ' MET . 0.6 OUTLIER -147.42 147.66 30.48 Favored 'General case' 0 C--O 1.241 0.622 0 CA-C-O 123.493 1.616 . . . . 0.0 113.178 -177.061 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.621 ' SD ' ' N ' ' I' ' 32' ' ' ILE . 29.6 ttm -122.9 128.02 49.75 Favored 'General case' 0 CA--C 1.502 -0.866 0 CA-C-N 112.0 -2.364 . . . . 0.0 109.101 179.226 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.686 ' O ' HG13 ' C' ' 36' ' ' VAL . 4.9 p -132.45 71.55 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 179.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.31 112.93 4.23 Favored Glycine 0 C--N 1.361 1.948 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.601 -178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.77 -144.34 0.07 OUTLIER Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.674 -0.97 . . . . 0.0 110.674 179.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 11.9 p -130.0 141.69 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-O 120.856 0.36 . . . . 0.0 110.705 -179.488 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . 0.423 HG22 ' H ' ' C' ' 40' ' ' VAL . 12.6 m . . . . . 0 C--O 1.219 -0.53 0 CA-C-O 117.907 -1.044 . . . . 0.0 110.738 -179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 N-CA-C 109.519 -1.432 . . . . 0.0 109.519 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 92.1 m-85 -111.19 136.91 49.58 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -151.1 143.24 24.04 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-O 121.015 0.436 . . . . 0.0 111.216 -179.773 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 19.8 m -139.09 163.4 26.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.195 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.176 -179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -97.54 -179.16 4.37 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.091 179.957 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.51 ' O ' ' ND1' ' C' ' 14' ' ' HIS . 77.0 t60 -77.07 169.48 18.26 Favored 'General case' 0 N--CA 1.444 -0.76 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.732 -179.159 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.434 ' N ' ' CG ' ' D' ' 14' ' ' HIS . 87.5 mt-30 -146.3 176.91 9.41 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.885 -0.598 . . . . 0.0 109.529 -179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -151.42 113.88 4.6 Favored 'General case' 0 N--CA 1.468 0.433 0 C-N-CA 120.477 -0.489 . . . . 0.0 112.053 -179.967 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -127.0 117.6 22.82 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 108.89 -0.782 . . . . 0.0 108.89 178.176 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 m -142.71 149.22 19.06 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.881 0 N-CA-C 114.36 1.244 . . . . 0.0 114.36 -178.483 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.559 ' CD2' ' CE2' ' E' ' 19' ' ' PHE . 2.5 m-30 -118.89 120.61 37.82 Favored 'General case' 0 CA--C 1.544 0.721 0 CA-C-N 113.749 -1.569 . . . . 0.0 108.894 178.382 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 23.6 m-85 -117.5 118.94 33.56 Favored 'General case' 0 N--CA 1.478 0.956 0 CA-C-N 118.39 0.541 . . . . 0.0 109.988 178.398 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.407 ' HB1' ' HB3' ' C' ' 26' ' ' SER . . . -123.64 121.6 35.96 Favored 'General case' 0 C--O 1.239 0.505 0 CA-C-N 116.652 -0.249 . . . . 0.0 110.887 -179.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 tt0 -164.83 106.34 0.83 Allowed 'General case' 0 N--CA 1.477 0.922 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -179.299 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 59.5 t0 -170.24 105.63 0.31 Allowed 'General case' 0 CA--C 1.545 0.76 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 174.506 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.573 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 8.1 p -27.26 140.09 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.473 0.696 0 CA-C-N 114.37 -1.287 . . . . 0.0 113.205 173.556 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . -170.88 -81.26 0.05 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 119.309 -1.424 . . . . 0.0 113.361 177.924 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.758 ' O ' ' O ' ' D' ' 27' ' ' ASN . 88.5 p -170.86 179.59 3.11 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 120.146 1.973 . . . . 0.0 110.535 178.779 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.758 ' O ' ' O ' ' D' ' 26' ' ' SER . 37.1 t30 25.58 -178.96 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.007 0 O-C-N 124.722 1.264 . . . . 0.0 113.431 178.78 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.444 ' H ' ' CG ' ' D' ' 27' ' ' ASN . 83.9 tttt -119.19 -111.18 0.34 Allowed 'General case' 0 N--CA 1.466 0.37 0 O-C-N 121.542 -0.724 . . . . 0.0 109.61 179.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . 41.69 91.52 0.01 OUTLIER Glycine 0 N--CA 1.467 0.717 0 N-CA-C 111.177 -0.769 . . . . 0.0 111.177 178.337 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -134.1 159.77 39.82 Favored 'General case' 0 CA--C 1.488 -1.428 0 N-CA-C 102.341 -3.207 . . . . 0.0 102.341 175.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.653 HD12 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -146.61 123.59 3.55 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.338 0 C-N-CA 117.865 -1.534 . . . . 0.0 112.351 -170.427 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.419 ' O ' HG22 ' D' ' 32' ' ' ILE . 1.5 mt -111.32 119.46 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.949 0 CA-C-O 121.315 0.578 . . . . 0.0 110.129 178.366 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.699 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -127.01 100.48 0.55 Allowed Glycine 0 C--N 1.311 -0.817 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.869 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.537 HD21 HG13 ' D' ' 36' ' ' VAL . 10.5 tt -124.92 130.58 52.65 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 122.04 0.924 . . . . 0.0 111.964 -177.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.54 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.4 ttt -112.89 123.32 50.04 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 114.056 -1.429 . . . . 0.0 110.365 179.38 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.537 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.82 78.15 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.545 0.775 0 CA-C-N 116.262 -0.426 . . . . 0.0 109.987 179.706 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -45.1 105.13 0.08 OUTLIER Glycine 0 C--N 1.348 1.211 0 N-CA-C 110.056 -1.218 . . . . 0.0 110.056 178.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.24 -154.1 2.66 Favored Glycine 0 CA--C 1.525 0.69 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.905 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -125.17 143.16 39.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.09 0.472 . . . . 0.0 110.329 -179.246 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 41.5 t . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 117.89 -1.052 . . . . 0.0 110.473 -179.644 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 42.6 p90 -140.97 150.49 43.15 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 110.255 -0.276 . . . . 0.0 110.255 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.409 ' OE1' ' C ' ' F' ' 11' ' ' GLU . 79.4 mm-40 -142.3 140.03 32.04 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.204 179.857 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.434 ' H ' HG22 ' F' ' 12' ' ' VAL . 59.4 t -128.79 133.58 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.359 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.315 179.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 76.2 m80 -78.34 -168.67 1.4 Allowed 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.517 -0.311 . . . . 0.0 110.437 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.561 ' CG ' ' O ' ' F' ' 14' ' ' HIS . 37.8 p-80 -146.73 177.32 9.18 Favored 'General case' 0 N--CA 1.446 -0.655 0 CA-C-O 120.988 0.423 . . . . 0.0 110.087 -179.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 87.8 mt-30 -100.26 169.68 8.96 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.24 -179.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -140.79 120.75 13.61 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.613 -179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 27.2 tp -122.2 121.83 37.76 Favored 'General case' 0 N--CA 1.467 0.411 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.667 179.84 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 45.4 t -130.49 126.83 61.54 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.756 0 C-N-CA 120.562 -0.455 . . . . 0.0 112.192 -179.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.559 ' CE2' ' CD2' ' D' ' 19' ' ' PHE . 10.8 m-85 -115.88 115.6 26.51 Favored 'General case' 0 N--CA 1.468 0.47 0 N-CA-C 107.789 -1.189 . . . . 0.0 107.789 176.909 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.516 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 66.3 t80 -123.74 124.97 43.9 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.666 -177.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.9 139.74 41.83 Favored 'General case' 0 N--CA 1.472 0.634 0 CA-C-O 121.114 0.483 . . . . 0.0 111.218 179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.516 ' OE2' ' CZ ' ' E' ' 20' ' ' PHE . 8.6 mm-40 -108.49 119.88 40.79 Favored 'General case' 0 N--CA 1.469 0.48 0 N-CA-C 112.229 0.455 . . . . 0.0 112.229 -179.365 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 66.9 t0 -166.81 101.18 0.56 Allowed 'General case' 0 N--CA 1.466 0.342 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.345 178.393 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 6.0 m -73.35 -158.84 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-O 121.711 0.767 . . . . 0.0 112.084 -178.371 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 62.17 79.61 0.13 Allowed Glycine 0 CA--C 1.526 0.776 0 CA-C-N 114.233 -1.349 . . . . 0.0 111.842 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.566 ' N ' ' OD1' ' F' ' 23' ' ' ASP . 26.3 t -61.25 171.88 1.24 Allowed 'General case' 0 N--CA 1.441 -0.89 0 N-CA-C 110.023 -0.362 . . . . 0.0 110.023 178.335 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' E' ' 26' ' ' SER . 9.6 p-10 102.9 177.26 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 O-C-N 124.772 1.295 . . . . 0.0 112.377 176.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.436 ' C ' ' O ' ' E' ' 27' ' ' ASN . 99.4 mttt -21.85 103.8 0.02 OUTLIER 'General case' 0 N--CA 1.474 0.742 0 CA-C-N 114.84 -1.073 . . . . 0.0 111.736 177.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.427 ' O ' ' CG1' ' E' ' 31' ' ' ILE . . . 166.4 -101.71 0.18 Allowed Glycine 0 CA--C 1.493 -1.337 0 C-N-CA 117.92 -2.086 . . . . 0.0 115.435 -178.866 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.428 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -55.06 155.44 4.61 Favored 'General case' 0 C--O 1.245 0.832 0 C-N-CA 117.792 -1.563 . . . . 0.0 110.39 -174.767 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.686 HG21 ' CA ' ' K' ' 37' ' ' GLY . 1.0 OUTLIER -147.16 124.29 3.28 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-N 114.302 -1.317 . . . . 0.0 107.819 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 77.9 mt -123.19 130.24 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.688 0 CA-C-O 120.958 0.409 . . . . 0.0 112.048 -176.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.31 121.1 3.23 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 178.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.674 HD22 ' CE1' ' F' ' 19' ' ' PHE . 18.6 tp -125.7 123.36 38.72 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.629 -0.285 . . . . 0.0 110.812 -179.568 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.547 ' SD ' ' CA ' ' K' ' 33' ' ' GLY . 12.8 ttt -117.86 117.81 30.3 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.611 -0.436 . . . . 0.0 110.219 178.302 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.6 t -122.54 83.81 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 N-CA-C 109.947 -0.39 . . . . 0.0 109.947 179.133 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -16.34 -95.19 0.01 OUTLIER Glycine 0 N--CA 1.471 1.03 0 O-C-N 123.404 0.44 . . . . 0.0 112.833 -179.118 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 115.33 176.57 18.57 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.23 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 25.6 m -100.53 142.61 15.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.923 0.392 . . . . 0.0 110.245 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 46.8 t . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.478 -179.865 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.193 -1.563 . . . . 0.0 109.193 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -82.88 137.47 34.24 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.704 0.288 . . . . 0.0 110.624 179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . 0.409 ' C ' ' OE1' ' E' ' 11' ' ' GLU . 82.4 tt0 -159.03 159.85 35.2 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 116.39 -0.368 . . . . 0.0 110.467 -179.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.434 HG22 ' H ' ' E' ' 12' ' ' VAL . 55.8 t -80.93 131.07 34.79 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.164 0 N-CA-C 109.795 -0.446 . . . . 0.0 109.795 -179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -85.36 146.69 26.88 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 120.837 0.351 . . . . 0.0 111.364 -179.094 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.561 ' O ' ' CG ' ' E' ' 14' ' ' HIS . 83.5 m-70 -94.88 179.49 5.22 Favored 'General case' 0 CA--C 1.51 -0.564 0 N-CA-C 108.141 -1.059 . . . . 0.0 108.141 178.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -79.82 166.25 21.91 Favored 'General case' 0 C--N 1.314 -0.953 0 C-N-CA 120.12 -0.632 . . . . 0.0 110.767 -179.191 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -135.96 118.8 16.2 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.463 -179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 22.7 mt -122.5 120.45 33.91 Favored 'General case' 0 N--CA 1.464 0.239 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 179.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.28 130.9 69.51 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.671 0 CA-C-O 121.209 0.528 . . . . 0.0 112.266 -178.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.674 ' CE1' HD22 ' E' ' 34' ' ' LEU . 26.2 m-85 -119.64 123.83 44.81 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 108.547 -0.908 . . . . 0.0 108.547 178.001 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 71.8 t80 -139.69 130.93 26.64 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 121.589 0.709 . . . . 0.0 112.025 -179.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.23 133.96 51.35 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 114.841 -1.072 . . . . 0.0 108.554 178.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.44 ' OE1' ' OE1' ' E' ' 22' ' ' GLU . 81.0 tt0 -76.65 90.48 3.38 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 119.468 -0.893 . . . . 0.0 110.937 -178.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.566 ' OD1' ' N ' ' E' ' 26' ' ' SER . 15.7 t70 173.87 113.34 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 115.415 -0.811 . . . . 0.0 109.632 178.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 19.3 m -58.85 130.72 22.56 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 C-N-CA 119.472 -0.891 . . . . 0.0 109.379 179.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -67.85 85.31 0.16 Allowed Glycine 0 CA--C 1.527 0.808 0 C-N-CA 120.419 -0.896 . . . . 0.0 111.709 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.9 p -64.67 -174.45 0.14 Allowed 'General case' 0 N--CA 1.442 -0.829 0 N-CA-C 107.486 -1.302 . . . . 0.0 107.486 178.084 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.443 ' O ' ' O ' ' F' ' 28' ' ' LYS . 21.2 m120 -90.7 178.59 6.03 Favored 'General case' 0 C--N 1.312 -1.045 0 C-N-CA 119.876 -0.73 . . . . 0.0 109.61 177.878 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.443 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.3 mttt 27.95 102.12 0.0 OUTLIER 'General case' 0 N--CA 1.469 0.499 0 N-CA-C 113.099 0.778 . . . . 0.0 113.099 177.517 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 146.72 -101.62 0.24 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 120.134 -1.032 . . . . 0.0 113.662 177.591 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -56.81 167.47 0.77 Allowed 'General case' 0 CA--C 1.512 -0.49 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 -179.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.591 HG21 ' HA2' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -150.08 126.86 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.722 0 C-N-CA 118.105 -1.438 . . . . 0.0 111.416 -176.939 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 5.1 mp -127.39 133.01 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.43 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.193 -178.693 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.7 131.8 6.33 Favored Glycine 0 N--CA 1.469 0.893 0 N-CA-C 111.676 -0.57 . . . . 0.0 111.676 179.557 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 15.8 tp -127.23 125.48 41.07 Favored 'General case' 0 N--CA 1.464 0.235 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 24.4 ttt -128.37 126.68 41.17 Favored 'General case' 0 N--CA 1.473 0.711 0 C-N-CA 120.787 -0.365 . . . . 0.0 110.818 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 m -118.17 81.15 0.65 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.607 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.438 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.596 ' CA ' HG21 ' L' ' 31' ' ' ILE . . . -45.29 100.9 0.02 OUTLIER Glycine 0 CA--C 1.529 0.936 0 C-N-CA 120.956 -0.64 . . . . 0.0 111.873 -179.051 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.82 162.01 35.78 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.655 -0.978 . . . . 0.0 110.655 179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -136.14 145.96 30.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.384 0 CA-C-O 120.788 0.327 . . . . 0.0 110.454 179.609 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 117.875 -1.059 . . . . 0.0 110.68 -179.647 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.4 m-85 -118.11 148.69 42.06 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.816 0.341 . . . . 0.0 110.99 -179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 22.2 pt-20 -53.32 163.86 0.53 Allowed 'General case' 0 C--O 1.232 0.184 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.012 179.21 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.418 ' O ' HG13 ' G' ' 12' ' ' VAL . 9.9 p -119.62 130.43 74.1 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.531 0 CA-C-O 120.897 0.379 . . . . 0.0 111.11 -179.177 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -159.77 156.09 26.98 Favored 'General case' 0 C--N 1.334 -0.092 0 CA-C-N 115.56 -0.746 . . . . 0.0 110.463 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.424 ' O ' ' CE1' ' H' ' 14' ' ' HIS . 22.8 m80 -97.55 178.65 5.11 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -118.26 -177.08 3.2 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.816 -0.629 . . . . 0.0 111.23 -178.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -98.59 154.44 17.92 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.406 -0.815 . . . . 0.0 109.174 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 48.1 tp -131.15 118.23 20.19 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-O 121.088 0.47 . . . . 0.0 110.439 179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 78.7 t -124.94 131.03 73.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.752 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 79.1 t80 -129.98 127.96 41.09 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.036 0.446 . . . . 0.0 110.304 179.74 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.523 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 55.2 p90 -130.3 128.59 41.84 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.181 179.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -116.89 123.04 46.05 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-O 120.981 0.42 . . . . 0.0 110.505 179.685 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' G' ' 23' ' ' ASP . 43.6 tt0 -141.06 142.28 34.19 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 115.855 -0.611 . . . . 0.0 109.913 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.48 ' O ' ' O ' ' G' ' 22' ' ' GLU . 97.5 m-20 50.54 113.88 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.937 -179.68 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.545 ' N ' ' OD2' ' H' ' 23' ' ' ASP . 70.0 t -149.34 112.84 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.333 0 C-N-CA 119.943 -0.703 . . . . 0.0 109.283 179.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 33.21 -91.02 0.01 OUTLIER Glycine 0 CA--C 1.529 0.924 0 CA-C-O 121.466 0.481 . . . . 0.0 112.898 177.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.78 ' O ' ' O ' ' G' ' 27' ' ' ASN . 21.2 p -161.76 174.57 13.03 Favored 'General case' 0 N--CA 1.441 -0.917 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -178.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.78 ' O ' ' O ' ' G' ' 26' ' ' SER . 81.7 m-20 -9.42 160.03 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.316 0 N-CA-C 114.901 1.445 . . . . 0.0 114.901 -177.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.418 ' O ' ' CB ' ' H' ' 26' ' ' SER . 17.1 pttp 179.26 102.0 0.02 OUTLIER 'General case' 0 CA--C 1.537 0.451 0 N-CA-C 112.828 0.677 . . . . 0.0 112.828 179.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.1 100.93 0.68 Allowed Glycine 0 N--CA 1.469 0.898 0 N-CA-C 107.061 -2.416 . . . . 0.0 107.061 176.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.42 157.43 22.48 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 123.473 1.606 . . . . 0.0 113.301 -174.429 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.415 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.83 111.61 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.051 0 CA-C-N 111.766 -2.47 . . . . 0.0 108.671 -178.197 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.449 ' C ' ' SD ' ' A' ' 35' ' ' MET . 1.9 mt -99.1 109.25 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.31 0 N-CA-C 107.078 -1.453 . . . . 0.0 107.078 177.889 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -121.59 105.75 1.04 Allowed Glycine 0 CA--C 1.504 -0.645 0 N-CA-C 109.326 -1.51 . . . . 0.0 109.326 -179.785 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 18.1 mt -139.46 145.32 38.67 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 123.061 1.41 . . . . 0.0 112.709 -178.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 48.4 ttp -113.87 114.24 25.98 Favored 'General case' 0 N--CA 1.44 -0.957 0 CA-C-N 113.538 -1.664 . . . . 0.0 106.803 177.071 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -110.1 71.0 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.712 0 N-CA-C 109.701 -0.481 . . . . 0.0 109.701 -179.336 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.495 ' O ' HG21 ' A' ' 31' ' ' ILE . . . -157.1 95.98 0.15 Allowed Glycine 0 C--N 1.355 1.604 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 179.14 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -138.16 -176.87 14.78 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 111.0 -0.84 . . . . 0.0 111.0 -179.531 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 33.0 m -132.84 159.21 43.3 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 N-CA-C 109.868 -0.419 . . . . 0.0 109.868 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 51.4 t . . . . . 0 C--O 1.22 -0.45 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.558 -179.745 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.597 -1.401 . . . . 0.0 109.597 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 99.0 m-85 -106.91 133.34 51.7 Favored 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 120.776 0.322 . . . . 0.0 110.609 -179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.524 ' OE1' ' N ' ' H' ' 11' ' ' GLU . 56.0 mp0 -111.89 132.7 54.56 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.069 -0.514 . . . . 0.0 109.848 179.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 27.7 m -141.75 162.31 20.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.29 0 N-CA-C 109.772 -0.455 . . . . 0.0 109.772 -179.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 73.8 m80 -152.57 97.67 2.28 Favored 'General case' 0 C--N 1.327 -0.399 0 C-N-CA 120.575 -0.45 . . . . 0.0 110.429 178.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.424 ' CE1' ' O ' ' G' ' 14' ' ' HIS . 54.2 p-80 -108.1 166.45 10.72 Favored 'General case' 0 CA--C 1.506 -0.744 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 179.356 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -152.54 168.9 24.03 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.778 0.799 . . . . 0.0 111.377 178.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.675 ' C ' HD12 ' H' ' 17' ' ' LEU . 64.8 tttm -169.58 117.35 0.6 Allowed 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.852 -1.067 . . . . 0.0 108.71 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.675 HD12 ' C ' ' H' ' 16' ' ' LYS . 11.0 mp -122.33 118.5 28.63 Favored 'General case' 0 N--CA 1.47 0.536 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 179.729 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.51 HG21 ' HZ1' ' H' ' 16' ' ' LYS . 60.3 t -121.03 124.16 71.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.328 0 N-CA-C 109.989 -0.375 . . . . 0.0 109.989 179.252 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.474 ' CD2' ' CE2' ' I' ' 19' ' ' PHE . 83.5 m-85 -119.7 106.55 12.24 Favored 'General case' 0 N--CA 1.466 0.368 0 N-CA-C 109.114 -0.699 . . . . 0.0 109.114 178.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 24.9 t80 -116.41 124.65 50.55 Favored 'General case' 0 N--CA 1.466 0.358 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.455 -179.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.98 130.04 49.28 Favored 'General case' 0 N--CA 1.475 0.816 0 C-N-CA 120.507 -0.477 . . . . 0.0 110.813 179.546 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 4.4 tm-20 -159.33 114.78 2.49 Favored 'General case' 0 N--CA 1.462 0.15 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.823 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.545 ' OD2' ' N ' ' G' ' 24' ' ' VAL . 28.5 t0 -174.65 123.3 0.27 Allowed 'General case' 0 CA--C 1.53 0.209 0 N-CA-C 112.981 0.734 . . . . 0.0 112.981 178.343 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.405 ' C ' ' O ' ' H' ' 23' ' ' ASP . 13.0 t -36.9 113.69 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.911 175.077 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.726 ' H ' ' CG2' ' I' ' 24' ' ' VAL . . . 169.37 -90.83 0.1 OUTLIER Glycine 0 CA--C 1.536 1.358 0 C-N-CA 118.854 -1.641 . . . . 0.0 115.188 -178.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.431 ' O ' ' O ' ' H' ' 25' ' ' GLY . 9.5 p -43.35 167.02 0.01 OUTLIER 'General case' 0 CA--C 1.511 -0.519 0 CA-C-N 118.374 1.087 . . . . 0.0 111.539 -174.055 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -109.57 171.75 7.26 Favored 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 114.8 -1.091 . . . . 0.0 113.361 -179.493 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 51.7 mmtt -37.07 111.5 0.16 Allowed 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 114.3 -1.318 . . . . 0.0 113.944 177.079 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.43 93.8 1.73 Allowed Glycine 0 CA--C 1.491 -1.442 0 CA-C-N 115.925 -0.58 . . . . 0.0 113.342 177.218 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -86.05 173.51 9.83 Favored 'General case' 0 N--CA 1.433 -1.323 0 N-CA-C 101.077 -3.675 . . . . 0.0 101.077 171.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.421 HG23 ' CG1' ' I' ' 31' ' ' ILE . 0.1 OUTLIER -134.08 118.72 29.27 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.111 0 C-N-CA 118.005 -1.478 . . . . 0.0 109.835 -178.295 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.43 HG22 ' O ' ' H' ' 32' ' ' ILE . 1.3 mt -109.78 115.47 49.75 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.461 -179.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.44 97.42 0.68 Allowed Glycine 0 CA--C 1.508 -0.345 0 N-CA-C 106.914 -2.475 . . . . 0.0 106.914 176.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.488 HD21 ' CZ ' ' I' ' 19' ' ' PHE . 2.9 mp -127.02 133.51 50.51 Favored 'General case' 0 CA--C 1.507 -0.693 0 CA-C-O 122.552 1.168 . . . . 0.0 111.456 -179.419 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.676 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 43.7 ttp -111.16 117.38 33.08 Favored 'General case' 0 N--CA 1.44 -0.932 0 CA-C-N 113.595 -1.639 . . . . 0.0 107.895 178.07 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -113.05 67.65 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.957 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 -179.465 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -56.81 -101.62 0.01 OUTLIER Glycine 0 C--N 1.352 1.446 0 N-CA-C 111.303 -0.719 . . . . 0.0 111.303 179.552 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 129.56 164.85 11.53 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -179.712 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 3.4 p -139.27 141.71 35.13 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.239 0 N-CA-C 109.898 -0.408 . . . . 0.0 109.898 179.842 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 33.1 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.044 -0.979 . . . . 0.0 110.765 -179.936 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.176 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -99.48 132.22 44.96 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.774 0.321 . . . . 0.0 110.496 179.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -74.14 158.59 33.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.21 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.566 HG12 ' N ' ' I' ' 13' ' ' HIS . 43.1 t -130.43 164.85 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 120.977 0.418 . . . . 0.0 111.331 -179.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.666 ' CG ' ' H ' ' I' ' 14' ' ' HIS . 44.6 t-80 -125.82 -172.35 2.58 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.047 179.746 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.666 ' H ' ' CG ' ' I' ' 13' ' ' HIS . 0.1 OUTLIER -76.45 166.65 23.12 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.204 0.526 . . . . 0.0 109.795 -179.205 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 78.6 mt-30 -148.65 170.68 17.59 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 116.09 -0.504 . . . . 0.0 110.174 179.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -150.35 137.78 19.68 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 121.041 -0.264 . . . . 0.0 111.149 179.707 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 52.8 mt -130.99 124.5 31.09 Favored 'General case' 0 N--CA 1.471 0.588 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 3.6 p -147.33 137.83 17.38 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.555 0 N-CA-C 113.164 0.802 . . . . 0.0 113.164 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.488 ' CZ ' HD21 ' H' ' 34' ' ' LEU . 60.8 m-85 -120.44 123.85 44.01 Favored 'General case' 0 CA--C 1.541 0.628 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.136 177.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.626 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 3.4 t80 -124.27 124.44 42.42 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.362 -0.381 . . . . 0.0 111.101 -177.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.83 126.05 42.7 Favored 'General case' 0 N--CA 1.474 0.745 0 CA-C-O 122.49 1.138 . . . . 0.0 113.451 -178.991 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 -154.28 82.83 1.12 Allowed 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.462 177.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.473 ' OD2' ' O ' ' H' ' 23' ' ' ASP . 13.1 t70 -105.79 -114.13 0.25 Allowed 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 179.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.726 ' CG2' ' H ' ' H' ' 25' ' ' GLY . 58.2 t -85.45 130.69 35.84 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.933 0 N-CA-C 104.426 -2.435 . . . . 0.0 104.426 176.088 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.607 ' CA ' ' H ' ' J' ' 24' ' ' VAL . . . -42.98 82.66 0.0 OUTLIER Glycine 0 CA--C 1.521 0.465 0 C-N-CA 120.189 -1.005 . . . . 0.0 111.974 -176.117 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.667 ' N ' ' O ' ' I' ' 24' ' ' VAL . 11.4 p -65.63 -176.2 0.33 Allowed 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 105.998 -1.853 . . . . 0.0 105.998 177.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.51 HD22 ' C ' ' I' ' 27' ' ' ASN . 0.2 OUTLIER -81.42 179.2 7.95 Favored 'General case' 0 C--N 1.299 -1.627 0 C-N-CA 119.998 -0.681 . . . . 0.0 110.671 177.631 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.492 ' O ' ' O ' ' I' ' 27' ' ' ASN . 85.0 tttt -42.39 -106.42 0.0 OUTLIER 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 121.984 0.897 . . . . 0.0 110.036 175.136 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.899 ' C ' ' HB1' ' J' ' 30' ' ' ALA . . . -82.8 96.98 1.92 Allowed Glycine 0 CA--C 1.45 -3.973 0 N-CA-C 108.928 -1.669 . . . . 0.0 108.928 -179.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.792 ' C ' HD13 ' I' ' 31' ' ' ILE . . . -68.73 -151.17 0.01 OUTLIER 'General case' 0 N--CA 1.403 -2.786 0 N-CA-C 101.899 -3.371 . . . . 0.0 101.899 178.438 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.9 ' N ' HD13 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -102.62 104.01 15.89 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.976 0 CA-C-N 123.782 2.992 . . . . 0.0 109.964 -176.0 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.621 ' N ' ' SD ' ' C' ' 35' ' ' MET . 2.6 mt -107.11 114.2 45.48 Favored 'Isoleucine or valine' 0 C--N 1.362 1.131 0 CA-C-N 113.765 -1.561 . . . . 0.0 111.126 -178.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.409 ' N ' ' CE ' ' B' ' 35' ' ' MET . . . -115.54 97.98 0.82 Allowed Glycine 0 C--O 1.242 0.641 0 N-CA-C 105.502 -3.039 . . . . 0.0 105.502 175.394 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.523 HD11 ' CZ ' ' J' ' 19' ' ' PHE . 0.2 OUTLIER -129.78 132.83 46.67 Favored 'General case' 0 C--O 1.242 0.686 0 CA-C-O 122.268 1.032 . . . . 0.0 111.077 -177.462 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.61 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.0 ttp -113.68 121.55 44.46 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 113.676 -1.602 . . . . 0.0 111.345 -178.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.435 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -127.51 70.03 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.02 0 N-CA-C 107.828 -1.175 . . . . 0.0 107.828 177.126 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.435 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -41.12 -100.66 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.309 -0.716 . . . . 0.0 111.309 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 169.81 -160.59 33.68 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 54.7 t -122.46 134.94 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 120.859 0.361 . . . . 0.0 110.04 -179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 70.1 t . . . . . 0 C--O 1.218 -0.582 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.604 -179.984 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -104.15 131.58 51.3 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.868 0.366 . . . . 0.0 110.624 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -68.52 128.34 36.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.711 -179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 2.5 p -147.26 155.35 10.98 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.852 -179.915 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 77.1 m80 -146.45 135.62 22.68 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-O 121.054 0.454 . . . . 0.0 111.523 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -152.43 155.94 38.53 Favored 'General case' 0 N--CA 1.447 -0.579 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 177.595 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 97.4 mt-30 -153.38 173.64 15.38 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-O 121.441 0.639 . . . . 0.0 111.706 179.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 49.0 mtpt -155.93 129.33 8.26 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.596 -1.184 . . . . 0.0 107.887 178.275 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.5 mp -122.84 116.94 24.52 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.597 -0.52 . . . . 0.0 109.597 179.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 22.2 t -120.5 123.62 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.432 0 CA-C-O 121.253 0.549 . . . . 0.0 110.896 -179.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.523 ' CZ ' HD11 ' I' ' 34' ' ' LEU . 3.9 m-85 -120.88 109.06 14.67 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 107.896 -1.149 . . . . 0.0 107.896 179.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.626 ' CE2' ' CD1' ' I' ' 20' ' ' PHE . 3.7 p90 -148.94 151.36 34.48 Favored 'General case' 0 N--CA 1.471 0.585 0 C-N-CA 117.772 -1.571 . . . . 0.0 114.649 -178.946 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -155.01 155.88 34.96 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 114.156 -1.384 . . . . 0.0 111.169 -179.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 91.1 mt-10 -127.22 144.03 51.13 Favored 'General case' 0 N--CA 1.484 1.266 0 N-CA-C 113.579 0.955 . . . . 0.0 113.579 -178.91 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.468 ' CG ' ' O ' ' I' ' 26' ' ' SER . 10.9 t0 -103.68 134.26 47.31 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.867 178.179 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.607 ' H ' ' CA ' ' I' ' 25' ' ' GLY . 57.4 t -110.43 111.78 37.66 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 C-N-CA 120.249 -0.58 . . . . 0.0 110.661 179.495 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.23 90.37 0.01 OUTLIER Glycine 0 CA--C 1.538 1.495 0 N-CA-C 115.708 1.043 . . . . 0.0 115.708 174.96 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.613 ' O ' ' O ' ' J' ' 27' ' ' ASN . 3.8 p 170.68 174.83 0.06 Allowed 'General case' 0 C--N 1.343 0.324 0 CA-C-N 118.369 1.084 . . . . 0.0 111.379 176.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' J' ' 26' ' ' SER . 3.8 m120 -28.04 -179.55 0.0 OUTLIER 'General case' 0 N--CA 1.486 1.354 0 N-CA-C 115.239 1.57 . . . . 0.0 115.239 -178.293 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.59 ' CD ' ' H ' ' K' ' 27' ' ' ASN . 55.3 tttt -130.51 -107.31 0.27 Allowed 'General case' 0 CA--C 1.544 0.732 0 N-CA-C 114.748 1.388 . . . . 0.0 114.748 177.135 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' J' ' 28' ' ' LYS . . . 41.61 91.81 0.01 OUTLIER Glycine 0 N--CA 1.481 1.677 0 N-CA-C 109.079 -1.608 . . . . 0.0 109.079 -176.688 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.899 ' HB1' ' C ' ' I' ' 29' ' ' GLY . . . -140.61 157.73 45.02 Favored 'General case' 0 N--CA 1.442 -0.83 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 -177.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.82 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -146.18 128.11 8.08 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.53 0 CA-C-O 121.461 0.648 . . . . 0.0 112.506 -178.286 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.54 ' C ' ' SD ' ' D' ' 35' ' ' MET . 1.3 tt -109.25 118.41 56.58 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 N-CA-C 108.535 -0.913 . . . . 0.0 108.535 177.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.52 101.66 0.99 Allowed Glycine 0 N--CA 1.47 0.963 0 N-CA-C 108.212 -1.955 . . . . 0.0 108.212 179.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.588 HD21 ' CG2' ' I' ' 32' ' ' ILE . 80.0 mt -127.05 131.68 50.88 Favored 'General case' 0 C--O 1.241 0.633 0 CA-C-O 121.431 0.634 . . . . 0.0 112.583 -177.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.699 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 33.2 ttp -113.82 120.6 41.3 Favored 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.015 178.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -124.74 67.46 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 N-CA-C 109.977 -0.379 . . . . 0.0 109.977 -179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.433 ' HA3' HD13 ' D' ' 31' ' ' ILE . . . -49.97 121.4 9.58 Favored Glycine 0 C--N 1.355 1.593 0 N-CA-C 110.472 -1.051 . . . . 0.0 110.472 178.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -66.54 -136.8 0.03 OUTLIER Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.34 -1.104 . . . . 0.0 110.34 179.9 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -127.86 134.42 65.34 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 N-CA-C 109.886 -0.413 . . . . 0.0 109.886 179.535 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 m . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.804 179.922 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.52 0 N-CA-C 109.524 -1.43 . . . . 0.0 109.524 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -105.18 137.35 43.1 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 120.872 0.368 . . . . 0.0 110.617 179.768 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -138.72 131.8 29.75 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.797 -179.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 25.6 m -139.83 134.21 37.38 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.156 178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 38.3 m80 -124.3 119.17 28.52 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.83 -0.623 . . . . 0.0 111.315 -179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -124.89 162.55 24.15 Favored 'General case' 0 CA--C 1.516 -0.353 0 CA-C-O 121.485 0.66 . . . . 0.0 109.444 178.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.515 ' OE1' ' NE2' ' L' ' 15' ' ' GLN . 85.4 mt-30 -151.35 178.78 8.92 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.353 179.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 88.9 tttt -172.69 128.15 0.51 Allowed 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 108.828 -0.804 . . . . 0.0 108.828 178.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 3.5 mp -124.39 123.44 40.18 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.825 0.345 . . . . 0.0 110.117 -179.784 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 57.4 t -127.48 125.38 65.54 Favored 'Isoleucine or valine' 0 C--O 1.234 0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.74 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.413 ' HB2' ' CD1' ' L' ' 19' ' ' PHE . 17.3 m-85 -115.77 114.92 25.44 Favored 'General case' 0 CA--C 1.542 0.635 0 N-CA-C 107.824 -1.176 . . . . 0.0 107.824 178.047 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 86.9 t80 -122.05 123.64 42.09 Favored 'General case' 0 N--CA 1.483 1.192 0 N-CA-C 112.501 0.556 . . . . 0.0 112.501 -178.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.01 128.08 39.62 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 121.49 0.662 . . . . 0.0 111.31 179.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 43.2 tt0 -99.12 128.29 45.22 Favored 'General case' 0 N--CA 1.474 0.733 0 C-N-CA 120.176 -0.609 . . . . 0.0 111.782 -179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.462 ' H ' ' HB3' ' L' ' 22' ' ' GLU . 9.2 p-10 -142.86 136.58 28.84 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.116 178.27 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.546 HG13 ' O ' ' K' ' 24' ' ' VAL . 7.8 p -91.1 112.27 24.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.577 -176.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.69 91.5 0.01 OUTLIER Glycine 0 CA--C 1.52 0.404 0 N-CA-C 111.231 -0.748 . . . . 0.0 111.231 179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.586 ' HB2' ' HZ1' ' J' ' 28' ' ' LYS . 5.4 t -42.32 154.63 0.05 Allowed 'General case' 0 N--CA 1.439 -0.98 0 CA-C-N 114.64 -0.78 . . . . 0.0 110.931 -179.031 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.59 ' H ' ' CD ' ' J' ' 28' ' ' LYS . 84.7 m-20 -126.97 -179.86 5.05 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.746 179.294 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.401 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.7 mttt -30.12 107.29 0.04 OUTLIER 'General case' 0 CA--C 1.539 0.545 0 N-CA-C 114.473 1.286 . . . . 0.0 114.473 -177.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.36 -96.48 1.74 Allowed Glycine 0 N--CA 1.47 0.93 0 CA-C-N 113.996 -1.456 . . . . 0.0 116.208 172.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.425 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 72.22 153.28 0.13 Allowed 'General case' 0 C--O 1.249 1.051 0 N-CA-C 101.885 -3.376 . . . . 0.0 101.885 -174.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.715 HG23 HG12 ' L' ' 31' ' ' ILE . 0.2 OUTLIER -149.65 127.47 2.73 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.8 0 C-N-CA 117.001 -1.88 . . . . 0.0 111.82 -176.98 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.504 ' O ' ' CE ' ' E' ' 35' ' ' MET . 82.7 mt -118.84 120.08 62.97 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.377 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.001 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.547 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -119.93 107.86 1.39 Allowed Glycine 0 N--CA 1.467 0.749 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.422 HD13 ' CD2' ' L' ' 19' ' ' PHE . 48.5 mt -121.43 120.6 35.45 Favored 'General case' 0 C--O 1.237 0.436 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.5 tmm? -117.97 124.78 49.03 Favored 'General case' 0 N--CA 1.473 0.686 0 C-N-CA 120.328 -0.549 . . . . 0.0 111.188 178.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 4.4 t -126.05 80.77 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.226 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.799 178.338 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.686 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -63.8 102.87 0.61 Allowed Glycine 0 N--CA 1.445 -0.758 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.884 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.78 -146.79 18.03 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 22.4 m -121.74 138.2 52.81 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 120.796 0.331 . . . . 0.0 110.661 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 17.0 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 118.088 -0.958 . . . . 0.0 110.789 179.449 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.31 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -90.33 136.75 32.86 Favored 'General case' 0 N--CA 1.463 0.202 0 CA-C-O 120.686 0.279 . . . . 0.0 110.933 -179.906 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -74.96 152.65 38.77 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.735 -0.468 . . . . 0.0 109.735 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 60.2 t -121.79 131.19 73.68 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.137 0.494 . . . . 0.0 110.382 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 51.5 p-80 -155.24 140.29 17.39 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.694 179.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 72.6 m80 -150.4 171.46 16.98 Favored 'General case' 0 N--CA 1.445 -0.69 0 N-CA-C 107.714 -1.217 . . . . 0.0 107.714 179.414 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.515 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 89.0 mt-30 -147.02 173.53 12.37 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.464 0.65 . . . . 0.0 111.228 -179.39 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 64.8 mttp -155.55 130.26 9.18 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 114.855 -1.066 . . . . 0.0 108.494 179.157 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.69 HD23 ' C ' ' L' ' 17' ' ' LEU . 7.6 tt -132.5 125.31 30.31 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 110.183 -0.303 . . . . 0.0 110.183 -179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . 0.496 ' N ' HD23 ' L' ' 17' ' ' LEU . 73.8 t -129.39 129.21 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-O 121.147 0.499 . . . . 0.0 111.835 -179.41 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.508 ' CD2' HD21 ' L' ' 17' ' ' LEU . 10.8 m-85 -113.43 114.27 26.34 Favored 'General case' 0 C--N 1.341 0.215 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -140.64 136.83 33.1 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 122.104 0.954 . . . . 0.0 112.249 -178.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -153.16 151.84 30.58 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.229 -0.896 . . . . 0.0 109.386 179.293 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.462 ' HB3' ' H ' ' K' ' 23' ' ' ASP . 81.8 tt0 -75.11 95.15 3.02 Favored 'General case' 0 N--CA 1.469 0.523 0 C-N-CA 119.137 -1.025 . . . . 0.0 109.991 -178.82 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.522 ' OD1' ' N ' ' L' ' 24' ' ' VAL . 67.9 t0 -175.36 136.1 0.35 Allowed 'General case' 0 N--CA 1.461 0.125 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.981 -178.338 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.543 HG23 ' O ' ' L' ' 24' ' ' VAL . 33.5 m -71.02 111.28 4.65 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 N-CA-C 107.041 -1.466 . . . . 0.0 107.041 178.675 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -50.95 -91.92 0.01 OUTLIER Glycine 0 CA--C 1.53 1.007 0 CA-C-N 114.894 -1.048 . . . . 0.0 115.528 -176.095 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 10.0 p -71.24 176.67 4.36 Favored 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 122.967 1.365 . . . . 0.0 114.362 -175.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.532 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 4.9 t-20 85.89 178.65 0.03 OUTLIER 'General case' 0 C--N 1.313 -0.984 0 CA-C-N 111.412 -2.631 . . . . 0.0 114.486 177.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.532 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.1 mttt -40.99 104.49 0.04 OUTLIER 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 116.61 2.078 . . . . 0.0 116.61 -178.93 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 140.0 -101.24 0.3 Allowed Glycine 0 N--CA 1.473 1.161 0 N-CA-C 115.823 1.089 . . . . 0.0 115.823 173.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.587 ' C ' HD13 ' L' ' 31' ' ' ILE . . . -58.37 172.8 0.43 Allowed 'General case' 0 CA--C 1.508 -0.636 0 CA-C-O 119.106 -0.474 . . . . 0.0 111.335 -177.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.845 ' N ' HD13 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -134.78 118.6 25.82 Favored 'Isoleucine or valine' 0 C--N 1.349 0.566 0 C-N-CA 118.405 -1.318 . . . . 0.0 111.148 179.661 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 84.7 mt -121.62 133.23 68.75 Favored 'Isoleucine or valine' 0 C--O 1.23 0.072 0 CA-C-N 113.77 -1.559 . . . . 0.0 109.786 -178.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.521 ' C ' HD12 ' L' ' 34' ' ' LEU . . . -131.3 118.88 2.49 Favored Glycine 0 CA--C 1.529 0.914 0 C-N-CA 121.05 -0.595 . . . . 0.0 112.381 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.521 HD12 ' C ' ' L' ' 33' ' ' GLY . 10.6 mp -114.5 124.34 51.65 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 177.933 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 2.9 tmm? -117.51 120.53 38.37 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 120.585 -0.446 . . . . 0.0 111.616 -179.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 3.2 t -137.72 81.13 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.405 0 CA-C-N 116.65 -0.25 . . . . 0.0 110.549 179.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.591 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . 44.13 -101.39 0.03 OUTLIER Glycine 0 N--CA 1.439 -1.126 0 N-CA-C 111.477 -0.649 . . . . 0.0 111.477 179.875 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 162.53 -169.29 37.76 Favored Glycine 0 CA--C 1.528 0.882 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.732 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.2 t -128.82 136.24 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.584 0 CA-C-O 120.904 0.383 . . . . 0.0 110.672 -179.656 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 57.3 t . . . . . 0 C--O 1.22 -0.464 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.813 179.726 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.333 0 N-CA-C 109.689 -1.364 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -115.26 138.57 50.8 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 120.905 0.383 . . . . 0.0 110.983 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -141.85 156.52 45.53 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.089 179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 68.3 t -123.51 133.55 68.86 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.506 0 CA-C-O 120.952 0.406 . . . . 0.0 110.737 -179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 72.7 m80 -135.8 -175.7 4.05 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.067 -179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 11.1 m170 -80.03 164.79 23.16 Favored 'General case' 0 N--CA 1.445 -0.715 0 CA-C-O 121.23 0.538 . . . . 0.0 109.836 -179.677 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 93.0 mt-30 -153.5 177.45 10.9 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.282 -0.872 . . . . 0.0 109.462 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -147.57 131.34 16.99 Favored 'General case' 0 N--CA 1.466 0.374 0 C-N-CA 121.118 -0.233 . . . . 0.0 110.809 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 95.6 mt -133.4 115.44 14.84 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-O 121.326 0.584 . . . . 0.0 110.135 179.365 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 2.1 p -133.63 133.44 57.1 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.205 0 CA-C-N 115.493 -0.776 . . . . 0.0 110.072 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 94.0 m-85 -145.72 148.93 33.54 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 121.681 0.753 . . . . 0.0 111.511 179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 p90 -135.92 149.3 48.9 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.214 -0.903 . . . . 0.0 108.717 178.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.81 136.54 27.24 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 122.275 1.035 . . . . 0.0 113.312 -178.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.504 ' O ' ' O ' ' A' ' 23' ' ' ASP . 98.8 mt-10 -111.51 178.72 4.24 Favored 'General case' 0 N--CA 1.453 -0.301 0 CA-C-N 113.532 -1.667 . . . . 0.0 107.705 177.473 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.529 ' H ' ' CB ' ' B' ' 23' ' ' ASP . 95.7 m-20 58.54 132.75 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.256 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 -178.941 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.489 ' N ' ' OD2' ' B' ' 23' ' ' ASP . 0.2 OUTLIER -71.88 113.09 8.18 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 110.181 -178.805 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -49.72 -91.11 0.01 OUTLIER Glycine 0 C--N 1.331 0.27 0 N-CA-C 108.003 -2.039 . . . . 0.0 108.003 177.621 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.586 ' OG ' HD11 ' A' ' 31' ' ' ILE . 32.2 t -66.91 -170.1 0.1 Allowed 'General case' 0 N--CA 1.432 -1.371 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 178.037 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 24.7 m120 -78.77 177.73 8.45 Favored 'General case' 0 C--N 1.304 -1.371 0 CA-C-O 121.699 0.762 . . . . 0.0 112.344 -176.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 8.9 mmtt -39.44 108.1 0.08 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.365 -1.289 . . . . 0.0 112.006 -178.604 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 108.3 99.2 2.59 Favored Glycine 0 CA--C 1.493 -1.289 0 CA-C-N 113.713 -1.585 . . . . 0.0 109.205 -176.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -65.18 160.66 20.83 Favored 'General case' 0 N--CA 1.437 -1.118 0 C-N-CA 118.77 -1.172 . . . . 0.0 109.392 -176.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.586 HD11 ' OG ' ' A' ' 26' ' ' SER . 0.0 OUTLIER -146.74 111.79 0.91 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.349 0 CA-C-N 114.614 -1.175 . . . . 0.0 108.775 -175.295 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.581 HG22 HD11 ' B' ' 34' ' ' LEU . 46.8 mt -121.29 104.88 15.73 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.524 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 177.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.641 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -113.96 114.2 3.26 Favored Glycine 0 CA--C 1.502 -0.78 0 N-CA-C 105.827 -2.909 . . . . 0.0 105.827 176.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 5.6 tp -146.04 144.93 30.37 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 122.754 1.264 . . . . 0.0 113.382 -176.52 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.597 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 17.5 ttm -112.91 117.36 31.88 Favored 'General case' 0 CA--C 1.5 -0.951 0 CA-C-N 113.327 -1.76 . . . . 0.0 108.888 178.394 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.89 67.3 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 107.27 -1.381 . . . . 0.0 107.27 177.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -60.3 -101.71 0.01 OUTLIER Glycine 0 C--N 1.366 2.21 0 N-CA-C 110.587 -1.005 . . . . 0.0 110.587 -179.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 167.95 -166.13 39.21 Favored Glycine 0 CA--C 1.525 0.658 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 26.9 m -133.97 158.08 42.18 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.836 0.35 . . . . 0.0 110.735 -179.867 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 91.3 t . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 117.915 -1.04 . . . . 0.0 110.533 -179.866 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.233 0 N-CA-C 109.421 -1.472 . . . . 0.0 109.421 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . 0.491 ' CD1' ' O ' ' C' ' 9' ' ' GLY . 91.9 m-85 -105.2 132.95 50.76 Favored 'General case' 0 N--CA 1.464 0.251 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.6 mm-40 -137.85 160.53 39.03 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 121.114 0.483 . . . . 0.0 111.14 -179.276 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 50.9 t -122.41 134.45 65.58 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.893 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -109.07 114.83 28.9 Favored 'General case' 0 N--CA 1.47 0.527 0 CA-C-O 120.985 0.421 . . . . 0.0 111.445 179.908 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.47 ' CG ' ' N ' ' B' ' 15' ' ' GLN . 83.5 t60 -142.23 160.45 40.22 Favored 'General case' 0 N--CA 1.448 -0.542 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 178.486 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.47 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 78.9 mt-30 -159.27 179.11 9.28 Favored 'General case' 0 C--N 1.311 -1.083 0 CA-C-N 115.464 -0.789 . . . . 0.0 110.13 179.813 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -161.35 119.02 2.31 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.519 178.346 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 4.1 mp -130.61 122.64 27.83 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 110.42 -0.215 . . . . 0.0 110.42 -179.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 4.3 p -139.12 137.12 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.618 0 CA-C-O 121.066 0.46 . . . . 0.0 110.582 178.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 76.8 m-85 -128.87 138.33 51.96 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.879 -179.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 92.8 m-85 -123.15 131.49 53.71 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.21 178.644 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.48 125.71 29.56 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 120.673 -0.411 . . . . 0.0 111.86 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' C' ' 22' ' ' GLU . 82.5 tt0 -170.82 139.76 1.53 Allowed 'General case' 0 N--CA 1.471 0.622 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.448 179.257 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.529 ' CB ' ' H ' ' A' ' 23' ' ' ASP . 14.3 p-10 -168.88 111.16 0.52 Allowed 'General case' 0 C--N 1.344 0.329 0 N-CA-C 114.277 1.214 . . . . 0.0 114.277 177.704 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.406 HG23 ' H ' ' B' ' 24' ' ' VAL . 6.2 t -31.45 131.31 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 114.161 -1.381 . . . . 0.0 112.241 175.208 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.22 -83.31 0.09 OUTLIER Glycine 0 CA--C 1.535 1.317 0 C-N-CA 118.815 -1.66 . . . . 0.0 114.849 177.743 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.59 ' O ' ' O ' ' B' ' 27' ' ' ASN . 6.2 p -170.53 -179.58 3.01 Favored 'General case' 0 N--CA 1.451 -0.41 0 CA-C-N 120.028 1.914 . . . . 0.0 113.125 -178.289 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.59 ' O ' ' O ' ' B' ' 26' ' ' SER . 89.2 m-20 26.77 -170.22 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.911 0 CA-C-N 112.712 -2.04 . . . . 0.0 113.544 -178.687 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.566 ' NZ ' ' O ' ' D' ' 23' ' ' ASP . 51.7 tttt -142.06 -104.52 0.14 Allowed 'General case' 0 CA--C 1.545 0.783 0 N-CA-C 113.68 0.992 . . . . 0.0 113.68 -177.51 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.24 95.59 0.01 OUTLIER Glycine 0 N--CA 1.477 1.429 0 N-CA-C 110.223 -1.151 . . . . 0.0 110.223 -177.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.452 ' O ' HG13 ' C' ' 31' ' ' ILE . . . -104.99 154.35 20.23 Favored 'General case' 0 CA--C 1.486 -1.487 0 N-CA-C 103.294 -2.854 . . . . 0.0 103.294 176.316 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.448 HD12 HG23 ' A' ' 31' ' ' ILE . 2.0 mt -139.8 108.14 3.14 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 C-N-CA 118.405 -1.318 . . . . 0.0 108.753 -173.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.483 ' O ' HG23 ' B' ' 32' ' ' ILE . 5.1 tt -122.37 116.55 49.4 Favored 'Isoleucine or valine' 0 C--O 1.241 0.646 0 CA-C-O 122.069 0.938 . . . . 0.0 109.619 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.781 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -127.99 117.92 2.72 Favored Glycine 0 N--CA 1.453 -0.188 0 N-CA-C 108.661 -1.776 . . . . 0.0 108.661 179.363 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.781 HD12 ' C ' ' B' ' 33' ' ' GLY . 7.0 mp -141.91 149.93 40.83 Favored 'General case' 0 CA--C 1.502 -0.885 0 CA-C-O 123.147 1.451 . . . . 0.0 113.214 -178.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.467 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 24.2 ttm -121.69 118.75 29.9 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 112.769 -2.014 . . . . 0.0 107.822 177.401 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -112.57 68.71 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 -179.6 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.82 -101.5 0.12 Allowed Glycine 0 C--N 1.352 1.417 0 C-N-CA 120.802 -0.713 . . . . 0.0 111.599 -178.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 95.41 167.71 35.49 Favored Glycine 0 CA--C 1.522 0.526 0 N-CA-C 110.428 -1.069 . . . . 0.0 110.428 -179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 35.4 m -131.74 161.92 40.4 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 120.906 0.384 . . . . 0.0 110.242 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 35.9 m . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.017 -0.992 . . . . 0.0 110.648 -179.899 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . 0.491 ' O ' ' CD1' ' B' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -82.59 142.38 31.82 Favored 'General case' 0 C--N 1.328 -0.331 0 N-CA-C 110.177 -0.305 . . . . 0.0 110.177 179.737 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' D' ' 11' ' ' GLU . 95.9 mt-10 -61.04 135.22 57.72 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.742 -179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 11.6 m -137.13 136.79 47.11 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.009 179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 2.7 m-70 -117.26 136.98 52.7 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-O 120.723 0.297 . . . . 0.0 111.57 -178.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.663 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 24.0 t-80 -141.37 163.2 33.6 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 107.971 -1.122 . . . . 0.0 107.971 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.663 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 83.0 mt-30 -156.03 169.74 23.77 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-O 121.183 0.516 . . . . 0.0 111.064 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -155.91 115.98 3.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.443 178.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 44.4 tp -121.5 124.09 43.6 Favored 'General case' 0 N--CA 1.473 0.697 0 N-CA-C 109.861 -0.422 . . . . 0.0 109.861 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.3 t -133.38 127.28 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.857 0 N-CA-C 113.466 0.913 . . . . 0.0 113.466 -177.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.522 ' CD2' ' CE1' ' D' ' 19' ' ' PHE . 50.6 m-85 -117.47 119.29 34.61 Favored 'General case' 0 N--CA 1.479 1.002 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 176.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 59.0 t80 -122.46 126.37 47.75 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-N 117.827 0.285 . . . . 0.0 111.421 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -143.12 149.2 37.79 Favored 'General case' 0 N--CA 1.491 1.602 0 N-CA-C 115.435 1.642 . . . . 0.0 115.435 -178.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.447 ' OE1' ' OE1' ' B' ' 22' ' ' GLU . 28.0 mt-10 -154.45 138.69 16.59 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 114.398 -1.274 . . . . 0.0 110.857 179.298 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 26.2 t0 -156.13 112.24 3.05 Favored 'General case' 0 N--CA 1.484 1.273 0 N-CA-C 114.504 1.298 . . . . 0.0 114.504 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.408 HG23 ' H ' ' C' ' 24' ' ' VAL . 61.9 t -34.77 126.9 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.651 0 N-CA-C 115.494 1.664 . . . . 0.0 115.494 175.132 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . 169.85 -84.83 0.09 OUTLIER Glycine 0 CA--C 1.539 1.536 0 C-N-CA 119.325 -1.417 . . . . 0.0 115.07 173.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.73 ' O ' ' O ' ' C' ' 27' ' ' ASN . 36.7 p -172.06 163.56 6.05 Favored 'General case' 0 CA--C 1.505 -0.76 0 CA-C-N 118.852 1.326 . . . . 0.0 109.474 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.73 ' O ' ' O ' ' C' ' 26' ' ' SER . 14.6 m120 35.73 -178.68 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.144 0 O-C-N 124.015 0.822 . . . . 0.0 110.276 179.338 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.613 ' O ' ' O ' ' D' ' 29' ' ' GLY . 87.3 tttt -96.78 110.61 23.05 Favored 'General case' 0 C--O 1.218 -0.581 0 C-N-CA 117.231 -1.788 . . . . 0.0 109.461 177.413 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.528 ' H ' ' HD3' ' B' ' 28' ' ' LYS . . . -77.45 94.34 1.15 Allowed Glycine 0 CA--C 1.477 -2.308 0 CA-C-O 117.522 -1.71 . . . . 0.0 109.771 173.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.426 ' C ' ' CG1' ' C' ' 31' ' ' ILE . . . -149.75 134.51 17.73 Favored 'General case' 0 CA--C 1.47 -2.113 0 C-N-CA 115.933 -2.307 . . . . 0.0 108.115 173.044 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.452 HG13 ' O ' ' B' ' 30' ' ' ALA 0.274 3.5 mt -138.78 102.22 1.82 Allowed 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 CA-C-N 110.469 -3.059 . . . . 0.0 105.045 -175.837 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.515 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.9 mt -109.19 118.14 55.96 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.636 0 CA-C-N 115.059 -0.973 . . . . 0.0 111.427 -176.679 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.708 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -129.92 99.08 0.44 Allowed Glycine 0 CA--C 1.5 -0.901 0 N-CA-C 106.122 -2.791 . . . . 0.0 106.122 176.169 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.475 ' HG ' ' H ' ' B' ' 34' ' ' LEU . 3.7 mp -132.05 147.35 52.44 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 122.64 1.209 . . . . 0.0 111.924 -177.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.494 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 26.7 ttm -129.01 127.94 42.64 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 112.87 -1.968 . . . . 0.0 110.375 -179.098 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -129.75 72.24 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.935 0 N-CA-C 107.831 -1.174 . . . . 0.0 107.831 179.154 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.9 102.76 2.39 Favored Glycine 0 C--N 1.364 2.102 0 N-CA-C 111.502 -0.639 . . . . 0.0 111.502 -178.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -149.4 154.61 25.86 Favored Glycine 0 CA--C 1.527 0.82 0 N-CA-C 111.134 -0.786 . . . . 0.0 111.134 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 18.0 m -134.72 161.57 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-O 120.735 0.302 . . . . 0.0 110.477 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 9.7 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.015 -0.993 . . . . 0.0 110.256 179.664 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 109.301 -1.52 . . . . 0.0 109.301 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 85.2 m-85 -106.56 132.01 53.06 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-O 120.843 0.354 . . . . 0.0 110.659 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.443 ' O ' ' O ' ' C' ' 11' ' ' GLU . 96.0 mt-10 -69.45 143.51 53.53 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.956 -179.99 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.96 139.26 34.04 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.305 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.642 179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 2.0 m-70 -85.78 166.42 16.09 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.884 0.373 . . . . 0.0 110.097 179.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.58 ' CD2' ' HE2' ' C' ' 14' ' ' HIS . 43.7 p-80 -76.52 175.11 9.54 Favored 'General case' 0 N--CA 1.444 -0.733 0 CA-C-N 116.026 -0.534 . . . . 0.0 110.225 -179.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 95.7 mt-30 -140.62 173.36 11.57 Favored 'General case' 0 N--CA 1.474 0.733 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.189 -179.372 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -141.04 130.75 24.17 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.494 0.664 . . . . 0.0 112.258 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 49.5 tp -122.54 120.31 33.46 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 114.912 -1.04 . . . . 0.0 108.761 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . 0.516 HG11 ' CE2' ' D' ' 20' ' ' PHE . 19.8 t -134.79 128.35 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 N-CA-C 113.28 0.845 . . . . 0.0 113.28 -178.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.522 ' CE1' ' CD2' ' C' ' 19' ' ' PHE . 65.2 m-85 -125.46 115.32 20.06 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 108.771 177.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.53 ' CD1' ' N ' ' D' ' 20' ' ' PHE . 0.0 OUTLIER -147.84 159.09 44.21 Favored 'General case' 0 N--CA 1.471 0.576 0 CA-C-O 122.786 1.279 . . . . 0.0 113.949 179.129 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -152.74 156.33 38.91 Favored 'General case' 0 N--CA 1.468 0.45 0 CA-C-N 113.867 -1.515 . . . . 0.0 112.013 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.432 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 33.1 mt-10 -148.24 141.71 25.35 Favored 'General case' 0 N--CA 1.473 0.712 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.685 -179.559 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.566 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 0.8 OUTLIER 168.09 103.68 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.867 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.447 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.56 ' O ' ' O ' ' D' ' 23' ' ' ASP . 3.4 t -27.57 158.95 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.321 0 C-N-CA 123.354 0.662 . . . . 0.0 112.044 176.527 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 176.97 -76.28 0.07 OUTLIER Glycine 0 CA--C 1.538 1.477 0 C-N-CA 119.454 -1.355 . . . . 0.0 114.192 -179.48 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.564 ' OG ' ' N ' ' D' ' 27' ' ' ASN . 0.1 OUTLIER 167.82 -167.26 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 105.345 -2.094 . . . . 0.0 105.345 -175.689 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.564 ' N ' ' OG ' ' D' ' 26' ' ' SER . 19.6 t30 -44.79 166.37 0.01 OUTLIER 'General case' 0 N--CA 1.469 0.503 0 C-N-CA 118.074 -1.45 . . . . 0.0 109.682 -175.451 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.564 ' HZ1' ' HB1' ' F' ' 21' ' ' ALA . 24.7 tttp -69.86 111.5 5.63 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 115.205 1.558 . . . . 0.0 115.205 -176.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.613 ' O ' ' O ' ' C' ' 28' ' ' LYS . . . -81.26 93.45 1.54 Allowed Glycine 0 CA--C 1.49 -1.497 0 N-CA-C 105.011 -3.236 . . . . 0.0 105.011 166.889 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -144.73 143.09 30.51 Favored 'General case' 0 CA--C 1.457 -2.597 0 CA-C-N 122.407 3.103 . . . . 0.0 109.429 178.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -140.98 99.67 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.062 0 CA-C-N 112.083 -2.326 . . . . 0.0 106.144 -176.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 2.0 mt -108.16 124.61 64.56 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.877 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.427 -177.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.743 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.08 100.55 0.58 Allowed Glycine 0 C--N 1.309 -0.934 0 N-CA-C 105.331 -3.108 . . . . 0.0 105.331 174.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.624 HD21 ' CZ ' ' E' ' 19' ' ' PHE . 0.1 OUTLIER -121.79 120.7 35.37 Favored 'General case' 0 CA--C 1.511 -0.544 0 CA-C-O 121.524 0.678 . . . . 0.0 110.148 -177.68 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.518 ' N ' HD13 ' D' ' 34' ' ' LEU . 3.5 ttt -112.99 115.43 28.37 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 114.682 -1.145 . . . . 0.0 108.068 178.064 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.495 ' O ' ' C ' ' D' ' 37' ' ' GLY . 0.0 OUTLIER -112.43 77.31 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.542 0.668 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 180.0 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.495 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -4.12 -101.93 0.0 OUTLIER Glycine 0 C--N 1.368 2.324 0 O-C-N 123.608 0.568 . . . . 0.0 112.899 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.5 -170.62 39.72 Favored Glycine 0 CA--C 1.521 0.464 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 33.3 m -132.59 159.73 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 179.797 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 11.3 m . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.436 179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.5 t80 -139.82 123.67 17.52 Favored 'General case' 0 N--CA 1.464 0.255 0 CA-C-O 120.744 0.306 . . . . 0.0 110.636 179.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -136.96 139.69 41.68 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.349 179.824 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.3 p -133.87 138.76 49.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.432 -0.349 . . . . 0.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 -139.74 126.86 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.37 179.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.576 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 45.4 t-80 -156.08 167.2 31.16 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-O 121.898 0.856 . . . . 0.0 110.952 179.78 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.576 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 47.5 tt0 -164.02 168.24 19.46 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.307 179.605 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.429 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 53.8 tttm -135.44 120.19 18.39 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.903 -0.589 . . . . 0.0 109.465 178.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 36.1 mt -107.34 118.83 37.75 Favored 'General case' 0 CA--C 1.519 -0.247 0 N-CA-C 107.728 -1.212 . . . . 0.0 107.728 179.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 21.5 t -128.96 121.58 54.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.332 0 N-CA-C 112.752 0.649 . . . . 0.0 112.752 -177.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD21 ' D' ' 34' ' ' LEU . 62.6 m-85 -115.62 115.76 26.97 Favored 'General case' 0 C--O 1.236 0.357 0 N-CA-C 105.812 -1.921 . . . . 0.0 105.812 176.342 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' F' ' 20' ' ' PHE . 25.3 t80 -142.21 149.09 39.2 Favored 'General case' 0 N--CA 1.476 0.828 0 N-CA-C 115.078 1.51 . . . . 0.0 115.078 -175.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.565 ' CB ' ' NZ ' ' C' ' 28' ' ' LYS . . . -149.73 138.63 21.06 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 113.751 1.019 . . . . 0.0 113.751 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.415 ' H ' ' HG2' ' D' ' 22' ' ' GLU . 81.5 tt0 -110.97 111.85 23.26 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 114.972 -1.013 . . . . 0.0 109.432 178.624 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.456 ' O ' ' C ' ' E' ' 24' ' ' VAL . 0.3 OUTLIER 176.37 122.52 0.03 OUTLIER 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 -178.049 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.456 ' C ' ' O ' ' E' ' 23' ' ' ASP . 41.5 t -37.32 117.03 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 CA-C-O 121.595 0.712 . . . . 0.0 110.332 -178.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . -117.81 89.6 0.48 Allowed Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.561 -1.2 . . . . 0.0 111.919 -178.124 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.512 ' O ' ' OD1' ' D' ' 27' ' ' ASN . 46.7 t -87.09 -179.36 6.45 Favored 'General case' 0 N--CA 1.447 -0.624 0 CA-C-O 122.616 1.198 . . . . 0.0 111.765 -177.386 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.579 ' N ' HD22 ' E' ' 27' ' ' ASN . 0.6 OUTLIER -61.85 -178.45 0.15 Allowed 'General case' 0 C--N 1.306 -1.298 0 CA-C-N 113.012 -1.903 . . . . 0.0 113.492 -178.508 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 78.1 tttt 68.1 -112.19 0.13 Allowed 'General case' 0 CA--C 1.541 0.615 0 N-CA-C 116.09 1.885 . . . . 0.0 116.09 178.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.33 91.7 0.25 Allowed Glycine 0 CA--C 1.532 1.105 0 N-CA-C 118.107 2.003 . . . . 0.0 118.107 -172.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.508 ' C ' HD13 ' E' ' 31' ' ' ILE . . . -163.98 147.86 9.96 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 105.575 -2.009 . . . . 0.0 105.575 170.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.668 ' N ' HD13 ' E' ' 31' ' ' ILE . 0.1 OUTLIER -148.16 128.54 4.83 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.595 0 CA-C-O 121.543 0.687 . . . . 0.0 111.086 -178.548 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . . . . . . . . . 91.9 mt -128.19 128.59 68.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.423 0 CA-C-N 115.244 -0.889 . . . . 0.0 111.109 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.4 124.58 5.64 Favored Glycine 0 N--CA 1.473 1.103 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.54 HD23 ' N ' ' E' ' 35' ' ' MET . 4.1 tt -130.17 121.71 26.79 Favored 'General case' 0 CA--C 1.541 0.597 0 N-CA-C 110.056 -0.349 . . . . 0.0 110.056 -179.055 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.54 ' N ' HD23 ' E' ' 34' ' ' LEU . 9.4 ttt -123.15 125.37 45.01 Favored 'General case' 0 N--CA 1.485 1.311 0 C-N-CA 121.065 -0.254 . . . . 0.0 111.477 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.496 ' O ' ' C ' ' E' ' 37' ' ' GLY . 1.3 t -127.59 78.64 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.994 0 N-CA-C 112.488 0.551 . . . . 0.0 112.488 -179.655 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.545 ' HA2' HG21 ' K' ' 31' ' ' ILE . . . 13.77 -109.25 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 N-CA-C 114.107 0.403 . . . . 0.0 114.107 177.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -150.1 165.27 29.8 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 111.492 -0.643 . . . . 0.0 111.492 -179.039 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.436 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 55.3 t -130.28 136.3 58.91 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 N-CA-C 109.923 -0.399 . . . . 0.0 109.923 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' F' ' 39' ' ' VAL . 46.3 t . . . . . 0 C--O 1.219 -0.541 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.358 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.268 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -108.15 136.12 48.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.814 0.34 . . . . 0.0 110.609 179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.23 133.83 47.7 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.245 179.389 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 14.7 p -135.71 135.27 51.19 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.394 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 31.3 p-80 -155.91 128.09 7.59 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 121.041 0.448 . . . . 0.0 111.593 -179.16 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 62.5 m80 -151.09 171.58 17.13 Favored 'General case' 0 CA--C 1.51 -0.583 0 N-CA-C 108.088 -1.079 . . . . 0.0 108.088 179.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -151.1 171.16 17.78 Favored 'General case' 0 C--N 1.313 -1.015 0 C-N-CA 120.415 -0.514 . . . . 0.0 110.331 -179.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 80.3 tttt -141.71 127.2 18.89 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.67 179.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -115.57 126.78 54.65 Favored 'General case' 0 N--CA 1.467 0.425 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 179.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -127.74 119.76 52.48 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.13 0.49 . . . . 0.0 111.934 -178.633 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.42 ' CE1' HD11 ' E' ' 34' ' ' LEU . 4.0 m-85 -113.7 105.93 13.89 Favored 'General case' 0 N--CA 1.465 0.322 0 N-CA-C 106.35 -1.722 . . . . 0.0 106.35 177.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.545 ' O ' ' CD2' ' E' ' 20' ' ' PHE . 5.7 m-85 -139.29 131.28 27.85 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 122.608 1.195 . . . . 0.0 112.558 -178.387 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.564 ' HB1' ' HZ1' ' D' ' 28' ' ' LYS . . . -148.94 163.16 38.29 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.357 178.818 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 76.4 mm-40 -71.15 85.03 0.74 Allowed 'General case' 0 C--N 1.322 -0.63 0 C-N-CA 118.798 -1.161 . . . . 0.0 110.818 -179.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.477 ' OD1' ' N ' ' F' ' 23' ' ' ASP . 11.1 p30 -165.3 112.77 0.98 Allowed 'General case' 0 CA--C 1.532 0.263 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.844 178.37 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.58 ' O ' ' N ' ' F' ' 26' ' ' SER . 98.1 t -70.74 132.55 33.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 CA-C-N 115.978 -0.556 . . . . 0.0 110.583 178.205 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -53.6 83.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.978 0 N-CA-C 109.206 -1.558 . . . . 0.0 109.206 177.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.58 ' N ' ' O ' ' F' ' 24' ' ' VAL . 13.1 p -66.07 -174.18 0.23 Allowed 'General case' 0 N--CA 1.441 -0.924 0 CA-C-O 122.492 1.139 . . . . 0.0 112.276 -177.14 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . . . . . . . . . 16.6 m120 -81.63 179.08 7.98 Favored 'General case' 0 C--N 1.312 -1.046 0 CA-C-N 112.722 -2.036 . . . . 0.0 111.719 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -37.25 104.22 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.553 -0.748 . . . . 0.0 109.66 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.448 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 167.88 -100.67 0.17 Allowed Glycine 0 C--O 1.217 -0.956 0 N-CA-C 108.843 -1.703 . . . . 0.0 108.843 -174.854 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . . . . . . . . . . . -50.24 166.02 0.08 Allowed 'General case' 0 N--CA 1.471 0.608 0 CA-C-N 119.674 1.737 . . . . 0.0 107.659 179.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.652 HD13 ' HA3' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -143.43 130.31 17.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 C-N-CA 118.093 -1.443 . . . . 0.0 112.604 -175.123 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 82.3 mt -128.98 122.87 57.64 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.127 0 CA-C-N 114.64 -1.164 . . . . 0.0 108.909 178.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -117.34 122.34 5.41 Favored Glycine 0 N--CA 1.468 0.833 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 36.7 mt -119.66 120.37 36.43 Favored 'General case' 0 N--CA 1.464 0.238 0 N-CA-C 108.978 -0.749 . . . . 0.0 108.978 179.517 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.461 ' CE ' ' O ' ' L' ' 32' ' ' ILE . 19.9 ttt -130.88 134.53 46.87 Favored 'General case' 0 N--CA 1.478 0.966 0 C-N-CA 120.433 -0.507 . . . . 0.0 111.873 179.824 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.481 HG22 ' O ' ' F' ' 36' ' ' VAL . 1.5 p -156.96 89.41 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.621 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.742 -179.09 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -66.39 94.83 0.23 Allowed Glycine 0 C--N 1.338 0.651 0 C-N-CA 119.224 -1.465 . . . . 0.0 110.757 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . 0.436 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -149.81 167.77 29.91 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.706 -0.957 . . . . 0.0 110.706 -179.962 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . 0.432 ' O ' ' O ' ' E' ' 40' ' ' VAL . 30.9 m -132.08 157.12 43.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.366 0 CA-C-O 120.893 0.378 . . . . 0.0 110.531 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 2.1 t . . . . . 0 C--O 1.219 -0.522 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.697 179.994 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.33 0 N-CA-C 109.556 -1.418 . . . . 0.0 109.556 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -105.88 135.4 47.39 Favored 'General case' 0 N--CA 1.464 0.262 0 CA-C-O 120.842 0.353 . . . . 0.0 110.38 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' N ' ' G' ' 11' ' ' GLU . 55.2 mp0 -94.14 141.75 28.18 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.547 -179.696 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 57.9 t -122.23 132.69 70.52 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 121.086 0.47 . . . . 0.0 110.278 179.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -142.78 115.34 8.58 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.625 -0.716 . . . . 0.0 110.414 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' H' ' 14' ' ' HIS . 57.0 p-80 -152.93 169.98 21.52 Favored 'General case' 0 CA--C 1.511 -0.526 0 N-CA-C 109.6 -0.519 . . . . 0.0 109.6 179.39 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 2.8 pp0? -154.31 170.54 21.06 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.379 179.232 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.6 mttm -156.63 164.27 38.37 Favored 'General case' 0 C--O 1.222 -0.37 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.747 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 2.9 mp -146.71 175.93 10.24 Favored 'General case' 0 C--O 1.172 -3.02 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 178.555 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.968 ' C ' ' O ' ' H' ' 18' ' ' VAL . 94.0 t -156.62 170.51 0.6 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.41 0 O-C-N 118.724 -2.485 . . . . 0.0 110.099 179.253 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.654 ' N ' HG12 ' G' ' 18' ' ' VAL . 26.3 p90 -162.58 105.2 1.09 Allowed 'General case' 0 C--O 1.169 -3.169 0 O-C-N 121.375 -0.828 . . . . 0.0 110.414 179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.695 ' C ' ' O ' ' H' ' 20' ' ' PHE . 35.3 t80 -109.78 108.19 18.45 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 120.549 -1.344 . . . . 0.0 110.839 177.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -82.42 103.12 11.74 Favored 'General case' 0 C--O 1.178 -2.684 0 C-N-CA 124.682 1.193 . . . . 0.0 111.012 179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.551 ' H ' ' HA ' ' H' ' 21' ' ' ALA . 73.7 mt-10 -75.39 147.92 39.61 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-N 120.27 1.395 . . . . 0.0 111.86 178.788 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.445 ' CG ' ' N ' ' G' ' 24' ' ' VAL . 7.8 p-10 -156.02 -144.75 0.14 Allowed 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.159 179.05 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.445 ' N ' ' CG ' ' G' ' 23' ' ' ASP . 18.3 t -29.58 103.9 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.324 -0.543 0 CA-C-N 114.988 -1.006 . . . . 0.0 112.501 178.412 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -178.39 -94.41 0.09 OUTLIER Glycine 0 CA--C 1.531 1.076 0 C-N-CA 119.298 -1.429 . . . . 0.0 113.643 178.176 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . . . . . . . . . 72.2 m -71.18 174.17 6.72 Favored 'General case' 0 CA--C 1.507 -0.68 0 CA-C-N 119.138 1.469 . . . . 0.0 110.388 -178.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -78.71 173.33 12.57 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.511 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.592 ' HZ2' ' CB ' ' I' ' 26' ' ' SER . 13.0 mmtt -46.04 111.77 0.4 Allowed 'General case' 0 C--N 1.33 -0.274 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 174.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 95.61 94.29 1.74 Allowed Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 -177.928 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -79.43 -179.92 7.08 Favored 'General case' 0 N--CA 1.428 -1.535 0 CA-C-O 122.349 1.071 . . . . 0.0 111.157 -178.397 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.462 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.0 OUTLIER -139.12 109.18 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.353 0 CA-C-N 113.28 -1.782 . . . . 0.0 108.91 -177.924 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.597 ' N ' ' SD ' ' A' ' 35' ' ' MET . 2.4 mt -107.02 112.41 39.82 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.853 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 178.8 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.612 ' O ' HD22 ' G' ' 34' ' ' LEU . . . -115.96 98.39 0.82 Allowed Glycine 0 CA--C 1.499 -0.927 0 N-CA-C 106.851 -2.5 . . . . 0.0 106.851 176.816 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.612 HD22 ' O ' ' G' ' 33' ' ' GLY . 1.6 mm? -125.22 133.9 52.55 Favored 'General case' 0 C--O 1.24 0.575 0 CA-C-O 122.305 1.05 . . . . 0.0 110.475 -179.267 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.641 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 42.7 ttp -109.93 120.08 41.35 Favored 'General case' 0 N--CA 1.445 -0.722 0 CA-C-N 113.8 -1.546 . . . . 0.0 108.973 179.869 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.468 HG23 HG13 ' H' ' 36' ' ' VAL . 0.9 OUTLIER -134.5 70.1 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.762 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -102.32 106.09 2.9 Favored Glycine 0 C--N 1.365 2.139 0 N-CA-C 111.614 -0.594 . . . . 0.0 111.614 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 60.78 179.03 2.36 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 112.017 -0.433 . . . . 0.0 112.017 178.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 28.0 m -138.07 160.84 32.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 115.436 -0.382 . . . . 0.0 110.273 179.783 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 87.1 t . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 118.028 -0.987 . . . . 0.0 110.523 179.859 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.457 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 92.4 m-85 -113.06 141.56 46.73 Favored 'General case' 0 N--CA 1.466 0.338 0 N-CA-C 110.249 -0.278 . . . . 0.0 110.249 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -54.08 163.27 0.81 Allowed 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.85 -0.34 . . . . 0.0 110.179 179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 63.2 t -111.87 127.48 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.383 -179.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 42.3 p-80 -174.88 -172.35 0.61 Allowed 'General case' 0 C--N 1.332 -0.167 0 CA-C-O 121.616 0.722 . . . . 0.0 111.459 -179.535 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.422 ' O ' ' O ' ' G' ' 14' ' ' HIS . 82.4 m-70 -149.09 163.49 37.4 Favored 'General case' 0 N--CA 1.444 -0.762 0 N-CA-C 108.152 -1.055 . . . . 0.0 108.152 178.371 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.415 ' HG2' ' N ' ' H' ' 16' ' ' LYS . 56.2 tt0 -160.25 167.44 27.56 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.127 -0.629 . . . . 0.0 110.427 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.528 ' O ' ' O ' ' G' ' 16' ' ' LYS . 73.1 mttt -156.57 151.67 26.31 Favored 'General case' 0 C--N 1.33 -0.278 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.373 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 94.5 mt -134.16 123.57 24.6 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.443 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.968 ' O ' ' C ' ' G' ' 18' ' ' VAL . 65.3 t -125.59 141.69 44.64 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 C-N-CA 118.113 -1.435 . . . . 0.0 113.838 -179.145 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.434 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 94.1 m-85 -118.62 115.01 23.66 Favored 'General case' 0 N--CA 1.472 0.644 0 O-C-N 120.723 -1.236 . . . . 0.0 109.722 179.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.695 ' O ' ' C ' ' G' ' 20' ' ' PHE . 8.2 t80 -109.89 106.89 16.63 Favored 'General case' 0 C--O 1.25 1.107 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 179.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.598 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -90.42 120.09 31.24 Favored 'General case' 0 C--N 1.36 1.052 0 O-C-N 124.864 1.352 . . . . 0.0 110.461 -179.048 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.477 ' O ' ' CB ' ' H' ' 23' ' ' ASP . 82.4 tt0 -153.26 156.53 38.63 Favored 'General case' 0 C--N 1.359 1.022 0 C-N-CA 117.898 -1.521 . . . . 0.0 113.125 -177.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' H' ' 22' ' ' GLU . 0.9 OUTLIER 149.23 121.02 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.255 0 CA-C-N 114.22 -1.355 . . . . 0.0 108.448 179.222 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.507 ' O ' HG23 ' H' ' 24' ' ' VAL . 25.0 m -55.15 121.15 3.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 C-N-CA 119.802 -0.759 . . . . 0.0 109.718 -179.002 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 72.81 88.81 0.16 Allowed Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.562 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.572 ' O ' ' O ' ' H' ' 27' ' ' ASN . 2.6 p 170.81 178.72 0.06 Allowed 'General case' 0 N--CA 1.445 -0.686 0 CA-C-O 121.377 0.608 . . . . 0.0 110.219 179.885 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.572 ' O ' ' O ' ' H' ' 26' ' ' SER . 5.8 m120 -27.89 172.85 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 113.776 -1.556 . . . . 0.0 114.841 -178.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.549 ' NZ ' ' O ' ' J' ' 22' ' ' GLU . 84.8 tttt 144.99 94.72 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.803 0 CA-C-N 114.013 -1.449 . . . . 0.0 109.833 176.748 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.697 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . 59.89 -117.08 10.12 Favored Glycine 1 CA--C 1.424 -5.625 0 N-CA-C 108.827 -1.709 . . . . 0.0 108.827 179.773 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.697 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . 77.03 -124.52 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.678 1 N-CA-C 99.706 -4.183 . . . . 0.0 99.706 -176.617 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.904 HD12 ' N ' ' H' ' 31' ' ' ILE . 1.9 mp -82.02 103.74 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.344 0 C-N-CA 119.437 -0.905 . . . . 0.0 109.287 174.822 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' B' ' 35' ' ' MET . 18.6 tt -121.32 121.34 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 CA-C-O 121.614 0.721 . . . . 0.0 111.009 179.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.82 116.59 2.39 Favored Glycine 0 C--O 1.244 0.74 0 N-CA-C 109.836 -1.306 . . . . 0.0 109.836 179.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . . . . . . . . . 6.3 tp -130.83 128.8 41.38 Favored 'General case' 0 C--O 1.244 0.813 0 CA-C-O 121.785 0.802 . . . . 0.0 110.785 179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.667 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 40.1 ttp -106.09 115.88 30.97 Favored 'General case' 0 CA--C 1.505 -0.755 0 CA-C-N 114.615 -1.175 . . . . 0.0 108.423 178.018 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.468 HG13 HG23 ' G' ' 36' ' ' VAL . 0.0 OUTLIER -120.2 70.54 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.209 0 N-CA-C 109.77 -0.455 . . . . 0.0 109.77 -179.637 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.421 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -38.77 -100.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.688 0 N-CA-C 111.756 -0.537 . . . . 0.0 111.756 178.55 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 179.02 -159.71 24.77 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.153 -1.179 . . . . 0.0 110.153 -179.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -131.3 142.56 43.07 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-O 120.852 0.358 . . . . 0.0 110.781 -179.526 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 15.7 m . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.671 179.869 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.618 -1.393 . . . . 0.0 109.618 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 52.5 p90 -144.89 156.4 43.98 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-O 120.701 0.286 . . . . 0.0 110.297 179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -133.94 135.59 43.65 Favored 'General case' 0 C--O 1.236 0.365 0 CA-C-N 116.29 -0.413 . . . . 0.0 110.157 -179.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 34.0 m -129.55 152.59 37.52 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 CA-C-O 121.863 0.839 . . . . 0.0 111.852 -179.725 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.546 ' O ' ' CG ' ' J' ' 13' ' ' HIS . 0.8 OUTLIER -149.27 109.04 4.03 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.397 -1.274 . . . . 0.0 109.658 179.034 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 39.1 m170 -114.17 162.49 16.45 Favored 'General case' 0 CA--C 1.513 -0.475 0 CA-C-O 121.641 0.734 . . . . 0.0 110.673 -179.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' I' ' 16' ' ' LYS . 43.4 tt0 -153.0 172.8 16.27 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.495 178.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' I' ' 15' ' ' GLN . 88.3 tttt -172.11 132.95 0.68 Allowed 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 121.015 -0.274 . . . . 0.0 110.838 -179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.42 HD23 ' N ' ' I' ' 18' ' ' VAL . 6.7 tt -124.99 125.92 44.64 Favored 'General case' 0 N--CA 1.472 0.643 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.288 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.709 ' HB ' HG22 ' H' ' 18' ' ' VAL . 52.7 t -124.46 126.58 72.09 Favored 'Isoleucine or valine' 0 C--O 1.235 0.291 0 CA-C-N 115.897 -0.592 . . . . 0.0 112.543 -178.903 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 13.8 m-85 -108.2 103.5 12.7 Favored 'General case' 0 CA--C 1.535 0.372 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 175.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.492 ' CE1' ' CZ ' ' H' ' 20' ' ' PHE . 25.7 t80 -117.32 131.06 56.88 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 117.864 0.302 . . . . 0.0 110.643 -178.3 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -145.29 145.94 31.45 Favored 'General case' 0 C--O 1.243 0.714 0 CA-C-O 122.043 0.925 . . . . 0.0 113.338 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 82.9 tt0 -137.61 135.29 36.46 Favored 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 113.941 -1.481 . . . . 0.0 110.81 -179.709 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.464 ' O ' ' CG ' ' J' ' 23' ' ' ASP . 48.0 t0 -139.5 137.84 35.86 Favored 'General case' 0 N--CA 1.472 0.625 0 N-CA-C 107.203 -1.406 . . . . 0.0 107.203 179.162 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 68.7 t -92.12 113.19 26.97 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 C-N-CA 118.685 -1.206 . . . . 0.0 111.806 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.91 86.97 0.01 OUTLIER Glycine 0 CA--C 1.532 1.144 0 CA-C-N 113.744 -1.571 . . . . 0.0 115.255 176.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.592 ' CB ' ' HZ2' ' G' ' 28' ' ' LYS . 30.9 t -140.68 169.95 16.69 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-N 118.487 1.144 . . . . 0.0 109.147 175.544 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.57 ' O ' ' O ' ' I' ' 26' ' ' SER . 89.7 m-20 -30.51 170.79 0.0 OUTLIER 'General case' 0 N--CA 1.474 0.757 0 O-C-N 124.009 0.818 . . . . 0.0 112.896 178.135 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.563 ' NZ ' ' O ' ' K' ' 25' ' ' GLY . 86.3 mttt -108.37 -112.23 0.3 Allowed 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 173.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . 40.86 90.73 0.01 OUTLIER Glycine 0 N--CA 1.466 0.66 0 CA-C-N 116.09 -0.505 . . . . 0.0 112.155 176.275 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.418 ' HA ' HD13 ' I' ' 31' ' ' ILE . . . -140.01 161.9 36.5 Favored 'General case' 0 C--O 1.248 1.005 0 CA-C-O 122.221 1.01 . . . . 0.0 108.35 177.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.697 HG22 ' HB ' ' J' ' 31' ' ' ILE . 0.1 OUTLIER -139.69 133.07 36.75 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.887 0 CA-C-N 113.455 -1.702 . . . . 0.0 110.089 -175.957 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.494 ' C ' ' SD ' ' C' ' 35' ' ' MET . 1.1 mt -113.39 114.85 48.07 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.964 0 N-CA-C 109.001 -0.74 . . . . 0.0 109.001 178.472 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.26 96.06 1.05 Allowed Glycine 0 CA--C 1.497 -1.058 0 N-CA-C 105.231 -3.148 . . . . 0.0 105.231 175.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.578 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 6.6 tp -114.05 125.91 54.52 Favored 'General case' 0 CA--C 1.502 -0.87 0 CA-C-O 121.738 0.78 . . . . 0.0 112.026 -177.127 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.708 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 4.6 ttp -119.14 109.92 16.45 Favored 'General case' 0 N--CA 1.446 -0.63 0 CA-C-N 114.458 -1.246 . . . . 0.0 108.914 177.712 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' I' ' 37' ' ' GLY . 0.0 OUTLIER -116.2 75.24 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.555 1.141 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 179.898 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -26.72 -98.37 0.01 OUTLIER Glycine 0 C--N 1.363 2.08 0 N-CA-C 111.755 -0.538 . . . . 0.0 111.755 178.698 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.59 -151.03 19.39 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 111.226 -0.75 . . . . 0.0 111.226 -179.742 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 7.6 p -124.59 138.92 52.43 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-O 120.82 0.343 . . . . 0.0 110.358 -179.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 118.118 -0.944 . . . . 0.0 110.603 -179.47 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . 0.506 ' CD1' ' O ' ' J' ' 10' ' ' TYR . 30.5 p90 -104.06 126.22 51.01 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 179.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -148.54 141.11 24.4 Favored 'General case' 0 N--CA 1.47 0.53 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.123 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 55.4 t -127.85 133.54 67.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.021 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.627 ' ND1' ' N ' ' J' ' 14' ' ' HIS . 6.2 t-80 -148.93 143.15 26.0 Favored 'General case' 0 N--CA 1.469 0.501 0 C-N-CA 120.675 -0.41 . . . . 0.0 111.252 -179.189 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' J' ' 13' ' ' HIS . 46.9 m-70 -141.28 163.66 32.35 Favored 'General case' 0 CA--C 1.51 -0.576 0 CA-C-O 121.482 0.658 . . . . 0.0 110.052 179.213 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.448 ' HG2' ' N ' ' J' ' 16' ' ' LYS . 50.9 tt0 -156.02 170.76 21.41 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.06 179.134 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.448 ' N ' ' HG2' ' J' ' 15' ' ' GLN . 54.2 mtmt -157.01 134.52 10.68 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.287 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 mt -123.83 124.51 42.82 Favored 'General case' 0 C--O 1.235 0.311 0 N-CA-C 109.514 -0.551 . . . . 0.0 109.514 -179.816 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 2.3 m -140.94 141.69 31.15 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.745 0 C-N-CA 118.768 -1.173 . . . . 0.0 113.867 -179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.637 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 5.5 m-85 -111.45 110.01 20.24 Favored 'General case' 0 CA--C 1.532 0.285 0 N-CA-C 107.134 -1.432 . . . . 0.0 107.134 177.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -114.03 120.89 42.14 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-N 118.455 0.571 . . . . 0.0 111.429 -179.357 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . 0.581 ' HB2' HD22 ' J' ' 27' ' ' ASN . . . -125.51 117.58 23.93 Favored 'General case' 0 C--O 1.239 0.539 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.011 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.549 ' O ' ' NZ ' ' H' ' 28' ' ' LYS . 97.2 mt-10 -120.12 142.37 48.98 Favored 'General case' 0 N--CA 1.477 0.914 0 C-N-CA 120.638 -0.425 . . . . 0.0 111.834 -178.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.504 ' HB3' ' NZ ' ' H' ' 28' ' ' LYS . 4.3 t70 146.31 159.21 0.0 OUTLIER 'General case' 0 C--N 1.345 0.407 0 O-C-N 124.373 1.046 . . . . 0.0 109.201 -179.329 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.441 ' N ' ' CG ' ' J' ' 23' ' ' ASP . 2.4 m -62.97 -110.72 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.719 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.8 93.04 0.14 Allowed Glycine 0 CA--C 1.53 0.97 0 C-N-CA 119.142 -1.504 . . . . 0.0 109.957 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.841 ' O ' ' O ' ' J' ' 27' ' ' ASN . 15.4 p -153.91 -170.61 3.62 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 108.495 -0.928 . . . . 0.0 108.495 -179.485 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.841 ' O ' ' O ' ' J' ' 26' ' ' SER . 50.2 m-20 -19.65 178.83 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.734 0 O-C-N 125.049 1.468 . . . . 0.0 114.258 179.361 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.588 ' O ' ' N ' ' J' ' 30' ' ' ALA . 58.0 tttp 138.88 102.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.09 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.246 -177.005 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' J' ' 28' ' ' LYS . . . -45.31 101.46 0.03 OUTLIER Glycine 0 N--CA 1.481 1.68 1 CA-C-O 128.54 4.411 . . . . 0.0 108.384 -174.271 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.588 ' N ' ' O ' ' J' ' 28' ' ' LYS . . . -99.51 -124.17 0.16 Allowed 'General case' 1 N--CA 1.368 -4.569 4 N-CA-C 89.89 -7.818 . . . . 0.0 89.89 177.972 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.867 HD12 ' N ' ' J' ' 31' ' ' ILE . 1.2 mp -76.99 102.89 3.82 Favored 'Isoleucine or valine' 0 C--N 1.257 -3.422 0 C-N-CA 115.006 -2.678 . . . . 0.0 109.583 176.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.673 HD11 HD21 ' J' ' 34' ' ' LEU . 14.2 tt -115.08 121.39 67.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.451 0 CA-C-O 121.322 0.582 . . . . 0.0 109.476 178.181 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.58 113.83 2.09 Favored Glycine 0 N--CA 1.466 0.681 0 N-CA-C 109.373 -1.491 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.989 HD22 ' CZ ' ' L' ' 19' ' ' PHE . 0.0 OUTLIER -125.16 128.11 47.89 Favored 'General case' 0 C--O 1.244 0.766 0 CA-C-O 122.019 0.914 . . . . 0.0 111.702 -178.4 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.743 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 32.7 ttp -107.63 119.26 38.93 Favored 'General case' 0 CA--C 1.512 -0.503 0 CA-C-N 114.329 -1.305 . . . . 0.0 109.445 178.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.519 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.02 72.83 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.203 0 N-CA-C 110.407 -0.219 . . . . 0.0 110.407 -179.443 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 38' ' ' GLY . . . -56.71 113.21 4.06 Favored Glycine 0 C--N 1.36 1.898 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 178.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' J' ' 37' ' ' GLY . . . -56.99 -150.07 0.01 OUTLIER Glycine 0 CA--C 1.527 0.81 0 N-CA-C 110.915 -0.874 . . . . 0.0 110.915 -179.797 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' J' ' 40' ' ' VAL . 77.8 t -105.38 133.62 49.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.955 0.407 . . . . 0.0 111.003 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.42 ' O ' ' O ' ' J' ' 39' ' ' VAL . 62.1 t . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.951 -1.023 . . . . 0.0 111.172 179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.54 -1.424 . . . . 0.0 109.54 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 84.2 m-85 -104.97 127.45 52.84 Favored 'General case' 0 C--O 1.233 0.214 0 CA-C-O 121.168 0.509 . . . . 0.0 110.851 -179.831 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -113.46 126.82 55.75 Favored 'General case' 0 N--CA 1.463 0.193 0 CA-C-N 115.874 -0.603 . . . . 0.0 110.192 179.696 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 56.9 t -123.94 133.13 70.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.583 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -146.96 147.87 31.17 Favored 'General case' 0 C--N 1.331 -0.204 0 C-N-CA 120.389 -0.524 . . . . 0.0 111.39 -179.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 54.5 m80 -146.9 164.35 33.18 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-O 121.716 0.769 . . . . 0.0 110.593 179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 80.8 mt-30 -154.57 179.1 9.36 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.388 179.427 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.0 tttt -169.79 131.79 1.11 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.562 179.316 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 1.1 mt -119.97 120.53 36.64 Favored 'General case' 0 N--CA 1.47 0.533 0 N-CA-C 110.251 -0.277 . . . . 0.0 110.251 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 91.4 t -127.28 124.93 65.09 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-O 121.032 0.444 . . . . 0.0 111.793 -179.084 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.637 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 41.0 m-85 -115.75 110.25 18.84 Favored 'General case' 0 N--CA 1.466 0.344 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.067 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . . . . . . . . . 92.1 t80 -120.98 127.36 51.72 Favored 'General case' 0 N--CA 1.472 0.627 0 N-CA-C 111.957 0.354 . . . . 0.0 111.957 -177.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -139.21 137.68 36.2 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.582 0.706 . . . . 0.0 112.49 -179.836 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 92.7 mt-10 -105.98 123.7 48.41 Favored 'General case' 0 N--CA 1.475 0.778 0 CA-C-N 116.189 -0.459 . . . . 0.0 112.22 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' J' ' 26' ' ' SER . 49.3 t0 -172.37 114.68 0.31 Allowed 'General case' 0 N--CA 1.468 0.468 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.459 178.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 8.5 p -79.58 131.34 34.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 116.057 -0.519 . . . . 0.0 111.244 -179.595 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.563 ' O ' ' NZ ' ' I' ' 28' ' ' LYS . . . 58.82 82.38 0.06 OUTLIER Glycine 0 N--CA 1.467 0.7 0 C-N-CA 121.384 -0.436 . . . . 0.0 112.07 178.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 3.9 p -67.32 -172.08 0.2 Allowed 'General case' 0 N--CA 1.442 -0.841 0 CA-C-O 121.541 0.686 . . . . 0.0 110.172 -179.182 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.495 ' C ' ' ND2' ' L' ' 27' ' ' ASN . 30.6 p-10 -79.63 179.28 7.59 Favored 'General case' 0 C--N 1.311 -1.072 0 CA-C-N 114.572 -1.195 . . . . 0.0 110.946 179.653 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.47 ' O ' ' O ' ' K' ' 27' ' ' ASN . 81.2 tttt -43.65 -110.11 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.629 0 CA-C-N 115.569 -0.742 . . . . 0.0 112.596 -179.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.4 94.15 1.69 Allowed Glycine 0 N--CA 1.471 1.006 0 CA-C-O 119.992 -0.338 . . . . 0.0 112.859 -178.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.02 173.48 11.73 Favored 'General case' 0 C--O 1.24 0.554 0 N-CA-C 104.317 -2.475 . . . . 0.0 104.317 176.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.572 HG23 HD13 ' L' ' 31' ' ' ILE . 0.1 OUTLIER -151.72 136.93 10.79 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.615 0 C-N-CA 117.35 -1.74 . . . . 0.0 112.116 -174.644 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 89.7 mt -122.71 117.86 53.25 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.374 0 CA-C-N 115.8 -0.636 . . . . 0.0 110.632 179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.513 ' CA ' ' SD ' ' E' ' 35' ' ' MET . . . -118.08 107.93 1.56 Allowed Glycine 0 C--N 1.334 0.467 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 178.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.428 HD11 HG21 ' J' ' 36' ' ' VAL . 51.9 tp -119.99 121.84 39.83 Favored 'General case' 0 N--CA 1.466 0.365 0 N-CA-C 110.464 -0.198 . . . . 0.0 110.464 -178.802 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.402 ' C ' ' SD ' ' K' ' 35' ' ' MET . 6.3 tmm? -120.34 120.25 35.47 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.704 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.519 HG22 HG23 ' J' ' 36' ' ' VAL . 96.1 t -133.68 82.31 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.436 0 N-CA-C 109.799 -0.445 . . . . 0.0 109.799 178.727 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.544 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -7.87 -97.81 0.0 OUTLIER Glycine 0 C--N 1.349 1.276 0 O-C-N 123.504 0.502 . . . . 0.0 113.703 179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 164.25 -168.85 38.85 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 110.397 -1.081 . . . . 0.0 110.397 -179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.53 159.57 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 120.779 0.323 . . . . 0.0 110.386 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.951 -1.023 . . . . 0.0 110.489 -179.975 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.413 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -99.69 134.02 43.19 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 120.737 0.303 . . . . 0.0 110.329 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 81.6 tt0 -144.73 135.07 24.3 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.753 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 17.2 m -134.74 132.31 54.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.241 0 CA-C-N 115.955 -0.566 . . . . 0.0 109.88 179.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 31.8 p-80 -159.67 154.11 23.96 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.133 0.492 . . . . 0.0 111.532 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -151.54 169.29 22.44 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.024 179.63 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 18.5 pt20 -157.58 178.21 10.53 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.995 -179.997 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -143.4 138.38 29.33 Favored 'General case' 0 CA--C 1.532 0.283 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.498 179.202 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 31.3 mt -121.68 119.43 31.77 Favored 'General case' 0 N--CA 1.466 0.373 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 179.447 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 30.8 m -143.01 135.91 25.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 N-CA-C 113.607 0.965 . . . . 0.0 113.607 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.989 ' CZ ' HD22 ' J' ' 34' ' ' LEU . 4.0 m-30 -116.33 127.91 55.09 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 26.8 t80 -141.55 139.44 33.19 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.777 0.798 . . . . 0.0 111.893 -178.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 142.95 34.63 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.716 -0.675 . . . . 0.0 109.78 179.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -77.43 100.96 6.18 Favored 'General case' 0 N--CA 1.467 0.385 0 C-N-CA 119.603 -0.839 . . . . 0.0 109.974 -179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 36.4 t70 -173.84 133.4 0.45 Allowed 'General case' 0 N--CA 1.456 -0.165 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.9 -178.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 113.75 18.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 179.981 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.521 ' O ' ' CB ' ' L' ' 26' ' ' SER . . . 54.39 -91.21 0.01 OUTLIER Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -178.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.521 ' CB ' ' O ' ' L' ' 25' ' ' GLY . 1.5 p 152.5 176.71 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.356 0 CA-C-O 122.006 0.908 . . . . 0.0 110.058 178.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.495 ' ND2' ' C ' ' K' ' 27' ' ' ASN . 18.4 m-20 -51.74 -179.45 0.01 OUTLIER 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 113.892 -1.504 . . . . 0.0 111.664 178.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 64.8 tttp -60.58 111.66 1.69 Allowed 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.923 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.597 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 81.07 -93.19 1.5 Allowed Glycine 0 N--CA 1.468 0.787 0 CA-C-N 114.993 -1.003 . . . . 0.0 112.22 179.833 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.597 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 79.11 165.56 0.2 Allowed 'General case' 0 CA--C 1.507 -0.684 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 -175.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.849 ' N ' HD12 ' L' ' 31' ' ' ILE . 0.0 OUTLIER -149.87 131.93 5.87 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.19 0 CA-C-N 122.07 2.214 . . . . 0.0 111.583 178.038 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.461 ' O ' ' CE ' ' F' ' 35' ' ' MET . 15.4 pt -124.46 142.08 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.16 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.115 -178.277 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.75 120.43 2.52 Favored Glycine 0 N--CA 1.463 0.457 0 N-CA-C 110.562 -1.015 . . . . 0.0 110.562 179.22 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 20.0 mt -115.62 118.66 33.74 Favored 'General case' 0 N--CA 1.463 0.184 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 4.6 ttt -111.01 117.46 33.38 Favored 'General case' 0 N--CA 1.473 0.676 0 C-N-CA 121.058 -0.257 . . . . 0.0 111.175 -179.156 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -145.1 81.41 0.16 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.552 0 N-CA-C 110.202 -0.295 . . . . 0.0 110.202 179.375 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.652 ' HA3' HD13 ' F' ' 31' ' ' ILE . . . -57.97 102.08 0.22 Allowed Glycine 0 C--N 1.337 0.621 0 C-N-CA 120.208 -0.996 . . . . 0.0 111.072 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -96.65 178.95 34.17 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.9 t -129.3 136.59 59.1 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.412 0 CA-C-O 120.842 0.353 . . . . 0.0 110.325 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.415 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.616 -179.698 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -110.33 132.72 53.93 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.785 0.326 . . . . 0.0 110.382 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 -131.02 132.12 44.76 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.251 -0.431 . . . . 0.0 109.902 179.637 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 2.9 p -144.14 141.94 24.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 120.879 0.371 . . . . 0.0 110.668 -179.68 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 33.1 p-80 -141.75 -168.97 2.8 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.828 -179.387 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 73.7 m-70 -75.92 168.77 19.41 Favored 'General case' 0 N--CA 1.445 -0.681 0 CA-C-O 121.295 0.569 . . . . 0.0 110.087 -179.103 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.411 ' HG2' ' H ' ' A' ' 16' ' ' LYS . 48.5 tt0 -158.33 173.98 15.85 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.252 -0.886 . . . . 0.0 109.361 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.411 ' H ' ' HG2' ' A' ' 15' ' ' GLN . 88.9 tttt -144.27 126.35 15.51 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 120.621 0.248 . . . . 0.0 110.886 179.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 86.7 mt -132.21 120.82 22.73 Favored 'General case' 0 N--CA 1.468 0.452 0 CA-C-O 120.978 0.418 . . . . 0.0 110.046 179.265 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -135.32 136.9 50.74 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.017 -0.538 . . . . 0.0 109.795 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -129.67 132.01 46.56 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 120.905 0.383 . . . . 0.0 111.396 -179.525 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 90.1 m-85 -114.84 123.06 48.23 Favored 'General case' 0 N--CA 1.467 0.409 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 178.627 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.9 123.44 42.52 Favored 'General case' 0 N--CA 1.47 0.569 0 CA-C-O 121.385 0.612 . . . . 0.0 111.249 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -141.78 124.68 16.13 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.73 -179.79 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' N ' ' A' ' 24' ' ' VAL . 62.3 t0 -65.22 140.69 58.76 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 179.287 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.489 ' N ' ' OD1' ' A' ' 23' ' ' ASP . 2.8 m -108.5 110.98 34.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.751 0.786 . . . . 0.0 109.804 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 32.57 90.19 0.01 OUTLIER Glycine 0 CA--C 1.526 0.76 0 CA-C-N 114.706 -1.133 . . . . 0.0 113.134 178.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.729 ' O ' ' O ' ' A' ' 27' ' ' ASN . 1.8 t 169.97 176.54 0.05 Allowed 'General case' 0 N--CA 1.441 -0.875 0 N-CA-C 108.917 -0.771 . . . . 0.0 108.917 176.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.729 ' O ' ' O ' ' A' ' 26' ' ' SER . 19.6 p30 -28.25 -179.13 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.903 0 O-C-N 124.792 1.308 . . . . 0.0 112.916 177.02 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.531 ' NZ ' ' O ' ' B' ' 26' ' ' SER . 78.3 tttt -128.86 -108.02 0.29 Allowed 'General case' 0 N--CA 1.469 0.5 0 O-C-N 121.523 -0.736 . . . . 0.0 110.111 175.366 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . 0.45 ' O ' ' O ' ' A' ' 28' ' ' LYS . . . 45.39 92.98 0.01 OUTLIER Glycine 0 N--CA 1.468 0.829 0 CA-C-O 118.191 -1.338 . . . . 0.0 110.261 178.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -105.04 160.36 15.1 Favored 'General case' 0 C--O 1.243 0.762 0 C-N-CA 116.627 -2.029 . . . . 0.0 109.831 179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.519 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.6 OUTLIER -152.22 117.87 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.64 0 CA-C-N 111.836 -2.438 . . . . 0.0 108.958 -171.736 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.543 ' O ' HG23 ' A' ' 32' ' ' ILE . 12.6 tt -128.85 109.28 18.64 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 N-CA-C 108.182 -1.044 . . . . 0.0 108.182 177.032 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.613 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -122.31 119.86 4.13 Favored Glycine 0 CA--C 1.51 -0.263 0 N-CA-C 106.652 -2.579 . . . . 0.0 106.652 178.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.57 HD23 ' N ' ' A' ' 35' ' ' MET . 8.4 tt -164.86 162.69 21.01 Favored 'General case' 0 C--N 1.321 -0.641 0 C-N-CA 118.847 -1.141 . . . . 0.0 112.321 -176.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' B' ' 35' ' ' MET . 5.1 ttp -135.45 143.24 45.79 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 114.507 -1.224 . . . . 0.0 110.244 179.264 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 10.6 m -121.89 71.53 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.764 177.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.548 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -47.05 -97.46 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 111.051 -0.819 . . . . 0.0 111.051 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 151.2 -168.85 30.83 Favored Glycine 0 CA--C 1.523 0.56 0 N-CA-C 110.335 -1.106 . . . . 0.0 110.335 -179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -125.43 134.35 66.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.349 0 N-CA-C 109.846 -0.427 . . . . 0.0 109.846 179.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 35.5 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.635 -179.707 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.354 0 N-CA-C 109.596 -1.401 . . . . 0.0 109.596 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -109.89 135.06 51.36 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.939 0.4 . . . . 0.0 110.708 179.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 mm-40 -76.94 161.29 28.5 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.1 179.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 28.8 m -131.04 160.85 41.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 N-CA-C 109.835 -0.431 . . . . 0.0 109.835 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.46 ' CD2' ' N ' ' B' ' 13' ' ' HIS . 2.8 m-70 -127.74 124.27 37.38 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.711 0.291 . . . . 0.0 110.628 -179.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.772 ' HD1' ' HB2' ' C' ' 14' ' ' HIS . 55.2 t60 -153.92 162.58 41.11 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 109.59 -0.522 . . . . 0.0 109.59 179.509 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.495 ' N ' ' CG ' ' B' ' 14' ' ' HIS . 73.5 mt-30 -159.22 175.91 12.85 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.792 178.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -153.94 126.9 8.31 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.149 178.554 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 37.1 mt -124.7 114.46 19.35 Favored 'General case' 0 C--O 1.233 0.214 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.122 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -124.48 128.99 73.96 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.812 0.339 . . . . 0.0 110.344 -179.682 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . 0.497 ' CE2' ' HB2' ' B' ' 21' ' ' ALA . 88.7 t80 -125.7 123.32 38.63 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.244 -0.435 . . . . 0.0 111.036 -179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -118.16 125.56 50.46 Favored 'General case' 0 N--CA 1.47 0.569 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 179.164 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . 0.497 ' HB2' ' CE2' ' B' ' 19' ' ' PHE . . . -133.0 131.93 41.29 Favored 'General case' 0 N--CA 1.475 0.787 0 C-N-CA 120.513 -0.475 . . . . 0.0 111.415 179.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.47 ' CB ' ' O ' ' C' ' 22' ' ' GLU . 16.6 pt-20 -158.39 154.88 27.68 Favored 'General case' 0 N--CA 1.47 0.525 0 C-N-CA 120.185 -0.606 . . . . 0.0 112.561 179.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.516 ' O ' ' O ' ' B' ' 24' ' ' VAL . 1.0 OUTLIER -164.52 114.25 1.17 Allowed 'General case' 0 CA--C 1.535 0.378 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.439 179.555 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.516 ' O ' ' O ' ' B' ' 23' ' ' ASP . 28.3 m -48.31 -131.07 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.543 0.68 0 CA-C-O 121.658 0.742 . . . . 0.0 112.943 -179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 74.42 -85.87 0.72 Allowed Glycine 0 CA--C 1.537 1.439 0 CA-C-N 115.735 -0.666 . . . . 0.0 113.301 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.715 ' O ' ' O ' ' B' ' 27' ' ' ASN . 77.4 p 172.13 -170.75 0.03 OUTLIER 'General case' 0 CA--C 1.51 -0.584 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.031 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.715 ' O ' ' O ' ' B' ' 26' ' ' SER . 22.0 t-20 -17.86 158.6 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.431 0 O-C-N 124.847 1.342 . . . . 0.0 112.473 179.107 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.518 ' O ' ' CG ' ' B' ' 28' ' ' LYS . 32.6 pttt -161.54 111.04 1.58 Allowed 'General case' 0 CA--C 1.531 0.247 0 C-N-CA 118.269 -1.373 . . . . 0.0 114.595 178.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.88 93.64 0.33 Allowed Glycine 0 CA--C 1.495 -1.202 0 N-CA-C 105.864 -2.894 . . . . 0.0 105.864 174.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -109.08 161.61 15.03 Favored 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 105.968 -1.864 . . . . 0.0 105.968 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.469 ' O ' ' SD ' ' H' ' 35' ' ' MET . 0.0 OUTLIER -141.62 121.11 10.92 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.286 0 CA-C-N 114.122 -1.399 . . . . 0.0 111.294 -172.346 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.467 HG22 ' O ' ' B' ' 32' ' ' ILE . 1.6 mt -110.53 115.11 48.94 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.953 178.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.428 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -120.04 93.65 0.54 Allowed Glycine 0 CA--C 1.507 -0.443 0 N-CA-C 104.198 -3.561 . . . . 0.0 104.198 174.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.549 HD23 ' O ' ' A' ' 34' ' ' LEU . 57.3 mt -122.58 140.22 53.04 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 122.958 1.361 . . . . 0.0 113.054 -176.225 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.639 ' SD ' ' SD ' ' A' ' 35' ' ' MET . 12.1 ttt -127.7 123.3 35.12 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 113.789 -1.55 . . . . 0.0 111.027 -177.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.416 HG23 HG22 ' C' ' 36' ' ' VAL . 0.0 OUTLIER -117.71 72.98 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.962 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.085 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -98.2 103.34 2.79 Favored Glycine 0 C--N 1.354 1.549 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -92.28 172.13 34.53 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 -179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 9.2 p -154.23 147.42 13.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.875 0.369 . . . . 0.0 110.949 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 61.0 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.372 179.668 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.352 0 N-CA-C 109.489 -1.444 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -109.46 146.41 34.58 Favored 'General case' 0 N--CA 1.467 0.417 0 N-CA-C 110.265 -0.272 . . . . 0.0 110.265 179.855 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 82.7 tt0 -60.67 130.67 47.69 Favored 'General case' 0 C--N 1.33 -0.24 0 C-N-CA 120.742 -0.383 . . . . 0.0 110.465 -179.835 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 23.7 m -139.95 159.44 26.66 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.224 0 CA-C-O 121.104 0.478 . . . . 0.0 110.494 179.753 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 23.8 t-160 -124.69 131.26 53.47 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.375 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.772 ' HB2' ' HD1' ' B' ' 14' ' ' HIS . 84.0 m-70 -143.49 168.55 19.58 Favored 'General case' 0 N--CA 1.447 -0.622 0 CA-C-O 121.402 0.62 . . . . 0.0 109.878 -179.404 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.402 ' HG2' ' H ' ' C' ' 16' ' ' LYS . 48.0 tt0 -159.53 172.99 16.85 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.625 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.402 ' H ' ' HG2' ' C' ' 15' ' ' GLN . 88.6 tttt -166.61 114.75 0.87 Allowed 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 179.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 40.9 tp -121.74 121.72 37.92 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 61.8 t -130.03 124.99 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 N-CA-C 112.381 0.511 . . . . 0.0 112.381 -178.704 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 14.7 m-85 -114.48 106.36 14.19 Favored 'General case' 0 N--CA 1.471 0.587 0 N-CA-C 107.669 -1.234 . . . . 0.0 107.669 177.131 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -113.26 127.14 56.06 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.15 0.5 . . . . 0.0 111.564 -179.004 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.66 125.25 44.46 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.705 -0.679 . . . . 0.0 109.952 178.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . 0.47 ' O ' ' CB ' ' B' ' 22' ' ' GLU . 97.2 mt-10 -143.57 158.76 43.41 Favored 'General case' 0 C--O 1.222 -0.345 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.988 -179.414 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.494 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 22.4 t0 177.58 120.99 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.573 -0.739 . . . . 0.0 109.284 179.263 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . . . . . . . . . 2.8 m -57.79 120.63 4.18 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 C-N-CA 119.136 -1.026 . . . . 0.0 110.299 -179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.479 ' O ' ' OG ' ' C' ' 26' ' ' SER . . . 74.66 90.08 0.19 Allowed Glycine 0 CA--C 1.532 1.14 0 C-N-CA 120.984 -0.627 . . . . 0.0 113.958 177.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.479 ' OG ' ' O ' ' C' ' 25' ' ' GLY . 2.8 m 162.21 160.16 0.02 OUTLIER 'General case' 0 C--N 1.341 0.23 0 CA-C-O 122.246 1.022 . . . . 0.0 111.022 175.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.703 HD21 ' ND2' ' B' ' 27' ' ' ASN . 1.1 m120 -31.62 170.54 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.084 -179.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.499 ' NZ ' ' CG ' ' F' ' 23' ' ' ASP . 26.1 pttt -108.37 -111.2 0.31 Allowed 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 107.101 -1.444 . . . . 0.0 107.101 171.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 1.104 ' O ' ' HB1' ' D' ' 30' ' ' ALA . . . -71.5 94.91 0.59 Allowed Glycine 1 CA--C 1.424 -5.626 0 N-CA-C 104.601 -3.4 . . . . 0.0 104.601 173.027 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.507 ' O ' ' C ' ' C' ' 29' ' ' GLY . . . -79.55 -140.47 0.03 OUTLIER 'General case' 0 N--CA 1.388 -3.564 1 N-CA-C 97.605 -4.961 . . . . 0.0 97.605 177.877 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.662 ' CD1' ' N ' ' C' ' 31' ' ' ILE . 1.0 OUTLIER -81.17 106.56 12.47 Favored 'Isoleucine or valine' 0 C--N 1.246 -3.904 0 C-N-CA 114.451 -2.9 . . . . 0.0 110.153 -177.751 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.498 ' O ' ' CE ' ' J' ' 35' ' ' MET . 0.3 OUTLIER -108.68 122.52 63.37 Favored 'Isoleucine or valine' 0 C--N 1.363 1.161 0 N-CA-C 108.151 -1.055 . . . . 0.0 108.151 177.766 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.725 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -138.76 113.23 0.93 Allowed Glycine 0 C--N 1.314 -0.666 0 N-CA-C 106.871 -2.492 . . . . 0.0 106.871 177.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.517 ' O ' HD12 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -140.65 158.55 43.81 Favored 'General case' 0 N--CA 1.449 -0.506 0 CA-C-O 123.115 1.436 . . . . 0.0 111.842 -176.673 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.479 ' CE ' ' O ' ' I' ' 32' ' ' ILE . 24.4 tpp -129.35 124.22 33.73 Favored 'General case' 0 CA--C 1.491 -1.289 0 CA-C-N 112.613 -2.085 . . . . 0.0 107.167 178.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.495 HG23 HD11 ' D' ' 34' ' ' LEU . 48.7 t -116.9 70.98 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 178.049 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.445 ' O ' ' O ' ' C' ' 36' ' ' VAL . . . -31.32 -101.09 0.01 OUTLIER Glycine 0 C--N 1.377 2.829 0 CA-C-N 115.756 -0.656 . . . . 0.0 112.086 -179.71 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 160.83 -158.82 30.41 Favored Glycine 0 CA--C 1.523 0.549 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 27.8 m -134.59 161.53 40.3 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-O 120.83 0.347 . . . . 0.0 110.341 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 t . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.662 -179.576 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.34 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -84.92 137.73 32.94 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.823 0.344 . . . . 0.0 110.598 179.781 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.473 ' OE2' ' CE1' ' D' ' 13' ' ' HIS . 80.5 tt0 -71.79 147.44 47.26 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.67 179.958 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.429 ' CG1' ' NE2' ' D' ' 14' ' ' HIS . 54.2 t -120.92 131.82 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 179.544 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.473 ' CE1' ' OE2' ' D' ' 11' ' ' GLU . 33.0 m-70 -118.38 106.08 12.36 Favored 'General case' 0 N--CA 1.469 0.499 0 CA-C-N 116.451 -0.34 . . . . 0.0 111.59 -178.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.429 ' NE2' ' CG1' ' D' ' 12' ' ' VAL . 60.8 m170 -108.67 166.51 10.74 Favored 'General case' 0 CA--C 1.508 -0.648 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 86.1 mt-30 -152.82 172.51 16.62 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.03 179.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -157.08 114.5 3.11 Favored 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 178.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 60.3 mt -119.81 115.4 23.77 Favored 'General case' 0 N--CA 1.465 0.317 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 41.7 t -129.82 127.07 63.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.545 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.479 ' CE2' ' CD2' ' C' ' 34' ' ' LEU . 7.9 m-85 -116.07 117.76 30.98 Favored 'General case' 0 C--O 1.232 0.159 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.4 t80 -132.9 128.56 36.82 Favored 'General case' 0 N--CA 1.472 0.631 0 C-N-CA 120.379 -0.529 . . . . 0.0 111.944 -177.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 130.36 45.12 Favored 'General case' 0 N--CA 1.466 0.367 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 178.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.537 ' O ' ' OD1' ' D' ' 23' ' ' ASP . 79.7 tt0 -141.81 107.91 5.21 Favored 'General case' 0 N--CA 1.477 0.894 0 C-N-CA 119.945 -0.702 . . . . 0.0 112.777 -178.496 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' O ' ' D' ' 22' ' ' GLU . 71.8 m-20 -166.28 127.27 1.75 Allowed 'General case' 0 CA--C 1.534 0.327 0 O-C-N 123.872 0.732 . . . . 0.0 110.158 178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 82.9 t -45.5 111.92 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.518 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.509 ' H ' ' HB2' ' E' ' 23' ' ' ASP . . . -127.71 86.21 0.33 Allowed Glycine 0 CA--C 1.538 1.48 0 N-CA-C 115.397 0.919 . . . . 0.0 115.397 -178.016 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . . . . . . . . . 17.3 p -88.04 175.91 7.54 Favored 'General case' 0 CA--C 1.511 -0.533 0 N-CA-C 104.609 -2.367 . . . . 0.0 104.609 175.038 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.645 ' O ' ' HG3' ' D' ' 28' ' ' LYS . 1.8 m120 63.45 -171.76 0.17 Allowed 'General case' 0 C--N 1.322 -0.625 0 C-N-CA 116.727 -1.989 . . . . 0.0 108.261 178.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.666 ' CD ' ' HB2' ' D' ' 30' ' ' ALA . 0.2 OUTLIER 46.0 112.85 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.132 0 N-CA-C 117.98 2.585 . . . . 0.0 117.98 177.876 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -80.61 94.61 1.54 Allowed Glycine 0 CA--C 1.49 -1.529 0 N-CA-C 104.39 -3.484 . . . . 0.0 104.39 174.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 1.104 ' HB1' ' O ' ' C' ' 29' ' ' GLY . . . -81.03 175.17 10.91 Favored 'General case' 0 N--CA 1.432 -1.364 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 -174.87 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.632 HG22 ' CE ' ' K' ' 35' ' ' MET . 0.2 OUTLIER -150.92 125.07 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 C-N-CA 116.683 -2.007 . . . . 0.0 111.846 -172.27 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.722 ' CG2' HG23 ' E' ' 32' ' ' ILE . 3.7 tt -116.31 116.99 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.895 0 N-CA-C 108.995 -0.742 . . . . 0.0 108.995 178.702 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.502 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -126.83 119.39 3.31 Favored Glycine 0 CA--C 1.5 -0.887 0 N-CA-C 108.694 -1.762 . . . . 0.0 108.694 178.756 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.591 HD23 ' CZ ' ' F' ' 19' ' ' PHE . 14.8 tp -138.84 126.46 21.96 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-O 122.161 0.981 . . . . 0.0 112.026 -178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.588 ' SD ' ' CA ' ' J' ' 33' ' ' GLY . 20.8 ttt -106.35 119.84 40.3 Favored 'General case' 0 N--CA 1.451 -0.421 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.191 177.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.499 ' CG2' HG22 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -107.99 76.75 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.807 0 CA-C-N 116.082 -0.508 . . . . 0.0 110.144 -178.579 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.461 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -26.43 -97.42 0.01 OUTLIER Glycine 0 C--N 1.354 1.552 0 N-CA-C 112.004 -0.438 . . . . 0.0 112.004 179.653 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.31 165.63 33.71 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 179.343 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 32.7 m -137.32 161.43 34.69 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.372 0 CA-C-O 120.825 0.345 . . . . 0.0 110.474 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 14.3 p . . . . . 0 C--O 1.219 -0.507 0 CA-C-O 118.005 -0.998 . . . . 0.0 110.492 179.689 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.27 0 N-CA-C 109.492 -1.443 . . . . 0.0 109.492 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 94.3 m-85 -103.58 131.17 50.95 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.862 0.363 . . . . 0.0 110.367 179.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 80.5 tt0 -143.67 148.92 36.48 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.218 -179.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.481 ' CG2' ' H ' ' F' ' 12' ' ' VAL . 0.2 OUTLIER -148.12 -153.9 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.36 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.462 -179.382 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.424 ' ND1' ' C ' ' E' ' 13' ' ' HIS . 7.2 t-80 -70.77 142.25 51.4 Favored 'General case' 0 CA--C 1.536 0.428 0 CA-C-O 121.464 0.65 . . . . 0.0 112.68 -177.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 -146.03 169.7 18.14 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 178.592 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.461 ' CG ' ' N ' ' E' ' 16' ' ' LYS . 50.4 tt0 -155.39 168.01 28.51 Favored 'General case' 0 N--CA 1.473 0.72 0 C-N-CA 119.924 -0.71 . . . . 0.0 112.233 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.461 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -148.75 123.48 9.88 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.614 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 34.0 tp -120.8 114.21 21.29 Favored 'General case' 0 C--O 1.235 0.314 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 72.9 t -128.43 129.02 68.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-O 121.381 0.61 . . . . 0.0 111.999 -178.759 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -124.07 123.93 41.42 Favored 'General case' 0 CA--C 1.53 0.211 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 177.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.619 ' CE1' ' CD1' ' F' ' 20' ' ' PHE . 2.0 t80 -133.64 130.14 37.85 Favored 'General case' 0 N--CA 1.469 0.509 0 CA-C-O 120.718 0.294 . . . . 0.0 110.768 -178.663 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.72 130.35 34.04 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 116.548 -0.296 . . . . 0.0 110.23 -179.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -122.96 141.09 52.32 Favored 'General case' 0 N--CA 1.474 0.747 0 N-CA-C 113.009 0.744 . . . . 0.0 113.009 -179.024 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.509 ' HB2' ' H ' ' D' ' 25' ' ' GLY . 19.5 p-10 -165.49 113.74 0.99 Allowed 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.274 -0.875 . . . . 0.0 109.563 177.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 90.0 t -66.09 131.0 31.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.196 -178.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 72.78 84.51 0.24 Allowed Glycine 0 CA--C 1.532 1.12 0 CA-C-N 116.007 -0.542 . . . . 0.0 114.12 177.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' E' ' 25' ' ' GLY . 88.7 p -34.61 170.72 0.0 OUTLIER 'General case' 0 N--CA 1.453 -0.284 0 C-N-CA 123.666 0.786 . . . . 0.0 111.765 177.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.59 ' ND2' ' NZ ' ' D' ' 28' ' ' LYS . 18.1 p30 -138.88 -178.61 5.4 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.323 -0.853 . . . . 0.0 112.259 179.628 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.431 ' C ' ' O ' ' E' ' 27' ' ' ASN . 70.1 mmtt -18.88 -103.85 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.087 0 CA-C-N 115.269 -0.878 . . . . 0.0 112.459 179.532 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.503 ' HA2' ' HB2' ' F' ' 30' ' ' ALA . . . -140.15 97.62 0.23 Allowed Glycine 0 CA--C 1.496 -1.096 0 C-N-CA 120.302 -0.951 . . . . 0.0 111.389 179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.417 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -67.72 172.06 5.72 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 176.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.825 HG23 HD13 ' F' ' 31' ' ' ILE . 0.3 OUTLIER -147.38 124.66 3.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 C-N-CA 118.402 -1.319 . . . . 0.0 109.553 -178.151 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' F' ' 32' ' ' ILE . 66.1 mt -123.73 124.47 69.39 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-N 115.599 -0.728 . . . . 0.0 112.705 -176.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.416 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -127.27 110.31 1.18 Allowed Glycine 0 CA--C 1.527 0.801 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 177.704 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.623 HD22 ' CE2' ' F' ' 19' ' ' PHE . 43.5 mt -119.02 128.9 54.8 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 109.43 -0.582 . . . . 0.0 109.43 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 12.3 ttt -133.3 131.16 39.85 Favored 'General case' 0 N--CA 1.477 0.922 0 C-N-CA 119.781 -0.768 . . . . 0.0 112.222 -179.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.512 ' O ' ' C ' ' E' ' 37' ' ' GLY . 40.1 t -130.65 81.73 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.715 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.576 179.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.512 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . 19.02 -102.7 0.01 OUTLIER Glycine 0 C--N 1.352 1.472 0 CA-C-N 117.848 0.294 . . . . 0.0 112.84 179.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 175.02 -174.51 46.79 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.714 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . 0.439 ' H ' ' HA3' ' F' ' 38' ' ' GLY . 30.3 m -135.69 161.71 38.2 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-O 120.798 0.332 . . . . 0.0 110.677 -179.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 9.1 p . . . . . 0 C--O 1.22 -0.468 0 CA-C-O 118.058 -0.972 . . . . 0.0 110.5 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.366 0 N-CA-C 109.36 -1.496 . . . . 0.0 109.36 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -147.23 155.78 42.38 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.099 0.476 . . . . 0.0 111.069 -179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -101.72 143.89 31.1 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.957 179.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . 0.481 ' H ' ' CG2' ' E' ' 12' ' ' VAL . 55.5 t -118.84 129.59 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-O 121.404 0.621 . . . . 0.0 110.54 -179.913 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 56.6 p-80 -154.49 130.12 9.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.045 179.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 65.8 m80 -145.74 170.38 16.63 Favored 'General case' 0 CA--C 1.508 -0.642 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.652 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 36.6 mt-30 -148.28 175.22 11.25 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.221 179.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -138.13 131.86 31.1 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.793 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.458 HD12 ' N ' ' F' ' 17' ' ' LEU . 5.2 mp -121.87 120.82 35.64 Favored 'General case' 0 N--CA 1.466 0.358 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 179.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 47.1 t -131.7 125.82 56.45 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.656 0 C-N-CA 120.584 -0.446 . . . . 0.0 111.985 -179.661 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.623 ' CE2' HD22 ' E' ' 34' ' ' LEU . 35.9 m-85 -117.48 115.68 25.64 Favored 'General case' 0 N--CA 1.468 0.467 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 177.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE1' ' E' ' 20' ' ' PHE . 34.7 t80 -128.3 123.19 33.4 Favored 'General case' 0 N--CA 1.467 0.396 0 CA-C-O 120.967 0.413 . . . . 0.0 110.084 179.209 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.84 134.33 36.82 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 179.559 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.494 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 80.1 tt0 -92.2 75.66 5.36 Favored 'General case' 0 N--CA 1.463 0.21 0 C-N-CA 119.888 -0.725 . . . . 0.0 112.066 -178.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.499 ' CG ' ' NZ ' ' C' ' 28' ' ' LYS . 19.3 m-20 -142.81 107.93 4.96 Favored 'General case' 0 C--N 1.324 -0.503 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 175.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.442 ' H ' ' HB3' ' E' ' 26' ' ' SER . 85.6 t -45.69 140.79 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.066 -177.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -84.85 83.61 1.63 Allowed Glycine 0 C--N 1.333 0.392 0 N-CA-C 107.865 -2.094 . . . . 0.0 107.865 177.743 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 4.8 p -68.63 -170.79 0.23 Allowed 'General case' 0 N--CA 1.434 -1.266 0 CA-C-O 122.393 1.092 . . . . 0.0 111.805 -177.582 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.438 ' O ' ' C ' ' F' ' 28' ' ' LYS . 49.9 p30 -80.23 179.19 7.78 Favored 'General case' 0 C--N 1.303 -1.453 0 CA-C-N 113.014 -1.903 . . . . 0.0 108.781 179.292 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.438 ' C ' ' O ' ' F' ' 27' ' ' ASN . 98.8 mttt -36.82 104.16 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 122.072 0.939 . . . . 0.0 109.445 -178.793 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.492 ' O ' HG13 ' F' ' 31' ' ' ILE . . . 168.07 -100.71 0.17 Allowed Glycine 0 C--O 1.209 -1.412 0 CA-C-O 117.308 -1.829 . . . . 0.0 109.28 -173.959 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.503 ' HB2' ' HA2' ' E' ' 29' ' ' GLY . . . -53.48 164.06 0.55 Allowed 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 121.51 2.655 . . . . 0.0 106.808 179.737 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.825 HD13 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -146.25 131.18 11.85 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 C-N-CA 118.119 -1.433 . . . . 0.0 112.175 -177.148 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.735 HD12 HD12 ' E' ' 32' ' ' ILE . 13.4 mm -115.5 125.54 72.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.478 0 CA-C-N 115.264 -0.88 . . . . 0.0 109.51 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -130.72 125.24 4.49 Favored Glycine 0 N--CA 1.473 1.151 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.106 -179.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.6 mt -124.68 128.02 48.19 Favored 'General case' 0 N--CA 1.469 0.489 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 179.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -130.81 127.63 39.04 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-O 121.699 0.761 . . . . 0.0 112.571 -179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 48.8 t -147.38 86.66 0.15 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.386 0 CA-C-N 114.807 -1.088 . . . . 0.0 108.813 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.45 96.79 1.28 Allowed Glycine 0 C--N 1.339 0.698 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.071 -177.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . 0.439 ' HA3' ' H ' ' E' ' 39' ' ' VAL . . . -155.21 163.57 31.54 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 62.2 t -123.88 135.61 62.94 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 13.9 t . . . . . 0 C--O 1.22 -0.473 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.307 179.77 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.274 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 34.6 p90 -146.3 156.58 43.46 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-O 120.955 0.407 . . . . 0.0 110.801 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -145.4 131.14 18.99 Favored 'General case' 0 N--CA 1.463 0.183 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.437 179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.434 HG22 ' N ' ' G' ' 13' ' ' HIS . 2.6 p -140.26 158.52 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.312 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.302 179.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.434 ' N ' HG22 ' G' ' 12' ' ' VAL . 75.8 m80 -120.26 166.6 13.27 Favored 'General case' 0 N--CA 1.475 0.78 0 CA-C-O 120.92 0.39 . . . . 0.0 111.704 -179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.434 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 94.3 m-70 -107.72 179.14 4.32 Favored 'General case' 0 C--N 1.341 0.204 0 CA-C-N 115.867 -0.606 . . . . 0.0 109.668 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.459 HE21 ' CD ' ' H' ' 16' ' ' LYS . 52.3 tt0 -100.07 172.66 7.06 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.714 -179.701 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.449 ' O ' ' O ' ' H' ' 16' ' ' LYS . 68.4 mttm -149.19 165.58 31.41 Favored 'General case' 0 C--O 1.217 -0.639 0 CA-C-O 121.193 0.521 . . . . 0.0 111.419 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . 0.515 ' O ' ' CG2' ' G' ' 18' ' ' VAL . 7.0 tt -145.14 161.84 38.49 Favored 'General case' 0 C--O 1.171 -3.039 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.958 ' C ' ' O ' ' H' ' 18' ' ' VAL . 86.3 t -156.07 170.77 0.62 Allowed 'Isoleucine or valine' 0 N--CA 1.482 1.126 0 O-C-N 118.701 -2.499 . . . . 0.0 110.529 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . 0.641 ' N ' HG12 ' G' ' 18' ' ' VAL . 31.2 p90 -158.86 108.32 1.96 Allowed 'General case' 0 C--O 1.165 -3.344 0 CA-C-O 118.373 -0.823 . . . . 0.0 109.803 -178.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.713 ' C ' ' O ' ' H' ' 20' ' ' PHE . 43.6 t80 -119.52 106.27 12.05 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-N 121.471 1.941 . . . . 0.0 112.026 178.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' H' ' 21' ' ' ALA . . . -114.74 113.0 23.71 Favored 'General case' 0 C--O 1.174 -2.887 0 CA-C-O 118.126 -0.94 . . . . 0.0 110.256 179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . 0.441 ' O ' ' O ' ' H' ' 22' ' ' GLU . 94.9 mt-10 -75.01 144.41 43.11 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 118.898 0.772 . . . . 0.0 112.032 177.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.438 ' OD1' ' O ' ' H' ' 22' ' ' GLU . 33.4 m-20 -140.62 -142.24 0.14 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.975 -179.685 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.436 ' C ' ' O ' ' G' ' 23' ' ' ASP . 13.7 t -27.44 103.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.357 0 CA-C-N 115.946 -0.57 . . . . 0.0 112.318 179.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.455 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 172.0 92.77 0.08 OUTLIER Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 179.438 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.455 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 0.9 OUTLIER 86.66 179.9 0.03 OUTLIER 'General case' 0 N--CA 1.443 -0.784 0 N-CA-C 108.628 -0.879 . . . . 0.0 108.628 179.793 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . . . . . . . . . 21.4 m120 -63.73 170.88 3.01 Favored 'General case' 0 C--N 1.308 -1.219 0 CA-C-O 121.309 0.576 . . . . 0.0 111.459 179.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.966 ' HZ2' ' H ' ' H' ' 26' ' ' SER . 0.0 OUTLIER -47.85 112.07 0.51 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.162 -0.926 . . . . 0.0 112.106 176.986 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.52 94.31 2.35 Favored Glycine 0 CA--C 1.486 -1.75 0 CA-C-O 122.493 1.052 . . . . 0.0 110.841 -179.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.504 ' C ' HD13 ' G' ' 31' ' ' ILE . . . -74.31 -179.05 3.72 Favored 'General case' 0 N--CA 1.421 -1.922 0 CA-C-N 112.795 -1.702 . . . . 0.0 110.607 -179.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.856 ' N ' HD13 ' G' ' 31' ' ' ILE . 0.0 OUTLIER -141.62 112.65 3.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 113.335 -1.757 . . . . 0.0 106.41 179.415 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.413 HG23 HD21 ' H' ' 34' ' ' LEU . 18.5 tt -117.31 117.65 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.622 0 CA-C-O 121.708 0.766 . . . . 0.0 110.414 179.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.16 106.41 2.35 Favored Glycine 0 N--CA 1.449 -0.464 0 N-CA-C 105.904 -2.878 . . . . 0.0 105.904 177.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.688 ' HB3' HD22 ' H' ' 34' ' ' LEU . 13.2 tp -132.81 130.52 39.96 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 122.604 1.192 . . . . 0.0 111.535 -177.774 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.613 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 24.7 ttp -102.81 124.19 47.87 Favored 'General case' 0 C--N 1.313 -1.017 0 CA-C-N 114.072 -1.422 . . . . 0.0 110.16 179.59 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -123.9 70.65 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 N-CA-C 109.222 -0.658 . . . . 0.0 109.222 179.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -92.98 -100.53 1.47 Allowed Glycine 0 C--N 1.354 1.572 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 179.01 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.7 170.25 24.04 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . 0.405 ' O ' ' OXT' ' G' ' 40' ' ' VAL . 27.4 m -141.24 163.68 20.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-O 120.832 0.348 . . . . 0.0 110.708 -179.796 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . 0.405 ' OXT' ' O ' ' G' ' 39' ' ' VAL . 7.8 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.572 179.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . 0.524 ' CD1' ' O ' ' I' ' 9' ' ' GLY . 91.8 m-85 -105.06 138.99 40.42 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.012 0.434 . . . . 0.0 110.737 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -59.39 133.7 56.34 Favored 'General case' 0 C--O 1.239 0.53 0 CA-C-O 121.604 0.716 . . . . 0.0 111.14 -179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.09 132.74 70.88 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.037 179.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.613 ' CD2' ' ND1' ' I' ' 13' ' ' HIS . 7.3 p-80 -158.68 152.01 22.82 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.672 0.749 . . . . 0.0 111.785 -179.484 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.509 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 15.9 m80 -144.64 162.27 37.07 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 178.232 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.509 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.2 mm-40 -152.96 172.91 16.09 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-O 121.313 0.578 . . . . 0.0 110.087 178.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.459 ' CD ' HE21 ' G' ' 15' ' ' GLN . 76.7 tttt -176.04 136.86 0.31 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.026 -0.988 . . . . 0.0 108.467 179.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 77.0 mt -141.07 132.3 26.51 Favored 'General case' 0 N--CA 1.473 0.691 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 -179.169 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.958 ' O ' ' C ' ' G' ' 18' ' ' VAL . 76.8 t -124.6 146.07 30.78 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.081 0 C-N-CA 118.184 -1.407 . . . . 0.0 113.385 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.414 ' HA ' ' H ' ' G' ' 20' ' ' PHE . 63.2 m-85 -125.19 119.33 28.21 Favored 'General case' 0 N--CA 1.478 0.949 0 O-C-N 120.141 -1.6 . . . . 0.0 111.479 -179.042 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.713 ' O ' ' C ' ' G' ' 20' ' ' PHE . 50.3 t80 -105.69 111.82 24.65 Favored 'General case' 0 C--O 1.248 0.981 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.698 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.876 ' HA ' ' HA ' ' G' ' 21' ' ' ALA . . . -93.97 113.44 25.44 Favored 'General case' 0 C--N 1.352 0.717 0 CA-C-O 118.631 -0.7 . . . . 0.0 112.734 -178.424 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.627 ' H ' ' HB1' ' G' ' 21' ' ' ALA . 48.6 tt0 -149.02 124.85 10.55 Favored 'General case' 0 C--N 1.379 1.884 0 C-N-CA 117.899 -1.52 . . . . 0.0 112.094 179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.501 ' O ' ' OD1' ' I' ' 23' ' ' ASP . 66.5 t0 -125.07 114.69 19.4 Favored 'General case' 0 N--CA 1.469 0.523 0 CA-C-O 121.484 0.659 . . . . 0.0 110.252 178.364 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.406 ' H ' HG23 ' H' ' 24' ' ' VAL . 40.1 t -38.72 122.88 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 113.561 0.949 . . . . 0.0 113.561 179.223 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 110.39 -88.71 0.52 Allowed Glycine 0 CA--C 1.538 1.505 0 N-CA-C 115.802 1.081 . . . . 0.0 115.802 176.6 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.966 ' H ' ' HZ2' ' G' ' 28' ' ' LYS . 83.7 p -65.94 -172.48 0.14 Allowed 'General case' 0 CA--C 1.502 -0.896 0 CA-C-O 122.234 1.016 . . . . 0.0 113.008 -175.075 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.643 ' ND2' ' HB2' ' I' ' 30' ' ' ALA . 4.7 p30 -81.17 179.88 7.66 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-N 113.136 -1.847 . . . . 0.0 114.895 -176.988 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . . . . . . . . . 86.2 mttt -41.42 -104.11 0.0 OUTLIER 'General case' 0 CA--C 1.516 -0.365 0 CA-C-N 112.189 -2.278 . . . . 0.0 109.662 176.281 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.966 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . -82.01 100.62 2.12 Favored Glycine 0 CA--C 1.465 -3.058 0 CA-C-O 123.208 1.449 . . . . 0.0 111.011 -176.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.807 ' C ' HD13 ' H' ' 31' ' ' ILE . . . -73.73 -134.15 0.01 OUTLIER 'General case' 0 CA--C 1.477 -1.834 2 N-CA-C 93.853 -6.351 . . . . 0.0 93.853 170.076 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.807 HD13 ' C ' ' H' ' 30' ' ' ALA . 0.9 OUTLIER -94.43 110.69 24.08 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.269 0 CA-C-N 124.149 3.159 . . . . 0.0 108.602 177.09 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.558 ' C ' ' SD ' ' B' ' 35' ' ' MET . 0.1 OUTLIER -112.86 110.58 32.71 Favored 'Isoleucine or valine' 0 C--N 1.361 1.075 0 CA-C-N 114.526 -1.215 . . . . 0.0 108.686 -179.582 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.931 ' O ' HD23 ' H' ' 34' ' ' LEU . . . -120.24 102.34 0.87 Allowed Glycine 0 N--CA 1.462 0.401 0 N-CA-C 108.716 -1.753 . . . . 0.0 108.716 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.931 HD23 ' O ' ' H' ' 33' ' ' GLY . 2.6 mt -136.84 149.46 47.73 Favored 'General case' 0 C--O 1.243 0.742 0 CA-C-O 122.508 1.147 . . . . 0.0 112.844 -179.537 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.469 ' SD ' ' O ' ' B' ' 31' ' ' ILE . 28.7 ttp -111.9 126.02 54.66 Favored 'General case' 0 CA--C 1.505 -0.772 0 CA-C-N 113.236 -1.802 . . . . 0.0 110.467 179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.402 ' O ' ' O ' ' H' ' 37' ' ' GLY . 0.0 OUTLIER -125.27 65.57 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.2 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 178.285 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.402 ' O ' ' O ' ' H' ' 36' ' ' VAL . . . -51.65 -104.6 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 178.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 178.81 -141.8 5.09 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 -179.194 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 55.9 t -122.82 135.98 61.11 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.768 0.318 . . . . 0.0 110.288 -179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 29.7 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 118.072 -0.966 . . . . 0.0 110.495 179.924 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . 0.524 ' O ' ' CD1' ' H' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 109.616 -1.393 . . . . 0.0 109.616 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . 0.508 ' CZ ' ' O ' ' K' ' 9' ' ' GLY . 97.6 m-85 -115.06 152.22 32.88 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 110.147 -0.316 . . . . 0.0 110.147 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -60.01 134.83 57.42 Favored 'General case' 0 C--N 1.332 -0.182 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.182 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 77.3 t -124.31 133.33 69.62 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-O 120.804 0.335 . . . . 0.0 110.173 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.66 ' HE2' ' NE2' ' I' ' 15' ' ' GLN . 75.4 t60 -150.86 104.75 3.19 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.864 -179.138 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.526 ' NE2' ' O ' ' J' ' 12' ' ' VAL . 64.7 m170 -112.6 160.12 18.18 Favored 'General case' 0 CA--C 1.511 -0.541 0 CA-C-O 121.37 0.605 . . . . 0.0 110.205 179.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.66 ' NE2' ' HE2' ' I' ' 13' ' ' HIS . 84.0 mt-30 -154.06 167.56 29.38 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.401 178.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.432 ' CG ' ' O ' ' I' ' 15' ' ' GLN . 95.2 mttt -164.69 128.46 2.47 Favored 'General case' 0 N--CA 1.466 0.328 0 N-CA-C 108.993 -0.744 . . . . 0.0 108.993 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 77.2 mt -126.97 126.14 42.69 Favored 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 179.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.668 ' HB ' HG22 ' H' ' 18' ' ' VAL . 19.8 t -125.0 129.92 73.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 N-CA-C 109.567 -0.531 . . . . 0.0 109.567 179.357 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.7 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.5 OUTLIER -133.57 108.64 8.72 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -179.185 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.422 ' CG ' ' CZ ' ' J' ' 20' ' ' PHE . 4.0 p90 -143.57 153.82 42.95 Favored 'General case' 0 N--CA 1.471 0.595 0 C-N-CA 118.624 -1.23 . . . . 0.0 112.797 -179.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.46 141.48 51.87 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 114.964 -1.016 . . . . 0.0 112.962 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -150.99 99.86 2.74 Favored 'General case' 0 CA--C 1.53 0.18 0 CA-C-N 114.234 -1.348 . . . . 0.0 110.072 -179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.553 ' OD1' ' O ' ' H' ' 26' ' ' SER . 3.1 t70 -103.05 120.24 40.31 Favored 'General case' 0 N--CA 1.472 0.636 0 C-N-CA 120.34 -0.544 . . . . 0.0 110.11 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.447 ' O ' HG23 ' I' ' 24' ' ' VAL . 27.5 m -59.21 121.36 6.66 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 179.295 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.523 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 81.97 90.31 0.61 Allowed Glycine 0 CA--C 1.535 1.305 0 N-CA-C 116.918 1.527 . . . . 0.0 116.918 174.769 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.523 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 10.4 p 137.43 167.3 0.0 OUTLIER 'General case' 0 CA--C 1.513 -0.453 0 C-N-CA 124.902 1.281 . . . . 0.0 110.707 173.57 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.535 ' OD1' ' ND2' ' J' ' 27' ' ' ASN . 16.2 m-20 -49.84 178.15 0.01 OUTLIER 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 115.841 1.793 . . . . 0.0 115.841 -178.604 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.504 ' CE ' ' HB1' ' K' ' 21' ' ' ALA . 12.9 tttt -61.82 -111.24 0.0 OUTLIER 'General case' 0 CA--C 1.552 1.052 0 CA-C-N 113.177 -1.829 . . . . 0.0 114.912 172.794 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.908 ' O ' ' HB3' ' J' ' 30' ' ' ALA . . . -79.59 96.3 1.52 Allowed Glycine 0 CA--C 1.458 -3.492 0 CA-C-N 110.762 -2.927 . . . . 0.0 114.677 -175.271 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.966 ' HB3' ' O ' ' H' ' 29' ' ' GLY . . . -76.61 -136.45 0.02 OUTLIER 'General case' 0 N--CA 1.412 -2.329 1 N-CA-C 93.992 -6.299 . . . . 0.0 93.992 169.066 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.749 HD12 ' N ' ' I' ' 31' ' ' ILE . 0.4 OUTLIER -98.46 121.91 49.55 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 1 CA-C-N 127.308 4.594 . . . . 0.0 111.412 -176.631 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.479 ' O ' ' CE ' ' C' ' 35' ' ' MET . 7.7 mt -112.09 112.26 39.74 Favored 'Isoleucine or valine' 0 C--N 1.359 1.022 0 CA-C-N 114.83 -1.077 . . . . 0.0 108.276 177.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.91 104.94 1.72 Allowed Glycine 0 CA--C 1.505 -0.541 0 N-CA-C 107.295 -2.322 . . . . 0.0 107.295 177.217 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . . . . . . . . . 65.0 mt -137.39 133.2 34.53 Favored 'General case' 0 C--O 1.24 0.561 0 CA-C-O 122.751 1.262 . . . . 0.0 113.549 -176.702 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.725 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 57.0 ttp -113.47 122.68 48.04 Favored 'General case' 0 CA--C 1.502 -0.876 0 CA-C-N 113.649 -1.614 . . . . 0.0 109.153 178.257 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -127.7 70.69 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.062 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -118.46 -103.57 2.15 Favored Glycine 0 C--N 1.36 1.881 0 N-CA-C 110.041 -1.224 . . . . 0.0 110.041 178.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 68.49 -174.17 31.95 Favored Glycine 0 CA--C 1.522 0.501 0 C-N-CA 120.512 -0.851 . . . . 0.0 111.113 179.203 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -132.82 161.9 40.82 Favored 'Isoleucine or valine' 0 C--O 1.235 0.292 0 CA-C-O 121.15 0.5 . . . . 0.0 110.85 -179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 32.1 m . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 118.042 -0.98 . . . . 0.0 110.438 -179.939 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.399 -1.481 . . . . 0.0 109.399 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 44.2 p90 -145.97 153.18 40.51 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-O 120.763 0.316 . . . . 0.0 110.686 -179.999 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -145.07 159.22 43.31 Favored 'General case' 0 N--CA 1.468 0.463 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.251 179.406 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.526 ' O ' ' NE2' ' I' ' 14' ' ' HIS . 19.3 m -138.67 -166.74 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.091 -177.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 52.7 m-70 -84.4 114.43 21.89 Favored 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 120.993 -0.283 . . . . 0.0 110.66 179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.489 ' NE2' ' CG2' ' J' ' 12' ' ' VAL . 49.6 m170 -134.78 165.2 25.83 Favored 'General case' 0 CA--C 1.518 -0.251 0 CA-C-O 121.827 0.822 . . . . 0.0 110.641 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 37.5 tt0 -161.84 166.81 25.82 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.823 178.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.583 ' C ' HD12 ' J' ' 17' ' ' LEU . 98.7 mttt -156.98 135.33 11.31 Favored 'General case' 0 N--CA 1.47 0.558 0 N-CA-C 110.253 -0.277 . . . . 0.0 110.253 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.583 HD12 ' C ' ' J' ' 16' ' ' LYS . 11.0 mp -122.16 120.41 34.14 Favored 'General case' 0 N--CA 1.471 0.6 0 N-CA-C 109.275 -0.639 . . . . 0.0 109.275 178.389 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -125.92 130.12 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.447 0 N-CA-C 109.942 -0.392 . . . . 0.0 109.942 179.691 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.532 ' HZ ' HD12 ' H' ' 34' ' ' LEU . 0.4 OUTLIER -140.3 126.81 20.19 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 -178.71 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.657 ' CG ' ' CZ ' ' K' ' 20' ' ' PHE . 51.2 p90 -158.75 160.53 36.45 Favored 'General case' 0 N--CA 1.477 0.885 0 N-CA-C 115.619 1.711 . . . . 0.0 115.619 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.1 119.02 32.11 Favored 'General case' 0 C--O 1.242 0.681 0 CA-C-N 114.071 -1.422 . . . . 0.0 108.279 178.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.406 ' HG2' ' N ' ' J' ' 23' ' ' ASP . 80.5 tt0 -157.08 157.16 34.04 Favored 'General case' 0 C--N 1.345 0.375 0 CA-C-O 122.116 0.96 . . . . 0.0 113.494 -177.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.498 ' CG ' ' N ' ' J' ' 24' ' ' VAL . 51.8 p-10 -157.54 -131.41 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.486 0 N-CA-C 104.975 -2.232 . . . . 0.0 104.975 178.092 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.537 HG13 ' O ' ' J' ' 24' ' ' VAL . 3.7 p -108.38 112.33 39.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 104.761 -2.311 . . . . 0.0 104.761 174.967 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.512 ' N ' ' OE1' ' K' ' 22' ' ' GLU . . . 32.02 87.94 0.01 OUTLIER Glycine 0 C--N 1.342 0.896 0 CA-C-O 118.218 -1.323 . . . . 0.0 110.781 -179.186 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.572 ' O ' ' N ' ' K' ' 24' ' ' VAL . 82.8 p -96.57 168.35 10.59 Favored 'General case' 0 CA--C 1.497 -1.079 0 CA-C-N 120.772 2.286 . . . . 0.0 109.998 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.535 ' ND2' ' OD1' ' I' ' 27' ' ' ASN . 84.3 m-20 -61.91 179.07 0.29 Allowed 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 116.501 2.037 . . . . 0.0 116.501 175.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . . . . . . . . 0.472 53.1 tttt -59.02 106.98 0.47 Allowed 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 110.424 -3.08 . . . . 0.0 116.321 170.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.69 ' O ' ' O ' ' J' ' 30' ' ' ALA . . . -63.08 109.6 2.81 Favored Glycine 1 CA--C 1.435 -4.967 0 CA-C-O 125.192 2.551 . . . . 0.0 108.826 -173.994 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.908 ' HB3' ' O ' ' I' ' 29' ' ' GLY . . . -52.79 -124.69 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.518 2 CA-C-N 104.888 -5.656 . . . . 0.0 97.823 179.984 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.979 HD12 ' N ' ' J' ' 31' ' ' ILE . 0.2 OUTLIER -93.43 115.25 31.8 Favored 'Isoleucine or valine' 0 C--N 1.263 -3.186 1 CA-C-N 126.896 4.407 . . . . 0.0 114.63 -173.485 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.507 ' C ' ' SD ' ' D' ' 35' ' ' MET . 16.1 tt -122.27 115.4 46.03 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.986 0 N-CA-C 109.006 -0.739 . . . . 0.0 109.006 175.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.588 ' CA ' ' SD ' ' D' ' 35' ' ' MET . . . -118.01 118.55 4.1 Favored Glycine 0 N--CA 1.464 0.51 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 -179.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.527 HD11 ' CZ ' ' K' ' 19' ' ' PHE . 2.2 mt -134.91 127.45 30.66 Favored 'General case' 0 C--O 1.239 0.509 0 N-CA-C 112.751 0.648 . . . . 0.0 112.751 -178.248 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.502 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 63.8 ttp -109.2 122.01 46.39 Favored 'General case' 0 CA--C 1.509 -0.597 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.711 176.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -129.55 70.99 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.378 0 CA-C-N 116.185 -0.461 . . . . 0.0 109.784 -179.569 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . 0.422 ' HA3' HG21 ' D' ' 31' ' ' ILE . . . -94.69 106.91 3.47 Favored Glycine 0 C--N 1.361 1.933 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 178.261 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -110.39 149.88 17.6 Favored Glycine 0 N--CA 1.464 0.552 0 N-CA-C 110.368 -1.093 . . . . 0.0 110.368 179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 8.2 p -145.23 143.77 21.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.716 0.293 . . . . 0.0 110.631 -179.674 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 40.0 t . . . . . 0 C--O 1.221 -0.419 0 CA-C-O 118.027 -0.987 . . . . 0.0 110.472 179.73 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . 0.508 ' O ' ' CZ ' ' I' ' 10' ' ' TYR . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.566 -1.413 . . . . 0.0 109.566 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -115.58 143.23 45.63 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-O 120.851 0.358 . . . . 0.0 110.568 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.52 133.93 48.26 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.432 179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.447 ' O ' ' CG2' ' J' ' 12' ' ' VAL . 42.8 t -126.25 130.8 72.02 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.376 0 CA-C-O 121.024 0.44 . . . . 0.0 110.542 -179.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 69.2 m-70 -103.57 129.0 50.72 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.145 -0.479 . . . . 0.0 111.244 -179.129 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.556 ' CD2' ' N ' ' K' ' 15' ' ' GLN . 49.4 t60 -136.44 165.19 26.4 Favored 'General case' 0 CA--C 1.51 -0.593 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 178.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.556 ' N ' ' CD2' ' K' ' 14' ' ' HIS . 81.7 mt-30 -157.37 176.45 12.66 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.403 178.699 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 85.9 tttt -173.05 133.82 0.54 Allowed 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.807 -0.442 . . . . 0.0 109.807 179.193 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -125.89 122.4 35.93 Favored 'General case' 0 N--CA 1.464 0.271 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 179.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -127.97 129.29 69.66 Favored 'Isoleucine or valine' 0 C--O 1.236 0.384 0 CA-C-O 120.908 0.385 . . . . 0.0 110.437 -179.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.527 ' CZ ' HD11 ' J' ' 34' ' ' LEU . 1.9 t80 -131.25 123.89 29.39 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 179.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.657 ' CZ ' ' CG ' ' J' ' 20' ' ' PHE . 52.4 p90 -144.77 151.39 38.78 Favored 'General case' 0 N--CA 1.48 1.027 0 N-CA-C 114.312 1.227 . . . . 0.0 114.312 179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' CE ' ' I' ' 28' ' ' LYS . . . -142.67 138.17 30.43 Favored 'General case' 0 CA--C 1.543 0.7 0 CA-C-N 115.046 -0.979 . . . . 0.0 112.244 -178.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.512 ' OE1' ' N ' ' J' ' 25' ' ' GLY . 36.2 tt0 -89.5 134.09 34.26 Favored 'General case' 0 N--CA 1.475 0.813 0 CA-C-N 114.933 -1.03 . . . . 0.0 111.654 -179.567 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.543 ' OD1' ' N ' ' J' ' 29' ' ' GLY . 13.8 m-20 -148.97 119.59 7.48 Favored 'General case' 0 CA--C 1.551 0.982 0 N-CA-C 111.804 0.298 . . . . 0.0 111.804 -179.579 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.572 ' N ' ' O ' ' J' ' 26' ' ' SER . 6.0 p -120.37 121.61 66.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 N-CA-C 112.505 0.557 . . . . 0.0 112.505 -178.266 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . . . . . . . . . . . 34.37 84.87 0.01 OUTLIER Glycine 0 N--CA 1.484 1.854 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 12.8 p -46.22 165.28 0.02 OUTLIER 'General case' 0 CA--C 1.496 -1.108 0 N-CA-C 114.53 1.307 . . . . 0.0 114.53 -179.393 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -109.22 170.57 7.97 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 112.733 -2.03 . . . . 0.0 107.151 171.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -38.37 111.08 0.15 Allowed 'General case' 0 CA--C 1.551 1.015 0 N-CA-C 114.576 1.325 . . . . 0.0 114.576 175.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 78.98 91.93 0.36 Allowed Glycine 0 N--CA 1.483 1.824 0 N-CA-C 117.832 1.893 . . . . 0.0 117.832 171.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -148.19 157.54 43.56 Favored 'General case' 0 C--N 1.316 -0.879 0 N-CA-C 106.776 -1.564 . . . . 0.0 106.776 173.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.411 ' O ' ' O ' ' J' ' 30' ' ' ALA . 0.0 OUTLIER -146.92 137.26 17.44 Favored 'Isoleucine or valine' 0 C--O 1.242 0.698 0 C-N-CA 119.447 -0.901 . . . . 0.0 112.848 -176.77 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -130.88 126.2 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.547 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.428 178.973 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.98 122.27 4.92 Favored Glycine 0 C--N 1.342 0.89 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.601 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.638 HD22 ' CD1' ' L' ' 19' ' ' PHE . 21.7 tp -120.6 121.07 37.57 Favored 'General case' 0 C--O 1.233 0.215 0 CA-C-N 114.91 -0.645 . . . . 0.0 110.257 179.985 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.632 ' CE ' HG22 ' D' ' 31' ' ' ILE . 15.9 ttt -117.14 116.6 27.62 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.516 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.62 HG13 HG12 ' L' ' 36' ' ' VAL . 2.3 p -139.91 79.76 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.559 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -178.852 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.734 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -52.93 104.17 0.17 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 111.06 -0.816 . . . . 0.0 111.06 179.183 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.417 ' O ' ' O ' ' K' ' 37' ' ' GLY . . . -55.35 -165.72 0.03 OUTLIER Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 32.5 m -111.18 156.54 12.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.395 0 CA-C-O 120.967 0.413 . . . . 0.0 110.382 -179.736 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 3.5 p . . . . . 0 C--O 1.22 -0.456 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.22 -179.89 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -84.35 137.75 33.25 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.777 0.323 . . . . 0.0 110.468 -179.978 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -121.87 139.26 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.453 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 3.9 m -131.81 158.63 43.33 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.377 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -95.76 151.97 18.9 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.864 0.364 . . . . 0.0 110.108 179.456 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.456 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 62.3 m80 -80.7 177.51 8.98 Favored 'General case' 0 N--CA 1.443 -0.812 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.067 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 14.3 pt20 -129.98 177.57 7.18 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.656 -179.534 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 54.8 mtmt -147.7 150.32 34.11 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.951 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -127.25 124.61 39.27 Favored 'General case' 0 N--CA 1.465 0.276 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.116 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 55.2 t -124.52 130.48 73.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.493 0 CA-C-O 120.903 0.382 . . . . 0.0 110.496 -179.65 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.638 ' CD1' HD22 ' K' ' 34' ' ' LEU . 17.0 t80 -133.31 120.49 21.1 Favored 'General case' 0 N--CA 1.463 0.214 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 179.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 57.3 t80 -144.68 140.13 28.43 Favored 'General case' 0 N--CA 1.471 0.577 0 N-CA-C 113.418 0.896 . . . . 0.0 113.418 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -136.56 135.83 38.76 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 107.799 -1.186 . . . . 0.0 107.799 177.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' O ' ' K' ' 23' ' ' ASP . 97.1 mt-10 -85.17 76.1 10.24 Favored 'General case' 0 N--CA 1.475 0.796 0 C-N-CA 119.099 -1.04 . . . . 0.0 112.528 -177.802 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 74.6 m-20 -118.2 122.07 42.08 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 120.929 0.395 . . . . 0.0 111.127 178.445 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.581 ' O ' ' N ' ' L' ' 26' ' ' SER . 18.0 t -88.96 123.2 41.08 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.6 0 N-CA-C 107.895 -1.15 . . . . 0.0 107.895 177.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.47 0.01 OUTLIER Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.581 ' N ' ' O ' ' L' ' 24' ' ' VAL . 88.2 p -63.14 -178.33 0.23 Allowed 'General case' 0 N--CA 1.439 -0.979 0 CA-C-O 121.403 0.621 . . . . 0.0 109.882 -179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . . . . . . . . . 88.0 m-20 -81.82 177.51 8.84 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.588 178.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . . . . . . . . . 86.7 tttt -38.8 103.99 0.03 OUTLIER 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.284 177.973 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.417 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 165.73 -100.78 0.18 Allowed Glycine 0 C--O 1.22 -0.763 0 C-N-CA 120.248 -0.977 . . . . 0.0 111.671 -177.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.39 170.87 0.2 Allowed 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.417 HG12 ' O ' ' L' ' 29' ' ' GLY . 0.0 OUTLIER -153.97 145.87 14.16 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.566 0 C-N-CA 118.099 -1.44 . . . . 0.0 112.427 -176.553 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 13.6 tt -138.2 137.46 44.14 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.308 -0.86 . . . . 0.0 111.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -127.78 123.91 4.65 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 111.04 -0.824 . . . . 0.0 111.04 179.654 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 47.5 mt -117.36 119.78 36.17 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 179.583 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -116.76 119.82 36.65 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 109.796 -0.446 . . . . 0.0 109.796 -179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.62 HG12 HG13 ' K' ' 36' ' ' VAL . 3.2 m -129.32 81.66 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 116.655 -0.248 . . . . 0.0 110.88 -178.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.743 ' HA2' HG21 ' F' ' 31' ' ' ILE . . . -58.56 101.64 0.22 Allowed Glycine 0 N--CA 1.443 -0.882 0 N-CA-C 111.489 -0.644 . . . . 0.0 111.489 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.01 168.99 33.06 Favored Glycine 0 CA--C 1.527 0.843 0 N-CA-C 110.6 -1.0 . . . . 0.0 110.6 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 34.5 m -131.18 159.12 43.27 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 120.699 0.285 . . . . 0.0 110.396 -179.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 27.2 m . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 118.008 -0.996 . . . . 0.0 110.781 -179.63 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 109.581 -1.408 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 57.0 t80 -82.47 130.54 35.13 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.854 0.359 . . . . 0.0 110.395 179.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -64.42 146.21 54.85 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.59 -179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 71.6 t -121.21 134.62 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.321 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.418 -179.668 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -96.72 -176.53 3.62 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.144 179.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 79.8 m80 -81.02 171.26 15.19 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 179.973 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.433 ' HG3' ' N ' ' A' ' 16' ' ' LYS . 61.8 tp60 -152.48 171.63 17.79 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.498 179.881 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.433 ' N ' ' HG3' ' A' ' 15' ' ' GLN . 99.4 mttt -145.58 119.74 9.49 Favored 'General case' 0 N--CA 1.467 0.418 0 CA-C-O 120.49 0.186 . . . . 0.0 111.104 -179.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -132.03 120.32 22.25 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-O 120.91 0.386 . . . . 0.0 110.061 178.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -142.23 139.28 29.89 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.365 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.662 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -135.87 140.2 43.95 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 116.01 -0.541 . . . . 0.0 110.386 179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -139.75 135.44 33.11 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.072 -179.464 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.39 124.27 47.29 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 116.483 -0.326 . . . . 0.0 110.648 179.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -172.75 99.91 0.14 Allowed 'General case' 0 CA--C 1.527 0.093 0 N-CA-C 109.624 -0.51 . . . . 0.0 109.624 179.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.403 ' O ' ' C ' ' A' ' 24' ' ' VAL . 49.2 t0 -146.12 113.85 6.43 Favored 'General case' 0 N--CA 1.469 0.476 0 N-CA-C 112.735 0.642 . . . . 0.0 112.735 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.403 ' C ' ' O ' ' A' ' 23' ' ' ASP . 61.6 t -28.5 125.13 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-N 115.152 -0.931 . . . . 0.0 112.06 177.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.48 -83.34 0.05 OUTLIER Glycine 0 CA--C 1.527 0.824 0 C-N-CA 119.895 -1.145 . . . . 0.0 112.106 178.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 27' ' ' ASN . 1.5 p 170.66 179.53 0.05 Allowed 'General case' 0 N--CA 1.447 -0.588 0 CA-C-N 118.224 1.012 . . . . 0.0 110.711 -179.761 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.533 ' O ' ' O ' ' A' ' 26' ' ' SER . 0.6 OUTLIER -28.38 159.58 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 113.76 -1.564 . . . . 0.0 112.28 179.095 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.519 ' O ' ' CG ' ' A' ' 28' ' ' LYS . 0.1 OUTLIER 179.37 101.91 0.03 OUTLIER 'General case' 0 CA--C 1.544 0.739 0 CA-C-O 121.881 0.848 . . . . 0.0 112.19 179.934 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.8 101.52 0.8 Allowed Glycine 0 CA--C 1.501 -0.817 0 N-CA-C 106.673 -2.571 . . . . 0.0 106.673 176.665 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.33 153.57 24.53 Favored 'General case' 0 N--CA 1.445 -0.709 0 C-N-CA 116.528 -2.069 . . . . 0.0 111.035 -175.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.654 HD13 ' O ' ' G' ' 37' ' ' GLY . 0.0 OUTLIER -142.55 111.93 2.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 111.674 -2.512 . . . . 0.0 107.869 -173.449 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.481 ' CG2' HD21 ' B' ' 34' ' ' LEU . 7.8 mt -109.32 107.7 23.52 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.207 0 N-CA-C 107.96 -1.126 . . . . 0.0 107.96 178.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -126.27 102.62 0.65 Allowed Glycine 0 CA--C 1.508 -0.4 0 N-CA-C 107.074 -2.411 . . . . 0.0 107.074 178.285 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 26.6 mt -138.36 149.12 45.27 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 122.666 1.222 . . . . 0.0 113.76 -177.135 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.438 ' SD ' ' HA3' ' H' ' 33' ' ' GLY . 97.7 mmm -109.65 107.25 17.24 Favored 'General case' 0 CA--C 1.498 -1.043 0 CA-C-N 112.684 -2.053 . . . . 0.0 106.507 175.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -98.04 71.91 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 N-CA-C 107.661 -1.237 . . . . 0.0 107.661 178.406 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -101.76 102.73 2.4 Favored Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 -179.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -157.08 146.62 14.01 Favored Glycine 0 CA--C 1.526 0.781 0 C-N-CA 120.909 -0.662 . . . . 0.0 111.463 -179.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 9.4 p -144.59 144.35 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.778 0.323 . . . . 0.0 110.649 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 13.1 p . . . . . 0 C--O 1.22 -0.5 0 CA-C-O 118.102 -0.952 . . . . 0.0 110.537 179.967 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.501 -1.439 . . . . 0.0 109.501 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . 0.489 ' CZ ' ' OH ' ' D' ' 10' ' ' TYR . 65.7 m-85 -118.62 140.88 49.2 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.101 -0.333 . . . . 0.0 110.101 179.828 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -61.57 134.11 56.45 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.572 -179.719 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.439 HG22 ' NE2' ' B' ' 14' ' ' HIS . 4.6 p -143.13 143.89 24.43 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.904 -179.917 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 49.3 m-70 -124.77 146.67 49.09 Favored 'General case' 0 N--CA 1.472 0.674 0 CA-C-O 120.487 0.184 . . . . 0.0 110.661 -179.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.566 ' CE1' ' H ' ' C' ' 14' ' ' HIS . 98.5 m-70 -153.89 162.07 41.51 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.589 0.709 . . . . 0.0 110.842 178.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.528 ' NE2' ' O ' ' B' ' 14' ' ' HIS . 99.5 mm-40 -158.16 174.21 15.54 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 114.172 -1.376 . . . . 0.0 108.476 177.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -157.85 125.57 5.26 Favored 'General case' 0 N--CA 1.467 0.408 0 N-CA-C 109.798 -0.445 . . . . 0.0 109.798 179.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 52.9 tp -130.99 122.58 27.09 Favored 'General case' 0 N--CA 1.476 0.863 0 C-N-CA 121.054 -0.258 . . . . 0.0 110.993 179.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.0 t -128.44 133.06 67.44 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.673 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.899 179.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 27.2 t80 -131.06 130.07 42.76 Favored 'General case' 0 N--CA 1.474 0.749 0 CA-C-N 116.541 -0.3 . . . . 0.0 110.391 179.671 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 79.0 t80 -132.23 125.73 31.81 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.615 -0.266 . . . . 0.0 111.288 -178.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -123.38 125.97 45.96 Favored 'General case' 0 N--CA 1.483 1.205 0 N-CA-C 112.554 0.576 . . . . 0.0 112.554 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 77.3 tt0 -168.37 117.76 0.74 Allowed 'General case' 0 N--CA 1.471 0.612 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.747 178.525 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 50.3 t0 -148.35 106.93 3.78 Favored 'General case' 0 N--CA 1.475 0.8 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -179.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 27.7 m -28.74 140.46 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.605 0 CA-C-N 114.998 -1.001 . . . . 0.0 113.077 176.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 168.25 -80.83 0.1 Allowed Glycine 0 CA--C 1.53 0.983 0 N-CA-C 111.551 -0.62 . . . . 0.0 111.551 178.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.653 ' O ' ' O ' ' B' ' 27' ' ' ASN . 2.9 p 170.29 170.78 0.06 Allowed 'General case' 0 CA--C 1.511 -0.545 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.676 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.653 ' O ' ' O ' ' B' ' 26' ' ' SER . 52.4 p30 -18.0 158.16 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 O-C-N 124.593 1.183 . . . . 0.0 113.194 179.658 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.478 ' H ' ' HB3' ' C' ' 26' ' ' SER . 0.0 OUTLIER -161.78 110.71 1.51 Allowed 'General case' 0 C--N 1.327 -0.372 0 C-N-CA 119.506 -0.877 . . . . 0.0 112.573 176.249 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.97 95.14 0.39 Allowed Glycine 0 CA--C 1.482 -1.988 0 N-CA-C 104.897 -3.281 . . . . 0.0 104.897 176.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . . . . . . . . . . . -93.94 161.73 14.18 Favored 'General case' 0 CA--C 1.483 -1.623 0 C-N-CA 116.293 -2.163 . . . . 0.0 108.608 -175.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.634 HG22 ' CE ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -145.31 127.64 9.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.621 0 CA-C-N 112.572 -2.104 . . . . 0.0 108.14 -173.74 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.455 HG22 ' O ' ' B' ' 32' ' ' ILE . 0.6 OUTLIER -121.59 115.99 48.16 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.726 0 CA-C-O 121.044 0.45 . . . . 0.0 109.993 -179.569 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -123.57 99.74 0.63 Allowed Glycine 0 N--CA 1.462 0.368 0 N-CA-C 105.622 -2.991 . . . . 0.0 105.622 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.481 HD21 ' CG2' ' A' ' 32' ' ' ILE . 75.1 mt -124.94 137.91 54.25 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-O 122.328 1.061 . . . . 0.0 112.903 -175.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.549 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.3 ttm -119.38 115.08 23.36 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 114.012 -1.449 . . . . 0.0 107.604 178.192 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.713 ' O ' HG13 ' B' ' 36' ' ' VAL . 3.3 p -126.84 66.88 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.795 0 N-CA-C 108.8 -0.815 . . . . 0.0 108.8 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -54.65 -102.57 0.01 OUTLIER Glycine 0 C--N 1.357 1.726 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.55 152.55 15.91 Favored Glycine 0 N--CA 1.466 0.689 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 179.441 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 60.2 t -130.88 135.62 59.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.833 0.349 . . . . 0.0 110.189 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.3 m . . . . . 0 C--O 1.221 -0.43 0 CA-C-O 117.959 -1.02 . . . . 0.0 110.206 179.502 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.252 0 N-CA-C 109.432 -1.467 . . . . 0.0 109.432 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 88.9 m-85 -112.01 133.17 54.35 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.953 0.406 . . . . 0.0 110.749 179.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.442 ' O ' HG12 ' D' ' 12' ' ' VAL . 98.3 mt-10 -87.15 136.9 32.75 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.047 179.599 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.526 HG22 ' O ' ' D' ' 11' ' ' GLU . 48.3 t -116.82 130.59 71.44 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 179.603 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.439 ' O ' ' O ' ' D' ' 13' ' ' HIS . 51.3 p-80 -161.87 141.74 10.13 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 119.618 -0.833 . . . . 0.0 112.085 -178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.566 ' H ' ' CE1' ' B' ' 14' ' ' HIS . 17.1 m80 -121.39 163.21 19.08 Favored 'General case' 0 CA--C 1.509 -0.624 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 177.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.431 ' HG2' ' N ' ' C' ' 16' ' ' LYS . 57.1 tt0 -168.62 169.23 10.37 Favored 'General case' 0 C--N 1.303 -1.416 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 179.476 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . 0.431 ' N ' ' HG2' ' C' ' 15' ' ' GLN . 62.8 pttt -158.61 132.91 7.94 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 121.877 0.846 . . . . 0.0 111.396 178.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 9.8 tt -120.31 125.23 47.54 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 114.279 -1.328 . . . . 0.0 108.01 179.302 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 20.5 t -127.47 123.3 61.34 Favored 'Isoleucine or valine' 0 C--O 1.234 0.245 0 CA-C-O 121.187 0.518 . . . . 0.0 112.133 -178.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CB ' ' CE1' ' D' ' 19' ' ' PHE . 2.1 m-85 -112.95 110.6 20.77 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 106.985 -1.487 . . . . 0.0 106.985 176.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.494 ' CE2' ' CD2' ' D' ' 20' ' ' PHE . 7.4 t80 -116.25 118.11 31.87 Favored 'General case' 0 C--O 1.239 0.533 0 CA-C-N 116.473 -0.33 . . . . 0.0 110.228 -178.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.56 129.33 55.28 Favored 'General case' 0 N--CA 1.472 0.661 0 CA-C-O 121.038 0.447 . . . . 0.0 111.469 -179.235 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -158.56 101.85 1.69 Allowed 'General case' 0 N--CA 1.455 -0.207 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.972 179.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.566 ' O ' ' N ' ' D' ' 24' ' ' VAL . 17.8 m-20 -127.5 -134.62 0.24 Allowed 'General case' 0 N--CA 1.465 0.323 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 178.4 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.525 ' O ' ' N ' ' C' ' 26' ' ' SER . 12.7 t -90.55 112.49 25.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.638 0 C-N-CA 120.396 -0.522 . . . . 0.0 111.336 179.538 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.6 91.69 0.01 OUTLIER Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 177.419 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.525 ' N ' ' O ' ' C' ' 24' ' ' VAL . 4.5 p -65.16 -173.93 0.14 Allowed 'General case' 0 CA--C 1.496 -1.125 0 N-CA-C 107.537 -1.282 . . . . 0.0 107.537 179.924 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . . . . . . . . . 93.1 m-20 -78.64 171.78 14.65 Favored 'General case' 0 C--N 1.306 -1.296 0 C-N-CA 118.926 -1.11 . . . . 0.0 109.957 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.504 ' NZ ' ' H ' ' E' ' 27' ' ' ASN 0.454 5.1 tttp -45.43 114.19 0.71 Allowed 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 179.317 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.652 ' HA2' ' HB1' ' D' ' 30' ' ' ALA . . . 99.12 91.5 2.02 Favored Glycine 0 CA--C 1.489 -1.535 0 C-N-CA 126.363 1.935 . . . . 0.0 116.727 -178.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.418 ' C ' HG12 ' C' ' 31' ' ' ILE . . . -100.43 173.36 6.61 Favored 'General case' 0 N--CA 1.42 -1.961 1 N-CA-C 99.988 -4.079 . . . . 0.0 99.988 166.663 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.517 HG13 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -141.26 111.4 3.16 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 C-N-CA 117.923 -1.511 . . . . 0.0 111.44 -177.109 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.596 ' O ' ' SD ' ' J' ' 35' ' ' MET . 1.0 OUTLIER -108.97 121.87 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.111 0 CA-C-N 115.74 -0.664 . . . . 0.0 109.493 178.492 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -128.43 119.47 3.08 Favored Glycine 0 C--O 1.237 0.335 0 N-CA-C 107.909 -2.076 . . . . 0.0 107.909 177.162 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.732 ' H ' HD23 ' D' ' 34' ' ' LEU . 3.6 tt -142.61 142.88 32.19 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 122.481 1.134 . . . . 0.0 112.935 -177.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.429 ' N ' HD23 ' C' ' 34' ' ' LEU . 0.1 OUTLIER -113.89 118.26 33.71 Favored 'General case' 0 C--O 1.238 0.466 0 CA-C-N 113.38 -1.736 . . . . 0.0 109.909 178.907 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.04 73.83 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.931 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 177.945 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.49 106.05 3.14 Favored Glycine 0 C--N 1.356 1.677 0 N-CA-C 111.196 -0.761 . . . . 0.0 111.196 -179.568 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -98.51 161.08 20.47 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 179.39 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 77.4 t -130.66 135.75 59.7 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.75 0.309 . . . . 0.0 110.641 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 94.7 t . . . . . 0 C--O 1.219 -0.511 0 CA-C-O 118.141 -0.933 . . . . 0.0 111.598 179.377 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.324 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . 0.489 ' OH ' ' CZ ' ' B' ' 10' ' ' TYR . 85.3 m-85 -107.08 133.65 51.39 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.894 0.378 . . . . 0.0 110.48 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.526 ' O ' HG22 ' C' ' 12' ' ' VAL . 79.6 tt0 -150.1 133.0 16.07 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.058 -0.519 . . . . 0.0 110.701 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.442 HG12 ' O ' ' C' ' 11' ' ' GLU . 29.2 m -99.65 166.34 2.18 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.279 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.076 179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.501 ' CD2' ' CD2' ' C' ' 14' ' ' HIS . 46.7 t60 -153.84 148.93 26.84 Favored 'General case' 0 N--CA 1.465 0.305 0 C-N-CA 120.207 -0.597 . . . . 0.0 111.227 179.361 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . . . . . . . . . 32.6 m170 -99.79 -178.68 3.94 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.337 -179.825 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.502 ' CG ' ' N ' ' D' ' 16' ' ' LYS . 44.0 tt0 -84.55 167.91 15.88 Favored 'General case' 0 C--N 1.315 -0.93 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.716 -179.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.502 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 95.5 mttt -119.86 139.23 52.7 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.838 -0.43 . . . . 0.0 109.838 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 75.6 mt -122.52 121.99 37.84 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 120.544 0.211 . . . . 0.0 110.462 179.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 75.4 t -129.84 128.02 64.7 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-O 121.092 0.472 . . . . 0.0 111.586 -179.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.488 ' CE1' ' CB ' ' C' ' 19' ' ' PHE . 7.9 m-85 -122.86 119.8 31.6 Favored 'General case' 0 N--CA 1.469 0.483 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.065 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.604 ' CE1' ' CD1' ' E' ' 20' ' ' PHE . 13.7 t80 -112.87 118.67 35.55 Favored 'General case' 0 C--O 1.239 0.503 0 N-CA-C 109.762 -0.459 . . . . 0.0 109.762 -179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -110.75 111.59 22.87 Favored 'General case' 0 C--O 1.251 1.184 0 CA-C-O 122.552 1.168 . . . . 0.0 111.92 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.468 ' HG2' ' H ' ' D' ' 23' ' ' ASP . 66.4 tt0 -139.31 178.25 7.33 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 178.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.48 ' O ' ' C ' ' D' ' 24' ' ' VAL . 19.8 p30 -179.93 126.13 0.08 Allowed 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 -178.395 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.566 ' N ' ' O ' ' C' ' 23' ' ' ASP . 57.8 t -41.2 115.26 0.1 OUTLIER 'Isoleucine or valine' 0 C--N 1.349 0.553 0 CA-C-O 122.563 1.173 . . . . 0.0 108.094 -176.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 89.53 92.55 1.17 Allowed Glycine 0 N--CA 1.44 -1.062 0 N-CA-C 105.336 -3.106 . . . . 0.0 105.336 -174.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.481 ' O ' ' CB ' ' D' ' 27' ' ' ASN . 11.0 p -44.46 169.83 0.01 OUTLIER 'General case' 0 N--CA 1.442 -0.86 0 CA-C-N 115.369 -0.415 . . . . 0.0 110.872 -179.974 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.533 ' CG ' ' N ' ' D' ' 28' ' ' LYS . 5.4 t-20 156.72 162.04 0.01 OUTLIER 'General case' 0 CA--C 1.561 1.377 0 CA-C-O 124.34 2.019 . . . . 0.0 114.669 174.541 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.585 ' N ' ' OD1' ' E' ' 23' ' ' ASP 0.827 13.5 tttt -29.6 112.08 0.07 Allowed 'General case' 0 C--N 1.323 -0.584 1 N-CA-C 127.623 6.157 . . . . 0.0 127.623 177.18 . . . . . . . . 4 3 . 1 . 005 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.07 100.16 1.6 Allowed Glycine 0 CA--C 1.461 -3.309 2 N-CA-C 100.274 -5.13 . . . . 0.0 100.274 176.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.652 ' HB1' ' HA2' ' C' ' 29' ' ' GLY . . . -73.6 -128.78 0.01 OUTLIER 'General case' 1 N--CA 1.348 -5.569 4 CA-C-N 100.45 -7.875 . . . . 0.0 100.162 -174.909 . . . . . . . . 4 3 . 1 . 005 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.963 HD12 ' N ' ' D' ' 31' ' ' ILE . 1.2 mp -76.78 113.87 16.4 Favored 'Isoleucine or valine' 0 C--N 1.255 -3.509 0 CA-C-N 123.247 2.749 . . . . 0.0 113.913 -174.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.562 ' CG2' HG23 ' E' ' 32' ' ' ILE . 2.6 tt -121.32 112.65 36.39 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.38 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 175.622 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.635 ' O ' HD23 ' D' ' 34' ' ' LEU . . . -121.95 110.89 1.71 Allowed Glycine 0 N--CA 1.468 0.777 0 N-CA-C 107.946 -2.062 . . . . 0.0 107.946 178.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.732 HD23 ' H ' ' C' ' 34' ' ' LEU . 21.2 mt -133.5 132.94 41.59 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 119.408 -0.917 . . . . 0.0 112.493 -176.916 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.502 ' SD ' ' C ' ' J' ' 32' ' ' ILE . 3.9 ttm -109.78 126.64 53.98 Favored 'General case' 0 CA--C 1.507 -0.7 0 CA-C-N 114.313 -1.312 . . . . 0.0 108.153 178.187 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 1.2 t -121.41 79.27 0.62 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.008 0 CA-C-N 116.671 -0.241 . . . . 0.0 110.989 -178.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -44.34 103.18 0.04 OUTLIER Glycine 0 C--N 1.357 1.72 0 N-CA-C 109.681 -1.367 . . . . 0.0 109.681 177.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -78.12 -166.63 29.05 Favored Glycine 0 CA--C 1.522 0.484 0 N-CA-C 111.605 -0.598 . . . . 0.0 111.605 -178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.4 t -122.47 136.21 60.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 121.021 0.439 . . . . 0.0 110.35 -179.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 13.2 t . . . . . 0 C--O 1.219 -0.514 0 CA-C-O 117.953 -1.023 . . . . 0.0 110.419 179.94 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.213 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . 0.419 ' O ' ' O ' ' D' ' 10' ' ' TYR . 98.8 m-85 -114.1 134.71 54.7 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-O 120.913 0.387 . . . . 0.0 110.807 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -119.34 148.13 43.53 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.311 179.777 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.468 ' CG1' ' CE1' ' E' ' 14' ' ' HIS . 72.8 t -123.79 134.09 67.42 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 121.176 0.512 . . . . 0.0 110.398 179.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 90.2 m-70 -118.99 101.99 8.43 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.475 -0.784 . . . . 0.0 109.118 179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.468 ' CE1' ' CG1' ' E' ' 12' ' ' VAL . 50.6 m170 -130.02 169.1 15.71 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-O 121.609 0.718 . . . . 0.0 110.264 -179.251 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 89.1 mt-30 -149.22 174.73 12.06 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.632 -1.167 . . . . 0.0 108.314 179.457 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -154.34 112.02 3.47 Favored 'General case' 0 N--CA 1.467 0.421 0 C-N-CA 120.455 -0.498 . . . . 0.0 111.493 179.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 25.8 tp -121.45 117.1 26.03 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 107.629 -1.249 . . . . 0.0 107.629 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.9 t -130.93 127.76 61.71 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -178.459 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 3.1 m-85 -118.53 115.98 25.71 Favored 'General case' 0 N--CA 1.47 0.525 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 177.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.604 ' CD1' ' CE1' ' D' ' 20' ' ' PHE . 36.1 t80 -114.98 122.88 47.61 Favored 'General case' 0 N--CA 1.471 0.609 0 O-C-N 122.385 -0.197 . . . . 0.0 111.171 -179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.56 132.72 42.87 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.999 -0.28 . . . . 0.0 110.633 179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.6 tt0 -100.14 136.64 39.73 Favored 'General case' 0 N--CA 1.491 1.619 0 C-N-CA 119.615 -0.834 . . . . 0.0 112.94 -178.791 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.585 ' OD1' ' N ' ' D' ' 28' ' ' LYS . 46.3 t0 -138.1 131.47 30.59 Favored 'General case' 0 C--N 1.368 1.382 0 CA-C-O 121.353 0.597 . . . . 0.0 112.559 178.201 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.416 ' CG2' ' OG ' ' D' ' 26' ' ' SER . 37.8 t -111.44 113.25 43.7 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.606 177.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.401 ' C ' ' O ' ' E' ' 24' ' ' VAL . . . 32.74 88.77 0.01 OUTLIER Glycine 0 CA--C 1.534 1.258 0 CA-C-O 121.794 0.663 . . . . 0.0 112.297 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.527 ' CB ' ' HG ' ' F' ' 26' ' ' SER . 3.4 p -46.67 170.9 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.696 0 N-CA-C 113.929 1.085 . . . . 0.0 113.929 179.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.504 ' H ' ' NZ ' ' C' ' 28' ' ' LYS . 0.3 OUTLIER -129.14 -179.21 5.0 Favored 'General case' 0 CA--C 1.552 1.034 0 CA-C-N 112.94 -1.936 . . . . 0.0 107.996 173.775 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -29.58 107.88 0.04 OUTLIER 'General case' 0 CA--C 1.564 1.508 0 N-CA-C 117.381 2.363 . . . . 0.0 117.381 -177.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.581 ' O ' ' HB3' ' E' ' 30' ' ' ALA . . . 81.55 -96.62 1.77 Allowed Glycine 0 N--CA 1.493 2.488 0 N-CA-C 118.129 2.011 . . . . 0.0 118.129 171.236 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.581 ' HB3' ' O ' ' E' ' 29' ' ' GLY . . . 75.28 149.56 0.1 Allowed 'General case' 0 C--O 1.252 1.219 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 -175.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.647 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.0 OUTLIER -154.33 122.82 0.69 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 C-N-CA 117.147 -1.821 . . . . 0.0 110.442 -175.152 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.562 HG23 ' CG2' ' D' ' 32' ' ' ILE . 93.5 mt -121.58 127.13 75.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.669 -0.696 . . . . 0.0 111.255 -177.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -135.94 118.99 1.94 Allowed Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.391 -0.684 . . . . 0.0 111.391 179.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.751 HD13 ' CD2' ' F' ' 19' ' ' PHE . 48.4 mt -123.87 123.64 40.89 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-N 114.807 -0.696 . . . . 0.0 109.951 -179.627 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -120.01 122.88 42.12 Favored 'General case' 0 N--CA 1.47 0.566 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.147 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 11.7 t -114.17 86.51 0.91 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.722 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.648 ' CA ' HG21 ' K' ' 31' ' ' ILE . . . -63.91 97.35 0.22 Allowed Glycine 0 CA--C 1.529 0.965 0 N-CA-C 110.774 -0.931 . . . . 0.0 110.774 179.848 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.09 168.86 38.74 Favored Glycine 0 CA--C 1.528 0.878 0 N-CA-C 111.373 -0.691 . . . . 0.0 111.373 -179.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 55.5 t -123.5 135.97 61.57 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.417 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.219 -0.532 0 CA-C-O 118.059 -0.972 . . . . 0.0 110.385 -179.807 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.315 0 N-CA-C 109.509 -1.437 . . . . 0.0 109.509 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -114.77 135.78 53.8 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-O 120.811 0.339 . . . . 0.0 110.779 -179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 17.2 pt-20 -85.6 159.86 19.76 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.85 -179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 81.1 t -94.78 133.68 34.84 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.194 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.658 -179.602 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 50.1 p-80 -139.97 125.95 19.68 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-O 121.335 0.588 . . . . 0.0 110.722 -179.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.614 ' CG ' ' H ' ' F' ' 15' ' ' GLN . 82.7 t60 -156.97 177.25 11.72 Favored 'General case' 0 N--CA 1.442 -0.84 0 N-CA-C 108.252 -1.018 . . . . 0.0 108.252 -179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.614 ' H ' ' CG ' ' F' ' 14' ' ' HIS . 86.9 mt-30 -144.21 173.87 11.38 Favored 'General case' 0 C--N 1.316 -0.876 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -148.94 112.43 5.02 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 121.277 0.561 . . . . 0.0 111.605 -179.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 1.7 mp -124.68 120.47 31.93 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 178.252 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 55.6 t -127.53 128.67 70.0 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 CA-C-O 121.817 0.818 . . . . 0.0 112.704 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.751 ' CD2' HD13 ' E' ' 34' ' ' LEU . 8.7 m-85 -115.09 104.98 12.41 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 176.963 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.403 ' CE2' ' OE2' ' F' ' 22' ' ' GLU . 18.7 t80 -114.94 120.71 40.83 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 -177.932 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.27 129.54 33.74 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.403 ' OE2' ' CE2' ' F' ' 20' ' ' PHE . 73.5 mm-40 -92.6 92.4 8.0 Favored 'General case' 0 N--CA 1.467 0.396 0 C-N-CA 120.49 -0.484 . . . . 0.0 111.507 -178.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.436 ' OD1' ' OD2' ' E' ' 23' ' ' ASP . 25.5 t0 -147.41 107.98 4.13 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 120.791 0.329 . . . . 0.0 111.5 178.777 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 20.2 m -77.49 -131.45 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.31 0.576 . . . . 0.0 110.147 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . . . . . . . . . . . -59.15 85.44 0.01 OUTLIER Glycine 0 CA--C 1.528 0.879 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.927 178.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.527 ' HG ' ' CB ' ' E' ' 26' ' ' SER . 3.7 t -61.82 -178.39 0.15 Allowed 'General case' 0 N--CA 1.44 -0.95 0 N-CA-C 107.692 -1.225 . . . . 0.0 107.692 -179.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.417 ' N ' ' OG ' ' E' ' 26' ' ' SER . 59.5 t30 -80.16 172.78 13.32 Favored 'General case' 0 C--N 1.316 -0.866 0 C-N-CA 119.863 -0.735 . . . . 0.0 111.228 -178.572 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -45.45 110.73 0.27 Allowed 'General case' 0 C--N 1.331 -0.222 0 C-N-CA 120.429 -0.508 . . . . 0.0 111.153 179.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . 79.0 92.95 0.32 Allowed Glycine 0 N--CA 1.463 0.48 0 C-N-CA 120.758 -0.734 . . . . 0.0 112.503 176.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.56 ' HB1' ' HZ3' ' D' ' 28' ' ' LYS . . . -120.84 162.5 19.71 Favored 'General case' 0 CA--C 1.489 -1.396 0 N-CA-C 102.047 -3.316 . . . . 0.0 102.047 173.283 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.46 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.0 OUTLIER -144.48 116.47 2.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 C-N-CA 115.625 -2.43 . . . . 0.0 112.728 -175.903 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 12.2 tt -125.95 135.55 63.53 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 114.531 -1.213 . . . . 0.0 111.029 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -136.31 128.02 4.37 Favored Glycine 0 CA--C 1.531 1.043 0 C-N-CA 121.361 -0.447 . . . . 0.0 112.022 -179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 22.9 mt -119.66 124.37 46.13 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 107.948 -1.13 . . . . 0.0 107.948 178.573 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.556 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 0.4 OUTLIER -130.64 129.63 42.92 Favored 'General case' 0 N--CA 1.477 0.906 0 CA-C-O 121.36 0.6 . . . . 0.0 112.363 -178.885 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.586 ' O ' HG13 ' F' ' 36' ' ' VAL . 7.7 p -152.95 81.89 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.517 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.702 179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -57.56 101.51 0.18 Allowed Glycine 0 CA--C 1.526 0.733 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.249 -178.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -151.19 160.46 28.69 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 12.7 p -137.46 141.62 39.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 120.837 0.351 . . . . 0.0 110.907 -179.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 35.6 m . . . . . 0 C--O 1.219 -0.533 0 CA-C-O 117.934 -1.031 . . . . 0.0 110.629 179.747 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -113.69 135.94 53.38 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-O 120.897 0.379 . . . . 0.0 110.359 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 45.2 tp10 -68.69 135.85 51.98 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.135 -178.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 2.6 p -144.49 151.06 15.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.282 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.476 179.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -130.87 122.02 26.29 Favored 'General case' 0 N--CA 1.472 0.627 0 CA-C-O 121.132 0.492 . . . . 0.0 111.721 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . . . . . . . . . 6.2 m-70 -145.48 164.58 31.16 Favored 'General case' 0 N--CA 1.448 -0.53 0 N-CA-C 108.103 -1.073 . . . . 0.0 108.103 178.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.416 ' HG3' ' N ' ' G' ' 16' ' ' LYS . 64.5 tp60 -164.9 165.17 20.59 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.242 178.758 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.416 ' N ' ' HG3' ' G' ' 15' ' ' GLN . 98.7 mttt -157.04 129.12 7.27 Favored 'General case' 0 C--N 1.325 -0.48 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 178.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 93.4 mt -136.43 122.14 19.79 Favored 'General case' 0 C--O 1.239 0.516 0 CA-C-O 121.535 0.683 . . . . 0.0 110.999 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . 0.452 HG22 ' CG1' ' H' ' 18' ' ' VAL . 71.4 t -123.44 129.55 74.66 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.566 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 58.0 m-85 -128.81 134.89 48.51 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-O 120.803 0.335 . . . . 0.0 110.909 179.48 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.513 ' O ' ' CD2' ' G' ' 20' ' ' PHE . 46.0 p90 -129.93 127.13 39.48 Favored 'General case' 0 N--CA 1.466 0.335 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.791 179.548 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.11 123.59 37.21 Favored 'General case' 0 N--CA 1.47 0.571 0 CA-C-O 121.418 0.627 . . . . 0.0 111.372 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 74.1 tt0 -174.48 98.72 0.09 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.212 -0.904 . . . . 0.0 109.545 179.289 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -152.63 114.7 4.4 Favored 'General case' 0 N--CA 1.467 0.386 0 N-CA-C 113.905 1.076 . . . . 0.0 113.905 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 59.2 t -28.99 122.55 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 113.9 -1.5 . . . . 0.0 113.358 176.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.44 -85.56 0.06 OUTLIER Glycine 0 CA--C 1.529 0.926 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.556 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.555 ' O ' ' O ' ' G' ' 27' ' ' ASN . 19.0 t -153.39 -173.59 4.63 Favored 'General case' 0 CA--C 1.508 -0.658 0 CA-C-N 119.462 1.631 . . . . 0.0 111.646 178.5 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.555 ' O ' ' O ' ' G' ' 26' ' ' SER . 98.3 m-20 -20.52 156.57 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.625 0 CA-C-N 113.58 -1.645 . . . . 0.0 112.903 177.873 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . . . . . . . . . 58.5 tttm -168.44 102.83 0.43 Allowed 'General case' 0 CA--C 1.53 0.184 0 C-N-CA 118.732 -1.187 . . . . 0.0 113.739 174.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.445 ' O ' HG13 ' G' ' 31' ' ' ILE . . . -76.81 104.45 1.89 Allowed Glycine 0 CA--C 1.495 -1.205 0 CA-C-O 115.789 -2.673 . . . . 0.0 106.86 172.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.469 ' C ' HG13 ' G' ' 31' ' ' ILE . . . -74.75 143.15 44.23 Favored 'General case' 0 C--O 1.252 1.203 1 CA-C-N 124.22 4.01 . . . . 0.0 105.782 -178.126 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.469 HG13 ' C ' ' G' ' 30' ' ' ALA . 69.6 mt -156.75 115.29 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 CA-C-N 112.883 -1.962 . . . . 0.0 108.509 -171.826 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.426 ' O ' ' HA ' ' H' ' 32' ' ' ILE . 10.4 tt -141.01 131.01 26.2 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.427 0 CA-C-O 122.683 1.23 . . . . 0.0 110.523 179.06 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.413 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -148.98 154.27 25.7 Favored Glycine 0 CA--C 1.484 -1.871 0 N-CA-C 107.265 -2.334 . . . . 0.0 107.265 176.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 52.2 tp -145.04 140.68 28.28 Favored 'General case' 0 C--N 1.302 -1.462 0 C-N-CA 119.423 -0.911 . . . . 0.0 110.691 -179.183 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 25.6 ttp -103.48 106.81 17.42 Favored 'General case' 0 N--CA 1.428 -1.528 0 N-CA-C 106.04 -1.837 . . . . 0.0 106.04 176.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -115.48 65.28 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.906 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 -179.568 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.654 ' O ' HD13 ' A' ' 31' ' ' ILE . . . -131.45 102.55 0.51 Allowed Glycine 0 C--N 1.369 2.374 0 N-CA-C 109.309 -1.516 . . . . 0.0 109.309 178.579 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -166.13 173.42 41.66 Favored Glycine 0 CA--C 1.523 0.587 0 C-N-CA 120.385 -0.912 . . . . 0.0 111.894 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 55.3 t -123.32 136.24 60.6 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 N-CA-C 110.109 -0.33 . . . . 0.0 110.109 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 34.8 m . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.402 179.608 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.228 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -85.18 158.13 20.45 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 22.4 pt-20 -52.58 151.07 4.5 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.43 -0.35 . . . . 0.0 110.835 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 33.0 m -130.42 159.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-N 115.977 -0.556 . . . . 0.0 109.877 -179.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 77.0 m80 -129.48 133.24 47.18 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.979 0.418 . . . . 0.0 111.948 -179.227 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 73.9 m80 -140.9 163.81 31.95 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 108.679 -0.859 . . . . 0.0 108.679 178.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 79.9 mt-30 -157.59 177.5 11.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-O 121.355 0.598 . . . . 0.0 111.307 179.249 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . 0.617 ' C ' HD22 ' H' ' 17' ' ' LEU . 45.0 tttp -170.64 115.53 0.47 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 114.958 -1.019 . . . . 0.0 108.81 178.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.744 HD22 ' N ' ' H' ' 17' ' ' LEU . 1.6 mm? -122.8 119.16 29.77 Favored 'General case' 0 N--CA 1.467 0.422 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.452 ' CG1' HG22 ' G' ' 18' ' ' VAL . 3.0 p -135.17 130.65 51.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 C-N-CA 120.183 -0.607 . . . . 0.0 110.713 178.29 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 96.6 m-85 -120.13 123.24 42.85 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.356 -0.838 . . . . 0.0 109.948 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 61.0 t80 -117.23 123.0 45.56 Favored 'General case' 0 N--CA 1.466 0.372 0 N-CA-C 109.752 -0.462 . . . . 0.0 109.752 179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.11 126.18 38.78 Favored 'General case' 0 N--CA 1.467 0.398 0 CA-C-O 121.321 0.581 . . . . 0.0 110.48 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.419 ' O ' ' CG ' ' H' ' 23' ' ' ASP . 84.1 tt0 -138.94 131.12 28.2 Favored 'General case' 0 CA--C 1.519 -0.212 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.146 -179.912 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.589 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 12.2 m-20 -163.05 122.92 2.23 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.474 -179.891 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.548 HG12 ' CG2' ' I' ' 24' ' ' VAL . 7.1 m -93.51 -113.1 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.318 -0.782 0 N-CA-C 107.923 -1.139 . . . . 0.0 107.923 179.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.507 ' N ' HG23 ' H' ' 24' ' ' VAL . . . 42.74 -91.37 0.01 OUTLIER Glycine 0 CA--C 1.528 0.888 0 C-N-CA 121.068 -0.587 . . . . 0.0 114.086 176.064 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.446 ' N ' ' O ' ' H' ' 24' ' ' VAL . 25.6 p -73.58 170.74 14.56 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.587 1.184 . . . . 0.0 113.606 -174.547 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . . . . . . . . . 23.3 m120 -46.97 179.97 0.0 OUTLIER 'General case' 0 C--N 1.316 -0.862 0 CA-C-N 112.597 -2.092 . . . . 0.0 113.564 -176.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.492 ' HZ1' ' HB2' ' J' ' 23' ' ' ASP . 82.4 tttt -119.29 -110.25 0.35 Allowed 'General case' 0 CA--C 1.536 0.44 0 CA-C-N 114.16 -1.382 . . . . 0.0 112.0 -176.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . 47.61 92.44 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.163 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 -178.012 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -106.04 159.59 15.94 Favored 'General case' 0 C--O 1.25 1.118 0 C-N-CA 118.049 -1.461 . . . . 0.0 110.266 -179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.41 ' HB ' ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -138.7 124.99 24.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 CA-C-N 113.084 -1.871 . . . . 0.0 111.55 -178.745 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.549 ' N ' ' SD ' ' B' ' 35' ' ' MET . 0.7 OUTLIER -114.52 117.29 55.15 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.875 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.195 178.054 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.438 ' HA3' ' SD ' ' A' ' 35' ' ' MET . . . -118.38 109.3 1.75 Allowed Glycine 0 N--CA 1.483 1.779 0 N-CA-C 108.077 -2.009 . . . . 0.0 108.077 177.699 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.756 HD13 ' CZ ' ' J' ' 19' ' ' PHE . 15.5 mt -118.36 122.73 43.55 Favored 'General case' 0 CA--C 1.49 -1.333 0 N-CA-C 112.848 0.684 . . . . 0.0 112.848 -175.393 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . . . . . . . . . 2.1 ttm -114.56 106.1 13.87 Favored 'General case' 0 CA--C 1.495 -1.148 0 N-CA-C 107.586 -1.265 . . . . 0.0 107.586 175.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.63 71.81 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.092 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.402 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.23 111.72 3.71 Favored Glycine 0 C--N 1.365 2.148 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -45.37 160.18 0.17 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 40' ' ' VAL . 3.3 p -140.5 141.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 CA-C-O 120.702 0.287 . . . . 0.0 110.314 -179.836 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' H' ' 39' ' ' VAL . 84.5 t . . . . . 0 C--O 1.219 -0.527 0 CA-C-O 117.964 -1.017 . . . . 0.0 110.955 179.758 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.356 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -113.86 138.68 49.97 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 109.999 -0.371 . . . . 0.0 109.999 179.841 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 98.4 mt-10 -140.14 159.26 42.59 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.27 0.557 . . . . 0.0 111.445 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 75.1 t -121.69 131.74 72.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.251 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.018 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -147.16 121.85 9.85 Favored 'General case' 0 N--CA 1.466 0.355 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.823 -179.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 87.7 m-70 -134.94 161.82 34.18 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.657 -0.498 . . . . 0.0 109.657 179.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 76.8 mt-30 -153.78 166.96 31.25 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-O 121.511 0.672 . . . . 0.0 111.576 179.277 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 68.6 mttm -156.91 127.32 6.52 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.285 -0.87 . . . . 0.0 109.352 178.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -128.8 125.73 38.4 Favored 'General case' 0 N--CA 1.467 0.4 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 179.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -128.86 126.82 65.49 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 116.691 -0.232 . . . . 0.0 111.189 -179.1 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.615 ' CD1' ' CE1' ' J' ' 19' ' ' PHE . 31.4 m-85 -115.17 107.37 15.21 Favored 'General case' 0 CA--C 1.545 0.765 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -108.25 122.74 47.58 Favored 'General case' 0 N--CA 1.483 1.222 0 CA-C-N 118.274 0.488 . . . . 0.0 110.795 -179.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.79 138.93 34.44 Favored 'General case' 0 N--CA 1.484 1.233 0 N-CA-C 113.358 0.873 . . . . 0.0 113.358 -179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.455 ' HG2' ' H ' ' J' ' 22' ' ' GLU . 72.7 mt-10 -152.29 121.87 6.88 Favored 'General case' 0 N--CA 1.476 0.837 0 CA-C-O 118.972 -0.537 . . . . 0.0 111.752 -179.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.589 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 63.7 m-20 -151.42 103.74 3.02 Favored 'General case' 0 C--N 1.362 1.115 0 N-CA-C 115.674 1.731 . . . . 0.0 115.674 176.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.548 ' CG2' HG12 ' H' ' 24' ' ' VAL . 59.8 t -31.87 142.82 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.92 0 C-N-CA 125.616 1.567 . . . . 0.0 114.215 170.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 167.68 -81.75 0.1 Allowed Glycine 0 CA--C 1.533 1.16 0 C-N-CA 119.187 -1.482 . . . . 0.0 114.779 174.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.54 ' O ' ' O ' ' I' ' 27' ' ' ASN . 91.5 p -132.61 -179.21 5.32 Favored 'General case' 0 CA--C 1.496 -1.129 0 N-CA-C 107.522 -1.288 . . . . 0.0 107.522 -179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.603 ' OD1' ' N ' ' I' ' 28' ' ' LYS . 46.5 t-20 -40.23 167.05 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.874 0 N-CA-C 107.864 -1.161 . . . . 0.0 107.864 178.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.603 ' N ' ' OD1' ' I' ' 27' ' ' ASN . 70.7 tttt -72.3 110.6 6.84 Favored 'General case' 0 C--N 1.344 0.337 0 C-N-CA 114.268 -2.973 . . . . 0.0 111.316 178.286 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -81.68 94.69 1.66 Allowed Glycine 0 CA--C 1.491 -1.433 0 CA-C-O 115.406 -2.885 . . . . 0.0 106.399 167.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -132.14 142.29 49.43 Favored 'General case' 0 CA--C 1.478 -1.8 0 CA-C-N 123.892 3.846 . . . . 0.0 109.0 177.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.512 HG23 HG13 ' J' ' 31' ' ' ILE . 0.0 OUTLIER -139.19 120.32 15.63 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.683 0 CA-C-N 111.54 -2.573 . . . . 0.0 109.261 -176.529 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.478 HG22 ' O ' ' I' ' 32' ' ' ILE . 0.8 OUTLIER -110.53 114.27 46.59 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.139 0 CA-C-O 121.333 0.587 . . . . 0.0 110.19 178.968 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -104.52 96.94 1.31 Allowed Glycine 0 CA--C 1.496 -1.099 0 N-CA-C 105.103 -3.199 . . . . 0.0 105.103 175.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.687 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 31.9 tp -111.88 122.93 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 112.068 0.395 . . . . 0.0 112.068 -175.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 34.1 ttp -121.57 114.77 21.67 Favored 'General case' 0 CA--C 1.512 -0.514 0 N-CA-C 108.532 -0.914 . . . . 0.0 108.532 176.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.478 HG11 HD22 ' K' ' 17' ' ' LEU . 0.0 OUTLIER -131.89 72.22 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 -179.284 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . 0.459 ' O ' ' O ' ' I' ' 36' ' ' VAL . . . -37.77 -98.49 0.01 OUTLIER Glycine 0 C--N 1.358 1.765 0 N-CA-C 111.343 -0.703 . . . . 0.0 111.343 179.927 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.07 -167.33 39.21 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 111.11 -0.796 . . . . 0.0 111.11 -179.703 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 45.3 t -123.44 135.6 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-O 120.938 0.399 . . . . 0.0 110.405 -179.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.412 HG22 ' H ' ' I' ' 40' ' ' VAL . 28.5 m . . . . . 0 C--O 1.22 -0.465 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.448 179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.219 0 N-CA-C 109.547 -1.421 . . . . 0.0 109.547 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 8.6 m-85 -129.26 141.34 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.012 -0.366 . . . . 0.0 110.012 179.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -88.01 130.32 35.0 Favored 'General case' 0 C--O 1.234 0.255 0 CA-C-O 121.047 0.451 . . . . 0.0 110.151 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -137.09 144.46 31.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 121.35 0.595 . . . . 0.0 110.796 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 12.0 t-80 -148.85 132.39 16.74 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.0 179.255 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.708 ' CD2' ' H ' ' J' ' 15' ' ' GLN . 11.3 t-80 -156.17 165.69 35.67 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-O 121.541 0.686 . . . . 0.0 109.523 179.841 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.708 ' H ' ' CD2' ' J' ' 14' ' ' HIS . 48.4 tt0 -165.0 168.89 17.01 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.316 179.67 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . 0.474 ' N ' ' CG ' ' J' ' 15' ' ' GLN . 88.5 tttt -153.7 132.63 12.45 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.449 179.048 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.43 127.23 47.2 Favored 'General case' 0 N--CA 1.467 0.387 0 N-CA-C 109.669 -0.493 . . . . 0.0 109.669 179.219 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 63.9 t -126.08 127.93 71.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.834 0.35 . . . . 0.0 110.884 -179.425 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.756 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 97.3 m-85 -113.52 109.56 18.84 Favored 'General case' 0 N--CA 1.464 0.234 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 177.87 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.583 ' CD1' ' OE2' ' J' ' 22' ' ' GLU . 0.1 OUTLIER -120.03 122.83 41.98 Favored 'General case' 0 N--CA 1.472 0.645 0 N-CA-C 111.733 0.271 . . . . 0.0 111.733 -176.91 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.22 132.21 41.23 Favored 'General case' 0 N--CA 1.471 0.607 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.498 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.583 ' OE2' ' CD1' ' J' ' 20' ' ' PHE . 18.6 mp0 -140.52 145.85 37.37 Favored 'General case' 0 N--CA 1.48 1.041 0 C-N-CA 120.19 -0.604 . . . . 0.0 112.36 -179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.537 ' OD1' ' N ' ' I' ' 23' ' ' ASP . 15.3 m-20 -167.33 124.24 1.18 Allowed 'General case' 0 CA--C 1.538 0.489 0 CA-C-O 121.5 0.666 . . . . 0.0 111.903 178.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.804 HG13 ' H ' ' J' ' 25' ' ' GLY . 7.1 p -62.93 -116.73 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 114.762 -1.108 . . . . 0.0 110.834 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.804 ' H ' HG13 ' J' ' 24' ' ' VAL . . . 60.72 -91.79 0.06 OUTLIER Glycine 0 CA--C 1.531 1.067 0 CA-C-N 114.976 -1.011 . . . . 0.0 114.42 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.83 ' O ' ' O ' ' J' ' 27' ' ' ASN . 35.1 p -171.63 172.52 4.97 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-N 118.173 0.986 . . . . 0.0 110.834 -176.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.83 ' O ' ' O ' ' J' ' 26' ' ' SER . 80.3 m-20 15.58 -178.6 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.382 0 O-C-N 125.627 1.83 . . . . 0.0 114.738 -179.486 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.544 ' CA ' ' OD1' ' I' ' 27' ' ' ASN 0.255 80.4 tttt -148.49 109.92 4.41 Favored 'General case' 0 CA--C 1.535 0.37 0 C-N-CA 118.359 -1.336 . . . . 0.0 113.906 179.422 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.506 ' O ' ' O ' ' I' ' 28' ' ' LYS . . . -73.73 94.13 0.75 Allowed Glycine 0 CA--C 1.489 -1.551 0 CA-C-O 116.172 -2.46 . . . . 0.0 107.683 169.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . . . . . . . . . . . -128.48 146.52 50.79 Favored 'General case' 0 CA--C 1.481 -1.709 0 CA-C-N 123.116 3.458 . . . . 0.0 110.587 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.53 ' CG2' HD12 ' K' ' 31' ' ' ILE . 0.1 OUTLIER -149.71 109.36 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.42 -1.942 0 CA-C-N 110.906 -2.861 . . . . 0.0 105.629 -178.141 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.537 HG22 HG23 ' K' ' 32' ' ' ILE . 1.1 tt -109.7 113.38 44.03 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.699 0 CA-C-O 121.773 0.797 . . . . 0.0 108.9 -177.646 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . 0.461 ' N ' ' SD ' ' D' ' 35' ' ' MET . . . -102.49 107.73 3.18 Favored Glycine 0 CA--C 1.507 -0.442 0 N-CA-C 108.135 -1.986 . . . . 0.0 108.135 -179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.794 HD22 ' CE1' ' L' ' 19' ' ' PHE . 6.4 mt -110.62 111.36 22.53 Favored 'General case' 0 CA--C 1.507 -0.677 0 CA-C-O 121.247 0.546 . . . . 0.0 110.748 -177.385 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.596 ' SD ' ' O ' ' C' ' 32' ' ' ILE . 18.9 ttt -110.28 110.34 21.12 Favored 'General case' 0 N--CA 1.441 -0.899 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 178.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 5.9 m -133.83 74.88 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.229 -179.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -94.27 102.21 2.85 Favored Glycine 0 C--N 1.35 1.357 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.552 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -152.86 157.1 27.1 Favored Glycine 0 CA--C 1.523 0.561 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -136.95 146.75 27.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.257 0 CA-C-O 120.795 0.331 . . . . 0.0 110.362 -179.661 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 9.9 t . . . . . 0 C--O 1.221 -0.426 0 CA-C-O 118.039 -0.981 . . . . 0.0 110.57 -179.885 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.236 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.5 m-85 -105.29 137.63 42.77 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.233 -0.284 . . . . 0.0 110.233 -179.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -156.22 129.81 8.32 Favored 'General case' 0 C--O 1.232 0.168 0 C-N-CA 120.863 -0.335 . . . . 0.0 110.773 179.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 32.8 m -133.42 133.8 57.41 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.776 179.656 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 -128.16 121.58 29.87 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.51 -179.894 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.449 ' ND1' ' NE2' ' L' ' 14' ' ' HIS . 96.6 m-70 -122.59 169.38 11.08 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.37 0.605 . . . . 0.0 109.72 -179.721 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.403 ' HG3' ' N ' ' K' ' 16' ' ' LYS . 66.4 tp60 -155.36 169.98 22.97 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.164 179.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.403 ' N ' ' HG3' ' K' ' 15' ' ' GLN . 88.4 tttt -172.61 125.32 0.48 Allowed 'General case' 0 C--O 1.233 0.218 0 CA-C-O 120.553 0.216 . . . . 0.0 110.503 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.478 HD22 HG11 ' I' ' 36' ' ' VAL . 5.1 mp -128.69 129.34 45.66 Favored 'General case' 0 N--CA 1.466 0.374 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 179.079 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.501 HG11 ' CE2' ' K' ' 20' ' ' PHE . 40.6 t -132.12 133.55 60.45 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.616 0 CA-C-O 121.067 0.46 . . . . 0.0 111.504 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.687 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 37.7 m-85 -114.58 111.73 21.81 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.601 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.501 ' CE2' HG11 ' K' ' 18' ' ' VAL . 54.8 m-85 -109.13 114.43 28.15 Favored 'General case' 0 N--CA 1.472 0.627 0 O-C-N 122.353 -0.217 . . . . 0.0 111.252 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -120.32 121.27 38.27 Favored 'General case' 0 N--CA 1.473 0.718 0 N-CA-C 108.73 -0.841 . . . . 0.0 108.73 177.958 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -121.68 130.87 53.77 Favored 'General case' 0 N--CA 1.474 0.752 0 N-CA-C 113.451 0.908 . . . . 0.0 113.451 -177.145 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.51 ' OD1' ' N ' ' K' ' 23' ' ' ASP . 16.4 p-10 179.25 102.25 0.02 OUTLIER 'General case' 0 CA--C 1.53 0.182 0 CA-C-N 114.936 -1.029 . . . . 0.0 109.415 176.93 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.607 HG22 ' N ' ' K' ' 25' ' ' GLY . 12.9 p -58.82 166.29 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-N 115.602 -0.726 . . . . 0.0 112.133 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.607 ' N ' HG22 ' K' ' 24' ' ' VAL . . . 88.23 81.6 1.26 Allowed Glycine 0 CA--C 1.53 0.969 0 CA-C-N 115.298 -0.865 . . . . 0.0 113.463 176.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 34.0 p -47.9 166.78 0.03 OUTLIER 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 109.141 -0.689 . . . . 0.0 109.141 177.346 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.611 ' ND2' ' ND2' ' J' ' 27' ' ' ASN . 9.6 t-20 -157.2 177.38 11.54 Favored 'General case' 0 C--N 1.32 -0.7 0 C-N-CA 120.033 -0.667 . . . . 0.0 112.68 177.576 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.544 ' H ' ' ND2' ' K' ' 27' ' ' ASN . 67.3 mmtt 2.31 -105.32 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.047 0 C-N-CA 124.358 1.063 . . . . 0.0 113.265 178.626 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -140.92 97.66 0.22 Allowed Glycine 0 N--CA 1.465 0.627 0 N-CA-C 110.212 -1.155 . . . . 0.0 110.212 179.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . . . . . . . . . . . -64.94 170.32 4.44 Favored 'General case' 0 C--O 1.24 0.562 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 178.953 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.648 HG21 ' CA ' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -152.18 126.37 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.508 0 C-N-CA 117.998 -1.481 . . . . 0.0 111.442 -178.687 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.537 HG23 HG22 ' J' ' 32' ' ' ILE . 96.6 mt -126.14 132.64 70.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 114.938 -1.028 . . . . 0.0 111.603 -178.416 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.76 116.34 2.97 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.308 -0.717 . . . . 0.0 111.308 179.559 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 12.6 mt -107.22 111.25 23.56 Favored 'General case' 0 C--O 1.239 0.53 0 N-CA-C 108.931 -0.766 . . . . 0.0 108.931 178.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.456 ' C ' ' SD ' ' K' ' 35' ' ' MET . 0.0 OUTLIER -113.03 111.99 23.12 Favored 'General case' 0 C--O 1.235 0.298 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.449 -178.943 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.4 t -123.09 81.79 0.74 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.502 0 N-CA-C 111.72 0.267 . . . . 0.0 111.72 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.647 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -79.16 100.88 1.8 Allowed Glycine 0 N--CA 1.444 -0.828 0 N-CA-C 109.675 -1.37 . . . . 0.0 109.675 178.164 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -165.82 161.43 34.97 Favored Glycine 0 CA--C 1.524 0.642 0 C-N-CA 120.644 -0.788 . . . . 0.0 111.455 -179.579 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.9 m -139.28 162.47 27.31 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.231 0 CA-C-O 120.763 0.316 . . . . 0.0 110.558 179.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 8.5 p . . . . . 0 C--O 1.221 -0.4 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.4 179.77 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -120.74 140.85 51.07 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-O 120.883 0.373 . . . . 0.0 110.615 -179.747 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -59.19 141.3 54.6 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.4 -179.96 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 7.9 m -121.62 133.74 67.14 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.517 0 CA-C-O 121.255 0.55 . . . . 0.0 110.876 179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 69.5 t60 -140.14 125.14 18.5 Favored 'General case' 0 CA--C 1.531 0.245 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.415 179.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.449 ' NE2' ' ND1' ' K' ' 14' ' ' HIS . 23.6 p80 -157.38 170.97 21.24 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 109.517 -0.549 . . . . 0.0 109.517 179.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 13.7 pt20 -148.75 174.2 12.44 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.48 179.248 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -152.86 139.5 18.81 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.457 179.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.5 mp -134.34 122.38 22.54 Favored 'General case' 0 C--N 1.332 -0.154 0 N-CA-C 109.094 -0.706 . . . . 0.0 109.094 178.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 58.1 t -126.12 132.82 70.12 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.721 0 CA-C-O 121.079 0.466 . . . . 0.0 111.755 -178.523 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.794 ' CE1' HD22 ' J' ' 34' ' ' LEU . 88.1 m-85 -112.62 112.01 23.24 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.944 -0.571 . . . . 0.0 109.565 178.691 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -120.73 119.45 32.82 Favored 'General case' 0 N--CA 1.464 0.232 0 CA-C-O 121.31 0.576 . . . . 0.0 110.715 -179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.44 128.62 47.27 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 178.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' L' ' 22' ' ' GLU . 11.3 tm-20 -78.59 96.51 5.5 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 119.852 -0.739 . . . . 0.0 111.188 -178.21 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 2.8 t0 -152.55 113.57 4.19 Favored 'General case' 0 CA--C 1.534 0.337 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.409 HG23 ' O ' ' L' ' 24' ' ' VAL . 31.9 m -98.62 130.51 47.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.785 0 CA-C-N 116.321 -0.399 . . . . 0.0 110.281 -179.467 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . 45.0 81.74 0.03 OUTLIER Glycine 0 C--N 1.336 0.581 0 C-N-CA 119.853 -1.165 . . . . 0.0 110.748 177.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 86.0 p -62.16 -178.15 0.16 Allowed 'General case' 0 N--CA 1.435 -1.191 0 CA-C-O 121.773 0.797 . . . . 0.0 110.459 -177.313 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.454 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 7.9 t-20 -80.63 178.46 8.33 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 114.393 -1.276 . . . . 0.0 112.449 -178.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.454 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 65.0 mttp -41.44 111.05 0.19 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.088 -0.96 . . . . 0.0 112.059 -178.725 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB3' ' L' ' 30' ' ' ALA . . . 83.71 -93.71 1.76 Allowed Glycine 0 N--CA 1.463 0.474 0 CA-C-N 113.951 -1.477 . . . . 0.0 112.982 179.513 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.598 ' HB3' ' O ' ' L' ' 29' ' ' GLY . . . 78.26 161.48 0.21 Allowed 'General case' 0 CA--C 1.508 -0.658 0 N-CA-C 100.636 -3.838 . . . . 0.0 100.636 -174.477 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.48 ' CG1' ' C ' ' L' ' 30' ' ' ALA . 0.1 OUTLIER -154.09 127.54 1.21 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.112 0 CA-C-N 122.665 2.484 . . . . 0.0 111.961 -179.11 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 48.5 pt -122.64 141.54 42.63 Favored 'Isoleucine or valine' 0 C--N 1.339 0.134 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.063 -178.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.88 121.21 3.33 Favored Glycine 0 N--CA 1.465 0.621 0 N-CA-C 110.214 -1.154 . . . . 0.0 110.214 179.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.4 tp -124.42 123.02 39.26 Favored 'General case' 0 N--CA 1.465 0.278 0 N-CA-C 110.335 -0.246 . . . . 0.0 110.335 -179.498 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.578 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.1 ppp? -131.67 136.05 47.38 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.475 0.655 . . . . 0.0 110.651 178.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' L' ' 37' ' ' GLY . 5.5 t -138.18 80.74 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.691 -179.259 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.46 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . 26.47 -104.32 0.01 OUTLIER Glycine 0 CA--C 1.531 1.09 0 O-C-N 123.419 0.45 . . . . 0.0 112.65 179.655 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 134.03 147.48 5.65 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -179.995 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -140.98 164.23 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 120.754 0.312 . . . . 0.0 110.734 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 28.4 t . . . . . 0 C--O 1.221 -0.441 0 CA-C-O 118.002 -0.999 . . . . 0.0 110.379 179.891 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.245 0 N-CA-C 109.412 -1.475 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 91.7 m-85 -114.63 139.67 49.44 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.935 0.398 . . . . 0.0 110.769 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -128.99 160.75 31.73 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.018 179.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 48.2 t -122.54 148.49 26.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.379 0 CA-C-N 116.278 -0.419 . . . . 0.0 109.898 179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -77.82 162.96 26.5 Favored 'General case' 0 N--CA 1.462 0.173 0 CA-C-N 115.896 -0.593 . . . . 0.0 112.036 -178.514 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.554 ' N ' ' ND1' ' A' ' 14' ' ' HIS . 1.4 m-70 -104.12 172.98 6.5 Favored 'General case' 0 N--CA 1.45 -0.45 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.167 -179.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.404 ' HG2' ' N ' ' A' ' 16' ' ' LYS . 51.6 tt0 -151.11 173.03 14.85 Favored 'General case' 0 C--N 1.317 -0.817 0 CA-C-N 115.867 -0.606 . . . . 0.0 110.006 179.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . 0.404 ' N ' ' HG2' ' A' ' 15' ' ' GLN . 88.0 tttt -155.25 132.39 10.9 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-O 120.666 0.27 . . . . 0.0 110.492 -179.912 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 52.1 tp -131.96 126.66 34.58 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-O 121.194 0.521 . . . . 0.0 111.13 179.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 24.2 m -128.17 132.83 68.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.298 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.767 179.375 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 21.3 t80 -135.14 131.23 36.57 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-O 120.973 0.416 . . . . 0.0 111.193 -179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 40.8 t80 -119.63 126.07 50.28 Favored 'General case' 0 N--CA 1.467 0.385 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 179.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.8 132.51 45.3 Favored 'General case' 0 N--CA 1.47 0.547 0 CA-C-O 121.968 0.889 . . . . 0.0 112.647 -178.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.8 tt0 -140.77 96.44 3.02 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.592 -1.185 . . . . 0.0 109.217 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.433 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 2.1 m-20 -59.81 143.53 50.9 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.54 179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 61.4 t -91.72 110.65 22.9 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-O 122.126 0.965 . . . . 0.0 108.465 -178.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 40.53 -92.7 0.01 OUTLIER Glycine 0 CA--C 1.53 1.027 0 CA-C-N 113.452 -1.704 . . . . 0.0 113.16 -179.154 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 10.7 t 61.66 179.33 0.12 Allowed 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 106.089 -1.819 . . . . 0.0 106.089 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.623 ' O ' ' O ' ' A' ' 28' ' ' LYS . 65.4 t30 -82.0 178.31 8.36 Favored 'General case' 0 C--N 1.317 -0.84 0 N-CA-C 105.81 -1.922 . . . . 0.0 105.81 173.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.623 ' O ' ' O ' ' A' ' 27' ' ' ASN . 45.3 tttp -49.01 -110.98 0.0 OUTLIER 'General case' 0 CA--C 1.545 0.774 0 CA-C-N 119.62 1.1 . . . . 0.0 110.508 176.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 59.63 92.09 0.01 OUTLIER Glycine 0 C--N 1.346 1.114 0 CA-C-O 118.089 -1.395 . . . . 0.0 114.766 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.569 ' HB1' ' HA2' ' C' ' 25' ' ' GLY . . . -138.06 142.2 40.3 Favored 'General case' 0 CA--C 1.504 -0.809 0 C-N-CA 116.645 -2.022 . . . . 0.0 109.227 174.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.462 ' HA ' ' O ' ' B' ' 31' ' ' ILE . 0.9 OUTLIER -155.67 128.55 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.431 -1.411 0 CA-C-N 111.603 -2.544 . . . . 0.0 109.499 -173.181 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.516 ' O ' ' SD ' ' H' ' 35' ' ' MET . 24.4 mt -126.62 107.92 18.06 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.775 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 176.032 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.01 102.32 1.36 Allowed Glycine 0 CA--C 1.505 -0.534 0 N-CA-C 106.021 -2.832 . . . . 0.0 106.021 177.379 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 75.7 mt -133.95 150.21 51.28 Favored 'General case' 0 CA--C 1.513 -0.474 0 CA-C-O 122.529 1.157 . . . . 0.0 112.802 -177.135 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 15.7 ttm -128.87 118.22 22.34 Favored 'General case' 0 CA--C 1.504 -0.815 0 CA-C-N 113.048 -1.887 . . . . 0.0 107.14 177.962 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.457 ' O ' ' O ' ' A' ' 37' ' ' GLY . 0.0 OUTLIER -109.01 71.03 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.066 0 N-CA-C 109.634 -0.506 . . . . 0.0 109.634 -179.158 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.457 ' O ' ' O ' ' A' ' 36' ' ' VAL . . . -37.54 -100.36 0.01 OUTLIER Glycine 0 C--N 1.362 2.024 0 N-CA-C 111.319 -0.713 . . . . 0.0 111.319 178.93 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 165.28 -171.76 40.68 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.394 -1.083 . . . . 0.0 110.394 -179.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 35.6 m -122.3 135.97 60.66 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.355 0 CA-C-O 121.01 0.433 . . . . 0.0 110.6 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 t . . . . . 0 C--O 1.219 -0.526 0 CA-C-O 117.891 -1.052 . . . . 0.0 110.773 -179.796 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.227 0 N-CA-C 109.576 -1.409 . . . . 0.0 109.576 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -112.68 144.13 42.7 Favored 'General case' 0 N--CA 1.467 0.397 0 N-CA-C 109.946 -0.39 . . . . 0.0 109.946 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.488 ' O ' ' NE2' ' C' ' 13' ' ' HIS . 96.3 mt-10 -61.96 129.9 43.05 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.98 0.419 . . . . 0.0 110.969 -179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.7 132.56 65.97 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.307 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.991 179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . . . . . . . . . 41.1 p-80 -157.08 170.12 23.25 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.16 0.505 . . . . 0.0 111.382 -178.812 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 21.4 m-70 -134.14 169.56 16.98 Favored 'General case' 0 N--CA 1.448 -0.525 0 N-CA-C 107.961 -1.125 . . . . 0.0 107.961 179.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 55.9 tt0 -155.01 165.0 38.1 Favored 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.128 179.003 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -156.28 113.5 3.19 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.163 179.377 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 57.7 tp -118.79 121.03 39.09 Favored 'General case' 0 N--CA 1.464 0.266 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 178.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 61.6 t -125.56 124.3 66.49 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 121.137 0.494 . . . . 0.0 110.575 179.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -121.79 119.02 30.46 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.06 179.479 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 39.4 t80 -120.19 120.0 34.87 Favored 'General case' 0 N--CA 1.465 0.314 0 N-CA-C 109.876 -0.416 . . . . 0.0 109.876 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.83 126.92 35.49 Favored 'General case' 0 N--CA 1.474 0.753 0 CA-C-O 121.368 0.604 . . . . 0.0 111.684 -179.42 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 81.8 mt-10 -153.26 145.1 23.55 Favored 'General case' 0 N--CA 1.467 0.391 0 C-N-CA 119.902 -0.719 . . . . 0.0 111.561 179.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.445 ' O ' ' C ' ' B' ' 24' ' ' VAL . 18.7 t70 -146.5 115.28 6.86 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.2 178.802 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.445 ' C ' ' O ' ' B' ' 23' ' ' ASP . 2.8 t 25.75 -124.1 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.594 179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . -154.22 83.18 0.16 Allowed Glycine 0 CA--C 1.528 0.859 0 N-CA-C 111.146 -0.781 . . . . 0.0 111.146 178.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.523 ' OG ' ' NZ ' ' A' ' 28' ' ' LYS . 4.9 p -93.49 179.95 5.23 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 179.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.524 ' O ' ' NZ ' ' A' ' 28' ' ' LYS . 77.3 m-20 -59.6 -176.61 0.04 OUTLIER 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.379 179.507 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.565 ' O ' ' CE ' ' A' ' 28' ' ' LYS . 13.8 tttp -63.22 -113.35 0.0 OUTLIER 'General case' 0 CA--C 1.542 0.656 0 C-N-CA 120.744 -0.383 . . . . 0.0 111.449 -179.867 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.733 ' HA2' ' HB2' ' C' ' 30' ' ' ALA . . . 45.27 90.88 0.01 OUTLIER Glycine 0 N--CA 1.479 1.518 0 N-CA-C 114.064 0.386 . . . . 0.0 114.064 176.463 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.936 ' O ' ' HB3' ' C' ' 30' ' ' ALA . . . -140.03 151.39 45.4 Favored 'General case' 0 N--CA 1.425 -1.699 0 N-CA-C 105.034 -2.21 . . . . 0.0 105.034 172.364 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.661 HG23 ' CG2' ' C' ' 31' ' ' ILE . 1.6 mt -137.63 105.09 3.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 118.672 -1.211 . . . . 0.0 108.262 -174.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.588 HD11 HD12 ' B' ' 34' ' ' LEU . 12.4 tt -126.18 123.59 64.06 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 C-N-CA 118.984 -1.086 . . . . 0.0 112.211 -179.581 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.601 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -114.9 104.94 1.42 Allowed Glycine 0 CA--C 1.503 -0.684 0 N-CA-C 106.975 -2.45 . . . . 0.0 106.975 177.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.624 HD11 ' CZ ' ' C' ' 19' ' ' PHE . 1.0 OUTLIER -122.62 125.94 46.67 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-O 122.605 1.193 . . . . 0.0 110.639 -179.027 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.536 ' SD ' ' C ' ' H' ' 32' ' ' ILE . 1.3 ttm -112.31 119.77 39.45 Favored 'General case' 0 N--CA 1.438 -1.068 0 CA-C-N 113.519 -1.673 . . . . 0.0 108.538 179.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.458 ' O ' ' O ' ' B' ' 37' ' ' GLY . 0.0 OUTLIER -123.31 70.95 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.875 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.635 -179.874 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -45.14 -99.06 0.01 OUTLIER Glycine 0 C--N 1.356 1.659 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 178.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 138.02 165.47 10.35 Favored Glycine 0 N--CA 1.465 0.609 0 N-CA-C 110.887 -0.885 . . . . 0.0 110.887 179.5 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 34.6 m -135.41 161.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.994 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . 0.404 ' H ' HG13 ' B' ' 40' ' ' VAL . 7.6 m . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.644 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.239 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -116.08 144.28 44.35 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 110.057 -0.349 . . . . 0.0 110.057 179.775 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -73.35 137.1 44.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.436 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 2.4 m -140.12 177.63 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.374 -178.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.488 ' NE2' ' O ' ' B' ' 11' ' ' GLU . 77.7 m80 -78.26 128.27 33.48 Favored 'General case' 0 N--CA 1.467 0.387 0 C-N-CA 120.186 -0.606 . . . . 0.0 110.294 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.578 ' ND1' ' N ' ' C' ' 15' ' ' GLN . 60.0 t-80 -151.64 163.88 38.12 Favored 'General case' 0 N--CA 1.453 -0.3 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.578 ' N ' ' ND1' ' C' ' 14' ' ' HIS . 80.9 mt-30 -157.43 175.58 13.79 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.284 179.247 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -170.46 115.7 0.49 Allowed 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 120.958 0.409 . . . . 0.0 111.069 179.187 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 55.0 mt -120.03 125.58 48.7 Favored 'General case' 0 N--CA 1.472 0.636 0 CA-C-N 116.149 -0.478 . . . . 0.0 109.889 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 75.0 t -131.65 124.68 54.56 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.63 0 N-CA-C 112.648 0.61 . . . . 0.0 112.648 -178.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.624 ' CZ ' HD11 ' B' ' 34' ' ' LEU . 2.9 m-85 -115.43 112.85 22.92 Favored 'General case' 0 N--CA 1.473 0.694 0 N-CA-C 106.846 -1.538 . . . . 0.0 106.846 175.608 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 20.6 t80 -118.6 130.4 55.86 Favored 'General case' 0 N--CA 1.474 0.767 0 N-CA-C 110.466 -0.198 . . . . 0.0 110.466 -178.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.504 ' O ' ' HB1' ' D' ' 21' ' ' ALA . . . -162.13 160.48 27.31 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 115.786 1.772 . . . . 0.0 115.786 -179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.2 tt0 -118.1 118.74 32.72 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 113.695 -1.593 . . . . 0.0 111.059 179.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.511 ' CG ' ' H ' ' C' ' 24' ' ' VAL . 47.9 t0 49.61 -123.41 1.91 Allowed 'General case' 0 CA--C 1.531 0.227 0 CA-C-O 121.801 0.81 . . . . 0.0 112.086 177.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.511 ' H ' ' CG ' ' C' ' 23' ' ' ASP . 12.1 t -30.96 112.98 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 114.153 -1.385 . . . . 0.0 114.121 -176.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.569 ' HA2' ' HB1' ' A' ' 30' ' ' ALA . . . 110.92 -93.33 0.71 Allowed Glycine 0 CA--C 1.53 0.98 0 CA-C-N 113.729 -1.578 . . . . 0.0 114.091 175.811 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.494 ' OG ' ' CB ' ' C' ' 21' ' ' ALA . 0.0 OUTLIER -80.36 172.0 14.33 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-O 122.243 1.02 . . . . 0.0 113.662 -178.47 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.507 ' O ' ' O ' ' C' ' 28' ' ' LYS . 37.5 t30 83.08 -178.82 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 112.399 -2.182 . . . . 0.0 113.673 176.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.507 ' O ' ' O ' ' C' ' 27' ' ' ASN . 34.7 mtmt -38.65 -101.5 0.0 OUTLIER 'General case' 0 CA--C 1.518 -0.272 0 CA-C-N 113.671 -1.604 . . . . 0.0 109.463 175.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.64 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 81.39 -110.58 3.18 Favored Glycine 0 CA--C 1.453 -3.819 0 CA-C-O 125.317 2.621 . . . . 0.0 116.097 176.343 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.936 ' HB3' ' O ' ' B' ' 30' ' ' ALA . . . -88.37 -130.87 0.07 Allowed 'General case' 2 N--CA 1.357 -5.093 2 N-CA-C 95.377 -5.786 . . . . 0.0 95.377 171.373 . . . . . . . . 4 3 . 1 . 006 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.684 HD11 ' CE ' ' J' ' 35' ' ' MET . 7.8 tp -87.91 135.61 25.08 Favored 'Isoleucine or valine' 1 C--N 1.232 -4.504 0 N-CA-C 114.345 1.239 . . . . 0.0 114.345 -179.109 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.488 ' O ' ' CE ' ' J' ' 35' ' ' MET . 8.1 tt -120.77 112.98 38.3 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 175.609 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.85 ' C ' HD12 ' C' ' 34' ' ' LEU . . . -122.36 122.84 5.21 Favored Glycine 0 CA--C 1.504 -0.636 0 CA-C-N 115.472 -0.785 . . . . 0.0 111.447 -178.546 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.85 HD12 ' C ' ' C' ' 33' ' ' GLY . 6.6 mp -143.78 146.25 32.97 Favored 'General case' 0 CA--C 1.495 -1.151 0 C-N-CA 118.694 -1.202 . . . . 0.0 112.041 178.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.59 ' SD ' ' C ' ' I' ' 32' ' ' ILE . 3.4 ttm -121.11 121.95 38.98 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 113.286 -1.779 . . . . 0.0 108.704 177.665 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.93 76.9 0.49 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.106 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' B' ' 37' ' ' GLY . . . -83.12 104.09 2.55 Favored Glycine 0 C--N 1.361 1.957 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.08 170.68 51.39 Favored Glycine 0 CA--C 1.523 0.548 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 -179.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 16.9 m -140.61 162.77 23.24 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-O 120.815 0.341 . . . . 0.0 110.756 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 6.7 t . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 118.029 -0.986 . . . . 0.0 110.428 179.676 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.513 -1.435 . . . . 0.0 109.513 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 94.6 m-85 -91.77 135.34 33.98 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-O 120.83 0.348 . . . . 0.0 110.542 179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -83.05 131.01 35.19 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.311 179.686 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 42.0 t -140.58 139.06 35.6 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-O 121.275 0.559 . . . . 0.0 110.889 -179.789 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 37.7 m80 -132.87 138.71 47.12 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.354 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.552 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 29.3 t-80 -144.9 166.11 26.23 Favored 'General case' 0 N--CA 1.446 -0.639 0 CA-C-O 121.408 0.623 . . . . 0.0 110.083 -179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.552 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 52.7 tt0 -160.23 171.26 19.52 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 114.996 -1.002 . . . . 0.0 109.39 179.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . 0.419 ' N ' ' CG ' ' D' ' 15' ' ' GLN . 86.8 tttt -169.96 118.25 0.59 Allowed 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.483 -0.487 . . . . 0.0 111.452 179.762 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 2.7 tt -128.63 127.03 41.42 Favored 'General case' 0 C--O 1.237 0.413 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 178.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 4.0 p -142.42 138.1 29.15 Favored 'Isoleucine or valine' 0 C--O 1.235 0.311 0 CA-C-O 121.8 0.809 . . . . 0.0 113.095 -178.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.583 ' CZ ' ' CD2' ' C' ' 34' ' ' LEU . 38.0 m-85 -113.36 117.94 33.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.036 177.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.566 ' CE2' ' CD1' ' E' ' 20' ' ' PHE . 22.6 t80 -127.59 124.55 38.38 Favored 'General case' 0 N--CA 1.474 0.759 0 CA-C-O 120.745 0.307 . . . . 0.0 110.654 -179.377 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.504 ' HB1' ' O ' ' C' ' 21' ' ' ALA . . . -158.14 164.72 36.32 Favored 'General case' 0 C--O 1.239 0.512 0 C-N-CA 118.515 -1.274 . . . . 0.0 113.724 -179.671 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 15.3 pt-20 -137.59 157.01 47.42 Favored 'General case' 0 N--CA 1.468 0.459 0 CA-C-N 114.333 -1.303 . . . . 0.0 112.381 -179.421 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 17.6 t0 -141.77 142.12 33.23 Favored 'General case' 0 C--N 1.331 -0.211 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.517 HG13 ' O ' ' D' ' 24' ' ' VAL . 7.3 p -90.88 112.68 25.48 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 122.712 1.244 . . . . 0.0 110.015 -177.09 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . . . . . . . . . . . 41.29 86.83 0.01 OUTLIER Glycine 0 CA--C 1.525 0.696 0 CA-C-N 112.976 -1.92 . . . . 0.0 113.01 -179.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.585 ' N ' ' O ' ' E' ' 24' ' ' VAL . 36.8 t -140.55 170.14 16.34 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 117.218 0.509 . . . . 0.0 109.71 175.892 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.52 ' O ' ' O ' ' D' ' 26' ' ' SER . 4.5 m-20 -31.55 173.79 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.834 0 N-CA-C 114.413 1.264 . . . . 0.0 114.413 178.296 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.529 ' O ' ' CB ' ' E' ' 30' ' ' ALA . 87.9 tttt -86.33 112.1 21.1 Favored 'General case' 0 C--O 1.209 -1.073 0 CA-C-N 114.477 -1.238 . . . . 0.0 107.905 171.849 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.56 ' O ' ' CB ' ' D' ' 30' ' ' ALA . . . 73.24 -93.39 0.69 Allowed Glycine 1 CA--C 1.446 -4.246 0 C-N-CA 119.334 -1.412 . . . . 0.0 112.994 179.125 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.64 ' CB ' ' O ' ' C' ' 29' ' ' GLY . . . 113.55 -150.12 0.0 OUTLIER 'General case' 0 N--CA 1.385 -3.718 1 N-CA-C 93.74 -6.393 . . . . 0.0 93.74 -168.681 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.901 HD12 ' N ' ' D' ' 31' ' ' ILE . 3.1 mp -103.42 122.51 56.08 Favored 'Isoleucine or valine' 0 C--N 1.264 -3.134 0 C-N-CA 116.517 -2.073 . . . . 0.0 113.116 -179.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.429 HG22 ' O ' ' D' ' 32' ' ' ILE . 0.2 OUTLIER -113.36 118.27 57.66 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.897 179.107 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.46 ' N ' ' CE ' ' J' ' 35' ' ' MET . . . -131.9 101.75 0.48 Allowed Glycine 0 N--CA 1.472 1.075 0 N-CA-C 106.792 -2.523 . . . . 0.0 106.792 177.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.442 HD23 ' H ' ' C' ' 34' ' ' LEU . 10.0 mt -130.64 125.63 34.52 Favored 'General case' 0 C--O 1.239 0.549 0 CA-C-O 122.187 0.994 . . . . 0.0 111.793 -175.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -105.54 117.6 34.42 Favored 'General case' 0 N--CA 1.448 -0.535 0 CA-C-N 113.983 -1.462 . . . . 0.0 107.115 177.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -114.4 80.91 0.59 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 120.874 0.368 . . . . 0.0 110.49 -177.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -61.73 103.27 0.54 Allowed Glycine 0 C--N 1.344 1.013 0 N-CA-C 110.382 -1.087 . . . . 0.0 110.382 179.219 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.72 -163.0 6.88 Favored Glycine 0 CA--C 1.525 0.664 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.352 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 53.2 t -117.41 133.94 62.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 CA-C-O 121.09 0.472 . . . . 0.0 110.673 -179.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 27.3 m . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.061 -0.971 . . . . 0.0 110.818 -179.861 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.726 -1.35 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.7 144.57 43.76 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-O 120.96 0.41 . . . . 0.0 110.872 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 83.2 tt0 -63.38 149.59 45.51 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.783 -179.807 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 p -133.51 142.86 40.56 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.417 179.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 69.7 t60 -143.18 139.9 30.52 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-O 120.92 0.391 . . . . 0.0 110.696 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.528 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 77.9 t60 -135.92 170.12 16.5 Favored 'General case' 0 CA--C 1.51 -0.591 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.528 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 43.7 tt0 -158.19 171.13 20.77 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 116.011 -0.541 . . . . 0.0 109.991 179.659 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.475 ' N ' ' CG ' ' E' ' 15' ' ' GLN . 98.0 mttt -150.39 113.14 4.75 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.33 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 81.4 mt -118.3 115.87 25.6 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -131.56 130.14 62.21 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.58 0 N-CA-C 113.547 0.943 . . . . 0.0 113.547 -177.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.433 ' HB2' ' CD1' ' F' ' 19' ' ' PHE . 7.2 m-85 -113.05 111.2 21.74 Favored 'General case' 0 CA--C 1.538 0.517 0 N-CA-C 106.76 -1.57 . . . . 0.0 106.76 176.488 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.566 ' CD1' ' CE2' ' D' ' 20' ' ' PHE . 25.5 t80 -122.49 121.33 36.32 Favored 'General case' 0 N--CA 1.477 0.888 0 CA-C-N 118.223 0.465 . . . . 0.0 111.292 -178.601 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -140.34 136.88 33.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 120.951 0.405 . . . . 0.0 111.469 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 79.9 tt0 -124.68 120.81 32.91 Favored 'General case' 0 N--CA 1.478 0.975 0 N-CA-C 112.316 0.487 . . . . 0.0 112.316 -179.606 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.448 ' O ' ' OD1' ' E' ' 23' ' ' ASP . 44.7 p-10 -163.75 101.77 0.9 Allowed 'General case' 0 CA--C 1.54 0.593 0 C-N-CA 119.602 -0.839 . . . . 0.0 113.251 177.828 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.588 HG12 ' N ' ' E' ' 25' ' ' GLY . 21.2 t -59.49 166.74 0.58 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 CA-C-N 115.164 -0.926 . . . . 0.0 112.353 177.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.588 ' N ' HG12 ' E' ' 24' ' ' VAL . . . 87.9 81.62 1.24 Allowed Glycine 0 N--CA 1.473 1.139 0 N-CA-C 115.336 0.894 . . . . 0.0 115.336 174.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 13.2 p -51.15 161.1 0.44 Allowed 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 120.565 0.221 . . . . 0.0 110.795 175.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.52 HD22 ' ND2' ' D' ' 27' ' ' ASN . 62.5 t30 -148.11 175.78 10.74 Favored 'General case' 0 N--CA 1.483 1.22 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.825 175.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.495 ' C ' ' O ' ' E' ' 27' ' ' ASN . 67.6 mmtt -9.4 -103.8 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.402 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 178.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -150.77 96.39 0.17 Allowed Glycine 0 C--N 1.349 1.273 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 177.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.673 ' H ' HD22 ' F' ' 27' ' ' ASN . . . -67.22 176.29 2.28 Favored 'General case' 0 C--O 1.238 0.473 0 CA-C-N 117.99 0.895 . . . . 0.0 111.095 178.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.601 ' CG2' HD13 ' F' ' 31' ' ' ILE . 0.0 OUTLIER -144.37 130.96 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.383 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.986 -179.601 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.655 ' CG1' HD11 ' E' ' 34' ' ' LEU . 0.1 OUTLIER -130.61 122.37 52.62 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 CA-C-O 121.084 0.469 . . . . 0.0 110.959 -178.255 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.81 124.39 5.37 Favored Glycine 0 N--CA 1.469 0.837 0 N-CA-C 110.607 -0.997 . . . . 0.0 110.607 179.616 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.681 HD12 ' N ' ' E' ' 34' ' ' LEU . 0.3 OUTLIER -126.94 128.27 46.16 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 120.891 0.377 . . . . 0.0 111.006 -179.284 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 1.8 tpp -120.19 120.2 35.46 Favored 'General case' 0 N--CA 1.472 0.653 0 CA-C-N 116.046 -0.525 . . . . 0.0 109.918 179.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.478 ' O ' ' C ' ' E' ' 37' ' ' GLY . 5.8 t -134.06 83.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.579 0 C-N-CA 121.36 -0.136 . . . . 0.0 111.131 -179.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -19.58 -94.62 0.01 OUTLIER Glycine 0 N--CA 1.473 1.162 0 O-C-N 123.461 0.475 . . . . 0.0 112.753 179.663 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 159.67 -167.58 35.26 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 4.6 p -138.76 145.67 27.51 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-O 120.802 0.334 . . . . 0.0 110.393 -179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 48.8 t . . . . . 0 C--O 1.22 -0.457 0 CA-C-O 118.043 -0.979 . . . . 0.0 110.515 179.78 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.165 0 N-CA-C 109.338 -1.505 . . . . 0.0 109.338 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 93.2 m-85 -85.44 134.6 34.06 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-O 120.874 0.369 . . . . 0.0 110.696 179.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -138.39 131.01 29.23 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.202 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 16.7 m -141.65 173.29 8.58 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.148 0 CA-C-O 121.237 0.541 . . . . 0.0 110.965 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 11.1 m80 -80.45 144.03 32.92 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.425 179.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.544 ' O ' ' NE2' ' F' ' 15' ' ' GLN . 34.6 m80 -134.03 172.21 13.14 Favored 'General case' 0 CA--C 1.518 -0.287 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.544 ' NE2' ' O ' ' F' ' 14' ' ' HIS . 99.3 mm-40 -144.54 178.3 8.05 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.41 -179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 89.0 tttt -169.23 116.19 0.61 Allowed 'General case' 0 CA--C 1.531 0.215 0 CA-C-O 120.987 0.422 . . . . 0.0 110.996 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.404 HD12 ' N ' ' F' ' 17' ' ' LEU . 2.0 mp -126.82 126.98 44.29 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.081 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 58.6 t -132.73 129.89 58.73 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.455 0 CA-C-O 121.572 0.701 . . . . 0.0 112.247 -179.772 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.453 ' CE2' HD23 ' E' ' 34' ' ' LEU . 4.0 m-85 -114.75 113.39 24.21 Favored 'General case' 0 N--CA 1.463 0.201 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.132 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.486 ' CD2' ' CE2' ' E' ' 20' ' ' PHE . 35.4 t80 -127.06 120.98 30.25 Favored 'General case' 0 C--O 1.236 0.373 0 CA-C-O 121.502 0.668 . . . . 0.0 111.387 -179.08 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.1 135.66 46.6 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.094 178.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 37.2 tp10 -78.02 120.79 23.36 Favored 'General case' 0 N--CA 1.465 0.321 0 C-N-CA 120.231 -0.588 . . . . 0.0 110.215 -179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.431 ' O ' ' O ' ' F' ' 24' ' ' VAL . 19.7 t70 -169.0 121.71 0.79 Allowed 'General case' 0 CA--C 1.53 0.194 0 C-N-CA 120.655 -0.418 . . . . 0.0 112.045 -178.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.431 ' O ' ' O ' ' F' ' 23' ' ' ASP . 4.5 m -63.06 -121.62 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 107.337 -1.357 . . . . 0.0 107.337 178.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.519 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . -64.39 -86.05 0.06 OUTLIER Glycine 0 CA--C 1.519 0.304 0 N-CA-C 105.736 -2.946 . . . . 0.0 105.736 178.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.548 ' OG ' ' N ' ' F' ' 27' ' ' ASN . 2.0 t 157.53 172.44 0.01 OUTLIER 'General case' 0 CA--C 1.509 -0.617 0 CA-C-O 122.316 1.055 . . . . 0.0 112.087 174.176 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.673 HD22 ' H ' ' E' ' 30' ' ' ALA . 43.3 m-20 -44.69 174.76 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 112.947 -1.933 . . . . 0.0 111.298 176.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -70.28 111.38 5.84 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 174.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.25 -92.94 0.87 Allowed Glycine 0 C--N 1.313 -0.725 0 N-CA-C 109.236 -1.545 . . . . 0.0 109.236 -178.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.498 ' HB2' ' HB2' ' F' ' 27' ' ' ASN . . . 82.17 163.72 0.14 Allowed 'General case' 0 CA--C 1.502 -0.886 0 N-CA-C 100.451 -3.907 . . . . 0.0 100.451 -176.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.828 HD12 ' N ' ' F' ' 31' ' ' ILE . 0.0 OUTLIER -148.11 128.16 4.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 CA-C-N 121.691 2.041 . . . . 0.0 110.653 179.297 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 3.3 tt -123.95 136.82 59.05 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-N 114.512 -1.222 . . . . 0.0 112.602 -176.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.77 117.93 2.47 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 109.382 -1.487 . . . . 0.0 109.382 178.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 9.2 tt -124.15 124.18 41.92 Favored 'General case' 0 N--CA 1.47 0.567 0 O-C-N 122.689 -0.301 . . . . 0.0 110.238 -179.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 42.2 mmm -123.27 130.38 52.66 Favored 'General case' 0 N--CA 1.477 0.921 0 CA-C-O 120.776 0.322 . . . . 0.0 110.745 -179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 2.8 m -136.16 81.02 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.591 0 CA-C-N 116.101 -0.499 . . . . 0.0 112.323 -178.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . . . . . . . . . . . -43.25 100.83 0.02 OUTLIER Glycine 0 C--N 1.341 0.839 0 C-N-CA 120.046 -1.073 . . . . 0.0 110.854 178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -128.77 163.75 22.1 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 56.0 t -123.21 135.19 63.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 120.838 0.352 . . . . 0.0 110.121 -179.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 8.1 p . . . . . 0 C--O 1.219 -0.525 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.486 -179.994 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.725 -1.35 . . . . 0.0 109.725 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -114.53 145.61 41.72 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.762 0.315 . . . . 0.0 110.231 -179.886 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -132.21 143.26 49.82 Favored 'General case' 0 N--CA 1.464 0.263 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 179.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -120.89 132.82 69.4 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-O 121.117 0.484 . . . . 0.0 110.075 -179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.485 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 39.7 p-80 -109.24 -169.64 1.52 Allowed 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.25 -179.633 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.485 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 33.9 p80 -77.46 171.33 15.07 Favored 'General case' 0 N--CA 1.445 -0.699 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 -179.415 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.403 ' HG2' ' H ' ' G' ' 16' ' ' LYS . 48.5 tt0 -155.92 172.37 18.49 Favored 'General case' 0 C--N 1.314 -0.938 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.395 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . 0.403 ' H ' ' HG2' ' G' ' 15' ' ' GLN . 71.7 mmtt -136.56 132.56 35.34 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.583 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -135.74 111.07 9.06 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.035 0.445 . . . . 0.0 110.517 -179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 77.7 t -129.68 133.1 65.54 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -139.64 148.74 42.86 Favored 'General case' 0 N--CA 1.473 0.693 0 N-CA-C 112.733 0.642 . . . . 0.0 112.733 -179.559 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -124.71 132.92 53.35 Favored 'General case' 0 N--CA 1.468 0.428 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 139.52 45.56 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-O 121.598 0.713 . . . . 0.0 112.104 -178.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -115.96 167.09 11.27 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.568 -179.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.664 ' CG ' ' H ' ' H' ' 25' ' ' GLY . 44.1 t0 -46.3 142.96 2.67 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 114.957 -1.02 . . . . 0.0 112.454 -179.747 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.445 ' HB ' ' O ' ' G' ' 23' ' ' ASP . 20.0 t 93.97 111.84 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.512 -0.505 0 O-C-N 124.565 1.166 . . . . 0.0 111.48 178.118 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.494 ' O ' ' CB ' ' G' ' 26' ' ' SER . . . 49.35 91.64 0.01 OUTLIER Glycine 0 C--N 1.338 0.647 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.54 178.494 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.494 ' CB ' ' O ' ' G' ' 25' ' ' GLY . 1.1 p 159.04 -179.57 0.01 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 122.187 0.994 . . . . 0.0 110.603 -179.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' G' ' 28' ' ' LYS . 90.5 m-20 -58.93 172.05 0.6 Allowed 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 113.408 -1.724 . . . . 0.0 112.323 -177.11 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.533 ' NZ ' ' OD2' ' I' ' 23' ' ' ASP . 84.5 tttt 52.75 105.53 0.01 OUTLIER 'General case' 0 C--N 1.351 0.642 0 C-N-CA 120.37 -0.532 . . . . 0.0 110.13 -179.703 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.727 ' O ' ' HB3' ' G' ' 30' ' ' ALA . . . 107.51 103.71 2.89 Favored Glycine 1 CA--C 1.427 -5.413 0 C-N-CA 119.342 -1.408 . . . . 0.0 110.102 -174.478 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.727 ' HB3' ' O ' ' G' ' 29' ' ' GLY . . . 87.66 -148.34 0.01 OUTLIER 'General case' 0 N--CA 1.384 -3.73 0 N-CA-C 103.138 -2.912 . . . . 0.0 103.138 -169.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.884 ' H ' HD12 ' G' ' 31' ' ' ILE 0.287 0.0 OUTLIER -109.54 114.79 47.93 Favored 'Isoleucine or valine' 0 C--N 1.252 -3.638 0 N-CA-C 118.043 2.608 . . . . 0.0 118.043 -174.012 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.543 HG23 ' O ' ' G' ' 32' ' ' ILE . 0.9 OUTLIER -112.36 116.37 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.061 0 N-CA-C 107.039 -1.467 . . . . 0.0 107.039 173.421 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -124.51 121.3 4.33 Favored Glycine 0 CA--C 1.498 -0.974 0 N-CA-C 108.902 -1.679 . . . . 0.0 108.902 179.238 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 49.0 mt -126.52 134.67 50.83 Favored 'General case' 0 C--O 1.238 0.479 0 CA-C-O 122.889 1.328 . . . . 0.0 111.302 179.246 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 20.1 ttt -98.02 110.91 23.4 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-N 112.494 -2.139 . . . . 0.0 107.081 179.109 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -134.44 64.77 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.517 0 C-N-CA 120.396 -0.522 . . . . 0.0 109.919 -178.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -82.11 -106.45 0.41 Allowed Glycine 0 C--N 1.367 2.296 0 N-CA-C 110.255 -1.138 . . . . 0.0 110.255 178.682 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . -161.85 165.11 35.62 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 179.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 66.7 t -127.93 134.26 65.6 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 120.833 0.349 . . . . 0.0 110.195 -179.893 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 12.6 p . . . . . 0 C--O 1.22 -0.466 0 CA-C-O 118.099 -0.953 . . . . 0.0 110.634 -179.936 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.17 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 77.2 m-85 -83.2 137.69 33.93 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.605 0.24 . . . . 0.0 110.368 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -68.91 137.29 53.7 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.534 -0.303 . . . . 0.0 110.718 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 24.4 m -136.23 160.1 38.38 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.457 0 CA-C-O 120.945 0.402 . . . . 0.0 110.932 -179.8 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 46.0 m-70 -128.71 -175.42 3.53 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 115.901 -0.591 . . . . 0.0 110.208 179.627 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 40.9 p-80 -80.61 168.52 18.79 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-O 122.153 0.978 . . . . 0.0 111.532 -178.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 82.8 mt-30 -153.11 177.81 10.41 Favored 'General case' 0 C--N 1.314 -0.936 0 CA-C-N 114.318 -1.31 . . . . 0.0 110.063 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -145.44 143.44 30.05 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.311 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 51.3 tp -135.24 117.04 15.09 Favored 'General case' 0 C--O 1.236 0.352 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 178.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.423 HG11 ' CE2' ' H' ' 20' ' ' PHE . 70.2 t -126.87 134.03 67.12 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.464 0 CA-C-O 120.872 0.368 . . . . 0.0 110.505 -179.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.415 ' CZ ' ' HB2' ' H' ' 21' ' ' ALA . 45.7 t80 -124.74 122.71 38.24 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.392 179.73 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.423 ' CE2' HG11 ' H' ' 18' ' ' VAL . 61.0 m-85 -115.2 125.66 53.65 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-N 116.268 -0.423 . . . . 0.0 110.155 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.415 ' HB2' ' CZ ' ' H' ' 19' ' ' PHE . . . -116.67 120.96 40.27 Favored 'General case' 0 N--CA 1.474 0.764 0 CA-C-N 118.222 0.464 . . . . 0.0 110.911 179.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.509 ' O ' ' O ' ' H' ' 23' ' ' ASP . 81.6 tt0 -123.27 154.98 38.09 Favored 'General case' 0 N--CA 1.472 0.669 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.756 -179.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.612 ' N ' ' OD1' ' I' ' 23' ' ' ASP . 54.6 t0 49.38 114.22 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 CA-C-O 121.05 0.452 . . . . 0.0 110.715 -178.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' H' ' 25' ' ' GLY . 42.8 t -126.8 121.28 57.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.944 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 -179.622 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.664 ' H ' ' CG ' ' G' ' 23' ' ' ASP . . . -28.21 -87.11 0.01 OUTLIER Glycine 0 N--CA 1.469 0.858 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 176.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.621 ' O ' ' O ' ' H' ' 27' ' ' ASN . 28.3 t -128.58 170.61 13.02 Favored 'General case' 0 N--CA 1.443 -0.815 0 N-CA-C 107.705 -1.221 . . . . 0.0 107.705 179.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.621 ' O ' ' O ' ' H' ' 26' ' ' SER . 62.2 t30 33.95 179.47 0.0 OUTLIER 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 122.138 0.97 . . . . 0.0 113.348 -178.301 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.823 ' NZ ' ' HB1' ' J' ' 21' ' ' ALA . 84.0 tttt -119.98 -105.45 0.39 Allowed 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.636 -176.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.88 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . -64.62 98.62 0.29 Allowed Glycine 1 CA--C 1.428 -5.35 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -178.476 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.601 ' C ' HD12 ' H' ' 31' ' ' ILE . . . -82.23 -136.58 0.04 OUTLIER 'General case' 0 N--CA 1.397 -3.086 1 N-CA-C 95.715 -5.661 . . . . 0.0 95.715 174.038 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.965 HD12 ' N ' ' H' ' 31' ' ' ILE . 0.3 OUTLIER -112.29 119.32 59.93 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.842 0 C-N-CA 116.236 -2.186 . . . . 0.0 112.291 -178.403 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.692 HG23 HG13 ' I' ' 32' ' ' ILE . 5.5 tt -117.49 120.03 63.56 Favored 'Isoleucine or valine' 0 C--N 1.361 1.106 0 CA-C-N 114.34 -1.3 . . . . 0.0 110.445 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.536 ' CA ' ' SD ' ' B' ' 35' ' ' MET . . . -114.77 116.9 3.89 Favored Glycine 0 CA--C 1.52 0.392 0 N-CA-C 109.239 -1.545 . . . . 0.0 109.239 178.525 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.518 HD22 ' O ' ' H' ' 33' ' ' GLY . 0.9 OUTLIER -124.18 125.84 45.13 Favored 'General case' 0 C--O 1.239 0.504 0 CA-C-O 121.681 0.753 . . . . 0.0 111.825 -179.367 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.601 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 7.3 ttt -105.92 110.03 22.18 Favored 'General case' 0 CA--C 1.509 -0.62 0 CA-C-N 114.37 -1.286 . . . . 0.0 108.577 178.049 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.43 HG11 ' CD2' ' J' ' 17' ' ' LEU . 0.0 OUTLIER -131.53 71.26 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.913 0 C-N-CA 120.62 -0.432 . . . . 0.0 111.12 -179.551 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -67.53 -97.13 0.03 OUTLIER Glycine 0 C--N 1.359 1.822 0 N-CA-C 110.267 -1.133 . . . . 0.0 110.267 177.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . 173.21 -166.26 38.68 Favored Glycine 0 CA--C 1.527 0.821 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 11.3 p -124.39 139.9 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.52 0 CA-C-O 120.869 0.366 . . . . 0.0 111.09 -178.694 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.219 -0.529 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.597 179.831 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.339 0 N-CA-C 109.592 -1.403 . . . . 0.0 109.592 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -145.48 157.16 44.05 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 110.184 -0.302 . . . . 0.0 110.184 179.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -133.59 138.81 46.18 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.914 0.388 . . . . 0.0 110.844 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.48 HG22 ' O ' ' J' ' 11' ' ' GLU . 22.3 t -128.11 129.55 69.49 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 179.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 13.7 p80 -175.69 113.86 0.13 Allowed 'General case' 0 C--N 1.327 -0.409 0 C-N-CA 120.465 -0.494 . . . . 0.0 111.148 179.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . . . . . . . . . 26.8 m-70 -82.19 165.9 20.09 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 179.001 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . . . . . . . . . 85.8 mt-30 -148.34 173.01 13.5 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-O 121.279 0.562 . . . . 0.0 110.985 179.209 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -154.96 127.56 7.98 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.152 -0.931 . . . . 0.0 108.629 179.533 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.567 HD23 ' N ' ' I' ' 18' ' ' VAL . 0.9 OUTLIER -129.2 119.56 24.27 Favored 'General case' 0 N--CA 1.469 0.497 0 N-CA-C 109.079 -0.711 . . . . 0.0 109.079 179.619 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.567 ' N ' HD23 ' I' ' 17' ' ' LEU . 48.1 t -125.94 128.94 72.36 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.39 0 CA-C-O 120.934 0.397 . . . . 0.0 111.754 -179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 35.2 m-85 -113.18 103.8 11.71 Favored 'General case' 0 CA--C 1.536 0.441 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 22.9 t80 -114.84 130.05 56.81 Favored 'General case' 0 N--CA 1.476 0.843 0 N-CA-C 111.751 0.278 . . . . 0.0 111.751 -177.564 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.0 135.82 29.68 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 121.277 0.561 . . . . 0.0 111.402 179.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 12.3 tm-20 -148.07 118.88 7.57 Favored 'General case' 0 N--CA 1.47 0.571 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.587 -179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.612 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 16.7 m-20 -158.64 110.5 2.2 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 121.828 0.823 . . . . 0.0 112.224 178.474 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . . . . . . . . . 50.5 t -48.16 133.97 5.36 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.041 0 N-CA-C 114.437 1.273 . . . . 0.0 114.437 178.022 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.497 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 99.3 86.03 1.87 Allowed Glycine 0 CA--C 1.54 1.636 0 N-CA-C 120.316 2.886 . . . . 0.0 120.316 171.948 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.497 ' CB ' ' O ' ' I' ' 25' ' ' GLY . 2.4 p 153.01 169.87 0.01 OUTLIER 'General case' 0 C--N 1.347 0.498 0 CA-C-O 122.635 1.207 . . . . 0.0 112.346 169.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.505 ' O ' ' O ' ' I' ' 28' ' ' LYS . 1.4 m120 -59.03 177.63 0.15 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 114.343 -1.299 . . . . 0.0 111.363 177.679 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.505 ' O ' ' O ' ' I' ' 27' ' ' ASN . 63.3 tttt -43.64 -100.86 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.223 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.027 172.731 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.761 ' O ' ' O ' ' I' ' 30' ' ' ALA . . . -170.59 106.33 0.24 Allowed Glycine 1 CA--C 1.42 -5.858 0 C-N-CA 119.061 -1.542 . . . . 0.0 116.527 -178.805 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.88 ' HB3' ' O ' ' H' ' 29' ' ' GLY 0.29 . . -0.46 -133.45 0.0 OUTLIER 'General case' 0 C--N 1.366 1.286 0 O-C-N 127.066 2.274 . . . . 0.0 108.333 170.579 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.859 HD12 ' C ' ' I' ' 30' ' ' ALA . 3.9 mp -122.52 132.82 70.41 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.019 0 N-CA-C 117.269 2.322 . . . . 0.0 117.269 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.692 HG13 HG23 ' H' ' 32' ' ' ILE . 17.9 tt -116.27 120.8 65.99 Favored 'Isoleucine or valine' 0 C--N 1.371 1.531 0 CA-C-N 114.44 -1.255 . . . . 0.0 110.58 177.698 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.475 ' CA ' ' SD ' ' C' ' 35' ' ' MET . . . -102.77 112.19 4.21 Favored Glycine 0 CA--C 1.498 -0.998 0 N-CA-C 107.157 -2.377 . . . . 0.0 107.157 177.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.859 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 32.8 tp -113.26 121.18 43.65 Favored 'General case' 0 N--CA 1.438 -1.048 0 CA-C-N 115.36 -0.42 . . . . 0.0 111.419 -177.339 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.513 ' SD ' ' O ' ' B' ' 32' ' ' ILE . 19.1 ttt -118.69 112.56 19.94 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 107.821 -1.177 . . . . 0.0 107.821 176.019 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.594 HG11 HD13 ' K' ' 17' ' ' LEU . 0.1 OUTLIER -126.31 71.45 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.208 0 CA-C-N 117.729 0.24 . . . . 0.0 111.273 -178.126 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -50.11 -97.97 0.01 OUTLIER Glycine 0 C--N 1.353 1.5 0 C-N-CA 120.255 -0.974 . . . . 0.0 111.405 179.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 147.14 -162.65 28.63 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.338 -1.105 . . . . 0.0 110.338 -179.388 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 27.2 m -123.05 138.67 52.29 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.54 0 CA-C-O 120.894 0.378 . . . . 0.0 110.703 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 24.3 m . . . . . 0 C--O 1.221 -0.442 0 CA-C-O 117.901 -1.047 . . . . 0.0 110.481 179.679 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.232 0 N-CA-C 109.52 -1.432 . . . . 0.0 109.52 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.3 m-85 -108.95 134.09 52.07 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.95 0.405 . . . . 0.0 110.708 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . 0.48 ' O ' HG22 ' I' ' 12' ' ' VAL . 98.2 mt-10 -143.35 167.53 21.94 Favored 'General case' 0 N--CA 1.467 0.404 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.192 -179.72 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.568 HG12 ' N ' ' J' ' 13' ' ' HIS . 60.0 t -127.66 164.98 27.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.871 0.367 . . . . 0.0 110.058 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.568 ' N ' HG12 ' J' ' 12' ' ' VAL . 2.9 p80 -66.58 134.11 51.69 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-O 121.196 0.522 . . . . 0.0 111.841 -178.292 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.436 ' NE2' ' O ' ' K' ' 12' ' ' VAL . 52.7 m170 -112.83 172.17 7.09 Favored 'General case' 0 N--CA 1.451 -0.381 0 N-CA-C 108.235 -1.024 . . . . 0.0 108.235 179.312 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 87.4 mt-30 -141.55 176.44 8.88 Favored 'General case' 0 C--N 1.316 -0.848 0 CA-C-O 121.333 0.587 . . . . 0.0 111.479 -179.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 87.5 tttt -174.01 124.48 0.34 Allowed 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.105 -179.446 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.43 ' CD2' HG11 ' H' ' 36' ' ' VAL . 4.0 mp -133.85 132.35 40.28 Favored 'General case' 0 C--O 1.238 0.46 0 CA-C-O 121.303 0.573 . . . . 0.0 110.973 179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 66.8 t -131.68 131.12 62.4 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.232 0 CA-C-N 115.516 -0.765 . . . . 0.0 112.015 -179.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.649 ' CD1' ' CZ ' ' K' ' 19' ' ' PHE . 20.1 m-85 -114.2 111.17 21.12 Favored 'General case' 0 N--CA 1.467 0.424 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 177.097 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -121.59 120.49 34.95 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 117.909 0.322 . . . . 0.0 110.155 -178.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . 0.823 ' HB1' ' NZ ' ' H' ' 28' ' ' LYS . . . -139.51 132.64 29.67 Favored 'General case' 0 CA--C 1.536 0.425 0 CA-C-O 121.136 0.494 . . . . 0.0 110.986 -179.603 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.478 ' C ' ' OD1' ' J' ' 23' ' ' ASP . 73.6 mt-10 -144.78 127.45 16.18 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 119.84 -0.744 . . . . 0.0 112.472 -179.277 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.604 ' OD2' ' N ' ' I' ' 23' ' ' ASP . 3.9 m-20 -159.68 110.98 2.0 Favored 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 118.938 -1.105 . . . . 0.0 113.353 176.741 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . . . . . . . . . 91.0 t -37.8 128.65 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 CA-C-N 115.016 -0.993 . . . . 0.0 111.464 172.32 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.453 ' HA3' ' O ' ' I' ' 26' ' ' SER . . . 168.85 -83.64 0.09 OUTLIER Glycine 0 N--CA 1.467 0.709 0 C-N-CA 117.108 -2.472 . . . . 0.0 116.087 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.582 ' O ' ' O ' ' J' ' 27' ' ' ASN . 5.0 p -170.39 -178.55 2.75 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 118.825 -1.15 . . . . 0.0 113.081 -175.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.584 ' CG ' ' H ' ' J' ' 28' ' ' LYS . 63.6 t30 27.13 177.37 0.0 OUTLIER 'General case' 0 N--CA 1.475 0.79 0 CA-C-N 112.113 -2.312 . . . . 0.0 115.565 -177.696 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.584 ' H ' ' CG ' ' J' ' 27' ' ' ASN . 96.7 mttt -119.71 -106.47 0.38 Allowed 'General case' 0 C--O 1.215 -0.724 0 CA-C-N 113.307 -1.769 . . . . 0.0 110.947 -176.775 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.93 ' C ' ' HB1' ' K' ' 30' ' ' ALA . . . -66.13 96.6 0.28 Allowed Glycine 0 CA--C 1.48 -2.141 0 CA-C-O 123.654 1.697 . . . . 0.0 112.643 -177.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.628 ' O ' ' C ' ' J' ' 29' ' ' GLY . . . -80.38 -145.12 0.05 OUTLIER 'General case' 0 C--N 1.293 -1.885 1 N-CA-C 93.921 -6.326 . . . . 0.0 93.921 170.407 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.567 ' H ' HG13 ' I' ' 31' ' ' ILE . 4.8 mm -100.89 115.34 42.32 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 1 CA-C-N 127.987 4.903 . . . . 0.0 111.035 -179.249 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.628 HG22 HG23 ' K' ' 32' ' ' ILE . 0.6 OUTLIER -112.76 110.19 31.32 Favored 'Isoleucine or valine' 0 C--N 1.366 1.307 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.684 -179.745 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -105.16 106.27 2.64 Favored Glycine 0 CA--C 1.505 -0.536 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 178.681 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.817 HD13 ' CE1' ' L' ' 19' ' ' PHE . 4.4 mt -104.78 106.87 17.55 Favored 'General case' 0 C--O 1.239 0.514 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 -179.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.684 ' CE ' HD11 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -106.09 113.2 26.59 Favored 'General case' 0 N--CA 1.444 -0.754 0 N-CA-C 106.919 -1.511 . . . . 0.0 106.919 178.819 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.451 ' O ' HG23 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -133.39 79.6 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.964 0 C-N-CA 119.741 -0.784 . . . . 0.0 111.085 -177.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.55 103.48 1.63 Allowed Glycine 0 C--N 1.349 1.258 0 N-CA-C 110.701 -0.959 . . . . 0.0 110.701 177.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -131.34 145.08 16.7 Favored Glycine 0 N--CA 1.469 0.899 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 63.0 t -136.85 139.42 44.72 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.364 0 CA-C-O 120.641 0.258 . . . . 0.0 110.312 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 89.5 t . . . . . 0 C--O 1.22 -0.476 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.189 179.365 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.316 0 N-CA-C 109.457 -1.457 . . . . 0.0 109.457 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -107.41 140.28 40.59 Favored 'General case' 0 N--CA 1.467 0.423 0 CA-C-O 120.781 0.324 . . . . 0.0 110.614 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 17.0 pt-20 -56.73 137.88 53.75 Favored 'General case' 0 C--O 1.231 0.089 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.289 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.436 ' O ' ' NE2' ' J' ' 14' ' ' HIS . 8.8 m -150.58 145.75 16.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.189 0 CA-C-O 121.408 0.623 . . . . 0.0 111.98 -179.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.538 ' N ' ' ND1' ' K' ' 13' ' ' HIS . 0.7 OUTLIER -119.3 116.13 25.59 Favored 'General case' 0 N--CA 1.464 0.246 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.202 178.446 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' L' ' 13' ' ' HIS . 70.6 t60 -122.61 165.99 15.58 Favored 'General case' 0 CA--C 1.509 -0.616 0 CA-C-O 121.403 0.621 . . . . 0.0 110.025 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.453 ' N ' ' CG ' ' K' ' 14' ' ' HIS . 47.5 tt0 -163.39 166.95 22.32 Favored 'General case' 0 C--N 1.312 -1.064 0 CA-C-N 114.987 -1.006 . . . . 0.0 109.453 178.386 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' K' ' 15' ' ' GLN . 98.9 mttt -155.53 129.96 9.0 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 108.955 -0.757 . . . . 0.0 108.955 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.594 HD13 HG11 ' I' ' 36' ' ' VAL . 26.9 tp -124.51 120.53 32.27 Favored 'General case' 0 N--CA 1.468 0.43 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 179.725 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.518 HG11 ' CE2' ' K' ' 20' ' ' PHE . 57.9 t -132.94 127.03 54.76 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.816 0 C-N-CA 119.975 -0.69 . . . . 0.0 111.935 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.859 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 6.8 m-85 -117.28 112.81 21.27 Favored 'General case' 0 CA--C 1.539 0.551 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.033 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.518 ' CE2' HG11 ' K' ' 18' ' ' VAL . 47.6 m-85 -108.12 118.57 37.1 Favored 'General case' 0 N--CA 1.474 0.757 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 178.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 132.86 36.93 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 118.772 0.714 . . . . 0.0 112.775 -179.526 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 83.1 tt0 -113.58 122.77 48.23 Favored 'General case' 0 N--CA 1.476 0.847 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.465 178.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -178.73 110.87 0.06 Allowed 'General case' 0 CA--C 1.534 0.354 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.244 -179.667 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . . . . . . . . . 16.1 m -107.05 -123.36 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 112.413 0.523 . . . . 0.0 112.413 -178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.439 ' O ' ' N ' ' J' ' 27' ' ' ASN . . . 31.49 85.51 0.01 OUTLIER Glycine 0 C--N 1.342 0.9 0 CA-C-N 115.51 -0.768 . . . . 0.0 112.009 -178.127 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . . . . . . . . . 24.1 p -50.1 158.82 0.5 Allowed 'General case' 0 N--CA 1.451 -0.389 0 CA-C-O 121.398 0.618 . . . . 0.0 111.754 178.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.566 ' ND2' ' OD1' ' J' ' 27' ' ' ASN . 0.0 OUTLIER -148.06 176.92 9.8 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 114.881 -1.054 . . . . 0.0 109.137 176.952 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.531 ' C ' ' O ' ' K' ' 27' ' ' ASN . 98.8 mttt -9.16 -103.27 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.599 0 O-C-N 123.664 0.603 . . . . 0.0 111.278 176.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.73 97.0 0.18 Allowed Glycine 0 CA--C 1.5 -0.896 0 N-CA-C 109.385 -1.486 . . . . 0.0 109.385 176.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.93 ' HB1' ' C ' ' J' ' 29' ' ' GLY . . . -66.2 172.17 4.09 Favored 'General case' 0 N--CA 1.44 -0.967 0 N-CA-C 106.133 -1.802 . . . . 0.0 106.133 177.423 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.661 ' N ' ' O ' ' J' ' 29' ' ' GLY . 0.4 OUTLIER -147.58 123.46 2.66 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.069 0 CA-C-N 120.996 1.726 . . . . 0.0 111.858 -175.782 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.628 HG23 HG22 ' J' ' 32' ' ' ILE . 91.1 mt -125.99 131.33 71.87 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.847 0 CA-C-N 114.717 -1.128 . . . . 0.0 112.475 -178.348 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -128.71 119.96 3.17 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.626 HD23 ' N ' ' K' ' 35' ' ' MET . 5.5 tt -121.84 120.53 34.81 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 120.629 0.252 . . . . 0.0 110.765 -179.683 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.626 ' N ' HD23 ' K' ' 34' ' ' LEU . 5.6 ppp? -130.49 130.24 43.94 Favored 'General case' 0 N--CA 1.473 0.703 0 CA-C-O 121.436 0.636 . . . . 0.0 111.058 178.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.534 ' O ' ' C ' ' K' ' 37' ' ' GLY . 3.2 p -158.11 79.98 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.869 -179.445 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.534 ' C ' ' O ' ' K' ' 36' ' ' VAL . . . -1.37 -100.89 0.0 OUTLIER Glycine 0 C--N 1.348 1.214 0 O-C-N 123.311 0.382 . . . . 0.0 113.615 179.223 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.45 -172.5 41.73 Favored Glycine 0 CA--C 1.523 0.567 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 -179.926 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 35.7 m -133.86 161.56 40.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 120.949 0.404 . . . . 0.0 110.724 -179.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 8.2 p . . . . . 0 C--O 1.221 -0.429 0 CA-C-O 118.033 -0.984 . . . . 0.0 110.306 179.901 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.241 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -119.69 140.58 50.45 Favored 'General case' 0 N--CA 1.469 0.488 0 CA-C-O 120.855 0.36 . . . . 0.0 110.904 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 46.0 tp10 -126.04 134.21 51.49 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.539 -0.541 . . . . 0.0 109.539 179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 33.3 m -135.66 161.86 38.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-N 116.588 -0.278 . . . . 0.0 110.411 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.613 ' ND1' ' ND1' ' K' ' 14' ' ' HIS . 49.1 t-80 -90.45 176.68 6.62 Favored 'General case' 0 N--CA 1.464 0.244 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 179.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.577 ' CG ' ' H ' ' L' ' 15' ' ' GLN . 27.5 t-80 -76.0 176.82 7.57 Favored 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 179.372 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.577 ' H ' ' CG ' ' L' ' 14' ' ' HIS . 99.2 mm-40 -121.48 178.04 4.97 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-O 120.968 0.413 . . . . 0.0 111.004 -179.191 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 82.9 tttt -165.98 113.48 0.92 Allowed 'General case' 0 C--O 1.234 0.256 0 CA-C-N 115.904 -0.589 . . . . 0.0 109.96 179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 18.3 mt -128.71 124.92 36.85 Favored 'General case' 0 N--CA 1.465 0.275 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -140.1 135.03 37.03 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.556 0 N-CA-C 112.997 0.74 . . . . 0.0 112.997 -178.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.817 ' CE1' HD13 ' J' ' 34' ' ' LEU . 7.3 m-85 -116.94 108.53 15.91 Favored 'General case' 0 N--CA 1.463 0.193 0 N-CA-C 108.105 -1.072 . . . . 0.0 108.105 177.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 52.0 t80 -116.0 123.09 47.13 Favored 'General case' 0 C--O 1.236 0.387 0 CA-C-O 121.24 0.543 . . . . 0.0 110.867 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.68 134.01 45.47 Favored 'General case' 0 C--N 1.331 -0.225 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 178.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.479 ' O ' ' OD1' ' L' ' 23' ' ' ASP . 81.0 tt0 -81.18 92.87 6.37 Favored 'General case' 0 C--N 1.328 -0.367 0 C-N-CA 119.964 -0.694 . . . . 0.0 111.03 -178.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.585 ' O ' ' O ' ' L' ' 24' ' ' VAL . 70.7 m-20 -160.94 133.14 5.95 Favored 'General case' 0 C--O 1.226 -0.159 0 CA-C-N 116.288 -0.414 . . . . 0.0 111.182 179.163 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.585 ' O ' ' O ' ' L' ' 23' ' ' ASP . 10.6 t -32.34 -110.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.566 0 O-C-N 124.003 0.815 . . . . 0.0 111.376 176.475 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -158.89 92.27 0.12 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 179.247 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.476 ' O ' ' ND2' ' L' ' 27' ' ' ASN . 23.3 p -47.3 152.68 0.57 Allowed 'General case' 0 N--CA 1.442 -0.826 0 CA-C-O 121.761 0.791 . . . . 0.0 111.443 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.488 ' O ' ' C ' ' L' ' 28' ' ' LYS . 31.8 m120 -157.42 -174.74 5.03 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-N 114.382 -1.281 . . . . 0.0 109.135 177.571 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.488 ' C ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 12.74 103.54 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.0 0 N-CA-C 113.119 0.785 . . . . 0.0 113.119 177.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 120.56 -101.48 0.81 Allowed Glycine 0 N--CA 1.47 0.961 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -55.5 171.48 0.19 Allowed 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 117.287 0.543 . . . . 0.0 110.152 -178.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.652 ' CG1' HG23 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -141.42 148.56 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 119.249 -0.98 . . . . 0.0 112.854 -177.977 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.481 HG23 ' O ' ' L' ' 32' ' ' ILE . 18.7 tt -133.53 126.75 52.31 Favored 'Isoleucine or valine' 0 C--O 1.232 0.135 0 CA-C-N 114.018 -1.447 . . . . 0.0 109.191 178.668 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.17 119.44 4.38 Favored Glycine 0 N--CA 1.466 0.657 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 -179.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 16.6 tp -126.09 120.75 31.01 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 116.857 0.328 . . . . 0.0 110.179 -179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.528 ' O ' ' SD ' ' L' ' 35' ' ' MET . 3.7 ppp? -132.86 133.06 42.81 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-O 121.872 0.844 . . . . 0.0 111.16 178.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 23.1 t -142.98 82.61 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.412 -178.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.416 ' N ' ' O ' ' K' ' 37' ' ' GLY . . . -66.26 101.22 0.59 Allowed Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.621 -0.992 . . . . 0.0 110.621 178.453 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -160.31 168.58 35.93 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 -179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 26.8 m -129.53 160.03 40.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 CA-C-O 120.884 0.373 . . . . 0.0 110.507 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 5.8 p . . . . . 0 C--O 1.219 -0.524 0 CA-C-O 118.079 -0.962 . . . . 0.0 110.425 179.983 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.4 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -83.96 139.25 32.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.7 0.286 . . . . 0.0 110.599 -179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 17.5 pt-20 -148.44 137.9 22.03 Favored 'General case' 0 N--CA 1.463 0.195 0 CA-C-O 121.128 0.49 . . . . 0.0 111.337 -179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.409 HG12 ' N ' ' A' ' 13' ' ' HIS . 45.8 t -133.3 158.42 42.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.409 ' N ' HG12 ' A' ' 12' ' ' VAL . 79.2 m80 -142.44 134.28 27.01 Favored 'General case' 0 N--CA 1.468 0.464 0 C-N-CA 120.539 -0.464 . . . . 0.0 111.384 179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 26.4 p-80 -155.11 166.87 32.22 Favored 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 115.864 -0.607 . . . . 0.0 109.368 179.412 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 78.8 mt-30 -155.83 175.73 13.55 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.898 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 65.2 mttp -153.37 115.57 4.37 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.567 -0.288 . . . . 0.0 110.926 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 96.0 mt -132.92 121.63 23.13 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-O 121.06 0.457 . . . . 0.0 110.67 178.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 55.8 t -128.54 131.38 68.82 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.443 0 CA-C-N 115.778 -0.647 . . . . 0.0 109.713 179.371 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 20.5 t80 -126.56 130.37 50.41 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-O 120.826 0.346 . . . . 0.0 110.627 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -126.24 126.92 44.81 Favored 'General case' 0 N--CA 1.469 0.485 0 N-CA-C 109.551 -0.537 . . . . 0.0 109.551 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.86 133.03 46.65 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-O 121.017 0.437 . . . . 0.0 111.87 -179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -150.53 117.33 5.85 Favored 'General case' 0 CA--C 1.532 0.277 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.187 179.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 11.7 m-20 -128.01 120.16 26.94 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.485 0.659 . . . . 0.0 111.928 -179.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 m -63.81 -121.27 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.19 178.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.51 -89.44 0.04 OUTLIER Glycine 0 CA--C 1.532 1.104 0 CA-C-N 115.62 -0.718 . . . . 0.0 113.353 -179.854 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.782 ' O ' ' O ' ' A' ' 27' ' ' ASN . 2.1 t 174.04 -172.98 0.06 Allowed 'General case' 0 N--CA 1.446 -0.655 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 -178.952 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.782 ' O ' ' O ' ' A' ' 26' ' ' SER . 67.5 m-80 -10.33 159.71 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.191 0 O-C-N 125.032 1.458 . . . . 0.0 113.873 -179.55 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.515 ' NZ ' ' OD1' ' B' ' 23' ' ' ASP . 18.3 pttp 178.99 101.98 0.02 OUTLIER 'General case' 0 CA--C 1.529 0.159 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 178.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.24 101.39 0.74 Allowed Glycine 0 CA--C 1.503 -0.674 0 N-CA-C 106.849 -2.5 . . . . 0.0 106.849 176.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -83.96 153.94 23.63 Favored 'General case' 0 CA--C 1.504 -0.79 0 C-N-CA 117.117 -1.833 . . . . 0.0 110.535 -175.957 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.407 HG22 ' HE3' ' H' ' 35' ' ' MET . 0.4 OUTLIER -146.34 115.59 1.42 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 CA-C-N 112.86 -1.973 . . . . 0.0 108.498 -173.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 32' ' ' ILE . 11.6 tt -127.55 108.78 18.85 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.524 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 176.586 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -125.24 122.61 4.69 Favored Glycine 0 N--CA 1.465 0.582 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -178.14 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.656 ' O ' HD12 ' B' ' 34' ' ' LEU . 0.9 OUTLIER -178.13 -162.58 0.06 Allowed 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 122.349 1.071 . . . . 0.0 111.228 179.149 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.462 ' SD ' ' HB ' ' H' ' 31' ' ' ILE . 1.1 ttp -149.89 157.6 43.34 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 -179.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -111.71 75.68 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.85 0 C-N-CA 120.507 -0.477 . . . . 0.0 109.811 179.25 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -89.5 103.42 3.0 Favored Glycine 0 C--N 1.357 1.745 0 N-CA-C 110.879 -0.888 . . . . 0.0 110.879 179.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -82.46 -172.1 47.54 Favored Glycine 0 CA--C 1.523 0.592 0 N-CA-C 110.566 -1.013 . . . . 0.0 110.566 -179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 30.7 m -132.93 161.68 41.21 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.401 0 CA-C-O 121.048 0.451 . . . . 0.0 110.864 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 8.6 p . . . . . 0 C--O 1.22 -0.492 0 CA-C-O 117.865 -1.064 . . . . 0.0 110.662 -179.951 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 42.4 p90 -147.8 157.82 43.73 Favored 'General case' 0 N--CA 1.463 0.204 0 CA-C-O 120.686 0.279 . . . . 0.0 110.682 -179.94 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -150.75 150.68 31.32 Favored 'General case' 0 CA--C 1.533 0.315 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.314 -179.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.418 HG22 ' N ' ' B' ' 13' ' ' HIS . 3.0 p -137.47 155.84 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.794 -179.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.418 ' N ' HG22 ' B' ' 12' ' ' VAL . 5.7 m-70 -128.31 142.46 51.13 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -143.2 169.56 17.38 Favored 'General case' 0 N--CA 1.451 -0.382 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 179.649 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 48.4 tt0 -162.2 166.63 25.3 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.762 178.732 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 63.1 mttp -154.48 111.43 3.34 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-O 120.697 0.284 . . . . 0.0 110.754 179.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 73.2 mt -121.84 117.49 26.65 Favored 'General case' 0 N--CA 1.466 0.336 0 N-CA-C 109.022 -0.733 . . . . 0.0 109.022 178.686 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -131.13 129.03 62.75 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.577 0 CA-C-O 121.338 0.59 . . . . 0.0 112.034 -179.491 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 57.0 t80 -122.28 127.37 49.8 Favored 'General case' 0 N--CA 1.467 0.383 0 CA-C-N 115.397 -0.819 . . . . 0.0 109.124 178.735 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.628 ' CE2' ' CD1' ' C' ' 20' ' ' PHE . 21.3 t80 -130.65 125.5 34.17 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-O 120.708 0.289 . . . . 0.0 110.949 -178.62 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -130.97 129.71 42.47 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.868 0.366 . . . . 0.0 110.504 179.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -157.76 135.59 10.68 Favored 'General case' 0 C--O 1.226 -0.17 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.34 179.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.523 ' O ' ' O ' ' B' ' 24' ' ' VAL . 0.5 OUTLIER -171.24 121.53 0.53 Allowed 'General case' 0 CA--C 1.53 0.21 0 C-N-CA 120.724 -0.391 . . . . 0.0 111.218 -179.892 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.523 ' O ' ' O ' ' B' ' 23' ' ' ASP . 3.0 t -49.18 -122.45 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 CA-C-N 115.419 -0.81 . . . . 0.0 111.229 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 75.16 -90.57 0.81 Allowed Glycine 0 CA--C 1.532 1.096 0 CA-C-N 115.741 -0.663 . . . . 0.0 113.857 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.749 ' O ' ' O ' ' B' ' 27' ' ' ASN . 2.8 p 174.39 -171.71 0.05 Allowed 'General case' 0 N--CA 1.447 -0.596 0 CA-C-N 117.362 0.581 . . . . 0.0 109.588 -177.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.749 ' O ' ' O ' ' B' ' 26' ' ' SER . 49.2 m-80 -10.04 160.53 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.304 0 O-C-N 125.406 1.691 . . . . 0.0 114.513 179.532 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.487 ' HE2' ' HB2' ' B' ' 30' ' ' ALA . 16.2 tttt 179.54 101.63 0.03 OUTLIER 'General case' 0 CA--C 1.539 0.535 0 CA-C-O 121.288 0.566 . . . . 0.0 111.607 178.817 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.2 102.03 0.88 Allowed Glycine 0 CA--C 1.487 -1.699 0 N-CA-C 106.605 -2.598 . . . . 0.0 106.605 174.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.487 ' HB2' ' HE2' ' B' ' 28' ' ' LYS . . . -91.08 149.14 21.94 Favored 'General case' 0 CA--C 1.498 -1.046 0 C-N-CA 115.357 -2.537 . . . . 0.0 106.434 -179.764 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.614 HG23 HD12 ' C' ' 31' ' ' ILE . 2.6 mt -148.74 106.64 0.48 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 CA-C-N 114.284 -1.326 . . . . 0.0 107.836 -174.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.426 ' O ' HG23 ' B' ' 32' ' ' ILE . 15.7 tt -116.15 123.18 71.08 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.866 0 CA-C-O 121.638 0.732 . . . . 0.0 110.955 179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.727 ' N ' ' SD ' ' H' ' 35' ' ' MET . . . -116.53 115.31 3.27 Favored Glycine 0 CA--C 1.502 -0.779 0 N-CA-C 106.008 -2.837 . . . . 0.0 106.008 177.675 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.656 HD12 ' O ' ' A' ' 34' ' ' LEU . 5.9 tp -144.12 144.33 31.54 Favored 'General case' 0 CA--C 1.512 -0.497 0 N-CA-C 115.407 1.632 . . . . 0.0 115.407 -175.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.644 ' SD ' ' N ' ' I' ' 33' ' ' GLY . 32.3 ttp -129.18 129.63 45.32 Favored 'General case' 0 C--O 1.238 0.488 0 CA-C-N 114.159 -1.382 . . . . 0.0 108.411 175.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -111.89 78.2 0.48 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.017 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.247 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.632 ' HA3' HG21 ' H' ' 31' ' ' ILE . . . -74.36 104.59 1.69 Allowed Glycine 0 C--N 1.35 1.339 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.158 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . -73.23 -179.14 36.84 Favored Glycine 0 CA--C 1.526 0.745 0 C-N-CA 120.869 -0.682 . . . . 0.0 111.751 -178.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.5 p -141.37 149.87 20.16 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.299 0 N-CA-C 110.026 -0.361 . . . . 0.0 110.026 -179.632 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 118.014 -0.994 . . . . 0.0 110.675 -179.851 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.26 0 N-CA-C 109.53 -1.428 . . . . 0.0 109.53 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 71.7 m-85 -110.2 128.25 55.39 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-O 120.62 0.248 . . . . 0.0 110.592 179.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.477 ' CD ' ' NE2' ' C' ' 13' ' ' HIS . 82.6 tt0 -133.13 148.22 52.11 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.302 179.454 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 66.1 t -123.68 133.02 70.39 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.403 0 CA-C-O 120.944 0.402 . . . . 0.0 110.449 -179.877 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.477 ' NE2' ' CD ' ' C' ' 11' ' ' GLU . 60.2 m80 -128.87 138.73 52.2 Favored 'General case' 0 N--CA 1.468 0.456 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.363 -179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.501 ' CG ' ' N ' ' C' ' 15' ' ' GLN . 82.8 t60 -155.37 164.85 38.18 Favored 'General case' 0 N--CA 1.447 -0.624 0 N-CA-C 109.432 -0.581 . . . . 0.0 109.432 179.047 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.501 ' N ' ' CG ' ' C' ' 14' ' ' HIS . 94.5 mt-30 -155.44 -179.36 8.02 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 115.486 -0.779 . . . . 0.0 109.308 179.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -165.05 112.97 1.01 Allowed 'General case' 0 CA--C 1.533 0.314 0 C-N-CA 120.648 -0.421 . . . . 0.0 110.53 179.012 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 67.8 tp -120.28 121.84 39.56 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.967 -0.56 . . . . 0.0 109.804 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 43.0 t -132.69 126.34 54.37 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 N-CA-C 112.627 0.603 . . . . 0.0 112.627 -179.101 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 21.1 m-85 -118.46 123.8 46.05 Favored 'General case' 0 N--CA 1.468 0.462 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 177.179 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.628 ' CD1' ' CE2' ' B' ' 20' ' ' PHE . 43.5 t80 -130.09 127.85 40.68 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-O 120.764 0.316 . . . . 0.0 111.373 -179.432 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.48 138.97 45.14 Favored 'General case' 0 N--CA 1.47 0.536 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.299 179.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 78.1 tt0 -143.82 151.81 40.4 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.408 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.443 ' CG ' ' H ' ' C' ' 24' ' ' VAL . 16.7 t70 -151.72 -132.91 0.05 OUTLIER 'General case' 0 N--CA 1.466 0.359 0 C-N-CA 119.112 -1.035 . . . . 0.0 112.673 178.79 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.511 ' O ' ' N ' ' C' ' 26' ' ' SER . 63.2 t -122.91 112.02 32.26 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.861 0 N-CA-C 112.36 0.504 . . . . 0.0 112.36 -177.863 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.454 ' C ' ' O ' ' C' ' 24' ' ' VAL . . . -28.95 89.5 0.01 OUTLIER Glycine 0 N--CA 1.475 1.247 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 175.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.773 ' O ' ' O ' ' C' ' 27' ' ' ASN . 46.9 t -151.91 -170.8 3.75 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 -177.044 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.773 ' O ' ' O ' ' C' ' 26' ' ' SER . 28.7 t-20 -21.53 170.54 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.237 0 O-C-N 124.829 1.331 . . . . 0.0 113.622 -176.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.454 ' N ' ' CG ' ' C' ' 27' ' ' ASN . 57.9 tttp -101.34 -113.49 0.19 Allowed 'General case' 0 CA--C 1.537 0.461 0 N-CA-C 113.548 0.944 . . . . 0.0 113.548 -179.088 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 41.65 90.8 0.01 OUTLIER Glycine 0 C--N 1.338 0.692 0 N-CA-C 111.816 -0.514 . . . . 0.0 111.816 179.645 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -141.54 153.64 44.99 Favored 'General case' 0 CA--C 1.496 -1.097 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 173.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.614 HD12 HG23 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -150.3 116.88 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.161 0 C-N-CA 118.979 -1.089 . . . . 0.0 111.305 -172.367 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.732 HD11 HD12 ' D' ' 32' ' ' ILE . 1.6 pt -119.15 115.88 49.2 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.0 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 176.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.681 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -126.14 118.45 3.13 Favored Glycine 0 CA--C 1.501 -0.836 0 N-CA-C 107.613 -2.195 . . . . 0.0 107.613 179.26 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.537 ' CB ' ' O ' ' B' ' 34' ' ' LEU . 0.4 OUTLIER -161.56 169.31 21.95 Favored 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 118.072 -1.451 . . . . 0.0 111.968 -177.513 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.419 ' HE3' ' O ' ' I' ' 32' ' ' ILE . 5.6 tmm? -141.37 137.26 32.18 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 113.538 -1.665 . . . . 0.0 109.654 -179.925 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -114.04 73.09 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.183 0 CA-C-N 113.893 -1.503 . . . . 0.0 108.564 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -95.75 103.84 3.02 Favored Glycine 0 C--N 1.37 2.437 0 N-CA-C 111.419 -0.673 . . . . 0.0 111.419 -179.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -125.58 154.58 18.63 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 110.264 -1.134 . . . . 0.0 110.264 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 24.3 m -135.38 163.29 36.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.852 0.358 . . . . 0.0 110.895 -179.67 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.4 p . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 117.96 -1.019 . . . . 0.0 110.395 -179.889 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.385 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -108.84 131.73 54.71 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-O 120.874 0.369 . . . . 0.0 110.507 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -133.49 131.09 39.42 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.26 0.552 . . . . 0.0 111.024 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' E' ' 12' ' ' VAL . 53.7 t -120.21 135.41 60.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.335 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' E' ' 13' ' ' HIS . 23.1 p80 -155.01 158.84 39.76 Favored 'General case' 0 N--CA 1.465 0.296 0 C-N-CA 119.035 -1.066 . . . . 0.0 112.841 -178.805 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.512 ' O ' ' NE2' ' D' ' 15' ' ' GLN . 51.5 m-70 -147.27 169.62 19.02 Favored 'General case' 0 N--CA 1.444 -0.728 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 179.016 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.512 ' NE2' ' O ' ' D' ' 14' ' ' HIS . 97.4 mm-40 -148.9 168.82 22.0 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.154 179.288 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.9 mttm -153.31 106.97 3.02 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.558 -0.746 . . . . 0.0 109.995 179.024 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 51.7 mt -118.5 116.79 27.39 Favored 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 107.612 -1.255 . . . . 0.0 107.612 178.27 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 79.4 t -130.24 128.16 63.9 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.272 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.112 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.55 ' CD1' ' CZ ' ' E' ' 19' ' ' PHE . 47.1 m-85 -121.02 111.8 17.93 Favored 'General case' 0 CA--C 1.541 0.618 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 177.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -120.21 132.1 55.23 Favored 'General case' 0 N--CA 1.484 1.27 0 CA-C-N 118.251 0.478 . . . . 0.0 111.919 -178.587 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.41 122.31 24.79 Favored 'General case' 0 N--CA 1.47 0.568 0 CA-C-O 121.51 0.671 . . . . 0.0 111.176 179.051 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.447 ' O ' ' CB ' ' D' ' 23' ' ' ASP . 80.9 tt0 -111.18 89.82 3.16 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.071 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.461 ' O ' ' C ' ' D' ' 24' ' ' VAL . 4.9 p30 154.48 124.6 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 114.508 -1.224 . . . . 0.0 108.446 179.039 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.461 ' C ' ' O ' ' D' ' 23' ' ' ASP . 18.4 m -29.44 111.68 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.464 0.263 0 O-C-N 123.559 0.537 . . . . 0.0 111.499 179.107 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.703 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . -177.45 -91.1 0.08 OUTLIER Glycine 0 C--O 1.215 -1.059 0 C-N-CA 118.568 -1.777 . . . . 0.0 114.871 179.405 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.435 ' O ' ' CB ' ' D' ' 27' ' ' ASN . 80.9 p -72.84 168.94 17.85 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 118.884 1.342 . . . . 0.0 113.697 -175.179 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.658 ' ND2' ' HB2' ' F' ' 21' ' ' ALA . 5.5 t-20 84.42 -178.32 0.03 OUTLIER 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 114.596 -1.184 . . . . 0.0 110.234 177.011 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.497 ' HA ' HD11 ' E' ' 32' ' ' ILE . 85.0 tttt -38.05 106.15 0.05 OUTLIER 'General case' 0 N--CA 1.474 0.775 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 175.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.664 ' O ' ' HB3' ' D' ' 30' ' ' ALA . . . 109.25 102.21 2.74 Favored Glycine 0 CA--C 1.466 -2.997 0 C-N-CA 119.244 -1.455 . . . . 0.0 110.07 -171.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.753 ' C ' HD12 ' D' ' 31' ' ' ILE . . . 86.99 -160.92 0.01 OUTLIER 'General case' 0 N--CA 1.412 -2.33 0 N-CA-C 100.355 -3.943 . . . . 0.0 100.355 -169.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.753 HD12 ' C ' ' D' ' 30' ' ' ALA . 4.6 mp -131.99 134.58 59.67 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.321 0 C-N-CA 115.074 -2.65 . . . . 0.0 117.751 -174.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.732 HD12 HD11 ' C' ' 32' ' ' ILE . 11.9 tt -126.77 123.91 63.83 Favored 'Isoleucine or valine' 0 C--N 1.367 1.334 0 CA-C-N 113.709 -1.587 . . . . 0.0 110.459 177.698 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.655 ' N ' ' SD ' ' J' ' 35' ' ' MET . . . -124.18 106.22 0.94 Allowed Glycine 0 C--O 1.237 0.29 0 N-CA-C 106.882 -2.487 . . . . 0.0 106.882 176.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.553 HD23 ' C ' ' D' ' 34' ' ' LEU . 10.0 tt -126.72 132.95 51.0 Favored 'General case' 0 C--O 1.241 0.631 0 CA-C-O 122.039 0.923 . . . . 0.0 112.431 -177.511 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.541 ' SD ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -122.1 126.66 48.87 Favored 'General case' 0 C--O 1.235 0.318 0 CA-C-N 114.32 -1.309 . . . . 0.0 109.865 178.887 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.498 HG13 HD21 ' D' ' 34' ' ' LEU . 0.0 OUTLIER -113.3 79.77 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 115.476 -0.784 . . . . 0.0 110.49 -178.182 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' E' ' 37' ' ' GLY . . . -25.8 -95.74 0.01 OUTLIER Glycine 0 C--N 1.358 1.759 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 179.44 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 150.89 -162.03 29.25 Favored Glycine 0 CA--C 1.524 0.632 0 C-N-CA 120.864 -0.684 . . . . 0.0 111.583 179.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 40' ' ' VAL . 56.0 t -115.2 136.06 53.15 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-O 120.932 0.396 . . . . 0.0 110.266 -179.477 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.411 ' O ' ' O ' ' D' ' 39' ' ' VAL . 70.9 t . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.445 -179.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -109.11 136.13 49.11 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 120.85 0.357 . . . . 0.0 110.463 179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.521 ' OE2' ' NE2' ' E' ' 13' ' ' HIS . 81.4 tt0 -64.69 136.27 56.77 Favored 'General case' 0 C--O 1.238 0.487 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.645 -179.485 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.481 HG13 HG13 ' D' ' 12' ' ' VAL . 9.4 p -131.91 134.6 59.78 Favored 'Isoleucine or valine' 0 C--O 1.236 0.349 0 CA-C-O 121.959 0.885 . . . . 0.0 112.596 -179.689 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.522 ' CD2' ' CD2' ' D' ' 13' ' ' HIS . 46.8 m170 -121.17 138.88 54.0 Favored 'General case' 0 N--CA 1.463 0.206 0 CA-C-N 114.066 -1.425 . . . . 0.0 108.559 178.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.572 ' CG ' ' N ' ' E' ' 15' ' ' GLN . 85.4 t60 -152.47 171.49 18.0 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-O 121.61 0.719 . . . . 0.0 110.742 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.572 ' N ' ' CG ' ' E' ' 14' ' ' HIS . 53.6 tt0 -154.01 173.27 16.22 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.742 -1.117 . . . . 0.0 108.774 179.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.401 ' N ' ' HG2' ' E' ' 15' ' ' GLN . 87.7 tttt -168.57 113.34 0.61 Allowed 'General case' 0 C--N 1.328 -0.362 0 C-N-CA 119.95 -0.7 . . . . 0.0 111.568 -179.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 2.9 tt -123.65 123.44 40.56 Favored 'General case' 0 N--CA 1.471 0.603 0 N-CA-C 109.365 -0.606 . . . . 0.0 109.365 178.981 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 39.4 t -132.98 122.3 45.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.279 0 CA-C-O 121.222 0.534 . . . . 0.0 112.173 -179.436 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.55 ' CZ ' ' CD1' ' D' ' 19' ' ' PHE . 7.5 m-85 -113.88 117.54 31.69 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.4 ' HA ' ' O ' ' F' ' 20' ' ' PHE . 90.4 t80 -124.58 131.94 53.46 Favored 'General case' 0 N--CA 1.477 0.882 0 N-CA-C 112.25 0.463 . . . . 0.0 112.25 -177.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.5 ' HB3' ' HB2' ' D' ' 27' ' ' ASN . . . -148.27 145.94 28.4 Favored 'General case' 0 N--CA 1.477 0.881 0 N-CA-C 113.427 0.899 . . . . 0.0 113.427 179.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -98.42 128.47 44.81 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 115.802 -0.635 . . . . 0.0 111.18 179.009 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.476 ' O ' ' O ' ' F' ' 22' ' ' GLU . 67.3 t0 -147.1 112.33 5.51 Favored 'General case' 0 N--CA 1.475 0.795 0 CA-C-N 116.585 -0.28 . . . . 0.0 111.238 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.756 HG13 ' H ' ' E' ' 25' ' ' GLY . 12.1 p -101.8 -121.96 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 C-N-CA 120.337 -0.545 . . . . 0.0 111.248 -179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.756 ' H ' HG13 ' E' ' 24' ' ' VAL . . . 34.2 -84.93 0.01 OUTLIER Glycine 0 N--CA 1.473 1.143 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 -177.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.572 ' N ' ' O ' ' E' ' 24' ' ' VAL . 1.4 p 161.95 160.31 0.02 OUTLIER 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.673 0.749 . . . . 0.0 109.913 175.733 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.412 ' O ' ' O ' ' E' ' 26' ' ' SER . 5.8 m120 -29.87 159.65 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 114.277 -1.329 . . . . 0.0 113.896 177.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.483 ' O ' ' O ' ' E' ' 29' ' ' GLY . 87.4 tttt 178.19 102.94 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 173.631 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.483 ' O ' ' O ' ' E' ' 28' ' ' LYS . . . 41.8 93.43 0.01 OUTLIER Glycine 0 N--CA 1.477 1.395 0 N-CA-C 108.679 -1.768 . . . . 0.0 108.679 179.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.701 ' HB2' ' H ' ' D' ' 30' ' ' ALA . . . -156.52 147.39 21.91 Favored 'General case' 0 CA--C 1.474 -1.947 0 C-N-CA 117.847 -1.541 . . . . 0.0 109.319 179.543 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.754 HG21 ' HA3' ' K' ' 37' ' ' GLY . 0.6 OUTLIER -151.49 137.54 11.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 CA-C-N 112.477 -2.147 . . . . 0.0 112.041 -171.693 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 1.031 HD13 HG22 ' F' ' 32' ' ' ILE . 2.8 mp -122.41 118.01 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.186 0 CA-C-N 114.275 -1.33 . . . . 0.0 110.35 -178.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.662 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -120.2 116.29 3.2 Favored Glycine 0 N--CA 1.476 1.32 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 178.338 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.754 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 39.6 mt -119.36 117.39 28.38 Favored 'General case' 0 CA--C 1.518 -0.255 0 N-CA-C 109.869 -0.419 . . . . 0.0 109.869 -179.515 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 11.9 ttt -120.27 126.35 50.36 Favored 'General case' 0 N--CA 1.477 0.9 0 C-N-CA 119.785 -0.766 . . . . 0.0 111.08 179.798 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.447 ' O ' HG23 ' F' ' 36' ' ' VAL . 2.6 t -115.44 89.1 1.25 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.494 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.01 -179.436 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.716 ' HA3' HG21 ' K' ' 31' ' ' ILE . . . -69.3 94.69 0.4 Allowed Glycine 0 CA--C 1.527 0.811 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 178.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -112.22 -171.79 18.73 Favored Glycine 0 N--CA 1.467 0.732 0 N-CA-C 111.878 -0.489 . . . . 0.0 111.878 -178.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 33.1 m -132.73 161.81 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 121.002 0.429 . . . . 0.0 110.654 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 58.0 t . . . . . 0 C--O 1.221 -0.423 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.753 -179.942 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.337 0 N-CA-C 109.41 -1.476 . . . . 0.0 109.41 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -103.33 129.75 50.45 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-O 121.004 0.43 . . . . 0.0 110.47 179.923 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -92.9 145.58 24.28 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.809 -0.632 . . . . 0.0 109.856 179.598 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 20.9 t -105.85 130.04 57.98 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 121.133 0.492 . . . . 0.0 110.689 -179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . . . . . . . . . 14.5 t60 -154.19 139.7 17.81 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 -179.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -149.74 170.61 18.32 Favored 'General case' 0 N--CA 1.444 -0.741 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 -179.767 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.427 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 50.8 tt0 -155.09 171.15 20.25 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 115.525 -0.762 . . . . 0.0 109.591 179.668 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . 0.482 ' C ' HD12 ' F' ' 17' ' ' LEU . 62.1 tttm -170.08 106.39 0.33 Allowed 'General case' 0 C--N 1.33 -0.281 0 C-N-CA 120.156 -0.617 . . . . 0.0 111.676 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.482 HD12 ' C ' ' F' ' 16' ' ' LYS . 6.1 mp -117.42 125.47 51.01 Favored 'General case' 0 N--CA 1.468 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 177.757 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 20.4 m -150.1 141.44 16.92 Favored 'Isoleucine or valine' 0 C--O 1.236 0.392 0 N-CA-C 113.846 1.054 . . . . 0.0 113.846 -179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.754 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 96.4 m-85 -117.0 122.0 42.97 Favored 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 113.637 -1.62 . . . . 0.0 107.377 177.197 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . 0.4 ' O ' ' HA ' ' E' ' 20' ' ' PHE . 47.7 m-85 -127.04 142.29 51.57 Favored 'General case' 0 N--CA 1.472 0.642 0 CA-C-O 121.749 0.785 . . . . 0.0 111.317 -179.497 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . 0.658 ' HB2' ' ND2' ' D' ' 27' ' ' ASN . . . -154.25 146.5 23.82 Favored 'General case' 0 C--N 1.322 -0.601 0 C-N-CA 120.291 -0.564 . . . . 0.0 110.54 178.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.476 ' O ' ' O ' ' E' ' 23' ' ' ASP . 97.6 mt-10 -89.48 98.86 12.01 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.958 -0.564 . . . . 0.0 109.845 179.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.434 ' O ' ' O ' ' F' ' 24' ' ' VAL . 6.2 t70 -120.47 110.87 17.01 Favored 'General case' 0 N--CA 1.472 0.665 0 CA-C-O 120.601 0.238 . . . . 0.0 110.758 -179.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.434 ' O ' ' O ' ' F' ' 23' ' ' ASP . 17.6 m -60.42 -133.74 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.5 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.696 179.535 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.562 ' O ' ' O ' ' F' ' 26' ' ' SER . . . -76.91 85.72 0.99 Allowed Glycine 0 CA--C 1.53 1.002 0 CA-C-O 119.784 -0.453 . . . . 0.0 112.797 179.911 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.562 ' O ' ' O ' ' F' ' 25' ' ' GLY . 5.9 p -34.97 170.09 0.0 OUTLIER 'General case' 0 N--CA 1.456 -0.144 0 CA-C-O 121.191 0.52 . . . . 0.0 111.292 178.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' F' ' 28' ' ' LYS . 8.0 t-20 -140.19 -178.96 5.71 Favored 'General case' 0 N--CA 1.474 0.757 0 CA-C-N 116.353 -0.385 . . . . 0.0 111.151 177.376 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' F' ' 27' ' ' ASN . 62.8 mttp 26.37 -107.59 0.02 OUTLIER 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.61 -0.723 . . . . 0.0 112.003 -179.142 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -152.39 94.46 0.15 Allowed Glycine 0 C--N 1.338 0.674 0 CA-C-O 119.269 -0.74 . . . . 0.0 111.988 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.403 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -67.4 178.99 1.38 Allowed 'General case' 0 CA--C 1.513 -0.444 0 N-CA-C 103.876 -2.639 . . . . 0.0 103.876 174.654 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.533 HD13 ' N ' ' L' ' 38' ' ' GLY . 0.2 OUTLIER -146.87 118.79 1.75 Allowed 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 CA-C-N 121.651 2.023 . . . . 0.0 111.03 -178.763 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 1.031 HG22 HD13 ' E' ' 32' ' ' ILE . 45.9 pt -118.56 140.91 40.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.462 -178.18 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -145.05 125.14 2.29 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 178.937 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 4.9 mp -116.88 127.86 54.68 Favored 'General case' 0 N--CA 1.464 0.243 0 N-CA-C 109.145 -0.687 . . . . 0.0 109.145 179.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.473 ' SD ' ' N ' ' F' ' 36' ' ' VAL . 2.9 tmm? -129.16 127.97 42.47 Favored 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 121.564 0.697 . . . . 0.0 112.876 -178.248 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.473 ' N ' ' SD ' ' F' ' 35' ' ' MET . 3.6 p -156.15 82.02 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.544 0.719 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.233 179.079 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.447 ' O ' HD13 ' L' ' 31' ' ' ILE . . . -71.23 101.39 0.96 Allowed Glycine 0 CA--C 1.53 0.988 0 C-N-CA 120.624 -0.798 . . . . 0.0 111.475 -179.019 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -144.04 165.01 27.45 Favored Glycine 0 CA--C 1.527 0.842 0 N-CA-C 111.116 -0.794 . . . . 0.0 111.116 -179.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.5 t -119.6 135.96 58.26 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.469 0 CA-C-O 121.024 0.44 . . . . 0.0 110.331 -179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 39.4 t . . . . . 0 C--O 1.22 -0.453 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.728 -179.992 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.348 0 N-CA-C 109.436 -1.465 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -83.32 141.46 31.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.831 0.348 . . . . 0.0 110.601 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -55.71 142.33 34.72 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.842 -179.676 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 8.0 m -121.24 132.86 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.59 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.847 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.514 ' CD2' ' O ' ' G' ' 14' ' ' HIS . 81.5 t60 -146.45 160.62 41.85 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.609 -179.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.514 ' O ' ' CD2' ' G' ' 13' ' ' HIS . 8.1 p-80 -96.81 172.25 8.0 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.099 0.476 . . . . 0.0 109.804 -179.692 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -148.4 177.52 9.37 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.054 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -143.95 145.82 32.52 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 80.6 mt -127.97 115.43 18.52 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.613 0.72 . . . . 0.0 110.306 179.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 74.6 t -125.82 121.98 61.03 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.127 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -153.24 158.23 41.38 Favored 'General case' 0 N--CA 1.469 0.484 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.611 178.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 49.4 p90 -132.56 150.16 52.2 Favored 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.415 -178.998 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.6 135.1 44.03 Favored 'General case' 0 C--O 1.241 0.621 0 CA-C-O 121.86 0.838 . . . . 0.0 112.283 -179.22 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 16.9 pt-20 -143.38 151.9 40.96 Favored 'General case' 0 CA--C 1.537 0.449 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.802 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.509 ' H ' ' CB ' ' H' ' 23' ' ' ASP . 57.5 t0 60.68 114.91 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.467 0 CA-C-O 121.261 0.553 . . . . 0.0 111.965 179.401 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.556 ' O ' ' O ' ' G' ' 26' ' ' SER . 0.3 OUTLIER -147.32 112.81 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 N-CA-C 107.964 -1.124 . . . . 0.0 107.964 179.524 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 36.82 -91.35 0.01 OUTLIER Glycine 0 CA--C 1.539 1.55 0 C-N-CA 121.135 -0.555 . . . . 0.0 112.383 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.556 ' O ' ' O ' ' G' ' 24' ' ' VAL . 10.8 p -89.33 -178.86 5.72 Favored 'General case' 0 CA--C 1.505 -0.756 0 N-CA-C 106.962 -1.495 . . . . 0.0 106.962 -179.013 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.468 ' ND2' ' OG ' ' H' ' 26' ' ' SER . 33.1 m-80 -60.31 166.05 3.21 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 115.87 -2.332 . . . . 0.0 107.564 -177.392 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.558 ' NZ ' ' O ' ' I' ' 23' ' ' ASP . 29.6 tttm -53.69 107.35 0.25 Allowed 'General case' 0 C--N 1.318 -0.778 0 C-N-CA 118.365 -1.334 . . . . 0.0 113.734 -177.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -92.51 100.81 2.71 Favored Glycine 0 N--CA 1.469 0.854 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 169.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . . . . . . . . . . . -82.17 148.09 28.66 Favored 'General case' 0 C--O 1.248 0.985 1 CA-C-N 125.131 4.465 . . . . 0.0 109.378 -178.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -162.71 107.36 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.305 -1.354 0 CA-C-N 112.47 -2.15 . . . . 0.0 106.96 -175.318 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.42 ' O ' ' O ' ' H' ' 33' ' ' GLY . 42.7 mm -108.8 104.73 17.54 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 C-N-CA 119.074 -1.051 . . . . 0.0 108.673 177.227 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -108.54 100.08 1.38 Allowed Glycine 0 CA--C 1.495 -1.17 0 N-CA-C 104.336 -3.506 . . . . 0.0 104.336 175.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 4.1 tp -147.32 149.07 32.11 Favored 'General case' 0 C--O 1.238 0.484 0 CA-C-O 123.321 1.534 . . . . 0.0 112.948 -177.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . . . . . . . . . 2.0 ttm -111.92 135.61 52.33 Favored 'General case' 0 N--CA 1.434 -1.247 0 CA-C-N 112.476 -2.147 . . . . 0.0 110.579 -179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . 0.409 ' O ' ' O ' ' G' ' 37' ' ' GLY . 0.2 OUTLIER -135.54 66.4 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.058 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.11 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . 0.409 ' O ' ' O ' ' G' ' 36' ' ' VAL . . . -53.1 -103.06 0.01 OUTLIER Glycine 0 C--N 1.358 1.783 0 N-CA-C 109.927 -1.269 . . . . 0.0 109.927 178.472 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 176.55 -177.89 47.93 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.4 -1.08 . . . . 0.0 110.4 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.41 144.66 27.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.431 0 CA-C-O 121.013 0.435 . . . . 0.0 110.729 -179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.221 -0.402 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.705 -179.847 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.115 0 N-CA-C 109.433 -1.467 . . . . 0.0 109.433 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -140.94 153.17 45.52 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-O 120.796 0.332 . . . . 0.0 110.164 179.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . 0.432 ' H ' ' HG3' ' I' ' 11' ' ' GLU . 95.7 mt-10 -128.54 129.95 46.73 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.358 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 51.6 t -131.11 130.98 63.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.62 179.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.643 ' NE2' ' CD2' ' I' ' 13' ' ' HIS . 19.3 p80 -167.96 156.65 9.23 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 119.68 -0.808 . . . . 0.0 111.568 179.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . . . . . . . . . 96.2 m-70 -144.44 170.4 16.09 Favored 'General case' 0 N--CA 1.448 -0.545 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 179.52 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 99.2 mt-30 -144.97 172.51 12.94 Favored 'General case' 0 C--N 1.319 -0.747 0 CA-C-O 120.951 0.405 . . . . 0.0 110.671 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 88.7 tttt -176.13 126.02 0.2 Allowed 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.646 -0.707 . . . . 0.0 109.664 179.843 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 4.0 mp -136.38 122.54 20.37 Favored 'General case' 0 N--CA 1.464 0.239 0 C-N-CA 120.91 -0.316 . . . . 0.0 110.665 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 34.2 m -123.79 129.45 74.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.974 0 CA-C-O 121.352 0.596 . . . . 0.0 110.344 178.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . 0.426 ' N ' ' CD1' ' H' ' 19' ' ' PHE . 5.0 m-85 -113.11 116.39 29.79 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.847 -179.027 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -110.65 117.53 33.75 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 178.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.02 129.84 51.59 Favored 'General case' 0 N--CA 1.475 0.814 0 O-C-N 121.269 -0.895 . . . . 0.0 112.884 -178.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 20.9 pt-20 -171.08 145.28 2.24 Favored 'General case' 0 N--CA 1.474 0.735 0 CA-C-N 115.44 -0.8 . . . . 0.0 111.549 179.58 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.509 ' CB ' ' H ' ' G' ' 23' ' ' ASP . 29.7 t70 -172.0 105.97 0.2 Allowed 'General case' 0 N--CA 1.47 0.537 0 N-CA-C 114.942 1.46 . . . . 0.0 114.942 178.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.407 ' C ' ' O ' ' H' ' 23' ' ' ASP . 58.5 t -29.17 141.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.303 173.769 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.414 ' O ' ' CB ' ' H' ' 26' ' ' SER . . . 169.4 -80.42 0.1 OUTLIER Glycine 0 CA--C 1.532 1.146 0 C-N-CA 118.833 -1.651 . . . . 0.0 114.448 179.425 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.522 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.3 OUTLIER 170.73 -179.11 0.05 OUTLIER 'General case' 0 N--CA 1.445 -0.683 0 CA-C-N 118.299 1.05 . . . . 0.0 109.557 -177.091 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.522 ' O ' ' O ' ' H' ' 26' ' ' SER . 76.8 m-20 -27.76 157.49 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 114.955 -1.021 . . . . 0.0 112.802 -176.426 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.89 ' HZ2' ' N ' ' I' ' 25' ' ' GLY . 3.4 pttp 179.18 101.71 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.405 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.531 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . . . . . . . . . . . -68.5 101.63 0.79 Allowed Glycine 0 N--CA 1.477 1.396 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 178.895 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -84.41 153.03 23.65 Favored 'General case' 0 C--O 1.255 1.379 0 CA-C-O 124.038 1.875 . . . . 0.0 112.777 -176.589 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.632 HG21 ' HA3' ' B' ' 37' ' ' GLY . 0.8 OUTLIER -152.95 128.27 1.57 Allowed 'Isoleucine or valine' 0 N--CA 1.444 -0.742 0 CA-C-N 111.519 -2.582 . . . . 0.0 109.797 -177.427 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.55 HG21 HD12 ' I' ' 32' ' ' ILE . 2.1 tt -119.45 116.12 49.8 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 N-CA-C 108.195 -1.039 . . . . 0.0 108.195 179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.42 ' O ' ' O ' ' G' ' 32' ' ' ILE . . . -121.28 115.17 2.77 Favored Glycine 0 C--O 1.24 0.526 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 -179.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.921 ' O ' HD12 ' I' ' 34' ' ' LEU . 0.5 OUTLIER -138.23 150.75 47.01 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 122.971 1.367 . . . . 0.0 112.924 -178.251 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.727 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 34.1 ttp -121.65 127.1 50.45 Favored 'General case' 0 CA--C 1.509 -0.598 0 CA-C-N 114.065 -1.425 . . . . 0.0 109.765 178.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.494 ' CG2' HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -132.15 72.69 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 120.619 -0.433 . . . . 0.0 110.035 179.515 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . 0.421 ' HA3' HG21 ' B' ' 31' ' ' ILE . . . -75.98 110.58 3.08 Favored Glycine 0 C--N 1.349 1.254 0 N-CA-C 109.694 -1.362 . . . . 0.0 109.694 178.46 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -57.75 163.44 8.07 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.5 m -137.66 159.33 34.46 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 120.835 0.35 . . . . 0.0 110.077 179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 17.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.697 -179.781 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.39 0 N-CA-C 109.402 -1.479 . . . . 0.0 109.402 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 53.3 p90 -148.93 160.17 43.52 Favored 'General case' 0 C--N 1.331 -0.197 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.503 ' OE1' ' N ' ' I' ' 11' ' ' GLU . 53.6 mp0 -137.01 131.45 32.9 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.476 -0.329 . . . . 0.0 110.677 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.473 ' C ' ' ND1' ' I' ' 13' ' ' HIS . 27.1 m -136.33 152.12 29.4 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.512 0 CA-C-O 121.339 0.59 . . . . 0.0 110.869 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.643 ' CD2' ' NE2' ' H' ' 13' ' ' HIS . 12.9 m80 -139.78 140.92 36.79 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 115.19 -0.914 . . . . 0.0 111.185 -178.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.592 ' ND1' ' N ' ' I' ' 15' ' ' GLN . 59.4 t-80 -153.48 162.12 41.58 Favored 'General case' 0 N--CA 1.447 -0.6 0 N-CA-C 108.949 -0.76 . . . . 0.0 108.949 178.48 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.592 ' N ' ' ND1' ' I' ' 14' ' ' HIS . 49.8 tt0 -162.17 172.24 16.11 Favored 'General case' 0 C--N 1.311 -1.074 0 C-N-CA 120.462 -0.495 . . . . 0.0 110.376 178.866 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.451 ' N ' ' CG ' ' I' ' 15' ' ' GLN . 88.0 tttt -172.59 128.65 0.53 Allowed 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.13 -0.486 . . . . 0.0 109.734 179.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.692 HD22 ' CE1' ' I' ' 19' ' ' PHE . 3.5 tt -130.27 121.47 26.18 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 109.391 -0.596 . . . . 0.0 109.391 179.902 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.66 ' N ' HD23 ' I' ' 17' ' ' LEU . 39.6 t -120.34 126.53 75.36 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.367 0 O-C-N 122.256 -0.277 . . . . 0.0 111.709 -179.271 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.692 ' CE1' HD22 ' I' ' 17' ' ' LEU . 73.3 m-85 -103.98 101.26 11.04 Favored 'General case' 0 C--O 1.236 0.363 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 176.16 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 27.4 t80 -113.27 117.85 33.01 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 111.917 0.34 . . . . 0.0 111.917 -176.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.22 124.87 35.61 Favored 'General case' 0 C--O 1.235 0.302 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 178.15 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.442 ' O ' ' CB ' ' I' ' 23' ' ' ASP . 14.4 pt-20 -127.09 75.41 1.58 Allowed 'General case' 0 N--CA 1.471 0.603 0 C-N-CA 119.427 -0.909 . . . . 0.0 111.707 -179.393 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.558 ' O ' ' NZ ' ' G' ' 28' ' ' LYS . 0.0 OUTLIER 164.03 115.0 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 114.198 -1.364 . . . . 0.0 109.872 176.158 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.687 ' C ' ' HZ2' ' H' ' 28' ' ' LYS . 39.5 t -148.57 107.47 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 C-N-CA 118.976 -1.089 . . . . 0.0 108.726 173.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.89 ' N ' ' HZ2' ' H' ' 28' ' ' LYS . . . -39.62 -93.93 0.01 OUTLIER Glycine 0 N--CA 1.462 0.406 0 CA-C-O 123.984 1.88 . . . . 0.0 109.929 171.395 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.508 ' H ' ' H ' ' H' ' 28' ' ' LYS . 79.5 p 47.28 -178.59 0.01 OUTLIER 'General case' 0 CA--C 1.481 -1.703 0 CA-C-N 110.276 -2.962 . . . . 0.0 111.025 177.244 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.404 ' O ' ' C ' ' I' ' 28' ' ' LYS . 29.4 m120 -126.47 164.4 21.22 Favored 'General case' 0 C--N 1.305 -1.344 0 CA-C-N 113.25 -1.795 . . . . 0.0 107.292 172.508 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.404 ' C ' ' O ' ' I' ' 27' ' ' ASN 0.263 45.1 mttm -27.85 112.56 0.06 Allowed 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 114.984 1.476 . . . . 0.0 114.984 174.809 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.467 ' HA2' ' HB2' ' J' ' 30' ' ' ALA . . . 103.35 92.64 2.24 Favored Glycine 0 N--CA 1.48 1.577 0 C-N-CA 124.602 1.096 . . . . 0.0 115.169 179.624 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.498 ' O ' ' CB ' ' J' ' 30' ' ' ALA . . . -87.64 179.71 6.47 Favored 'General case' 0 N--CA 1.444 -0.756 0 N-CA-C 104.674 -2.343 . . . . 0.0 104.674 173.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.49 ' HB ' HG22 ' H' ' 31' ' ' ILE . 0.4 OUTLIER -141.83 124.65 14.7 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.109 0 C-N-CA 116.517 -2.073 . . . . 0.0 111.471 -176.902 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.55 HD12 HG21 ' H' ' 32' ' ' ILE . 9.1 tt -125.89 127.24 71.04 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.862 0 CA-C-O 121.213 0.53 . . . . 0.0 111.778 -179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . 0.644 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -124.81 117.46 3.04 Favored Glycine 0 C--O 1.24 0.482 0 N-CA-C 108.736 -1.746 . . . . 0.0 108.736 177.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.921 HD12 ' O ' ' H' ' 34' ' ' LEU . 16.9 tp -137.84 135.36 36.13 Favored 'General case' 0 C--O 1.245 0.839 0 CA-C-O 121.611 0.719 . . . . 0.0 111.744 -178.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.681 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 54.9 ttp -105.21 125.3 50.83 Favored 'General case' 0 CA--C 1.509 -0.631 0 CA-C-N 114.547 -1.206 . . . . 0.0 108.75 176.409 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -126.79 72.09 0.43 Allowed 'Isoleucine or valine' 0 CA--C 1.564 1.482 0 CA-C-N 116.456 -0.338 . . . . 0.0 110.135 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -72.58 111.3 3.5 Favored Glycine 0 C--N 1.364 2.128 0 N-CA-C 110.275 -1.13 . . . . 0.0 110.275 177.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -71.99 160.51 54.07 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.016 -0.834 . . . . 0.0 111.016 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 35.3 m -136.79 162.01 35.35 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.341 0 CA-C-O 120.805 0.336 . . . . 0.0 110.314 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 23.4 m . . . . . 0 C--O 1.22 -0.459 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.552 -179.879 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -108.23 138.04 45.19 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.715 0.293 . . . . 0.0 110.329 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -75.95 128.18 34.54 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.016 -179.979 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 23.4 m -140.97 161.14 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-O 121.268 0.556 . . . . 0.0 111.416 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 68.9 m80 -139.11 134.74 33.29 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.675 179.231 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . 0.642 ' CD2' ' N ' ' J' ' 15' ' ' GLN . 4.8 t60 -148.56 158.11 43.91 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-O 121.759 0.79 . . . . 0.0 110.464 179.433 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.642 ' N ' ' CD2' ' J' ' 14' ' ' HIS . 83.2 mt-30 -150.59 174.46 12.95 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 114.605 -1.179 . . . . 0.0 109.546 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 54.0 tttp -175.82 127.3 0.23 Allowed 'General case' 0 N--CA 1.464 0.262 0 CA-C-N 116.511 -0.313 . . . . 0.0 110.193 179.347 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.3 mp -130.4 129.96 43.73 Favored 'General case' 0 N--CA 1.471 0.596 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 178.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' K' ' 18' ' ' VAL . 1.4 p -144.99 140.62 23.02 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.887 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -178.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.489 ' CZ ' HD13 ' H' ' 34' ' ' LEU . 0.6 OUTLIER -114.26 120.37 40.2 Favored 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 177.69 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -118.72 117.53 29.16 Favored 'General case' 0 N--CA 1.474 0.735 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 179.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -119.44 120.34 36.54 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 121.487 0.66 . . . . 0.0 111.653 179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -159.69 104.45 1.58 Allowed 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 114.028 1.121 . . . . 0.0 114.028 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.498 ' HB2' ' H ' ' I' ' 24' ' ' VAL . 60.2 t0 -82.93 -133.52 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.245 0 N-CA-C 104.666 -2.346 . . . . 0.0 104.666 175.424 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.54 ' O ' ' O ' ' J' ' 25' ' ' GLY . 21.9 t -92.2 112.17 25.4 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 N-CA-C 101.05 -3.685 . . . . 0.0 101.05 172.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . 0.54 ' O ' ' O ' ' J' ' 24' ' ' VAL . . . 42.38 90.14 0.01 OUTLIER Glycine 0 CA--C 1.536 1.344 0 N-CA-C 107.01 -2.436 . . . . 0.0 107.01 -173.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.547 ' CB ' ' O ' ' K' ' 22' ' ' GLU . 0.0 OUTLIER -61.65 -179.82 0.2 Allowed 'General case' 0 N--CA 1.438 -1.034 0 C-N-CA 118.784 -1.167 . . . . 0.0 109.638 -174.865 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.466 ' N ' ' OG ' ' J' ' 26' ' ' SER . 1.6 m-20 -80.48 173.61 12.43 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 116.825 2.157 . . . . 0.0 116.825 -176.521 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.552 ' O ' ' N ' ' J' ' 30' ' ' ALA 0.369 48.2 tttp -48.06 111.81 0.49 Allowed 'General case' 0 C--N 1.313 -1.013 0 CA-C-N 109.221 -3.627 . . . . 0.0 116.782 173.499 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.531 ' O ' ' CB ' ' K' ' 30' ' ' ALA . . . -68.34 99.19 0.56 Allowed Glycine 1 CA--C 1.446 -4.275 2 CA-C-O 128.699 4.5 . . . . 0.0 102.799 -176.331 . . . . . . . . 4 3 . 1 . 007 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.783 ' C ' HD13 ' J' ' 31' ' ' ILE . . . -77.08 -132.78 0.01 OUTLIER 'General case' 1 N--CA 1.339 -6.005 3 CA-C-N 97.435 -9.383 . . . . 0.0 107.55 -167.012 . . . . . . . . 4 3 . 1 . 007 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.861 ' N ' HD13 ' J' ' 31' ' ' ILE . 0.1 OUTLIER -90.02 108.94 20.0 Favored 'Isoleucine or valine' 0 N--CA 1.385 -3.692 0 CA-C-N 114.57 -1.195 . . . . 0.0 110.467 -175.592 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.541 ' O ' ' SD ' ' D' ' 35' ' ' MET . 0.3 OUTLIER -106.58 111.05 33.78 Favored 'Isoleucine or valine' 0 C--N 1.363 1.169 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.699 179.486 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -110.89 103.85 1.67 Allowed Glycine 0 CA--C 1.505 -0.545 0 N-CA-C 107.819 -2.112 . . . . 0.0 107.819 178.184 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.58 HD13 ' CZ ' ' L' ' 19' ' ' PHE . 66.9 mt -126.03 121.72 33.8 Favored 'General case' 0 CA--C 1.511 -0.545 0 CA-C-O 121.951 0.881 . . . . 0.0 112.514 -177.253 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.655 ' SD ' ' N ' ' D' ' 33' ' ' GLY . 6.1 ttt -102.94 120.37 40.51 Favored 'General case' 0 CA--C 1.509 -0.632 0 CA-C-N 114.252 -1.34 . . . . 0.0 108.391 177.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.478 ' HB ' HG22 ' K' ' 36' ' ' VAL . 3.6 t -137.23 66.86 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 C-N-CA 120.581 -0.448 . . . . 0.0 111.327 -178.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -58.28 -102.63 0.01 OUTLIER Glycine 0 C--N 1.356 1.685 0 N-CA-C 109.981 -1.248 . . . . 0.0 109.981 178.389 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.13 154.88 30.65 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 179.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 50.5 t -130.67 136.57 58.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.289 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 179.495 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 32.7 t . . . . . 0 N--CA 1.468 0.457 0 CA-C-O 117.967 -1.016 . . . . 0.0 110.29 179.591 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.632 -1.387 . . . . 0.0 109.632 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . 0.43 ' CD1' ' N ' ' K' ' 10' ' ' TYR . 11.6 p90 -133.68 152.12 51.81 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.783 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 78.9 tt0 -91.97 138.79 31.25 Favored 'General case' 0 N--CA 1.464 0.237 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.347 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.44 HG13 ' ND1' ' L' ' 13' ' ' HIS . 74.1 t -126.58 134.72 65.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.431 ' O ' ' O ' ' L' ' 13' ' ' HIS . 44.3 t60 -116.41 123.48 47.64 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 117.845 0.293 . . . . 0.0 111.309 -179.484 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . . . . . . . . . 86.6 m-70 -114.86 158.95 21.23 Favored 'General case' 0 CA--C 1.513 -0.452 0 N-CA-C 108.302 -0.999 . . . . 0.0 108.302 178.137 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.418 ' O ' ' CG ' ' K' ' 16' ' ' LYS . 53.4 tt0 -170.05 161.58 8.71 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.226 177.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.418 ' CG ' ' O ' ' K' ' 15' ' ' GLN . 95.5 mttt -163.03 132.23 4.12 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 109.397 -0.594 . . . . 0.0 109.397 178.662 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.416 HD23 HD13 ' L' ' 17' ' ' LEU . 15.5 tp -122.9 119.21 29.81 Favored 'General case' 0 C--O 1.235 0.3 0 N-CA-C 107.956 -1.127 . . . . 0.0 107.956 178.221 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 96.6 t -136.42 133.74 49.48 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 N-CA-C 113.502 0.927 . . . . 0.0 113.502 -177.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.604 ' CZ ' ' CD2' ' L' ' 19' ' ' PHE . 23.4 p90 -145.62 130.4 18.1 Favored 'General case' 0 N--CA 1.48 1.04 0 C-N-CA 119.262 -0.975 . . . . 0.0 112.296 177.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.638 ' N ' ' CD1' ' K' ' 20' ' ' PHE . 0.0 OUTLIER -149.35 163.77 36.78 Favored 'General case' 0 CA--C 1.545 0.753 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -178.475 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -138.73 141.67 38.89 Favored 'General case' 0 N--CA 1.475 0.776 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.328 -179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . 0.547 ' O ' ' CB ' ' J' ' 26' ' ' SER . 78.1 tt0 -89.71 156.59 18.45 Favored 'General case' 0 N--CA 1.494 1.773 0 N-CA-C 113.839 1.051 . . . . 0.0 113.839 -178.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.52 ' OD2' ' N ' ' J' ' 28' ' ' LYS . 58.6 t0 176.11 130.79 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 C-N-CA 123.465 0.706 . . . . 0.0 110.522 178.589 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.456 HG23 ' H ' ' K' ' 25' ' ' GLY . 5.3 m -87.53 -112.27 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 C-N-CA 120.569 -0.452 . . . . 0.0 112.084 -178.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.53 ' O ' ' O ' ' K' ' 26' ' ' SER . . . -48.75 92.11 0.01 OUTLIER Glycine 0 CA--C 1.531 1.062 0 N-CA-C 114.838 0.695 . . . . 0.0 114.838 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.53 ' O ' ' O ' ' K' ' 25' ' ' GLY . 8.6 t -35.46 170.32 0.0 OUTLIER 'General case' 0 N--CA 1.454 -0.231 0 CA-C-O 121.611 0.719 . . . . 0.0 111.368 176.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.481 ' OD1' ' N ' ' K' ' 28' ' ' LYS . 0.7 OUTLIER -139.22 -177.15 4.78 Favored 'General case' 0 N--CA 1.477 0.883 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.946 177.751 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . 0.481 ' N ' ' OD1' ' K' ' 27' ' ' ASN . 98.9 mttt -17.84 -104.87 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 113.242 0.83 . . . . 0.0 113.242 -178.304 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.552 ' HA2' ' HB2' ' L' ' 30' ' ' ALA . . . -150.44 95.34 0.16 Allowed Glycine 0 C--N 1.346 1.089 0 C-N-CA 119.672 -1.251 . . . . 0.0 114.692 -179.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.575 ' C ' HD13 ' K' ' 31' ' ' ILE . . . -67.82 -173.13 0.32 Allowed 'General case' 0 C--O 1.237 0.444 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 175.135 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.716 HG21 ' HA3' ' E' ' 37' ' ' GLY . 0.0 OUTLIER -144.77 130.03 14.06 Favored 'Isoleucine or valine' 0 C--O 1.243 0.725 0 CA-C-O 122.212 1.006 . . . . 0.0 110.22 -179.465 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 11.1 mm -114.84 122.5 69.07 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 CA-C-N 114.164 -1.38 . . . . 0.0 110.485 -178.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.482 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -127.98 119.72 3.22 Favored Glycine 0 N--CA 1.473 1.121 0 C-N-CA 121.023 -0.608 . . . . 0.0 111.722 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 22.0 tp -129.39 122.25 29.05 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 114.524 -0.838 . . . . 0.0 110.211 179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.662 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 38.8 ttp -105.96 119.62 39.64 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-N 115.519 -0.764 . . . . 0.0 109.88 178.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.702 HG12 ' O ' ' K' ' 36' ' ' VAL . 54.7 t -139.8 71.06 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.532 0 CA-C-O 119.415 -0.326 . . . . 0.0 110.53 179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.754 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -53.88 -97.87 0.01 OUTLIER Glycine 0 C--N 1.342 0.897 0 N-CA-C 109.268 -1.533 . . . . 0.0 109.268 178.802 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . 94.32 163.83 35.86 Favored Glycine 0 N--CA 1.461 0.309 0 N-CA-C 111.271 -0.732 . . . . 0.0 111.271 178.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 34.7 m -137.01 162.5 34.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 N-CA-C 110.11 -0.33 . . . . 0.0 110.11 179.626 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . 0.407 HG22 ' O ' ' K' ' 40' ' ' VAL . 7.2 p . . . . . 0 C--O 1.219 -0.518 0 CA-C-O 117.962 -1.018 . . . . 0.0 110.575 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.222 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -104.53 132.46 50.75 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.653 0.264 . . . . 0.0 110.395 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -80.84 131.29 35.38 Favored 'General case' 0 C--N 1.332 -0.178 0 N-CA-C 109.922 -0.399 . . . . 0.0 109.922 179.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t -133.56 137.87 52.02 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.405 -179.277 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.44 ' ND1' HG13 ' K' ' 12' ' ' VAL . 15.5 m80 -81.58 145.95 30.37 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.191 0.52 . . . . 0.0 111.047 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -83.45 177.78 8.31 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.196 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 29.2 pt20 -110.73 178.69 4.28 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.813 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -146.24 140.85 26.83 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.045 179.057 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.416 HD13 HD23 ' K' ' 17' ' ' LEU . 28.6 tp -125.33 119.99 29.89 Favored 'General case' 0 N--CA 1.467 0.415 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.721 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . 0.482 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 7.3 t -141.45 131.9 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.633 0 CA-C-O 121.643 0.735 . . . . 0.0 112.026 -179.129 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.604 ' CD2' ' CZ ' ' K' ' 19' ' ' PHE . 8.0 p90 -147.5 144.58 28.66 Favored 'General case' 0 C--N 1.322 -0.597 0 O-C-N 121.363 -0.835 . . . . 0.0 110.926 178.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.509 ' CG ' ' O ' ' L' ' 19' ' ' PHE . 60.2 m-85 -157.77 157.35 33.21 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 122.52 1.152 . . . . 0.0 113.958 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.35 139.42 52.88 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 114.468 -1.242 . . . . 0.0 107.868 177.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 76.9 tt0 -74.48 101.71 4.24 Favored 'General case' 0 C--N 1.327 -0.398 0 C-N-CA 119.462 -0.895 . . . . 0.0 111.786 -177.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' L' ' 23' ' ' ASP . 35.6 p-10 -171.4 113.76 0.37 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.168 -0.924 . . . . 0.0 109.778 178.627 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.518 ' O ' ' N ' ' L' ' 26' ' ' SER . 73.7 t -64.99 131.71 30.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.861 -178.41 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -54.51 83.76 0.01 OUTLIER Glycine 0 N--CA 1.466 0.655 0 N-CA-C 109.89 -1.284 . . . . 0.0 109.89 179.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.518 ' N ' ' O ' ' L' ' 24' ' ' VAL . 15.4 m -67.52 -171.1 0.17 Allowed 'General case' 0 N--CA 1.437 -1.124 0 CA-C-O 122.541 1.163 . . . . 0.0 112.488 -177.309 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.497 ' CG ' ' H ' ' L' ' 28' ' ' LYS . 54.3 t30 -80.51 179.39 7.76 Favored 'General case' 0 C--N 1.309 -1.181 0 CA-C-N 112.512 -2.131 . . . . 0.0 112.788 -177.857 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.497 ' H ' ' CG ' ' L' ' 27' ' ' ASN . 99.4 mttt -36.41 104.4 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.577 -178.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.436 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 168.09 -100.36 0.16 Allowed Glycine 0 C--O 1.22 -0.774 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -175.796 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.552 ' HB2' ' HA2' ' K' ' 29' ' ' GLY . . . -51.35 172.13 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.682 1.741 . . . . 0.0 108.054 -179.957 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.447 HD13 ' O ' ' F' ' 37' ' ' GLY . 0.1 OUTLIER -152.53 149.41 13.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.837 0 C-N-CA 118.144 -1.423 . . . . 0.0 111.253 -176.44 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . 0.403 HG21 HD13 ' L' ' 32' ' ' ILE . 38.5 pt -125.89 143.63 38.77 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.151 0 CA-C-N 115.563 -0.744 . . . . 0.0 110.153 -179.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -132.27 114.73 1.51 Allowed Glycine 0 CA--C 1.522 0.514 0 N-CA-C 110.323 -1.111 . . . . 0.0 110.323 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 50.6 mt -119.09 120.31 36.77 Favored 'General case' 0 CA--C 1.521 -0.145 0 N-CA-C 108.609 -0.885 . . . . 0.0 108.609 179.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 25.3 ttp -111.75 123.99 51.39 Favored 'General case' 0 N--CA 1.48 1.03 0 C-N-CA 120.204 -0.599 . . . . 0.0 111.47 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.446 ' O ' ' O ' ' L' ' 37' ' ' GLY . 4.9 t -133.91 69.68 0.33 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.51 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 178.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.465 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -27.17 -105.69 0.0 OUTLIER Glycine 0 CA--C 1.533 1.187 0 CA-C-O 121.344 0.413 . . . . 0.0 114.064 -179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . 0.533 ' N ' HD13 ' F' ' 31' ' ' ILE . . . -38.09 156.9 0.01 OUTLIER Glycine 0 CA--C 1.523 0.585 0 CA-C-N 115.312 -0.444 . . . . 0.0 112.459 -177.665 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 19.7 m -140.79 159.32 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.219 0 CA-C-N 115.189 -0.505 . . . . 0.0 110.06 179.161 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 4.2 t . . . . . 0 C--O 1.221 -0.445 0 CA-C-O 117.982 -1.008 . . . . 0.0 110.828 -179.721 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.603 -1.399 . . . . 0.0 109.603 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -110.25 133.94 52.74 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.807 0.337 . . . . 0.0 110.259 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 81.9 tt0 -62.45 130.8 46.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.197 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.447 HG11 ' ND1' ' B' ' 13' ' ' HIS . 9.9 p -146.15 146.93 18.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.203 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.729 -179.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.526 ' CD2' ' O ' ' A' ' 14' ' ' HIS . 37.5 p-80 -91.12 -178.63 5.22 Favored 'General case' 0 N--CA 1.462 0.143 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.451 179.946 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.526 ' O ' ' CD2' ' A' ' 13' ' ' HIS . 24.8 m-70 -74.26 172.5 11.72 Favored 'General case' 0 N--CA 1.443 -0.793 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 88.8 mt-30 -145.36 176.73 9.35 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.504 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -150.01 112.09 4.61 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.26 -179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 41.1 tp -124.45 115.46 20.95 Favored 'General case' 0 C--O 1.24 0.6 0 CA-C-O 121.424 0.631 . . . . 0.0 110.261 179.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 65.5 t -123.6 128.96 74.78 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.136 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.403 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.2 t80 -128.76 124.13 34.7 Favored 'General case' 0 C--N 1.326 -0.416 0 N-CA-C 109.279 -0.637 . . . . 0.0 109.279 179.632 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.543 ' O ' ' CD1' ' A' ' 20' ' ' PHE . 54.9 p90 -128.04 125.63 39.71 Favored 'General case' 0 CA--C 1.52 -0.209 0 CA-C-O 120.94 0.4 . . . . 0.0 110.253 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -115.12 119.03 35.04 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 179.24 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 84.9 tt0 -164.2 120.27 1.59 Allowed 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 179.545 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.462 ' CG ' ' H ' ' A' ' 24' ' ' VAL . 38.7 t0 65.42 -136.22 0.21 Allowed 'General case' 0 C--N 1.322 -0.619 0 C-N-CA 120.123 -0.631 . . . . 0.0 109.561 -178.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.462 ' H ' ' CG ' ' A' ' 23' ' ' ASP . 12.1 m -29.49 104.39 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 N-CA-C 114.427 1.269 . . . . 0.0 114.427 -178.267 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . 130.54 -101.22 0.49 Allowed Glycine 0 N--CA 1.468 0.799 0 CA-C-N 113.15 -1.841 . . . . 0.0 110.675 175.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . . . . . . . . . 30.3 t -129.79 140.43 51.04 Favored 'General case' 0 C--N 1.354 0.787 0 CA-C-N 120.115 1.957 . . . . 0.0 111.99 174.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . . . . . . . . . 89.2 m-20 -57.22 179.86 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.457 0 CA-C-N 114.028 -1.442 . . . . 0.0 113.139 170.577 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.506 ' HG2' ' H ' ' B' ' 29' ' ' GLY 0.442 74.5 tttt -59.76 110.62 1.2 Allowed 'General case' 0 CA--C 1.538 0.495 0 CA-C-N 112.073 -2.331 . . . . 0.0 111.576 169.135 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.66 104.03 1.23 Allowed Glycine 0 C--N 1.302 -1.317 0 CA-C-O 127.334 3.741 . . . . 0.0 112.02 -169.246 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.545 ' O ' ' N ' ' A' ' 32' ' ' ILE . . . -69.81 -122.2 0.0 OUTLIER 'General case' 0 CA--C 1.479 -1.778 3 CA-C-N 103.478 -6.361 . . . . 0.0 96.052 -179.563 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.818 ' O ' HD13 ' A' ' 31' ' ' ILE . 0.0 OUTLIER -51.16 99.6 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.587 2.401 0 CA-C-N 124.89 3.495 . . . . 0.0 107.895 175.942 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.545 ' N ' ' O ' ' A' ' 30' ' ' ALA . 4.9 tt -128.78 113.44 29.24 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 119.419 -2.051 . . . . 0.0 109.387 178.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.55 ' HA2' ' O ' ' B' ' 33' ' ' GLY . . . -129.36 126.06 5.04 Favored Glycine 0 N--CA 1.441 -1.028 0 N-CA-C 106.617 -2.593 . . . . 0.0 106.617 178.027 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . 0.498 ' H ' ' HG ' ' B' ' 34' ' ' LEU . 36.8 tp -133.67 135.22 43.96 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 122.529 1.157 . . . . 0.0 111.641 -178.251 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.409 ' HE1' ' O ' ' H' ' 31' ' ' ILE . 12.5 ttm -104.66 110.54 22.9 Favored 'General case' 0 N--CA 1.436 -1.135 0 CA-C-N 113.752 -1.567 . . . . 0.0 107.198 177.629 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -116.15 72.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 N-CA-C 108.301 -0.999 . . . . 0.0 108.301 -179.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.7 110.83 3.12 Favored Glycine 0 C--N 1.355 1.594 0 N-CA-C 110.111 -1.195 . . . . 0.0 110.111 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -60.15 165.74 11.95 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 -179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 20.8 t -95.01 135.98 27.45 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-O 120.952 0.406 . . . . 0.0 110.711 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.432 ' H ' HG23 ' A' ' 40' ' ' VAL . 11.5 t . . . . . 0 C--O 1.221 -0.435 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.62 179.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.562 -1.415 . . . . 0.0 109.562 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 90.0 m-85 -102.92 134.93 45.52 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 13.3 tm-20 -141.21 130.35 23.42 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.952 0.406 . . . . 0.0 110.834 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 3.2 p -144.17 146.06 21.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.243 0 CA-C-N 115.707 -0.679 . . . . 0.0 109.627 179.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.447 ' ND1' HG11 ' A' ' 12' ' ' VAL . 26.0 t60 -154.83 104.68 2.52 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.038 0.447 . . . . 0.0 111.16 179.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.632 ' CD2' ' ND1' ' C' ' 14' ' ' HIS . 31.3 m170 -119.35 164.51 15.59 Favored 'General case' 0 N--CA 1.448 -0.558 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 179.029 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 88.3 mt-30 -154.47 173.03 16.81 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.01 178.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -153.67 114.11 3.98 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.809 178.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.421 HD12 ' N ' ' B' ' 17' ' ' LEU . 4.1 mp -128.39 114.49 16.91 Favored 'General case' 0 C--O 1.24 0.557 0 N-CA-C 109.926 -0.398 . . . . 0.0 109.926 -179.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 31.6 m -129.92 133.73 64.12 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.606 0 CA-C-O 121.101 0.477 . . . . 0.0 111.064 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 77.2 m-85 -119.46 129.61 54.83 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.997 -179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 87.3 t80 -124.65 129.07 49.84 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 116.691 -0.231 . . . . 0.0 110.468 -179.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -129.13 128.34 43.27 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.254 0.549 . . . . 0.0 111.859 -179.581 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . 0.41 ' O ' ' OD1' ' B' ' 23' ' ' ASP . 82.8 tt0 -136.79 149.36 47.73 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.552 ' O ' HG23 ' C' ' 24' ' ' VAL . 81.3 m-20 -137.99 145.78 42.32 Favored 'General case' 0 N--CA 1.468 0.441 0 CA-C-O 120.812 0.339 . . . . 0.0 111.344 -178.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . . . . . . . . . 1.6 m -107.33 110.59 32.35 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.948 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 178.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.896 ' H ' HG21 ' C' ' 24' ' ' VAL . . . 34.41 90.89 0.01 OUTLIER Glycine 0 N--CA 1.471 0.977 0 N-CA-C 111.364 -0.694 . . . . 0.0 111.364 -178.258 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.793 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.9 t 152.41 171.79 0.0 OUTLIER 'General case' 0 N--CA 1.448 -0.563 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -178.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.793 ' O ' ' O ' ' B' ' 26' ' ' SER . 1.3 t-20 20.51 179.79 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.141 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 177.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.461 ' CB ' ' O ' ' B' ' 27' ' ' ASN . 82.0 tttt 151.28 92.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.988 0 CA-C-O 122.472 1.13 . . . . 0.0 110.27 -175.186 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.62 ' O ' ' CB ' ' B' ' 30' ' ' ALA . . . 31.54 -128.7 0.21 Allowed Glycine 1 CA--C 1.419 -5.908 0 CA-C-N 113.362 -1.745 . . . . 0.0 109.918 -178.814 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.62 ' CB ' ' O ' ' B' ' 29' ' ' GLY . . . 119.44 -112.39 0.0 OUTLIER 'General case' 0 N--CA 1.391 -3.425 1 N-CA-C 100.172 -4.01 . . . . 0.0 100.172 -173.213 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.783 ' H ' HD12 ' B' ' 31' ' ' ILE . 2.3 mp -79.79 113.29 18.95 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.037 0 CA-C-N 114.346 -1.297 . . . . 0.0 112.507 179.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.447 ' O ' HG23 ' B' ' 32' ' ' ILE . 14.7 tt -124.85 109.35 22.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 N-CA-C 108.324 -0.991 . . . . 0.0 108.324 176.25 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.833 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -130.06 120.37 3.07 Favored Glycine 0 N--CA 1.468 0.815 0 N-CA-C 109.764 -1.334 . . . . 0.0 109.764 -179.681 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.899 ' O ' HD12 ' C' ' 34' ' ' LEU . 7.4 mp -136.5 160.34 39.07 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 123.219 1.485 . . . . 0.0 113.67 -178.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.513 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 4.6 ttm -127.5 112.33 14.82 Favored 'General case' 0 N--CA 1.444 -0.768 0 CA-C-N 112.791 -2.004 . . . . 0.0 107.677 179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.749 ' CG2' HD11 ' C' ' 34' ' ' LEU . 0.0 OUTLIER -119.6 74.07 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.845 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 -179.583 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' B' ' 36' ' ' VAL . . . -31.89 -97.99 0.01 OUTLIER Glycine 0 C--N 1.357 1.749 0 N-CA-C 111.557 -0.617 . . . . 0.0 111.557 179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 143.48 -173.09 24.59 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 8.0 p -141.35 141.8 30.07 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 CA-C-O 120.95 0.405 . . . . 0.0 110.511 179.795 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 118.02 -0.991 . . . . 0.0 110.945 -179.972 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.319 -1.512 . . . . 0.0 109.319 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 34.2 p90 -146.27 156.24 43.23 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.871 0.367 . . . . 0.0 110.787 179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -116.32 137.87 51.79 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.65 -179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 52.2 t -124.21 132.25 71.63 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.416 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.156 179.683 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 17.2 p-80 -155.63 143.0 19.42 Favored 'General case' 0 N--CA 1.467 0.416 0 CA-C-O 121.13 0.491 . . . . 0.0 111.241 179.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.632 ' ND1' ' CD2' ' B' ' 14' ' ' HIS . 6.1 m80 -140.91 167.38 22.33 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-O 121.11 0.481 . . . . 0.0 109.931 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 97.0 mt-30 -150.99 169.88 20.7 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.566 -0.743 . . . . 0.0 109.964 178.277 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -156.96 117.9 3.66 Favored 'General case' 0 N--CA 1.468 0.469 0 N-CA-C 110.091 -0.337 . . . . 0.0 110.091 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 6.4 mt -124.55 123.79 40.86 Favored 'General case' 0 N--CA 1.471 0.58 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.648 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 93.2 t -133.54 133.28 57.43 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.708 0 N-CA-C 113.891 1.071 . . . . 0.0 113.891 -179.274 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -116.82 107.4 14.58 Favored 'General case' 0 CA--C 1.54 0.565 0 N-CA-C 105.287 -2.116 . . . . 0.0 105.287 175.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.619 ' CE2' ' CD1' ' D' ' 20' ' ' PHE . 24.3 t80 -122.48 134.84 54.56 Favored 'General case' 0 N--CA 1.477 0.878 0 O-C-N 122.312 -0.242 . . . . 0.0 110.532 -177.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . 0.426 ' CB ' ' NZ ' ' A' ' 28' ' ' LYS . . . -145.61 144.11 30.27 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 113.818 1.044 . . . . 0.0 113.818 -179.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.1 tt0 -142.61 110.73 5.99 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 114.147 -1.388 . . . . 0.0 109.642 179.462 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.543 ' O ' ' O ' ' C' ' 24' ' ' VAL . 4.1 m-20 -118.8 133.24 55.98 Favored 'General case' 0 C--O 1.215 -0.723 0 N-CA-C 112.117 0.414 . . . . 0.0 112.117 -178.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.896 HG21 ' H ' ' B' ' 25' ' ' GLY . 4.9 t -28.81 -112.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.776 0 N-CA-C 113.395 0.887 . . . . 0.0 113.395 179.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -144.09 90.54 0.16 Allowed Glycine 0 CA--C 1.533 1.201 0 O-C-N 122.114 -0.366 . . . . 0.0 113.358 -176.05 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.57 ' O ' ' O ' ' C' ' 27' ' ' ASN . 33.4 p -140.4 170.61 15.47 Favored 'General case' 0 CA--C 1.516 -0.329 0 CA-C-N 117.83 0.815 . . . . 0.0 109.483 179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.57 ' O ' ' O ' ' C' ' 26' ' ' SER . 33.3 m120 -30.21 170.81 0.0 OUTLIER 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 114.487 1.291 . . . . 0.0 114.487 -177.023 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . . . . . . . . . 64.4 tttt -108.6 -111.7 0.31 Allowed 'General case' 0 CA--C 1.54 0.586 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.105 178.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 43.13 91.24 0.01 OUTLIER Glycine 0 CA--C 1.489 -1.593 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.279 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . . . . . . . . . . . -135.95 155.8 49.72 Favored 'General case' 0 N--CA 1.423 -1.799 0 N-CA-C 106.321 -1.733 . . . . 0.0 106.321 177.285 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.492 ' O ' ' SD ' ' I' ' 35' ' ' MET . 0.0 OUTLIER -141.5 117.39 6.5 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.127 0 CA-C-N 112.295 -2.23 . . . . 0.0 109.204 -170.592 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.408 ' O ' HG22 ' C' ' 32' ' ' ILE . 5.4 mt -105.5 111.64 35.62 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.485 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.499 ' N ' ' SD ' ' I' ' 35' ' ' MET . . . -122.11 104.39 0.91 Allowed Glycine 0 CA--C 1.506 -0.499 0 N-CA-C 106.273 -2.731 . . . . 0.0 106.273 176.419 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.899 HD12 ' O ' ' B' ' 34' ' ' LEU . 54.6 tp -132.59 141.05 48.52 Favored 'General case' 0 C--O 1.242 0.702 0 CA-C-O 123.3 1.524 . . . . 0.0 113.806 -176.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.793 ' SD ' HG22 ' I' ' 31' ' ' ILE . 8.3 ttm -115.56 118.43 33.11 Favored 'General case' 0 CA--C 1.505 -0.774 0 CA-C-N 112.4 -2.182 . . . . 0.0 109.262 178.413 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.557 HG11 HD23 ' D' ' 17' ' ' LEU . 1.3 m -128.57 74.12 0.47 Allowed 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 179.19 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.1 105.68 3.08 Favored Glycine 0 C--N 1.354 1.545 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -129.76 148.29 18.34 Favored Glycine 0 N--CA 1.466 0.685 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 -179.615 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 4.0 m -134.05 159.8 42.12 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-O 120.944 0.402 . . . . 0.0 110.834 -179.759 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 2.5 t . . . . . 0 C--O 1.22 -0.494 0 CA-C-O 117.909 -1.043 . . . . 0.0 109.914 179.816 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.251 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -107.15 129.93 54.77 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.867 0.365 . . . . 0.0 110.529 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . 0.507 ' O ' HG23 ' E' ' 12' ' ' VAL . 15.1 pt-20 -72.76 150.85 42.47 Favored 'General case' 0 C--N 1.328 -0.352 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 179.166 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.591 HG22 ' O ' ' E' ' 11' ' ' GLU . 2.8 t -103.57 126.86 57.99 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.361 0 N-CA-C 110.213 -0.292 . . . . 0.0 110.213 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . . . . . . . . . 48.8 p-80 -157.8 148.74 21.14 Favored 'General case' 0 C--N 1.324 -0.513 0 C-N-CA 119.643 -0.823 . . . . 0.0 111.632 -179.446 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.565 ' ND1' ' N ' ' D' ' 15' ' ' GLN . 56.7 t-80 -144.98 158.83 43.69 Favored 'General case' 0 CA--C 1.507 -0.674 0 N-CA-C 109.549 -0.537 . . . . 0.0 109.549 179.253 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . 0.565 ' N ' ' ND1' ' D' ' 14' ' ' HIS . 67.7 mt-30 -156.22 172.15 18.96 Favored 'General case' 0 C--N 1.313 -1.009 0 C-N-CA 120.372 -0.531 . . . . 0.0 110.106 177.963 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 75.3 tttt -155.63 122.3 5.29 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.709 179.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.557 HD23 HG11 ' C' ' 36' ' ' VAL . 47.7 tp -117.39 123.1 45.63 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 178.523 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 39.1 t -130.53 131.22 65.15 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.452 0 N-CA-C 113.419 0.896 . . . . 0.0 113.419 -177.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.724 ' CZ ' HD22 ' C' ' 34' ' ' LEU . 10.7 m-85 -112.73 108.88 18.06 Favored 'General case' 0 N--CA 1.468 0.466 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 175.743 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.619 ' CD1' ' CE2' ' C' ' 20' ' ' PHE . 24.0 t80 -123.35 123.76 41.43 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 120.93 0.395 . . . . 0.0 112.026 -176.809 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.61 127.32 30.96 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.253 178.694 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 72.5 tt0 -140.46 114.29 8.91 Favored 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.771 179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.517 ' OD1' ' N ' ' D' ' 23' ' ' ASP . 0.2 OUTLIER 178.65 117.85 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.242 0 C-N-CA 120.143 -0.623 . . . . 0.0 111.971 179.875 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -43.52 120.88 0.44 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.452 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 176.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.497 ' H ' HG23 ' E' ' 24' ' ' VAL . . . -109.43 -82.43 1.37 Allowed Glycine 0 CA--C 1.53 1.004 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.175 179.405 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.862 ' O ' ' O ' ' D' ' 27' ' ' ASN . 2.9 p 151.74 171.41 0.0 OUTLIER 'General case' 0 CA--C 1.506 -0.713 0 N-CA-C 104.95 -2.241 . . . . 0.0 104.95 -178.717 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.862 ' O ' ' O ' ' D' ' 26' ' ' SER . 68.7 m-80 22.09 -178.18 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.632 0 O-C-N 123.919 0.762 . . . . 0.0 113.005 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.482 ' HZ3' ' CG ' ' F' ' 27' ' ' ASN . 73.3 mttt -119.17 -111.19 0.34 Allowed 'General case' 0 N--CA 1.476 0.863 0 O-C-N 120.477 -1.39 . . . . 0.0 112.518 -177.079 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.402 ' C ' ' O ' ' D' ' 28' ' ' LYS . . . 41.78 91.29 0.01 OUTLIER Glycine 0 N--CA 1.477 1.405 0 C-N-CA 120.293 -0.956 . . . . 0.0 110.747 -179.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . . . . . . . . . . . -136.5 156.21 48.91 Favored 'General case' 0 CA--C 1.487 -1.452 0 N-CA-C 101.352 -3.574 . . . . 0.0 101.352 175.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.455 HG13 HG23 ' C' ' 31' ' ' ILE . 0.0 OUTLIER -136.27 122.59 30.65 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.226 0 C-N-CA 118.053 -1.459 . . . . 0.0 111.647 -171.33 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.474 ' O ' ' CE ' ' K' ' 35' ' ' MET . 78.4 mt -116.36 123.27 71.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.118 0 CA-C-N 116.37 -0.377 . . . . 0.0 111.055 179.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -126.57 109.19 1.08 Allowed Glycine 0 N--CA 1.463 0.461 0 N-CA-C 107.609 -2.196 . . . . 0.0 107.609 175.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.419 HD13 ' CZ ' ' E' ' 19' ' ' PHE . 14.7 tp -122.09 124.53 44.12 Favored 'General case' 0 C--O 1.243 0.717 0 CA-C-O 121.541 0.686 . . . . 0.0 112.243 -178.708 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.508 ' SD ' ' N ' ' J' ' 32' ' ' ILE . 13.5 ttm -102.86 113.6 27.18 Favored 'General case' 0 CA--C 1.505 -0.754 0 N-CA-C 107.146 -1.427 . . . . 0.0 107.146 175.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.01 72.85 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.739 0 CA-C-N 116.193 -0.458 . . . . 0.0 109.809 -179.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.14 111.53 3.86 Favored Glycine 0 C--N 1.357 1.718 0 N-CA-C 110.706 -0.958 . . . . 0.0 110.706 178.91 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . -139.73 135.47 7.22 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 55.6 t -124.27 135.95 62.04 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 120.797 0.332 . . . . 0.0 110.309 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 48.5 t . . . . . 0 C--O 1.219 -0.549 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.588 179.914 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 97.2 m-85 -111.49 148.25 33.56 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-O 120.788 0.328 . . . . 0.0 110.237 179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . 0.591 ' O ' HG22 ' D' ' 12' ' ' VAL . 59.9 mm-40 -57.45 136.36 56.65 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.296 -0.411 . . . . 0.0 109.951 -179.94 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . 0.507 HG23 ' O ' ' D' ' 11' ' ' GLU . 2.7 p -135.33 142.86 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.46 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 -179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 45.7 m-70 -109.85 -178.89 3.65 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-N 118.179 0.445 . . . . 0.0 110.959 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CD2' ' F' ' 13' ' ' HIS . 93.8 m-70 -142.41 -178.66 5.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-O 121.751 0.786 . . . . 0.0 110.149 -179.078 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 40.2 mt-30 -88.46 168.0 12.99 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.661 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 99.7 mttt -141.42 143.38 33.88 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.273 179.607 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.529 HD13 ' CD2' ' F' ' 17' ' ' LEU . 5.2 mp -131.22 124.35 30.4 Favored 'General case' 0 N--CA 1.471 0.599 0 CA-C-O 121.146 0.498 . . . . 0.0 111.671 -178.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 65.1 t -128.3 129.39 69.15 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.854 -179.929 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.438 ' HZ ' HD23 ' C' ' 34' ' ' LEU . 35.9 m-85 -117.99 120.85 39.05 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 177.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -128.59 127.66 42.71 Favored 'General case' 0 N--CA 1.476 0.864 0 CA-C-N 117.927 0.331 . . . . 0.0 111.124 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -131.3 131.55 43.89 Favored 'General case' 0 N--CA 1.472 0.666 0 CA-C-O 122.381 1.086 . . . . 0.0 113.058 -179.032 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -138.27 85.73 2.11 Favored 'General case' 0 CA--C 1.532 0.28 0 CA-C-N 115.096 -0.956 . . . . 0.0 111.069 178.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -93.97 -130.71 0.14 Allowed 'General case' 0 CA--C 1.511 -0.521 0 N-CA-C 105.0 -2.222 . . . . 0.0 105.0 176.415 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.497 HG23 ' H ' ' D' ' 25' ' ' GLY . 82.9 t -106.2 112.32 38.9 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.941 0 N-CA-C 104.747 -2.316 . . . . 0.0 104.747 175.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 31.76 88.08 0.01 OUTLIER Glycine 0 CA--C 1.531 1.048 0 CA-C-N 113.904 -1.498 . . . . 0.0 112.977 -179.874 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.509 ' N ' ' HB2' ' F' ' 23' ' ' ASP . 35.3 p -128.24 141.51 51.43 Favored 'General case' 0 C--N 1.35 0.597 0 CA-C-N 119.262 1.531 . . . . 0.0 108.718 173.992 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.841 ' ND2' ' H ' ' E' ' 28' ' ' LYS . 1.8 t-20 -58.21 178.91 0.08 Allowed 'General case' 0 C--N 1.304 -1.377 0 N-CA-C 114.479 1.289 . . . . 0.0 114.479 178.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.841 ' H ' ' ND2' ' E' ' 27' ' ' ASN . 98.1 mttt -50.19 -105.24 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.968 0 CA-C-N 111.528 -2.578 . . . . 0.0 105.626 168.109 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.846 ' O ' ' HB1' ' F' ' 30' ' ' ALA . . . -80.9 99.26 1.88 Allowed Glycine 0 CA--C 1.476 -2.396 0 CA-C-N 113.611 -1.631 . . . . 0.0 110.88 179.731 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.644 ' O ' ' C ' ' E' ' 29' ' ' GLY . . . -76.38 -136.84 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.886 1 N-CA-C 93.028 -6.656 . . . . 0.0 93.028 168.326 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.642 ' CD1' ' N ' ' E' ' 31' ' ' ILE . 0.5 OUTLIER -85.09 114.91 26.0 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.194 1 CA-C-N 127.789 4.813 . . . . 0.0 109.163 176.935 . . . . . . . . 4 4 . 1 . 008 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.467 ' C ' ' SD ' ' K' ' 35' ' ' MET . 16.1 tt -136.69 134.94 48.91 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.798 0 CA-C-O 121.719 0.771 . . . . 0.0 112.452 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.703 ' N ' ' SD ' ' K' ' 35' ' ' MET . . . -131.9 127.36 4.95 Favored Glycine 0 C--N 1.336 0.582 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.914 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.512 HD13 ' CE1' ' F' ' 19' ' ' PHE . 23.9 tp -121.03 124.26 44.41 Favored 'General case' 0 C--O 1.234 0.283 0 CA-C-N 115.637 -0.282 . . . . 0.0 111.679 -178.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 3.1 tpp -115.99 114.6 24.82 Favored 'General case' 0 N--CA 1.471 0.604 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 177.622 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . . . . . . . . . 3.9 t -113.86 88.51 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 C-N-CA 120.769 -0.372 . . . . 0.0 111.62 -178.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.58 95.62 0.39 Allowed Glycine 0 N--CA 1.443 -0.868 0 C-N-CA 119.67 -1.253 . . . . 0.0 110.342 178.154 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -159.28 162.56 32.86 Favored Glycine 0 CA--C 1.52 0.377 0 N-CA-C 110.83 -0.908 . . . . 0.0 110.83 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 35.5 m -136.56 162.77 34.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 N-CA-C 110.087 -0.338 . . . . 0.0 110.087 179.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 13.3 m . . . . . 0 C--O 1.221 -0.405 0 CA-C-O 117.939 -1.029 . . . . 0.0 110.311 179.908 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.302 0 N-CA-C 109.559 -1.416 . . . . 0.0 109.559 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 23.6 p90 -148.26 159.59 43.82 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.016 0.436 . . . . 0.0 111.256 -179.94 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 -67.25 137.9 56.5 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 116.033 -0.53 . . . . 0.0 110.985 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 26.8 m -127.16 132.38 69.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.425 0 CA-C-O 121.326 0.584 . . . . 0.0 110.999 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.631 ' CD2' ' NE2' ' E' ' 14' ' ' HIS . 27.2 t-80 -156.07 100.95 2.06 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.888 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 95.0 m-70 -147.23 173.3 12.68 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 89.0 mt-30 -145.03 174.65 10.85 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.792 -0.64 . . . . 0.0 109.319 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -145.99 112.71 5.98 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.924 0.392 . . . . 0.0 111.032 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.529 ' CD2' HD13 ' E' ' 17' ' ' LEU . 35.8 mt -125.07 110.2 13.86 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 107.214 -1.402 . . . . 0.0 107.214 177.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 30.1 m -145.93 147.12 18.65 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 118.682 -1.207 . . . . 0.0 114.244 -178.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.512 ' CE1' HD13 ' E' ' 34' ' ' LEU . 73.0 m-85 -126.7 128.3 46.48 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 113.967 -1.469 . . . . 0.0 108.431 177.822 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 m-85 -138.36 146.48 42.35 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.12 0.486 . . . . 0.0 111.458 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -144.55 146.48 32.39 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 115.932 -0.576 . . . . 0.0 109.956 179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 41.4 tt0 -88.07 127.47 35.4 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 113.006 0.743 . . . . 0.0 113.006 -177.866 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.509 ' HB2' ' N ' ' E' ' 26' ' ' SER . 67.1 t0 178.1 114.36 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 179.807 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . . . . . . . . . 79.6 t -65.39 132.44 31.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.359 0 N-CA-C 108.539 -0.912 . . . . 0.0 108.539 178.173 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.551 ' O ' ' CB ' ' F' ' 26' ' ' SER . . . 71.68 -85.08 0.45 Allowed Glycine 0 N--CA 1.47 0.958 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 -176.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . 0.551 ' CB ' ' O ' ' F' ' 25' ' ' GLY . 2.8 t 140.23 165.4 0.0 OUTLIER 'General case' 0 C--N 1.352 0.703 0 CA-C-O 122.577 1.18 . . . . 0.0 112.905 174.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.573 ' CG ' ' H ' ' E' ' 27' ' ' ASN . 0.5 OUTLIER -46.48 171.93 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 112.598 -2.092 . . . . 0.0 112.44 175.535 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -69.93 111.53 5.71 Favored 'General case' 0 N--CA 1.446 -0.627 0 N-CA-C 106.19 -1.782 . . . . 0.0 106.19 170.31 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.442 ' O ' ' HB3' ' F' ' 30' ' ' ALA . . . 75.88 -92.88 0.93 Allowed Glycine 0 N--CA 1.475 1.257 0 C-N-CA 120.424 -0.893 . . . . 0.0 112.861 179.07 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.846 ' HB1' ' O ' ' E' ' 29' ' ' GLY . . . 83.38 160.28 0.12 Allowed 'General case' 0 CA--C 1.513 -0.479 0 N-CA-C 100.439 -3.911 . . . . 0.0 100.439 -174.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.5 ' CG1' ' C ' ' F' ' 30' ' ' ALA . 0.2 OUTLIER -151.67 127.87 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.761 0 CA-C-N 122.45 2.386 . . . . 0.0 111.039 -176.286 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 86.2 mt -121.43 132.77 69.88 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.647 0 CA-C-N 114.151 -1.386 . . . . 0.0 114.254 -175.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . 0.608 ' N ' ' SD ' ' L' ' 35' ' ' MET . . . -130.22 115.12 1.78 Allowed Glycine 0 N--CA 1.475 1.234 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 175.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 19.3 mt -118.45 127.49 53.71 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.534 ' CE ' HG22 ' L' ' 31' ' ' ILE . 1.8 ttt -132.09 126.7 34.41 Favored 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 120.13 -0.628 . . . . 0.0 111.539 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . . . . . . . . . 5.4 t -143.33 82.52 0.23 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.532 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.442 -179.599 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.666 ' HA3' HD13 ' L' ' 31' ' ' ILE . . . -51.23 100.37 0.04 OUTLIER Glycine 0 C--N 1.337 0.61 0 C-N-CA 119.423 -1.37 . . . . 0.0 110.674 -179.209 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -164.11 163.09 35.76 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 53.7 t -121.45 132.94 69.5 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.479 0 CA-C-O 120.924 0.393 . . . . 0.0 110.315 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.3 t . . . . . 0 C--O 1.22 -0.482 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.897 -179.566 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.386 0 N-CA-C 109.462 -1.455 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -105.63 129.36 53.89 Favored 'General case' 0 N--CA 1.466 0.326 0 N-CA-C 110.098 -0.334 . . . . 0.0 110.098 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 50.3 tp10 -147.29 147.73 30.69 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-O 121.126 0.488 . . . . 0.0 110.475 -179.791 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 33.6 m -133.85 163.48 37.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.705 -0.68 . . . . 0.0 109.239 179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 65.1 t60 -157.71 149.02 21.52 Favored 'General case' 0 C--N 1.325 -0.475 0 C-N-CA 120.64 -0.424 . . . . 0.0 110.675 179.588 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.545 ' CG ' ' N ' ' G' ' 15' ' ' GLN . 14.8 t60 -147.84 163.56 36.38 Favored 'General case' 0 N--CA 1.447 -0.598 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 179.555 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . 0.545 ' N ' ' CG ' ' G' ' 14' ' ' HIS . 85.3 mt-30 -151.64 178.17 9.61 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.326 0.584 . . . . 0.0 110.871 179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 25.5 pttm -167.72 133.57 2.02 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.024 -0.989 . . . . 0.0 109.266 179.262 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 73.8 mt -133.57 125.05 28.0 Favored 'General case' 0 C--N 1.332 -0.176 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 -179.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.1 p -134.95 138.14 49.55 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.248 -179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -134.77 137.25 43.24 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.491 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . 0.483 ' O ' ' CD1' ' G' ' 20' ' ' PHE . 54.3 p90 -135.18 129.05 33.16 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 108.834 -0.802 . . . . 0.0 108.834 179.142 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -126.38 134.75 50.96 Favored 'General case' 0 N--CA 1.478 0.949 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -178.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 82.3 tt0 -157.21 124.66 5.28 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.773 -0.648 . . . . 0.0 110.359 179.252 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.558 ' O ' ' O ' ' G' ' 24' ' ' VAL . 12.0 m-20 -154.13 122.71 6.21 Favored 'General case' 0 N--CA 1.463 0.189 0 C-N-CA 120.827 -0.349 . . . . 0.0 111.849 -179.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.558 ' O ' ' O ' ' G' ' 23' ' ' ASP . 11.8 m -43.67 -122.1 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 O-C-N 124.273 0.983 . . . . 0.0 111.621 178.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 80.49 -90.79 1.35 Allowed Glycine 0 CA--C 1.528 0.886 0 CA-C-O 119.52 -0.6 . . . . 0.0 113.023 -179.583 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.686 ' O ' ' O ' ' G' ' 27' ' ' ASN . 1.3 p 173.76 -170.58 0.04 OUTLIER 'General case' 0 CA--C 1.513 -0.448 0 CA-C-N 117.587 0.694 . . . . 0.0 109.625 -177.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.686 ' O ' ' O ' ' G' ' 26' ' ' SER . 16.4 t-20 -16.98 158.51 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.093 0 O-C-N 125.149 1.53 . . . . 0.0 113.49 -178.192 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.531 ' N ' ' OD1' ' G' ' 27' ' ' ASN . 28.6 tttt -161.56 108.54 1.4 Allowed 'General case' 0 CA--C 1.542 0.669 0 N-CA-C 113.754 1.02 . . . . 0.0 113.754 179.146 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . -70.58 98.1 0.66 Allowed Glycine 0 N--CA 1.467 0.746 0 CA-C-O 116.221 -2.433 . . . . 0.0 107.935 172.804 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.406 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -90.08 154.24 19.95 Favored 'General case' 0 C--N 1.354 0.786 0 CA-C-N 123.627 3.714 . . . . 0.0 110.552 -176.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.4 ' HB ' ' SD ' ' A' ' 35' ' ' MET . 0.3 OUTLIER -153.82 114.55 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 CA-C-N 112.528 -2.124 . . . . 0.0 109.75 -173.626 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.437 ' O ' ' CG2' ' G' ' 32' ' ' ILE . 6.0 tt -122.78 113.79 39.61 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.438 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 176.355 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' H' ' 33' ' ' GLY . . . -132.68 137.61 9.52 Favored Glycine 0 CA--C 1.502 -0.731 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -179.123 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . . . . . . . . . 5.4 tp -153.26 146.81 25.01 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 122.447 1.117 . . . . 0.0 112.024 -179.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.402 ' CE ' ' O ' ' A' ' 31' ' ' ILE . 31.0 mtp -105.19 119.15 38.34 Favored 'General case' 0 N--CA 1.442 -0.874 0 CA-C-N 113.257 -1.792 . . . . 0.0 107.878 178.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -111.76 65.72 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.559 1.297 0 C-N-CA 119.743 -0.783 . . . . 0.0 109.283 178.912 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.95 102.42 0.56 Allowed Glycine 0 C--N 1.376 2.754 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 178.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 177.08 170.3 39.35 Favored Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.619 -0.992 . . . . 0.0 110.619 179.982 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 6.6 m -139.73 142.94 31.44 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.93 0.395 . . . . 0.0 110.258 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 21.1 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.022 -0.99 . . . . 0.0 110.736 -179.863 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.533 -1.427 . . . . 0.0 109.533 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.2 m-85 -83.63 136.41 34.23 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.979 0.419 . . . . 0.0 110.414 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -80.45 164.48 23.0 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.83 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . 0.405 HG13 ' CG2' ' I' ' 12' ' ' VAL . 54.3 t -86.9 132.57 32.07 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.838 179.83 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.904 ' HD1' ' CD2' ' I' ' 13' ' ' HIS . 40.7 m80 -137.18 145.78 44.13 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.953 0.406 . . . . 0.0 111.396 -178.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.531 ' O ' ' NE2' ' H' ' 15' ' ' GLN . 99.1 m-70 -147.09 155.96 42.61 Favored 'General case' 0 N--CA 1.447 -0.608 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 177.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' H' ' 14' ' ' HIS . 99.4 mm-40 -148.73 168.29 23.3 Favored 'General case' 0 C--N 1.319 -0.718 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.41 178.716 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 97.3 mttt -163.6 128.63 2.96 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.46 -0.791 . . . . 0.0 108.983 178.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . 0.597 ' C ' HD23 ' H' ' 17' ' ' LEU . 5.6 tt -127.46 118.11 23.4 Favored 'General case' 0 N--CA 1.471 0.614 0 N-CA-C 109.268 -0.641 . . . . 0.0 109.268 178.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.58 ' N ' HD23 ' H' ' 17' ' ' LEU . 72.8 t -122.2 129.48 75.31 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.468 0 CA-C-N 116.85 -0.159 . . . . 0.0 111.202 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 81.7 t80 -126.25 122.87 36.78 Favored 'General case' 0 N--CA 1.471 0.585 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 178.489 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . . . . . . . . . 39.3 t80 -126.84 127.66 45.33 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 120.702 0.286 . . . . 0.0 111.374 -179.312 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.36 125.61 50.38 Favored 'General case' 0 N--CA 1.475 0.806 0 CA-C-O 120.981 0.42 . . . . 0.0 111.525 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.427 ' OE1' ' O ' ' I' ' 22' ' ' GLU . 52.7 tp10 -132.67 157.4 44.94 Favored 'General case' 0 N--CA 1.468 0.474 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.664 -179.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -158.64 142.03 14.98 Favored 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 21.4 t -91.42 112.72 25.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.658 0 CA-C-O 122.344 1.068 . . . . 0.0 110.391 -177.878 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . 0.641 ' H ' ' CG1' ' I' ' 24' ' ' VAL . . . 41.1 86.92 0.01 OUTLIER Glycine 0 CA--C 1.521 0.417 0 CA-C-N 113.177 -1.828 . . . . 0.0 114.122 179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.769 ' O ' ' O ' ' H' ' 27' ' ' ASN . 82.9 p -152.94 170.95 19.14 Favored 'General case' 0 N--CA 1.445 -0.704 0 C-N-CA 120.105 -0.638 . . . . 0.0 109.673 175.022 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.769 ' O ' ' O ' ' H' ' 26' ' ' SER . 63.3 t30 -19.67 -173.71 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.167 0 O-C-N 125.293 1.621 . . . . 0.0 115.293 175.168 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.556 ' HZ1' ' HE3' ' I' ' 28' ' ' LYS . 15.2 mmtt -138.12 -104.64 0.18 Allowed 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 115.14 -0.936 . . . . 0.0 108.995 174.927 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 40.61 95.3 0.01 OUTLIER Glycine 0 N--CA 1.475 1.238 0 C-N-CA 120.239 -0.981 . . . . 0.0 110.749 179.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -129.11 145.41 51.29 Favored 'General case' 0 CA--C 1.497 -1.082 0 CA-C-O 123.279 1.514 . . . . 0.0 107.546 -179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.554 ' CG2' HD12 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -140.03 121.21 14.91 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.205 0 CA-C-N 112.404 -2.18 . . . . 0.0 110.529 -173.474 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.513 ' N ' ' SD ' ' B' ' 35' ' ' MET . 8.7 tt -111.33 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.36 1.063 0 CA-C-O 121.613 0.72 . . . . 0.0 110.112 179.559 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.415 ' O ' ' HA2' ' G' ' 33' ' ' GLY . . . -112.37 94.85 0.76 Allowed Glycine 0 N--CA 1.461 0.366 0 N-CA-C 108.195 -1.962 . . . . 0.0 108.195 179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.653 ' O ' HD12 ' I' ' 34' ' ' LEU . 35.6 mt -117.0 129.25 55.9 Favored 'General case' 0 CA--C 1.509 -0.628 0 CA-C-O 122.273 1.035 . . . . 0.0 111.551 -178.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.629 ' SD ' ' N ' ' B' ' 33' ' ' GLY . 21.9 ttp -116.27 115.52 26.1 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-N 114.221 -1.354 . . . . 0.0 108.312 178.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -119.89 71.15 0.37 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.897 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 -178.738 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -75.61 112.41 3.61 Favored Glycine 0 C--N 1.35 1.333 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -50.64 152.52 4.55 Favored Glycine 0 CA--C 1.525 0.685 0 N-CA-C 110.754 -0.938 . . . . 0.0 110.754 -179.687 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 27.4 m -136.84 162.02 35.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-O 120.837 0.351 . . . . 0.0 110.922 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 4.9 m . . . . . 0 C--O 1.22 -0.49 0 CA-C-O 117.985 -1.007 . . . . 0.0 110.297 179.901 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.323 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -103.29 125.89 50.17 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.666 0.269 . . . . 0.0 110.336 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -88.12 121.9 31.06 Favored 'General case' 0 C--O 1.236 0.391 0 N-CA-C 109.589 -0.522 . . . . 0.0 109.589 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.405 ' CG2' HG13 ' H' ' 12' ' ' VAL . 16.3 m -137.8 161.7 32.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-O 121.553 0.692 . . . . 0.0 111.757 -179.164 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.904 ' CD2' ' HD1' ' H' ' 13' ' ' HIS . 71.2 m80 -150.07 101.85 3.05 Favored 'General case' 0 C--O 1.233 0.185 0 CA-C-N 114.689 -1.141 . . . . 0.0 109.134 178.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.546 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 84.9 t60 -121.23 162.91 19.39 Favored 'General case' 0 CA--C 1.514 -0.404 0 CA-C-O 121.853 0.835 . . . . 0.0 111.376 -178.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.546 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 84.3 mt-30 -148.47 177.73 9.21 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.098 179.369 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -171.01 125.28 0.66 Allowed 'General case' 0 C--O 1.234 0.278 0 N-CA-C 109.797 -0.446 . . . . 0.0 109.797 179.995 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 56.4 mt -126.71 123.34 37.28 Favored 'General case' 0 N--CA 1.475 0.812 0 N-CA-C 109.63 -0.507 . . . . 0.0 109.63 179.095 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' J' ' 18' ' ' VAL . 12.6 p -136.41 133.32 49.44 Favored 'Isoleucine or valine' 0 C--N 1.351 0.663 0 N-CA-C 113.987 1.106 . . . . 0.0 113.987 -179.517 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -115.68 126.06 53.63 Favored 'General case' 0 CA--C 1.542 0.659 0 CA-C-N 114.72 -1.127 . . . . 0.0 108.649 177.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 1.8 t80 -129.38 121.85 28.26 Favored 'General case' 0 N--CA 1.48 1.051 0 CA-C-N 118.327 0.512 . . . . 0.0 111.03 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.31 128.46 51.08 Favored 'General case' 0 N--CA 1.475 0.805 0 CA-C-O 121.077 0.465 . . . . 0.0 111.224 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . 0.427 ' O ' ' OE1' ' H' ' 22' ' ' GLU . 82.1 tt0 -149.02 124.67 10.43 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.311 -179.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 53.6 t0 -157.11 103.97 2.05 Favored 'General case' 0 CA--C 1.542 0.668 0 C-N-CA 118.909 -1.116 . . . . 0.0 113.799 179.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.641 ' CG1' ' H ' ' H' ' 25' ' ' GLY . 2.2 p -31.78 147.67 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 CA-C-N 114.525 -1.216 . . . . 0.0 113.07 175.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.4 ' O ' ' CB ' ' I' ' 26' ' ' SER . . . 168.52 -79.42 0.1 Allowed Glycine 0 CA--C 1.535 1.315 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.282 178.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 1.001 ' O ' ' O ' ' I' ' 27' ' ' ASN . 2.1 p 161.66 179.86 0.01 OUTLIER 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 106.306 -1.738 . . . . 0.0 106.306 -179.957 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 1.001 ' O ' ' O ' ' I' ' 26' ' ' SER . 8.2 m120 10.52 -178.74 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.112 0 O-C-N 124.841 1.338 . . . . 0.0 113.251 -179.257 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.556 ' HE3' ' HZ1' ' H' ' 28' ' ' LYS . 12.7 tttt -149.15 109.77 4.24 Favored 'General case' 0 N--CA 1.471 0.58 0 C-N-CA 116.202 -2.199 . . . . 0.0 114.646 177.625 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . . . . . . . . . . . -73.96 94.65 0.79 Allowed Glycine 0 CA--C 1.49 -1.475 0 N-CA-C 106.248 -2.741 . . . . 0.0 106.248 168.194 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . . . . . . . . . . . -127.43 144.4 51.06 Favored 'General case' 0 CA--C 1.476 -1.882 0 CA-C-N 122.543 3.171 . . . . 0.0 107.094 177.714 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.793 HG22 ' SD ' ' C' ' 35' ' ' MET . 0.0 OUTLIER -144.15 125.24 9.51 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.16 0 CA-C-N 113.09 -1.868 . . . . 0.0 109.504 -175.189 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.543 ' N ' ' SD ' ' C' ' 35' ' ' MET . 0.8 OUTLIER -105.22 110.76 32.02 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.81 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.064 179.583 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.69 101.73 1.24 Allowed Glycine 0 CA--C 1.494 -1.243 0 N-CA-C 104.817 -3.313 . . . . 0.0 104.817 175.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.653 HD12 ' O ' ' H' ' 34' ' ' LEU . 17.0 tp -136.82 137.55 39.88 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-O 122.11 0.957 . . . . 0.0 112.508 -175.085 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.499 ' SD ' ' N ' ' C' ' 33' ' ' GLY . 31.1 ttp -122.86 123.42 40.94 Favored 'General case' 0 CA--C 1.509 -0.6 0 CA-C-N 113.74 -1.573 . . . . 0.0 110.164 178.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.559 ' CG2' HD11 ' J' ' 34' ' ' LEU . 0.1 OUTLIER -126.35 71.56 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 178.826 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -68.84 113.1 5.03 Favored Glycine 0 C--N 1.358 1.779 0 N-CA-C 110.531 -1.027 . . . . 0.0 110.531 178.979 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.16 147.81 41.66 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.822 -0.911 . . . . 0.0 110.822 179.972 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 64.3 t -130.87 137.29 56.3 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.427 0 N-CA-C 110.104 -0.332 . . . . 0.0 110.104 179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . 0.402 HG23 ' O ' ' I' ' 40' ' ' VAL . 30.4 m . . . . . 0 C--O 1.22 -0.455 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.44 179.815 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.379 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 91.4 m-85 -82.96 138.94 33.6 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 120.846 0.355 . . . . 0.0 110.362 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -81.28 135.22 35.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.642 -179.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.0 p -139.19 144.97 28.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.686 0 CA-C-N 116.348 -0.387 . . . . 0.0 109.998 -179.837 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.513 ' CD2' ' N ' ' J' ' 13' ' ' HIS . 0.9 OUTLIER -131.31 155.98 46.25 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-O 121.19 0.519 . . . . 0.0 110.943 179.758 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -152.4 160.18 43.32 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.134 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 73.6 mt-30 -154.67 172.25 18.2 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 120.219 -0.592 . . . . 0.0 110.634 178.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -155.75 127.96 7.65 Favored 'General case' 0 C--O 1.239 0.503 0 CA-C-N 115.059 -0.973 . . . . 0.0 108.747 178.527 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . 0.427 HD12 HD11 ' K' ' 17' ' ' LEU . 87.4 mt -120.47 120.12 34.98 Favored 'General case' 0 C--O 1.237 0.44 0 N-CA-C 108.192 -1.04 . . . . 0.0 108.192 178.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' I' ' 18' ' ' VAL . 2.0 p -143.06 137.92 26.78 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.272 0 N-CA-C 113.447 0.906 . . . . 0.0 113.447 -177.898 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -147.83 127.9 13.7 Favored 'General case' 0 N--CA 1.472 0.651 0 C-N-CA 119.684 -0.806 . . . . 0.0 111.403 176.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . . . . . . . . . 43.2 p90 -147.77 160.82 42.31 Favored 'General case' 0 C--O 1.241 0.639 0 CA-C-O 122.443 1.116 . . . . 0.0 113.752 -178.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.96 140.17 43.76 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-N 113.934 -1.484 . . . . 0.0 109.946 179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -142.17 149.44 39.74 Favored 'General case' 0 N--CA 1.469 0.515 0 C-N-CA 120.395 -0.522 . . . . 0.0 111.968 -178.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.428 ' O ' ' OD1' ' K' ' 23' ' ' ASP . 33.7 t70 -173.49 126.46 0.41 Allowed 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.08 0.467 . . . . 0.0 111.293 179.125 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.444 HG22 ' H ' ' J' ' 24' ' ' VAL . 5.4 m -62.61 -116.0 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.516 179.778 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . 60.47 -92.22 0.06 OUTLIER Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.45 -0.795 . . . . 0.0 112.603 -178.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.831 ' O ' ' O ' ' J' ' 27' ' ' ASN . 9.3 t -171.24 170.05 6.17 Favored 'General case' 0 N--CA 1.445 -0.684 0 CA-C-N 117.535 0.668 . . . . 0.0 109.986 179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.831 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.8 m120 10.85 -179.16 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.497 0 O-C-N 125.763 1.914 . . . . 0.0 115.567 -179.941 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.595 ' H ' ' N ' ' K' ' 27' ' ' ASN . 15.8 pttt -149.4 110.76 4.44 Favored 'General case' 0 CA--C 1.558 1.25 0 O-C-N 120.635 -1.29 . . . . 0.0 114.284 178.263 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.497 ' N ' ' O ' ' I' ' 28' ' ' LYS . . . -61.48 93.22 0.07 OUTLIER Glycine 0 N--CA 1.479 1.517 0 N-CA-C 106.869 -2.492 . . . . 0.0 106.869 172.077 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.487 ' HB2' ' HG3' ' J' ' 28' ' ' LYS . . . -126.39 149.33 49.3 Favored 'General case' 0 CA--C 1.486 -1.489 0 CA-C-N 121.677 2.739 . . . . 0.0 111.069 -178.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.736 HG13 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -148.33 114.42 0.85 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.816 0 CA-C-N 108.989 -3.732 . . . . 0.0 107.612 -174.968 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.508 ' N ' ' SD ' ' D' ' 35' ' ' MET . 3.1 mt -105.56 118.74 53.6 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.203 0 CA-C-O 120.749 0.309 . . . . 0.0 110.429 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.96 100.78 0.91 Allowed Glycine 0 C--O 1.239 0.421 0 N-CA-C 106.9 -2.48 . . . . 0.0 106.9 176.618 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.627 ' CD2' ' CE1' ' L' ' 19' ' ' PHE . 55.7 tp -129.58 135.39 48.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 CA-C-O 122.003 0.906 . . . . 0.0 112.415 -177.39 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.418 ' SD ' ' C ' ' D' ' 31' ' ' ILE . 48.9 ttp -117.87 117.07 28.28 Favored 'General case' 0 CA--C 1.502 -0.881 0 CA-C-N 113.812 -1.54 . . . . 0.0 108.55 175.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.506 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -120.26 72.2 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.945 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 178.608 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -63.51 111.87 4.5 Favored Glycine 0 C--N 1.36 1.861 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 178.503 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -75.36 -151.58 3.07 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 -179.199 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 29.9 m -133.26 158.07 42.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-O 121.097 0.475 . . . . 0.0 110.74 179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . 0.422 ' H ' HG12 ' J' ' 40' ' ' VAL . 4.3 p . . . . . 0 C--O 1.221 -0.424 0 CA-C-O 117.882 -1.056 . . . . 0.0 110.626 -179.852 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -97.48 131.37 44.17 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.797 0.332 . . . . 0.0 110.144 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 79.5 mm-40 -97.21 148.06 23.47 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.702 -179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 19.5 m -118.88 126.66 75.5 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.47 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.099 179.466 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . 0.631 ' CE1' ' NE2' ' L' ' 14' ' ' HIS . 1.8 p80 -161.7 168.87 22.56 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.343 -0.389 . . . . 0.0 111.475 -179.319 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.537 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 39.4 t-80 -138.71 165.67 26.36 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-O 121.548 0.69 . . . . 0.0 110.901 -179.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.537 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 87.4 mt-30 -148.42 178.69 8.38 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 114.966 -1.015 . . . . 0.0 110.091 -179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . 0.433 ' C ' HD12 ' K' ' 17' ' ' LEU . 38.2 ttmt -172.76 123.41 0.44 Allowed 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 118.419 -0.8 . . . . 0.0 111.45 -178.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . 0.943 ' O ' ' C ' ' L' ' 17' ' ' LEU . 9.4 mp -110.73 119.07 37.92 Favored 'General case' 0 C--N 1.379 1.85 0 CA-C-O 123.836 1.779 . . . . 0.0 111.111 177.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' L' ' 18' ' ' VAL . 7.1 p -138.25 112.07 7.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.256 0 O-C-N 120.675 -1.266 . . . . 0.0 111.432 -179.764 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.578 ' CZ ' ' CD2' ' I' ' 34' ' ' LEU . 1.7 p90 -134.51 139.62 45.59 Favored 'General case' 0 N--CA 1.472 0.644 0 N-CA-C 108.976 -0.75 . . . . 0.0 108.976 176.383 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.47 ' CB ' ' O ' ' L' ' 20' ' ' PHE . 30.3 p90 -154.77 162.9 40.94 Favored 'General case' 0 N--CA 1.467 0.376 0 N-CA-C 115.134 1.531 . . . . 0.0 115.134 -176.553 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -128.35 130.61 48.0 Favored 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.19 -1.368 . . . . 0.0 109.412 178.628 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 97.5 mt-10 -129.31 137.13 50.83 Favored 'General case' 0 N--CA 1.474 0.744 0 CA-C-O 121.158 0.504 . . . . 0.0 111.965 -178.781 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.428 ' OD1' ' O ' ' J' ' 23' ' ' ASP . 56.6 t0 -159.56 -121.01 0.02 OUTLIER 'General case' 0 CA--C 1.534 0.365 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.323 178.96 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.619 ' O ' ' N ' ' K' ' 26' ' ' SER . 55.9 t -123.88 123.02 66.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.896 0 N-CA-C 107.443 -1.318 . . . . 0.0 107.443 179.047 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.476 ' O ' ' CB ' ' K' ' 26' ' ' SER . . . 32.0 -84.35 0.0 OUTLIER Glycine 0 N--CA 1.483 1.783 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 -179.52 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.619 ' N ' ' O ' ' K' ' 24' ' ' VAL . 8.1 t 154.31 172.0 0.01 OUTLIER 'General case' 0 N--CA 1.45 -0.453 0 CA-C-O 121.748 0.785 . . . . 0.0 111.235 174.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.595 ' N ' ' H ' ' J' ' 28' ' ' LYS . 43.1 p-10 -53.63 179.94 0.02 OUTLIER 'General case' 0 C--N 1.319 -0.752 0 CA-C-N 114.137 -1.392 . . . . 0.0 111.43 176.094 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.72 112.09 1.88 Allowed 'General case' 0 N--CA 1.448 -0.574 0 N-CA-C 107.343 -1.355 . . . . 0.0 107.343 176.176 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.617 ' O ' ' HB2' ' L' ' 30' ' ' ALA . . . 75.4 -91.74 0.85 Allowed Glycine 0 CA--C 1.532 1.145 0 C-N-CA 121.285 -0.483 . . . . 0.0 112.083 -178.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.519 ' C ' HD13 ' K' ' 31' ' ' ILE . . . 106.48 161.13 0.0 OUTLIER 'General case' 0 CA--C 1.504 -0.818 0 N-CA-C 104.562 -2.384 . . . . 0.0 104.562 -178.436 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.519 HD13 ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -144.88 132.15 16.07 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 C-N-CA 118.027 -1.469 . . . . 0.0 112.796 -178.269 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 95.5 mt -124.42 123.68 66.8 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.34 0 CA-C-N 114.642 -1.163 . . . . 0.0 111.3 -179.29 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . . . . . . . . . . . -118.95 114.93 2.94 Favored Glycine 0 N--CA 1.473 1.126 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 179.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 46.0 mt -122.42 127.31 49.51 Favored 'General case' 0 C--O 1.238 0.482 0 N-CA-C 111.753 0.279 . . . . 0.0 111.753 -179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.703 ' SD ' ' N ' ' E' ' 33' ' ' GLY . 56.8 ttp -119.83 121.29 38.77 Favored 'General case' 0 N--CA 1.475 0.812 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.234 177.758 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.506 HG22 HG23 ' J' ' 36' ' ' VAL . 60.0 t -115.4 88.17 1.12 Allowed 'Isoleucine or valine' 0 N--CA 1.473 0.678 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.333 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . . . . . . . . . . . -73.23 96.06 0.78 Allowed Glycine 0 CA--C 1.526 0.773 0 N-CA-C 111.219 -0.752 . . . . 0.0 111.219 179.062 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -156.85 162.19 31.51 Favored Glycine 0 CA--C 1.527 0.808 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -124.9 137.05 58.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.77 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 23.3 m . . . . . 0 C--O 1.219 -0.52 0 CA-C-O 117.981 -1.009 . . . . 0.0 110.448 -179.564 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 109.581 -1.407 . . . . 0.0 109.581 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 52.7 t80 -82.05 131.19 35.24 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 120.853 0.359 . . . . 0.0 110.406 179.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -77.93 155.0 31.13 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.098 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 22.2 t -110.39 131.81 60.46 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.413 0 CA-C-O 121.116 0.484 . . . . 0.0 110.368 -179.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 94.8 m-70 -99.45 176.79 5.38 Favored 'General case' 0 N--CA 1.462 0.158 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.276 -179.702 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . 0.631 ' NE2' ' CE1' ' K' ' 13' ' ' HIS . 0.4 OUTLIER -92.36 165.76 12.91 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-O 121.302 0.573 . . . . 0.0 110.04 -179.614 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 66.6 tp60 -168.19 168.58 11.54 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 115.054 -0.976 . . . . 0.0 108.548 178.496 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -154.52 108.71 2.98 Favored 'General case' 0 C--O 1.171 -3.049 0 N-CA-C 109.089 -0.708 . . . . 0.0 109.089 179.17 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . 0.943 ' C ' ' O ' ' K' ' 17' ' ' LEU . 2.7 mm? -73.09 160.73 31.56 Favored 'General case' 0 C--N 1.305 -1.329 0 O-C-N 119.654 -1.903 . . . . 0.0 107.622 176.138 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . 0.529 ' O ' ' HA ' ' K' ' 18' ' ' VAL . 14.3 m -99.89 -121.06 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.898 0 N-CA-C 114.021 1.119 . . . . 0.0 114.021 -173.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.627 ' CE1' ' CD2' ' J' ' 34' ' ' LEU . 7.7 p90 -147.6 162.11 39.78 Favored 'General case' 0 N--CA 1.47 0.551 0 O-C-N 121.618 -0.676 . . . . 0.0 112.588 -177.178 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.47 ' O ' ' CB ' ' K' ' 20' ' ' PHE . 93.6 m-85 -144.72 151.48 38.96 Favored 'General case' 0 N--CA 1.474 0.728 0 CA-C-O 121.718 0.77 . . . . 0.0 112.087 179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.64 138.27 39.3 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -69.79 95.08 0.87 Allowed 'General case' 0 C--N 1.328 -0.334 0 C-N-CA 120.0 -0.68 . . . . 0.0 110.128 -178.657 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . . . . . . . . . 5.0 t0 -164.06 121.57 1.75 Allowed 'General case' 0 CA--C 1.532 0.262 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.589 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' L' ' 26' ' ' SER . 13.5 t -88.53 123.56 40.98 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 116.429 -0.35 . . . . 0.0 110.61 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -45.12 85.3 0.01 OUTLIER Glycine 0 CA--C 1.528 0.895 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 178.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.578 ' N ' ' O ' ' L' ' 24' ' ' VAL . 12.8 t -68.13 -171.59 0.25 Allowed 'General case' 0 N--CA 1.441 -0.921 0 CA-C-O 122.593 1.187 . . . . 0.0 112.333 -177.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.415 ' O ' ' C ' ' L' ' 28' ' ' LYS . 35.4 p-10 -81.0 179.29 7.93 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-N 112.547 -2.115 . . . . 0.0 109.814 178.924 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.415 ' C ' ' O ' ' L' ' 27' ' ' ASN . 70.1 tttt -37.17 104.15 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 -179.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . 0.402 ' O ' HG12 ' L' ' 31' ' ' ILE . . . 167.84 -100.42 0.16 Allowed Glycine 0 C--O 1.22 -0.726 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -174.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.617 ' HB2' ' O ' ' K' ' 29' ' ' GLY . . . -49.55 169.37 0.03 OUTLIER 'General case' 0 N--CA 1.473 0.723 0 CA-C-N 119.137 1.469 . . . . 0.0 108.734 -178.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.666 HD13 ' HA3' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -153.37 133.2 3.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 C-N-CA 118.574 -1.25 . . . . 0.0 111.454 -177.659 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 83.7 mt -120.41 128.91 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.202 0 CA-C-N 114.43 -1.259 . . . . 0.0 108.921 179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.428 ' CA ' ' SD ' ' F' ' 35' ' ' MET . . . -125.7 124.82 5.36 Favored Glycine 0 N--CA 1.468 0.808 0 N-CA-C 111.658 -0.577 . . . . 0.0 111.658 -179.529 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 53.2 tp -126.99 120.04 28.12 Favored 'General case' 0 C--N 1.331 -0.213 0 N-CA-C 108.92 -0.77 . . . . 0.0 108.92 179.205 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . 0.608 ' SD ' ' N ' ' F' ' 33' ' ' GLY . 36.8 ttp -110.34 126.67 54.48 Favored 'General case' 0 N--CA 1.473 0.681 0 C-N-CA 120.805 -0.358 . . . . 0.0 111.0 -179.974 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 43.2 t -130.28 81.73 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 178.056 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.489 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -60.83 101.43 0.3 Allowed Glycine 0 N--CA 1.439 -1.161 0 N-CA-C 110.528 -1.029 . . . . 0.0 110.528 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -168.16 169.28 41.36 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 110.724 -0.95 . . . . 0.0 110.724 -179.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 57.6 t -122.73 135.84 61.48 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.405 0 CA-C-O 120.742 0.306 . . . . 0.0 110.218 179.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 21.8 t . . . . . 0 C--O 1.22 -0.485 0 CA-C-O 118.041 -0.981 . . . . 0.0 110.446 -179.919 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.15 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -113.83 143.89 43.91 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.804 0.335 . . . . 0.0 110.645 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . 0.538 ' OE1' ' CE1' ' B' ' 13' ' ' HIS . 42.6 tp10 -56.69 144.22 33.28 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 109.576 -0.527 . . . . 0.0 109.576 179.605 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.2 160.2 42.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 121.445 0.641 . . . . 0.0 111.386 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . . . . . . . . . 76.0 m80 -89.0 -170.17 2.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.905 179.876 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -80.49 168.64 18.7 Favored 'General case' 0 N--CA 1.446 -0.672 0 CA-C-O 121.357 0.599 . . . . 0.0 110.002 -179.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 3.1 pt20 -157.21 -179.86 8.6 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.878 -1.055 . . . . 0.0 108.993 179.266 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 82.7 tttt -155.22 129.32 8.82 Favored 'General case' 0 C--N 1.332 -0.169 0 C-N-CA 120.334 -0.547 . . . . 0.0 111.695 -179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 72.9 mt -129.28 118.95 23.13 Favored 'General case' 0 C--O 1.237 0.413 0 CA-C-N 115.719 -0.673 . . . . 0.0 109.597 179.313 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 75.9 t -130.17 131.19 65.92 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.233 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.336 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 77.4 m-85 -127.65 131.53 49.84 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-O 121.009 0.433 . . . . 0.0 110.712 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 85.2 t80 -132.53 125.94 31.74 Favored 'General case' 0 N--CA 1.464 0.245 0 N-CA-C 108.983 -0.747 . . . . 0.0 108.983 179.552 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -133.94 137.16 44.69 Favored 'General case' 0 N--CA 1.472 0.633 0 CA-C-O 121.778 0.799 . . . . 0.0 112.955 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . 0.418 ' OE2' HG21 ' B' ' 24' ' ' VAL . 78.2 tt0 -126.8 126.77 43.94 Favored 'General case' 0 CA--C 1.528 0.12 0 CA-C-N 114.625 -1.17 . . . . 0.0 108.449 178.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 24' ' ' VAL . 20.7 t70 -85.81 107.86 17.84 Favored 'General case' 0 C--N 1.325 -0.457 0 N-CA-C 112.077 0.399 . . . . 0.0 112.077 -178.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.447 ' C ' ' O ' ' A' ' 23' ' ' ASP . 6.7 p -32.97 141.65 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 O-C-N 123.423 0.452 . . . . 0.0 109.849 178.718 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -83.24 82.75 1.65 Allowed Glycine 0 CA--C 1.527 0.829 0 C-N-CA 120.103 -1.046 . . . . 0.0 113.729 -176.393 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.541 ' O ' ' O ' ' A' ' 27' ' ' ASN . 74.8 m -141.19 170.87 14.9 Favored 'General case' 0 N--CA 1.444 -0.767 0 N-CA-C 106.235 -1.765 . . . . 0.0 106.235 176.057 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.541 ' O ' ' O ' ' A' ' 26' ' ' SER . 34.8 m120 -29.47 158.47 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.157 0 CA-C-O 118.958 -0.544 . . . . 0.0 110.941 177.447 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.47 ' O ' ' CG ' ' B' ' 27' ' ' ASN . 64.4 tttt 179.44 101.12 0.03 OUTLIER 'General case' 0 C--O 1.217 -0.624 0 C-N-CA 119.154 -1.018 . . . . 0.0 113.568 176.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -69.16 102.9 0.98 Allowed Glycine 0 N--CA 1.467 0.706 0 N-CA-C 103.622 -3.791 . . . . 0.0 103.622 170.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . . . . . . . . . . . -97.35 144.11 27.43 Favored 'General case' 0 C--N 1.356 0.858 0 CA-C-N 123.311 3.555 . . . . 0.0 115.527 -172.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.46 ' C ' ' SD ' ' G' ' 35' ' ' MET . 1.7 pt -159.82 105.56 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.421 -1.907 1 CA-C-N 107.016 -4.629 . . . . 0.0 106.245 -173.895 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.554 HG23 HD11 ' B' ' 34' ' ' LEU . 8.1 tt -108.45 114.53 46.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 CA-C-N 120.524 1.511 . . . . 0.0 108.107 178.236 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' N ' ' SD ' ' G' ' 35' ' ' MET . . . -121.58 124.72 5.89 Favored Glycine 0 CA--C 1.508 -0.351 0 N-CA-C 109.772 -1.331 . . . . 0.0 109.772 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 24.8 tp -148.83 140.4 23.47 Favored 'General case' 0 C--O 1.237 0.421 0 CA-C-O 122.806 1.288 . . . . 0.0 113.002 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . 0.586 ' SD ' ' N ' ' G' ' 32' ' ' ILE . 3.7 ttm -109.82 117.65 34.42 Favored 'General case' 0 CA--C 1.505 -0.786 0 CA-C-N 113.038 -1.892 . . . . 0.0 108.094 177.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -111.12 68.04 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 179.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -120.79 101.53 0.81 Allowed Glycine 0 C--N 1.359 1.842 0 N-CA-C 110.404 -1.079 . . . . 0.0 110.404 179.678 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -178.39 165.73 35.2 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.329 -0.709 . . . . 0.0 111.329 -179.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . 0.479 ' O ' HG13 ' A' ' 40' ' ' VAL . 31.4 m -135.96 156.24 36.84 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-O 120.663 0.268 . . . . 0.0 110.385 179.453 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . 0.479 HG13 ' O ' ' A' ' 39' ' ' VAL . 17.0 m . . . . . 0 C--O 1.22 -0.497 0 CA-C-O 118.148 -0.93 . . . . 0.0 110.129 179.261 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.325 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.86 145.37 42.92 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-O 120.6 0.238 . . . . 0.0 110.447 179.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -68.04 126.87 30.86 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 120.66 -0.416 . . . . 0.0 110.279 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . . . . . . . . . 29.2 m -137.08 164.1 30.77 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.449 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.092 -179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.538 ' CE1' ' OE1' ' A' ' 11' ' ' GLU . 59.4 m80 -91.36 98.14 11.52 Favored 'General case' 0 C--N 1.329 -0.288 0 C-N-CA 120.546 -0.461 . . . . 0.0 109.971 179.254 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.519 ' ND1' ' O ' ' B' ' 13' ' ' HIS . 3.7 m-70 -134.51 166.83 21.98 Favored 'General case' 0 CA--C 1.513 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 179.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . . . . . . . . . 83.3 mt-30 -154.57 175.11 14.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.465 -0.789 . . . . 0.0 109.059 179.017 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -154.46 117.04 4.35 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.823 0.344 . . . . 0.0 110.495 179.2 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . . . . . . . . . 47.2 tp -124.03 119.5 29.69 Favored 'General case' 0 C--O 1.238 0.495 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.454 179.607 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 2.7 t -122.33 127.68 75.22 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.351 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.961 178.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 83.0 t80 -130.22 126.26 36.93 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.425 -0.352 . . . . 0.0 110.834 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -128.48 132.59 48.38 Favored 'General case' 0 N--CA 1.467 0.416 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.63 132.35 38.89 Favored 'General case' 0 C--O 1.238 0.458 0 CA-C-O 121.126 0.489 . . . . 0.0 111.114 -179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -147.88 168.0 23.36 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.227 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . . . . . . . . . 67.3 t0 -140.27 123.2 16.55 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-O 121.153 0.502 . . . . 0.0 111.245 -179.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.418 HG21 ' OE2' ' A' ' 22' ' ' GLU . 75.9 t -94.39 121.7 45.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.655 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.552 179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . 0.405 ' O ' ' CB ' ' B' ' 26' ' ' SER . . . 45.74 85.53 0.01 OUTLIER Glycine 0 CA--C 1.53 1.023 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.853 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.714 ' O ' ' O ' ' B' ' 27' ' ' ASN . 1.9 t 162.12 161.0 0.02 OUTLIER 'General case' 0 CA--C 1.508 -0.654 0 N-CA-C 106.589 -1.634 . . . . 0.0 106.589 178.65 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.714 ' O ' ' O ' ' B' ' 26' ' ' SER . 11.9 m120 -30.13 171.99 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.063 0 N-CA-C 112.658 0.614 . . . . 0.0 112.658 -179.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.494 ' HB3' ' N ' ' C' ' 24' ' ' VAL . 95.7 mttt -159.6 103.89 1.58 Allowed 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -178.064 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.799 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . 69.42 -105.32 1.48 Allowed Glycine 1 CA--C 1.417 -6.093 0 CA-C-O 115.111 -3.05 . . . . 0.0 111.33 -178.689 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.799 ' HB3' ' O ' ' B' ' 29' ' ' GLY . . . 76.0 -135.22 0.02 OUTLIER 'General case' 0 N--CA 1.405 -2.71 2 C-N-CA 108.667 -5.213 . . . . 0.0 99.248 -174.351 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.973 ' N ' HD13 ' B' ' 31' ' ' ILE . 0.0 OUTLIER -75.47 122.65 29.74 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -179.325 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . . . . . . . . . 83.3 mt -121.73 122.16 66.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.809 0 N-CA-C 108.693 -0.855 . . . . 0.0 108.693 175.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . 0.701 ' C ' HD12 ' B' ' 34' ' ' LEU . . . -132.47 111.07 0.99 Allowed Glycine 0 N--CA 1.473 1.119 0 C-N-CA 120.558 -0.829 . . . . 0.0 111.075 179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.701 HD12 ' C ' ' B' ' 33' ' ' GLY . 6.4 mp -138.31 144.85 40.61 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 123.47 1.605 . . . . 0.0 113.168 179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.506 ' SD ' ' N ' ' H' ' 32' ' ' ILE . 19.6 ttm -119.07 115.85 25.16 Favored 'General case' 0 CA--C 1.499 -0.999 0 CA-C-N 113.002 -1.908 . . . . 0.0 107.41 177.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -117.26 70.62 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.879 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 179.096 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -79.3 112.5 3.46 Favored Glycine 0 C--N 1.363 2.057 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 -179.105 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . 0.53 ' N ' ' O ' ' C' ' 37' ' ' GLY . . . -73.04 147.73 40.07 Favored Glycine 0 CA--C 1.524 0.646 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 27.0 m -139.49 161.34 27.64 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.329 0 CA-C-O 120.807 0.337 . . . . 0.0 110.424 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 20.3 t . . . . . 0 C--O 1.221 -0.433 0 CA-C-O 118.026 -0.987 . . . . 0.0 110.518 179.897 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.399 0 N-CA-C 109.529 -1.428 . . . . 0.0 109.529 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -81.71 128.13 33.65 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.798 0.332 . . . . 0.0 110.413 -179.83 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . . . . . . . . . 40.6 tt0 -148.96 132.04 16.3 Favored 'General case' 0 C--N 1.332 -0.164 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.157 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . 0.432 HG12 ' H ' ' D' ' 12' ' ' VAL . 18.6 m -140.76 162.69 22.85 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.268 0 CA-C-O 121.3 0.571 . . . . 0.0 111.364 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . . . . . . . . . 89.3 m-70 -118.8 138.29 52.8 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.877 179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . 0.783 ' HD1' ' N ' ' C' ' 15' ' ' GLN . 28.8 t-80 -152.38 165.45 34.97 Favored 'General case' 0 CA--C 1.513 -0.463 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 179.339 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . 0.783 ' N ' ' HD1' ' C' ' 14' ' ' HIS . 75.8 mt-30 -156.44 170.35 22.51 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.025 178.999 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -158.87 111.59 2.26 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.155 -0.475 . . . . 0.0 109.829 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 5.7 mp -121.96 122.07 38.52 Favored 'General case' 0 C--O 1.236 0.376 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 179.025 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 60.5 t -126.67 124.52 65.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 121.128 0.49 . . . . 0.0 111.831 -179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . 0.488 ' CZ ' ' CD2' ' B' ' 34' ' ' LEU . 1.0 OUTLIER -116.54 110.75 18.99 Favored 'General case' 0 C--O 1.234 0.277 0 N-CA-C 105.89 -1.893 . . . . 0.0 105.89 177.456 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -115.36 121.02 41.54 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -178.442 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -122.87 130.59 53.06 Favored 'General case' 0 C--O 1.24 0.573 0 CA-C-O 121.697 0.761 . . . . 0.0 111.673 -179.253 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -121.18 91.53 3.55 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 114.891 -1.05 . . . . 0.0 108.994 178.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -169.86 123.67 0.75 Allowed 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.816 -1.154 . . . . 0.0 113.129 -179.343 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.494 ' N ' ' HB3' ' B' ' 28' ' ' LYS . 11.5 t -146.89 106.9 0.63 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 174.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . 0.444 ' N ' ' HB2' ' B' ' 28' ' ' LYS . . . -38.33 -94.97 0.01 OUTLIER Glycine 0 N--CA 1.482 1.729 0 CA-C-O 122.201 0.89 . . . . 0.0 112.828 -177.929 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . 0.611 ' O ' ' O ' ' C' ' 27' ' ' ASN . 25.5 p -150.57 170.0 20.2 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 103.968 -2.605 . . . . 0.0 103.968 176.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.611 ' O ' ' O ' ' C' ' 26' ' ' SER . 5.5 t-20 43.18 -179.37 0.0 OUTLIER 'General case' 0 C--N 1.312 -1.054 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.999 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.61 ' HZ1' ' N ' ' E' ' 27' ' ' ASN . 81.6 mttt -86.67 -117.69 0.04 OUTLIER 'General case' 0 C--N 1.319 -0.719 0 O-C-N 120.94 -1.1 . . . . 0.0 109.87 179.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . . . . . . . . . . . 43.6 89.69 0.01 OUTLIER Glycine 0 N--CA 1.469 0.873 0 C-N-CA 121.018 -0.61 . . . . 0.0 112.342 177.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.401 ' C ' HD13 ' C' ' 31' ' ' ILE . . . -157.48 165.74 34.84 Favored 'General case' 0 C--N 1.301 -1.527 0 N-CA-C 104.577 -2.379 . . . . 0.0 104.577 175.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.498 HG22 ' HB ' ' D' ' 31' ' ' ILE . 0.0 OUTLIER -139.94 121.29 15.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 C-N-CA 118.481 -1.287 . . . . 0.0 111.237 -173.687 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . 0.458 ' O ' ' CE ' ' I' ' 35' ' ' MET . 12.1 tt -116.72 122.35 69.72 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.317 0 CA-C-O 121.487 0.661 . . . . 0.0 111.039 178.831 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . 0.418 ' N ' ' HE1' ' H' ' 35' ' ' MET . . . -110.61 117.36 4.62 Favored Glycine 0 CA--C 1.504 -0.608 0 N-CA-C 108.721 -1.752 . . . . 0.0 108.721 179.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.876 HD11 ' CZ ' ' D' ' 19' ' ' PHE . 0.4 OUTLIER -146.2 138.23 25.07 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 122.861 1.315 . . . . 0.0 113.006 -178.099 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . . . . . . . . . 15.0 ttm -129.09 127.37 41.35 Favored 'General case' 0 CA--C 1.505 -0.753 0 CA-C-N 113.446 -1.707 . . . . 0.0 109.449 179.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -114.91 78.06 0.5 Allowed 'Isoleucine or valine' 0 CA--C 1.551 1.013 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 -179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . 0.53 ' O ' ' N ' ' B' ' 38' ' ' GLY . . . -69.64 104.78 1.37 Allowed Glycine 0 C--N 1.351 1.399 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 179.475 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . -83.56 -179.33 52.2 Favored Glycine 0 CA--C 1.526 0.757 0 N-CA-C 110.604 -0.998 . . . . 0.0 110.604 179.848 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.89 144.21 28.71 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-O 120.939 0.399 . . . . 0.0 110.771 -179.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.1 p . . . . . 0 C--O 1.22 -0.452 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.561 179.943 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.261 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 90.8 m-85 -106.05 136.68 45.3 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.938 0.399 . . . . 0.0 110.571 -179.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 17.4 pt-20 -82.16 148.53 28.44 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.365 179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . 0.432 ' H ' HG12 ' C' ' 12' ' ' VAL . 3.4 m -134.56 160.98 41.2 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.405 179.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.435 ' O ' ' ND1' ' D' ' 14' ' ' HIS . 9.5 m80 -123.44 154.81 38.55 Favored 'General case' 0 N--CA 1.468 0.471 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.685 -179.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.435 ' ND1' ' O ' ' D' ' 13' ' ' HIS . 47.2 m80 -151.02 164.99 35.13 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-O 121.158 0.504 . . . . 0.0 110.06 -179.852 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -158.99 169.51 24.14 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.553 178.41 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -159.43 117.13 2.73 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.538 -0.301 . . . . 0.0 110.316 178.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . 0.402 HD13 ' CD2' ' E' ' 17' ' ' LEU . 5.9 mp -119.34 123.78 45.01 Favored 'General case' 0 N--CA 1.471 0.597 0 N-CA-C 109.135 -0.691 . . . . 0.0 109.135 179.147 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 81.1 t -126.29 127.05 70.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.319 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . 0.876 ' CZ ' HD11 ' C' ' 34' ' ' LEU . 1.8 t80 -125.39 113.5 17.62 Favored 'General case' 0 N--CA 1.469 0.498 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 176.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -122.8 131.55 53.82 Favored 'General case' 0 N--CA 1.476 0.851 0 N-CA-C 112.475 0.546 . . . . 0.0 112.475 -176.026 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . . . . . . . . . . . -118.32 109.77 16.7 Favored 'General case' 0 C--O 1.249 1.079 0 N-CA-C 108.79 -0.818 . . . . 0.0 108.79 177.687 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' E' ' 22' ' ' GLU . 87.2 tt0 -165.23 91.46 0.53 Allowed 'General case' 0 C--N 1.347 0.487 0 N-CA-C 113.939 1.089 . . . . 0.0 113.939 -179.548 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . . . . . . . . . 34.1 t70 -76.06 -131.34 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.531 0 N-CA-C 102.915 -2.995 . . . . 0.0 102.915 173.259 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.439 ' O ' ' O ' ' D' ' 25' ' ' GLY . 57.1 t -90.98 112.35 25.04 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.591 0 N-CA-C 101.089 -3.671 . . . . 0.0 101.089 173.792 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' D' ' 24' ' ' VAL . . . 41.32 89.69 0.01 OUTLIER Glycine 0 CA--C 1.535 1.294 0 N-CA-C 107.879 -2.089 . . . . 0.0 107.879 -173.883 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.434 ' O ' ' O ' ' E' ' 22' ' ' GLU . 4.0 m -69.95 164.54 23.63 Favored 'General case' 0 CA--C 1.498 -1.028 0 C-N-CA 118.608 -1.237 . . . . 0.0 109.854 -178.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . 0.444 ' O ' ' O ' ' E' ' 22' ' ' GLU . 51.1 p-10 -79.2 174.39 11.61 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-O 123.875 1.798 . . . . 0.0 115.495 178.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . 0.46 ' O ' ' N ' ' D' ' 30' ' ' ALA 0.319 21.6 tttt -49.02 111.17 0.44 Allowed 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 109.624 -3.444 . . . . 0.0 116.797 172.1 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' D' ' 30' ' ' ALA . . . -72.22 100.57 0.96 Allowed Glycine 0 CA--C 1.45 -3.998 1 N-CA-C 102.656 -4.178 . . . . 0.0 102.656 -178.344 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.46 ' N ' ' O ' ' D' ' 28' ' ' LYS . . . -70.56 -130.8 0.0 OUTLIER 'General case' 1 N--CA 1.372 -4.338 4 CA-C-N 101.161 -7.519 . . . . 0.0 97.485 -176.469 . . . . . . . . 4 3 . 1 . 009 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.786 ' CD1' ' N ' ' D' ' 31' ' ' ILE . 1.0 OUTLIER -74.74 111.88 11.29 Favored 'Isoleucine or valine' 1 C--N 1.243 -4.029 0 CA-C-N 123.176 2.716 . . . . 0.0 111.714 -176.013 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . 0.54 HG21 HG23 ' E' ' 32' ' ' ILE . 0.2 OUTLIER -110.92 115.51 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.981 0 N-CA-C 108.809 -0.812 . . . . 0.0 108.809 178.126 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . 0.551 ' CA ' ' SD ' ' J' ' 35' ' ' MET . . . -113.72 98.67 0.93 Allowed Glycine 0 CA--C 1.503 -0.689 0 N-CA-C 107.61 -2.196 . . . . 0.0 107.61 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . 0.426 HD22 ' CZ ' ' E' ' 19' ' ' PHE . 61.7 mt -128.31 128.46 44.64 Favored 'General case' 0 C--O 1.239 0.534 0 N-CA-C 113.245 0.832 . . . . 0.0 113.245 -176.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . 0.508 ' CE ' ' O ' ' J' ' 32' ' ' ILE . 3.9 ttt -123.5 128.85 50.37 Favored 'General case' 0 CA--C 1.508 -0.636 0 CA-C-N 114.524 -1.216 . . . . 0.0 109.068 177.214 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.521 ' O ' HG23 ' E' ' 36' ' ' VAL . 0.0 OUTLIER -122.9 80.36 0.68 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.922 0 N-CA-C 109.084 -0.709 . . . . 0.0 109.084 -179.117 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.457 ' C ' ' O ' ' D' ' 36' ' ' VAL . . . -23.36 -95.45 0.01 OUTLIER Glycine 0 C--N 1.361 1.955 0 O-C-N 123.0 0.187 . . . . 0.0 112.639 -179.728 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 125.84 -178.28 16.73 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.9 -0.88 . . . . 0.0 110.9 179.948 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 40' ' ' VAL . 34.3 m -123.27 137.1 57.75 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.481 0 N-CA-C 110.316 -0.253 . . . . 0.0 110.316 -179.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . 0.422 ' O ' ' O ' ' D' ' 39' ' ' VAL . 11.2 t . . . . . 0 C--O 1.219 -0.538 0 CA-C-O 118.086 -0.959 . . . . 0.0 110.392 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.659 -1.376 . . . . 0.0 109.659 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 73.6 m-85 -116.89 140.12 49.82 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-O 120.789 0.328 . . . . 0.0 110.716 -179.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -63.88 145.17 56.31 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.692 179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 55.8 t -120.53 127.93 75.97 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.337 0 CA-C-O 121.029 0.442 . . . . 0.0 110.029 179.605 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . 0.553 ' CE1' ' CB ' ' F' ' 13' ' ' HIS . 43.7 p-80 -164.38 157.74 17.81 Favored 'General case' 0 C--N 1.326 -0.428 0 C-N-CA 120.578 -0.449 . . . . 0.0 110.945 -179.888 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . . . . . . . . . 73.4 m80 -135.54 167.78 20.46 Favored 'General case' 0 CA--C 1.51 -0.565 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.652 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . . . . . . . . . 69.7 mt-30 -155.29 167.83 29.06 Favored 'General case' 0 C--N 1.315 -0.924 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.362 178.385 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . . . . . . . . . 98.2 mttt -148.19 117.37 6.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.123 179.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . 0.402 ' CD2' HD13 ' D' ' 17' ' ' LEU . 25.5 mt -114.66 122.17 45.63 Favored 'General case' 0 C--N 1.328 -0.335 0 N-CA-C 106.633 -1.617 . . . . 0.0 106.633 177.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -137.28 136.35 46.9 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.576 0 CA-C-O 122.125 0.964 . . . . 0.0 113.578 -177.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . 0.478 ' CB ' ' CE1' ' F' ' 19' ' ' PHE . 0.6 OUTLIER -121.37 126.05 48.48 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 113.832 -1.531 . . . . 0.0 109.091 178.783 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -127.22 129.85 48.56 Favored 'General case' 0 N--CA 1.481 1.076 0 O-C-N 122.079 -0.388 . . . . 0.0 110.663 178.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . . . . . . . . . . . -142.12 125.68 16.8 Favored 'General case' 0 N--CA 1.471 0.61 0 CA-C-O 121.002 0.43 . . . . 0.0 110.749 179.371 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.465 ' OE2' ' OE2' ' D' ' 22' ' ' GLU . 93.9 mt-10 -93.25 156.32 16.9 Favored 'General case' 0 N--CA 1.485 1.318 0 C-N-CA 119.494 -0.882 . . . . 0.0 113.313 -179.24 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -133.02 141.39 48.24 Favored 'General case' 0 N--CA 1.474 0.775 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.201 -179.407 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . . . . . . . . . 21.6 t -107.35 111.08 34.22 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.981 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . 0.543 ' O ' ' O ' ' E' ' 26' ' ' SER . . . 34.6 90.81 0.01 OUTLIER Glycine 0 N--CA 1.472 1.049 0 N-CA-C 111.6 -0.6 . . . . 0.0 111.6 -178.919 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . 0.543 ' O ' ' O ' ' E' ' 25' ' ' GLY . 11.6 p -32.9 170.53 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 122.232 1.015 . . . . 0.0 113.179 -179.095 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.61 ' N ' ' HZ1' ' C' ' 28' ' ' LYS . 19.6 m120 -158.52 178.15 10.46 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.466 177.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . 0.472 ' C ' ' O ' ' E' ' 27' ' ' ASN . 64.4 mttp 4.78 -106.36 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 123.994 0.918 . . . . 0.0 113.437 -179.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . . . . . . . . . . . -147.0 95.57 0.17 Allowed Glycine 0 C--N 1.346 1.114 0 C-N-CA 120.592 -0.813 . . . . 0.0 113.275 178.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.438 ' C ' ' CG1' ' E' ' 31' ' ' ILE . . . -66.63 177.62 1.53 Allowed 'General case' 0 C--O 1.241 0.608 0 N-CA-C 106.203 -1.777 . . . . 0.0 106.203 175.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.601 HG21 ' CA ' ' K' ' 37' ' ' GLY . 0.3 OUTLIER -149.62 120.28 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 C-N-CA 117.972 -1.491 . . . . 0.0 109.168 -176.685 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.54 HG23 HG21 ' D' ' 32' ' ' ILE . 97.0 mt -117.69 126.56 74.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.386 0 CA-C-N 115.381 -0.827 . . . . 0.0 112.569 -176.489 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . . . . . . . . . . . -120.14 110.63 1.82 Allowed Glycine 0 CA--C 1.528 0.857 0 N-CA-C 110.38 -1.088 . . . . 0.0 110.38 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.588 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 60.7 mt -121.14 123.22 41.78 Favored 'General case' 0 N--CA 1.467 0.375 0 O-C-N 122.756 -0.261 . . . . 0.0 110.742 -179.805 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . . . . . . . . . 4.7 ttt -135.46 131.21 35.88 Favored 'General case' 0 N--CA 1.473 0.704 0 C-N-CA 119.678 -0.809 . . . . 0.0 112.46 178.871 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.644 HG22 ' O ' ' E' ' 36' ' ' VAL . 0.6 OUTLIER -158.11 81.36 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 109.85 178.986 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . . . . . . . . . . . -77.13 101.64 1.61 Allowed Glycine 0 C--N 1.338 0.675 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -179.613 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . -132.98 154.89 21.36 Favored Glycine 0 CA--C 1.522 0.473 0 N-CA-C 110.359 -1.096 . . . . 0.0 110.359 179.859 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 3.1 p -140.43 145.1 26.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 N-CA-C 109.709 -0.478 . . . . 0.0 109.709 179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 18.7 m . . . . . 0 C--O 1.221 -0.401 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.404 -179.661 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.444 0 N-CA-C 109.684 -1.366 . . . . 0.0 109.684 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 91.8 m-85 -111.0 133.41 53.41 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.779 0.323 . . . . 0.0 110.572 179.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 71.3 mm-40 -70.71 142.2 51.51 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.195 179.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 3.1 m -139.31 176.0 6.68 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.245 0 CA-C-O 121.082 0.467 . . . . 0.0 110.552 -179.243 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.553 ' CB ' ' CE1' ' E' ' 13' ' ' HIS . 56.8 p-80 -99.37 159.88 14.68 Favored 'General case' 0 C--O 1.232 0.144 0 CA-C-N 115.729 -0.669 . . . . 0.0 110.64 179.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -153.48 178.37 9.89 Favored 'General case' 0 N--CA 1.446 -0.641 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 -179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . 0.471 ' CG ' ' N ' ' F' ' 16' ' ' LYS . 42.7 tt0 -148.92 166.64 27.99 Favored 'General case' 0 C--N 1.312 -1.053 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 179.281 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . 0.471 ' N ' ' CG ' ' F' ' 15' ' ' GLN . 68.5 mttm -142.68 131.54 22.86 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 121.295 0.569 . . . . 0.0 111.608 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . 0.427 ' CD2' HG11 ' E' ' 36' ' ' VAL . 56.1 tp -121.75 123.45 41.86 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.72 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 53.7 t -126.34 127.43 70.58 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 CA-C-O 121.553 0.692 . . . . 0.0 111.14 -179.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.588 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 0.5 OUTLIER -122.13 114.48 20.94 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.9 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 80.3 t80 -120.41 117.3 27.36 Favored 'General case' 0 CA--C 1.52 -0.181 0 CA-C-O 121.313 0.578 . . . . 0.0 110.358 -179.925 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.97 136.87 46.33 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 179.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . 0.487 ' O ' ' OD1' ' F' ' 23' ' ' ASP . 70.5 mm-40 -70.18 122.1 18.81 Favored 'General case' 0 C--N 1.325 -0.483 0 C-N-CA 119.07 -1.052 . . . . 0.0 111.524 -178.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' F' ' 22' ' ' GLU . 1.8 p-10 108.6 131.94 0.0 OUTLIER 'General case' 0 N--CA 1.472 0.673 0 C-N-CA 125.888 1.675 . . . . 0.0 109.33 -179.516 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.429 ' O ' ' C ' ' F' ' 25' ' ' GLY . 2.4 m -110.22 113.44 44.24 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.76 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.429 ' C ' ' O ' ' F' ' 24' ' ' VAL . . . 32.28 87.72 0.01 OUTLIER Glycine 0 CA--C 1.527 0.797 0 N-CA-C 111.838 -0.505 . . . . 0.0 111.838 178.953 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 62.7 m -65.17 -174.6 0.17 Allowed 'General case' 0 N--CA 1.438 -1.028 0 CA-C-O 121.448 0.642 . . . . 0.0 109.74 -179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.432 ' O ' ' C ' ' F' ' 28' ' ' LYS . 96.5 m-20 -81.06 178.24 8.54 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 114.703 -1.135 . . . . 0.0 109.289 178.783 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.432 ' C ' ' O ' ' F' ' 27' ' ' ASN . 87.3 tttt -38.15 103.93 0.03 OUTLIER 'General case' 0 N--CA 1.471 0.583 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . 0.44 ' O ' HG12 ' F' ' 31' ' ' ILE . . . 166.02 -100.54 0.17 Allowed Glycine 0 C--O 1.219 -0.796 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 -176.008 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.414 ' C ' ' CG1' ' F' ' 31' ' ' ILE . . . -53.75 168.54 0.19 Allowed 'General case' 0 CA--C 1.509 -0.61 0 CA-C-N 118.038 0.919 . . . . 0.0 108.953 -178.56 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.547 HG21 ' CA ' ' L' ' 37' ' ' GLY . 0.1 OUTLIER -150.91 128.1 2.23 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.921 0 C-N-CA 119.331 -0.947 . . . . 0.0 109.309 -174.586 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . . . . . . . . . 17.2 tt -128.2 138.86 53.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 CA-C-O 120.909 0.385 . . . . 0.0 111.873 -177.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -133.41 124.27 3.64 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 20.2 tp -119.11 122.57 42.37 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 109.302 -0.629 . . . . 0.0 109.302 179.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . . . . . . . . . 4.6 tpt -118.54 121.28 39.86 Favored 'General case' 0 N--CA 1.478 0.966 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.485 ' O ' ' C ' ' F' ' 37' ' ' GLY . 2.9 m -141.84 80.63 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.803 0 N-CA-C 110.213 -0.291 . . . . 0.0 110.213 177.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.485 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . 18.1 -104.86 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 CA-C-N 117.516 0.144 . . . . 0.0 113.169 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . -172.64 -161.29 22.82 Favored Glycine 0 CA--C 1.529 0.907 0 N-CA-C 111.074 -0.81 . . . . 0.0 111.074 -179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 34.4 m -134.37 161.45 40.6 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-O 120.868 0.366 . . . . 0.0 111.035 -179.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 m . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.982 -1.009 . . . . 0.0 110.387 179.939 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 109.693 -1.363 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 94.8 m-85 -121.16 139.04 53.89 Favored 'General case' 0 N--CA 1.467 0.425 0 CA-C-O 120.652 0.263 . . . . 0.0 110.607 179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -69.11 157.2 37.33 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.902 0.382 . . . . 0.0 110.717 179.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . 0.415 ' CG1' ' ND1' ' H' ' 13' ' ' HIS . 55.3 t -118.12 134.48 61.59 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.265 -179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . . . . . . . . . 88.8 m-70 -112.26 157.98 20.27 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.533 -179.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.528 ' CB ' ' CE1' ' H' ' 14' ' ' HIS . 12.9 p80 -81.99 174.58 11.12 Favored 'General case' 0 N--CA 1.442 -0.866 0 N-CA-C 109.075 -0.713 . . . . 0.0 109.075 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -143.93 179.47 7.16 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.089 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 64.2 tttm -152.71 135.19 15.17 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.596 -0.729 . . . . 0.0 109.694 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 83.3 mt -136.24 117.85 14.91 Favored 'General case' 0 C--O 1.236 0.376 0 CA-C-O 121.421 0.629 . . . . 0.0 110.539 179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 2.6 p -132.81 136.31 55.89 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.39 -0.823 . . . . 0.0 109.619 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -136.09 131.81 35.3 Favored 'General case' 0 C--O 1.233 0.222 0 CA-C-O 121.369 0.604 . . . . 0.0 111.319 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -125.95 130.67 51.7 Favored 'General case' 0 C--N 1.33 -0.28 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 178.726 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -137.61 148.26 45.69 Favored 'General case' 0 C--O 1.239 0.514 0 CA-C-O 122.316 1.055 . . . . 0.0 113.207 -177.785 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 88.4 mt-10 -101.93 -177.67 3.48 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 113.406 -1.724 . . . . 0.0 108.901 179.197 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . 0.44 ' OD1' ' O ' ' G' ' 26' ' ' SER . 67.3 t0 -58.45 123.86 17.62 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.203 -0.599 . . . . 0.0 110.184 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . 0.53 ' O ' HG23 ' G' ' 24' ' ' VAL . 23.0 m -95.56 120.59 45.17 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.926 -179.042 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . . . . . . . . . . . 43.93 -88.73 0.01 OUTLIER Glycine 0 CA--C 1.527 0.83 0 CA-C-N 116.111 -0.495 . . . . 0.0 112.607 177.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.474 ' N ' ' O ' ' G' ' 24' ' ' VAL . 72.2 m -67.52 -171.6 0.2 Allowed 'General case' 0 N--CA 1.441 -0.877 0 N-CA-C 108.944 -0.761 . . . . 0.0 108.944 -178.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.549 ' CG ' ' H ' ' G' ' 28' ' ' LYS . 14.7 t-20 -78.79 178.77 7.66 Favored 'General case' 0 C--N 1.311 -1.105 0 C-N-CA 120.03 -0.668 . . . . 0.0 111.186 -178.388 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.549 ' H ' ' CG ' ' G' ' 27' ' ' ASN . 83.9 tttt -44.17 -110.18 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 113.143 0.794 . . . . 0.0 113.143 -178.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . . . . . . . . . . . 54.33 91.88 0.01 OUTLIER Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 108.476 -1.85 . . . . 0.0 108.476 -178.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.424 ' O ' HG13 ' H' ' 31' ' ' ILE . . . -102.62 161.9 13.36 Favored 'General case' 0 CA--C 1.496 -1.104 0 C-N-CA 116.696 -2.002 . . . . 0.0 108.628 179.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.505 ' C ' ' SD ' ' A' ' 35' ' ' MET . 0.1 OUTLIER -152.36 110.06 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.308 -1.21 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.023 -174.829 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . 0.586 ' N ' ' SD ' ' A' ' 35' ' ' MET . 97.3 mt -108.36 110.21 31.13 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.197 0.523 . . . . 0.0 110.241 179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -113.24 92.49 0.62 Allowed Glycine 0 CA--C 1.502 -0.761 0 N-CA-C 105.648 -2.981 . . . . 0.0 105.648 175.984 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.723 ' O ' HD12 ' H' ' 34' ' ' LEU . 16.7 mt -130.93 134.19 46.53 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-O 123.725 1.726 . . . . 0.0 111.984 -178.328 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.593 ' SD ' ' N ' ' A' ' 33' ' ' GLY . 0.0 OUTLIER -108.4 117.96 35.53 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 112.678 -2.055 . . . . 0.0 109.019 -179.879 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -125.35 66.85 0.32 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.828 0 N-CA-C 109.244 -0.651 . . . . 0.0 109.244 178.877 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -84.22 -103.52 0.59 Allowed Glycine 0 C--N 1.363 2.063 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 178.75 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 172.84 162.61 25.23 Favored Glycine 0 CA--C 1.527 0.782 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.562 179.002 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 9.9 p -145.21 147.87 18.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 -179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 12.2 p . . . . . 0 C--O 1.221 -0.411 0 CA-C-O 117.958 -1.02 . . . . 0.0 110.826 -179.741 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.102 0 N-CA-C 109.396 -1.482 . . . . 0.0 109.396 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -113.21 142.59 45.62 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 120.853 0.358 . . . . 0.0 110.519 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -77.44 127.35 32.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.605 179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 52.9 t -137.27 139.35 44.08 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.262 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.036 -179.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . 0.415 ' ND1' ' CG1' ' G' ' 12' ' ' VAL . 82.8 t60 -147.26 107.83 4.12 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.683 -0.407 . . . . 0.0 109.99 178.625 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.618 ' CG ' ' CE1' ' I' ' 14' ' ' HIS . 15.0 p-80 -146.73 171.17 15.56 Favored 'General case' 0 N--CA 1.447 -0.586 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.283 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 93.4 mt-30 -144.35 177.25 8.76 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.13 -179.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -152.8 131.22 12.13 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.333 -0.849 . . . . 0.0 108.9 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 18.7 mt -129.36 118.56 22.42 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-O 120.934 0.397 . . . . 0.0 110.414 -179.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . . . . . . . . . 70.1 t -128.34 131.32 69.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.93 179.846 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -126.1 128.99 48.22 Favored 'General case' 0 N--CA 1.469 0.513 0 N-CA-C 109.346 -0.613 . . . . 0.0 109.346 178.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.601 ' CZ ' ' CD1' ' I' ' 20' ' ' PHE . 0.9 OUTLIER -134.76 128.03 32.07 Favored 'General case' 0 N--CA 1.469 0.5 0 CA-C-N 116.605 -0.27 . . . . 0.0 110.389 -179.187 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . . . . . . . . . . . -124.52 123.54 40.33 Favored 'General case' 0 N--CA 1.471 0.594 0 CA-C-O 120.858 0.361 . . . . 0.0 110.226 178.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . 0.551 ' OE2' ' CE1' ' H' ' 20' ' ' PHE . 9.7 pt-20 -168.42 130.05 1.35 Allowed 'General case' 0 N--CA 1.464 0.248 0 C-N-CA 119.897 -0.721 . . . . 0.0 112.157 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.4 ' HB3' ' H ' ' G' ' 23' ' ' ASP . 20.0 t70 178.83 114.72 0.04 OUTLIER 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.389 0.614 . . . . 0.0 112.376 177.386 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . . . . . . . . . 38.4 t -28.89 122.86 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 114.724 -1.126 . . . . 0.0 112.364 176.582 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . -171.48 -84.78 0.06 OUTLIER Glycine 0 CA--C 1.526 0.763 0 C-N-CA 119.959 -1.115 . . . . 0.0 112.098 178.513 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.545 ' O ' ' O ' ' H' ' 27' ' ' ASN . 0.4 OUTLIER -170.77 -179.96 3.02 Favored 'General case' 0 N--CA 1.442 -0.867 0 CA-C-N 119.001 1.401 . . . . 0.0 112.276 179.42 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.545 ' O ' ' O ' ' H' ' 26' ' ' SER . 11.4 m120 26.62 -170.79 0.0 OUTLIER 'General case' 0 C--N 1.314 -0.945 0 CA-C-N 112.426 -2.17 . . . . 0.0 115.216 179.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.408 ' O ' ' O ' ' H' ' 29' ' ' GLY . 86.3 tttt -143.7 -103.98 0.12 Allowed 'General case' 0 N--CA 1.466 0.364 0 CA-C-N 114.601 -1.181 . . . . 0.0 111.776 -179.637 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.408 ' O ' ' O ' ' H' ' 28' ' ' LYS . . . 39.94 95.43 0.01 OUTLIER Glycine 0 CA--C 1.494 -1.278 0 N-CA-C 110.178 -1.169 . . . . 0.0 110.178 -177.578 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . . . . . . . . . . . -111.92 153.14 27.16 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 105.265 -2.124 . . . . 0.0 105.265 178.276 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.491 HG22 ' SD ' ' B' ' 35' ' ' MET . 0.0 OUTLIER -139.55 123.1 18.52 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 C-N-CA 119.512 -0.875 . . . . 0.0 109.457 -176.356 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.506 ' N ' ' SD ' ' B' ' 35' ' ' MET . 1.7 mt -115.45 119.09 60.83 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.597 0 CA-C-N 116.102 -0.499 . . . . 0.0 109.974 179.435 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.89 103.69 1.14 Allowed Glycine 0 C--O 1.241 0.588 0 N-CA-C 105.769 -2.932 . . . . 0.0 105.769 175.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.723 HD12 ' O ' ' G' ' 34' ' ' LEU . 5.9 tp -133.74 144.13 48.89 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 122.919 1.342 . . . . 0.0 114.01 -176.16 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.418 ' HE1' ' N ' ' C' ' 33' ' ' GLY . 5.8 tpt -122.25 115.58 22.62 Favored 'General case' 0 CA--C 1.508 -0.665 0 CA-C-N 113.448 -1.706 . . . . 0.0 108.873 178.074 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -119.47 65.11 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.544 0.736 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -128.19 103.86 0.64 Allowed Glycine 0 C--N 1.353 1.504 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . . . . . . . . . . . -90.24 176.41 41.95 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . 0.522 HG12 ' N ' ' H' ' 40' ' ' VAL . 40.5 t -137.24 161.45 34.94 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-O 120.929 0.395 . . . . 0.0 110.634 -179.629 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . 0.522 ' N ' HG12 ' H' ' 39' ' ' VAL . 7.8 p . . . . . 0 C--O 1.22 -0.483 0 CA-C-O 117.957 -1.02 . . . . 0.0 110.424 179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.342 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 76.3 t80 -90.73 125.03 35.56 Favored 'General case' 0 C--N 1.331 -0.205 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.94 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . 0.494 ' O ' ' CD2' ' I' ' 13' ' ' HIS . 96.9 mt-10 -82.48 164.48 20.9 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.935 -179.498 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . 0.428 HG12 ' H ' ' J' ' 12' ' ' VAL . 34.4 m -93.26 135.14 28.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.528 -179.876 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . 0.494 ' CD2' ' O ' ' I' ' 11' ' ' GLU . 3.3 m-70 -142.09 156.97 45.4 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.125 -178.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.618 ' CE1' ' CG ' ' H' ' 14' ' ' HIS . 16.9 p-80 -156.66 167.53 30.17 Favored 'General case' 0 N--CA 1.44 -0.937 0 N-CA-C 108.821 -0.807 . . . . 0.0 108.821 177.413 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.449 ' CG ' ' N ' ' I' ' 16' ' ' LYS . 52.1 tt0 -150.98 166.66 29.99 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-O 121.629 0.728 . . . . 0.0 111.519 -179.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . 0.525 ' NZ ' ' CG2' ' I' ' 18' ' ' VAL . 65.9 tttm -154.41 127.57 8.37 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 114.928 -1.033 . . . . 0.0 108.85 179.205 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . 0.41 HD21 ' CE2' ' I' ' 19' ' ' PHE . 59.3 tp -124.36 121.77 35.86 Favored 'General case' 0 C--O 1.236 0.372 0 N-CA-C 109.991 -0.374 . . . . 0.0 109.991 -179.599 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . 0.525 ' CG2' ' NZ ' ' I' ' 16' ' ' LYS . 47.8 t -122.95 125.54 72.41 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.558 0 C-N-CA 120.853 -0.339 . . . . 0.0 111.832 -179.459 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.41 ' CE2' HD21 ' I' ' 17' ' ' LEU . 60.5 m-85 -114.2 105.86 13.68 Favored 'General case' 0 N--CA 1.468 0.475 0 N-CA-C 107.001 -1.481 . . . . 0.0 107.001 176.936 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . 0.601 ' CD1' ' CZ ' ' H' ' 20' ' ' PHE . 1.4 t80 -117.76 126.53 52.62 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 112.517 0.562 . . . . 0.0 112.517 -177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.46 132.97 39.92 Favored 'General case' 0 N--CA 1.479 0.982 0 CA-C-O 121.141 0.496 . . . . 0.0 111.813 179.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 77.2 tt0 -159.35 114.47 2.45 Favored 'General case' 0 C--N 1.348 0.52 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -179.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . 0.401 ' OD1' ' C ' ' I' ' 23' ' ' ASP . 9.4 t0 -171.9 111.02 0.29 Allowed 'General case' 0 CA--C 1.551 1.005 0 N-CA-C 114.435 1.272 . . . . 0.0 114.435 175.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.462 HG13 ' O ' ' I' ' 24' ' ' VAL . 12.4 p -31.99 131.06 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.634 0 CA-C-N 112.611 -2.086 . . . . 0.0 115.425 174.478 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . . . . . . . . . . . 170.35 -84.22 0.09 OUTLIER Glycine 0 CA--C 1.543 1.841 0 C-N-CA 119.605 -1.283 . . . . 0.0 115.157 174.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . . . . . . . . . 11.3 m -96.76 175.41 6.37 Favored 'General case' 0 CA--C 1.5 -0.944 0 CA-C-N 120.401 2.1 . . . . 0.0 108.916 179.732 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.45 ' O ' ' O ' ' I' ' 28' ' ' LYS . 8.9 m120 -62.52 175.62 0.76 Allowed 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.45 ' O ' ' O ' ' I' ' 27' ' ' ASN . 53.4 tttt -45.1 -107.88 0.0 OUTLIER 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 122.301 1.048 . . . . 0.0 113.796 178.078 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' J' ' 29' ' ' GLY . . . 87.73 -100.01 2.56 Favored Glycine 0 C--O 1.207 -1.577 0 N-CA-C 108.481 -1.848 . . . . 0.0 108.481 -176.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.907 ' C ' HD13 ' I' ' 31' ' ' ILE . . . 62.81 143.6 0.02 OUTLIER 'General case' 0 C--N 1.288 -2.083 0 O-C-N 121.498 -1.001 . . . . 0.0 109.135 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.907 HD13 ' C ' ' I' ' 30' ' ' ALA . 0.0 OUTLIER -145.26 114.47 1.58 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 N-CA-C 107.148 -1.427 . . . . 0.0 107.148 176.373 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' I' ' 32' ' ' ILE . 1.2 tt -108.19 112.38 40.01 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.875 0 N-CA-C 106.97 -1.492 . . . . 0.0 106.97 178.67 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -119.97 113.86 2.56 Favored Glycine 0 CA--C 1.493 -1.288 0 N-CA-C 109.886 -1.286 . . . . 0.0 109.886 -179.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 0.549 HD23 ' N ' ' I' ' 34' ' ' LEU . 2.0 pt? -162.06 160.73 27.83 Favored 'General case' 0 C--O 1.249 1.041 0 CA-C-O 123.304 1.526 . . . . 0.0 112.695 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.491 ' SD ' ' HB ' ' C' ' 31' ' ' ILE . 33.2 ttm -127.71 136.6 51.77 Favored 'General case' 0 CA--C 1.503 -0.827 0 CA-C-N 112.351 -2.204 . . . . 0.0 111.052 -177.925 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . . . . . . . . . 4.2 t -132.99 70.63 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-N 114.065 -1.425 . . . . 0.0 108.186 -179.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -97.98 106.37 3.28 Favored Glycine 0 C--N 1.364 2.098 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.488 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . -77.7 172.01 55.16 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 111.214 -0.755 . . . . 0.0 111.214 -179.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 2.8 p -144.36 149.01 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.275 0 N-CA-C 110.293 -0.262 . . . . 0.0 110.293 -179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 11.5 p . . . . . 0 C--O 1.219 -0.523 0 CA-C-O 117.919 -1.038 . . . . 0.0 110.408 179.975 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -144.96 155.72 43.56 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 110.079 -0.341 . . . . 0.0 110.079 179.943 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 98.0 mt-10 -103.78 144.07 31.97 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-O 120.922 0.392 . . . . 0.0 111.252 -179.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . 0.428 ' H ' HG12 ' I' ' 12' ' ' VAL . 5.5 p -136.91 150.79 26.86 Favored 'Isoleucine or valine' 0 C--O 1.238 0.449 0 CA-C-O 121.981 0.896 . . . . 0.0 112.591 -178.739 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . 0.445 ' CD2' HE21 ' J' ' 15' ' ' GLN . 17.3 t-160 -150.9 105.62 3.28 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 114.08 -1.418 . . . . 0.0 109.548 178.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 54.0 p-80 -149.27 166.8 27.86 Favored 'General case' 0 CA--C 1.508 -0.643 0 O-C-N 121.641 -0.662 . . . . 0.0 110.598 -179.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . 0.445 HE21 ' CD2' ' J' ' 13' ' ' HIS . 13.3 mp0 -146.68 169.97 17.93 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-O 121.675 0.75 . . . . 0.0 111.414 179.072 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 96.5 mttt -143.71 135.88 26.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.607 -0.724 . . . . 0.0 109.152 179.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -133.87 124.61 26.75 Favored 'General case' 0 C--O 1.238 0.468 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -131.65 133.69 61.25 Favored 'Isoleucine or valine' 0 C--O 1.238 0.469 0 CA-C-O 121.289 0.566 . . . . 0.0 112.078 -178.701 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CE2' ' K' ' 19' ' ' PHE . 91.7 m-85 -112.02 113.84 26.37 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 107.921 -1.14 . . . . 0.0 107.921 178.39 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.45 ' CD1' ' CZ ' ' I' ' 20' ' ' PHE . 5.7 t80 -122.16 123.15 40.84 Favored 'General case' 0 N--CA 1.479 1.011 0 CA-C-N 118.518 0.599 . . . . 0.0 112.592 -178.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -134.24 131.52 38.59 Favored 'General case' 0 N--CA 1.472 0.66 0 O-C-N 122.047 -0.408 . . . . 0.0 110.873 179.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . 0.482 ' O ' ' CB ' ' J' ' 23' ' ' ASP . 18.2 pt-20 -151.88 168.44 25.13 Favored 'General case' 0 N--CA 1.474 0.743 0 C-N-CA 120.362 -0.535 . . . . 0.0 111.461 -179.622 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.482 ' CB ' ' O ' ' J' ' 22' ' ' GLU . 6.7 p30 150.94 164.12 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.608 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 -179.149 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.422 ' C ' ' O ' ' J' ' 23' ' ' ASP . 48.8 t -35.83 101.5 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 N-CA-C 109.61 -0.515 . . . . 0.0 109.61 179.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -122.44 93.36 0.5 Allowed Glycine 0 CA--C 1.529 0.95 0 CA-C-N 115.227 -0.897 . . . . 0.0 114.87 -175.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.751 ' O ' ' O ' ' J' ' 27' ' ' ASN . 39.3 p -102.79 160.63 14.43 Favored 'General case' 0 CA--C 1.505 -0.77 0 N-CA-C 103.221 -2.881 . . . . 0.0 103.221 175.95 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.751 ' O ' ' O ' ' J' ' 26' ' ' SER . 92.2 m-20 38.17 -179.22 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.666 0 N-CA-C 108.221 -1.029 . . . . 0.0 108.221 -174.035 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.677 ' N ' ' ND2' ' K' ' 27' ' ' ASN . 88.0 tttt -148.95 108.37 3.96 Favored 'General case' 0 N--CA 1.473 0.724 0 C-N-CA 114.968 -2.693 . . . . 0.0 115.747 176.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.633 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . -76.23 95.07 1.05 Allowed Glycine 0 CA--C 1.493 -1.285 0 CA-C-O 114.938 -3.146 . . . . 0.0 108.65 166.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.53 ' HA ' ' O ' ' I' ' 29' ' ' GLY . . . -137.32 142.7 41.85 Favored 'General case' 0 CA--C 1.463 -2.381 1 CA-C-N 124.891 4.346 . . . . 0.0 108.061 176.136 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.621 HD12 HG23 ' I' ' 31' ' ' ILE . 0.0 OUTLIER -142.91 106.12 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.213 0 C-N-CA 118.59 -1.244 . . . . 0.0 108.357 -177.774 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.517 HG22 ' H ' ' K' ' 33' ' ' GLY . 0.1 OUTLIER -105.32 116.7 49.63 Favored 'Isoleucine or valine' 0 C--N 1.359 0.993 0 CA-C-N 114.265 -1.334 . . . . 0.0 110.677 -178.356 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -116.38 96.45 0.72 Allowed Glycine 0 C--O 1.24 0.49 0 N-CA-C 106.447 -2.661 . . . . 0.0 106.447 176.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.803 HD23 ' CZ ' ' L' ' 19' ' ' PHE . 8.2 tp -134.25 124.87 26.63 Favored 'General case' 0 C--O 1.246 0.897 0 CA-C-O 122.695 1.236 . . . . 0.0 111.975 -177.19 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . 0.562 ' N ' HD12 ' J' ' 34' ' ' LEU . 4.3 ttt -119.87 126.96 52.21 Favored 'General case' 0 CA--C 1.506 -0.714 0 CA-C-N 113.345 -1.752 . . . . 0.0 109.176 178.597 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . 0.557 HG23 HG22 ' K' ' 36' ' ' VAL . 0.0 OUTLIER -113.58 73.18 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.549 0.937 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.187 -178.952 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -41.66 112.46 0.4 Allowed Glycine 0 C--N 1.354 1.543 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 178.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -72.49 -139.86 0.33 Allowed Glycine 0 CA--C 1.524 0.65 0 N-CA-C 111.583 -0.607 . . . . 0.0 111.583 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 54.5 t -109.42 133.66 53.93 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.254 0 CA-C-O 120.972 0.415 . . . . 0.0 110.089 -179.472 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 31.6 m . . . . . 0 C--O 1.219 -0.508 0 CA-C-O 118.07 -0.967 . . . . 0.0 110.928 -179.542 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.626 -1.39 . . . . 0.0 109.626 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 91.6 m-85 -112.54 145.64 39.94 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 120.836 0.35 . . . . 0.0 110.618 -179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . 0.491 ' OE1' ' N ' ' K' ' 11' ' ' GLU . 54.9 mp0 -84.5 134.43 34.43 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.678 -179.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . . . . . . . . . 62.0 t -119.71 131.0 73.42 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.608 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 178.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 76.4 m80 -114.49 117.23 30.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-O 120.775 0.321 . . . . 0.0 111.403 -179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.527 ' CE1' ' O ' ' K' ' 15' ' ' GLN . 55.6 t-80 -135.33 164.39 27.85 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-O 121.42 0.629 . . . . 0.0 109.846 179.549 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . 0.527 ' O ' ' CE1' ' K' ' 14' ' ' HIS . 86.0 mt-30 -157.05 172.49 18.58 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.634 178.468 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 52.5 tttm -155.92 122.77 5.29 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-N 115.534 -0.757 . . . . 0.0 109.36 179.217 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 34.6 mt -125.13 120.42 31.33 Favored 'General case' 0 N--CA 1.468 0.433 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.744 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 4.2 m -136.38 134.17 49.62 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.751 0 CA-C-O 121.538 0.685 . . . . 0.0 112.654 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 0.623 ' CE2' ' CD1' ' J' ' 19' ' ' PHE . 87.5 m-85 -115.31 110.7 19.79 Favored 'General case' 0 CA--C 1.539 0.544 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 178.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.409 ' HA ' ' O ' ' L' ' 20' ' ' PHE . 7.8 m-85 -114.01 124.11 51.33 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 113.636 0.976 . . . . 0.0 113.636 -177.818 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -132.57 127.05 34.21 Favored 'General case' 0 N--CA 1.474 0.739 0 O-C-N 121.758 -0.589 . . . . 0.0 110.57 178.317 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -101.18 127.61 47.66 Favored 'General case' 0 N--CA 1.475 0.782 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.583 -179.055 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . 0.474 ' O ' ' O ' ' K' ' 24' ' ' VAL . 3.6 t70 174.96 146.69 0.07 Allowed 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 108.512 -0.922 . . . . 0.0 108.512 179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.523 HG23 ' H ' ' K' ' 25' ' ' GLY . 2.8 m -21.89 -101.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 123.487 0.492 . . . . 0.0 111.712 -179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.523 ' H ' HG23 ' K' ' 24' ' ' VAL . . . 159.84 -91.36 0.11 Allowed Glycine 0 CA--C 1.523 0.571 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.807 177.706 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.683 ' O ' ' ND2' ' K' ' 27' ' ' ASN . 75.3 m -54.23 160.8 1.5 Allowed 'General case' 0 N--CA 1.443 -0.816 0 CA-C-N 118.147 0.974 . . . . 0.0 108.381 178.185 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . 0.683 ' ND2' ' O ' ' K' ' 26' ' ' SER . 23.2 p30 132.52 171.04 0.0 OUTLIER 'General case' 0 N--CA 1.484 1.24 0 O-C-N 125.083 1.49 . . . . 0.0 111.715 176.129 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -30.27 104.92 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.462 0 N-CA-C 115.768 1.766 . . . . 0.0 115.768 -179.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . 0.462 ' O ' ' HA ' ' L' ' 30' ' ' ALA . . . 81.8 -100.6 2.09 Favored Glycine 0 C--O 1.215 -1.056 0 N-CA-C 115.737 1.055 . . . . 0.0 115.737 170.28 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.431 ' C ' ' CG1' ' K' ' 31' ' ' ILE . . . 60.77 145.29 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.711 0 N-CA-C 106.436 -1.691 . . . . 0.0 106.436 -178.72 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.431 ' CG1' ' C ' ' K' ' 30' ' ' ALA . 0.0 OUTLIER -160.85 134.41 1.26 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 121.614 2.006 . . . . 0.0 113.219 -179.253 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . . . . . . . . . 98.0 mt -124.98 121.23 60.54 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.766 179.727 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.517 ' H ' HG22 ' J' ' 32' ' ' ILE . . . -119.26 115.53 3.07 Favored Glycine 0 N--CA 1.469 0.845 0 N-CA-C 111.058 -0.817 . . . . 0.0 111.058 179.353 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . 0.423 HD11 ' CG2' ' J' ' 36' ' ' VAL . 38.1 tp -124.98 121.62 34.96 Favored 'General case' 0 C--O 1.238 0.478 0 CA-C-N 115.149 -0.525 . . . . 0.0 111.271 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . . . . . . . . . 6.1 mmm -131.33 133.01 44.91 Favored 'General case' 0 N--CA 1.478 0.934 0 C-N-CA 119.829 -0.749 . . . . 0.0 111.348 178.683 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . 0.557 HG22 HG23 ' J' ' 36' ' ' VAL . 15.0 t -123.22 82.58 0.77 Allowed 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.444 179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.601 ' CA ' HG21 ' E' ' 31' ' ' ILE . . . -70.6 101.33 0.9 Allowed Glycine 0 N--CA 1.445 -0.713 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . 0.453 ' O ' ' O ' ' L' ' 37' ' ' GLY . . . -158.4 155.62 26.63 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.523 -1.031 . . . . 0.0 110.523 -179.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 10.6 p -135.74 146.85 28.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-O 120.859 0.361 . . . . 0.0 110.836 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 12.1 t . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.917 -1.04 . . . . 0.0 110.408 179.893 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.216 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 50.9 p90 -149.16 159.34 44.33 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-O 120.625 0.25 . . . . 0.0 110.608 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . 0.469 ' O ' ' O ' ' K' ' 11' ' ' GLU . 80.7 tt0 -102.99 154.24 19.43 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-O 121.105 0.479 . . . . 0.0 110.439 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . . . . . . . . . 2.1 p -138.94 151.96 23.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 -179.906 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . . . . . . . . . 11.2 m170 -116.24 171.15 8.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 120.961 0.41 . . . . 0.0 110.241 178.951 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 69.8 m80 -78.34 176.28 9.47 Favored 'General case' 0 N--CA 1.445 -0.698 0 CA-C-N 115.736 -0.666 . . . . 0.0 109.646 -179.437 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . 0.412 ' NE2' ' OE1' ' K' ' 15' ' ' GLN . 93.4 mt-30 -138.37 175.32 9.67 Favored 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 109.087 -0.708 . . . . 0.0 109.087 179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt -146.07 142.31 28.43 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-O 121.324 0.583 . . . . 0.0 111.808 -179.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 25.9 tp -126.17 113.01 16.46 Favored 'General case' 0 CA--C 1.529 0.138 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.241 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 73.8 t -130.35 128.45 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.909 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.329 -178.784 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.803 ' CZ ' HD23 ' J' ' 34' ' ' LEU . 9.3 m-30 -109.06 109.03 19.95 Favored 'General case' 0 N--CA 1.47 0.526 0 N-CA-C 107.622 -1.251 . . . . 0.0 107.622 177.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . 0.409 ' O ' ' HA ' ' K' ' 20' ' ' PHE . 33.7 t80 -112.53 114.03 26.48 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.392 0.615 . . . . 0.0 110.637 -179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . 0.422 ' O ' ' OD2' ' L' ' 23' ' ' ASP . . . -126.74 133.93 50.76 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.354 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . 0.471 ' O ' ' O ' ' K' ' 24' ' ' VAL . 84.3 tt0 -60.68 105.48 0.45 Allowed 'General case' 0 C--N 1.324 -0.528 0 C-N-CA 118.905 -1.118 . . . . 0.0 110.308 -177.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.422 ' OD2' ' O ' ' L' ' 21' ' ' ALA . 7.0 m-20 -154.46 136.21 14.44 Favored 'General case' 0 C--O 1.231 0.116 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.329 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . 0.624 HG23 ' O ' ' L' ' 24' ' ' VAL . 22.5 m -109.99 111.74 37.45 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 C-N-CA 119.862 -0.735 . . . . 0.0 110.566 179.945 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . 0.446 ' O ' ' O ' ' L' ' 26' ' ' SER . . . 31.84 -91.3 0.01 OUTLIER Glycine 0 CA--C 1.533 1.193 0 CA-C-N 115.194 -0.912 . . . . 0.0 114.438 176.688 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . 0.446 ' O ' ' O ' ' L' ' 25' ' ' GLY . 3.9 m 47.23 171.91 0.0 OUTLIER 'General case' 0 N--CA 1.447 -0.585 0 CA-C-N 114.033 -1.083 . . . . 0.0 110.965 -176.635 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.526 ' O ' ' O ' ' L' ' 28' ' ' LYS . 72.3 m-80 -140.09 -177.88 5.2 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 113.99 -1.459 . . . . 0.0 110.365 -179.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.526 ' O ' ' O ' ' L' ' 27' ' ' ASN . 99.2 mttt 26.5 102.13 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.068 0 O-C-N 123.716 0.635 . . . . 0.0 112.196 177.126 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 152.39 -101.57 0.21 Allowed Glycine 0 CA--C 1.493 -1.283 0 C-N-CA 119.913 -1.137 . . . . 0.0 111.791 -176.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' K' ' 29' ' ' GLY . . . -52.29 161.11 0.69 Allowed 'General case' 0 CA--C 1.514 -0.404 0 C-N-CA 119.007 -1.077 . . . . 0.0 108.375 -176.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -136.04 121.79 29.59 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.438 0 C-N-CA 118.588 -1.245 . . . . 0.0 109.641 -177.331 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -129.03 138.46 54.46 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.279 0 CA-C-N 115.637 -0.711 . . . . 0.0 111.626 -178.263 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . . . . . . . . . . . -129.97 120.99 3.25 Favored Glycine 0 N--CA 1.46 0.253 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 179.337 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . 0.435 ' O ' HD12 ' L' ' 34' ' ' LEU . 2.9 pp -126.12 122.24 35.16 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 38.2 mtp -134.81 143.49 47.08 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 122.147 0.975 . . . . 0.0 112.681 -178.958 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . . . . . . . . . 2.4 m -131.25 80.73 0.61 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.62 0 CA-C-N 113.642 -1.617 . . . . 0.0 110.159 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.547 ' CA ' HG21 ' F' ' 31' ' ' ILE . . . -55.31 102.47 0.16 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 110.141 -1.184 . . . . 0.0 110.141 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . -155.17 -177.53 28.53 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 111.111 -0.795 . . . . 0.0 111.111 -179.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 51.1 t -116.32 134.19 60.5 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-O 120.871 0.367 . . . . 0.0 110.073 -179.852 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 15.1 t . . . . . 0 C--O 1.22 -0.499 0 CA-C-O 117.937 -1.03 . . . . 0.0 110.588 -179.843 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.273 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . . . . . . . . . 96.0 m-85 -103.72 131.54 50.8 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-O 120.803 0.335 . . . . 0.0 110.427 179.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLU . . . . . . . . . . . . . 80.3 mm-40 -136.92 133.11 35.34 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 120.932 0.396 . . . . 0.0 110.061 179.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' B' ' 12' ' ' VAL . 2.4 p -136.28 145.11 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.285 0 CA-C-N 116.065 -0.516 . . . . 0.0 109.634 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' HIS . . . . . 0.474 ' O ' ' ND1' ' B' ' 13' ' ' HIS . 72.9 m80 -114.72 106.35 14.11 Favored 'General case' 0 C--N 1.329 -0.291 0 N-CA-C 110.187 -0.301 . . . . 0.0 110.187 179.694 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' HIS . . . . . 0.685 ' CD2' ' H ' ' A' ' 15' ' ' GLN . 11.6 t-160 -135.55 159.72 40.73 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.119 0.485 . . . . 0.0 109.767 179.577 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.685 ' H ' ' CD2' ' A' ' 14' ' ' HIS . 98.1 mm-40 -157.64 -178.93 7.69 Favored 'General case' 0 C--N 1.314 -0.976 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.847 179.772 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -147.8 122.54 9.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.383 178.714 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' LEU . . . . . . . . . . . . . 79.6 mt -129.64 117.25 20.07 Favored 'General case' 0 N--CA 1.47 0.528 0 CA-C-O 121.062 0.458 . . . . 0.0 110.659 179.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' VAL . . . . . . . . . . . . . 48.9 t -129.5 131.05 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.878 -0.601 . . . . 0.0 110.098 179.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -123.25 134.17 54.12 Favored 'General case' 0 N--CA 1.47 0.545 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.519 ' O ' ' CD2' ' A' ' 20' ' ' PHE . 54.6 p90 -137.12 124.84 22.41 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.898 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.24 128.21 45.67 Favored 'General case' 0 N--CA 1.475 0.816 0 CA-C-O 120.733 0.302 . . . . 0.0 111.253 -179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 99.4 mt-10 -147.39 146.66 29.7 Favored 'General case' 0 N--CA 1.468 0.469 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.248 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.497 ' CG ' ' H ' ' A' ' 24' ' ' VAL . 22.7 t0 -152.09 -141.21 0.1 Allowed 'General case' 0 N--CA 1.463 0.176 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 177.272 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.497 ' H ' ' CG ' ' A' ' 23' ' ' ASP . 80.3 t -90.26 111.28 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.336 0 C-N-CA 119.248 -0.981 . . . . 0.0 109.72 179.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLY . . . . . . . . . . . . . . . -46.65 91.47 0.01 OUTLIER Glycine 0 CA--C 1.536 1.346 0 CA-C-O 118.943 -0.92 . . . . 0.0 113.208 177.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' SER . . . . . 0.504 ' O ' ' O ' ' A' ' 27' ' ' ASN . 88.2 p -141.22 169.99 16.58 Favored 'General case' 0 CA--C 1.509 -0.618 0 CA-C-N 119.419 1.61 . . . . 0.0 108.985 175.578 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASN . . . . . 0.504 ' O ' ' O ' ' A' ' 26' ' ' SER . 99.8 m-20 -29.52 157.62 0.0 OUTLIER 'General case' 0 N--CA 1.477 0.912 0 O-C-N 123.799 0.687 . . . . 0.0 111.296 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.479 ' NZ ' ' OD1' ' C' ' 23' ' ' ASP . 33.1 pttt 178.83 102.03 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.137 0 N-CA-C 113.878 1.066 . . . . 0.0 113.878 175.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -67.53 100.61 0.62 Allowed Glycine 0 CA--C 1.496 -1.151 0 N-CA-C 105.216 -3.154 . . . . 0.0 105.216 174.145 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ALA . . . . . 0.574 ' O ' ' HB3' ' B' ' 30' ' ' ALA . . . -99.37 151.89 20.57 Favored 'General case' 0 C--O 1.251 1.169 0 C-N-CA 117.507 -1.677 . . . . 0.0 110.005 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ILE . . . . . 0.472 ' C ' ' SD ' ' G' ' 35' ' ' MET . 0.0 OUTLIER -143.77 107.36 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.423 -1.781 0 CA-C-N 110.443 -3.071 . . . . 0.0 108.449 -173.284 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ILE . . . . . 0.598 ' CG2' HD21 ' B' ' 34' ' ' LEU . 10.6 mt -103.43 111.0 31.52 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.719 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 178.035 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -115.72 92.48 0.58 Allowed Glycine 0 CA--C 1.501 -0.805 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 177.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' LEU . . . . . . . . . . . . . 6.5 tp -138.03 135.02 35.49 Favored 'General case' 0 CA--C 1.513 -0.478 0 CA-C-O 122.704 1.24 . . . . 0.0 111.169 -178.82 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' MET . . . . . . . . . . . . . 3.1 ptm -111.04 123.31 49.94 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 113.3 -1.773 . . . . 0.0 108.403 179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -116.14 70.1 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.031 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.842 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.649 ' HA3' HG21 ' G' ' 31' ' ' ILE . . . -82.92 -100.39 0.5 Allowed Glycine 0 C--N 1.354 1.544 0 N-CA-C 110.781 -0.928 . . . . 0.0 110.781 179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 156.8 -170.74 34.24 Favored Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.309 -0.717 . . . . 0.0 111.309 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' VAL . . . . . . . . . . . . . 29.4 m -136.07 162.07 36.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.348 0 CA-C-O 120.863 0.364 . . . . 0.0 110.548 -179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' VAL . . . . . . . . . . . . . 81.2 t . . . . . 0 C--O 1.22 -0.462 0 CA-C-O 117.955 -1.021 . . . . 0.0 110.379 179.749 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.319 0 N-CA-C 109.611 -1.395 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 10' ' ' TYR . . . . . . . . . . . . . 91.5 m-85 -110.57 134.34 52.48 Favored 'General case' 0 N--CA 1.467 0.383 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 11' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' C' ' 11' ' ' GLU . 94.8 mt-10 -138.79 142.76 38.75 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 12' ' ' VAL . . . . . 0.519 HG23 HG23 ' A' ' 12' ' ' VAL . 19.8 m -131.17 161.02 41.83 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.567 0 N-CA-C 110.201 -0.296 . . . . 0.0 110.201 179.849 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 13' ' ' HIS . . . . . 0.499 ' O ' ' O ' ' C' ' 13' ' ' HIS . 2.1 t60 -130.29 129.03 42.72 Favored 'General case' 0 N--CA 1.47 0.555 0 C-N-CA 121.083 -0.247 . . . . 0.0 110.515 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 14' ' ' HIS . . . . . 0.629 ' NE2' ' CG ' ' C' ' 13' ' ' HIS . 72.6 m80 -133.48 167.08 21.1 Favored 'General case' 0 CA--C 1.512 -0.515 0 CA-C-O 121.309 0.576 . . . . 0.0 109.678 179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 15' ' ' GLN . . . . . 0.477 HE21 HD21 ' B' ' 17' ' ' LEU . 46.2 tt0 -168.93 169.56 9.61 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.495 178.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 16' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -155.02 125.77 7.0 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 178.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 17' ' ' LEU . . . . . 0.477 HD21 HE21 ' B' ' 15' ' ' GLN . 66.3 mt -122.22 110.97 16.37 Favored 'General case' 0 C--O 1.24 0.57 0 CA-C-O 121.058 0.456 . . . . 0.0 109.796 179.606 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 18' ' ' VAL . . . . . . . . . . . . . 93.7 t -119.94 126.93 75.8 Favored 'Isoleucine or valine' 0 C--O 1.235 0.333 0 CA-C-N 115.97 -0.559 . . . . 0.0 110.94 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 19' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -125.81 120.37 30.35 Favored 'General case' 0 C--O 1.235 0.313 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.608 179.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 20' ' ' PHE . . . . . 0.418 ' HB2' ' CZ ' ' C' ' 20' ' ' PHE . 3.7 t80 -125.63 129.15 49.03 Favored 'General case' 0 N--CA 1.467 0.423 0 N-CA-C 109.114 -0.698 . . . . 0.0 109.114 179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 21' ' ' ALA . . . . . . . . . . . . . . . -151.92 155.93 39.07 Favored 'General case' 0 C--O 1.241 0.619 0 N-CA-C 116.767 2.136 . . . . 0.0 116.767 -178.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 22' ' ' GLU . . . . . . . . . . . . . 75.9 tt0 -162.75 78.34 0.47 Allowed 'General case' 0 N--CA 1.451 -0.375 0 CA-C-N 111.145 -2.752 . . . . 0.0 106.1 177.702 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 23' ' ' ASP . . . . . 0.405 ' O ' ' C ' ' B' ' 24' ' ' VAL . 67.2 t0 -170.33 131.33 0.95 Allowed 'General case' 0 N--CA 1.465 0.281 0 C-N-CA 120.889 -0.324 . . . . 0.0 110.887 -176.384 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 24' ' ' VAL . . . . . 0.451 HG23 ' H ' ' B' ' 24' ' ' VAL . 2.5 t -35.13 111.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 CA-C-O 121.555 0.693 . . . . 0.0 111.795 -178.426 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 25' ' ' GLY . . . . . . . . . . . . . . . 121.11 -93.12 0.52 Allowed Glycine 0 N--CA 1.466 0.68 0 N-CA-C 108.576 -1.81 . . . . 0.0 108.576 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 26' ' ' SER . . . . . 0.544 ' O ' ' ND2' ' B' ' 27' ' ' ASN . 4.4 m -60.9 171.91 1.1 Allowed 'General case' 0 N--CA 1.436 -1.139 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 175.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 27' ' ' ASN . . . . . 0.576 ' OD1' ' N ' ' B' ' 28' ' ' LYS . 0.9 OUTLIER 100.07 -170.88 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 CA-C-O 122.16 0.981 . . . . 0.0 113.506 178.441 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 28' ' ' LYS . . . . . 0.576 ' N ' ' OD1' ' B' ' 27' ' ' ASN . 86.7 tttt -29.26 111.07 0.06 Allowed 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 113.349 -1.751 . . . . 0.0 113.016 179.549 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 29' ' ' GLY . . . . . 0.598 ' O ' ' HB1' ' C' ' 30' ' ' ALA . . . -80.99 100.91 2.02 Favored Glycine 0 CA--C 1.49 -1.518 0 CA-C-O 127.632 3.907 . . . . 0.0 109.401 -176.86 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 30' ' ' ALA . . . . . 0.574 ' HB3' ' O ' ' A' ' 30' ' ' ALA . . . -79.31 -125.07 0.01 OUTLIER 'General case' 1 N--CA 1.37 -4.446 3 N-CA-C 87.399 -8.741 . . . . 0.0 87.399 166.239 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild full ' B' B ' 31' ' ' ILE . . . . . 0.481 ' C ' ' SD ' ' H' ' 35' ' ' MET . 0.2 OUTLIER -72.9 115.62 13.94 Favored 'Isoleucine or valine' 1 C--N 1.226 -4.792 0 CA-C-N 125.138 3.608 . . . . 0.0 111.128 176.465 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' B' B ' 32' ' ' ILE . . . . . 0.565 ' N ' ' SD ' ' H' ' 35' ' ' MET . 0.1 OUTLIER -109.41 115.48 49.7 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.219 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 178.774 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.7 90.94 0.58 Allowed Glycine 0 C--O 1.24 0.473 0 N-CA-C 105.658 -2.977 . . . . 0.0 105.658 177.274 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 34' ' ' LEU . . . . . 0.598 HD21 ' CG2' ' A' ' 32' ' ' ILE . 74.4 mt -121.27 137.0 54.88 Favored 'General case' 0 CA--C 1.511 -0.521 0 CA-C-O 122.422 1.106 . . . . 0.0 112.06 -177.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 35' ' ' MET . . . . . 0.736 ' SD ' ' N ' ' H' ' 33' ' ' GLY . 34.2 ttp -126.25 117.3 22.77 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.378 -1.283 . . . . 0.0 108.864 -179.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 36' ' ' VAL . . . . . 0.616 HG22 HD11 ' C' ' 34' ' ' LEU . 34.0 m -123.36 71.49 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 C-N-CA 120.343 -0.543 . . . . 0.0 110.066 179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 37' ' ' GLY . . . . . . . . . . . . . . . -116.1 -101.72 2.28 Favored Glycine 0 C--N 1.353 1.523 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 38' ' ' GLY . . . . . . . . . . . . . . . 90.4 166.78 41.41 Favored Glycine 0 CA--C 1.527 0.822 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 39' ' ' VAL . . . . . . . . . . . . . 3.8 p -134.46 142.0 41.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-O 120.759 0.314 . . . . 0.0 110.306 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 40' ' ' VAL . . . . . . . . . . . . . 19.8 m . . . . . 0 C--O 1.22 -0.467 0 CA-C-O 118.036 -0.983 . . . . 0.0 110.398 179.801 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.258 -1.537 . . . . 0.0 109.258 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' C' C ' 10' ' ' TYR . . . . . . . . . . . . . 97.0 m-85 -123.74 141.47 51.99 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 120.989 0.424 . . . . 0.0 110.958 -179.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 11' ' ' GLU . . . . . 0.453 ' O ' ' O ' ' B' ' 11' ' ' GLU . 80.7 tt0 -111.2 137.15 49.27 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 115.802 -0.636 . . . . 0.0 109.782 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 12' ' ' VAL . . . . . . . . . . . . . 16.6 m -146.56 167.2 6.98 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.542 0 CA-C-O 120.993 0.425 . . . . 0.0 111.643 -179.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 13' ' ' HIS . . . . . 0.629 ' CG ' ' NE2' ' B' ' 14' ' ' HIS . 29.7 m-70 -133.32 145.12 50.14 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 178.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 14' ' ' HIS . . . . . . . . . . . . . 36.6 m170 -84.48 -179.46 7.16 Favored 'General case' 0 N--CA 1.447 -0.575 0 CA-C-O 121.32 0.581 . . . . 0.0 110.272 -178.883 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 15' ' ' GLN . . . . . . . . . . . . . 33.6 mt-30 -90.91 175.23 7.05 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.994 -179.069 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 16' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -130.01 134.46 47.43 Favored 'General case' 0 N--CA 1.469 0.514 0 CA-C-N 115.817 -0.629 . . . . 0.0 109.363 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 17' ' ' LEU . . . . . . . . . . . . . 37.8 tp -131.55 121.46 24.46 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-O 121.257 0.551 . . . . 0.0 112.412 -178.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 18' ' ' VAL . . . . . . . . . . . . . 18.0 m -132.04 127.26 57.77 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.458 0 CA-C-O 121.989 0.9 . . . . 0.0 110.734 177.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 19' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -115.13 119.49 36.59 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 114.716 -1.129 . . . . 0.0 108.97 179.691 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 20' ' ' PHE . . . . . 0.418 ' CZ ' ' HB2' ' B' ' 20' ' ' PHE . 53.2 p90 -147.37 150.81 35.43 Favored 'General case' 0 C--O 1.237 0.427 0 C-N-CA 118.615 -1.234 . . . . 0.0 112.512 177.534 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 21' ' ' ALA . . . . . . . . . . . . . . . -149.14 150.19 32.29 Favored 'General case' 0 C--O 1.241 0.634 0 N-CA-C 113.997 1.11 . . . . 0.0 113.997 -176.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 22' ' ' GLU . . . . . . . . . . . . . 81.0 tt0 -119.01 117.15 28.0 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 113.307 -1.77 . . . . 0.0 107.673 177.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 23' ' ' ASP . . . . . 0.581 ' O ' ' O ' ' C' ' 24' ' ' VAL . 57.3 m-20 -147.45 135.88 21.71 Favored 'General case' 0 CA--C 1.51 -0.595 0 C-N-CA 120.58 -0.448 . . . . 0.0 111.964 -177.579 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 24' ' ' VAL . . . . . 0.581 ' O ' ' O ' ' C' ' 23' ' ' ASP . 8.5 t -29.4 -110.62 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.468 0.448 0 O-C-N 124.54 1.15 . . . . 0.0 111.283 178.132 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 25' ' ' GLY . . . . . . . . . . . . . . . -159.7 91.88 0.12 Allowed Glycine 0 CA--C 1.526 0.761 0 C-N-CA 119.999 -1.096 . . . . 0.0 112.886 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 26' ' ' SER . . . . . . . . . . . . . 12.3 p -62.8 -176.98 0.13 Allowed 'General case' 0 N--CA 1.442 -0.838 0 N-CA-C 106.901 -1.518 . . . . 0.0 106.901 178.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 27' ' ' ASN . . . . . 0.464 ' CG ' ' N ' ' C' ' 28' ' ' LYS . 50.8 t30 -79.49 170.56 16.4 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 118.842 -1.143 . . . . 0.0 112.632 -178.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 28' ' ' LYS . . . . . 0.722 ' NZ ' HD21 ' E' ' 27' ' ' ASN . 29.1 mmtt -46.24 111.9 0.42 Allowed 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 115.712 1.745 . . . . 0.0 115.712 178.986 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 29' ' ' GLY . . . . . 0.551 ' H ' ' HA3' ' D' ' 25' ' ' GLY . . . 92.69 93.78 1.45 Allowed Glycine 0 N--CA 1.473 1.13 0 CA-C-N 115.378 -0.828 . . . . 0.0 114.495 177.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 30' ' ' ALA . . . . . 0.598 ' HB1' ' O ' ' B' ' 29' ' ' GLY . . . -85.41 176.71 8.11 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 101.411 -3.552 . . . . 0.0 101.411 172.199 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 31' ' ' ILE . . . . . 0.438 HG12 ' C ' ' C' ' 30' ' ' ALA . 0.0 OUTLIER -141.97 111.72 2.76 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.986 0 C-N-CA 118.717 -1.193 . . . . 0.0 110.248 -175.62 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 32' ' ' ILE . . . . . . . . . . . . . 46.4 mt -98.75 111.17 27.71 Favored 'Isoleucine or valine' 0 C--N 1.349 0.569 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 178.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 33' ' ' GLY . . . . . . . . . . . . . . . -111.41 99.64 1.13 Allowed Glycine 0 CA--C 1.505 -0.581 0 N-CA-C 106.048 -2.821 . . . . 0.0 106.048 175.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 34' ' ' LEU . . . . . 0.616 HD11 HG22 ' B' ' 36' ' ' VAL . 19.6 tp -135.83 133.17 37.54 Favored 'General case' 0 C--O 1.237 0.414 0 CA-C-O 123.056 1.408 . . . . 0.0 112.419 -176.901 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 35' ' ' MET . . . . . 0.774 ' SD ' HG22 ' I' ' 31' ' ' ILE . 41.2 ttp -110.49 122.06 46.82 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 113.269 -1.787 . . . . 0.0 109.532 179.445 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' C' C ' 36' ' ' VAL . . . . . 0.416 HG13 ' CG2' ' B' ' 36' ' ' VAL . 0.0 OUTLIER -109.61 66.76 0.2 Allowed 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 179.618 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' C' C ' 37' ' ' GLY . . . . . . . . . . . . . . . -52.59 -102.81 0.01 OUTLIER Glycine 0 C--N 1.362 1.99 0 N-CA-C 111.128 -0.789 . . . . 0.0 111.128 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 38' ' ' GLY . . . . . . . . . . . . . . . 101.88 158.03 26.47 Favored Glycine 0 CA--C 1.526 0.781 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.752 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 39' ' ' VAL . . . . . . . . . . . . . 33.8 m -134.4 162.74 38.47 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-O 120.792 0.33 . . . . 0.0 110.438 -179.841 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' C' C ' 40' ' ' VAL . . . . . . . . . . . . . 7.9 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.961 -1.019 . . . . 0.0 110.851 -179.897 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.358 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' D' D ' 10' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -85.37 133.81 34.11 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 11' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -129.79 130.64 45.6 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.306 179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 12' ' ' VAL . . . . . . . . . . . . . 53.4 t -112.73 131.07 65.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.311 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 178.948 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 13' ' ' HIS . . . . . 0.449 ' CD2' ' O ' ' D' ' 14' ' ' HIS . 84.3 t60 -89.67 130.18 35.99 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-O 121.0 0.428 . . . . 0.0 111.864 -178.388 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 14' ' ' HIS . . . . . 0.449 ' O ' ' CD2' ' D' ' 13' ' ' HIS . 2.8 m-70 -82.84 178.16 8.31 Favored 'General case' 0 N--CA 1.445 -0.695 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 179.356 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 15' ' ' GLN . . . . . . . . . . . . . 15.0 pt20 -96.42 178.4 5.37 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.548 -178.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 16' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -142.29 137.69 30.81 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.825 179.279 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 17' ' ' LEU . . . . . . . . . . . . . 41.7 tp -120.82 115.06 22.53 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.982 -0.554 . . . . 0.0 109.618 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 18' ' ' VAL . . . . . . . . . . . . . 46.3 t -125.3 127.08 71.74 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.827 0 C-N-CA 120.408 -0.517 . . . . 0.0 112.153 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 19' ' ' PHE . . . . . . . . . . . . . 15.4 m-85 -118.12 114.46 23.12 Favored 'General case' 0 N--CA 1.467 0.402 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 177.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 20' ' ' PHE . . . . . 0.532 ' CZ ' ' OE2' ' E' ' 22' ' ' GLU . 21.5 t80 -127.6 119.08 25.15 Favored 'General case' 0 N--CA 1.481 1.111 0 CA-C-O 121.179 0.514 . . . . 0.0 110.328 -179.728 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 21' ' ' ALA . . . . . 0.428 ' O ' ' OE1' ' E' ' 22' ' ' GLU . . . -132.19 133.31 44.04 Favored 'General case' 0 C--O 1.243 0.761 0 CA-C-O 121.928 0.87 . . . . 0.0 112.629 -178.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 22' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -91.4 133.61 35.32 Favored 'General case' 0 C--N 1.339 0.112 0 CA-C-N 114.677 -1.147 . . . . 0.0 108.627 178.091 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 23' ' ' ASP . . . . . 0.458 ' O ' ' NZ ' ' B' ' 28' ' ' LYS . 5.8 t0 71.55 103.54 0.07 Allowed 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 121.203 0.525 . . . . 0.0 110.191 -178.934 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 24' ' ' VAL . . . . . 0.543 ' O ' ' C ' ' D' ' 25' ' ' GLY . 8.4 p -134.83 135.15 53.43 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 N-CA-C 105.747 -1.946 . . . . 0.0 105.747 -178.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 25' ' ' GLY . . . . . 0.551 ' HA3' ' H ' ' C' ' 29' ' ' GLY . . . -24.39 -82.51 0.01 OUTLIER Glycine 0 N--CA 1.48 1.62 0 CA-C-O 118.425 -1.208 . . . . 0.0 111.648 -174.696 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 26' ' ' SER . . . . . 0.453 ' OG ' ' O ' ' E' ' 27' ' ' ASN . 5.5 p -166.8 176.22 7.25 Favored 'General case' 0 N--CA 1.448 -0.56 0 CA-C-N 120.698 2.249 . . . . 0.0 113.037 174.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 27' ' ' ASN . . . . . . . . . . . . . 11.9 t-20 48.28 178.2 0.01 OUTLIER 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 113.074 -1.875 . . . . 0.0 113.057 174.611 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 28' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -71.66 111.55 7.04 Favored 'General case' 0 N--CA 1.437 -1.077 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 174.782 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 29' ' ' GLY . . . . . 0.942 ' O ' ' HB1' ' E' ' 30' ' ' ALA . . . 84.87 94.49 0.73 Allowed Glycine 0 CA--C 1.482 -2.019 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.811 -177.807 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 30' ' ' ALA . . . . . 0.811 ' C ' HD13 ' D' ' 31' ' ' ILE . . . -75.46 -149.84 0.03 OUTLIER 'General case' 0 CA--C 1.498 -1.051 1 N-CA-C 96.892 -5.225 . . . . 0.0 96.892 168.435 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 31' ' ' ILE . . . . . 0.87 ' N ' HD13 ' D' ' 31' ' ' ILE . 0.1 OUTLIER -97.51 102.12 13.07 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.163 1 CA-C-N 127.292 4.587 . . . . 0.0 109.907 178.45 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' D' D ' 32' ' ' ILE . . . . . . . . . . . . . 11.0 tt -112.97 121.94 66.15 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.612 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.849 -179.599 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 33' ' ' GLY . . . . . . . . . . . . . . . -112.46 100.1 1.1 Allowed Glycine 0 N--CA 1.442 -0.917 0 N-CA-C 107.064 -2.414 . . . . 0.0 107.064 177.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 34' ' ' LEU . . . . . . . . . . . . . 8.5 tp -117.19 120.7 39.07 Favored 'General case' 0 CA--C 1.508 -0.64 0 CA-C-O 121.702 0.763 . . . . 0.0 110.492 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 35' ' ' MET . . . . . . . . . . . . . 4.9 tmm? -104.26 115.91 31.24 Favored 'General case' 0 CA--C 1.502 -0.888 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 177.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 36' ' ' VAL . . . . . 0.473 ' O ' ' O ' ' D' ' 37' ' ' GLY . 0.1 OUTLIER -118.19 71.43 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.556 1.18 0 N-CA-C 109.3 -0.63 . . . . 0.0 109.3 -179.0 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' D' D ' 37' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' D' ' 36' ' ' VAL . . . -30.24 -101.12 0.01 OUTLIER Glycine 0 C--N 1.366 2.228 0 N-CA-C 111.86 -0.496 . . . . 0.0 111.86 178.766 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' D' D ' 38' ' ' GLY . . . . . . . . . . . . . . . 171.48 -179.81 43.02 Favored Glycine 0 CA--C 1.524 0.602 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.61 -179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 39' ' ' VAL . . . . . . . . . . . . . 51.7 t -125.34 135.76 62.98 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.454 -0.373 . . . . 0.0 110.086 -179.533 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' D' D ' 40' ' ' VAL . . . . . . . . . . . . . 19.6 t . . . . . 0 C--O 1.22 -0.479 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.593 179.951 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.253 0 N-CA-C 109.554 -1.419 . . . . 0.0 109.554 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' E' E ' 10' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -103.91 135.35 45.61 Favored 'General case' 0 N--CA 1.466 0.366 0 CA-C-O 120.916 0.388 . . . . 0.0 110.21 179.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 11' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -106.8 151.39 25.24 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.927 -179.378 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 12' ' ' VAL . . . . . . . . . . . . . 28.6 m -131.09 156.94 43.15 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.078 -0.51 . . . . 0.0 109.969 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 13' ' ' HIS . . . . . . . . . . . . . 93.1 m-70 -93.75 174.28 7.26 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.798 0.332 . . . . 0.0 110.329 179.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 14' ' ' HIS . . . . . 0.627 ' N ' ' ND1' ' E' ' 14' ' ' HIS . 0.2 OUTLIER -78.32 174.04 11.67 Favored 'General case' 0 N--CA 1.444 -0.731 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 -179.374 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 15' ' ' GLN . . . . . 0.405 ' HG2' ' H ' ' E' ' 16' ' ' LYS . 44.1 tt0 -122.63 172.15 8.61 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.878 -0.601 . . . . 0.0 109.614 179.884 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 16' ' ' LYS . . . . . 0.405 ' H ' ' HG2' ' E' ' 15' ' ' GLN . 65.7 mttp -153.82 119.07 5.12 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 121.101 0.477 . . . . 0.0 111.6 -179.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 17' ' ' LEU . . . . . . . . . . . . . 12.8 mt -126.31 116.43 21.21 Favored 'General case' 0 C--O 1.235 0.291 0 N-CA-C 107.309 -1.367 . . . . 0.0 107.309 178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 18' ' ' VAL . . . . . 0.533 HG21 ' CE2' ' E' ' 20' ' ' PHE . 5.6 p -143.16 147.56 20.31 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 N-CA-C 113.558 0.947 . . . . 0.0 113.558 -178.182 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 19' ' ' PHE . . . . . . . . . . . . . 40.0 m-85 -120.04 124.33 45.61 Favored 'General case' 0 N--CA 1.467 0.387 0 CA-C-N 114.227 -1.351 . . . . 0.0 109.747 179.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 20' ' ' PHE . . . . . 0.533 ' CE2' HG21 ' E' ' 18' ' ' VAL . 31.9 m-85 -121.39 126.81 50.29 Favored 'General case' 0 N--CA 1.475 0.784 0 O-C-N 122.373 -0.205 . . . . 0.0 110.529 179.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 21' ' ' ALA . . . . . 0.446 ' HB1' HG11 ' D' ' 24' ' ' VAL . . . -138.06 137.57 37.92 Favored 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 112.795 0.665 . . . . 0.0 112.795 -179.236 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 22' ' ' GLU . . . . . 0.532 ' OE2' ' CZ ' ' D' ' 20' ' ' PHE . 58.0 mp0 -113.22 137.84 50.87 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 113.213 0.82 . . . . 0.0 113.213 -179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 23' ' ' ASP . . . . . 0.477 ' OD1' ' O ' ' D' ' 25' ' ' GLY . 27.4 t70 -150.0 132.46 15.68 Favored 'General case' 0 N--CA 1.474 0.771 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.383 178.434 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 24' ' ' VAL . . . . . 0.527 ' O ' HG23 ' E' ' 24' ' ' VAL . 30.1 m -74.59 113.08 12.67 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.071 179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 25' ' ' GLY . . . . . . . . . . . . . . . 59.08 92.18 0.01 OUTLIER Glycine 0 CA--C 1.527 0.824 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.447 178.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 26' ' ' SER . . . . . . . . . . . . . 74.0 m -47.81 151.63 0.86 Allowed 'General case' 0 N--CA 1.443 -0.798 0 CA-C-N 115.693 -0.253 . . . . 0.0 111.518 178.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 27' ' ' ASN . . . . . 0.722 HD21 ' NZ ' ' C' ' 28' ' ' LYS . 10.3 p30 -157.35 178.43 10.32 Favored 'General case' 0 CA--C 1.55 0.957 0 N-CA-C 114.74 1.385 . . . . 0.0 114.74 173.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 28' ' ' LYS . . . . . . . . . . . . . 98.1 mttt 1.63 104.4 0.01 OUTLIER 'General case' 0 N--CA 1.481 1.084 0 N-CA-C 119.236 3.051 . . . . 0.0 119.236 177.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 29' ' ' GLY . . . . . 0.501 ' O ' ' CB ' ' F' ' 30' ' ' ALA . . . 90.43 -100.63 2.7 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 116.404 1.322 . . . . 0.0 116.404 167.881 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 30' ' ' ALA . . . . . 0.942 ' HB1' ' O ' ' D' ' 29' ' ' GLY . . . 56.86 149.78 0.01 OUTLIER 'General case' 0 C--O 1.255 1.356 0 CA-C-N 112.138 -2.031 . . . . 0.0 106.645 -177.407 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 31' ' ' ILE . . . . . 0.721 HG23 HG12 ' F' ' 31' ' ' ILE . 0.1 OUTLIER -158.23 134.48 2.0 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.713 0 C-N-CA 118.669 -1.212 . . . . 0.0 110.734 -174.341 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 32' ' ' ILE . . . . . 0.534 HD11 HD11 ' E' ' 34' ' ' LEU . 0.7 OUTLIER -128.57 121.45 55.11 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.709 0 CA-C-O 121.4 0.619 . . . . 0.0 110.769 179.705 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' E' E ' 33' ' ' GLY . . . . . 0.546 ' CA ' ' SD ' ' K' ' 35' ' ' MET . . . -114.64 117.02 3.94 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 34' ' ' LEU . . . . . 0.74 HD22 ' CZ ' ' F' ' 19' ' ' PHE . 22.9 mt -118.72 120.15 36.56 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 115.548 -0.326 . . . . 0.0 110.479 -178.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 35' ' ' MET . . . . . 0.669 ' SD ' ' N ' ' K' ' 33' ' ' GLY . 15.5 ttp -116.61 115.54 25.9 Favored 'General case' 0 N--CA 1.47 0.561 0 C-N-CA 120.401 -0.52 . . . . 0.0 109.884 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 36' ' ' VAL . . . . . 0.654 HG13 HG22 ' F' ' 36' ' ' VAL . 2.8 p -144.03 83.77 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 C-N-CA 120.516 -0.474 . . . . 0.0 111.52 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 37' ' ' GLY . . . . . 0.475 ' C ' ' O ' ' E' ' 36' ' ' VAL . . . -18.95 -94.49 0.01 OUTLIER Glycine 0 CA--C 1.529 0.931 0 CA-C-N 115.768 -0.651 . . . . 0.0 112.663 179.178 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' E' E ' 38' ' ' GLY . . . . . . . . . . . . . . . 166.12 -164.05 37.24 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 111.249 -0.74 . . . . 0.0 111.249 -179.972 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 39' ' ' VAL . . . . . . . . . . . . . 31.2 m -134.07 161.01 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.317 0 CA-C-O 120.847 0.356 . . . . 0.0 110.707 -179.409 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' E' E ' 40' ' ' VAL . . . . . . . . . . . . . 5.4 p . . . . . 0 C--O 1.221 -0.434 0 CA-C-O 117.987 -1.006 . . . . 0.0 110.433 179.828 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.331 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' F' F ' 10' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -112.28 149.66 32.06 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-O 120.81 0.338 . . . . 0.0 110.387 179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 11' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -54.01 149.14 9.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.132 179.997 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 12' ' ' VAL . . . . . . . . . . . . . 65.3 t -114.34 130.84 67.93 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.49 0 CA-C-O 121.077 0.465 . . . . 0.0 110.948 -179.638 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 13' ' ' HIS . . . . . 0.414 ' O ' ' CG ' ' F' ' 14' ' ' HIS . 31.1 p-80 -154.07 134.61 13.53 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.532 -179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 14' ' ' HIS . . . . . 0.414 ' CG ' ' O ' ' F' ' 13' ' ' HIS . 93.9 m-70 -155.23 170.03 22.8 Favored 'General case' 0 N--CA 1.445 -0.694 0 CA-C-O 121.303 0.573 . . . . 0.0 109.602 -179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 15' ' ' GLN . . . . . . . . . . . . . 96.6 mt-30 -143.96 173.81 11.39 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.431 -0.804 . . . . 0.0 108.884 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 16' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -152.44 129.85 11.36 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.013 0.435 . . . . 0.0 111.045 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 17' ' ' LEU . . . . . . . . . . . . . 32.1 tp -121.08 117.9 28.38 Favored 'General case' 0 N--CA 1.465 0.293 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 178.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 18' ' ' VAL . . . . . . . . . . . . . 56.1 t -133.51 133.14 57.57 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.702 0 N-CA-C 113.483 0.92 . . . . 0.0 113.483 -177.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 19' ' ' PHE . . . . . 0.74 ' CZ ' HD22 ' E' ' 34' ' ' LEU . 86.2 m-85 -118.48 114.73 23.3 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 115.313 -0.858 . . . . 0.0 108.902 177.62 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 20' ' ' PHE . . . . . . . . . . . . . 7.9 m-85 -134.18 144.86 48.73 Favored 'General case' 0 N--CA 1.477 0.885 0 CA-C-O 122.282 1.039 . . . . 0.0 112.086 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 21' ' ' ALA . . . . . . . . . . . . . . . -148.43 148.35 30.2 Favored 'General case' 0 N--CA 1.452 -0.343 0 CA-C-N 114.569 -1.196 . . . . 0.0 109.128 178.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 22' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -76.52 136.83 39.32 Favored 'General case' 0 N--CA 1.471 0.578 0 C-N-CA 119.86 -0.736 . . . . 0.0 111.712 -178.379 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 23' ' ' ASP . . . . . . . . . . . . . 17.3 p-10 -149.62 134.03 17.46 Favored 'General case' 0 CA--C 1.534 0.339 0 CA-C-O 121.418 0.628 . . . . 0.0 111.086 179.701 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 24' ' ' VAL . . . . . 0.455 ' O ' ' O ' ' F' ' 25' ' ' GLY . 12.9 t -93.71 112.55 26.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.841 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.292 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 25' ' ' GLY . . . . . 0.463 ' O ' ' ND2' ' F' ' 27' ' ' ASN . . . 42.64 91.42 0.01 OUTLIER Glycine 0 N--CA 1.472 1.063 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 179.393 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 26' ' ' SER . . . . . . . . . . . . . 85.7 p -45.2 152.16 0.29 Allowed 'General case' 0 N--CA 1.439 -1.022 0 CA-C-O 123.066 1.412 . . . . 0.0 111.989 -176.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 27' ' ' ASN . . . . . 0.622 ' O ' ' O ' ' F' ' 28' ' ' LYS . 69.0 m-80 -156.84 -170.9 3.46 Favored 'General case' 0 C--N 1.304 -1.402 0 CA-C-N 111.679 -2.51 . . . . 0.0 106.304 -179.031 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 28' ' ' LYS . . . . . 0.622 ' O ' ' O ' ' F' ' 27' ' ' ASN . 99.7 mttt 19.19 110.52 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 121.797 0.808 . . . . 0.0 113.166 177.647 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 29' ' ' GLY . . . . . . . . . . . . . . . -89.19 96.62 2.23 Favored Glycine 0 CA--C 1.492 -1.395 0 CA-C-O 123.412 1.562 . . . . 0.0 111.877 -174.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 30' ' ' ALA . . . . . 0.501 ' CB ' ' O ' ' E' ' 29' ' ' GLY . . . -63.94 -171.15 0.05 OUTLIER 'General case' 0 CA--C 1.489 -1.376 0 CA-C-N 110.989 -2.606 . . . . 0.0 107.537 -179.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 31' ' ' ILE . . . . . 0.721 HG12 HG23 ' E' ' 31' ' ' ILE . 0.0 OUTLIER -132.74 133.76 59.01 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.614 0 C-N-CA 117.261 -1.776 . . . . 0.0 113.191 -176.283 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' F' F ' 32' ' ' ILE . . . . . 0.444 HG23 ' O ' ' F' ' 32' ' ' ILE . 14.9 tt -126.71 132.41 70.17 Favored 'Isoleucine or valine' 0 C--N 1.345 0.386 0 CA-C-N 113.747 -1.57 . . . . 0.0 112.202 -177.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 33' ' ' GLY . . . . . . . . . . . . . . . -122.7 115.54 2.74 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 178.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 34' ' ' LEU . . . . . . . . . . . . . 25.4 tp -119.47 119.51 34.09 Favored 'General case' 0 C--N 1.329 -0.285 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 35' ' ' MET . . . . . 0.623 ' SD ' ' N ' ' L' ' 33' ' ' GLY . 30.8 ttp -114.03 118.61 34.58 Favored 'General case' 0 N--CA 1.475 0.801 0 C-N-CA 121.267 -0.173 . . . . 0.0 111.196 -178.91 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 36' ' ' VAL . . . . . 0.654 HG22 HG13 ' E' ' 36' ' ' VAL . 5.0 t -139.11 83.05 0.42 Allowed 'Isoleucine or valine' 0 N--CA 1.47 0.552 0 CA-C-O 119.295 -0.384 . . . . 0.0 110.686 179.595 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 37' ' ' GLY . . . . . 0.514 ' C ' ' O ' ' F' ' 36' ' ' VAL . . . -15.73 -95.66 0.01 OUTLIER Glycine 0 C--N 1.351 1.367 0 O-C-N 123.063 0.227 . . . . 0.0 112.886 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' F' F ' 38' ' ' GLY . . . . . . . . . . . . . . . 127.92 163.05 11.26 Favored Glycine 0 N--CA 1.466 0.695 0 N-CA-C 110.855 -0.898 . . . . 0.0 110.855 179.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 39' ' ' VAL . . . . . . . . . . . . . 28.6 m -140.31 160.38 25.41 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.253 0 CA-C-O 120.825 0.345 . . . . 0.0 110.655 179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' F' F ' 40' ' ' VAL . . . . . . . . . . . . . 18.9 m . . . . . 0 C--O 1.221 -0.42 0 CA-C-O 118.025 -0.988 . . . . 0.0 110.532 -179.968 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.525 -1.43 . . . . 0.0 109.525 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' G' G ' 10' ' ' TYR . . . . . . . . . . . . . 95.6 m-85 -106.03 135.37 47.62 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-O 120.907 0.385 . . . . 0.0 110.724 -179.91 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 11' ' ' GLU . . . . . 0.426 ' OE2' ' O ' ' H' ' 9' ' ' GLY . 73.1 mm-40 -84.28 142.6 30.11 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.53 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 12' ' ' VAL . . . . . . . . . . . . . 12.0 p -127.09 136.84 59.62 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.725 -179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 13' ' ' HIS . . . . . 0.475 ' N ' ' ND1' ' G' ' 13' ' ' HIS . 2.5 p-80 -149.23 168.49 23.14 Favored 'General case' 0 N--CA 1.463 0.192 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.995 -179.137 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 14' ' ' HIS . . . . . 0.571 ' CD2' ' H ' ' H' ' 14' ' ' HIS . 89.0 m-70 -132.83 178.26 7.0 Favored 'General case' 0 CA--C 1.514 -0.426 0 N-CA-C 109.265 -0.642 . . . . 0.0 109.265 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 15' ' ' GLN . . . . . . . . . . . . . 77.9 mt-30 -129.09 -179.13 4.94 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.086 179.928 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 16' ' ' LYS . . . . . . . . . . . . . 89.2 tttt -99.23 142.53 30.6 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.643 -179.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 17' ' ' LEU . . . . . . . . . . . . . 74.7 mt -125.68 118.79 26.38 Favored 'General case' 0 C--O 1.236 0.354 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 179.042 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 18' ' ' VAL . . . . . . . . . . . . . 3.8 p -136.28 138.67 46.7 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.204 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.753 -179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 19' ' ' PHE . . . . . . . . . . . . . 81.8 m-85 -119.64 126.36 50.96 Favored 'General case' 0 N--CA 1.462 0.168 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.211 179.827 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 20' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -122.5 120.76 34.82 Favored 'General case' 0 N--CA 1.467 0.405 0 N-CA-C 109.525 -0.546 . . . . 0.0 109.525 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 21' ' ' ALA . . . . . . . . . . . . . . . -127.08 127.61 44.94 Favored 'General case' 0 N--CA 1.475 0.812 0 CA-C-O 121.105 0.479 . . . . 0.0 111.806 -179.294 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 22' ' ' GLU . . . . . . . . . . . . . 83.3 tt0 -160.83 87.27 0.73 Allowed 'General case' 0 CA--C 1.533 0.324 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.685 179.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 23' ' ' ASP . . . . . . . . . . . . . 67.0 t0 -178.37 123.13 0.1 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 120.925 0.393 . . . . 0.0 110.628 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 24' ' ' VAL . . . . . . . . . . . . . 57.8 t -38.93 114.34 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.466 0.363 0 CA-C-N 115.979 -0.555 . . . . 0.0 112.185 179.485 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 25' ' ' GLY . . . . . 0.808 ' H ' HG21 ' H' ' 24' ' ' VAL . . . -98.14 -86.41 1.84 Allowed Glycine 0 N--CA 1.47 0.907 0 N-CA-C 109.989 -1.244 . . . . 0.0 109.989 177.279 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 26' ' ' SER . . . . . 0.747 ' O ' ' O ' ' G' ' 27' ' ' ASN . 17.0 m -151.58 -173.06 4.4 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 107.003 -1.481 . . . . 0.0 107.003 177.536 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 27' ' ' ASN . . . . . 0.747 ' O ' ' O ' ' G' ' 26' ' ' SER . 97.0 m-20 -22.79 170.0 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.312 0 O-C-N 124.313 1.008 . . . . 0.0 113.235 179.387 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 28' ' ' LYS . . . . . 0.498 ' NZ ' ' O ' ' I' ' 26' ' ' SER . 32.4 tttt -102.03 -112.82 0.21 Allowed 'General case' 0 N--CA 1.476 0.828 0 O-C-N 121.606 -0.684 . . . . 0.0 112.265 176.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 29' ' ' GLY . . . . . 0.551 ' H ' ' ND2' ' I' ' 27' ' ' ASN . . . 47.98 91.57 0.01 OUTLIER Glycine 0 CA--C 1.495 -1.192 0 N-CA-C 109.075 -1.61 . . . . 0.0 109.075 -178.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 30' ' ' ALA . . . . . 0.558 ' O ' ' HB3' ' H' ' 30' ' ' ALA . . . -106.18 162.37 13.7 Favored 'General case' 0 N--CA 1.443 -0.812 0 CA-C-O 123.85 1.786 . . . . 0.0 111.127 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 31' ' ' ILE . . . . . 0.649 HG21 ' HA3' ' A' ' 37' ' ' GLY . 1.0 OUTLIER -160.29 121.94 0.32 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.862 0 CA-C-N 110.547 -3.024 . . . . 0.0 106.84 -172.733 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' G' G ' 32' ' ' ILE . . . . . . . . . . . . . 14.0 tt -139.64 122.73 17.79 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.913 0 C-N-CA 118.948 -1.101 . . . . 0.0 110.249 178.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 33' ' ' GLY . . . . . . . . . . . . . . . -100.7 117.41 5.86 Favored Glycine 0 CA--C 1.506 -0.519 0 N-CA-C 106.821 -2.511 . . . . 0.0 106.821 177.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 34' ' ' LEU . . . . . 0.678 HD13 ' CZ ' ' I' ' 19' ' ' PHE . 70.9 mt -113.59 120.17 40.02 Favored 'General case' 0 CA--C 1.499 -0.99 0 CA-C-O 121.562 0.696 . . . . 0.0 111.931 -177.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 35' ' ' MET . . . . . 0.472 ' SD ' ' C ' ' A' ' 31' ' ' ILE . 3.8 ttm -120.84 108.02 13.43 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 106.339 -1.726 . . . . 0.0 106.339 177.046 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 36' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -119.72 71.56 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.546 0.819 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 -178.933 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' G' G ' 37' ' ' GLY . . . . . . . . . . . . . . . -87.11 -98.31 0.85 Allowed Glycine 0 C--N 1.361 1.921 0 N-CA-C 110.539 -1.024 . . . . 0.0 110.539 179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 38' ' ' GLY . . . . . . . . . . . . . . . 168.6 -173.63 43.26 Favored Glycine 0 CA--C 1.527 0.793 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 39' ' ' VAL . . . . . . . . . . . . . 67.2 t -126.83 136.14 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.428 0 CA-C-O 120.809 0.337 . . . . 0.0 110.102 -179.597 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' G' G ' 40' ' ' VAL . . . . . . . . . . . . . 33.7 m . . . . . 0 C--O 1.22 -0.474 0 CA-C-O 117.98 -1.01 . . . . 0.0 110.789 -179.809 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' H' H ' 9' ' ' GLY . . . . . 0.426 ' O ' ' OE2' ' G' ' 11' ' ' GLU . . . . . . . . 0 N--CA 1.489 2.201 0 N-CA-C 109.405 -1.478 . . . . 0.0 109.405 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 10' ' ' TYR . . . . . . . . . . . . . 79.6 t80 -105.06 129.0 53.59 Favored 'General case' 0 N--CA 1.466 0.354 0 N-CA-C 110.334 -0.247 . . . . 0.0 110.334 179.993 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 11' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -67.06 131.07 45.08 Favored 'General case' 0 C--N 1.33 -0.241 0 C-N-CA 120.671 -0.412 . . . . 0.0 110.452 179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 12' ' ' VAL . . . . . . . . . . . . . 3.8 p -145.67 148.73 17.15 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.314 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.494 -179.775 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 13' ' ' HIS . . . . . . . . . . . . . 78.1 t60 -121.61 124.07 43.45 Favored 'General case' 0 N--CA 1.469 0.494 0 CA-C-O 120.69 0.281 . . . . 0.0 110.664 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 14' ' ' HIS . . . . . 0.571 ' H ' ' CD2' ' G' ' 14' ' ' HIS . 37.1 m-70 -144.58 166.18 25.91 Favored 'General case' 0 CA--C 1.513 -0.446 0 CA-C-O 121.345 0.593 . . . . 0.0 110.277 179.65 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 15' ' ' GLN . . . . . . . . . . . . . 55.6 tp60 -160.81 161.15 31.9 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.134 -0.939 . . . . 0.0 108.795 177.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 16' ' ' LYS . . . . . . . . . . . . . 96.2 mttt -158.83 118.06 3.05 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 109.994 -0.373 . . . . 0.0 109.994 -179.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 17' ' ' LEU . . . . . . . . . . . . . 62.9 mt -121.54 110.5 16.1 Favored 'General case' 0 C--N 1.331 -0.214 0 N-CA-C 108.99 -0.745 . . . . 0.0 108.99 178.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 18' ' ' VAL . . . . . 0.485 HG11 ' CE2' ' H' ' 20' ' ' PHE . 72.4 t -124.29 130.07 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.763 0 C-N-CA 120.551 -0.46 . . . . 0.0 111.045 -179.394 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 19' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -119.39 114.25 22.05 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.973 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 20' ' ' PHE . . . . . 0.485 ' CE2' HG11 ' H' ' 18' ' ' VAL . 52.4 m-85 -110.1 117.28 33.3 Favored 'General case' 0 N--CA 1.468 0.463 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 178.53 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 21' ' ' ALA . . . . . 0.401 ' HB3' ' H ' ' H' ' 27' ' ' ASN . . . -136.1 134.44 38.36 Favored 'General case' 0 N--CA 1.472 0.667 0 C-N-CA 119.558 -0.857 . . . . 0.0 112.867 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 22' ' ' GLU . . . . . . . . . . . . . 81.3 tt0 -152.02 89.65 1.47 Allowed 'General case' 0 C--O 1.224 -0.261 0 CA-C-N 114.488 -1.233 . . . . 0.0 110.677 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 23' ' ' ASP . . . . . 0.444 ' OD1' ' N ' ' H' ' 23' ' ' ASP . 26.5 p-10 169.85 -121.23 0.0 OUTLIER 'General case' 0 N--CA 1.47 0.554 0 O-C-N 123.366 0.416 . . . . 0.0 110.073 179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 24' ' ' VAL . . . . . 0.808 HG21 ' H ' ' G' ' 25' ' ' GLY . 1.5 m -85.28 122.41 38.25 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 179.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 25' ' ' GLY . . . . . . . . . . . . . . . 50.65 84.25 0.03 OUTLIER Glycine 0 CA--C 1.527 0.811 0 N-CA-C 110.832 -0.907 . . . . 0.0 110.832 -178.902 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 26' ' ' SER . . . . . 0.401 ' HB2' ' HB1' ' I' ' 21' ' ' ALA . 22.0 p -68.95 -168.54 0.14 Allowed 'General case' 0 N--CA 1.442 -0.874 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 178.412 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 27' ' ' ASN . . . . . 0.613 ' O ' ' O ' ' H' ' 28' ' ' LYS . 89.5 m-20 -80.2 175.91 10.23 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 28' ' ' LYS . . . . . 0.68 ' HA ' HD12 ' H' ' 32' ' ' ILE . 29.7 tttt 35.34 100.49 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.171 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -172.121 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 29' ' ' GLY . . . . . 0.615 ' O ' ' C ' ' H' ' 30' ' ' ALA . . . -98.3 110.31 3.99 Favored Glycine 1 CA--C 1.445 -4.315 1 CA-C-O 112.742 -4.366 . . . . 0.0 120.858 -176.647 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild full ' H' H ' 30' ' ' ALA . . . . . 0.746 ' O ' ' O ' ' I' ' 29' ' ' GLY . . . 53.43 -122.32 2.0 Allowed 'General case' 0 C--N 1.39 2.342 2 C-N-CA 107.778 -5.569 . . . . 0.0 109.505 161.431 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' H' H ' 31' ' ' ILE . . . . . 0.894 ' H ' HD12 ' H' ' 31' ' ' ILE . 4.1 mp -67.4 107.98 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.413 -2.314 0 CA-C-N 109.966 -3.288 . . . . 0.0 109.796 171.345 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 32' ' ' ILE . . . . . 0.68 HD12 ' HA ' ' H' ' 28' ' ' LYS . 10.3 tt -122.47 120.44 61.02 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 CA-C-O 122.246 1.022 . . . . 0.0 109.789 174.816 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 33' ' ' GLY . . . . . 0.736 ' N ' ' SD ' ' B' ' 35' ' ' MET . . . -98.87 117.96 6.02 Favored Glycine 0 CA--C 1.497 -1.075 0 N-CA-C 106.304 -2.718 . . . . 0.0 106.304 177.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 34' ' ' LEU . . . . . 0.424 HD11 HG22 ' H' ' 36' ' ' VAL . 56.0 tp -120.04 119.66 34.03 Favored 'General case' 0 C--N 1.324 -0.53 0 N-CA-C 113.836 1.051 . . . . 0.0 113.836 -175.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 35' ' ' MET . . . . . 0.565 ' SD ' ' N ' ' B' ' 32' ' ' ILE . 17.6 ttm -124.8 115.31 20.49 Favored 'General case' 0 CA--C 1.514 -0.42 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 175.517 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 36' ' ' VAL . . . . . 0.444 ' O ' HG12 ' I' ' 36' ' ' VAL . 0.0 OUTLIER -129.32 71.25 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.877 0 N-CA-C 108.397 -0.964 . . . . 0.0 108.397 -179.85 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' H' H ' 37' ' ' GLY . . . . . . . . . . . . . . . -105.16 -100.81 2.66 Favored Glycine 0 C--N 1.358 1.8 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 38' ' ' GLY . . . . . 0.422 ' H ' HD13 ' B' ' 31' ' ' ILE . . . 110.54 166.17 19.21 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' H' H ' 39' ' ' VAL . . . . . . . . . . . . . 30.3 m -132.04 156.62 42.67 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.425 0 CA-C-O 120.686 0.279 . . . . 0.0 110.357 179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' H' H ' 40' ' ' VAL . . . . . . . . . . . . . 21.9 t . . . . . 0 C--O 1.22 -0.449 0 CA-C-O 117.909 -1.044 . . . . 0.0 110.636 -179.826 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' I' I ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.375 0 N-CA-C 109.651 -1.38 . . . . 0.0 109.651 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' I' I ' 10' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -97.29 135.01 39.82 Favored 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 120.74 0.305 . . . . 0.0 110.278 -179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 11' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -143.18 160.1 41.07 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-O 121.222 0.534 . . . . 0.0 111.487 -179.131 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 12' ' ' VAL . . . . . . . . . . . . . 47.0 t -120.61 133.63 66.68 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.358 0 CA-C-N 115.506 -0.77 . . . . 0.0 109.253 179.504 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 13' ' ' HIS . . . . . . . . . . . . . 75.7 m80 -129.61 131.96 46.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-O 120.84 0.352 . . . . 0.0 111.514 -179.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 14' ' ' HIS . . . . . 0.52 ' CG ' ' N ' ' I' ' 15' ' ' GLN . 86.3 t60 -154.18 165.76 35.24 Favored 'General case' 0 N--CA 1.449 -0.512 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 177.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 15' ' ' GLN . . . . . 0.52 ' N ' ' CG ' ' I' ' 14' ' ' HIS . 76.0 mt-30 -158.76 171.22 20.49 Favored 'General case' 0 C--N 1.316 -0.889 0 C-N-CA 120.587 -0.445 . . . . 0.0 110.502 179.628 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 16' ' ' LYS . . . . . . . . . . . . . 99.8 mttt -151.05 121.48 7.36 Favored 'General case' 0 N--CA 1.47 0.533 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.071 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 17' ' ' LEU . . . . . . . . . . . . . 5.4 mp -127.67 123.82 36.44 Favored 'General case' 0 N--CA 1.473 0.679 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.603 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 18' ' ' VAL . . . . . . . . . . . . . 46.7 t -134.44 130.29 53.64 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 19' ' ' PHE . . . . . 0.678 ' CZ ' HD13 ' G' ' 34' ' ' LEU . 45.4 m-85 -111.35 108.45 18.05 Favored 'General case' 0 CA--C 1.54 0.596 0 N-CA-C 106.916 -1.513 . . . . 0.0 106.916 176.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 20' ' ' PHE . . . . . . . . . . . . . 28.5 t80 -116.47 119.53 35.9 Favored 'General case' 0 N--CA 1.478 0.964 0 O-C-N 122.184 -0.323 . . . . 0.0 111.109 -178.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 21' ' ' ALA . . . . . 0.401 ' HB1' ' HB2' ' H' ' 26' ' ' SER . . . -136.78 127.5 27.17 Favored 'General case' 0 N--CA 1.476 0.86 0 N-CA-C 113.918 1.081 . . . . 0.0 113.918 -178.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 22' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -138.49 109.17 6.62 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.732 177.013 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 23' ' ' ASP . . . . . . . . . . . . . 42.0 p-10 -161.69 125.14 3.17 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.183 -0.462 . . . . 0.0 109.96 179.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 24' ' ' VAL . . . . . 0.495 ' O ' ' N ' ' I' ' 26' ' ' SER . 3.8 m -89.82 -112.81 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 C-N-CA 120.595 -0.442 . . . . 0.0 109.971 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 25' ' ' GLY . . . . . 0.407 ' H ' HG23 ' I' ' 24' ' ' VAL . . . 43.98 -92.02 0.01 OUTLIER Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.755 -0.938 . . . . 0.0 110.755 -179.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 26' ' ' SER . . . . . 0.676 ' O ' ' O ' ' I' ' 27' ' ' ASN . 3.0 p -129.19 170.27 13.77 Favored 'General case' 0 N--CA 1.446 -0.643 0 N-CA-C 109.258 -0.645 . . . . 0.0 109.258 179.54 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 27' ' ' ASN . . . . . 0.676 ' O ' ' O ' ' I' ' 26' ' ' SER . 73.5 m-80 31.98 172.58 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 114.406 1.261 . . . . 0.0 114.406 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 28' ' ' LYS . . . . . 0.548 ' O ' ' HA ' ' J' ' 23' ' ' ASP . 23.3 pttt 148.55 95.36 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.543 0 C-N-CA 123.344 0.658 . . . . 0.0 111.571 179.465 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 29' ' ' GLY . . . . . 0.801 ' O ' ' HB3' ' I' ' 30' ' ' ALA . . . 58.46 -112.59 4.12 Favored Glycine 1 CA--C 1.433 -5.059 0 CA-C-O 114.948 -3.14 . . . . 0.0 111.849 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 30' ' ' ALA . . . . . 0.801 ' HB3' ' O ' ' I' ' 29' ' ' GLY 0.529 . . 97.96 -125.45 0.0 OUTLIER 'General case' 0 N--CA 1.409 -2.513 1 C-N-CA 109.781 -4.768 . . . . 0.0 113.355 179.294 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild full ' I' I ' 31' ' ' ILE . . . . . 0.774 HG22 ' SD ' ' C' ' 35' ' ' MET 0.426 3.0 mt -64.05 110.74 0.96 Allowed 'Isoleucine or valine' 0 N--CA 1.402 -2.852 1 CA-C-N 106.479 -4.873 . . . . 0.0 109.967 173.924 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild full ' I' I ' 32' ' ' ILE . . . . . 0.659 HG23 HG13 ' J' ' 32' ' ' ILE . 10.6 tt -135.36 126.15 44.59 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.299 0 CA-C-O 122.333 1.064 . . . . 0.0 112.496 178.158 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 33' ' ' GLY . . . . . . . . . . . . . . . -107.7 119.49 5.8 Favored Glycine 0 N--CA 1.465 0.59 0 N-CA-C 108.796 -1.722 . . . . 0.0 108.796 177.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 34' ' ' LEU . . . . . 1.0 HD22 ' CZ ' ' K' ' 19' ' ' PHE . 13.7 tp -114.68 125.72 54.06 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-O 121.638 0.733 . . . . 0.0 112.277 -178.887 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 35' ' ' MET . . . . . 0.421 ' N ' HD12 ' I' ' 34' ' ' LEU . 12.6 tpp -123.77 111.0 15.61 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 114.322 -1.308 . . . . 0.0 107.784 175.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' I' I ' 36' ' ' VAL . . . . . 0.734 HG13 HD11 ' I' ' 34' ' ' LEU . 0.0 OUTLIER -128.03 68.28 0.35 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.843 0 N-CA-C 109.646 -0.502 . . . . 0.0 109.646 179.374 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' I' I ' 37' ' ' GLY . . . . . . . . . . . . . . . -70.11 -101.53 0.04 OUTLIER Glycine 0 C--N 1.355 1.625 0 N-CA-C 110.464 -1.055 . . . . 0.0 110.464 179.475 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 38' ' ' GLY . . . . . . . . . . . . . . . 105.01 160.02 23.54 Favored Glycine 0 CA--C 1.521 0.469 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 39' ' ' VAL . . . . . . . . . . . . . 55.7 t -124.73 135.95 62.29 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.293 0 N-CA-C 110.04 -0.356 . . . . 0.0 110.04 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' I' I ' 40' ' ' VAL . . . . . . . . . . . . . 9.4 p . . . . . 0 C--O 1.22 -0.489 0 CA-C-O 117.968 -1.015 . . . . 0.0 110.519 -179.648 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' J' J ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.586 -1.406 . . . . 0.0 109.586 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' J' J ' 10' ' ' TYR . . . . . . . . . . . . . 96.9 m-85 -115.11 154.65 28.54 Favored 'General case' 0 N--CA 1.465 0.28 0 N-CA-C 110.016 -0.365 . . . . 0.0 110.016 179.914 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 11' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -51.01 139.26 17.88 Favored 'General case' 0 C--N 1.326 -0.415 0 C-N-CA 120.727 -0.389 . . . . 0.0 110.004 -179.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 12' ' ' VAL . . . . . . . . . . . . . 3.4 p -129.47 140.7 48.43 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.181 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.607 -179.128 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 13' ' ' HIS . . . . . . . . . . . . . 47.9 m80 -137.59 103.78 5.14 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.759 -179.63 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 14' ' ' HIS . . . . . . . . . . . . . 65.5 m170 -117.7 164.66 14.64 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 15' ' ' GLN . . . . . . . . . . . . . 74.4 mt-30 -157.77 172.83 17.78 Favored 'General case' 0 C--N 1.314 -0.967 0 C-N-CA 120.397 -0.521 . . . . 0.0 111.217 179.059 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 16' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -155.41 115.64 3.77 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.526 178.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 17' ' ' LEU . . . . . . . . . . . . . 5.1 mp -124.27 124.15 41.78 Favored 'General case' 0 N--CA 1.466 0.355 0 N-CA-C 109.249 -0.648 . . . . 0.0 109.249 179.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 18' ' ' VAL . . . . . . . . . . . . . 57.6 t -134.07 132.43 55.97 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.507 0 N-CA-C 112.953 0.723 . . . . 0.0 112.953 -178.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 19' ' ' PHE . . . . . 0.522 ' CZ ' ' CD2' ' I' ' 19' ' ' PHE . 14.8 m-85 -114.16 107.11 15.19 Favored 'General case' 0 CA--C 1.531 0.228 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 177.219 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 20' ' ' PHE . . . . . 0.57 ' CE2' ' CD1' ' K' ' 20' ' ' PHE . 35.4 t80 -120.92 117.55 27.63 Favored 'General case' 0 N--CA 1.471 0.613 0 N-CA-C 109.44 -0.578 . . . . 0.0 109.44 -179.455 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 21' ' ' ALA . . . . . . . . . . . . . . . -166.96 175.68 7.47 Favored 'General case' 0 C--O 1.235 0.334 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 -178.389 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 22' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -88.22 138.83 31.09 Favored 'General case' 0 CA--C 1.531 0.246 0 CA-C-N 113.134 -1.848 . . . . 0.0 109.032 177.861 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 23' ' ' ASP . . . . . 0.548 ' HA ' ' O ' ' I' ' 28' ' ' LYS . 74.0 m-20 -117.61 -161.0 0.8 Allowed 'General case' 0 CA--C 1.542 0.635 0 CA-C-O 121.384 0.611 . . . . 0.0 111.575 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 24' ' ' VAL . . . . . 0.554 HG13 ' H ' ' J' ' 29' ' ' GLY . 76.4 t 52.77 103.95 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.901 0 N-CA-C 116.56 2.059 . . . . 0.0 116.56 179.497 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 25' ' ' GLY . . . . . . . . . . . . . . . -64.59 -92.63 0.03 OUTLIER Glycine 0 C--N 1.35 1.307 0 N-CA-C 108.519 -1.832 . . . . 0.0 108.519 172.32 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 26' ' ' SER . . . . . 0.692 ' O ' ' O ' ' J' ' 27' ' ' ASN . 13.9 p -124.63 166.31 16.35 Favored 'General case' 0 CA--C 1.51 -0.57 0 N-CA-C 102.683 -3.08 . . . . 0.0 102.683 175.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 27' ' ' ASN . . . . . 0.692 ' O ' ' O ' ' J' ' 26' ' ' SER . 9.9 m120 47.84 174.23 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 104.976 -2.231 . . . . 0.0 104.976 -174.46 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 28' ' ' LYS . . . . . 0.745 ' NZ ' ' HB2' ' K' ' 30' ' ' ALA . 86.2 tttt -73.06 110.91 7.71 Favored 'General case' 0 C--N 1.35 0.626 1 C-N-CA 111.064 -4.254 . . . . 0.0 106.046 178.279 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 29' ' ' GLY . . . . . 0.554 ' H ' HG13 ' J' ' 24' ' ' VAL . . . -86.27 93.4 1.86 Allowed Glycine 0 CA--C 1.485 -1.807 0 CA-C-O 117.518 -1.712 . . . . 0.0 112.255 173.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 30' ' ' ALA . . . . . 0.454 ' C ' ' CG1' ' J' ' 31' ' ' ILE . . . -163.16 140.21 7.49 Favored 'General case' 0 C--N 1.281 -2.406 0 CA-C-N 121.194 2.497 . . . . 0.0 108.348 171.193 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 31' ' ' ILE . . . . . 0.508 HG23 HD12 ' K' ' 31' ' ' ILE . 0.0 OUTLIER -158.39 116.54 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.058 0 CA-C-N 112.249 -2.25 . . . . 0.0 107.08 -173.32 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' J' J ' 32' ' ' ILE . . . . . 0.659 HG13 HG23 ' I' ' 32' ' ' ILE . 15.6 tt -124.87 117.33 49.89 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.723 0 CA-C-O 121.896 0.855 . . . . 0.0 110.994 179.489 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 33' ' ' GLY . . . . . . . . . . . . . . . -97.62 118.95 6.24 Favored Glycine 0 CA--C 1.505 -0.569 0 N-CA-C 106.925 -2.47 . . . . 0.0 106.925 177.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 34' ' ' LEU . . . . . 0.773 HD22 ' CE1' ' L' ' 19' ' ' PHE . 50.8 mt -113.54 107.29 15.6 Favored 'General case' 0 CA--C 1.505 -0.783 0 CA-C-O 121.322 0.582 . . . . 0.0 111.125 -176.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 35' ' ' MET . . . . . . . . . . . . . 9.0 tpt -111.5 112.0 23.42 Favored 'General case' 0 CA--C 1.514 -0.421 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.297 178.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 36' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -131.63 74.71 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.553 1.068 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.668 -177.72 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' J' J ' 37' ' ' GLY . . . . . . . . . . . . . . . -85.23 106.23 2.97 Favored Glycine 0 C--N 1.355 1.6 0 N-CA-C 111.153 -0.779 . . . . 0.0 111.153 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 38' ' ' GLY . . . . . . . . . . . . . . . -80.77 169.39 52.15 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.819 -0.912 . . . . 0.0 110.819 -179.658 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 39' ' ' VAL . . . . . . . . . . . . . 70.0 t -133.94 138.57 50.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.391 0 CA-C-O 120.644 0.259 . . . . 0.0 110.524 -179.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' J' J ' 40' ' ' VAL . . . . . . . . . . . . . 8.7 p . . . . . 0 C--O 1.22 -0.448 0 CA-C-O 117.983 -1.008 . . . . 0.0 110.758 179.754 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' K' K ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.417 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' K' K ' 10' ' ' TYR . . . . . . . . . . . . . 90.3 m-85 -111.11 134.75 52.47 Favored 'General case' 0 N--CA 1.466 0.328 0 CA-C-O 120.8 0.333 . . . . 0.0 110.478 179.965 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 11' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -110.94 148.89 31.51 Favored 'General case' 0 N--CA 1.464 0.241 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 12' ' ' VAL . . . . . 0.557 ' CG2' ' NE2' ' K' ' 14' ' ' HIS . 2.6 m -140.24 -171.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.48 0 N-CA-C 112.596 0.591 . . . . 0.0 112.596 -177.413 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 13' ' ' HIS . . . . . . . . . . . . . 26.0 m-70 -92.44 132.05 37.1 Favored 'General case' 0 CA--C 1.535 0.398 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.807 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 14' ' ' HIS . . . . . 0.557 ' NE2' ' CG2' ' K' ' 12' ' ' VAL . 80.0 m-70 -148.03 169.75 19.25 Favored 'General case' 0 CA--C 1.515 -0.403 0 N-CA-C 109.376 -0.602 . . . . 0.0 109.376 179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 15' ' ' GLN . . . . . . . . . . . . . 70.7 mt-30 -157.27 178.96 9.73 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.805 179.269 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 16' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -160.57 121.5 2.96 Favored 'General case' 0 N--CA 1.462 0.16 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.173 179.598 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 17' ' ' LEU . . . . . . . . . . . . . 5.2 mp -126.62 125.09 41.33 Favored 'General case' 0 N--CA 1.47 0.534 0 N-CA-C 109.88 -0.415 . . . . 0.0 109.88 179.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 18' ' ' VAL . . . . . . . . . . . . . 59.8 t -130.68 129.61 64.21 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 C-N-CA 120.82 -0.352 . . . . 0.0 111.927 -179.7 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 19' ' ' PHE . . . . . 1.0 ' CZ ' HD22 ' I' ' 34' ' ' LEU . 19.8 m-85 -113.45 108.89 17.82 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 177.631 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 20' ' ' PHE . . . . . 0.57 ' CD1' ' CE2' ' J' ' 20' ' ' PHE . 35.1 t80 -118.51 121.13 39.51 Favored 'General case' 0 N--CA 1.475 0.779 0 CA-C-N 118.141 0.428 . . . . 0.0 110.855 -179.396 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.03 139.84 45.13 Favored 'General case' 0 N--CA 1.472 0.654 0 N-CA-C 112.988 0.736 . . . . 0.0 112.988 -179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 22' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.71 167.53 26.18 Favored 'General case' 0 N--CA 1.477 0.887 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.781 179.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 23' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -166.38 -136.42 0.02 OUTLIER 'General case' 0 C--O 1.233 0.203 0 C-N-CA 119.869 -0.732 . . . . 0.0 111.144 177.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 24' ' ' VAL . . . . . 0.42 ' O ' ' C ' ' K' ' 25' ' ' GLY . 18.7 t -110.62 110.36 31.9 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.877 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 179.935 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 25' ' ' GLY . . . . . 0.42 ' C ' ' O ' ' K' ' 24' ' ' VAL . . . 32.54 91.44 0.01 OUTLIER Glycine 0 CA--C 1.53 0.981 0 N-CA-C 112.156 -0.377 . . . . 0.0 112.156 177.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 26' ' ' SER . . . . . 0.413 ' OG ' ' CG ' ' L' ' 23' ' ' ASP . 5.8 p -47.5 154.71 0.42 Allowed 'General case' 0 N--CA 1.443 -0.818 0 N-CA-C 109.84 -0.43 . . . . 0.0 109.84 179.73 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 27' ' ' ASN . . . . . . . . . . . . . 25.8 m120 -119.15 172.58 7.48 Favored 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 122.239 1.018 . . . . 0.0 113.166 -179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 28' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -32.8 110.75 0.09 Allowed 'General case' 0 CA--C 1.545 0.763 0 N-CA-C 116.248 1.944 . . . . 0.0 116.248 179.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 29' ' ' GLY . . . . . . . . . . . . . . . 80.59 93.42 0.44 Allowed Glycine 0 N--CA 1.475 1.286 0 N-CA-C 116.386 1.314 . . . . 0.0 116.386 172.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 30' ' ' ALA . . . . . 0.745 ' HB2' ' NZ ' ' J' ' 28' ' ' LYS . . . -101.11 165.71 11.16 Favored 'General case' 0 C--O 1.244 0.797 0 N-CA-C 101.628 -3.471 . . . . 0.0 101.628 170.096 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 31' ' ' ILE . . . . . 0.508 HD12 HG23 ' J' ' 31' ' ' ILE . 0.2 OUTLIER -138.29 122.77 22.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.442 0 C-N-CA 116.926 -1.91 . . . . 0.0 111.854 -178.224 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' K' K ' 32' ' ' ILE . . . . . 0.438 ' O ' ' SD ' ' F' ' 35' ' ' MET . 76.0 mt -131.96 130.92 61.63 Favored 'Isoleucine or valine' 0 C--N 1.352 0.686 0 CA-C-N 115.729 -0.669 . . . . 0.0 112.443 -177.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 33' ' ' GLY . . . . . 0.669 ' N ' ' SD ' ' E' ' 35' ' ' MET . . . -122.47 122.22 4.96 Favored Glycine 0 N--CA 1.473 1.145 0 N-CA-C 110.201 -1.16 . . . . 0.0 110.201 178.371 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 34' ' ' LEU . . . . . . . . . . . . . 14.4 mt -114.7 114.95 26.32 Favored 'General case' 0 N--CA 1.467 0.4 0 CA-C-N 117.266 0.533 . . . . 0.0 111.8 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 35' ' ' MET . . . . . 0.546 ' SD ' ' CA ' ' E' ' 33' ' ' GLY . 8.1 ttt -128.36 120.89 27.88 Favored 'General case' 0 N--CA 1.469 0.492 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 177.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 36' ' ' VAL . . . . . . . . . . . . . 3.1 t -125.08 81.61 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.487 0 CA-C-N 116.235 -0.438 . . . . 0.0 111.05 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 37' ' ' GLY . . . . . 0.702 ' HA3' HG21 ' E' ' 31' ' ' ILE . . . -65.41 102.05 0.63 Allowed Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.07 -0.812 . . . . 0.0 111.07 179.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' K' K ' 38' ' ' GLY . . . . . . . . . . . . . . . -146.75 152.64 24.76 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 179.689 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 39' ' ' VAL . . . . . . . . . . . . . 23.6 m -130.61 157.71 42.98 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 N-CA-C 110.106 -0.331 . . . . 0.0 110.106 179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' K' K ' 40' ' ' VAL . . . . . . . . . . . . . 16.2 t . . . . . 0 C--O 1.22 -0.488 0 CA-C-O 118.055 -0.974 . . . . 0.0 110.702 -179.663 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' L' L ' 9' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.368 -1.493 . . . . 0.0 109.368 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' L' L ' 10' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -110.29 146.83 35.01 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-O 120.756 0.312 . . . . 0.0 110.646 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 11' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -58.36 145.54 37.81 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.521 -179.715 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 12' ' ' VAL . . . . . 0.476 ' O ' ' CG2' ' K' ' 12' ' ' VAL . 66.9 t -128.28 130.13 69.34 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.414 0 CA-C-O 121.922 0.868 . . . . 0.0 111.389 -179.778 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 13' ' ' HIS . . . . . 0.493 ' CD2' ' N ' ' L' ' 13' ' ' HIS . 4.4 m-70 -117.66 110.79 18.31 Favored 'General case' 0 N--CA 1.462 0.164 0 CA-C-N 114.883 -1.053 . . . . 0.0 109.699 178.685 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 14' ' ' HIS . . . . . . . . . . . . . 34.0 m80 -138.78 173.63 11.38 Favored 'General case' 0 N--CA 1.447 -0.585 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 15' ' ' GLN . . . . . . . . . . . . . 76.2 mt-30 -144.93 177.09 9.0 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.179 179.986 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 16' ' ' LYS . . . . . . . . . . . . . 99.2 mttt -149.36 126.1 11.09 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.752 179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 17' ' ' LEU . . . . . . . . . . . . . 4.8 mp -129.29 125.92 37.87 Favored 'General case' 0 N--CA 1.466 0.333 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 179.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 18' ' ' VAL . . . . . . . . . . . . . 63.7 t -123.63 128.63 74.58 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.474 0 CA-C-O 120.94 0.4 . . . . 0.0 110.425 -179.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 19' ' ' PHE . . . . . 0.773 ' CE1' HD22 ' J' ' 34' ' ' LEU . 70.7 m-85 -113.81 112.3 23.18 Favored 'General case' 0 N--CA 1.462 0.173 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 20' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -133.49 127.72 33.85 Favored 'General case' 0 N--CA 1.473 0.675 0 CA-C-O 121.696 0.76 . . . . 0.0 112.689 -178.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 21' ' ' ALA . . . . . . . . . . . . . . . -135.57 137.61 42.15 Favored 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.949 -1.023 . . . . 0.0 108.644 178.293 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 22' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -80.44 109.19 14.7 Favored 'General case' 0 N--CA 1.469 0.508 0 C-N-CA 119.953 -0.699 . . . . 0.0 112.302 -178.073 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 23' ' ' ASP . . . . . 0.413 ' CG ' ' OG ' ' K' ' 26' ' ' SER . 37.0 t0 178.91 113.28 0.04 OUTLIER 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.711 178.731 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 24' ' ' VAL . . . . . . . . . . . . . 63.3 t -59.16 130.55 22.75 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.247 0 C-N-CA 119.079 -1.048 . . . . 0.0 108.607 177.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 25' ' ' GLY . . . . . . . . . . . . . . . -68.39 85.29 0.19 Allowed Glycine 0 CA--C 1.526 0.757 0 C-N-CA 119.609 -1.281 . . . . 0.0 110.847 178.512 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 26' ' ' SER . . . . . . . . . . . . . 49.2 m -65.6 -175.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.869 0 N-CA-C 107.919 -1.141 . . . . 0.0 107.919 178.083 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 27' ' ' ASN . . . . . 0.535 ' O ' ' O ' ' L' ' 28' ' ' LYS . 2.7 m120 -91.13 178.9 5.86 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 107.972 -1.121 . . . . 0.0 107.972 176.509 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 28' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' L' ' 27' ' ' ASN . 98.7 mttt 28.03 102.07 0.0 OUTLIER 'General case' 0 N--CA 1.479 1.023 0 O-C-N 123.42 0.45 . . . . 0.0 111.69 177.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 29' ' ' GLY . . . . . . . . . . . . . . . 149.85 -101.71 0.22 Allowed Glycine 0 N--CA 1.467 0.702 0 C-N-CA 119.251 -1.452 . . . . 0.0 112.556 -178.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 30' ' ' ALA . . . . . . . . . . . . . . . -53.65 161.72 1.01 Allowed 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 120.309 -0.556 . . . . 0.0 110.135 -177.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 31' ' ' ILE . . . . . 0.415 HG21 ' CA ' ' F' ' 37' ' ' GLY . 0.0 OUTLIER -150.12 127.14 2.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.502 0 C-N-CA 119.654 -0.819 . . . . 0.0 110.438 -176.108 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' L' L ' 32' ' ' ILE . . . . . . . . . . . . . 65.6 mt -127.01 129.36 71.21 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.267 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.33 -178.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 33' ' ' GLY . . . . . 0.623 ' N ' ' SD ' ' F' ' 35' ' ' MET . . . -122.11 132.74 9.0 Favored Glycine 0 N--CA 1.484 1.838 0 C-N-CA 120.723 -0.751 . . . . 0.0 111.244 179.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 34' ' ' LEU . . . . . . . . . . . . . 61.5 tp -120.44 121.82 39.34 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 117.07 0.435 . . . . 0.0 111.088 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 35' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -127.2 123.16 35.97 Favored 'General case' 0 N--CA 1.472 0.644 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.14 179.921 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 36' ' ' VAL . . . . . 0.73 ' O ' HG23 ' L' ' 36' ' ' VAL . 16.7 m -145.41 78.92 0.14 Allowed 'Isoleucine or valine' 0 CA--C 1.543 0.685 0 CA-C-N 116.701 -0.227 . . . . 0.0 111.586 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 37' ' ' GLY . . . . . 0.515 ' C ' ' O ' ' L' ' 36' ' ' VAL . . . -3.63 -101.22 0.0 OUTLIER Glycine 0 C--N 1.359 1.814 0 C-N-CA 122.948 0.309 . . . . 0.0 113.284 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' L' L ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.6 162.74 21.49 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 39' ' ' VAL . . . . . . . . . . . . . 54.4 t -132.39 156.08 42.05 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.426 0 CA-C-O 120.868 0.366 . . . . 0.0 110.274 179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' L' L ' 40' ' ' VAL . . . . . . . . . . . . . 16.1 m . . . . . 0 C--O 1.219 -0.51 0 CA-C-O 117.936 -1.031 . . . . 0.0 111.076 -179.534 . . . . . . . . 0 0 . 1 stop_ save_